US20180289792A1 - Sexually transmitted disease vaccines - Google Patents

Abstract

The disclosure relates to sexually transmitted disease ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.

Description

RELATED APPLICATIONS
• This application claims the benefit under 35 U.S.C. § 119(e) of U.S. provisional application No. 62/244,884, filed Oct. 22, 2015, U.S. provisional application No. 62/247,418, filed Oct. 28, 2015, U.S. provisional application No. 62/244,822, filed Oct. 22, 2015, and U.S. provisional application No. 62/247,374, filed Oct. 28, 2015, each of which is incorporated by reference herein in its entirety. This application also claims the benefit under 35 U.S.C. § 119(e) of U.S. provisional application No. 62/245,031, filed Oct. 22, 2015, which is incorporated by reference herein in its entirety.
BACKGROUND
• Sexually transmitted diseases (STDs) are a major global cause of acute illness, infertility, long-term disability, and death, with severe medical and psychological consequences for millions of men, women, and children (Hafner L. et al. Mucosal Immunology (2008) 1, 116-130).
• Human papillomavirus (HPV) is a group of over 170 small DNA viruses from the papillomavirus family. It is the most commonly sexually transmitted infection, and while most HPV infections are subclinical, HPV is an etiological agent for cervical cancer, the second greatest cause of mortality among cancer-affected women worldwide. HPV-associated cancers account for over 5% of the total diagnosed cancer cases internationally, and the incidence is higher in developing countries, where HPV is estimated to cause about 500,000 cases annually. The high levels of HPV exposure and health consequences indicate the importance of developing safe vaccine candidates against HPV.
• Chlamydia infection is caused by the Chlamydia trachomatis (C. trachomatis) bacterium. It is one of the most commonly sexually transmitted infections worldwide, affecting approximately 215 million people internationally. In the United States, there are around 2.8 million new cases of Chlamydia each year. Chlamydia trachomatis can also cause Chlamydia conjunctivitis or trachoma, a disease that can result in blindness. Worldwide, approximately 80 million people have active infections, resulting in impaired vision and blindness for nearly 2.2 million individuals. The international health consequences associated with Chlamydia exemplify the importance of developing effective and safe vaccine candidates against Chlamydia.
• Herpes simplex viruses (HSV) are double-stranded linear DNA viruses in the Herpesviridae family. Two members of the herpes simplex virus family infect humans—known as HSV-1 and HSV-2. Symptoms of HSV infection include the formation of blisters in the skin or mucous membranes of the mouth, lips, and/or genitals. HSV is a neuroinvasive virus that can cause sporadic recurring episodes of viral reactivation in infected individuals. HSV is transmitted by contact with an infected area of the skin during a period of viral activation.
• Deoxyribonucleic acid (DNA) vaccination is one technique used to stimulate humoral and cellular immune responses to foreign antigens, such as HPV antigens, HSV antigens and/or Chlamydia antigens. The direct injection of genetically engineered DNA (e.g., naked plasmid DNA) into a living host results in a small number of its cells directly producing an antigen, resulting in a protective immunological response. With this technique, however, comes potential problems, including the possibility of insertional mutagenesis, which could lead to the activation of oncogenes or the inhibition of tumor suppressor genes.
SUMMARY
• Provided herein are ribonucleic acid (RNA) vaccines that build on the knowledge that RNA (e.g., messenger RNA (mRNA)) can safely direct the body's cellular machinery to produce nearly any protein of interest, from native proteins to antibodies and other entirely novel protein constructs that can have therapeutic activity inside and outside of cells. The RNA (e.g., mRNA) vaccines of the present disclosure may be used to induce a balanced immune response against HPV, HSV and/or Chlamydia (e.g., C. trachomatis), comprising both cellular and humoral immunity, without risking the possibility of insertional mutagenesis, for example. HPV, HSV and/or Chlamydia are referred to herein as “sexually transmitted diseases (STDs).” Thus, the term “STD RNA vaccines” and “HPV, HSV and/or Chlamydia” encompasses HPV RNA vaccines, HSV RNA vaccines, Chlamydia RNA vaccines, and combination vaccines comprising: at least one HPV RNA vaccine and at least one HSV RNA vaccine; at least one HPV RNA vaccine and at least one Chlamydia RNA vaccine, at least one HSV vaccine and at least one Chlamydia RNA vaccine; and at least one HPV RNA vaccine, at least one HSV RNA vaccine and at least one Chlamydia RNA vaccine.
• The RNA (e.g., mRNA) vaccines may be utilized in various settings depending on the prevalence of the infection or the degree or level of unmet medical need. The RNA (e.g. mRNA) vaccines may be utilized to treat and/or prevent HPV, HSV and/or Chlamydia of various genotypes, strains, and isolates. The RNA (e.g., mRNA) vaccines have superior properties in that they produce much larger antibody titers and produce responses earlier than commercially available anti-viral therapeutic treatments. While not wishing to be bound by theory, it is believed that the RNA (e.g., mRNA) vaccines, as mRNA polynucleotides, are better designed to produce the appropriate protein conformation upon translation as the RNA (e.g., mRNA) vaccines co-opt natural cellular machinery. Unlike traditional vaccines, which are manufactured ex vivo and may trigger unwanted cellular responses, RNA (e.g., mRNA) vaccines are presented to the cellular system in a more native fashion.
• Surprisingly, it has been shown that efficacy of mRNA vaccines can be significantly enhanced when combined with a flagellin adjuvant, in particular, when one or more antigen-encoding mRNAs is combined with an mRNA encoding flagellin. RNA (e.g., mRNA) vaccines combined with the flagellin adjuvant (e.g., mRNA-encoded flagellin adjuvant) have superior properties in that they may produce much larger antibody titers and produce responses earlier than commercially available vaccine formulations.
• Some embodiments of the present disclosure provide RNA (e.g., mRNA) vaccines that include at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding at least one antigenic polypeptide or an immunogenic fragment thereof (e.g., an immunogenic fragment capable of inducing an immune response to the antigenic polypeptide) and at least one RNA (e.g., mRNA polynucleotide) having an open reading frame encoding a flagellin adjuvant.
• In some embodiments, at least one flagellin polypeptide (e.g., encoded flagellin polypeptide) is a flagellin protein. In some embodiments, at least one flagellin polypeptide (e.g., encoded flagellin polypeptide) is an immunogenic flagellin fragment. In some embodiments, at least one flagellin polypeptide and at least one antigenic polypeptide are encoded by a single RNA (e.g., mRNA) polynucleotide. In other embodiments, at least one flagellin polypeptide and at least one antigenic polypeptide are each encoded by a different RNA polynucleotide.
• In some embodiments at least one flagellin polypeptide has at least 80%, at least 85%, at least 90%, or at least 95% identity to a flagellin polypeptide having a sequence of SEQ ID NO: 301-303.
• Provided herein, in some embodiments, is a ribonucleic acid (RNA) (e.g., mRNA) vaccine, comprising at least one (e.g., at least 2, 3, 4 or 5) RNA (e.g., mRNA) polynucleotide having an open reading frame encoding at least one (e.g., at least 2, 3, 4 or 5) HPV, HSV and/or Chlamydia (e.g., C. trachomatis) antigenic polypeptide, or any combination of two or more of the foregoing antigenic polypeptides. Herein, use of the term “antigenic polypeptide” encompasses immunogenic fragments of the antigenic polypeptide (an immunogenic fragment that induces (or is capable of inducing) an immune response to HPV, HSV and/or Chlamydia (e.g., C. trachomatis), unless otherwise stated.
• Also provided herein, in some embodiments, is a RNA (e.g., mRNA) vaccine comprising at least one (e.g., at least 2, 3, 4 or 5) RNA polynucleotide having an open reading frame encoding at least one (e.g., at least 2, 3, 4 or 5) HPV, HSV and/or Chlamydia (e.g., C. trachomatis) antigenic polypeptide or an immunogenic fragment thereof, linked to a signal peptide.
• Further provided herein, in some embodiments, is a nucleic acid (e.g., DNA) encoding at least one (e.g., at least 2, 3, 4 or 5) HPV, HSV and/or Chlamydia (e.g., C. trachomatis) RNA (e.g., mRNA) polynucleotide.
• Further still, provided herein, in some embodiments, is a method of inducing an immune response in a subject, the method comprising administering to the subject a vaccine comprising at least one (e.g., at least 2, 3, 4 or 5) RNA (e.g., mRNA) polynucleotide having an open reading frame encoding at least one (e.g., at least 2, 3, 4 or 5) HPV, HSV and/or Chlamydia (e.g., C. trachomatis) antigenic polypeptide, or any combination of two or more of the foregoing antigenic polypeptides.
• HPV
• In some embodiments, a RNA (e.g., mRNA) vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding at least one HPV antigenic polypeptide or an immunogenic fragment thereof (e.g., an immunogenic fragment capable of inducing an immune response to HPV). In some embodiments, at least one antigenic polypeptide is selected from E1, E2, E4, E5, E6, E7, L1, and L2. In some embodiments, the at least one antigenic polypeptide is selected from E1, E2, E4, E5, E6, and E7. In some embodiments, the at least one antigenic polypeptide is E6, E7, or a combination of E6 and E7. In some embodiments, the at least one antigenic polypeptide is L1, L2, or a combination of L1 and L2.
• In some embodiments, the at least one antigenic polypeptide is L1. In some embodiments, the L1 protein is obtained from HPV serotypes 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 or 82.
• In some embodiments, the at least one antigenic polypeptide is L1, L2 or a combination of L1 and L2, and E6, E7, or a combination of E6 and E7.
• In some embodiments, the at least one antigenic polypeptide is from HPV strain HPV type 16 (HPV16), HPV type 18 (HPV18), HPV type 26 (HPV26), HPV type 31 (HPV31), HPV type 33 (HPV33), HPV type 35 (HPV35), HPV type 45 (HPV45), HPV type 51 (HPV51), HPV type 52 (HPV52), HPV type 53 (HPV53), HPV type 56 (HPV56), HPV type 58 (HPV58), HPV type 59 (HPV59), HPV type 66 (HPV66), HPV type 68 (HPV68), HPV type 82 (HPV82), or a combination thereof. In some embodiments, the at least one antigenic polypeptide is from HPV strain HPV16, HPV18, or a combination thereof.
• In some embodiments, the at least one antigenic polypeptide is from HPV strain HPV type 6 (HPV6), HPV type 11 (HPV11), HPV type 13 (HPV13), HPV type 40 (HPV40), HPV type 42 (HPV42), HPV type 43 (HPV43), HPV type 44 (HPV44), HPV type 54 (HPV54), HPV type 61 (HPV61), HPV type 70 (HPV70), HPV type 72 (HPV72), HPV type 81 (HPV81), HPV type 89 (HPV89), or a combination thereof.
• In some embodiments, the at least one antigenic polypeptide is from HPV strain HPV type 30 (HPV30), HPV type 34 (HPV34), HPV type 55 (HPV55), HPV type 62 (HPV62), HPV type 64 (HPV64), HPV type 67 (HPV67), HPV type 69 (HPV69), HPV type 71 (HPV71), HPV type 73 (HPV73), HPV type 74 (HPV74), HPV type 83 (HPV83), HPV type 84 (HPV84), HPV type 85 (HPV85), or a combination thereof.
• In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding at least one (e.g., one, two, three, four, five, six, seven, or eight) of E1, E2, E4, E5, E6, E7, L1, and L2 protein obtained from HPV, or a combination thereof. In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding at least one (e.g., one, two, three, four, five, or six) polypeptide selected from E1, E2, E4, E5, E6, and E7 protein obtained from HPV, or a combination thereof. In some embodiments a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding at least one polypeptide selected from E6 and E7 protein obtained from HPV, or a combination thereof. In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a polypeptide selected from L1 or L2 protein obtained from HPV, or a combination thereof.
• In some embodiments, the at least one RNA polynucleotide encodes an antigenic polypeptide that structurally modifies an infected cell.
• In some embodiments, the at least one RNA polynucleotide encodes an antigenic polypeptide that forms part or all of the HPV viral capsid.
• In some embodiments, the at least one RNA polynucleotide encodes an antigenic polypeptide that is capable of self-assembling into virus-like particles.
• In some embodiments, the at least one RNA polynucleotide encodes an antigenic polypeptide that is responsible for binding of the HPV to a cell being infected.
• In some embodiments, the at least one RNA polynucleotide encodes an antigenic polypeptide that interacts with retinoblastoma protein (pRb). In some embodiments, the at least one RNA polynucleotide encodes an antigenic polypeptide that interacts with p53.
• In some embodiments, at least one HPV antigenic polypeptide comprises an amino acid sequence of SEQ ID NO: 31-59 (Table 2). In some embodiments, the amino acid sequence of the HPV antigenic polypeptide is, or is a fragment of, or is a homolog or variant having at least 80% (e.g., 85%, 90%, 95%, 98%, 99%) identity to, the amino acid sequence of SEQ ID NO: 31-59 (Table 2).
• In some embodiments, at least one HPV antigenic polypeptide is encoded by a nucleic acid sequence identified by any one of SEQ ID NO: 1-28 (Table 1).
• In some embodiments, at least one HPV RNA (e.g., mRNA) polynucleotide is encoded by a nucleic acid sequence, or a fragment of a nucleotide sequence, identified by any one of SEQ ID NO: 1-28 (Table 1).
• In some embodiments, at least one HPV RNA (e.g., mRNA) polynucleotide comprises a nucleic acid sequence, or a fragment of a nucleotide sequence, identified by any one of SEQ ID NO: 431-461 (Table 1).
• Chlamydia
• In some embodiments, a RNA (e.g., mRNA) vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding at least one Chlamydia (e.g., C. trachomatis) antigenic polypeptide or an immunogenic fragment thereof (e.g., an immunogenic fragment capable of inducing an immune response to Chlamydia, e.g., C. trachomatis).
• In some embodiments, at least one antigenic polypeptide is a major outer membrane protein (MOMP or OmpA) or an immunogenic fragment thereof. The MOMP may be from Chlamydia trachomatis serovar (serotype) H, F, E, D, I, G, J or K.
• In some embodiments, at least one antigenic polypeptide is from a virulence related outer membrane protein family (such as OmpA, OmpL, OmpF, OprF) or an immunogenic fragment thereof. The OMP may be from Chlamydia trachomatis or any Gram negative bacteria (e.g., Pseudomonas aeruginosa).
• In some embodiments, at least one Chlamydia antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 65-72 or 73-183 (Tables 5 or 7). In some embodiments, the amino acid sequence of the Chlamydia antigenic polypeptide is, or is a fragment of, or is a homolog or variant having at least 80% (e.g., 85%, 90%, 95%, 98%, 99%) identity to, the amino acid sequence of SEQ ID NO: 65-72 or 73-183 (Tables 5 or 7).
• In some embodiments, at least one Chlamydia antigenic polypeptide is encoded by a nucleic acid sequence identified by any one of SEQ ID NO: 62-64 or 184-294 (Tables 4 or 8).
• In some embodiments, at least one Chlamydia RNA (e.g., mRNA) polynucleotide comprises a nucleic acid sequence, or a fragment of a nucleotide sequence, identified by any one of SEQ ID NO: 317-319 or 320-430 (Tables 4 or 8).
• HSV
• In some embodiments, a RNA (e.g., mRNA) vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding at least one herpes simplex virus (HSV) antigenic polypeptide or an immunogenic fragment thereof (e.g., an immunogenic fragment capable of inducing an immune response to HSV).
• In some embodiments, at least one antigenic polypeptide is HSV (HSV-1 or HSV-2) glycoprotein B, HSV (HSV-1 or HSV-2) glycoprotein C, HSV (HSV-1 or HSV-2) glycoprotein D, HSV (HSV-1 or HSV-2) glycoprotein E, HSV (HSV-1 or HSV-2) glycoprotein I. In some embodiments, at least one antigenic polypeptide has at least 95%, at least 96%, at least 97%, at least 98% or at least 99% to HSV (HSV-1 or HSV-2) glycoprotein B, HSV (HSV-1 or HSV-2) glycoprotein C, HSV (HSV-1 or HSV-2) glycoprotein D, HSV (HSV-1 or HSV-2) glycoprotein E, HSV (HSV-1 or HSV-2) glycoprotein I or HSV (HSV-1 or HSV-2) ICP4 protein.
• In some embodiments, at least one antigen polypeptide is a non-glycogenic polypeptide, for example, not limited to, HSV (HSV-1 or HSV-2) ICP4 protein, HSV (HSV-1 or HSV-2) ICP0 protein, or an immunogenic fragment thereof.
• In some embodiments, at least one antigenic polypeptide has at least 95%, at least 96%, at least 97%, at least 98% or at least 99% to HSV (HSV-1 or HSV-2) glycoprotein B, HSV (HSV-1 or HSV-2) glycoprotein C, HSV (HSV-1 or HSV-2) glycoprotein D, HSV (HSV-1 or HSV-2) glycoprotein E, HSV (HSV-1 or HSV-2) glycoprotein I or HSV (HSV-1 or HSV-2) ICP4 protein.
• In some embodiments, at least one antigenic polypeptide is HSV (HSV-1 or HSV-2) glycoprotein C, HSV (HSV-1 or HSV-2) glycoprotein D, a combination of HSV (HSV-1 or HSV-2) glycoprotein C and HSV (HSV-1 or HSV-2) glycoprotein D, or an immunogenic fragment thereof.
• In some embodiments, a HSV vaccine includes at least one RNA polynucleotide having an open reading frame encoding HSV (HSV-1 or HSV-2) glycoprotein D. In some embodiments, the HSV vaccine is formulated for intramuscular injection.
• In some embodiments, an open reading frame of a RNA (e.g., mRNA) vaccine is codon-optimized. In some embodiments, at least one RNA polynucleotide encodes at least one antigenic polypeptide comprising an amino acid sequence identified by any one of SEQ ID NO: 31-59, 65-72, or 73-183 (Tables 2, 5 or 7; see also amino acid sequences of Tables 3 and 6) and is codon optimized mRNA.
• In some embodiments, a RNA (e.g., mRNA) vaccine further comprising an adjuvant.
• Tables 3 and 6 provide National Center for Biotechnology Information (NCBI) accession numbers of interest. It should be understood that the phrase “an amino acid sequence of Tables 3 and 6” refers to an amino acid sequence identified by one or more NCBI accession numbers listed in Tables 3 and 6. Each of the amino acid sequences, and variants having greater than 95% identity or greater than 98% identity to each of the amino acid sequences encompassed by the accession numbers of Tables 3 and 6 are included within the constructs (polynucleotides/polypeptides) of the present disclosure.
• In some embodiments, at least one mRNA polynucleotide is encoded by a nucleic acid comprising a sequence identified by any one of SEQ ID NO: 1-28, 62-64 or 184-294 (Tables 1, 4 and 8) and having less than 80% identity to wild-type mRNA sequence. In some embodiments, at least one mRNA polynucleotide is encoded by a nucleic acid comprising a sequence identified by any one of SEQ ID NO: 1-28, 62-64 or 184-294 (Tables 1, 4 and 8) and having less than 75%, 85% or 95% identity to a wild-type mRNA sequence. In some embodiments, at least one mRNA polynucleotide is encoded by nucleic acid comprising a sequence identified by any one of SEQ ID NO: 1-28, 62-64 or 184-294 (Tables 1, 4 and 8) and having less than 50-80%, 60-80%, 40-80%, 30-80%, 70-80%, 75-80% or 78-80% identity to wild-type mRNA sequence. In some embodiments, at least one mRNA polynucleotide is encoded by a nucleic acid comprising a sequence identified by any one of SEQ ID NO: 1-28, 62-64 or 184-294 (Tables 1, 4 and 8) and having less than 40-85%, 50-85%, 60-85%, 30-85%, 70-85%, 75-85% or 80-85% identity to wild-type mRNA sequence. In some embodiments, at least one mRNA polynucleotide is encoded by a nucleic acid comprising a sequence identified by any one of SEQ ID NO: 1-28, 62-64 or 184-294 (Tables 1, 4 and 8) and having less than 40-90%, 50-90%, 60-90%, 30-90%, 70-90%, 75-90%, 80-90%, or 85-90% identity to wild-type mRNA sequence.
• In some embodiments, at least one RNA polynucleotide encodes at least one antigenic polypeptide comprising an amino acid sequence identified by any one of SEQ ID NO: 31-59, 65-72, or 73-183 (Tables 2, 5 or 7; see also amino acid sequences of Tables 3 and 6) and having at least 80% (e.g., 85%, 90%, 95%, 98%, 99%) identity to wild-type mRNA sequence, but does not include wild-type mRNA sequence.
• In some embodiments, at least one RNA polynucleotide encodes at least one antigenic polypeptide comprising an amino acid sequence identified by any one of SEQ ID NO: 31-59, 65-72, or 73-183 (Tables 2, 5 or 7; see also amino acid sequences of Tables 3 and 6) and has less than 95%, 90%, 85%, 80% or 75% identity to wild-type mRNA sequence. In some embodiments, at least one RNA polynucleotide encodes at least one antigenic polypeptide comprising an amino acid sequence identified by any one of SEQ ID NO: 31-59, 65-72, or 73-183 (Tables 2, 5 or 7; see also amino acid sequences of Tables 3 and 6) and has 30-80%, 40-80%, 50-80%, 60-80%, 70-80%, 75-80% or 78-80%, 30-85%, 40-85%, 50-805%, 60-85%, 70-85%, 75-85% or 78-85%, 30-90%, 40-90%, 50-90%, 60-90%, 70-90%, 75-90%, 80-90% or 85-90% identity to wild-type mRNA sequence.
• In some embodiments, at least one RNA polynucleotide encodes at least one antigenic polypeptide having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to an amino acid sequence identified by any one of SEQ ID NO: 31-59, 65-72, or 73-183 (Tables 2, 5 or 7; see also amino acid sequences of Tables 3 and 6). In some embodiments, at least one RNA polynucleotide encodes at least one antigenic polypeptide having 95%-99% identity to an amino acid sequence identified by any one of SEQ ID NO: 31-59, 65-72, or 73-183 (Tables 2, 5 or 7; see also amino acid sequences of Tables 3 and 6).
• In some embodiments, at least one RNA polynucleotide encodes at least one antigenic polypeptide having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to amino acid sequence identified by any one of SEQ ID NO: 31-59, 65-72, or 73-183 (Tables 2, 5 or 7; see also amino acid sequences of Tables 3 and 6) and having membrane fusion activity. In some embodiments, at least one RNA polynucleotide encodes at least one antigenic polypeptide having 95%-99% identity to amino acid sequence identified by any one of SEQ ID NO: 31-59, 65-72, or 73-183 (Tables 2, 5 or 7; see also amino acid sequences of Tables 3 and 6) and having membrane fusion activity.
• In some embodiments, at least one RNA polynucleotide encodes at least one antigenic polypeptide (e.g., at least one HPV antigenic polypeptide, at least one HSV antigenic polypeptide and/or at least one Chlamydia (e.g., C. trachomatis) antigenic polypeptide) that attaches to cell receptors.
• In some embodiments, at least one RNA polynucleotide encodes at least one antigenic polypeptide (e.g., at least one HPV antigenic polypeptide, at least one HSV antigenic polypeptide and/or at least one Chlamydia (e.g., C. trachomatis) antigenic polypeptide) that causes fusion of viral and cellular membranes.
• In some embodiments, at least one RNA polynucleotide encodes at least one antigenic polypeptide (e.g., at least one HPV antigenic polypeptide, at least one HSV antigenic polypeptide and/or at least one Chlamydia (e.g., C. trachomatis) antigenic polypeptide) that is responsible for binding of the virus to a cell being infected.
• Some embodiments of the present disclosure provide a vaccine that includes at least one ribonucleic acid (RNA) (e.g., mRNA) polynucleotide having an open reading frame encoding at least one antigenic polypeptide (e.g., at least one HPV antigenic polypeptide, at least one HSV antigenic polypeptide and/or at least one Chlamydia (e.g., C. trachomatis) antigenic polypeptide), at least one 5′ terminal cap and at least one chemical modification, formulated within a lipid nanoparticle.
• In some embodiments, a 5′ terminal cap is 7mG(5′)ppp(5′)NlmpNp.
• In some embodiments, at least one chemical modification is selected from pseudouridine, N1-methylpseudouridine, N1-ethylpseudouridine, 2-thiouridine, 4′-thiouridine, 5-methylcytosine, 5-methyluridine, 2-thio-1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methoxyuridine and 2′-O-methyl uridine. In some embodiments, the chemical modification is in the 5-position of the uracil. In some embodiments, the chemical modification is a N1-methylpseudouridine. In some embodiments, the chemical modification is a N1-ethylpseudouridine.
• In some embodiments, a lipid nanoparticle comprises a cationic lipid, a PEG-modified lipid, a sterol and a non-cationic lipid. In some embodiments, a cationic lipid is an ionizable cationic lipid and the non-cationic lipid is a neutral lipid, and the sterol is a cholesterol. In some embodiments, a cationic lipid is selected from the group consisting of 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), (12Z,15Z)—N,N-dimethyl-2-nonylhenicosa-12,15-dien-1-amine (L608), and N,N-dimethyl-1-[(1S,2R)-2-octylcyclopropyl]heptadecan-8-amine (L530).
• In some embodiments, the lipid is
• 
• In some embodiments, the lipid is
• 
• In some embodiments, a lipid nanoparticle comprises compounds of Formula (I) and/or Formula (II), discussed below.
• In some embodiments, a lipid nanoparticle comprises Compounds 3, 18, 20, 25, 26, 29, 30, 60, 108-112, or 122, as discussed below
• Some embodiments of the present disclosure provide a vaccine that includes at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding at least one antigenic polypeptide (e.g., at least one HPV antigenic polypeptide, at least one HSV antigenic polypeptide and/or at least one Chlamydia (e.g., C. trachomatis) antigenic polypeptide), wherein at least 80% (e.g., 85%, 90%, 95%, 98%, 99%) of the uracil in the open reading frame have a chemical modification, optionally wherein the vaccine is formulated in a lipid nanoparticle (e.g., a lipid nanoparticle comprises a cationic lipid, a PEG-modified lipid, a sterol and a non-cationic lipid).
• In some embodiments, 100% of the uracil in the open reading frame have a chemical modification. In some embodiments, a chemical modification is in the 5-position of the uracil. In some embodiments, a chemical modification is a N1-methyl pseudouridine. In some embodiments, 100% of the uracil in the open reading frame have a N1-methyl pseudouridine in the 5-position of the uracil.
• In some embodiments, an open reading frame of a RNA (e.g., mRNA) polynucleotide encodes at least two antigenic polypeptides (e.g., at least one HPV antigenic polypeptide, at least one HSV antigenic polypeptide and/or at least one Chlamydia (e.g., C. trachomatis) antigenic polypeptide). In some embodiments, the open reading frame encodes at least five or at least ten antigenic polypeptides. In some embodiments, the open reading frame encodes at least 100 antigenic polypeptides. In some embodiments, the open reading frame encodes 2-100 antigenic polypeptides.
• In some embodiments, a vaccine comprises at least two RNA (e.g., mRNA) polynucleotides, each having an open reading frame encoding at least one antigenic polypeptide (e.g., at least one HPV antigenic polypeptide, at least one HSV antigenic polypeptide and/or at least one Chlamydia (e.g., C. trachomatis) antigenic polypeptide). In some embodiments, the vaccine comprises at least five or at least ten RNA (e.g., mRNA) polynucleotides, each having an open reading frame encoding at least one antigenic polypeptide or an immunogenic fragment thereof. In some embodiments, the vaccine comprises at least 100 RNA (e.g., mRNA) polynucleotides, each having an open reading frame encoding at least one antigenic polypeptide. In some embodiments, the vaccine comprises 2-100 RNA (e.g., mRNA) polynucleotides, each having an open reading frame encoding at least one antigenic polypeptide.
• In some embodiments, at least one antigenic polypeptide (e.g., at least one HPV antigenic polypeptide, at least one HSV antigenic polypeptide and/or at least one Chlamydia (e.g., C. trachomatis) antigenic polypeptide) is fused to a signal peptide. In some embodiments, the signal peptide is selected from: a HuIgGk signal peptide (METPAQLLFLLLLWLPDTTG; SEQ ID NO: 304); IgE heavy chain epsilon-1 signal peptide (MDWTWILFLVAAATRVHS; SEQ ID NO: 305); Japanese encephalitis PRM signal sequence (MLGSNSGQRVVFTILLLLVAPAYS; SEQ ID NO: 306), VSVg protein signal sequence (MKCLLYLAFLFIGVNCA; SEQ ID NO: 307) and Japanese encephalitis JEV signal sequence (MWLVSLAIVTACAGA; SEQ ID NO: 308).
• In some embodiments, the signal peptide is fused to the N-terminus of at least one antigenic polypeptide. In some embodiments, a signal peptide is fused to the C-terminus of at least one antigenic polypeptide.
• In some embodiments, at least one antigenic polypeptide (e.g., at least one HPV antigenic polypeptide, at least one HSV antigenic polypeptide and/or at least one Chlamydia (e.g., C. trachomatis) antigenic polypeptide) comprises a mutated N-linked glycosylation site.
• Also provided herein is a RNA (e.g., mRNA) vaccine of any one of the foregoing paragraphs (e.g., at least one HPV antigenic polypeptide, at least one HSV antigenic polypeptide and/or at least one Chlamydia (e.g., C. trachomatis) antigenic polypeptide), formulated in a nanoparticle (e.g., a lipid nanoparticle).
• In some embodiments, the nanoparticle has a mean diameter of 50-200 nm. In some embodiments, the nanoparticle is a lipid nanoparticle. In some embodiments, the lipid nanoparticle comprises a cationic lipid, a PEG-modified lipid, a sterol and a non-cationic lipid. In some embodiments, the lipid nanoparticle comprises a molar ratio of about 20-60% cationic lipid, 0.5-15% PEG-modified lipid, 25-55% sterol, and 25% non-cationic lipid. In some embodiments, the cationic lipid is an ionizable cationic lipid and the non-cationic lipid is a neutral lipid, and the sterol is a cholesterol. In some embodiments, the cationic lipid is selected from 2,2-dilinoleyl-4-dimethylaminoethyl[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319).
• In some embodiments, a lipid nanoparticle comprises compounds of Formula (I) and/or Formula (II), discussed below.
• In some embodiments, a STD RNA (e.g., mRNA) vaccine is formulated in a lipid nanoparticle that comprises a compound selected from Compounds 3, 18, 20, 25, 26, 29, 30, 60, 108-112 and 122, described below.
• In some embodiments, the nanoparticle has a polydispersity value of less than 0.4 (e.g., less than 0.3, 0.2 or 0.1).
• In some embodiments, the nanoparticle has a net neutral charge at a neutral pH value.
• In some embodiments, the RNA (e.g., mRNA) vaccine is multivalent.
• Some embodiments of the present disclosure provide methods of inducing an antigen specific immune response in a subject, comprising administering to the subject any of the RNA (e.g., mRNA) vaccine as provided herein in an amount effective to produce an antigen-specific immune response. In some embodiments, the RNA (e.g., mRNA) vaccine is a HPV vaccine, a HSV vaccine or a Chlamydia (e.g., C. trachomatis) vaccine. In some embodiments, the RNA (e.g., mRNA) vaccine is a combination vaccine comprising a combination of HPV vaccine, a HSV vaccine and Chlamydia (e.g., C. trachomatis) vaccine.
• In some embodiments, an antigen-specific immune response comprises a T cell response or a B cell response.
• In some embodiments, a method of producing an antigen-specific immune response comprises administering to a subject a single dose (no booster dose) of a RNA (e.g., mRNA) vaccine of the present disclosure. In some embodiments, the RNA (e.g., mRNA) vaccine is a HPV vaccine, a HSV vaccine and/or Chlamydia (e.g., C. trachomatis) vaccine. In some embodiments, the RNA (e.g., mRNA) vaccine is a combination vaccine comprising a combination of any two or more of the foregoing vaccines.
• In some embodiments, a method further comprises administering to the subject a second (booster) dose of a RNA (e.g., mRNA) vaccine. Additional doses of a RNA (e.g., mRNA) vaccine may be administered.
• In some embodiments, the subjects exhibit a seroconversion rate of at least 80% (e.g., at least 85%, at least 90%, or at least 95%) following the first dose or the second (booster) dose of the vaccine. Seroconversion is the time period during which a specific antibody develops and becomes detectable in the blood. After seroconversion has occurred, a virus can be detected in blood tests for the antibody. During an infection or immunization, antigens enter the blood, and the immune system begins to produce antibodies in response. Before seroconversion, the antigen itself may or may not be detectable, but antibodies are considered absent. During seroconversion, antibodies are present but not yet detectable. Any time after seroconversion, the antibodies can be detected in the blood, indicating a prior or current infection.
• In some embodiments, a RNA (e.g., mRNA) vaccine is administered to a subject by intradermal, intramuscular injection, or by intranasal administration.
• Some embodiments, of the present disclosure provide methods of inducing an antigen specific immune response in a subject, including administering to a subject a RNA (e.g., mRNA) vaccine in an effective amount to produce an antigen specific immune response in a subject. Antigen-specific immune responses in a subject may be determined, in some embodiments, by assaying for antibody titer (for titer of an antibody that binds to a HPV antigenic polypeptide, a HSV antigenic polypeptide and/or a Chlamydia (e.g., C. trachomatis) antigenic polypeptide) following administration to the subject of any of the RNA (e.g., mRNA) vaccines of the present disclosure. In some embodiments, the anti-antigenic polypeptide antibody titer produced in the subject is increased by at least 1 log relative to a control. In some embodiments, the anti-antigenic polypeptide antibody titer produced in the subject is increased by 1-3 log relative to a control.
• In some embodiments, the anti-antigenic polypeptide antibody titer produced in a subject is increased at least 2 times relative to a control. In some embodiments, the anti-antigenic polypeptide antibody titer produced in the subject is increased at least 5 times relative to a control. In some embodiments, the anti-antigenic polypeptide antibody titer produced in the subject is increased at least 10 times relative to a control. In some embodiments, the anti-antigenic polypeptide antibody titer produced in the subject is increased 2-10 times relative to a control.
• In some embodiments, the control is an anti-antigenic polypeptide antibody titer produced in a subject who has not been administered a RNA (e.g., mRNA) vaccine of the present disclosure. In some embodiments, the control is an anti-antigenic polypeptide antibody titer produced in a subject who has been administered a live attenuated or inactivated HPV, HSV and/or Chlamydia vaccine (see, e.g., Ren J. et al. J of Gen. Virol. 2015; 96: 1515-1520), or wherein the control is an anti-antigenic polypeptide antibody titer produced in a subject who has been administered a recombinant or purified HPV, HSV and/or Chlamydia protein vaccine. In some embodiments, the control is an anti-antigenic polypeptide antibody titer produced in a subject who has been administered a HPV, HSV and/or Chlamydia virus-like particle (VLP) vaccine (see, e.g., Cox R G et al., J Virol. 2014 June; 88(11): 6368-6379).
• A RNA (e.g., mRNA) vaccine of the present disclosure is administered to a subject in an effective amount (an amount effective to induce an immune response). In some embodiments, the effective amount is a dose equivalent to an at least 2-fold, at least 4-fold, at least 10-fold, at least 100-fold, at least 1000-fold reduction in the standard of care dose of a recombinant HPV, HSV and/or Chlamydia protein vaccine, wherein the anti-antigenic polypeptide antibody titer produced in the subject is equivalent to an anti-antigenic polypeptide antibody titer produced in a control subject administered the standard of care dose of a recombinant HPV, HSV and/or Chlamydia protein vaccine, a purified HPV, HSV and/or Chlamydia protein vaccine, a live attenuated HPV, HSV and/or Chlamydia vaccine, an inactivated HPV, HSV and/or Chlamydia vaccine, or a HPV, HSV and/or Chlamydia VLP vaccine. In some embodiments, the effective amount is a dose equivalent to 2-1000-fold reduction in the standard of care dose of a recombinant HPV, HSV and/or Chlamydia protein vaccine, wherein the anti-antigenic polypeptide antibody titer produced in the subject is equivalent to an anti-antigenic polypeptide antibody titer produced in a control subject administered the standard of care dose of a recombinant HPV, HSV and/or Chlamydia protein vaccine, a purified HPV, HSV and/or Chlamydia protein vaccine, a live attenuated HPV, HSV and/or Chlamydia vaccine, an inactivated HPV, HSV and/or Chlamydia vaccine, or a HPV, HSV and/or Chlamydia VLP vaccine.
• In some embodiments, the control is an anti-antigenic polypeptide antibody titer produced in a subject who has been administered a virus-like particle (VLP) vaccine comprising structural proteins of HPV, HSV and/or Chlamydia.
• In some embodiments, the RNA (e.g., mRNA) vaccine is formulated in an effective amount to produce an antigen specific immune response in a subject.
• In some embodiments, the effective amount is a total dose of 25 μg to 1000 μg, or 50 μg to 1000 μg. In some embodiments, the effective amount is a total dose of 100 μg. In some embodiments, the effective amount is a dose of 25 μg administered to the subject a total of two times. In some embodiments, the effective amount is a dose of 100 μg administered to the subject a total of two times. In some embodiments, the effective amount is a dose of 400 μg administered to the subject a total of two times. In some embodiments, the effective amount is a dose of 500 μg administered to the subject a total of two times.
• In some embodiments, the efficacy (or effectiveness) of a RNA (e.g., mRNA) vaccine is greater than 60%. In some embodiments, the RNA (e.g., mRNA) polynucleotide of the vaccine at least one HPV antigenic polypeptide, at least one HSV antigenic polypeptide and/or at least one Chlamydia (e.g., C. trachomatis) antigenic polypeptide.
• Vaccine efficacy may be assessed using standard analyses (see, e.g., Weinberg et al., J Infect Dis. 2010 Jun. 1; 201(11):1607-10). For example, vaccine efficacy may be measured by double-blind, randomized, clinical controlled trials. Vaccine efficacy may be expressed as a proportionate reduction in disease attack rate (AR) between the unvaccinated (ARU) and vaccinated (ARV) study cohorts and can be calculated from the relative risk (RR) of disease among the vaccinated group with use of the following formulas:
• 
  Efficacy=(ARU−ARV)/ARU×100; and
• 
  Efficacy=(1−RR)×100.
• Likewise, vaccine effectiveness may be assessed using standard analyses (see, e.g., Weinberg et al., J Infect Dis. 2010 Jun. 1; 201(11):1607-10). Vaccine effectiveness is an assessment of how a vaccine (which may have already proven to have high vaccine efficacy) reduces disease in a population. This measure can assess the net balance of benefits and adverse effects of a vaccination program, not just the vaccine itself, under natural field conditions rather than in a controlled clinical trial. Vaccine effectiveness is proportional to vaccine efficacy (potency) but is also affected by how well target groups in the population are immunized, as well as by other non-vaccine-related factors that influence the ‘real-world’ outcomes of hospitalizations, ambulatory visits, or costs. For example, a retrospective case control analysis may be used, in which the rates of vaccination among a set of infected cases and appropriate controls are compared. Vaccine effectiveness may be expressed as a rate difference, with use of the odds ratio (OR) for developing infection despite vaccination:
• 
  Effectiveness=(1−OR)×100.
• In some embodiments, the efficacy (or effectiveness) of a RNA (e.g., mRNA) vaccine is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, or at least 90%.
• In some embodiments, the vaccine immunizes the subject against HPV, a HSV antigenic polypeptide and/or Chlamydia (e.g., C. trachomatis) for up to 2 years. In some embodiments, the vaccine immunizes the subject against HPV, HSV and/or Chlamydia (e.g., C. trachomatis) for more than 2 years, more than 3 years, more than 4 years, or for 5-10 years.
• In some embodiments, the subject is about 5 years old or younger. For example, the subject may be between the ages of about 1 year and about 5 years (e.g., about 1, 2, 3, 5 or 5 years), or between the ages of about 6 months and about 1 year (e.g., about 6, 7, 8, 9, 10, 11 or 12 months). In some embodiments, the subject is about 12 months or younger (e.g., 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 months or 1 month). In some embodiments, the subject is about 6 months or younger.
• In some embodiments, the subject was born full term (e.g., about 37-42 weeks). In some embodiments, the subject was born prematurely, for example, at about 36 weeks of gestation or earlier (e.g., about 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26 or 25 weeks). For example, the subject may have been born at about 32 weeks of gestation or earlier. In some embodiments, the subject was born prematurely between about 32 weeks and about 36 weeks of gestation. In such subjects, a RNA (e.g., mRNA) vaccine may be administered later in life, for example, at the age of about 6 months to about 5 years, or older.
• In some embodiments, the subject is a young adult between the ages of about 20 years and about 50 years (e.g., about 20, 25, 30, 35, 40, 45 or 50 years old).
• In some embodiments, the subject is an elderly subject about 60 years old, about 70 years old, or older (e.g., about 60, 65, 70, 75, 80, 85 or 90 years old).
• In some embodiments, the subject has been exposed to HPV, HSV and/or Chlamydia (e.g., C. trachomatis); the subject is infected with HPV, HSV and/or Chlamydia (e.g., C. trachomatis); or subject is at risk of infection by HPV, HSV and/or Chlamydia (e.g., C. trachomatis).
• In some embodiments, the subject is immunocompromised (has an impaired immune system, e.g., has an immune disorder or autoimmune disorder).
• In some embodiments the nucleic acid vaccines described herein are chemically modified. In other embodiments the nucleic acid vaccines are unmodified.
• Yet other aspects provide compositions for and methods of vaccinating a subject comprising administering to the subject a nucleic acid vaccine comprising one or more RNA polynucleotides having an open reading frame encoding a first respiratory virus antigenic polypeptide, wherein the RNA polynucleotide does not include a stabilization element, and wherein an adjuvant is not coformulated or co-administered with the vaccine.
• In other aspects the invention is a composition for or method of vaccinating a subject comprising administering to the subject a nucleic acid vaccine comprising one or more RNA polynucleotides having an open reading frame encoding a first antigenic polypeptide wherein a dosage of between 10 μg/kg and 400 μg/kg of the nucleic acid vaccine is administered to the subject. In some embodiments the dosage of the RNA polynucleotide is 1-5 μg, 5-10 μg, 10-15 μg, 15-20 μg, 10-25 μg, 20-25 μg, 20-50 μg, 30-50 μg, 40-50 μg, 40-60 μg, 60-80 μg, 60-100 μg, 50-100 μg, 80-120 μg, 40-120 μg, 40-150 μg, 50-150 μg, 50-200 μg, 80-200 μg, 100-200 μg, 120-250 μg, 150-250 μg, 180-280 μg, 200-300 μg, 50-300 μg, 80-300 μg, 100-300 μg, 40-300 μg, 50-350 μg, 100-350 μg, 200-350 μg, 300-350 μg, 320-400 μg, 40-380 μg, 40-100 μg, 100-400 μg, 200-400 μg, or 300-400 μg per dose. In some embodiments, the nucleic acid vaccine is administered to the subject by intradermal or intramuscular injection. In some embodiments, the nucleic acid vaccine is administered to the subject on day zero. In some embodiments, a second dose of the nucleic acid vaccine is administered to the subject on day twenty one.
• In some embodiments, a dosage of 25 micrograms of the RNA polynucleotide is included in the nucleic acid vaccine administered to the subject. In some embodiments, a dosage of 100 micrograms of the RNA polynucleotide is included in the nucleic acid vaccine administered to the subject. In some embodiments, a dosage of 50 micrograms of the RNA polynucleotide is included in the nucleic acid vaccine administered to the subject. In some embodiments, a dosage of 75 micrograms of the RNA polynucleotide is included in the nucleic acid vaccine administered to the subject. In some embodiments, a dosage of 150 micrograms of the RNA polynucleotide is included in the nucleic acid vaccine administered to the subject. In some embodiments, a dosage of 400 micrograms of the RNA polynucleotide is included in the nucleic acid vaccine administered to the subject. In some embodiments, a dosage of 200 micrograms of the RNA polynucleotide is included in the nucleic acid vaccine administered to the subject. In some embodiments, the RNA polynucleotide accumulates at a 100 fold higher level in the local lymph node in comparison with the distal lymph node. In other embodiments the nucleic acid vaccine is chemically modified and in other embodiments the nucleic acid vaccine is not chemically modified.
• Aspects of the invention provide a nucleic acid vaccine comprising one or more RNA polynucleotides having an open reading frame encoding a first antigenic polypeptide, wherein the RNA polynucleotide does not include a stabilization element, and a pharmaceutically acceptable carrier or excipient, wherein an adjuvant is not included in the vaccine. In some embodiments, the stabilization element is a histone stem-loop. In some embodiments, the stabilization element is a nucleic acid sequence having increased GC content relative to wild type sequence.
• Aspects of the invention provide nucleic acid vaccines comprising one or more RNA polynucleotides having an open reading frame encoding a first antigenic polypeptide, wherein the RNA polynucleotide is present in the formulation for in vivo administration to a host, which confers an antibody titer superior to the criterion for seroprotection for the first antigen for an acceptable percentage of human subjects. In some embodiments, the antibody titer produced by the mRNA vaccines of the invention is a neutralizing antibody titer. In some embodiments the neutralizing antibody titer is greater than a protein vaccine. In other embodiments the neutralizing antibody titer produced by the mRNA vaccines of the invention is greater than an adjuvanted protein vaccine. In yet other embodiments the neutralizing antibody titer produced by the mRNA vaccines of the invention is 1,000-10,000, 1,200-10,000, 1,400-10,000, 1,500-10,000, 1,000-5,000, 1,000-4,000, 1,800-10,000, 2000-10,000, 2,000-5,000, 2,000-3,000, 2,000-4,000, 3,000-5,000, 3,000-4,000, or 2,000-2,500. A neutralization titer is typically expressed as the highest serum dilution required to achieve a 50% reduction in the number of plaques.
• Also provided are nucleic acid vaccines comprising one or more RNA polynucleotides having an open reading frame encoding a first antigenic polypeptide, wherein the RNA polynucleotide is present in a formulation for in vivo administration to a host for eliciting a longer lasting high antibody titer than an antibody titer elicited by an mRNA vaccine having a stabilizing element or formulated with an adjuvant and encoding the first antigenic polypeptide. In some embodiments, the RNA polynucleotide is formulated to produce a neutralizing antibodies within one week of a single administration. In some embodiments, the adjuvant is selected from a cationic peptide and an immunostimulatory nucleic acid. In some embodiments, the cationic peptide is protamine.
• Aspects provide nucleic acid vaccines comprising one or more RNA polynucleotides having an open reading frame comprising at least one chemical modification or optionally no chemical modification, the open reading frame encoding a first antigenic polypeptide, wherein the RNA polynucleotide is present in the formulation for in vivo administration to a host such that the level of antigen expression in the host significantly exceeds a level of antigen expression produced by an mRNA vaccine having a stabilizing element or formulated with an adjuvant and encoding the first antigenic polypeptide.
• Other aspects provide nucleic acid vaccines comprising one or more RNA polynucleotides having an open reading frame comprising at least one chemical modification or optionally no chemical modification, the open reading frame encoding a first antigenic polypeptide, wherein the vaccine has at least 10 fold less RNA polynucleotide than is required for an unmodified mRNA vaccine to produce an equivalent antibody titer. In some embodiments, the RNA polynucleotide is present in a dosage of 25-100 micrograms.
• Aspects of the invention also provide a unit of use vaccine, comprising between 10 ug and 400 ug of one or more RNA polynucleotides having an open reading frame comprising at least one chemical modification or optionally no chemical modification, the open reading frame encoding a first antigenic polypeptide, and a pharmaceutically acceptable carrier or excipient, formulated for delivery to a human subject. In some embodiments, the vaccine further comprises a cationic lipid nanoparticle.
• Aspects of the invention provide methods of creating, maintaining or restoring antigenic memory to a respiratory virus strain in an individual or population of individuals comprising administering to said individual or population an antigenic memory booster nucleic acid vaccine comprising (a) at least one RNA polynucleotide, said polynucleotide comprising at least one chemical modification or optionally no chemical modification and two or more codon-optimized open reading frames, said open reading frames encoding a set of reference antigenic polypeptides, and (b) optionally a pharmaceutically acceptable carrier or excipient. In some embodiments, the vaccine is administered to the individual via a route selected from the group consisting of intramuscular administration, intradermal administration and subcutaneous administration. In some embodiments, the administering step comprises contacting a muscle tissue of the subject with a device suitable for injection of the composition. In some embodiments, the administering step comprises contacting a muscle tissue of the subject with a device suitable for injection of the composition in combination with electroporation.
• Aspects of the invention provide methods of vaccinating a subject comprising administering to the subject a single dosage of between 25 ug/kg and 400 ug/kg of a nucleic acid vaccine comprising one or more RNA polynucleotides having an open reading frame encoding a first antigenic polypeptide in an effective amount to vaccinate the subject.
• Other aspects provide nucleic acid vaccines comprising one or more RNA polynucleotides having an open reading frame comprising at least one chemical modification, the open reading frame encoding a first antigenic polypeptide, wherein the vaccine has at least 10 fold less RNA polynucleotide than is required for an unmodified mRNA vaccine to produce an equivalent antibody titer. In some embodiments, the RNA polynucleotide is present in a dosage of 25-100 micrograms.
• Other aspects provide nucleic acid vaccines comprising an LNP formulated RNA polynucleotide having an open reading frame comprising no modifications (unmodified), the open reading frame encoding a first antigenic polypeptide, wherein the vaccine has at least 10 fold less RNA polynucleotide than is required for an unmodified mRNA vaccine not formulated in a LNP to produce an equivalent antibody titer. In some embodiments, the RNA polynucleotide is present in a dosage of 25-100 micrograms.
• The data presented in the Examples demonstrate significant enhanced immune responses using the formulations of the invention. The data demonstrated the effectiveness of both chemically modified and unmodified RNA vaccines of the invention. Surprisingly, in contrast to prior art reports that it was preferable to use chemically unmodified mRNA formulated in a carrier for the production of vaccines, it was discovered herein that chemically modified mRNA-LNP vaccines required a much lower effective mRNA dose than unmodified mRNA, i.e., tenfold less than unmodified mRNA when formulated in carriers other than LNP. Both the chemically modified and unmodified RNA vaccines of the invention produce better immune responses than mRNA vaccines formulated in a different lipid carrier.
• In other aspects the invention encompasses a method of treating an elderly subject age 60 years or older comprising administering to the subject a nucleic acid vaccine comprising one or more RNA polynucleotides having an open reading frame encoding a respiratory virus antigenic polypeptide in an effective amount to vaccinate the subject.
• In other aspects the invention encompasses a method of treating a young subject age 17 years or younger comprising administering to the subject a nucleic acid vaccine comprising one or more RNA polynucleotides having an open reading frame encoding a respiratory virus antigenic polypeptide in an effective amount to vaccinate the subject.
• In other aspects the invention encompasses a method of treating an adult subject comprising administering to the subject a nucleic acid vaccine comprising one or more RNA polynucleotides having an open reading frame encoding a respiratory virus antigenic polypeptide in an effective amount to vaccinate the subject.
• In some aspects the invention is a method of vaccinating a subject with a combination vaccine including at least two nucleic acid sequences encoding respiratory antigens wherein the dosage for the vaccine is a combined therapeutic dosage wherein the dosage of each individual nucleic acid encoding an antigen is a sub therapeutic dosage. In some embodiments, the combined dosage is 25 micrograms of the RNA polynucleotide in the nucleic acid vaccine administered to the subject. In some embodiments, the combined dosage is 100 micrograms of the RNA polynucleotide in the nucleic acid vaccine administered to the subject. In some embodiments the combined dosage is 50 micrograms of the RNA polynucleotide in the nucleic acid vaccine administered to the subject. In some embodiments, the combined dosage is 75 micrograms of the RNA polynucleotide in the nucleic acid vaccine administered to the subject. In some embodiments, the combined dosage is 150 micrograms of the RNA polynucleotide in the nucleic acid vaccine administered to the subject. In some embodiments, the combined dosage is 400 micrograms of the RNA polynucleotide in the nucleic acid vaccine administered to the subject. In some embodiments, the sub therapeutic dosage of each individual nucleic acid encoding an antigen is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 micrograms. In other embodiments the nucleic acid vaccine is chemically modified and in other embodiments the nucleic acid vaccine is not chemically modified.
• The RNA polynucleotide is one of SEQ ID NO: 1-28, 62-64, 184-294 431-461 and includes at least one chemical modification. In other embodiments the RNA polynucleotide is one of SEQ ID NO: 1-28, 62-64, 184-294 431-461 and does not include any nucleotide modifications, or is unmodified. In yet other embodiments the at least one RNA polynucleotide encodes an antigenic protein of any of SEQ ID NO: 31-59, 65-72, or 73-183 and includes at least one chemical modification. In other embodiments the RNA polynucleotide encodes an antigenic protein of any of SEQ ID NO: 31-59, 65-72, or 73-183 and does not include any nucleotide modifications, or is unmodified.
• In preferred aspects, vaccines of the invention (e.g., LNP-encapsulated mRNA vaccines) produce prophylactically- and/or therapeutically-efficacious levels, concentrations and/or titers of antigen-specific antibodies in the blood or serum of a vaccinated subject. As defined herein, the term antibody titer refers to the amount of antigen-specific antibody produces in s subject, e.g., a human subject. In exemplary embodiments, antibody titer is expressed as the inverse of the greatest dilution (in a serial dilution) that still gives a positive result. In exemplary embodiments, antibody titer is determined or measured by enzyme-linked immunosorbent assay (ELISA). In exemplary embodiments, antibody titer is determined or measured by neutralization assay, e.g., by microneutralization assay. In certain aspects, antibody titer measurement is expressed as a ratio, such as 1:40, 1:100, etc.
• In exemplary embodiments of the invention, an efficacious vaccine produces an antibody titer of greater than 1:40, greater that 1:100, greater than 1:400, greater than 1:1000, greater than 1:2000, greater than 1:3000, greater than 1:4000, greater than 1:500, greater than 1:6000, greater than 1:7500, greater than 1:10000. In exemplary embodiments, the antibody titer is produced or reached by 10 days following vaccination, by 20 days following vaccination, by 30 days following vaccination, by 40 days following vaccination, or by 50 or more days following vaccination. In exemplary embodiments, the titer is produced or reached following a single dose of vaccine administered to the subject. In other embodiments, the titer is produced or reached following multiple doses, e.g., following a first and a second dose (e.g., a booster dose.)
• In exemplary aspects of the invention, antigen-specific antibodies are measured in units of μg/ml or are measured in units of IU/L (International Units per liter) or mIU/ml (milli International Units per ml). In exemplary embodiments of the invention, an efficacious vaccine produces >0.5 μg/ml, >0.1 μg/ml, >0.2 μg/ml, >0.35 μg/ml, >0.5 μg/ml, >1 μg/ml, >2 μg/ml, >5 μg/ml or >10 μg/ml. In exemplary embodiments of the invention, an efficacious vaccine produces >10 mIU/ml, >20 mIU/ml, >50 mIU/ml, >100 mIU/ml, >200 mIU/ml, >500 mIU/ml or >1000 mIU/ml. In exemplary embodiments, the antibody level or concentration is produced or reached by 10 days following vaccination, by 20 days following vaccination, by 30 days following vaccination, by 40 days following vaccination, or by 50 or more days following vaccination. In exemplary embodiments, the level or concentration is produced or reached following a single dose of vaccine administered to the subject. In other embodiments, the level or concentration is produced or reached following multiple doses, e.g., following a first and a second dose (e.g., a booster dose.) In exemplary embodiments, antibody level or concentration is determined or measured by enzyme-linked immunosorbent assay (ELISA). In exemplary embodiments, antibody level or concentration is determined or measured by neutralization assay, e.g., by microneutralization assay.
• The details of various embodiments of the disclosure are set forth in the description below. Other features, objects, and advantages of the disclosure will be apparent from the description and from the claims.
BRIEF DESCRIPTION OF THE DRAWINGS
• FIGS. 1A-1B are western blot graphs showing the in vitro expression of Chlamydia trachomatis antigens (Ct089, Ct858, and Ct875) encoded by candidate mRNA vaccines. FIG. 2A shows the expression of these antigens in concentrated or dilute supernatant of HEK293K cells. Expression of Ct875 and Ct089 was detected in the supernatants. FIG. 2B shows the expression of these antigens in HEK293F cell lysates. Expression of Ct858 and Ct089 was detected in the cell lysates.
• FIGS. 2A-2B are western blot graphs showing the in vitro expression of Chlamydia trachomatis antigens encoded by candidate mRNA vaccines. All antigens tested expressed in HEK293F cells. FIG. 2A shows the expression of PmPG_pd, Ct460, and Ct622 in concentrated supernatant of HEK293K cells. FIG. 2B shows the expression of Cta1 in HEK293F cell lysates.
• FIG. 3 is a western blot graph showing the in vitro expression of Chlamydia trachomatis antigens (Ct 443 and Ct812pd_D) encoded by candidate mRNA vaccines. The expression of Ct443 and Ct812pd_D were detected in the cell lysates.
• FIG. 4 shows data from an ELISA of sera collected from mice bled on day 21 (post prime; left graph) and on day 35 (post-boost, right graph), analyzed for IgG antibody titers against Ct089 using rCt089 produced in E. coli as the antigen, following administration of Ct089mRNA, Ct089NGM mRNA or rCt089.
DETAILED DESCRIPTION
• The present disclosure provides, in some embodiments, vaccines that comprise RNA (e.g., mRNA) polynucleotides encoding a human papillomavirus (HPV) antigenic polypeptide, a herpes simplex virus (HSV) antigenic polypeptide, and/or a Chlamydia (e.g., C. trachomatis) antigenic polypeptide. The present disclosure also provides, in some embodiments, combination vaccines that comprise at least one RNA (e.g., mRNA) polynucleotide encoding at least two antigenic polypeptides selected from HPV antigenic polypeptides, HSV antigenic polypeptides, and Chlamydia (e.g., C. trachomatis) antigenic polypeptides. Also provided herein are methods of administering the RNA (e.g., mRNA) vaccines, methods of producing the RNA (e.g., mRNA) vaccines, compositions (e.g., pharmaceutical compositions) comprising the RNA (e.g., mRNA) vaccines, and nucleic acids (e.g., DNA) encoding the RNA (e.g., mRNA) vaccines. In some embodiments, a RNA (e.g., mRNA) vaccine comprises an adjuvant, such as a flagellin adjuvant, as provided herein.
• The RNA (e.g., mRNA) vaccines (e.g., HPV, HSV and/or Chlamydia RNA vaccines), in some embodiments, may be used to induce a balanced immune response, comprising both cellular and humoral immunity, without many of the risks associated with DNA vaccination.
• The entire contents of International Application No. PCT/US2015/02740 is incorporated herein by reference.
Human Papillomavirus (HPV)
• Major capsid protein L1 forms an icosahedral capsid with a T=7 symmetry and a 50 nm diameter. The capsid is composed of 72 pentamers linked to each other by disulfide bonds and associated with L2 proteins. HPV capsid proteins bind to heparan sulfate proteoglycans on the basement membrane of target cells to provide initial virion attachment to the target cells. The basement membrane is exposed only after epithelium trauma. Additionally, the alpha6 integrin complexed with either beta1 or beta4 integrin acts as a coreceptor recognized by L1. Once attached, the virion enters the host cell via clathrin-mediated endocytosis, and the genomic DNA is released to the host nucleus. The virion assembly takes place within the cell nucleus. L1 protein encapsulates the genomic DNA together with L2 protein.
• A HPV vaccine may comprise, for example, at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding at least one HPV antigenic polypeptide identified by SEQ ID NO: 35-59 (Table 2).
• A HPV vaccine may comprise, for example, at least one RNA (e.g., mRNA) polynucleotide encoded by a nucleic acid (e.g., DNA) identified by SEQ ID NO: 1-28 (Table 1).
• The present disclosure is not limited by a particular strain of HPV. The strain of HPV used in a vaccine may be any strain of HPV. Non-limiting examples of strains of HPV are provided elsewhere herein.
• In some embodiments, HPV vaccines comprise RNA (e.g., mRNA) encoding a HPV antigenic polypeptide having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity with HPV L1 or HPV L2 activity and having HPV L1 or HPV L2 activity, respectively.
• A protein is considered to have HPV L1 protein activity if, for example, it binds to heparan sulfate proteoglycans on the basement membrane to provide initial virion attachment to target cells.
Chlamydia
• Embodiments of the present disclosure provide RNA (e.g., mRNA) vaccines that include at least one polynucleotide encoding at least one Chlamydia (e.g., C. trachomatis) antigen. Chlamydia trachomatis, an obligate intracellular human pathogen, is one of four bacterial species in the genus Chlamydia. Chlamydia trachomatis is a Gram-negative bacterium, ovoid in shape. Chlamydia trachomatis includes three human biovars (variant prokaryotic strains): (1) serovars (or serotypes) Ab, B, Ba and C, which cause trachoma infection of the eyes, which can lead to blindness; (2) serovars D-K, which cause urethritis, pelvic inflammatory disease, ectopic pregnancy, neonatal pneumonia, and neonatal conjunctivitis; and (3) serovars L1, L2 and L3, which cause lymphogranuloma venereum. Major outer membrane protein (MOMP) is the dominant surface protein of the bacteria (contributing to 60% of the total protein mass in the outer membrane) and consists of four variable domains interspersed among five constant domains. The four variable domains contain serovar-specific epitopes; the five constant domains are highly conserved among the different serovars and contain several conserved CD4 and CD8 T cell epitopes. MOMP, if its native trimeric structure is preserved, induces protection against Chlamydia infection in animals (Kari L et al. The Journal of Immunology 2009; 182:8063-70).
• Thus, in some embodiments, a Chlamydia (e.g., C. trachomatis) RNA (e.g., mRNA) vaccine of the present disclosure comprises a RNA polynucleotide encoding any one of, or any combination of at least two of, MOMP serovar H, F, E, D, I, G, J and K.
• In some embodiments, a Chlamydia (e.g., C. trachomatis) RNA (e.g., mRNA) vaccine of the present disclosure comprises at least one RNA polynucleotide encoding major outer membrane protein (MOMP), serovar H.
• In some embodiments, a Chlamydia (e.g., C. trachomatis) RNA (e.g., mRNA) vaccine of the present disclosure comprises at least one RNA polynucleotide encoding MOMP serovar F.
• In some embodiments, a Chlamydia (e.g., C. trachomatis) RNA (e.g., mRNA) vaccine of the present disclosure comprises at least one RNA polynucleotide encoding MOMP serovar E.
• In some embodiments, a Chlamydia (e.g., C. trachomatis) RNA (e.g., mRNA) vaccine of the present disclosure comprises at least one RNA polynucleotide encoding MOMP serovar D.
• In some embodiments, a Chlamydia (e.g., C. trachomatis) RNA (e.g., mRNA) vaccine of the present disclosure comprises at least one RNA polynucleotide encoding MOMP serovar I.
• In some embodiments, a Chlamydia (e.g., C. trachomatis) RNA (e.g., mRNA) vaccine of the present disclosure comprises at least one RNA polynucleotide encoding MOMP serovar G.
• In some embodiments, a Chlamydia (e.g., C. trachomatis) RNA (e.g., mRNA) vaccine of the present disclosure comprises at least one RNA polynucleotide encoding MOMP serovar J.
• In some embodiments, a Chlamydia (e.g., C. trachomatis) RNA (e.g., mRNA) vaccine of the present disclosure comprises at least one RNA polynucleotide encoding MOMP serovar K.
• In some embodiments, a Chlamydia (e.g., C. trachomatis) vaccine may comprise, for example, at least one RNA (e.g., mRNA) encoded by a nucleic acid sequence identified by SEQ ID NO: 62-64 or 184-294 (Table 4 or 8) or a variant thereof having at least 90 identity to a nucleic acid sequence identified by SEQ ID NO: 62-64 or 184-294 (Table 4 or 8).
• In some embodiments, a Chlamydia trachomatis vaccine may comprise, for example, at least one RNA (e.g., mRNA) encoding an amino acid sequence identified by any one of SEQ ID NO: 65-183 (Tables 5 or 7) or a variant thereof having at least 90 identity to an amino acid sequence identified by any one of SEQ ID NO: 65-183 (Tables 5 or 7).
• It should be understood that the present disclosure is not intended to be limited by a particular strain or serotype of Chlamydia. The strain or serotype of Chlamydia used, as provided herein, may be any strain or serotype of Chlamydia, including, for example, Chlamydia trachomatis.
• In some embodiments, a Chlamydia (e.g., C. trachomatis) RNA (e.g., mRNA) vaccine of the present disclosure comprises a RNA polynucleotide encoding a variable domain of Chlamydia (e.g., C. trachomatis) MOMP. In some embodiments, a Chlamydia (e.g., C. trachomatis) RNA (e.g., mRNA) vaccine of the present disclosure comprises a RNA polynucleotide encoding a serovar-specific epitope of a variable domain of Chlamydia (e.g., C. trachomatis) MOMP.
• In some embodiments, Chlamydia vaccines comprise RNA (e.g., mRNA) encoding a Chlamydia (e.g., C. trachomatis) antigenic polypeptide having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity with Chlamydia (e.g., C. trachomatis) MOMP serovar H, F, E, D, I, G, J and K and having Chlamydia trachomatis MOMP serovar H, F, E, D, I, G, J and K activity, respectively.
• A protein is considered to have major outer membrane protein (MOMP) activity if, for example, it facilitates porin formation and maintains the structural rigidity of the outer membrane. MOMP permits the diffusion of specific solutes through the intracellular reticulate body membrane. In elementary bodies (EBs, the infectious stage, which is able to survive outside the host cell), MOMP provides the structural integrity of the outer envelope through disulfide cross-links with the small cysteine-rich protein and the large cysteine-rich periplasmic protein. In Chlamydia trachomatis, the protein contains four symmetrically-spaced variable domains (VD I-IV). Disulfide bond interactions within and between MOMP molecules and other components form high molecular weight oligomers of the elementary shell. The protein determines the different serotypes and serves as the functional equivalent of peptidoglycan.
Herpes Simplex Virus
• HSV is a double-stranded, linear DNA virus in the Herpesviridae. Two members of the herpes simplex virus family infect humans—known as HSV-1 and HSV-2. Symptoms of HSV infection include the formation of blisters in the skin or mucous membranes of the mouth, lips and/or genitals. HSV is a neuroinvasive virus that can cause sporadic recurring episodes of viral reactivation in infected individuals. HSV is transmitted by contact with an infected area of the skin during a period of viral activation. HSV most commonly infects via the oral or genital mucosa and replicates in the stratified squamous epithelium, followed by uptake into ramifying unmyelinated sensory nerve fibers within the stratified squamous epithelium. The virus is then transported to the cell body of the neuron in the dorsal root ganglion, where it persists in a latent cellular infection (Cunningham A L et al. J Infect Dis. (2006) 194 (Supplement 1): S11-S18).
• The genome of Herpes Simplex Viruses (HSV-1 and HSV-2) contains about 85 open reading frames, such that HSV can generate at least 85 unique proteins. These genes encode 4 major classes of proteins: (1) those associated with the outermost external lipid bilayer of HSV (the envelope), (2) the internal protein coat (the capsid), (3) an intermediate complex connecting the envelope with the capsid coat (the tegument), and (4) proteins responsible for replication and infection.
• Examples of envelope proteins include UL1 (gL), UL10 (gM), UL20, UL22, UL27 (gB), UL43, UL44 (gC), UL45, UL49A, UL53 (gK), US4 (gG), US5 (gJ), US6 (gD), US7 (gI), US8 (gE), and US10. Examples of capsid proteins include UL6, UL18, UL19, UL35, and UL38. Tegument proteins include UL11, UL13, UL21, UL36, UL37, UL41, UL45, UL46, UL47, UL48, UL49, US9, and US10. Other HSV proteins include UL2, UL3 UL4, UL5, UL7, UL8, UL9, UL12, UL14, UL15, UL16, UL17, UL23, UL24, UL25, UL26, UL26.5, UL28, UL29, UL30, UL31, UL32, UL33, UL34, UL39, UL40, UL42, UL50, UL51, UL52, UL54, UL55, UL56, US1, US2, US3, US81, US11, US12, ICP0, and ICP4.
• Since the envelope (most external portion of an HSV particle) is the first to encounter target cells, the present disclosure encompasses antigenic polypeptides associated with the envelope as immunogenic agents. In brief, surface and membrane proteins—glycoprotein D (gD), glycoprotein B (gB), glycoprotein H (gH), glycoprotein L (gL)—as single antigens or in combination with or without adjuvants may be used as HSV vaccine antigens.
• In some embodiments, HSV vaccines comprise RNA (e.g., mRNA) encoding HSV (HSV-1 or HSV-2) glycoprotein D.
• In some embodiments, HSV vaccines comprise RNA (e.g., mRNA) encoding HSV (HSV-1 or HSV-2) glycoprotein B.
• In some embodiments, HSV vaccines comprise RNA (e.g., mRNA) encoding HSV (HSV-1 or HSV-2) glycoprotein D and glycoprotein C.
• In some embodiments, HSV vaccines comprise RNA (e.g., mRNA) encoding HSV (HSV-1 or HSV-2) glycoprotein D and glycoprotein E (or glycoprotein I).
• In some embodiments, HSV vaccines comprise RNA (e.g., mRNA) encoding HSV (HSV-1 or HSV-2) glycoprotein B and glycoprotein C.
• In some embodiments, HSV vaccines comprise RNA (e.g., mRNA) encoding HSV (HSV-1 or HSV-2) glycoprotein B and glycoprotein E (or glycoprotein I).
• In some embodiments, HSV vaccines comprise RNA (e.g., mRNA) encoding a HSV (HSV-1 or HSV-2) antigenic polypeptide having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity with HSV (HSV-1 or HSV-2) glycoprotein D and has HSV (HSV-1 or HSV-2) glycoprotein D activity.
• In some embodiments, HSV vaccines comprise RNA (e.g., mRNA) encoding a HSV (HSV-1 or HSV-2) antigenic polypeptide having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity with HSV (HSV-1 or HSV-2) glycoprotein C and has HSV (HSV-1 or HSV-2) glycoprotein C activity.
• In some embodiments, HSV vaccines comprise RNA (e.g., mRNA) encoding a HSV (HSV-1 or HSV-2) antigenic polypeptide having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity with HSV (HSV-1 or HSV-2) glycoprotein B and has HSV (HSV-1 or HSV-2) glycoprotein B activity.
• In some embodiments, HSV vaccines comprise RNA (e.g., mRNA) encoding a HSV (HSV-1 or HSV-2) antigenic polypeptide having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity with HSV (HSV-1 or HSV-2) glycoprotein E and has HSV (HSV-1 or HSV-2) glycoprotein E activity.
• In some embodiments, HSV vaccines comprise RNA (e.g., mRNA) encoding a HSV (HSV-1 or HSV-2) antigenic polypeptide having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity with HSV (HSV-1 or HSV-2) glycoprotein I and has HSV (HSV-1 or HSV-2) glycoprotein I activity.
• Glycoprotein “activity” of the present disclosure is described below.
• Glycoprotein C (gC) is a glycoprotein involved in viral attachment to host cells; e.g., it acts as an attachment protein that mediates binding of the HSV-2 virus to host adhesion receptors, namely cell surface heparan sulfate and/or chondroitin sulfate. gC plays a role in host immune evasion (aka viral immunoevasion) by inhibiting the host complement cascade activation. In particular, gC binds to and/or interacts with host complement component C3b; this interaction then inhibits the host immune response by disregulating the complement cascade (e.g., binds host complement C3b to block neutralization of virus).
• Glycoprotein D (gD) is an envelope glycoprotein that binds to cell surface receptors and/or is involved in cell attachment via poliovirus receptor-related protein and/or herpesvirus entry mediator, facilitating virus entry. gD binds to the potential host cell entry receptors (tumor necrosis factor receptor superfamily, member 14(TNFRSF14)/herpesvirus entry mediator (HVEM), poliovirus receptor-related protein 1 (PVRL1) and or poliovirus receptor-related protein 2 (PVRL2) and is proposed to trigger fusion with host membrane, by recruiting the fusion machinery composed of, for example, gB and gH/gL. gD interacts with host cell receptors TNFRSF14 and/or PVRL1 and/or PVRL2 and (1) interacts (via profusion domain) with gB; an interaction which can occur in the absence of related HSV glycoproteins, e.g., gH and/or gL; and (2) gD interacts (via profusion domain) with gH/gL heterodimer, an interaction which can occur in the absence of gB. As such, gD associates with the gB-gH/gL-gD complex. gD also interacts (via C-terminus) with UL11 tegument protein.
• Glycoprotein B (gB) is a viral glycoprotein involved in the viral cell activity of herpes simplex virus (HSV) and is required for the fusion of the HSV's envelope with the cellular membrane. It is the most highly conserved of all surface glycoproteins and primarily acts as a fusion protein, constituting the core fusion machinery. gB, a class III membrane fusion glycoprotein, is a type-1 transmembrane protein trimer of five structural domains. Domain I includes two internal fusion loops and is through to insert into the cellular membrane during virus-cell fusion. Domain II appears to interact with gH/gL during the fusion process, domain III contains an elongated alpha helix, and domain IV interacts with cellular receptors. In epithelial cells, the heterodimer glycoprotein E/glycoproteinl (gE/gI) is required for the cell-to-cell spread of the virus, by sorting nascent virions to cell junctions. Once the virus reaches the cell junctions, virus particles can spread to adjacent cells extremely rapidly through interactions with cellular receptors that accumulate at these junctions. By similarity, it is implicated in basolateral spread in polarized cells. In neuronal cells, gE/gI is essential for the anterograde spread of the infection throughout the host nervous system. Together with US9, the heterodimer gE/gI is involved in the sorting and transport of viral structural components toward axon tips. The heterodimer gE/gI serves as a receptor for the Fc part of host IgG. Dissociation of gE/gI from IgG occurs at acidic pH, thus may be involved in anti-HSV antibodies bipolar bridging, followed by intracellular endocytosis and degradation, thereby interfering with host IgG-mediated immune responses. gE/gI interacts (via C-terminus) with VP22 tegument protein; this interaction is necessary for the recruitment of VP22 to the Golgi and its packaging into virions.
Combination Vaccines
• Embodiments of the present disclosure also provide combination RNA (e.g., mRNA) vaccines. A “combination RNA (e.g., mRNA) vaccine” of the present disclosure refers to a vaccine comprising at least one (e.g., at least 2, 3, 4, or 5) RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a combination of at least one HPV antigenic polypeptide (e.g., selected from E1, E2, E4, E5, E6, E7, L1, and L2), at least one HSV antigenic polypeptide (e.g., selected from glycoprotein D, glycoprotein B, glycoprotein C, and glycoprotein E), at least one Chlamydia antigenic polypeptide (e.g., selected from MOMP serovar H, F, E, D, I, G, J and K), or any combination of two or more of the foregoing antigenic polypeptides.
• It has been discovered that the mRNA vaccines described herein are superior to current vaccines in several ways. First, the lipid nanoparticle (LNP) delivery is superior to other formulations including a protamine base approach described in the literature and no additional adjuvants are to be necessary. The use of LNPs enables the effective delivery of chemically modified or unmodified mRNA vaccines. Additionally it has been demonstrated herein that both modified and unmodified LNP formulated mRNA vaccines were superior to conventional vaccines by a significant degree. In some embodiments the mRNA vaccines of the invention are superior to conventional vaccines by a factor of at least 10 fold, 20 fold, 40 fold, 50 fold, 100 fold, 500 fold or 1,000 fold.
• Although attempts have been made to produce functional RNA vaccines, including mRNA vaccines and self-replicating RNA vaccines, the therapeutic efficacy of these RNA vaccines have not yet been fully established. Quite surprisingly, the inventors have discovered, according to aspects of the invention a class of formulations for delivering mRNA vaccines in vivo that results in significantly enhanced, and in many respects synergistic, immune responses including enhanced antigen generation and functional antibody production with neutralization capability. These results can be achieved even when significantly lower doses of the mRNA are administered in comparison with mRNA doses used in other classes of lipid based formulations. The formulations of the invention have demonstrated significant unexpected in vivo immune responses sufficient to establish the efficacy of functional mRNA vaccines as prophylactic and therapeutic agents. Additionally, self-replicating RNA vaccines rely on viral replication pathways to deliver enough RNA to a cell to produce an immunogenic response. The formulations of the invention do not require viral replication to produce enough protein to result in a strong immune response. Thus, the mRNA of the invention are not self-replicating RNA and do not include components necessary for viral replication.
• The invention involves, in some aspects, the surprising finding that lipid nanoparticle (LNP) formulations significantly enhance the effectiveness of mRNA vaccines, including chemically modified and unmodified mRNA vaccines. The efficacy of mRNA vaccines formulated in LNP was examined in vivo using several distinct antigens. The results presented herein demonstrate the unexpected superior efficacy of the mRNA vaccines formulated in LNP over other commercially available vaccines.
• In addition to providing an enhanced immune response, the formulations of the invention generate a more rapid immune response with fewer doses of antigen than other vaccines tested. The mRNA-LNP formulations of the invention also produce quantitatively and qualitatively better immune responses than vaccines formulated in a different carriers.
• The LNP used in the studies described herein has been used previously to deliver siRNA in various animal models as well as in humans. In view of the observations made in association with the siRNA delivery of LNP formulations, the fact that LNP is useful in vaccines is quite surprising. It has been observed that therapeutic delivery of siRNA formulated in LNP causes an undesirable inflammatory response associated with a transient IgM response, typically leading to a reduction in antigen production and a compromised immune response. In contrast to the findings observed with siRNA, the LNP-mRNA formulations of the invention are demonstrated herein to generate enhanced IgG levels, sufficient for prophylactic and therapeutic methods rather than transient IgM responses.
Nucleic Acids/Polynucleotides
• STD vaccines, as provided herein, comprise at least one (one or more) ribonucleic acid (RNA) (e.g., mRNA) polynucleotide having an open reading frame encoding at least one HPV antigenic polypeptide, at least one HSV antigenic polypeptide, and/or at least one Chlamydia (e.g., C. trachomatis) antigenic polypeptide. The term “nucleic acid” includes any compound and/or substance that comprises a polymer of nucleotides (nucleotide monomer). These polymers are referred to as polynucleotides. Thus, the terms “nucleic acid” and “polynucleotide” are used interchangeably.
• Nucleic acids may be or may include, for example, ribonucleic acids (RNAs), deoxyribonucleic acids (DNAs), threose nucleic acids (TNAs), glycol nucleic acids (GNAs), peptide nucleic acids (PNAs), locked nucleic acids (LNAs, including LNA having a β-D-ribo configuration, α-LNA having an α-L-ribo configuration (a diastereomer of LNA), 2′-amino-LNA having a 2′-amino functionalization, and 2′-amino-α-LNA having a 2′-amino functionalization), ethylene nucleic acids (ENA), cyclohexenyl nucleic acids (CeNA) or chimeras or combinations thereof.
• In some embodiments, polynucleotides of the present disclosure function as messenger RNA (mRNA). “Messenger RNA” (mRNA) refers to any polynucleotide that encodes a (at least one) polypeptide (a naturally-occurring, non-naturally-occurring, or modified polymer of amino acids) and can be translated to produce the encoded polypeptide in vitro, in vivo, in situ or ex vivo. The skilled artisan will appreciate that, except where otherwise noted, polynucleotide sequences set forth in the instant application will recite “T”s in a representative DNA sequence but where the sequence represents RNA (e.g., mRNA), the “T”s would be substituted for “U”s. Thus, any of the RNA polynucleotides encoded by a DNA identified by a particular sequence identification number may also comprise the corresponding RNA (e.g., mRNA) sequence encoded by the DNA, where each “T” of the DNA sequence is substituted with “U.”
• The basic components of an mRNA molecule typically include at least one coding region, a 5′ untranslated region (UTR), a 3′ UTR, a 5′ cap and a poly-A tail. Polynucleotides of the present disclosure may function as mRNA but can be distinguished from wild-type mRNA in their functional and/or structural design features, which serve to overcome existing problems of effective polypeptide expression using nucleic-acid based therapeutics.
• In some embodiments, a RNA polynucleotide of an RNA (e.g., mRNA) vaccine encodes 2-10, 2-9, 2-8, 2-7, 2-6, 2-5, 2-4, 2-3, 3-10, 3-9, 3-8, 3-7, 3-6, 3-5, 3-4, 4-10, 4-9, 4-8, 4-7, 4-6, 4-5, 5-10, 5-9, 5-8, 5-7, 5-6, 6-10, 6-9, 6-8, 6-7, 7-10, 7-9, 7-8, 8-10, 8-9 or 9-10 antigenic polypeptides. In some embodiments, a RNA (e.g., mRNA) polynucleotide of a STD vaccine encodes at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 antigenic polypeptides.
• In some embodiments, a RNA (e.g., mRNA) polynucleotide of a STD vaccine encodes at least 100 or at least 200 antigenic polypeptides. In some embodiments, a RNA polynucleotide of an STD vaccine encodes 1-10, 5-15, 10-20, 15-25, 20-30, 25-35, 30-40, 35-45, 40-50, 1-50, 1-100, 2-50 or 2-100 antigenic polypeptides.
• Polynucleotides of the present disclosure, in some embodiments, are codon optimized. Codon optimization methods are known in the art and may be used as provided herein. Codon optimization, in some embodiments, may be used to match codon frequencies in target and host organisms to ensure proper folding; bias GC content to increase mRNA stability or reduce secondary structures; minimize tandem repeat codons or base runs that may impair gene construction or expression; customize transcriptional and translational control regions; insert or remove protein trafficking sequences; remove/add post translation modification sites in encoded protein (e.g. glycosylation sites); add, remove or shuffle protein domains; insert or delete restriction sites; modify ribosome binding sites and mRNA degradation sites; adjust translational rates to allow the various domains of the protein to fold properly; or to reduce or eliminate problem secondary structures within the polynucleotide. Codon optimization tools, algorithms and services are known in the art—non-limiting examples include services from GeneArt (Life Technologies), DNA2.0 (Menlo Park Calif.) and/or proprietary methods. In some embodiments, the open reading frame (ORF) sequence is optimized using optimization algorithms.
• In some embodiments, a codon optimized sequence shares less than 95% sequence identity, less than 90% sequence identity, less than 85% sequence identity, less than 80% sequence identity, or less than 75% sequence identity to a naturally-occurring or wild-type sequence (e.g., a naturally-occurring or wild-type mRNA sequence encoding a polypeptide or protein of interest (e.g., an antigenic protein or antigenic polypeptide)).
• In some embodiments, a codon-optimized sequence shares between 65% and 85% (e.g., between about 67% and about 85%, or between about 67% and about 80%) sequence identity to a naturally-occurring sequence or a wild-type sequence (e.g., a naturally-occurring or wild-type mRNA sequence encoding a polypeptide or protein of interest (e.g., an antigenic protein or polypeptide)). In some embodiments, a codon-optimized sequence shares between 65% and 75%, or about 80% sequence identity to a naturally-occurring sequence or wild-type sequence (e.g., a naturally-occurring or wild-type mRNA sequence encoding a polypeptide or protein of interest (e.g., an antigenic protein or polypeptide)).
• In some embodiments a codon-optimized RNA (e.g., mRNA) may, for instance, be one in which the levels of G/C are enhanced. The G/C-content of nucleic acid molecules may influence the stability of the RNA. RNA having an increased amount of guanine (G) and/or cytosine (C) residues may be functionally more stable than nucleic acids containing a large amount of adenine (A) and thymine (T) or uracil (U) nucleotides. WO02/098443 discloses a pharmaceutical composition containing an mRNA stabilized by sequence modifications in the translated region. Due to the degeneracy of the genetic code, the modifications work by substituting existing codons for those that promote greater RNA stability without changing the resulting amino acid. The approach is limited to coding regions of the RNA.
Antigens/Antigenic Polypeptides
• In some embodiments, an antigenic polypeptide (e.g., HPV, HSV and/or Chlamydia antigenic polypeptide) is longer than 25 amino acids and shorter than 50 amino acids. Polypeptides include gene products, naturally occurring polypeptides, synthetic polypeptides, homologs, orthologs, paralogs, fragments and other equivalents, variants, and analogs of the foregoing. A polypeptide may be a single molecule or may be a multi-molecular complex such as a dimer, trimer or tetramer. Polypeptides may also comprise single chain polypeptides or multichain polypeptides, such as antibodies or insulin, and may be associated or linked to each other. Most commonly, disulfide linkages are found in multichain polypeptides. The term “polypeptide” may also apply to amino acid polymers in which at least one amino acid residue is an artificial chemical analogue of a corresponding naturally-occurring amino acid.
• A “polypeptide variant” is a molecule that differs in its amino acid sequence relative to a native sequence or a reference sequence. Amino acid sequence variants may possess substitutions, deletions, insertions, or a combination of any two or three of the foregoing, at certain positions within the amino acid sequence, as compared to a native sequence or a reference sequence. Ordinarily, variants possess at least 50% identity to a native sequence or a reference sequence. In some embodiments, variants share at least 80% identity or at least 90% identity with a native sequence or a reference sequence.
• In some embodiments “variant mimics” are provided. A “variant mimic” contains at least one amino acid that would mimic an activated sequence. For example, glutamate may serve as a mimic for phosphoro-threonine and/or phosphoro-serine. Alternatively, variant mimics may result in deactivation or in an inactivated product containing the mimic. For example, phenylalanine may act as an inactivating substitution for tyrosine, or alanine may act as an inactivating substitution for serine.
• “Orthologs” refers to genes in different species that evolved from a common ancestral gene by speciation. Normally, orthologs retain the same function in the course of evolution. Identification of orthologs is important for reliable prediction of gene function in newly sequenced genomes.
• “Analogs” is meant to include polypeptide variants that differ by one or more amino acid alterations, for example, substitutions, additions or deletions of amino acid residues that still maintain one or more of the properties of the parent or starting polypeptide.
• The present disclosure provides several types of compositions that are polynucleotide or polypeptide based, including variants and derivatives. These include, for example, substitutional, insertional, deletion and covalent variants and derivatives. The term “derivative” is synonymous with the term “variant” and generally refers to a molecule that has been modified and/or changed in any way relative to a reference molecule or a starting molecule.
• As such, polynucleotides encoding peptides or polypeptides containing substitutions, insertions and/or additions, deletions and covalent modifications with respect to reference sequences, in particular the polypeptide sequences disclosed herein, are included within the scope of this disclosure. For example, sequence tags or amino acids, such as one or more lysines, can be added to peptide sequences (e.g., at the N-terminal or C-terminal ends). Sequence tags can be used for peptide detection, purification or localization. Lysines can be used to increase peptide solubility or to allow for biotinylation. Alternatively, amino acid residues located at the carboxy and amino terminal regions of the amino acid sequence of a peptide or protein may optionally be deleted providing for truncated sequences. Certain amino acids (e.g., C-terminal residues or N-terminal residues) alternatively may be deleted depending on the use of the sequence, as for example, expression of the sequence as part of a larger sequence that is soluble, or linked to a solid support.
• “Substitutional variants” when referring to polypeptides are those that have at least one amino acid residue in a native or starting sequence removed and a different amino acid inserted in its place at the same position. Substitutions may be single, where only one amino acid in the molecule has been substituted, or they may be multiple, where two or more (e.g., 3, 4 or 5) amino acids have been substituted in the same molecule.
• As used herein the term “conservative amino acid substitution” refers to the substitution of an amino acid that is normally present in the sequence with a different amino acid of similar size, charge, or polarity. Examples of conservative substitutions include the substitution of a non-polar (hydrophobic) residue such as isoleucine, valine and leucine for another non-polar residue. Likewise, examples of conservative substitutions include the substitution of one polar (hydrophilic) residue for another such as between arginine and lysine, between glutamine and asparagine, and between glycine and serine. Additionally, the substitution of a basic residue such as lysine, arginine or histidine for another, or the substitution of one acidic residue such as aspartic acid or glutamic acid for another acidic residue are additional examples of conservative substitutions. Examples of non-conservative substitutions include the substitution of a non-polar (hydrophobic) amino acid residue such as isoleucine, valine, leucine, alanine, methionine for a polar (hydrophilic) residue such as cysteine, glutamine, glutamic acid or lysine and/or a polar residue for a non-polar residue.
• “Features” when referring to polypeptide or polynucleotide are defined as distinct amino acid sequence-based or nucleotide-based components of a molecule respectively. Features of the polypeptides encoded by the polynucleotides include surface manifestations, local conformational shape, folds, loops, half-loops, domains, half-domains, sites, termini and any combination(s) thereof.
• As used herein when referring to polypeptides the term “domain” refers to a motif of a polypeptide having one or more identifiable structural or functional characteristics or properties (e.g., binding capacity, serving as a site for protein-protein interactions).
• As used herein when referring to polypeptides the terms “site” as it pertains to amino acid based embodiments is used synonymously with “amino acid residue” and “amino acid side chain.” As used herein when referring to polynucleotides the terms “site” as it pertains to nucleotide based embodiments is used synonymously with “nucleotide.” A site represents a position within a peptide or polypeptide or polynucleotide that may be modified, manipulated, altered, derivatized or varied within the polypeptide-based or polynucleotide-based molecules.
• As used herein the terms “termini” or “terminus” when referring to polypeptides or polynucleotides refers to an extremity of a polypeptide or polynucleotide respectively. Such extremity is not limited only to the first or final site of the polypeptide or polynucleotide but may include additional amino acids or nucleotides in the terminal regions. Polypeptide-based molecules may be characterized as having both an N-terminus (terminated by an amino acid with a free amino group (NH2)) and a C-terminus (terminated by an amino acid with a free carboxyl group (COOH)). Proteins are in some cases made up of multiple polypeptide chains brought together by disulfide bonds or by non-covalent forces (multimers, oligomers). These proteins have multiple N- and C-termini. Alternatively, the termini of the polypeptides may be modified such that they begin or end, as the case may be, with a non-polypeptide based moiety such as an organic conjugate.
• As recognized by those skilled in the art, protein fragments, functional protein domains, and homologous proteins are also considered to be within the scope of polypeptides of interest. For example, provided herein is any protein fragment (meaning a polypeptide sequence at least one amino acid residue shorter than a reference polypeptide sequence but otherwise identical) of a reference protein having a length of 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 or longer than 100 amino acids. In another example, any protein that includes a stretch of 20, 30, 40, 50, or 100 (contiguous) amino acids that are 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 100% identical to any of the sequences described herein can be utilized in accordance with the disclosure. In some embodiments, a polypeptide includes 2, 3, 4, 5, 6, 7, 8, 9, 10, or more mutations as shown in any of the sequences provided herein or referenced herein. In another example, any protein that includes a stretch of 20, 30, 40, 50, or 100 amino acids that are greater than 80%, 90%, 95%, or 100% identical to any of the sequences described herein, wherein the protein has a stretch of 5, 10, 15, 20, 25, or 30 amino acids that are less than 80%, 75%, 70%, 65% to 60% identical to any of the sequences described herein can be utilized in accordance with the disclosure.
• Polypeptide or polynucleotide molecules of the present disclosure may share a certain degree of sequence similarity or identity with the reference molecules (e.g., reference polypeptides or reference polynucleotides), for example, with art-described molecules (e.g., engineered or designed molecules or wild-type molecules). The term “identity,” as known in the art, refers to a relationship between the sequences of two or more polypeptides or polynucleotides, as determined by comparing the sequences. In the art, identity also means the degree of sequence relatedness between two sequences as determined by the number of matches between strings of two or more amino acid residues or nucleic acid residues.
• Identity measures the percent of identical matches between the smaller of two or more sequences with gap alignments (if any) addressed by a particular mathematical model or computer program (e.g., “algorithms”). Identity of related peptides can be readily calculated by known methods. “% identity” as it applies to polypeptide or polynucleotide sequences is defined as the percentage of residues (amino acid residues or nucleic acid residues) in the candidate amino acid or nucleic acid sequence that are identical with the residues in the amino acid sequence or nucleic acid sequence of a second sequence after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent identity. Methods and computer programs for the alignment are well known in the art. Identity depends on a calculation of percent identity but may differ in value due to gaps and penalties introduced in the calculation. Generally, variants of a particular polynucleotide or polypeptide have at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% but less than 100% sequence identity to that particular reference polynucleotide or polypeptide as determined by sequence alignment programs and parameters described herein and known to those skilled in the art. Such tools for alignment include those of the BLAST suite (Stephen F. Altschul, et al. (1997).” Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,” Nucleic Acids Res. 25:3389-3402). Another popular local alignment technique is based on the Smith-Waterman algorithm (Smith, T. F. & Waterman, M. S. (1981) “Identification of common molecular subsequences.” J. Mol. Biol. 147:195-197). A general global alignment technique based on dynamic programming is the Needleman-Wunsch algorithm (Needleman, S. B. & Wunsch, C. D. (1970) “A general method applicable to the search for similarities in the amino acid sequences of two proteins.” J. Mol. Biol. 48:443-453). More recently, a Fast Optimal Global Sequence Alignment Algorithm (FOGSAA) was developed that purportedly produces global alignment of nucleotide and protein sequences faster than other optimal global alignment methods, including the Needleman-Wunsch algorithm. Other tools are described herein, specifically in the definition of “identity” below.
• As used herein, the term “homology” refers to the overall relatedness between polymeric molecules, e.g. between nucleic acid molecules (e.g. DNA molecules and/or RNA molecules) and/or between polypeptide molecules. Polymeric molecules (e.g. nucleic acid molecules (e.g. DNA molecules and/or RNA molecules) and/or polypeptide molecules) that share a threshold level of similarity or identity determined by alignment of matching residues are termed homologous. Homology is a qualitative term that describes a relationship between molecules and can be based upon the quantitative similarity or identity. Similarity or identity is a quantitative term that defines the degree of sequence match between two compared sequences. In some embodiments, polymeric molecules are considered to be “homologous” to one another if their sequences are at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% identical or similar. The term “homologous” necessarily refers to a comparison between at least two sequences (polynucleotide or polypeptide sequences). Two polynucleotide sequences are considered homologous if the polypeptides they encode are at least 50%, 60%, 70%, 80%, 90%, 95%, or even 99% for at least one stretch of at least 20 amino acids. In some embodiments, homologous polynucleotide sequences are characterized by the ability to encode a stretch of at least 4-5 uniquely specified amino acids. For polynucleotide sequences less than 60 nucleotides in length, homology is determined by the ability to encode a stretch of at least 4-5 uniquely specified amino acids. Two protein sequences are considered homologous if the proteins are at least 50%, 60%, 70%, 80%, or 90% identical for at least one stretch of at least 20 amino acids.
• Homology implies that the compared sequences diverged in evolution from a common origin. The term “homolog” refers to a first amino acid sequence or nucleic acid sequence (e.g., gene (DNA or RNA) or protein sequence) that is related to a second amino acid sequence or nucleic acid sequence by descent from a common ancestral sequence. The term “homolog” may apply to the relationship between genes and/or proteins separated by the event of speciation or to the relationship between genes and/or proteins separated by the event of genetic duplication. “Orthologs” are genes (or proteins) in different species that evolved from a common ancestral gene (or protein) by speciation. Typically, orthologs retain the same function in the course of evolution. “Paralogs” are genes (or proteins) related by duplication within a genome. Orthologs retain the same function in the course of evolution, whereas paralogs evolve new functions, even if these are related to the original one.
• The term “identity” refers to the overall relatedness between polymeric molecules, for example, between polynucleotide molecules (e.g. DNA molecules and/or RNA molecules) and/or between polypeptide molecules. Calculation of the percent identity of two polynucleic acid sequences, for example, can be performed by aligning the two sequences for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second nucleic acid sequences for optimal alignment and non-identical sequences can be disregarded for comparison purposes). In certain embodiments, the length of a sequence aligned for comparison purposes is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or 100% of the length of the reference sequence. The nucleotides at corresponding nucleotide positions are then compared. When a position in the first sequence is occupied by the same nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which needs to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. For example, the percent identity between two nucleic acid sequences can be determined using methods such as those described in Computational Molecular Biology, Lesk, A. M., ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D. W., ed., Academic Press, New York, 1993; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; Computer Analysis of Sequence Data, Part I, Griffin, A. M., and Griffin, H. G., eds., Humana Press, New Jersey, 1994; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; each of which is incorporated herein by reference. For example, the percent identity between two nucleic acid sequences can be determined using the algorithm of Meyers and Miller (CABIOS, 1989, 4:11-17), which has been incorporated into the ALIGN program (version 2.0) using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. The percent identity between two nucleic acid sequences can, alternatively, be determined using the GAP program in the GCG software package using an NWSgapdna.CMP matrix. Methods commonly employed to determine percent identity between sequences include, but are not limited to those disclosed in Carillo, H., and Lipman, D., SIAM J Applied Math., 48:1073 (1988); incorporated herein by reference. Techniques for determining identity are codified in publicly available computer programs. Exemplary computer software to determine homology between two sequences include, but are not limited to, GCG program package, Devereux, J., et al., Nucleic Acids Research, 12, 387 (1984)), BLASTP, BLASTN, and FASTA Altschul, S. F. et al., J. Molec. Biol., 215, 403 (1990)).
Multiprotein and Multicomponent Vaccines
• The present disclosure encompasses STD vaccines comprising multiple RNA (e.g., mRNA) polynucleotides, each encoding a single antigenic polypeptide, as well as STD vaccines comprising a single RNA polynucleotide encoding more than one antigenic polypeptide (e.g., as a fusion polypeptide). Thus, a vaccine composition comprising a RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a first antigenic polypeptide and a RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a second antigenic polypeptide encompasses (a) vaccines that comprise a first RNA polynucleotide encoding a first antigenic polypeptide and a second RNA polynucleotide encoding a second antigenic polypeptide, and (b) vaccines that comprise a single RNA polynucleotide encoding a first and second antigenic polypeptide (e.g., as a fusion polypeptide). RNA (e.g., mRNA) vaccines of the present disclosure, in some embodiments, comprise 2-10 (e.g., 2, 3, 4, 5, 6, 7, 8, 9 or 10), or more, RNA polynucleotides having an open reading frame, each of which encodes a different antigenic polypeptide (or a single RNA polynucleotide encoding 2-10, or more, different antigenic polypeptides). The antigenic polypeptides may be selected from HPV antigenic polypeptides, HSV antigenic polypeptides, and Chlamydia (e.g., C. trachomatis) antigenic polypeptides.
• In some embodiments, a STD vaccine comprises a RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a viral capsid protein, a RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a viral premembrane/membrane protein, and a RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a viral envelope protein. In some embodiments, a STD vaccine comprises a RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a viral fusion (F) protein and a RNA polynucleotide having an open reading frame encoding a viral major surface glycoprotein (G protein). In some embodiments, a vaccine comprises a RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a viral F protein. In some embodiments, a vaccine comprises a RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a viral G protein. In some embodiments, a vaccine comprises a RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HN protein.
• In some embodiments, a multicomponent vaccine comprises at least one RNA (e.g., mRNA) polynucleotide encoding at least one antigenic polypeptide fused to a signal peptide (e.g., SEQ ID NO: 304-307). The signal peptide may be fused at the N-terminus or the C-terminus of an antigenic polypeptide. An antigenic polypeptide fused to a signal peptide may be selected from HPV antigenic polypeptides, HSV antigenic polypeptides, and Chlamydia (e.g., C. trachomatis) antigenic polypeptides.
Signal Peptides and Leader Sequences
• In some embodiments, antigenic polypeptides encoded by STD RNA (e.g., mRNA) polynucleotides comprise a signal peptide. Signal peptides, comprising the N-terminal 15-60 amino acids of proteins, are typically needed for the translocation across the membrane on the secretory pathway and, thus, universally control the entry of most proteins both in eukaryotes and prokaryotes to the secretory pathway. Signal peptides generally include three regions: an N-terminal region of differing length, which usually comprises positively charged amino acids; a hydrophobic region; and a short carboxy-terminal peptide region. In eukaryotes, the signal peptide of a nascent precursor protein (pre-protein) directs the ribosome to the rough endoplasmic reticulum (ER) membrane and initiates the transport of the growing peptide chain across it for processing. ER processing produces mature proteins, wherein the signal peptide is cleaved from precursor proteins, typically by a ER-resident signal peptidase of the host cell, or they remain uncleaved and function as a membrane anchor. A signal peptide may also facilitate the targeting of the protein to the cell membrane. The signal peptide, however, is not responsible for the final destination of the mature protein. Secretory proteins devoid of additional address tags in their sequence are by default secreted to the external environment. During recent years, a more advanced view of signal peptides has evolved, showing that the functions and immunodominance of certain signal peptides are much more versatile than previously anticipated.
• In some embodiments, a Chlamydia antigenic polypeptide may be comprise a leader sequence to facilitate cell surface expression of the antigenic polypeptide. In some embodiments, a Chlamydia trachomatis MOMP antigenic polypeptide comprises a leader sequence that facilitates cell surface expression of the MOMP. See, e.g., Jones H M, et al. Gene. 2000, 258: 173-181; and Findlay H E, et al. BMC Microbiology. 2005, 5:5. In some embodiments, a Chlamydia trachomatis antigenic polypeptide (e.g., a MOMP antigenic polypeptide) comprises (is linked to) a leader sequence comprising an amino acid identified by any one of SEQ ID NO: 301-316. It should be understood that any antigenic polypeptide (e.g., HPV, HSV and/or Chlamydia antigenic polypeptide) as provided herein may comprise a leader sequence.
• STD vaccines of the present disclosure may comprise, for example, RNA (e.g., mRNA) polynucleotides encoding an artificial signal peptide, wherein the signal peptide coding sequence is operably linked to and is in frame with the coding sequence of the antigenic polypeptide. Thus, STD vaccines of the present disclosure, in some embodiments, produce an antigenic polypeptide (e.g., a HPV antigenic polypeptide, HSV antigenic polypeptides and/or a Chlamydia antigenic polypeptide) fused to a signal peptide. In some embodiments, a signal peptide is fused to the N-terminus of the antigenic polypeptide. In some embodiments, a signal peptide is fused to the C-terminus of the antigenic polypeptide.
• In some embodiments, the signal peptide fused to the antigenic polypeptide is an artificial signal peptide. In some embodiments, an artificial signal peptide fused to the antigenic polypeptide encoded by the RNA (e.g., mRNA) vaccine is obtained from an immunoglobulin protein, e.g., an IgE signal peptide or an IgG signal peptide. In some embodiments, a signal peptide fused to the antigenic polypeptide encoded by a RNA (e.g., mRNA) vaccine is an Ig heavy chain epsilon-1 signal peptide (IgE HC SP) having the sequence of: MDWTWILFLVAAATRVHS; SEQ ID NO: 305. In some embodiments, a signal peptide fused to the antigenic polypeptide encoded by the (e.g., mRNA) RNA (e.g., mRNA) vaccine is an IgGk chain V-III region HAH signal peptide (IgGk SP) having the sequence of METPAQLLFLLLLWLPDTTG; SEQ ID NO: 304. In some embodiments, the signal peptide is selected from: Japanese encephalitis PRM signal sequence (MLGSNSGQRVVFTILLLLVAPAYS; SEQ ID NO: 306), VSVg protein signal sequence (MKCLLYLAFLFIGVNCA; SEQ ID NO: 307) and Japanese encephalitis JEV signal sequence (MWLVSLAIVTACAGA; SEQ ID NO: 308).
• In some embodiments, the antigenic polypeptide encoded by a RNA (e.g., mRNA) vaccine comprises an amino acid sequence identified by any one of 8, 12-14, 24-34, 47-50 or 54-56 (Tables 3, 6, 11, 14 or 17; see also amino acid sequences of Tables 4, 7, 12 or 15) fused to a signal peptide identified by any one of −19 (Table 8). The examples disclosed herein are not meant to be limiting and any signal peptide that is known in the art to facilitate targeting of a protein to ER for processing and/or targeting of a protein to the cell membrane may be used in accordance with the present disclosure.
• A signal peptide may have a length of 15-60 amino acids. For example, a signal peptide may have a length of 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60 amino acids. In some embodiments, a signal peptide has a length of 20-60, 25-60, 30-60, 35-60, 40-60, 45-60, 50-60, 55-60, 15-55, 20-55, 25-55, 30-55, 35-55, 40-55, 45-55, 50-55, 15-50, 20-50, 25-50, 30-50, 35-50, 40-50, 45-50, 15-45, 20-45, 25-45, 30-45, 35-45, 40-45, 15-40, 20-40, 25-40, 30-40, 35-40, 15-35, 20-35, 25-35, 30-35, 15-30, 20-30, 25-30, 15-25, 20-25, or 15-20 amino acids.
• A signal peptide is typically cleaved from the nascent polypeptide at the cleavage junction during ER processing. The mature antigenic polypeptide produce by a STD RNA (e.g., mRNA) vaccine of the present disclosure typically does not comprise a signal peptide.
Chemical Modifications
• STD vaccines of the present disclosure, in some embodiments, comprise at least RNA (e.g. mRNA) polynucleotide having an open reading frame encoding at least one antigenic polypeptide that comprises at least one chemical modification.
• The terms “chemical modification” and “chemically modified” refer to modification with respect to adenosine (A), guanosine (G), uridine (U), thymidine (T) or cytidine (C) ribonucleosides or deoxyribnucleosides in at least one of their position, pattern, percent or population. Generally, these terms do not refer to the ribonucleotide modifications in naturally occurring 5′-terminal mRNA cap moieties. With respect to a polypeptide, the term “modification” refers to a modification relative to the canonical set 20 amino acids. Polypeptides, as provided herein, are also considered “modified” of they contain amino acid substitutions, insertions or a combination of substitutions and insertions.
• Polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides), in some embodiments, comprise various (more than one) different modifications. In some embodiments, a particular region of a polynucleotide contains one, two or more (optionally different) nucleoside or nucleotide modifications. In some embodiments, a modified RNA polynucleotide (e.g., a modified mRNA polynucleotide), introduced to a cell or organism, exhibits reduced degradation in the cell or organism, respectively, relative to an unmodified polynucleotide. In some embodiments, a modified RNA polynucleotide (e.g., a modified mRNA polynucleotide), introduced into a cell or organism, may exhibit reduced immunogenicity in the cell or organism, respectively (e.g., a reduced innate response).
• Modifications of polynucleotides include, without limitation, those described herein. Polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) may comprise modifications that are naturally-occurring, non-naturally-occurring or the polynucleotide may comprise a combination of naturally-occurring and non-naturally-occurring modifications. Polynucleotides may include any useful modification, for example, of a sugar, a nucleobase, or an internucleoside linkage (e.g., to a linking phosphate, to a phosphodiester linkage or to the phosphodiester backbone).
• Polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides), in some embodiments, comprise non-natural modified nucleotides that are introduced during synthesis or post-synthesis of the polynucleotides to achieve desired functions or properties. The modifications may be present on an internucleotide linkages, purine or pyrimidine bases, or sugars. The modification may be introduced with chemical synthesis or with a polymerase enzyme at the terminal of a chain or anywhere else in the chain. Any of the regions of a polynucleotide may be chemically modified.
• The present disclosure provides for modified nucleosides and nucleotides of a polynucleotide (e.g., RNA polynucleotides, such as mRNA polynucleotides). A “nucleoside” refers to a compound containing a sugar molecule (e.g., a pentose or ribose) or a derivative thereof in combination with an organic base (e.g., a purine or pyrimidine) or a derivative thereof (also referred to herein as “nucleobase”). A nucleotide” refers to a nucleoside, including a phosphate group. Modified nucleotides may by synthesized by any useful method, such as, for example, chemically, enzymatically, or recombinantly, to include one or more modified or non-natural nucleosides. Polynucleotides may comprise a region or regions of linked nucleosides. Such regions may have variable backbone linkages. The linkages may be standard phosphdioester linkages, in which case the polynucleotides would comprise regions of nucleotides.
• Modified nucleotide base pairing encompasses not only the standard adenosine-thymine, adenosine-uracil, or guanosine-cytosine base pairs, but also base pairs formed between nucleotides and/or modified nucleotides comprising non-standard or modified bases, wherein the arrangement of hydrogen bond donors and hydrogen bond acceptors permits hydrogen bonding between a non-standard base and a standard base or between two complementary non-standard base structures. One example of such non-standard base pairing is the base pairing between the modified nucleotide inosine and adenine, cytosine or uracil. Any combination of base/sugar or linker may be incorporated into polynucleotides of the present disclosure.
• Modifications of polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) that are useful in the vaccines of the present disclosure include, but are not limited to the following: 2-methylthio-N6-(cis-hydroxyisopentenyl)adenosine; 2-methylthio-N6-methyladenosine; 2-methylthio-N6-threonyl carbamoyladenosine; N6-glycinylcarbamoyladenosine; N6-isopentenyladenosine; N6-methyladenosine; N6-threonylcarbamoyladenosine; 1,2′-O-dimethyladenosine; 1-methyladenosine; 2′-O-methyladenosine; 2′-O-ribosyladenosine (phosphate); 2-methyladenosine; 2-methylthio-N6 isopentenyladenosine; 2-methylthio-N6-hydroxynorvalyl carbamoyladenosine; 2′-O-methyladenosine; 2′-O-ribosyladenosine (phosphate); Isopentenyladenosine; N6-(cis-hydroxyisopentenyl)adenosine; N6,2′-O-dimethyladenosine; N6,2′-O-dimethyladenosine; N6,N6,2′-O-trimethyladenosine; N6,N6-dimethyladenosine; N6-acetyladenosine; N6-hydroxynorvalylcarbamoyladenosine; N6-methyl-N6-threonylcarbamoyladenosine; 2-methyladenosine; 2-methylthio-N6-isopentenyladenosine; 7-deaza-adenosine; N1-methyl-adenosine; N6,N6 (dimethyl)adenine; N6-cis-hydroxy-isopentenyl-adenosine; α-thio-adenosine; 2 (amino)adenine; 2 (aminopropyl)adenine; 2 (methylthio) N6 (isopentenyl)adenine; 2-(alkyl)adenine; 2-(aminoalkyl)adenine; 2-(aminopropyl)adenine; 2-(halo)adenine; 2-(halo)adenine; 2-(propyl)adenine; 2′-Amino-2′-deoxy-ATP; 2′-Azido-2′-deoxy-ATP; 2′-Deoxy-2′-α-aminoadenosine TP; 2′-Deoxy-2′-a-azidoadenosine TP; 6 (alkyl)adenine; 6 (methyl)adenine; 6-(alkyl)adenine; 6-(methyl)adenine; 7 (deaza)adenine; 8 (alkenyl)adenine; 8 (alkynyl)adenine; 8 (amino)adenine; 8 (thioalkyl)adenine; 8-(alkenyl)adenine; 8-(alkyl)adenine; 8-(alkynyl)adenine; 8-(amino)adenine; 8-(halo)adenine; 8-(hydroxyl)adenine; 8-(thioalkyl)adenine; 8-(thiol)adenine; 8-azido-adenosine; aza adenine; deaza adenine; N6 (methyl)adenine; N6-(isopentyl)adenine; 7-deaza-8-aza-adenosine; 7-methyladenine; 1-Deazaadenosine TP; 2′Fluoro-N6-Bz-deoxyadenosine TP; 2′-OMe-2-Amino-ATP; 2′O-methyl-N6-Bz-deoxyadenosine TP; 2′-a-Ethynyladenosine TP; 2-aminoadenine; 2-Aminoadenosine TP; 2-Amino-ATP; 2′-a-Trifluoromethyladenosine TP; 2-Azidoadenosine TP; 2′-b-Ethynyladenosine TP; 2-Bromoadenosine TP; 2′-b-Trifluoromethyladenosine TP; 2-Chloroadenosine TP; 2′-Deoxy-2′,2′-difluoroadenosine TP; 2′-Deoxy-2′-a-mercaptoadenosine TP; 2′-Deoxy-2′-a-thiomethoxyadenosine TP; 2′-Deoxy-2′-b-aminoadenosine TP; 2′-Deoxy-2′-b-azidoadenosine TP; 2′-Deoxy-2′-b-bromoadenosine TP; 2′-Deoxy-2′-b-chloroadenosine TP; 2′-Deoxy-2′-b-fluoroadenosine TP; 2′-Deoxy-2′-b-iodoadenosine TP; 2′-Deoxy-2′-b-mercaptoadenosine TP; 2′-Deoxy-2′-b-thiomethoxyadenosine TP; 2-Fluoroadenosine TP; 2-Iodoadenosine TP; 2-Mercaptoadenosine TP; 2-methoxy-adenine; 2-methylthio-adenine; 2-Trifluoromethyladenosine TP; 3-Deaza-3-bromoadenosine TP; 3-Deaza-3-chloroadenosine TP; 3-Deaza-3-fluoroadenosine TP; 3-Deaza-3-iodoadenosine TP; 3-Deazaadenosine TP; 4′-Azidoadenosine TP; 4′-Carbocyclic adenosine TP; 4′-Ethynyladenosine TP; 5′-Homo-adenosine TP; 8-Aza-ATP; 8-bromo-adenosine TP; 8-Trifluoromethyladenosine TP; 9-Deazaadenosine TP; 2-aminopurine; 7-deaza-2,6-diaminopurine; 7-deaza-8-aza-2,6-diaminopurine; 7-deaza-8-aza-2-aminopurine; 2,6-diaminopurine; 7-deaza-8-aza-adenine, 7-deaza-2-aminopurine; 2-thiocytidine; 3-methylcytidine; 5-formylcytidine; 5-hydroxymethylcytidine; 5-methylcytidine; N4-acetylcytidine; 2′-O-methylcytidine; 2′-O-methylcytidine; 5,2′-O-dimethylcytidine; 5-formyl-2′-O-methylcytidine; Lysidine; N4,2′-O-dimethylcytidine; N4-acetyl-2′-O-methylcytidine; N4-methylcytidine; N4,N4-Dimethyl-2′-OMe-Cytidine TP; 4-methylcytidine; 5-aza-cytidine; Pseudo-iso-cytidine; pyrrolo-cytidine; α-thio-cytidine; 2-(thio)cytosine; 2′-Amino-2′-deoxy-CTP; 2′-Azido-2′-deoxy-CTP; 2′-Deoxy-2′-a-aminocytidine TP; 2′-Deoxy-2′-a-azidocytidine TP; 3 (deaza) 5 (aza)cytosine; 3 (methyl)cytosine; 3-(alkyl)cytosine; 3-(deaza) 5 (aza)cytosine; 3-(methyl)cytidine; 4,2′-O-dimethylcytidine; 5 (halo)cytosine; 5 (methyl)cytosine; 5 (propynyl)cytosine; 5 (trifluoromethyl)cytosine; 5-(alkyl)cytosine; 5-(alkynyl)cytosine; 5-(halo)cytosine; 5-(propynyl)cytosine; 5-(trifluoromethyl)cytosine; 5-bromo-cytidine; 5-iodo-cytidine; 5-propynyl cytosine; 6-(azo)cytosine; 6-aza-cytidine; aza cytosine; deaza cytosine; N4 (acetyl)cytosine; 1-methyl-1-deaza-pseudoisocytidine; 1-methyl-pseudoisocytidine; 2-methoxy-5-methyl-cytidine; 2-methoxy-cytidine; 2-thio-5-methyl-cytidine; 4-methoxy-1-methyl-pseudoisocytidine; 4-methoxy-pseudoisocytidine; 4-thio-1-methyl-1-deaza-pseudoisocytidine; 4-thio-1-methyl-pseudoisocytidine; 4-thio-pseudoisocytidine; 5-aza-zebularine; 5-methyl-zebularine; pyrrolo-pseudoisocytidine; Zebularine; (E)-5-(2-Bromo-vinyl)cytidine TP; 2,2′-anhydro-cytidine TP hydrochloride; 2′Fluor-N4-Bz-cytidine TP; 2′Fluoro-N4-Acetyl-cytidine TP; 2′-O-Methyl-N4-Acetyl-cytidine TP; 2′O-methyl-N4-Bz-cytidine TP; 2′-a-Ethynylcytidine TP; 2′-a-Trifluoromethylcytidine TP; 2′-b-Ethynylcytidine TP; 2′-b-Trifluoromethylcytidine TP; 2′-Deoxy-2′,2′-difluorocytidine TP; 2′-Deoxy-2′-a-mercaptocytidine TP; 2′-Deoxy-2′-a-thiomethoxycytidine TP; 2′-Deoxy-2′-b-aminocytidine TP; 2′-Deoxy-2′-b-azidocytidine TP; 2′-Deoxy-2′-b-bromocytidine TP; 2′-Deoxy-2′-b-chlorocytidine TP; 2′-Deoxy-2′-b-fluorocytidine TP; 2′-Deoxy-2′-b-iodocytidine TP; 2′-Deoxy-2′-b-mercaptocytidine TP; 2′-Deoxy-2′-b-thiomethoxycytidine TP; 2′-O-Methyl-5-(1-propynyl)cytidine TP; 3′-Ethynylcytidine TP; 4′-Azidocytidine TP; 4′-Carbocyclic cytidine TP; 4′-Ethynylcytidine TP; 5-(1-Propynyl)ara-cytidine TP; 5-(2-Chloro-phenyl)-2-thiocytidine TP; 5-(4-Amino-phenyl)-2-thiocytidine TP; 5-Aminoallyl-CTP; 5-Cyanocytidine TP; 5-Ethynylara-cytidine TP; 5-Ethynylcytidine TP; 5′-Homo-cytidine TP; 5-Methoxycytidine TP; 5-Trifluoromethyl-Cytidine TP; N4-Amino-cytidine TP; N4-Benzoyl-cytidine TP; Pseudoisocytidine; 7-methylguanosine; N2,2′-O-dimethylguanosine; N2-methylguanosine; Wyosine; 1,2′-O-dimethylguanosine; 1-methylguanosine; 2′-O-methylguanosine; 2′-O-ribosylguanosine (phosphate); 2′-O-methylguanosine; 2′-O-ribosylguanosine (phosphate); 7-aminomethyl-7-deazaguanosine; 7-cyano-7-deazaguanosine; Archaeosine; Methylwyosine; N2,7-dimethylguanosine; N2,N2,2′-O-trimethylguanosine; N2,N2,7-trimethylguanosine; N2,N2-dimethylguanosine; N2,7,2′-O-trimethylguanosine; 6-thio-guanosine; 7-deaza-guanosine; 8-oxo-guanosine; N1-methyl-guanosine; α-thio-guanosine; 2 (propyl)guanine; 2-(alkyl)guanine; 2′-Amino-2′-deoxy-GTP; 2′-Azido-2′-deoxy-GTP; 2′-Deoxy-2′-a-aminoguanosine TP; 2′-Deoxy-2′-a-azidoguanosine TP; 6 (methyl)guanine; 6-(alkyl)guanine; 6-(methyl)guanine; 6-methyl-guanosine; 7 (alkyl)guanine; 7 (deaza)guanine; 7 (methyl)guanine; 7-(alkyl)guanine; 7-(deaza)guanine; 7-(methyl)guanine; 8 (alkyl)guanine; 8 (alkynyl)guanine; 8 (halo)guanine; 8 (thioalkyl)guanine; 8-(alkenyl)guanine; 8-(alkyl)guanine; 8-(alkynyl)guanine; 8-(amino)guanine; 8-(halo)guanine; 8-(hydroxyl)guanine; 8-(thioalkyl)guanine; 8-(thiol)guanine; aza guanine; deaza guanine; N (methyl)guanine; N-(methyl)guanine; 1-methyl-6-thio-guanosine; 6-methoxy-guanosine; 6-thio-7-deaza-8-aza-guanosine; 6-thio-7-deaza-guanosine; 6-thio-7-methyl-guanosine; 7-deaza-8-aza-guanosine; 7-methyl-8-oxo-guanosine; N2,N2-dimethyl-6-thio-guanosine; N2-methyl-6-thio-guanosine; 1-Me-GTP; 2′Fluoro-N2-isobutyl-guanosine TP; 2′O-methyl-N2-isobutyl-guanosine TP; 2′-a-Ethynylguanosine TP; 2′-a-Trifluoromethylguanosine TP; 2′-b-Ethynylguanosine TP; 2′-b-Trifluoromethylguanosine TP; 2′-Deoxy-2′,2′-difluoroguanosine TP; 2′-Deoxy-2′-a-mercaptoguanosine TP; 2′-Deoxy-2′-a-thiomethoxyguanosine TP; 2′-Deoxy-2′-b-aminoguanosine TP; 2′-Deoxy-2′-b-azidoguanosine TP; 2′-Deoxy-2′-b-bromoguanosine TP; 2′-Deoxy-2′-b-chloroguanosine TP; 2′-Deoxy-2′-b-fluoroguanosine TP; 2′-Deoxy-2′-b-iodoguanosine TP; 2′-Deoxy-2′-b-mercaptoguanosine TP; 2′-Deoxy-2′-b-thiomethoxyguanosine TP; 4′-Azidoguanosine TP; 4′-Carbocyclic guanosine TP; 4′-Ethynylguanosine TP; 5′-Homo-guanosine TP; 8-bromo-guanosine TP; 9-Deazaguanosine TP; N2-isobutyl-guanosine TP; 1-methylinosine; Inosine; 1,2′-O-dimethylinosine; 2′-O-methylinosine; 7-methylinosine; 2′-O-methylinosine; Epoxyqueuosine; galactosyl-queuosine; Mannosylqueuosine; Queuosine; allyamino-thymidine; aza thymidine; deaza thymidine; deoxy-thymidine; 2′-O-methyluridine; 2-thiouridine; 3-methyluridine; 5-carboxymethyluridine; 5-hydroxyuridine; 5-methyluridine; 5-taurinomethyl-2-thiouridine; 5-taurinomethyluridine; Dihydrouridine; Pseudouridine; (3-(3-amino-3-carboxypropyl)uridine; 1-methyl-3-(3-amino-5-carboxypropyl)pseudouridine; 1-methylpseduouridine; 1-methyl-pseudouridine; 2′-O-methyluridine; 2′-O-methylpseudouridine; 2′-O-methyluridine; 2-thio-2′-O-methyluridine; 3-(3-amino-3-carboxypropyl)uridine; 3,2′-O-dimethyluridine; 3-Methyl-pseudo-Uridine TP; 4-thiouridine; 5-(carboxyhydroxymethyl)uridine; 5-(carboxyhydroxymethyl)uridine methyl ester; 5,2′-O-dimethyluridine; 5,6-dihydro-uridine; 5-aminomethyl-2-thiouridine; 5-carbamoylmethyl-2′-O-methyluridine; 5-carbamoylmethyluridine; 5-carboxyhydroxymethyluridine; 5-carboxyhydroxymethyluridine methyl ester; 5-carboxymethylaminomethyl-2′-O-methyluridine; 5-carboxymethylaminomethyl-2-thiouridine; 5-carboxymethylaminomethyl-2-thiouridine; 5-carboxymethylaminomethyluridine; 5-carboxymethylaminomethyluridine; 5-Carbamoylmethyluridine TP; 5-methoxycarbonylmethyl-2′-O-methyluridine; 5-methoxycarbonylmethyl-2-thiouridine; 5-methoxycarbonylmethyluridine; 5-methoxyuridine; 5-methyl-2-thiouridine; 5-methylaminomethyl-2-selenouridine; 5-methylaminomethyl-2-thiouridine; 5-methylaminomethyluridine; 5-Methyldihydrouridine; 5-Oxyacetic acid-Uridine TP; 5-Oxyacetic acid-methyl ester-Uridine TP; N1-methyl-pseudo-uridine; uridine 5-oxyacetic acid; uridine 5-oxyacetic acid methyl ester; 3-(3-Amino-3-carboxypropyl)-Uridine TP; 5-(iso-Pentenylaminomethyl)-2-thiouridine TP; 5-(iso-Pentenylaminomethyl)-2′-O-methyluridine TP; 5-(iso-Pentenylaminomethyl)uridine TP; 5-propynyl uracil; α-thio-uridine; 1 (aminoalkylamino-carbonylethylenyl)-2(thio)-pseudouracil; 1 (aminoalkylaminocarbonylethylenyl)-2,4-(dithio)pseudouracil; 1 (aminoalkylaminocarbonylethylenyl)-4 (thio)pseudouracil; 1 (aminoalkylaminocarbonylethylenyl)-pseudouracil; 1 (aminocarbonylethylenyl)-2(thio)-pseudouracil; 1 (aminocarbonylethylenyl)-2,4-(dithio)pseudouracil; 1 (aminocarbonylethylenyl)-4 (thio)pseudouracil; 1 (aminocarbonylethylenyl)-pseudouracil; 1 substituted 2(thio)-pseudouracil; 1 substituted 2,4-(dithio)pseudouracil; 1 substituted 4 (thio)pseudouracil; 1 substituted pseudouracil; 1-(aminoalkylamino-carbonylethylenyl)-2-(thio)-pseudouracil; 1-Methyl-3-(3-amino-3-carboxypropyl) pseudouridine TP; 1-Methyl-3-(3-amino-3-carboxypropyl)pseudo-UTP; 1-Methyl-pseudo-UTP; 2 (thio)pseudouracil; 2′ deoxy uridine; 2′ fluorouridine; 2-(thio)uracil; 2,4-(dithio)psuedouracil; 2′ methyl, 2′amino, 2′azido, 2′fluro-guanosine; 2′-Amino-2′-deoxy-UTP; 2′-Azido-2′-deoxy-UTP; 2′-Azido-deoxyuridine TP; 2′-O-methylpseudouridine; 2′ deoxy uridine; 2′ fluorouridine; 2′-Deoxy-2′-a-aminouridine TP; 2′-Deoxy-2′-a-azidouridine TP; 2-methylpseudouridine; 3 (3 amino-3 carboxypropyl)uracil; 4 (thio)pseudouracil; 4-(thio)pseudouracil; 4-(thio)uracil; 4-thiouracil; 5 (1,3-diazole-1-alkyl)uracil; 5 (2-aminopropyl)uracil; 5 (aminoalkyl)uracil; 5 (dimethylaminoalkyl)uracil; 5 (guanidiniumalkyl)uracil; 5 (methoxycarbonylmethyl)-2-(thio)uracil; 5 (methoxycarbonyl-methyl)uracil; 5 (methyl) 2 (thio)uracil; 5 (methyl) 2,4 (dithio)uracil; 5 (methyl) 4 (thio)uracil; 5 (methylaminomethyl)-2 (thio)uracil; 5 (methylaminomethyl)-2,4 (dithio)uracil; 5 (methylaminomethyl)-4 (thio)uracil; 5 (propynyl)uracil; 5 (trifluoromethyl)uracil; 5-(2-aminopropyl)uracil; 5-(alkyl)-2-(thio)pseudouracil; 5-(alkyl)-2,4 (dithio)pseudouracil; 5-(alkyl)-4 (thio)pseudouracil; 5-(alkyl)pseudouracil; 5-(alkyl)uracil; 5-(alkynyl)uracil; 5-(allylamino)uracil; 5-(cyanoalkyl)uracil; 5-(dialkylaminoalkyl)uracil; 5-(dimethylaminoalkyl)uracil; 5-(guanidiniumalkyl)uracil; 5-(halo)uracil; 5-(1,3-diazole-1-alkyl)uracil; 5-(methoxy)uracil; 5-(methoxycarbonylmethyl)-2-(thio)uracil; 5-(methoxycarbonyl-methyl)uracil; 5-(methyl) 2(thio)uracil; 5-(methyl) 2,4 (dithio)uracil; 5-(methyl) 4 (thio)uracil; 5-(methyl)-2-(thio)pseudouracil; 5-(methyl)-2,4 (dithio)pseudouracil; 5-(methyl)-4 (thio)pseudouracil; 5-(methyl)pseudouracil; 5-(methylaminomethyl)-2 (thio)uracil; 5-(methylaminomethyl)-2,4(dithio)uracil; 5-(methylaminomethyl)-4-(thio)uracil; 5-(propynyl)uracil; 5-(trifluoromethyl)uracil; 5-aminoallyl-uridine; 5-bromo-uridine; 5-iodo-uridine; 5-uracil; 6 (azo)uracil; 6-(azo)uracil; 6-aza-uridine; allyamino-uracil; aza uracil; deaza uracil; N3 (methyl)uracil; Pseudo-UTP-1-2-ethanoic acid; Pseudouracil; 4-Thio-pseudo-UTP; 1-carboxymethyl-pseudouridine; 1-methyl-1-deaza-pseudouridine; 1-propynyl-uridine; 1-taurinomethyl-1-methyl-uridine; 1-taurinomethyl-4-thio-uridine; 1-taurinomethyl-pseudouridine; 2-methoxy-4-thio-pseudouridine; 2-thio-1-methyl-1-deaza-pseudouridine; 2-thio-1-methyl-pseudouridine; 2-thio-5-aza-uridine; 2-thio-dihydropseudouridine; 2-thio-dihydrouridine; 2-thio-pseudouridine; 4-methoxy-2-thio-pseudouridine; 4-methoxy-pseudouridine; 4-thio-1-methyl-pseudouridine; 4-thio-pseudouridine; 5-aza-uridine; Dihydropseudouridine; (±)1-(2-Hydroxypropyl)pseudouridine TP; (2R)-1-(2-Hydroxypropyl)pseudouridine TP; (2S)-1-(2-Hydroxypropyl)pseudouridine TP; (E)-5-(2-Bromo-vinyl)ara-uridine TP; (E)-5-(2-Bromo-vinyl)uridine TP; (Z)-5-(2-Bromo-vinyl)ara-uridine TP; (Z)-5-(2-Bromo-vinyl)uridine TP; 1-(2,2,2-Trifluoroethyl)-pseudo-UTP; 1-(2,2,3,3,3-Pentafluoropropyl)pseudouridine TP; 1-(2,2-Diethoxyethyl)pseudouridine TP; 1-(2,4,6-Trimethylbenzyl)pseudouridine TP; 1-(2,4,6-Trimethyl-benzyl)pseudo-UTP; 1-(2,4,6-Trimethyl-phenyl)pseudo-UTP; 1-(2-Amino-2-carboxyethyl)pseudo-UTP; 1-(2-Amino-ethyl)pseudo-UTP; 1-(2-Hydroxyethyl)pseudouridine TP; 1-(2-Methoxyethyl)pseudouridine TP; 1-(3,4-Bis-trifluoromethoxybenzyl)pseudouridine TP; 1-(3,4-Dimethoxybenzyl)pseudouridine TP; 1-(3-Amino-3-carboxypropyl)pseudo-UTP; 1-(3-Amino-propyl)pseudo-UTP; 1-(3-Cyclopropyl-prop-2-ynyl)pseudouridine TP; 1-(4-Amino-4-carboxybutyl)pseudo-UTP; 1-(4-Amino-benzyl)pseudo-UTP; 1-(4-Amino-butyl)pseudo-UTP; 1-(4-Amino-phenyl)pseudo-UTP; 1-(4-Azidobenzyl)pseudouridine TP; 1-(4-Bromobenzyl)pseudouridine TP; 1-(4-Chlorobenzyl)pseudouridine TP; 1-(4-Fluorobenzyl)pseudouridine TP; 1-(4-Iodobenzyl)pseudouridine TP; 1-(4-Methanesulfonylbenzyl)pseudouridine TP; 1-(4-Methoxybenzyl)pseudouridine TP; 1-(4-Methoxy-benzyl)pseudo-UTP; 1-(4-Methoxy-phenyl)pseudo-UTP; 1-(4-Methylbenzyl)pseudouridine TP; 1-(4-Methyl-benzyl)pseudo-UTP; 1-(4-Nitrobenzyl)pseudouridine TP; 1-(4-Nitro-benzyl)pseudo-UTP; 1(4-Nitro-phenyl)pseudo-UTP; 1-(4-Thiomethoxybenzyl)pseudouridine TP; 1-(4-Trifluoromethoxybenzyl)pseudouridine TP; 1-(4-Trifluoromethylbenzyl)pseudouridine TP; 1-(5-Amino-pentyl)pseudo-UTP; 1-(6-Amino-hexyl)pseudo-UTP; 1,6-Dimethyl-pseudo-UTP; 1-[3-(2-{2-[2-(2-Aminoethoxy)-ethoxy]-ethoxy}-ethoxy)-propionyl]pseudouridine TP; 1-{3-[2-(2-Aminoethoxy)-ethoxy]-propionyl}pseudouridine TP; 1-Acetylpseudouridine TP; 1-Alkyl-6-(1-propynyl)-pseudo-UTP; 1-Alkyl-6-(2-propynyl)-pseudo-UTP; 1-Alkyl-6-allyl-pseudo-UTP; 1-Alkyl-6-ethynyl-pseudo-UTP; 1-Alkyl-6-homoallyl-pseudo-UTP; 1-Alkyl-6-vinyl-pseudo-UTP; 1-Allylpseudouridine TP; 1-Aminomethyl-pseudo-UTP; 1-Benzoylpseudouridine TP; 1-Benzyloxymethylpseudouridine TP; 1-Benzyl-pseudo-UTP; 1-Biotinyl-PEG2-pseudouridine TP; 1-Biotinylpseudouridine TP; 1-Butyl-pseudo-UTP; 1-Cyanomethylpseudouridine TP; 1-Cyclobutylmethyl-pseudo-UTP; 1-Cyclobutyl-pseudo-UTP; 1-Cycloheptylmethyl-pseudo-UTP; 1-Cycloheptyl-pseudo-UTP; 1-Cyclohexylmethyl-pseudo-UTP; 1-Cyclohexyl-pseudo-UTP; 1-Cyclooctylmethyl-pseudo-UTP; 1-Cyclooctyl-pseudo-UTP; 1-Cyclopentylmethyl-pseudo-UTP; 1-Cyclopentyl-pseudo-UTP; 1-Cyclopropylmethyl-pseudo-UTP; 1-Cyclopropyl-pseudo-UTP; 1-Ethyl-pseudo-UTP; 1-Hexyl-pseudo-UTP; 1-Homoallylpseudouridine TP; 1-Hydroxymethylpseudouridine TP; 1-iso-propyl-pseudo-UTP; 1-Me-2-thio-pseudo-UTP; 1-Me-4-thio-pseudo-UTP; 1-Me-alpha-thio-pseudo-UTP; 1-Methanesulfonylmethylpseudouridine TP; 1-Methoxymethylpseudouridine TP; 1-Methyl-6-(2,2,2-Trifluoroethyl)pseudo-UTP; 1-Methyl-6-(4-morpholino)-pseudo-UTP; 1-Methyl-6-(4-thiomorpholino)-pseudo-UTP; 1-Methyl-6-(substituted phenyl)pseudo-UTP; 1-Methyl-6-amino-pseudo-UTP; 1-Methyl-6-azido-pseudo-UTP; 1-Methyl-6-bromo-pseudo-UTP; 1-Methyl-6-butyl-pseudo-UTP; 1-Methyl-6-chloro-pseudo-UTP; 1-Methyl-6-cyano-pseudo-UTP; 1-Methyl-6-dimethylamino-pseudo-UTP; 1-Methyl-6-ethoxy-pseudo-UTP; 1-Methyl-6-ethylcarboxylate-pseudo-UTP; 1-Methyl-6-ethyl-pseudo-UTP; 1-Methyl-6-fluoro-pseudo-UTP; 1-Methyl-6-formyl-pseudo-UTP; 1-Methyl-6-hydroxyamino-pseudo-UTP; 1-Methyl-6-hydroxy-pseudo-UTP; 1-Methyl-6-iodo-pseudo-UTP; 1-Methyl-6-iso-propyl-pseudo-UTP; 1-Methyl-6-methoxy-pseudo-UTP; 1-Methyl-6-methylamino-pseudo-UTP; 1-Methyl-6-phenyl-pseudo-UTP; 1-Methyl-6-propyl-pseudo-UTP; 1-Methyl-6-tert-butyl-pseudo-UTP; 1-Methyl-6-trifluoromethoxy-pseudo-UTP; 1-Methyl-6-trifluoromethyl-pseudo-UTP; 1-Morpholinomethylpseudouridine TP; 1-Pentyl-pseudo-UTP; 1-Phenyl-pseudo-UTP; 1-Pivaloylpseudouridine TP; 1-Propargylpseudouridine TP; 1-Propyl-pseudo-UTP; 1-propynyl-pseudouridine; 1-p-tolyl-pseudo-UTP; 1-tert-Butyl-pseudo-UTP; 1-Thiomethoxymethylpseudouridine TP; 1-Thiomorpholinomethylpseudouridine TP; 1-Trifluoroacetylpseudouridine TP; 1-Trifluoromethyl-pseudo-UTP; 1-Vinylpseudouridine TP; 2,2′-anhydro-uridine TP; 2′-bromo-deoxyuridine TP; 2′-F-5-Methyl-2′-deoxy-UTP; 2′-OMe-5-Me-UTP; 2′-OMe-pseudo-UTP; 2′-a-Ethynyluridine TP; 2′-a-Trifluoromethyluridine TP; 2′-b-Ethynyluridine TP; 2′-b-Trifluoromethyluridine TP; 2′-Deoxy-2′,2′-difluorouridine TP; 2′-Deoxy-2′-a-mercaptouridine TP; 2′-Deoxy-2′-a-thiomethoxyuridine TP; 2′-Deoxy-2′-b-aminouridine TP; 2′-Deoxy-2′-b-azidouridine TP; 2′-Deoxy-2′-b-bromouridine TP; 2′-Deoxy-2′-b-chlorouridine TP; 2′-Deoxy-2′-b-fluorouridine TP; 2′-Deoxy-2′-b-iodouridine TP; 2′-Deoxy-2′-b-mercaptouridine TP; 2′-Deoxy-2′-b-thiomethoxyuridine TP; 2-methoxy-4-thio-uridine; 2-methoxyuridine; 2′-O-Methyl-5-(1-propynyl)uridine TP; 3-Alkyl-pseudo-UTP; 4′-Azidouridine TP; 4′-Carbocyclic uridine TP; 4′-Ethynyluridine TP; 5-(1-Propynyl)ara-uridine TP; 5-(2-Furanyl)uridine TP; 5-Cyanouridine TP; 5-Dimethylaminouridine TP; 5′-Homo-uridine TP; 5-iodo-2′-fluoro-deoxyuridine TP; 5-Phenylethynyluridine TP; 5-Trideuteromethyl-6-deuterouridine TP; 5-Trifluoromethyl-Uridine TP; 5-Vinylarauridine TP; 6-(2,2,2-Trifluoroethyl)-pseudo-UTP; 6-(4-Morpholino)-pseudo-UTP; 6-(4-Thiomorpholino)-pseudo-UTP; 6-(Substituted-Phenyl)-pseudo-UTP; 6-Amino-pseudo-UTP; 6-Azido-pseudo-UTP; 6-Bromo-pseudo-UTP; 6-Butyl-pseudo-UTP; 6-Chloro-pseudo-UTP; 6-Cyano-pseudo-UTP; 6-Dimethylamino-pseudo-UTP; 6-Ethoxy-pseudo-UTP; 6-Ethylcarboxylate-pseudo-UTP; 6-Ethyl-pseudo-UTP; 6-Fluoro-pseudo-UTP; 6-Formyl-pseudo-UTP; 6-Hydroxyamino-pseudo-UTP; 6-Hydroxy-pseudo-UTP; 6-Iodo-pseudo-UTP; 6-iso-Propyl-pseudo-UTP; 6-Methoxy-pseudo-UTP; 6-Methylamino-pseudo-UTP; 6-Methyl-pseudo-UTP; 6-Phenyl-pseudo-UTP; 6-Phenyl-pseudo-UTP; 6-Propyl-pseudo-UTP; 6-tert-Butyl-pseudo-UTP; 6-Trifluoromethoxy-pseudo-UTP; 6-Trifluoromethyl-pseudo-UTP; Alpha-thio-pseudo-UTP; Pseudouridine 1-(4-methylbenzenesulfonic acid) TP; Pseudouridine 1-(4-methylbenzoic acid) TP; Pseudouridine TP 1-[3-(2-ethoxy)]propionic acid; Pseudouridine TP 1-[3-{2-(2-[2-(2-ethoxy)-ethoxy]-ethoxy)-ethoxy}]propionic acid; Pseudouridine TP 1-[3-{2-(2-[2-{2(2-ethoxy)-ethoxy}-ethoxy]-ethoxy)-ethoxy}]propionic acid; Pseudouridine TP 1-[3-{2-(2-[2-ethoxy]-ethoxy)-ethoxy}]propionic acid; Pseudouridine TP 1-[3-{2-(2-ethoxy)-ethoxy}]propionic acid; Pseudouridine TP 1-methylphosphonic acid; Pseudouridine TP 1-methylphosphonic acid diethyl ester; Pseudo-UTP-N1-3-propionic acid; Pseudo-UTP-N1-4-butanoic acid; Pseudo-UTP-N1-5-pentanoic acid; Pseudo-UTP-N1-6-hexanoic acid; Pseudo-UTP-N1-7-heptanoic acid; Pseudo-UTP-N1-methyl-p-benzoic acid; Pseudo-UTP-N1-p-benzoic acid; Wybutosine; Hydroxywybutosine; Isowyosine; Peroxywybutosine; undermodified hydroxywybutosine; 4-demethylwyosine; 2,6-(diamino)purine; 1-(aza)-2-(thio)-3-(aza)-phenoxazin-1-yl: 1,3-(diaza)-2-(oxo)-phenthiazin-1-yl; 1,3-(diaza)-2-(oxo)-phenoxazin-1-yl; 1,3,5-(triaza)-2,6-(dioxa)-naphthalene; 2 (amino)purine; 2,4,5-(trimethyl)phenyl; 2′ methyl, 2′amino, 2′azido, 2′fluro-cytidine; 2′ methyl, 2′amino, 2′azido, 2′fluro-adenine; 2′methyl, 2′amino, 2′azido, 2′fluro-uridine; 2′-amino-2′-deoxyribose; 2-amino-6-Chloro-purine; 2-aza-inosinyl; 2′-azido-2′-deoxyribose; 2′fluoro-2′-deoxyribose; 2′-fluoro-modified bases; 2′-O-methyl-ribose; 2-oxo-7-aminopyridopyrimidin-3-yl; 2-oxo-pyridopyrimidine-3-yl; 2-pyridinone; 3 nitropyrrole; 3-(methyl)-7-(propynyl)isocarbostyrilyl; 3-(methyl)isocarbostyrilyl; 4-(fluoro)-6-(methyl)benzimidazole; 4-(methyl)benzimidazole; 4-(methyl)indolyl; 4,6-(dimethyl)indolyl; 5 nitroindole; 5 substituted pyrimidines; 5-(methyl)isocarbostyrilyl; 5-nitroindole; 6-(aza)pyrimidine; 6-(azo)thymine; 6-(methyl)-7-(aza)indolyl; 6-chloro-purine; 6-phenyl-pyrrolo-pyrimidin-2-on-3-yl; 7-(aminoalkylhydroxy)-1-(aza)-2-(thio)-3-(aza)-phenthiazin-1-yl; 7-(aminoalkylhydroxy)-1-(aza)-2-(thio)-3-(aza)-phenoxazin-1-yl; 7-(aminoalkylhydroxy)-1,3-(diaza)-2-(oxo)-phenoxazin-1-yl; 7-(aminoalkylhydroxy)-1,3-(diaza)-2-(oxo)-phenthiazin-1-yl; 7-(aminoalkylhydroxy)-1,3-(diaza)-2-(oxo)-phenoxazin-1-yl; 7-(aza)indolyl; 7-(guanidiniumalkylhydroxy)-1-(aza)-2-(thio)-3-(aza)-phenoxazin-1-yl; 7-(guanidiniumalkylhydroxy)-1-(aza)-2-(thio)-3-(aza)-phenthiazin-1-yl; 7-(guanidiniumalkylhydroxy)-1-(aza)-2-(thio)-3-(aza)-phenoxazin-1-yl; 7-(guanidiniumalkylhydroxy)-1,3-(diaza)-2-(oxo)-phenoxazin-1-yl; 7-(guanidiniumalkylhydroxy)-1,3-(diaza)-2-(oxo)-phenthiazin-1-yl; 7-(guanidiniumalkylhydroxy)-1,3-(diaza)-2-(oxo)-phenoxazin-1-yl; 7-(propynyl)isocarbostyrilyl; 7-(propynyl)isocarbostyrilyl, propynyl-7-(aza)indolyl; 7-deaza-inosinyl; 7-substituted 1-(aza)-2-(thio)-3-(aza)-phenoxazin-1-yl; 7-substituted 1,3-(diaza)-2-(oxo)-phenoxazin-1-yl; 9-(methyl)-imidizopyridinyl; Aminoindolyl; Anthracenyl; bis-ortho-(aminoalkylhydroxy)-6-phenyl-pyrrolo-pyrimidin-2-on-3-yl; bis-ortho-substituted-6-phenyl-pyrrolo-pyrimidin-2-on-3-yl; Difluorotolyl; Hypoxanthine; Imidizopyridinyl; Inosinyl; Isocarbostyrilyl; Isoguanisine; N2-substituted purines; N6-methyl-2-amino-purine; N6-substituted purines; N-alkylated derivative; Napthalenyl; Nitrobenzimidazolyl; Nitroimidazolyl; Nitroindazolyl; Nitropyrazolyl; Nubularine; O6-substituted purines; O-alkylated derivative; ortho-(aminoalkylhydroxy)-6-phenyl-pyrrolo-pyrimidin-2-on-3-yl; ortho-substituted-6-phenyl-pyrrolo-pyrimidin-2-on-3-yl; Oxoformycin TP; para-(aminoalkylhydroxy)-6-phenyl-pyrrolo-pyrimidin-2-on-3-yl; para-substituted-6-phenyl-pyrrolo-pyrimidin-2-on-3-yl; Pentacenyl; Phenanthracenyl; Phenyl; propynyl-7-(aza)indolyl; Pyrenyl; pyridopyrimidin-3-yl; pyridopyrimidin-3-yl, 2-oxo-7-aminopyridopyrimidin-3-yl; pyrrolo-pyrimidin-2-on-3-yl; Pyrrolopyrimidinyl; Pyrrolopyrizinyl; Stilbenzyl; substituted 1,2,4-triazoles; Tetracenyl; Tubercidine; Xanthine; Xanthosine-5′-TP; 2-thio-zebularine; 5-aza-2-thio-zebularine; 7-deaza-2-amino-purine; pyridin-4-one ribonucleoside; 2-Amino-riboside-TP; Formycin A TP; Formycin B TP; Pyrrolosine TP; 2′-OH-ara-adenosine TP; 2′-OH-ara-cytidine TP; 2′-OH-ara-uridine TP; 2′-OH-ara-guanosine TP; 5-(2-carbomethoxyvinyl)uridine TP; and N6-(19-Amino-pentaoxanonadecyl)adenosine TP.
• In some embodiments, polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) include a combination of at least two (e.g., 2, 3, 4 or more) of the aforementioned modified nucleobases.
• In some embodiments, modified nucleobases in polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) are selected from the group consisting of pseudouridine (ψ), N1-methylpseudouridine (m¹ψ), N1-ethylpseudouridine, 2-thiouridine, 4′-thiouridine, 5-methylcytosine, 2-thio-1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methoxyuridine and 2′-O-methyl uridine. In some embodiments, polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) include a combination of at least two (e.g., 2, 3, 4 or more) of the aforementioned modified nucleobases.
• In some embodiments, modified nucleobases in polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) are selected from the group consisting of 1-methyl-pseudouridine (m¹ψ), 5-methoxy-uridine (mo⁵U), 5-methyl-cytidine (m⁵C), pseudouridine (ψ), α-thio-guanosine and α-thio-adenosine. In some embodiments, polynucleotides includes a combination of at least two (e.g., 2, 3, 4 or more) of the aforementioned modified nucleobases.
• In some embodiments, polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) comprise pseudouridine (ψ) and 5-methyl-cytidine (m⁵C). In some embodiments, polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) comprise 1-methyl-pseudouridine (m¹ψ). In some embodiments, polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) comprise 1-methyl-pseudouridine (m¹ψ) and 5-methyl-cytidine (m⁵C). In some embodiments, polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) comprise 2-thiouridine (s²U). In some embodiments, polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) comprise 2-thiouridine and 5-methyl-cytidine (m⁵C). In some embodiments, polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) comprise methoxy-uridine (mo⁵U). In some embodiments, polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) comprise 5-methoxy-uridine (mo⁵U) and 5-methyl-cytidine (m⁵C). In some embodiments, polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) comprise 2′-O-methyl uridine. In some embodiments polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) comprise 2′-O-methyl uridine and 5-methyl-cytidine (m⁵C). In some embodiments, polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) comprise N6-methyl-adenosine (m⁶A). In some embodiments, polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) comprise N6-methyl-adenosine (m⁶A) and 5-methyl-cytidine (m⁵C).
• In some embodiments, polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) are uniformly modified (e.g., fully modified, modified throughout the entire sequence) for a particular modification. For example, a polynucleotide can be uniformly modified with 5-methyl-cytidine (m⁵C), meaning that all cytosine residues in the mRNA sequence are replaced with 5-methyl-cytidine (m⁵C). Similarly, a polynucleotide can be uniformly modified for any type of nucleoside residue present in the sequence by replacement with a modified residue such as those set forth above.
• Exemplary nucleobases and nucleosides having a modified cytosine include N4-acetyl-cytidine (ac4C), 5-methyl-cytidine (m5C), 5-halo-cytidine (e.g., 5-iodo-cytidine), 5-hydroxymethyl-cytidine (hm5C), 1-methyl-pseudoisocytidine, 2-thio-cytidine (s2C), and 2-thio-5-methyl-cytidine.
• In some embodiments, a modified nucleobase is a modified uridine. Exemplary nucleobases and In some embodiments, a modified nucleobase is a modified cytosine. nucleosides having a modified uridine include 5-cyano uridine, and 4′-thio uridine.
• In some embodiments, a modified nucleobase is a modified adenine. Exemplary nucleobases and nucleosides having a modified adenine include 7-deaza-adenine, 1-methyl-adenosine (m1A), 2-methyl-adenine (m2A), and N6-methyl-adenosine (m6A).
• In some embodiments, a modified nucleobase is a modified guanine. Exemplary nucleobases and nucleosides having a modified guanine include inosine (I), 1-methyl-inosine (m1I), wyosine (imG), methylwyosine (mimG), 7-deaza-guanosine, 7-cyano-7-deaza-guanosine (preQ0), 7-aminomethyl-7-deaza-guanosine (preQ1), 7-methyl-guanosine (m7G), 1-methyl-guanosine (m1G), 8-oxo-guanosine, 7-methyl-8-oxo-guanosine.
• The polynucleotides of the present disclosure may be partially or fully modified along the entire length of the molecule. For example, one or more or all or a given type of nucleotide (e.g., purine or pyrimidine, or any one or more or all of A, G, U, C) may be uniformly modified in a polynucleotide of the disclosure, or in a given predetermined sequence region thereof (e.g., in the mRNA including or excluding the polyA tail). In some embodiments, all nucleotides X in a polynucleotide of the present disclosure (or in a given sequence region thereof) are modified nucleotides, wherein X may any one of nucleotides A, G, U, C, or any one of the combinations A+G, A+U, A+C, G+U, G+C, U+C, A+G+U, A+G+C, G+U+C or A+G+C.
• The polynucleotide may contain from about 1% to about 100% modified nucleotides (either in relation to overall nucleotide content, or in relation to one or more types of nucleotide, i.e., any one or more of A, G, U or C) or any intervening percentage (e.g., from 1% to 20%, from 1% to 25%, from 1% to 50%, from 1% to 60%, from 1% to 70%, from 1% to 80%, from 1% to 90%, from 1% to 95%, from 10% to 20%, from 10% to 25%, from 10% to 50%, from 10% to 60%, from 10% to 70%, from 10% to 80%, from 10% to 90%, from 10% to 95%, from 10% to 100%, from 20% to 25%, from 20% to 50%, from 20% to 60%, from 20% to 70%, from 20% to 80%, from 20% to 90%, from 20% to 95%, from 20% to 100%, from 50% to 60%, from 50% to 70%, from 50% to 80%, from 50% to 90%, from 50% to 95%, from 50% to 100%, from 70% to 80%, from 70% to 90%, from 70% to 95%, from 70% to 100%, from 80% to 90%, from 80% to 95%, from 80% to 100%, from 90% to 95%, from 90% to 100%, and from 95% to 100%). Any remaining percentage is accounted for by the presence of unmodified A, G, U, or C.
• The polynucleotides may contain at a minimum 1% and at maximum 100% modified nucleotides, or any intervening percentage, such as at least 5% modified nucleotides, at least 10% modified nucleotides, at least 25% modified nucleotides, at least 50% modified nucleotides, at least 80% modified nucleotides, or at least 90% modified nucleotides. For example, the polynucleotides may contain a modified pyrimidine such as a modified uracil or cytosine. In some embodiments, at least 5%, at least 10%, at least 25%, at least 50%, at least 80%, at least 90% or 100% of the uracil in the polynucleotide is replaced with a modified uracil (e.g., a 5-substituted uracil). The modified uracil can be replaced by a compound having a single unique structure, or can be replaced by a plurality of compounds having different structures (e.g., 2, 3, 4 or more unique structures). n some embodiments, at least 5%, at least 10%, at least 25%, at least 50%, at least 80%, at least 90% or 100% of the cytosine in the polynucleotide is replaced with a modified cytosine (e.g., a 5-substituted cytosine). The modified cytosine can be replaced by a compound having a single unique structure, or can be replaced by a plurality of compounds having different structures (e.g., 2, 3, 4 or more unique structures).
• Thus, in some embodiments, the RNA (e.g., mRNA) vaccines comprise a 5′UTR element, an optionally codon optimized open reading frame, and a 3′UTR element, a poly(A) sequence and/or a polyadenylation signal wherein the RNA is not chemically modified.
• In some embodiments, the modified nucleobase is a modified uracil. Exemplary nucleobases and nucleosides having a modified uracil include pseudouridine (w), pyridin-4-one ribonucleoside, 5-aza-uridine, 6-aza-uridine, 2-thio-5-aza-uridine, 2-thio-uridine (s²U), 4-thio-uridine (s⁴U), 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxy-uridine (ho⁵U), 5-aminoallyl-uridine, 5-halo-uridine (e.g., 5-iodo-uridineor 5-bromo-uridine), 3-methyl-uridine (m³U), 5-methoxy-uridine (mo⁵U), uridine 5-oxyacetic acid (cmo⁵U), uridine 5-oxyacetic acid methyl ester (mcmo⁵U), 5-carboxymethyl-uridine (cm⁵U), 1-carboxymethyl-pseudouridine, 5-carboxyhydroxymethyl-uridine (chm⁵U), 5-carboxyhydroxymethyl-uridine methyl ester (mchm⁵U), 5-methoxycarbonylmethyl-uridine (mcm⁵U), 5-methoxycarbonylmethyl-2-thio-uridine (mcm⁵s²U), 5-aminomethyl-2-thio-uridine (nm⁵s²U), 5-methylaminomethyl-uridine (mnm⁵U), 5-methylaminomethyl-2-thio-uridine (mnm⁵s²U), 5-methylaminomethyl-2-seleno-uridine (mnm⁵se²U), 5-carbamoylmethyl-uridine (ncm⁵U), 5-carboxymethylaminomethyl-uridine (cmnm⁵U), 5-carboxymethylaminomethyl-2-thio-uridine (cmnm⁵s²U), 5-propynyl-uridine, 1-propynyl-pseudouridine, 5-taurinomethyl-uridine (τm⁵U), 1-taurinomethyl-pseudouridine, 5-taurinomethyl-2-thio-uridine(τm⁵s²U), 1-taurinomethyl-4-thio-pseudouridine, 5-methyl-uridine (m⁵U, i.e., having the nucleobase deoxythymine), 1-methyl-pseudouridine (m¹ψ), 5-methyl-2-thio-uridine (m⁵s²U), 1-methyl-4-thio-pseudouridine(m¹s⁴ψ), 4-thio-1-methyl-pseudouridine, 3-methyl-pseudouridine (m³ψ), 2-thio-1-methyl-pseudouridine, 1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-1-deaza-pseudouridine, dihydrouridine (D), dihydropseudouridine, 5,6-dihydrouridine, 5-methyldihydrouridine (m⁵D), 2-thio-dihydrouridine, 2-thio-dihydropseudouridine, 2-methoxy-uridine, 2-methoxy-4-thio-uridine, 4-methoxy-pseudouridine, 4-methoxy-2-thio-pseudouridine, N1-methyl-pseudouridine, 3-(3-amino-3-carboxypropyl)uridine (acp³U), 1-methyl-3-(3-amino-3-carboxypropyl)pseudouridine (acp³ ψ), 5-(isopentenylaminomethyl)uridine (inm⁵U), 5-(isopentenylaminomethyl)-2-thio-uridine (inm⁵s²U), α-thio-uridine, 2′-O-methyl-uridine (Um), 5,2′-O-dimethyl-uridine (m⁵Um), 2′-O-methyl-pseudouridine (ψm), 2-thio-2′-O-methyl-uridine (s²Um), 5-methoxycarbonylmethyl-2′-O-methyl-uridine (mcm⁵Um), 5-carbamoylmethyl-2′-O-methyl-uridine (ncm⁵Um), 5-carboxymethylaminomethyl-2′-O-methyl-uridine (cmnm⁵Um), 3,2′-O-dimethyl-uridine (m³Um), and 5-(isopentenylaminomethyl)-2′-O-methyl-uridine (inm⁵Um), 1-thio-uridine, deoxythymidine, 2′-F-ara-uridine, 2′-F-uridine, 2′-OH-ara-uridine, 5-(2-carbomethoxyvinyl) uridine, and 5-[3-(1-E-propenylamino)]uridine.
• In some embodiments, the modified nucleobase is a modified cytosine. Exemplary nucleobases and nucleosides having a modified cytosine include 5-aza-cytidine, 6-aza-cytidine, pseudoisocytidine, 3-methyl-cytidine (m³C), N4-acetyl-cytidine (ac⁴C), 5-formylcytidine (f⁵C), N4-methyl-cytidine (m⁴C), 5-methyl-cytidine (m⁵C), 5-halo-cytidine (e.g., 5-iodo-cytidine), 5-hydroxymethyl-cytidine (hm⁵C), 1-methyl-pseudoisocytidine, pyrrolo-cytidine, pyrrolo-pseudoisocytidine, 2-thio-cytidine (s²C), 2-thio-5-methyl-cytidine, 4-thio-pseudoisocytidine, 4-thio-1-methyl-pseudoisocytidine, 4-thio-1-methyl-1-deaza-pseudoisocytidine, 1-methyl-1-deaza-pseudoisocytidine, zebularine, 5-aza-zebularine, 5-methyl-zebularine, 5-aza-2-thio-zebularine, 2-thio-zebularine, 2-methoxy-cytidine, 2-methoxy-5-methyl-cytidine, 4-methoxy-pseudoisocytidine, 4-methoxy-1-methyl-pseudoisocytidine, lysidine (k₂C), α-thio-cytidine, 2′-O-methyl-cytidine (Cm), 5,2′-O-dimethylcytidine (m⁵Cm), N4-acetyl-2′-O-methyl-cytidine (ac⁴Cm), N4,2′-O-dimethylcytidine (m⁴Cm), 5-formyl-2′-O-methyl-cytidine (f⁵Cm), N4,N4,2′-O-trimethyl-cytidine (m⁴ ₂Cm), 1-thio-cytidine, 2′-F-ara-cytidine, 2′-F-cytidine, and 2′-OH-ara-cytidine.
• In some embodiments, the modified nucleobase is a modified adenine. Exemplary nucleobases and nucleosides having a modified adenine include 2-amino-purine, 2, 6-diaminopurine, 2-amino-6-halo-purine (e.g., 2-amino-6-chloro-purine), 6-halo-purine (e.g., 6-chloro-purine), 2-amino-6-methyl-purine, 8-azido-adenosine, 7-deaza-adenine, 7-deaza-8-aza-adenine, 7-deaza-2-amino-purine, 7-deaza-8-aza-2-amino-purine, 7-deaza-2,6-diaminopurine, 7-deaza-8-aza-2,6-diaminopurine, 1-methyl-adenosine (m¹A), 2-methyl-adenine (m²A), N6-methyl-adenosine (m⁶A), 2-methylthio-N6-methyl-adenosine (ms² m⁶A), N6-isopentenyl-adenosine (i⁶A), 2-methylthio-N6-isopentenyl-adenosine (ms²i⁶A), N6-(cis-hydroxyisopentenyl)adenosine (io⁶A), 2-methylthio-N6-(cis-hydroxyisopentenyl)adenosine (ms²io⁶A), N6-glycinylcarbamoyl-adenosine (g⁶A), N6-threonylcarbamoyl-adenosine (t⁶A), N6-methyl-N6-threonylcarbamoyl-adenosine (m⁶t⁶A), 2-methylthio-N6-threonylcarbamoyl-adenosine (ms²g⁶A), N6,N6-dimethyl-adenosine (m⁶ ₂A), N6-hydroxynorvalylcarbamoyl-adenosine (hn⁶A), 2-methylthio-N6-hydroxynorvalylcarbamoyl-adenosine (ms²hn⁶A), N6-acetyl-adenosine (ac⁶A), 7-methyl-adenine, 2-methylthio-adenine, 2-methoxy-adenine, α-thio-adenosine, 2′-O-methyl-adenosine (Am), N6,2′-O-dimethyl-adenosine (m⁶Am), N6,N6,2′-O-trimethyl-adenosine (m⁶ ₂Am), 1,2′-O-dimethyl-adenosine (m¹Am), 2′-O-ribosyladenosine (phosphate) (Ar(p)), 2-amino-N6-methyl-purine, 1-thio-adenosine, 8-azido-adenosine, 2′-F-ara-adenosine, 2′-F-adenosine, 2′-OH-ara-adenosine, and N6-(19-amino-pentaoxanonadecyl)-adenosine.
• In some embodiments, the modified nucleobase is a modified guanine. Exemplary nucleobases and nucleosides having a modified guanine include inosine (I), 1-methyl-inosine (m¹I), wyosine (imG), methylwyosine (mimG), 4-demethyl-wyosine (imG-14), isowyosine (imG2), wybutosine (yW), peroxywybutosine (o₂yW), hydroxywybutosine (OhyW), undermodified hydroxywybutosine (OhyW*), 7-deaza-guanosine, queuosine (Q), epoxyqueuosine (oQ), galactosyl-queuosine (galQ), mannosyl-queuosine (manQ), 7-cyano-7-deaza-guanosine (preQ₀), 7-aminomethyl-7-deaza-guanosine (preQ₁), archaeosine (G⁺), 7-deaza-8-aza-guanosine, 6-thio-guanosine, 6-thio-7-deaza-guanosine, 6-thio-7-deaza-8-aza-guanosine, 7-methyl-guanosine (m⁷G), 6-thio-7-methyl-guanosine, 7-methyl-inosine, 6-methoxy-guanosine, 1-methyl-guanosine (m¹G), N2-methyl-guanosine (m²G), N2,N2-dimethyl-guanosine (m² ₂G), N2,7-dimethyl-guanosine (m^2,7G), N2,N2,7-dimethyl-guanosine (m^2,2,7G), 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, 1-methyl-6-thio-guanosine, N2-methyl-6-thio-guanosine, N2,N2-dimethyl-6-thio-guanosine, α-thio-guanosine, 2′-O-methyl-guanosine (Gm), N2-methyl-2′-O-methyl-guanosine (m²Gm), N2,N2-dimethyl-2′-O-methyl-guanosine (m² ₂Gm), 1-methyl-2′-O-methyl-guanosine (m¹Gm), N2,7-dimethyl-2′-O-methyl-guanosine (m^2,7Gm), 2′-O-methyl-inosine (Im), 1,2′-O-dimethyl-inosine (m¹Im), 2′-O-ribosylguanosine (phosphate) (Gr(p)), 1-thio-guanosine, O6-methyl-guanosine, 2′-F-ara-guanosine, and 2′-F-guanosine.
N-Linked Glycosylation Site Mutants
• N-linked glycans of viral proteins play important roles in modulating the immune response. Glycans can be important for maintaining the appropriate antigenic conformations, shielding potential neutralization epitopes, and may alter the proteolytic susceptibility of proteins. Some viruses have putative N-linked glycosylation sites. Deletion or modification of an N-linked glycosylation site may enhance the immune response. Thus, the present disclosure provides, in some embodiments, RNA (e.g., mRNA) vaccines comprising nucleic acids (e.g., mRNA) encoding antigenic polypeptides that comprise a deletion or modification at one or more N-linked glycosylation sites.
• In Vitro Transcription of RNA (e.g., mRNA)
• STD vaccines of the present disclosure comprise at least one RNA polynucleotide, such as a mRNA (e.g., modified mRNA). mRNA, for example, is transcribed in vitro from template DNA, referred to as an “in vitro transcription template.” In some embodiments, an in vitro transcription template encodes a 5′ untranslated (UTR) region, contains an open reading frame, and encodes a 3′ UTR and a polyA tail. The particular nucleic acid sequence composition and length of an in vitro transcription template will depend on the mRNA encoded by the template.
• A “5′ untranslated region” (5′UTR) refers to a region of an mRNA that is directly upstream (i.e., 5′) from the start codon (i.e., the first codon of an mRNA transcript translated by a ribosome) that does not encode a polypeptide.
• A “3′ untranslated region” (3′UTR) refers to a region of an mRNA that is directly downstream (i.e., 3′) from the stop codon (i.e., the codon of an mRNA transcript that signals a termination of translation) that does not encode a polypeptide.
• An “open reading frame” is a continuous stretch of DNA beginning with a start codon (e.g., methionine (ATG)), and ending with a stop codon (e.g., TAA, TAG or TGA) and encodes a polypeptide.
• A “polyA tail” is a region of mRNA that is downstream, e.g., directly downstream (i.e., 3′), from the 3′ UTR that contains multiple, consecutive adenosine monophosphates. A polyA tail may contain 10 to 300 adenosine monophosphates. For example, a polyA tail may contain 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290 or 300 adenosine monophosphates. In some embodiments, a polyA tail contains 50 to 250 adenosine monophosphates. In a relevant biological setting (e.g., in cells, in vivo) the poly(A) tail functions to protect mRNA from enzymatic degradation, e.g., in the cytoplasm, and aids in transcription termination, export of the mRNA from the nucleus and translation.
• In some embodiments, a polynucleotide includes 200 to 3,000 nucleotides. For example, a polynucleotide may include 200 to 500, 200 to 1000, 200 to 1500, 200 to 3000, 500 to 1000, 500 to 1500, 500 to 2000, 500 to 3000, 1000 to 1500, 1000 to 2000, 1000 to 3000, 1500 to 3000, or 2000 to 3000 nucleotides.
Flagellin Adjuvants
• Flagellin is an approximately 500 amino acid monomeric protein that polymerizes to form the flagella associated with bacterial motion. Flagellin is expressed by a variety of flagellated bacteria (Salmonella typhimurium for example) as well as non-flagellated bacteria (such as Escherichia coli). Sensing of flagellin by cells of the innate immune system (dendritic cells, macrophages, etc.) is mediated by the Toll-like receptor 5 (TLR5) as well as by Nod-like receptors (NLRs) Ipaf and Naip5. TLRs and NLRs have been identified as playing a role in the activation of innate immune response and adaptive immune response. As such, flagellin provides an adjuvant effect in a vaccine.
• The nucleotide and amino acid sequences encoding known flagellin polypeptides are publicly available in the NCBI GenBank database. The flagellin sequences from S. Typhimurium, H. Pylori, V. Cholera, S. marcesens, S. flexneri, T. Pallidum, L. pneumophila, B. burgdorferei, C. difficile, R. meliloti, A. tumefaciens, R. lupini, B. clarridgeiae, P. Mirabilis, B. subtilus, L. monocytogenes, P. aeruginosa, and E. coli, among others are known.
• A flagellin polypeptide, as used herein, refers to a full length flagellin protein, immunogenic fragments thereof, and peptides having at least 50% sequence identify to a flagellin protein or immunogenic fragments thereof. Exemplary flagellin proteins include flagellin from Salmonella typhi (UniPro Entry number: Q56086), Salmonella typhimurium (A0A0C9DG09), Salmonella enteritidis (A0A0C9BAB7), and Salmonella choleraesuis (Q6V2X8), and −56 (Table 17). In some embodiments, the flagellin polypeptide has at least 60%, 70%, 75%, 80%, 90%, 95%, 97%, 98%, or 99% sequence identify to a flagellin protein or immunogenic fragments thereof.
• In some embodiments, the flagellin polypeptide is an immunogenic fragment. An immunogenic fragment is a portion of a flagellin protein that provokes an immune response. In some embodiments, the immune response is a TLR5 immune response. An example of an immunogenic fragment is a flagellin protein in which all or a portion of a hinge region has been deleted or replaced with other amino acids. For example, an antigenic polypeptide may be inserted in the hinge region. Hinge regions are the hypervariable regions of a flagellin. Hinge regions of a flagellin are also referred to as “D3 domain or region, “propeller domain or region,” “hypervariable domain or region” and “variable domain or region.” “At least a portion of a hinge region,” as used herein, refers to any part of the hinge region of the flagellin, or the entirety of the hinge region. In other embodiments an immunogenic fragment of flagellin is a 20, 25, 30, 35, or 40 amino acid C-terminal fragment of flagellin.
• The flagellin monomer is formed by domains D0 through D3. D0 and D1, which form the stem, are composed of tandem long alpha helices and are highly conserved among different bacteria. The D1 domain includes several stretches of amino acids that are useful for TLR5 activation. The entire D1 domain or one or more of the active regions within the domain are immunogenic fragments of flagellin. Examples of immunogenic regions within the D1 domain include residues 88-114 and residues 411-431 (in Salmonella typhimurium FliC flagellin. Within the 13 amino acids in the 88-100 region, at least 6 substitutions are permitted between Salmonella flagellin and other flagellins that still preserve TLR5 activation. Thus, immunogenic fragments of flagellin include flagellin like sequences that activate TLR5 and contain a 13 amino acid motif that is 53% or more identical to the Salmonella sequence in 88-100 of FliC (LQRVRELAVQSAN; SEQ ID NO: 462).
• In some embodiments, the RNA (e.g., mRNA) vaccine includes an RNA that encodes a fusion protein of flagellin and one or more antigenic polypeptides. A “fusion protein” as used herein, refers to a linking of two components of the construct. In some embodiments, a carboxy-terminus of the antigenic polypeptide is fused or linked to an amino terminus of the flagellin polypeptide. In other embodiments, an amino-terminus of the antigenic polypeptide is fused or linked to a carboxy-terminus of the flagellin polypeptide. The fusion protein may include, for example, one, two, three, four, five, six or more flagellin polypeptides linked to one, two, three, four, five, six or more antigenic polypeptides. When two or more flagellin polypeptides and/or two or more antigenic polypeptides are linked such a construct may be referred to as a “multimer.”
• Each of the components of a fusion protein may be directly linked to one another or they may be connected through a linker. For instance, the linker may be an amino acid linker. The amino acid linker encoded for by the RNA (e.g., mRNA) vaccine to link the components of the fusion protein may include, for instance, at least one member selected from the group consisting of a lysine residue, a glutamic acid residue, a serine residue and an arginine residue. In some embodiments the linker is 1-30, 1-25, 1-25, 5-10, 5, 15, or 5-20 amino acids in length.
• In other embodiments the RNA (e.g., mRNA) vaccine includes at least two separate RNA polynucleotides, one encoding one or more antigenic polypeptides and the other encoding the flagellin polypeptide. The at least two RNA polynucleotides may be co-formulated in a carrier such as a lipid nanoparticle.
• Broad Spectrum RNA (e.g., mRNA) Vaccines
• There may be situations where persons are at risk for infection with more than one strain of HPV, HSV and/or Chlamydia. RNA (e.g., mRNA) therapeutic vaccines are particularly amenable to combination vaccination approaches due to a number of factors including, but not limited to, speed of manufacture, ability to rapidly tailor vaccines to accommodate perceived geographical threat, and the like. Moreover, because the vaccines utilize the human body to produce the antigenic protein, the vaccines are amenable to the production of larger, more complex antigenic proteins, allowing for proper folding, surface expression, antigen presentation, etc. in the human subject. To protect against more than one strain of HPV, HSV and/or Chlamydia, a combination vaccine can be administered that includes RNA (e.g., mRNA) encoding at least one antigenic polypeptide protein (or antigenic portion thereof) of a first STD virus and further includes RNA encoding at least one antigenic polypeptide protein (or antigenic portion thereof) of a second STD virus. RNA (e.g., mRNA) can be co-formulated, for example, in a single lipid nanoparticle (LNP) or can be formulated in separate LNPs for co-administration.
Methods of Treatment
• Provided herein are compositions (e.g., pharmaceutical compositions), methods, kits and reagents for prevention and/or treatment of STD s in humans and other mammals. STD RNA (e.g. mRNA) vaccines can be used as therapeutic or prophylactic agents, alone or in combination with other vaccine(s). They may be used in medicine to prevent and/or treat STD. In exemplary aspects, the RNA (e.g., mRNA) vaccines of the present disclosure are used to provide prophylactic protection from HPV, HSV and/or Chlamydia. Prophylactic protection from HPV, HSV and/or Chlamydia can be achieved following administration of a RNA (e.g., mRNA) vaccine of the present disclosure. STD RNA (e.g., mRNA) vaccines of the present disclosure may be used to treat or prevent viral “co-infections” containing two or more STD infections. Vaccines can be administered once, twice, three times, four times or more, but it is likely sufficient to administer the vaccine once (optionally followed by a single booster). It is possible, although less desirable, to administer the vaccine to an infected individual to achieve a therapeutic response. Dosing may need to be adjusted accordingly.
• A method of eliciting an immune response in a subject against HPV, HSV and/or Chlamydia is provided in aspects of the present disclosure. The method involves administering to the subject a STD RNA (e.g., mRNA) vaccine comprising at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding at least one HPV antigenic polypeptide, HSV antigenic polypeptide and/or at least one Chlamydia antigenic polypeptide, thereby inducing in the subject an immune response specific to HPV, HSV and/or Chlamydia antigenic polypeptide or an immunogenic fragment thereof, wherein anti-antigenic polypeptide antibody titer in the subject is increased following vaccination relative to anti-antigenic polypeptide antibody titer in a subject vaccinated with a prophylactically effective dose of a traditional vaccine against HPV, HSV and/or Chlamydia. An “anti-antigenic polypeptide antibody” is a serum antibody the binds specifically to the antigenic polypeptide.
• In some embodiments, a RNA (e.g., mRNA) vaccine (e.g., a HPV RNA vaccine, a HSV RNA vaccine, or a Chlamydia RNA vaccine) capable of eliciting an immune response is administered intramuscularly or intranasally via a composition including a compound according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe) (e.g., Compound 3, 18, 20, 25, 26, 29, 30, 60, 108-112, or 122).
• A prophylactically effective dose is a therapeutically effective dose that prevents infection with the virus at a clinically acceptable level. In some embodiments the therapeutically effective dose is a dose listed in a package insert for the vaccine. A traditional vaccine, as used herein, refers to a vaccine other than the RNA (e.g., mRNA) vaccines of the present disclosure. For instance, a traditional vaccine includes but is not limited to live/attenuated microorganism vaccines, killed/inactivated microorganism vaccines, subunit vaccines, protein antigen vaccines, DNA vaccines, VLP vaccines, etc. In exemplary embodiments, a traditional vaccine is a vaccine that has achieved regulatory approval and/or is registered by a national drug regulatory body, for example the Food and Drug Administration (FDA) in the United States or the European Medicines Agency (EMA).
• In some embodiments the anti-antigenic polypeptide antibody titer in the subject is increased 1 log to 10 log following vaccination relative to anti-antigenic polypeptide antibody titer in a subject vaccinated with a prophylactically effective dose of a traditional vaccine against HPV, HSV and/or Chlamydia.
• In some embodiments the anti-antigenic polypeptide antibody titer in the subject is increased 1 log, 2 log, 3 log, 5 log or 10 log following vaccination relative to anti-antigenic polypeptide antibody titer in a subject vaccinated with a prophylactically effective dose of a traditional vaccine against HPV, HSV and/or Chlamydia.
• A method of eliciting an immune response in a subject against HPV, HSV and/or Chlamydia is provided in other aspects of the disclosure. The method involves administering to the subject a STD RNA (e.g., mRNA) vaccine comprising at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding at least one HPV antigenic polypeptide, HSV antigenic polypeptide, and/or Chlamydia antigenic polypeptide or an immunogenic fragment thereof, thereby inducing in the subject an immune response specific to HPV antigenic polypeptide, HSV antigenic polypeptide, and/or Chlamydia antigenic polypeptide or an immunogenic fragment thereof, wherein the immune response in the subject is equivalent to an immune response in a subject vaccinated with a traditional vaccine against the HPV, HSV and/or Chlamydia at 2 times to 100 times the dosage level relative to the RNA (e.g., mRNA) vaccine.
• In some embodiments, the immune response in the subject is equivalent to an immune response in a subject vaccinated with a traditional vaccine at 2, 3, 4, 5, 10, 50, 100 times the dosage level relative to the HPV, HSV and/or Chlamydia RNA (e.g., mRNA) vaccine. In some embodiments the immune response in the subject is equivalent to an immune response in a subject vaccinated with a traditional vaccine at 10-100 times, or 100-1000 times, the dosage level relative to the HPV, HSV and/or Chlamydia RNA (e.g., mRNA) vaccine.
• In some embodiments the immune response is assessed by determining [protein] antibody titer in the subject.
• Some aspects of the present disclosure provide a method of eliciting an immune response in a subject against a In some embodiments the immune response in the subject is equivalent to an immune response in a subject vaccinated with a traditional vaccine at 2, 3, 4, 5, 10, 50, 100 times the dosage level relative to the HPV, HSV and/or Chlamydia RNA (e.g., mRNA) vaccine by administering to the subject a STD RNA (e.g., mRNA) vaccine comprising at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding at least one HPV, HSV and/or Chlamydia antigenic polypeptide, thereby inducing in the subject an immune response specific to the antigenic polypeptide or an immunogenic fragment thereof, wherein the immune response in the subject is induced 2 days to 10 weeks earlier relative to an immune response induced in a subject vaccinated with a prophylactically effective dose of a traditional vaccine against HPV, HSV and/or Chlamydia. In some embodiments, the immune response in the subject is induced in a subject vaccinated with a prophylactically effective dose of a traditional vaccine at 2 times to 100 times the dosage level relative to the RNA (e.g., mRNA) vaccine.
• In some embodiments, the immune response in the subject is induced 2 days earlier, or 3 days earlier, relative to an immune response induced in a subject vaccinated with a prophylactically effective dose of a traditional vaccine.
• In some embodiments the immune response in the subject is induced 1 week, 2 weeks, 3 weeks, 5 weeks, or 10 weeks earlier relative to an immune response induced in a subject vaccinated with a prophylactically effective dose of a traditional vaccine.
• Also provided herein is a method of eliciting an immune response in a subject against HPV, HSV and/or Chlamydia by administering to the subject a STD RNA (e.g., mRNA) vaccine having an open reading frame encoding a first antigenic polypeptide, wherein the RNA polynucleotide does not include a stabilization element, and wherein an adjuvant is not co-formulated or co-administered with the vaccine.
Therapeutic and Prophylactic Compositions
• Provided herein are compositions (e.g., pharmaceutical compositions), methods, kits and reagents for prevention, treatment or diagnosis of HPV, HSV and/or Chlamydia in humans and other mammals, for example. STD RNA (e.g. mRNA) vaccines can be used as therapeutic or prophylactic agents. They may be used in medicine to prevent and/or treat infectious disease. In some embodiments, the respiratory RNA (e.g., mRNA) vaccines of the present disclosure are used fin the priming of immune effector cells, for example, to activate peripheral blood mononuclear cells (PBMCs) ex vivo, which are then infused (re-infused) into a subject.
• In some embodiments, STD vaccine containing RNA (e.g., mRNA) polynucleotides as described herein can be administered to a subject (e.g., a mammalian subject, such as a human subject), and the RNA (e.g., mRNA) polynucleotides are translated in vivo to produce an antigenic polypeptide.
• The STD RNA (e.g., mRNA) vaccines may be induced for translation of a polypeptide (e.g., antigen or immunogen) in a cell, tissue or organism. In some embodiments, such translation occurs in vivo, although such translation may occur ex vivo, in culture or in vitro. In some embodiments, the cell, tissue or organism is contacted with an effective amount of a composition containing a STD RNA (e.g., mRNA) vaccine that contains a polynucleotide that has at least one a translatable region encoding an antigenic polypeptide.
• An “effective amount” of an STD RNA (e.g. mRNA) vaccine is provided based, at least in part, on the target tissue, target cell type, means of administration, physical characteristics of the polynucleotide (e.g., size, and extent of modified nucleosides) and other components of the vaccine, and other determinants. In general, an effective amount of the STD RNA (e.g., mRNA) vaccine composition provides an induced or boosted immune response as a function of antigen production in the cell, preferably more efficient than a composition containing a corresponding unmodified polynucleotide encoding the same antigen or a peptide antigen. Increased antigen production may be demonstrated by increased cell transfection (the percentage of cells transfected with the RNA, e.g., mRNA, vaccine), increased protein translation from the polynucleotide, decreased nucleic acid degradation (as demonstrated, for example, by increased duration of protein translation from a modified polynucleotide), or altered antigen specific immune response of the host cell.
• In some embodiments, RNA (e.g. mRNA) vaccines (including polynucleotides their encoded polypeptides) in accordance with the present disclosure may be used for treatment of HPV, HSV and/or Chlamydia.
• Respiratory RNA (e.g. mRNA) vaccines may be administered prophylactically or therapeutically as part of an active immunization scheme to healthy individuals or early in infection during the incubation phase or during active infection after onset of symptoms. In some embodiments, the amount of RNA (e.g., mRNA) vaccine of the present disclosure provided to a cell, a tissue or a subject may be an amount effective for immune prophylaxis.
• STD RNA (e.g. mRNA) vaccines may be administrated with other prophylactic or therapeutic compounds. As a non-limiting example, a prophylactic or therapeutic compound may be an adjuvant or a booster. As used herein, when referring to a prophylactic composition, such as a vaccine, the term “booster” refers to an extra administration of the prophylactic (vaccine) composition. A booster (or booster vaccine) may be given after an earlier administration of the prophylactic composition. The time of administration between the initial administration of the prophylactic composition and the booster may be, but is not limited to, 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 6 minutes, 7 minutes, 8 minutes, 9 minutes, 10 minutes, 15 minutes, 20 minutes 35 minutes, 40 minutes, 45 minutes, 50 minutes, 55 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 1 day, 36 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 10 days, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 18 months, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years, 11 years, 12 years, 13 years, 14 years, 15 years, 16 years, 17 years, 18 years, 19 years, 20 years, 25 years, 30 years, 35 years, 40 years, 45 years, 50 years, 55 years, 60 years, 65 years, 70 years, 75 years, 80 years, 85 years, 90 years, 95 years or more than 99 years. In some embodiments, the time of administration between the initial administration of the prophylactic composition and the booster may be, but is not limited to, 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 6 months or 1 year.
• In some embodiments, STD RNA (e.g. mRNA) vaccines may be administered intramuscularly, intradermally, or intranasally, similarly to the administration of inactivated vaccines known in the art.
• STD RNA (e.g. mRNA) vaccines may be utilized in various settings depending on the prevalence of the infection or the degree or level of unmet medical need. As a non-limiting example, the RNA (e.g., mRNA) vaccines may be utilized to treat and/or prevent a variety of STDs. RNA (e.g., mRNA) vaccines have superior properties in that they produce much larger antibody titers and produce responses early than commercially available anti-viral agents/compositions.
• Provided herein are pharmaceutical compositions including STD RNA (e.g. mRNA) vaccines and RNA (e.g. mRNA) vaccine compositions and/or complexes optionally in combination with one or more pharmaceutically acceptable excipients.
• HPV, HSV and/or Chlamydia RNA (e.g. mRNA) vaccines may be formulated or administered alone or in conjunction with one or more other components. For instance, HPV, HSV and/or Chlamydia RNA (e.g., mRNA) vaccines (vaccine compositions) may comprise other components including, but not limited to, adjuvants.
• In some embodiments, STD (e.g. mRNA) vaccines do not include an adjuvant (they are adjuvant free).
• STD RNA (e.g. mRNA) vaccines may be formulated or administered in combination with one or more pharmaceutically-acceptable excipients. In some embodiments, vaccine compositions comprise at least one additional active substances, such as, for example, a therapeutically-active substance, a prophylactically-active substance, or a combination of both. Vaccine compositions may be sterile, pyrogen-free or both sterile and pyrogen-free. General considerations in the formulation and/or manufacture of pharmaceutical agents, such as vaccine compositions, may be found, for example, in Remington: The Science and Practice of Pharmacy 21st ed., Lippincott Williams & Wilkins, 2005 (incorporated herein by reference in its entirety).
• In some embodiments, STD RNA (e.g. mRNA) vaccines are administered to humans, human patients or subjects. For the purposes of the present disclosure, the phrase “active ingredient” generally refers to the RNA (e.g., mRNA) vaccines or the polynucleotides contained therein, for example, RNA polynucleotides (e.g., mRNA polynucleotides) encoding antigenic polypeptides.
• Formulations of the STD vaccine compositions described herein may be prepared by any method known or hereafter developed in the art of pharmacology. In general, such preparatory methods include the step of bringing the active ingredient (e.g., mRNA polynucleotide) into association with an excipient and/or one or more other accessory ingredients, and then, if necessary and/or desirable, dividing, shaping and/or packaging the product into a desired single- or multi-dose unit.
• Relative amounts of the active ingredient, the pharmaceutically acceptable excipient, and/or any additional ingredients in a pharmaceutical composition in accordance with the disclosure will vary, depending upon the identity, size, and/or condition of the subject treated and further depending upon the route by which the composition is to be administered. By way of example, the composition may comprise between 0.1% and 100%, e.g., between 0.5 and 50%, between 1-30%, between 5-80%, at least 80% (w/w) active ingredient.
• STD RNA (e.g. mRNA) vaccines can be formulated using one or more excipients to: increase stability; increase cell transfection; permit the sustained or delayed release (e.g., from a depot formulation); alter the biodistribution (e.g., target to specific tissues or cell types); increase the translation of encoded protein in vivo; and/or alter the release profile of encoded protein (antigen) in vivo. In addition to traditional excipients such as any and all solvents, dispersion media, diluents, or other liquid vehicles, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, excipients can include, without limitation, lipidoids, liposomes, lipid nanoparticles, polymers, lipoplexes, core-shell nanoparticles, peptides, proteins, cells transfected with STD RNA (e.g. mRNA) vaccines (e.g., for transplantation into a subject), hyaluronidase, nanoparticle mimics and combinations thereof.
Stabilizing Elements
• Naturally-occurring eukaryotic mRNA molecules have been found to contain stabilizing elements, including, but not limited to untranslated regions (UTR) at their 5′-end (5′UTR) and/or at their 3′-end (3′UTR), in addition to other structural features, such as a 5′-cap structure or a 3′-poly(A) tail. Both the 5′UTR and the 3′UTR are typically transcribed from the genomic DNA and are elements of the premature mRNA. Characteristic structural features of mature mRNA, such as the 5′-cap and the 3′-poly(A) tail are usually added to the transcribed (premature) mRNA during mRNA processing. The 3′-poly(A) tail is typically a stretch of adenine nucleotides added to the 3′-end of the transcribed mRNA. It can comprise up to about 400 adenine nucleotides. In some embodiments the length of the 3′-poly(A) tail may be an essential element with respect to the stability of the individual mRNA.
• In some embodiments the RNA (e.g., mRNA) vaccine may include one or more stabilizing elements. Stabilizing elements may include for instance a histone stem-loop. A stem-loop binding protein (SLBP), a 32 kDa protein has been identified. It is associated with the histone stem-loop at the 3′-end of the histone messages in both the nucleus and the cytoplasm. Its expression level is regulated by the cell cycle; it is peaks during the S-phase, when histone mRNA levels are also elevated. The protein has been shown to be essential for efficient 3′-end processing of histone pre-mRNA by the U7 snRNP. SLBP continues to be associated with the stem-loop after processing, and then stimulates the translation of mature histone mRNAs into histone proteins in the cytoplasm. The RNA binding domain of SLBP is conserved through metazoa and protozoa; its binding to the histone stem-loop depends on the structure of the loop. The minimum binding site includes at least three nucleotides 5′ and two nucleotides 3′ relative to the stem-loop.
• In some embodiments, the RNA (e.g., mRNA) vaccines include a coding region, at least one histone stem-loop, and optionally, a poly(A) sequence or polyadenylation signal. The poly(A) sequence or polyadenylation signal generally should enhance the expression level of the encoded protein. The encoded protein, in some embodiments, is not a histone protein, a reporter protein (e.g. Luciferase, GFP, EGFP, β-Galactosidase, EGFP), or a marker or selection protein (e.g. alpha-Globin, Galactokinase and Xanthine:guanine phosphoribosyl transferase (GPT)).
• In some embodiments, the combination of a poly(A) sequence or polyadenylation signal and at least one histone stem-loop, even though both represent alternative mechanisms in nature, acts synergistically to increase the protein expression beyond the level observed with either of the individual elements. It has been found that the synergistic effect of the combination of poly(A) and at least one histone stem-loop does not depend on the order of the elements or the length of the poly(A) sequence.
• In some embodiments, the RNA (e.g., mRNA) vaccine does not comprise a histone downstream element (HDE). “Histone downstream element” (HDE) includes a purine-rich polynucleotide stretch of approximately 15 to 20 nucleotides 3′ of naturally occurring stem-loops, representing the binding site for the U7 snRNA, which is involved in processing of histone pre-mRNA into mature histone mRNA. Ideally, the inventive nucleic acid does not include an intron.
• In some embodiments, the RNA (e.g., mRNA) vaccine may or may not contain a enhancer and/or promoter sequence, which may be modified or unmodified or which may be activated or inactivated. In some embodiments, the histone stem-loop is generally derived from histone genes, and includes an intramolecular base pairing of two neighbored partially or entirely reverse complementary sequences separated by a spacer, including (e.g., consisting of) a short sequence, which forms the loop of the structure. The unpaired loop region is typically unable to base pair with either of the stem loop elements. It occurs more often in RNA, as is a key component of many RNA secondary structures, but may be present in single-stranded DNA as well. Stability of the stem-loop structure generally depends on the length, number of mismatches or bulges, and base composition of the paired region. In some embodiments, wobble base pairing (non-Watson-Crick base pairing) may result. In some embodiments, the at least one histone stem-loop sequence comprises a length of 15 to 45 nucleotides.
• In other embodiments the RNA (e.g., mRNA) vaccine may have one or more AU-rich sequences removed. These sequences, sometimes referred to as AURES are destabilizing sequences found in the 3′UTR. The AURES may be removed from the RNA (e.g., mRNA) vaccines. Alternatively the AURES may remain in the RNA (e.g., mRNA) vaccine.
Nanoparticle Formulations
• In some embodiments, STD RNA (e.g. mRNA) vaccines are formulated in a nanoparticle. In some embodiments, STD RNA (e.g. mRNA) vaccines are formulated in a lipid nanoparticle. In some embodiments, STD RNA (e.g. mRNA) vaccines are formulated in a lipid-polycation complex, referred to as a cationic lipid nanoparticle. As a non-limiting example, the polycation may include a cationic peptide or a polypeptide such as, but not limited to, polylysine, polyornithine and/or polyarginine. In some embodiments, STD RNA (e.g., mRNA) vaccines are formulated in a lipid nanoparticle that includes a non-cationic lipid such as, but not limited to, cholesterol or dioleoyl phosphatidylethanolamine (DOPE).
• A lipid nanoparticle formulation may be influenced by, but not limited to, the selection of the cationic lipid component, the degree of cationic lipid saturation, the nature of the PEGylation, ratio of all components and biophysical parameters such as size. In one example by Semple et al. (Nature Biotech. 2010 28:172-176), the lipid nanoparticle formulation is composed of 57.1% cationic lipid, 7.1% dipalmitoylphosphatidylcholine, 34.3% cholesterol, and 1.4% PEG-c-DMA. As another example, changing the composition of the cationic lipid can more effectively deliver siRNA to various antigen presenting cells (Basha et al. Mol Ther. 2011 19:2186-2200).
• In some embodiments, lipid nanoparticle formulations may comprise 35 to 45% cationic lipid, 40% to 50% cationic lipid, 50% to 60% cationic lipid and/or 55% to 65% cationic lipid. In some embodiments, the ratio of lipid to RNA (e.g., mRNA) in lipid nanoparticles may be 5:1 to 20:1, 10:1 to 25:1, 15:1 to 30:1 and/or at least 30:1.
• In some embodiments, the ratio of PEG in the lipid nanoparticle formulations may be increased or decreased and/or the carbon chain length of the PEG lipid may be modified from C14 to C18 to alter the pharmacokinetics and/or biodistribution of the lipid nanoparticle formulations. As a non-limiting example, lipid nanoparticle formulations may contain 0.5% to 3.0%, 1.0% to 3.5%, 1.5% to 4.0%, 2.0% to 4.5%, 2.5% to 5.0% and/or 3.0% to 6.0% of the lipid molar ratio of PEG-c-DOMG (R-3-[(ω-methoxy-poly(ethyleneglycol)2000)carbamoyl)]-1,2-dimyristyloxypropyl-3-amine) (also referred to herein as PEG-DOMG) as compared to the cationic lipid, DSPC and cholesterol. In some embodiments, the PEG-c-DOMG may be replaced with a PEG lipid such as, but not limited to, PEG-DSG (1,2-Distearoyl-sn-glycerol, methoxypolyethylene glycol), PEG-DMG (1,2-Dimyristoyl-sn-glycerol) and/or PEG-DPG (1,2-Dipalmitoyl-sn-glycerol, methoxypolyethylene glycol). The cationic lipid may be selected from any lipid known in the art such as, but not limited to, DLin-MC3-DMA, DLin-DMA, C12-200 and DLin-KC2-DMA.
• In some embodiments, an STD RNA (e.g. mRNA) vaccine formulation is a nanoparticle that comprises at least one lipid. The lipid may be selected from, but is not limited to, DLin-DMA, DLin-K-DMA, 98N12-5, C12-200, DLin-MC3-DMA, DLin-KC2-DMA, DODMA, PLGA, PEG, PEG-DMG, PEGylated lipids and amino alcohol lipids. In some embodiments, the lipid may be a cationic lipid such as, but not limited to, DLin-DMA, DLin-D-DMA, DLin-MC3-DMA, DLin-KC2-DMA, DODMA and amino alcohol lipids. The amino alcohol cationic lipid may be the lipids described in and/or made by the methods described in U.S. Patent Publication No. US20130150625, herein incorporated by reference in its entirety. As a non-limiting example, the cationic lipid may be 2-amino-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-2-{[(9Z,2Z)-octadeca-9,12-dien-1-yloxy]methyl}propan-1-ol (Compound 1 in US20130150625); 2-amino-3-[(9Z)-octadec-9-en-1-yloxy]-2-{[(9Z)-octadec-9-en-1-yloxy]methyl}propan-1-ol (Compound 2 in US20130150625); 2-amino-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-2-[(octyloxy)methyl]propan-1-ol (Compound 3 in US20130150625); and 2-(dimethylamino)-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-2-{[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]methyl}propan-1-ol (Compound 4 in US20130150625); or any pharmaceutically acceptable salt or stereoisomer thereof.
• Lipid nanoparticle formulations typically comprise a lipid, in particular, an ionizable cationic lipid, for example, 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), or di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), and further comprise a neutral lipid, a sterol and a molecule capable of reducing particle aggregation, for example a PEG or PEG-modified lipid.
• In some embodiments, a lipid nanoparticle formulation consists essentially of (i) at least one lipid selected from the group consisting of 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319); (ii) a neutral lipid selected from DSPC, DPPC, POPC, DOPE and SM; (iii) a sterol, e.g., cholesterol; and (iv) a PEG-lipid, e.g., PEG-DMG or PEG-cDMA, in a molar ratio of 20-60% cationic lipid: 5-25% neutral lipid: 25-55% sterol; 0.5-15% PEG-lipid.
• In some embodiments, a lipid nanoparticle formulation includes 25% to 75% on a molar basis of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), e.g., 35 to 65%, 45 to 65%, 60%, 57.5%, 50% or 40% on a molar basis.
• In some embodiments, a lipid nanoparticle formulation includes 0.5% to 15% on a molar basis of the neutral lipid, e.g., 3 to 12%, 5 to 10% or 15%, 10%, or 7.5% on a molar basis. Examples of neutral lipids include, without limitation, DSPC, POPC, DPPC, DOPE and SM. In some embodiments, the formulation includes 5% to 50% on a molar basis of the sterol (e.g., 15 to 45%, 20 to 40%, 40%, 38.5%, 35%, or 31% on a molar basis. A non-limiting example of a sterol is cholesterol. In some embodiments, a lipid nanoparticle formulation includes 0.5% to 20% on a molar basis of the PEG or PEG-modified lipid (e.g., 0.5 to 10%, 0.5 to 5%, 1.5%, 0.5%, 1.5%, 3.5%, or 5% on a molar basis. In some embodiments, a PEG or PEG modified lipid comprises a PEG molecule of an average molecular weight of 2,000 Da. In some embodiments, a PEG or PEG modified lipid comprises a PEG molecule of an average molecular weight of less than 2,000, for example around 1,500 Da, around 1,000 Da, or around 500 Da. Non-limiting examples of PEG-modified lipids include PEG-distearoyl glycerol (PEG-DMG) (also referred herein as PEG-C14 or C14-PEG), PEG-cDMA (further discussed in Reyes et al. J. Controlled Release, 107, 276-287 (2005) the contents of which are herein incorporated by reference in their entirety).
• In some embodiments, lipid nanoparticle formulations include 25-75% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), 0.5-15% of the neutral lipid, 5-50% of the sterol, and 0.5-20% of the PEG or PEG-modified lipid on a molar basis.
• In some embodiments, lipid nanoparticle formulations include 35-65% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), 3-12% of the neutral lipid, 15-45% of the sterol, and 0.5-10% of the PEG or PEG-modified lipid on a molar basis.
• In some embodiments, lipid nanoparticle formulations include 45-65% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), 5-10% of the neutral lipid, 25-40% of the sterol, and 0.5-10% of the PEG or PEG-modified lipid on a molar basis.
• In some embodiments, lipid nanoparticle formulations include 60% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), 7.5% of the neutral lipid, 31% of the sterol, and 1.5% of the PEG or PEG-modified lipid on a molar basis.
• In some embodiments, lipid nanoparticle formulations include 50% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), 10% of the neutral lipid, 38.5% of the sterol, and 1.5% of the PEG or PEG-modified lipid on a molar basis.
• In some embodiments, lipid nanoparticle formulations include 50% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), 10% of the neutral lipid, 35% of the sterol, 4.5% or 5% of the PEG or PEG-modified lipid, and 0.5% of the targeting lipid on a molar basis.
• In some embodiments, lipid nanoparticle formulations include 40% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), 15% of the neutral lipid, 40% of the sterol, and 5% of the PEG or PEG-modified lipid on a molar basis.
• In some embodiments, lipid nanoparticle formulations include 57.2% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), 7.1% of the neutral lipid, 34.3% of the sterol, and 1.4% of the PEG or PEG-modified lipid on a molar basis.
• In some embodiments, lipid nanoparticle formulations include 57.5% of a cationic lipid selected from the PEG lipid is PEG-cDMA (PEG-cDMA is further discussed in Reyes et al. (J. Controlled Release, 107, 276-287 (2005), the contents of which are herein incorporated by reference in their entirety), 7.5% of the neutral lipid, 31.5% of the sterol, and 3.5% of the PEG or PEG-modified lipid on a molar basis.
• In some embodiments, lipid nanoparticle formulations consists essentially of a lipid mixture in molar ratios of 20-70% cationic lipid: 5-45% neutral lipid: 20-55% cholesterol: 0.5-15% PEG-modified lipid. In some embodiments, lipid nanoparticle formulations consists essentially of a lipid mixture in a molar ratio of 20-60% cationic lipid: 5-25% neutral lipid: 25-55% cholesterol: 0.5-15% PEG-modified lipid.
• In some embodiments, the molar lipid ratio is 50/10/38.5/1.5 (mol % cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DMG, PEG-DSG or PEG-DPG), 57.2/7.1134.3/1.4 (mol % cationic lipid/neutral lipid, e.g., DPPC/Chol/PEG-modified lipid, e.g., PEG-cDMA), 40/15/40/5 (mol % cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DMG), 50/10/35/4.5/0.5 (mol % cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DSG), 50/10/35/5 (cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DMG), 40/10/40/10 (mol % cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DMG or PEG-cDMA), 35/15/40/10 (mol % cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DMG or PEG-cDMA) or 52/13/30/5 (mol % cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DMG or PEG-cDMA).
• Non-limiting examples of lipid nanoparticle compositions and methods of making them are described, for example, in Semple et al. (2010) Nat. Biotechnol. 28:172-176; Jayarama et al. (2012), Angew. Chem. Int. Ed., 51: 8529-8533; and Maier et al. (2013) Molecular Therapy 21, 1570-1578 (the contents of each of which are incorporated herein by reference in their entirety).
• In some embodiments, lipid nanoparticle formulations may comprise a cationic lipid, a PEG lipid and a structural lipid and optionally comprise a non-cationic lipid. As a non-limiting example, a lipid nanoparticle may comprise 40-60% of cationic lipid, 5-15% of a non-cationic lipid, 1-2% of a PEG lipid and 30-50% of a structural lipid. As another non-limiting example, the lipid nanoparticle may comprise 50% cationic lipid, 10% non-cationic lipid, 1.5% PEG lipid and 38.5% structural lipid. As yet another non-limiting example, a lipid nanoparticle may comprise 55% cationic lipid, 10% non-cationic lipid, 2.5% PEG lipid and 32.5% structural lipid. In some embodiments, the cationic lipid may be any cationic lipid described herein such as, but not limited to, DLin-KC2-DMA, DLin-MC3-DMA and L319.
• In some embodiments, the lipid nanoparticle formulations described herein may be 4 component lipid nanoparticles. The lipid nanoparticle may comprise a cationic lipid, a non-cationic lipid, a PEG lipid and a structural lipid. As a non-limiting example, the lipid nanoparticle may comprise 40-60% of cationic lipid, 5-15% of a non-cationic lipid, 1-2% of a PEG lipid and 30-50% of a structural lipid. As another non-limiting example, the lipid nanoparticle may comprise 50% cationic lipid, 10% non-cationic lipid, 1.5% PEG lipid and 38.5% structural lipid. As yet another non-limiting example, the lipid nanoparticle may comprise 55% cationic lipid, 10% non-cationic lipid, 2.5% PEG lipid and 32.5% structural lipid. In some embodiments, the cationic lipid may be any cationic lipid described herein such as, but not limited to, DLin-KC2-DMA, DLin-MC3-DMA and L319.
• In some embodiments, the lipid nanoparticle formulations described herein may comprise a cationic lipid, a non-cationic lipid, a PEG lipid and a structural lipid. As a non-limiting example, the lipid nanoparticle comprise 50% of the cationic lipid DLin-KC2-DMA, 10% of the non-cationic lipid DSPC, 1.5% of the PEG lipid PEG-DOMG and 38.5% of the structural lipid cholesterol. As a non-limiting example, the lipid nanoparticle comprise 50% of the cationic lipid DLin-MC3-DMA, 10% of the non-cationic lipid DSPC, 1.5% of the PEG lipid PEG-DOMG and 38.5% of the structural lipid cholesterol. As a non-limiting example, the lipid nanoparticle comprise 50% of the cationic lipid DLin-MC3-DMA, 10% of the non-cationic lipid DSPC, 1.5% of the PEG lipid PEG-DMG and 38.5% of the structural lipid cholesterol. As yet another non-limiting example, the lipid nanoparticle comprise 55% of the cationic lipid L319, 10% of the non-cationic lipid DSPC, 2.5% of the PEG lipid PEG-DMG and 32.5% of the structural lipid cholesterol.
• Relative amounts of the active ingredient, the pharmaceutically acceptable excipient, and/or any additional ingredients in a vaccine composition may vary, depending upon the identity, size, and/or condition of the subject being treated and further depending upon the route by which the composition is to be administered. For example, the composition may comprise between 0.1% and 99% (w/w) of the active ingredient. By way of example, the composition may comprise between 0.1% and 100%, e.g., between 0.5 and 50%, between 1-30%, between 5-80%, at least 80% (w/w) active ingredient.
• In some embodiments, the STD RNA (e.g. mRNA) vaccine composition may comprise the polynucleotide described herein, formulated in a lipid nanoparticle comprising MC3, Cholesterol, DSPC and PEG2000-DMG, the buffer trisodium citrate, sucrose and water for injection. As a non-limiting example, the composition comprises: 2.0 mg/mL of drug substance, 21.8 mg/mL of MC3, 10.1 mg/mL of cholesterol, 5.4 mg/mL of DSPC, 2.7 mg/mL of PEG2000-DMG, 5.16 mg/mL of trisodium citrate, 71 mg/mL of sucrose and 1.0 mL of water for injection.
• In some embodiments, a nanoparticle (e.g., a lipid nanoparticle) has a mean diameter of 10-500 nm, 20-400 nm, 30-300 nm, 40-200 nm. In some embodiments, a nanoparticle (e.g., a lipid nanoparticle) has a mean diameter of 50-150 nm, 50-200 nm, 80-100 nm or 80-200 nm.
• Liposomes, Lipoplexes, and Lipid Nanoparticles
• The RNA (e.g., mRNA) vaccines of the disclosure can be formulated using one or more liposomes, lipoplexes, or lipid nanoparticles. In some embodiments, pharmaceutical compositions of RNA (e.g., mRNA) vaccines include liposomes. Liposomes are artificially-prepared vesicles which may primarily be composed of a lipid bilayer and may be used as a delivery vehicle for the administration of nutrients and pharmaceutical formulations. Liposomes can be of different sizes such as, but not limited to, a multilamellar vesicle (MLV) which may be hundreds of nanometers in diameter and may contain a series of concentric bilayers separated by narrow aqueous compartments, a small unicellular vesicle (SUV) which may be smaller than 50 nm in diameter, and a large unilamellar vesicle (LUV) which may be between 50 and 500 nm in diameter. Liposome design may include, but is not limited to, opsonins or ligands in order to improve the attachment of liposomes to unhealthy tissue or to activate events such as, but not limited to, endocytosis. Liposomes may contain a low or a high pH in order to improve the delivery of the pharmaceutical formulations.
• The formation of liposomes may depend on the physicochemical characteristics such as, but not limited to, the pharmaceutical formulation entrapped and the liposomal ingredients, the nature of the medium in which the lipid vesicles are dispersed, the effective concentration of the entrapped substance and its potential toxicity, any additional processes involved during the application and/or delivery of the vesicles, the optimization size, polydispersity and the shelf-life of the vesicles for the intended application, and the batch-to-batch reproducibility and possibility of large-scale production of safe and efficient liposomal products.
• In some embodiments, pharmaceutical compositions described herein may include, without limitation, liposomes such as those formed from 1,2-dioleyloxy-N,N-dimethylaminopropane (DODMA) liposomes, DiLa2 liposomes from Marina Biotech (Bothell, Wash.), 1,2-dilinoleyloxy-3-dimethylaminopropane (DLin-DMA), 2,2-dilinoleyl-4-(2-dimethylaminoethyl)[1,3]-dioxolane (DLin-KC2-DMA), and MC3 (US20100324120; herein incorporated by reference in its entirety) and liposomes which may deliver small molecule drugs such as, but not limited to, DOXIL® from Janssen Biotech, Inc. (Horsham, Pa.).
• In some embodiments, pharmaceutical compositions described herein may include, without limitation, liposomes such as those formed from the synthesis of stabilized plasmid-lipid particles (SPLP) or stabilized nucleic acid lipid particle (SNALP) that have been previously described and shown to be suitable for oligonucleotide delivery in vitro and in vivo (see Wheeler et al. Gene Therapy. 1999 6:271-281; Zhang et al. Gene Therapy. 1999 6:1438-1447; Jeffs et al. Pharm Res. 2005 22:362-372; Morrissey et al., Nat Biotechnol. 2005 2:1002-1007; Zimmermann et al., Nature. 2006 441:111-114; Heyes et al. J Contr Rel. 2005 107:276-287; Semple et al. Nature Biotech. 2010 28:172-176; Judge et al. J Clin Invest. 2009 119:661-673; deFougerolles Hum Gene Ther. 2008 19:125-132; U.S. Patent Publication No US20130122104; all of which are incorporated herein in their entireties). The original manufacture method by Wheeler et al. was a detergent dialysis method, which was later improved by Jeffs et al. and is referred to as the spontaneous vesicle formation method. The liposome formulations are composed of 3 to 4 lipid components in addition to the polynucleotide. As an example a liposome can contain, but is not limited to, 55% cholesterol, 20% disteroylphosphatidyl choline (DSPC), 10% PEG-S-DSG, and 15% 1,2-dioleyloxy-N,N-dimethylaminopropane (DODMA), as described by Jeffs et al. As another example, certain liposome formulations may contain, but are not limited to, 48% cholesterol, 20% DSPC, 2% PEG-c-DMA, and 30% cationic lipid, where the cationic lipid can be 1,2-distearloxy-N,N-dimethylaminopropane (DSDMA), DODMA, DLin-DMA, or 1,2-dilinolenyloxy-3-dimethylaminopropane (DLenDMA), as described by Heyes et al.
• In some embodiments, liposome formulations may comprise from about 25.0% cholesterol to about 40.0% cholesterol, from about 30.0% cholesterol to about 45.0% cholesterol, from about 35.0% cholesterol to about 50.0% cholesterol and/or from about 48.5% cholesterol to about 60% cholesterol. In some embodiments, formulations may comprise a percentage of cholesterol selected from the group consisting of 28.5%, 31.5%, 33.5%, 36.5%, 37.0%, 38.5%, 39.0% and 43.5%. In some embodiments, formulations may comprise from about 5.0% to about 10.0% DSPC and/or from about 7.0% to about 15.0% DSPC.
• In some embodiments, the RNA (e.g., mRNA) vaccine pharmaceutical compositions may be formulated in liposomes such as, but not limited to, DiLa2 liposomes (Marina Biotech, Bothell, Wash.), SMARTICLES® (Marina Biotech, Bothell, Wash.), neutral DOPC (1,2-dioleoyl-sn-glycero-3-phosphocholine) based liposomes (e.g., siRNA delivery for ovarian cancer (Landen et al. Cancer Biology & Therapy 2006 5(12)1708-1713); herein incorporated by reference in its entirety) and hyaluronan-coated liposomes (Quiet Therapeutics, Israel).
• In some embodiments, the cationic lipid may be a low molecular weight cationic lipid such as those described in U.S. Patent Application No. 20130090372, the contents of which are herein incorporated by reference in their entirety.
• In some embodiments, the RNA (e.g., mRNA) vaccines may be formulated in a lipid vesicle, which may have crosslinks between functionalized lipid bilayers.
• In some embodiments, the RNA (e.g., mRNA) vaccines may be formulated in a lipid-polycation complex. The formation of the lipid-polycation complex may be accomplished by methods known in the art and/or as described in U.S. Pub. No. 20120178702, herein incorporated by reference in its entirety. As a non-limiting example, the polycation may include a cationic peptide or a polypeptide such as, but not limited to, polylysine, polyornithine and/or polyarginine. In some embodiments, the RNA (e.g., mRNA) vaccines may be formulated in a lipid-polycation complex, which may further include a non-cationic lipid such as, but not limited to, cholesterol or dioleoyl phosphatidylethanolamine (DOPE).
• In some embodiments, the ratio of PEG in the lipid nanoparticle (LNP) formulations may be increased or decreased and/or the carbon chain length of the PEG lipid may be modified from C14 to C18 to alter the pharmacokinetics and/or biodistribution of the LNP formulations. As a non-limiting example, LNP formulations may contain from about 0.5% to about 3.0%, from about 1.0% to about 3.5%, from about 1.5% to about 4.0%, from about 2.0% to about 4.5%, from about 2.5% to about 5.0% and/or from about 3.0% to about 6.0% of the lipid molar ratio of PEG-c-DOMG (R-3-[(ω-methoxy-poly(ethyleneglycol)2000)carbamoyl)]-1,2-dimyristyloxypropyl-3-amine) (also referred to herein as PEG-DOMG) as compared to the cationic lipid, DSPC and cholesterol. In some embodiments, the PEG-c-DOMG may be replaced with a PEG lipid such as, but not limited to, PEG-DSG (1,2-Distearoyl-sn-glycerol, methoxypolyethylene glycol), PEG-DMG (1,2-Dimyristoyl-sn-glycerol) and/or PEG-DPG (1,2-Dipalmitoyl-sn-glycerol, methoxypolyethylene glycol). The cationic lipid may be selected from any lipid known in the art such as, but not limited to, DLin-MC3-DMA, DLin-DMA, C12-200 and DLin-KC2-DMA.
• In some embodiments, the RNA (e.g., mRNA) vaccines may be formulated in a lipid nanoparticle.
• In some embodiments, the RNA (e.g., mRNA) vaccine formulation comprising the polynucleotide is a nanoparticle which may comprise at least one lipid. The lipid may be selected from, but is not limited to, DLin-DMA, DLin-K-DMA, 98N12-5, C12-200, DLin-MC3-DMA, DLin-KC2-DMA, DODMA, PLGA, PEG, PEG-DMG, PEGylated lipids and amino alcohol lipids. In another aspect, the lipid may be a cationic lipid such as, but not limited to, DLin-DMA, DLin-D-DMA, DLin-MC3-DMA, DLin-KC2-DMA, DODMA and amino alcohol lipids. The amino alcohol cationic lipid may be the lipids described in and/or made by the methods described in U.S. Patent Publication No. US20130150625, herein incorporated by reference in its entirety. As a non-limiting example, the cationic lipid may be 2-amino-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-2-{[(9Z,2Z)-octadeca-9,12-dien-1-yloxy]methyl}propan-1-ol (Compound 1 in US20130150625); 2-amino-3-[(9Z)-octadec-9-en-1-yloxy]-2-{[(9Z)-octadec-9-en-1-yloxy]methyl}propan-1-ol (Compound 2 in US20130150625); 2-amino-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-2-[(octyloxy)methyl]propan-1-ol (Compound 3 in US20130150625); and 2-(dimethylamino)-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-2-{[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]methyl}propan-1-ol (Compound 4 in US20130150625); or any pharmaceutically acceptable salt or stereoisomer thereof.
• Lipid nanoparticle formulations typically comprise a lipid, in particular, an ionizable cationic lipid, for example, 2,2-dilinoleyl-4-dimethylaminoethyl[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), or di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), and further comprise a neutral lipid, a sterol and a molecule capable of reducing particle aggregation, for example a PEG or PEG-modified lipid.
• In some embodiments, the lipid nanoparticle formulation consists essentially of (i) at least one lipid selected from the group consisting of 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319); (ii) a neutral lipid selected from DSPC, DPPC, POPC, DOPE and SM; (iii) a sterol, e.g., cholesterol; and (iv) a PEG-lipid, e.g., PEG-DMG or PEG-cDMA, in a molar ratio of about 20-60% cationic lipid: 5-25% neutral lipid: 25-55% sterol; 0.5-15% PEG-lipid.
• In some embodiments, the formulation includes from about 25% to about 75% on a molar basis of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), e.g., from about 35 to about 65%, from about 45 to about 65%, about 60%, about 57.5%, about 50% or about 40% on a molar basis.
• In some embodiments, the formulation includes from about 0.5% to about 15% on a molar basis of the neutral lipid e.g., from about 3 to about 12%, from about 5 to about 10% or about 15%, about 10%, or about 7.5% on a molar basis. Examples of neutral lipids include, but are not limited to, DSPC, POPC, DPPC, DOPE and SM. In some embodiments, the formulation includes from about 5% to about 50% on a molar basis of the sterol (e.g., about 15 to about 45%, about 20 to about 40%, about 40%, about 38.5%, about 35%, or about 31% on a molar basis. An exemplary sterol is cholesterol. In some embodiments, the formulation includes from about 0.5% to about 20% on a molar basis of the PEG or PEG-modified lipid (e.g., about 0.5 to about 10%, about 0.5 to about 5%, about 1.5%, about 0.5%, about 1.5%, about 3.5%, or about 5% on a molar basis. In some embodiments, the PEG or PEG modified lipid comprises a PEG molecule of an average molecular weight of 2,000 Da. In other embodiments, the PEG or PEG modified lipid comprises a PEG molecule of an average molecular weight of less than 2,000, for example around 1,500 Da, around 1,000 Da, or around 500 Da. Examples of PEG-modified lipids include, but are not limited to, PEG-distearoyl glycerol (PEG-DMG) (also referred herein as PEG-C14 or C14-PEG), PEG-cDMA (further discussed in Reyes et al. J. Controlled Release, 107, 276-287 (2005) the contents of which are herein incorporated by reference in their entirety)
• In some embodiments, the formulations of the present disclosure include 25-75% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), 0.5-15% of the neutral lipid, 5-50% of the sterol, and 0.5-20% of the PEG or PEG-modified lipid on a molar basis.
• In some embodiments, the formulations of the present disclosure include 35-65% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), 3-12% of the neutral lipid, 15-45% of the sterol, and 0.5-10% of the PEG or PEG-modified lipid on a molar basis.
• In some embodiments, the formulations of the present disclosure include 45-65% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), 5-10% of the neutral lipid, 25-40% of the sterol, and 0.5-10% of the PEG or PEG-modified lipid on a molar basis.
• In some embodiments, the formulations of the present disclosure include about 60% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), about 7.5% of the neutral lipid, about 31% of the sterol, and about 1.5% of the PEG or PEG-modified lipid on a molar basis.
• In some embodiments, the formulations of the present disclosure include about 50% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), about 10% of the neutral lipid, about 38.5% of the sterol, and about 1.5% of the PEG or PEG-modified lipid on a molar basis.
• In some embodiments, the formulations of the present disclosure include about 50% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), about 10% of the neutral lipid, about 35% of the sterol, about 4.5% or about 5% of the PEG or PEG-modified lipid, and about 0.5% of the targeting lipid on a molar basis.
• In some embodiments, the formulations of the present disclosure include about 40% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), about 15% of the neutral lipid, about 40% of the sterol, and about 5% of the PEG or PEG-modified lipid on a molar basis.
• In some embodiments, the formulations of the present disclosure include about 57.2% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), about 7.1% of the neutral lipid, about 34.3% of the sterol, and about 1.4% of the PEG or PEG-modified lipid on a molar basis.
• In some embodiments, the formulations of the present disclosure include about 57.5% of a cationic lipid selected from the PEG lipid is PEG-cDMA (PEG-cDMA is further discussed in Reyes et al. (J. Controlled Release, 107, 276-287 (2005), the contents of which are herein incorporated by reference in their entirety), about 7.5% of the neutral lipid, about 31.5% of the sterol, and about 3.5% of the PEG or PEG-modified lipid on a molar basis.
• In some embodiments, lipid nanoparticle formulation consists essentially of a lipid mixture in molar ratios of about 20-70% cationic lipid: 5-45% neutral lipid: 20-55% cholesterol: 0.5-15% PEG-modified lipid; more preferably in a molar ratio of about 20-60% cationic lipid: 5-25% neutral lipid: 25-55% cholesterol: 0.5-15% PEG-modified lipid.
• In some embodiments, the molar lipid ratio is approximately 50/10/38.5/1.5 (mol % cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DMG, PEG-DSG or PEG-DPG), 57.2/7.1134.3/1.4 (mol % cationic lipid/neutral lipid, e.g., DPPC/Chol/PEG-modified lipid, e.g., PEG-cDMA), 40/15/40/5 (mol % cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DMG), 50/10/35/4.5/0.5 (mol % cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DSG), 50/10/35/5 (cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DMG), 40/10/40/10 (mol % cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DMG or PEG-cDMA), 35/15/40/10 (mol % cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DMG or PEG-cDMA) or 52/13/30/5 (mol % cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DMG or PEG-cDMA).
• Examples of lipid nanoparticle compositions and methods of making same are described, for example, in Semple et al. (2010) Nat. Biotechnol. 28:172-176; Jayarama et al. (2012), Angew. Chem. Int. Ed., 51: 8529-8533; and Maier et al. (2013) Molecular Therapy 21, 1570-1578 (the contents of each of which are incorporated herein by reference in their entirety).
• In some embodiments, the lipid nanoparticle formulations described herein may comprise a cationic lipid, a PEG lipid and a structural lipid and optionally comprise a non-cationic lipid. As a non-limiting example, the lipid nanoparticle may comprise about 40-60% of cationic lipid, about 5-15% of a non-cationic lipid, about 1-2% of a PEG lipid and about 30-50% of a structural lipid. As another non-limiting example, the lipid nanoparticle may comprise about 50% cationic lipid, about 10% non-cationic lipid, about 1.5% PEG lipid and about 38.5% structural lipid. As yet another non-limiting example, the lipid nanoparticle may comprise about 55% cationic lipid, about 10% non-cationic lipid, about 2.5% PEG lipid and about 32.5% structural lipid. In some embodiments, the cationic lipid may be any cationic lipid described herein such as, but not limited to, DLin-KC2-DMA, DLin-MC3-DMA and L319.
• In some embodiments, the lipid nanoparticle formulations described herein may be 4 component lipid nanoparticles. The lipid nanoparticle may comprise a cationic lipid, a non-cationic lipid, a PEG lipid and a structural lipid. As a non-limiting example, the lipid nanoparticle may comprise about 40-60% of cationic lipid, about 5-15% of a non-cationic lipid, about 1-2% of a PEG lipid and about 30-50% of a structural lipid. As another non-limiting example, the lipid nanoparticle may comprise about 50% cationic lipid, about 10% non-cationic lipid, about 1.5% PEG lipid and about 38.5% structural lipid. As yet another non-limiting example, the lipid nanoparticle may comprise about 55% cationic lipid, about 10% non-cationic lipid, about 2.5% PEG lipid and about 32.5% structural lipid. In some embodiments, the cationic lipid may be any cationic lipid described herein such as, but not limited to, DLin-KC2-DMA, DLin-MC3-DMA and L319.
• In some embodiments, the lipid nanoparticle formulations described herein may comprise a cationic lipid, a non-cationic lipid, a PEG lipid and a structural lipid. As a non-limiting example, the lipid nanoparticle comprise about 50% of the cationic lipid DLin-KC2-DMA, about 10% of the non-cationic lipid DSPC, about 1.5% of the PEG lipid PEG-DOMG and about 38.5% of the structural lipid cholesterol. As a non-limiting example, the lipid nanoparticle comprise about 50% of the cationic lipid DLin-MC3-DMA, about 10% of the non-cationic lipid DSPC, about 1.5% of the PEG lipid PEG-DOMG and about 38.5% of the structural lipid cholesterol. As a non-limiting example, the lipid nanoparticle comprise about 50% of the cationic lipid DLin-MC3-DMA, about 10% of the non-cationic lipid DSPC, about 1.5% of the PEG lipid PEG-DMG and about 38.5% of the structural lipid cholesterol. As yet another non-limiting example, the lipid nanoparticle comprise about 55% of the cationic lipid L319, about 10% of the non-cationic lipid DSPC, about 2.5% of the PEG lipid PEG-DMG and about 32.5% of the structural lipid cholesterol.
• As a non-limiting example, the cationic lipid may be selected from (20Z,23Z)—N,N-dimethylnonacosa-20,23-dien-10-amine, (17Z,20Z)—N,N-dimemylhexacosa-17,20-dien-9-amine, (1Z,19Z)—N5N-dimethylpentacosa-16, 19-dien-8-amine, (13Z,16Z)—N,N-dimethyldocosa-13,16-dien-5-amine, (12Z,15Z)—N,N-dimethylhenicosa-12,15-dien-4-amine, (14Z,17Z)—N,N-dimethyltricosa-14,17-dien-6-amine, (15Z,18Z)—N,N-dimethyltetracosa-15,18-dien-7-amine, (18Z,21Z)—N,N-dimethylheptacosa-18,21-dien-10-amine, (15Z,18Z)—N,N-dimethyltetracosa-15,18-dien-5-amine, (14Z,17Z)—N,N-dimethyltricosa-14,17-dien-4-amine, (19Z,22Z)—N,N-dimeihyloctacosa-19,22-dien-9-amine, (18Z,21 Z)—N,N-dimethylheptacosa-18,21-dien-8-amine, (17Z,20Z)—N,N-dimethylhexacosa-17,20-dien-7-amine, (16Z,19Z)—N,N-dimethylpentacosa-16,19-dien-6-amine, (22Z,25Z)—N,N-dimethylhentriaconta-22,25-dien-10-amine, (21 Z,24Z)—N,N-dimethyltriaconta-21,24-dien-9-amine, (18Z)—N,N-dimetylheptacos-18-en-10-amine, (17Z)—N,N-dimethylhexacos-17-en-9-amine, (19Z,22Z)—N,N-dimethyloctacosa-19,22-dien-7-amine, N,N-dimethylheptacosan-10-amine, (20Z,23Z)—N-ethyl-N-methylnonacosa-20,23-dien-10-amine, 1-[(11Z,14Z)-1-nonylicosa-11,14-dien-1-yl]pyrrolidine, (20Z)—N,N-dimethylheptacos-20-en-10-amine, (15Z)—N,N-dimethyl eptacos-15-en-10-amine, (14Z)—N,N-dimethylnonacos-14-en-10-amine, (17Z)—N,N-dimethylnonacos-17-en-10-amine, (24Z)—N,N-dimethyltritriacont-24-en-10-amine, (20Z)—N,N-dimethylnonacos-20-en-10-amine, (22Z)—N,N-dimethylhentriacont-22-en-10-amine, (16Z)—N,N-dimethylpentacos-16-en-8-amine, (12Z,15Z)—N,N-dimethyl-2-nonylhenicosa-12,15-dien-1-amine, (13Z,16Z)—N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine, N,N-dimethyl-1-[(1S,2R)-2-octylcyclopropyl]eptadecan-8-amine, 1-[(1S,2R)-2-hexylcyclopropyl]-N,N-dimethylnonadecan-10-amine, N,N-dimethyl-1-[(1S,2R)-2-octylcyclopropyl]nonadecan-10-amine, N,N-dimethyl-21-[(1S,2R)-2-octylcyclopropyl]henicosan-10-amine,N,N-dimethyl-1-[(1S,2S)-2-{[(1R,2R)-2-pentylcycIopropyl]methyl}cyclopropyl]nonadecan-10-amine,N,N-dimethyl-1-[(1S,2R)-2-octylcyclopropyl]hexadecan-8-amine, N,N-dimethyl-[(1R,2S)-2-undecyIcyclopropyl]tetradecan-5-amine, N,N-dimethyl-3-{7-[(1S,2R)-2-octylcyclopropyl]heptyl}dodecan-1-amine, 1-[(1R,2S)-2-heptylcyclopropyl]-N,N-dimethyloctadecan-9-amine, 1-[(1S,2R)-2-decylcyclopropyl]-N,N-dimethylpentadecan-6-amine, N,N-dimethyl-1-[(1S,2R)-2-octylcyclopropyl]pentadecan-8-amine, R—N,N-dimethyl-1-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-3-(octyloxy)propan-2-amine, S—N,N-dimethyl-1-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-3-(octyloxy)propan-2-amine, 1-{2-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-1-[(octyloxy)methyl]ethyl}pyrrolidine, (2S)—N,N-dimethyl-1-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-3-[(S2)-oct-5-en-1-yloxy]propan-2-amine, 1-{2-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-1-[(octyloxy)methyl]ethyl}azetidine, (2S)-1-(hexyloxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-2-amine, (2S)-1-(heptyloxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-2-amine, N,N-dimethyl-1-(nonyloxy)-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-2-amine, N,N-dimethyl-1-[(9Z)-octadec-9-en-1-yloxy]-3-(octyloxy)propan-2-amine; (2S)—N,N-dimethyl-1-[(6Z,9Z,12Z)-octadeca-6,9,12-trien-1-yloxy]-3-(octyloxy)propan-2-amine, (2S)-1-[(11Z,14Z)-icosa-11,14-dien-1-yloxy]-N,N-dimethyl-3-(pentyloxy)propan-2-amine, (2S)-1-(hexyloxy)-3-[(11Z,14Z)-icosa-11,14-dien-1-yloxy]-N,N-dimethylpropan-2-amine, 1-[(11Z,14Z)-icosa-11,14-dien-1-yloxy]-N,N-dimethyl-3-(octyloxy)propan-2-amine, 1-[(13Z,16Z)-docosa-13,16-dien-1-yloxy]-N,N-dimethyl-3-(octyloxy)propan-2-amine, (2S)-1-[(13Z,16Z)-docosa-13,16-dien-1-yloxy]-3-(hexyloxy)-N,N-dimethylpropan-2-amine, (2S)-1-[(13Z)-docos-13-en-1-yloxy]-3-(hexyloxy)-N,N-dimethylpropan-2-amine, 1-[(13Z)-docos-13-en-1-yloxy]-N,N-dimethyl-3-(octyloxy)propan-2-amine, 1-[(9Z)-hexadec-9-en-1-yloxy]-N,N-dimethyl-3-(octyloxy)propan-2-amine, (2R)—N,N-dimethyl-H(1-metoyloctyl)oxy]-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-2-amine, (2R)-1-[(3,7-dimethyloctyl)oxy]-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-2-amine, N,N-dimethyl-1-(octyloxy)-3-({8-[(1S,2S)-2-{[(1R,2R)-2-pentylcyclopropyl]methyl}cyclopropyl]octyl}oxy)propan-2-amine, N,N-dimethyl-1-{[8-(2-oclylcyclopropyl)octyl]oxy}-3-(octyloxy)propan-2-amine and (11E,20Z,23Z)—N,N-dimethylnonacosa-11,20,2-trien-10-amine or a pharmaceutically acceptable salt or stereoisomer thereof.
• In some embodiments, the LNP formulations of the RNA (e.g., mRNA) vaccines may contain PEG-c-DOMG at 3% lipid molar ratio. In some embodiments, the LNP formulations of the RNA (e.g., mRNA) vaccines may contain PEG-c-DOMG at 1.5% lipid molar ratio.
• In some embodiments, the pharmaceutical compositions of the RNA (e.g., mRNA) vaccines may include at least one of the PEGylated lipids described in International Publication No. WO2012099755, the contents of which are herein incorporated by reference in their entirety.
• In some embodiments, the LNP formulation may contain PEG-DMG 2000 (1,2-dimyristoyl-sn-glycero-3-phophoethanolamine-N-[methoxy(polyethylene glycol)-2000). In some embodiments, the LNP formulation may contain PEG-DMG 2000, a cationic lipid known in the art and at least one other component. In some embodiments, the LNP formulation may contain PEG-DMG 2000, a cationic lipid known in the art, DSPC and cholesterol. As a non-limiting example, the LNP formulation may contain PEG-DMG 2000, DLin-DMA, DSPC and cholesterol. As another non-limiting example the LNP formulation may contain PEG-DMG 2000, DLin-DMA, DSPC and cholesterol in a molar ratio of 2:40:10:48 (see e.g., Geall et al., Nonviral delivery of self-amplifying RNA (e.g., mRNA) vaccines, PNAS 2012; PMID: 22908294, the contents of each of which are herein incorporated by reference in their entirety).
• The lipid nanoparticles described herein may be made in a sterile environment.
• In some embodiments, the LNP formulation may be formulated in a nanoparticle such as a nucleic acid-lipid particle. As a non-limiting example, the lipid particle may comprise one or more active agents or therapeutic agents; one or more cationic lipids comprising from about 50 mol % to about 85 mol % of the total lipid present in the particle; one or more non-cationic lipids comprising from about 13 mol % to about 49.5 mol % of the total lipid present in the particle; and one or more conjugated lipids that inhibit aggregation of particles comprising from about 0.5 mol % to about 2 mol % of the total lipid present in the particle.
• The nanoparticle formulations may comprise a phosphate conjugate. The phosphate conjugate may increase in vivo circulation times and/or increase the targeted delivery of the nanoparticle. As a non-limiting example, the phosphate conjugates may include a compound of any one of the formulas described in International Application No. WO2013033438, the contents of which are herein incorporated by reference in its entirety.
• The nanoparticle formulation may comprise a polymer conjugate. The polymer conjugate may be a water soluble conjugate. The polymer conjugate may have a structure as described in U.S. Patent Application No. 20130059360, the contents of which are herein incorporated by reference in its entirety. In some embodiments, polymer conjugates with the polynucleotides of the present disclosure may be made using the methods and/or segmented polymeric reagents described in U.S. Patent Application No. 20130072709, the contents of which are herein incorporated by reference in its entirety. In some embodiments, the polymer conjugate may have pendant side groups comprising ring moieties such as, but not limited to, the polymer conjugates described in U.S. Patent Publication No. US20130196948, the contents which are herein incorporated by reference in its entirety.
• The nanoparticle formulations may comprise a conjugate to enhance the delivery of nanoparticles of the present disclosure in a subject. Further, the conjugate may inhibit phagocytic clearance of the nanoparticles in a subject. In one aspect, the conjugate may be a “self” peptide designed from the human membrane protein CD47 (e.g., the “self” particles described by Rodriguez et al. (Science 2013 339, 971-975), herein incorporated by reference in its entirety). As shown by Rodriguez et al., the self peptides delayed macrophage-mediated clearance of nanoparticles which enhanced delivery of the nanoparticles. In another aspect, the conjugate may be the membrane protein CD47 (e.g., see Rodriguez et al. Science 2013 339, 971-975, herein incorporated by reference in its entirety). Rodriguez et al. showed that, similarly to “self” peptides, CD47 can increase the circulating particle ratio in a subject as compared to scrambled peptides and PEG coated nanoparticles.
• In some embodiments, the RNA (e.g., mRNA) vaccines of the present disclosure are formulated in nanoparticles which comprise a conjugate to enhance the delivery of the nanoparticles of the present disclosure in a subject. The conjugate may be the CD47 membrane or the conjugate may be derived from the CD47 membrane protein, such as the “self” peptide described previously. In some embodiments, the nanoparticle may comprise PEG and a conjugate of CD47 or a derivative thereof. In some embodiments, the nanoparticle may comprise both the “self” peptide described above and the membrane protein CD47.
• In some embodiments, a “self” peptide and/or CD47 protein may be conjugated to a virus-like particle or pseudovirion, as described herein for delivery of the RNA (e.g., mRNA) vaccines of the present disclosure.
• In some embodiments, RNA (e.g., mRNA) vaccine pharmaceutical compositions comprising the polynucleotides of the present disclosure and a conjugate that may have a degradable linkage. Non-limiting examples of conjugates include an aromatic moiety comprising an ionizable hydrogen atom, a spacer moiety, and a water-soluble polymer. As a non-limiting example, pharmaceutical compositions comprising a conjugate with a degradable linkage and methods for delivering such pharmaceutical compositions are described in U.S. Patent Publication No. US20130184443, the contents of which are herein incorporated by reference in their entirety.
• The nanoparticle formulations may be a carbohydrate nanoparticle comprising a carbohydrate carrier and a RNA (e.g., mRNA) vaccine. As a non-limiting example, the carbohydrate carrier may include, but is not limited to, an anhydride-modified phytoglycogen or glycogen-type material, phtoglycogen octenyl succinate, phytoglycogen beta-dextrin, anhydride-modified phytoglycogen beta-dextrin. (See e.g., International Publication No. WO2012109121; the contents of which are herein incorporated by reference in their entirety).
• Nanoparticle formulations of the present disclosure may be coated with a surfactant or polymer in order to improve the delivery of the particle. In some embodiments, the nanoparticle may be coated with a hydrophilic coating such as, but not limited to, PEG coatings and/or coatings that have a neutral surface charge. The hydrophilic coatings may help to deliver nanoparticles with larger payloads such as, but not limited to, RNA (e.g., mRNA) vaccines within the central nervous system. As a non-limiting example nanoparticles comprising a hydrophilic coating and methods of making such nanoparticles are described in U.S. Patent Publication No. US20130183244, the contents of which are herein incorporated by reference in their entirety.
• In some embodiments, the lipid nanoparticles of the present disclosure may be hydrophilic polymer particles. Non-limiting examples of hydrophilic polymer particles and methods of making hydrophilic polymer particles are described in U.S. Patent Publication No. US20130210991, the contents of which are herein incorporated by reference in their entirety.
• In some embodiments, the lipid nanoparticles of the present disclosure may be hydrophobic polymer particles.
• Lipid nanoparticle formulations may be improved by replacing the cationic lipid with a biodegradable cationic lipid which is known as a rapidly eliminated lipid nanoparticle (reLNP). Ionizable cationic lipids, such as, but not limited to, DLinDMA, DLin-KC2-DMA, and DLin-MC3-DMA, have been shown to accumulate in plasma and tissues over time and may be a potential source of toxicity. The rapid metabolism of the rapidly eliminated lipids can improve the tolerability and therapeutic index of the lipid nanoparticles by an order of magnitude from a 1 mg/kg dose to a 10 mg/kg dose in rat. Inclusion of an enzymatically degraded ester linkage can improve the degradation and metabolism profile of the cationic component, while still maintaining the activity of the reLNP formulation. The ester linkage can be internally located within the lipid chain or it may be terminally located at the terminal end of the lipid chain. The internal ester linkage may replace any carbon in the lipid chain.
• In some embodiments, the internal ester linkage may be located on either side of the saturated carbon.
• In some embodiments, an immune response may be elicited by delivering a lipid nanoparticle which may include a nanospecies, a polymer and an immunogen. (U.S. Publication No. 20120189700 and International Publication No. WO2012099805; each of which is herein incorporated by reference in their entirety). The polymer may encapsulate the nanospecies or partially encapsulate the nanospecies. The immunogen may be a recombinant protein, a modified RNA and/or a polynucleotide described herein. In some embodiments, the lipid nanoparticle may be formulated for use in a vaccine such as, but not limited to, against a pathogen.
• Lipid nanoparticles may be engineered to alter the surface properties of particles so the lipid nanoparticles may penetrate the mucosal barrier. Mucus is located on mucosal tissue such as, but not limited to, oral (e.g., the buccal and esophageal membranes and tonsil tissue), ophthalmic, gastrointestinal (e.g., stomach, small intestine, large intestine, colon, rectum), nasal, respiratory (e.g., nasal, pharyngeal, tracheal and bronchial membranes), genital (e.g., vaginal, cervical and urethral membranes). Nanoparticles larger than 10-200 nm which are preferred for higher drug encapsulation efficiency and the ability to provide the sustained delivery of a wide array of drugs have been thought to be too large to rapidly diffuse through mucosal barriers. Mucus is continuously secreted, shed, discarded or digested and recycled so most of the trapped particles may be removed from the mucosa tissue within seconds or within a few hours. Large polymeric nanoparticles (200 nm-500 nm in diameter) which have been coated densely with a low molecular weight polyethylene glycol (PEG) diffused through mucus only 4 to 6-fold lower than the same particles diffusing in water (Lai et al. PNAS 2007 104:1482-487; Lai et al. Adv Drug Deliv Rev. 2009 61: 158-171; each of which is herein incorporated by reference in their entirety). The transport of nanoparticles may be determined using rates of permeation and/or fluorescent microscopy techniques including, but not limited to, fluorescence recovery after photobleaching (FRAP) and high resolution multiple particle tracking (MPT). As a non-limiting example, compositions which can penetrate a mucosal barrier may be made as described in U.S. Pat. No. 8,241,670 or International Patent Publication No. WO2013110028, the contents of each of which are herein incorporated by reference in its entirety.
• The lipid nanoparticle engineered to penetrate mucus may comprise a polymeric material (i.e. a polymeric core) and/or a polymer-vitamin conjugate and/or a tri-block co-polymer. The polymeric material may include, but is not limited to, polyamines, polyethers, polyamides, polyesters, polycarbamates, polyureas, polycarbonates, poly(styrenes), polyimides, polysulfones, polyurethanes, polyacetylenes, polyethylenes, polyethyeneimines, polyisocyanates, polyacrylates, polymethacrylates, polyacrylonitriles, and polyarylates. The polymeric material may be biodegradable and/or biocompatible. Non-limiting examples of biocompatible polymers are described in International Patent Publication No. WO2013116804, the contents of which are herein incorporated by reference in their entirety. The polymeric material may additionally be irradiated. As a non-limiting example, the polymeric material may be gamma irradiated (see e.g., International App. No. WO201282165, herein incorporated by reference in its entirety). Non-limiting examples of specific polymers include poly(caprolactone) (PCL), ethylene vinyl acetate polymer (EVA), poly(lactic acid) (PLA), poly(L-lactic acid) (PLLA), poly(glycolic acid) (PGA), poly(lactic acid-co-glycolic acid) (PLGA), poly(L-lactic acid-co-glycolic acid) (PLLGA), poly(D,L-lactide) (PDLA), poly(L-lactide) (PLLA), poly(D,L-lactide-co-caprolactone), poly(D,L-lactide-co-caprolactone-co-glycolide), poly(D,L-lactide-co-PEO-co-D,L-lactide), poly(D,L-lactide-co-PPO-co-D,L-lactide), polyalkyl cyanoacralate, polyurethane, poly-L-lysine (PLL), hydroxypropyl methacrylate (HPMA), polyethyleneglycol, poly-L-glutamic acid, poly(hydroxy acids), polyanhydrides, polyorthoesters, poly(ester amides), polyamides, poly(ester ethers), polycarbonates, polyalkylenes such as polyethylene and polypropylene, polyalkylene glycols such as poly(ethylene glycol) (PEG), polyalkylene oxides (PEO), polyalkylene terephthalates such as poly(ethylene terephthalate), polyvinyl alcohols (PVA), polyvinyl ethers, polyvinyl esters such as poly(vinyl acetate), polyvinyl halides such as poly(vinyl chloride) (PVC), polyvinylpyrrolidone, polysiloxanes, polystyrene (PS), polyurethanes, derivatized celluloses such as alkyl celluloses, hydroxyalkyl celluloses, cellulose ethers, cellulose esters, nitro celluloses, hydroxypropylcellulose, carboxymethylcellulose, polymers of acrylic acids, such as poly(methyl(meth)acrylate) (PMMA), poly(ethyl(meth)acrylate), poly(butyl(meth)acrylate), poly(isobutyl(meth)acrylate), poly(hexyl(meth)acrylate), poly(isodecyl(meth)acrylate), poly(lauryl(meth)acrylate), poly(phenyl(meth)acrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), poly(octadecyl acrylate) and copolymers and mixtures thereof, polydioxanone and its copolymers, polyhydroxyalkanoates, polypropylene fumarate, polyoxymethylene, poloxamers, poly(ortho)esters, poly(butyric acid), poly(valeric acid), poly(lactide-co-caprolactone), PEG-PLGA-PEG and trimethylene carbonate, polyvinylpyrrolidone. The lipid nanoparticle may be coated or associated with a co-polymer such as, but not limited to, a block co-polymer (such as a branched polyether-polyamide block copolymer described in International Publication No. WO2013012476, herein incorporated by reference in its entirety), and (poly(ethylene glycol))-(poly(propylene oxide))-(poly(ethylene glycol)) triblock copolymer (see e.g., U.S. Publication 20120121718 and U.S. Publication 20100003337 and U.S. Pat. No. 8,263,665, the contents of each of which is herein incorporated by reference in their entirety). The co-polymer may be a polymer that is generally regarded as safe (GRAS) and the formation of the lipid nanoparticle may be in such a way that no new chemical entities are created. For example, the lipid nanoparticle may comprise poloxamers coating PLGA nanoparticles without forming new chemical entities which are still able to rapidly penetrate human mucus (Yang et al. Angew. Chem. Int. Ed. 2011 50:2597-2600; the contents of which are herein incorporated by reference in their entirety). A non-limiting scalable method to produce nanoparticles which can penetrate human mucus is described by Xu et al. (see, e.g., J Control Release 2013, 170:279-86; the contents of which are herein incorporated by reference in their entirety).
• The vitamin of the polymer-vitamin conjugate may be vitamin E. The vitamin portion of the conjugate may be substituted with other suitable components such as, but not limited to, vitamin A, vitamin E, other vitamins, cholesterol, a hydrophobic moiety, or a hydrophobic component of other surfactants (e.g., sterol chains, fatty acids, hydrocarbon chains and alkylene oxide chains).
• The lipid nanoparticle engineered to penetrate mucus may include surface altering agents such as, but not limited to, polynucleotides, anionic proteins (e.g., bovine serum albumin), surfactants (e.g., cationic surfactants such as for example dimethyldioctadecylammonium bromide), sugars or sugar derivatives (e.g., cyclodextrin), nucleic acids, polymers (e.g., heparin, polyethylene glycol and poloxamer), mucolytic agents (e.g., N-acetylcysteine, mugwort, bromelain, papain, clerodendrum, acetylcysteine, bromhexine, carbocisteine, eprazinone, mesna, ambroxol, sobrerol, domiodol, letosteine, stepronin, tiopronin, gelsolin, thymosin β4 dornase alfa, neltenexine, erdosteine) and various DNases including rhDNase. The surface altering agent may be embedded or enmeshed in the particle's surface or disposed (e.g., by coating, adsorption, covalent linkage, or other process) on the surface of the lipid nanoparticle. (see e.g., U.S. Publication 20100215580 and U.S. Publication 20080166414 and US20130164343; the contents of each of which are herein incorporated by reference in their entirety).
• In some embodiments, the mucus penetrating lipid nanoparticles may comprise at least one polynucleotide described herein. The polynucleotide may be encapsulated in the lipid nanoparticle and/or disposed on the surface of the particle. The polynucleotide may be covalently coupled to the lipid nanoparticle. Formulations of mucus penetrating lipid nanoparticles may comprise a plurality of nanoparticles. Further, the formulations may contain particles which may interact with the mucus and alter the structural and/or adhesive properties of the surrounding mucus to decrease mucoadhesion, which may increase the delivery of the mucus penetrating lipid nanoparticles to the mucosal tissue.
• In some embodiments, the mucus penetrating lipid nanoparticles may be a hypotonic formulation comprising a mucosal penetration enhancing coating. The formulation may be hypotonic for the epithelium to which it is being delivered. Non-limiting examples of hypotonic formulations may be found in International Patent Publication No. WO2013110028, the contents of which are herein incorporated by reference in their entirety.
• In some embodiments, in order to enhance the delivery through the mucosal barrier the RNA (e.g., mRNA) vaccine formulation may comprise or be a hypotonic solution. Hypotonic solutions were found to increase the rate at which mucoinert particles such as, but not limited to, mucus-penetrating particles, were able to reach the vaginal epithelial surface (see e.g., Ensign et al. Biomaterials 2013 34(28):6922-9, the contents of which are herein incorporated by reference in their entirety).
• In some embodiments, the RNA (e.g., mRNA) vaccine is formulated as a lipoplex, such as, without limitation, the ATUPLEX™ system, the DACC system, the DBTC system and other siRNA-lipoplex technology from Silence Therapeutics (London, United Kingdom), STEMFECT™ from STEMGENT® (Cambridge, Mass.), and polyethylenimine (PEI) or protamine-based targeted and non-targeted delivery of nucleic acids (Aleku et al. Cancer Res. 2008 68:9788-9798; Strumberg et al. Int J Clin Pharmacol Ther 2012 50:76-78; Santel et al., Gene Ther 2006 13:1222-1234; Santel et al., Gene Ther 2006 13:1360-1370; Gutbier et al., Pulm Pharmacol. Ther. 2010 23:334-344; Kaufmann et al. Microvasc Res 2010 80:286-293Weide et al. J Immunother. 2009 32:498-507; Weide et al. J Immunother. 2008 31:180-188; Pascolo Expert Opin. Biol. Ther. 4:1285-1294; Fotin-Mleczek et al., 2011 J. Immunother. 34:1-15; Song et al., Nature Biotechnol. 2005, 23:709-717; Peer et al., Proc Natl Acad Sci USA. 2007 6; 104:4095-4100; deFougerolles Hum Gene Ther. 2008 19:125-132, the contents of each of which are incorporated herein by reference in their entirety).
• In some embodiments, such formulations may also be constructed or compositions altered such that they passively or actively are directed to different cell types in vivo, including but not limited to hepatocytes, immune cells, tumor cells, endothelial cells, antigen presenting cells, and leukocytes (Akinc et al. Mol Ther. 2010 18:1357-1364; Song et al., Nat Biotechnol. 2005 23:709-717; Judge et al., J Clin Invest. 2009 119:661-673; Kaufmann et al., Microvasc Res 2010 80:286-293; Santel et al., Gene Ther 2006 13:1222-1234; Santel et al., Gene Ther 2006 13:1360-1370; Gutbier et al., Pulm Pharmacol. Ther. 2010 23:334-344; Basha et al., Mol. Ther. 2011 19:2186-2200; Fenske and Cullis, Expert Opin Drug Deliv. 2008 5:25-44; Peer et al., Science. 2008 319:627-630; Peer and Lieberman, Gene Ther. 2011 18:1127-1133, the contents of each of which are incorporated herein by reference in their entirety). One example of passive targeting of formulations to liver cells includes the DLin-DMA, DLin-KC2-DMA and DLin-MC3-DMA-based lipid nanoparticle formulations, which have been shown to bind to apolipoprotein E and promote binding and uptake of these formulations into hepatocytes in vivo (Akinc et al. Mol Ther. 2010 18:1357-1364, the contents of which are incorporated herein by reference in their entirety). Formulations can also be selectively targeted through expression of different ligands on their surface as exemplified by, but not limited by, folate, transferrin, N-acetylgalactosamine (GalNAc), and antibody targeted approaches (Kolhatkar et al., Curr Drug Discov Technol. 2011 8:197-206; Musacchio and Torchilin, Front Biosci. 2011 16:1388-1412; Yu et al., Mol Membr Biol. 2010 27:286-298; Patil et al., Crit Rev Ther Drug Carrier Syst. 2008 25:1-61; Benoit et al., Biomacromolecules. 2011 12:2708-2714; Zhao et al., Expert Opin Drug Deliv. 2008 5:309-319; Akinc et al., Mol Ther. 2010 18:1357-1364; Srinivasan et al., Methods Mol Biol. 2012 820:105-116; Ben-Arie et al., Methods Mol Biol. 2012 757:497-507; Peer 2010 J Control Release. 20:63-68; Peer et al., Proc Natl Acad Sci USA. 2007 104:4095-4100; Kim et al., Methods Mol Biol. 2011 721:339-353; Subramanya et al., Mol Ther. 2010 18:2028-2037; Song et al., Nat Biotechnol. 2005 23:709-717; Peer et al., Science. 2008 319:627-630; Peer and Lieberman, Gene Ther. 2011 18:1127-1133, the contents of each of which are incorporated herein by reference in their entirety).
• In some embodiments, the RNA (e.g., mRNA) vaccine is formulated as a solid lipid nanoparticle. A solid lipid nanoparticle (SLN) may be spherical with an average diameter between 10 to 1000 nm. SLN possess a solid lipid core matrix that can solubilize lipophilic molecules and may be stabilized with surfactants and/or emulsifiers. In some embodiments, the lipid nanoparticle may be a self-assembly lipid-polymer nanoparticle (see Zhang et al., ACS Nano, 2008, 2, pp 1696-1702; the contents of which are herein incorporated by reference in their entirety). As a non-limiting example, the SLN may be the SLN described in International Patent Publication No. WO2013105101, the contents of which are herein incorporated by reference in their entirety. As another non-limiting example, the SLN may be made by the methods or processes described in International Patent Publication No. WO2013105101, the contents of which are herein incorporated by reference in their entirety.
• Liposomes, lipoplexes, or lipid nanoparticles may be used to improve the efficacy of polynucleotides directed protein production as these formulations may be able to increase cell transfection by the RNA (e.g., mRNA) vaccine; and/or increase the translation of encoded protein. One such example involves the use of lipid encapsulation to enable the effective systemic delivery of polyplex plasmid DNA (Heyes et al., Mol Ther. 2007 15:713-720; the contents of which are incorporated herein by reference in their entirety). The liposomes, lipoplexes, or lipid nanoparticles may also be used to increase the stability of the polynucleotide.
• In some embodiments, the RNA (e.g., mRNA) vaccines of the present disclosure can be formulated for controlled release and/or targeted delivery. As used herein, “controlled release” refers to a pharmaceutical composition or compound release profile that conforms to a particular pattern of release to effect a therapeutic outcome. In some embodiments, the RNA (e.g., mRNA) vaccines may be encapsulated into a delivery agent described herein and/or known in the art for controlled release and/or targeted delivery. As used herein, the term “encapsulate” means to enclose, surround or encase. As it relates to the formulation of the compounds of the disclosure, encapsulation may be substantial, complete or partial. The term “substantially encapsulated” means that at least greater than 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99, 99.9, 99.9 or greater than 99.999% of the pharmaceutical composition or compound of the disclosure may be enclosed, surrounded or encased within the delivery agent. “Partially encapsulation” means that less than 10, 10, 20, 30, 40 50 or less of the pharmaceutical composition or compound of the disclosure may be enclosed, surrounded or encased within the delivery agent. Advantageously, encapsulation may be determined by measuring the escape or the activity of the pharmaceutical composition or compound of the disclosure using fluorescence and/or electron micrograph. For example, at least 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99, 99.9, 99.99 or greater than 99.99% of the pharmaceutical composition or compound of the disclosure are encapsulated in the delivery agent.
• In some embodiments, the controlled release formulation may include, but is not limited to, tri-block co-polymers. As a non-limiting example, the formulation may include two different types of tri-block co-polymers (International Pub. No. WO2012131104 and WO2012131106, the contents of each of which are incorporated herein by reference in their entirety).
• In some embodiments, the RNA (e.g., mRNA) vaccines may be encapsulated into a lipid nanoparticle or a rapidly eliminated lipid nanoparticle and the lipid nanoparticles or a rapidly eliminated lipid nanoparticle may then be encapsulated into a polymer, hydrogel and/or surgical sealant described herein and/or known in the art. As a non-limiting example, the polymer, hydrogel or surgical sealant may be PLGA, ethylene vinyl acetate (EVAc), poloxamer, GELSITE® (Nanotherapeutics, Inc. Alachua, Fla.), HYLENEX® (Halozyme Therapeutics, San Diego Calif.), surgical sealants such as fibrinogen polymers (Ethicon Inc. Cornelia, Ga.), TISSELL® (Baxter International, Inc Deerfield, Ill.), PEG-based sealants, and COSEAL® (Baxter International, Inc Deerfield, Ill.).
• In some embodiments, the lipid nanoparticle may be encapsulated into any polymer known in the art which may form a gel when injected into a subject. As another non-limiting example, the lipid nanoparticle may be encapsulated into a polymer matrix which may be biodegradable.
• In some embodiments, the RNA (e.g., mRNA) vaccine formulation for controlled release and/or targeted delivery may also include at least one controlled release coating. Controlled release coatings include, but are not limited to, OPADRY®, polyvinylpyrrolidone/vinyl acetate copolymer, polyvinylpyrrolidone, hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, EUDRAGIT RL®, EUDRAGIT RS® and cellulose derivatives such as ethylcellulose aqueous dispersions (AQUACOAT® and SURELEASE®).
• In some embodiments, the RNA (e.g., mRNA) vaccine controlled release and/or targeted delivery formulation may comprise at least one degradable polyester which may contain polycationic side chains. Degradeable polyesters include, but are not limited to, poly(serine ester), poly(L-lactide-co-L-lysine), poly(4-hydroxy-L-proline ester), and combinations thereof. In some embodiments, the degradable polyesters may include a PEG conjugation to form a PEGylated polymer.
• In some embodiments, the RNA (e.g., mRNA) vaccine controlled release and/or targeted delivery formulation comprising at least one polynucleotide may comprise at least one PEG and/or PEG related polymer derivatives as described in U.S. Pat. No. 8,404,222, the contents of which are incorporated herein by reference in their entirety.
• In some embodiments, the RNA (e.g., mRNA) vaccine controlled release delivery formulation comprising at least one polynucleotide may be the controlled release polymer system described in US20130130348, the contents of which are incorporated herein by reference in their entirety.
• In some embodiments, the RNA (e.g., mRNA) vaccines of the present disclosure may be encapsulated in a therapeutic nanoparticle, referred to herein as “therapeutic nanoparticle RNA (e.g., mRNA) vaccines.” Therapeutic nanoparticles may be formulated by methods described herein and known in the art such as, but not limited to, International Pub Nos. WO2010005740, WO2010030763, WO2010005721, WO2010005723, WO2012054923, U.S. Publication Nos. US20110262491, US20100104645, US20100087337, US20100068285, US20110274759, US20100068286, US20120288541, US20130123351 and US20130230567 and U.S. Pat. Nos. 8,206,747, 8,293,276, 8,318,208 and 8,318,211; the contents of each of which are herein incorporated by reference in their entirety. In some embodiments, therapeutic polymer nanoparticles may be identified by the methods described in US Pub No. US20120140790, the contents of which are herein incorporated by reference in their entirety.
• In some embodiments, the therapeutic nanoparticle RNA (e.g., mRNA) vaccine may be formulated for sustained release. As used herein, “sustained release” refers to a pharmaceutical composition or compound that conforms to a release rate over a specific period of time. The period of time may include, but is not limited to, hours, days, weeks, months and years. As a non-limiting example, the sustained release nanoparticle may comprise a polymer and a therapeutic agent such as, but not limited to, the polynucleotides of the present disclosure (see International Pub No. 2010075072 and US Pub No. US20100216804, US20110217377 and US20120201859, the contents of each of which are incorporated herein by reference in their entirety). In another non-limiting example, the sustained release formulation may comprise agents which permit persistent bioavailability such as, but not limited to, crystals, macromolecular gels and/or particulate suspensions (see U.S. Patent Publication No US20130150295, the contents of each of which are incorporated herein by reference in their entirety).
• In some embodiments, the therapeutic nanoparticle RNA (e.g., mRNA) vaccines may be formulated to be target specific. As a non-limiting example, the therapeutic nanoparticles may include a corticosteroid (see International Pub. No. WO2011084518, the contents of which are incorporated herein by reference in their entirety). As a non-limiting example, the therapeutic nanoparticles may be formulated in nanoparticles described in International Pub No. WO2008121949, WO2010005726, WO2010005725, WO2011084521 and US Pub No. US20100069426, US20120004293 and US20100104655, the contents of each of which are incorporated herein by reference in their entirety.
• In some embodiments, the nanoparticles of the present disclosure may comprise a polymeric matrix. As a non-limiting example, the nanoparticle may comprise two or more polymers such as, but not limited to, polyethylenes, polycarbonates, polyanhydrides, polyhydroxyacids, polypropylfumerates, polycaprolactones, polyamides, polyacetals, polyethers, polyesters, poly(orthoesters), polycyanoacrylates, polyvinyl alcohols, polyurethanes, polyphosphazenes, polyacrylates, polymethacrylates, polycyanoacrylates, polyureas, polystyrenes, polyamines, polylysine, poly(ethylene imine), poly(serine ester), poly(L-lactide-co-L-lysine), poly(4-hydroxy-L-proline ester) or combinations thereof.
• In some embodiments, the therapeutic nanoparticle comprises a diblock copolymer. In some embodiments, the diblock copolymer may include PEG in combination with a polymer such as, but not limited to, polyethylenes, polycarbonates, polyanhydrides, polyhydroxyacids, polypropylfumerates, polycaprolactones, polyamides, polyacetals, polyethers, polyesters, poly(orthoesters), polycyanoacrylates, polyvinyl alcohols, polyurethanes, polyphosphazenes, polyacrylates, polymethacrylates, polycyanoacrylates, polyureas, polystyrenes, polyamines, polylysine, poly(ethylene imine), poly(serine ester), poly(L-lactide-co-L-lysine), poly(4-hydroxy-L-proline ester) or combinations thereof. In yet another embodiment, the diblock copolymer may be a high-X diblock copolymer such as those described in International Patent Publication No. WO2013120052, the contents of which are incorporated herein by reference in their entirety.
• As a non-limiting example the therapeutic nanoparticle comprises a PLGA-PEG block copolymer (see U.S. Publication No. US20120004293 and U.S. Pat. No. 8,236,330, each of which is herein incorporated by reference in their entirety). In another non-limiting example, the therapeutic nanoparticle is a stealth nanoparticle comprising a diblock copolymer of PEG and PLA or PEG and PLGA (see U.S. Pat. No. 8,246,968 and International Publication No. WO2012166923, the contents of each of which are herein incorporated by reference in their entirety). In yet another non-limiting example, the therapeutic nanoparticle is a stealth nanoparticle or a target-specific stealth nanoparticle as described in U.S. Patent Publication No. US20130172406, the contents of which are herein incorporated by reference in their entirety.
• In some embodiments, the therapeutic nanoparticle may comprise a multiblock copolymer (see e.g., U.S. Pat. Nos. 8,263,665 and 8,287,910 and U.S. Patent Pub. No. US20130195987, the contents of each of which are herein incorporated by reference in their entirety).
• In yet another non-limiting example, the lipid nanoparticle comprises the block copolymer PEG-PLGA-PEG (see e.g., the thermosensitive hydrogel (PEG-PLGA-PEG) was used as a TGF-beta1 gene delivery vehicle in Lee et al. Thermosensitive Hydrogel as a TGF-β1 Gene Delivery Vehicle Enhances Diabetic Wound Healing. Pharmaceutical Research, 2003 20(12): 1995-2000; as a controlled gene delivery system in Li et al. Controlled Gene Delivery System Based on Thermosensitive Biodegradable Hydrogel. Pharmaceutical Research 2003 20:884-888; and Chang et al., Non-ionic amphiphilic biodegradable PEG-PLGA-PEG copolymer enhances gene delivery efficiency in rat skeletal muscle. J Controlled Release. 2007 118:245-253, the contents of each of which are herein incorporated by reference in their entirety). The RNA (e.g., mRNA) vaccines of the present disclosure may be formulated in lipid nanoparticles comprising the PEG-PLGA-PEG block copolymer.
• In some embodiments, the therapeutic nanoparticle may comprise a multiblock copolymer (see e.g., U.S. Pat. Nos. 8,263,665 and 8,287,910 and U.S. Patent Pub. No. US20130195987, the contents of each of which are herein incorporated by reference in their entirety).
• In some embodiments, the block copolymers described herein may be included in a polyion complex comprising a non-polymeric micelle and the block copolymer. (see e.g., U.S. Publication No. 20120076836, the contents of which are herein incorporated by reference in their entirety).
• In some embodiments, the therapeutic nanoparticle may comprise at least one acrylic polymer. Acrylic polymers include but are not limited to, acrylic acid, methacrylic acid, acrylic acid and methacrylic acid copolymers, methyl methacrylate copolymers, ethoxyethyl methacrylates, cyanoethyl methacrylate, amino alkyl methacrylate copolymer, poly(acrylic acid), poly(methacrylic acid), polycyanoacrylates and combinations thereof.
• In some embodiments, the therapeutic nanoparticles may comprise at least one poly(vinyl ester) polymer. The poly(vinyl ester) polymer may be a copolymer such as a random copolymer. As a non-limiting example, the random copolymer may have a structure such as those described in International Application No. WO2013032829 or U.S. Patent Publication No US20130121954, the contents of each of which are herein incorporated by reference in their entirety. In some embodiments, the poly(vinyl ester) polymers may be conjugated to the polynucleotides described herein.
• In some embodiments, the therapeutic nanoparticle may comprise at least one diblock copolymer. The diblock copolymer may be, but it not limited to, a poly(lactic) acid-poly(ethylene)glycol copolymer (see, e.g., International Patent Publication No. WO2013044219, the contents of which are herein incorporated by reference in their entirety). As a non-limiting example, the therapeutic nanoparticle may be used to treat cancer (see International publication No. WO2013044219, the contents of which are herein incorporated by reference in their entirety).
• In some embodiments, the therapeutic nanoparticles may comprise at least one cationic polymer described herein and/or known in the art.
• In some embodiments, the therapeutic nanoparticles may comprise at least one amine-containing polymer such as, but not limited to polylysine, polyethylene imine, poly(amidoamine) dendrimers, poly(beta-amino esters) (see, e.g., U.S. Pat. No. 8,287,849, the contents of which are herein incorporated by reference in their entirety) and combinations thereof.
• In some embodiments, the nanoparticles described herein may comprise an amine cationic lipid such as those described in International Patent Application No. WO2013059496, the contents of which are herein incorporated by reference in their entirety. In some embodiments, the cationic lipids may have an amino-amine or an amino-amide moiety.
• In some embodiments, the therapeutic nanoparticles may comprise at least one degradable polyester which may contain polycationic side chains. Degradeable polyesters include, but are not limited to, poly(serine ester), poly(L-lactide-co-L-lysine), poly(4-hydroxy-L-proline ester), and combinations thereof. In some embodiments, the degradable polyesters may include a PEG conjugation to form a PEGylated polymer.
• In some embodiments, the synthetic nanocarriers may contain an immunostimulatory agent to enhance the immune response from delivery of the synthetic nanocarrier. As a non-limiting example, the synthetic nanocarrier may comprise a Th1 immunostimulatory agent, which may enhance a Th1-based response of the immune system (see International Pub No. WO2010123569 and U.S. Publication No. US20110223201, the contents of each of which are herein incorporated by reference in their entirety).
• In some embodiments, the synthetic nanocarriers may be formulated for targeted release. In some embodiments, the synthetic nanocarrier is formulated to release the polynucleotides at a specified pH and/or after a desired time interval. As a non-limiting example, the synthetic nanoparticle may be formulated to release the RNA (e.g., mRNA) vaccines after 24 hours and/or at a pH of 4.5 (see International Publication Nos. WO2010138193 and WO2010138194 and US Pub Nos. US20110020388 and US20110027217, each of which is herein incorporated by reference in their entireties).
• In some embodiments, the synthetic nanocarriers may be formulated for controlled and/or sustained release of the polynucleotides described herein. As a non-limiting example, the synthetic nanocarriers for sustained release may be formulated by methods known in the art, described herein and/or as described in International Pub No. WO2010138192 and US Pub No. 20100303850, each of which is herein incorporated by reference in their entirety.
• In some embodiments, the RNA (e.g., mRNA) vaccine may be formulated for controlled and/or sustained release wherein the formulation comprises at least one polymer that is a crystalline side chain (CYSC) polymer. CYSC polymers are described in U.S. Pat. No. 8,399,007, herein incorporated by reference in its entirety.
• In some embodiments, the synthetic nanocarrier may be formulated for use as a vaccine. In some embodiments, the synthetic nanocarrier may encapsulate at least one polynucleotide which encode at least one antigen. As a non-limiting example, the synthetic nanocarrier may include at least one antigen and an excipient for a vaccine dosage form (see International Publication No. WO2011150264 and U.S. Publication No. US20110293723, the contents of each of which are herein incorporated by reference in their entirety). As another non-limiting example, a vaccine dosage form may include at least two synthetic nanocarriers with the same or different antigens and an excipient (see International Publication No. WO2011150249 and U.S. Publication No. US20110293701, the contents of each of which are herein incorporated by reference in their entirety). The vaccine dosage form may be selected by methods described herein, known in the art and/or described in International Publication No. WO2011150258 and U.S. Publication No. US20120027806, the contents of each of which are herein incorporated by reference in their entirety).
• In some embodiments, the synthetic nanocarrier may comprise at least one polynucleotide which encodes at least one adjuvant. As non-limiting example, the adjuvant may comprise dimethyldioctadecylammonium-bromide, dimethyldioctadecylammonium-chloride, dimethyldioctadecylammonium-phosphate or dimethyldioctadecylammonium-acetate (DDA) and an apolar fraction or part of said apolar fraction of a total lipid extract of a mycobacterium (see, e.g., U.S. Pat. No. 8,241,610, the content of which is herein incorporated by reference in its entirety). In some embodiments, the synthetic nanocarrier may comprise at least one polynucleotide and an adjuvant. As a non-limiting example, the synthetic nanocarrier comprising and adjuvant may be formulated by the methods described in International Publication No. WO2011150240 and U.S. Publication No. US20110293700, the contents of each of which are herein incorporated by reference in their entirety.
• In some embodiments, the synthetic nanocarrier may encapsulate at least one polynucleotide that encodes a peptide, fragment or region from a virus. As a non-limiting example, the synthetic nanocarrier may include, but is not limited to, any of the nanocarriers described in International Publication No. WO2012024621, WO201202629, WO2012024632 and U.S. Publication No. US20120064110, US20120058153 and US20120058154, the contents of each of which are herein incorporated by reference in their entirety.
• In some embodiments, the synthetic nanocarrier may be coupled to a polynucleotide which may be able to trigger a humoral and/or cytotoxic T lymphocyte (CTL) response (see, e.g., International Publication No. WO2013019669, the contents of which are herein incorporated by reference in their entirety).
• In some embodiments, the RNA (e.g., mRNA) vaccine may be encapsulated in, linked to and/or associated with zwitterionic lipids. Non-limiting examples of zwitterionic lipids and methods of using zwitterionic lipids are described in U.S. Patent Publication No. US20130216607, the contents of which are herein incorporated by reference in their entirety. In some aspects, the zwitterionic lipids may be used in the liposomes and lipid nanoparticles described herein.
• In some embodiments, the RNA (e.g., mRNA) vaccine may be formulated in colloid nanocarriers as described in U.S. Patent Publication No. US20130197100, the contents of which are herein incorporated by reference in their entirety.
• In some embodiments, the nanoparticle may be optimized for oral administration. The nanoparticle may comprise at least one cationic biopolymer such as, but not limited to, chitosan or a derivative thereof. As a non-limiting example, the nanoparticle may be formulated by the methods described in U.S. Publication No. 20120282343, the contents of which are herein incorporated by reference in their entirety.
• In some embodiments, LNPs comprise the lipid KL52 (an amino-lipid disclosed in U.S. Application Publication No. 2012/0295832, the contents of which are herein incorporated by reference in their entirety. Activity and/or safety (as measured by examining one or more of ALT/AST, white blood cell count and cytokine induction, for example) of LNP administration may be improved by incorporation of such lipids. LNPs comprising
• KL52 may be administered intravenously and/or in one or more doses. In some embodiments, administration of LNPs comprising KL52 results in equal or improved mRNA and/or protein expression as compared to LNPs comprising MC3.
• In some embodiments, RNA (e.g., mRNA) vaccine may be delivered using smaller LNPs. Such particles may comprise a diameter from below 0.1 um up to 100 nm such as, but not limited to, less than 0.1 um, less than 1.0 um, less than 5 um, less than 10 um, less than 15 um, less than 20 um, less than 25 um, less than 30 um, less than 35 um, less than 40 um, less than 50 um, less than 55 um, less than 60 um, less than 65 um, less than 70 um, less than 75 um, less than 80 um, less than 85 um, less than 90 um, less than 95 um, less than 100 um, less than 125 um, less than 150 um, less than 175 um, less than 200 um, less than 225 um, less than 250 um, less than 275 um, less than 300 um, less than 325 um, less than 350 um, less than 375 um, less than 400 um, less than 425 um, less than 450 um, less than 475 um, less than 500 um, less than 525 um, less than 550 um, less than 575 um, less than 600 um, less than 625 um, less than 650 um, less than 675 um, less than 700 um, less than 725 um, less than 750 um, less than 775 um, less than 800 um, less than 825 um, less than 850 um, less than 875 um, less than 900 um, less than 925 um, less than 950 um, less than 975 um, or less than 1000 um.
• In some embodiments, RNA (e.g., mRNA) vaccines may be delivered using smaller LNPs, which may comprise a diameter from about 1 nm to about 100 nm, from about 1 nm to about 10 nm, about 1 nm to about 20 nm, from about 1 nm to about 30 nm, from about 1 nm to about 40 nm, from about 1 nm to about 50 nm, from about 1 nm to about 60 nm, from about 1 nm to about 70 nm, from about 1 nm to about 80 nm, from about 1 nm to about 90 nm, from about 5 nm to about from 100 nm, from about 5 nm to about 10 nm, about 5 nm to about 20 nm, from about 5 nm to about 30 nm, from about 5 nm to about 40 nm, from about 5 nm to about 50 nm, from about 5 nm to about 60 nm, from about 5 nm to about 70 nm, from about 5 nm to about 80 nm, from about 5 nm to about 90 nm, about 10 to about 50 nm, from about 20 to about 50 nm, from about 30 to about 50 nm, from about 40 to about 50 nm, from about 20 to about 60 nm, from about 30 to about 60 nm, from about 40 to about 60 nm, from about 20 to about 70 nm, from about 30 to about 70 nm, from about 40 to about 70 nm, from about 50 to about 70 nm, from about 60 to about 70 nm, from about 20 to about 80 nm, from about 30 to about 80 nm, from about 40 to about 80 nm, from about 50 to about 80 nm, from about 60 to about 80 nm, from about 20 to about 90 nm, from about 30 to about 90 nm, from about 40 to about 90 nm, from about 50 to about 90 nm, from about 60 to about 90 nm and/or from about 70 to about 90 nm.
• In some embodiments, such LNPs are synthesized using methods comprising microfluidic mixers. Examples of microfluidic mixers may include, but are not limited to, a slit interdigital micromixer including, but not limited to those manufactured by Microinnova (Allerheiligen bei Wildon, Austria) and/or a staggered herringbone micromixer (SHM) (Zhigaltsev, I. V. et al., Bottom-up design and synthesis of limit size lipid nanoparticle systems with aqueous and triglyceride cores using millisecond microfluidic mixing have been published (Langmuir. 2012. 28:3633-40; Belliveau, N. M. et al., Microfluidic synthesis of highly potent limit-size lipid nanoparticles for in vivo delivery of siRNA. Molecular Therapy-Nucleic Acids. 2012. 1:e37; Chen, D. et al., Rapid discovery of potent siRNA-containing lipid nanoparticles enabled by controlled microfluidic formulation. J Am Chem Soc. 2012. 134(16):6948-51, the contents of each of which are herein incorporated by reference in their entirety). In some embodiments, methods of LNP generation comprising SHM, further comprise the mixing of at least two input streams wherein mixing occurs by microstructure-induced chaotic advection (MICA). According to this method, fluid streams flow through channels present in a herringbone pattern causing rotational flow and folding the fluids around each other. This method may also comprise a surface for fluid mixing wherein the surface changes orientations during fluid cycling. Methods of generating LNPs using SHM include those disclosed in U.S. Application Publication Nos. 2004/0262223 and 2012/0276209, the contents of each of which are herein incorporated by reference in their entirety.
• In some embodiments, the RNA (e.g., mRNA) vaccine of the present disclosure may be formulated in lipid nanoparticles created using a micromixer such as, but not limited to, a Slit Interdigital Microstructured Mixer (SIMM-V2) or a Standard Slit Interdigital Micro Mixer (SSIMM) or Caterpillar (CPMM) or Impinging-jet (IJMM) from the Institut für Mikrotechnik Mainz GmbH, Mainz Germany).
• In some embodiments, the RNA (e.g., mRNA) vaccines of the present disclosure may be formulated in lipid nanoparticles created using microfluidic technology (see, e.g., Whitesides, George M. The Origins and the Future of Microfluidics. Nature, 2006 442: 368-373; and Abraham et al. Chaotic Mixer for Microchannels. Science, 2002 295: 647-651; each of which is herein incorporated by reference in its entirety). As a non-limiting example, controlled microfluidic formulation includes a passive method for mixing streams of steady pressure-driven flows in micro channels at a low Reynolds number (see, e.g., Abraham et al. Chaotic Mixer for Microchannels. Science, 2002 295: 647-651, the contents of which are herein incorporated by reference in their entirety).
• In some embodiments, the RNA (e.g., mRNA) vaccines of the present disclosure may be formulated in lipid nanoparticles created using a micromixer chip such as, but not limited to, those from Harvard Apparatus (Holliston, Mass.) or Dolomite Microfluidics (Royston, UK). A micromixer chip can be used for rapid mixing of two or more fluid streams with a split and recombine mechanism.
• In some embodiments, the RNA (e.g., mRNA) vaccines of the disclosure may be formulated for delivery using the drug encapsulating microspheres described in International Patent Publication No. WO2013063468 or U.S. Pat. No. 8,440,614, the contents of each of which are herein incorporated by reference in their entirety. The microspheres may comprise a compound of the formula (I), (II), (III), (IV), (V) or (VI) as described in International Patent Publication No. WO2013063468, the contents of which are herein incorporated by reference in their entirety. In some embodiments, the amino acid, peptide, polypeptide, lipids (APPL) are useful in delivering the RNA (e.g., mRNA) vaccines of the disclosure to cells (see International Patent Publication No. WO2013063468, the contents of which are herein incorporated by reference in their entirety).
• In some embodiments, the RNA (e.g., mRNA) vaccines of the disclosure may be formulated in lipid nanoparticles having a diameter from about 10 to about 100 nm such as, but not limited to, about 10 to about 20 nm, about 10 to about 30 nm, about 10 to about 40 nm, about 10 to about 50 nm, about 10 to about 60 nm, about 10 to about 70 nm, about 10 to about 80 nm, about 10 to about 90 nm, about 20 to about 30 nm, about 20 to about 40 nm, about 20 to about 50 nm, about 20 to about 60 nm, about 20 to about 70 nm, about 20 to about 80 nm, about 20 to about 90 nm, about 20 to about 100 nm, about 30 to about 40 nm, about 30 to about 50 nm, about 30 to about 60 nm, about 30 to about 70 nm, about 30 to about 80 nm, about 30 to about 90 nm, about 30 to about 100 nm, about 40 to about 50 nm, about 40 to about 60 nm, about 40 to about 70 nm, about 40 to about 80 nm, about 40 to about 90 nm, about 40 to about 100 nm, about 50 to about 60 nm, about 50 to about 70 nm about 50 to about 80 nm, about 50 to about 90 nm, about 50 to about 100 nm, about 60 to about 70 nm, about 60 to about 80 nm, about 60 to about 90 nm, about 60 to about 100 nm, about 70 to about 80 nm, about 70 to about 90 nm, about 70 to about 100 nm, about 80 to about 90 nm, about 80 to about 100 nm and/or about 90 to about 100 nm.
• In some embodiments, the lipid nanoparticles may have a diameter from about 10 to 500 nm.
• In some embodiments, the lipid nanoparticle may have a diameter greater than 100 nm, greater than 150 nm, greater than 200 nm, greater than 250 nm, greater than 300 nm, greater than 350 nm, greater than 400 nm, greater than 450 nm, greater than 500 nm, greater than 550 nm, greater than 600 nm, greater than 650 nm, greater than 700 nm, greater than 750 nm, greater than 800 nm, greater than 850 nm, greater than 900 nm, greater than 950 nm or greater than 1000 nm.
• In some embodiments, the lipid nanoparticle may be a limit size lipid nanoparticle described in International Patent Publication No. WO2013059922, the contents of which are herein incorporated by reference in their entirety. The limit size lipid nanoparticle may comprise a lipid bilayer surrounding an aqueous core or a hydrophobic core; where the lipid bilayer may comprise a phospholipid such as, but not limited to, diacylphosphatidylcholine, a diacylphosphatidylethanolamine, a ceramide, a sphingomyelin, a dihydrosphingomyelin, a cephalin, a cerebroside, a C8-C20 fatty acid diacylphophatidylcholine, and 1-palmitoyl-2-oleoyl phosphatidylcholine (POPC). In some embodiments, the limit size lipid nanoparticle may comprise a polyethylene glycol-lipid such as, but not limited to, DLPE-PEG, DMPE-PEG, DPPC-PEG and DSPE-PEG.
• In some embodiments, the RNA (e.g., mRNA) vaccines may be delivered, localized and/or concentrated in a specific location using the delivery methods described in International Patent Publication No. WO2013063530, the contents of which are herein incorporated by reference in their entirety. As a non-limiting example, a subject may be administered an empty polymeric particle prior to, simultaneously with or after delivering the RNA (e.g., mRNA) vaccines to the subject. The empty polymeric particle undergoes a change in volume once in contact with the subject and becomes lodged, embedded, immobilized or entrapped at a specific location in the subject.
• In some embodiments, the RNA (e.g., mRNA) vaccines may be formulated in an active substance release system (see, e.g., U.S. Patent Publication No. US20130102545, the contents of which are herein incorporated by reference in their entirety). The active substance release system may comprise 1) at least one nanoparticle bonded to an oligonucleotide inhibitor strand which is hybridized with a catalytically active nucleic acid and 2) a compound bonded to at least one substrate molecule bonded to a therapeutically active substance (e.g., polynucleotides described herein), where the therapeutically active substance is released by the cleavage of the substrate molecule by the catalytically active nucleic acid.
• In some embodiments, the RNA (e.g., mRNA) vaccines may be formulated in a nanoparticle comprising an inner core comprising a non-cellular material and an outer surface comprising a cellular membrane. The cellular membrane may be derived from a cell or a membrane derived from a virus. As a non-limiting example, the nanoparticle may be made by the methods described in International Patent Publication No. WO2013052167, the contents of which are herein incorporated by reference in their entirety. As another non-limiting example, the nanoparticle described in International Patent Publication No. WO2013052167, the contents of which are herein incorporated by reference in their entirety, may be used to deliver the RNA (e.g., mRNA) vaccines described herein.
• In some embodiments, the RNA (e.g., mRNA) vaccines may be formulated in porous nanoparticle-supported lipid bilayers (protocells). Protocells are described in International Patent Publication No. WO2013056132, the contents of which are herein incorporated by reference in their entirety.
• In some embodiments, the RNA (e.g., mRNA) vaccines described herein may be formulated in polymeric nanoparticles as described in or made by the methods described in U.S. Pat. Nos. 8,420,123 and 8,518,963 and European Patent No. EP2073848B1, the contents of each of which are herein incorporated by reference in their entirety. As a non-limiting example, the polymeric nanoparticle may have a high glass transition temperature such as the nanoparticles described in or nanoparticles made by the methods described in U.S. Pat. No. 8,518,963, the contents of which are herein incorporated by reference in their entirety. As another non-limiting example, the polymer nanoparticle for oral and parenteral formulations may be made by the methods described in European Patent No. EP2073848B1, the contents of which are herein incorporated by reference in their entirety.
• In some embodiments, the RNA (e.g., mRNA) vaccines described herein may be formulated in nanoparticles used in imaging. The nanoparticles may be liposome nanoparticles such as those described in U.S. Patent Publication No US20130129636, herein incorporated by reference in its entirety. As a non-limiting example, the liposome may comprise gadolinium(III)2-{4,7-bis-carboxymethyl-10-[(N,N-distearylamidomethyl-N′-amido-methyl]-1,4,7,10-tetra-azacyclododec-1-yl}-acetic acid and a neutral, fully saturated phospholipid component (see, e.g., U.S. Patent Publication No US20130129636, the contents of which are herein incorporated by reference in their entirety).
• In some embodiments, the nanoparticles which may be used in the present disclosure are formed by the methods described in U.S. Patent Application No. US20130130348, the contents of which are herein incorporated by reference in their entirety.
• The nanoparticles of the present disclosure may further include nutrients such as, but not limited to, those which deficiencies can lead to health hazards from anemia to neural tube defects (see, e.g., the nanoparticles described in International Patent Publication No WO2013072929, the contents of which are herein incorporated by reference in their entirety). As a non-limiting example, the nutrient may be iron in the form of ferrous, ferric salts or elemental iron, iodine, folic acid, vitamins or micronutrients.
• In some embodiments, the RNA (e.g., mRNA) vaccines of the present disclosure may be formulated in a swellable nanoparticle. The swellable nanoparticle may be, but is not limited to, those described in U.S. Pat. No. 8,440,231, the contents of which are herein incorporated by reference in their entirety. As a non-limiting embodiment, the swellable nanoparticle may be used for delivery of the RNA (e.g., mRNA) vaccines of the present disclosure to the pulmonary system (see, e.g., U.S. Pat. No. 8,440,231, the contents of which are herein incorporated by reference in their entirety).
• The RNA (e.g., mRNA) vaccines of the present disclosure may be formulated in polyanhydride nanoparticles such as, but not limited to, those described in U.S. Pat. No. 8,449,916, the contents of which are herein incorporated by reference in their entirety.
• The nanoparticles and microparticles of the present disclosure may be geometrically engineered to modulate macrophage and/or the immune response. In some embodiments, the geometrically engineered particles may have varied shapes, sizes and/or surface charges in order to incorporated the polynucleotides of the present disclosure for targeted delivery such as, but not limited to, pulmonary delivery (see, e.g., International Publication No WO2013082111, the contents of which are herein incorporated by reference in their entirety). Other physical features the geometrically engineering particles may have include, but are not limited to, fenestrations, angled arms, asymmetry and surface roughness, charge which can alter the interactions with cells and tissues. As a non-limiting example, nanoparticles of the present disclosure may be made by the methods described in International Publication No WO2013082111, the contents of which are herein incorporated by reference in their entirety.
• In some embodiments, the nanoparticles of the present disclosure may be water soluble nanoparticles such as, but not limited to, those described in International Publication No. WO2013090601, the contents of which are herein incorporated by reference in their entirety. The nanoparticles may be inorganic nanoparticles which have a compact and zwitterionic ligand in order to exhibit good water solubility. The nanoparticles may also have small hydrodynamic diameters (HD), stability with respect to time, pH, and salinity and a low level of non-specific protein binding.
• In some embodiments the nanoparticles of the present disclosure may be developed by the methods described in U.S. Patent Publication No. US20130172406, the contents of which are herein incorporated by reference in their entirety.
• In some embodiments, the nanoparticles of the present disclosure are stealth nanoparticles or target-specific stealth nanoparticles such as, but not limited to, those described in U.S. Patent Publication No. US20130172406, the contents of which are herein incorporated by reference in their entirety. The nanoparticles of the present disclosure may be made by the methods described in U.S. Patent Publication No. US20130172406, the contents of which are herein incorporated by reference in their entirety.
• In some embodiments, the stealth or target-specific stealth nanoparticles may comprise a polymeric matrix. The polymeric matrix may comprise two or more polymers such as, but not limited to, polyethylenes, polycarbonates, polyanhydrides, polyhydroxyacids, polypropylfumerates, polycaprolactones, polyamides, polyacetals, polyethers, polyesters, poly(orthoesters), polycyanoacrylates, polyvinyl alcohols, polyurethanes, polyphosphazenes, polyacrylates, polymethacrylates, polycyanoacrylates, polyureas, polystyrenes, polyamines, polyesters, polyanhydrides, polyethers, polyurethanes, polymethacrylates, polyacrylates, polycyanoacrylates or combinations thereof.
• In some embodiments, the nanoparticle may be a nanoparticle-nucleic acid hybrid structure having a high density nucleic acid layer. As a non-limiting example, the nanoparticle-nucleic acid hybrid structure may made by the methods described in U.S. Patent Publication No. US20130171646, the contents of which are herein incorporated by reference in their entirety. The nanoparticle may comprise a nucleic acid such as, but not limited to, polynucleotides described herein and/or known in the art.
• At least one of the nanoparticles of the present disclosure may be embedded in in the core a nanostructure or coated with a low density porous 3-D structure or coating which is capable of carrying or associating with at least one payload within or on the surface of the nanostructure. Non-limiting examples of the nanostructures comprising at least one nanoparticle are described in International Patent Publication No. WO2013123523, the contents of which are herein incorporated by reference in their entirety.
• In some embodiments the RNA (e.g., mRNA) vaccine may be associated with a cationic or polycationic compounds, including protamine, nucleoline, spermine or spermidine, or other cationic peptides or proteins, such as poly-L-lysine (PLL), polyarginine, basic polypeptides, cell penetrating peptides (CPPs), including HIV-binding peptides, HIV-1 Tat (HIV), Tat-derived peptides, Penetratin, VP²² derived or analog peptides, Pestivirus Ems, HSV, VP²² (Herpes simplex), MAP, KALA or protein transduction domains (PTDs), PpT620, prolin-rich peptides, arginine-rich peptides, lysine-rich peptides, MPG-peptide(s), Pep-1, L-oligomers, Calcitonin peptide(s), Antennapedia-derived peptides (particularly from Drosophila antennapedia), pAntp, plsl, FGF, Lactoferrin, Transportan, Buforin-2, Bac715-24, SynB, SynB, pVEC, hCT-derived peptides, SAP, histones, cationic polysaccharides, for example chitosan, polybrene, cationic polymers, e.g. polyethyleneimine (PEI), cationic lipids, e.g. DOTMA: [1-(2,3-sioleyloxy)propyl)]-N,N,N-trimethylammonium chloride, DMRIE, di-C14-amidine, DOTIM, SAINT, DC-Chol, BGTC, CTAP, DOPC, DODAP, DOPE: Dioleyl phosphatidylethanol-amine, DOSPA, DODAB, DOIC, DMEPC, DOGS: Dioctadecylamidoglicylspermin, DIMRI: Dimyristooxypropyl dimethyl hydroxyethyl ammonium bromide, DOTAP: dioleoyloxy-3-(trimethylammonio)propane, DC-6-14: O,O-ditetradecanoyl-N-.alpha.-trimethylammonioacetyl)diethanolamine chloride, CLIP 1: rac-[(2,3-dioctadecyloxypropyl)(2-hydroxyethyl)]-dimethylammonium chloride, CLIP6: rac-[2(2,3-dihexadecyloxypropyloxymethyloxy)ethyl]-trimethylammonium, CLIP9: rac-[2(2,3-dihexadecyloxypropyloxysuccinyloxy)ethyl]-trimethylammo-nium, oligofectamine, or cationic or polycationic polymers, e.g. modified polyaminoacids, such as beta-aminoacid-polymers or reversed polyamides, etc., modified polyethylenes, such as PVP (poly(N-ethyl-4-vinylpyridinium bromide)), etc., modified acrylates, such as pDMAEMA (poly(dimethylaminoethyl methylacrylate)), etc., modified amidoamines such as pAMAM (poly(amidoamine)), etc., modified polybetaminoester (PBAE), such as diamine end modified 1,4 butanediol diacrylate-co-5-amino-1-pentanol polymers, etc., dendrimers, such as polypropylamine dendrimers or pAMAM based dendrimers, etc., polyimine(s), such as PEI: poly(ethyleneimine), poly(propyleneimine), etc., polyallylamine, sugar backbone based polymers, such as cyclodextrin based polymers, dextran based polymers, chitosan, etc., silan backbone based polymers, such as PMOXA-PDMS copolymers, etc., blockpolymers consisting of a combination of one or more cationic blocks (e.g. selected from a cationic polymer as mentioned above) and of one or more hydrophilic or hydrophobic blocks (e.g. polyethyleneglycole), etc.
• In other embodiments the RNA (e.g., mRNA) vaccine is not associated with a cationic or polycationic compounds.
• In some embodiments, a nanoparticle comprises compounds of Formula (I):
• 
• or a salt or isomer thereof, wherein:
• R₁ is selected from the group consisting of C_5-30 alkyl, C_5-20 alkenyl, —R*YR″, —YR″, and —R″M′R′;
• R₂ and R₃ are independently selected from the group consisting of H, C_1-14 alkyl, C_2-14 alkenyl, —R*YR″, —YR″, and —R*OR″, or R₂ and R₃, together with the atom to which they are attached, form a heterocycle or carbocycle;
• R₄ is selected from the group consisting of a C_3-6 carbocycle, —(CH₂)_nQ, —(CH₂)_nCHQR, —CHQR, —CQ(R)₂, and unsubstituted C_1-6 alkyl, where Q is selected from a carbocycle, heterocycle, —OR, —O(CH₂)_nN(R)₂, —C(O)OR, —OC(O)R, —CX₃, —CX₂H, —CXH₂, —CN, —N(R)₂, —C(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R, —N(R)C(O)N(R)₂, —N(R)C(S)N(R)₂, —N(R)R₈, —O(CH₂)_nOR, —N(R)C(═NR₉)N(R)₂, —N(R)C(═CHR₉)N(R)₂, —OC(O)N(R)₂, —N(R)C(O)OR, —N(OR)C(O)R, —N(OR)S(O)₂R, —N(OR)C(O)OR, —N(OR)C(O)N(R)₂, —N(OR)C(S)N(R)₂, —N(OR)C(═NR₉)N(R)₂, —N(OR)C(═CHR₉)N(R)₂, —C(═NR₉)N(R)₂, —C(═NR₉)R, —C(O)N(R)OR, and —C(R)N(R)₂C(O)OR, and each n is independently selected from 1, 2, 3, 4, and 5;
• each R₅ is independently selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;
• each R₆ is independently selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;
• M and M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—,
• —N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)₂—, —S—S—, an aryl group, and a heteroaryl group;
• R₇ is selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;
• R₈ is selected from the group consisting of C_3-6 carbocycle and heterocycle;
• R₉ is selected from the group consisting of H, CN, NO₂, C_1-6 alkyl, —OR, —S(O)₂R, —S(O)₂N(R)₂, C_2-6 alkenyl, C_3-6 carbocycle and heterocycle;
• each R is independently selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;
• each R′ is independently selected from the group consisting of C_1-18 alkyl, C_2-18 alkenyl, —R*YR″, —YR″, and H;
• • each R″ is independently selected from the group consisting of C_3-14 alkyl and C_3-14 alkenyl;
  • each R* is independently selected from the group consisting of C_1-12 alkyl and C_2-12 alkenyl;
• each Y is independently a C_3-6 carbocycle;
• each X is independently selected from the group consisting of F, Cl, Br, and I; and
• m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13.
• In some embodiments, a subset of compounds of Formula (I) includes those in which when R₄ is —(CH₂)_nQ, —(CH₂)_nCHQR, —CHQR, or —CQ(R)₂, then (i) Q is not —N(R)₂ when n is 1, 2, 3, 4 or 5, or (ii) Q is not 5, 6, or 7-membered heterocycloalkyl when n is 1 or 2.
• In some embodiments, another subset of compounds of Formula (I) includes those in which
• R₁ is selected from the group consisting of C_5-30 alkyl, C_5-20 alkenyl, —R*YR″, —YR″, and —R″M′R′;
• R₂ and R₃ are independently selected from the group consisting of H, C_1-14 alkyl, C_2-14 alkenyl, —R*YR″, —YR″, and —R*OR″, or R₂ and R₃, together with the atom to which they are attached, form a heterocycle or carbocycle;
• R₄ is selected from the group consisting of a C_3-6
• carbocycle, —(CH₂)_nQ, —(CH₂)_nCHQR, —CHQR, —CQ(R)₂, and unsubstituted C_1-6 alkyl, where Q is selected from a C_3-6 carbocycle, a 5- to 14-membered heteroaryl having one or more heteroatoms selected from N, O, and S, —OR,
  —O(CH₂)_nN(R)₂, —C(O)OR, —OC(O)R, —CX₃, —CX₂H, —CXH₂, —CN, —C(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R, —N(R)C(O)N(R)₂, —N(R)C(S)N(R)₂, —CRN(R)₂C(O)OR, —N(R)R₈, —O(CH₂)_nOR, —N(R)C(═NR₉)N(R)₂, —N(R)C(═CHR₉)N(R)₂, —OC(O)N(R)₂, —N(R)C(O)OR, —N(OR)C(O)R, —N(OR)S(O)₂R, —N(OR)C(O)OR, —N(OR)C(O)N(R)₂, —N(OR)C(S)N(R)₂, —N(OR)C(═NR₉)N(R)₂, —N(OR)C(═CHR₉)N(R)₂, —C(═NR₉)N(R)₂, —C(═NR₉)R, —C(O)N(R)O R, and a 5- to 14-membered heterocycloalkyl having one or more heteroatoms selected from N, O, and S which is substituted with one or more substituents selected from oxo (═O), OH, amino, mono- or di-alkylamino, and C_1-3 alkyl, and each n is independently selected from 1, 2, 3, 4, and 5;
• each R₅ is independently selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;
• each R₆ is independently selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;
• M and M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)₂—, —S—S—, an aryl group, and a heteroaryl group;
• R₇ is selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;
• R₈ is selected from the group consisting of C_3-6 carbocycle and heterocycle;
• R₉ is selected from the group consisting of H, CN, NO₂, C_1-6 alkyl, —OR, —S(O)₂R, —S(O)₂N(R)₂, C_2-6 alkenyl, C_3-6 carbocycle and heterocycle;
• each R is independently selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;
• each R′ is independently selected from the group consisting of C_1-18 alkyl, C_2-18 alkenyl, —R*YR″, —YR″, and H;
• each R″ is independently selected from the group consisting of C_3-14 alkyl and C_3-14 alkenyl;
• each R* is independently selected from the group consisting of C_1-12 alkyl and C_2-12 alkenyl;
• each Y is independently a C_3-6 carbocycle;
• each X is independently selected from the group consisting of F, Cl, Br, and I; and
• m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,
• or salts or isomers thereof.
• In some embodiments, another subset of compounds of Formula (I) includes those in which
• R₁ is selected from the group consisting of C_5-30 alkyl, C_5-20 alkenyl, —R*YR″, —YR″, and —R″M′R′;
• R₂ and R₃ are independently selected from the group consisting of H, C_1-14 alkyl, C_2-14 alkenyl, —R*YR″, —YR″, and —R*OR″, or R₂ and R₃, together with the atom to which they are attached, form a heterocycle or carbocycle;
• R₄ is selected from the group consisting of a C_3-6
• carbocycle, —(CH₂)_nQ, —(CH₂)_nCHQR, —CHQR, —CQ(R)₂, and unsubstituted C_1-6 alkyl, where Q is selected from a C_3-6 carbocycle, a 5- to 14-membered heterocycle having one or more heteroatoms selected from N, O, and S, —OR,
  —O(CH₂)_nN(R)₂, —C(O)OR, —OC(O)R, —CX₃, —CX₂H, —CXH₂, —CN, —C(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R, —N(R)C(O)N(R)₂, —N(R)C(S)N(R)₂, —CRN(R)₂C(O)OR, —N(R)R₈, —O(CH₂)_nOR, —N(R)C(═NR₉)N(R)₂, —N(R)C(═CHR₉)N(R)₂, —OC(O)N(R)₂, —N(R)C(O)OR, —N(OR)C(O)R, —N(OR)S(O)₂R, —N(OR)C(O)OR, —N(OR)C(O)N(R)₂, —N(OR)C(S)N(R)₂, —N(OR)C(═NR₉)N(R)₂, —N(OR)C(═CHR₉)N(R)₂, —C(═NR₉)R, —C(O)N(R)OR, and —C(═NR₉)N(R)₂, and each n is independently selected from 1, 2, 3, 4, and 5; and when Q is a 5- to 14-membered heterocycle and (i) R₄ is —(CH₂).Q in which n is 1 or 2, or (ii) R₄ is —(CH₂)_nCHQR in which n is 1, or (iii) R₄ is —CHQR, and —CQ(R)₂, then Q is either a 5- to 14-membered heteroaryl or 8- to 14-membered heterocycloalkyl;
• each R₅ is independently selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;
• each R₆ is independently selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;
• M and M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)₂—, —S—S—, an aryl group, and a heteroaryl group;
• R₇ is selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;
• R₈ is selected from the group consisting of C_3-6 carbocycle and heterocycle;
• R₉ is selected from the group consisting of H, CN, NO₂, C_1-6 alkyl, —OR, —S(O)₂R, —S(O)₂N(R)₂, C_2-6 alkenyl, C_3-6 carbocycle and heterocycle;
• each R is independently selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;
• each R′ is independently selected from the group consisting of C_1-18 alkyl, C_2-18 alkenyl, —R*YR″, —YR″, and H;
• each R″ is independently selected from the group consisting of C_3-14 alkyl and C_3-14 alkenyl;
• each R* is independently selected from the group consisting of C_1-12 alkyl and C_2-12 alkenyl;
• each Y is independently a C_3-6 carbocycle;
• each X is independently selected from the group consisting of F, Cl, Br, and I; and
• m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,
• or salts or isomers thereof.
• In some embodiments, another subset of compounds of Formula (I) includes those in which
• R₁ is selected from the group consisting of C_5-30 alkyl, C_5-20 alkenyl, —R*YR″, —YR″, and —R″M′R′;
• R₂ and R₃ are independently selected from the group consisting of H, C_1-14 alkyl, C_2-14 alkenyl, —R*YR″, —YR″, and —R*OR″, or R₂ and R₃, together with the atom to which they are attached, form a heterocycle or carbocycle;
• R₄ is selected from the group consisting of a C_3-6
• carbocycle, —(CH₂)_nQ, —(CH₂)_nCHQR, —CHQR, —CQ(R)₂, and unsubstituted C_1-6 alkyl, where Q is selected from a C_3-6 carbocycle, a 5- to 14-membered heteroaryl having one or more heteroatoms selected from N, O, and S, —OR,
  —O(CH₂), N(R)₂, —C(O)OR, —OC(O)R, —CX₃, —CX₂H, —CXH₂, —CN, —C(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R, —N(R)C(O)N(R)₂, —N(R)C(S)N(R)₂, —CRN(R)₂C(O)OR, —N(R)R₈, —O(CH₂)_nOR, —N(R)C(═NR₉)N(R)₂, —N(R)C(═CHR₉)N(R)₂, —OC(O)N(R)₂, —N(R)C(O)OR, —N(OR)C(O)R, —N(OR)S(O)₂R, —N(OR)C(O)OR, —N(OR)C(O)N(R)₂, —N(OR)C(S)N(R)₂, —N(OR)C(═NR₉)N(R)₂, —N(OR)C(═CHR₉)N(R)₂, —C(═NR₉)R, —C(O)N(R)OR,
  and —C(═NR₉)N(R)₂, and each n is independently selected from 1, 2, 3, 4, and 5;
• each R₅ is independently selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;
• each R₆ is independently selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;
• M and M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)₂—, —S—S—, an aryl group, and a heteroaryl group;
• R₇ is selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;
• R₈ is selected from the group consisting of C_3-6 carbocycle and heterocycle;
• R₉ is selected from the group consisting of H, CN, NO₂, C_1-6 alkyl, —OR, —S(O)₂R, —S(O)₂N(R)₂, C_2-6 alkenyl, C_3-6 carbocycle and heterocycle;
• each R is independently selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;
• each R′ is independently selected from the group consisting of C_1-18 alkyl, C_2-18 alkenyl, —R*YR″, —YR″, and H;
• each R″ is independently selected from the group consisting of C_3-14 alkyl and C_3-14 alkenyl;
• each R* is independently selected from the group consisting of C_1-12 alkyl and C_2-12 alkenyl;
• each Y is independently a C_3-6 carbocycle;
• each X is independently selected from the group consisting of F, Cl, Br, and I; and
• m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,
• or salts or isomers thereof.
• In some embodiments, another subset of compounds of Formula (I) includes those in which
• R₁ is selected from the group consisting of C_5-30 alkyl, C_5-20 alkenyl, —R*YR″, —YR″, and —R″M′R′;
• R₂ and R₃ are independently selected from the group consisting of H, C_2-14 alkyl, C_2-14 alkenyl, —R*YR″, —YR″, and —R*OR″, or R₂ and R₃, together with the atom to which they are attached, form a heterocycle or carbocycle;
• R₄ is —(CH₂)_nQ or —(CH₂)_nCHQR, where Q is —N(R)₂, and n is selected from 3, 4, and 5;
• each R₅ is independently selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;
• each R₆ is independently selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;
• M and M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)₂—, —S—S—, an aryl group, and a heteroaryl group;
• R₇ is selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;
• each R is independently selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;
• each R′ is independently selected from the group consisting of C_1-18 alkyl, C_2-18 alkenyl, —R*YR″, —YR″, and H;
• each R″ is independently selected from the group consisting of C_3-14 alkyl and C_3-14 alkenyl;
• each R* is independently selected from the group consisting of C_1-12 alkyl and C_1-12 alkenyl;
• each Y is independently a C_3-6 carbocycle;
• each X is independently selected from the group consisting of F, Cl, Br, and I; and
• m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,
• or salts or isomers thereof.
• In some embodiments, another subset of compounds of Formula (I) includes those in which
• R₁ is selected from the group consisting of C_5-30 alkyl, C_5-20 alkenyl, —R*YR″, —YR″, and —R″M′R′;
• R₂ and R₃ are independently selected from the group consisting of C_1-14 alkyl, C_2-14 alkenyl, —R*YR″, —YR″, and —R*OR″, or R₂ and R₃, together with the atom to which they are attached, form a heterocycle or carbocycle;
• R₄ is selected from the group consisting of —(CH₂)_nQ, —(CH₂)_nCHQR, —CHQR, and —CQ(R)₂, where Q is —N(R)₂, and n is selected from 1, 2, 3, 4, and 5;
• each R₅ is independently selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;
• each R₆ is independently selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;
• M and M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)₂—, —S—S—, an aryl group, and a heteroaryl group;
• R₇ is selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;
• each R is independently selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;
• each R′ is independently selected from the group consisting of C_1-18 alkyl, C_2-18 alkenyl, —R*YR″, —YR″, and H;
• each R″ is independently selected from the group consisting of C_3-14 alkyl and C_3-14 alkenyl;
• each R* is independently selected from the group consisting of C_1-12 alkyl and C_1-12 alkenyl;
• each Y is independently a C_3-6 carbocycle;
• each X is independently selected from the group consisting of F, Cl, Br, and I; and
• m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,
• or salts or isomers thereof.
• In some embodiments, a subset of compounds of Formula (I) includes those of Formula (IA):
• 
• or a salt or isomer thereof, wherein 1 is selected from 1, 2, 3, 4, and 5; m is selected from 5, 6, 7, 8, and 9; M₁ is a bond or M′; R₄ is unsubstituted C_1-3 alkyl, or —(CH₂)_nQ, in which Q is OH, —NHC(S)N(R)₂, —NHC(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R, —N(R)R₈, —NHC(═NR₉)N(R)₂, —NHC(═CHR₉)N(R)₂, —OC(O)N(R)₂, —N(R)C(O)OR, heteroaryl or heterocycloalkyl; M and M′ are independently selected
• from —C(O)O—, —OC(O)—, —C(O)N(R′)—, —P(O)(OR′)O—, —S—S—, an aryl group, and a heteroaryl group; and R₂ and R₃ are independently selected from the group consisting of H, C_1-14 alkyl, and C_2-14 alkenyl.
• In some embodiments, a subset of compounds of Formula (I) includes those of Formula (II):
• 
• or a salt or isomer thereof, wherein 1 is selected from 1, 2, 3, 4, and 5; M₁ is a bond or M′; R₄ is unsubstituted C_1-3 alkyl,
  or —(CH₂)_nQ, in which n is 2, 3, or 4, and Q is OH, —NHC(S)N(R)₂, —NHC(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R, —N(R)R₈, —NHC(═NR₉)N(R)₂, —NHC(═CHR₉)N(R)₂, —OC(O)N(R)₂, —N(R)C(O)OR, heteroaryl or heterocycloalkyl; M and M′ are independently selected
  from —C(O)O—, —OC(O)—, —C(O)N(R′)—, —P(O)(OR′)O—, —S—S—, an aryl group, and a heteroaryl group; and R₂ and R₃ are independently selected from the group consisting of H, C_1-14 alkyl, and C_2-14 alkenyl.
• In some embodiments, a subset of compounds of Formula (I) includes those of Formula (IIa), (IIb), (IIc), or (IIe):
• 
• or a salt or isomer thereof, wherein R₄ is as described herein.
• In some embodiments, a subset of compounds of Formula (I) includes those of Formula (IId):
• 
• or a salt or isomer thereof, wherein n is 2, 3, or 4; and m, R′, R″, and R₂ through R₆ are as described herein. For example, each of R₂ and R₃ may be independently selected from the group consisting of C_5-14 alkyl and C_5-14 alkenyl.
• In some embodiments, the compound of Formula (I) is selected from the group consisting of:
• 

  

  

  

  

  

  

  

  

  

  
• In further embodiments, the compound of Formula (I) is selected from the group consisting of:
• 
• In some embodiments, the compound of Formula (I) is selected from the group consisting of:
• 

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  
• and salts and isomers thereof.
• In some embodiments, a nanoparticle comprises the following compound:
• 
• or salts and isomers thereof.
• In some embodiments, the disclosure features a nanoparticle composition including a lipid component comprising a compound as described herein (e.g., a compound according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe)).
• In some embodiments, the disclosure features a pharmaceutical composition comprising a nanoparticle composition according to the preceding embodiments and a pharmaceutically acceptable carrier. For example, the pharmaceutical composition is refrigerated or frozen for storage and/or shipment (e.g., being stored at a temperature of 4° C. or lower, such as a temperature between about −150° C. and about 0° C. or between about −80° C. and about −20° C. (e.g., about −5° C., −10° C., −15° C., −20° C., −25° C., −30° C., −40° C., −50° C., −60° C., −70° C., −80° C., −90° C., −130° C. or −150° C.). For example, the pharmaceutical composition is a solution that is refrigerated for storage and/or shipment at, for example, about −20° C., −30° C., −40° C., −50° C., −60° C., −70° C., or −80° C.
• In some embodiments, the disclosure provides a method of delivering a therapeutic and/or prophylactic (e.g., RNA, such as mRNA) to a cell (e.g., a mammalian cell). This method includes the step of administering to a subject (e.g., a mammal, such as a human) a nanoparticle composition including (i) a lipid component including a phospholipid (such as a polyunsaturated lipid), a PEG lipid, a structural lipid, and a compound of Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe) and (ii) a therapeutic and/or prophylactic, in which administering involves contacting the cell with the nanoparticle composition, whereby the therapeutic and/or prophylactic is delivered to the cell.
• In some embodiments, the disclosure provides a method of producing a polypeptide of interest in a cell (e.g., a mammalian cell). The method includes the step of contacting the cell with a nanoparticle composition including (i) a lipid component including a phospholipid (such as a polyunsaturated lipid), a PEG lipid, a structural lipid, and a compound of Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe) and (ii) an mRNA encoding the polypeptide of interest, whereby the mRNA is capable of being translated in the cell to produce the polypeptide.
• In some embodiments, the disclosure provides a method of treating a disease or disorder in a mammal (e.g., a human) in need thereof. The method includes the step of administering to the mammal a therapeutically effective amount of a nanoparticle composition including (i) a lipid component including a phospholipid (such as a polyunsaturated lipid), a PEG lipid, a structural lipid, and a compound of Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe) and (ii) a therapeutic and/or prophylactic (e.g., an mRNA). In some embodiments, the disease or disorder is characterized by dysfunctional or aberrant protein or polypeptide activity. For example, the disease or disorder is selected from the group consisting of rare diseases, infectious diseases, cancer and proliferative diseases, genetic diseases (e.g., cystic fibrosis), autoimmune diseases, diabetes, neurodegenerative diseases, cardio- and reno-vascular diseases, and metabolic diseases.
• In some embodiments, the disclosure provides a method of delivering (e.g., specifically delivering) a therapeutic and/or prophylactic to a mammalian organ (e.g., a liver, spleen, lung, or femur). This method includes the step of administering to a subject (e.g., a mammal) a nanoparticle composition including (i) a lipid component including a phospholipid, a PEG lipid, a structural lipid, and a compound of Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe) and (ii) a therapeutic and/or prophylactic (e.g., an mRNA), in which administering involves contacting the cell with the nanoparticle composition, whereby the therapeutic and/or prophylactic is delivered to the target organ (e.g., a liver, spleen, lung, or femur).
• In some embodiments, the disclosure features a method for the enhanced delivery of a therapeutic and/or prophylactic (e.g., an mRNA) to a target tissue (e.g., a liver, spleen, lung, or femur). This method includes administering to a subject (e.g., a mammal) a nanoparticle composition, the composition including (i) a lipid component including a compound of Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe), a phospholipid, a structural lipid, and a PEG lipid; and (ii) a therapeutic and/or prophylactic, the administering including contacting the target tissue with the nanoparticle composition, whereby the therapeutic and/or prophylactic is delivered to the target tissue.
• In some embodiments, the disclosure features a method of lowering immunogenicity comprising introducing the nanoparticle composition of the disclosure into cells, wherein the nanoparticle composition reduces the induction of the cellular immune response of the cells to the nanoparticle composition, as compared to the induction of the cellular immune response in cells induced by a reference composition which comprises a reference lipid instead of a compound of Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe). For example, the cellular immune response is an innate immune response, an adaptive immune response, or both.
• The disclosure also includes methods of synthesizing a compound of Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe) and methods of making a nanoparticle composition including a lipid component comprising the compound of Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe).
Modes of Vaccine Administration
• STD RNA (e.g. mRNA) vaccines may be administered by any route which results in a therapeutically effective outcome. These include, but are not limited, to intradermal, intramuscular, intranasal and/or subcutaneous administration. The present disclosure provides methods comprising administering RNA (e.g., mRNA) vaccines to a subject in need thereof. The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the disease, the particular composition, its mode of administration, its mode of activity, and the like. STD RNA (e.g., mRNA) vaccines compositions are typically formulated in dosage unit form for ease of administration and uniformity of dosage. It will be understood, however, that the total daily usage of RNA (e.g., mRNA) vaccine compositions may be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective, prophylactically effective, or appropriate imaging dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known in the medical arts.
• In some embodiments, STD RNA (e.g. mRNA) vaccines compositions may be administered at dosage levels sufficient to deliver 0.0001 mg/kg to 100 mg/kg, 0.001 mg/kg to 0.05 mg/kg, 0.005 mg/kg to 0.05 mg/kg, 0.001 mg/kg to 0.005 mg/kg, 0.05 mg/kg to 0.5 mg/kg, 0.01 mg/kg to 50 mg/kg, 0.1 mg/kg to 40 mg/kg, 0.5 mg/kg to 30 mg/kg, 0.01 mg/kg to 10 mg/kg, 0.1 mg/kg to 10 mg/kg, or 1 mg/kg to 25 mg/kg, of subject body weight per day, one or more times a day, per week, per month, etc. to obtain the desired therapeutic, diagnostic, prophylactic, or imaging effect (see, e.g., the range of unit doses described in International Publication No WO2013078199, the contents of which are herein incorporated by reference in their entirety). The desired dosage may be delivered three times a day, two times a day, once a day, every other day, every third day, every week, every two weeks, every three weeks, every four weeks, every 2 months, every three months, every 6 months, etc. In some embodiments, the desired dosage may be delivered using multiple administrations (e.g., two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or more administrations). When multiple administrations are employed, split dosing regimens such as those described herein may be used. In exemplary embodiments, STD RNA (e.g., mRNA) vaccines compositions may be administered at dosage levels sufficient to deliver 0.0005 mg/kg to 0.01 mg/kg, e.g., about 0.0005 mg/kg to about 0.0075 mg/kg, e.g., about 0.0005 mg/kg, about 0.001 mg/kg, about 0.002 mg/kg, about 0.003 mg/kg, about 0.004 mg/kg or about 0.005 mg/kg.
• In some embodiments, STD RNA (e.g., mRNA) vaccine compositions may be administered once or twice (or more) at dosage levels sufficient to deliver 0.025 mg/kg to 0.250 mg/kg, 0.025 mg/kg to 0.500 mg/kg, 0.025 mg/kg to 0.750 mg/kg, or 0.025 mg/kg to 1.0 mg/kg.
• In some embodiments, STD RNA (e.g., mRNA) vaccine compositions may be administered twice (e.g., Day 0 and Day 7, Day 0 and Day 14, Day 0 and Day 21, Day 0 and Day 28, Day 0 and Day 60, Day 0 and Day 90, Day 0 and Day 120, Day 0 and Day 150, Day 0 and Day 180, Day 0 and 3 months later, Day 0 and 6 months later, Day 0 and 9 months later, Day 0 and 12 months later, Day 0 and 18 months later, Day 0 and 2 years later, Day 0 and 5 years later, or Day 0 and 10 years later) at a total dose of or at dosage levels sufficient to deliver a total dose of 0.0100 mg, 0.025 mg, 0.050 mg, 0.075 mg, 0.100 mg, 0.125 mg, 0.150 mg, 0.175 mg, 0.200 mg, 0.225 mg, 0.250 mg, 0.275 mg, 0.300 mg, 0.325 mg, 0.350 mg, 0.375 mg, 0.400 mg, 0.425 mg, 0.450 mg, 0.475 mg, 0.500 mg, 0.525 mg, 0.550 mg, 0.575 mg, 0.600 mg, 0.625 mg, 0.650 mg, 0.675 mg, 0.700 mg, 0.725 mg, 0.750 mg, 0.775 mg, 0.800 mg, 0.825 mg, 0.850 mg, 0.875 mg, 0.900 mg, 0.925 mg, 0.950 mg, 0.975 mg, or 1.0 mg. Higher and lower dosages and frequency of administration are encompassed by the present disclosure. For example, a STD RNA (e.g., mRNA) vaccine composition may be administered three or four times.
• In some embodiments, STD RNA (e.g., mRNA) vaccine compositions may be administered twice (e.g., Day 0 and Day 7, Day 0 and Day 14, Day 0 and Day 21, Day 0 and Day 28, Day 0 and Day 60, Day 0 and Day 90, Day 0 and Day 120, Day 0 and Day 150, Day 0 and Day 180, Day 0 and 3 months later, Day 0 and 6 months later, Day 0 and 9 months later, Day 0 and 12 months later, Day 0 and 18 months later, Day 0 and 2 years later, Day 0 and 5 years later, or Day 0 and 10 years later) at a total dose of or at dosage levels sufficient to deliver a total dose of 0.010 mg, 0.025 mg, 0.100 mg or 0.400 mg.
• In some embodiments, the STD RNA (e.g., mRNA) vaccine for use in a method of vaccinating a subject is administered to the subject as a single dosage of between 10 μg/kg and 400 μg/kg of the nucleic acid vaccine (in an effective amount to vaccinate the subject). In some embodiments the RNA (e.g., mRNA) vaccine for use in a method of vaccinating a subject is administered to the subject as a single dosage of between 10 μg and 400 μg of the nucleic acid vaccine (in an effective amount to vaccinate the subject). In some embodiments, a STD RNA (e.g., mRNA) vaccine for use in a method of vaccinating a subject is administered to the subject as a single dosage of 25-1000 μg (e.g., a single dosage of mRNA encoding HPV, HSV and/or Chlamydia antigen). In some embodiments, a STD RNA (e.g., mRNA) vaccine is administered to the subject as a single dosage of 25, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950 or 1000 μg. For example, a STD RNA (e.g., mRNA) vaccine may be administered to a subject as a single dose of 25-100, 25-500, 50-100, 50-500, 50-1000, 100-500, 100-1000, 250-500, 250-1000, or 500-1000 μg. In some embodiments, a STD RNA (e.g., mRNA) vaccine for use in a method of vaccinating a subject is administered to the subject as two dosages, the combination of which equals 25-1000 μg of the STD RNA (e.g., mRNA) vaccine.
• A STD RNA (e.g. mRNA) vaccine pharmaceutical composition described herein can be formulated into a dosage form described herein, such as an intranasal, intratracheal, or injectable (e.g., intravenous, intraocular, intravitreal, intramuscular, intradermal, intracardiac, intraperitoneal, intranasal and subcutaneous).
• STD RNA (e.g., mRNA) Vaccine Formulations and Methods of Use
• Some aspects of the present disclosure provide formulations of the STD RNA (e.g., mRNA) vaccine, wherein the RNA (e.g., mRNA) vaccine is formulated in an effective amount to produce an antigen specific immune response in a subject (e.g., production of antibodies specific to an HPV, HSV and/or Chlamydia antigenic polypeptide). “An effective amount” is a dose of an RNA (e.g., mRNA) vaccine effective to produce an antigen-specific immune response. Also provided herein are methods of inducing an antigen-specific immune response in a subject.
• In some embodiments, the antigen-specific immune response is characterized by measuring an anti-HPV, anti-HSV and/or anti-Chlamydia antigenic polypeptide antibody titer produced in a subject administered a STD RNA (e.g., mRNA) vaccine as provided herein. An antibody titer is a measurement of the amount of antibodies within a subject, for example, antibodies that are specific to a particular antigen (e.g., an anti-HPV, anti-HSV and/or anti-Chlamydia antigenic polypeptide) or epitope of an antigen. Antibody titer is typically expressed as the inverse of the greatest dilution that provides a positive result. Enzyme-linked immunosorbent assay (ELISA) is a common assay for determining antibody titers, for example.
• In some embodiments, an antibody titer is used to assess whether a subject has had an infection or to determine whether immunizations are required. In some embodiments, an antibody titer is used to determine the strength of an autoimmune response, to determine whether a booster immunization is needed, to determine whether a previous vaccine was effective, and to identify any recent or prior infections. In accordance with the present disclosure, an antibody titer may be used to determine the strength of an immune response induced in a subject by the STD RNA (e.g., mRNA) vaccine.
• In some embodiments, an anti-antigenic polypeptide (e.g., an anti-HPV, HSV and/or Chlamydia antigenic polypeptide) antibody titer produced in a subject is increased by at least 1 log relative to a control. For example, anti-antigenic polypeptide antibody titer produced in a subject may be increased by at least 1.5, at least 2, at least 2.5, or at least 3 log relative to a control. In some embodiments, the anti-antigenic polypeptide antibody titer produced in the subject is increased by 1, 1.5, 2, 2.5 or 3 log relative to a control. In some embodiments, the anti-antigenic polypeptide antibody titer produced in the subject is increased by 1-3 log relative to a control. For example, the anti-antigenic polypeptide antibody titer produced in a subject may be increased by 1-1.5, 1-2, 1-2.5, 1-3, 1.5-2, 1.5-2.5, 1.5-3, 2-2.5, 2-3, or 2.5-3 log relative to a control.
• In some embodiments, the anti-antigenic polypeptide (e.g., an anti-HPV, HSV and/or Chlamydia antigenic polypeptide) antibody titer produced in a subject is increased at least 2 times relative to a control. For example, the anti-antigenic polypeptide antibody titer produced in a subject may be increased at least 3 times, at least 4 times, at least 5 times, at least 6 times, at least 7 times, at least 8 times, at least 9 times, or at least 10 times relative to a control. In some embodiments, the anti-antigenic polypeptide antibody titer produced in the subject is increased 2, 3, 4, 5, 6, 7, 8, 9, or 10 times relative to a control. In some embodiments, the anti-antigenic polypeptide antibody titer produced in a subject is increased 2-10 times relative to a control. For example, the anti-antigenic polypeptide antibody titer produced in a subject may be increased 2-10, 2-9, 2-8, 2-7, 2-6, 2-5, 2-4, 2-3, 3-10, 3-9, 3-8, 3-7, 3-6, 3-5, 3-4, 4-10, 4-9, 4-8, 4-7, 4-6, 4-5, 5-10, 5-9, 5-8, 5-7, 5-6, 6-10, 6-9, 6-8, 6-7, 7-10, 7-9, 7-8, 8-10, 8-9, or 9-10 times relative to a control.
• A control, in some embodiments, is the anti-antigenic polypeptide (e.g., an anti-HPV, HSV and/or Chlamydia antigenic polypeptide) antibody titer produced in a subject who has not been administered a STD RNA (e.g., mRNA) vaccine of the present disclosure. In some embodiments, a control is an anti-antigenic polypeptide (e.g., an anti-HPV, HSV and/or Chlamydia antigenic polypeptide) antibody titer produced in a subject who has been administered a live attenuated HPV, HSV and/or Chlamydia vaccine. An attenuated vaccine is a vaccine produced by reducing the virulence of a viable (live). An attenuated virus is altered in a manner that renders it harmless or less virulent relative to live, unmodified virus. In some embodiments, a control is an anti-antigenic polypeptide (e.g., an anti-HPV, HSV and/or Chlamydia antigenic polypeptide) antibody titer produced in a subject administered inactivated HPV, HSV and/or Chlamydia vaccine. In some embodiments, a control is an anti-antigenic polypeptide (e.g., an anti-HPV, HSV and/or Chlamydia antigenic polypeptide) antibody titer produced in a subject administered a recombinant or purified HPV, HSV and/or Chlamydia protein vaccine. Recombinant protein vaccines typically include protein antigens that either have been produced in a heterologous expression system (e.g., bacteria or yeast) or purified from large amounts of the pathogenic organism. In some embodiments, a control is an anti-antigenic polypeptide (e.g., an anti-HPV, HSV and/or Chlamydia antigenic polypeptide) antibody titer produced in a subject who has been administered an HPV, HSV and/or Chlamydia virus-like particle (VLP) vaccine.
• In some embodiments, an effective amount of a STD RNA (e.g., mRNA) vaccine is a dose that is reduced compared to the standard of care dose of a recombinant HPV, HSV and/or Chlamydia protein vaccine. A “standard of care,” as provided herein, refers to a medical or psychological treatment guideline and can be general or specific. “Standard of care” specifies appropriate treatment based on scientific evidence and collaboration between medical professionals involved in the treatment of a given condition. It is the diagnostic and treatment process that a physician/clinician should follow for a certain type of patient, illness or clinical circumstance. A “standard of care dose,” as provided herein, refers to the dose of a recombinant or purified HPV, HSV and/or Chlamydia protein vaccine, or a live attenuated or inactivated HPV, HSV and/or Chlamydia vaccine, that a physician/clinician or other medical professional would administer to a subject to treat or prevent HPV, HSV and/or Chlamydia, or a related condition, while following the standard of care guideline for treating or preventing HPV, HSV and/or Chlamydia, or a related condition.
• In some embodiments, the anti-antigenic polypeptide (e.g., an anti-HPV, anti-HSV and/or anti Chlamydia antigenic polypeptide) antibody titer produced in a subject administered an effective amount of a STD RNA (e.g., mRNA) vaccine is equivalent to an anti-antigenic polypeptide (e.g., an anti-HPV, anti-HSV and/or anti Chlamydia antigenic polypeptide) antibody titer produced in a control subject administered a standard of care dose of a recombinant or purified HPV, HSV and/or Chlamydia protein vaccine or a live attenuated or inactivated HPV, HSV and/or Chlamydia vaccine.
• In some embodiments, an effective amount of a STD RNA (e.g., mRNA) vaccine is a dose equivalent to an at least 2-fold reduction in a standard of care dose of a recombinant or purified HPV, HSV and/or Chlamydia protein vaccine. For example, an effective amount of a STD RNA (e.g., mRNA) vaccine may be a dose equivalent to an at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, or at least 10-fold reduction in a standard of care dose of a recombinant or purified HPV, HSV and/or Chlamydia protein vaccine. In some embodiments, an effective amount of a STD RNA (e.g., mRNA) vaccine is a dose equivalent to an at least at least 100-fold, at least 500-fold, or at least 1000-fold reduction in a standard of care dose of a recombinant or purified HPV, HSV and/or Chlamydia protein vaccine. In some embodiments, an effective amount of a STD RNA (e.g., mRNA) vaccine is a dose equivalent to a 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 20-, 50-, 100-, 250-, 500-, or 1000-fold reduction in a standard of care dose of a recombinant or purified HPV, HSV and/or Chlamydia protein vaccine. In some embodiments, the anti-antigenic polypeptide antibody titer produced in a subject administered an effective amount of a STD RNA (e.g., mRNA) vaccine is equivalent to an anti-antigenic polypeptide antibody titer produced in a control subject administered the standard of care dose of a recombinant or protein HPV, HSV and/or Chlamydia protein vaccine or a live attenuated or inactivated HPV, HSV and/or Chlamydia vaccine. In some embodiments, an effective amount of a STD RNA (e.g., mRNA) vaccine is a dose equivalent to a 2-fold to 1000-fold (e.g., 2-fold to 100-fold, 10-fold to 1000-fold) reduction in the standard of care dose of a recombinant or purified HPV, HSV and/or Chlamydia protein vaccine, wherein the anti-antigenic polypeptide antibody titer produced in the subject is equivalent to an anti-antigenic polypeptide antibody titer produced in a control subject administered the standard of care dose of a recombinant or purified HPV, HSV and/or Chlamydia protein vaccine or a live attenuated or inactivated HPV, HSV and/or Chlamydia vaccine.
• In some embodiments, the effective amount of a STD RNA (e.g., mRNA) vaccine is a dose equivalent to a 2 to 1000-, 2 to 900-, 2 to 800-, 2 to 700-, 2 to 600-, 2 to 500-, 2 to 400-, 2 to 300-, 2 to 200-, 2 to 100-, 2 to 90-, 2 to 80-, 2 to 70-, 2 to 60-, 2 to 50-, 2 to 40-, 2 to 30-, 2 to 20-, 2 to 10-, 2 to 9-, 2 to 8-, 2 to 7-, 2 to 6-, 2 to 5-, 2 to 4-, 2 to 3-, 3 to 1000-, 3 to 900-, 3 to 800-, 3 to 700-, 3 to 600-, 3 to 500-, 3 to 400-, 3 to 3 to 00-, 3 to 200-, 3 to 100-, 3 to 90-, 3 to 80-, 3 to 70-, 3 to 60-, 3 to 50-, 3 to 40-, 3 to 30-, 3 to 20-, 3 to 10-, 3 to 9-, 3 to 8-, 3 to 7-, 3 to 6-, 3 to 5-, 3 to 4-, 4 to 1000-, 4 to 900-, 4 to 800-, 4 to 700-, 4 to 600-, 4 to 500-, 4 to 400-, 4 to 4 to 00-, 4 to 200-, 4 to 100-, 4 to 90-, 4 to 80-, 4 to 70-, 4 to 60-, 4 to 50-, 4 to 40-, 4 to 30-, 4 to 20-, 4 to 10-, 4 to 9-, 4 to 8-, 4 to 7-, 4 to 6-, 4 to 5-, 4 to 4-, 5 to 1000-, 5 to 900-, 5 to 800-, 5 to 700-, 5 to 600-, 5 to 500-, 5 to 400-, 5 to 300-, 5 to 200-, 5 to 100-, 5 to 90-, 5 to 80-, 5 to 70-, 5 to 60-, 5 to 50-, 5 to 40-, 5 to 30-, 5 to 20-, 5 to 10-, 5 to 9-, 5 to 8-, 5 to 7-, 5 to 6-, 6 to 1000-, 6 to 900-, 6 to 800-, 6 to 700-, 6 to 600-, 6 to 500-, 6 to 400-, 6 to 300-, 6 to 200-, 6 to 100-, 6 to 90-, 6 to 80-, 6 to 70-, 6 to 60-, 6 to 50-, 6 to 40-, 6 to 30-, 6 to 20-, 6 to 10-, 6 to 9-, 6 to 8-, 6 to 7-, 7 to 1000-, 7 to 900-, 7 to 800-, 7 to 700-, 7 to 600-, 7 to 500-, 7 to 400-, 7 to 300-, 7 to 200-, 7 to 100-, 7 to 90-, 7 to 80-, 7 to 70-, 7 to 60-, 7 to 50-, 7 to 40-, 7 to 30-, 7 to 20-, 7 to 10-, 7 to 9-, 7 to 8-, 8 to 1000-, 8 to 900-, 8 to 800-, 8 to 700-, 8 to 600-, 8 to 500-, 8 to 400-, 8 to 300-, 8 to 200-, 8 to 100-, 8 to 90-, 8 to 80-, 8 to 70-, 8 to 60-, 8 to 50-, 8 to 40-, 8 to 30-, 8 to 20-, 8 to 10-, 8 to 9-, 9 to 1000-, 9 to 900-, 9 to 800-, 9 to 700-, 9 to 600-, 9 to 500-, 9 to 400-, 9 to 300-, 9 to 200-, 9 to 100-, 9 to 90-, 9 to 80-, 9 to 70-, 9 to 60-, 9 to 50-, 9 to 40-, 9 to 30-, 9 to 20-, 9 to 10-, 10 to 1000-, 10 to 900-, 10 to 800-, 10 to 700-, 10 to 600-, 10 to 500-, 10 to 400-, 10 to 300-, 10 to 200-, 10 to 100-, 10 to 90-, 10 to 80-, 10 to 70-, 10 to 60-, 10 to 50-, 10 to 40-, 10 to 30-, 10 to 20-, 20 to 1000-, 20 to 900-, 20 to 800-, 20 to 700-, 20 to 600-, 20 to 500-, 20 to 400-, 20 to 300-, 20 to 200-, 20 to 100-, 20 to 90-, 20 to 80-, 20 to 70-, 20 to 60-, 20 to 50-, 20 to 40-, 20 to 30-, 30 to 1000-, 30 to 900-, 30 to 800-, 30 to 700-, 30 to 600-, 30 to 500-, 30 to 400-, 30 to 300-, 30 to 200-, 30 to 100-, 30 to 90-, 30 to 80-, 30 to 70-, 30 to 60-, 30 to 50-, 30 to 40-, 40 to 1000-, 40 to 900-, 40 to 800-, 40 to 700-, 40 to 600-, 40 to 500-, 40 to 400-, 40 to 300-, 40 to 200-, 40 to 100-, 40 to 90-, 40 to 80-, 40 to 70-, 40 to 60-, 40 to 50-, 50 to 1000-, 50 to 900-, 50 to 800-, 50 to 700-, 50 to 600-, 50 to 500-, 50 to 400-, 50 to 300-, 50 to 200-, 50 to 100-, 50 to 90-, 50 to 80-, 50 to 70-, 50 to 60-, 60 to 1000-, 60 to 900-, 60 to 800-, 60 to 700-, 60 to 600-, 60 to 500-, 60 to 400-, 60 to 300-, 60 to 200-, 60 to 100-, 60 to 90-, 60 to 80-, 60 to 70-, 70 to 1000-, 70 to 900-, 70 to 800-, 70 to 700-, 70 to 600-, 70 to 500-, 70 to 400-, 70 to 300-, 70 to 200-, 70 to 100-, 70 to 90-, 70 to 80-, 80 to 1000-, 80 to 900-, 80 to 800-, 80 to 700-, 80 to 600-, 80 to 500-, 80 to 400-, 80 to 300-, 80 to 200-, 80 to 100-, 80 to 90-, 90 to 1000-, 90 to 900-, 90 to 800-, 90 to 700-, 90 to 600-, 90 to 500-, 90 to 400-, 90 to 300-, 90 to 200-, 90 to 100-, 100 to 1000-, 100 to 900-, 100 to 800-, 100 to 700-, 100 to 600-, 100 to 500-, 100 to 400-, 100 to 300-, 100 to 200-, 200 to 1000-, 200 to 900-, 200 to 800-, 200 to 700-, 200 to 600-, 200 to 500-, 200 to 400-, 200 to 300-, 300 to 1000-, 300 to 900-, 300 to 800-, 300 to 700-, 300 to 600-, 300 to 500-, 300 to 400-, 400 to 1000-, 400 to 900-, 400 to 800-, 400 to 700-, 400 to 600-, 400 to 500-, 500 to 1000-, 500 to 900-, 500 to 800-, 500 to 700-, 500 to 600-, 600 to 1000-, 600 to 900-, 600 to 800-, 600 to 700-, 700 to 1000-, 700 to 900-, 700 to 800-, 800 to 1000-, 800 to 900-, or 900 to 1000-fold reduction in the standard of care dose of a recombinant HPV, HSV and/or Chlamydia protein vaccine. In some embodiments, the anti-antigenic polypeptide antibody titer produced in the subject is equivalent to an anti-antigenic polypeptide antibody titer produced in a control subject administered the standard of care dose of a recombinant or purified HPV, HSV and/or Chlamydia protein vaccine or a live attenuated or inactivated HPV, HSV and/or Chlamydia vaccine. In some embodiments, the effective amount is a dose equivalent to (or equivalent to an at least) 2-, 3-,4-,5-,6-, 7-, 8-, 9-, 10-, 20-, 30-, 40-, 50-, 60-, 70-, 80-, 90-, 100-, 110-, 120-, 130-, 140-, 150-, 160-, 170-, 1280-, 190-, 200-, 210-, 220-, 230-, 240-, 250-, 260-, 270-, 280-, 290-, 300-, 310-, 320-, 330-, 340-, 350-, 360-, 370-, 380-, 390-, 400-, 410-, 420-, 430-, 440-, 450-, 4360-, 470-, 480-, 490-, 500-, 510-, 520-, 530-, 540-, 550-, 560-, 5760-, 580-, 590-, 600-, 610-, 620-, 630-, 640-, 650-, 660-, 670-, 680-, 690-, 700-, 710-, 720-, 730-, 740-, 750-, 760-, 770-, 780-, 790-, 800-, 810-, 820--, 830-, 840-, 850-, 860-, 870-, 880-, 890-, 900-, 910-, 920-, 930-, 940-, 950-, 960-, 970-, 980-, 990-, or 1000-fold reduction in the standard of care dose of a recombinant HPV, HSV and/or Chlamydia protein vaccine. In some embodiments, an anti-antigenic polypeptide antibody titer produced in the subject is equivalent to an anti-antigenic polypeptide antibody titer produced in a control subject administered the standard of care dose of a recombinant or purified HPV, HSV and/or Chlamydia protein vaccine or a live attenuated or inactivated HPV, HSV and/or Chlamydia vaccine.
• In some embodiments, the effective amount of a STD RNA (e.g., mRNA) vaccine is a total dose of 50-1000 μg. In some embodiments, the effective amount of a STD RNA (e.g., mRNA) vaccine is a total dose of 50-1000, 50-900, 50-800, 50-700, 50-600, 50-500, 50-400, 50-300, 50-200, 50-100, 50-90, 50-80, 50-70, 50-60, 60-1000, 60-900, 60-800, 60-700, 60-600, 60-500, 60-400, 60-300, 60-200, 60-100, 60-90, 60-80, 60-70, 70-1000, 70-900, 70-800, 70-700, 70-600, 70-500, 70-400, 70-300, 70-200, 70-100, 70-90, 70-80, 80-1000, 80-900, 80-800, 80-700, 80-600, 80-500, 80-400, 80-300, 80-200, 80-100, 80-90, 90-1000, 90-900, 90-800, 90-700, 90-600, 90-500, 90-400, 90-300, 90-200, 90-100, 100-1000, 100-900, 100-800, 100-700, 100-600, 100-500, 100-400, 100-300, 100-200, 200-1000, 200-900, 200-800, 200-700, 200-600, 200-500, 200-400, 200-300, 300-1000, 300-900, 300-800, 300-700, 300-600, 300-500, 300-400, 400-1000, 400-900, 400-800, 400-700, 400-600, 400-500, 500-1000, 500-900, 500-800, 500-700, 500-600, 600-1000, 600-900, 600-900, 600-700, 700-1000, 700-900, 700-800, 800-1000, 800-900, or 900-1000 μg. In some embodiments, the effective amount of a STD RNA (e.g., mRNA) vaccine is a total dose of 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950 or 1000 μg. In some embodiments, the effective amount is a dose of 25-500 μg administered to the subject a total of two times. In some embodiments, the effective amount of a STD RNA (e.g., mRNA) vaccine is a dose of 25-500, 25-400, 25-300, 25-200, 25-100, 25-50, 50-500, 50-400, 50-300, 50-200, 50-100, 100-500, 100-400, 100-300, 100-200, 150-500, 150-400, 150-300, 150-200, 200-500, 200-400, 200-300, 250-500, 250-400, 250-300, 300-500, 300-400, 350-500, 350-400, 400-500 or 450-500 μg administered to the subject a total of two times. In some embodiments, the effective amount of a STD RNA (e.g., mRNA) vaccine is a total dose of 25, 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 μg administered to the subject a total of two times.
Additional Embodiments
• 1. A sexually transmitted disease (STD) vaccine, comprising:
• at least one RNA polynucleotide having an open reading frame encoding at least one human papillomavirus (HPV) antigenic polypeptide and at least one herpes simplex virus (HSV) antigenic polypeptide, optionally formulated in a cationic lipid nanoparticle having a molar ratio of about 20-60% cationic lipid, about 5-25% non-cationic lipid, about 25-55% sterol, and about 0.5-15% PEG-modified lipid, optionally wherein the at least one RNA polynucleotide comprises at least one chemical modification.
• 2. A sexually transmitted disease (STD) vaccine, comprising:
• at least one RNA polynucleotide having an open reading frame encoding at least one human papillomavirus (HPV) antigenic polypeptide and at least one Chlamydia trachomatis antigenic polypeptide, optionally formulated in a cationic lipid nanoparticle having a molar ratio of about 20-60% cationic lipid, about 5-25% non-cationic lipid, about 25-55% sterol, and about 0.5-15% PEG-modified lipid, optionally wherein the at least one RNA polynucleotide comprises at least one chemical modification.
• 3. A sexually transmitted disease (STD) vaccine, comprising:
• at least one RNA polynucleotide having an open reading frame encoding at least one herpes simplex virus (HSV) antigenic polypeptide and at least one Chlamydia trachomatis antigenic polypeptide, optionally formulated in a cationic lipid nanoparticle having a molar ratio of about 20-60% cationic lipid, about 5-25% non-cationic lipid, about 25-55% sterol, and about 0.5-15% PEG-modified lipid, optionally wherein the at least one RNA polynucleotide comprises at least one chemical modification.
• 4. The vaccine of paragraph 1 or 2, wherein the at least one antigenic polypeptide is selected from HPV E1 protein, HPV E2 protein, HPV E4 protein, HPV E5 protein, HPV E6 protein, HPV E7 protein, HPV L1 protein, and HPV L2 protein, optionally wherein the HPV serotype is selected from HPV serotypes 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 and 82.
  5. The vaccine of paragraph 1, 2 or 4, wherein the vaccine comprises at least one RNA polynucleotide having an open reading frame encoding at least two antigenic polypeptides or immunogenic fragments thereof selected from HPV E1 protein, HPV E2 protein, HPV E4 protein, HPV E5 protein, HPV E6 protein, HPV E7 protein, HPV L1 protein, and HPV L2 protein.
  6. The vaccine of paragraph 1, 2, 4 or 5, wherein the vaccine comprises at least two RNA polynucleotides, each having an open reading frame encoding at least one antigenic polypeptide or an immunogenic fragment thereof selected from HPV E1 protein, HPV E2 protein, HPV E4 protein, HPV E5 protein, HPV E6 protein, HPV E7 protein, HPV L1 protein, and HPV L2 protein, wherein the HPV antigenic polypeptide encoded by one of the open reading frames differs from the HPV antigenic polypeptide encoded by another of the open reading frames.
  7. The vaccine of any one of paragraphs 1, 2 or 4-6, wherein the at least one antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 31-61.
  8. The vaccine of any one of paragraphs 1, 2 or 4-7, wherein the at least one RNA polypeptide is encoded by a nucleic acid sequence identified by any one of SEQ ID NO: 1-30, and/or wherein the at least one RNA polypeptide comprises a nucleic acid sequence identified by any one of SEQ ID NO: 431-461.
  9. The vaccine of any one of paragraphs 1, 2 or 4-8, wherein the at least one antigenic polypeptide has an amino acid sequence that has at least 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 31-61.
  10. The vaccine of any one of paragraphs 1, 2 or 4-9, wherein the at least one antigenic polypeptide has an amino acid sequence that has 95%-99% identity to an amino acid sequence identified by any one of SEQ ID NO: 31-61.
  11. The vaccine of any one of paragraphs 1, 2 or 4-10, wherein the at least one antigenic polypeptide has an amino acid sequence that has at least 90% identity to an amino acid sequence of SEQ ID NO: 31-61 and wherein the antigenic polypeptide or immunogenic fragment thereof has membrane fusion activity, attaches to cell receptors, causes fusion of viral and cellular membranes, and/or is responsible for binding of the virus to a cell being infected.
  12. The vaccine of any one of paragraphs 1, 2 or 4-11, wherein the at least one antigenic polypeptide has an amino acid sequence that has 90%-99% identity to an amino acid sequence of SEQ ID NO: 31-61 and wherein the antigenic polypeptide or immunogenic fragment thereof has membrane fusion activity, attaches to cell receptors, causes fusion of viral and cellular membranes, and/or is responsible for binding of the virus to a cell being infected.
  13. The vaccine of any one of paragraphs 2-12, wherein the at least one antigenic polypeptide is a major outer membrane protein (MOMP) or an immunogenic fragment thereof, optionally having a Chlamydia trachomatis serovar selected serovar H, F, E, D, I, G, J and K.
  14. The vaccine of any one of paragraphs 2-13, wherein the vaccine comprises at least one RNA polynucleotide having an open reading frame encoding at least two antigenic polypeptides or immunogenic fragments thereof selected from a MOMP of serovar H, a MOMP of serovar F, a MOMP of serovar E, a MOMP of serovar D, a MOMP of serovar I, a MOMP of serovar G, a MOMP of serovar J, and a MOMP of serovar K.
  15. The vaccine of any one of paragraphs 2-14, wherein the vaccine comprises at least two RNA polynucleotides, each having an open reading frame encoding at least one antigenic polypeptide or an immunogenic fragment thereof selected from a MOMP of serovar H, a MOMP of serovar F, a MOMP of serovar E, a MOMP of serovar D, a MOMP of serovar I, a MOMP of serovar G, a MOMP of serovar J, and a MOMP of serovar K, wherein the antigenic polypeptide encoded by one of the open reading frames differs from the antigenic polypeptide encoded by another of the open reading frames.
  16. The vaccine of any one of paragraphs 2-15, wherein the at least one antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 65-183.
  17. The vaccine of any one of paragraphs 2-16, wherein the at least one RNA polypeptide is encoded by a nucleic acid sequence identified by any one of SEQ ID NO: 62-64 or 184-294, and/or wherein the at least one RNA polypeptide comprises a nucleic acid sequence identified by any one of SEQ ID NO: 317-430.
  18. The vaccine of any one of paragraphs 2-17, wherein the at least one antigenic polypeptide has an amino acid sequence that has at least 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 65-183.
  19. The vaccine of any one of paragraphs 2-18, wherein the at least one antigenic polypeptide has an amino acid sequence that has 95%-99% identity to an amino acid sequence identified by any one of SEQ ID NO: 65-183.
  20. The vaccine of any one of paragraphs 2-19, wherein the at least one antigenic polypeptide has an amino acid sequence that has at least 90% identity to an amino acid sequence of SEQ ID NO: 65-183 and wherein the antigenic polypeptide or immunogenic fragment thereof has membrane fusion activity, attaches to cell receptors, causes fusion of viral and cellular membranes, and/or is responsible for binding of the virus to a cell being infected.
  21. The vaccine of any one of paragraphs 2-20, wherein the at least one antigenic polypeptide has an amino acid sequence that has 90%-99% identity to an amino acid sequence of SEQ ID NO: 65-183 and wherein the antigenic polypeptide or immunogenic fragment thereof has membrane fusion activity, attaches to cell receptors, causes fusion of viral and cellular membranes, and/or is responsible for binding of the virus to a cell being infected.
  22. The vaccine of any one of paragraphs 1-21, wherein the at least one RNA polynucleotide has less than 80% identity to wild-type mRNA sequence.
  23. The vaccine of any one of paragraphs 1-21, wherein at least one RNA polynucleotide has at least 80% identity to wild-type mRNA sequence, but does not include wild-type mRNA sequence.
  24. The vaccine of any one of paragraphs 1-23, wherein the at least one antigenic polypeptide has membrane fusion activity, attaches to cell receptors, causes fusion of viral and cellular membranes, and/or is responsible for binding of the virus to a cell being infected.
  25. The vaccine of any one of paragraphs 1-24, wherein the at least one RNA polynucleotide comprises at least one chemical modification.
  26. The vaccine of paragraph 1-25, wherein the chemical modification is selected from pseudouridine, N1-methylpseudouridine, N1-ethylpseudouridine, 2-thiouridine, 4′-thiouridine, 5-methylcytosine, 5-methyluridine, 2-thio-1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methoxyuridine and 2′-O-methyl uridine.
  27. The vaccine of paragraph 1-26, wherein the chemical modification is in the 5-position of the uracil.
  28. The vaccine of any one of paragraphs 1-27, wherein the chemical modification is a N1-methylpseudouridine or N1-ethylpseudouridine.
  29. The vaccine of any one of paragraphs 1-28, wherein at least 80% of the uracil in the open reading frame have a chemical modification.
  30. The vaccine of any one of paragraphs 1-29, wherein at least 90% of the uracil in the open reading frame have a chemical modification.
  31. The vaccine of any one of paragraphs 1-30, wherein 100% of the uracil in the open reading frame have a chemical modification.
  32. The vaccine of any one of paragraphs 1-31, wherein at least one RNA polynucleotide further encodes at least one 5′ terminal cap.
  33. The vaccine of paragraph 32, wherein the 5′ terminal cap is 7mG(5′)ppp(5′)NlmpNp.
  34. The vaccine of any one of paragraphs 1-33, wherein at least one antigenic polypeptide or immunogenic fragment thereof is fused to a signal peptide selected from: a HuIgGk signal peptide (METPAQLLFLLLLWLPDTTG; SEQ ID NO: 304); IgE heavy chain epsilon-1 signal peptide (MDWTWILFLVAAATRVHS; SEQ ID NO: 305); Japanese encephalitis PRM signal sequence (MLGSNSGQRVVFTILLLLVAPAYS; SEQ ID NO: 306), VSVg protein signal sequence (MKCLLYLAFLFIGVNCA; SEQ ID NO: 307) and Japanese encephalitis JEV signal sequence (MWLVSLAIVTACAGA; SEQ ID NO: 308).
  35. The vaccine of paragraph 34, wherein the signal peptide is fused to the N-terminus of at least one antigenic polypeptide.
  36. The vaccine of paragraph 34, wherein the signal peptide is fused to the C-terminus of at least one antigenic polypeptide.
  37. The vaccine of any one of paragraphs 1-36, wherein the antigenic polypeptide or immunogenic fragment thereof comprises a mutated N-linked glycosylation site.
  38. The vaccine of any one of paragraphs 1-37, formulated in a nanoparticle.
  39. The vaccine of paragraph 38, wherein the nanoparticle is a lipid nanoparticle.
  40. The vaccine of any one of paragraphs 1-39, wherein the nanoparticle has a mean diameter of 50-200 nm.
  41. The vaccine of any one of paragraphs 1-40, wherein the lipid nanoparticle comprises a cationic lipid, a PEG-modified lipid, a sterol and a non-cationic lipid.
  42. The vaccine of paragraph 41, wherein the lipid nanoparticle carrier comprises a molar ratio of about 20-60% cationic lipid, 0.5-15% PEG-modified lipid, 25-55% sterol, and 25% non-cationic lipid.
  43. The vaccine of paragraph 41 or 42, wherein the cationic lipid is an ionizable cationic lipid and the non-cationic lipid is a neutral lipid, and the sterol is a cholesterol.
  44. The vaccine of any one of paragraphs 41-43, wherein the cationic lipid is selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319).
  45. The vaccine of any one of paragraphs 1-44, wherein the lipid nanoparticle comprises a compound of Formula (I), optionally Compound 3, 18, 20, 25, 26, 29, 30, 60, 108-112, or 122. 46. The vaccine of any one of paragraphs 1-45, wherein the lipid nanoparticle comprises a compound of Formula (II).
  47. The vaccine of any one of paragraphs 1-46, wherein the nanoparticle has a polydispersity value of less than 0.4.
  48. The vaccine of any one of paragraphs 1-47, wherein the nanoparticle has a net neutral charge at a neutral pH value.
  49. The vaccine of any one of paragraphs 1-48 further comprising an adjuvant.
  50. The vaccine of paragraph 49, wherein the adjuvant is a flagellin protein or peptide.
  51. The vaccine of paragraph 50, wherein the flagellin protein or peptide comprises an amino acid sequence identified by any one of SEQ ID NO: 301-303.
  52. The vaccine of any one of paragraphs 1-51, wherein the open reading frame is codon-optimized.
  53. The vaccine of any one of paragraphs 1-52, wherein the vaccine is multivalent.
  54. The vaccine of any one of paragraphs 1-53 formulated in an effective amount to produce an antigen-specific immune response.
  55. A method of inducing an immune response in a subject, the method comprising administering to the subject the vaccine of any one of paragraphs 1-54 in an amount effective to produce an antigen-specific immune response in the subject.
  56. The method of paragraph 55, wherein the antigen specific immune response comprises a T cell response or a B cell response.
  57. The method of paragraph 55 or 56, wherein the subject is administered a single dose of the vaccine.
  58. The method of paragraph 55 or 56 wherein the subject is administered a booster dose of the vaccine.
  59. The method of any one of paragraphs 55-58, wherein the vaccine is administered to the subject by intradermal injection or intramuscular injection.
  60. The method of any one of paragraphs 55-59, wherein an anti-antigenic polypeptide antibody titer produced in the subject is increased by at least 1 log relative to a control.
  61. The method of any one of paragraphs 55-60, wherein an anti-antigenic polypeptide antibody titer produced in the subject is increased by 1-3 log relative to a control.
  62 The method of any one of paragraphs 55-61, wherein the anti-antigenic polypeptide antibody titer produced in the subject is increased at least 2 times relative to a control.
  63. The method of any one of paragraphs 55-62, wherein the anti-antigenic polypeptide antibody titer produced in the subject is increased 2-10 times relative to a control.
  64. The method of any one of paragraphs 60-63, wherein the control is an anti-antigenic polypeptide antibody titer produced in a subject who has not been administered a vaccine against the virus.
  65. The method of any one of paragraphs 60-63, wherein the control is an anti-antigenic polypeptide antibody titer produced in a subject who has been administered a live attenuated vaccine or an inactivated vaccine against the virus.
  66. The method of any one of paragraphs 60-63, wherein the control is an anti-antigenic polypeptide antibody titer produced in a subject who has been administered a recombinant protein vaccine or purified protein vaccine against the virus.
  67. The method of any one of paragraphs 60-63, wherein the control is an anti-antigenic polypeptide antibody titer produced in a subject who has been administered a VLP vaccine against the virus.
  68. The method of any one of paragraphs 55-67, wherein the effective amount is a dose equivalent to an at least 2-fold reduction in the standard of care dose of a recombinant protein vaccine or a purified protein vaccine against the virus, and wherein an anti-antigenic polypeptide antibody titer produced in the subject is equivalent to an anti-antigenic polypeptide antibody titer produced in a control subject administered the standard of care dose of a recombinant protein vaccine or a purified protein vaccine against the virus, respectively.
  69. The method of any one of paragraphs 55-67, wherein the effective amount is a dose equivalent to an at least 2-fold reduction in the standard of care dose of a live attenuated vaccine or an inactivated vaccine against the virus, and wherein an anti-antigenic polypeptide antibody titer produced in the subject is equivalent to an anti-antigenic polypeptide antibody titer produced in a control subject administered the standard of care dose of a live attenuated vaccine or an inactivated vaccine against the virus, respectively.
  70. The method of any one of paragraphs 55-67, wherein the effective amount is a dose equivalent to an at least 2-fold reduction in the standard of care dose of a VLP vaccine against the virus, and wherein an anti-antigenic polypeptide antibody titer produced in the subject is equivalent to an anti-antigenic polypeptide antibody titer produced in a control subject administered the standard of care dose of a VLP vaccine against the virus.
  71. The method of any one of paragraphs 55-70, wherein the effective amount is a total dose of 50 μg-1000 μg.
  72. The method of paragraph 55-71, wherein the effective amount is a dose of 25 μg, 100 μg, 400 μg, or 500 μg administered to the subject a total of two times.
  73. The method of any one of paragraphs 55-72, wherein the efficacy of the vaccine against the virus is greater than 65%.
  74. The method of any one of paragraphs 55-73, wherein the efficacy of the vaccine against the virus is greater than 80%.
  75. The method of any one of paragraphs 55-74, wherein the vaccine immunizes the subject against the virus for up to 2 years.
  76. The method of any one of paragraphs 55-74, wherein the vaccine immunizes the subject against the virus for more than 2 years.
  77. The method of any one of paragraphs 55-76, wherein the subject has an age of about 12 to about 50 years old.
  78. The method of any one of paragraphs 55-77, wherein the subject has been exposed to the virus, wherein the subject is infected with the virus, or wherein the subject is at risk of infection by the virus.
  79. The method of any one of paragraphs 55-78, wherein the subject is immunocompromised.
  80. The vaccine of any one of paragraphs 1-54 for use in a method of inducing an antigen specific immune response in a subject, the method comprising administering to the subject the vaccine in an amount effective to produce an antigen specific immune response in the subject.
  81. Use of the vaccine of any one of paragraphs 1-54 in the manufacture of a medicament for use in a method of inducing an antigen specific immune response in a subject, the method comprising administering to the subject the vaccine in an amount effective to produce an antigen specific immune response in the subject.
  82. An engineered nucleic acid encoding at least one RNA polynucleotide of a vaccine of any one of paragraphs 1-54.
  83. A tropical disease vaccine, comprising:
• at least one messenger ribonucleic acid (mRNA) polynucleotide having a 5′ terminal cap, an open reading frame encoding at least one tropical disease antigenic polypeptide, and a 3′ polyA tail.
• 84. The vaccine of paragraph 1, wherein the at least one mRNA polynucleotide is encoded by a sequence identified by any one of SEQ ID NO: 1-28.
  85. The vaccine of paragraph 1, wherein the at least one mRNA polynucleotide comprises a sequence identified by any one of SEQ ID NO: 431-461.
  86. The vaccine of paragraph 1, wherein the at least one antigenic polypeptide comprises a sequence identified by any one of SEQ ID NO: 31-61.
  87. The vaccine of paragraph 1, wherein the at least one mRNA polynucleotide is encoded by a sequence identified by any one of SEQ ID NO: 62-64.
  88. The vaccine of paragraph 1, wherein the at least one mRNA polynucleotide comprises a sequence identified by any one of SEQ ID NO: 317-319.
  89. The vaccine of paragraph 1, wherein the at least one antigenic polypeptide comprises a sequence identified by any one of SEQ ID NO: 65-72.
  90. The vaccine of paragraph 1, wherein the at least one mRNA polynucleotide is encoded by a sequence identified by any one of SEQ ID NO: 184-294.
  91. The vaccine of paragraph 1, wherein the at least one mRNA polynucleotide comprises a sequence identified by any one of SEQ ID NO: 320-430.
  92. The vaccine of paragraph 1, wherein the at least one antigenic polypeptide comprises a sequence identified by any one of SEQ ID NO: 73-183.
  93. The vaccine of any one of paragraphs 83-92, wherein the 5′ terminal cap is or comprises 7mG(5′)ppp(5′)NlmpNp.
  94. The vaccine of any one of paragraphs 83-93, wherein 100% of the uracil in the open reading frame is modified to include N1-methyl pseudouridine at the 5-position of the uracil.
  95. The vaccine of any one of paragraphs 83-94, wherein the vaccine is formulated in a lipid nanoparticle comprising: DLin-MC3-DMA; cholesterol; 1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC); and polyethylene glycol (PEG)2000-DMG.
  96. The vaccine of paragraph 95, wherein the lipid nanoparticle further comprises trisodium citrate buffer, sucrose and water.
  97. A sexually transmitted disease (STD) vaccine, comprising:
• at least one messenger ribonucleic acid (mRNA) polynucleotide having a 5′ terminal cap 7mG(5′)ppp(5′)NlmpNp, a sequence identified by SEQ ID NO: 431-461 and a 3′ polyA tail, wherein the uracil nucleotides of the sequence identified by SEQ ID NO: 431-461 are modified to include N1-methyl pseudouridine at the 5-position of the uracil nucleotide.
• 98. A sexually transmitted disease (STD) vaccine, comprising:
• at least one messenger ribonucleic acid (mRNA) polynucleotide having a 5′ terminal cap 7mG(5′)ppp(5′)NlmpNp, a sequence identified by SEQ ID NO: 317-319 and a 3′ polyA tail, wherein the uracil nucleotides of the sequence identified by SEQ ID NO: 317-319 are modified to include N1-methyl pseudouridine at the 5-position of the uracil nucleotide.
• 99. A sexually transmitted disease (STD) vaccine, comprising:
• at least one messenger ribonucleic acid (mRNA) polynucleotide having a 5′ terminal cap 7mG(5′)ppp(5′)NlmpNp, a sequence identified by SEQ ID NO: 320-430 and a 3′ polyA tail, wherein the uracil nucleotides of the sequence identified by SEQ ID NO: 320-430 are modified to include N1-methyl pseudouridine at the 5-position of the uracil nucleotide.
• 100. The vaccine of paragraph X formulated in a lipid nanoparticle comprising DLin-MC3-DMA, cholesterol, 1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC), and polyethylene glycol (PEG)2000-DMG.
• This disclosure is not limited in its application to the details of construction and the arrangement of components set forth in the following description or illustrated in the drawings. The disclosure is capable of other embodiments and of being practiced or of being carried out in various ways. Also, the phraseology and terminology used herein is for the purpose of description and should not be regarded as limiting. The use of “including,” “comprising,” or “having,” “containing,” “involving,” and variations thereof herein, is meant to encompass the items listed thereafter and equivalents thereof as well as additional items.
EXAMPLES Example 1: Manufacture of Polynucleotides
• According to the present disclosure, the manufacture of polynucleotides and/or parts or regions thereof may be accomplished utilizing the methods taught in International Publication WO2014/152027, entitled “Manufacturing Methods for Production of RNA Transcripts,” the contents of which is incorporated herein by reference in its entirety.
• Purification methods may include those taught in International Publication WO2014/152030 and International Publication WO2014/152031, each of which is incorporated herein by reference in its entirety.
• Detection and characterization methods of the polynucleotides may be performed as taught in International Publication WO2014/144039, which is incorporated herein by reference in its entirety.
• Characterization of the polynucleotides of the disclosure may be accomplished using polynucleotide mapping, reverse transcriptase sequencing, charge distribution analysis, detection of RNA impurities, or any combination of two or more of the foregoing. “Characterizing” comprises determining the RNA transcript sequence, determining the purity of the RNA transcript, or determining the charge heterogeneity of the RNA transcript, for example. Such methods are taught in, for example, International Publication WO2014/144711 and International Publication WO2014/144767, the content of each of which is incorporated herein by reference in its entirety.
Example 2: Chimeric Polynucleotide Synthesis
• According to the present disclosure, two regions or parts of a chimeric polynucleotide may be joined or ligated using triphosphate chemistry. A first region or part of 100 nucleotides or less is chemically synthesized with a 5′ monophosphate and terminal 3′desOH or blocked OH, for example. If the region is longer than 80 nucleotides, it may be synthesized as two strands for ligation.
• If the first region or part is synthesized as a non-positionally modified region or part using in vitro transcription (IVT), conversion the 5′monophosphate with subsequent capping of the 3′ terminus may follow.
• Monophosphate protecting groups may be selected from any of those known in the art.
• The second region or part of the chimeric polynucleotide may be synthesized using either chemical synthesis or IVT methods. IVT methods may include an RNA polymerase that can utilize a primer with a modified cap. Alternatively, a cap of up to 130 nucleotides may be chemically synthesized and coupled to the IVT region or part.
• For ligation methods, ligation with DNA T4 ligase, followed by treatment with DNase should readily avoid concatenation.
• The entire chimeric polynucleotide need not be manufactured with a phosphate-sugar backbone. If one of the regions or parts encodes a polypeptide, then such region or part may comprise a phosphate-sugar backbone.
• Ligation is then performed using any known click chemistry, orthoclick chemistry, solulink, or other bioconjugate chemistries known to those in the art.
• Synthetic Route
• The chimeric polynucleotide may be made using a series of starting segments. Such segments include:
• (a) a capped and protected 5′ segment comprising a normal 3′OH (SEG. 1)
• (b) a 5′ triphosphate segment, which may include the coding region of a polypeptide and a normal 3′OH (SEG. 2)
• (c) a 5′ monophosphate segment for the 3′ end of the chimeric polynucleotide (e.g., the tail) comprising cordycepin or no 3′OH (SEG. 3)
• After synthesis (chemical or IVT), segment 3 (SEG. 3) may be treated with cordycepin and then with pyrophosphatase to create the 5′ monophosphate.
• Segment 2 (SEG. 2) may then be ligated to SEG. 3 using RNA ligase. The ligated polynucleotide is then purified and treated with pyrophosphatase to cleave the diphosphate. The treated SEG.2-SEG. 3 construct may then be purified and SEG. 1 is ligated to the 5′ terminus. A further purification step of the chimeric polynucleotide may be performed.
• Where the chimeric polynucleotide encodes a polypeptide, the ligated or joined segments may be represented as: 5′UTR (SEG. 1), open reading frame or ORF (SEG. 2) and 3′UTR+PolyA (SEG. 3).
• The yields of each step may be as much as 90-95%.
Example 3: PCR for cDNA Production
• PCR procedures for the preparation of cDNA may be performed using 2×KAPA HIFI™ HotStart ReadyMix by Kapa Biosystems (Woburn, Mass.). This system includes 2×KAPA ReadyMix 12.5 μl; Forward Primer (10 μM) 0.75 μl; Reverse Primer (10 μM) 0.75 μl; Template cDNA 100 ng; and dH₂O diluted to 25.0 μl. The reaction conditions may be at 95° C. for 5 min. The reaction may be performed for 25 cycles of 98° C. for 20 sec, then 58° C. for 15 sec, then 72° C. for 45 sec, then 72° C. for 5 min, then 4° C. to termination.
• The reaction may be cleaned up using Invitrogen's PURELINK™ PCR Micro Kit (Carlsbad, Calif.) per manufacturer's instructions (up to 5 μg). Larger reactions may require a cleanup using a product with a larger capacity. Following the cleanup, the cDNA may be quantified using the NANODROP™ and analyzed by agarose gel electrophoresis to confirm that the cDNA is the expected size. The cDNA may then be submitted for sequencing analysis before proceeding to the in vitro transcription reaction.
Example 4: In Vitro Transcription (IVT)
• The in vitro transcription reaction generates RNA polynucleotides. Such polynucleotides may comprise a region or part of the polynucleotides of the disclosure, including chemically modified RNA (e.g., mRNA) polynucleotides. The chemically modified RNA polynucleotides can be uniformly modified polynucleotides. The in vitro transcription reaction utilizes a custom mix of nucleotide triphosphates (NTPs). The NTPs may comprise chemically modified NTPs, or a mix of natural and chemically modified NTPs, or natural NTPs.
• A typical in vitro transcription reaction includes the following:

• 1)	Template cDNA	1.0 μg
  2)	10x transcription buffer	2.0 μl
  	(400 mM Tris-HCl pH 8.0,
  	190 mM MgCl2, 50 mM DTT,
  	10 mM Spermidine)
  3)	Custom NTPs (25 mM each)	0.2 μl
  4)	RNase Inhibitor	20 U
  5)	T7 RNA polymerase	3000 U
  6)	dH20	up to 20.0
  		μl. and
  7)	Incubation at 37° C.
  	for 3 hr-5 hrs.

• The crude IVT mix may be stored at 4° C. overnight for cleanup the next day. 1 U of RNase-free DNase may then be used to digest the original template. After 15 minutes of incubation at 37° C., the mRNA may be purified using Ambion's MEGACLEAR™ Kit (Austin, Tex.) following the manufacturer's instructions. This kit can purify up to 500 μg of RNA. Following the cleanup, the RNA polynucleotide may be quantified using the NanoDrop and analyzed by agarose gel electrophoresis to confirm the RNA polynucleotide is the proper size and that no degradation of the RNA has occurred.
Example 5: Enzymatic Capping
• Capping of a RNA polynucleotide is performed as follows where the mixture includes: IVT RNA 60 μg-180 μg and dH₂O up to 72 μl. The mixture is incubated at 65° C. for 5 minutes to denature RNA, and then is transferred immediately to ice.
• The protocol then involves the mixing of 10× Capping Buffer (0.5 M Tris-HCl (pH 8.0), 60 mM KCl, 12.5 mM MgCl₂) (10.0 μl); 20 mM GTP (5.0 μl); 20 mM S-Adenosyl Methionine (2.5 μl); RNase Inhibitor (100 U); 2′-O-Methyltransferase (400U); Vaccinia capping enzyme (Guanylyl transferase) (40 U); dH₂O (Up to 28 μl); and incubation at 37° C. for 30 minutes for 60 μg RNA or up to 2 hours for 180 μg of RNA.
• The RNA polynucleotide may then be purified using Ambion's MEGACLEAR™ Kit (Austin, Tex.) following the manufacturer's instructions. Following the cleanup, the RNA may be quantified using the NANODROP™ (ThermoFisher, Waltham, Mass.) and analyzed by agarose gel electrophoresis to confirm the RNA polynucleotide is the proper size and that no degradation of the RNA has occurred. The RNA polynucleotide product may also be sequenced by running a reverse-transcription-PCR to generate the cDNA for sequencing.
Example 6: PolyA Tailing Reaction
• Without a poly-T in the cDNA, a poly-A tailing reaction must be performed before cleaning the final product. This is done by mixing capped IVT RNA (100 μl); RNase Inhibitor (20 U); 10× Tailing Buffer (0.5 M Tris-HCl (pH 8.0), 2.5 M NaCl, 100 mM MgCl₂) (12.0 μl); 20 mM ATP (6.0 μl); Poly-A Polymerase (20 U); dH₂O up to 123.5 μl and incubation at 37° C. for 30 min. If the poly-A tail is already in the transcript, then the tailing reaction may be skipped and proceed directly to cleanup with Ambion's MEGACLEAR™ kit (Austin, Tex.) (up to 500 μg). Poly-A Polymerase may be a recombinant enzyme expressed in yeast.
• It should be understood that the processivity or integrity of the polyA tailing reaction may not always result in an exact size polyA tail. Hence, polyA tails of approximately between 40-200 nucleotides, e.g., about 40, 50, 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 150-165, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164 or 165 are within the scope of the present disclosure.
Example 7: Natural 5′ Caps and 5′ Cap Analogues
• 5′-capping of polynucleotides may be completed concomitantly during the in vitro-transcription reaction using the following chemical RNA cap analogs to generate the 5′-guanosine cap structure according to manufacturer protocols: 3′-O-Me-m7G(5′)ppp(5′) G [the ARCA cap]; G(5′)ppp(5′)A; G(5′)ppp(5′)G; m7G(5′)ppp(5′)A; m7G(5′)ppp(5′)G (New England BioLabs, Ipswich, Mass.). 5′-capping of modified RNA may be completed post-transcriptionally using a Vaccinia Virus Capping Enzyme to generate the “Cap 0” structure: m7G(5′)ppp(5′)G (New England BioLabs, Ipswich, Mass.). Cap 1 structure may be generated using both Vaccinia Virus Capping Enzyme and a 2′-O methyl-transferase to generate: m7G(5′)ppp(5′)G-2′-O-methyl. Cap 2 structure may be generated from the Cap 1 structure followed by the 2′-O-methylation of the 5′-antepenultimate nucleotide using a 2′-O methyl-transferase. Cap 3 structure may be generated from the Cap 2 structure followed by the 2′-O-methylation of the 5′-preantepenultimate nucleotide using a 2′-O methyl-transferase. Enzymes are preferably derived from a recombinant source.
• When transfected into mammalian cells, the modified mRNAs have a stability of between 12-18 hours or more than 18 hours, e.g., 24, 36, 48, 60, 72 or greater than 72 hours.
Example 8: Capping Assays Protein Expression Assay
• Polynucleotides (e.g., mRNA) encoding a polypeptide, containing any of the caps taught herein, can be transfected into cells at equal concentrations. The amount of protein secreted into the culture medium can be assayed by ELISA at 6, 12, 24 and/or 36 hours post-transfection. Synthetic polynucleotides that secrete higher levels of protein into the medium correspond to a synthetic polynucleotide with a higher translationally-competent cap structure.
Purity Analysis Synthesis
• RNA (e.g., mRNA) polynucleotides encoding a polypeptide, containing any of the caps taught herein can be compared for purity using denaturing Agarose-Urea gel electrophoresis or HPLC analysis. RNA polynucleotides with a single, consolidated band by electrophoresis correspond to the higher purity product compared to polynucleotides with multiple bands or streaking bands. Chemically modified RNA polynucleotides with a single HPLC peak also correspond to a higher purity product. The capping reaction with a higher efficiency provides a more pure polynucleotide population.
Cytokine Analysis
• RNA (e.g., mRNA) polynucleotides encoding a polypeptide, containing any of the caps taught herein can be transfected into cells at multiple concentrations. The amount of pro-inflammatory cytokines, such as TNF-alpha and IFN-beta, secreted into the culture medium can be assayed by ELISA at 6, 12, 24 and/or 36 hours post-transfection. RNA polynucleotides resulting in the secretion of higher levels of pro-inflammatory cytokines into the medium correspond to a polynucleotides containing an immune-activating cap structure.
Capping Reaction Efficiency
• RNA (e.g., mRNA) polynucleotides encoding a polypeptide, containing any of the caps taught herein can be analyzed for capping reaction efficiency by LC-MS after nuclease treatment. Nuclease treatment of capped polynucleotides yield a mixture of free nucleotides and the capped 5′-5-triphosphate cap structure detectable by LC-MS. The amount of capped product on the LC-MS spectra can be expressed as a percent of total polynucleotide from the reaction and correspond to capping reaction efficiency. The cap structure with a higher capping reaction efficiency has a higher amount of capped product by LC-MS.
Example 9: Agarose Gel Electrophoresis of Modified RNA or RT PCR Products
• Individual RNA polynucleotides (200-400 ng in a 20 μl volume) or reverse transcribed PCR products (200-400 ng) may be loaded into a well on a non-denaturing 1.2% Agarose E-Gel (Invitrogen, Carlsbad, Calif.) and run for 12-15 minutes, according to the manufacturer protocol.
Example 10: Nanodrop Modified RNA Quantification and UV Spectral Data
• Chemically modified RNA polynucleotides in TE buffer (1 μl) are used for Nanodrop UV absorbance readings to quantitate the yield of each polynucleotide from an chemical synthesis or in vitro transcription reaction.
Example 11: Formulation of Modified mRNA Using Lipidoids
• RNA (e.g., mRNA) polynucleotides may be formulated for in vitro experiments by mixing the polynucleotides with the lipidoid at a set ratio prior to addition to cells. In vivo formulation may require the addition of extra ingredients to facilitate circulation throughout the body. To test the ability of these lipidoids to form particles suitable for in vivo work, a standard formulation process used for siRNA-lipidoid formulations may be used as a starting point. After formation of the particle, polynucleotide is added and allowed to integrate with the complex. The encapsulation efficiency is determined using a standard dye exclusion assays.
Example 12: HPV Immunogenicity Study
• The instant study is designed to test the immunogenicity in mice of candidate HPV vaccines comprising a chemically modified or unmodified mRNA polynucleotide encoding HPV L1 protein obtained from HPV serotypes 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 or 82.
• Mice are immunized intravenously (IV), intramuscularly (IM), or intradermally (ID) with candidate vaccines. Up to three immunizations are given at 3-week intervals (i.e., at weeks 0, 3, 6, and 9), and sera are collected after each immunization until weeks 33-51. Serum antibody titers against HPV L1 protein are determined by ELISA.
Example 13: HPV Challenge
• The instant study is designed to test the efficacy in guinea pig of candidate HPV vaccines against a lethal challenge using a HPV vaccine comprising a chemically modified or unmodified mRNA encoding HPV L1 protein obtained from HPV serotypes 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 or 82. Animals are challenged with a lethal dose of the HPV.
• Animals are immunized intravenously (IV), intramuscularly (IM), or intradermally (ID) at week 0 and week 3 with candidate HPV vaccines with and without adjuvant. The animals are then challenged with a lethal dose of HPV on week 7 via IV, IM or ID. Endpoint is day 13 post infection, death or euthanasia. Animals displaying severe illness as determined by >30% weight loss, extreme lethargy or paralysis are euthanized. Body temperature and weight are assessed and recorded daily.
• In experiments where a lipid nanoparticle (LNP) formulation is used, the formulation may include a cationic lipid, non-cationic lipid, PEG lipid and structural lipid in the ratios 50:10:1.5:38.5. The cationic lipid is DLin-KC2-DMA (50 mol %) or DLin-MC3-DMA (50 mol %), the non-cationic lipid is DSPC (10 mol %), the PEG lipid is PEG-DOMG (1.5 mol %) and the structural lipid is cholesterol (38.5 mol %), for example.
• Efficacy of HPV vaccine candidates against HPV challenge are compared to efficacy of vaccination of animals with Gardasil® (Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant, Merck).
Example 14: Chlamydia Immunogenicity Study
• The instant study was designed to test the immunogenicity in C57BL/6 mice with different Chlamydia Ct089mRNA vaccines. Mice (n=10) were immunized intramuscularly (IM) with candidate vaccines designated Ct089mRNA, Ct089NGM mRNA (N-glycosylated) or rCt089 protein (in Addvax). 2 μg or 10 μg doses in a 50 μl volume were administered to mice on day 0 and on day 21 (boost). The MC3/mRNA concentration used was 0.2 mg/ml for 10 μg dose, or 0.04 mg/ml for 2 μg dose. Mice were bled for serum preparation on day −3, 21 and 35. Anti-Ct089 antibody titers in serum were measured using rCt089 produced in E. coli as the antigen. FIG. 4 shows antibody titers measured on day 21 and on day 35.
• Excellent IgG titers were detected with native Ct089mRNA (present after single dose and boosted after second dose). Dose titration was observed with lower dose immunization, but positive titers were observed with both 2 μg and 10 μg doses. 10 μg Ct089mRNA responses surpass the 10 μg rCt089 protein control.
• N-glycosylation mutant Ct089 (Ct089NGM) mRNA was also immunogenic but to a slightly weaker extent.
• Ct089 is a promising Ct vaccine antigen candidate. Ct089 displayed both N- and O-glycosylation when expressed in mammalian cells. Given the extensive glycosylation observed with Ct089, mammalian glycosylation of mRNA encoded bacterial proteins in mammalian cells does not appear to mask immune epitopes or impede immunogenicity.
Example 15: Chlamydia trachomatis Rodent Challenge
• The instant study is designed to test the efficacy in Guinea pigs of candidate Chlamydia vaccines against a lethal challenge using a Chlamydia vaccine comprising chemically modified or unmodified mRNA encoding MOMP obtained from Chlamydia trachomatis serovar H, F, E, D, I, G, J or K. Mice are challenged with a lethal dose of the Chlamydia trachomatis.
• Animals are immunized intravaginally (IG), intramuscularly (IM), or intradermally (ID) at week 0 and week 3 with candidate Chlamydia vaccines with and without adjuvant. The animals are then challenged with a lethal dose of Chlamydia trachomatis on week 7 via an IG, IM or ID route. Endpoint is day 13 post infection, death or euthanasia. Animals displaying severe illness as determined by >30% weight loss, extreme lethargy or paralysis are euthanized. Body temperature and weight are assessed and recorded daily.
• In experiments where a lipid nanoparticle (LNP) formulation is used, the formulation may include a cationic lipid, non-cationic lipid, PEG lipid and structural lipid in the ratios 50:10:1.5:38.5. The cationic lipid is DLin-KC2-DMA (50 mol %), the non-cationic lipid is DSPC (10 mol %), the PEG lipid is PEG-DOMG (1.5 mol %) and the structural lipid is cholesterol (38.5 mol %), for example.
Example 16: In Vitro Expression of Chlamydia trachomatis Antigens from Candidate mRNA Vaccines
• This study was designed to test the in vitro expression of Chlamydia trachomatis antigens from candidate mRNA vaccines. Candidate mRNA vaccines encoding MOMP, Ct875, Ct858, Ct089, PmPG_pd, Ct460, Ct622, Cta1, Ct443, or Ct812pd_D were tested. The candidate mRNA vaccines encoding MOMP were transfected into Hela cells. The expression of MOMP in Hela cells was visualized by immunofluorescence by staining the transfected Hela cells using mouse anti-MOMP antibodies. Fluorescent microscopy images showed co-localization of the anti-MOMP antibodies and Hela cells (data not shown). The mRNA vaccine constructs encoding Ct875, Ct858, Ct089, PmPG_pd, Ct460, Ct622, Cta1, Ct443, or Ct812pd_D were transfected into HEK293F cells. Twenty hours post transfection, the cell culture supernatant (concentrated or dilute) or HEK293F cell lysates were collected and the expression of the antigens were analyzed by Western blot. The Chlamydia trachomatis antigens were tagged with a HisX6 tag. Mouse anti-6×His antibodies were used as the primary antibody, and anti-mouse A1647 antibodies were used as the secondary antibody. The cellular GAPDH was also detected as control. Rabbit anti-GAPDH antibodies were used as the primary antibody, and anti-rabbit Cy3 antibodies were used as the secondary antibody. The results of the Western blot are shown in FIGS. 1A-1B, FIGS. 2A-2B, FIG. 3 and Table 14.
• Each of the sequences described herein encompasses a chemically modified sequence or an unmodified sequence which includes no modifications.

• TABLE 1
  HPV Nucleic Acid Sequences

  		SEQ ID
  Description	Sequence	NO:

  HPV6_L1	ATGTGGCGGCCTAGCGACAGCACAGTATATGTGCCTCCT	1
  	CCTAACCCTGTATCCAAAGTTGTTGCCACGGATGCTTAT
  	GTTACTCGCACCAACATATTTTATCATGCCAGCAGTTCC
  	AGACTTCTTGCAGTGGGACATCCTTATTTTTCCATAAAA
  	CGGGCTAACAAAACTGTTGTGCCAAAGGTGTCAGGATA
  	TCAATACAGGGTATTTAAGGTGGTGTTACCAGATCCTAA
  	CAAATTTGCATTGCCTGACTCGTCTCTTTTCGATCCCACA
  	ACACAACGTTTAGTATGGGCATGCACAGGCCTAGAGGT
  	GGGCAGGGGACAGCCATTAGGTGTGGGTGTAAGTGGAC
  	ATCCTTTCCTAAATAAATATGATGATGTTGAAAATTCAG
  	GGAGTGGTGGTAACCCTGGACAGGATAACAGGGTTAAT
  	GTAGGTATGGATTATAAACAAACACAATTATGCATGGTT
  	GGATGTGCCCCCCCTTTGGGCGAGCATTGGGGTAAAGGT
  	AAACAGTGTACTAATACACCTGTACAGGCTGGTGACTGC
  	CCGCCCTTAGAACTTATTACCAGTGTTATACAGGATGGC
  	GATATGGTTGACACAGGCTTTGGTGCTATGAATTTTGCT
  	GATTTGCAGACCAATAAATCAGATGTTCCTATTGACATA
  	TGTGGCACTACATGTAAATATCCAGATTATTTACAAATG
  	GCTGCAGACCCATATGGTGATAGATTATTTTTTTTTCTAC
  	GGAAGGAACAAATGTTTGCCAGACATTTTTTTAACAGGG
  	CTGGCGAGGTGGGGGAACCTGTGCCTGATACACTTATAA
  	TTAAGGGTAGTGGAAATCGCACGTCTGTAGGGAGTAGT
  	ATATATGTTAACACCCCGAGCGGCTCTTTGGTGTCCTCT
  	GAGGCACAATTGTTTAATAAGCCATATTGGCTACAAAAA
  	GCCCAGGGACATAACAATGGTATTTGTTGGGGTAATCAA
  	CTGTTTGTTACTGTGGTAGATACCACACGCAGTACCAAC
  	ATGACATTATGTGCATCCGTAACTACATCTTCCACATAC
  	ACCAATTCTGATTATAAAGAGTACATGCGTCATGTGGAA
  	GAGTATGATTTACAATTTATTTTTCAATTATGTAGCATTA
  	CATTGTCTGCTGAAGTAATGGCCTATATTCACACAATGA
  	ATCCCTCTGTTTTGGAAGACTGGAACTTTGGGTTATCGC
  	CTCCCCCAAATGGTACATTAGAAGATACCTATAGGTATG
  	TGCAGTCACAGGCCATTACCTGTCAAAAGCCCACTCCTG
  	AAAAGGAAAAGCCAGATCCCTATAAGAACCTTAGTTTTT
  	GGGAGGTTAATTTAAAAGAAAAGTTTTCTAGTGAATTGG
  	ATCAGTATCCTTTGGGACGCAAGTTTTTGTTACAAAGTG
  	GATATAGGGGACGGTCCTCTATTCGTACAGGTGTTAAGC
  	GCCCTGCTGTTTCCAAAGCCTCTGCTGCCCCTAAACGTA
  	AGCGCGCCAAAACTAAAAGG
  HPV11_L1	ATGTGGCGGCCTAGCGACAGCACAGTATATGTGCCTCCT	2
  	CCCAACCCTGTATCCAAGGTTGTTGCCACGGATGCGTAT
  	GTTAAACGCACCAACATATTTTATCATGCCAGCAGTTCC
  	AGACTCCTTGCTGTGGGACATCCATATTACTCTATCAAA
  	AAAGTTAACAAAACAGTTGTACCAAAGGTGTCTGGATA
  	TCAATATAGAGTGTTTAAGGTAGTGTTGCCAGATCCTAA
  	CAAGTTTGCATTACCTGATTCATCCCTGTTTGACCCCACT
  	ACACAGCGTTTAGTATGGGCGTGCACAGGGTTGGAGGT
  	AGGCAGGGGTCAACCTTTAGGCGTTGGTGTTAGTGGGCA
  	TCCATTGCTAAACAAATATGATGATGTAGAAAATAGTGG
  	TGGGTATGGTGGTAATCCTGGTCAGGATAATAGGGTTAA
  	TGTAGGTATGGATTATAAACAAACCCAGCTATGTATGGT
  	GGGCTGTGCTCCACCGTTAGGTGAACATTGGGGTAAGG
  	GTACACAATGTTCAAATACCTCTGTACAAAATGGTGACT
  	GCCCCCCGTTGGAACTTATTACCAGTGTTATACAGGATG
  	GGGACATGGTTGATACAGGCTTTGGTGCTATGAATTTTG
  	CAGACTTACAAACCAATAAATCGGATGTTCCCCTTGATA
  	TTTGTGGAACTGTCTGCAAATATCCTGATTATTTGCAAA
  	TGGCTGCAGACCCTTATGGTGATAGGTTGTTTTTTTATTT
  	GCGAAAGGAACAAATGTTTGCTAGACACTTTTTTAATAG
  	GGCCGGTACTGTGGGGGAACCTGTGCCTGATGACCTGTT
  	GGTAAAAGGGGGTAATAACAGATCATCTGTAGCTAGTA
  	GTATTTATGTACATACACCTAGTGGCTCATTGGTGTCTTC
  	AGAGGCTCAATTATTTAATAAACCATATTGGCTTCAAAA
  	GGCTCAGGGACATAACAATGGTATTTGCTGGGGAAACC
  	ACTTGTTTGTTACTGTGGTAGATACCACACGCAGTACAA
  	ATATGACACTATGTGCATCTGTGTCTAAATCTGCTACAT
  	ACACTAATTCAGATTATAAGGAATACATGCGCCATGTGG
  	AGGAGTTTGATTTACAGTTTATTTTTCAATTGTGTAGCAT
  	TACATTATCTGCAGAAGTCATGGCCTATATACACACAAT
  	GAATCCTTCTGTTTTGGAGGACTGGAACTTTGGTTTATC
  	GCCTCCACCAAATGGTACACTGGAGGATACTTATAGATA
  	TGTACAGTCACAGGCCATTACCTGTCAGAAACCCACACC
  	TGAAAAAGAAAAACAGGATCCCTATAAGGATATGAGTT
  	TTTGGGAGGTTAACTTAAAAGAAAAGTTTTCAAGTGAAT
  	TAGATCAGTTTCCCCTTGGACGTAAGTTTTTATTGCAAA
  	GTGGATATCGAGGACGGACGTCTGCTCGTACAGGTATA
  	AAGCGCCCAGCTGTGTCTAAGCCCTCTACAGCCCCCAAA
  	CGAAAACGTACCAAAACCAAAAAG
  HPV16_L1	ATGTCTCTTTGGCTGCCTAGTGAGGCCACTGTCTACTTGC	3
  	CTCCTGTCCCAGTATCTAAGGTTGTAAGCACGGATGAAT
  	ATGTTGCACGCACAAACATATATTATCATGCAGGAACAT
  	CCAGACTACTTGCAGTTGGACATCCCTATTTTCCTATTAA
  	AAAACCTAACAATAACAAAATATTAGTTCCTAAAGTATC
  	AGGATTACAATACAGGGTATTTAGAATACATTTACCTGA
  	CCCCAATAAGTTTGGTTTTCCTGACACCTCATTTTATAAT
  	CCAGATACACAGCGGCTGGTTTGGGCCTGTGTAGGTGTT
  	GAGGTAGGTCGTGGTCAGCCATTAGGTGTGGGCATTAGT
  	GGCCATCCTTTATTAAATAAATTGGATGACACAGAAAAT
  	GCTAGTGCTTATGCAGCAAATGCAGGTGTGGATAATAG
  	AGAATGTATATCTATGGATTACAAACAAACACAATTGTG
  	TTTAATTGGTTGCAAACCACCTATAGGGGAACACTGGGG
  	CAAAGGATCCCCATGTACCAATGTTGCAGTAAATCCAGG
  	TGATTGTCCACCATTAGAGTTAATAAACACAGTTATTCA
  	GGATGGTGATATGGTTGATACTGGCTTTGGTGCTATGGA
  	CTTTACTACATTACAGGCTAACAAAAGTGAAGTTCCACT
  	GGATATTTGTACATCTATTTGCAAATATCCAGATTATATT
  	AAAATGGTGTCAGAACCATATGGCGACAGCTTATTTTTT
  	TATTTACGAAGGGAACAAATGTTTGTTAGACATTTATTT
  	AATAGGGCTGGTACTGTTGGTGAAAATGTACCAGACGA
  	TTTATACATTAAAGGCTCTGGGTCTACTGCAAATTTAGC
  	CAGTTCAAATTATTTTCCTACACCTAGTGGTTCTATGGTT
  	ACCTCTGATGCCCAAATATTCAATAAACCTTATTGGTTA
  	CAACGAGCACAGGGCCACAATAATGGCATTTGTTGGGG
  	TAACCAACTATTTGTTACTGTTGTTGATACTACACGCAG
  	TACAAATATGTCATTATGTGCTGCCATATCTACTTCAGA
  	AACTACATATAAAAATACTAACTTTAAGGAGTACCTACG
  	ACATGGGGAGGAATATGATTTACAGTTTATTTTTCAACT
  	GTGCAAAATAACCTTAACTGCAGACGTTATGACATACAT
  	ACATTCTATGAATTCCACTATTTTGGAGGACTGGAATTT
  	TGGTCTACAACCTCCCCCAGGAGGCACACTAGAAGATA
  	CTTATAGGTTTGTAACATCCCAGGCAATTGCTTGTCAAA
  	AACATACACCTCCAGCACCTAAAGAAGATCCCCTTAAA
  	AAATACACTTTTTGGGAAGTAAATTTAAAGGAAAAGTTT
  	TCTGCAGACCTAGATCAGTTTCCTTTAGGACGCAAATTT
  	TTACTACAAGCAGGATTGAAGGCCAAACCAAAATTTAC
  	ATTAGGAAAACGAAAAGCTACACCCACCACCTCATCTA
  	CCTCTACAACTGCTAAACGCAAAAAACGTAAGCTG
  HPV18_L1	ATGGCTTTGTGGCGGCCTAGTGACAATACCGTATATCTT	4
  	CCACCTCCTTCTGTGGCAAGAGTTGTAAATACCGATGAT
  	TATGTGACTCGCACAAGCATATTTTATCATGCTGGCAGC
  	TCCAGATTATTAACTGTTGGTAATCCATATTTTAGGGTTC
  	CTGCAGGTGGTGGCAATAAGCAGGATATTCCTAAGGTTT
  	CTGCATACCAATATAGAGTATTTAGGGTGCAGTTACCTG
  	ACCCAAATAAATTTGGTTTACCTGATACTAGTATTTATA
  	ATCCTGAAACACAACGTTTAGTGTGGGCCTGTGCTGGAG
  	TGGAAATTGGCCGTGGTCAGCCTTTAGGTGTTGGCCTTA
  	GTGGGCATCCATTTTATAATAAATTAGATGACACTGAAA
  	GTTCCCATGCCGCCACGTCTAATGTTTCTGAGGACGTTA
  	GGGACAATGTGTCTGTAGATTATAAGCAGACACAGTTAT
  	GTATTTTGGGCTGTGCCCCTGCTATTGGGGAACACTGGG
  	CTAAAGGCACTGCTTGTAAATCGCGTCCTTTATCACAGG
  	GCGATTGCCCCCCTTTAGAACTTAAAAACACAGTTTTGG
  	AAGATGGTGATATGGTAGATACTGGATATGGTGCCATG
  	GACTTTAGTACATTGCAAGATACTAAATGTGAGGTACCA
  	TTGGATATTTGTCAGTCTATTTGTAAATATCCTGATTATT
  	TACAAATGTCTGCAGATCCTTATGGGGATTCCATGTTTTT
  	TTGCTTACGGCGTGAGCAGCTTTTTGCTAGGCATTTTTGG
  	AATAGAGCAGGTACTATGGGTGACACTGTGCCTCAATCC
  	TTATATATTAAAGGCACAGGTATGCGTGCTTCACCTGGC
  	AGCTGTGTGTATTCTCCCTCTCCAAGTGGCTCTATTGTTA
  	CCTCTGACTCCCAGTTGTTTAATAAACCATATTGGTTAC
  	ATAAGGCACAGGGTCATAACAATGGTGTTTGCTGGCATA
  	ATCAATTATTTGTTACTGTGGTAGATACCACTCGCAGTA
  	CCAATTTAACAATATGTGCTTCTACACAGTCTCCTGTAC
  	CTGGGCAATATGATGCTACCAAATTTAAGCAGTATAGCA
  	GACATGTTGAGGAATATGATTTGCAGTTTATTTTTCAGTT
  	GTGTACTATTACTTTAACTGCAGATGTTATGTCCTATATT
  	CATAGTATGAATAGCAGTATTTTAGAGGATTGGAACTTT
  	GGTGTTCCCCCCCCGCCAACTACTAGTTTGGTGGATACA
  	TATCGTTTTGTACAATCTGTTGCTATTACCTGTCAAAAGG
  	ATGCTGCACCGGCTGAAAATAAGGATCCCTATGATAAGT
  	TAAAGTTTTGGAATGTGGATTTAAAGGAAAAGTTTTCTT
  	TAGACTTAGATCAATATCCCCTTGGACGTAAATTTTTGG
  	TTCAGGCTGGATTGCGTCGCAAGCCCACCATAGGCCCTC
  	GCAAACGTTCTGCTCCATCTGCCACTACGTCTTCTAAAC
  	CTGCCAAGCGTGTGCGTGTACGTGCCAGGAAG
  HPV31_L1	ATGTCTCTGTGGCGGCCTAGCGAGGCTACTGTCTACTTA	5
  	CCACCTGTCCCAGTGTCTAAAGTTGTAAGCACGGATGAA
  	TATGTAACACGAACCAACATATATTATCACGCAGGCAGT
  	GCTAGGCTGCTTACAGTAGGCCATCCATATTATTCCATA
  	CCTAAATCTGACAATCCTAAAAAAATAGTTGTACCAAAG
  	GTGTCAGGATTACAATATAGGGTATTTAGGGTTCGTTTA
  	CCAGATCCAAACAAATTTGGATTTCCTGATACATCTTTTT
  	ATAATCCTGAAACTCAACGCTTAGTTTGGGCCTGTGTTG
  	GTTTAGAGGTAGGTCGCGGGCAGCCATTAGGTGTAGGT
  	ATTAGTGGTCATCCATTATTAAATAAATTTGATGACACT
  	GAAAACTCTAATAGATATGCCGGTGGTCCTGGCACTGAT
  	AATAGGGAATGTATATCAATGGATTATAAACAAACACA
  	ACTGTGTTTACTTGGTTGCAAACCACCTATTGGAGAGCA
  	TTGGGGTAAAGGTAGTCCTTGTAGTAACAATGCTATTAC
  	CCCTGGTGATTGTCCTCCATTAGAATTAAAAAATTCAGT
  	TATACAAGATGGGGATATGGTTGATACAGGCTTTGGAGC
  	TATGGATTTTACTGCTTTACAAGACACTAAAAGTAATGT
  	TCCTTTGGACATTTGTAATTCTATTTGTAAATATCCAGAT
  	TATCTTAAAATGGTTGCTGAGCCATATGGCGATACATTA
  	TTTTTTTATTTACGTAGGGAACAAATGTTTGTAAGGCATT
  	TTTTTAATAGATCAGGCACGGTTGGTGAATCGGTCCCTA
  	CTGACTTATATATTAAAGGCTCCGGTTCAACAGCTACTT
  	TAGCTAACAGTACATACTTTCCTACACCTAGCGGCTCCA
  	TGGTTACTTCAGATGCACAAATTTTTAATAAACCATATT
  	GGATGCAACGTGCTCAGGGACACAATAATGGTATTTGTT
  	GGGGCAATCAGTTATTTGTTACTGTGGTAGATACCACAC
  	GTAGTACCAATATGTCTGTTTGTGCTGCAATTGCAAACA
  	GTGATACTACATTTAAAAGTAGTAATTTTAAAGAGTATT
  	TAAGACATGGTGAGGAATTTGATTTACAATTTATATTTC
  	AGTTATGCAAAATAACATTATCTGCAGACATAATGACAT
  	ATATTCACAGTATGAATCCTGCTATTTTGGAAGATTGGA
  	ATTTTGGATTGACCACACCTCCCTCAGGTTCTTTGGAGG
  	ATACCTATAGGTTTGTCACCTCACAGGCCATTACATGTC
  	AAAAAACTGCCCCCCAAAAGCCCAAGGAAGATCCATTT
  	AAAGATTATGTATTTTGGGAGGTTAATTTAAAAGAAAAG
  	TTTTCTGCAGATTTAGATCAGTTTCCACTGGGTCGCAAA
  	TTTTTATTACAGGCAGGATATAGGGCACGTCCTAAATTT
  	AAAGCAGGTAAACGTAGTGCACCCTCAGCATCTACCACT
  	ACACCAGCAAAACGTAAAAAAACTAAAAAG
  HPV33_L1	ATGTCCGTGTGGCGGCCTAGTGAGGCCACAGTGTACCTG	6
  	CCTCCTGTACCTGTATCTAAAGTTGTCAGCACTGATGAA
  	TATGTGTCTCGCACAAGCATTTATTATTATGCTGGTAGTT
  	CCAGACTTCTTGCTGTTGGCCATCCATATTTTTCTATTAA
  	AAATCCTACTAACGCTAAAAAATTATTGGTACCCAAAGT
  	ATCAGGCTTGCAATATAGGGTTTTTAGGGTCCGTTTACC
  	AGATCCTAATAAATTTGGATTTCCTGACACCTCCTTTTAT
  	AACCCTGATACACAACGATTAGTATGGGCATGTGTAGGC
  	CTTGAAATAGGTAGAGGGCAGCCATTAGGCGTTGGCAT
  	AAGTGGTCATCCTTTATTAAACAAATTTGATGACACTGA
  	AACCGGTAACAAGTATCCTGGACAACCGGGTGCTGATA
  	ATAGGGAATGTTTATCCATGGATTATAAACAAACACAGT
  	TATGTTTACTTGGATGTAAGCCTCCAACAGGGGAACATT
  	GGGGTAAAGGTGTTGCTTGTACTAATGCAGCACCTGCCA
  	ATGATTGTCCACCTTTAGAACTTATAAATACTATTATTG
  	AGGATGGTGATATGGTGGACACAGGATTTGGTTGCATG
  	GATTTTAAAACATTGCAGGCTAATAAAAGTGATGTTCCT
  	ATTGATATTTGTGGCAGTACATGCAAATATCCAGATTAT
  	TTAAAAATGACTAGTGAGCCTTATGGTGATAGTTTATTT
  	TTCTTTCTTCGACGTGAACAAATGTTTGTAAGACACTTTT
  	TTAATAGGGCTGGTACATTAGGAGAGGCTGTTCCCGATG
  	ACCTGTACATTAAAGGTTCAGGAACTACTGCCTCTATTC
  	AAAGCAGTGCTTTTTTTCCCACTCCTAGTGGATCAATGG
  	TTACTTCCGAATCTCAGTTATTTAATAAGCCATATTGGCT
  	ACAACGTGCACAAGGTCATAATAATGGTATTTGTTGGGG
  	CAATCAGGTATTTGTTACTGTGGTAGATACCACTCGCAG
  	TACTAATATGACTTTATGCACACAAGTAACTAGTGACAG
  	TACATATAAAAATGAAAATTTTAAAGAATATATAAGAC
  	ATGTTGAAGAATATGATCTACAGTTTGTTTTTCAACTAT
  	GCAAAGTTACCTTAACTGCAGAAGTTATGACATATATTC
  	ATGCTATGAATCCAGATATTTTAGAAGATTGGCAATTTG
  	GTTTAACACCTCCTCCATCTGCTAGTTTACAGGATACCT
  	ATAGGTTTGTTACCTCTCAGGCTATTACGTGTCAAAAAA
  	CAGTACCTCCAAAGGAAAAGGAAGACCCCTTAGGTAAA
  	TATACATTTTGGGAAGTGGATTTAAAGGAAAAATTTTCA
  	GCAGATTTAGATCAGTTTCCTTTGGGACGCAAGTTTTTA
  	TTACAGGCAGGTCTTAAAGCAAAACCTAAACTTAAACGT
  	GCAGCCCCCACATCCACCCGCACATCGTCTGCAAAACGC
  	AAAAAGGTTAAAAAA
  HPV35_L1_DX	ATGTCTCTGTGGCGGTCTAACGAAGCCACTGTCTACCTG	7
  	CCTCCAGTGTCAGTGTCTAAGGTTGTTAGCACTGATGAA
  	TATGTAACACGCACAAACATCTACTATCATGCAGGCAGT
  	TCTAGGCTATTAGCTGTGGGTCACCCATACTATGCTATT
  	AAAAAACAAGATTCTAATAAAATAGCAGTACCCAAGGT
  	ATCTGGTTTGCAATACAGAGTATTTAGAGTAAAATTACC
  	AGATCCTAATAAGTTTGGATTTCCAGACACATCATTTTA
  	TGATCCTGCCTCCCAGCGTTTGGTTTGGGCCTGTACAGG
  	AGTTGAAGTAGGTCGTGGTCAGCCATTGGGTGTAGGTAT
  	TAGTGGTCATCCTTTACTCAATAAATTGGATGATACTGA
  	AAATTCTAATAAATATGTTGGTAACTCTGGTACAGATAA
  	CAGGGAATGCATTTCTATGGATTATAAACAAACACAATT
  	GTGTTTAATAGGTTGTAGGCCTCCTATAGGTGAACATTG
  	GGGAAAAGGCACACCTTGTAATGCTAACCAGGTAAAAG
  	CAGGAGAATGTCCTCCTTTGGAGTTACTAAACACTGTAC
  	TACAAGACGGGGACATGGTAGACACAGGATTTGGTGCA
  	ATGGATTTTACTACATTACAAGCTAATAAAAGTGATGTT
  	CCCCTAGATATATGCAGTTCCATTTGCAAATATCCTGAT
  	TATCTAAAAATGGTTTCTGAGCCATATGGAGATATGTTA
  	TTTTTTTATCTACGTAGGGAGCAAATGTTTGTGAGACAT
  	TTATTTAATAGGGCTGGAACTGTAGGTGAAACAGTACCT
  	GCAGACCTATATATTAAGGGTACCACTGGCACATTGCCT
  	AGTACTAGTTATTTTCCTACTCCTAGTGGCTCTATGGTAA
  	CCTCCGATGCACAAATATTTAATAAACCATATTGGTTGC
  	AACGTGCACAAGGCCATAATAATGGTATTTGTTGGAGTA
  	ACCAATTGTTTGTTACTGTAGTTGATACAACCCGTAGTA
  	CAAATATGTCTGTGTGTTCTGCTGTGTCTTCTAGTGACAG
  	TACATATAAAAACGACAATTTTAAGGAATATTTAAGGCA
  	TGGTGAAGAATATGACCTGCAGTTTATTTTTCAGTTATG
  	TAAAATAACACTAACAGCAGATGTTATGACATATATTCA
  	TAGTATGAACCCGTCCATTTTAGAGGATTGGAATTTTGG
  	CCTTACACCACCGCCTTCTGGTACCTTAGAGGACACATA
  	TCGCTATGTAACATCACAGGCTGTAACTTGTCAAAAACC
  	CAGTGCACCAAAACCTAAAGATGATCCATTAAAAAATT
  	ATACTTTTTGGGAGGTTGATTTAAAGGAAAAGTTTTCTG
  	CAGACTTAGATCAATTTCCGTTGGGCCGTAAATTTTTGTT
  	ACAAGCAGGACTAAAGGCCAGGCCTAATTTTAGATTAG
  	GCAAGCGTGCAGCTCCAGCATCTACATCTAAAAAATCTT
  	CTACTAAACGTAGAAAAGTAAAAAGT
  HPV39_L1_DX	ATGGCTATGTGGCGGTCTAGTGACAGCATGGTGTATTTG	8
  	CCTCCACCTTCTGTGGCGAAGGTTGTCAATACTGATGAT
  	TATGTTACACGCACAGGCATATATTATTATGCTGGCAGC
  	TCCAGATTATTAACAGTAGGACATCCATATTTTAAAGTG
  	GGTATGAATGGTGGTCGCAAGCAGGACATTCCAAAGGT
  	GTCTGCATATCAATATAGGGTATTTCGCGTGACATTGCC
  	CGATCCTAATAAATTCAGTATTCCAGATGCATCCTTATA
  	TAATCCAGAAACACAACGTTTAGTATGGGCTTGTGTAGG
  	GGTGGAGGTGGGCAGGGGCCAGCCATTGGGTGTTGGTA
  	TTAGTGGACACCCATTATATAATAGACAGGATGATACTG
  	AAAACTCACCATTTTCATCAACCACCAATAAGGACAGTA
  	GGGATAATGTGTCTGTGGATTATAAACAGACACAGTTGT
  	GCATTATAGGCTGTGTTCCCGCCATTGGGGAGCACTGGG
  	GTAAGGGAAAGGCATGCAAGCCCAATAATGTATCTACG
  	GGGGACTGTCCTCCTTTGGAACTAGTAAACACCCCTATT
  	GAGGATGGTGATATGATTGATACTGGCTATGGAGCTATG
  	GACTTTGGTGCATTGCAGGAAACCAAAAGTGAGGTGCC
  	TTTAGATATTTGTCAATCCATTTGTAAATATCCTGATTAT
  	TTGCAAATGTCTGCAGATGTGTATGGGGACAGTATGTTC
  	TTCTGTTTACGTAGGGAACAACTGTTTGCAAGACATTTT
  	TGGAATCGTGGTGGTATGGTGGGTGACGCCATTCCTGCC
  	CAATTGTATATTAAGGGCACAGATATACGTGCAAACCCC
  	GGTAGTTCTGTATACTGCCCCTCTCCCAGCGGTTCCATG
  	GTAACCTCTGATTCCCAGTTATTTAATAAGCCTTATTGGC
  	TACATAAGGCCCAGGGCCACAACAATGGTATATGTTGG
  	CATAATCAATTATTTCTTACTGTTGTGGACACTACCCGTA
  	GTACCAACTTTACATTATCTACCTCTATAGAGTCTTCCAT
  	ACCTTCTACATATGATCCTTCTAAGTTTAAGGAATATAC
  	CAGGCACGTGGAGGAGTATGATTTACAGTTTATATTTCA
  	ACTGTGTACTGTCACATTAACAACTGATGTTATGTCTTAT
  	ATTCACACTATGAATTCCTCTATATTGGACAATTGGAAT
  	TTTGCTGTAGCTCCTCCACCATCTGCCAGTTTGGTAGAC
  	ACTTACAGATACCTACAGTCTGCAGCCATTACATGTCAA
  	AAGGATGCTCCAGCACCTGAAAAGAAAGATCCATATGA
  	CGGTCTAAAGTTTTGGAATGTTGACTTAAGGGAAAAGTT
  	TAGTTTGGAACTTGATCAATTCCCTTTGGGACGTAAATT
  	TTTGTTGCAGGCCAGGGTCCGCAGGCGCCCTACTATAGG
  	TCCCCGAAAGCGGCCTGCTGCATCCACTTCCTCGTCCTC
  	AGCTACTAAACACAAACGTAAACGTGTGTCTAAA
  HPV45_L1_DX	ATGGCTTTGTGGCGGCCTAGTGACAGTACGGTATATCTT	9
  	CCACCACCTTCTGTGGCCAGAGTTGTCAGCACTGATGAT
  	TATGTGTCTCGCACAAGCATATTTTATCATGCAGGCAGT
  	TCCCGATTATTAACTGTAGGCAATCCATATTTTAGGGTT
  	GTACCTAATGGTGCAGGTAATAAACAGGCTGTTCCTAAG
  	GTATCCGCATATCAGTATAGGGTGTTTAGAGTAGCTTTA
  	CCCGATCCTAATAAATTTGGATTACCTGATTCTACTATAT
  	ATAATCCTGAAACACAACGTTTGGTTTGGGCATGTGTAG
  	GTATGGAAATTGGTCGTGGGCAGCCTTTAGGTATTGGCC
  	TAAGTGGCCATCCATTTTATAATAAATTGGATGATACAG
  	AAAGTGCTCATGCAGCTACAGCTGTTATTACGCAGGATG
  	TTAGGGATAATGTGTCAGTTGATTATAAGCAAACACAGC
  	TGTGTATTTTAGGTTGTGTACCTGCTATTGGTGAGCACTG
  	GGCCAAGGGCACACTTTGTAAACCTGCACAATTGCAACC
  	TGGTGACTGTCCTCCTTTGGAACTTAAAAACACCATTAT
  	TGAGGATGGTGATATGGTGGATACAGGTTATGGGGCAA
  	TGGATTTTAGTACATTGCAGGATACAAAGTGCGAGGTTC
  	CATTAGACATTTGTCAATCCATCTGTAAATATCCAGATT
  	ATTTGCAAATGTCTGCTGATCCCTATGGGGATTCTATGTT
  	TTTTTGCCTACGCCGTGAACAACTGTTTGCAAGACATTTT
  	TGGAATAGGGCAGGTGTTATGGGTGACACAGTACCTAC
  	GGACCTATATATTAAAGGCACTAGCGCTAATATGCGTGA
  	AACCCCTGGCAGTTGTGTGTATTCCCCTTCTCCCAGTGG
  	CTCTATTATTACTTCTGATTCTCAATTATTTAATAAGCCA
  	TATTGGTTACATAAGGCCCAGGGCCATAACAATGGTATT
  	TGTTGGCATAATCAGTTGTTTGTTACTGTAGTGGACACT
  	ACCCGCAGTACTAATTTAACATTATGTGCCTCTACACAA
  	AATCCTGTGCCAAGTACATATGACCCTACTAAGTTTAAG
  	CAGTATAGTAGACATGTGGAGGAATATGATTTACAGTTT
  	ATTTTTCAGTTGTGCACTATTACTCTCACTGCAGAGGTTA
  	TGTCATATATCCATAGTATGAATAGTAGTATATTAGAAA
  	ATTGGAATTTTGGTGTCCCTCCACCACCTACTACAAGTTT
  	GGTGGATACATATCGTTTTGTGCAATCAGTTGCTGTTAC
  	CTGTCAAAAGGATACTACACCTCCAGAAAAGCAGGATC
  	CATATGATAAATTAAAGTTTTGGACTGTTGACCTAAAGG
  	AAAAATTTTCCTCCGATTTGGATCAATATCCCCTTGGTC
  	GAAAGTTTTTAGTTCAGGCTGGGTTACGTCGTAGGCCTA
  	CCATAGGACCTCGTAAGCGTCCTGCTGCTTCCACGTCTA
  	CTGCATCTACTGCATCTAGGCCTGCCAAACGTGTACGTA
  	TACGTAGTAAGAAA
  HPV51_L1_DX	ATGGCATTGTGGCGCACTAATGACAGCAAGGTGTATTTG	10
  	CCACCTGCACCTGTGTCTCGAATTGTGAATACAGAAGAA
  	TATATCACACGCACCGGCATATATTACTATGCAGGCAGT
  	TCCAGACTAATAACATTAGGACATCCCTATTTTCCAATA
  	CCTAAAACCTCAACGCGTGCTGCTATTCCTAAAGTATCT
  	GCATTTCAATACAGGGTATTTAGGGTACAGTTACCAGAT
  	CCTAACAAGTTTGGACTCCCGGATCCAAATTTATATAAT
  	CCAGACACAGATAGGTTGGTGTGGGGTTGTGTGGGCGTT
  	GAGGTGGGCAGAGGACAGCCCCTTGGTGTTGGCCTTAGT
  	GGTCATCCCTTATTTAATAAATATGATGACACAGAAAAT
  	TCACGCATAGCAAATGGCAATGCACAACAAGATGTTAG
  	AGATAACACATCTGTTGACAACAAACAGACTCAGTTATG
  	TATAATAGGCTGTGCTCCACCTATTGGGGAACACTGGGG
  	TATTGGCACTACATGCAAAAACACACCTGTACCTCCAGG
  	AGACTGCCCCCCCCTGGAACTTGTATCCTCTGTCATTCA
  	GGATGGCGATATGATTGATACAGGGTTTGGAGCTATGG
  	ATTTCGCTGCCCTACAGGCCACCAAATCAGACGTCCCTT
  	TGGATATTTCACAGTCTGTTTGTAAATATCCTGATTATTT
  	AAAAATGTCTGCAGACACATATGGTAATTCCATGTTTTT
  	TCATTTACGCAGGGAGCAAATCTTTGCTAGGCACTATTA
  	TAATAAACTTGTAGGTGTTGGGGAAGACATTCCTAACGA
  	TTATTATATTAAGGGTAGTGGTAATGGCCGTGACCCTAT
  	AGAAAGTTATATATACTCTGCTACTCCCAGTGGGTCTAT
  	GATAACATCTGATTCTCAAATTTTTAATAAGCCTTATTG
  	GCTCCACCGTGCGCAGGGTCACAATAATGGCATTTGCTG
  	GAACAATCAGCTTTTTATTACCTGTGTTGATACTACCAG
  	AAGTACAAATTTAACTATTAGCACTGCCACTGCTGCGGT
  	TTCCCCAACATTTACTCCAAGTAACTTTAAGCAATATAT
  	TAGGCATGGGGAAGAGTATGAATTGCAATTTATTTTTCA
  	ATTATGTAAAATTACTCTGACTACAGAGGTAATGGCTTA
  	TTTACACACAATGGATCCTACCATTCTTGAACAGTGGAA
  	TTTTGGATTAACATTACCTCCGTCTGCTAGTTTGGAGGAT
  	GCATATAGGTTTGTTAGAAATGCAGCTACTAGCTGTCAA
  	AAGGACACCCCTCCACAGGCTAAGCCAGATCCTTTGGCC
  	AAATATAAATTTTGGGATGTTGATTTAAAGGAACGATTT
  	TCTTTAGATTTAGACCAATTTGCATTGGGTCGCAAGTTTT
  	TGTTGCAGGTTGGCGTACAACGCAAGCCCAGACCAGGC
  	CTTAAACGCCCGGCCTCATCGGCATCCTCTTCCTCTTCCT
  	CTTCAGCCAAACGTAAACGTGTTAAAAAG
  HPV52_L1_DX	ATGTCCGTGTGGCGGCCTAGTGAGGCCACTGTGTACCTG	11
  	CCTCCTGTACCTGTCTCTAAGGTTGTAAGCACTGATGAG
  	TATGTGTCTCGCACAAGCATCTATTATTATGCAGGCAGT
  	TCTCGATTACTAACAGTAGGACATCCCTATTTTTCTATTA
  	AAAACACCAGTAGTGGTAATGGTAAAAAAGTTTTAGTTC
  	CCAAGGTGTCTGGCCTGCAATACAGGGTATTTAGAATTA
  	AATTGCCGGACCCTAATAAATTTGGTTTTCCAGATACAT
  	CTTTTTATAACCCAGAAACCCAAAGGTTGGTGTGGGCCT
  	GTACAGGCTTGGAAATTGGTAGGGGACAGCCTTTAGGT
  	GTGGGTATTAGTGGGCATCCTTTATTAAACAAGTTTGAT
  	GATACTGAAACCAGTAACAAATATGCTGGTAAACCTGG
  	TATAGATAATAGGGAATGTTTATCTATGGATTATAAGCA
  	GACTCAGTTATGCATTTTAGGATGCAAACCTCCTATAGG
  	TGAACATTGGGGTAAGGGAACCCCTTGTAATAATAATTC
  	AGGAAATCCTGGGGATTGTCCTCCCCTACAGCTCATTAA
  	CAGTGTAATACAGGATGGGGACATGGTAGATACAGGAT
  	TTGGTTGCATGGATTTTAATACCTTGCAAGCTAGTAAAA
  	GTGATGTGCCCATTGATATATGTAGCAGTGTATGTAAGT
  	ATCCAGATTATTTGCAAATGGCTAGCGAGCCATATGGTG
  	ACAGTTTGTTCTTTTTTCTTAGACGTGAGCAAATGTTTGT
  	TAGACACTTTTTTAATAGGGCCGGTACCTTAGGTGACCC
  	TGTGCCAGGTGATTTATATATACAAGGGTCTAACTCTGG
  	CAATACTGCCACTGTACAAAGCAGTGCTTTTTTTCCTACT
  	CCTAGTGGTTCTATGGTAACCTCAGAATCCCAATTATTT
  	AATAAACCGTACTGGTTACAACGTGCGCAGGGCCACAA
  	TAATGGCATATGTTGGGGCAATCAGTTGTTTGTCACAGT
  	TGTGGATACCACTCGTAGCACTAACATGACTTTATGTGC
  	TGAGGTTAAAAAGGAAAGCACATATAAAAATGAAAATT
  	TTAAGGAATACCTTCGTCATGGCGAGGAATTTGATTTAC
  	AGTTTATTTTTCAGTTGTGCAAAATTACATTAACAGCTG
  	ATGTTATGACATACATTCATAAGATGGATGCCACTATTT
  	TAGAGGACTGGCAATTTGGCCTTACCCCACCACCGTCTG
  	CATCTTTGGAGGACACATACAGATTTGTCACTTCTACTG
  	CTATAACTTGTCAAAAAAACACACCACCTAAAGGAAAG
  	GAAGATCCTTTAAAGGACTATATGTTTTGGGAGGTGGAT
  	TTAAAAGAAAAGTTTTCTGCAGATTTAGATCAGTTTCCT
  	TTAGGTAGGAAGTTTTTGTTACAGGCAGGGCTACAGGCT
  	AGGCCCAAACTAAAACGCCCTGCATCATCGGCCCCACGT
  	ACCTCCACAAAGAAGAAAAAGGTTAAAAGG
  HPV56_L1_DX	ATGGCGACGTGGCGGCCTAGTGAAAATAAGGTGTATCT	12
  	ACCTCCAACACCTGTTTCAAAGGTTGTGGCAACGGATTC
  	CTATGTAAAACGCACTAGTATATTTTATCATGCAGGCAG
  	TTCACGATTGCTTGCCGTAGGACATCCCTATTACTCTGTG
  	ACTAAGGACAATACCAAAACAAACATTCCCAAAGTTAG
  	TGCATATCAATATAGGGTATTTAGGGTACGGTTGCCCGA
  	CCCTAATAAGTTTGGGCTTCCAGATACTAATATTTATAA
  	TCCGGACCAGGAACGGTTAGTGTGGGCATGTGTAGGTTT
  	GGAGGTAGGCCGCGGACAGCCTTTAGGTGCTGGGCTAA
  	GTGGCCATCCATTGTTTAATAGGCTGGATGATACTGAAA
  	GTTCCAATTTAGCAAATAATAATGTTATAGAAGATAGTA
  	GGGACAATATATCAGTTGATGGCAAGCAAACACAGTTG
  	TGTATTGTTGGATGTACTCCCGCTATGGGTGAACATTGG
  	ACTAAAGGTGCTGTGTGTAAGTCCACACAAGTTACCACA
  	GGGGACTGCCCGCCTCTTGCATTAATTAATACACCTATA
  	GAGGATGGGGACATGATAGACACAGGATTTGGCGCTAT
  	GGACTTTAAGGTGTTGCAGGAATCTAAGGCTGAGGTACC
  	TTTAGACATTGTACAATCCACCTGTAAATATCCTGACTA
  	TTTAAAAATGTCTGCAGATGCCTATGGTGATTCTATGTG
  	GTTTTACTTACGCAGGGAACAATTATTTGCCAGACATTA
  	TTTTAATAGGGCTGGTAAAGTTGGGGAAACAATACCTGC
  	AGAGTTATATTTAAAGGGTAGCAATGGTAGAGAACCCC
  	CTCCGAGTTCTGTATATGTTGCTACGCCTAGTGGGTCTAT
  	GATTACGTCTGAGGCACAGTTATTTAATAAACCTTATTG
  	GTTGCAACGTGCCCAAGGCCATAATAATGGCATTTGCTG
  	GGGTAATCAATTATTTGTTACTGTAGTAGATACTACTAG
  	AAGTACTAACATGACTATTAGTACTGCTACAGAACAGCT
  	CAGTAAATATGATGCACGAAAAATTAATCAGTACCTTAG
  	ACATGTGGAGGAATATGAATTACAATTTGTTTTTCAATT
  	ATGCAAAATTACTTTGTCTGCAGAGGTTATGGCATATTT
  	ACATAATATGAATGCTAACCTACTGGAGGACTGGAATAT
  	TGGGTTATCCCCGCCAGTGGCCACCAGCCTAGAAGATAA
  	ATATAGATATGTTAGAAGCACAGCTATAACATGTCAACG
  	GGAACAGCCACCAACAGAAAAACAGGACCCATTAGCTA
  	AATATAAATTTTGGGATGTTAACTTACAGGACAGTTTTT
  	CTACAGACCTGGATCAATTTCCACTGGGTAGAAAATTTT
  	TAATGCAACTGGGCACTAGGTCAAAGCCTGCTGTAGCTA
  	CCTCTAAAAAGCGATCTGCTCCTACCTCCACCTCTACAC
  	CAGCAAAACGTAAAAGGCGG
  HPV58_L1_DX	ATGTCCGTGTGGCGGCCTAGTGAGGCCACTGTGTACCTG	13
  	CCTCCTGTGCCTGTGTCTAAGGTTGTAAGCACTGATGAA
  	TATGTGTCACGCACAAGCATTTATTATTATGCTGGCAGT
  	TCCAGACTTTTGGCTGTTGGCAATCCATATTTTTCCATCA
  	AAAGTCCCAATAACAATAAAAAAGTATTAGTTCCCAAG
  	GTATCAGGCTTACAGTATAGGGTCTTTAGGGTGCGTTTA
  	CCTGATCCCAATAAATTTGGTTTTCCTGATACATCTTTTT
  	ATAACCCTGATACACAACGTTTGGTCTGGGCATGTGTAG
  	GCCTTGAAATAGGTAGGGGACAGCCATTGGGTGTTGGC
  	GTAAGTGGTCATCCTTATTTAAATAAATTTGATGACACT
  	GAAACCAGTAACAGATATCCCGCACAGCCAGGGTCTGA
  	TAACAGGGAATGCTTATCTATGGATTATAAACAAACACA
  	ATTATGTTTAATTGGCTGTAAACCTCCCACTGGTGAGCA
  	TTGGGGTAAAGGTGTTGCCTGTAACAATAATGCAGCTGC
  	TACTGATTGTCCTCCATTGGAACTTTTTAATTCTATTATT
  	GAGGATGGTGACATGGTAGATACAGGGTTTGGATGCAT
  	GGACTTTGGTACATTGCAGGCTAATAAAAGTGATGTGCC
  	TATTGATATTTGTAACAGTACATGCAAATATCCAGATTA
  	TTTAAAAATGGCCAGTGAACCTTATGGGGATAGTTTGTT
  	CTTTTTTCTTAGACGTGAGCAGATGTTTGTTAGACACTTT
  	TTTAATAGGGCTGGAAAACTTGGCGAGGCTGTCCCGGAT
  	GACCTTTATATTAAAGGGTCCGGTAATACTGCAGTTATC
  	CAAAGTAGTGCATTTTTTCCAACTCCTAGTGGCTCTATA
  	GTTACCTCAGAATCACAATTATTTAATAAGCCTTATTGG
  	CTACAGCGTGCACAAGGTCATAACAATGGCATTTGCTGG
  	GGCAATCAGTTATTTGTTACCGTGGTTGATACCACTCGT
  	AGCACTAATATGACATTATGCACTGAAGTAACTAAGGA
  	AGGTACATATAAAAATGATAATTTTAAGGAATATGTACG
  	TCATGTTGAAGAATATGACCTACAGTTTGTTTTTCAGCTT
  	TGCAAAATTACACTAACTGCAGAGATAATGACATATATA
  	CATACTATGGATTCCAATATTTTGGAGGACTGGCAATTT
  	GGTTTAACACCTCCTCCGTCTGCCAGTTTACAGGACACA
  	TATAGATTTGTTACCTCCCAGGCTATTACTTGCCAAAAA
  	ACAGCACCCCCTAAAGAAAAGGAAGATCCATTAAATAA
  	ATATACTTTTTGGGAGGTTAACTTAAAGGAAAAGTTTTC
  	TGCAGATCTTGATCAGTTTCCTTTGGGACGAAAGTTTTT
  	ATTACAATCAGGCCTTAAAGCAAAGCCCAGACTAAAAC
  	GTTCGGCCCCTACTACCCGTGCACCATCCACCAAACGCA
  	AAAAGGTTAAAAAA
  HPV59_L1_DX	ATGGCTCTATGGCGTTCTAGTGACAACAAGGTGTATCTA	14
  	CCTCCACCTTCGGTAGCTAAGGTTGTCAGCACTGATGAG
  	TATGTCACCCGTACCAGTATTTTCTACCACGCAGGCAGT
  	TCCAGACTTCTTACAGTTGGACATCCATATTTTAAAGTA
  	CCTAAAGGTGGTAATGGTAGACAGGATGTTCCTAAGGT
  	GTCTGCATATCAATACAGAGTATTTAGGGTTAAGTTACC
  	TGATCCCAATAAATTTGGCCTTCCAGATAACACAGTATA
  	TGATCCTAACTCTCAACGCTTGGTCTGGGCCTGTGTAGG
  	TGTTGAAATCGGTCGGGGCCAACCTTTAGGGGTAGGACT
  	CAGTGGTCATCCATTATATAATAAATTGGATGACACTGA
  	AAACTCTCATGTAGCATCTGCTGTTGATACCAAAGATAC
  	ACGTGATAATGTATCTGTGGATTATAAACAAACTCAGCT
  	GTGTATTATTGGCTGTGTACCTGCCATTGGAGAACACTG
  	GACAAAGGGCACTGCTTGTAAGCCTACTACTGTGGTTCA
  	GGGCGATTGTCCTCCACTAGAATTAATAAATACACCAAT
  	TGAAGATGGTGATATGGTAGACACAGGATATGGGGCTA
  	TGGACTTTAAATTGTTGCAGGATAACAAAAGTGAAGTAC
  	CATTGGATATTTGTCAGTCTATTTGTAAATATCCTGATTA
  	TTTACAAATGTCAGCAGATGCTTATGGAGACAGTATGTT
  	TTTTTGTTTAAGGCGAGAACAGGTTTTTGCCAGACATTTT
  	TGGAATAGATCTGGTACTATGGGTGATCAACTTCCTGAA
  	TCACTATATATTAAAGGTACTGACATACGTGCCAACCCA
  	GGCAGTTATTTATATTCCCCTTCCCCAAGTGGGTCTGTG
  	GTTACTTCTGATTCACAATTATTTAATAAACCATATTGGC
  	TGCACAAGGCTCAGGGTTTAAACAATGGTATATGTTGGC
  	ACAATCAATTGTTTTTAACAGTTGTAGATACTACTCGCA
  	GCACCAATCTTTCTGTGTGTGCTTCTACTACTTCTTCTAT
  	TCCTAATGTATACACACCTACCAGTTTTAAAGAATATGC
  	CAGACATGTGGAGGAATTTGATTTGCAGTTTATATTTCA
  	GCTGTGTAAAATAACATTAACTACAGAGGTAATGTCATA
  	CATTCATAATATGAATACCACTATTTTGGAGGATTGGAA
  	TTTTGGTGTTACACCACCTCCTACTGCTAGTTTAGTTGAC
  	ACATACCGTTTTGTTCAATCTGCTGCTGTAACTTGTCAAA
  	AGGACACCGCACCGCCAGTTAAACAGGACCCTTATGAC
  	AAACTAAAGTTTTGGCCTGTAGATCTTAAGGAAAGGTTT
  	TCTGCAGATCTTGATCAGTTTCCTTTGGGACGTAAATTTT
  	TATTGCAATTAGGAGCTAGACCTAAGCCCACTATAGGCC
  	CACGCAAACGTGCAGCGCCTGCCCCTACCTCTACCCCAT
  	CACCAAAACGTGTTAAGCGTCGCAAGTCTTCCAGAAAA
  HPV68_L1_DX	ATGGCATTGTGGCGAGCTAGCGACAACATGGTGTATTTG	15
  	CCTCCCCCCTCAGTGGCGAAGGTTGTCAATACAGATGAT
  	TATGTGACACGCACTGGCATGTATTACTATGCTGGTACA
  	TCTAGGTTATTAACTGTAGGCCATCCATATTTTAAGGTTC
  	CTATGTCTGGGGGCCGCAAGCAGGGCATTCCTAAGGTGT
  	CTGCATATCAATACAGAGTGTTTAGGGTTACCTTACCTG
  	ATCCTAATAAATTTAGTGTTCCTGAGTCTACATTATATA
  	ATCCAGATACACAGCGCATGGTATGGGCCTGTGTTGGTG
  	TTGAAATAGGTAGGGGGCAGCCATTGGGCGTTGGCCTTA
  	GTGGGCATCCACTATATAATAGGCTGGATGATACTGAAA
  	ATTCCCCGTTTTCCTCTAATAAAAATCCTAAAGATAGTA
  	GGGACAATGTTGCAGTGGACTGTAAACAAACACAGCTG
  	TGTATTATAGGCTGTGTTCCTGCTATTGGAGAGCACTGG
  	GCCAAAGGTAAATCTTGTAAGCCTACCAATGTACAACA
  	AGGGGACTGTCCCCCATTGGAATTGGTAAATACTCCTAT
  	TGAGGATGGCGATATGATTGATACAGGATATGGTGCTAT
  	GGACTTTGGTACATTACAAGAAACGAAAAGCGAGGTAC
  	CTTTGGATATATGTCAATCTGTTTGCAAATATCCTGACTA
  	TTTGCAAATGTCTGCAGATGTGTATGGAGACAGTATGTT
  	TTTTTGTTTACGTAGGGAACAGTTATTTGCCAGGCATTTT
  	TGGAATAGGGGAGGCATGGTAGGGGACACTATTCCCAC
  	TGACATGTATATTAAGGGCACTGACATTCGTGAAACTCC
  	TAGTAGTTATGTGTATGCCCCCTCGCCTAGCGGGTCTAT
  	GGTGTCCTCTGACTCCCAGTTATTTAACAAGCCCTATTG
  	GCTGCACAAGGCACAGGGACACAACAATGGTATTTGTT
  	GGCATAATCAATTATTTCTTACCGTTGTGGATACAACGC
  	GCAGTACTAATTTTACATTGTCCACTACTACAGACTCTA
  	CTGTACCAGCTGTGTATGATTCTAATAAATTTAAGGAAT
  	ATGTTAGGCATGTTGAGGAATATGATTTGCAGTTTATAT
  	TTCAGTTGTGTACTATAACATTATCCACTGACGTAATGT
  	CATATATACATACTATGAATCCTGCTATTTTGGATGATT
  	GGAATTTTGGTGTTGCCCCTCCACCATCTGCTAGTCTTGT
  	AGATACATACCGCTACCTACAATCAGCAGCAATTACATG
  	TCAAAAGGACGCCCCTGCACCTGTTAAAAAAGATCCCTA
  	TGATGGTCTTAACTTTTGGAATGTGGATTTAAAGGAAAA
  	GTTTAGTTCTGAACTGGACCAATTCCCATTAGGACGCAA
  	ATTTCTGTTACAGGCAGGTGTTCGCAGACGGCCCACCAT
  	AGGCCCTCGTAAACGCACTGCCACTGCAGCTACCACATC
  	TACCTCTAAACACAAACGTAAACGTGTGTCAAAA
  HPV73_L1_DX	ATGTGGCGACCTACTGATGCAAAGGTATACCTGCCCCCT	16
  	GTGTCTGTGTCTAAGGTTGTAAGCACAGATGAATATGTA
  	ACAAGAACAAATATATATTATTATGCAGGTAGCACACGT
  	TTGTTGGCTGTGGGACACCCATATTTTCCTATCAAGGAT
  	TCTCAAAAACGTAAAACCATAGTTCCTAAAGTTTCAGGT
  	TTGCAATACAGGGTGTTTAGGCTTCGTTTACCAGATCCT
  	AATAAATTTGGATTTCCAGATGCATCCTTTTATAATCCTG
  	ATAAGGAGCGCCTAGTATGGGCCTGTTCTGGTGTGGAGG
  	TTGGACGTGGACAACCCTTAGGTATAGGTACTAGTGGCA
  	ATCCATTTATGAATAAATTAGATGATACTGAAAATGCTC
  	CTAAATACATTGCTGGACAAAATACAGATGGTAGAGAA
  	TGTATGTCAGTGGATTATAAACAAACACAGTTGTGTATT
  	TTAGGTTGTAGGCCTCCCTTAGGGGAACATTGGGGTCCA
  	GGCACGCCATGTACTTCACAAACTGTTAATACTGGTGAT
  	TGTCCCCCACTGGAATTAAAGAACACCCCTATACAGGAT
  	GGTGATATGATAGATGTTGGCTTTGGAGCCATGGATTTT
  	AAAGCTTTACAAGCAAATAAAAGTGATGTACCTATTGAT
  	ATTTCTAACACTACCTGTAAATACCCAGATTATTTAGGC
  	ATGGCTGCTGATCCCTATGGTGATTCCATGTGGTTTTATC
  	TTCGTAGGGAACAAATGTTTGTTCGACACTTATTTAACA
  	GGGCTGGTGATACCGGTGATAAAATCCCAGATGACCTA
  	ATGATTAAAGGCACAGGCAATACTGCAACACCATCCAG
  	TTGTGTTTTTTATCCTACACCTAGTGGTTCCATGGTTTCT
  	TCAGATGCACAGTTGTTTAATAAACCTTATTGGTTGCAA
  	AAGGCACAGGGACAAAATAATGGTATTTGTTGGCATAA
  	TCAATTATTTTTAACTGTTGTAGATACTACTAGAAGCAC
  	TAATTTTTCTGTATGTGTAGGTACACAGGCTAGTAGCTC
  	TACTACAACGTATGCCAACTCTAATTTTAAGGAATATTT
  	AAGACATGCAGAAGAGTTTGACTTACAGTTTGTTTTTCA
  	GTTATGTAAAATTAGTTTAACCACTGAGGTGATGACATA
  	TATCCATTCTATGAATTCTACTATATTGGAAGAGTGGAA
  	TTTTGGTCTTACCCCACCACCGTCAGGTACTTTAGAGGA
  	AACATATAGATATGTAACATCACAGGCTATTAGTTGCCA
  	ACGTCCTCAACCTCCTAAAGAAACAGAGGACCCATATG
  	CCAAGCTATCCTTTTGGGATGTAGATCTTAAGGAAAAGT
  	TTTCTGCAGAATTAGACCAGTTTCCTTTGGGAAGAAAAT
  	TTTTATTACAACTTGGTATGCGTGCACGTCCTAAGTTAC
  	AAGCTTCTAAACGTTCTGCATCTGCTACCACAAGTGCCA
  	CACCTAAGAAAAAACGTGCTAAACGTATT
  HPV82_L1_DX	ATGGCTTTGTGGCGTACTAATGACAGCAAAGTGTATTTA	17
  	CCACCTGCACCAGTGTCACGCATTGTCAACACAGAAGA
  	ATATATAACCCGCACCGGCATATATTATTATGCAGGCAG
  	TTCCAGACTTATTACCTTAGGACATCCATATTTTTCAATA
  	CCCAAAACCAATACACGTGCTGAAATACCTAAGGTATCT
  	GCCTTTCAGTATAGGGTGTTTAGGGTACAGTTACCTGAC
  	CCCAACAAATTTGGTCTTCCTGATCCTAATTTGTTTAATC
  	CAGACACAGATCGTTTGGTGTGGGGATGTGTTGGTGTTG
  	AAGTAGGTAGGGGTCAGCCGTTAGGTGTTGGCCTTAGTG
  	GTCATCCTTTATTTAATAAGTATGATGATACTGAAAACT
  	CTAGGTTTGCCAATGGCAACGACCAACAGGATGTTAGG
  	GACAACATATCTGTGGACAACAAACAAACTCAGTTATG
  	CATTATAGGCTGCGCTCCTCCTATTGGGGAACACTGGGC
  	CACAGGTACCACATGTAAAAACGTACCTGTACCTCAGG
  	GTGACTGTCCACCTTTGGAACTTGTGTCTACTGTCATTGA
  	GGATGGCGATATGGTGGACACTGGTTTTGGGGCCATGG
  	ATTTTGCTAATTTACAAGCTACTAAATCAGATGTTCCATT
  	GGATATTGCTCAGTCTGTGTGTAAATACCCTGATTACTT
  	AAAAATGTCAGCAGATACATATGGCAATTCTATGTTTTT
  	TCATTTACGCAGGGAGCAAATATTTGCTAGGCATTACTA
  	TAATAAGGCTGGTGTGGTTGGTGATGCCATTCCAGACAA
  	GGCTTATATTAAGGGTACTGGTGCTGGCCGCGACCCTAT
  	TAGTAGTTATATTTATTCAGCTACTCCCAGTGGTTCTATG
  	ATAACCTCTGATTCTCAGATTTTTAATAAGCCTTATTGGT
  	TGCATCGCGCCCAGGGCCACAATAATGGCATTTGCTGGA
  	ATAATCAGCTTTTTATTACTTGTGTTGACACTACTAAAA
  	GTACCAATTTAACCATTAGCACTGCTGTTACTCCATCTGT
  	TGCACAAACATTTACTCCAGCAAACTTTAAGCAGTACAT
  	TAGGCATGGGGAAGAATATGAATTGCAATTTATATTTCA
  	ATTGTGTAAAATCACTTTAACTACTGAAATTATGGCTTA
  	CCTGCACACCATGGATTCTACAATTTTAGAACAGTGGAA
  	TTTTGGATTAACATTGCCCCCCTCCGCTAGTTTGGAGGA
  	TGCCTATCGATTTGTAAAAAATGCAGCAACATCCTGTCA
  	CAAGGACAGTCCTCCACAGGCTAAAGAAGACCCTTTGG
  	CAAAATATAAATTTTGGAATGTAGACCTTAAGGAACGCT
  	TTTCTTTGGATTTGGATCAGTTTGCATTGGGTCGCAAGTT
  	TTTATTACAAATCGGTGCCCAACGCAAACCCAGACCAGG
  	CCTTAAAAGGCCTGCCCCATCCTCTTCCGCTTCCTCGTCT
  	GCCAAACGTAAAAGGGTTAAAAAA
  IgK_HPV18_E7_Rb_mut	ATGGAGACCCCCGCCCAGCTGCTGTTCCTGCTGCTGCTG	18
  	TGGCTGCCCGACACCACCGGCCACGGCCCCAAGGCCAC
  	CCTGCAGGACATCGTGCTGCACCTGGAGCCCCAGAACG
  	AGATCCCCGTGGACCTGCTGGGCCACGGCCAGCTGAGC
  	GACAGCGAGGAGGAGAACGACGAGATCGACGGCGTGA
  	ACCACCAGCACCTGCCCGCCAGAAGAGCCGAGCCCCAG
  	AGACACACCATGCTGTGCATGTGCTGCAAGTGCGAGGC
  	CAGAATCAAGCTGGTGGTGGAGAGCAGCGCCGACGACC
  	TGAGAGCCTTCCAGCAGCTGTTCCTGAACACCCTGAGCT
  	TCGTGTGCCCCTGGTGCGCCAGCCAGCAG
  HPV18_E7_Rb_mut	ATGCACGGCCCCAAGGCCACCCTGCAGGACATCGTGCT	19
  	GCACCTGGAGCCCCAGAACGAGATCCCCGTGGACCTGC
  	TGGGCCACGGCCAGCTGAGCGACAGCGAGGAGGAGAAC
  	GACGAGATCGACGGCGTGAACCACCAGCACCTGCCCGC
  	CAGAAGAGCCGAGCCCCAGAGACACACCATGCTGTGCA
  	TGTGCTGCAAGTGCGAGGCCAGAATCAAGCTGGTGGTG
  	GAGAGCAGCGCCGACGACCTGAGAGCCTTCCAGCAGCT
  	GTTCCTGAACACCCTGAGCTTCGTGTGCCCCTGGTGCGC
  	CAGCCAGCAG
  IgK_HPV16_E7_Rb_mut	ATGGAGACCCCCGCCCAGCTGCTGTTCCTGCTGCTGCTG	20
  	TGGCTGCCCGACACCACCGGCCACGGCGACACCCCCAC
  	CCTGCACGAGTACATGCTGGACCTGCAGCCCGAGACCA
  	CCGACCTGTACGGCTACGGCCAGCTGAACGACAGCAGC
  	GAGGAGGAGGACGAGATCGACGGCCCCGCCGGCCAGGC
  	CGAGCCCGACAGAGCCCACTACAACATCGTGACCTTCTG
  	CTGCAAGTGCGACAGCACCCTGAGACTGTGCGTGCAGA
  	GCACCCACGTGGACATCAGAACCCTGGAGGACCTGCTG
  	ATGGGCACCCTGGGCATCGTGTGCCCCATCTGCAGCCAG
  	AAGCCC
  HPV16_E7_Rb_mut	ATGCACGGCGACACCCCCACCCTGCACGAGTACATGCTG	21
  	GACCTGCAGCCCGAGACCACCGACCTGTACGGCTACGG
  	CCAGCTGAACGACAGCAGCGAGGAGGAGGACGAGATCG
  	ACGGCCCCGCCGGCCAGGCCGAGCCCGACAGAGCCCAC
  	TACAACATCGTGACCTTCTGCTGCAAGTGCGACAGCACC
  	CTGAGACTGTGCGTGCAGAGCACCCACGTGGACATCAG
  	AACCCTGGAGGACCTGCTGATGGGCACCCTGGGCATCGT
  	GTGCCCCATCTGCAGCCAGAAGCCC
  IgK_HPV18_E6_p53_mutdel	ATGGAGACCCCCGCCCAGCTGCTGTTCCTGCTGCTGCTG	22
  	TGGCTGCCCGACACCACCGGCGCCAGATTCGAGGACCC
  	CACCAGAAGCGGCTACAAGCTGCCCGACCTGTGCACCG
  	AGCTGAACACCAGCCTGCAGGACATCGAGATCACCTGC
  	GTGTACTGCAAGACCGTGCTGGAGCTGACCGAGGTGTTC
  	GAGAAGGACCTGTTCGTGGTGTACAGAGACAGCATCCC
  	CCACGCCGCCTGCCACAAGTGCATCGACTTCTACAGCAG
  	AATCAGAGAGCTGAGACACTACAGCGACAGCGTGTACG
  	GCGACACCCTGGAGAAGCTGACCAACACCGGCCTGTAC
  	AACCTGCTGATCAGATGCCTGAGATGCCAGAAGCCCCTG
  	CTGAGACACCTGAACGAGAAGAGAAGATTCCACAACAT
  	CGCCGGCCACTACAGAGGCCAGTGCCACAGCTGCTGCA
  	ACAGAGCCAGACAGGAGAGACTGCAGAGAAGAAGAGA
  	GACCCAGGTG
  HPV18_E6_p53_mutdel	ATGGCCAGATTCGAGGACCCCACCAGAAGCGGCTACAA	23
  	GCTGCCCGACCTGTGCACCGAGCTGAACACCAGCCTGCA
  	GGACATCGAGATCACCTGCGTGTACTGCAAGACCGTGCT
  	GGAGCTGACCGAGGTGTTCGAGAAGGACCTGTTCGTGG
  	TGTACAGAGACAGCATCCCCCACGCCGCCTGCCACAAGT
  	GCATCGACTTCTACAGCAGAATCAGAGAGCTGAGACAC
  	TACAGCGACAGCGTGTACGGCGACACCCTGGAGAAGCT
  	GACCAACACCGGCCTGTACAACCTGCTGATCAGATGCCT
  	GAGATGCCAGAAGCCCCTGCTGAGACACCTGAACGAGA
  	AGAGAAGATTCCACAACATCGCCGGCCACTACAGAGGC
  	CAGTGCCACAGCTGCTGCAACAGAGCCAGACAGGAGAG
  	ACTGCAGAGAAGAAGAGAGACCCAGGTG
  IgK_HPV16_E6_p53_mutdel	ATGGAGACCCCCGCCCAGCTGCTGTTCCTGCTGCTGCTG	24
  	TGGCTGCCCGACACCACCGGCCACCAGAAGAGAACCGC
  	CATGTTCCAGGACCCCCAGGAGAGCGGCAGAAAGCTGC
  	CCCAGCTGTGCACCGAGCTGCAGACCACCATCCACGAC
  	ATCATCCTGGAGTGCGTGTACTGCAAGCAGCAGCTGCTG
  	AGAAGAGAGGTGTACGACAGAGACCTGTGCATCGTGTA
  	CAGAGACGGCAACCCCTACGCCGTGTGCGACAAGTGCC
  	TGAAGTTCTACAGCAAGATCAGCGAGTACAGACACTAC
  	TGCTACAGCCTGTACGGCACCACCCTGGAGCAGCAGTAC
  	AACAAGCCCCTGTGCGACCTGCTGATCAGATGCATCAAC
  	TGCCAGAAGCCCCTGCAGAGACACCTGGACAAGAAGCA
  	GAGATTCCACAACATCAGAGGCAGATGGACCGGCAGAT
  	GCATGAGCTGCTGCAGAAGCAGCAGAACCAGAAGAGAG
  	ACCCAGCTG
  HPV16_E6_p53_mutdel	ATGCACCAGAAGAGAACCGCCATGTTCCAGGACCCCCA	463
  	GGAGAGCGGCAGAAAGCTGCCCCAGCTGTGCACCGAGC
  	TGCAGACCACCATCCACGACATCATCCTGGAGTGCGTGT
  	ACTGCAAGCAGCAGCTGCTGAGAAGAGAGGTGTACGAC
  	AGAGACCTGTGCATCGTGTACAGAGACGGCAACCCCTA
  	CGCCGTGTGCGACAAGTGCCTGAAGTTCTACAGCAAGAT
  	CAGCGAGTACAGACACTACTGCTACAGCCTGTACGGCA
  	CCACCCTGGAGCAGCAGTACAACAAGCCCCTGTGCGAC
  	CTGCTGATCAGATGCATCAACTGCCAGAAGCCCCTGCAG
  	AGACACCTGGACAAGAAGCAGAGATTCCACAACATCAG
  	AGGCAGATGGACCGGCAGATGCATGAGCTGCTGCAGAA
  	GCAGCAGAACCAGAAGAGAGACCCAGCTG
  HPV18_E7	ATGCATGGACCTAAGGCAACATTGCAAGACATTGTATTG	25
  	CATTTAGAGCCCCAAAATGAAATTCCGGTTGACCTTCTA
  	TGTCACGAGCAATTAAGCGACTCAGAGGAAGAAAACGA
  	TGAAATAGATGGAGTTAATCATCAACATTTACCAGCCCG
  	ACGAGCCGAACCACAACGTCACACAATGTTGTGTATGTG
  	TTGTAAGTGTGAAGCCAGAATTGAGCTAGTAGTAGAAA
  	GCTCAGCAGACGACCTTCGAGCATTCCAGCAGCTGTTTC
  	TGAACACCCTGTCCTTTGTGTGTCCGTGGTGTGCATCCC
  	AGCAG
  HPV16_E7	ATGCATGGAGATACACCTACATTGCATGAATATATGTTA	26
  	GATTTGCAACCAGAGACAACTGATCTCTACTGTTATGAG
  	CAATTAAATGACAGCTCAGAGGAGGAGGATGAAATAGA
  	TGGTCCAGCTGGACAAGCAGAACCGGACAGAGCCCATT
  	ACAATATTGTAACCTTTTGTTGCAAGTGTGACTCTACGC
  	TTCGGTTGTGCGTACAAAGCACACACGTAGACATTCGTA
  	CTTTGGAAGACCTGTTAATGGGCACACTAGGAATTGTGT
  	GCCCCATCTGTTCTCAGAAACCA
  HPV18_E6	ATGGCGCGCTTTGAGGATCCAACACGGCGACCCTACAA	27
  	GCTACCTGATCTGTGCACGGAACTGAACACTTCACTGCA
  	AGACATAGAAATAACCTGTGTATATTGCAAGACAGTATT
  	GGAACTTACAGAGGTATTTGAATTTGCATTTAAAGATTT
  	ATTTGTGGTGTATAGAGACAGTATACCCCATGCTGCATG
  	CCATAAATGTATAGATTTTTATTCCAGAATTAGAGAATT
  	AAGACATTATTCAGACTCTGTGTATGGAGACACATTGGA
  	AAAACTAACTAACACTGGGTTATACAATTTATTAATAAG
  	GTGCCTGCGGTGCCAGAAACCGTTGAATCCAGCAGAAA
  	AACTTAGACACCTTAATGAAAAACGACGATTTCACAAC
  	ATAGCTGGGCACTATAGAGGCCAGTGCCATTCGTGCTGC
  	AACCGAGCACGACAGGAACGACTCCAACGACGCAGAGA
  	AACACAAGTA
  HPV16_E6	ATGCACCAAAAGAGAACTGCAATGTTTCAGGACCCACA	28
  	GGAGCGACCCAGAAAGTTACCACAGTTATGCACAGAGC
  	TGCAAACAACTATACATGATATAATATTAGAATGTGTGT
  	ACTGCAAGCAACAGTTACTGCGACGTGAGGTATATGACT
  	TTGCTTTTCGGGATTTATGCATAGTATATAGAGATGGGA
  	ATCCATATGCTGTATGTGATAAATGTTTAAAGTTTTATTC
  	TAAAATTAGTGAGTATAGACATTATTGTTATAGTTTGTA
  	TGGAACAACATTAGAACAGCAATACAACAAACCGTTGT
  	GTGATTTGTTAATTAGGTGTATTAACTGTCAAAAGCCAC
  	TGTGTCCTGAAGAAAAGCAAAGACATCTGGACAAAAAG
  	CAAAGATTCCATAATATAAGGGGTCGGTGGACCGGTCG
  	ATGTATGTCTTGTTGCAGATCATCAAGAACACGTAGAGA
  	AACCCAGCTG
  mGMCSF	ATGTGGCTTCAAAATCTCTTGTTTCTTGGAATCGTCGTGT	29
  	ACAGCCTGTCAGCCCCAACTAGATCGCCTATCACTGTGA
  	CGCGCCCGTGGAAGCACGTGGAAGCCATCAAGGAGGCT
  	CTGAATCTGCTCGACGATATGCCAGTGACCCTGAACGAG
  	GAAGTCGAAGTGGTGTCCAACGAATTTTCCTTCAAAAAG
  	TTGACCTGTGTTCAGACCCGGCTGAAGATTTTCGAGCAG
  	GGCCTCAGGGGAAACTTCACCAAACTGAAGGGTGCACT
  	GAACATGACCGCCAGCTACTACCAGACCTATTGCCCTCC
  	GACTCCGGAAACTGATTGCGAGACTCAAGTCACCACCTA
  	CGCGGACTTCATCGACTCGCTCAAGACGTTCCTGACTGA
  	CATCCCCTTCGAGTGCAAGAAGCCGGGGCAGAAA
  hGMCSF	ATGTGGCTACAGTCTCTCCTGCTCCTGGGAACCGTGGCT	30
  	TGCAGCATATCAGCGCCTGCCAGGAGCCCCAGCCCATCT
  	ACCCAGCCATGGGAGCACGTAAACGCCATACAGGAAGC
  	CCGGCGGCTGCTTAATCTATCCCGCGATACAGCAGCCGA
  	AATGAACGAAACCGTGGAGGTCATCAGTGAGATGTTTG
  	ATCTACAAGAGCCTACTTGCTTACAAACCCGCCTAGAGC
  	TTTACAAGCAAGGCCTCCGGGGCTCTCTCACAAAGCTGA
  	AAGGTCCATTAACTATGATGGCCTCCCACTATAAACAGC
  	ACTGCCCACCTACACCAGAGACCTCCTGTGCCACCCAGA
  	TTATAACCTTCGAAAGCTTTAAGGAGAATTTAAAGGATT
  	TCCTCCTGGTCATCCCCTTCGACTGCTGGGAACCAGTCC
  	AG

  hMPV mRNA Sequences

  HPV6_L1	AUGUGGCGGCCUAGCGACAGCACAGUAUAUGUGCCUC	431
  	CUCCUAACCCUGUAUCCAAAGUUGUUGCCACGGAUGC
  	UUAUGUUACUCGCACCAACAUAUUUUAUCAUGCCAGC
  	AGUUCCAGACUUCUUGCAGUGGGACAUCCUUAUUUUU
  	CCAUAAAACGGGCUAACAAAACUGUUGUGCCAAAGGU
  	GUCAGGAUAUCAAUACAGGGUAUUUAAGGUGGUGUUA
  	CCAGAUCCUAACAAAUUUGCAUUGCCUGACUCGUCUC
  	UUUUCGAUCCCACAACACAACGUUUAGUAUGGGCAUG
  	CACAGGCCUAGAGGUGGGCAGGGGACAGCCAUUAGGU
  	GUGGGUGUAAGUGGACAUCCUUUCCUAAAUAAAUAUG
  	AUGAUGUUGAAAAUUCAGGGAGUGGUGGUAACCCUGG
  	ACAGGAUAACAGGGUUAAUGUAGGUAUGGAUUAUAAA
  	CAAACACAAUUAUGCAUGGUUGGAUGUGCCCCCCCUU
  	UGGGCGAGCAUUGGGGUAAAGGUAAACAGUGUACUAA
  	UACACCUGUACAGGCUGGUGACUGCCCGCCCUUAGAAC
  	UUAUUACCAGUGUUAUACAGGAUGGCGAUAUGGUUGA
  	CACAGGCUUUGGUGCUAUGAAUUUUGCUGAUUUGCAG
  	ACCAAUAAAUCAGAUGUUCCUAUUGACAUAUGUGGCA
  	CUACAUGUAAAUAUCCAGAUUAUUUACAAAUGGCUGC
  	AGACCCAUAUGGUGAUAGAUUAUUUUUUUUUCUACGG
  	AAGGAACAAAUGUUUGCCAGACAUUUUUUUAACAGGG
  	CUGGCGAGGUGGGGGAACCUGUGCCUGAUACACUUAU
  	AAUUAAGGGUAGUGGAAAUCGCACGUCUGUAGGGAGU
  	AGUAUAUAUGUUAACACCCCGAGCGGCUCUUUGGUGU
  	CCUCUGAGGCACAAUUGUUUAAUAAGCCAUAUUGGCU
  	ACAAAAAGCCCAGGGACAUAACAAUGGUAUUUGUUGG
  	GGUAAUCAACUGUUUGUUACUGUGGUAGAUACCACAC
  	GCAGUACCAACAUGACAUUAUGUGCAUCCGUAACUAC
  	AUCUUCCACAUACACCAAUUCUGAUUAUAAAGAGUAC
  	AUGCGUCAUGUGGAAGAGUAUGAUUUACAAUUUAUUU
  	UUCAAUUAUGUAGCAUUACAUUGUCUGCUGAAGUAAU
  	GGCCUAUAUUCACACAAUGAAUCCCUCUGUUUUGGAA
  	GACUGGAACUUUGGGUUAUCGCCUCCCCCAAAUGGUA
  	CAUUAGAAGAUACCUAUAGGUAUGUGCAGUCACAGGC
  	CAUUACCUGUCAAAAGCCCACUCCUGAAAAGGAAAAG
  	CCAGAUCCCUAUAAGAACCUUAGUUUUUGGGAGGUUA
  	AUUUAAAAGAAAAGUUUUCUAGUGAAUUGGAUCAGUA
  	UCCUUUGGGACGCAAGUUUUUGUUACAAAGUGGAUAU
  	AGGGGACGGUCCUCUAUUCGUACAGGUGUUAAGCGCC
  	CUGCUGUUUCCAAAGCCUCUGCUGCCCCUAAACGUAAG
  	CGCGCCAAAACUAAAAGG
  HPV11_L1	AUGUGGCGGCCUAGCGACAGCACAGUAUAUGUGCCUC	432
  	CUCCCAACCCUGUAUCCAAGGUUGUUGCCACGGAUGCG
  	UAUGUUAAACGCACCAACAUAUUUUAUCAUGCCAGCA
  	GUUCCAGACUCCUUGCUGUGGGACAUCCAUAUUACUC
  	UAUCAAAAAAGUUAACAAAACAGUUGUACCAAAGGUG
  	UCUGGAUAUCAAUAUAGAGUGUUUAAGGUAGUGUUGC
  	CAGAUCCUAACAAGUUUGCAUUACCUGAUUCAUCCCU
  	GUUUGACCCCACUACACAGCGUUUAGUAUGGGCGUGC
  	ACAGGGUUGGAGGUAGGCAGGGGUCAACCUUUAGGCG
  	UUGGUGUUAGUGGGCAUCCAUUGCUAAACAAAUAUGA
  	UGAUGUAGAAAAUAGUGGUGGGUAUGGUGGUAAUCCU
  	GGUCAGGAUAAUAGGGUUAAUGUAGGUAUGGAUUAUA
  	AACAAACCCAGCUAUGUAUGGUGGGCUGUGCUCCACC
  	GUUAGGUGAACAUUGGGGUAAGGGUACACAAUGUUCA
  	AAUACCUCUGUACAAAAUGGUGACUGCCCCCCGUUGG
  	AACUUAUUACCAGUGUUAUACAGGAUGGGGACAUGGU
  	UGAUACAGGCUUUGGUGCUAUGAAUUUUGCAGACUUA
  	CAAACCAAUAAAUCGGAUGUUCCCCUUGAUAUUUGUG
  	GAACUGUCUGCAAAUAUCCUGAUUAUUUGCAAAUGGC
  	UGCAGACCCUUAUGGUGAUAGGUUGUUUUUUUAUUUG
  	CGAAAGGAACAAAUGUUUGCUAGACACUUUUUUAAUA
  	GGGCCGGUACUGUGGGGGAACCUGUGCCUGAUGACCU
  	GUUGGUAAAAGGGGGUAAUAACAGAUCAUCUGUAGCU
  	AGUAGUAUUUAUGUACAUACACCUAGUGGCUCAUUGG
  	UGUCUUCAGAGGCUCAAUUAUUUAAUAAACCAUAUUG
  	GCUUCAAAAGGCUCAGGGACAUAACAAUGGUAUUUGC
  	UGGGGAAACCACUUGUUUGUUACUGUGGUAGAUACCA
  	CACGCAGUACAAAUAUGACACUAUGUGCAUCUGUGUC
  	UAAAUCUGCUACAUACACUAAUUCAGAUUAUAAGGAA
  	UACAUGCGCCAUGUGGAGGAGUUUGAUUUACAGUUUA
  	UUUUUCAAUUGUGUAGCAUUACAUUAUCUGCAGAAGU
  	CAUGGCCUAUAUACACACAAUGAAUCCUUCUGUUUUG
  	GAGGACUGGAACUUUGGUUUAUCGCCUCCACCAAAUG
  	GUACACUGGAGGAUACUUAUAGAUAUGUACAGUCACA
  	GGCCAUUACCUGUCAGAAACCCACACCUGAAAAAGAA
  	AAACAGGAUCCCUAUAAGGAUAUGAGUUUUUGGGAGG
  	UUAACUUAAAAGAAAAGUUUUCAAGUGAAUUAGAUCA
  	GUUUCCCCUUGGACGUAAGUUUUUAUUGCAAAGUGGA
  	UAUCGAGGACGGACGUCUGCUCGUACAGGUAUAAAGC
  	GCCCAGCUGUGUCUAAGCCCUCUACAGCCCCCAAACGA
  	AAACGUACCAAAACCAAAAAG
  HPV16_L1	AUGUCUCUUUGGCUGCCUAGUGAGGCCACUGUCUACU	433
  	UGCCUCCUGUCCCAGUAUCUAAGGUUGUAAGCACGGA
  	UGAAUAUGUUGCACGCACAAACAUAUAUUAUCAUGCA
  	GGAACAUCCAGACUACUUGCAGUUGGACAUCCCUAUU
  	UUCCUAUUAAAAAACCUAACAAUAACAAAAUAUUAGU
  	UCCUAAAGUAUCAGGAUUACAAUACAGGGUAUUUAGA
  	AUACAUUUACCUGACCCCAAUAAGUUUGGUUUUCCUG
  	ACACCUCAUUUUAUAAUCCAGAUACACAGCGGCUGGU
  	UUGGGCCUGUGUAGGUGUUGAGGUAGGUCGUGGUCAG
  	CCAUUAGGUGUGGGCAUUAGUGGCCAUCCUUUAUUAA
  	AUAAAUUGGAUGACACAGAAAAUGCUAGUGCUUAUGC
  	AGCAAAUGCAGGUGUGGAUAAUAGAGAAUGUAUAUCU
  	AUGGAUUACAAACAAACACAAUUGUGUUUAAUUGGUU
  	GCAAACCACCUAUAGGGGAACACUGGGGCAAAGGAUC
  	CCCAUGUACCAAUGUUGCAGUAAAUCCAGGUGAUUGU
  	CCACCAUUAGAGUUAAUAAACACAGUUAUUCAGGAUG
  	GUGAUAUGGUUGAUACUGGCUUUGGUGCUAUGGACUU
  	UACUACAUUACAGGCUAACAAAAGUGAAGUUCCACUG
  	GAUAUUUGUACAUCUAUUUGCAAAUAUCCAGAUUAUA
  	UUAAAAUGGUGUCAGAACCAUAUGGCGACAGCUUAUU
  	UUUUUAUUUACGAAGGGAACAAAUGUUUGUUAGACAU
  	UUAUUUAAUAGGGCUGGUACUGUUGGUGAAAAUGUAC
  	CAGACGAUUUAUACAUUAAAGGCUCUGGGUCUACUGC
  	AAAUUUAGCCAGUUCAAAUUAUUUUCCUACACCUAGU
  	GGUUCUAUGGUUACCUCUGAUGCCCAAAUAUUCAAUA
  	AACCUUAUUGGUUACAACGAGCACAGGGCCACAAUAA
  	UGGCAUUUGUUGGGGUAACCAACUAUUUGUUACUGUU
  	GUUGAUACUACACGCAGUACAAAUAUGUCAUUAUGUG
  	CUGCCAUAUCUACUUCAGAAACUACAUAUAAAAAUAC
  	UAACUUUAAGGAGUACCUACGACAUGGGGAGGAAUAU
  	GAUUUACAGUUUAUUUUUCAACUGUGCAAAAUAACCU
  	UAACUGCAGACGUUAUGACAUACAUACAUUCUAUGAA
  	UUCCACUAUUUUGGAGGACUGGAAUUUUGGUCUACAA
  	CCUCCCCCAGGAGGCACACUAGAAGAUACUUAUAGGU
  	UUGUAACAUCCCAGGCAAUUGCUUGUCAAAAACAUAC
  	ACCUCCAGCACCUAAAGAAGAUCCCCUUAAAAAAUAC
  	ACUUUUUGGGAAGUAAAUUUAAAGGAAAAGUUUUCUG
  	CAGACCUAGAUCAGUUUCCUUUAGGACGCAAAUUUUU
  	ACUACAAGCAGGAUUGAAGGCCAAACCAAAAUUUACA
  	UUAGGAAAACGAAAAGCUACACCCACCACCUCAUCUAC
  	CUCUACAACUGCUAAACGCAAAAAACGUAAGCUG
  HPV18_L1	AUGGCUUUGUGGCGGCCUAGUGACAAUACCGUAUAUC	434
  	UUCCACCUCCUUCUGUGGCAAGAGUUGUAAAUACCGA
  	UGAUUAUGUGACUCGCACAAGCAUAUUUUAUCAUGCU
  	GGCAGCUCCAGAUUAUUAACUGUUGGUAAUCCAUAUU
  	UUAGGGUUCCUGCAGGUGGUGGCAAUAAGCAGGAUAU
  	UCCUAAGGUUUCUGCAUACCAAUAUAGAGUAUUUAGG
  	GUGCAGUUACCUGACCCAAAUAAAUUUGGUUUACCUG
  	AUACUAGUAUUUAUAAUCCUGAAACACAACGUUUAGU
  	GUGGGCCUGUGCUGGAGUGGAAAUUGGCCGUGGUCAG
  	CCUUUAGGUGUUGGCCUUAGUGGGCAUCCAUUUUAUA
  	AUAAAUUAGAUGACACUGAAAGUUCCCAUGCCGCCAC
  	GUCUAAUGUUUCUGAGGACGUUAGGGACAAUGUGUCU
  	GUAGAUUAUAAGCAGACACAGUUAUGUAUUUUGGGCU
  	GUGCCCCUGCUAUUGGGGAACACUGGGCUAAAGGCAC
  	UGCUUGUAAAUCGCGUCCUUUAUCACAGGGCGAUUGC
  	CCCCCUUUAGAACUUAAAAACACAGUUUUGGAAGAUG
  	GUGAUAUGGUAGAUACUGGAUAUGGUGCCAUGGACUU
  	UAGUACAUUGCAAGAUACUAAAUGUGAGGUACCAUUG
  	GAUAUUUGUCAGUCUAUUUGUAAAUAUCCUGAUUAUU
  	UACAAAUGUCUGCAGAUCCUUAUGGGGAUUCCAUGUU
  	UUUUUGCUUACGGCGUGAGCAGCUUUUUGCUAGGCAU
  	UUUUGGAAUAGAGCAGGUACUAUGGGUGACACUGUGC
  	CUCAAUCCUUAUAUAUUAAAGGCACAGGUAUGCGUGC
  	UUCACCUGGCAGCUGUGUGUAUUCUCCCUCUCCAAGU
  	GGCUCUAUUGUUACCUCUGACUCCCAGUUGUUUAAUA
  	AACCAUAUUGGUUACAUAAGGCACAGGGUCAUAACAA
  	UGGUGUUUGCUGGCAUAAUCAAUUAUUUGUUACUGUG
  	GUAGAUACCACUCGCAGUACCAAUUUAACAAUAUGUG
  	CUUCUACACAGUCUCCUGUACCUGGGCAAUAUGAUGC
  	UACCAAAUUUAAGCAGUAUAGCAGACAUGUUGAGGAA
  	UAUGAUUUGCAGUUUAUUUUUCAGUUGUGUACUAUUA
  	CUUUAACUGCAGAUGUUAUGUCCUAUAUUCAUAGUAU
  	GAAUAGCAGUAUUUUAGAGGAUUGGAACUUUGGUGUU
  	CCCCCCCCGCCAACUACUAGUUUGGUGGAUACAUAUCG
  	UUUUGUACAAUCUGUUGCUAUUACCUGUCAAAAGGAU
  	GCUGCACCGGCUGAAAAUAAGGAUCCCUAUGAUAAGU
  	UAAAGUUUUGGAAUGUGGAUUUAAAGGAAAAGUUUUC
  	UUUAGACUUAGAUCAAUAUCCCCUUGGACGUAAAUUU
  	UUGGUUCAGGCUGGAUUGCGUCGCAAGCCCACCAUAG
  	GCCCUCGCAAACGUUCUGCUCCAUCUGCCACUACGUCU
  	UCUAAACCUGCCAAGCGUGUGCGUGUACGUGCCAGGA
  	AG
  HPV31_L1	AUGUCUCUGUGGCGGCCUAGCGAGGCUACUGUCUACU	435
  	UACCACCUGUCCCAGUGUCUAAAGUUGUAAGCACGGA
  	UGAAUAUGUAACACGAACCAACAUAUAUUAUCACGCA
  	GGCAGUGCUAGGCUGCUUACAGUAGGCCAUCCAUAUU
  	AUUCCAUACCUAAAUCUGACAAUCCUAAAAAAAUAGU
  	UGUACCAAAGGUGUCAGGAUUACAAUAUAGGGUAUUU
  	AGGGUUCGUUUACCAGAUCCAAACAAAUUUGGAUUUC
  	CUGAUACAUCUUUUUAUAAUCCUGAAACUCAACGCUU
  	AGUUUGGGCCUGUGUUGGUUUAGAGGUAGGUCGCGGG
  	CAGCCAUUAGGUGUAGGUAUUAGUGGUCAUCCAUUAU
  	UAAAUAAAUUUGAUGACACUGAAAACUCUAAUAGAUA
  	UGCCGGUGGUCCUGGCACUGAUAAUAGGGAAUGUAUA
  	UCAAUGGAUUAUAAACAAACACAACUGUGUUUACUUG
  	GUUGCAAACCACCUAUUGGAGAGCAUUGGGGUAAAGG
  	UAGUCCUUGUAGUAACAAUGCUAUUACCCCUGGUGAU
  	UGUCCUCCAUUAGAAUUAAAAAAUUCAGUUAUACAAG
  	AUGGGGAUAUGGUUGAUACAGGCUUUGGAGCUAUGGA
  	UUUUACUGCUUUACAAGACACUAAAAGUAAUGUUCCU
  	UUGGACAUUUGUAAUUCUAUUUGUAAAUAUCCAGAUU
  	AUCUUAAAAUGGUUGCUGAGCCAUAUGGCGAUACAUU
  	AUUUUUUUAUUUACGUAGGGAACAAAUGUUUGUAAGG
  	CAUUUUUUUAAUAGAUCAGGCACGGUUGGUGAAUCGG
  	UCCCUACUGACUUAUAUAUUAAAGGCUCCGGUUCAAC
  	AGCUACUUUAGCUAACAGUACAUACUUUCCUACACCU
  	AGCGGCUCCAUGGUUACUUCAGAUGCACAAAUUUUUA
  	AUAAACCAUAUUGGAUGCAACGUGCUCAGGGACACAA
  	UAAUGGUAUUUGUUGGGGCAAUCAGUUAUUUGUUACU
  	GUGGUAGAUACCACACGUAGUACCAAUAUGUCUGUUU
  	GUGCUGCAAUUGCAAACAGUGAUACUACAUUUAAAAG
  	UAGUAAUUUUAAAGAGUAUUUAAGACAUGGUGAGGAA
  	UUUGAUUUACAAUUUAUAUUUCAGUUAUGCAAAAUAA
  	CAUUAUCUGCAGACAUAAUGACAUAUAUUCACAGUAU
  	GAAUCCUGCUAUUUUGGAAGAUUGGAAUUUUGGAUUG
  	ACCACACCUCCCUCAGGUUCUUUGGAGGAUACCUAUA
  	GGUUUGUCACCUCACAGGCCAUUACAUGUCAAAAAAC
  	UGCCCCCCAAAAGCCCAAGGAAGAUCCAUUUAAAGAU
  	UAUGUAUUUUGGGAGGUUAAUUUAAAAGAAAAGUUUU
  	CUGCAGAUUUAGAUCAGUUUCCACUGGGUCGCAAAUU
  	UUUAUUACAGGCAGGAUAUAGGGCACGUCCUAAAUUU
  	AAAGCAGGUAAACGUAGUGCACCCUCAGCAUCUACCA
  	CUACACCAGCAAAACGUAAAAAAACUAAAAAG
  HPV33_L1	AUGUCCGUGUGGCGGCCUAGUGAGGCCACAGUGUACC	436
  	UGCCUCCUGUACCUGUAUCUAAAGUUGUCAGCACUGA
  	UGAAUAUGUGUCUCGCACAAGCAUUUAUUAUUAUGCU
  	GGUAGUUCCAGACUUCUUGCUGUUGGCCAUCCAUAUU
  	UUUCUAUUAAAAAUCCUACUAACGCUAAAAAAUUAUU
  	GGUACCCAAAGUAUCAGGCUUGCAAUAUAGGGUUUUU
  	AGGGUCCGUUUACCAGAUCCUAAUAAAUUUGGAUUUC
  	CUGACACCUCCUUUUAUAACCCUGAUACACAACGAUU
  	AGUAUGGGCAUGUGUAGGCCUUGAAAUAGGUAGAGGG
  	CAGCCAUUAGGCGUUGGCAUAAGUGGUCAUCCUUUAU
  	UAAACAAAUUUGAUGACACUGAAACCGGUAACAAGUA
  	UCCUGGACAACCGGGUGCUGAUAAUAGGGAAUGUUUA
  	UCCAUGGAUUAUAAACAAACACAGUUAUGUUUACUUG
  	GAUGUAAGCCUCCAACAGGGGAACAUUGGGGUAAAGG
  	UGUUGCUUGUACUAAUGCAGCACCUGCCAAUGAUUGU
  	CCACCUUUAGAACUUAUAAAUACUAUUAUUGAGGAUG
  	GUGAUAUGGUGGACACAGGAUUUGGUUGCAUGGAUUU
  	UAAAACAUUGCAGGCUAAUAAAAGUGAUGUUCCUAUU
  	GAUAUUUGUGGCAGUACAUGCAAAUAUCCAGAUUAUU
  	UAAAAAUGACUAGUGAGCCUUAUGGUGAUAGUUUAUU
  	UUUCUUUCUUCGACGUGAACAAAUGUUUGUAAGACAC
  	UUUUUUAAUAGGGCUGGUACAUUAGGAGAGGCUGUUC
  	CCGAUGACCUGUACAUUAAAGGUUCAGGAACUACUGC
  	CUCUAUUCAAAGCAGUGCUUUUUUUCCCACUCCUAGU
  	GGAUCAAUGGUUACUUCCGAAUCUCAGUUAUUUAAUA
  	AGCCAUAUUGGCUACAACGUGCACAAGGUCAUAAUAA
  	UGGUAUUUGUUGGGGCAAUCAGGUAUUUGUUACUGUG
  	GUAGAUACCACUCGCAGUACUAAUAUGACUUUAUGCA
  	CACAAGUAACUAGUGACAGUACAUAUAAAAAUGAAAA
  	UUUUAAAGAAUAUAUAAGACAUGUUGAAGAAUAUGAU
  	CUACAGUUUGUUUUUCAACUAUGCAAAGUUACCUUAA
  	CUGCAGAAGUUAUGACAUAUAUUCAUGCUAUGAAUCC
  	AGAUAUUUUAGAAGAUUGGCAAUUUGGUUUAACACCU
  	CCUCCAUCUGCUAGUUUACAGGAUACCUAUAGGUUUG
  	UUACCUCUCAGGCUAUUACGUGUCAAAAAACAGUACC
  	UCCAAAGGAAAAGGAAGACCCCUUAGGUAAAUAUACA
  	UUUUGGGAAGUGGAUUUAAAGGAAAAAUUUUCAGCAG
  	AUUUAGAUCAGUUUCCUUUGGGACGCAAGUUUUUAUU
  	ACAGGCAGGUCUUAAAGCAAAACCUAAACUUAAACGU
  	GCAGCCCCCACAUCCACCCGCACAUCGUCUGCAAAACG
  	CAAAAAGGUUAAAAAA
  HPV35_L1_DX	AUGUCUCUGUGGCGGUCUAACGAAGCCACUGUCUACC	437
  	UGCCUCCAGUGUCAGUGUCUAAGGUUGUUAGCACUGA
  	UGAAUAUGUAACACGCACAAACAUCUACUAUCAUGCA
  	GGCAGUUCUAGGCUAUUAGCUGUGGGUCACCCAUACU
  	AUGCUAUUAAAAAACAAGAUUCUAAUAAAAUAGCAGU
  	ACCCAAGGUAUCUGGUUUGCAAUACAGAGUAUUUAGA
  	GUAAAAUUACCAGAUCCUAAUAAGUUUGGAUUUCCAG
  	ACACAUCAUUUUAUGAUCCUGCCUCCCAGCGUUUGGU
  	UUGGGCCUGUACAGGAGUUGAAGUAGGUCGUGGUCAG
  	CCAUUGGGUGUAGGUAUUAGUGGUCAUCCUUUACUCA
  	AUAAAUUGGAUGAUACUGAAAAUUCUAAUAAAUAUGU
  	UGGUAACUCUGGUACAGAUAACAGGGAAUGCAUUUCU
  	AUGGAUUAUAAACAAACACAAUUGUGUUUAAUAGGUU
  	GUAGGCCUCCUAUAGGUGAACAUUGGGGAAAAGGCAC
  	ACCUUGUAAUGCUAACCAGGUAAAAGCAGGAGAAUGU
  	CCUCCUUUGGAGUUACUAAACACUGUACUACAAGACG
  	GGGACAUGGUAGACACAGGAUUUGGUGCAAUGGAUUU
  	UACUACAUUACAAGCUAAUAAAAGUGAUGUUCCCCUA
  	GAUAUAUGCAGUUCCAUUUGCAAAUAUCCUGAUUAUC
  	UAAAAAUGGUUUCUGAGCCAUAUGGAGAUAUGUUAUU
  	UUUUUAUCUACGUAGGGAGCAAAUGUUUGUGAGACAU
  	UUAUUUAAUAGGGCUGGAACUGUAGGUGAAACAGUAC
  	CUGCAGACCUAUAUAUUAAGGGUACCACUGGCACAUU
  	GCCUAGUACUAGUUAUUUUCCUACUCCUAGUGGCUCU
  	AUGGUAACCUCCGAUGCACAAAUAUUUAAUAAACCAU
  	AUUGGUUGCAACGUGCACAAGGCCAUAAUAAUGGUAU
  	UUGUUGGAGUAACCAAUUGUUUGUUACUGUAGUUGAU
  	ACAACCCGUAGUACAAAUAUGUCUGUGUGUUCUGCUG
  	UGUCUUCUAGUGACAGUACAUAUAAAAACGACAAUUU
  	UAAGGAAUAUUUAAGGCAUGGUGAAGAAUAUGACCUG
  	CAGUUUAUUUUUCAGUUAUGUAAAAUAACACUAACAG
  	CAGAUGUUAUGACAUAUAUUCAUAGUAUGAACCCGUC
  	CAUUUUAGAGGAUUGGAAUUUUGGCCUUACACCACCG
  	CCUUCUGGUACCUUAGAGGACACAUAUCGCUAUGUAA
  	CAUCACAGGCUGUAACUUGUCAAAAACCCAGUGCACC
  	AAAACCUAAAGAUGAUCCAUUAAAAAAUUAUACUUUU
  	UGGGAGGUUGAUUUAAAGGAAAAGUUUUCUGCAGACU
  	UAGAUCAAUUUCCGUUGGGCCGUAAAUUUUUGUUACA
  	AGCAGGACUAAAGGCCAGGCCUAAUUUUAGAUUAGGC
  	AAGCGUGCAGCUCCAGCAUCUACAUCUAAAAAAUCUU
  	CUACUAAACGUAGAAAAGUAAAAAGU
  HPV39_L1_DX	AUGGCUAUGUGGCGGUCUAGUGACAGCAUGGUGUAUU	438
  	UGCCUCCACCUUCUGUGGCGAAGGUUGUCAAUACUGA
  	UGAUUAUGUUACACGCACAGGCAUAUAUUAUUAUGCU
  	GGCAGCUCCAGAUUAUUAACAGUAGGACAUCCAUAUU
  	UUAAAGUGGGUAUGAAUGGUGGUCGCAAGCAGGACAU
  	UCCAAAGGUGUCUGCAUAUCAAUAUAGGGUAUUUCGC
  	GUGACAUUGCCCGAUCCUAAUAAAUUCAGUAUUCCAG
  	AUGCAUCCUUAUAUAAUCCAGAAACACAACGUUUAGU
  	AUGGGCUUGUGUAGGGGUGGAGGUGGGCAGGGGCCAG
  	CCAUUGGGUGUUGGUAUUAGUGGACACCCAUUAUAUA
  	AUAGACAGGAUGAUACUGAAAACUCACCAUUUUCAUC
  	AACCACCAAUAAGGACAGUAGGGAUAAUGUGUCUGUG
  	GAUUAUAAACAGACACAGUUGUGCAUUAUAGGCUGUG
  	UUCCCGCCAUUGGGGAGCACUGGGGUAAGGGAAAGGC
  	AUGCAAGCCCAAUAAUGUAUCUACGGGGGACUGUCCU
  	CCUUUGGAACUAGUAAACACCCCUAUUGAGGAUGGUG
  	AUAUGAUUGAUACUGGCUAUGGAGCUAUGGACUUUGG
  	UGCAUUGCAGGAAACCAAAAGUGAGGUGCCUUUAGAU
  	AUUUGUCAAUCCAUUUGUAAAUAUCCUGAUUAUUUGC
  	AAAUGUCUGCAGAUGUGUAUGGGGACAGUAUGUUCUU
  	CUGUUUACGUAGGGAACAACUGUUUGCAAGACAUUUU
  	UGGAAUCGUGGUGGUAUGGUGGGUGACGCCAUUCCUG
  	CCCAAUUGUAUAUUAAGGGCACAGAUAUACGUGCAAA
  	CCCCGGUAGUUCUGUAUACUGCCCCUCUCCCAGCGGUU
  	CCAUGGUAACCUCUGAUUCCCAGUUAUUUAAUAAGCC
  	UUAUUGGCUACAUAAGGCCCAGGGCCACAACAAUGGU
  	AUAUGUUGGCAUAAUCAAUUAUUUCUUACUGUUGUGG
  	ACACUACCCGUAGUACCAACUUUACAUUAUCUACCUCU
  	AUAGAGUCUUCCAUACCUUCUACAUAUGAUCCUUCUA
  	AGUUUAAGGAAUAUACCAGGCACGUGGAGGAGUAUGA
  	UUUACAGUUUAUAUUUCAACUGUGUACUGUCACAUUA
  	ACAACUGAUGUUAUGUCUUAUAUUCACACUAUGAAUU
  	CCUCUAUAUUGGACAAUUGGAAUUUUGCUGUAGCUCC
  	UCCACCAUCUGCCAGUUUGGUAGACACUUACAGAUAC
  	CUACAGUCUGCAGCCAUUACAUGUCAAAAGGAUGCUC
  	CAGCACCUGAAAAGAAAGAUCCAUAUGACGGUCUAAA
  	GUUUUGGAAUGUUGACUUAAGGGAAAAGUUUAGUUUG
  	GAACUUGAUCAAUUCCCUUUGGGACGUAAAUUUUUGU
  	UGCAGGCCAGGGUCCGCAGGCGCCCUACUAUAGGUCCC
  	CGAAAGCGGCCUGCUGCAUCCACUUCCUCGUCCUCAGC
  	UACUAAACACAAACGUAAACGUGUGUCUAAA
  HPV45_L1_DX	AUGGCUUUGUGGCGGCCUAGUGACAGUACGGUAUAUC	439
  	UUCCACCACCUUCUGUGGCCAGAGUUGUCAGCACUGA
  	UGAUUAUGUGUCUCGCACAAGCAUAUUUUAUCAUGCA
  	GGCAGUUCCCGAUUAUUAACUGUAGGCAAUCCAUAUU
  	UUAGGGUUGUACCUAAUGGUGCAGGUAAUAAACAGGC
  	UGUUCCUAAGGUAUCCGCAUAUCAGUAUAGGGUGUUU
  	AGAGUAGCUUUACCCGAUCCUAAUAAAUUUGGAUUAC
  	CUGAUUCUACUAUAUAUAAUCCUGAAACACAACGUUU
  	GGUUUGGGCAUGUGUAGGUAUGGAAAUUGGUCGUGGG
  	CAGCCUUUAGGUAUUGGCCUAAGUGGCCAUCCAUUUU
  	AUAAUAAAUUGGAUGAUACAGAAAGUGCUCAUGCAGC
  	UACAGCUGUUAUUACGCAGGAUGUUAGGGAUAAUGUG
  	UCAGUUGAUUAUAAGCAAACACAGCUGUGUAUUUUAG
  	GUUGUGUACCUGCUAUUGGUGAGCACUGGGCCAAGGG
  	CACACUUUGUAAACCUGCACAAUUGCAACCUGGUGAC
  	UGUCCUCCUUUGGAACUUAAAAACACCAUUAUUGAGG
  	AUGGUGAUAUGGUGGAUACAGGUUAUGGGGCAAUGGA
  	UUUUAGUACAUUGCAGGAUACAAAGUGCGAGGUUCCA
  	UUAGACAUUUGUCAAUCCAUCUGUAAAUAUCCAGAUU
  	AUUUGCAAAUGUCUGCUGAUCCCUAUGGGGAUUCUAU
  	GUUUUUUUGCCUACGCCGUGAACAACUGUUUGCAAGA
  	CAUUUUUGGAAUAGGGCAGGUGUUAUGGGUGACACAG
  	UACCUACGGACCUAUAUAUUAAAGGCACUAGCGCUAA
  	UAUGCGUGAAACCCCUGGCAGUUGUGUGUAUUCCCCU
  	UCUCCCAGUGGCUCUAUUAUUACUUCUGAUUCUCAAU
  	UAUUUAAUAAGCCAUAUUGGUUACAUAAGGCCCAGGG
  	CCAUAACAAUGGUAUUUGUUGGCAUAAUCAGUUGUUU
  	GUUACUGUAGUGGACACUACCCGCAGUACUAAUUUAA
  	CAUUAUGUGCCUCUACACAAAAUCCUGUGCCAAGUAC
  	AUAUGACCCUACUAAGUUUAAGCAGUAUAGUAGACAU
  	GUGGAGGAAUAUGAUUUACAGUUUAUUUUUCAGUUGU
  	GCACUAUUACUCUCACUGCAGAGGUUAUGUCAUAUAU
  	CCAUAGUAUGAAUAGUAGUAUAUUAGAAAAUUGGAAU
  	UUUGGUGUCCCUCCACCACCUACUACAAGUUUGGUGG
  	AUACAUAUCGUUUUGUGCAAUCAGUUGCUGUUACCUG
  	UCAAAAGGAUACUACACCUCCAGAAAAGCAGGAUCCA
  	UAUGAUAAAUUAAAGUUUUGGACUGUUGACCUAAAGG
  	AAAAAUUUUCCUCCGAUUUGGAUCAAUAUCCCCUUGG
  	UCGAAAGUUUUUAGUUCAGGCUGGGUUACGUCGUAGG
  	CCUACCAUAGGACCUCGUAAGCGUCCUGCUGCUUCCAC
  	GUCUACUGCAUCUACUGCAUCUAGGCCUGCCAAACGU
  	GUACGUAUACGUAGUAAGAAA
  HPV51_L1_DX	AUGGCAUUGUGGCGCACUAAUGACAGCAAGGUGUAUU	440
  	UGCCACCUGCACCUGUGUCUCGAAUUGUGAAUACAGA
  	AGAAUAUAUCACACGCACCGGCAUAUAUUACUAUGCA
  	GGCAGUUCCAGACUAAUAACAUUAGGACAUCCCUAUU
  	UUCCAAUACCUAAAACCUCAACGCGUGCUGCUAUUCCU
  	AAAGUAUCUGCAUUUCAAUACAGGGUAUUUAGGGUAC
  	AGUUACCAGAUCCUAACAAGUUUGGACUCCCGGAUCC
  	AAAUUUAUAUAAUCCAGACACAGAUAGGUUGGUGUGG
  	GGUUGUGUGGGCGUUGAGGUGGGCAGAGGACAGCCCC
  	UUGGUGUUGGCCUUAGUGGUCAUCCCUUAUUUAAUAA
  	AUAUGAUGACACAGAAAAUUCACGCAUAGCAAAUGGC
  	AAUGCACAACAAGAUGUUAGAGAUAACACAUCUGUUG
  	ACAACAAACAGACUCAGUUAUGUAUAAUAGGCUGUGC
  	UCCACCUAUUGGGGAACACUGGGGUAUUGGCACUACA
  	UGCAAAAACACACCUGUACCUCCAGGAGACUGCCCCCC
  	CCUGGAACUUGUAUCCUCUGUCAUUCAGGAUGGCGAU
  	AUGAUUGAUACAGGGUUUGGAGCUAUGGAUUUCGCUG
  	CCCUACAGGCCACCAAAUCAGACGUCCCUUUGGAUAUU
  	UCACAGUCUGUUUGUAAAUAUCCUGAUUAUUUAAAAA
  	UGUCUGCAGACACAUAUGGUAAUUCCAUGUUUUUUCA
  	UUUACGCAGGGAGCAAAUCUUUGCUAGGCACUAUUAU
  	AAUAAACUUGUAGGUGUUGGGGAAGACAUUCCUAACG
  	AUUAUUAUAUUAAGGGUAGUGGUAAUGGCCGUGACCC
  	UAUAGAAAGUUAUAUAUACUCUGCUACUCCCAGUGGG
  	UCUAUGAUAACAUCUGAUUCUCAAAUUUUUAAUAAGC
  	CUUAUUGGCUCCACCGUGCGCAGGGUCACAAUAAUGG
  	CAUUUGCUGGAACAAUCAGCUUUUUAUUACCUGUGUU
  	GAUACUACCAGAAGUACAAAUUUAACUAUUAGCACUG
  	CCACUGCUGCGGUUUCCCCAACAUUUACUCCAAGUAAC
  	UUUAAGCAAUAUAUUAGGCAUGGGGAAGAGUAUGAAU
  	UGCAAUUUAUUUUUCAAUUAUGUAAAAUUACUCUGAC
  	UACAGAGGUAAUGGCUUAUUUACACACAAUGGAUCCU
  	ACCAUUCUUGAACAGUGGAAUUUUGGAUUAACAUUAC
  	CUCCGUCUGCUAGUUUGGAGGAUGCAUAUAGGUUUGU
  	UAGAAAUGCAGCUACUAGCUGUCAAAAGGACACCCCU
  	CCACAGGCUAAGCCAGAUCCUUUGGCCAAAUAUAAAU
  	UUUGGGAUGUUGAUUUAAAGGAACGAUUUUCUUUAGA
  	UUUAGACCAAUUUGCAUUGGGUCGCAAGUUUUUGUUG
  	CAGGUUGGCGUACAACGCAAGCCCAGACCAGGCCUUA
  	AACGCCCGGCCUCAUCGGCAUCCUCUUCCUCUUCCUCU
  	UCAGCCAAACGUAAACGUGUUAAAAAG
  HPV52_L1_DX	AUGUCCGUGUGGCGGCCUAGUGAGGCCACUGUGUACC	441
  	UGCCUCCUGUACCUGUCUCUAAGGUUGUAAGCACUGA
  	UGAGUAUGUGUCUCGCACAAGCAUCUAUUAUUAUGCA
  	GGCAGUUCUCGAUUACUAACAGUAGGACAUCCCUAUU
  	UUUCUAUUAAAAACACCAGUAGUGGUAAUGGUAAAAA
  	AGUUUUAGUUCCCAAGGUGUCUGGCCUGCAAUACAGG
  	GUAUUUAGAAUUAAAUUGCCGGACCCUAAUAAAUUUG
  	GUUUUCCAGAUACAUCUUUUUAUAACCCAGAAACCCA
  	AAGGUUGGUGUGGGCCUGUACAGGCUUGGAAAUUGGU
  	AGGGGACAGCCUUUAGGUGUGGGUAUUAGUGGGCAUC
  	CUUUAUUAAACAAGUUUGAUGAUACUGAAACCAGUAA
  	CAAAUAUGCUGGUAAACCUGGUAUAGAUAAUAGGGAA
  	UGUUUAUCUAUGGAUUAUAAGCAGACUCAGUUAUGCA
  	UUUUAGGAUGCAAACCUCCUAUAGGUGAACAUUGGGG
  	UAAGGGAACCCCUUGUAAUAAUAAUUCAGGAAAUCCU
  	GGGGAUUGUCCUCCCCUACAGCUCAUUAACAGUGUAA
  	UACAGGAUGGGGACAUGGUAGAUACAGGAUUUGGUUG
  	CAUGGAUUUUAAUACCUUGCAAGCUAGUAAAAGUGAU
  	GUGCCCAUUGAUAUAUGUAGCAGUGUAUGUAAGUAUC
  	CAGAUUAUUUGCAAAUGGCUAGCGAGCCAUAUGGUGA
  	CAGUUUGUUCUUUUUUCUUAGACGUGAGCAAAUGUUU
  	GUUAGACACUUUUUUAAUAGGGCCGGUACCUUAGGUG
  	ACCCUGUGCCAGGUGAUUUAUAUAUACAAGGGUCUAA
  	CUCUGGCAAUACUGCCACUGUACAAAGCAGUGCUUUU
  	UUUCCUACUCCUAGUGGUUCUAUGGUAACCUCAGAAU
  	CCCAAUUAUUUAAUAAACCGUACUGGUUACAACGUGC
  	GCAGGGCCACAAUAAUGGCAUAUGUUGGGGCAAUCAG
  	UUGUUUGUCACAGUUGUGGAUACCACUCGUAGCACUA
  	ACAUGACUUUAUGUGCUGAGGUUAAAAAGGAAAGCAC
  	AUAUAAAAAUGAAAAUUUUAAGGAAUACCUUCGUCAU
  	GGCGAGGAAUUUGAUUUACAGUUUAUUUUUCAGUUGU
  	GCAAAAUUACAUUAACAGCUGAUGUUAUGACAUACAU
  	UCAUAAGAUGGAUGCCACUAUUUUAGAGGACUGGCAA
  	UUUGGCCUUACCCCACCACCGUCUGCAUCUUUGGAGGA
  	CACAUACAGAUUUGUCACUUCUACUGCUAUAACUUGU
  	CAAAAAAACACACCACCUAAAGGAAAGGAAGAUCCUU
  	UAAAGGACUAUAUGUUUUGGGAGGUGGAUUUAAAAGA
  	AAAGUUUUCUGCAGAUUUAGAUCAGUUUCCUUUAGGU
  	AGGAAGUUUUUGUUACAGGCAGGGCUACAGGCUAGGC
  	CCAAACUAAAACGCCCUGCAUCAUCGGCCCCACGUACC
  	UCCACAAAGAAGAAAAAGGUUAAAAGG
  HPV56_L1_DX	AUGGCGACGUGGCGGCCUAGUGAAAAUAAGGUGUAUC	442
  	UACCUCCAACACCUGUUUCAAAGGUUGUGGCAACGGA
  	UUCCUAUGUAAAACGCACUAGUAUAUUUUAUCAUGCA
  	GGCAGUUCACGAUUGCUUGCCGUAGGACAUCCCUAUU
  	ACUCUGUGACUAAGGACAAUACCAAAACAAACAUUCC
  	CAAAGUUAGUGCAUAUCAAUAUAGGGUAUUUAGGGUA
  	CGGUUGCCCGACCCUAAUAAGUUUGGGCUUCCAGAUA
  	CUAAUAUUUAUAAUCCGGACCAGGAACGGUUAGUGUG
  	GGCAUGUGUAGGUUUGGAGGUAGGCCGCGGACAGCCU
  	UUAGGUGCUGGGCUAAGUGGCCAUCCAUUGUUUAAUA
  	GGCUGGAUGAUACUGAAAGUUCCAAUUUAGCAAAUAA
  	UAAUGUUAUAGAAGAUAGUAGGGACAAUAUAUCAGUU
  	GAUGGCAAGCAAACACAGUUGUGUAUUGUUGGAUGUA
  	CUCCCGCUAUGGGUGAACAUUGGACUAAAGGUGCUGU
  	GUGUAAGUCCACACAAGUUACCACAGGGGACUGCCCG
  	CCUCUUGCAUUAAUUAAUACACCUAUAGAGGAUGGGG
  	ACAUGAUAGACACAGGAUUUGGCGCUAUGGACUUUAA
  	GGUGUUGCAGGAAUCUAAGGCUGAGGUACCUUUAGAC
  	AUUGUACAAUCCACCUGUAAAUAUCCUGACUAUUUAA
  	AAAUGUCUGCAGAUGCCUAUGGUGAUUCUAUGUGGUU
  	UUACUUACGCAGGGAACAAUUAUUUGCCAGACAUUAU
  	UUUAAUAGGGCUGGUAAAGUUGGGGAAACAAUACCUG
  	CAGAGUUAUAUUUAAAGGGUAGCAAUGGUAGAGAACC
  	CCCUCCGAGUUCUGUAUAUGUUGCUACGCCUAGUGGG
  	UCUAUGAUUACGUCUGAGGCACAGUUAUUUAAUAAAC
  	CUUAUUGGUUGCAACGUGCCCAAGGCCAUAAUAAUGG
  	CAUUUGCUGGGGUAAUCAAUUAUUUGUUACUGUAGUA
  	GAUACUACUAGAAGUACUAACAUGACUAUUAGUACUG
  	CUACAGAACAGCUCAGUAAAUAUGAUGCACGAAAAAU
  	UAAUCAGUACCUUAGACAUGUGGAGGAAUAUGAAUUA
  	CAAUUUGUUUUUCAAUUAUGCAAAAUUACUUUGUCUG
  	CAGAGGUUAUGGCAUAUUUACAUAAUAUGAAUGCUAA
  	CCUACUGGAGGACUGGAAUAUUGGGUUAUCCCCGCCA
  	GUGGCCACCAGCCUAGAAGAUAAAUAUAGAUAUGUUA
  	GAAGCACAGCUAUAACAUGUCAACGGGAACAGCCACC
  	AACAGAAAAACAGGACCCAUUAGCUAAAUAUAAAUUU
  	UGGGAUGUUAACUUACAGGACAGUUUUUCUACAGACC
  	UGGAUCAAUUUCCACUGGGUAGAAAAUUUUUAAUGCA
  	ACUGGGCACUAGGUCAAAGCCUGCUGUAGCUACCUCU
  	AAAAAGCGAUCUGCUCCUACCUCCACCUCUACACCAGC
  	AAAACGUAAAAGGCGG
  HPV58_L1_DX	AUGUCCGUGUGGCGGCCUAGUGAGGCCACUGUGUACC	443
  	UGCCUCCUGUGCCUGUGUCUAAGGUUGUAAGCACUGA
  	UGAAUAUGUGUCACGCACAAGCAUUUAUUAUUAUGCU
  	GGCAGUUCCAGACUUUUGGCUGUUGGCAAUCCAUAUU
  	UUUCCAUCAAAAGUCCCAAUAACAAUAAAAAAGUAUU
  	AGUUCCCAAGGUAUCAGGCUUACAGUAUAGGGUCUUU
  	AGGGUGCGUUUACCUGAUCCCAAUAAAUUUGGUUUUC
  	CUGAUACAUCUUUUUAUAACCCUGAUACACAACGUUU
  	GGUCUGGGCAUGUGUAGGCCUUGAAAUAGGUAGGGGA
  	CAGCCAUUGGGUGUUGGCGUAAGUGGUCAUCCUUAUU
  	UAAAUAAAUUUGAUGACACUGAAACCAGUAACAGAUA
  	UCCCGCACAGCCAGGGUCUGAUAACAGGGAAUGCUUA
  	UCUAUGGAUUAUAAACAAACACAAUUAUGUUUAAUUG
  	GCUGUAAACCUCCCACUGGUGAGCAUUGGGGUAAAGG
  	UGUUGCCUGUAACAAUAAUGCAGCUGCUACUGAUUGU
  	CCUCCAUUGGAACUUUUUAAUUCUAUUAUUGAGGAUG
  	GUGACAUGGUAGAUACAGGGUUUGGAUGCAUGGACUU
  	UGGUACAUUGCAGGCUAAUAAAAGUGAUGUGCCUAUU
  	GAUAUUUGUAACAGUACAUGCAAAUAUCCAGAUUAUU
  	UAAAAAUGGCCAGUGAACCUUAUGGGGAUAGUUUGUU
  	CUUUUUUCUUAGACGUGAGCAGAUGUUUGUUAGACAC
  	UUUUUUAAUAGGGCUGGAAAACUUGGCGAGGCUGUCC
  	CGGAUGACCUUUAUAUUAAAGGGUCCGGUAAUACUGC
  	AGUUAUCCAAAGUAGUGCAUUUUUUCCAACUCCUAGU
  	GGCUCUAUAGUUACCUCAGAAUCACAAUUAUUUAAUA
  	AGCCUUAUUGGCUACAGCGUGCACAAGGUCAUAACAA
  	UGGCAUUUGCUGGGGCAAUCAGUUAUUUGUUACCGUG
  	GUUGAUACCACUCGUAGCACUAAUAUGACAUUAUGCA
  	CUGAAGUAACUAAGGAAGGUACAUAUAAAAAUGAUAA
  	UUUUAAGGAAUAUGUACGUCAUGUUGAAGAAUAUGAC
  	CUACAGUUUGUUUUUCAGCUUUGCAAAAUUACACUAA
  	CUGCAGAGAUAAUGACAUAUAUACAUACUAUGGAUUC
  	CAAUAUUUUGGAGGACUGGCAAUUUGGUUUAACACCU
  	CCUCCGUCUGCCAGUUUACAGGACACAUAUAGAUUUG
  	UUACCUCCCAGGCUAUUACUUGCCAAAAAACAGCACCC
  	CCUAAAGAAAAGGAAGAUCCAUUAAAUAAAUAUACUU
  	UUUGGGAGGUUAACUUAAAGGAAAAGUUUUCUGCAGA
  	UCUUGAUCAGUUUCCUUUGGGACGAAAGUUUUUAUUA
  	CAAUCAGGCCUUAAAGCAAAGCCCAGACUAAAACGUU
  	CGGCCCCUACUACCCGUGCACCAUCCACCAAACGCAAA
  	AAGGUUAAAAAA
  HPV59_L1_DX	AUGGCUCUAUGGCGUUCUAGUGACAACAAGGUGUAUC	444
  	UACCUCCACCUUCGGUAGCUAAGGUUGUCAGCACUGA
  	UGAGUAUGUCACCCGUACCAGUAUUUUCUACCACGCA
  	GGCAGUUCCAGACUUCUUACAGUUGGACAUCCAUAUU
  	UUAAAGUACCUAAAGGUGGUAAUGGUAGACAGGAUGU
  	UCCUAAGGUGUCUGCAUAUCAAUACAGAGUAUUUAGG
  	GUUAAGUUACCUGAUCCCAAUAAAUUUGGCCUUCCAG
  	AUAACACAGUAUAUGAUCCUAACUCUCAACGCUUGGU
  	CUGGGCCUGUGUAGGUGUUGAAAUCGGUCGGGGCCAA
  	CCUUUAGGGGUAGGACUCAGUGGUCAUCCAUUAUAUA
  	AUAAAUUGGAUGACACUGAAAACUCUCAUGUAGCAUC
  	UGCUGUUGAUACCAAAGAUACACGUGAUAAUGUAUCU
  	GUGGAUUAUAAACAAACUCAGCUGUGUAUUAUUGGCU
  	GUGUACCUGCCAUUGGAGAACACUGGACAAAGGGCAC
  	UGCUUGUAAGCCUACUACUGUGGUUCAGGGCGAUUGU
  	CCUCCACUAGAAUUAAUAAAUACACCAAUUGAAGAUG
  	GUGAUAUGGUAGACACAGGAUAUGGGGCUAUGGACUU
  	UAAAUUGUUGCAGGAUAACAAAAGUGAAGUACCAUUG
  	GAUAUUUGUCAGUCUAUUUGUAAAUAUCCUGAUUAUU
  	UACAAAUGUCAGCAGAUGCUUAUGGAGACAGUAUGUU
  	UUUUUGUUUAAGGCGAGAACAGGUUUUUGCCAGACAU
  	UUUUGGAAUAGAUCUGGUACUAUGGGUGAUCAACUUC
  	CUGAAUCACUAUAUAUUAAAGGUACUGACAUACGUGC
  	CAACCCAGGCAGUUAUUUAUAUUCCCCUUCCCCAAGUG
  	GGUCUGUGGUUACUUCUGAUUCACAAUUAUUUAAUAA
  	ACCAUAUUGGCUGCACAAGGCUCAGGGUUUAAACAAU
  	GGUAUAUGUUGGCACAAUCAAUUGUUUUUAACAGUUG
  	UAGAUACUACUCGCAGCACCAAUCUUUCUGUGUGUGC
  	UUCUACUACUUCUUCUAUUCCUAAUGUAUACACACCU
  	ACCAGUUUUAAAGAAUAUGCCAGACAUGUGGAGGAAU
  	UUGAUUUGCAGUUUAUAUUUCAGCUGUGUAAAAUAAC
  	AUUAACUACAGAGGUAAUGUCAUACAUUCAUAAUAUG
  	AAUACCACUAUUUUGGAGGAUUGGAAUUUUGGUGUUA
  	CACCACCUCCUACUGCUAGUUUAGUUGACACAUACCGU
  	UUUGUUCAAUCUGCUGCUGUAACUUGUCAAAAGGACA
  	CCGCACCGCCAGUUAAACAGGACCCUUAUGACAAACUA
  	AAGUUUUGGCCUGUAGAUCUUAAGGAAAGGUUUUCUG
  	CAGAUCUUGAUCAGUUUCCUUUGGGACGUAAAUUUUU
  	AUUGCAAUUAGGAGCUAGACCUAAGCCCACUAUAGGC
  	CCACGCAAACGUGCAGCGCCUGCCCCUACCUCUACCCC
  	AUCACCAAAACGUGUUAAGCGUCGCAAGUCUUCCAGA
  	AAA
  HPV68_L1_DX	AUGGCAUUGUGGCGAGCUAGCGACAACAUGGUGUAUU	445
  	UGCCUCCCCCCUCAGUGGCGAAGGUUGUCAAUACAGA
  	UGAUUAUGUGACACGCACUGGCAUGUAUUACUAUGCU
  	GGUACAUCUAGGUUAUUAACUGUAGGCCAUCCAUAUU
  	UUAAGGUUCCUAUGUCUGGGGGCCGCAAGCAGGGCAU
  	UCCUAAGGUGUCUGCAUAUCAAUACAGAGUGUUUAGG
  	GUUACCUUACCUGAUCCUAAUAAAUUUAGUGUUCCUG
  	AGUCUACAUUAUAUAAUCCAGAUACACAGCGCAUGGU
  	AUGGGCCUGUGUUGGUGUUGAAAUAGGUAGGGGGCAG
  	CCAUUGGGCGUUGGCCUUAGUGGGCAUCCACUAUAUA
  	AUAGGCUGGAUGAUACUGAAAAUUCCCCGUUUUCCUC
  	UAAUAAAAAUCCUAAAGAUAGUAGGGACAAUGUUGCA
  	GUGGACUGUAAACAAACACAGCUGUGUAUUAUAGGCU
  	GUGUUCCUGCUAUUGGAGAGCACUGGGCCAAAGGUAA
  	AUCUUGUAAGCCUACCAAUGUACAACAAGGGGACUGU
  	CCCCCAUUGGAAUUGGUAAAUACUCCUAUUGAGGAUG
  	GCGAUAUGAUUGAUACAGGAUAUGGUGCUAUGGACUU
  	UGGUACAUUACAAGAAACGAAAAGCGAGGUACCUUUG
  	GAUAUAUGUCAAUCUGUUUGCAAAUAUCCUGACUAUU
  	UGCAAAUGUCUGCAGAUGUGUAUGGAGACAGUAUGUU
  	UUUUUGUUUACGUAGGGAACAGUUAUUUGCCAGGCAU
  	UUUUGGAAUAGGGGAGGCAUGGUAGGGGACACUAUUC
  	CCACUGACAUGUAUAUUAAGGGCACUGACAUUCGUGA
  	AACUCCUAGUAGUUAUGUGUAUGCCCCCUCGCCUAGC
  	GGGUCUAUGGUGUCCUCUGACUCCCAGUUAUUUAACA
  	AGCCCUAUUGGCUGCACAAGGCACAGGGACACAACAA
  	UGGUAUUUGUUGGCAUAAUCAAUUAUUUCUUACCGUU
  	GUGGAUACAACGCGCAGUACUAAUUUUACAUUGUCCA
  	CUACUACAGACUCUACUGUACCAGCUGUGUAUGAUUC
  	UAAUAAAUUUAAGGAAUAUGUUAGGCAUGUUGAGGAA
  	UAUGAUUUGCAGUUUAUAUUUCAGUUGUGUACUAUAA
  	CAUUAUCCACUGACGUAAUGUCAUAUAUACAUACUAU
  	GAAUCCUGCUAUUUUGGAUGAUUGGAAUUUUGGUGUU
  	GCCCCUCCACCAUCUGCUAGUCUUGUAGAUACAUACCG
  	CUACCUACAAUCAGCAGCAAUUACAUGUCAAAAGGAC
  	GCCCCUGCACCUGUUAAAAAAGAUCCCUAUGAUGGUC
  	UUAACUUUUGGAAUGUGGAUUUAAAGGAAAAGUUUAG
  	UUCUGAACUGGACCAAUUCCCAUUAGGACGCAAAUUU
  	CUGUUACAGGCAGGUGUUCGCAGACGGCCCACCAUAG
  	GCCCUCGUAAACGCACUGCCACUGCAGCUACCACAUCU
  	ACCUCUAAACACAAACGUAAACGUGUGUCAAAA
  HPV73_L1_DX	AUGUGGCGACCUACUGAUGCAAAGGUAUACCUGCCCC	446
  	CUGUGUCUGUGUCUAAGGUUGUAAGCACAGAUGAAUA
  	UGUAACAAGAACAAAUAUAUAUUAUUAUGCAGGUAGC
  	ACACGUUUGUUGGCUGUGGGACACCCAUAUUUUCCUA
  	UCAAGGAUUCUCAAAAACGUAAAACCAUAGUUCCUAA
  	AGUUUCAGGUUUGCAAUACAGGGUGUUUAGGCUUCGU
  	UUACCAGAUCCUAAUAAAUUUGGAUUUCCAGAUGCAU
  	CCUUUUAUAAUCCUGAUAAGGAGCGCCUAGUAUGGGC
  	CUGUUCUGGUGUGGAGGUUGGACGUGGACAACCCUUA
  	GGUAUAGGUACUAGUGGCAAUCCAUUUAUGAAUAAAU
  	UAGAUGAUACUGAAAAUGCUCCUAAAUACAUUGCUGG
  	ACAAAAUACAGAUGGUAGAGAAUGUAUGUCAGUGGAU
  	UAUAAACAAACACAGUUGUGUAUUUUAGGUUGUAGGC
  	CUCCCUUAGGGGAACAUUGGGGUCCAGGCACGCCAUG
  	UACUUCACAAACUGUUAAUACUGGUGAUUGUCCCCCA
  	CUGGAAUUAAAGAACACCCCUAUACAGGAUGGUGAUA
  	UGAUAGAUGUUGGCUUUGGAGCCAUGGAUUUUAAAGC
  	UUUACAAGCAAAUAAAAGUGAUGUACCUAUUGAUAUU
  	UCUAACACUACCUGUAAAUACCCAGAUUAUUUAGGCA
  	UGGCUGCUGAUCCCUAUGGUGAUUCCAUGUGGUUUUA
  	UCUUCGUAGGGAACAAAUGUUUGUUCGACACUUAUUU
  	AACAGGGCUGGUGAUACCGGUGAUAAAAUCCCAGAUG
  	ACCUAAUGAUUAAAGGCACAGGCAAUACUGCAACACC
  	AUCCAGUUGUGUUUUUUAUCCUACACCUAGUGGUUCC
  	AUGGUUUCUUCAGAUGCACAGUUGUUUAAUAAACCUU
  	AUUGGUUGCAAAAGGCACAGGGACAAAAUAAUGGUAU
  	UUGUUGGCAUAAUCAAUUAUUUUUAACUGUUGUAGAU
  	ACUACUAGAAGCACUAAUUUUUCUGUAUGUGUAGGUA
  	CACAGGCUAGUAGCUCUACUACAACGUAUGCCAACUC
  	UAAUUUUAAGGAAUAUUUAAGACAUGCAGAAGAGUUU
  	GACUUACAGUUUGUUUUUCAGUUAUGUAAAAUUAGUU
  	UAACCACUGAGGUGAUGACAUAUAUCCAUUCUAUGAA
  	UUCUACUAUAUUGGAAGAGUGGAAUUUUGGUCUUACC
  	CCACCACCGUCAGGUACUUUAGAGGAAACAUAUAGAU
  	AUGUAACAUCACAGGCUAUUAGUUGCCAACGUCCUCA
  	ACCUCCUAAAGAAACAGAGGACCCAUAUGCCAAGCUA
  	UCCUUUUGGGAUGUAGAUCUUAAGGAAAAGUUUUCUG
  	CAGAAUUAGACCAGUUUCCUUUGGGAAGAAAAUUUUU
  	AUUACAACUUGGUAUGCGUGCACGUCCUAAGUUACAA
  	GCUUCUAAACGUUCUGCAUCUGCUACCACAAGUGCCAC
  	ACCUAAGAAAAAACGUGCUAAACGUAUU
  HPV82_L1_DX	AUGGCUUUGUGGCGUACUAAUGACAGCAAAGUGUAUU	447
  	UACCACCUGCACCAGUGUCACGCAUUGUCAACACAGAA
  	GAAUAUAUAACCCGCACCGGCAUAUAUUAUUAUGCAG
  	GCAGUUCCAGACUUAUUACCUUAGGACAUCCAUAUUU
  	UUCAAUACCCAAAACCAAUACACGUGCUGAAAUACCU
  	AAGGUAUCUGCCUUUCAGUAUAGGGUGUUUAGGGUAC
  	AGUUACCUGACCCCAACAAAUUUGGUCUUCCUGAUCC
  	UAAUUUGUUUAAUCCAGACACAGAUCGUUUGGUGUGG
  	GGAUGUGUUGGUGUUGAAGUAGGUAGGGGUCAGCCGU
  	UAGGUGUUGGCCUUAGUGGUCAUCCUUUAUUUAAUAA
  	GUAUGAUGAUACUGAAAACUCUAGGUUUGCCAAUGGC
  	AACGACCAACAGGAUGUUAGGGACAACAUAUCUGUGG
  	ACAACAAACAAACUCAGUUAUGCAUUAUAGGCUGCGC
  	UCCUCCUAUUGGGGAACACUGGGCCACAGGUACCACA
  	UGUAAAAACGUACCUGUACCUCAGGGUGACUGUCCAC
  	CUUUGGAACUUGUGUCUACUGUCAUUGAGGAUGGCGA
  	UAUGGUGGACACUGGUUUUGGGGCCAUGGAUUUUGCU
  	AAUUUACAAGCUACUAAAUCAGAUGUUCCAUUGGAUA
  	UUGCUCAGUCUGUGUGUAAAUACCCUGAUUACUUAAA
  	AAUGUCAGCAGAUACAUAUGGCAAUUCUAUGUUUUUU
  	CAUUUACGCAGGGAGCAAAUAUUUGCUAGGCAUUACU
  	AUAAUAAGGCUGGUGUGGUUGGUGAUGCCAUUCCAGA
  	CAAGGCUUAUAUUAAGGGUACUGGUGCUGGCCGCGAC
  	CCUAUUAGUAGUUAUAUUUAUUCAGCUACUCCCAGUG
  	GUUCUAUGAUAACCUCUGAUUCUCAGAUUUUUAAUAA
  	GCCUUAUUGGUUGCAUCGCGCCCAGGGCCACAAUAAU
  	GGCAUUUGCUGGAAUAAUCAGCUUUUUAUUACUUGUG
  	UUGACACUACUAAAAGUACCAAUUUAACCAUUAGCAC
  	UGCUGUUACUCCAUCUGUUGCACAAACAUUUACUCCA
  	GCAAACUUUAAGCAGUACAUUAGGCAUGGGGAAGAAU
  	AUGAAUUGCAAUUUAUAUUUCAAUUGUGUAAAAUCAC
  	UUUAACUACUGAAAUUAUGGCUUACCUGCACACCAUG
  	GAUUCUACAAUUUUAGAACAGUGGAAUUUUGGAUUAA
  	CAUUGCCCCCCUCCGCUAGUUUGGAGGAUGCCUAUCGA
  	UUUGUAAAAAAUGCAGCAACAUCCUGUCACAAGGACA
  	GUCCUCCACAGGCUAAAGAAGACCCUUUGGCAAAAUA
  	UAAAUUUUGGAAUGUAGACCUUAAGGAACGCUUUUCU
  	UUGGAUUUGGAUCAGUUUGCAUUGGGUCGCAAGUUUU
  	UAUUACAAAUCGGUGCCCAACGCAAACCCAGACCAGGC
  	CUUAAAAGGCCUGCCCCAUCCUCUUCCGCUUCCUCGUC
  	UGCCAAACGUAAAAGGGUUAAAAAA
  IgK_HPV18_E7_Rb_mut	AUGGAGACCCCCGCCCAGCUGCUGUUCCUGCUGCUGCU	448
  	GUGGCUGCCCGACACCACCGGCCACGGCCCCAAGGCCA
  	CCCUGCAGGACAUCGUGCUGCACCUGGAGCCCCAGAAC
  	GAGAUCCCCGUGGACCUGCUGGGCCACGGCCAGCUGAG
  	CGACAGCGAGGAGGAGAACGACGAGAUCGACGGCGUG
  	AACCACCAGCACCUGCCCGCCAGAAGAGCCGAGCCCCA
  	GAGACACACCAUGCUGUGCAUGUGCUGCAAGUGCGAG
  	GCCAGAAUCAAGCUGGUGGUGGAGAGCAGCGCCGACG
  	ACCUGAGAGCCUUCCAGCAGCUGUUCCUGAACACCCUG
  	AGCUUCGUGUGCCCCUGGUGCGCCAGCCAGCAG
  HPV18_E7_Rb_mut	AUGCACGGCCCCAAGGCCACCCUGCAGGACAUCGUGCU	449
  	GCACCUGGAGCCCCAGAACGAGAUCCCCGUGGACCUGC
  	UGGGCCACGGCCAGCUGAGCGACAGCGAGGAGGAGAA
  	CGACGAGAUCGACGGCGUGAACCACCAGCACCUGCCCG
  	CCAGAAGAGCCGAGCCCCAGAGACACACCAUGCUGUGC
  	AUGUGCUGCAAGUGCGAGGCCAGAAUCAAGCUGGUGG
  	UGGAGAGCAGCGCCGACGACCUGAGAGCCUUCCAGCA
  	GCUGUUCCUGAACACCCUGAGCUUCGUGUGCCCCUGGU
  	GCGCCAGCCAGCAG
  IgK_HPV16_E7_Rb_mut	AUGGAGACCCCCGCCCAGCUGCUGUUCCUGCUGCUGCU	450
  	GUGGCUGCCCGACACCACCGGCCACGGCGACACCCCCA
  	CCCUGCACGAGUACAUGCUGGACCUGCAGCCCGAGACC
  	ACCGACCUGUACGGCUACGGCCAGCUGAACGACAGCAG
  	CGAGGAGGAGGACGAGAUCGACGGCCCCGCCGGCCAG
  	GCCGAGCCCGACAGAGCCCACUACAACAUCGUGACCUU
  	CUGCUGCAAGUGCGACAGCACCCUGAGACUGUGCGUG
  	CAGAGCACCCACGUGGACAUCAGAACCCUGGAGGACCU
  	GCUGAUGGGCACCCUGGGCAUCGUGUGCCCCAUCUGCA
  	GCCAGAAGCCC
  HPV16_E7_Rb_mut	AUGCACGGCGACACCCCCACCCUGCACGAGUACAUGCU	451
  	GGACCUGCAGCCCGAGACCACCGACCUGUACGGCUACG
  	GCCAGCUGAACGACAGCAGCGAGGAGGAGGACGAGAU
  	CGACGGCCCCGCCGGCCAGGCCGAGCCCGACAGAGCCC
  	ACUACAACAUCGUGACCUUCUGCUGCAAGUGCGACAG
  	CACCCUGAGACUGUGCGUGCAGAGCACCCACGUGGACA
  	UCAGAACCCUGGAGGACCUGCUGAUGGGCACCCUGGG
  	CAUCGUGUGCCCCAUCUGCAGCCAGAAGCCC
  IgK_HPV18_E6_p53_mutdel	AUGGAGACCCCCGCCCAGCUGCUGUUCCUGCUGCUGCU	452
  	GUGGCUGCCCGACACCACCGGCGCCAGAUUCGAGGACC
  	CCACCAGAAGCGGCUACAAGCUGCCCGACCUGUGCACC
  	GAGCUGAACACCAGCCUGCAGGACAUCGAGAUCACCU
  	GCGUGUACUGCAAGACCGUGCUGGAGCUGACCGAGGU
  	GUUCGAGAAGGACCUGUUCGUGGUGUACAGAGACAGC
  	AUCCCCCACGCCGCCUGCCACAAGUGCAUCGACUUCUA
  	CAGCAGAAUCAGAGAGCUGAGACACUACAGCGACAGC
  	GUGUACGGCGACACCCUGGAGAAGCUGACCAACACCG
  	GCCUGUACAACCUGCUGAUCAGAUGCCUGAGAUGCCA
  	GAAGCCCCUGCUGAGACACCUGAACGAGAAGAGAAGA
  	UUCCACAACAUCGCCGGCCACUACAGAGGCCAGUGCCA
  	CAGCUGCUGCAACAGAGCCAGACAGGAGAGACUGCAG
  	AGAAGAAGAGAGACCCAGGUG
  HPV18_E6_p53_mutdel	AUGGCCAGAUUCGAGGACCCCACCAGAAGCGGCUACA	453
  	AGCUGCCCGACCUGUGCACCGAGCUGAACACCAGCCUG
  	CAGGACAUCGAGAUCACCUGCGUGUACUGCAAGACCG
  	UGCUGGAGCUGACCGAGGUGUUCGAGAAGGACCUGUU
  	CGUGGUGUACAGAGACAGCAUCCCCCACGCCGCCUGCC
  	ACAAGUGCAUCGACUUCUACAGCAGAAUCAGAGAGCU
  	GAGACACUACAGCGACAGCGUGUACGGCGACACCCUG
  	GAGAAGCUGACCAACACCGGCCUGUACAACCUGCUGA
  	UCAGAUGCCUGAGAUGCCAGAAGCCCCUGCUGAGACA
  	CCUGAACGAGAAGAGAAGAUUCCACAACAUCGCCGGC
  	CACUACAGAGGCCAGUGCCACAGCUGCUGCAACAGAGC
  	CAGACAGGAGAGACUGCAGAGAAGAAGAGAGACCCAG
  	GUG
  IgK_HPV16_E6_p53_mutdel	AUGGAGACCCCCGCCCAGCUGCUGUUCCUGCUGCUGCU	454
  	GUGGCUGCCCGACACCACCGGCCACCAGAAGAGAACCG
  	CCAUGUUCCAGGACCCCCAGGAGAGCGGCAGAAAGCU
  	GCCCCAGCUGUGCACCGAGCUGCAGACCACCAUCCACG
  	ACAUCAUCCUGGAGUGCGUGUACUGCAAGCAGCAGCU
  	GCUGAGAAGAGAGGUGUACGACAGAGACCUGUGCAUC
  	GUGUACAGAGACGGCAACCCCUACGCCGUGUGCGACA
  	AGUGCCUGAAGUUCUACAGCAAGAUCAGCGAGUACAG
  	ACACUACUGCUACAGCCUGUACGGCACCACCCUGGAGC
  	AGCAGUACAACAAGCCCCUGUGCGACCUGCUGAUCAG
  	AUGCAUCAACUGCCAGAAGCCCCUGCAGAGACACCUGG
  	ACAAGAAGCAGAGAUUCCACAACAUCAGAGGCAGAUG
  	GACCGGCAGAUGCAUGAGCUGCUGCAGAAGCAGCAGA
  	ACCAGAAGAGAGACCCAGCUG
  HPV16_E6_p53_mutdel	AUGCACCAGAAGAGAACCGCCAUGUUCCAGGACCCCCA	455
  	GGAGAGCGGCAGAAAGCUGCCCCAGCUGUGCACCGAG
  	CUGCAGACCACCAUCCACGACAUCAUCCUGGAGUGCGU
  	GUACUGCAAGCAGCAGCUGCUGAGAAGAGAGGUGUAC
  	GACAGAGACCUGUGCAUCGUGUACAGAGACGGCAACC
  	CCUACGCCGUGUGCGACAAGUGCCUGAAGUUCUACAG
  	CAAGAUCAGCGAGUACAGACACUACUGCUACAGCCUG
  	UACGGCACCACCCUGGAGCAGCAGUACAACAAGCCCCU
  	GUGCGACCUGCUGAUCAGAUGCAUCAACUGCCAGAAG
  	CCCCUGCAGAGACACCUGGACAAGAAGCAGAGAUUCC
  	ACAACAUCAGAGGCAGAUGGACCGGCAGAUGCAUGAG
  	CUGCUGCAGAAGCAGCAGAACCAGAAGAGAGACCCAG
  	CUG
  HPV18_E7	AUGCAUGGACCUAAGGCAACAUUGCAAGACAUUGUAU	456
  	UGCAUUUAGAGCCCCAAAAUGAAAUUCCGGUUGACCU
  	UCUAUGUCACGAGCAAUUAAGCGACUCAGAGGAAGAA
  	AACGAUGAAAUAGAUGGAGUUAAUCAUCAACAUUUAC
  	CAGCCCGACGAGCCGAACCACAACGUCACACAAUGUUG
  	UGUAUGUGUUGUAAGUGUGAAGCCAGAAUUGAGCUAG
  	UAGUAGAAAGCUCAGCAGACGACCUUCGAGCAUUCCA
  	GCAGCUGUUUCUGAACACCCUGUCCUUUGUGUGUCCG
  	UGGUGUGCAUCCCAGCAG
  HPV16_E7	AUGCAUGGAGAUACACCUACAUUGCAUGAAUAUAUGU	457
  	UAGAUUUGCAACCAGAGACAACUGAUCUCUACUGUUA
  	UGAGCAAUUAAAUGACAGCUCAGAGGAGGAGGAUGAA
  	AUAGAUGGUCCAGCUGGACAAGCAGAACCGGACAGAG
  	CCCAUUACAAUAUUGUAACCUUUUGUUGCAAGUGUGA
  	CUCUACGCUUCGGUUGUGCGUACAAAGCACACACGUA
  	GACAUUCGUACUUUGGAAGACCUGUUAAUGGGCACAC
  	UAGGAAUUGUGUGCCCCAUCUGUUCUCAGAAACCA
  HPV18_E6	AUGGCGCGCUUUGAGGAUCCAACACGGCGACCCUACA	458
  	AGCUACCUGAUCUGUGCACGGAACUGAACACUUCACU
  	GCAAGACAUAGAAAUAACCUGUGUAUAUUGCAAGACA
  	GUAUUGGAACUUACAGAGGUAUUUGAAUUUGCAUUUA
  	AAGAUUUAUUUGUGGUGUAUAGAGACAGUAUACCCCA
  	UGCUGCAUGCCAUAAAUGUAUAGAUUUUUAUUCCAGA
  	AUUAGAGAAUUAAGACAUUAUUCAGACUCUGUGUAUG
  	GAGACACAUUGGAAAAACUAACUAACACUGGGUUAUA
  	CAAUUUAUUAAUAAGGUGCCUGCGGUGCCAGAAACCG
  	UUGAAUCCAGCAGAAAAACUUAGACACCUUAAUGAAA
  	AACGACGAUUUCACAACAUAGCUGGGCACUAUAGAGG
  	CCAGUGCCAUUCGUGCUGCAACCGAGCACGACAGGAAC
  	GACUCCAACGACGCAGAGAAACACAAGUA
  HPV16_E6	AUGCACCAAAAGAGAACUGCAAUGUUUCAGGACCCAC	459
  	AGGAGCGACCCAGAAAGUUACCACAGUUAUGCACAGA
  	GCUGCAAACAACUAUACAUGAUAUAAUAUUAGAAUGU
  	GUGUACUGCAAGCAACAGUUACUGCGACGUGAGGUAU
  	AUGACUUUGCUUUUCGGGAUUUAUGCAUAGUAUAUAG
  	AGAUGGGAAUCCAUAUGCUGUAUGUGAUAAAUGUUUA
  	AAGUUUUAUUCUAAAAUUAGUGAGUAUAGACAUUAUU
  	GUUAUAGUUUGUAUGGAACAACAUUAGAACAGCAAUA
  	CAACAAACCGUUGUGUGAUUUGUUAAUUAGGUGUAUU
  	AACUGUCAAAAGCCACUGUGUCCUGAAGAAAAGCAAA
  	GACAUCUGGACAAAAAGCAAAGAUUCCAUAAUAUAAG
  	GGGUCGGUGGACCGGUCGAUGUAUGUCUUGUUGCAGA
  	UCAUCAAGAACACGUAGAGAAACCCAGCUG
  mGMCSF	AUGUGGCUUCAAAAUCUCUUGUUUCUUGGAAUCGUCG	460
  	UGUACAGCCUGUCAGCCCCAACUAGAUCGCCUAUCACU
  	GUGACGCGCCCGUGGAAGCACGUGGAAGCCAUCAAGG
  	AGGCUCUGAAUCUGCUCGACGAUAUGCCAGUGACCCU
  	GAACGAGGAAGUCGAAGUGGUGUCCAACGAAUUUUCC
  	UUCAAAAAGUUGACCUGUGUUCAGACCCGGCUGAAGA
  	UUUUCGAGCAGGGCCUCAGGGGAAACUUCACCAAACU
  	GAAGGGUGCACUGAACAUGACCGCCAGCUACUACCAG
  	ACCUAUUGCCCUCCGACUCCGGAAACUGAUUGCGAGAC
  	UCAAGUCACCACCUACGCGGACUUCAUCGACUCGCUCA
  	AGACGUUCCUGACUGACAUCCCCUUCGAGUGCAAGAA
  	GCCGGGGCAGAAA
  hGMCSF	AUGUGGCUACAGUCUCUCCUGCUCCUGGGAACCGUGG	461
  	CUUGCAGCAUAUCAGCGCCUGCCAGGAGCCCCAGCCCA
  	UCUACCCAGCCAUGGGAGCACGUAAACGCCAUACAGG
  	AAGCCCGGCGGCUGCUUAAUCUAUCCCGCGAUACAGCA
  	GCCGAAAUGAACGAAACCGUGGAGGUCAUCAGUGAGA
  	UGUUUGAUCUACAAGAGCCUACUUGCUUACAAACCCG
  	CCUAGAGCUUUACAAGCAAGGCCUCCGGGGCUCUCUCA
  	CAAAGCUGAAAGGUCCAUUAACUAUGAUGGCCUCCCA
  	CUAUAAACAGCACUGCCCACCUACACCAGAGACCUCCU
  	GUGCCACCCAGAUUAUAACCUUCGAAAGCUUUAAGGA
  	GAAUUUAAAGGAUUUCCUCCUGGUCAUCCCCUUCGAC
  	UGCUGGGAACCAGUCCAG

• TABLE 2
  HPV Amino Acid Sequences

  		SEQ ID
  Description	Sequence	NO:
  HPV6_L1	MWRPSDSTVYVPPPNPVSKVVATDAYVTRTNIFYHASSSR	31
  	LLAVGHPYFSIKRANKTVVPKVSGYQYRVFKVVLPDPNKF
  	ALPDSSLFDPTTQRLVWACTGLEVGRGQPLGVGVSGHPFL
  	NKYDDVENSGSGGNPGQDNRVNVGMDYKQTQLCMVGC
  	APPLGEHWGKGKQCTNTPVQAGDCPPLELITSVIQDGDMV
  	DTGFGAMNFADLQTNKSDVPIDICGTTCKYPDYLQMAADP
  	YGDRLFFFLRKEQMFARHFFNRAGEVGEPVPDTLIIKGSGN
  	RTSVGSSIYVNTPSGSLVSSEAQLFNKPYWLQKAQGHNNGI
  	CWGNQLFVTVVDTTRSTNMTLCASVTTSSTYTNSDYKEY
  	MRHVEEYDLQFIFQLCSITLSAEVMAYIHTMNPSVLEDWN
  	FGLSPPPNGTLEDTYRYVQSQAITCQKPTPEKEKPDPYKNL
  	SFWEVNLKEKFSSELDQYPLGRKFLLQSGYRGRSSIRTGVK
  	RPAVSKASAAPKRKRAKTKR
  HPV11_L1	MWRPSDSTVYVPPPNPVSKVVATDAYVKRTNIFYHASSSR	32
  	LLAVGHPYYSIKKVNKTVVPKVSGYQYRVFKVVLPDPNKF
  	ALPDSSLFDPTTQRLVWACTGLEVGRGQPLGVGVSGHPLL
  	NKYDDVENSGGYGGNPGQDNRVNVGMDYKQTQLCMVG
  	CAPPLGEHWGKGTQCSNTSVQNGDCPPLELITSVIQDGDM
  	VDTGFGAMNFADLQTNKSDVPLDICGTVCKYPDYLQMAA
  	DPYGDRLFFYLRKEQMFARHFFNRAGTVGEPVPDDLLVKG
  	GNNRSSVASSIYVHTPSGSLVSSEAQLFNKPYWLQKAQGH
  	NNGICWGNHLFVTVVDTTRSTNMTLCASVSKSATYTNSDY
  	KEYMRHVEEFDLQFIFQLCSITLSAEVMAYIHTMNPSVLED
  	WNFGLSPPPNGTLEDTYRYVQSQAITCQKPTPEKEKQDPY
  	KDMSFWEVNLKEKFSSELDQFPLGRKFLLQSGYRGRTSAR
  	TGIKRPAVSKPSTAPKRKRTKTKK
  HPV16_L1	MSLWLPSEATVYLPPVPVSKVVSTDEYVARTNIYYHAGTS	33
  	RLLAVGHPYFPIKKPNNNKILVPKVSGLQYRVFRIHLPDPN
  	KFGFPDTSFYNPDTQRLVWACVGVEVGRGQPLGVGISGHP
  	LLNKLDDTENASAYAANAGVDNRECISMDYKQTQLCLIGC
  	KPPIGEHWGKGSPCTNVAVNPGDCPPLELINTVIQDGDMV
  	DTGFGAMDFTTLQANKSEVPLDICTSICKYPDYIKMVSEPY
  	GDSLFFYLRREQMFVRHLFNRAGTVGENVPDDLYIKGSGS
  	TANLASSNYFPTPSGSMVTSDAQIFNKPYWLQRAQGHNNG
  	ICWGNQLFVTVVDTTRSTNMSLCAAISTSETTYKNTNFKEY
  	LRHGEEYDLQFIFQLCKITLTADVMTYIHSMNSTILEDWNF
  	GLQPPPGGTLEDTYRFVTSQAIACQKHTPPAPKEDPLKKYT
  	FWEVNLKEKFSADLDQFPLGRKFLLQAGLKAKPKFTLGKR
  	KATPTTSSTSTTAKRKKRKL
  HPV18_L1	MALWRPSDNTVYLPPPSVARVVNTDDYVTRTSIFYHAGSS	34
  	RLLTVGNPYFRVPAGGGNKQDIPKVSAYQYRVFRVQLPDP
  	NKFGLPDTSIYNPETQRLVWACAGVEIGRGQPLGVGLSGH
  	PFYNKLDDTESSHAATSNVSEDVRDNVSVDYKQTQLCILG
  	CAPAIGEHWAKGTACKSRPLSQGDCPPLELKNTVLEDGDM
  	VDTGYGAMDFSTLQDTKCEVPLDICQSICKYPDYLQMSAD
  	PYGDSMFFCLRREQLFARHFWNRAGTMGDTVPQSLYIKGT
  	GMRASPGSCVYSPSPSGSIVTSDSQLFNKPYWLHKAQGHN
  	NGVCWHNQLFVTVVDTTRSTNLTICASTQSPVPGQYDATK
  	FKQYSRHVEEYDLQFIFQLCTITLTADVMSYIHSMNSSILED
  	WNFGVPPPPTTSLVDTYRFVQSVAITCQKDAAPAENKDPY
  	DKLKFWNVDLKEKFSLDLDQYPLGRKFLVQAGLRRKPTIG
  	PRKRSAPSATTSSKPAKRVRVRARK
  HPV31_L1	MSLWRPSEATVYLPPVPVSKVVSTDEYVTRTNIYYHAGSA	35
  	RLLTVGHPYYSIPKSDNPKKIVVPKVSGLQYRVFRVRLPDP
  	NKFGFPDTSFYNPETQRLVWACVGLEVGRGQPLGVGISGH
  	PLLNKFDDTENSNRYAGGPGTDNRECISMDYKQTQLCLLG
  	CKPPIGEHWGKGSPCSNNAITPGDCPPLELKNSVIQDGDMV
  	DTGFGAMDFTALQDTKSNVPLDICNSICKYPDYLKMVAEP
  	YGDTLFFYLRREQMFVRHFFNRSGTVGESVPTDLYIKGSGS
  	TATLANSTYFPTPSGSMVTSDAQIFNKPYWMQRAQGHNN
  	GICWGNQLFVTVVDTTRSTNMSVCAAIANSDTTFKSSNFK
  	EYLRHGEEFDLQFIFQLCKITLSADIMTYIHSMNPAILEDWN
  	FGLTTPPSGSLEDTYRFVTSQAITCQKTAPQKPKEDPFKDY
  	VFWEVNLKEKFSADLDQFPLGRKFLLQAGYRARPKFKAG
  	KRSAPSASTTTPAKRKKTKK
  HPV33_L1	MSVWRPSEATVYLPPVPVSKVVSTDEYVSRTSIYYYAGSS	36
  	RLLAVGHPYFSIKNPTNAKKLLVPKVSGLQYRVFRVRLPDP
  	NKFGFPDTSFYNPDTQRLVWACVGLEIGRGQPLGVGISGHP
  	LLNKFDDTETGNKYPGQPGADNRECLSMDYKQTQLCLLG
  	CKPPTGEHWGKGVACTNAAPANDCPPLELINTIIEDGDMV
  	DTGFGCMDFKTLQANKSDVPIDICGSTCKYPDYLKMTSEP
  	YGDSLFFFLRREQMFVRHFFNRAGTLGEAVPDDLYIKGSG
  	TTASIQSSAFFPTPSGSMVTSESQLFNKPYWLQRAQGHNNG
  	ICWGNQVFVTVVDTTRSTNMTLCTQVTSDSTYKNENFKEY
  	IRHVEEYDLQFVFQLCKVTLTAEVMTYIHAMNPDILEDWQ
  	FGLTPPPSASLQDTYRFVTSQAITCQKTVPPKEKEDPLGKY
  	TFWEVDLKEKFSADLDQFPLGRKFLLQAGLKAKPKLKRAA
  	PTSTRTSSAKRKKVKK
  HPV35_L1_DX	MSLWRSNEATVYLPPVSVSKVVSTDEYVTRTNIYYHAGSS	37
  	RLLAVGHPYYAIKKQDSNKIAVPKVSGLQYRVFRVKLPDP
  	NKFGFPDTSFYDPASQRLVWACTGVEVGRGQPLGVGISGH
  	PLLNKLDDTENSNKYVGNSGTDNRECISMDYKQTQLCLIG
  	CRPPIGEHWGKGTPCNANQVKAGECPPLELLNTVLQDGD
  	MVDTGFGAMDFTTLQANKSDVPLDICSSICKYPDYLKMVS
  	EPYGDMLFFYLRREQMFVRHLFNRAGTVGETVPADLYIKG
  	TTGTLPSTSYFPTPSGSMVTSDAQIFNKPYWLQRAQGHNN
  	GICWSNQLFVTVVDTTRSTNMSVCSAVSSSDSTYKNDNFK
  	EYLRHGEEYDLQFIFQLCKITLTADVMTYIHSMNPSILEDW
  	NFGLTPPPSGTLEDTYRYVTSQAVTCQKPSAPKPKDDPLKN
  	YTFWEVDLKEKFSADLDQFPLGRKFLLQAGLKARPNFRLG
  	KRAAPASTSKKSSTKRRKVKS
  HPV39_L1_DX	MAMWRSSDSMVYLPPPSVAKVVNTDDYVTRTGIYYYAGS	38
  	SRLLTVGHPYFKVGMNGGRKQDIPKVSAYQYRVFRVTLPD
  	PNKFSIPDASLYNPETQRLVWACVGVEVGRGQPLGVGISG
  	HPLYNRQDDTENSPFSSTTNKDSRDNVSVDYKQTQLCIIGC
  	VPAIGEHWGKGKACKPNNVSTGDCPPLELVNTPIEDGDMI
  	DTGYGAMDFGALQETKSEVPLDICQSICKYPDYLQMSADV
  	YGDSMFFCLRREQLFARHFWNRGGMVGDAIPAQLYIKGT
  	DIRANPGSSVYCPSPSGSMVTSDSQLFNKPYWLHKAQGHN
  	NGICWHNQLFLTVVDTTRSTNFTLSTSIESSIPSTYDPSKFKE
  	YTRHVEEYDLQFIFQLCTVTLTTDVMSYIHTMNSSILDNWN
  	FAVAPPPSASLVDTYRYLQSAAITCQKDAPAPEKKDPYDG
  	LKFWNVDLREKFSLELDQFPLGRKFLLQARVRRRPTIGPRK
  	RPAASTSSSSATKHKRKRVSK
  HPV45_L1_DX	MALWRPSDSTVYLPPPSVARVVSTDDYVSRTSIFYHAGSSR	39
  	LLTVGNPYFRVVPNGAGNKQAVPKVSAYQYRVFRVALPD
  	PNKFGLPDSTIYNPETQRLVWACVGMEIGRGQPLGIGLSGH
  	PFYNKLDDTESAHAATAVITQDVRDNVSVDYKQTQLCILG
  	CVPAIGEHWAKGTLCKPAQLQPGDCPPLELKNTIIEDGDM
  	VDTGYGAMDFSTLQDTKCEVPLDICQSICKYPDYLQMSAD
  	PYGDSMFFCLRREQLFARHFWNRAGVMGDTVPTDLYIKG
  	TSANMRETPGSCVYSPSPSGSIITSDSQLFNKPYWLHKAQG
  	HNNGICWHNQLFVTVVDTTRSTNLTLCASTQNPVPSTYDP
  	TKFKQYSRHVEEYDLQFIFQLCTITLTAEVMSYIHSMNSSIL
  	ENWNFGVPPPPTTSLVDTYRFVQSVAVTCQKDTTPPEKQD
  	PYDKLKFWTVDLKEKFSSDLDQYPLGRKFLVQAGLRRRPT
  	IGPRKRPAASTSTASTASRPAKRVRIRSKK
  HPV51_L1_DX	MALWRTNDSKVYLPPAPVSRIVNTEEYITRTGIYYYAGSSR	40
  	LITLGHPYFPIPKTSTRAAIPKVSAFQYRVFRVQLPDPNKFG
  	LPDPNLYNPDTDRLVWGCVGVEVGRGQPLGVGLSGHPLF
  	NKYDDTENSRIANGNAQQDVRDNTSVDNKQTQLCIIGCAP
  	PIGEHWGIGTTCKNTPVPPGDCPPLELVSSVIQDGDMIDTGF
  	GAMDFAALQATKSDVPLDISQSVCKYPDYLKMSADTYGN
  	SMFFHLRREQIFARHYYNKLVGVGEDIPNDYYIKGSGNGR
  	DPIESYIYSATPSGSMITSDSQIFNKPYWLHRAQGHNNGIC
  	WNNQLFITCVDTTRSTNLTISTATAAVSPTFTPSNFKQYIRH
  	GEEYELQFIFQLCKITLTTEVMAYLHTMDPTILEQWNFGLT
  	LPPSASLEDAYRFVRNAATSCQKDTPPQAKPDPLAKYKFW
  	DVDLKERFSLDLDQFALGRKFLLQVGVQRKPRPGLKRPAS
  	SASSSSSSSAKRKRVKK
  HPV52_L1_DX	MSVWRPSEATVYLPPVPVSKVVSTDEYVSRTSIYYYAGSS	41
  	RLLTVGHPYFSIKNTSSGNGKKVLVPKVSGLQYRVFRIKLP
  	DPNKFGFPDTSFYNPETQRLVWACTGLEIGRGQPLGVGISG
  	HPLLNKFDDTETSNKYAGKPGIDNRECLSMDYKQTQLCIL
  	GCKPPIGEHWGKGTPCNNNSGNPGDCPPLQLINSVIQDGD
  	MVDTGFGCMDFNTLQASKSDVPIDICSSVCKYPDYLQMAS
  	EPYGDSLFFFLRREQMFVRHFFNRAGTLGDPVPGDLYIQGS
  	NSGNTATVQSSAFFPTPSGSMVTSESQLFNKPYWLQRAQG
  	HNNGICWGNQLFVTVVDTTRSTNMTLCAEVKKESTYKNE
  	NFKEYLRHGEEFDLQFIFQLCKITLTADVMTYIHKMDATIL
  	EDWQFGLTPPPSASLEDTYRFVTSTAITCQKNTPPKGKEDP
  	LKDYMFWEVDLKEKFSADLDQFPLGRKFLLQAGLQARPK
  	LKRPASSAPRTSTKKKKVKR
  HPV56_L1_DX	MATWRPSENKVYLPPTPVSKVVATDSYVKRTSIFYHAGSS	42
  	RLLAVGHPYYSVTKDNTKTNIPKVSAYQYRVFRVRLPDPN
  	KFGLPDTNIYNPDQERLVWACVGLEVGRGQPLGAGLSGHP
  	LFNRLDDTESSNLANNNVIEDSRDNISVDGKQTQLCIVGCT
  	PAMGEHWTKGAVCKSTQVTTGDCPPLALINTPIEDGDMID
  	TGFGAMDFKVLQESKAEVPLDIVQSTCKYPDYLKMSADA
  	YGDSMWFYLRREQLFARHYFNRAGKVGETIPAELYLKGS
  	NGREPPPSSVYVATPSGSMITSEAQLFNKPYWLQRAQGHN
  	NGICWGNQLFVTVVDTTRSTNMTISTATEQLSKYDARKIN
  	QYLRHVEEYELQFVFQLCKITLSAEVMAYLHNMNANLLE
  	DWNIGLSPPVATSLEDKYRYVRSTAITCQREQPPTEKQDPL
  	AKYKFWDVNLQDSFSTDLDQFPLGRKFLMQLGTRSKPAV
  	ATSKKRSAPTSTSTPAKRKRR
  HPV58_L1_DX	MSVWRPSEATVYLPPVPVSKVVSTDEYVSRTSIYYYAGSS	43
  	RLLAVGNPYFSIKSPNNNKKVLVPKVSGLQYRVFRVRLPD
  	PNKFGFPDTSFYNPDTQRLVWACVGLEIGRGQPLGVGVSG
  	HPYLNKFDDTETSNRYPAQPGSDNRECLSMDYKQTQLCLI
  	GCKPPTGEHWGKGVACNNNAAATDCPPLELFNSIIEDGDM
  	VDTGFGCMDFGTLQANKSDVPIDICNSTCKYPDYLKMASE
  	PYGDSLFFFLRREQMFVRHFFNRAGKLGEAVPDDLYIKGS
  	GNTAVIQSSAFFPTPSGSIVTSESQLFNKPYWLQRAQGHNN
  	GICWGNQLFVTVVDTTRSTNMTLCTEVTKEGTYKNDNFK
  	EYVRHVEEYDLQFVFQLCKITLTAEIMTYIHTMDSNILEDW
  	QFGLTPPPSASLQDTYRFVTSQAITCQKTAPPKEKEDPLNK
  	YTFWEVNLKEKFSADLDQFPLGRKFLLQSGLKAKPRLKRS
  	APTTRAPSTKRKKVKK
  HPV59_L1_DX	MALWRSSDNKVYLPPPSVAKVVSTDEYVTRTSIFYHAGSS	44
  	RLLTVGHPYFKVPKGGNGRQDVPKVSAYQYRVFRVKLPD
  	PNKFGLPDNTVYDPNSQRLVWACVGVEIGRGQPLGVGLSG
  	HPLYNKLDDTENSHVASAVDTKDTRDNVSVDYKQTQLCII
  	GCVPAIGEHWTKGTACKPTTVVQGDCPPLELINTPIEDGDM
  	VDTGYGAMDFKLLQDNKSEVPLDICQSICKYPDYLQMSAD
  	AYGDSMFFCLRREQVFARHFWNRSGTMGDQLPESLYIKGT
  	DIRANPGSYLYSPSPSGSVVTSDSQLFNKPYWLHKAQGLN
  	NGICWHNQLFLTVVDTTRSTNLSVCASTTSSIPNVYTPTSFK
  	EYARHVEEFDLQFIFQLCKITLTTEVMSYIHNMNTTILEDW
  	NFGVTPPPTASLVDTYRFVQSAAVTCQKDTAPPVKQDPYD
  	KLKFWPVDLKERFSADLDQFPLGRKFLLQLGARPKPTIGPR
  	KRAAPAPTSTPSPKRVKRRKSSRK
  HPV68_L1_DX	MALWRASDNMVYLPPPSVAKVVNTDDYVTRTGMYYYAG	45
  	TSRLLTVGHPYFKVPMSGGRKQGIPKVSAYQYRVFRVTLP
  	DPNKFSVPESTLYNPDTQRMVWACVGVEIGRGQPLGVGLS
  	GHPLYNRLDDTENSPFSSNKNPKDSRDNVAVDCKQTQLCII
  	GCVPAIGEHWAKGKSCKPTNVQQGDCPPLELVNTPIEDGD
  	MIDTGYGAMDFGTLQETKSEVPLDICQSVCKYPDYLQMSA
  	DVYGDSMFFCLRREQLFARHFWNRGGMVGDTIPTDMYIK
  	GTDIRETPSSYVYAPSPSGSMVSSDSQLFNKPYWLHKAQG
  	HNNGICWHNQLFLTVVDTTRSTNFTLSTTTDSTVPAVYDS
  	NKFKEYVRHVEEYDLQFIFQLCTITLSTDVMSYIHTMNPAI
  	LDDWNFGVAPPPSASLVDTYRYLQSAAITCQKDAPAPVKK
  	DPYDGLNFWNVDLKEKFSSELDQFPLGRKFLLQAGVRRRP
  	TIGPRKRTATAATTSTSKHKRKRVSK
  HPV73_L1_DX	MWRPTDAKVYLPPVSVSKVVSTDEYVTRTNIYYYAGSTRL	46
  	LAVGHPYFPIKDSQKRKTIVPKVSGLQYRVFRLRLPDPNKF
  	GFPDASFYNPDKERLVWACSGVEVGRGQPLGIGTSGNPFM
  	NKLDDTENAPKYIAGQNTDGRECMSVDYKQTQLCILGCRP
  	PLGEHWGPGTPCTSQTVNTGDCPPLELKNTPIQDGDMIDV
  	GFGAMDFKALQANKSDVPIDISNTTCKYPDYLGMAADPY
  	GDSMWFYLRREQMFVRHLFNRAGDTGDKIPDDLMIKGTG
  	NTATPSSCVFYPTPSGSMVSSDAQLFNKPYWLQKAQGQNN
  	GICWHNQLFLTVVDTTRSTNFSVCVGTQASSSTTTYANSNF
  	KEYLRHAEEFDLQFVFQLCKISLTTEVMTYIHSMNSTILEE
  	WNFGLTPPPSGTLEETYRYVTSQAISCQRPQPPKETEDPYA
  	KLSFWDVDLKEKFSAELDQFPLGRKFLLQLGMRARPKLQA
  	SKRSASATTSATPKKKRAKRI
  HPV82_L1_DX	MALWRTNDSKVYLPPAPVSRIVNTEEYITRTGIYYYAGSSR	47
  	LITLGHPYFSIPKTNTRAEIPKVSAFQYRVFRVQLPDPNKFG
  	LPDPNLFNPDTDRLVWGCVGVEVGRGQPLGVGLSGHPLFN
  	KYDDTENSRFANGNDQQDVRDNISVDNKQTQLCIIGCAPPI
  	GEHWATGTTCKNVPVPQGDCPPLELVSTVIEDGDMVDTGF
  	GAMDFANLQATKSDVPLDIAQSVCKYPDYLKMSADTYGN
  	SMFFHLRREQIFARHYYNKAGVVGDAIPDKAYIKGTGAGR
  	DPISSYIYSATPSGSMITSDSQIFNKPYWLHRAQGHNNGICW
  	NNQLFITCVDTTKSTNLTISTAVTPSVAQTFTPANFKQYIRH
  	GEEYELQFIFQLCKITLTTEIMAYLHTMDSTILEQWNFGLTL
  	PPSASLEDAYRFVKNAATSCHKDSPPQAKEDPLAKYKFWN
  	VDLKERFSLDLDQFALGRKFLLQIGAQRKPRPGLKRPAPSS
  	SASSSAKRKRVKK
  IgK_HPV18_E7_Rb_mut	METPAQLLFLLLLWLPDTTGHGPKATLQDIVLHLEPQNEIP	48
  	VDLLGHGQLSDSEEENDEIDGVNHQHLPARRAEPQRHTML
  	CMCCKCEARIKLVVESSADDLRAFQQLFLNTLSFVCPWCA
  	SQQ
  HPV18_E7_Rb_mut	MHGPKATLQDIVLHLEPQNEIPVDLLGHGQLSDSEEENDEI	49
  	DGVNHQHLPARRAEPQRHTMLCMCCKCEARIKLVVESSA
  	DDLRAFQQLFLNTLSFVCPWCASQQ
  IgK_HPV16_E7_Rb_mut	METPAQLLFLLLLWLPDTTGHGDTPTLHEYMLDLQPETTD	50
  	LYGYGQLNDSSEEEDEIDGPAGQAEPDRAHYNIVTFCCKC
  	DSTLRLCVQSTHVDIRTLEDLLMGTLGIVCPICSQKP
  HPV16_E7_Rb_mut	MHGDTPTLHEYMLDLQPETTDLYGYGQLNDSSEEEDEIDG	51
  	PAGQAEPDRAHYNIVTFCCKCDSTLRLCVQSTHVDIRTLED
  	LLMGTLGIVCPICSQKP
  IgK_HPV18_E6_p53_mutdel	METPAQLLFLLLLWLPDTTGARFEDPTRSGYKLPDLCTELN	52
  	TSLQDIEITCVYCKTVLELTEVFEKDLFVVYRDSIPHAACH
  	KCIDFYSRIRELRHYSDSVYGDTLEKLTNTGLYNLLIRCLRC
  	QKPLLRHLNEKRRFHNIAGHYRGQCHSCCNRARQERLQRR
  	RETQV
  HPV18_E6_p53_mutdel	MARFEDPTRSGYKLPDLCTELNTSLQDIEITCVYCKTVLEL	53
  	TEVFEKDLFVVYRDSIPHAACHKCIDFYSRIRELRHYSDSV
  	YGDTLEKLTNTGLYNLLIRCLRCQKPLLRHLNEKRRFHNIA
  	GHYRGQCHSCCNRARQERLQRRRETQV
  IgK_HPV16_E6_p53_mutdel	METPAQLLFLLLLWLPDTTGHQKRTAMFQDPQESGRKLPQ	54
  	LCTELQTTIHDIILECVYCKQQLLRREVYDRDLCIVYRDGN
  	PYAVCDKCLKFYSKISEYRHYCYSLYGTTLEQQYNKPLCD
  	LLIRCINCQKPLQRHLDKKQRFHNIRGRWTGRCMSCCRSSR
  	TRRETQL
  HPV16_E6_p53_mutdel	MHQKRTAMFQDPQESGRKLPQLCTELQTTIHDIILECVYCK	55
  	QQLLRREVYDRDLCIVYRDGNPYAVCDKCLKFYSKISEYR
  	HYCYSLYGTTLEQQYNKPLCDLLIRCINCQKPLQRHLDKK
  	QRFHNIRGRWTGRCMSCCRSSRTRRETQL
  HPV18_E7	MHGPKATLQDIVLHLEPQNEIPVDLLCHEQLSDSEEENDEI	56
  	DGVNHQHLPARRAEPQRHTMLCMCCKCEARIELVVESSA
  	DDLRAFQQLFLNTLSFVCPWCASQQ
  HPV16_E7	MHGDTPTLHEYMLDLQPETTDLYCYEQLNDSSEEEDEIDG	57
  	PAGQAEPDRAHYNIVTFCCKCDSTLRLCVQSTHVDIRTLED
  	LLMGTLGIVCPICSQKP
  HPV18_E6	MARFEDPTRRPYKLPDLCTELNTSLQDIEITCVYCKTVLEL	58
  	TEVFEFAFKDLFVVYRDSIPHAACHKCIDFYSRIRELRHYSD
  	SVYGDTLEKLTNTGLYNLLIRCLRCQKPLNPAEKLRHLNE
  	KRRFHNIAGHYRGQCHSCCNRARQERLQRRRETQV
  HPV16_E6	MHQKRTAMFQDPQERPRKLPQLCTELQTTIHDIILECVYCK	59
  	QQLLRREVYDFAFRDLCIVYRDGNPYAVCDKCLKFYSKIS
  	EYRHYCYSLYGTTLEQQYNKPLCDLLIRCINCQKPLCPEEK
  	QRHLDKKQRFHNIRGRWTGRCMSCCRSSRTRRETQL
  mGMCSF	MWLQNLLFLGIVVYSLSAPTRSPITVTRPWKHVEAIKEALN	60
  	LLDDMPVTLNEEVEVVSNEFSFKKLTCVQTRLKIFEQGLRG
  	NFTKLKGALNMTASYYQTYCPPTPETDCETQVTTYADFID
  	SLKTFLTDIPFECKKPGQK
  hGMCSF	MWLQSLLLLGTVACSISAPARSPSPSTQPWEHVNAIQEARR	61
  	LLNLSRDTAAEMNETVEVISEMFDLQEPTCLQTRLELYKQ
  	GLRGSLTKLKGPLTMMASHYKQHCPPTPETSCATQIITFESF
  	KENLKDFLLVIPFDCWEPVQ

• TABLE 3
  HPV NCBI Accession Numbers (Amino Acid Sequences)

  		GenBank
  Type	Virus Name	Accession

  L1	hypothetical protein HpV63gp7	NP_040902.1
  	[Human papillomavirus type 63]
  L1	L1 protein [Human papillomavirus type 204]	AKG54930.1
  L1	RecName: Full = Major capsid protein L1	P27557.2
  	[Human papillomavirus type 41]
  L1	hypothetical protein [Human papillomavirus type 41]	NP_040294.1
  L1	major capsid protein [Human papillomavirus type 138]	AEM24620.1
  L1	L1 protein [Human papillomavirus type 98]	CAW42222.1
  L1	RecName: Full = Major capsid protein L1	P50790.1
  L1	L1 [Human papillomavirus type 16]	AFS33363.1
  L1	major capsid protein [Human papillomavirus type 139]	AEM24627.1
  L1	L1 [Human papillomavirus type 16]	AFS33339.1
  L1	L1 [Human papillomavirus type 16]	AAV91659.1
  L1	Chain A, L1 Protein Of Human Papillomavirus 16	1DZL_A
  L1	L1 protein [Human papillomavirus type 16]	AGK28592.1
  L1	late major capsid protein [Human papillomavirus type 16]	AAC09292.1
  L1	major capsid protein L1 [Human papillomavirus type 16]	ACV53971.1
  L1	L1 [Human papillomavirus type 16]	ACN91157.1
  L1	HPV-16 L1 [synthetic construct]	AAY79402.1
  L1	L1 [Human papillomavirus type 16]	AFS33347.1
  L1	L1 protein [Human papillomavirus type 42]	CCI11841.1
  L1	L1 protein [Human papillomavirus type 42]	CCI11834.1
  L1	L1 [Human papillomavirus type 93]	AAQ88285.1
  L1	major capsid protein L1 [Human papillomavirus type 16]	ACV53973.1
  L1	coat protein L1 [Cloning vector p119L1e]	AAX54678.1
  L1	late major capsid protein [Human papillomavirus type 16]	AAC61736.1
  L1	L1 [Human papillomavirus type 16]	AAV91667.1
  L1	major capsid protein L1 [Human papillomavirus type 16]	AGC65525.1
  L1	L1 [Human papillomavirus type 16]	AFS33350.1
  L1	L1 protein [Human papillomavirus type 16]	AFP44558.1
  L1	L1 protein [Human papillomavirus type 16]	AFP44198.1
  L1	L1 protein [Human papillomavirus type 42]	CCI11844.1
  L1	putative major capsid protein L1	AAQ10410.1
  	[Human papillomavirus type 16]
  L1	L1 [Human papillomavirus type 16]	ALB35275.1
  L1	RecName: Full = Major capsid protein L1	P03101.2
  L1	L1 [Human papillomavirus type 16]	AIQ82817.1
  L1	major capsid protein L1 [Human papillomavirus type 16]	ACV84004.1
  L1	L1 capsid protein [Human papillomavirus type 16]	AAA92892.1
  L1	L1 protein [Human papillomavirus type 16]	AEZ01705.1
  L1	L1 [Human papillomavirus type 16]	AFS33335.1
  L1	L1 protein [Human papillomavirus type 16]	AFP44382.1
  L1	RecName: Full = Major capsid protein L1	P27233.1
  L1	putative major capsid protein L1	AAO15712.1
  	[Human papillomavirus type 16]
  L1	L1 protein [Human papillomavirus type 16]	AFP44630.1
  L2	minor capsid protein L2 [Mupapillomavirus 1]	NP_040308.1
  L2	hypothetical protein HpV63gp6	NP_040901.1
  	[Human papillomavirus type 63]
  L2	L2 protein [Human papillomavirus type 204]	AKG54929.1
  L2	late protein [Lambdapapillomavirus 2]	NP_056818.1
  L2	L2 protein [Panthera leo persica papillomavirus type 1]	AAX86631.1
  L2	L2 [Procyon lotor papillomavirus 1]	YP_249603.1
  L2	L2 [Enhydra lutris papillomavirus 1]	YP_009021868.1
  L2	L2 [Canis familiaris papillomavirus 6]	YP_003204680.1
  L2	L2 [Uncia uncia papillomavirus type 1]	ABA61876.1
  L2	L2 protein [Felis domesticus papillomavirus type 1]	NP_848024.1
  L2	L2 [Castor canadensis papillomavirus 1]	YP_008992243.1
  L2	L2 protein [Puma concolor papillomavirus type 1]	AAX86624.1
  L2	L2 protein [Crocuta crocuta papillomavirus 1]	YP_006666519.1
  L2	L2 protein [Lynx rufus papillomavirus type 1]	AAX86617.1
  L2	late protein [Human papillomavirus type 9]	NP_041865.1
  L2	L2 [Macaca fascicularis papillomavirus 2]	YP_004646336.1
  L2	L2 [Human papillomavirus type 96]	NP_932324.1
  L2	minor capsid protein L2	ADH29817.1
  	[Human papillomavirus type 122]
  L2	putative L2 product [Human papillomavirus type 150]	CBK38951.1
  L2	L2 protein [Human papillomavirus type 98]	CAW42221.1
  L2	minor capsid protein [Human papillomavirus type 5]	NP_041371.1
  L2	L2 protein [Human papillomavirus type 75]	CAA75453.1
  L2	L2 protein [Human papillomavirus type 104]	CAW42255.1
  L2	L2 protein [Human papillomavirus FA75/KI88-03]	ACC78261.1
  L2	L2 [Human papillomavirus type 5]	AAY86491.1
  L2	L2 protein [Human papillomavirus type 174]	CCV02863.1
  L2	L2 protein [Human papillomavirus type 76]	CAA75460.1
  L2	RecName: Full = Minor capsid protein	P50798.1
  	L2 [Human papillomavirus type 24]
  L2	L2 [Human papillomavirus type 80]	CAA75475.1
  L2	minor capsid protein [Human papillomavirus type 145]	AEM24668.1
  L2	L2 protein [Human papillomavirus type 107]	ABN79872.1
  L2	L2 protein [Human papillomavirus type 111]	ACC78275.1
  L2	L2 [Human papillomavirus type 92]	NP_775310.1
  L2	RecName: Full = Minor capsid protein	P50795.1
  	L2 [Human papillomavirus type 21]
  L2	RecName: Full = Minor capsid protein	P36749.1
  	L2 [Human papillomavirus type 14]
  L2	minor capsid protein [Human papillomavirus type 143]	AEM24654.1
  L2	late protein L2 [Human papillomavirus type 115]	ACZ58408.1
  L2	RecName: Full = Minor capsid protein	Q80912.1
  	L2 [Human papillomavirus type 38]
  L2	putative L2 [uncultured Papillomavirus]	AEY63592.1
  L2	L2 protein [Human papillomavirus type 49]	NP_041836.1
  L2	putative late L2 protein [Rhinolophus ferrumequinum	AHJ81406.1
  	papillomavirus type 1]
  L2	early protein L2 [Human papillomavirus type 36]	AEA35083.1
  L2	RecName: Full = Minor capsid protein	P50794.1
  	L2 [Human papillomavirus type 20]
  L2	L2 [Human papillomavirus type 5]	AFL02857.1
  L2	RecName: Full = Minor capsid protein	P26540.1
  	L2 [Human papillomavirus type 5b]
  L2	RecName: Full = Minor capsid protein	P50827.1
  	L2 [Human papillomavirus type 36]
  L2	L2 protein [Human papillomavirus type 38b]	AAY89823.2
  L2	L2 [Human papillomavirus type 93]	AAQ88284.1
  L2	RecName: Full = Minor capsid protein	P06419.1
  	L2 [Human papillomavirus type 8]
  L2	L2 protein [Human papillomavirus type 113]	CAW42275.1
  L2	L2 protein [Human papillomavirus type 159]	CCJ27720.1
  L2	RecName: Full = Minor capsid protein	P36752.1
  	L2 [Human papillomavirus type 19]
  L2	L2 [Human papillomavirus type 38]	AFL02871.1
  L2	L2 [Human papillomavirus type 118]	ACV30152.1
  L2	early protein L2 [Human papillomavirus type 152]	AEA35077.1
  L2	L2 [Macaca fascicularis papillomavirus type 1]	ABM67069.1
  L2	L2 protein [Human papillomavirus type 105]	CAW42266.1
  L2	minor capsid protein L2	ADH29831.1
  	[Human papillomavirus type 124]
  L2	RecName: Full = Minor capsid protein	P36750.1
  	L2 [Human papillomavirus type 15]
  L2	L2 [Human papillomavirus RTRX7]	AAB61645.1
  L2	L2 [Human papillomavirus type 17]	AFL02864.1
  L2	RecName: Full = Minor capsid protein	P36748.1
  	L2 [Human papillomavirus type 12]
  L2	L2 [Human papillomavirus type 110]	ACC78268.1
  L2	RecName: Full = Minor capsid protein	P36753.1
  	L2 [Human papillomavirus type 25]
  L2	L2 protein [Human papillomavirus type 100]	CAW42243.1
  L2	L2 protein [Human papillomavirus type 99]	CAW42231.1
  L2	RecName: Full = Minor capsid protein	P22425.1
  	L2 [Human papillomavirus type 74]
  L2	L2 [Human papillomavirus type 120]	AFJ32711.1
  L2	putative L2 protein [Human papillomavirus type 120]	CBI67303.1
  L2	RecName: Full = Minor capsid protein	Q80905.1
  	L2 [Human papillomavirus type 37]
  L2	RecName: Full = Minor capsid protein	P36751.1
  	L2 [Human papillomavirus type 17]
  L2	putative L2 product [Human papillomavirus type 151]	CBK38958.1
  L2	L2 [Colobus guereza papillomavirus type 2]	YP_004646342.1
  L2	RecName: Full = Minor capsid protein	P50796.1
  	L2 [Human papillomavirus type 22]
  L2	minor capsid protein L2 [Kappapapillomavirus 1]	NP_057847.1
  L2	RecName: Full = Minor capsid protein	P50797.1
  	L2 [Human papillomavirus type 23]
  L2	L2 [Kappapapillomavirus 2]	NP_077112.1
  L2	L2 [Expression vector pBCGL2]	ABM68360.1
  L2	L2 [Kappapapillomavirus 2]	CAB96168.1
  L2	L2 [Kappapapillomavirus 2]	CAB96120.1
  L2	L2 [Peromyscus papillomavirus type 1]	AEM05820.1
  L2	putative late L2 protein	AHJ81394.1
  	[Eptesicus serotinus papillomavirus type 2]
  L2	L2 [Kappapapillomavirus 2]	AEG21068.1
  L2	minor capsid protein	YP_002427695.1
  	[Erinaceus europaeus papillomavirus]
  L2	L2 [Human papillomavirus type 180]	AGC93440.1
  L2	L2 [Canis familiaris papillomavirus 2]	YP_164634.1
  L2	L2 [Human papillomavirus type 134]	YP_004169296.1
  L2	L2 [Eidolon helvum papillomavirus type 1]	AGB34180.1
  L2	L2 protein [Bovine papillomavirus type 11]	BAJ12077.1
  L2	minor capsid protein [Human papillomavirus type 139]	AEM24626.1
  L2	L2 [Human papillomavirus type 173]	AHC00355.1
  L2	minor capsid protein L2	YP_003668030.1
  	[Human papillomavirus type 121]
  L2	unnamed protein product [Canine papillomavirus 10]	YP_004895385.1
  L2	L2 [Human papillomavirus type 133]	ADQ85974.1
  L2	L2 protein [Bovine papillomavirus]	AJG05911.1
  L2	L2 [Human papillomavirus type 155]	AEQ98810.1
  L2	L2 protein [Iotapapillomavirus 1]	NP_042018.1
  L2	minor capsid protein [Human papillomavirus type 138]	AEM24619.1
  L2	putative L2 [Equus asinus papillomavirus AA-2014]	YP_009021885.1
  L2	putative minor capsid protein [Canine papillomavirus 3]	YP_717905.1

• TABLE 4
  		SEQ ID
  Description	Sequence	NO:

  Chlamydia MOMP Nucleic Acid Sequences

  Chlamydia	ATGAAAAAACTCTTGAAATCGGTATTAGTATTTGCCGCT	62
  trachomatis strain	TTGAGTTCTGCTTCCTCCTTGCAAGCTCTGCCTGTGGGGA
  C1 major outer	ATCCTGCTGAACCAAGCCTTATGATCGACGGAATTCTGT
  membrane protein	GGGAAGGTTTTGGCGGAGATCCTTGCGATCCTTGCACCA
  (ompA) gene,	CTTGGTGTGACGCTATCAGCATGCGTGTTGGTTACTACG
  complete cds;	GAGACTTTGTTTTCGACCGTGTTTTGAAAACTGATGTGA
  Accession No.	ATAAAGAATTTCAGATGGGAGCGGCGCCTACTACCAGC
  EU040363	GATGTAGTAGGCTTACAAAACGATCCAACAACAAACGT
  	TGCTCGTCCAAATCCCGCTTATGGCAAACACATGCAAGA
  	TGCTGAAATGTTTACGAACGCTGCTTACATGGCATTAAA
  	TATCTGGGATCGTTTTGATGTATTTTGTACATTGGGAGC
  	AACTACCGGTTATTTAAAAGGAAACTCTGCTTCCTTCAA
  	CTTAGTTGGATTATTCGGAACAAAAACACAATCTTCTAG
  	CTTTAATACAGCGAAGCTTATTCCTAACACTGCTTTGAA
  	TGAAGCTGTGGTTGAGCTTTATATAAACACTACCTTTGC
  	TTGGAGCGTAGGTGCTCGTGCAGCTCTCTGGGAATGTGG
  	GTGTGCAACGTTAGGAGCTTCTTTCCAATATGCTCAATC
  	TAAACCTAAAGTAGAAGAGTTAAATGTTCTTTGTAATGC
  	ATCCGAATTTACTATTAATAAGCCGAAAGGATATGTTGG
  	GGCGGAATTTCCACTTAATATTACCGCAGGAACAGAAG
  	CTGCGACAGGGACTAAGGATGCCTCTATTGACTACCATG
  	AGTGGCAAGCAAGTTTAGCCCTTTCTTACAGATTAAATA
  	TGTTCACTCCTTACATTGGAGTTAAATGGTCTAGAGTAA
  	GTTTTGATGCCGACACGATCCGTATCGCTCAGCCTAAAT
  	TGGCTGAAGCAATCTTGGATGTCACTACTCTAAACCCGA
  	CCATCGCTGGTAAAGGAAGTGTGGTCTCTGCCGGAACCG
  	ATAACGAACTGGCTGATACAATGCAAATCGTTTCCTTGC
  	AGTTGAACAAGATGAAATCTAGAAAATCTTGCGGTATTG
  	CAGTAGGAACGACTATTGTAGATGCAGACAAATACGCA
  	GTTACAGTTGAGGCTCGCTTGATCGATGAGAGAGCAGCT
  	CACGTAAATGCACAATTCCGGTTCTAA
  Chlamydia	ATGAAAAAACTCTTGAAATCGGTATTAGTATTTGCCGCT	63
  trachomatis strain	TTGAGTTCTGCTTCCTCCTTGCAAGCTCTGCCTGTGGGGA
  C2 major outer	ATCCTGCTGAACCAAGCCTTATGATCGACGGAATTCTGT
  membrane protein	GGGAAGGTTTTGGCGGAGATCCTTGCGATCCTTGCACCA
  (ompA) gene,	CTTGGTGTGACGCTATCAGCATGCGTGTTGGTTACTACG
  complete cds;	GAGACTTTGTTTTCGACCGTGTTTTGAAAACTGATGTGA
  Accession No.	ATAAAGAATTTCAGATGGGAGCGGCGCCTACTACCAGC
  EU040364	GATGTAGCAGGCTTACAAAACGATCCAACAACAAACGT
  	TGCTCGTCCAAATCCCGCTTATGGCAAACACATGCAAGA
  	TGCTGAAATGTTTACGAACGCTGCTTACATGGCATTAAA
  	TATCTGGGATCGTTTTGATGTATTTTGTACATTGGGAGC
  	AACTACCGGTTATTTAAAAGGAAACTCTGCTTCCTTCAA
  	CTTAGTTGGATTATTCGGAACAAAAACACAATCTTCTAG
  	CTTTAATACAGCGAAGCTTATTCCTAACACTGCTTTGAA
  	TGAAGCTGTGGTTGAGCTTTATATAAACACTACCTTTGC
  	TTGGAGCGTAGGTGCTCGTGCAGCTCTCTGGGAATGTGG
  	GTGTGCAACGTTAGGAGCTTCTTTCCAATATGCTCAATC
  	TAAACCTAAAGTAGAAGAGTTAAATGTTCTTTGTAATGC
  	ATCCGAATTTACTATTAATAAGCCGAAAGGATATGTTGG
  	GGCGGAATTTCCACTTAATATTACCGCAGGAACAGAAG
  	CTGCGACAGGGACTAAGGATGCCTCTATTGACTACCATG
  	AGTGGCAAGCAAGTTTAGCCCTTTCTTACAGATTAAATA
  	TGTTCACTCCTTACATTGGAGTTAAATGGTCTAGAGTAA
  	GTTTTGATGCCGACACGATCCGTATCGCTCAGCCTAAAT
  	TGGCTGAAGCAATCTTGGATGTCACTACTCTAAACCCGA
  	CCATCGCTGGTAAAGGAAGTGTGGTCTCTTCCGGAACCG
  	ATAACGAACTGGCTGATACAATGCAAATCGTTTCCTTGC
  	AGTTGAACAAGATGAAATCTAGAAAATCTTGCGGTATTG
  	CAGTAGGAACGACTATTGTAGATGCAGACAAATACGCA
  	GTTACAGTTGAGGCTCGCTTGATCGATGAGAGAGCAGCT
  	CACGTAAATGCACAATTCCGGTTCTAA;
  Chlamydia	ATGAAAAAACTCTTGAAATCGGTATTAGTATTTGCCGCT	64
  trachomatis strain	TTGAGTTCTGCTTCCTCCTTGCAAGCTCTGCCTGTGGGGA
  C3 major outer	ATCCTGCTGAACCAAGCCTTATGATCGACGGAATTCTGT
  membrane protein	GGGAAGGTTTTGGCGGAGATCCTTGCGATCCTTGCACCA
  (ompA) gene,	CTTGGTGTGACGCTATCAGCATGCGTGTTGGTTACTACG
  complete cds;	GAGACTTTGTTTTCGACCGTGTTTTGAAAACTGATGTGA
  Accession No.	ATAAAGAATTTCAGATGGGAGCGGCGCCTACTACCAGC
  EU040365	GATGTAGTAGGCTTACAAAACGATCCAACAACAAACGT
  	TGCTCGTCCAAATCCCGCTTATGGCAAACACATGCAAGA
  	TGCTGAAATGTTTACGAACGCTGCTTACATGGCATTAAA
  	TATCTGGGATCGTTTTGATGTATTTTGTACATTGGGAGC
  	AACTACCGGTTATTTAAAAGGAAACTCTGCTTCCTTCAA
  	CTTAGTTGGATTATTCGGAACAAAAACACAATCTTCTAG
  	CTTTAATACAGCGAAGCTTATTCCTAACACTGCTTTGAA
  	TGAAGCTGTGGTTGAGCTTTATATAAACACTACCTTTGC
  	TTGGAGCGTAGGTGCTCGTGCAGCTCTCTGGGAATGTGG
  	GTGTGCAACGTTAGGAGCTTCTTTCCAATATGCTCAATC
  	TAAACCTAAAGTAGAAGAGTTAAATGTTCTTTGTAATGC
  	ATCCGAATTTACTATTAATAAGCCGAAAGGATATGTTGG
  	GGCGGAATTTCCACTTAATATTACCGCAGGAACAGAAG
  	CTGCGACAGGGACTAAGGATGCCTCTATTGACTACCATG
  	AGTGGCAAGCAAGTTTAGCCCTTTCTTACAGATTAAATA
  	TGTTCACTCCTTACATTGGAGTTAAATGGTCTAGAGTAA
  	GTTTTGATGCCGACACGATCCGTATCGCTCAGCCTAAAT
  	TGGCTGAAGCAATCTTGGATGTCACTACTCTAAACCCGA
  	CCATCGCTGGTAAAGGAAGTGTGGTCTCTTCCGGAACCG
  	ATAACGAACTGGCTGATACAATGCAAATCGTTTCCTTGC
  	AGTTGAACAAGATGAAATCTAGAAAATCTTGCGGTATTG
  	CAGTAGGAACGACTATTGTAGATGCAGACAAATACGCA
  	GTTACAGTTGAGGCTCGCTTGATCGATGAGAGAGCAGCT
  	CACGTAAATGCACAATTCCGGTTCTAA

  Chlamydia mRNA Sequences

  Chlamydia	AUGAAAAAACUCUUGAAAUCGGUAUUAGUAUUUGCCG	317
  trachomatis strain	CUUUGAGUUCUGCUUCCUCCUUGCAAGCUCUGCCUGU
  C1 major outer	GGGGAAUCCUGCUGAACCAAGCCUUAUGAUCGACGGA
  membrane protein	AUUCUGUGGGAAGGUUUUGGCGGAGAUCCUUGCGAUC
  (ompA) gene,	CUUGCACCACUUGGUGUGACGCUAUCAGCAUGCGUGU
  complete cds;	UGGUUACUACGGAGACUUUGUUUUCGACCGUGUUUUG
  Accession No.	AAAACUGAUGUGAAUAAAGAAUUUCAGAUGGGAGCGG
  EU040363	CGCCUACUACCAGCGAUGUAGUAGGCUUACAAAACGA
  	UCCAACAACAAACGUUGCUCGUCCAAAUCCCGCUUAUG
  	GCAAACACAUGCAAGAUGCUGAAAUGUUUACGAACGC
  	UGCUUACAUGGCAUUAAAUAUCUGGGAUCGUUUUGAU
  	GUAUUUUGUACAUUGGGAGCAACUACCGGUUAUUUAA
  	AAGGAAACUCUGCUUCCUUCAACUUAGUUGGAUUAUU
  	CGGAACAAAAACACAAUCUUCUAGCUUUAAUACAGCG
  	AAGCUUAUUCCUAACACUGCUUUGAAUGAAGCUGUGG
  	UUGAGCUUUAUAUAAACACUACCUUUGCUUGGAGCGU
  	AGGUGCUCGUGCAGCUCUCUGGGAAUGUGGGUGUGCA
  	ACGUUAGGAGCUUCUUUCCAAUAUGCUCAAUCUAAAC
  	CUAAAGUAGAAGAGUUAAAUGUUCUUUGUAAUGCAUC
  	CGAAUUUACUAUUAAUAAGCCGAAAGGAUAUGUUGGG
  	GCGGAAUUUCCACUUAAUAUUACCGCAGGAACAGAAG
  	CUGCGACAGGGACUAAGGAUGCCUCUAUUGACUACCA
  	UGAGUGGCAAGCAAGUUUAGCCCUUUCUUACAGAUUA
  	AAUAUGUUCACUCCUUACAUUGGAGUUAAAUGGUCUA
  	GAGUAAGUUUUGAUGCCGACACGAUCCGUAUCGCUCA
  	GCCUAAAUUGGCUGAAGCAAUCUUGGAUGUCACUACU
  	CUAAACCCGACCAUCGCUGGUAAAGGAAGUGUGGUCU
  	CUGCCGGAACCGAUAACGAACUGGCUGAUACAAUGCA
  	AAUCGUUUCCUUGCAGUUGAACAAGAUGAAAUCUAGA
  	AAAUCUUGCGGUAUUGCAGUAGGAACGACUAUUGUAG
  	AUGCAGACAAAUACGCAGUUACAGUUGAGGCUCGCUU
  	GAUCGAUGAGAGAGCAGCUCACGUAAAUGCACAAUUC
  	CGGUUCUAA
  Chlamydia	AUGAAAAAACUCUUGAAAUCGGUAUUAGUAUUUGCCG	318
  trachomatis strain	CUUUGAGUUCUGCUUCCUCCUUGCAAGCUCUGCCUGU
  C2 major outer	GGGGAAUCCUGCUGAACCAAGCCUUAUGAUCGACGGA
  membrane protein	AUUCUGUGGGAAGGUUUUGGCGGAGAUCCUUGCGAUC
  (ompA) gene,	CUUGCACCACUUGGUGUGACGCUAUCAGCAUGCGUGU
  complete cds;	UGGUUACUACGGAGACUUUGUUUUCGACCGUGUUUUG
  Accession No.	AAAACUGAUGUGAAUAAAGAAUUUCAGAUGGGAGCGG
  EU040364	CGCCUACUACCAGCGAUGUAGCAGGCUUACAAAACGA
  	UCCAACAACAAACGUUGCUCGUCCAAAUCCCGCUUAUG
  	GCAAACACAUGCAAGAUGCUGAAAUGUUUACGAACGC
  	UGCUUACAUGGCAUUAAAUAUCUGGGAUCGUUUUGAU
  	GUAUUUUGUACAUUGGGAGCAACUACCGGUUAUUUAA
  	AAGGAAACUCUGCUUCCUUCAACUUAGUUGGAUUAUU
  	CGGAACAAAAACACAAUCUUCUAGCUUUAAUACAGCG
  	AAGCUUAUUCCUAACACUGCUUUGAAUGAAGCUGUGG
  	UUGAGCUUUAUAUAAACACUACCUUUGCUUGGAGCGU
  	AGGUGCUCGUGCAGCUCUCUGGGAAUGUGGGUGUGCA
  	ACGUUAGGAGCUUCUUUCCAAUAUGCUCAAUCUAAAC
  	CUAAAGUAGAAGAGUUAAAUGUUCUUUGUAAUGCAUC
  	CGAAUUUACUAUUAAUAAGCCGAAAGGAUAUGUUGGG
  	GCGGAAUUUCCACUUAAUAUUACCGCAGGAACAGAAG
  	CUGCGACAGGGACUAAGGAUGCCUCUAUUGACUACCA
  	UGAGUGGCAAGCAAGUUUAGCCCUUUCUUACAGAUUA
  	AAUAUGUUCACUCCUUACAUUGGAGUUAAAUGGUCUA
  	GAGUAAGUUUUGAUGCCGACACGAUCCGUAUCGCUCA
  	GCCUAAAUUGGCUGAAGCAAUCUUGGAUGUCACUACU
  	CUAAACCCGACCAUCGCUGGUAAAGGAAGUGUGGUCU
  	CUUCCGGAACCGAUAACGAACUGGCUGAUACAAUGCA
  	AAUCGUUUCCUUGCAGUUGAACAAGAUGAAAUCUAGA
  	AAAUCUUGCGGUAUUGCAGUAGGAACGACUAUUGUAG
  	AUGCAGACAAAUACGCAGUUACAGUUGAGGCUCGCUU
  	GAUCGAUGAGAGAGCAGCUCACGUAAAUGCACAAUUC
  	CGGUUCUAA;
  Chlamydia	AUGAAAAAACUCUUGAAAUCGGUAUUAGUAUUUGCCG	319
  trachomatis strain	CUUUGAGUUCUGCUUCCUCCUUGCAAGCUCUGCCUGU
  C3 major outer	GGGGAAUCCUGCUGAACCAAGCCUUAUGAUCGACGGA
  membrane protein	AUUCUGUGGGAAGGUUUUGGCGGAGAUCCUUGCGAUC
  (ompA) gene,	CUUGCACCACUUGGUGUGACGCUAUCAGCAUGCGUGU
  complete cds;	UGGUUACUACGGAGACUUUGUUUUCGACCGUGUUUUG
  Accession No.	AAAACUGAUGUGAAUAAAGAAUUUCAGAUGGGAGCGG
  EU040365	CGCCUACUACCAGCGAUGUAGUAGGCUUACAAAACGA
  	UCCAACAACAAACGUUGCUCGUCCAAAUCCCGCUUAUG
  	GCAAACACAUGCAAGAUGCUGAAAUGUUUACGAACGC
  	UGCUUACAUGGCAUUAAAUAUCUGGGAUCGUUUUGAU
  	GUAUUUUGUACAUUGGGAGCAACUACCGGUUAUUUAA
  	AAGGAAACUCUGCUUCCUUCAACUUAGUUGGAUUAUU
  	CGGAACAAAAACACAAUCUUCUAGCUUUAAUACAGCG
  	AAGCUUAUUCCUAACACUGCUUUGAAUGAAGCUGUGG
  	UUGAGCUUUAUAUAAACACUACCUUUGCUUGGAGCGU
  	AGGUGCUCGUGCAGCUCUCUGGGAAUGUGGGUGUGCA
  	ACGUUAGGAGCUUCUUUCCAAUAUGCUCAAUCUAAAC
  	CUAAAGUAGAAGAGUUAAAUGUUCUUUGUAAUGCAUC
  	CGAAUUUACUAUUAAUAAGCCGAAAGGAUAUGUUGGG
  	GCGGAAUUUCCACUUAAUAUUACCGCAGGAACAGAAG
  	CUGCGACAGGGACUAAGGAUGCCUCUAUUGACUACCA
  	UGAGUGGCAAGCAAGUUUAGCCCUUUCUUACAGAUUA
  	AAUAUGUUCACUCCUUACAUUGGAGUUAAAUGGUCUA
  	GAGUAAGUUUUGAUGCCGACACGAUCCGUAUCGCUCA
  	GCCUAAAUUGGCUGAAGCAAUCUUGGAUGUCACUACU
  	CUAAACCCGACCAUCGCUGGUAAAGGAAGUGUGGUCU
  	CUUCCGGAACCGAUAACGAACUGGCUGAUACAAUGCA
  	AAUCGUUUCCUUGCAGUUGAACAAGAUGAAAUCUAGA
  	AAAUCUUGCGGUAUUGCAGUAGGAACGACUAUUGUAG
  	AUGCAGACAAAUACGCAGUUACAGUUGAGGCUCGCUU
  	GAUCGAUGAGAGAGCAGCUCACGUAAAUGCACAAUUC
  	CGGUUCUAA

• TABLE 5
  Chlamydia MOMP Amino Acid Sequences

  		SEQ ID
  Description	Sequence	NO:
  sp|P13467|MOMP_Serovar_H_Chlamydia_trachomatis	MKKLLKSVLVFAALSSASSLQALPVGNPAEPSLMID	65
  	GILWEGFGGDPCDPCATWCDAISMRVGYYGDFVFD
  	RVLKTDVNKEFQMGAAPTTNDAADLQNDPKTNVA
  	RPNPAYGKHMQDAEMFTNAAYMALNIWDRFDVFC
  	TLGATTGYLKGNSASFNLVGLFGTKTKSSDFNTAKL
  	VPNIALNRAVVELYTDTTFAWSVGARAALWECGCA
  	TLGASFQYAQSKPKVEELNVLCNASEFTINKPKGYV
  	GAEFPLDITAGTEAATGTKDASIDYHEWQASLALSY
  	RLNMFTPYIGVKWSRVSFDADTIRIAQPKLAEAILDV
  	TTLNPTIAGKGTVVASGSDNDLADTMQIVSLQLNKM
  	KSRKSCGIAVGTTIVDADKYAVTVETRLIDERAAHV
  	NAQFRF
  sp|P16155|MOMP_Serovar_F_Chlamydia_trachomatis	MKKLLKSVLVFAALSSASSLQALPVGNPAEPSLMID	66
  	GILWEGFGGDPCDPCTTWCDAISMRMGYYGDFVFD
  	RVLKTDVNKEFEMGEALAGASGNTTSTLSKLVERTN
  	PAYGKHMQDAEMFTNAACMTLNIWDRFDVFCTLG
  	ATSGYLKGNSASFNLVGLFGDGVNATKPAADSIPNV
  	QLNQSVVELYTDTTFAWSVGARAALWECGCATLGA
  	SFQYAQSKPKIEELNVLCNAAEFTINKPKGYVGKEFP
  	LDLTAGTDAATGTKDASIDYHEWQASLSLSYRLNMF
  	TPYIGVKWSRASFDSDTIRIAQPRLVTPVVDITTLNPT
  	IAGCGSVAGANTEGQISDTMQIVSLQLNKMKSRKSC
  	GIAVGTTIVDADKYAVTVETRLIDERAAHVNAQFRF
  sp|P17451|MOMP_Serovar_E_Chlamydia_trachomatis	MKKLLKSVLVFAALSSASSLQALPVGNPAEPSLMID	67
  	GILWEGFGGDPCDPCTTWCDAISMRMGYYGDFVFD
  	RVLKTDVNKEFQMGDKPTSTTGNATAPTTLTARENP
  	AYGRHMQDAEMFTNAACMALNIWDRFDVFCTLGA
  	SSGYLKGNSASFNLVGLFGDNENQSTVKTNSVPNMS
  	LDQSVVELYTDTAFSWSVGARAALWECGCATLGAS
  	FQYAQSKPKVEELNVLCNAAEFTINKPKGYVGQEFP
  	LALIAGTDAATGTKDASIDYHEWQASLALSYRLNMF
  	TPYIGVKWSRASFDADTIRIAQPKSATAIFDTTTLNPT
  	IAGAGDVKASAEGQLGDTMQIVSLQLNKMKSRKSC
  	GIAVGTTIVDADKYAVTVETRLIDERAAHVNAQFRF
  sp|Q46409|MOMP_Serovar_D_Chlamydia_trachomatis_strain_D/	MKKLLKSVLVFAALSSASSLQALPVGNPAEPSLMID	68
  UW-3/Cx	GILWEGFGGDPCDPCATWCDAISMRVGYYGDFVFD
  	RVLKTDVNKEFQMGAKPTTDTGNSAAPSTLTARENP
  	AYGRHMQDAEMFTNAACMALNIWDRFDVFCTLGA
  	TSGYLKGNSASFNLVGLFGDNENQKTVKAESVPNM
  	SFDQSVVELYTDTTFAWSVGARAALWECGCATLGA
  	SFQYAQSKPKVEELNVLCNAAEFTINKPKGYVGKEF
  	PLDLTAGTDAATGTKDASIDYHEWQASLALSYRLN
  	MFTPYIGVKWSRASFDADTIRIAQPKSATAIFDTTTL
  	NPTIAGAGDVKTGAEGQLGDTMQIVSLQLNKMKSR
  	KSCGIAVGTTIVDADKYAVTVETRLIDERAAHVNAQ
  	FRF
  gi|592971106|MOMP_Serovar_I_Chlamydia_trachomatis	MKKLLKSVLVFAALSSASSLQALPVGNPAEPSLMID	69
  	GILWEGFGGDPCDPCTTWCDAISMRMGYYGDFVFD
  	RVLKTDVNKEFQMGAAPTTKDVAGLENDPTTNVAR
  	PNPAYGKHMQDAEMFTNAAYMALNIWDRFDVFCT
  	LGATTGYLKGNSASFNLVGLFGTKTQSSNFNTAKLV
  	PNAALNQAVVELYTDTTFAWSVGARAALWECGCA
  	TLGASFQYAQSKPKVEELNVLCNASEFTINKPKGYV
  	GAEFPLDIIAGTEAATGTKDASIDYHEWQASLALSYR
  	LNMFTPYIGVKWSRVSFDADTIRIAQPKLAEAILDVT
  	TLNPTIAGKGTVVSSAENELADTMQIVSLQLNKMKS
  	RKSCGIAVGTTIVDADKYAVTVETRLIDERAAHVNA
  	QFRF
  gi|297140585||MOMP_Serovar_G_Chlamydia_trachomatis	MKKLLKSVLVFAALSSASSLQALPVGNPAEPSLMID	70
  	GILWEGFGGDPCDPCTTWCDAISMRMGYYGDFVFD
  	RVLKTDVNKEFEMGEALAGASGNTTSTLSKLVERTN
  	PAYGKHMQDAEMFTNAACMALNIWDRFDVFCTLG
  	ATSGYLRGNSASFNLVGLFGDGENATQPAATSIPNV
  	QLNQSVVELYTDTAFAWSVGARAALWECGCATLG
  	ASFQYAQSKPKVEELNVLCNAAEFTINKPKGYVGQE
  	FPLALTAGTDAATGTKDASIDYHEWQASLSLSYRLN
  	MFTPYIGVKWSRASFDSNTIRIAQPKLAKPVVDITTL
  	NPTIAGCGSVVAANAEGQISDTMQIVSLQLNKMKSR
  	KSCGIAVGTTIVDADKYAVTVETRLIDERAAHVNAQ
  	FRF
  gi|527133542|MOMP_Serovar_J_Chlamydia_trachomatis	MKKLLKSVLVFAALSSASSLQALPVGNPAEPSLMID	71
  	GILWEGFGGDPCDPCTTWCDAISMRMGYYGDFVFD
  	RVLKTDVNKEFQMGAAPTTSDVAGLQNDPTTNVAR
  	PNPAYGKHMQDAEMFTNAAYMALNIWDRFDVFCT
  	LGATTGYLKGNSASFNLVGLFGTKTQASSFNTANLF
  	PNTALNQAVVELYTDTTFAWSVGARAALWECGCAT
  	LGASFQYAQSKPKVEELNVLCNASEFTINKPKGYVG
  	AEFPLDITAGTEAATGTKDASIDYHEWQASLALSYR
  	LNMFTPYIGVKWSRVSFDADTIRIAQPKLAEAILDVT
  	TLNPTIAGKGTVVASGSENDLADTMQIVSLQLNKMK
  	SRKSCGIAVGTTIVDADKYAVTVETRLIDERAAHVN
  	AQFRF
  gi|440525609|MOMP_Serovar_K_Chlamydia_trachomatis	MKKLLKSVLVFAALSSASSLQALPVGNPAEPSLMID	72
  	GILWEGFGGDPCDPCTTWCDAISMRVGYYGDFVFD
  	RVLKTDVNKEFQMGAAPTTSDVEGLQNDPTTNVAR
  	PNPAYGKHMQDAEMFTNAAYMALNIWDRFDVFCT
  	LGATTGYLRGNSASFNLVGLFGTKTQYSKFNTANLV
  	PNTALDRAVVELYTDTTFAWSVGARAALWECGCAT
  	LGASFQYAQSKPKVEELNVLCNASEFTINKPKGYVG
  	VEFPLDITGTEAATGTKDASIDYHEWQASLALSYRL
  	NMFTPYIGVKWSRVSFDADTIRIAQPKLAEAILDVTT
  	LNPTIAGKGAVVSSGSDNELADTMQIVSLQLNKLKS
  	RKSCGIAVGTTIVDADKYAVTVETRLIDERAAHVNA
  	QFRF

• TABLE 6
  NCBI Accession Numbers (Amino Acid Sequences)

  	GenBank
  Description	Accession

  membrane protein [Chlamydia trachomatis]	WP_014736636.1
  membrane protein [Chlamydia trachomatis]	WP_020967105.1
  hypothetical protein [Chlamydia trachomatis]	WP_050866621.1
  membrane protein [Chlamydia trachomatis]	WP_014541314.1
  hypothetical protein [Chlamydia trachomatis]	WP_020915665.1
  membrane protein [Chlamydia trachomatis]	WP_020966654.1
  hypothetical protein [Chlamydia trachomatis]	WP_010725381.1
  membrane protein [Chlamydia trachomatis]	WP_014541104.1
  polymorphic membrane protein I [Chlamydia trachomatis]	AAQ74460.1
  membrane protein [Chlamydia trachomatis]	WP_009873481.1
  membrane protein [Chlamydia trachomatis]	WP_009872264.1
  hypothetical protein [Chlamydia trachomatis]	WP_015505760.1
  polymorphic membrane protein I [Chlamydia trachomatis]	AAQ74451.1
  polymorphic membrane protein I [Chlamydia trachomatis]	AAQ74444.1
  membrane protein [Chlamydia trachomatis]	WP_012728025.1
  membrane protein [Chlamydia trachomatis]	WP_024067304.1
  membrane protein [Chlamydia trachomatis]	WP_011324917.1
  membrane protein [Chlamydia trachomatis]	WP_012728213.1
  polymorphic outer membrane protein [Chlamydia trachomatis]	CRH27059.1
  polymorphic membrane protein I [Chlamydia trachomatis]	AAO29993.1
  polymorphic membrane protein I [Chlamydia trachomatis]	AAO29992.1
  polymorphic membrane protein I [Chlamydia trachomatis]	AAO29987.1
  polymorphic membrane protein I [Chlamydia trachomatis]	AAO29991.1
  polymorphic membrane protein I [Chlamydia trachomatis]	AAO29988.1
  polymorphic membrane protein I [Chlamydia trachomatis]	AAO29994.1
  polymorphic membrane protein I [Chlamydia trachomatis]	AAO29990.1
  polymorphic membrane protein I [Chlamydia trachomatis]	AAO29999.1
  polymorphic membrane protein I [Chlamydia trachomatis]	AAO29989.1
  polymorphic membrane protein I [Chlamydia trachomatis]	AAO29997.1
  polymorphic membrane protein I [Chlamydia trachomatis]	AAO29998.1
  polymorphic outer membrane protein [Chlamydia trachomatis]	CRH24400.1
  Chlamydial polymorphic outer membrane protein repeat	CCP50073.1
  [Chlamydia trachomatis A/7249]
  polymorphic outer membrane protein [Chlamydia trachomatis]	CRI74229.1
  polymorphic outer membrane protein [Chlamydia trachomatis]	CPR78550.1
  polymorphic outer membrane protein [Chlamydia trachomatis]	CRH27024.1
  polymorphic outer membrane protein [Chlamydia trachomatis]	CRH87199.1
  membrane protein [Chlamydia trachomatis]	WP_009873248.1
  PmpH [Chlamydia trachomatis]	ABY76804.1
  hypothetical protein [Chlamydia trachomatis]	WP_010725378.1
  Polymorphic outer membrane protein [Chlamydia trachomatis D-EC]	ADI51545.1
  membrane protein [Chlamydia trachomatis]	WP_009872990.1
  membrane protein [Chlamydia trachomatis]	WP_009872262.1
  membrane protein [Chlamydia trachomatis]	WP_020967104.1
  membrane protein [Chlamydia trachomatis]	WP_014541209.1
  polymorphic membrane protein H [Chlamydia trachomatis]	AAX76608.1
  membrane protein [Chlamydia trachomatis]	WP_014541103.1
  polymorphic membrane protein H [Chlamydia trachomatis]	AAO30024.1
  polymorphic membrane protein H [Chlamydia trachomatis]	AAO30025.1
  polymorphic membrane protein H [Chlamydia trachomatis]	AAO30023.1
  polymorphic membrane protein H [Chlamydia trachomatis I/UW-12/UR]	AAO30028.1
  polymorphic membrane protein H [Chlamydia trachomatis]	AAO30029.1
  Polymorphic outer membrane protein [Chlamydia trachomatis A2497]	AEP35781.1
  membrane protein [Chlamydia trachomatis]	WP_011324915.1
  membrane protein [Chlamydia trachomatis]	WP_009873479.1
  hypothetical protein [Chlamydia trachomatis]	WP_015505933.1
  hypothetical protein [Chlamydia trachomatis]	WP_015505759.1
  hypothetical protein [Chlamydia trachomatis]	WP_015506646.1
  Chlamydial polymorphic outer membrane protein repeat	CCP63815.1
  [Chlamydia trachomatis L1/1 322/p2]
  membrane protein [Chlamydia trachomatis]	WP_012263579.1
  polymorphic membrane protein H [Chlamydia trachomatis]	AAO30019.1
  polymorphic membrane protein H [Chlamydia trachomatis]	AAO30020.1
  polymorphic membrane protein H [Chlamydia trachomatis]	AAO30032.1
  polymorphic membrane protein H [Chlamydia trachomatis]	AAO30031.1
  polymorphic membrane protein H [Chlamydia trachomatis]	AAO30033.1
  polymorphic membrane protein H [Chlamydia trachomatis]	ABQ08057.1
  Polymorphic outer membrane protein [Chlamydia trachomatis]	CRH60974.1
  membrane protein [Chlamydia trachomatis]	WP_009872260.1
  PmpF [Chlamydia trachomatis]	AAZ20335.1
  membrane protein [Chlamydia trachomatis]	WP_020967102.1
  hypothetical protein [Chlamydia trachomatis]	WP_022564835.1
  membrane protein [Chlamydia trachomatis]	WP_014541101.1
  membrane protein [Chlamydia trachomatis]	WP_014541207.1
  PmpF [Chlamydia trachomatis]	AAZ20334.1
  PmpF [Chlamydia trachomatis]	AAZ20333.1
  membrane protein [Chlamydia trachomatis]	WP_024067300.1
  membrane protein [Chlamydia trachomatis]	WP_011324913.1
  membrane protein [Chlamydia trachomatis]	WP_009873477.1
  membrane protein [Chlamydia trachomatis]	WP_012728023.1
  polymorphic membrane protein F [Chlamydia trachomatis]	AAX76564.1
  membrane protein [Chlamydia trachomatis]	WP_014316077.1
  membrane protein [Chlamydia trachomatis]	WP_012263577.1
  polymorphic membrane protein F [Chlamydia trachomatis]	AAX76565.1
  membrane protein [Chlamydia trachomatis]	WP_012728212.1
  PmpF [Chlamydia trachomatis]	AAZ20337.1
  polymorphic membrane protein F [Chlamydia trachomatis]	AKG95439.1
  membrane protein [Chlamydia suis]	WP_035407888.1
  polymorphic outer membrane protein[Chlamydia trachomatis]	CRH67080.1
  Polymorphic outer membrane protein [Chlamydia trachomatis D-EC]	ADI51544.1
  Polymorphic outer membrane protein [Chlamydia trachomatis]	CRH42293.1
  hypothetical protein [Chlamydia trachomatis]	WP_050866642.1
  polymorphic membrane protein G [Chlamydia trachomatis]	AAX76599.1
  membrane protein [Chlamydia trachomatis]	WP_014541208.1
  membrane protein [Chlamydia trachomatis]	WP_011324914.1
  Polymorphic outer membrane protein [Chlamydia trachomatis A2497]	AEP35780.1
  polymorphic membrane protein G [Chlamydia trachomatis]	AAX76596.1
  Polymorphic outer membrane protein [Chlamydia trachomatis]	CRH57809.1
  polymorphic membrane protein G [Chlamydia trachomatis]	AAX76587.1
  membrane protein [Chlamydia trachomatis]	WP_020967103.1
  membrane protein [Chlamydia trachomatis]	WP_012728024.1
  polymorphic membrane protein G [Chlamydia trachomatis]	AAX76590.1
  membrane protein [Chlamydia trachomatis]	WP_014541102.1
  membrane protein [Chlamydia trachomatis]	WP_024067301.1
  polymorphic membrane protein G [Chlamydia trachomatis]	AAX76592.1
  Polymorphic outer membrane protein [Chlamydia trachomatis]	CRH45212.1
  Chlamydial polymorphic outer membrane protein repeat	CCP55746.1
  [Chlamydia trachomatis E/SotonE4]
  hypothetical protein [Chlamydia trachomatis]	WP_015505758.1
  hypothetical protein [Chlamydia trachomatis]	WP_015506645.1
  polymorphic membrane protein G [Chlamydia trachomatis]	AAX76604.1
  membrane protein [Chlamydia trachomatis]	WP_012263578.1
  membrane protein [Chlamydia trachomatis]	WP_009873478.1
  Polymorphic outer membrane protein [Chlamydia trachomatis]	CPR43068.1
  Polymorphic outer membrane protein [Chlamydia trachomatis]	CRH24397.1
  Chlamydial polymorphic outer membrane protein repeat	CCP63814.1
  [Chlamydia trachomatis L1/1322/p2]
  Polymorphic outer membrane protein [Chlamydia trachomatis]	CRH86260.1
  Chlamydial polymorphic outer membrane protein repeat	CCP66483.1
  [Chlamydia trachomatis] L2/25667R]
  deubiquitinase [Chlamydia trachomatis]	WP_009873246.1
  deubiquitinase [Chlamydia trachomatis]	WP_020967101.1
  deubiquitinase [Chlamydia trachomatis]	WP_014541312.1
  deubiquitinase [Chlamydia trachomatis]	WP_020967682.1
  deubiquitinase [Chlamydia trachomatis]	WP_009872987.1
  deubiquitinase [Chlamydia trachomatis]	WP_014541099.1
  hypothetical protein [Chlamydia trachomatis]	ABX82376.1
  membrane thiol protease [Chlamydia trachomatis]	AFU24067.1
  membrane thiol protease [Chlamydia trachomatis]	CRH57812.1
  deubiquitinase [Chlamydia trachomatis]	WP_014541784.1
  deubiquitinase [Chlamydia trachomatis]	WP_020967726.1
  deubiquitinase [Chlamydia trachomatis]	WP_014541837.1
  deubiquitinase [Chlamydia trachomatis]	WP_012728210.1
  membrane thiol protease [Chlamydia trachomatis]	AFU24069.1
  deubiquitinase [Chlamydia trachomatis]	WP_009872258.1
  deubiquitinase [Chlamydia trachomatis]	WP_014316076.1
  deubiquitinase [Chlamydia trachomatis]	WP_012728021.1
  deubiquitinase [Chlamydia trachomatis]	WP_024067298.1
  deubiquitinase [Chlamydia trachomatis]	WP_011324911.1
  membrane thiol protease [Chlamydia trachomatis]	AFU24057.1
  deubiquitinase [Chlamydia trachomatis]	WP_013984939.1
  deubiquitinase [Chlamydia trachomatis]	WP_009873475.1
  hypothetical protein [Chlamydia trachomatis]	WP_015506643.1
  deubiquitinase [Chlamydia trachomatis]	WP_012263576.1
  hypothetical protein [Chlamydia trachomatis]	WP_015505932.1
  deubiquitinase [Chlamydia trachomatis]	WP_054088494.1
  membrane thiol protease [Chlamydia trachomatis]	CQB85418.1

• TABLE 7
  Chlamydia mRNA Constructs (Amino Acids)

  mRNA		SEQ ID
  Name	ORF Sequence (Amino Acid)	NO:

  Cta1_E_EXT_noTM_nIgK	METPAQLLFLLLLWLPDTTGPPLPSSTQDNRSMDQQDSEEFLLQN	73
  	TLEDSEIISIPDTMNQIAIDTEKWFYLNKDCTNVGPISIVQLTAFLK
  	ECKHSPEKGIDPQELWVWKKGMPNWEKVKNIPELSGTVKDE
  Cta1_E_EXT_noTM_nIgK_cHis	METPAQLLFLLLLWLPDTTGPPLPSSTQDNRSMDQQDSEEFLLQN	74
  	TLEDSEIISIPDTMNQIAIDTEKWFYLNKDCTNVGPISIVQLTAFLK
  	ECKHSPEKGIDPQELWVWKKGMPNWEKVKNIPELSGTVKDEHH
  	HHHH
  Ct875_E_NGM_nFC_cHis	METPAQLLFLLLLWLPDTTGEPKSCDKTHTCPPCPAPELLGGPSV	75
  	FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEV
  	HNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKA
  	LPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFY
  	PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
  	QGNVFSCSVMHEALHNHYTQKSLSLSPGKMSIRGVGGNGNSRIPS
  	HNGDGSNRRSQNTKGNNKVEDRVCSLYSSRSNENRESPYAVVD
  	VSSMIESTPTSGETTRASRGVLSRFQRGLVRIADKVRRAVQCAWS
  	SVSTSRSSATRAAESGSSSRTARGASSGYREYSPSAARGLRLMFT
  	DFWRTRVLRQTSPMAGVFGNLDVNEARLMAAYTSECADHLEAK
  	ELAGPDGVAAAREIAKRWEKRVRDLQDKGAARKLLNDPLGRRT
  	PNYQSKNPGEYTVGNSMFYDGPQVANLQNVDTGFWLDMQHLS
  	DVVLSREIQTGLRARATLEESMPMLENLEERFRRLQETCDAARTE
  	IEESGWTRESASRMEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSF
  	GEHVRVLCARVSRGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSP
  	EGASLAETLARFADDMGIERGADGTYDIPLVDDWRRGVPSIEGE
  	GSDSIYEIMMPIYEVMNMDLETRRSFAVQQGHYQDPRASDYDLP
  	RASDYDLPRSPYPTPPLPPRYQLQNMDVEAGFREAVYASFVAGM
  	YNYVVTQPQERIPNSQQVEGILRDMLTNGDQTFRDLMKRWNRE
  	VDREMSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDK
  	WRNKKFELGLEFPNLPYYIDGDVKLTQSMAIIRYIADKHNMLGG
  	CPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLKVDFLSKLPEML
  	KMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDA
  	FPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPK
  Ct875_E_nFC_cHis	METPAQLLFLLLLWLPDTTGEPKSCDKTHTCPPCPAPELLGGPSV	76
  	FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEV
  	HNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKA
  	LPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFY
  	PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
  	QGNVFSCSVMHEALHNHYTQKSLSLSPGKMSIRGVGGNGNSRIPS
  	HNGDGSNRRSQNTKGNNKVEDRVCSLYSSRSNENRESPYAVVD
  	VSSMIESTPTSGETTRASRGVLSRFQRGLVRIADKVRRAVQCAWS
  	SVSTSRSSATRAAESGSSSRTARGASSGYREYSPSAARGLRLMFT
  	DFWRTRVLRQTSPMAGVFGNLDVNEARLMAAYTSECADHLEAK
  	ELAGPDGVAAAREIAKRWEKRVRDLQDKGAARKLLNDPLGRRT
  	PNYQSKNPGEYTVGNSMFYDGPQVANLQNVDTGFWLDMSNLSD
  	VVLSREIQTGLRARATLEESMPMLENLEERFRRLQETCDAARTEI
  	EESGWTRESASRMEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSF
  	GEHVRVLCARVSRGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSP
  	EGASLAETLARFADDMGIERGADGTYDIPLVDDWRRGVPSIEGE
  	GSDSIYEIMMPIYEVMNMDLETRRSFAVQQGHYQDPRASDYDLP
  	RASDYDLPRSPYPTPPLPPRYQLQNMDVEAGFREAVYASFVAGM
  	YNYVVTQPQERIPNSQQVEGILRDMLTNGSQTFRDLMKRWNREV
  	DREHHHHHH
  Ct875_E_NGM_nFC	METPAQLLFLLLLWLPDTTGEPKSCDKTHTCPPCPAPELLGGPSV	77
  	FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEV
  	HNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKA
  	LPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFY
  	PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
  	QGNVFSCSVMHEALHNHYTQKSLSLSPGKMSIRGVGGNGNSRIPS
  	HNGDGSNRRSQNTKGNNKVEDRVCSLYSSRSNENRESPYAVVD
  	VSSMIESTPTSGETTRASRGVLSRFQRGLVRIADKVRRAVQCAWS
  	SVSTSRSSATRAAESGSSSRTARGASSGYREYSPSAARGLRLMFT
  	DFWRTRVLRQTSPMAGVFGNLDVNEARLMAAYTSECADHLEAK
  	ELAGPDGVAAAREIAKRWEKRVRDLQDKGAARKLLNDPLGRRT
  	PNYQSKNPGEYTVGNSMFYDGPQVANLQNVDTGFWLDMQHLS
  	DVVLSREIQTGLRARATLEESMPMLENLEERFRRLQETCDAARTE
  	IEESGWTRESASRMEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSF
  	GEHVRVLCARVSRGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSP
  	EGASLAETLARFADDMGIERGADGTYDIPLVDDWRRGVPSIEGE
  	GSDSIYEIMMPIYEVMNMDLETRRSFAVQQGHYQDPRASDYDLP
  	RASDYDLPRSPYPTPPLPPRYQLQNMDVEAGFREAVYASFVAGM
  	YNYVVTQPQERIPNSQQVEGILRDMLTNGDQTFRDLMKRWNRE
  	VDRE
  Ct875_E_nFC	METPAQLLFLLLLWLPDTTGEPKSCDKTHTCPPCPAPELLGGPSV	78
  	FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEV
  	HNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKA
  	LPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFY
  	PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
  	QGNVFSCSVMHEALHNHYTQKSLSLSPGKMSIRGVGGNGNSRIPS
  	HNGDGSNRRSQNTKGNNKVEDRVCSLYSSRSNENRESPYAVVD
  	VSSMIESTPTSGETTRASRGVLSRFQRGLVRIADKVRRAVQCAWS
  	SVSTSRSSATRAAESGSSSRTARGASSGYREYSPSAARGLRLMFT
  	DFWRTRVLRQTSPMAGVFGNLDVNEARLMAAYTSECADHLEAK
  	ELAGPDGVAAAREIAKRWEKRVRDLQDKGAARKLLNDPLGRRT
  	PNYQSKNPGEYTVGNSMFYDGPQVANLQNVDTGFWLDMSNLSD
  	VVLSREIQTGLRARATLEESMPMLENLEERFRRLQETCDAARTEI
  	EESGWTRESASRMEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSF
  	GEHVRVLCARVSRGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSP
  	EGASLAETLARFADDMGIERGADGTYDIPLVDDWRRGVPSIEGE
  	GSDSIYEIMMPIYEVMNMDLETRRSFAVQQGHYQDPRASDYDLP
  	RASDYDLPRSPYPTPPLPPRYQLQNMDVEAGFREAVYASFVAGM
  	YNYVVTQPQERIPNSQQVEGILRDMLTNGSQTFRDLMKRWNREV
  	DRE
  Ct875_E_NGM_nIgK_nGst_cHis	METPAQLLFLLLLWLPDTTGMSPILGYWKIKGLVQPTRLLLEYLE	79
  	EKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVKLTQSM
  	AIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDF
  	ETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDA
  	LDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPL
  	QGWQATFGGGDHPPKMSIRGVGGNGNSRIPSHNGDGSNRRSQNT
  	KGNNKVEDRVCSLYSSRSNENRESPYAVVDVSSMIESTPTSGETT
  	RASRGVLSRFQRGLVRIADKVRRAVQCAWSSVSTSRSSATRAAE
  	SGSSSRTARGASSGYREYSPSAARGLRLMFTDFWRTRVLRQTSP
  	MAGVFGNLDVNEARLMAAYTSECADHLEAKELAGPDGVAAAR
  	EIAKRWEKRVRDLQDKGAARKLLNDPLGRRTPNYQSKNPGEYT
  	VGNSMFYDGPQVANLQNVDTGFWLDMQHLSDVVLSREIQTGLR
  	ARATLEESMPMLENLEERFRRLQETCDAARTEIEESGWTRESASR
  	MEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSFGEHVRVLCARVS
  	RGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSPEGASLAETLARFA
  	DDMGIERGADGTYDIPLVDDWRRGVPSIEGEGSDSIYEIMMPIYE
  	VMNMDLETRRSFAVQQGHYQDPRASDYDLPRASDYDLPRSPYPT
  	PPLPPRYQLQNMDVEAGFREAVYASFVAGMYNYVVTQPQERIPN
  	SQQVEGILRDMLTNGDQTFRDLMKRWNREVDREHHHHHH
  Ct875_E_nIgK_nGst_cHis	METPAQLLFLLLLWLPDTTGMSPILGYWKIKGLVQPTRLLLEYLE	80
  	EKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVKLTQSM
  	AIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDF
  	ETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDA
  	LDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPL
  	QGWQATFGGGDHPPKMSIRGVGGNGNSRIPSHNGDGSNRRSQNT
  	KGNNKVEDRVCSLYSSRSNENRESPYAVVDVSSMIESTPTSGETT
  	RASRGVLSRFQRGLVRIADKVRRAVQCAWSSVSTSRSSATRAAE
  	SGSSSRTARGASSGYREYSPSAARGLRLMFTDFWRTRVLRQTSP
  	MAGVFGNLDVNEARLMAAYTSECADHLEAKELAGPDGVAAAR
  	EIAKRWEKRVRDLQDKGAARKLLNDPLGRRTPNYQSKNPGEYT
  	VGNSMFYDGPQVANLQNVDTGFWLDMSNLSDVVLSREIQTGLR
  	ARATLEESMPMLENLEERFRRLQETCDAARTEIEESGWTRESASR
  	MEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSFGEHVRVLCARVS
  	RGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSPEGASLAETLARFA
  	DDMGIERGADGTYDIPLVDDWRRGVPSIEGEGSDSIYEIMMPIYE
  	VMNMDLETRRSFAVQQGHYQDPRASDYDLPRASDYDLPRSPYPT
  	PPLPPRYQLQNMDVEAGFREAVYASFVAGMYNYVVTQPQERIPN
  	SQQVEGILRDMLTNGSQTFRDLMKRWNREVDREHHHHHH
  Ct875_E_NGM_nIgK_nGst	METPAQLLFLLLLWLPDTTGMSPILGYWKIKGLVQPTRLLLEYLE	81
  	EKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVKLTQSM
  	AIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDF
  	ETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDA
  	LDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPL
  	QGWQATFGGGDHPPKMSIRGVGGNGNSRIPSHNGDGSNRRSQNT
  	KGNNKVEDRVCSLYSSRSNENRESPYAVVDVSSMIESTPTSGETT
  	RASRGVLSRFQRGLVRIADKVRRAVQCAWSSVSTSRSSATRAAE
  	SGSSSRTARGASSGYREYSPSAARGLRLMFTDFWRTRVLRQTSP
  	MAGVFGNLDVNEARLMAAYTSECADHLEAKELAGPDGVAAAR
  	EIAKRWEKRVRDLQDKGAARKLLNDPLGRRTPNYQSKNPGEYT
  	VGNSMFYDGPQVANLQNVDTGFWLDMQHLSDVVLSREIQTGLR
  	ARATLEESMPMLENLEERFRRLQETCDAARTEIEESGWTRESASR
  	MEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSFGEHVRVLCARVS
  	RGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSPEGASLAETLARFA
  	DDMGIERGADGTYDIPLVDDWRRGVPSIEGEGSDSIYEIMMPIYE
  	VMNMDLETRRSFAVQQGHYQDPRASDYDLPRASDYDLPRSPYPT
  	PPLPPRYQLQNMDVEAGFREAVYASFVAGMYNYVVTQPQERIPN
  	SQQVEGILRDMLTNGDQTFRDLMKRWNREVDRE
  Ct875_E_nIgK_nGst	METPAQLLFLLLLWLPDTTGMSPILGYWKIKGLVQPTRLLLEYLE	82
  	EKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVKLTQSM
  	AIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDF
  	ETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDA
  	LDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPL
  	QGWQATFGGGDHPPKMSIRGVGGNGNSRIPSHNGDGSNRRSQNT
  	KGNNKVEDRVCSLYSSRSNENRESPYAVVDVSSMIESTPTSGETT
  	RASRGVLSRFQRGLVRIADKVRRAVQCAWSSVSTSRSSATRAAE
  	SGSSSRTARGASSGYREYSPSAARGLRLMFTDFWRTRVLRQTSP
  	MAGVFGNLDVNEARLMAAYTSECADHLEAKELAGPDGVAAAR
  	EIAKRWEKRVRDLQDKGAARKLLNDPLGRRTPNYQSKNPGEYT
  	VGNSMFYDGPQVANLQNVDTGFWLDMSNLSDVVLSREIQTGLR
  	ARATLEESMPMLENLEERFRRLQETCDAARTEIEESGWTRESASR
  	MEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSFGEHVRVLCARVS
  	RGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSPEGASLAETLARFA
  	DDMGIERGADGTYDIPLVDDWRRGVPSIEGEGSDSIYEIMMPIYE
  	VMNMDLETRRSFAVQQGHYQDPRASDYDLPRASDYDLPRSPYPT
  	PPLPPRYQLQNMDVEAGFREAVYASFVAGMYNYVVTQPQERIPN
  	SQQVEGILRDMLTNGSQTFRDLMKRWNREVDRE
  Ct875_E_574_NGM_nIgK_cHis	METPAQLLFLLLLWLPDTTGMSIRGVGGNGNSRIPSHNGDGSNRR	83
  	SQNTKGNNKVEDRVCSLYSSRSNENRESPYAVVDVSSMIESTPTS
  	GETTRASRGVLSRFQRGLVRIADKVRRAVQCAWSSVSTSRSSATR
  	AAESGSSSRTARGASSGYREYSPSAARGLRLMFTDFWRTRVLRQ
  	TSPMAGVFGNLDVNEARLMAAYTSECADHLEAKELAGPDGVAA
  	AREIAKRWEKRVRDLQDKGAARKLLNDPLGRRTPNYQSKNPGE
  	YTVGNSMFYDGPQVANLQNVDTGFWLDMQHLSDVVLSREIQTG
  	LRARATLEESMPMLENLEERFRRLQETCDAARTEIEESGWTRESA
  	SRMEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSFGEHVRVLCAR
  	VSRGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSPEGASLAETLAR
  	FADDMGIERGADGTYDIPLVDDWRRGVPSIEGEGSDSIYEIMMPI
  	YEVMNMDLETRRSFAVQQGHYQDPRASDYDLPRASDYDLPRSP
  	YPTPPLPPRYQLQNMDVEAGFREAVYASFVAGMYNYVVTQPQE
  	RIPNSQQVEGILRDMLTNGDHHHHHH
  Ct875_E_458_NGM_nIgK_cHis	METPAQLLFLLLLWLPDTTGMSIRGVGGNGNSRIPSHNGDGSNRR	84
  	SQNTKGNNKVEDRVCSLYSSRSNENRESPYAVVDVSSMIESTPTS
  	GETTRASRGVLSRFQRGLVRIADKVRRAVQCAWSSVSTSRSSATR
  	AAESGSSSRTARGASSGYREYSPSAARGLRLMFTDFWRTRVLRQ
  	TSPMAGVFGNLDVNEARLMAAYTSECADHLEAKELAGPDGVAA
  	AREIAKRWEKRVRDLQDKGAARKLLNDPLGRRTPNYQSKNPGE
  	YTVGNSMFYDGPQVANLQNVDTGFWLDMQHLSDVVLSREIQTG
  	LRARATLEESMPMLENLEERFRRLQETCDAARTEIEESGWTRESA
  	SRMEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSFGEHVRVLCAR
  	VSRGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSPEGASLAETLAR
  	FADDMGIERGADGTYDIPLVDDWRRGVPSIEGEGSHHHHHH
  Ct875_E_574_nIgK_cHis	METPAQLLFLLLLWLPDTTGMSIRGVGGNGNSRIPSHNGDGSNRR	85
  	SQNTKGNNKVEDRVCSLYSSRSNENRESPYAVVDVSSMIESTPTS
  	GETTRASRGVLSRFQRGLVRIADKVRRAVQCAWSSVSTSRSSATR
  	AAESGSSSRTARGASSGYREYSPSAARGLRLMFTDFWRTRVLRQ
  	TSPMAGVFGNLDVNEARLMAAYTSECADHLEAKELAGPDGVAA
  	AREIAKRWEKRVRDLQDKGAARKLLNDPLGRRTPNYQSKNPGE
  	YTVGNSMFYDGPQVANLQNVDTGFWLDMSNLSDVVLSREIQTG
  	LRARATLEESMPMLENLEERFRRLQETCDAARTEIEESGWTRESA
  	SRMEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSFGEHVRVLCAR
  	VSRGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSPEGASLAETLAR
  	FADDMGIERGADGTYDIPLVDDWRRGVPSIEGEGSDSIYEIMMPI
  	YEVMNMDLETRRSFAVQQGHYQDPRASDYDLPRASDYDLPRSP
  	YPTPPLPPRYQLQNMDVEAGFREAVYASFVAGMYNYVVTQPQE
  	RIPNSQQVEGILRDMLTNGSHHHHHH
  Ct875_E_458_nIgK_cHis	METPAQLLFLLLLWLPDTTGMSIRGVGGNGNSRIPSHNGDGSNRR	86
  	SQNTKGNNKVEDRVCSLYSSRSNENRESPYAVVDVSSMIESTPTS
  	GETTRASRGVLSRFQRGLVRIADKVRRAVQCAWSSVSTSRSSATR
  	AAESGSSSRTARGASSGYREYSPSAARGLRLMFTDFWRTRVLRQ
  	TSPMAGVFGNLDVNEARLMAAYTSECADHLEAKELAGPDGVAA
  	AREIAKRWEKRVRDLQDKGAARKLLNDPLGRRTPNYQSKNPGE
  	YTVGNSMFYDGPQVANLQNVDTGFWLDMSNLSDVVLSREIQTG
  	LRARATLEESMPMLENLEERFRRLQETCDAARTEIEESGWTRESA
  	SRMEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSFGEHVRVLCAR
  	VSRGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSPEGASLAETLAR
  	FADDMGIERGADGTYDIPLVDDWRRGVPSIEGEGSHHHHHH
  Ct875_E_574_NGM_nIgK	METPAQLLFLLLLWLPDTTGMSIRGVGGNGNSRIPSHNGDGSNRR	87
  	SQNTKGNNKVEDRVCSLYSSRSNENRESPYAVVDVSSMIESTPTS
  	GETTRASRGVLSRFQRGLVRIADKVRRAVQCAWSSVSTSRSSATR
  	AAESGSSSRTARGASSGYREYSPSAARGLRLMFTDFWRTRVLRQ
  	TSPMAGVFGNLDVNEARLMAAYTSECADHLEAKELAGPDGVAA
  	AREIAKRWEKRVRDLQDKGAARKLLNDPLGRRTPNYQSKNPGE
  	YTVGNSMFYDGPQVANLQNVDTGFWLDMQHLSDVVLSREIQTG
  	LRARATLEESMPMLENLEERFRRLQETCDAARTEIEESGWTRESA
  	SRMEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSFGEHVRVLCAR
  	VSRGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSPEGASLAETLAR
  	FADDMGIERGADGTYDIPLVDDWRRGVPSIEGEGSDSIYEIMMPI
  	YEVMNMDLETRRSFAVQQGHYQDPRASDYDLPRASDYDLPRSP
  	YPTPPLPPRYQLQNMDVEAGFREAVYASFVAGMYNYVVTQPQE
  	RIPNSQQVEGILRDMLTNGD
  Ct875_E_458_NGM_nIgK	METPAQLLFLLLLWLPDTTGMSIRGVGGNGNSRIPSHNGDGSNRR	88
  	SQNTKGNNKVEDRVCSLYSSRSNENRESPYAVVDVSSMIESTPTS
  	GETTRASRGVLSRFQRGLVRIADKVRRAVQCAWSSVSTSRSSATR
  	AAESGSSSRTARGASSGYREYSPSAARGLRLMFTDFWRTRVLRQ
  	TSPMAGVFGNLDVNEARLMAAYTSECADHLEAKELAGPDGVAA
  	AREIAKRWEKRVRDLQDKGAARKLLNDPLGRRTPNYQSKNPGE
  	YTVGNSMFYDGPQVANLQNVDTGFWLDMQHLSDVVLSREIQTG
  	LRARATLEESMPMLENLEERFRRLQETCDAARTEIEESGWTRESA
  	SRMEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSFGEHVRVLCAR
  	VSRGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSPEGASLAETLAR
  	FADDMGIERGADGTYDIPLVDDWRRGVPSIEGEGS
  Ct875_E_574_nIgK	METPAQLLFLLLLWLPDTTGMSIRGVGGNGNSRIPSHNGDGSNRR	89
  	SQNTKGNNKVEDRVCSLYSSRSNENRESPYAVVDVSSMIESTPTS
  	GETTRASRGVLSRFQRGLVRIADKVRRAVQCAWSSVSTSRSSATR
  	AAESGSSSRTARGASSGYREYSPSAARGLRLMFTDFWRTRVLRQ
  	TSPMAGVFGNLDVNEARLMAAYTSECADHLEAKELAGPDGVAA
  	AREIAKRWEKRVRDLQDKGAARKLLNDPLGRRTPNYQSKNPGE
  	YTVGNSMFYDGPQVANLQNVDTGFWLDMSNLSDVVLSREIQTG
  	LRARATLEESMPMLENLEERFRRLQETCDAARTEIEESGWTRESA
  	SRMEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSFGEHVRVLCAR
  	VSRGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSPEGASLAETLAR
  	FADDMGIERGADGTYDIPLVDDWRRGVPSIEGEGSDSIYEIMMPI
  	YEVMNMDLETRRSFAVQQGHYQDPRASDYDLPRASDYDLPRSP
  	YPTPPLPPRYQLQNMDVEAGFREAVYASFVAGMYNYVVTQPQE
  	RIPNSQQVEGILRDMLTNGS
  Ct875_E_458_nIgK	METPAQLLFLLLLWLPDTTGMSIRGVGGNGNSRIPSHNGDGSNRR	90
  	SQNTKGNNKVEDRVCSLYSSRSNENRESPYAVVDVSSMIESTPTS
  	GETTRASRGVLSRFQRGLVRIADKVRRAVQCAWSSVSTSRSSATR
  	AAESGSSSRTARGASSGYREYSPSAARGLRLMFTDFWRTRVLRQ
  	TSPMAGVFGNLDVNEARLMAAYTSECADHLEAKELAGPDGVAA
  	AREIAKRWEKRVRDLQDKGAARKLLNDPLGRRTPNYQSKNPGE
  	YTVGNSMFYDGPQVANLQNVDTGFWLDMSNLSDVVLSREIQTG
  	LRARATLEESMPMLENLEERFRRLQETCDAARTEIEESGWTRESA
  	SRMEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSFGEHVRVLCAR
  	VSRGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSPEGASLAETLAR
  	FADDMGIERGADGTYDIPLVDDWRRGVPSIEGEGS
  Ct875_E_1_574_NGM_nIgK_cHis	METPAQLLFLLLLWLPDTTGMSIRGVGGNGNSRIPSHNGDGSNRR	91
  	SQNTKGNNKVEDRVCSLYSSRSNENRESPYAVVDVSSMIESTPTS
  	GETTRASRGVLSRFQRGLVRIADKVRRAVQCAWSSVSTSRSSATR
  	AAESGSSSRTARGASSGYREYSPSAARGLRLMFTDFWRTRVLRQ
  	TSPMAGVFGNLDVNEARLMAAYTSECADHLEAKELAGPDGVAA
  	AREIAKRWEKRVRDLQDKGAARKLLNDPLGRRTPNYQSKNPGE
  	YTVGNSMFYDGPQVANLQNVDTGFWLDMQHLSDVVLSREIQTG
  	LRARATLEESMPMLENLEERFRRLQETCDAARTEIEESGWTRESA
  	SRMEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSFGEHVRVLCAR
  	VSRGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSPEGASLAETLAR
  	FADDMGIERGADGTYDIPLVDDWRRGVPSIEGEGSDSIYEIMMPI
  	YEVMNMDLETRRSFAVQQGHYQDPRASDYDLPRASDYDLPRSP
  	YPTPPLPPRYQLQNMDVEAGFREAVYASFVAGMYNYVVTQPQE
  	RIPNSQQVEGILRDMLTNGDHHHHHH
  Ct875_E_NGM_nFc	METPAQLLFLLLLWLPDTTGEPKSCDKTHTCPPCPAPELLGGPSV	92
  	FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEV
  	HNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKA
  	LPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFY
  	PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
  	QGNVFSCSVMHEALHNHYTQKSLSLSPGKMSIRGVGGNGNSRIPS
  	HNGDGSNRRSQNTKGNNKVEDRVCSLYSSRSNENRESPYAVVD
  	VSSMIESTPTSGETTRASRGVLSRFQRGLVRIADKVRRAVQCAWS
  	SVSTSRSSATRAAESGSSSRTARGASSGYREYSPSAARGLRLMFT
  	DFWRTRVLRQTSPMAGVFGNLDVNEARLMAAYTSECADHLEAK
  	ELAGPDGVAAAREIAKRWEKRVRDLQDKGAARKLLNDPLGRRT
  	PNYQSKNPGEYTVGNSMFYDGPQVANLQNVDTGFWLDMQHLS
  	DVVLSREIQTGLRARATLEESMPMLENLEERFRRLQETCDAARTE
  	IEESGWTRESASRMEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSF
  	GEHVRVLCARVSRGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSP
  	EGASLAETLARFADDMGIERGADGTYDIPLVDDWRRGVPSIEGE
  	GSDSIYEIMMPIYEVMNMDLETRRSFAVQQGHYQDPRASDYDLP
  	RASDYDLPRSPYPTPPLPPRYQLQNMDVEAGFREAVYASFVAGM
  	YNYVVTQPQERIPNSQQVEGILRDMLTNGDQTFRDLMKRWNRE
  	VDRE
  Ct875_E_NGM_nFc_cHis	METPAQLLFLLLLWLPDTTGEPKSCDKTHTCPPCPAPELLGGPSV	93
  	FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEV
  	HNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKA
  	LPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFY
  	PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
  	QGNVFSCSVMHEALHNHYTQKSLSLSPGKMSIRGVGGNGNSRIPS
  	HNGDGSNRRSQNTKGNNKVEDRVCSLYSSRSNENRESPYAVVD
  	VSSMIESTPTSGETTRASRGVLSRFQRGLVRIADKVRRAVQCAWS
  	SVSTSRSSATRAAESGSSSRTARGASSGYREYSPSAARGLRLMFT
  	DFWRTRVLRQTSPMAGVFGNLDVNEARLMAAYTSECADHLEAK
  	ELAGPDGVAAAREIAKRWEKRVRDLQDKGAARKLLNDPLGRRT
  	PNYQSKNPGEYTVGNSMFYDGPQVANLQNVDTGFWLDMQHLS
  	DVVLSREIQTGLRARATLEESMPMLENLEERFRRLQETCDAARTE
  	IEESGWTRESASRMEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSF
  	GEHVRVLCARVSRGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSP
  	EGASLAETLARFADDMGIERGADGTYDIPLVDDWRRGVPSIEGE
  	GSDSIYEIMMPIYEVMNMDLETRRSFAVQQGHYQDPRASDYDLP
  	RASDYDLPRSPYPTPPLPPRYQLQNMDVEAGFREAVYASFVAGM
  	YNYVVTQPQERIPNSQQVEGILRDMLTNGDQTFRDLMKRWNRE
  	VDREHHHHHH
  Ct875_E_1_574_NGM_nIgK_nGST	METPAQLLFLLLLWLPDTTGMSPILGYWKIKGLVQPTRLLLEYLE	94
  	EKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVKLTQSM
  	AIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDF
  	ETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDA
  	LDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPL
  	QGWQATFGGGDHPPKMSIRGVGGNGNSRIPSHNGDGSNRRSQNT
  	KGNNKVEDRVCSLYSSRSNENRESPYAVVDVSSMIESTPTSGETT
  	RASRGVLSRFQRGLVRIADKVRRAVQCAWSSVSTSRSSATRAAE
  	SGSSSRTARGASSGYREYSPSAARGLRLMFTDFWRTRVLRQTSP
  	MAGVFGNLDVNEARLMAAYTSECADHLEAKELAGPDGVAAAR
  	EIAKRWEKRVRDLQDKGAARKLLNDPLGRRTPNYQSKNPGEYT
  	VGNSMFYDGPQVANLQNVDTGFWLDMQHLSDVVLSREIQTGLR
  	ARATLEESMPMLENLEERFRRLQETCDAARTEIEESGWTRESASR
  	MEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSFGEHVRVLCARVS
  	RGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSPEGASLAETLARFA
  	DDMGIERGADGTYDIPLVDDWRRGVPSIEGEGSDSIYEIMMPIYE
  	VMNMDLETRRSFAVQQGHYQDPRASDYDLPRASDYDLPRSPYPT
  	PPLPPRYQLQNMDVEAGFREAVYASFVAGMYNYVVTQPQERIPN
  	SQQVEGILRDMLTNGD
  Ct875_E_1_574_NGM_nIgK_nGST_cHis	METPAQLLFLLLLWLPDTTGMSPILGYWKIKGLVQPTRLLLEYLE	95
  	EKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVKLTQSM
  	AIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDF
  	ETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDA
  	LDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPL
  	QGWQATFGGGDHPPKMSIRGVGGNGNSRIPSHNGDGSNRRSQNT
  	KGNNKVEDRVCSLYSSRSNENRESPYAVVDVSSMIESTPTSGETT
  	RASRGVLSRFQRGLVRIADKVRRAVQCAWSSVSTSRSSATRAAE
  	SGSSSRTARGASSGYREYSPSAARGLRLMFTDFWRTRVLRQTSP
  	MAGVFGNLDVNEARLMAAYTSECADHLEAKELAGPDGVAAAR
  	EIAKRWEKRVRDLQDKGAARKLLNDPLGRRTPNYQSKNPGEYT
  	VGNSMFYDGPQVANLQNVDTGFWLDMQHLSDVVLSREIQTGLR
  	ARATLEESMPMLENLEERFRRLQETCDAARTEIEESGWTRESASR
  	MEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSFGEHVRVLCARVS
  	RGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSPEGASLAETLARFA
  	DDMGIERGADGTYDIPLVDDWRRGVPSIEGEGSDSIYEIMMPIYE
  	VMNMDLETRRSFAVQQGHYQDPRASDYDLPRASDYDLPRSPYPT
  	PPLPPRYQLQNMDVEAGFREAVYASFVAGMYNYVVTQPQERIPN
  	SQQVEGILRDMLTNGDHHHHHH
  Ct875_E_NGM_nIgK_nGST	METPAQLLFLLLLWLPDTTGMSPILGYWKIKGLVQPTRLLLEYLE	96
  	EKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVKLTQSM
  	AIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDF
  	ETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDA
  	LDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPL
  	QGWQATFGGGDHPPKMSIRGVGGNGNSRIPSHNGDGSNRRSQNT
  	KGNNKVEDRVCSLYSSRSNENRESPYAVVDVSSMIESTPTSGETT
  	RASRGVLSRFQRGLVRIADKVRRAVQCAWSSVSTSRSSATRAAE
  	SGSSSRTARGASSGYREYSPSAARGLRLMFTDFWRTRVLRQTSP
  	MAGVFGNLDVNEARLMAAYTSECADHLEAKELAGPDGVAAAR
  	EIAKRWEKRVRDLQDKGAARKLLNDPLGRRTPNYQSKNPGEYT
  	VGNSMFYDGPQVANLQNVDTGFWLDMQHLSDVVLSREIQTGLR
  	ARATLEESMPMLENLEERFRRLQETCDAARTEIEESGWTRESASR
  	MEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSFGEHVRVLCARVS
  	RGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSPEGASLAETLARFA
  	DDMGIERGADGTYDIPLVDDWRRGVPSIEGEGSDSIYEIMMPIYE
  	VMNMDLETRRSFAVQQGHYQDPRASDYDLPRASDYDLPRSPYPT
  	PPLPPRYQLQNMDVEAGFREAVYASFVAGMYNYVVTQPQERIPN
  	SQQVEGILRDMLTNGDQTFRDLMKRWNREVDRE
  Ct875_E_NGM_nIgK_nGST_cHis	METPAQLLFLLLLWLPDTTGMSPILGYWKIKGLVQPTRLLLEYLE	97
  	EKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVKLTQSM
  	AIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDF
  	ETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDA
  	LDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPL
  	QGWQATFGGGDHPPKMSIRGVGGNGNSRIPSHNGDGSNRRSQNT
  	KGNNKVEDRVCSLYSSRSNENRESPYAVVDVSSMIESTPTSGETT
  	RASRGVLSRFQRGLVRIADKVRRAVQCAWSSVSTSRSSATRAAE
  	SGSSSRTARGASSGYREYSPSAARGLRLMFTDFWRTRVLRQTSP
  	MAGVFGNLDVNEARLMAAYTSECADHLEAKELAGPDGVAAAR
  	EIAKRWEKRVRDLQDKGAARKLLNDPLGRRTPNYQSKNPGEYT
  	VGNSMFYDGPQVANLQNVDTGFWLDMQHLSDVVLSREIQTGLR
  	ARATLEESMPMLENLEERFRRLQETCDAARTEIEESGWTRESASR
  	MEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSFGEHVRVLCARVS
  	RGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSPEGASLAETLARFA
  	DDMGIERGADGTYDIPLVDDWRRGVPSIEGEGSDSIYEIMMPIYE
  	VMNMDLETRRSFAVQQGHYQDPRASDYDLPRASDYDLPRSPYPT
  	PPLPPRYQLQNMDVEAGFREAVYASFVAGMYNYVVTQPQERIPN
  	SQQVEGILRDMLTNGDQTFRDLMKRWNREVDREHHHHHH
  Ct875_E_1_458_NGM_nIgK_nGST	METPAQLLFLLLLWLPDTTGMSPILGYWKIKGLVQPTRLLLEYLE	98
  	EKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVKLTQSM
  	AIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDF
  	ETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDA
  	LDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPL
  	QGWQATFGGGDHPPKMSIRGVGGNGNSRIPSHNGDGSNRRSQNT
  	KGNNKVEDRVCSLYSSRSNENRESPYAVVDVSSMIESTPTSGETT
  	RASRGVLSRFQRGLVRIADKVRRAVQCAWSSVSTSRSSATRAAE
  	SGSSSRTARGASSGYREYSPSAARGLRLMFTDFWRTRVLRQTSP
  	MAGVFGNLDVNEARLMAAYTSECADHLEAKELAGPDGVAAAR
  	EIAKRWEKRVRDLQDKGAARKLLNDPLGRRTPNYQSKNPGEYT
  	VGNSMFYDGPQVANLQNVDTGFWLDMQHLSDVVLSREIQTGLR
  	ARATLEESMPMLENLEERFRRLQETCDAARTEIEESGWTRESASR
  	MEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSFGEHVRVLCARVS
  	RGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSPEGASLAETLARFA
  	DDMGIERGADGTYDIPLVDDWRRGVPSIEGEGS
  Ct875_E_1_458_NGM_nIgK_nGST_cHis	METPAQLLFLLLLWLPDTTGMSPILGYWKIKGLVQPTRLLLEYLE	99
  	EKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVKLTQSM
  	AIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDF
  	ETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDA
  	LDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPL
  	QGWQATFGGGDHPPKMSIRGVGGNGNSRIPSHNGDGSNRRSQNT
  	KGNNKVEDRVCSLYSSRSNENRESPYAVVDVSSMIESTPTSGETT
  	RASRGVLSRFQRGLVRIADKVRRAVQCAWSSVSTSRSSATRAAE
  	SGSSSRTARGASSGYREYSPSAARGLRLMFTDFWRTRVLRQTSP
  	MAGVFGNLDVNEARLMAAYTSECADHLEAKELAGPDGVAAAR
  	EIAKRWEKRVRDLQDKGAARKLLNDPLGRRTPNYQSKNPGEYT
  	VGNSMFYDGPQVANLQNVDTGFWLDMQHLSDVVLSREIQTGLR
  	ARATLEESMPMLENLEERFRRLQETCDAARTEIEESGWTRESASR
  	MEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSFGEHVRVLCARVS
  	RGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSPEGASLAETLARFA
  	DDMGIERGADGTYDIPLVDDWRRGVPSIEGEGSHHHHHH
  Ct875_E_1_458_NGM_nIgK	METPAQLLFLLLLWLPDTTGMSIRGVGGNGNSRIPSHNGDGSNRR	100
  	SQNTKGNNKVEDRVCSLYSSRSNENRESPYAVVDVSSMIESTPTS
  	GETTRASRGVLSRFQRGLVRIADKVRRAVQCAWSSVSTSRSSATR
  	AAESGSSSRTARGASSGYREYSPSAARGLRLMFTDFWRTRVLRQ
  	TSPMAGVFGNLDVNEARLMAAYTSECADHLEAKELAGPDGVAA
  	AREIAKRWEKRVRDLQDKGAARKLLNDPLGRRTPNYQSKNPGE
  	YTVGNSMFYDGPQVANLQNVDTGFWLDMQHLSDVVLSREIQTG
  	LRARATLEESMPMLENLEERFRRLQETCDAARTEIEESGWTRESA
  	SRMEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSFGEHVRVLCAR
  	VSRGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSPEGASLAETLAR
  	FADDMGIERGADGTYDIPLVDDWRRGVPSIEGEGS
  Ct875_E_1_458_NGM_nIgK_cHis	METPAQLLFLLLLWLPDTTGMSIRGVGGNGNSRIPSHNGDGSNRR	101
  	SQNTKGNNKVEDRVCSLYSSRSNENRESPYAVVDVSSMIESTPTS
  	GETTRASRGVLSRFQRGLVRIADKVRRAVQCAWSSVSTSRSSATR
  	AAESGSSSRTARGASSGYREYSPSAARGLRLMFTDFWRTRVLRQ
  	TSPMAGVFGNLDVNEARLMAAYTSECADHLEAKELAGPDGVAA
  	AREIAKRWEKRVRDLQDKGAARKLLNDPLGRRTPNYQSKNPGE
  	YTVGNSMFYDGPQVANLQNVDTGFWLDMQHLSDVVLSREIQTG
  	LRARATLEESMPMLENLEERFRRLQETCDAARTEIEESGWTRESA
  	SRMEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSFGEHVRVLCAR
  	VSRGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSPEGASLAETLAR
  	FADDMGIERGADGTYDIPLVDDWRRGVPSIEGEGSHHHHHH
  Ct875_E_1_574_NGM_nIgK	METPAQLLFLLLLWLPDTTGMSIRGVGGNGNSRIPSHNGDGSNRR	102
  	SQNTKGNNKVEDRVCSLYSSRSNENRESPYAVVDVSSMIESTPTS
  	GETTRASRGVLSRFQRGLVRIADKVRRAVQCAWSSVSTSRSSATR
  	AAESGSSSRTARGASSGYREYSPSAARGLRLMFTDFWRTRVLRQ
  	TSPMAGVFGNLDVNEARLMAAYTSECADHLEAKELAGPDGVAA
  	AREIAKRWEKRVRDLQDKGAARKLLNDPLGRRTPNYQSKNPGE
  	YTVGNSMFYDGPQVANLQNVDTGFWLDMQHLSDVVLSREIQTG
  	LRARATLEESMPMLENLEERFRRLQETCDAARTEIEESGWTRESA
  	SRMEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSFGEHVRVLCAR
  	VSRGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSPEGASLAETLAR
  	FADDMGIERGADGTYDIPLVDDWRRGVPSIEGEGSDSIYEIMMPI
  	YEVMNMDLETRRSFAVQQGHYQDPRASDYDLPRASDYDLPRSP
  	YPTPPLPPRYQLQNMDVEAGFREAVYASFVAGMYNYVVTQPQE
  	RIPNSQQVEGILRDMLTNGD
  Ct875_E_1_574_nIgK_nGST	METPAQLLFLLLLWLPDTTGMSPILGYWKIKGLVQPTRLLLEYLE	103
  	EKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVKLTQSM
  	AIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDF
  	ETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDA
  	LDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPL
  	QGWQATFGGGDHPPKMSIRGVGGNGNSRIPSHNGDGSNRRSQNT
  	KGNNKVEDRVCSLYSSRSNENRESPYAVVDVSSMIESTPTSGETT
  	RASRGVLSRFQRGLVRIADKVRRAVQCAWSSVSTSRSSATRAAE
  	SGSSSRTARGASSGYREYSPSAARGLRLMFTDFWRTRVLRQTSP
  	MAGVFGNLDVNEARLMAAYTSECADHLEAKELAGPDGVAAAR
  	EIAKRWEKRVRDLQDKGAARKLLNDPLGRRTPNYQSKNPGEYT
  	VGNSMFYDGPQVANLQNVDTGFWLDMSNLSDVVLSREIQTGLR
  	ARATLEESMPMLENLEERFRRLQETCDAARTEIEESGWTRESASR
  	MEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSFGEHVRVLCARVS
  	RGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSPEGASLAETLARFA
  	DDMGIERGADGTYDIPLVDDWRRGVPSIEGEGSDSIYEIMMPIYE
  	VMNMDLETRRSFAVQQGHYQDPRASDYDLPRASDYDLPRSPYPT
  	PPLPPRYQLQNMDVEAGFREAVYASFVAGMYNYVVTQPQERIPN
  	SQQVEGILRDMLTNGS
  Ct875_E_1_574_nIgK_nGST_cHis	METPAQLLFLLLLWLPDTTGMSPILGYWKIKGLVQPTRLLLEYLE	104
  	EKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVKLTQSM
  	AIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDF
  	ETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDA
  	LDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPL
  	QGWQATFGGGDHPPKMSIRGVGGNGNSRIPSHNGDGSNRRSQNT
  	KGNNKVEDRVCSLYSSRSNENRESPYAVVDVSSMIESTPTSGETT
  	RASRGVLSRFQRGLVRIADKVRRAVQCAWSSVSTSRSSATRAAE
  	SGSSSRTARGASSGYREYSPSAARGLRLMFTDFWRTRVLRQTSP
  	MAGVFGNLDVNEARLMAAYTSECADHLEAKELAGPDGVAAAR
  	EIAKRWEKRVRDLQDKGAARKLLNDPLGRRTPNYQSKNPGEYT
  	VGNSMFYDGPQVANLQNVDTGFWLDMSNLSDVVLSREIQTGLR
  	ARATLEESMPMLENLEERFRRLQETCDAARTEIEESGWTRESASR
  	MEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSFGEHVRVLCARVS
  	RGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSPEGASLAETLARFA
  	DDMGIERGADGTYDIPLVDDWRRGVPSIEGEGSDSIYEIMMPIYE
  	VMNMDLETRRSFAVQQGHYQDPRASDYDLPRASDYDLPRSPYPT
  	PPLPPRYQLQNMDVEAGFREAVYASFVAGMYNYVVTQPQERIPN
  	SQQVEGILRDMLTNGSHHHHHH
  Ct875_E_nIgK_nGST	METPAQLLFLLLLWLPDTTGMSPILGYWKIKGLVQPTRLLLEYLE	105
  	EKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVKLTQSM
  	AIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDF
  	ETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDA
  	LDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPL
  	QGWQATFGGGDHPPKMSIRGVGGNGNSRIPSHNGDGSNRRSQNT
  	KGNNKVEDRVCSLYSSRSNENRESPYAVVDVSSMIESTPTSGETT
  	RASRGVLSRFQRGLVRIADKVRRAVQCAWSSVSTSRSSATRAAE
  	SGSSSRTARGASSGYREYSPSAARGLRLMFTDFWRTRVLRQTSP
  	MAGVFGNLDVNEARLMAAYTSECADHLEAKELAGPDGVAAAR
  	EIAKRWEKRVRDLQDKGAARKLLNDPLGRRTPNYQSKNPGEYT
  	VGNSMFYDGPQVANLQNVDTGFWLDMSNLSDVVLSREIQTGLR
  	ARATLEESMPMLENLEERFRRLQETCDAARTEIEESGWTRESASR
  	MEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSFGEHVRVLCARVS
  	RGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSPEGASLAETLARFA
  	DDMGIERGADGTYDIPLVDDWRRGVPSIEGEGSDSIYEIMMPIYE
  	VMNMDLETRRSFAVQQGHYQDPRASDYDLPRASDYDLPRSPYPT
  	PPLPPRYQLQNMDVEAGFREAVYASFVAGMYNYVVTQPQERIPN
  	SQQVEGILRDMLTNGSQTFRDLMKRWNREVDRE
  Ct875_E_nIgK_nGST_cHis	METPAQLLFLLLLWLPDTTGMSPILGYWKIKGLVQPTRLLLEYLE	106
  	EKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVKLTQSM
  	AIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDF
  	ETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDA
  	LDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPL
  	QGWQATFGGGDHPPKMSIRGVGGNGNSRIPSHNGDGSNRRSQNT
  	KGNNKVEDRVCSLYSSRSNENRESPYAVVDVSSMIESTPTSGETT
  	RASRGVLSRFQRGLVRIADKVRRAVQCAWSSVSTSRSSATRAAE
  	SGSSSRTARGASSGYREYSPSAARGLRLMFTDFWRTRVLRQTSP
  	MAGVFGNLDVNEARLMAAYTSECADHLEAKELAGPDGVAAAR
  	EIAKRWEKRVRDLQDKGAARKLLNDPLGRRTPNYQSKNPGEYT
  	VGNSMFYDGPQVANLQNVDTGFWLDMSNLSDVVLSREIQTGLR
  	ARATLEESMPMLENLEERFRRLQETCDAARTEIEESGWTRESASR
  	MEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSFGEHVRVLCARVS
  	RGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSPEGASLAETLARFA
  	DDMGIERGADGTYDIPLVDDWRRGVPSIEGEGSDSIYEIMMPIYE
  	VMNMDLETRRSFAVQQGHYQDPRASDYDLPRASDYDLPRSPYPT
  	PPLPPRYQLQNMDVEAGFREAVYASFVAGMYNYVVTQPQERIPN
  	SQQVEGILRDMLTNGSQTFRDLMKRWNREVDREHHHHHH
  Ct875_E_nFc	METPAQLLFLLLLWLPDTTGEPKSCDKTHTCPPCPAPELLGGPSV	107
  	FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEV
  	HNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKA
  	LPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFY
  	PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
  	QGNVFSCSVMHEALHNHYTQKSLSLSPGKMSIRGVGGNGNSRIPS
  	HNGDGSNRRSQNTKGNNKVEDRVCSLYSSRSNENRESPYAVVD
  	VSSMIESTPTSGETTRASRGVLSRFQRGLVRIADKVRRAVQCAWS
  	SVSTSRSSATRAAESGSSSRTARGASSGYREYSPSAARGLRLMFT
  	DFWRTRVLRQTSPMAGVFGNLDVNEARLMAAYTSECADHLEAK
  	ELAGPDGVAAAREIAKRWEKRVRDLQDKGAARKLLNDPLGRRT
  	PNYQSKNPGEYTVGNSMFYDGPQVANLQNVDTGFWLDMSNLSD
  	VVLSREIQTGLRARATLEESMPMLENLEERFRRLQETCDAARTEI
  	EESGWTRESASRMEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSF
  	GEHVRVLCARVSRGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSP
  	EGASLAETLARFADDMGIERGADGTYDIPLVDDWRRGVPSIEGE
  	GSDSIYEIMMPIYEVMNMDLETRRSFAVQQGHYQDPRASDYDLP
  	RASDYDLPRSPYPTPPLPPRYQLQNMDVEAGFREAVYASFVAGM
  	YNYVVTQPQERIPNSQQVEGILRDMLTNGSQTFRDLMKRWNREV
  	DRE
  Ct875_E_nFc_cHis	METPAQLLFLLLLWLPDTTGEPKSCDKTHTCPPCPAPELLGGPSV	108
  	FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEV
  	HNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKA
  	LPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFY
  	PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
  	QGNVFSCSVMHEALHNHYTQKSLSLSPGKMSIRGVGGNGNSRIPS
  	HNGDGSNRRSQNTKGNNKVEDRVCSLYSSRSNENRESPYAVVD
  	VSSMIESTPTSGETTRASRGVLSRFQRGLVRIADKVRRAVQCAWS
  	SVSTSRSSATRAAESGSSSRTARGASSGYREYSPSAARGLRLMFT
  	DFWRTRVLRQTSPMAGVFGNLDVNEARLMAAYTSECADHLEAK
  	ELAGPDGVAAAREIAKRWEKRVRDLQDKGAARKLLNDPLGRRT
  	PNYQSKNPGEYTVGNSMFYDGPQVANLQNVDTGFWLDMSNLSD
  	VVLSREIQTGLRARATLEESMPMLENLEERFRRLQETCDAARTEI
  	EESGWTRESASRMEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSF
  	GEHVRVLCARVSRGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSP
  	EGASLAETLARFADDMGIERGADGTYDIPLVDDWRRGVPSIEGE
  	GSDSIYEIMMPIYEVMNMDLETRRSFAVQQGHYQDPRASDYDLP
  	RASDYDLPRSPYPTPPLPPRYQLQNMDVEAGFREAVYASFVAGM
  	YNYVVTQPQERIPNSQQVEGILRDMLTNGSQTFRDLMKRWNREV
  	DREHHHHHH
  Ct043_E_NGM_nIgK_no4A	METPAQLLFLLLLWLPDTTGMSRQNAEENLKNFAKELKLPDVAF	109
  	DQNNACILFVDGEFSLHLTYEEHSDRLYVYAPLLDGLPDNPQRKL
  	ALYEKLLEGSMLGGQMAGGGVGVATKEQLILMHCVLDMKYAE
  	TNLLKAFAQLFIETVVKWRTVCSDISAGREPTVDTMPQMPQGGG
  	GGIQPPPAGIRA
  Ct043_E_NGM_nIgK_cHis_no4A	METPAQLLFLLLLWLPDTTGMSRQNAEENLKNFAKELKLPDVAF	110
  	DQNNACILFVDGEFSLHLTYEEHSDRLYVYAPLLDGLPDNPQRKL
  	ALYEKLLEGSMLGGQMAGGGVGVATKEQLILMHCVLDMKYAE
  	TNLLKAFAQLFIETVVKWRTVCSDISAGREPTVDTMPQMPQGGG
  	GGIQPPPAGIRAHHHHHH
  Ct043_E_nIgK_no4A	METPAQLLFLLLLWLPDTTGMSRQNAEENLKNFAKELKLPDVAF	111
  	DQNNTCILFVDGEFSLHLTYEEHSDRLYVYAPLLDGLPDNPQRKL
  	ALYEKLLEGSMLGGQMAGGGVGVATKEQLILMHCVLDMKYAE
  	TNLLKAFAQLFIETVVKWRTVCSDISAGREPTVDTMPQMPQGGG
  	GGIQPPPAGIRA
  Ct043_E_nIgK_cHis_no4A	METPAQLLFLLLLWLPDTTGMSRQNAEENLKNFAKELKLPDVAF	112
  	DQNNTCILFVDGEFSLHLTYEEHSDRLYVYAPLLDGLPDNPQRKL
  	ALYEKLLEGSMLGGQMAGGGVGVATKEQLILMHCVLDMKYAE
  	TNLLKAFAQLFIETVVKWRTVCSDISAGREPTVDTMPQMPQGGG
  	GGIQPPPAGIRAHHHHHH
  Chlamydia_Ct812_pd_serovarD_nIgK_cHis_nopolyN	METPAQLLFLLLLWLPDTTGSCVDLHAGGQSVNELVYVGPQAVL	113
  	LLDQIRDLFVGSKDSQAEGQYRLIVGDPSSFQEKDADTLPGKVEQ
  	STLFSVTNPVVFQGVDQQDQVSSQGLICSFTSSNLDSPRDGESFLG
  	IAFVGDSSKAGITLTDVKASLSGAALYSTEDLIFEKIKGGLEFASCS
  	SLEQGGACAAQSILIHDCQGLQVKHCTTAVNAEGSSANDHLGFG
  	GGAFFVTGSLSGEKSLYMPAGDMVVANCDGAISFEGNSANFANG
  	GAIAASGKVLFVANDKKTSFIENRALSGGAIAASSDIAFQNCAEL
  	VFKGNCAIGTEDKGSLGGGAISSLGTVLLQGNHGITCDKNESASQ
  	GGAIFGKNCQISDNEGPVVFRDSTACLGGGAIAAQEIVSIQNNQA
  	GISFEGGKASFGGGIACGSFSSAGGASVLGTIDISKNLGAISFSRTL
  	CTTSDLGQMEYQGGGALFGENISLSENAGVLTFKDNIVKTFASNG
  	KILGGGAILATGKVEITNNSEGISFTGNARAPQALPTQEEFPLFSKK
  	EGRPLSSGYSGGGAILGREVAILHNAAVVFEQNRLQCSEEEATLL
  	GCCGGGAVHGMDSTSIVGNSSVRFGNNYAMGQGVSGGALLSKT
  	VQLAGNGSVDFSRNIASLGGGALQASEGNCELVDNGYVLFRDNR
  	GRVYGGAISCLRGDVVISGNKGRVEFKDNIATRLYVEETVEKVEE
  	VEPAPEQKDNNELSFLGRAEQSFITAANQALFASEDGDLSPESSIS
  	SEELAKRRECAGGAIFAKRVRIVDNQEAVVFSNNFSDIYGGAIFT
  	GSLREEDKLDGQIPEVLISGNAGDVVFSGNSSKRDEHLPHTGGGA
  	ICTQNLTISQNTGNVLFYNNVACSGGAVRIEDHGNVLLEAFGGDI
  	VFKGNSSFRAQGSDAIYFAGKESHITALNATEGHAIVFHDALVFE
  	NLEERKSAEVLLINSRENPGYTGSIRFLEAESKVPQCIHVQQGSLE
  	LLNGATLCSYGFKQDAGAKLVLAAGAKLKILDSGTPVQQGHAIS
  	KPEAEIESSSEPEGAHSLWIAKNAQTTVPMVDIHTISVDLASFSSSQ
  	QEGTVEAPQVIVPGGSYVRSGELNLELVNTTGTGYENHALLKNE
  	AKVPLMSFVASGDEASAEISNLSVSDLQIHVVTPEIEEDTYGHMG
  	DWSEAKIQDGTLVISWNPTGHHHHHH
  Chlamydia_Ct812_pd_serovarD_nIgK_nopolyN	METPAQLLFLLLLWLPDTTGSCVDLHAGGQSVNELVYVGPQAVL	114
  	LLDQIRDLFVGSKDSQAEGQYRLIVGDPSSFQEKDADTLPGKVEQ
  	STLFSVTNPVVFQGVDQQDQVSSQGLICSFTSSNLDSPRDGESFLG
  	IAFVGDSSKAGITLTDVKASLSGAALYSTEDLIFEKIKGGLEFASCS
  	SLEQGGACAAQSILIHDCQGLQVKHCTTAVNAEGSSANDHLGFG
  	GGAFFVTGSLSGEKSLYMPAGDMVVANCDGAISFEGNSANFANG
  	GAIAASGKVLFVANDKKTSFIENRALSGGAIAASSDIAFQNCAEL
  	VFKGNCAIGTEDKGSLGGGAISSLGTVLLQGNHGITCDKNESASQ
  	GGAIFGKNCQISDNEGPVVFRDSTACLGGGAIAAQEIVSIQNNQA
  	GISFEGGKASFGGGIACGSFSSAGGASVLGTIDISKNLGAISFSRTL
  	CTTSDLGQMEYQGGGALFGENISLSENAGVLTFKDNIVKTFASNG
  	KILGGGAILATGKVEITNNSEGISFTGNARAPQALPTQEEFPLFSKK
  	EGRPLSSGYSGGGAILGREVAILHNAAVVFEQNRLQCSEEEATLL
  	GCCGGGAVHGMDSTSIVGNSSVRFGNNYAMGQGVSGGALLSKT
  	VQLAGNGSVDFSRNIASLGGGALQASEGNCELVDNGYVLFRDNR
  	GRVYGGAISCLRGDVVISGNKGRVEFKDNIATRLYVEETVEKVEE
  	VEPAPEQKDNNELSFLGRAEQSFITAANQALFASEDGDLSPESSIS
  	SEELAKRRECAGGAIFAKRVRIVDNQEAVVFSNNFSDIYGGAIFT
  	GSLREEDKLDGQIPEVLISGNAGDVVFSGNSSKRDEHLPHTGGGA
  	ICTQNLTISQNTGNVLFYNNVACSGGAVRIEDHGNVLLEAFGGDI
  	VFKGNSSFRAQGSDAIYFAGKESHITALNATEGHAIVFHDALVFE
  	NLEERKSAEVLLINSRENPGYTGSIRFLEAESKVPQCIHVQQGSLE
  	LLNGATLCSYGFKQDAGAKLVLAAGAKLKILDSGTPVQQGHAIS
  	KPEAEIESSSEPEGAHSLWIAKNAQTTVPMVDIHTISVDLASFSSSQ
  	QEGTVEAPQVIVPGGSYVRSGELNLELVNTTGTGYENHALLKNE
  	AKVPLMSFVASGDEASAEISNLSVSDLQIHVVTPEIEEDTYGHMG
  	DWSEAKIQDGTLVISWNPTG
  Ct812pd_PmpD_D_NGM_nIgK_nopolyN	METPAQLLFLLLLWLPDTTGSCVDLHAGGQSVNELVYVGPQAVL	115
  	LLDQIRDLFVGSKDSQAEGQYRLIVGDPSSFQEKDADTLPGKVEQ
  	STLFSVTNPVVFQGVDQQDQVSSQGLICSFTSSNLDSPRDGESFLG
  	IAFVGDSSKAGITLTDVKASLSGAALYSTEDLIFEKIKGGLEFASCS
  	SLEQGGACAAQSILIHDCQGLQVKHCTTAVNAEGSSANDHLGFG
  	GGAFFVTGSLSGEKSLYMPAGDMVVANCDGAISFEGNSANFANG
  	GAIAASGKVLFVANDKKTSFIENRALSGGAIAASSDIAFQNCAEL
  	VFKGNCAIGTEDKGSLGGGAISSLGTVLLQGNHGITCDKNEAASQ
  	GGAIFGKNCQISDNEGPVVFRDSTACLGGGAIAAQEIVSIQNNQA
  	GISFEGGKASFGGGIACGSFSSAGGASVLGTIDISKNLGAISFSRTL
  	CTTSDLGQMEYQGGGALFGENIALSENAGVLTFKDNIVKTFASN
  	GKILGGGAILATGKVEITNNAEGISFTGNARAPQALPTQEEFPLFS
  	KKEGRPLSSGYSGGGAILGREVAILHNAAVVFEQNRLQCSEEEAT
  	LLGCCGGGAVHGMDSTSIVGNSAVRFGNNYAMGQGVSGGALLS
  	KTVQLAGNGAVDFSRNIASLGGGALQASEGNCELVDNGYVLFRD
  	NRGRVYGGAISCLRGDVVISGNKGRVEFKDNIATRLYVEETVEK
  	VEEVEPAPEQKDNNELSFLGRAEQSFITAANQALFASEDGDLSPES
  	SISSEELAKRRECAGGAIFAKRVRIVDNQEAVVFSNNFADIYGGAI
  	FTGSLREEDKLDGQIPEVLISGNAGDVVFSGNSAKRDEHLPHTGG
  	GAICTQNLAISQNTGNVLFYNNVACSGGAVRIEDHGNVLLEAFG
  	GDIVFKGNSAFRAQGSDAIYFAGKESHITALNAAEGHAIVFHDAL
  	VFENLEERKSAEVLLINSRENPGYTGSIRFLEAESKVPQCIHVQQG
  	SLELLNGATLCSYGFKQDAGAKLVLAAGAKLKILDSGTPVQQGH
  	AISKPEAEIESSSEPEGAHSLWIAKNAQTTVPMVDIHTISVDLASFS
  	SSQQEGTVEAPQVIVPGGSYVRSGELNLELVNTAGTGYENHALL
  	KNEAKVPLMSFVASGDEASAEISNLAVSDLQIHVVTPEIEEDTYG
  	HMGDWSEAKIQDGTLVISWNPAG
  Ct812pd_PmpD_D_NGM_nIgK_cHis_nopolyN	METPAQLLFLLLLWLPDTTGSCVDLHAGGQSVNELVYVGPQAVL	116
  	LLDQIRDLFVGSKDSQAEGQYRLIVGDPSSFQEKDADTLPGKVEQ
  	STLFSVTNPVVFQGVDQQDQVSSQGLICSFTSSNLDSPRDGESFLG
  	IAFVGDSSKAGITLTDVKASLSGAALYSTEDLIFEKIKGGLEFASCS
  	SLEQGGACAAQSILIHDCQGLQVKHCTTAVNAEGSSANDHLGFG
  	GGAFFVTGSLSGEKSLYMPAGDMVVANCDGAISFEGNSANFANG
  	GAIAASGKVLFVANDKKTSFIENRALSGGAIAASSDIAFQNCAEL
  	VFKGNCAIGTEDKGSLGGGAISSLGTVLLQGNHGITCDKNEAASQ
  	GGAIFGKNCQISDNEGPVVFRDSTACLGGGAIAAQEIVSIQNNQA
  	GISFEGGKASFGGGIACGSFSSAGGASVLGTIDISKNLGAISFSRTL
  	CTTSDLGQMEYQGGGALFGENIALSENAGVLTFKDNIVKTFASN
  	GKILGGGAILATGKVEITNNAEGISFTGNARAPQALPTQEEFPLFS
  	KKEGRPLSSGYSGGGAILGREVAILHNAAVVFEQNRLQCSEEEAT
  	LLGCCGGGAVHGMDSTSIVGNSAVRFGNNYAMGQGVSGGALLS
  	KTVQLAGNGAVDFSRNIASLGGGALQASEGNCELVDNGYVLFRD
  	NRGRVYGGAISCLRGDVVISGNKGRVEFKDNIATRLYVEETVEK
  	VEEVEPAPEQKDNNELSFLGRAEQSFITAANQALFASEDGDLSPES
  	SISSEELAKRRECAGGAIFAKRVRIVDNQEAVVFSNNFADIYGGAI
  	FTGSLREEDKLDGQIPEVLISGNAGDVVFSGNSAKRDEHLPHTGG
  	GAICTQNLAISQNTGNVLFYNNVACSGGAVRIEDHGNVLLEAFG
  	GDIVFKGNSAFRAQGSDAIYFAGKESHITALNAAEGHAIVFHDAL
  	VFENLEERKSAEVLLINSRENPGYTGSIRFLEAESKVPQCIHVQQG
  	SLELLNGATLCSYGFKQDAGAKLVLAAGAKLKILDSGTPVQQGH
  	AISKPEAEIESSSEPEGAHSLWIAKNAQTTVPMVDIHTISVDLASFS
  	SSQQEGTVEAPQVIVPGGSYVRSGELNLELVNTAGTGYENHALL
  	KNEAKVPLMSFVASGDEASAEISNLAVSDLQIHVVTPEIEEDTYG
  	HMGDWSEAKIQDGTLVISWNPAGHHHHHH
  Ct871pd_PmpG_D_NGM_nIgK	METPAQLLFLLLLWLPDTTGAEIMIPQGIYDGETLTVSFPYTVIGD	117
  	PSGTTVFSAGELTLKNLDNSIAALPLSCFGNLLGSFTVLGRGHSLT
  	FENIRTSTNGAALSDSANSGLFTIEGFKELSFSNCNSLLAVLPAATT
  	NSGSQTPTTTSTPSNGAIYSKTDLLLLNNEKFSFYSNLVSGDGGAI
  	DAKSLTVQGISKLCVFQENTAQADGGACQVVTSFSAMANEAPIA
  	FIANVAGVRGGGIAAVQDGQQGVSSSTSTEDPVVSFSRNTAVEFD
  	GNVARVGGGIYSYGNVAFLNNGKTLFLNNVASPVYIAAEQPTNG
  	QASNTADNYGDGGAIFCKNGAQAAGSNNAGSVSFDGEGVVFFSS
  	NVAAGKGGAIYAKKLSVANCGPVQFLGNIANDGGAIYLGESGEL
  	SLSADYGDIIFDGNLKRTAKENAADVNGVTVSSQAISMGSGGKIT
  	TLRAKAGHQILFNDPIEMANGNNQPAQSSEPLKINDGEGYTGDIV
  	FANGNSALYQNVAIEQGRIVLREKAKLSVNSLSQTGGSLYMEAG
  	STLDFVTPQPPQQPPAANQLITLSNLHLSLSSLLANNAVTNPPTNP
  	PAQDSHPAIIGSTTAGSVTISGPIFFEDLDDTAYDRYDWLGSNQKI
  	DVLKLQLGTQPSANAPSDLTLGNEMPKYGYQGSWKLAWDPNTA
  	NNGPYTLKATWTKTG
  Ct871pd_PmpG_D_NGM_nIgK_cHis	METPAQLLFLLLLWLPDTTGAEIMIPQGIYDGETLTVSFPYTVIGD	118
  	PSGTTVFSAGELTLKNLDNSIAALPLSCFGNLLGSFTVLGRGHSLT
  	FENIRTSTNGAALSDSANSGLFTIEGFKELSFSNCNSLLAVLPAATT
  	NSGSQTPTTTSTPSNGAIYSKTDLLLLNNEKFSFYSNLVSGDGGAI
  	DAKSLTVQGISKLCVFQENTAQADGGACQVVTSFSAMANEAPIA
  	FIANVAGVRGGGIAAVQDGQQGVSSSTSTEDPVVSFSRNTAVEFD
  	GNVARVGGGIYSYGNVAFLNNGKTLFLNNVASPVYIAAEQPTNG
  	QASNTADNYGDGGAIFCKNGAQAAGSNNAGSVSFDGEGVVFFSS
  	NVAAGKGGAIYAKKLSVANCGPVQFLGNIANDGGAIYLGESGEL
  	SLSADYGDIIFDGNLKRTAKENAADVNGVTVSSQAISMGSGGKIT
  	TLRAKAGHQILFNDPIEMANGNNQPAQSSEPLKINDGEGYTGDIV
  	FANGNSALYQNVAIEQGRIVLREKAKLSVNSLSQTGGSLYMEAG
  	STLDFVTPQPPQQPPAANQLITLSNLHLSLSSLLANNAVTNPPTNP
  	PAQDSHPAIIGSTTAGSVTISGPIFFEDLDDTAYDRYDWLGSNQKI
  	DVLKLQLGTQPSANAPSDLTLGNEMPKYGYQGSWKLAWDPNTA
  	NNGPYTLKATWTKTGHHHHHH
  Ct460_D_S16A_nIgK	METPAQLLFLLLLWLPDTTGMSQNKNSAFMQPVNVAADLAAIV	119
  	GAGPMPRTEIIKKMWDYIKKNGLQDPTNKRNINPDDKLAKVFGT
  	EKPIDMFQMTKMVSQHIIK
  Ct460_D_S16A_nIgK_cHis	METPAQLLFLLLLWLPDTTGMSQNKNSAFMQPVNVAADLAAIV	120
  	GAGPMPRTEIIKKMWDYIKKNGLQDPTNKRNINPDDKLAKVFGT
  	EKPIDMFQMTKMVSQHIIKHHHHHH
  Ct875_E_S274Q_N275H_S574D_nIgK	METPAQLLFLLLLWLPDTTGMSIRGVGGNGNSRIPSHNGDGSNRR	121
  	SQNTKGNNKVEDRVCSLYSSRSNENRESPYAVVDVSSMIESTPTS
  	GETTRASRGVLSRFQRGLVRIADKVRRAVQCAWSSVSTSRSSATR
  	AAESGSSSRTARGASSGYREYSPSAARGLRLMFTDFWRTRVLRQ
  	TSPMAGVFGNLDVNEARLMAAYTSECADHLEAKELAGPDGVAA
  	AREIAKRWEKRVRDLQDKGAARKLLNDPLGRRTPNYQSKNPGE
  	YTVGNSMFYDGPQVANLQNVDTGFWLDMQHLSDVVLSREIQTG
  	LRARATLEESMPMLENLEERFRRLQETCDAARTEIEESGWTRESA
  	SRMEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSFGEHVRVLCAR
  	VSRGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSPEGASLAETLAR
  	FADDMGIERGADGTYDIPLVDDWRRGVPSIEGEGSDSIYEIMMPI
  	YEVMNMDLETRRSFAVQQGHYQDPRASDYDLPRASDYDLPRSP
  	YPTPPLPPRYQLQNMDVEAGFREAVYASFVAGMYNYVVTQPQE
  	RIPNSQQVEGILRDMLTNGDQTFRDLMKRWNREVDRE
  Ct875_E_S274Q_N275H_S574D_nIgK_cHis	METPAQLLFLLLLWLPDTTGMSIRGVGGNGNSRIPSHNGDGSNRR	122
  	SQNTKGNNKVEDRVCSLYSSRSNENRESPYAVVDVSSMIESTPTS
  	GETTRASRGVLSRFQRGLVRIADKVRRAVQCAWSSVSTSRSSATR
  	AAESGSSSRTARGASSGYREYSPSAARGLRLMFTDFWRTRVLRQ
  	TSPMAGVFGNLDVNEARLMAAYTSECADHLEAKELAGPDGVAA
  	AREIAKRWEKRVRDLQDKGAARKLLNDPLGRRTPNYQSKNPGE
  	YTVGNSMFYDGPQVANLQNVDTGFWLDMQHLSDVVLSREIQTG
  	LRARATLEESMPMLENLEERFRRLQETCDAARTEIEESGWTRESA
  	SRMEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSFGEHVRVLCAR
  	VSRGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSPEGASLAETLAR
  	FADDMGIERGADGTYDIPLVDDWRRGVPSIEGEGSDSIYEIMMPI
  	YEVMNMDLETRRSFAVQQGHYQDPRASDYDLPRASDYDLPRSP
  	YPTPPLPPRYQLQNMDVEAGFREAVYASFVAGMYNYVVTQPQE
  	RIPNSQQVEGILRDMLTNGDQTFRDLMKRWNREVDREHHHHHH
  Ct622_E_S13N_S179A_S220N_nIgK	METPAQLLFLLLLWLPDTTGMESGPESVSSNQNSMNPIINGQIASN	123
  	SETKESTKASEASPSASSSVSSWSFLSSAKNALISLRDAILNKNSSP
  	TDSLSQLEASTSTSTVTRVAAKDYDEAKSNFDTAKSGLENAKTL
  	AEYETKMADLMAALQDMERLANSDPSNNHTEEVNNIKKALEAQ
  	KDTIDKLNKLVTLQNQNKALTEVLKTTDSADQIPAINSQLEINKN
  	SADQIIKDLERQNINYEAVLTNAGEVIKASSEAGIKLGQALQSIVD
  	AGDQSQAAVLQAQQNNSPDNIAATKELIDAAETKVNELKQEHTG
  	LTDSPLVKKAEEQISQAQKDIQEIKPSGSDIPIVGPSGSAASAGSAA
  	GALKSSNNSGRISLLLDDVDNEMAAIALQGFRSMIEQFNVNNPAT
  	AKELQAMEAQLTAMSDQLVGADGELPAEIQAIKDALAQALKQPS
  	ADGLATAMGQVAFAAAKVGGGSAGTAGTVQMNVKQLYKTAFS
  	STSSSSYAAALSDGYSAYKTLNSLYSESRSGVQSAISQTANPALSR
  	SVSRSGIESQGRSADASQRAAETIVRDSQTLGDVYSRLQVLDSLM
  	STIVSNPQANQEEIMQKLTASISKAPQFGYPAVQNSADSLQKFAA
  	QLEREFVDGERSLAESQENAFRKQPAFIQQVLVNIASLFSGYLS
  Ct622_E_S13N_S179A_S220N_nIgK_cHis	METPAQLLFLLLLWLPDTTGMESGPESVSSNQNSMNPIINGQIASN	124
  	SETKESTKASEASPSASSSVSSWSFLSSAKNALISLRDAILNKNSSP
  	TDSLSQLEASTSTSTVTRVAAKDYDEAKSNFDTAKSGLENAKTL
  	AEYETKMADLMAALQDMERLANSDPSNNHTEEVNNIKKALEAQ
  	KDTIDKLNKLVTLQNQNKALTEVLKTTDSADQIPAINSQLEINKN
  	SADQIIKDLERQNINYEAVLTNAGEVIKASSEAGIKLGQALQSIVD
  	AGDQSQAAVLQAQQNNSPDNIAATKELIDAAETKVNELKQEHTG
  	LTDSPLVKKAEEQISQAQKDIQEIKPSGSDIPIVGPSGSAASAGSAA
  	GALKSSNNSGRISLLLDDVDNEMAAIALQGFRSMIEQFNVNNPAT
  	AKELQAMEAQLTAMSDQLVGADGELPAEIQAIKDALAQALKQPS
  	ADGLATAMGQVAFAAAKVGGGSAGTAGTVQMNVKQLYKTAFS
  	STSSSSYAAALSDGYSAYKTLNSLYSESRSGVQSAISQTANPALSR
  	SVSRSGIESQGRSADASQRAAETIVRDSQTLGDVYSRLQVLDSLM
  	STIVSNPQANQEEIMQKLTASISKAPQFGYPAVQNSADSLQKFAA
  	QLEREFVDGERSLAESQENAFRKQPAFIQQVLVNIASLFSGYLSHH
  	HHHH
  Cta1_E_noTM_nIgK_cHis	METPAQLLFLLLLWLPDTTGPSSTQDNRSMDQQDSEEFLLQNTLE	125
  	DSEIISIPDTMNQIAIDTEKWFYLNKDCTNVGPISIVQLTAFLKECK
  	HSPEKGIDPQELWVWKKGMPNWEKVKNIPELSGTVKDEHHHHHH
  Cta1_E_noTM_nIgK	METPAQLLFLLLLWLPDTTGPSSTQDNRSMDQQDSEEFLLQNTLE	126
  	DSEIISIPDTMNQIAIDTEKWFYLNKDCTNVGPISIVQLTAFLKECK
  	HSPEKGIDPQELWVWKKGMPNWEKVKNIPELSGTVKDE
  Cta1_E_cHis	MNSGMFPFTFFLLYICLGMLTAYLANKKNRNLIGWFLAGMFFGIF	127
  	AIIFLLILPPLPSSTQDNRSMDQQDSEEFLLQNTLEDSEIISIPDTMN
  	QIAIDTEKWFYLNKDCTNVGPISIVQLTAFLKECKHSPEKGIDPQE
  	LWVWKKGMPNWEKVKNIPELSGTVKDEHHHHHH
  Cta1_E	MNSGMFPFTFFLLYICLGMLTAYLANKKNRNLIGWFLAGMFFGIF	128
  	AIIFLLILPPLPSSTQDNRSMDQQDSEEFLLQNTLEDSEIISIPDTMN
  	QIAIDTEKWFYLNKDCTNVGPISIVQLTAFLKECKHSPEKGIDPQE
  	LWVWKKGMPNWEKVKNIPELSGTVKDE
  Ct443_E_nIgK_cHis_mod	METPAQLLFLLLLWLPDTTGSGVLETSMAESLSTNVISLADTKAK	129
  	DNTSHKSKKARKNHSKETLVDRKEVAPVHESKATGPKQDSCFGR
  	MYTVKVNDDRNVEITQAVPEYATVGSPYPIEITATGKRDCVDVII
  	TQQLPCEAEFVRSDPATTPTADGKLVWKIDRLGQGEKSKITVWV
  	KPLKEGCCFTAATVCACPEIRSVTKCGQPAICVKQEGPENACLRC
  	PVVYKINVVNQGTAIARNVVVENPVPDGYAHSSGQRVLTFTLGD
  	MQPGEHRTITVEFCPLKRGRATNIATVSYCGGHKNTASVTTVINE
  	PCVQVSIAGADWSYVCKPVEYVISVSNPGDLVLRDVVVEDTLSP
  	GVTVLEAAGAQISCNKVVWTVKELNPGESLQYKVLVRAQTPGQ
  	FTNNVVVKSCSDCGTCTSCAEATTYWKGVAATHMCVVDTCDPV
  	CVGENTVYRICVTNRGSAEDTNVSLMLKFSKELQPVSFSGPTKGT
  	ITGNTVVFDSLPRLGSKETVEFSVTLKAVSAGDARGEAILSSDTLT
  	VPVSDTENTHIYHHHHHH
  Ct443_E_nIgK_mod	METPAQLLFLLLLWLPDTTGSGVLETSMAESLSTNVISLADTKAK	130
  	DNTSHKSKKARKNHSKETLVDRKEVAPVHESKATGPKQDSCFGR
  	MYTVKVNDDRNVEITQAVPEYATVGSPYPIEITATGKRDCVDVII
  	TQQLPCEAEFVRSDPATTPTADGKLVWKIDRLGQGEKSKITVWV
  	KPLKEGCCFTAATVCACPEIRSVTKCGQPAICVKQEGPENACLRC
  	PVVYKINVVNQGTAIARNVVVENPVPDGYAHSSGQRVLTFTLGD
  	MQPGEHRTITVEFCPLKRGRATNIATVSYCGGHKNTASVTTVINE
  	PCVQVSIAGADWSYVCKPVEYVISVSNPGDLVLRDVVVEDTLSP
  	GVTVLEAAGAQISCNKVVWTVKELNPGESLQYKVLVRAQTPGQ
  	FTNNVVVKSCSDCGTCTSCAEATTYWKGVAATHMCVVDTCDPV
  	CVGENTVYRICVTNRGSAEDTNVSLMLKFSKELQPVSFSGPTKGT
  	ITGNTVVFDSLPRLGSKETVEFSVTLKAVSAGDARGEAILSSDTLT
  	VPVSDTENTHIY
  Ct875_E_nIgK_CO004	METPAQLLFLLLLWLPDTTGMSIRGVGGNGNSRIPSHNGDGSNRR	131
  	SQNTKGNNKVEDRVCSLYSSRSNENRESPYAVVDVSSMIESTPTS
  	GETTRASRGVLSRFQRGLVRIADKVRRAVQCAWSSVSTSRSSATR
  	AAESGSSSRTARGASSGYREYSPSAARGLRLMFTDFWRTRVLRQ
  	TSPMAGVFGNLDVNEARLMAAYTSECADHLEAKELAGPDGVAA
  	AREIAKRWEKRVRDLQDKGAARKLLNDPLGRRTPNYQSKNPGE
  	YTVGNSMFYDGPQVANLQNVDTGFWLDMSNLSDVVLSREIQTG
  	LRARATLEESMPMLENLEERFRRLQETCDAARTEIEESGWTRESA
  	SRMEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSFGEHVRVLCAR
  	VSRGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSPEGASLAETLAR
  	FADDMGIERGADGTYDIPLVDDWRRGVPSIEGEGSDSIYEIMMPI
  	YEVMNMDLETRRSFAVQQGHYQDPRASDYDLPRASDYDLPRSP
  	YPTPPLPPRYQLQNMDVEAGFREAVYASFVAGMYNYVVTQPQE
  	RIPNSQQVEGILRDMLTNGSQTFRDLMKRWNREVDRE
  Ct875_E_nIgK_CO003	METPAQLLFLLLLWLPDTTGMSIRGVGGNGNSRIPSHNGDGSNRR	132
  	SQNTKGNNKVEDRVCSLYSSRSNENRESPYAVVDVSSMIESTPTS
  	GETTRASRGVLSRFQRGLVRIADKVRRAVQCAWSSVSTSRSSATR
  	AAESGSSSRTARGASSGYREYSPSAARGLRLMFTDFWRTRVLRQ
  	TSPMAGVFGNLDVNEARLMAAYTSECADHLEAKELAGPDGVAA
  	AREIAKRWEKRVRDLQDKGAARKLLNDPLGRRTPNYQSKNPGE
  	YTVGNSMFYDGPQVANLQNVDTGFWLDMSNLSDVVLSREIQTG
  	LRARATLEESMPMLENLEERFRRLQETCDAARTEIEESGWTRESA
  	SRMEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSFGEHVRVLCAR
  	VSRGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSPEGASLAETLAR
  	FADDMGIERGADGTYDIPLVDDWRRGVPSIEGEGSDSIYEIMMPI
  	YEVMNMDLETRRSFAVQQGHYQDPRASDYDLPRASDYDLPRSP
  	YPTPPLPPRYQLQNMDVEAGFREAVYASFVAGMYNYVVTQPQE
  	RIPNSQQVEGILRDMLTNGSQTFRDLMKRWNREVDRE
  Ct875_E_nIgK_CO002	METPAQLLFLLLLWLPDTTGMSIRGVGGNGNSRIPSHNGDGSNRR	133
  	SQNTKGNNKVEDRVCSLYSSRSNENRESPYAVVDVSSMIESTPTS
  	GETTRASRGVLSRFQRGLVRIADKVRRAVQCAWSSVSTSRSSATR
  	AAESGSSSRTARGASSGYREYSPSAARGLRLMFTDFWRTRVLRQ
  	TSPMAGVFGNLDVNEARLMAAYTSECADHLEAKELAGPDGVAA
  	AREIAKRWEKRVRDLQDKGAARKLLNDPLGRRTPNYQSKNPGE
  	YTVGNSMFYDGPQVANLQNVDTGFWLDMSNLSDVVLSREIQTG
  	LRARATLEESMPMLENLEERFRRLQETCDAARTEIEESGWTRESA
  	SRMEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSFGEHVRVLCAR
  	VSRGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSPEGASLAETLAR
  	FADDMGIERGADGTYDIPLVDDWRRGVPSIEGEGSDSIYEIMMPI
  	YEVMNMDLETRRSFAVQQGHYQDPRASDYDLPRASDYDLPRSP
  	YPTPPLPPRYQLQNMDVEAGFREAVYASFVAGMYNYVVTQPQE
  	RIPNSQQVEGILRDMLTNGSQTFRDLMKRWNREVDRE
  Ct875_E_nIgK_CO001	METPAQLLFLLLLWLPDTTGMSIRGVGGNGNSRIPSHNGDGSNRR	134
  	SQNTKGNNKVEDRVCSLYSSRSNENRESPYAVVDVSSMIESTPTS
  	GETTRASRGVLSRFQRGLVRIADKVRRAVQCAWSSVSTSRSSATR
  	AAESGSSSRTARGASSGYREYSPSAARGLRLMFTDFWRTRVLRQ
  	TSPMAGVFGNLDVNEARLMAAYTSECADHLEAKELAGPDGVAA
  	AREIAKRWEKRVRDLQDKGAARKLLNDPLGRRTPNYQSKNPGE
  	YTVGNSMFYDGPQVANLQNVDTGFWLDMSNLSDVVLSREIQTG
  	LRARATLEESMPMLENLEERFRRLQETCDAARTEIEESGWTRESA
  	SRMEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSFGEHVRVLCAR
  	VSRGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSPEGASLAETLAR
  	FADDMGIERGADGTYDIPLVDDWRRGVPSIEGEGSDSIYEIMMPI
  	YEVMNMDLETRRSFAVQQGHYQDPRASDYDLPRASDYDLPRSP
  	YPTPPLPPRYQLQNMDVEAGFREAVYASFVAGMYNYVVTQPQE
  	RIPNSQQVEGILRDMLTNGSQTFRDLMKRWNREVDRE
  Ct875_E_nIgK_cHis_CO005	METPAQLLFLLLLWLPDTTGMSIRGVGGNGNSRIPSHNGDGSNRR	135
  	SQNTKGNNKVEDRVCSLYSSRSNENRESPYAVVDVSSMIESTPTS
  	GETTRASRGVLSRFQRGLVRIADKVRRAVQCAWSSVSTSRSSATR
  	AAESGSSSRTARGASSGYREYSPSAARGLRLMFTDFWRTRVLRQ
  	TSPMAGVFGNLDVNEARLMAAYTSECADHLEAKELAGPDGVAA
  	AREIAKRWEKRVRDLQDKGAARKLLNDPLGRRTPNYQSKNPGE
  	YTVGNSMFYDGPQVANLQNVDTGFWLDMSNLSDVVLSREIQTG
  	LRARATLEESMPMLENLEERFRRLQETCDAARTEIEESGWTRESA
  	SRMEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSFGEHVRVLCAR
  	VSRGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSPEGASLAETLAR
  	FADDMGIERGADGTYDIPLVDDWRRGVPSIEGEGSDSIYEIMMPI
  	YEVMNMDLETRRSFAVQQGHYQDPRASDYDLPRASDYDLPRSP
  	YPTPPLPPRYQLQNMDVEAGFREAVYASFVAGMYNYVVTQPQE
  	RIPNSQQVEGILRDMLTNGSQTFRDLMKRWNREVDREHHHHHH
  Ct875_E_nIgK_cHis_CO004	METPAQLLFLLLLWLPDTTGMSIRGVGGNGNSRIPSHNGDGSNRR	136
  	SQNTKGNNKVEDRVCSLYSSRSNENRESPYAVVDVSSMIESTPTS
  	GETTRASRGVLSRFQRGLVRIADKVRRAVQCAWSSVSTSRSSATR
  	AAESGSSSRTARGASSGYREYSPSAARGLRLMFTDFWRTRVLRQ
  	TSPMAGVFGNLDVNEARLMAAYTSECADHLEAKELAGPDGVAA
  	AREIAKRWEKRVRDLQDKGAARKLLNDPLGRRTPNYQSKNPGE
  	YTVGNSMFYDGPQVANLQNVDTGFWLDMSNLSDVVLSREIQTG
  	LRARATLEESMPMLENLEERFRRLQETCDAARTEIEESGWTRESA
  	SRMEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSFGEHVRVLCAR
  	VSRGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSPEGASLAETLAR
  	FADDMGIERGADGTYDIPLVDDWRRGVPSIEGEGSDSIYEIMMPI
  	YEVMNMDLETRRSFAVQQGHYQDPRASDYDLPRASDYDLPRSP
  	YPTPPLPPRYQLQNMDVEAGFREAVYASFVAGMYNYVVTQPQE
  	RIPNSQQVEGILRDMLTNGSQTFRDLMKRWNREVDREHHHHHH
  Ct875_E_nIgK_cHis_CO003	METPAQLLFLLLLWLPDTTGMSIRGVGGNGNSRIPSHNGDGSNRR	137
  	SQNTKGNNKVEDRVCSLYSSRSNENRESPYAVVDVSSMIESTPTS
  	GETTRASRGVLSRFQRGLVRIADKVRRAVQCAWSSVSTSRSSATR
  	AAESGSSSRTARGASSGYREYSPSAARGLRLMFTDFWRTRVLRQ
  	TSPMAGVFGNLDVNEARLMAAYTSECADHLEAKELAGPDGVAA
  	AREIAKRWEKRVRDLQDKGAARKLLNDPLGRRTPNYQSKNPGE
  	YTVGNSMFYDGPQVANLQNVDTGFWLDMSNLSDVVLSREIQTG
  	LRARATLEESMPMLENLEERFRRLQETCDAARTEIEESGWTRESA
  	SRMEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSFGEHVRVLCAR
  	VSRGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSPEGASLAETLAR
  	FADDMGIERGADGTYDIPLVDDWRRGVPSIEGEGSDSIYEIMMPI
  	YEVMNMDLETRRSFAVQQGHYQDPRASDYDLPRASDYDLPRSP
  	YPTPPLPPRYQLQNMDVEAGFREAVYASFVAGMYNYVVTQPQE
  	RIPNSQQVEGILRDMLTNGSQTFRDLMKRWNREVDREHHHHHH
  Ct875_E_nIgK_cHis_CO002	METPAQLLFLLLLWLPDTTGMSIRGVGGNGNSRIPSHNGDGSNRR	138
  	SQNTKGNNKVEDRVCSLYSSRSNENRESPYAVVDVSSMIESTPTS
  	GETTRASRGVLSRFQRGLVRIADKVRRAVQCAWSSVSTSRSSATR
  	AAESGSSSRTARGASSGYREYSPSAARGLRLMFTDFWRTRVLRQ
  	TSPMAGVFGNLDVNEARLMAAYTSECADHLEAKELAGPDGVAA
  	AREIAKRWEKRVRDLQDKGAARKLLNDPLGRRTPNYQSKNPGE
  	YTVGNSMFYDGPQVANLQNVDTGFWLDMSNLSDVVLSREIQTG
  	LRARATLEESMPMLENLEERFRRLQETCDAARTEIEESGWTRESA
  	SRMEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSFGEHVRVLCAR
  	VSRGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSPEGASLAETLAR
  	FADDMGIERGADGTYDIPLVDDWRRGVPSIEGEGSDSIYEIMMPI
  	YEVMNMDLETRRSFAVQQGHYQDPRASDYDLPRASDYDLPRSP
  	YPTPPLPPRYQLQNMDVEAGFREAVYASFVAGMYNYVVTQPQE
  	RIPNSQQVEGILRDMLTNGSQTFRDLMKRWNREVDREHHHHHH
  Ct875_E_nIgK_cHis_CO001	METPAQLLFLLLLWLPDTTGMSIRGVGGNGNSRIPSHNGDGSNRR	139
  	SQNTKGNNKVEDRVCSLYSSRSNENRESPYAVVDVSSMIESTPTS
  	GETTRASRGVLSRFQRGLVRIADKVRRAVQCAWSSVSTSRSSATR
  	AAESGSSSRTARGASSGYREYSPSAARGLRLMFTDFWRTRVLRQ
  	TSPMAGVFGNLDVNEARLMAAYTSECADHLEAKELAGPDGVAA
  	AREIAKRWEKRVRDLQDKGAARKLLNDPLGRRTPNYQSKNPGE
  	YTVGNSMFYDGPQVANLQNVDTGFWLDMSNLSDVVLSREIQTG
  	LRARATLEESMPMLENLEERFRRLQETCDAARTEIEESGWTRESA
  	SRMEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSFGEHVRVLCAR
  	VSRGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSPEGASLAETLAR
  	FADDMGIERGADGTYDIPLVDDWRRGVPSIEGEGSDSIYEIMMPI
  	YEVMNMDLETRRSFAVQQGHYQDPRASDYDLPRASDYDLPRSP
  	YPTPPLPPRYQLQNMDVEAGFREAVYASFVAGMYNYVVTQPQE
  	RIPNSQQVEGILRDMLTNGSQTFRDLMKRWNREVDREHHHHHH
  Ct875_E_nIgK_nFLAG	METPAQLLFLLLLWLPDTTGDYKDHDGDYKDHDIDYKDDDDKM	140
  	SIRGVGGNGNSRIPSHNGDGSNRRSQNTKGNNKVEDRVCSLYSSR
  	SNENRESPYAVVDVSSMIESTPTSGETTRASRGVLSRFQRGLVRIA
  	DKVRRAVQCAWSSVSTSRSSATRAAESGSSSRTARGASSGYREY
  	SPSAARGLRLMFTDFWRTRVLRQTSPMAGVFGNLDVNEARLMA
  	AYTSECADHLEAKELAGPDGVAAAREIAKRWEKRVRDLQDKGA
  	ARKLLNDPLGRRTPNYQSKNPGEYTVGNSMFYDGPQVANLQNV
  	DTGFWLDMSNLSDVVLSREIQTGLRARATLEESMPMLENLEERF
  	RRLQETCDAARTEIEESGWTRESASRMEGDEAQGPSRVQQAFQS
  	FVNECNSIEFSFGSFGEHVRVLCARVSRGLAAAGEAIRRCFSCCK
  	GSTHRYAPRDDLSPEGASLAETLARFADDMGIERGADGTYDIPLV
  	DDWRRGVPSIEGEGSDSIYEIMMPIYEVMNMDLETRRSFAVQQG
  	HYQDPRASDYDLPRASDYDLPRSPYPTPPLPPRYQLQNMDVEAG
  	FREAVYASFVAGMYNYVVTQPQERIPNSQQVEGILRDMLTNGSQ
  	TFRDLMKRWNREVDRE
  Ct875_E_nIgK_cFLAG	METPAQLLFLLLLWLPDTTGMSIRGVGGNGNSRIPSHNGDGSNRR	141
  	SQNTKGNNKVEDRVCSLYSSRSNENRESPYAVVDVSSMIESTPTS
  	GETTRASRGVLSRFQRGLVRIADKVRRAVQCAWSSVSTSRSSATR
  	AAESGSSSRTARGASSGYREYSPSAARGLRLMFTDFWRTRVLRQ
  	TSPMAGVFGNLDVNEARLMAAYTSECADHLEAKELAGPDGVAA
  	AREIAKRWEKRVRDLQDKGAARKLLNDPLGRRTPNYQSKNPGE
  	YTVGNSMFYDGPQVANLQNVDTGFWLDMSNLSDVVLSREIQTG
  	LRARATLEESMPMLENLEERFRRLQETCDAARTEIEESGWTRESA
  	SRMEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSFGEHVRVLCAR
  	VSRGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSPEGASLAETLAR
  	FADDMGIERGADGTYDIPLVDDWRRGVPSIEGEGSDSIYEIMMPI
  	YEVMNMDLETRRSFAVQQGHYQDPRASDYDLPRASDYDLPRSP
  	YPTPPLPPRYQLQNMDVEAGFREAVYASFVAGMYNYVVTQPQE
  	RIPNSQQVEGILRDMLTNGSQTFRDLMKRWNREVDREDYKDHD
  	GDYKDHDIDYKDDDDK
  Ct875_E_nIgK_nHis	METPAQLLFLLLLWLPDTTGHHHHHHMSIRGVGGNGNSRIPSHN	142
  	GDGSNRRSQNTKGNNKVEDRVCSLYSSRSNENRESPYAVVDVSS
  	MIESTPTSGETTRASRGVLSRFQRGLVRIADKVRRAVQCAWSSVS
  	TSRSSATRAAESGSSSRTARGASSGYREYSPSAARGLRLMFTDFW
  	RTRVLRQTSPMAGVFGNLDVNEARLMAAYTSECADHLEAKELA
  	GPDGVAAAREIAKRWEKRVRDLQDKGAARKLLNDPLGRRTPNY
  	QSKNPGEYTVGNSMFYDGPQVANLQNVDTGFWLDMSNLSDVVL
  	SREIQTGLRARATLEESMPMLENLEERFRRLQETCDAARTEIEESG
  	WTRESASRMEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSFGEHV
  	RVLCARVSRGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSPEGASL
  	AETLARFADDMGIERGADGTYDIPLVDDWRRGVPSIEGEGSDSIY
  	EIMMPIYEVMNMDLETRRSFAVQQGHYQDPRASDYDLPRASDY
  	DLPRSPYPTPPLPPRYQLQNMDVEAGFREAVYASFVAGMYNYVV
  	TQPQERIPNSQQVEGILRDMLTNGSQTFRDLMKRWNREVDRE
  MOMP_E_nTMEM149	MGPGRCLLTALLLLALAPPPEALPVGNPAEPSLMIDGILWEGFGG	143
  	DPCDPCTTWCDAISMRMGYYGDFVFDRVLKTDVNKEFQMGDKP
  	TSTTGNATAPTTLTARENPAYGRHMQDAEMFTNAACMALNIWD
  	RFDVFCTLGASSGYLKGNSASFNLVGLFGDNENQSTVKTNSVPN
  	MSLDQSVVELYTDTAFSWSVGARAALWECGCATLGASFQYAQS
  	KPKVEELNVLCNAAEFTINKPKGYVGQEFPLALIAGTDAATGTKD
  	ASIDYHEWQASLALSYRLNMFTPYIGVKWSRASFDADTIRIAQPK
  	SATAIFDTTTLNPTIAGAGDVKASAEGQLGDTMQIVSLQLNKMKS
  	RKSCGIAVGTTIVDADKYAVTVETRLIDERAAHVNAQFRF
  MOMP_E_nTMEM149_cHis	MGPGRCLLTALLLLALAPPPEALPVGNPAEPSLMIDGILWEGFGG	144
  	DPCDPCTTWCDAISMRMGYYGDFVFDRVLKTDVNKEFQMGDKP
  	TSTTGNATAPTTLTARENPAYGRHMQDAEMFTNAACMALNIWD
  	RFDVFCTLGASSGYLKGNSASFNLVGLFGDNENQSTVKTNSVPN
  	MSLDQSVVELYTDTAFSWSVGARAALWECGCATLGASFQYAQS
  	KPKVEELNVLCNAAEFTINKPKGYVGQEFPLALIAGTDAATGTKD
  	ASIDYHEWQASLALSYRLNMFTPYIGVKWSRASFDADTIRIAQPK
  	SATAIFDTTTLNPTIAGAGDVKASAEGQLGDTMQIVSLQLNKMKS
  	RKSCGIAVGTTIVDADKYAVTVETRLIDERAAHVNAQFRFHHHH
  	HH
  MOMP_E_nFLRT2	MGLQTTKWPSHGAFFLKSWLIISLGLYSQVSKLLALPVGNPAEPS	145
  	LMIDGILWEGFGGDPCDPCTTWCDAISMRMGYYGDFVFDRVLKT
  	DVNKEFQMGDKPTSTTGNATAPTTLTARENPAYGRHMQDAEMF
  	TNAACMALNIWDRFDVFCTLGASSGYLKGNSASFNLVGLFGDNE
  	NQSTVKTNSVPNMSLDQSVVELYTDTAFSWSVGARAALWECGC
  	ATLGASFQYAQSKPKVEELNVLCNAAEFTINKPKGYVGQEFPLAL
  	IAGTDAATGTKDASIDYHEWQASLALSYRLNMFTPYIGVKWSRA
  	SFDADTIRIAQPKSATAIFDTTTLNPTIAGAGDVKASAEGQLGDTM
  	QIVSLQLNKMKSRKSCGIAVGTTIVDADKYAVTVETRLIDERAAH
  	VNAQFRF
  MOMP_E_nFLRT2_cHis	MGLQTTKWPSHGAFFLKSWLIISLGLYSQVSKLLALPVGNPAEPS	146
  	LMIDGILWEGFGGDPCDPCTTWCDAISMRMGYYGDFVFDRVLKT
  	DVNKEFQMGDKPTSTTGNATAPTTLTARENPAYGRHMQDAEMF
  	TNAACMALNIWDRFDVFCTLGASSGYLKGNSASFNLVGLFGDNE
  	NQSTVKTNSVPNMSLDQSVVELYTDTAFSWSVGARAALWECGC
  	ATLGASFQYAQSKPKVEELNVLCNAAEFTINKPKGYVGQEFPLAL
  	IAGTDAATGTKDASIDYHEWQASLALSYRLNMFTPYIGVKWSRA
  	SFDADTIRIAQPKSATAIFDTTTLNPTIAGAGDVKASAEGQLGDTM
  	QIVSLQLNKMKSRKSCGIAVGTTIVDADKYAVTVETRLIDERAAH
  	VNAQFRFHHHHHH
  MOMP_E_nIgK	METPAQLLFLLLLWLPDTTGLPVGNPAEPSLMIDGILWEGFGGDP	147
  	CDPCTTWCDAISMRMGYYGDFVFDRVLKTDVNKEFQMGDKPTS
  	TTGNATAPTTLTARENPAYGRHMQDAEMFTNAACMALNIWDRF
  	DVFCTLGASSGYLKGNSASFNLVGLFGDNENQSTVKTNSVPNMS
  	LDQSVVELYTDTAFSWSVGARAALWECGCATLGASFQYAQSKP
  	KVEELNVLCNAAEFTINKPKGYVGQEFPLALIAGTDAATGTKDAS
  	IDYHEWQASLALSYRLNMFTPYIGVKWSRASFDADTIRIAQPKSA
  	TAIFDTTTLNPTIAGAGDVKASAEGQLGDTMQIVSLQLNKMKSR
  	KSCGIAVGTTIVDADKYAVTVETRLIDERAAHVNAQFRF
  MOMP_E_nIgK_cHis	METPAQLLFLLLLWLPDTTGLPVGNPAEPSLMIDGILWEGFGGDP	148
  	CDPCTTWCDAISMRMGYYGDFVFDRVLKTDVNKEFQMGDKPTS
  	TTGNATAPTTLTARENPAYGRHMQDAEMFTNAACMALNIWDRF
  	DVFCTLGASSGYLKGNSASFNLVGLFGDNENQSTVKTNSVPNMS
  	LDQSVVELYTDTAFSWSVGARAALWECGCATLGASFQYAQSKP
  	KVEELNVLCNAAEFTINKPKGYVGQEFPLALIAGTDAATGTKDAS
  	IDYHEWQASLALSYRLNMFTPYIGVKWSRASFDADTIRIAQPKSA
  	TAIFDTTTLNPTIAGAGDVKASAEGQLGDTMQIVSLQLNKMKSR
  	KSCGIAVGTTIVDADKYAVTVETRLIDERAAHVNAQFRFHHHHHH
  MOMP_E_nOsteo	MWWRLWWLLLLLLLLWPMVWALPVGNPAEPSLMIDGILWEGF	149
  	GGDPCDPCTTWCDAISMRMGYYGDFVFDRVLKTDVNKEFQMG
  	DKPTSTTGNATAPTTLTARENPAYGRHMQDAEMFTNAACMALN
  	IWDRFDVFCTLGASSGYLKGNSASFNLVGLFGDNENQSTVKTNS
  	VPNMSLDQSVVELYTDTAFSWSVGARAALWECGCATLGASFQY
  	AQSKPKVEELNVLCNAAEFTINKPKGYVGQEFPLALIAGTDAATG
  	TKDASIDYHEWQASLALSYRLNMFTPYIGVKWSRASFDADTIRIA
  	QPKSATAIFDTTTLNPTIAGAGDVKASAEGQLGDTMQIVSLQLNK
  	MKSRKSCGIAVGTTIVDADKYAVTVETRLIDERAAHVNAQFRF
  MOMP_E_nOsteo_cHis	MWWRLWWLLLLLLLLWPMVWALPVGNPAEPSLMIDGILWEGF	150
  	GGDPCDPCTTWCDAISMRMGYYGDFVFDRVLKTDVNKEFQMG
  	DKPTSTTGNATAPTTLTARENPAYGRHMQDAEMFTNAACMALN
  	IWDRFDVFCTLGASSGYLKGNSASFNLVGLFGDNENQSTVKTNS
  	VPNMSLDQSVVELYTDTAFSWSVGARAALWECGCATLGASFQY
  	AQSKPKVEELNVLCNAAEFTINKPKGYVGQEFPLALIAGTDAATG
  	TKDASIDYHEWQASLALSYRLNMFTPYIGVKWSRASFDADTIRIA
  	QPKSATAIFDTTTLNPTIAGAGDVKASAEGQLGDTMQIVSLQLNK
  	MKSRKSCGIAVGTTIVDADKYAVTVETRLIDERAAHVNAQFRFH
  	HHHHH
  Ct-858_E_H97A_nIgK	METPAQLLFLLLLWLPDTTGVRGESLVCKNALQDLSFLEHLLQV	151
  	KYAPKTWKEQYLGWDLVQSSVSAQQKLRTQENPSTSFCQQVLA
  	DFIGGLNDFAAGVTFFAIESAYLPYTVQKSSDGRFYFVDIMTFSSE
  	IRVGDELLEVDGAPVQDVLATLYGSNHKGTAAEESAALRTLFSR
  	MASLGHKVPSGRTTLKIRRPFGTTREVRVKWRYVPEGVGDLATI
  	APSIRAPQLQKSMRSFFPKKDDAFHRSSSLFYSPMVPHFWAELRN
  	HYATSGLKSGYNIGSTDGFLPVIGPVIWESEGLFRAYISSVTDGDG
  	KSHKVGFLRIPTYSWQDMEDFDPSGPPPWEEFAKIIQVFSSNTEAL
  	IIDQTNNPGGSVLYLYALLSMLTDRPLELPKHRMILTQDEVVDAL
  	DWLTLLENVDTNVESRLALGDNMEGYTVDLQVAEYLKSFGRQV
  	LNCWSKGDIELSTPIPLFGFEKIHPHPRVQYSKPICVLINEQDFSCA
  	DFFPVVLKDNDRALIVGTRTAGAGGFVFNVQFPNRTGIKTCSLTG
  	SLAVREHGAFIENIGVEPHIDLPFTANDIRYKGYSEYLDKVKKLVC
  	QLINNDGTIILAEDGSF
  Ct858_E_H97A_nIgK_cHis	METPAQLLFLLLLWLPDTTGVRGESLVCKNALQDLSFLEHLLQV	152
  	KYAPKTWKEQYLGWDLVQSSVSAQQKLRTQENPSTSFCQQVLA
  	DFIGGLNDFAAGVTFFAIESAYLPYTVQKSSDGRFYFVDIMTFSSE
  	IRVGDELLEVDGAPVQDVLATLYGSNHKGTAAEESAALRTLFSR
  	MASLGHKVPSGRTTLKIRRPFGTTREVRVKWRYVPEGVGDLATI
  	APSIRAPQLQKSMRSFFPKKDDAFHRSSSLFYSPMVPHFWAELRN
  	HYATSGLKSGYNIGSTDGFLPVIGPVIWESEGLFRAYISSVTDGDG
  	KSHKVGFLRIPTYSWQDMEDFDPSGPPPWEEFAKIIQVFSSNTEAL
  	IIDQTNNPGGSVLYLYALLSMLTDRPLELPKHRMILTQDEVVDAL
  	DWLTLLENVDTNVESRLALGDNMEGYTVDLQVAEYLKSFGRQV
  	LNCWSKGDIELSTPIPLFGFEKIHPHPRVQYSKPICVLINEQDFSCA
  	DFFPVVLKDNDRALIVGTRTAGAGGFVFNVQFPNRTGIKTCSLTG
  	SLAVREHGAFIENIGVEPHIDLPFTANDIRYKGYSEYLDKVKKLVC
  	QLINNDGTIILAEDGSFHHHHHH
  Ct858_E_S491A_nIgK	METPAQLLFLLLLWLPDTTGVRGESLVCKNALQDLSFLEHLLQV	153
  	KYAPKTWKEQYLGWDLVQSSVSAQQKLRTQENPSTSFCQQVLA
  	DFIGGLNDFHAGVTFFAIESAYLPYTVQKSSDGRFYFVDIMTFSSE
  	IRVGDELLEVDGAPVQDVLATLYGSNHKGTAAEESAALRTLFSR
  	MASLGHKVPSGRTTLKIRRPFGTTREVRVKWRYVPEGVGDLATI
  	APSIRAPQLQKSMRSFFPKKDDAFHRSSSLFYSPMVPHFWAELRN
  	HYATSGLKSGYNIGSTDGFLPVIGPVIWESEGLFRAYISSVTDGDG
  	KSHKVGFLRIPTYSWQDMEDFDPSGPPPWEEFAKIIQVFSSNTEAL
  	IIDQTNNPGGSVLYLYALLSMLTDRPLELPKHRMILTQDEVVDAL
  	DWLTLLENVDTNVESRLALGDNMEGYTVDLQVAEYLKSFGRQV
  	LNCWSKGDIELSTPIPLFGFEKIHPHPRVQYSKPICVLINEQDFACA
  	DFFPVVLKDNDRALIVGTRTAGAGGFVFNVQFPNRTGIKTCSLTG
  	SLAVREHGAFIENIGVEPHIDLPFTANDIRYKGYSEYLDKVKKLVC
  	QLINNDGTIILAEDGSF
  Ct858_E_S491A_nIgK_cHis	METPAQLLFLLLLWLPDTTGVRGESLVCKNALQDLSFLEHLLQV	154
  	KYAPKTWKEQYLGWDLVQSSVSAQQKLRTQENPSTSFCQQVLA
  	DFIGGLNDFHAGVTFFAIESAYLPYTVQKSSDGRFYFVDIMTFSSE
  	IRVGDELLEVDGAPVQDVLATLYGSNHKGTAAEESAALRTLFSR
  	MASLGHKVPSGRTTLKIRRPFGTTREVRVKWRYVPEGVGDLATI
  	APSIRAPQLQKSMRSFFPKKDDAFHRSSSLFYSPMVPHFWAELRN
  	HYATSGLKSGYNIGSTDGFLPVIGPVIWESEGLFRAYISSVTDGDG
  	KSHKVGFLRIPTYSWQDMEDFDPSGPPPWEEFAKIIQVFSSNTEAL
  	IIDQTNNPGGSVLYLYALLSMLTDRPLELPKHRMILTQDEVVDAL
  	DWLTLLENVDTNVESRLALGDNMEGYTVDLQVAEYLKSFGRQV
  	LNCWSKGDIELSTPIPLFGFEKIHPHPRVQYSKPICVLINEQDFACA
  	DFFPVVLKDNDRALIVGTRTAGAGGFVFNVQFPNRTGIKTCSLTG
  	SLAVREHGAFIENIGVEPHIDLPFTANDIRYKGYSEYLDKVKKLVC
  	QLINNDGTIILAEDGSFHHHHHH
  Ct089_E_T306A_nIgK	METPAQLLFLLLLWLPDTTGMTASGGAGGLGSTQTVDVARAQA	155
  	AAATQDAQEVIGSQEASEASMLKGCEDLINPAAATRIKKKEEKFE
  	SLEARRKPTADKAEKKSESTEEKGDTPLEDRFTEDLSEVSGEDFR
  	GLKNSFDDDSSPEEILDALTSKFSDPTIKDLALDYLIQTAPSDRKL
  	KSALIQAKHQLMSQNPQAIVGGRNVLLASETFASRANTSPSSLRS
  	LYLQVTSSPSNCDNLRQMLASYLPSEKTAVMEFLVNGMVADLKS
  	EGPSIPPAKLQVYMTELSNLQALHSVDSFFDRNIGNLENSLKHEG
  	HAPIPSLTTGNLAKTFLQLVEDKFPSSSKAQKALNELVGPDTGPQ
  	TEVLNLFFRALNGCSPRIFSGAEKKQQLASVITNTLDAINADNEDY
  	PKPGDFPRSSFSSTPPHAPVPQSEIPTSPTSTQPPSP
  Ct089_E_T306A_nIgK_cHis	METPAQLLFLLLLWLPDTTGMTASGGAGGLGSTQTVDVARAQA	156
  	AAATQDAQEVIGSQEASEASMLKGCEDLINPAAATRIKKKEEKFE
  	SLEARRKPTADKAEKKSESTEEKGDTPLEDRFTEDLSEVSGEDFR
  	GLKNSFDDDSSPEEILDALTSKFSDPTIKDLALDYLIQTAPSDRKL
  	KSALIQAKHQLMSQNPQAIVGGRNVLLASETFASRANTSPSSLRS
  	LYLQVTSSPSNCDNLRQMLASYLPSEKTAVMEFLVNGMVADLKS
  	EGPSIPPAKLQVYMTELSNLQALHSVDSFFDRNIGNLENSLKHEG
  	HAPIPSLTTGNLAKTFLQLVEDKFPSSSKAQKALNELVGPDTGPQ
  	TEVLNLFFRALNGCSPRIFSGAEKKQQLASVITNTLDAINADNEDY
  	PKPGDFPRSSFSSTPPHAPVPQSEIPTSPTSTQPPSPHHHHHH
  Ct089_E_S198A_T306A_nIgK	METPAQLLFLLLLWLPDTTGMTASGGAGGLGSTQTVDVARAQA	157
  	AAATQDAQEVIGSQEASEASMLKGCEDLINPAAATRIKKKEEKFE
  	SLEARRKPTADKAEKKSESTEEKGDTPLEDRFTEDLSEVSGEDFR
  	GLKNSFDDDSSPEEILDALTSKFSDPTIKDLALDYLIQTAPSDRKL
  	KSALIQAKHQLMSQNPQAIVGGRNVLLASETFASRANTAPSSLRS
  	LYLQVTSSPSNCDNLRQMLASYLPSEKTAVMEFLVNGMVADLKS
  	EGPSIPPAKLQVYMTELSNLQALHSVDSFFDRNIGNLENSLKHEG
  	HAPIPSLTTGNLAKTFLQLVEDKFPSSSKAQKALNELVGPDTGPQ
  	TEVLNLFFRALNGCSPRIFSGAEKKQQLASVITNTLDAINADNEDY
  	PKPGDFPRSSFSSTPPHAPVPQSEIPTSPTSTQPPSP
  Ct089_E_S198A_T306A_nIgK_cHis	METPAQLLFLLLLWLPDTTGMTASGGAGGLGSTQTVDVARAQA	158
  	AAATQDAQEVIGSQEASEASMLKGCEDLINPAAATRIKKKEEKFE
  	SLEARRKPTADKAEKKSESTEEKGDTPLEDRFTEDLSEVSGEDFR
  	GLKNSFDDDSSPEEILDALTSKFSDPTIKDLALDYLIQTAPSDRKL
  	KSALIQAKHQLMSQNPQAIVGGRNVLLASETFASRANTAPSSLRS
  	LYLQVTSSPSNCDNLRQMLASYLPSEKTAVMEFLVNGMVADLKS
  	EGPSIPPAKLQVYMTELSNLQALHSVDSFFDRNIGNLENSLKHEG
  	HAPIPSLTTGNLAKTFLQLVEDKFPSSSKAQKALNELVGPDTGPQ
  	TEVLNLFFRALNGCSPRIFSGAEKKQQLASVITNTLDAINADNEDY
  	PKPGDFPRSSFSSTPPHAPVPQSEIPTSPTSTQPPSPHHHHHH
  Ct089_E_S198A_nIgK	METPAQLLFLLLLWLPDTTGMTASGGAGGLGSTQTVDVARAQA	159
  	AAATQDAQEVIGSQEASEASMLKGCEDLINPAAATRIKKKEEKFE
  	SLEARRKPTADKAEKKSESTEEKGDTPLEDRFTEDLSEVSGEDFR
  	GLKNSFDDDSSPEEILDALTSKFSDPTIKDLALDYLIQTAPSDRKL
  	KSALIQAKHQLMSQNPQAIVGGRNVLLASETFASRANTAPSSLRS
  	LYLQVTSSPSNCDNLRQMLASYLPSEKTAVMEFLVNGMVADLKS
  	EGPSIPPAKLQVYMTELSNLQALHSVDSFFDRNIGNLENSLKHEG
  	HAPIPSLTTGNLTKTFLQLVEDKFPSSSKAQKALNELVGPDTGPQT
  	EVLNLFFRALNGCSPRIFSGAEKKQQLASVITNTLDAINADNEDYP
  	KPGDFPRSSFSSTPPHAPVPQSEIPTSPTSTQPPSP
  Ct089_E_S198A_nIgK_cHis	METPAQLLFLLLLWLPDTTGMTASGGAGGLGSTQTVDVARAQA	160
  	AAATQDAQEVIGSQEASEASMLKGCEDLINPAAATRIKKKEEKFE
  	SLEARRKPTADKAEKKSESTEEKGDTPLEDRFTEDLSEVSGEDFR
  	GLKNSFDDDSSPEEILDALTSKFSDPTIKDLALDYLIQTAPSDRKL
  	KSALIQAKHQLMSQNPQAIVGGRNVLLASETFASRANTAPSSLRS
  	LYLQVTSSPSNCDNLRQMLASYLPSEKTAVMEFLVNGMVADLKS
  	EGPSIPPAKLQVYMTELSNLQALHSVDSFFDRNIGNLENSLKHEG
  	HAPIPSLTTGNLTKTFLQLVEDKFPSSSKAQKALNELVGPDTGPQT
  	EVLNLFFRALNGCSPRIFSGAEKKQQLASVITNTLDAINADNEDYP
  	KPGDFPRSSFSSTPPHAPVPQSEIPTSPTSTQPPSPHHHHHH
  Chlamydia_Ct875_nIgk_cHis	METPAQLLFLLLLWLPDTTGMSIRGVGGNGNSRIPSHNGDGSNRR	161
  	SQNTKGNNKVEDRVCSLYSSRSNENRESPYAVVDVSSMIESTPTS
  	GETTRASRGVLSRFQRGLVRIADKVRRAVQCAWSSVSTSRSSATR
  	AAESGSSSRTARGASSGYREYSPSAARGLRLMFTDFWRTRVLRQ
  	TSPMAGVFGNLDVNEARLMAAYTSECADHLEAKELAGPDGVAA
  	AREIAKRWEKRVRDLQDKGAARKLLNDPLGRRTPNYQSKNPGE
  	YTVGNSMFYDGPQVANLQNVDTGFWLDMSNLSDVVLSREIQTG
  	LRARATLEESMPMLENLEERFRRLQETCDAARTEIEESGWTRESA
  	SRMEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSFGEHVRVLCAR
  	VSRGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSPEGASLAETLAR
  	FADDMGIERGADGTYDIPLVDDWRRGVPSIEGEGSDSIYEIMMPI
  	YEVMNMDLETRRSFAVQQGHYQDPRASDYDLPRASDYDLPRSP
  	YPTPPLPPRYQLQNMDVEAGFREAVYASFVAGMYNYVVTQPQE
  	RIPNSQQVEGILRDMLTNGSQTFRDLMKRWNREVDREHHHHHH
  MOMP_serovarD	MKKLLKSVLVFAALSSASSLQALPVGNPAEPSLMIDGILWEGFGG	162
  	DPCDPCATWCDAISMRVGYYGDFVFDRVLKTDVNKEFQMGAKP
  	TTDTGNSAAPSTLTARENPAYGRHMQDAEMFTNAACMALNIWD
  	RFDVFCTLGATSGYLKGNSASFNLVGLFGDNENQKTVKAESVPN
  	MSFDQSVVELYTDTTFAWSVGARAALWECGCATLGASFQYAQS
  	KPKVEELNVLCNAAEFTINKPKGYVGKEFPLDLTAGTDAATGTK
  	DASIDYHEWQASLALSYRLNMFTPYIGVKWSRASFDADTIRIAQP
  	KSATAIFDTTTLNPTIAGAGDVKTGAEGQLGDTMQIVSLQLNKM
  	KSRKSCGIAVGTTIVDADKYAVTVETRLIDERAAHVNAQFRF
  Chlamydia_Ct871_pd_serovarD_nIgK	METPAQLLFLLLLWLPDTTGAEIMIPQGIYDGETLTVSFPYTVIGD	163
  	PSGTTVFSAGELTLKNLDNSIAALPLSCFGNLLGSFTVLGRGHSLT
  	FENIRTSTNGAALSDSANSGLFTIEGFKELSFSNCNSLLAVLPAATT
  	NNGSQTPTTTSTPSNGTIYSKTDLLLLNNEKFSFYSNLVSGDGGAI
  	DAKSLTVQGISKLCVFQENTAQADGGACQVVTSFSAMANEAPIA
  	FIANVAGVRGGGIAAVQDGQQGVSSSTSTEDPVVSFSRNTAVEFD
  	GNVARVGGGIYSYGNVAFLNNGKTLFLNNVASPVYIAAEQPTNG
  	QASNTSDNYGDGGAIFCKNGAQAAGSNNSGSVSFDGEGVVFFSS
  	NVAAGKGGAIYAKKLSVANCGPVQFLGNIANDGGAIYLGESGEL
  	SLSADYGDIIFDGNLKRTAKENAADVNGVTVSSQAISMGSGGKIT
  	TLRAKAGHQILFNDPIEMANGNNQPAQSSEPLKINDGEGYTGDIV
  	FANGNSTLYQNVTIEQGRIVLREKAKLSVNSLSQTGGSLYMEAGS
  	TLDFVTPQPPQQPPAANQLITLSNLHLSLSSLLANNAVTNPPTNPP
  	AQDSHPAIIGSTTAGSVTISGPIFFEDLDDTAYDRYDWLGSNQKID
  	VLKLQLGTQPSANAPSDLTLGNEMPKYGYQGSWKLAWDPNTAN
  	NGPYTLKATWTKTG
  Chlamydia_Ct871_pd_serovarD_nIgK_cHis	METPAQLLFLLLLWLPDTTGAEIMIPQGIYDGETLTVSFPYTVIGD	164
  	PSGTTVFSAGELTLKNLDNSIAALPLSCFGNLLGSFTVLGRGHSLT
  	FENIRTSTNGAALSDSANSGLFTIEGFKELSFSNCNSLLAVLPAATT
  	NNGSQTPTTTSTPSNGTIYSKTDLLLLNNEKFSFYSNLVSGDGGAI
  	DAKSLTVQGISKLCVFQENTAQADGGACQVVTSFSAMANEAPIA
  	FIANVAGVRGGGIAAVQDGQQGVSSSTSTEDPVVSFSRNTAVEFD
  	GNVARVGGGIYSYGNVAFLNNGKTLFLNNVASPVYIAAEQPTNG
  	QASNTSDNYGDGGAIFCKNGAQAAGSNNSGSVSFDGEGVVFFSS
  	NVAAGKGGAIYAKKLSVANCGPVQFLGNIANDGGAIYLGESGEL
  	SLSADYGDIIFDGNLKRTAKENAADVNGVTVSSQAISMGSGGKIT
  	TLRAKAGHQILFNDPIEMANGNNQPAQSSEPLKINDGEGYTGDIV
  	FANGNSTLYQNVTIEQGRIVLREKAKLSVNSLSQTGGSLYMEAGS
  	TLDFVTPQPPQQPPAANQLITLSNLHLSLSSLLANNAVTNPPTNPP
  	AQDSHPAIIGSTTAGSVTISGPIFFEDLDDTAYDRYDWLGSNQKID
  	VLKLQLGTQPSANAPSDLTLGNEMPKYGYQGSWKLAWDPNTAN
  	NGPYTLKATWTKTGHHHHHH
  Chlamydia_Ct871_pd_serovarL2_nIgK	METPAQLLFLLLLWLPDTTGAEIMIPQGIYDGETLTVSFPYTVIGD	165
  	PSGTTVFSAGELTLKNLDNSIAALPLSCFGNLLGSFTVLGRGHSLT
  	FENIRTSTNGAALSNSAADGLFTIEGFKELSFSNCNSLLAVLPAAT
  	TNKGSQTPTTTSTPSNGTIYSKTDLLLLNNEKFSFYSNLVSGDGGA
  	IDAKSLTVQGISKLCVFQENTAQADGGACQVVTSFSAMANEAPIA
  	FVANVAGVRGGGIAAVQDGQQGVSSSTSTEDPVVSFSRNTAVEF
  	DGNVARVGGGIYSYGNVAFLNNGKTLFLNNVASPVYIAAKQPTS
  	GQASNTSNNYGDGGAIFCKNGAQAGSNNSGSVSFDGEGVVFFSS
  	NVAAGKGGAIYAKKLSVANCGPVQFLRNIANDGGAIYLGESGEL
  	SLSADYGDIIFDGNLKRTAKENAADVNGVTVSSQAISMGSGGKIT
  	TLRAKAGHQILFNDPIEMANGNNQPAQSSKLLKINDGEGYTGDIV
  	FANGSSTLYQNVTIEQGRIVLREKAKLSVNSLSQTGGSLYMEAGS
  	TLDFVTPQPPQQPPAANQLITLSNLHLSLSSLLANNAVTNPPTNPP
  	AQDSHPAVIGSTTAGSVTISGPIFFEDLDDTAYDRYDWLGSNQKI
  	NVLKLQLGTKPPANAPSDLTLGNEMPKYGYQGSWKLAWDPNTA
  	NNGPYTLKATWTKTG
  Chlamydia_Ct871_pd_serovarL2_nIgK_cHis	METPAQLLFLLLLWLPDTTGAEIMIPQGIYDGETLTVSFPYTVIGD	166
  	PSGTTVFSAGELTLKNLDNSIAALPLSCFGNLLGSFTVLGRGHSLT
  	FENIRTSTNGAALSNSAADGLFTIEGFKELSFSNCNSLLAVLPAAT
  	TNKGSQTPTTTSTPSNGTIYSKTDLLLLNNEKFSFYSNLVSGDGGA
  	IDAKSLTVQGISKLCVFQENTAQADGGACQVVTSFSAMANEAPIA
  	FVANVAGVRGGGIAAVQDGQQGVSSSTSTEDPVVSFSRNTAVEF
  	DGNVARVGGGIYSYGNVAFLNNGKTLFLNNVASPVYIAAKQPTS
  	GQASNTSNNYGDGGAIFCKNGAQAGSNNSGSVSFDGEGVVFFSS
  	NVAAGKGGAIYAKKLSVANCGPVQFLRNIANDGGAIYLGESGEL
  	SLSADYGDIIFDGNLKRTAKENAADVNGVTVSSQAISMGSGGKIT
  	TLRAKAGHQILFNDPIEMANGNNQPAQSSKLLKINDGEGYTGDIV
  	FANGSSTLYQNVTIEQGRIVLREKAKLSVNSLSQTGGSLYMEAGS
  	TLDFVTPQPPQQPPAANQLITLSNLHLSLSSLLANNAVTNPPTNPP
  	AQDSHPAVIGSTTAGSVTISGPIFFEDLDDTAYDRYDWLGSNQKI
  	NVLKLQLGTKPPANAPSDLTLGNEMPKYGYQGSWKLAWDPNTA
  	NNGPYTLKATWTKTGHHHHHH
  Chlamydia_Ct812_pd_serovarD_nIgK	METPAQLLFLLLLWLPDTTGSCVDLHAGGQSVNELVYVGPQAVL	167
  	LLDQIRDLFVGSKDSQAEGQYRLIVGDPSSFQEKDADTLPGKVEQ
  	STLFSVTNPVVFQGVDQQDQVSSQGLICSFTSSNLDSPRDGESFLG
  	IAFVGDSSKAGITLTDVKASLSGAALYSTEDLIFEKIKGGLEFASCS
  	SLEQGGACAAQSILIHDCQGLQVKHCTTAVNAEGSSANDHLGFG
  	GGAFFVTGSLSGEKSLYMPAGDMVVANCDGAISFEGNSANFANG
  	GAIAASGKVLFVANDKKTSFIENRALSGGAIAASSDIAFQNCAEL
  	VFKGNCAIGTEDKGSLGGGAISSLGTVLLQGNHGITCDKNESASQ
  	GGAIFGKNCQISDNEGPVVFRDSTACLGGGAIAAQEIVSIQNNQA
  	GISFEGGKASFGGGIACGSFSSAGGASVLGTIDISKNLGAISFSRTL
  	CTTSDLGQMEYQGGGALFGENISLSENAGVLTFKDNIVKTFASNG
  	KILGGGAILATGKVEITNNSEGISFTGNARAPQALPTQEEFPLFSKK
  	EGRPLSSGYSGGGAILGREVAILHNAAVVFEQNRLQCSEEEATLL
  	GCCGGGAVHGMDSTSIVGNSSVRFGNNYAMGQGVSGGALLSKT
  	VQLAGNGSVDFSRNIASLGGGALQASEGNCELVDNGYVLFRDNR
  	GRVYGGAISCLRGDVVISGNKGRVEFKDNIATRLYVEETVEKVEE
  	VEPAPEQKDNNELSFLGRAEQSFITAANQALFASEDGDLSPESSIS
  	SEELAKRRECAGGAIFAKRVRIVDNQEAVVFSNNFSDIYGGAIFT
  	GSLREEDKLDGQIPEVLISGNAGDVVFSGNSSKRDEHLPHTGGGA
  	ICTQNLTISQNTGNVLFYNNVACSGGAVRIEDHGNVLLEAFGGDI
  	VFKGNSSFRAQGSDAIYFAGKESHITALNATEGHAIVFHDALVFE
  	NLEERKSAEVLLINSRENPGYTGSIRFLEAESKVPQCIHVQQGSLE
  	LLNGATLCSYGFKQDAGAKLVLAAGAKLKILDSGTPVQQGHAIS
  	KPEAEIESSSEPEGAHSLWIAKNAQTTVPMVDIHTISVDLASFSSSQ
  	QEGTVEAPQVIVPGGSYVRSGELNLELVNTTGTGYENHALLKNE
  	AKVPLMSFVASGDEASAEISNLSVSDLQIHVVTPEIEEDTYGHMG
  	DWSEAKIQDGTLVISWNPTG
  Chlamydia_Ct812_pd_serovarD_nIgK_cHis	METPAQLLFLLLLWLPDTTGSCVDLHAGGQSVNELVYVGPQAVL	168
  	LLDQIRDLFVGSKDSQAEGQYRLIVGDPSSFQEKDADTLPGKVEQ
  	STLFSVTNPVVFQGVDQQDQVSSQGLICSFTSSNLDSPRDGESFLG
  	IAFVGDSSKAGITLTDVKASLSGAALYSTEDLIFEKIKGGLEFASCS
  	SLEQGGACAAQSILIHDCQGLQVKHCTTAVNAEGSSANDHLGFG
  	GGAFFVTGSLSGEKSLYMPAGDMVVANCDGAISFEGNSANFANG
  	GAIAASGKVLFVANDKKTSFIENRALSGGAIAASSDIAFQNCAEL
  	VFKGNCAIGTEDKGSLGGGAISSLGTVLLQGNHGITCDKNESASQ
  	GGAIFGKNCQISDNEGPVVFRDSTACLGGGAIAAQEIVSIQNNQA
  	GISFEGGKASFGGGIACGSFSSAGGASVLGTIDISKNLGAISFSRTL
  	CTTSDLGQMEYQGGGALFGENISLSENAGVLTFKDNIVKTFASNG
  	KILGGGAILATGKVEITNNSEGISFTGNARAPQALPTQEEFPLFSKK
  	EGRPLSSGYSGGGAILGREVAILHNAAVVFEQNRLQCSEEEATLL
  	GCCGGGAVHGMDSTSIVGNSSVRFGNNYAMGQGVSGGALLSKT
  	VQLAGNGSVDFSRNIASLGGGALQASEGNCELVDNGYVLFRDNR
  	GRVYGGAISCLRGDVVISGNKGRVEFKDNIATRLYVEETVEKVEE
  	VEPAPEQKDNNELSFLGRAEQSFITAANQALFASEDGDLSPESSIS
  	SEELAKRRECAGGAIFAKRVRIVDNQEAVVFSNNFSDIYGGAIFT
  	GSLREEDKLDGQIPEVLISGNAGDVVFSGNSSKRDEHLPHTGGGA
  	ICTQNLTISQNTGNVLFYNNVACSGGAVRIEDHGNVLLEAFGGDI
  	VFKGNSSFRAQGSDAIYFAGKESHITALNATEGHAIVFHDALVFE
  	NLEERKSAEVLLINSRENPGYTGSIRFLEAESKVPQCIHVQQGSLE
  	LLNGATLCSYGFKQDAGAKLVLAAGAKLKILDSGTPVQQGHAIS
  	KPEAEIESSSEPEGAHSLWIAKNAQTTVPMVDIHTISVDLASFSSSQ
  	QEGTVEAPQVIVPGGSYVRSGELNLELVNTTGTGYENHALLKNE
  	AKVPLMSFVASGDEASAEISNLSVSDLQIHVVTPEIEEDTYGHMG
  	DWSEAKIQDGTLVISWNPTGHHHHHH
  Chlamydia_Ct812_pd_serovarL2_nIgk	METPAQLLFLLLLWLPDTTGSCVDLHAGGQSVNELVYVGPQAVL	169
  	LLDQIRDLFVGSKDSQAEGQYRLIVGDPSSFQEKDADTLPGKVEQ
  	STLFSVTNPVVFQGVDQQDQVSSQGLICSFTSSNLDSPRDGESFLG
  	IAFVGDSSKAGITLTDVKASLSGAALYSTEDLIFEKIKGGLEFASCS
  	SLEQGGACAAQSILIHDCQGLQVKHCTTAVNAEGSSANDHLGFG
  	GGAFFVTGSLSGEKSLYMPAGDMVVANCDGAISFEGNSANFANG
  	GAIAASGKVLFVANDKKTSFIENRALSGGAIAASSDIAFQNCAEL
  	VFKGNCAIGTEDKGSLGGGAISSLGTVLLQGNHGITCDKNESASQ
  	GGAIFGKNCQISDNEGPVVFRDSTACLGGGAIAAQEIVSIQNNQA
  	GISFEGGKASFGGGIACGSFSSAGGASVLGTIDISKNLGAISFSRTL
  	CTTSDLGQMEYQGGGALFGENISLSENAGVLTFKDNIVKTFASNG
  	KILGGGAILATGKVEITNNSGGISFTGNARAPQALPTQEEFPLFSK
  	KEGRPLSSGYSGGGAILGREVAILHNAAVVFEQNRLQCSEEEATL
  	LGCCGGGAVHGMDSTSIVGNSSVRFGNNYAMGQGVSGGALLSK
  	TVQLAGNGSVDFSRNIASLGGGALQASEGNCELVDNGYVLFRDN
  	RGRVYGGAISCLRGDVVISGNKGRVEFKDNIATRLYVEETVEKVE
  	EVEPAPEQKDNNELSFLGSVEQSFITAANQALFASEDGDLSPESSIS
  	SEELAKRRECAGGAIFAKRVRIVDNQEAVVFSNNFSDIYGGAIFT
  	GSLREEDKLDGQIPEVLISGNAGDVVFSGNSSKRDEHLPHTGGGA
  	ICTQNLTISQNTGNVLFYNNVACSGGAVRIEDHGNVLLEAFGGDI
  	VFKGNSSFRAQGSDAIYFAGKESHITALNATEGHAIVFHDALVFE
  	NLKERKSAEVLLINSRENPGYTGSIRFLEAESKVPQCIHVQQGSLE
  	LLNGATLCSYGFKQDAGAKLVLAAGSKLKILDSGTPVQGHAISKP
  	EAEIESSSEPEGAHSLWIAKNAQTTVPMVDIHTISVDLASFSSSQQ
  	EGTVEAPQVIVPGGSYVRSGELNLELVNTTGTGYENHALLKNEA
  	KVPLMSFVASSDEASAEISNLSVSDLQIHVATPEIEEDTYGHMGD
  	WSEAKIQDGTLVISWNPTG
  Chlamydia_Ct812_pd_serovarL2_nIgk_cHis	METPAQLLFLLLLWLPDTTGSCVDLHAGGQSVNELVYVGPQAVL	170
  	LLDQIRDLFVGSKDSQAEGQYRLIVGDPSSFQEKDADTLPGKVEQ
  	STLFSVTNPVVFQGVDQQDQVSSQGLICSFTSSNLDSPRDGESFLG
  	IAFVGDSSKAGITLTDVKASLSGAALYSTEDLIFEKIKGGLEFASCS
  	SLEQGGACAAQSILIHDCQGLQVKHCTTAVNAEGSSANDHLGFG
  	GGAFFVTGSLSGEKSLYMPAGDMVVANCDGAISFEGNSANFANG
  	GAIAASGKVLFVANDKKTSFIENRALSGGAIAASSDIAFQNCAEL
  	VFKGNCAIGTEDKGSLGGGAISSLGTVLLQGNHGITCDKNESASQ
  	GGAIFGKNCQISDNEGPVVFRDSTACLGGGAIAAQEIVSIQNNQA
  	GISFEGGKASFGGGIACGSFSSAGGASVLGTIDISKNLGAISFSRTL
  	CTTSDLGQMEYQGGGALFGENISLSENAGVLTFKDNIVKTFASNG
  	KILGGGAILATGKVEITNNSGGISFTGNARAPQALPTQEEFPLFSK
  	KEGRPLSSGYSGGGAILGREVAILHNAAVVFEQNRLQCSEEEATL
  	LGCCGGGAVHGMDSTSIVGNSSVRFGNNYAMGQGVSGGALLSK
  	TVQLAGNGSVDFSRNIASLGGGALQASEGNCELVDNGYVLFRDN
  	RGRVYGGAISCLRGDVVISGNKGRVEFKDNIATRLYVEETVEKVE
  	EVEPAPEQKDNNELSFLGSVEQSFITAANQALFASEDGDLSPESSIS
  	SEELAKRRECAGGAIFAKRVRIVDNQEAVVFSNNFSDIYGGAIFT
  	GSLREEDKLDGQIPEVLISGNAGDVVFSGNSSKRDEHLPHTGGGA
  	ICTQNLTISQNTGNVLFYNNVACSGGAVRIEDHGNVLLEAFGGDI
  	VFKGNSSFRAQGSDAIYFAGKESHITALNATEGHAIVFHDALVFE
  	NLKERKSAEVLLINSRENPGYTGSIRFLEAESKVPQCIHVQQGSLE
  	LLNGATLCSYGFKQDAGAKLVLAAGSKLKILDSGTPVQGHAISKP
  	EAEIESSSEPEGAHSLWIAKNAQTTVPMVDIHTISVDLASFSSSQQ
  	EGTVEAPQVIVPGGSYVRSGELNLELVNTTGTGYENHALLKNEA
  	KVPLMSFVASSDEASAEISNLSVSDLQIHVATPEIEEDTYGHMGD
  	WSEAKIQDGTLVISWNPTGHHHHHH
  Chlamydia_Ct460_serovarD_nIgk	METPAQLLFLLLLWLPDTTGMSQNKNSAFMQPVNVSADLAAIVG	171
  	AGPMPRTEIIKKMWDYIKKNGLQDPTNKRNINPDDKLAKVFGTE
  	KPIDMFQMTKMVSQHIIK
  Chlamydia_Ct460_serovarD_nIgk_cHis	METPAQLLFLLLLWLPDTTGMSQNKNSAFMQPVNVSADLAAIVG	172
  	AGPMPRTEIIKKMWDYIKKNGLQDPTNKRNINPDDKLAKVFGTE
  	KPIDMFQMTKMVSQHIIKHHHHHH
  Chlamydia_Ct460_serovarL2_nIgk	METPAQLLFLLLLWLPDTTGMSQNKNSAFMQPVNVSADLAAIVG	173
  	AGPMPRTEIIKKMWDYIKENSLQDPTNKRNINPDDKLAKVFGTEK
  	PIDMFQMTKMVSQHIIK
  Chlamydia_Ct460_serovarL2_nIgk_cHis	METPAQLLFLLLLWLPDTTGMSQNKNSAFMQPVNVSADLAAIVG	174
  	AGPMPRTEIIKKMWDYIKENSLQDPTNKRNINPDDKLAKVFGTEK
  	PIDMFQMTKMVSQHIIKHHHHHH
  Chlamydia_Ct622_serovarE_nIgk	METPAQLLFLLLLWLPDTTGMESGPESVSSNQSSMNPIINGQIASN	175
  	SETKESTKASEASPSASSSVSSWSFLSSAKNALISLRDAILNKNSSP
  	TDSLSQLEASTSTSTVTRVAAKDYDEAKSNFDTAKSGLENAKTL
  	AEYETKMADLMAALQDMERLANSDPSNNHTEEVNNIKKALEAQ
  	KDTIDKLNKLVTLQNQNKSLTEVLKTTDSADQIPAINSQLEINKNS
  	ADQIIKDLERQNISYEAVLTNAGEVIKASSEAGIKLGQALQSIVDA
  	GDQSQAAVLQAQQNNSPDNIAATKELIDAAETKVNELKQEHTGL
  	TDSPLVKKAEEQISQAQKDIQEIKPSGSDIPIVGPSGSAASAGSAAG
  	ALKSSNNSGRISLLLDDVDNEMAAIALQGFRSMIEQFNVNNPATA
  	KELQAMEAQLTAMSDQLVGADGELPAEIQAIKDALAQALKQPSA
  	DGLATAMGQVAFAAAKVGGGSAGTAGTVQMNVKQLYKTAFSS
  	TSSSSYAAALSDGYSAYKTLNSLYSESRSGVQSAISQTANPALSRS
  	VSRSGIESQGRSADASQRAAETIVRDSQTLGDVYSRLQVLDSLMS
  	TIVSNPQANQEEIMQKLTASISKAPQFGYPAVQNSADSLQKFAAQ
  	LEREFVDGERSLAESQENAFRKQPAFIQQVLVNIASLFSGYLS
  Chlamydia_Ct622_serovarE_nIgk_cHis	METPAQLLFLLLLWLPDTTGMESGPESVSSNQSSMNPIINGQIASN	176
  	SETKESTKASEASPSASSSVSSWSFLSSAKNALISLRDAILNKNSSP
  	TDSLSQLEASTSTSTVTRVAAKDYDEAKSNFDTAKSGLENAKTL
  	AEYETKMADLMAALQDMERLANSDPSNNHTEEVNNIKKALEAQ
  	KDTIDKLNKLVTLQNQNKSLTEVLKTTDSADQIPAINSQLEINKNS
  	ADQIIKDLERQNISYEAVLTNAGEVIKASSEAGIKLGQALQSIVDA
  	GDQSQAAVLQAQQNNSPDNIAATKELIDAAETKVNELKQEHTGL
  	TDSPLVKKAEEQISQAQKDIQEIKPSGSDIPIVGPSGSAASAGSAAG
  	ALKSSNNSGRISLLLDDVDNEMAAIALQGFRSMIEQFNVNNPATA
  	KELQAMEAQLTAMSDQLVGADGELPAEIQAIKDALAQALKQPSA
  	DGLATAMGQVAFAAAKVGGGSAGTAGTVQMNVKQLYKTAFSS
  	TSSSSYAAALSDGYSAYKTLNSLYSESRSGVQSAISQTANPALSRS
  	VSRSGIESQGRSADASQRAAETIVRDSQTLGDVYSRLQVLDSLMS
  	TIVSNPQANQEEIMQKLTASISKAPQFGYPAVQNSADSLQKFAAQ
  	LEREFVDGERSLAESQENAFRKQPAFIQQVLVNIASLFSGYLSHHH
  	HHH
  Chlamydia_Ct858_nIgk	METPAQLLFLLLLWLPDTTGVRGESLVCKNALQDLSFLEHLLQV	177
  	KYAPKTWKEQYLGWDLVQSSVSAQQKLRTQENPSTSFCQQVLA
  	DFIGGLNDFHAGVTFFAIESAYLPYTVQKSSDGRFYFVDIMTFSSE
  	IRVGDELLEVDGAPVQDVLATLYGSNHKGTAAEESAALRTLFSR
  	MASLGHKVPSGRTTLKIRRPFGTTREVRVKWRYVPEGVGDLATI
  	APSIRAPQLQKSMRSFFPKKDDAFHRSSSLFYSPMVPHFWAELRN
  	HYATSGLKSGYNIGSTDGFLPVIGPVIWESEGLFRAYISSVTDGDG
  	KSHKVGFLRIPTYSWQDMEDFDPSGPPPWEEFAKIIQVFSSNTEAL
  	IIDQTNNPGGSVLYLYALLSMLTDRPLELPKHRMILTQDEVVDAL
  	DWLTLLENVDTNVESRLALGDNMEGYTVDLQVAEYLKSFGRQV
  	LNCWSKGDIELSTPIPLFGFEKIHPHPRVQYSKPICVLINEQDFSCA
  	DFFPVVLKDNDRALIVGTRTAGAGGFVFNVQFPNRTGIKTCSLTG
  	SLAVREHGAFIENIGVEPHIDLPFTANDIRYKGYSEYLDKVKKLVC
  	QLINNDGTIILAEDGSF
  Chlamydia_Ct858_nIgk_cHis	METPAQLLFLLLLWLPDTTGVRGESLVCKNALQDLSFLEHLLQV	178
  	KYAPKTWKEQYLGWDLVQSSVSAQQKLRTQENPSTSFCQQVLA
  	DFIGGLNDFHAGVTFFAIESAYLPYTVQKSSDGRFYFVDIMTFSSE
  	IRVGDELLEVDGAPVQDVLATLYGSNHKGTAAEESAALRTLFSR
  	MASLGHKVPSGRTTLKIRRPFGTTREVRVKWRYVPEGVGDLATI
  	APSIRAPQLQKSMRSFFPKKDDAFHRSSSLFYSPMVPHFWAELRN
  	HYATSGLKSGYNIGSTDGFLPVIGPVIWESEGLFRAYISSVTDGDG
  	KSHKVGFLRIPTYSWQDMEDFDPSGPPPWEEFAKIIQVFSSNTEAL
  	IIDQTNNPGGSVLYLYALLSMLTDRPLELPKHRMILTQDEVVDAL
  	DWLTLLENVDTNVESRLALGDNMEGYTVDLQVAEYLKSFGRQV
  	LNCWSKGDIELSTPIPLFGFEKIHPHPRVQYSKPICVLINEQDFSCA
  	DFFPVVLKDNDRALIVGTRTAGAGGFVFNVQFPNRTGIKTCSLTG
  	SLAVREHGAFIENIGVEPHIDLPFTANDIRYKGYSEYLDKVKKLVC
  	QLINNDGTIILAEDGSFHHHHHH
  Chlamydia_Ct875_nIgk	METPAQLLFLLLLWLPDTTGMSIRGVGGNGNSRIPSHNGDGSNRR	179
  	SQNTKGNNKVEDRVCSLYSSRSNENRESPYAVVDVSSMIESTPTS
  	GETTRASRGVLSRFQRGLVRIADKVRRAVQCAWSSVSTSRSSATR
  	AAESGSSSRTARGASSGYREYSPSAARGLRLMFTDFWRTRVLRQ
  	TSPMAGVFGNLDVNEARLMAAYTSECADHLEAKELAGPDGVAA
  	AREIAKRWEKRVRDLQDKGAARKLLNDPLGRRTPNYQSKNPGE
  	YTVGNSMFYDGPQVANLQNVDTGFWLDMSNLSDVVLSREIQTG
  	LRARATLEESMPMLENLEERFRRLQETCDAARTEIEESGWTRESA
  	SRMEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSFGEHVRVLCAR
  	VSRGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSPEGASLAETLAR
  	FADDMGIERGADGTYDIPLVDDWRRGVPSIEGEGSDSIYEIMMPI
  	YEVMNMDLETRRSFAVQQGHYQDPRASDYDLPRASDYDLPRSP
  	YPTPPLPPRYQLQNMDVEAGFREAVYASFVAGMYNYVVTQPQE
  	RIPNSQQVEGILRDMLTNGSQTFRDLMKRWNREVDRE
  Chlamydia_Ct875_nIgk_cHis	METPAQLLFLLLLWLPDTTGMSIRGVGGNGNSRIPSHNGDGSNRR	180
  	SQNTKGNNKVEDRVCSLYSSRSNENRESPYAVVDVSSMIESTPTS
  	GETTRASRGVLSRFQRGLVRIADKVRRAVQCAWSSVSTSRSSATR
  	AAESGSSSRTARGASSGYREYSPSAARGLRLMFTDFWRTRVLRQ
  	TSPMAGVFGNLDVNEARLMAAYTSECADHLEAKELAGPDGVAA
  	AREIAKRWEKRVRDLQDKGAARKLLNDPLGRRTPNYQSKNPGE
  	YTVGNSMFYDGPQVANLQNVDTGFWLDMSNLSDVVLSREIQTG
  	LRARATLEESMPMLENLEERFRRLQETCDAARTEIEESGWTRESA
  	SRMEGDEAQGPSRVQQAFQSFVNECNSIEFSFGSFGEHVRVLCAR
  	VSRGLAAAGEAIRRCFSCCKGSTHRYAPRDDLSPEGASLAETLAR
  	FADDMGIERGADGTYDIPLVDDWRRGVPSIEGEGSDSIYEIMMPI
  	YEVMNMDLETRRSFAVQQGHYQDPRASDYDLPRASDYDLPRSP
  	YPTPPLPPRYQLQNMDVEAGFREAVYASFVAGMYNYVVTQPQE
  	RIPNSQQVEGILRDMLTNGSQTFRDLMKRWNREVDREHHHHHH
  Chlamydia_Ct089_nIgk	METPAQLLFLLLLWLPDTTGMTASGGAGGLGSTQTVDVARAQA	181
  	AAATQDAQEVIGSQEASEASMLKGCEDLINPAAATRIKKKEEKFE
  	SLEARRKPTADKAEKKSESTEEKGDTPLEDRFTEDLSEVSGEDFR
  	GLKNSFDDDSSPEEILDALTSKFSDPTIKDLALDYLIQTAPSDRKL
  	KSALIQAKHQLMSQNPQAIVGGRNVLLASETFASRANTSPSSLRS
  	LYLQVTSSPSNCDNLRQMLASYLPSEKTAVMEFLVNGMVADLKS
  	EGPSIPPAKLQVYMTELSNLQALHSVDSFFDRNIGNLENSLKHEG
  	HAPIPSLTTGNLTKTFLQLVEDKFPSSSKAQKALNELVGPDTGPQT
  	EVLNLFFRALNGCSPRIFSGAEKKQQLASVITNTLDAINADNEDYP
  	KPGDFPRSSFSSTPPHAPVPQSEIPTSPTSTQPPSP
  Chlamydia_Ct089_nIgk_cHis	METPAQLLFLLLLWLPDTTGMTASGGAGGLGSTQTVDVARAQA	182
  	AAATQDAQEVIGSQEASEASMLKGCEDLINPAAATRIKKKEEKFE
  	SLEARRKPTADKAEKKSESTEEKGDTPLEDRFTEDLSEVSGEDFR
  	GLKNSFDDDSSPEEILDALTSKFSDPTIKDLALDYLIQTAPSDRKL
  	KSALIQAKHQLMSQNPQAIVGGRNVLLASETFASRANTSPSSLRS
  	LYLQVTSSPSNCDNLRQMLASYLPSEKTAVMEFLVNGMVADLKS
  	EGPSIPPAKLQVYMTELSNLQALHSVDSFFDRNIGNLENSLKHEG
  	HAPIPSLTTGNLTKTFLQLVEDKFPSSSKAQKALNELVGPDTGPQT
  	EVLNLFFRALNGCSPRIFSGAEKKQQLASVITNTLDAINADNEDYP
  	KPGDFPRSSFSSTPPHAPVPQSEIPTSPTSTQPPSPHHHHHH
  Chlamydia_MOMP	MKKLLKSAFLSAAFFAGHASLHALPVGNPAEPSLLIDGTIWEGMS	183
  	GDPCDPCATWCDAISLRVGFYGDYVFDRVLKTDVPQKFSMGPIP
  	TSSTSPEDSAILTERNNAAYGKHMHDAELFTNAGYIALNIWDRFD
  	IFCTLGATSGYFKGNSSSFNLIGLIGISGADLNSKLPNANISNGVVE
  	LYTDTTFSWSVGARGALWECGCATLGAEFQYAQSKPRVQELNV
  	LSNVAQFTVHKPRGYVGQPLPLPLTAGTATDSNDKLKNATINYH
  	EWQVGAALSYRLNMLVPYIGVQWSRATFDADTIQIAEPKLASPIF
  	NLTTWNPTLLGQATSVDSGNKFADSLQIVSLQINKLKSRKACGVS
  	MGATLLDADKWAINGELRLINERAAHLSAQCRF
  * All Chlamydia mRNA vaccines contain standard 5′UTR and 3′UTR sequences and G5 Cap
  5′UTR: TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAATATAAGAGCCACC (SEQ ID NO: 295)
  5′UTR without promoter sequence: (SEQ ID NO: 296) GGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAATATAAGAGCCACC
  3′UTR: TGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC (SEQ ID NO: 297)

• TABLE 8
  Chlamydia mRNA Constructs (Nucleic Acids)

  		SEQ
  mRNA		ID
  Name	ORF Sequence (Nucleotide)	NO:
  Cta1_E_EXT_noTM_nIgK	ATGGAAACCCCTGCCCAGCTGCTGTTCCTGCTGCTGCTGTGGC	184
  	TGCCTGATACCACCGGCCCTCCCCTGCCCAGCAGCACACAGGA
  	CAACAGATCCATGGACCAGCAGGACAGCGAAGAGTTCCTGCT
  	GCAGAACACCCTGGAAGATAGCGAGATCATCAGCATCCCCGA
  	CACCATGAACCAGATCGCCATCGACACCGAGAAGTGGTTCTAC
  	CTGAACAAGGACTGCACCAACGTGGGCCCCATCTCCATCGTGC
  	AGCTGACAGCCTTCCTGAAAGAGTGCAAGCACAGCCCCGAGA
  	AGGGCATCGACCCCCAGGAACTGTGGGTGTGGAAGAAAGGCA
  	TGCCCAACTGGGAGAAAGTGAAGAACATCCCCGAGCTGAGCG
  	GCACCGTGAAGGACGAG
  Cta1_E_EXT_noTM_nIgK_cHis	ATGGAAACCCCTGCCCAGCTGCTGTTCCTGCTGCTGCTGTGGC	185
  	TGCCTGATACCACCGGCCCTCCCCTGCCCAGCAGCACACAGGA
  	CAACAGATCCATGGACCAGCAGGACAGCGAAGAGTTCCTGCT
  	GCAGAACACCCTGGAAGATAGCGAGATCATCAGCATCCCCGA
  	CACCATGAACCAGATCGCCATCGACACCGAGAAGTGGTTCTAC
  	CTGAACAAGGACTGCACCAACGTGGGCCCCATCTCCATCGTGC
  	AGCTGACAGCCTTCCTGAAAGAGTGCAAGCACAGCCCCGAGA
  	AGGGCATCGACCCCCAGGAACTGTGGGTGTGGAAGAAAGGCA
  	TGCCCAACTGGGAGAAAGTGAAGAACATCCCCGAGCTGAGCG
  	GCACCGTGAAGGACGAGCACCACCACCATCACCAC
  Ct875_E_NGM_nFC_cHis	ATGGAAACCCCTGCTCAGCTGCTGTTCCTGCTGCTGCTGTGGC	186
  	TGCCTGATACAACCGGCGAGCCTAAGAGCTGCGACAAGACCC
  	ACACCTGTCCTCCATGTCCTGCTCCAGAACTGCTCGGCGGACC
  	TTCCGTGTTCCTGTTTCCTCCAAAGCCTAAGGACACCCTGATG
  	ATCAGCAGAACCCCTGAAGTGACCTGCGTGGTGGTGGATGTGT
  	CCCACGAGGATCCCGAAGTGAAGTTCAATTGGTACGTGGACG
  	GCGTGGAAGTGCACAACGCCAAGACCAAGCCTAGAGAGGAAC
  	AGTACAACAGCACCTACAGAGTGGTGTCCGTGCTGACCGTGCT
  	GCACCAGGATTGGCTGAACGGCAAAGAGTACAAGTGCAAGGT
  	GTCCAACAAGGCCCTGCCTGCTCCTATCGAGAAGACCATCAGC
  	AAGGCCAAGGGCCAGCCAAGAGAACCCCAGGTGTACACACTG
  	CCTCCAAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTG
  	ACCTGTCTGGTCAAGGGCTTCTACCCCTCCGATATCGCCGTGG
  	AATGGGAGAGCAATGGCCAGCCTGAGAACAACTACAAGACAA
  	CCCCTCCTGTGCTGGACAGCGACGGCTCATTCTTCCTGTACAG
  	CAAGCTGACAGTGGACAAGAGCAGATGGCAGCAGGGCAACGT
  	GTTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAATCACTAC
  	ACCCAGAAGTCCCTGTCTCTGAGCCCCGGCAAGATGAGCATCA
  	GAGGCGTGGGCGGCAACGGCAACAGCAGAATCCCTAGCCACA
  	ACGGCGACGGCAGCAACAGGCGGAGCCAGAACACCAAGGGC
  	AACAACAAGGTGGAAGATAGAGTGTGCAGCCTGTACAGCAGC
  	CGGTCCAACGAGAACCGCGAGAGCCCTTATGCCGTGGTGGAC
  	GTGTCCAGCATGATCGAGAGCACCCCCACCAGCGGCGAGACA
  	ACCAGAGCTAGTAGAGGCGTGCTGAGCCGGTTCCAGAGGGGC
  	CTCGTGCGGATTGCTGACAAAGTGCGGAGAGCCGTGCAGTGC
  	GCTTGGAGCAGCGTGTCCACAAGCAGAAGCAGCGCCACAAGA
  	GCCGCCGAGAGCGGCAGCTCTAGCAGAACAGCTAGAGGCGCC
  	AGCAGCGGCTACAGAGAGTACAGCCCTTCTGCCGCTCGGGGC
  	CTGCGGCTGATGTTCACCGACTTTTGGCGGACCCGGGTGCTGA
  	GACAGACCTCTCCTATGGCCGGCGTGTTCGGCAACCTGGACGT
  	GAACGAGGCCAGACTGATGGCCGCCTACACCAGCGAGTGTGC
  	CGATCACCTGGAAGCCAAAGAGCTGGCCGGACCTGACGGCGT
  	GGCAGCCGCTAGAGAAATCGCCAAGAGATGGGAGAAGAGAGT
  	GCGGGACCTGCAGGACAAGGGCGCTGCCAGAAAGCTGCTGAA
  	CGACCCCCTGGGCAGACGGACCCCCAACTACCAGAGCAAGAA
  	CCCCGGCGAGTACACCGTGGGCAACTCCATGTTCTACGACGGC
  	CCCCAGGTGGCCAACCTGCAGAATGTGGATACCGGCTTCTGGC
  	TGGACATGCAGCACCTGAGCGACGTGGTGCTGTCCAGAGAGA
  	TCCAGACCGGCCTGAGAGCCAGAGCCACCCTGGAAGAGTCCA
  	TGCCCATGCTGGAAAATCTGGAAGAGAGATTCCGGCGGCTGC
  	AGGAAACCTGCGACGCCGCCAGAACCGAGATCGAGGAAAGCG
  	GCTGGACCCGGGAAAGCGCCTCCAGAATGGAAGGCGACGAAG
  	CCCAGGGCCCCAGCAGAGTGCAGCAGGCCTTTCAGAGCTTCGT
  	GAATGAGTGCAACAGCATCGAGTTCAGCTTCGGCTCCTTCGGC
  	GAGCACGTGCGGGTGCTGTGTGCCAGAGTGTCAAGAGGACTG
  	GCCGCTGCCGGCGAGGCCATCAGAAGATGCTTCAGCTGCTGCA
  	AGGGCAGCACCCACAGATACGCCCCCAGAGATGACCTGTCTC
  	CTGAGGGCGCCTCTCTGGCCGAAACCCTGGCCAGATTCGCCGA
  	CGACATGGGCATCGAAAGAGGCGCCGACGGCACCTACGACAT
  	CCCCCTGGTGGACGATTGGAGAAGGGGCGTGCCATCCATCGA
  	GGGCGAGGGCAGCGATAGCATCTACGAGATCATGATGCCCAT
  	CTACGAAGTGATGAACATGGACCTGGAAACCCGGCGGAGCTT
  	CGCCGTGCAGCAGGGCCATTACCAGGACCCCAGAGCCAGCGA
  	CTACGACCTGCCTAGAGCCTCCGATTACGATCTGCCCAGAAGC
  	CCCTACCCCACCCCTCCACTGCCTCCCAGATACCAGCTGCAGA
  	ACATGGATGTGGAAGCCGGCTTTCGCGAGGCCGTGTACGCCTC
  	TTTTGTGGCCGGCATGTACAACTACGTCGTGACCCAGCCCCAG
  	GAACGGATCCCCAATAGCCAGCAGGTGGAAGGCATCCTGCGG
  	GACATGCTGACCAACGGCGACCAGACCTTCCGGGACCTGATG
  	AAGCGGTGGAACAGAGAGGTGGACCGCGAGATGAGCCCTATC
  	CTCGGCTACTGGAAGATCAAAGGCCTGGTGCAGCCCACCAGA
  	CTGCTGCTGGAATACCTGGAAGAGAAGTACGAGGAACACCTG
  	TACGAGCGCGACGAGGGCGATAAGTGGCGGAACAAGAAGTTC
  	GAGCTGGGCCTCGAGTTCCCCAACCTGCCTTACTACATCGACG
  	GCGACGTGAAGCTGACCCAGAGCATGGCCATCATCCGGTATAT
  	CGCCGACAAGCACAACATGCTCGGCGGCTGCCCTAAAGAGCG
  	GGCCGAGATTTCTATGCTGGAAGGCGCCGTGCTGGACATCAGA
  	TACGGCGTGTCCAGAATCGCCTACAGCAAGGACTTCGAAACCC
  	TGAAGGTGGACTTCCTGAGCAAGCTGCCCGAGATGCTGAAGA
  	TGTTCGAGGACCGGCTGTGCCACAAGACCTACCTGAATGGCGA
  	CCACGTGACACACCCCGACTTCATGCTGTACGACGCCCTGGAT
  	GTGGTGCTGTACATGGACCCCATGTGCCTGGACGCCTTTCCAA
  	AGCTCGTGTGCTTCAAGAAGCGGATCGAGGCCATTCCTCAGAT
  	CGACAAGTACCTGAAGTCCAGCAAGTATATCGCTTGGCCCCTG
  	CAAGGCTGGCAGGCCACATTTGGAGGCGGAGATCACCCTCCT
  	AAG
  Ct875_E_nFC_cHis	ATGGAAACCCCTGCTCAGCTGCTGTTCCTGCTGCTGCTGTGGC	187
  	TGCCTGATACAACCGGCGAGCCTAAGAGCTGCGACAAGACCC
  	ACACCTGTCCTCCATGTCCTGCTCCAGAACTGCTCGGCGGACC
  	TTCCGTGTTCCTGTTTCCTCCAAAGCCTAAGGACACCCTGATG
  	ATCAGCAGAACCCCTGAAGTGACCTGCGTGGTGGTGGATGTGT
  	CCCACGAGGATCCCGAAGTGAAGTTCAATTGGTACGTGGACG
  	GCGTGGAAGTGCACAACGCCAAGACCAAGCCTAGAGAGGAAC
  	AGTACAACAGCACCTACAGAGTGGTGTCCGTGCTGACCGTGCT
  	GCACCAGGATTGGCTGAACGGCAAAGAGTACAAGTGCAAGGT
  	GTCCAACAAGGCCCTGCCTGCTCCTATCGAGAAGACCATCAGC
  	AAGGCCAAGGGCCAGCCAAGAGAACCCCAGGTGTACACACTG
  	CCTCCAAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTG
  	ACCTGTCTGGTCAAGGGCTTCTACCCCTCCGATATCGCCGTGG
  	AATGGGAGAGCAATGGCCAGCCTGAGAACAACTACAAGACAA
  	CCCCTCCTGTGCTGGACAGCGACGGCTCATTCTTCCTGTACAG
  	CAAGCTGACAGTGGACAAGAGCAGATGGCAGCAGGGCAACGT
  	GTTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAATCACTAC
  	ACCCAGAAGTCCCTGTCTCTGAGCCCCGGCAAGATGAGCATCA
  	GAGGCGTGGGCGGCAACGGCAACAGCAGAATCCCTAGCCACA
  	ACGGCGACGGCAGCAACAGGCGGAGCCAGAACACCAAGGGC
  	AACAACAAGGTGGAAGATAGAGTGTGCAGCCTGTACAGCAGC
  	CGGTCCAACGAGAACCGCGAGAGCCCTTATGCCGTGGTGGAC
  	GTGTCCAGCATGATCGAGAGCACCCCCACCAGCGGCGAGACA
  	ACCAGAGCTAGTAGAGGCGTGCTGAGCCGGTTCCAGAGGGGC
  	CTCGTGCGGATTGCTGACAAAGTGCGGAGAGCCGTGCAGTGC
  	GCTTGGAGCAGCGTGTCCACAAGCAGAAGCAGCGCCACAAGA
  	GCCGCCGAGAGCGGCAGCTCTAGCAGAACAGCTAGAGGCGCC
  	AGCAGCGGCTACAGAGAGTACAGCCCTTCTGCCGCTCGGGGC
  	CTGCGGCTGATGTTCACCGACTTTTGGCGGACCCGGGTGCTGA
  	GACAGACCTCTCCTATGGCCGGCGTGTTCGGCAACCTGGACGT
  	GAACGAGGCCAGACTGATGGCCGCCTACACCAGCGAGTGTGC
  	CGATCACCTGGAAGCCAAAGAGCTGGCCGGACCTGACGGCGT
  	GGCAGCCGCTAGAGAAATCGCCAAGAGATGGGAGAAGAGAGT
  	GCGGGACCTGCAGGACAAGGGCGCTGCCAGAAAGCTGCTGAA
  	CGACCCCCTGGGCAGACGGACCCCCAACTACCAGAGCAAGAA
  	CCCCGGCGAGTACACCGTGGGCAACTCCATGTTCTACGACGGC
  	CCCCAGGTGGCCAACCTGCAGAATGTGGATACCGGCTTCTGGC
  	TGGACATGAGCAACCTGAGCGACGTGGTGCTGTCCAGAGAGA
  	TCCAGACCGGCCTGAGAGCCAGAGCCACCCTGGAAGAGTCCA
  	TGCCCATGCTGGAAAATCTGGAAGAGAGATTCCGGCGGCTGC
  	AGGAAACCTGCGACGCCGCCAGAACCGAGATCGAGGAAAGCG
  	GCTGGACCCGGGAAAGCGCCTCCAGAATGGAAGGCGACGAAG
  	CCCAGGGCCCCAGCAGAGTGCAGCAGGCCTTTCAGAGCTTCGT
  	GAATGAGTGCAACAGCATCGAGTTCAGCTTCGGCTCCTTCGGC
  	GAGCACGTGCGGGTGCTGTGTGCCAGAGTGTCAAGAGGACTG
  	GCCGCTGCCGGCGAGGCCATCAGAAGATGCTTCAGCTGCTGCA
  	AGGGCAGCACCCACAGATACGCCCCCAGAGATGACCTGTCTC
  	CTGAGGGCGCCTCTCTGGCCGAAACCCTGGCCAGATTCGCCGA
  	CGACATGGGCATCGAAAGAGGCGCCGACGGCACCTACGACAT
  	CCCCCTGGTGGACGATTGGAGAAGGGGCGTGCCATCCATCGA
  	GGGCGAGGGCAGCGATAGCATCTACGAGATCATGATGCCCAT
  	CTACGAAGTGATGAACATGGACCTGGAAACCCGGCGGAGCTT
  	CGCCGTGCAGCAGGGCCATTACCAGGACCCCAGAGCCAGCGA
  	CTACGACCTGCCTAGAGCCTCCGATTACGATCTGCCCAGAAGC
  	CCCTACCCCACCCCTCCACTGCCTCCCAGATACCAGCTGCAGA
  	ACATGGATGTGGAAGCCGGCTTTCGCGAGGCCGTGTACGCCTC
  	TTTTGTGGCCGGCATGTACAACTACGTCGTGACCCAGCCCCAG
  	GAACGGATCCCCAATAGCCAGCAGGTGGAAGGCATCCTGCGG
  	GACATGCTGACCAACGGCAGCCAGACCTTCCGGGACCTGATG
  	AAGCGGTGGAACAGAGAGGTGGACCGCGAGCACCACCATCAC
  	CACCAC
  Ct875_E_NGM_nFC	ATGGAAACCCCTGCTCAGCTGCTGTTCCTGCTGCTGCTGTGGC	188
  	TGCCTGATACAACCGGCGAGCCTAAGAGCTGCGACAAGACCC
  	ACACCTGTCCTCCATGTCCTGCTCCAGAACTGCTCGGCGGACC
  	TTCCGTGTTCCTGTTTCCTCCAAAGCCTAAGGACACCCTGATG
  	ATCAGCAGAACCCCTGAAGTGACCTGCGTGGTGGTGGATGTGT
  	CCCACGAGGATCCCGAAGTGAAGTTCAATTGGTACGTGGACG
  	GCGTGGAAGTGCACAACGCCAAGACCAAGCCTAGAGAGGAAC
  	AGTACAACAGCACCTACAGAGTGGTGTCCGTGCTGACCGTGCT
  	GCACCAGGATTGGCTGAACGGCAAAGAGTACAAGTGCAAGGT
  	GTCCAACAAGGCCCTGCCTGCTCCTATCGAGAAGACCATCAGC
  	AAGGCCAAGGGCCAGCCAAGAGAACCCCAGGTGTACACACTG
  	CCTCCAAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTG
  	ACCTGTCTGGTCAAGGGCTTCTACCCCTCCGATATCGCCGTGG
  	AATGGGAGAGCAATGGCCAGCCTGAGAACAACTACAAGACAA
  	CCCCTCCTGTGCTGGACAGCGACGGCTCATTCTTCCTGTACAG
  	CAAGCTGACAGTGGACAAGAGCAGATGGCAGCAGGGCAACGT
  	GTTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAATCACTAC
  	ACCCAGAAGTCCCTGTCTCTGAGCCCCGGCAAGATGAGCATCA
  	GAGGCGTGGGCGGCAACGGCAACAGCAGAATCCCTAGCCACA
  	ACGGCGACGGCAGCAACAGGCGGAGCCAGAACACCAAGGGC
  	AACAACAAGGTGGAAGATAGAGTGTGCAGCCTGTACAGCAGC
  	CGGTCCAACGAGAACCGCGAGAGCCCTTATGCCGTGGTGGAC
  	GTGTCCAGCATGATCGAGAGCACCCCCACCAGCGGCGAGACA
  	ACCAGAGCTAGTAGAGGCGTGCTGAGCCGGTTCCAGAGGGGC
  	CTCGTGCGGATTGCTGACAAAGTGCGGAGAGCCGTGCAGTGC
  	GCTTGGAGCAGCGTGTCCACAAGCAGAAGCAGCGCCACAAGA
  	GCCGCCGAGAGCGGCAGCTCTAGCAGAACAGCTAGAGGCGCC
  	AGCAGCGGCTACAGAGAGTACAGCCCTTCTGCCGCTCGGGGC
  	CTGCGGCTGATGTTCACCGACTTTTGGCGGACCCGGGTGCTGA
  	GACAGACCTCTCCTATGGCCGGCGTGTTCGGCAACCTGGACGT
  	GAACGAGGCCAGACTGATGGCCGCCTACACCAGCGAGTGTGC
  	CGATCACCTGGAAGCCAAAGAGCTGGCCGGACCTGACGGCGT
  	GGCAGCCGCTAGAGAAATCGCCAAGAGATGGGAGAAGAGAGT
  	GCGGGACCTGCAGGACAAGGGCGCTGCCAGAAAGCTGCTGAA
  	CGACCCCCTGGGCAGACGGACCCCCAACTACCAGAGCAAGAA
  	CCCCGGCGAGTACACCGTGGGCAACTCCATGTTCTACGACGGC
  	CCCCAGGTGGCCAACCTGCAGAATGTGGATACCGGCTTCTGGC
  	TGGACATGCAGCACCTGAGCGACGTGGTGCTGTCCAGAGAGA
  	TCCAGACCGGCCTGAGAGCCAGAGCCACCCTGGAAGAGTCCA
  	TGCCCATGCTGGAAAATCTGGAAGAGAGATTCCGGCGGCTGC
  	AGGAAACCTGCGACGCCGCCAGAACCGAGATCGAGGAAAGCG
  	GCTGGACCCGGGAAAGCGCCTCCAGAATGGAAGGCGACGAAG
  	CCCAGGGCCCCAGCAGAGTGCAGCAGGCCTTTCAGAGCTTCGT
  	GAATGAGTGCAACAGCATCGAGTTCAGCTTCGGCTCCTTCGGC
  	GAGCACGTGCGGGTGCTGTGTGCCAGAGTGTCAAGAGGACTG
  	GCCGCTGCCGGCGAGGCCATCAGAAGATGCTTCAGCTGCTGCA
  	AGGGCAGCACCCACAGATACGCCCCCAGAGATGACCTGTCTC
  	CTGAGGGCGCCTCTCTGGCCGAAACCCTGGCCAGATTCGCCGA
  	CGACATGGGCATCGAAAGAGGCGCCGACGGCACCTACGACAT
  	CCCCCTGGTGGACGATTGGAGAAGGGGCGTGCCATCCATCGA
  	GGGCGAGGGCAGCGATAGCATCTACGAGATCATGATGCCCAT
  	CTACGAAGTGATGAACATGGACCTGGAAACCCGGCGGAGCTT
  	CGCCGTGCAGCAGGGCCATTACCAGGACCCCAGAGCCAGCGA
  	CTACGACCTGCCTAGAGCCTCCGATTACGATCTGCCCAGAAGC
  	CCCTACCCCACCCCTCCACTGCCTCCCAGATACCAGCTGCAGA
  	ACATGGATGTGGAAGCCGGCTTTCGCGAGGCCGTGTACGCCTC
  	TTTTGTGGCCGGCATGTACAACTACGTCGTGACCCAGCCCCAG
  	GAACGGATCCCCAATAGCCAGCAGGTGGAAGGCATCCTGCGG
  	GACATGCTGACCAACGGCGACCAGACCTTCCGGGACCTGATG
  	AAGCGGTGGAACAGAGAGGTGGACCGCGAG
  Ct875_E_nFC	ATGGAAACCCCTGCTCAGCTGCTGTTCCTGCTGCTGCTGTGGC	189
  	TGCCTGATACAACCGGCGAGCCTAAGAGCTGCGACAAGACCC
  	ACACCTGTCCTCCATGTCCTGCTCCAGAACTGCTCGGCGGACC
  	TTCCGTGTTCCTGTTTCCTCCAAAGCCTAAGGACACCCTGATG
  	ATCAGCAGAACCCCTGAAGTGACCTGCGTGGTGGTGGATGTGT
  	CCCACGAGGATCCCGAAGTGAAGTTCAATTGGTACGTGGACG
  	GCGTGGAAGTGCACAACGCCAAGACCAAGCCTAGAGAGGAAC
  	AGTACAACAGCACCTACAGAGTGGTGTCCGTGCTGACCGTGCT
  	GCACCAGGATTGGCTGAACGGCAAAGAGTACAAGTGCAAGGT
  	GTCCAACAAGGCCCTGCCTGCTCCTATCGAGAAGACCATCAGC
  	AAGGCCAAGGGCCAGCCAAGAGAACCCCAGGTGTACACACTG
  	CCTCCAAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTG
  	ACCTGTCTGGTCAAGGGCTTCTACCCCTCCGATATCGCCGTGG
  	AATGGGAGAGCAATGGCCAGCCTGAGAACAACTACAAGACAA
  	CCCCTCCTGTGCTGGACAGCGACGGCTCATTCTTCCTGTACAG
  	CAAGCTGACAGTGGACAAGAGCAGATGGCAGCAGGGCAACGT
  	GTTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAATCACTAC
  	ACCCAGAAGTCCCTGTCTCTGAGCCCCGGCAAGATGAGCATCA
  	GAGGCGTGGGCGGCAACGGCAACAGCAGAATCCCTAGCCACA
  	ACGGCGACGGCAGCAACAGGCGGAGCCAGAACACCAAGGGC
  	AACAACAAGGTGGAAGATAGAGTGTGCAGCCTGTACAGCAGC
  	CGGTCCAACGAGAACCGCGAGAGCCCTTATGCCGTGGTGGAC
  	GTGTCCAGCATGATCGAGAGCACCCCCACCAGCGGCGAGACA
  	ACCAGAGCTAGTAGAGGCGTGCTGAGCCGGTTCCAGAGGGGC
  	CTCGTGCGGATTGCTGACAAAGTGCGGAGAGCCGTGCAGTGC
  	GCTTGGAGCAGCGTGTCCACAAGCAGAAGCAGCGCCACAAGA
  	GCCGCCGAGAGCGGCAGCTCTAGCAGAACAGCTAGAGGCGCC
  	AGCAGCGGCTACAGAGAGTACAGCCCTTCTGCCGCTCGGGGC
  	CTGCGGCTGATGTTCACCGACTTTTGGCGGACCCGGGTGCTGA
  	GACAGACCTCTCCTATGGCCGGCGTGTTCGGCAACCTGGACGT
  	GAACGAGGCCAGACTGATGGCCGCCTACACCAGCGAGTGTGC
  	CGATCACCTGGAAGCCAAAGAGCTGGCCGGACCTGACGGCGT
  	GGCAGCCGCTAGAGAAATCGCCAAGAGATGGGAGAAGAGAGT
  	GCGGGACCTGCAGGACAAGGGCGCTGCCAGAAAGCTGCTGAA
  	CGACCCCCTGGGCAGACGGACCCCCAACTACCAGAGCAAGAA
  	CCCCGGCGAGTACACCGTGGGCAACTCCATGTTCTACGACGGC
  	CCCCAGGTGGCCAACCTGCAGAATGTGGATACCGGCTTCTGGC
  	TGGACATGAGCAACCTGAGCGACGTGGTGCTGTCCAGAGAGA
  	TCCAGACCGGCCTGAGAGCCAGAGCCACCCTGGAAGAGTCCA
  	TGCCCATGCTGGAAAATCTGGAAGAGAGATTCCGGCGGCTGC
  	AGGAAACCTGCGACGCCGCCAGAACCGAGATCGAGGAAAGCG
  	GCTGGACCCGGGAAAGCGCCTCCAGAATGGAAGGCGACGAAG
  	CCCAGGGCCCCAGCAGAGTGCAGCAGGCCTTTCAGAGCTTCGT
  	GAATGAGTGCAACAGCATCGAGTTCAGCTTCGGCTCCTTCGGC
  	GAGCACGTGCGGGTGCTGTGTGCCAGAGTGTCAAGAGGACTG
  	GCCGCTGCCGGCGAGGCCATCAGAAGATGCTTCAGCTGCTGCA
  	AGGGCAGCACCCACAGATACGCCCCCAGAGATGACCTGTCTC
  	CTGAGGGCGCCTCTCTGGCCGAAACCCTGGCCAGATTCGCCGA
  	CGACATGGGCATCGAAAGAGGCGCCGACGGCACCTACGACAT
  	CCCCCTGGTGGACGATTGGAGAAGGGGCGTGCCATCCATCGA
  	GGGCGAGGGCAGCGATAGCATCTACGAGATCATGATGCCCAT
  	CTACGAAGTGATGAACATGGACCTGGAAACCCGGCGGAGCTT
  	CGCCGTGCAGCAGGGCCATTACCAGGACCCCAGAGCCAGCGA
  	CTACGACCTGCCTAGAGCCTCCGATTACGATCTGCCCAGAAGC
  	CCCTACCCCACCCCTCCACTGCCTCCCAGATACCAGCTGCAGA
  	ACATGGATGTGGAAGCCGGCTTTCGCGAGGCCGTGTACGCCTC
  	TTTTGTGGCCGGCATGTACAACTACGTCGTGACCCAGCCCCAG
  	GAACGGATCCCCAATAGCCAGCAGGTGGAAGGCATCCTGCGG
  	GACATGCTGACCAACGGCAGCCAGACCTTCCGGGACCTGATG
  	AAGCGGTGGAACAGAGAGGTGGACCGCGAG
  Ct875_E_NGM_nIgK_nGst_cHis	ATGGAAACCCCTGCCCAGCTGCTGTTCCTGCTGCTGCTGTGGC	190
  	TGCCTGACACCACCGGCATGAGCCCTATCCTCGGCTACTGGAA
  	GATCAAAGGCCTGGTGCAGCCCACCAGACTGCTGCTGGAATA
  	CCTGGAAGAGAAGTACGAGGAACACCTGTACGAGCGCGACGA
  	GGGCGATAAGTGGCGGAACAAGAAGTTCGAGCTGGGCCTCGA
  	GTTCCCCAACCTGCCTTACTACATCGACGGCGACGTGAAGCTG
  	ACCCAGAGCATGGCCATCATCCGGTATATCGCCGACAAGCAC
  	AACATGCTCGGCGGCTGCCCTAAAGAGCGGGCCGAGATTTCTA
  	TGCTGGAAGGCGCCGTGCTGGACATCAGATACGGCGTGTCCA
  	GAATCGCCTACAGCAAGGACTTCGAAACCCTGAAGGTGGACT
  	TCCTGAGCAAGCTGCCCGAGATGCTGAAGATGTTCGAGGACC
  	GGCTGTGCCACAAGACCTACCTGAATGGCGACCACGTGACAC
  	ACCCCGACTTCATGCTGTACGACGCCCTGGATGTGGTGCTGTA
  	CATGGACCCCATGTGCCTGGACGCCTTTCCAAAGCTCGTGTGC
  	TTCAAGAAGCGGATCGAGGCCATTCCTCAGATCGACAAGTACC
  	TGAAGTCCAGCAAGTATATCGCTTGGCCCCTGCAAGGCTGGCA
  	GGCCACATTTGGAGGCGGAGATCACCCTCCTAAGATGAGCATC
  	AGAGGCGTGGGCGGCAACGGCAACAGCAGAATCCCTAGCCAC
  	AACGGCGACGGCAGCAACAGGCGGAGCCAGAACACCAAGGG
  	CAACAACAAGGTGGAAGATAGAGTGTGCAGCCTGTACAGCAG
  	CCGGTCCAACGAGAACCGCGAGAGCCCTTATGCCGTGGTGGA
  	CGTGTCCAGCATGATCGAGAGCACCCCCACCAGCGGCGAGAC
  	AACCAGAGCTAGTAGAGGCGTGCTGAGCCGGTTCCAGAGGGG
  	CCTCGTGCGGATTGCTGACAAAGTGCGGAGAGCCGTGCAGTG
  	CGCTTGGAGCAGCGTGTCCACAAGCAGAAGCAGCGCCACAAG
  	AGCCGCCGAGAGCGGCAGCTCTAGCAGAACAGCTAGAGGCGC
  	CAGCAGCGGCTACAGAGAGTACAGCCCTTCTGCCGCTCGGGG
  	CCTGCGGCTGATGTTCACCGACTTTTGGCGGACCCGGGTGCTG
  	AGACAGACCTCTCCTATGGCCGGCGTGTTCGGCAACCTGGACG
  	TGAACGAGGCCAGACTGATGGCCGCCTACACCAGCGAGTGTG
  	CCGATCACCTGGAAGCCAAAGAGCTGGCCGGACCTGACGGCG
  	TGGCAGCCGCTAGAGAAATCGCCAAGAGATGGGAGAAGAGAG
  	TGCGGGACCTGCAGGACAAGGGCGCTGCCAGAAAGCTGCTGA
  	ACGACCCCCTGGGCAGACGGACCCCCAACTACCAGAGCAAGA
  	ACCCCGGCGAGTACACCGTGGGCAACTCCATGTTCTACGACGG
  	CCCCCAGGTGGCCAACCTGCAGAATGTGGATACCGGCTTCTGG
  	CTGGACATGCAGCACCTGAGCGACGTGGTGCTGTCCAGAGAG
  	ATCCAGACCGGCCTGAGAGCCAGAGCCACCCTGGAAGAGTCC
  	ATGCCCATGCTGGAAAATCTGGAAGAGAGATTCCGGCGGCTG
  	CAGGAAACCTGCGACGCCGCCAGAACCGAGATCGAGGAAAGC
  	GGCTGGACCCGGGAAAGCGCCTCCAGAATGGAAGGCGACGAA
  	GCCCAGGGCCCCAGCAGAGTGCAGCAGGCCTTTCAGAGCTTC
  	GTGAATGAGTGCAACAGCATCGAGTTCAGCTTCGGCTCCTTCG
  	GCGAGCACGTGCGGGTGCTGTGTGCCAGAGTGTCAAGAGGAC
  	TGGCCGCTGCCGGCGAGGCCATCAGAAGATGCTTCAGCTGCTG
  	CAAGGGCAGCACCCACAGATACGCCCCCAGAGATGACCTGTC
  	TCCTGAGGGCGCCTCTCTGGCCGAAACCCTGGCCAGATTCGCC
  	GACGACATGGGCATCGAAAGAGGCGCCGACGGCACCTACGAC
  	ATCCCCCTGGTGGACGATTGGAGAAGGGGCGTGCCATCCATCG
  	AGGGCGAGGGCAGCGATAGCATCTACGAGATCATGATGCCCA
  	TCTACGAAGTGATGAACATGGACCTGGAAACCCGGCGGAGCT
  	TCGCCGTGCAGCAGGGCCATTACCAGGACCCCAGAGCCAGCG
  	ACTACGACCTGCCTAGAGCCTCCGATTACGATCTGCCCAGAAG
  	CCCCTACCCCACCCCTCCACTGCCTCCCAGATACCAGCTGCAG
  	AACATGGATGTGGAAGCCGGCTTTCGCGAGGCCGTGTACGCCT
  	CTTTTGTGGCCGGCATGTACAACTACGTCGTGACCCAGCCCCA
  	GGAACGGATCCCCAATAGCCAGCAGGTGGAAGGCATCCTGCG
  	GGACATGCTGACCAACGGCGACCAGACCTTCCGGGACCTGAT
  	GAAGCGGTGGAACAGAGAGGTGGACCGCGAGCACCACCATCA
  	CCACCAC
  Ct875_E_nIgK_nGst_cHis	ATGGAAACCCCTGCCCAGCTGCTGTTCCTGCTGCTGCTGTGGC	191
  	TGCCTGACACCACCGGCATGAGCCCTATCCTCGGCTACTGGAA
  	GATCAAAGGCCTGGTGCAGCCCACCAGACTGCTGCTGGAATA
  	CCTGGAAGAGAAGTACGAGGAACACCTGTACGAGCGCGACGA
  	GGGCGATAAGTGGCGGAACAAGAAGTTCGAGCTGGGCCTCGA
  	GTTCCCCAACCTGCCTTACTACATCGACGGCGACGTGAAGCTG
  	ACCCAGAGCATGGCCATCATCCGGTATATCGCCGACAAGCAC
  	AACATGCTCGGCGGCTGCCCTAAAGAGCGGGCCGAGATTTCTA
  	TGCTGGAAGGCGCCGTGCTGGACATCAGATACGGCGTGTCCA
  	GAATCGCCTACAGCAAGGACTTCGAAACCCTGAAGGTGGACT
  	TCCTGAGCAAGCTGCCCGAGATGCTGAAGATGTTCGAGGACC
  	GGCTGTGCCACAAGACCTACCTGAATGGCGACCACGTGACAC
  	ACCCCGACTTCATGCTGTACGACGCCCTGGATGTGGTGCTGTA
  	CATGGACCCCATGTGCCTGGACGCCTTTCCAAAGCTCGTGTGC
  	TTCAAGAAGCGGATCGAGGCCATTCCTCAGATCGACAAGTACC
  	TGAAGTCCAGCAAGTATATCGCTTGGCCCCTGCAAGGCTGGCA
  	GGCCACATTTGGAGGCGGAGATCACCCTCCTAAGATGAGCATC
  	AGAGGCGTGGGCGGCAACGGCAACAGCAGAATCCCTAGCCAC
  	AACGGCGACGGCAGCAACAGGCGGAGCCAGAACACCAAGGG
  	CAACAACAAGGTGGAAGATAGAGTGTGCAGCCTGTACAGCAG
  	CCGGTCCAACGAGAACCGCGAGAGCCCTTATGCCGTGGTGGA
  	CGTGTCCAGCATGATCGAGAGCACCCCCACCAGCGGCGAGAC
  	AACCAGAGCTAGTAGAGGCGTGCTGAGCCGGTTCCAGAGGGG
  	CCTCGTGCGGATTGCTGACAAAGTGCGGAGAGCCGTGCAGTG
  	CGCTTGGAGCAGCGTGTCCACAAGCAGAAGCAGCGCCACAAG
  	AGCCGCCGAGAGCGGCAGCTCTAGCAGAACAGCTAGAGGCGC
  	CAGCAGCGGCTACAGAGAGTACAGCCCTTCTGCCGCTCGGGG
  	CCTGCGGCTGATGTTCACCGACTTTTGGCGGACCCGGGTGCTG
  	AGACAGACCTCTCCTATGGCCGGCGTGTTCGGCAACCTGGACG
  	TGAACGAGGCCAGACTGATGGCCGCCTACACCAGCGAGTGTG
  	CCGATCACCTGGAAGCCAAAGAGCTGGCCGGACCTGACGGCG
  	TGGCAGCCGCTAGAGAAATCGCCAAGAGATGGGAGAAGAGAG
  	TGCGGGACCTGCAGGACAAGGGCGCTGCCAGAAAGCTGCTGA
  	ACGACCCCCTGGGCAGACGGACCCCCAACTACCAGAGCAAGA
  	ACCCCGGCGAGTACACCGTGGGCAACTCCATGTTCTACGACGG
  	CCCCCAGGTGGCCAACCTGCAGAATGTGGATACCGGCTTCTGG
  	CTGGACATGAGCAACCTGAGCGACGTGGTGCTGTCCAGAGAG
  	ATCCAGACCGGCCTGAGAGCCAGAGCCACCCTGGAAGAGTCC
  	ATGCCCATGCTGGAAAATCTGGAAGAGAGATTCCGGCGGCTG
  	CAGGAAACCTGCGACGCCGCCAGAACCGAGATCGAGGAAAGC
  	GGCTGGACCCGGGAAAGCGCCTCCAGAATGGAAGGCGACGAA
  	GCCCAGGGCCCCAGCAGAGTGCAGCAGGCCTTTCAGAGCTTC
  	GTGAATGAGTGCAACAGCATCGAGTTCAGCTTCGGCTCCTTCG
  	GCGAGCACGTGCGGGTGCTGTGTGCCAGAGTGTCAAGAGGAC
  	TGGCCGCTGCCGGCGAGGCCATCAGAAGATGCTTCAGCTGCTG
  	CAAGGGCAGCACCCACAGATACGCCCCCAGAGATGACCTGTC
  	TCCTGAGGGCGCCTCTCTGGCCGAAACCCTGGCCAGATTCGCC
  	GACGACATGGGCATCGAAAGAGGCGCCGACGGCACCTACGAC
  	ATCCCCCTGGTGGACGATTGGAGAAGGGGCGTGCCATCCATCG
  	AGGGCGAGGGCAGCGATAGCATCTACGAGATCATGATGCCCA
  	TCTACGAAGTGATGAACATGGACCTGGAAACCCGGCGGAGCT
  	TCGCCGTGCAGCAGGGCCATTACCAGGACCCCAGAGCCAGCG
  	ACTACGACCTGCCTAGAGCCTCCGATTACGATCTGCCCAGAAG
  	CCCCTACCCCACCCCTCCACTGCCTCCCAGATACCAGCTGCAG
  	AACATGGATGTGGAAGCCGGCTTTCGCGAGGCCGTGTACGCCT
  	CTTTTGTGGCCGGCATGTACAACTACGTCGTGACCCAGCCCCA
  	GGAACGGATCCCCAATAGCCAGCAGGTGGAAGGCATCCTGCG
  	GGACATGCTGACCAACGGCAGCCAGACCTTCCGGGACCTGAT
  	GAAGCGGTGGAACAGAGAGGTGGACCGCGAGCACCACCATCA
  	CCACCAC
  Ct875_E_NGM_nIgK_nGst	ATGGAAACCCCTGCCCAGCTGCTGTTCCTGCTGCTGCTGTGGC	192
  	TGCCTGACACCACCGGCATGAGCCCTATCCTCGGCTACTGGAA
  	GATCAAAGGCCTGGTGCAGCCCACCAGACTGCTGCTGGAATA
  	CCTGGAAGAGAAGTACGAGGAACACCTGTACGAGCGCGACGA
  	GGGCGATAAGTGGCGGAACAAGAAGTTCGAGCTGGGCCTCGA
  	GTTCCCCAACCTGCCTTACTACATCGACGGCGACGTGAAGCTG
  	ACCCAGAGCATGGCCATCATCCGGTATATCGCCGACAAGCAC
  	AACATGCTCGGCGGCTGCCCTAAAGAGCGGGCCGAGATTTCTA
  	TGCTGGAAGGCGCCGTGCTGGACATCAGATACGGCGTGTCCA
  	GAATCGCCTACAGCAAGGACTTCGAAACCCTGAAGGTGGACT
  	TCCTGAGCAAGCTGCCCGAGATGCTGAAGATGTTCGAGGACC
  	GGCTGTGCCACAAGACCTACCTGAATGGCGACCACGTGACAC
  	ACCCCGACTTCATGCTGTACGACGCCCTGGATGTGGTGCTGTA
  	CATGGACCCCATGTGCCTGGACGCCTTTCCAAAGCTCGTGTGC
  	TTCAAGAAGCGGATCGAGGCCATTCCTCAGATCGACAAGTACC
  	TGAAGTCCAGCAAGTATATCGCTTGGCCCCTGCAAGGCTGGCA
  	GGCCACATTTGGAGGCGGAGATCACCCTCCTAAGATGAGCATC
  	AGAGGCGTGGGCGGCAACGGCAACAGCAGAATCCCTAGCCAC
  	AACGGCGACGGCAGCAACAGGCGGAGCCAGAACACCAAGGG
  	CAACAACAAGGTGGAAGATAGAGTGTGCAGCCTGTACAGCAG
  	CCGGTCCAACGAGAACCGCGAGAGCCCTTATGCCGTGGTGGA
  	CGTGTCCAGCATGATCGAGAGCACCCCCACCAGCGGCGAGAC
  	AACCAGAGCTAGTAGAGGCGTGCTGAGCCGGTTCCAGAGGGG
  	CCTCGTGCGGATTGCTGACAAAGTGCGGAGAGCCGTGCAGTG
  	CGCTTGGAGCAGCGTGTCCACAAGCAGAAGCAGCGCCACAAG
  	AGCCGCCGAGAGCGGCAGCTCTAGCAGAACAGCTAGAGGCGC
  	CAGCAGCGGCTACAGAGAGTACAGCCCTTCTGCCGCTCGGGG
  	CCTGCGGCTGATGTTCACCGACTTTTGGCGGACCCGGGTGCTG
  	AGACAGACCTCTCCTATGGCCGGCGTGTTCGGCAACCTGGACG
  	TGAACGAGGCCAGACTGATGGCCGCCTACACCAGCGAGTGTG
  	CCGATCACCTGGAAGCCAAAGAGCTGGCCGGACCTGACGGCG
  	TGGCAGCCGCTAGAGAAATCGCCAAGAGATGGGAGAAGAGAG
  	TGCGGGACCTGCAGGACAAGGGCGCTGCCAGAAAGCTGCTGA
  	ACGACCCCCTGGGCAGACGGACCCCCAACTACCAGAGCAAGA
  	ACCCCGGCGAGTACACCGTGGGCAACTCCATGTTCTACGACGG
  	CCCCCAGGTGGCCAACCTGCAGAATGTGGATACCGGCTTCTGG
  	CTGGACATGCAGCACCTGAGCGACGTGGTGCTGTCCAGAGAG
  	ATCCAGACCGGCCTGAGAGCCAGAGCCACCCTGGAAGAGTCC
  	ATGCCCATGCTGGAAAATCTGGAAGAGAGATTCCGGCGGCTG
  	CAGGAAACCTGCGACGCCGCCAGAACCGAGATCGAGGAAAGC
  	GGCTGGACCCGGGAAAGCGCCTCCAGAATGGAAGGCGACGAA
  	GCCCAGGGCCCCAGCAGAGTGCAGCAGGCCTTTCAGAGCTTC
  	GTGAATGAGTGCAACAGCATCGAGTTCAGCTTCGGCTCCTTCG
  	GCGAGCACGTGCGGGTGCTGTGTGCCAGAGTGTCAAGAGGAC
  	TGGCCGCTGCCGGCGAGGCCATCAGAAGATGCTTCAGCTGCTG
  	CAAGGGCAGCACCCACAGATACGCCCCCAGAGATGACCTGTC
  	TCCTGAGGGCGCCTCTCTGGCCGAAACCCTGGCCAGATTCGCC
  	GACGACATGGGCATCGAAAGAGGCGCCGACGGCACCTACGAC
  	ATCCCCCTGGTGGACGATTGGAGAAGGGGCGTGCCATCCATCG
  	AGGGCGAGGGCAGCGATAGCATCTACGAGATCATGATGCCCA
  	TCTACGAAGTGATGAACATGGACCTGGAAACCCGGCGGAGCT
  	TCGCCGTGCAGCAGGGCCATTACCAGGACCCCAGAGCCAGCG
  	ACTACGACCTGCCTAGAGCCTCCGATTACGATCTGCCCAGAAG
  	CCCCTACCCCACCCCTCCACTGCCTCCCAGATACCAGCTGCAG
  	AACATGGATGTGGAAGCCGGCTTTCGCGAGGCCGTGTACGCCT
  	CTTTTGTGGCCGGCATGTACAACTACGTCGTGACCCAGCCCCA
  	GGAACGGATCCCCAATAGCCAGCAGGTGGAAGGCATCCTGCG
  	GGACATGCTGACCAACGGCGACCAGACCTTCCGGGACCTGAT
  	GAAGCGGTGGAACAGAGAGGTGGACCGCGAG
  Ct875_E_nIgK_nGst	ATGGAAACCCCTGCCCAGCTGCTGTTCCTGCTGCTGCTGTGGC	193
  	TGCCTGACACCACCGGCATGAGCCCTATCCTCGGCTACTGGAA
  	GATCAAAGGCCTGGTGCAGCCCACCAGACTGCTGCTGGAATA
  	CCTGGAAGAGAAGTACGAGGAACACCTGTACGAGCGCGACGA
  	GGGCGATAAGTGGCGGAACAAGAAGTTCGAGCTGGGCCTCGA
  	GTTCCCCAACCTGCCTTACTACATCGACGGCGACGTGAAGCTG
  	ACCCAGAGCATGGCCATCATCCGGTATATCGCCGACAAGCAC
  	AACATGCTCGGCGGCTGCCCTAAAGAGCGGGCCGAGATTTCTA
  	TGCTGGAAGGCGCCGTGCTGGACATCAGATACGGCGTGTCCA
  	GAATCGCCTACAGCAAGGACTTCGAAACCCTGAAGGTGGACT
  	TCCTGAGCAAGCTGCCCGAGATGCTGAAGATGTTCGAGGACC
  	GGCTGTGCCACAAGACCTACCTGAATGGCGACCACGTGACAC
  	ACCCCGACTTCATGCTGTACGACGCCCTGGATGTGGTGCTGTA
  	CATGGACCCCATGTGCCTGGACGCCTTTCCAAAGCTCGTGTGC
  	TTCAAGAAGCGGATCGAGGCCATTCCTCAGATCGACAAGTACC
  	TGAAGTCCAGCAAGTATATCGCTTGGCCCCTGCAAGGCTGGCA
  	GGCCACATTTGGAGGCGGAGATCACCCTCCTAAGATGAGCATC
  	AGAGGCGTGGGCGGCAACGGCAACAGCAGAATCCCTAGCCAC
  	AACGGCGACGGCAGCAACAGGCGGAGCCAGAACACCAAGGG
  	CAACAACAAGGTGGAAGATAGAGTGTGCAGCCTGTACAGCAG
  	CCGGTCCAACGAGAACCGCGAGAGCCCTTATGCCGTGGTGGA
  	CGTGTCCAGCATGATCGAGAGCACCCCCACCAGCGGCGAGAC
  	AACCAGAGCTAGTAGAGGCGTGCTGAGCCGGTTCCAGAGGGG
  	CCTCGTGCGGATTGCTGACAAAGTGCGGAGAGCCGTGCAGTG
  	CGCTTGGAGCAGCGTGTCCACAAGCAGAAGCAGCGCCACAAG
  	AGCCGCCGAGAGCGGCAGCTCTAGCAGAACAGCTAGAGGCGC
  	CAGCAGCGGCTACAGAGAGTACAGCCCTTCTGCCGCTCGGGG
  	CCTGCGGCTGATGTTCACCGACTTTTGGCGGACCCGGGTGCTG
  	AGACAGACCTCTCCTATGGCCGGCGTGTTCGGCAACCTGGACG
  	TGAACGAGGCCAGACTGATGGCCGCCTACACCAGCGAGTGTG
  	CCGATCACCTGGAAGCCAAAGAGCTGGCCGGACCTGACGGCG
  	TGGCAGCCGCTAGAGAAATCGCCAAGAGATGGGAGAAGAGAG
  	TGCGGGACCTGCAGGACAAGGGCGCTGCCAGAAAGCTGCTGA
  	ACGACCCCCTGGGCAGACGGACCCCCAACTACCAGAGCAAGA
  	ACCCCGGCGAGTACACCGTGGGCAACTCCATGTTCTACGACGG
  	CCCCCAGGTGGCCAACCTGCAGAATGTGGATACCGGCTTCTGG
  	CTGGACATGAGCAACCTGAGCGACGTGGTGCTGTCCAGAGAG
  	ATCCAGACCGGCCTGAGAGCCAGAGCCACCCTGGAAGAGTCC
  	ATGCCCATGCTGGAAAATCTGGAAGAGAGATTCCGGCGGCTG
  	CAGGAAACCTGCGACGCCGCCAGAACCGAGATCGAGGAAAGC
  	GGCTGGACCCGGGAAAGCGCCTCCAGAATGGAAGGCGACGAA
  	GCCCAGGGCCCCAGCAGAGTGCAGCAGGCCTTTCAGAGCTTC
  	GTGAATGAGTGCAACAGCATCGAGTTCAGCTTCGGCTCCTTCG
  	GCGAGCACGTGCGGGTGCTGTGTGCCAGAGTGTCAAGAGGAC
  	TGGCCGCTGCCGGCGAGGCCATCAGAAGATGCTTCAGCTGCTG
  	CAAGGGCAGCACCCACAGATACGCCCCCAGAGATGACCTGTC
  	TCCTGAGGGCGCCTCTCTGGCCGAAACCCTGGCCAGATTCGCC
  	GACGACATGGGCATCGAAAGAGGCGCCGACGGCACCTACGAC
  	ATCCCCCTGGTGGACGATTGGAGAAGGGGCGTGCCATCCATCG
  	AGGGCGAGGGCAGCGATAGCATCTACGAGATCATGATGCCCA
  	TCTACGAAGTGATGAACATGGACCTGGAAACCCGGCGGAGCT
  	TCGCCGTGCAGCAGGGCCATTACCAGGACCCCAGAGCCAGCG
  	ACTACGACCTGCCTAGAGCCTCCGATTACGATCTGCCCAGAAG
  	CCCCTACCCCACCCCTCCACTGCCTCCCAGATACCAGCTGCAG
  	AACATGGATGTGGAAGCCGGCTTTCGCGAGGCCGTGTACGCCT
  	CTTTTGTGGCCGGCATGTACAACTACGTCGTGACCCAGCCCCA
  	GGAACGGATCCCCAATAGCCAGCAGGTGGAAGGCATCCTGCG
  	GGACATGCTGACCAACGGCAGCCAGACCTTCCGGGACCTGAT
  	GAAGCGGTGGAACAGAGAGGTGGACCGCGAG
  Ct875_E_574_NGM_nIgK_cHis	ATGGAAACCCCTGCCCAGCTGCTGTTCCTGCTGCTGCTGTGGC	194
  	TGCCTGACACCACCGGCATGAGCATCAGAGGCGTGGGCGGCA
  	ACGGCAACAGCAGAATCCCTAGCCACAACGGCGACGGCAGCA
  	ACAGGCGGAGCCAGAACACCAAGGGCAACAACAAGGTGGAA
  	GATAGAGTGTGCAGCCTGTACAGCAGCCGGTCCAACGAGAAC
  	CGCGAGAGCCCTTATGCCGTGGTGGACGTGTCCAGCATGATCG
  	AGAGCACCCCCACCAGCGGCGAGACAACCAGAGCTAGTAGAG
  	GCGTGCTGAGCCGGTTCCAGAGGGGCCTCGTGCGGATTGCTGA
  	CAAAGTGCGGAGAGCCGTGCAGTGCGCTTGGAGCAGCGTGTC
  	CACAAGCAGAAGCAGCGCCACAAGAGCCGCCGAGAGCGGCA
  	GCTCTAGCAGAACAGCTAGAGGCGCCAGCAGCGGCTACAGAG
  	AGTACAGCCCTTCTGCCGCTCGGGGCCTGCGGCTGATGTTCAC
  	CGACTTTTGGCGGACCCGGGTGCTGAGACAGACCTCTCCTATG
  	GCCGGCGTGTTCGGCAACCTGGACGTGAACGAGGCCAGACTG
  	ATGGCCGCCTACACCAGCGAGTGTGCCGATCACCTGGAAGCC
  	AAAGAGCTGGCCGGACCTGACGGCGTGGCAGCCGCTAGAGAA
  	ATCGCCAAGAGATGGGAGAAGAGAGTGCGGGACCTGCAGGAC
  	AAGGGCGCTGCCAGAAAGCTGCTGAACGACCCCCTGGGCAGA
  	CGGACCCCCAACTACCAGAGCAAGAACCCCGGCGAGTACACC
  	GTGGGCAACTCCATGTTCTACGACGGCCCCCAGGTGGCCAACC
  	TGCAGAATGTGGATACCGGCTTCTGGCTGGACATGCAGCACCT
  	GAGCGACGTGGTGCTGTCCAGAGAGATCCAGACCGGCCTGAG
  	AGCCAGAGCCACCCTGGAAGAGTCCATGCCCATGCTGGAAAA
  	TCTGGAAGAGAGATTCCGGCGGCTGCAGGAAACCTGCGACGC
  	CGCCAGAACCGAGATCGAGGAAAGCGGCTGGACCCGGGAAAG
  	CGCCTCCAGAATGGAAGGCGACGAAGCCCAGGGCCCCAGCAG
  	AGTGCAGCAGGCCTTTCAGAGCTTCGTGAATGAGTGCAACAGC
  	ATCGAGTTCAGCTTCGGCTCCTTCGGCGAGCACGTGCGGGTGC
  	TGTGTGCCAGAGTGTCAAGAGGACTGGCCGCTGCCGGCGAGG
  	CCATCAGAAGATGCTTCAGCTGCTGCAAGGGCAGCACCCACA
  	GATACGCCCCCAGAGATGACCTGTCTCCTGAGGGCGCCTCTCT
  	GGCCGAAACCCTGGCCAGATTCGCCGACGACATGGGCATCGA
  	AAGAGGCGCCGACGGCACCTACGACATCCCCCTGGTGGACGA
  	TTGGAGAAGGGGCGTGCCATCCATCGAGGGCGAGGGCAGCGA
  	TAGCATCTACGAGATCATGATGCCCATCTACGAAGTGATGAAC
  	ATGGACCTGGAAACCCGGCGGAGCTTCGCCGTGCAGCAGGGC
  	CATTACCAGGACCCCAGAGCCAGCGACTACGACCTGCCTAGA
  	GCCTCCGATTACGATCTGCCCAGAAGCCCCTACCCCACCCCTC
  	CACTGCCTCCCAGATACCAGCTGCAGAACATGGATGTGGAAG
  	CCGGCTTTCGCGAGGCCGTGTACGCCTCTTTTGTGGCCGGCAT
  	GTACAACTACGTCGTGACCCAGCCCCAGGAACGGATCCCCAAT
  	AGCCAGCAGGTGGAAGGCATCCTGCGGGACATGCTGACCAAC
  	GGCGACCACCACCATCACCACCAC
  Ct875_E_458_NGM_nIgK_cHis	ATGGAAACCCCTGCCCAGCTGCTGTTCCTGCTGCTGCTGTGGC	195
  	TGCCTGACACCACCGGCATGAGCATCAGAGGCGTGGGCGGCA
  	ACGGCAACAGCAGAATCCCTAGCCACAACGGCGACGGCAGCA
  	ACAGGCGGAGCCAGAACACCAAGGGCAACAACAAGGTGGAA
  	GATAGAGTGTGCAGCCTGTACAGCAGCCGGTCCAACGAGAAC
  	CGCGAGAGCCCTTATGCCGTGGTGGACGTGTCCAGCATGATCG
  	AGAGCACCCCCACCAGCGGCGAGACAACCAGAGCTAGTAGAG
  	GCGTGCTGAGCCGGTTCCAGAGGGGCCTCGTGCGGATTGCTGA
  	CAAAGTGCGGAGAGCCGTGCAGTGCGCTTGGAGCAGCGTGTC
  	CACAAGCAGAAGCAGCGCCACAAGAGCCGCCGAGAGCGGCA
  	GCTCTAGCAGAACAGCTAGAGGCGCCAGCAGCGGCTACAGAG
  	AGTACAGCCCTTCTGCCGCTCGGGGCCTGCGGCTGATGTTCAC
  	CGACTTTTGGCGGACCCGGGTGCTGAGACAGACCTCTCCTATG
  	GCCGGCGTGTTCGGCAACCTGGACGTGAACGAGGCCAGACTG
  	ATGGCCGCCTACACCAGCGAGTGTGCCGATCACCTGGAAGCC
  	AAAGAGCTGGCCGGACCTGACGGCGTGGCAGCCGCTAGAGAA
  	ATCGCCAAGAGATGGGAGAAGAGAGTGCGGGACCTGCAGGAC
  	AAGGGCGCTGCCAGAAAGCTGCTGAACGACCCCCTGGGCAGA
  	CGGACCCCCAACTACCAGAGCAAGAACCCCGGCGAGTACACC
  	GTGGGCAACTCCATGTTCTACGACGGCCCCCAGGTGGCCAACC
  	TGCAGAATGTGGATACCGGCTTCTGGCTGGACATGCAGCACCT
  	GAGCGACGTGGTGCTGTCCAGAGAGATCCAGACCGGCCTGAG
  	AGCCAGAGCCACCCTGGAAGAGTCCATGCCCATGCTGGAAAA
  	TCTGGAAGAGAGATTCCGGCGGCTGCAGGAAACCTGCGACGC
  	CGCCAGAACCGAGATCGAGGAAAGCGGCTGGACCCGGGAAAG
  	CGCCTCCAGAATGGAAGGCGACGAAGCCCAGGGCCCCAGCAG
  	AGTGCAGCAGGCCTTTCAGAGCTTCGTGAATGAGTGCAACAGC
  	ATCGAGTTCAGCTTCGGCTCCTTCGGCGAGCACGTGCGGGTGC
  	TGTGTGCCAGAGTGTCAAGAGGACTGGCCGCTGCCGGCGAGG
  	CCATCAGAAGATGCTTCAGCTGCTGCAAGGGCAGCACCCACA
  	GATACGCCCCCAGAGATGACCTGTCTCCTGAGGGCGCCTCTCT
  	GGCCGAAACCCTGGCCAGATTCGCCGACGACATGGGCATCGA
  	AAGAGGCGCCGACGGCACCTACGACATCCCCCTGGTGGACGA
  	TTGGAGAAGGGGCGTGCCATCCATCGAGGGCGAGGGCAGCCA
  	CCACCATCACCACCAC
  Ct875_E_574_nIgK_cHis	ATGGAAACCCCTGCCCAGCTGCTGTTCCTGCTGCTGCTGTGGC	196
  	TGCCTGACACCACCGGCATGAGCATCAGAGGCGTGGGCGGCA
  	ACGGCAACAGCAGAATCCCTAGCCACAACGGCGACGGCAGCA
  	ACAGGCGGAGCCAGAACACCAAGGGCAACAACAAGGTGGAA
  	GATAGAGTGTGCAGCCTGTACAGCAGCCGGTCCAACGAGAAC
  	CGCGAGAGCCCTTATGCCGTGGTGGACGTGTCCAGCATGATCG
  	AGAGCACCCCCACCAGCGGCGAGACAACCAGAGCTAGTAGAG
  	GCGTGCTGAGCCGGTTCCAGAGGGGCCTCGTGCGGATTGCTGA
  	CAAAGTGCGGAGAGCCGTGCAGTGCGCTTGGAGCAGCGTGTC
  	CACAAGCAGAAGCAGCGCCACAAGAGCCGCCGAGAGCGGCA
  	GCTCTAGCAGAACAGCTAGAGGCGCCAGCAGCGGCTACAGAG
  	AGTACAGCCCTTCTGCCGCTCGGGGCCTGCGGCTGATGTTCAC
  	CGACTTTTGGCGGACCCGGGTGCTGAGACAGACCTCTCCTATG
  	GCCGGCGTGTTCGGCAACCTGGACGTGAACGAGGCCAGACTG
  	ATGGCCGCCTACACCAGCGAGTGTGCCGATCACCTGGAAGCC
  	AAAGAGCTGGCCGGACCTGACGGCGTGGCAGCCGCTAGAGAA
  	ATCGCCAAGAGATGGGAGAAGAGAGTGCGGGACCTGCAGGAC
  	AAGGGCGCTGCCAGAAAGCTGCTGAACGACCCCCTGGGCAGA
  	CGGACCCCCAACTACCAGAGCAAGAACCCCGGCGAGTACACC
  	GTGGGCAACTCCATGTTCTACGACGGCCCCCAGGTGGCCAACC
  	TGCAGAATGTGGATACCGGCTTCTGGCTGGACATGAGCAACCT
  	GAGCGACGTGGTGCTGTCCAGAGAGATCCAGACCGGCCTGAG
  	AGCCAGAGCCACCCTGGAAGAGTCCATGCCCATGCTGGAAAA
  	TCTGGAAGAGAGATTCCGGCGGCTGCAGGAAACCTGCGACGC
  	CGCCAGAACCGAGATCGAGGAAAGCGGCTGGACCCGGGAAAG
  	CGCCTCCAGAATGGAAGGCGACGAAGCCCAGGGCCCCAGCAG
  	AGTGCAGCAGGCCTTTCAGAGCTTCGTGAATGAGTGCAACAGC
  	ATCGAGTTCAGCTTCGGCTCCTTCGGCGAGCACGTGCGGGTGC
  	TGTGTGCCAGAGTGTCAAGAGGACTGGCCGCTGCCGGCGAGG
  	CCATCAGAAGATGCTTCAGCTGCTGCAAGGGCAGCACCCACA
  	GATACGCCCCCAGAGATGACCTGTCTCCTGAGGGCGCCTCTCT
  	GGCCGAAACCCTGGCCAGATTCGCCGACGACATGGGCATCGA
  	AAGAGGCGCCGACGGCACCTACGACATCCCCCTGGTGGACGA
  	TTGGAGAAGGGGCGTGCCATCCATCGAGGGCGAGGGCAGCGA
  	TAGCATCTACGAGATCATGATGCCCATCTACGAAGTGATGAAC
  	ATGGACCTGGAAACCCGGCGGAGCTTCGCCGTGCAGCAGGGC
  	CATTACCAGGACCCCAGAGCCAGCGACTACGACCTGCCTAGA
  	GCCTCCGATTACGATCTGCCCAGAAGCCCCTACCCCACCCCTC
  	CACTGCCTCCCAGATACCAGCTGCAGAACATGGATGTGGAAG
  	CCGGCTTTCGCGAGGCCGTGTACGCCTCTTTTGTGGCCGGCAT
  	GTACAACTACGTCGTGACCCAGCCCCAGGAACGGATCCCCAAT
  	AGCCAGCAGGTGGAAGGCATCCTGCGGGACATGCTGACCAAC
  	GGCAGCCACCACCATCACCACCAC
  Ct875_E_458_nIgK_cHis	ATGGAAACCCCTGCCCAGCTGCTGTTCCTGCTGCTGCTGTGGC	197
  	TGCCTGACACCACCGGCATGAGCATCAGAGGCGTGGGCGGCA
  	ACGGCAACAGCAGAATCCCTAGCCACAACGGCGACGGCAGCA
  	ACAGGCGGAGCCAGAACACCAAGGGCAACAACAAGGTGGAA
  	GATAGAGTGTGCAGCCTGTACAGCAGCCGGTCCAACGAGAAC
  	CGCGAGAGCCCTTATGCCGTGGTGGACGTGTCCAGCATGATCG
  	AGAGCACCCCCACCAGCGGCGAGACAACCAGAGCTAGTAGAG
  	GCGTGCTGAGCCGGTTCCAGAGGGGCCTCGTGCGGATTGCTGA
  	CAAAGTGCGGAGAGCCGTGCAGTGCGCTTGGAGCAGCGTGTC
  	CACAAGCAGAAGCAGCGCCACAAGAGCCGCCGAGAGCGGCA
  	GCTCTAGCAGAACAGCTAGAGGCGCCAGCAGCGGCTACAGAG
  	AGTACAGCCCTTCTGCCGCTCGGGGCCTGCGGCTGATGTTCAC
  	CGACTTTTGGCGGACCCGGGTGCTGAGACAGACCTCTCCTATG
  	GCCGGCGTGTTCGGCAACCTGGACGTGAACGAGGCCAGACTG
  	ATGGCCGCCTACACCAGCGAGTGTGCCGATCACCTGGAAGCC
  	AAAGAGCTGGCCGGACCTGACGGCGTGGCAGCCGCTAGAGAA
  	ATCGCCAAGAGATGGGAGAAGAGAGTGCGGGACCTGCAGGAC
  	AAGGGCGCTGCCAGAAAGCTGCTGAACGACCCCCTGGGCAGA
  	CGGACCCCCAACTACCAGAGCAAGAACCCCGGCGAGTACACC
  	GTGGGCAACTCCATGTTCTACGACGGCCCCCAGGTGGCCAACC
  	TGCAGAATGTGGATACCGGCTTCTGGCTGGACATGAGCAACCT
  	GAGCGACGTGGTGCTGTCCAGAGAGATCCAGACCGGCCTGAG
  	AGCCAGAGCCACCCTGGAAGAGTCCATGCCCATGCTGGAAAA
  	TCTGGAAGAGAGATTCCGGCGGCTGCAGGAAACCTGCGACGC
  	CGCCAGAACCGAGATCGAGGAAAGCGGCTGGACCCGGGAAAG
  	CGCCTCCAGAATGGAAGGCGACGAAGCCCAGGGCCCCAGCAG
  	AGTGCAGCAGGCCTTTCAGAGCTTCGTGAATGAGTGCAACAGC
  	ATCGAGTTCAGCTTCGGCTCCTTCGGCGAGCACGTGCGGGTGC
  	TGTGTGCCAGAGTGTCAAGAGGACTGGCCGCTGCCGGCGAGG
  	CCATCAGAAGATGCTTCAGCTGCTGCAAGGGCAGCACCCACA
  	GATACGCCCCCAGAGATGACCTGTCTCCTGAGGGCGCCTCTCT
  	GGCCGAAACCCTGGCCAGATTCGCCGACGACATGGGCATCGA
  	AAGAGGCGCCGACGGCACCTACGACATCCCCCTGGTGGACGA
  	TTGGAGAAGGGGCGTGCCATCCATCGAGGGCGAGGGCAGCCA
  	CCACCATCACCACCAC
  Ct875_E_574_NGM_nIgK	ATGGAAACCCCTGCCCAGCTGCTGTTCCTGCTGCTGCTGTGGC	198
  	TGCCTGACACCACCGGCATGAGCATCAGAGGCGTGGGCGGCA
  	ACGGCAACAGCAGAATCCCTAGCCACAACGGCGACGGCAGCA
  	ACAGGCGGAGCCAGAACACCAAGGGCAACAACAAGGTGGAA
  	GATAGAGTGTGCAGCCTGTACAGCAGCCGGTCCAACGAGAAC
  	CGCGAGAGCCCTTATGCCGTGGTGGACGTGTCCAGCATGATCG
  	AGAGCACCCCCACCAGCGGCGAGACAACCAGAGCTAGTAGAG
  	GCGTGCTGAGCCGGTTCCAGAGGGGCCTCGTGCGGATTGCTGA
  	CAAAGTGCGGAGAGCCGTGCAGTGCGCTTGGAGCAGCGTGTC
  	CACAAGCAGAAGCAGCGCCACAAGAGCCGCCGAGAGCGGCA
  	GCTCTAGCAGAACAGCTAGAGGCGCCAGCAGCGGCTACAGAG
  	AGTACAGCCCTTCTGCCGCTCGGGGCCTGCGGCTGATGTTCAC
  	CGACTTTTGGCGGACCCGGGTGCTGAGACAGACCTCTCCTATG
  	GCCGGCGTGTTCGGCAACCTGGACGTGAACGAGGCCAGACTG
  	ATGGCCGCCTACACCAGCGAGTGTGCCGATCACCTGGAAGCC
  	AAAGAGCTGGCCGGACCTGACGGCGTGGCAGCCGCTAGAGAA
  	ATCGCCAAGAGATGGGAGAAGAGAGTGCGGGACCTGCAGGAC
  	AAGGGCGCTGCCAGAAAGCTGCTGAACGACCCCCTGGGCAGA
  	CGGACCCCCAACTACCAGAGCAAGAACCCCGGCGAGTACACC
  	GTGGGCAACTCCATGTTCTACGACGGCCCCCAGGTGGCCAACC
  	TGCAGAATGTGGATACCGGCTTCTGGCTGGACATGCAGCACCT
  	GAGCGACGTGGTGCTGTCCAGAGAGATCCAGACCGGCCTGAG
  	AGCCAGAGCCACCCTGGAAGAGTCCATGCCCATGCTGGAAAA
  	TCTGGAAGAGAGATTCCGGCGGCTGCAGGAAACCTGCGACGC
  	CGCCAGAACCGAGATCGAGGAAAGCGGCTGGACCCGGGAAAG
  	CGCCTCCAGAATGGAAGGCGACGAAGCCCAGGGCCCCAGCAG
  	AGTGCAGCAGGCCTTTCAGAGCTTCGTGAATGAGTGCAACAGC
  	ATCGAGTTCAGCTTCGGCTCCTTCGGCGAGCACGTGCGGGTGC
  	TGTGTGCCAGAGTGTCAAGAGGACTGGCCGCTGCCGGCGAGG
  	CCATCAGAAGATGCTTCAGCTGCTGCAAGGGCAGCACCCACA
  	GATACGCCCCCAGAGATGACCTGTCTCCTGAGGGCGCCTCTCT
  	GGCCGAAACCCTGGCCAGATTCGCCGACGACATGGGCATCGA
  	AAGAGGCGCCGACGGCACCTACGACATCCCCCTGGTGGACGA
  	TTGGAGAAGGGGCGTGCCATCCATCGAGGGCGAGGGCAGCGA
  	TAGCATCTACGAGATCATGATGCCCATCTACGAAGTGATGAAC
  	ATGGACCTGGAAACCCGGCGGAGCTTCGCCGTGCAGCAGGGC
  	CATTACCAGGACCCCAGAGCCAGCGACTACGACCTGCCTAGA
  	GCCTCCGATTACGATCTGCCCAGAAGCCCCTACCCCACCCCTC
  	CACTGCCTCCCAGATACCAGCTGCAGAACATGGATGTGGAAG
  	CCGGCTTTCGCGAGGCCGTGTACGCCTCTTTTGTGGCCGGCAT
  	GTACAACTACGTCGTGACCCAGCCCCAGGAACGGATCCCCAAT
  	AGCCAGCAGGTGGAAGGCATCCTGCGGGACATGCTGACCAAC
  	GGCGAC
  Ct875_E_458_NGM_nIgK	ATGGAAACCCCTGCCCAGCTGCTGTTCCTGCTGCTGCTGTGGC	199
  	TGCCTGACACCACCGGCATGAGCATCAGAGGCGTGGGCGGCA
  	ACGGCAACAGCAGAATCCCTAGCCACAACGGCGACGGCAGCA
  	ACAGGCGGAGCCAGAACACCAAGGGCAACAACAAGGTGGAA
  	GATAGAGTGTGCAGCCTGTACAGCAGCCGGTCCAACGAGAAC
  	CGCGAGAGCCCTTATGCCGTGGTGGACGTGTCCAGCATGATCG
  	AGAGCACCCCCACCAGCGGCGAGACAACCAGAGCTAGTAGAG
  	GCGTGCTGAGCCGGTTCCAGAGGGGCCTCGTGCGGATTGCTGA
  	CAAAGTGCGGAGAGCCGTGCAGTGCGCTTGGAGCAGCGTGTC
  	CACAAGCAGAAGCAGCGCCACAAGAGCCGCCGAGAGCGGCA
  	GCTCTAGCAGAACAGCTAGAGGCGCCAGCAGCGGCTACAGAG
  	AGTACAGCCCTTCTGCCGCTCGGGGCCTGCGGCTGATGTTCAC
  	CGACTTTTGGCGGACCCGGGTGCTGAGACAGACCTCTCCTATG
  	GCCGGCGTGTTCGGCAACCTGGACGTGAACGAGGCCAGACTG
  	ATGGCCGCCTACACCAGCGAGTGTGCCGATCACCTGGAAGCC
  	AAAGAGCTGGCCGGACCTGACGGCGTGGCAGCCGCTAGAGAA
  	ATCGCCAAGAGATGGGAGAAGAGAGTGCGGGACCTGCAGGAC
  	AAGGGCGCTGCCAGAAAGCTGCTGAACGACCCCCTGGGCAGA
  	CGGACCCCCAACTACCAGAGCAAGAACCCCGGCGAGTACACC
  	GTGGGCAACTCCATGTTCTACGACGGCCCCCAGGTGGCCAACC
  	TGCAGAATGTGGATACCGGCTTCTGGCTGGACATGCAGCACCT
  	GAGCGACGTGGTGCTGTCCAGAGAGATCCAGACCGGCCTGAG
  	AGCCAGAGCCACCCTGGAAGAGTCCATGCCCATGCTGGAAAA
  	TCTGGAAGAGAGATTCCGGCGGCTGCAGGAAACCTGCGACGC
  	CGCCAGAACCGAGATCGAGGAAAGCGGCTGGACCCGGGAAAG
  	CGCCTCCAGAATGGAAGGCGACGAAGCCCAGGGCCCCAGCAG
  	AGTGCAGCAGGCCTTTCAGAGCTTCGTGAATGAGTGCAACAGC
  	ATCGAGTTCAGCTTCGGCTCCTTCGGCGAGCACGTGCGGGTGC
  	TGTGTGCCAGAGTGTCAAGAGGACTGGCCGCTGCCGGCGAGG
  	CCATCAGAAGATGCTTCAGCTGCTGCAAGGGCAGCACCCACA
  	GATACGCCCCCAGAGATGACCTGTCTCCTGAGGGCGCCTCTCT
  	GGCCGAAACCCTGGCCAGATTCGCCGACGACATGGGCATCGA
  	AAGAGGCGCCGACGGCACCTACGACATCCCCCTGGTGGACGA
  	TTGGAGAAGGGGCGTGCCATCCATCGAGGGCGAGGGCAGC
  Ct875_E_574_nIgK	ATGGAAACCCCTGCCCAGCTGCTGTTCCTGCTGCTGCTGTGGC	200
  	TGCCTGACACCACCGGCATGAGCATCAGAGGCGTGGGCGGCA
  	ACGGCAACAGCAGAATCCCTAGCCACAACGGCGACGGCAGCA
  	ACAGGCGGAGCCAGAACACCAAGGGCAACAACAAGGTGGAA
  	GATAGAGTGTGCAGCCTGTACAGCAGCCGGTCCAACGAGAAC
  	CGCGAGAGCCCTTATGCCGTGGTGGACGTGTCCAGCATGATCG
  	AGAGCACCCCCACCAGCGGCGAGACAACCAGAGCTAGTAGAG
  	GCGTGCTGAGCCGGTTCCAGAGGGGCCTCGTGCGGATTGCTGA
  	CAAAGTGCGGAGAGCCGTGCAGTGCGCTTGGAGCAGCGTGTC
  	CACAAGCAGAAGCAGCGCCACAAGAGCCGCCGAGAGCGGCA
  	GCTCTAGCAGAACAGCTAGAGGCGCCAGCAGCGGCTACAGAG
  	AGTACAGCCCTTCTGCCGCTCGGGGCCTGCGGCTGATGTTCAC
  	CGACTTTTGGCGGACCCGGGTGCTGAGACAGACCTCTCCTATG
  	GCCGGCGTGTTCGGCAACCTGGACGTGAACGAGGCCAGACTG
  	ATGGCCGCCTACACCAGCGAGTGTGCCGATCACCTGGAAGCC
  	AAAGAGCTGGCCGGACCTGACGGCGTGGCAGCCGCTAGAGAA
  	ATCGCCAAGAGATGGGAGAAGAGAGTGCGGGACCTGCAGGAC
  	AAGGGCGCTGCCAGAAAGCTGCTGAACGACCCCCTGGGCAGA
  	CGGACCCCCAACTACCAGAGCAAGAACCCCGGCGAGTACACC
  	GTGGGCAACTCCATGTTCTACGACGGCCCCCAGGTGGCCAACC
  	TGCAGAATGTGGATACCGGCTTCTGGCTGGACATGAGCAACCT
  	GAGCGACGTGGTGCTGTCCAGAGAGATCCAGACCGGCCTGAG
  	AGCCAGAGCCACCCTGGAAGAGTCCATGCCCATGCTGGAAAA
  	TCTGGAAGAGAGATTCCGGCGGCTGCAGGAAACCTGCGACGC
  	CGCCAGAACCGAGATCGAGGAAAGCGGCTGGACCCGGGAAAG
  	CGCCTCCAGAATGGAAGGCGACGAAGCCCAGGGCCCCAGCAG
  	AGTGCAGCAGGCCTTTCAGAGCTTCGTGAATGAGTGCAACAGC
  	ATCGAGTTCAGCTTCGGCTCCTTCGGCGAGCACGTGCGGGTGC
  	TGTGTGCCAGAGTGTCAAGAGGACTGGCCGCTGCCGGCGAGG
  	CCATCAGAAGATGCTTCAGCTGCTGCAAGGGCAGCACCCACA
  	GATACGCCCCCAGAGATGACCTGTCTCCTGAGGGCGCCTCTCT
  	GGCCGAAACCCTGGCCAGATTCGCCGACGACATGGGCATCGA
  	AAGAGGCGCCGACGGCACCTACGACATCCCCCTGGTGGACGA
  	TTGGAGAAGGGGCGTGCCATCCATCGAGGGCGAGGGCAGCGA
  	TAGCATCTACGAGATCATGATGCCCATCTACGAAGTGATGAAC
  	ATGGACCTGGAAACCCGGCGGAGCTTCGCCGTGCAGCAGGGC
  	CATTACCAGGACCCCAGAGCCAGCGACTACGACCTGCCTAGA
  	GCCTCCGATTACGATCTGCCCAGAAGCCCCTACCCCACCCCTC
  	CACTGCCTCCCAGATACCAGCTGCAGAACATGGATGTGGAAG
  	CCGGCTTTCGCGAGGCCGTGTACGCCTCTTTTGTGGCCGGCAT
  	GTACAACTACGTCGTGACCCAGCCCCAGGAACGGATCCCCAAT
  	AGCCAGCAGGTGGAAGGCATCCTGCGGGACATGCTGACCAAC
  	GGCAGC
  Ct875_E_458_nIgK	ATGGAAACCCCTGCCCAGCTGCTGTTCCTGCTGCTGCTGTGGC	201
  	TGCCTGACACCACCGGCATGAGCATCAGAGGCGTGGGCGGCA
  	ACGGCAACAGCAGAATCCCTAGCCACAACGGCGACGGCAGCA
  	ACAGGCGGAGCCAGAACACCAAGGGCAACAACAAGGTGGAA
  	GATAGAGTGTGCAGCCTGTACAGCAGCCGGTCCAACGAGAAC
  	CGCGAGAGCCCTTATGCCGTGGTGGACGTGTCCAGCATGATCG
  	AGAGCACCCCCACCAGCGGCGAGACAACCAGAGCTAGTAGAG
  	GCGTGCTGAGCCGGTTCCAGAGGGGCCTCGTGCGGATTGCTGA
  	CAAAGTGCGGAGAGCCGTGCAGTGCGCTTGGAGCAGCGTGTC
  	CACAAGCAGAAGCAGCGCCACAAGAGCCGCCGAGAGCGGCA
  	GCTCTAGCAGAACAGCTAGAGGCGCCAGCAGCGGCTACAGAG
  	AGTACAGCCCTTCTGCCGCTCGGGGCCTGCGGCTGATGTTCAC
  	CGACTTTTGGCGGACCCGGGTGCTGAGACAGACCTCTCCTATG
  	GCCGGCGTGTTCGGCAACCTGGACGTGAACGAGGCCAGACTG
  	ATGGCCGCCTACACCAGCGAGTGTGCCGATCACCTGGAAGCC
  	AAAGAGCTGGCCGGACCTGACGGCGTGGCAGCCGCTAGAGAA
  	ATCGCCAAGAGATGGGAGAAGAGAGTGCGGGACCTGCAGGAC
  	AAGGGCGCTGCCAGAAAGCTGCTGAACGACCCCCTGGGCAGA
  	CGGACCCCCAACTACCAGAGCAAGAACCCCGGCGAGTACACC
  	GTGGGCAACTCCATGTTCTACGACGGCCCCCAGGTGGCCAACC
  	TGCAGAATGTGGATACCGGCTTCTGGCTGGACATGAGCAACCT
  	GAGCGACGTGGTGCTGTCCAGAGAGATCCAGACCGGCCTGAG
  	AGCCAGAGCCACCCTGGAAGAGTCCATGCCCATGCTGGAAAA
  	TCTGGAAGAGAGATTCCGGCGGCTGCAGGAAACCTGCGACGC
  	CGCCAGAACCGAGATCGAGGAAAGCGGCTGGACCCGGGAAAG
  	CGCCTCCAGAATGGAAGGCGACGAAGCCCAGGGCCCCAGCAG
  	AGTGCAGCAGGCCTTTCAGAGCTTCGTGAATGAGTGCAACAGC
  	ATCGAGTTCAGCTTCGGCTCCTTCGGCGAGCACGTGCGGGTGC
  	TGTGTGCCAGAGTGTCAAGAGGACTGGCCGCTGCCGGCGAGG
  	CCATCAGAAGATGCTTCAGCTGCTGCAAGGGCAGCACCCACA
  	GATACGCCCCCAGAGATGACCTGTCTCCTGAGGGCGCCTCTCT
  	GGCCGAAACCCTGGCCAGATTCGCCGACGACATGGGCATCGA
  	AAGAGGCGCCGACGGCACCTACGACATCCCCCTGGTGGACGA
  	TTGGAGAAGGGGCGTGCCATCCATCGAGGGCGAGGGCAGC
  Ct875_E_1_574_NGM_nIgK_cHis	ATGGAAACCCCTGCTCAGCTGCTGTTCCTGCTGCTGCTGTGGC	202
  	TGCCTGATACCACCGGCATGTCTATCAGAGGCGTTGGCGGCAA
  	CGGCAACAGCAGAATCCCTAGCCATAATGGCGACGGCAGCAA
  	CAGGCGGAGCCAGAATACCAAGGGCAACAACAAGGTGGAAG
  	ATCGCGTGTGCAGCCTGTACAGCTCCAGAAGCAACGAGAACC
  	GCGAGAGCCCTTATGCCGTGGTGGATGTGTCCAGCATGATCGA
  	GAGCACCCCTACCAGCGGCGAGACAACAAGAGCTAGTAGAGG
  	CGTGCTGAGCCGGTTTCAGAGAGGCCTCGTTCGGATCGCTGAC
  	AAAGTGCGGAGAGCCGTGCAGTGTGCCTGGTCTAGTGTGTCCA
  	CAAGCAGAAGCAGCGCCACAAGAGCCGCCGAGAGCGGATCTT
  	CTAGCAGAACAGCTAGAGGCGCCAGCAGCGGCTACAGAGAGT
  	ATTCTCCATCTGCCGCCAGAGGCCTGCGGCTGATGTTTACAGA
  	TTTCTGGCGGACCCGGGTGCTGAGACAGACATCTCCTATGGCT
  	GGCGTGTTCGGCAACCTGGATGTGAATGAGGCCAGACTGATG
  	GCCGCCTACACAAGCGAATGTGCCGATCACCTGGAAGCCAAA
  	GAGCTGGCTGGACCTGACGGTGTTGCCGCCGCTAGAGAAATC
  	GCCAAGAGATGGGAGAAGAGAGTGCGGGACCTGCAGGATAA
  	GGGCGCTGCTAGAAAGCTGCTGAACGACCCTCTGGGCAGAAG
  	AACCCCTAACTACCAGAGCAAGAACCCCGGCGAGTACACCGT
  	GGGCAACTCCATGTTCTACGACGGACCCCAGGTGGCCAACCTG
  	CAGAATGTGGATACAGGCTTCTGGCTGGATATGCAGCACCTGA
  	GCGACGTGGTGCTGTCCAGAGAGATCCAGACAGGCCTGAGAG
  	CCAGAGCCACACTGGAAGAGTCCATGCCTATGCTCGAGAACCT
  	GGAAGAGAGATTCCGGCGGCTGCAAGAGACATGTGACGCCGC
  	CAGAACCGAGATCGAGGAAAGCGGCTGGACAAGAGAAAGCG
  	CCTCCAGAATGGAAGGCGACGAAGCCCAAGGACCTAGCAGAG
  	TGCAGCAGGCCTTCCAGAGCTTCGTGAACGAGTGCAACAGCAT
  	CGAGTTCAGCTTCGGCTCCTTCGGCGAACATGTGCGGGTGCTG
  	TGTGCCAGAGTTAGCAGAGGACTTGCTGCCGCTGGCGAGGCC
  	ATCAGAAGATGCTTCTCTTGCTGCAAGGGCAGCACCCACAGAT
  	ACGCCCCTAGAGATGATCTGAGCCCTGAGGGCGCTTCTCTGGC
  	CGAAACACTGGCCAGATTCGCCGACGATATGGGCATTGAAAG
  	AGGCGCCGACGGAACCTACGACATCCCTCTGGTGGACGATTG
  	GAGAAGGGGCGTGCCATCTATCGAAGGCGAGGGCAGCGATAG
  	CATCTACGAGATCATGATGCCCATCTACGAAGTGATGAACATG
  	GACCTGGAAACCCGGCGGAGCTTTGCCGTGCAGCAAGGCCAT
  	TACCAGGATCCTAGAGCCAGCGACTACGACCTGCCTAGAGCCT
  	CCGATTATGATCTGCCTCGGAGCCCCTATCCTACACCTCCTCTG
  	CCTCCAAGATACCAGCTTCAGAATATGGACGTGGAAGCCGGA
  	TTCCGCGAGGCCGTGTATGCTAGCTTTGTGGCCGGCATGTACA
  	ACTACGTGGTCACCCAGCCTCAAGAGAGAATCCCCAACAGCC
  	AGCAGGTCGAGGGCATCCTGAGAGATATGCTGACCAACGGCG
  	ACCACCACCATCACCATCAT
  Ct875_E_NGM_nFc	ATGGAAACCCCTGCTCAGCTGCTGTTCCTGCTGCTGCTGTGGC	203
  	TGCCTGATACAACCGGCGAGCCTAAGAGCTGCGACAAGACCC
  	ACACCTGTCCTCCATGTCCTGCTCCAGAACTGCTCGGCGGACC
  	TTCCGTGTTCCTGTTTCCTCCAAAGCCTAAGGACACCCTGATG
  	ATCAGCAGAACCCCTGAAGTGACCTGCGTGGTGGTGGATGTGT
  	CCCACGAGGATCCCGAAGTGAAGTTCAATTGGTACGTGGACG
  	GCGTGGAAGTGCACAACGCCAAGACCAAGCCTAGAGAGGAAC
  	AGTACAACAGCACCTACAGAGTGGTGTCCGTGCTGACCGTGCT
  	GCACCAGGATTGGCTGAACGGCAAAGAGTACAAGTGCAAGGT
  	GTCCAACAAGGCCCTGCCTGCTCCTATCGAGAAGACCATCAGC
  	AAGGCCAAGGGCCAGCCAAGAGAACCCCAGGTGTACACACTG
  	CCTCCAAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTG
  	ACCTGTCTGGTCAAGGGCTTCTACCCCTCCGATATCGCCGTGG
  	AATGGGAGAGCAATGGCCAGCCTGAGAACAACTACAAGACAA
  	CCCCTCCTGTGCTGGACAGCGACGGCTCATTCTTCCTGTACAG
  	CAAGCTGACAGTGGACAAGAGCAGATGGCAGCAGGGCAACGT
  	GTTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAATCACTAC
  	ACCCAGAAGTCCCTGTCTCTGAGCCCCGGCAAGATGAGCATCA
  	GAGGCGTTGGCGGCAACGGCAACAGCAGAATCCCTAGCCATA
  	ATGGCGACGGCAGCAACAGGCGGAGCCAGAATACCAAGGGCA
  	ACAACAAGGTGGAAGATCGCGTGTGCAGCCTGTACTCCAGCA
  	GAAGCAACGAGAACCGCGAGAGCCCTTATGCCGTGGTCGACG
  	TGTCCAGCATGATCGAGAGCACACCTACCAGCGGCGAGACAA
  	CCAGAGCTAGTAGAGGCGTGCTGAGCCGGTTTCAGAGAGGCC
  	TCGTTCGGATCGCTGACAAAGTGCGGAGAGCCGTGCAGTGTGC
  	CTGGTCTAGTGTGTCCACCAGCAGATCCTCTGCCACAAGAGCC
  	GCCGAGTCTGGCAGCTCTAGCAGAACAGCTAGAGGCGCCAGC
  	AGCGGCTACAGAGAGTATTCTCCATCTGCCGCCAGAGGCCTGC
  	GGCTGATGTTTACAGATTTCTGGCGGACCCGGGTGCTGAGACA
  	GACATCTCCTATGGCTGGCGTGTTCGGCAACCTGGATGTGAAT
  	GAGGCCAGACTGATGGCCGCCTACACAAGCGAATGTGCCGAT
  	CACCTGGAAGCCAAAGAGCTGGCTGGACCTGACGGTGTTGCC
  	GCCGCTAGAGAAATCGCCAAGAGATGGGAGAAGAGAGTGCGG
  	GACCTGCAGGATAAGGGCGCTGCTAGAAAGCTGCTGAACGAC
  	CCTCTGGGCAGAAGAACCCCTAACTACCAGAGCAAGAACCCC
  	GGCGAGTACACCGTGGGCAACTCCATGTTCTACGACGGACCTC
  	AGGTGGCCAACCTGCAGAATGTGGATACCGGCTTCTGGCTGGA
  	TATGCAGCACCTGTCCGATGTGGTGCTGTCCAGAGAGATCCAG
  	ACCGGCCTGAGAGCCAGAGCCACACTGGAAGAGTCCATGCCT
  	ATGCTCGAGAACCTGGAAGAGAGATTCCGGCGGCTGCAAGAG
  	ACATGTGACGCCGCCAGAACCGAGATCGAGGAAAGCGGCTGG
  	ACCAGAGAAAGCGCCTCCAGAATGGAAGGCGACGAAGCCCAA
  	GGACCTAGCAGAGTGCAGCAGGCCTTCCAGAGCTTCGTGAAC
  	GAGTGCAACAGCATCGAGTTCAGCTTCGGCTCCTTCGGCGAAC
  	ATGTGCGGGTGCTGTGTGCCAGAGTTAGCAGAGGACTTGCTGC
  	CGCTGGCGAGGCCATCAGAAGATGCTTCTCTTGCTGCAAGGGC
  	AGCACCCACAGATACGCCCCTAGAGATGATCTGAGCCCTGAG
  	GGCGCATCTCTGGCCGAAACACTGGCCAGATTCGCCGACGATA
  	TGGGCATTGAAAGAGGCGCCGACGGAACCTACGACATCCCTC
  	TGGTGGACGATTGGAGAAGGGGCGTGCCATCTATCGAAGGCG
  	AGGGCAGCGATAGCATCTACGAGATCATGATGCCCATCTACG
  	AAGTGATGAACATGGACCTGGAAACCCGGCGGAGCTTCGCTG
  	TTCAGCAGGGCCATTACCAGGATCCTAGAGCCAGCGACTACG
  	ACCTGCCTAGAGCCTCCGATTATGATCTGCCTCGGAGCCCCTA
  	TCCTACACCTCCACTGCCACCTAGATACCAGCTCCAGAATATG
  	GACGTGGAAGCCGGATTCCGCGAGGCCGTGTATGCTAGCTTTG
  	TGGCCGGCATGTACAACTACGTGGTCACCCAGCCTCAAGAGCG
  	GATCCCCAATTCTCAGCAGGTCGAGGGCATCCTGAGGGACATG
  	CTGACCAATGGCGACCAGACCTTCCGGGACCTGATGAAGAGA
  	TGGAACAGAGAGGTGGACAGAGAG
  Ct875_E_NGM_nFc_cHis	ATGGAAACCCCTGCTCAGCTGCTGTTCCTGCTGCTGCTGTGGC	204
  	TGCCTGATACAACCGGCGAGCCTAAGAGCTGCGACAAGACCC
  	ACACCTGTCCTCCATGTCCTGCTCCAGAACTGCTCGGCGGACC
  	TTCCGTGTTCCTGTTTCCTCCAAAGCCTAAGGACACCCTGATG
  	ATCAGCAGAACCCCTGAAGTGACCTGCGTGGTGGTGGATGTGT
  	CCCACGAGGATCCCGAAGTGAAGTTCAATTGGTACGTGGACG
  	GCGTGGAAGTGCACAACGCCAAGACCAAGCCTAGAGAGGAAC
  	AGTACAACAGCACCTACAGAGTGGTGTCCGTGCTGACCGTGCT
  	GCACCAGGATTGGCTGAACGGCAAAGAGTACAAGTGCAAGGT
  	GTCCAACAAGGCCCTGCCTGCTCCTATCGAGAAGACCATCAGC
  	AAGGCCAAGGGCCAGCCAAGAGAACCCCAGGTGTACACACTG
  	CCTCCAAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTG
  	ACCTGTCTGGTCAAGGGCTTCTACCCCTCCGATATCGCCGTGG
  	AATGGGAGAGCAATGGCCAGCCTGAGAACAACTACAAGACAA
  	CCCCTCCTGTGCTGGACAGCGACGGCTCATTCTTCCTGTACAG
  	CAAGCTGACAGTGGACAAGAGCAGATGGCAGCAGGGCAACGT
  	GTTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAATCACTAC
  	ACCCAGAAGTCCCTGTCTCTGAGCCCCGGCAAGATGAGCATCA
  	GAGGCGTTGGCGGCAACGGCAACAGCAGAATCCCTAGCCATA
  	ATGGCGACGGCAGCAACAGGCGGAGCCAGAATACCAAGGGCA
  	ACAACAAGGTGGAAGATCGCGTGTGCAGCCTGTACTCCAGCA
  	GAAGCAACGAGAACCGCGAGAGCCCTTATGCCGTGGTCGACG
  	TGTCCAGCATGATCGAGAGCACACCTACCAGCGGCGAGACAA
  	CCAGAGCTAGTAGAGGCGTGCTGAGCCGGTTTCAGAGAGGCC
  	TCGTTCGGATCGCTGACAAAGTGCGGAGAGCCGTGCAGTGTGC
  	CTGGTCTAGTGTGTCCACCAGCAGATCCTCTGCCACAAGAGCC
  	GCCGAGTCTGGCAGCTCTAGCAGAACAGCTAGAGGCGCCAGC
  	AGCGGCTACAGAGAGTATTCTCCATCTGCCGCCAGAGGCCTGC
  	GGCTGATGTTTACAGATTTCTGGCGGACCCGGGTGCTGAGACA
  	GACATCTCCTATGGCTGGCGTGTTCGGCAACCTGGATGTGAAT
  	GAGGCCAGACTGATGGCCGCCTACACAAGCGAATGTGCCGAT
  	CACCTGGAAGCCAAAGAGCTGGCTGGACCTGACGGTGTTGCC
  	GCCGCTAGAGAAATCGCCAAGAGATGGGAGAAGAGAGTGCGG
  	GACCTGCAGGATAAGGGCGCTGCTAGAAAGCTGCTGAACGAC
  	CCTCTGGGCAGAAGAACCCCTAACTACCAGAGCAAGAACCCC
  	GGCGAGTACACCGTGGGCAACTCCATGTTCTACGACGGACCTC
  	AGGTGGCCAACCTGCAGAATGTGGATACCGGCTTCTGGCTGGA
  	TATGCAGCACCTGTCCGATGTGGTGCTGTCCAGAGAGATCCAG
  	ACCGGCCTGAGAGCCAGAGCCACACTGGAAGAGTCCATGCCT
  	ATGCTCGAGAACCTGGAAGAGAGATTCCGGCGGCTGCAAGAG
  	ACATGTGACGCCGCCAGAACCGAGATCGAGGAAAGCGGCTGG
  	ACCAGAGAAAGCGCCTCCAGAATGGAAGGCGACGAAGCCCAA
  	GGACCTAGCAGAGTGCAGCAGGCCTTCCAGAGCTTCGTGAAC
  	GAGTGCAACAGCATCGAGTTCAGCTTCGGCTCCTTCGGCGAAC
  	ATGTGCGGGTGCTGTGTGCCAGAGTTAGCAGAGGACTTGCTGC
  	CGCTGGCGAGGCCATCAGAAGATGCTTCTCTTGCTGCAAGGGC
  	AGCACCCACAGATACGCCCCTAGAGATGATCTGAGCCCTGAG
  	GGCGCATCTCTGGCCGAAACACTGGCCAGATTCGCCGACGATA
  	TGGGCATTGAAAGAGGCGCCGACGGAACCTACGACATCCCTC
  	TGGTGGACGATTGGAGAAGGGGCGTGCCATCTATCGAAGGCG
  	AGGGCAGCGATAGCATCTACGAGATCATGATGCCCATCTACG
  	AAGTGATGAACATGGACCTGGAAACCCGGCGGAGCTTCGCTG
  	TTCAGCAGGGCCATTACCAGGATCCTAGAGCCAGCGACTACG
  	ACCTGCCTAGAGCCTCCGATTATGATCTGCCTCGGAGCCCCTA
  	TCCTACACCTCCACTGCCACCTAGATACCAGCTCCAGAATATG
  	GACGTGGAAGCCGGATTCCGCGAGGCCGTGTATGCTAGCTTTG
  	TGGCCGGCATGTACAACTACGTGGTCACCCAGCCTCAAGAGCG
  	GATCCCCAATTCTCAGCAGGTCGAGGGCATCCTGAGGGACATG
  	CTGACCAATGGCGACCAGACCTTCCGGGACCTGATGAAGAGA
  	TGGAACAGAGAGGTGGACCGCGAGCACCACCACCATCACCAT
  Ct875_E_1_574_NGM_nIgK_nGST	ATGGAAACCCCTGCTCAGCTGCTGTTCCTGCTGCTGCTGTGGC	205
  	TGCCTGATACCACAGGCATGAGCCCTATCCTCGGCTACTGGAA
  	GATCAAAGGCCTGGTGCAGCCCACCAGACTGCTGCTGGAATA
  	CCTGGAAGAGAAGTACGAGGAACACCTGTACGAGCGCGACGA
  	GGGCGATAAGTGGCGGAACAAGAAGTTCGAGCTGGGCCTCGA
  	GTTCCCCAACCTGCCTTACTACATCGACGGCGACGTGAAGCTG
  	ACCCAGAGCATGGCCATCATCCGGTATATCGCCGACAAGCAC
  	AACATGCTCGGCGGCTGCCCTAAAGAGCGGGCCGAGATTTCTA
  	TGCTGGAAGGCGCCGTGCTGGACATCAGATACGGCGTGTCCA
  	GAATCGCCTACAGCAAGGACTTCGAAACCCTGAAGGTGGACT
  	TCCTGAGCAAGCTGCCCGAGATGCTGAAGATGTTCGAGGACC
  	GGCTGTGCCACAAGACCTACCTGAATGGCGACCACGTGACAC
  	ACCCCGACTTCATGCTGTACGACGCCCTGGATGTGGTGCTGTA
  	CATGGACCCCATGTGCCTGGACGCCTTTCCAAAGCTCGTGTGC
  	TTCAAGAAGCGGATCGAGGCCATTCCTCAGATCGACAAGTACC
  	TGAAGTCCAGCAAGTATATCGCTTGGCCCCTGCAAGGCTGGCA
  	GGCCACATTTGGAGGCGGAGATCACCCTCCTAAGATGAGCATC
  	AGAGGCGTCGGCGGCAACGGCAACAGCAGAATCCCTTCTCAC
  	AATGGCGACGGCAGCAACAGGCGGAGCCAGAATACCAAGGGC
  	AACAACAAGGTGGAAGATCGCGTGTGCAGCCTGTACAGCTCC
  	AGAAGCAACGAGAACCGCGAGAGCCCTTATGCCGTGGTGGAT
  	GTGTCCAGCATGATCGAGAGCACCCCTACCAGCGGCGAGACA
  	ACAAGAGCTAGTAGAGGCGTGCTGAGCCGGTTTCAGAGAGGC
  	CTCGTTCGGATTGCCGACAAAGTGCGGAGAGCCGTGCAGTGTG
  	CTTGGAGCAGTGTGTCCACAAGCAGAAGCAGCGCCACAAGAG
  	CCGCCGAATCTGGCAGCTCTAGCAGAACAGCTAGAGGCGCCA
  	GCAGCGGCTACAGAGAGTATTCTCCATCTGCCGCCAGAGGCCT
  	GCGGCTGATGTTTACAGATTTCTGGCGGACCCGGGTGCTGAGA
  	CAGACATCTCCTATGGCTGGCGTGTTCGGCAACCTGGACGTGA
  	ACGAAGCCAGACTGATGGCCGCCTACACAAGCGAGTGTGCCG
  	ATCACCTGGAAGCCAAAGAACTGGCCGGACCTGATGGCGTGG
  	CAGCCGCTAGAGAAATCGCCAAGAGATGGGAGAAGAGAGTGC
  	GGGACCTGCAGGATAAGGGCGCTGCTAGAAAGCTGCTGAACG
  	ACCCTCTGGGCAGAAGAACCCCTAACTACCAGAGCAAGAACC
  	CCGGCGAGTACACCGTGGGCAACTCCATGTTCTACGACGGACC
  	CCAGGTGGCCAACCTGCAGAATGTGGATACAGGCTTCTGGCTG
  	GACATGCAGCACCTGTCTGATGTGGTCCTGAGCAGAGAGATCC
  	AGACCGGCCTGAGAGCCAGAGCCACACTGGAAGAGTCCATGC
  	CTATGCTCGAGAATCTGGAAGAACGGTTCAGACGGCTGCAAG
  	AGACATGCGACGCCGCCAGAACAGAGATCGAGGAAAGCGGCT
  	GGACCAGAGAAAGCGCCTCCAGAATGGAAGGCGACGAAGCCC
  	AAGGACCTAGCAGAGTGCAGCAGGCCTTCCAGAGCTTCGTGA
  	ACGAGTGCAACAGCATCGAGTTCAGCTTCGGCTCCTTCGGCGA
  	ACATGTGCGGGTGCTGTGTGCCAGAGTTAGCAGAGGACTTGCT
  	GCCGCTGGCGAGGCCATCAGAAGATGCTTCTCTTGCTGCAAGG
  	GCAGCACCCACAGATACGCCCCTAGAGATGATCTGAGCCCTG
  	AGGGCGCATCTCTGGCCGAAACACTGGCCAGATTTGCCGACG
  	ACATGGGCATTGAAAGAGGCGCCGACGGAACCTACGACATCC
  	CTCTGGTGGACGATTGGAGAAGGGGCGTGCCATCTATCGAAG
  	GCGAGGGCAGCGATAGCATCTACGAGATCATGATGCCCATCT
  	ACGAAGTGATGAACATGGACCTGGAAACCCGGCGGAGCTTTG
  	CCGTGCAACAGGGCCATTACCAGGATCCTAGAGCCAGCGACT
  	ACGACCTGCCTAGAGCCTCCGATTATGATCTGCCTCGGAGCCC
  	CTATCCTACACCTCCTCTGCCTCCAAGATACCAGCTTCAGAAT
  	ATGGACGTGGAAGCCGGATTCCGCGAGGCCGTGTATGCTAGCT
  	TTGTGGCCGGCATGTACAACTACGTGGTCACCCAGCCTCAAGA
  	GAGAATCCCCAACAGCCAGCAGGTCGAGGGCATCCTGAGAGA
  	TATGCTGACCAACGGCGAC
  Ct875_E_1_574_NGM_nIgK_nGST_cHis	ATGGAAACCCCTGCTCAGCTGCTGTTCCTGCTGCTGCTGTGGC	206
  	TGCCTGATACCACAGGCATGAGCCCTATCCTCGGCTACTGGAA
  	GATCAAAGGCCTGGTGCAGCCCACCAGACTGCTGCTGGAATA
  	CCTGGAAGAGAAGTACGAGGAACACCTGTACGAGCGCGACGA
  	GGGCGATAAGTGGCGGAACAAGAAGTTCGAGCTGGGCCTCGA
  	GTTCCCCAACCTGCCTTACTACATCGACGGCGACGTGAAGCTG
  	ACCCAGAGCATGGCCATCATCCGGTATATCGCCGACAAGCAC
  	AACATGCTCGGCGGCTGCCCTAAAGAGCGGGCCGAGATTTCTA
  	TGCTGGAAGGCGCCGTGCTGGACATCAGATACGGCGTGTCCA
  	GAATCGCCTACAGCAAGGACTTCGAAACCCTGAAGGTGGACT
  	TCCTGAGCAAGCTGCCCGAGATGCTGAAGATGTTCGAGGACC
  	GGCTGTGCCACAAGACCTACCTGAATGGCGACCACGTGACAC
  	ACCCCGACTTCATGCTGTACGACGCCCTGGATGTGGTGCTGTA
  	CATGGACCCCATGTGCCTGGACGCCTTTCCAAAGCTCGTGTGC
  	TTCAAGAAGCGGATCGAGGCCATTCCTCAGATCGACAAGTACC
  	TGAAGTCCAGCAAGTATATCGCTTGGCCCCTGCAAGGCTGGCA
  	GGCCACATTTGGAGGCGGAGATCACCCTCCTAAGATGAGCATC
  	AGAGGCGTCGGCGGCAACGGCAACAGCAGAATCCCTTCTCAC
  	AATGGCGACGGCAGCAACAGGCGGAGCCAGAATACCAAGGGC
  	AACAACAAGGTGGAAGATCGCGTGTGCAGCCTGTACAGCTCC
  	AGAAGCAACGAGAACCGCGAGAGCCCTTATGCCGTGGTGGAT
  	GTGTCCAGCATGATCGAGAGCACCCCTACCAGCGGCGAGACA
  	ACAAGAGCTAGTAGAGGCGTGCTGAGCCGGTTTCAGAGAGGC
  	CTCGTTCGGATTGCCGACAAAGTGCGGAGAGCCGTGCAGTGTG
  	CTTGGAGCAGTGTGTCCACAAGCAGAAGCAGCGCCACAAGAG
  	CCGCCGAATCTGGCAGCTCTAGCAGAACAGCTAGAGGCGCCA
  	GCAGCGGCTACAGAGAGTATTCTCCATCTGCCGCCAGAGGCCT
  	GCGGCTGATGTTTACAGATTTCTGGCGGACCCGGGTGCTGAGA
  	CAGACATCTCCTATGGCTGGCGTGTTCGGCAACCTGGACGTGA
  	ACGAAGCCAGACTGATGGCCGCCTACACAAGCGAGTGTGCCG
  	ATCACCTGGAAGCCAAAGAACTGGCCGGACCTGATGGCGTGG
  	CAGCCGCTAGAGAAATCGCCAAGAGATGGGAGAAGAGAGTGC
  	GGGACCTGCAGGATAAGGGCGCTGCTAGAAAGCTGCTGAACG
  	ACCCTCTGGGCAGAAGAACCCCTAACTACCAGAGCAAGAACC
  	CCGGCGAGTACACCGTGGGCAACTCCATGTTCTACGACGGACC
  	CCAGGTGGCCAACCTGCAGAATGTGGATACAGGCTTCTGGCTG
  	GACATGCAGCACCTGTCTGATGTGGTCCTGAGCAGAGAGATCC
  	AGACCGGCCTGAGAGCCAGAGCCACACTGGAAGAGTCCATGC
  	CTATGCTCGAGAATCTGGAAGAACGGTTCAGACGGCTGCAAG
  	AGACATGCGACGCCGCCAGAACAGAGATCGAGGAAAGCGGCT
  	GGACCAGAGAAAGCGCCTCCAGAATGGAAGGCGACGAAGCCC
  	AAGGACCTAGCAGAGTGCAGCAGGCCTTCCAGAGCTTCGTGA
  	ACGAGTGCAACAGCATCGAGTTCAGCTTCGGCTCCTTCGGCGA
  	ACATGTGCGGGTGCTGTGTGCCAGAGTTAGCAGAGGACTTGCT
  	GCCGCTGGCGAGGCCATCAGAAGATGCTTCTCTTGCTGCAAGG
  	GCAGCACCCACAGATACGCCCCTAGAGATGATCTGAGCCCTG
  	AGGGCGCATCTCTGGCCGAAACACTGGCCAGATTTGCCGACG
  	ACATGGGCATTGAAAGAGGCGCCGACGGAACCTACGACATCC
  	CTCTGGTGGACGATTGGAGAAGGGGCGTGCCATCTATCGAAG
  	GCGAGGGCAGCGATAGCATCTACGAGATCATGATGCCCATCT
  	ACGAAGTGATGAACATGGACCTGGAAACCCGGCGGAGCTTTG
  	CCGTGCAACAGGGCCATTACCAGGATCCTAGAGCCAGCGACT
  	ACGACCTGCCTAGAGCCTCCGATTATGATCTGCCTCGGAGCCC
  	CTATCCTACACCTCCTCTGCCTCCAAGATACCAGCTTCAGAAT
  	ATGGACGTGGAAGCCGGATTCCGCGAGGCCGTGTATGCTAGCT
  	TTGTGGCCGGCATGTACAACTACGTGGTCACCCAGCCTCAAGA
  	GAGAATCCCCAACAGCCAGCAGGTCGAGGGCATCCTGAGAGA
  	TATGCTGACCAACGGCGACCACCACCATCACCATCAT
  Ct875_E_NGM_nIgK_nGST	ATGGAAACCCCTGCTCAGCTGCTGTTCCTGCTGCTGCTGTGGC	207
  	TGCCTGATACCACAGGCATGAGCCCTATCCTCGGCTACTGGAA
  	GATCAAAGGCCTGGTGCAGCCCACCAGACTGCTGCTGGAATA
  	CCTGGAAGAGAAGTACGAGGAACACCTGTACGAGCGCGACGA
  	GGGCGATAAGTGGCGGAACAAGAAGTTCGAGCTGGGCCTCGA
  	GTTCCCCAACCTGCCTTACTACATCGACGGCGACGTGAAGCTG
  	ACCCAGAGCATGGCCATCATCCGGTATATCGCCGACAAGCAC
  	AACATGCTCGGCGGCTGCCCTAAAGAGCGGGCCGAGATTTCTA
  	TGCTGGAAGGCGCCGTGCTGGACATCAGATACGGCGTGTCCA
  	GAATCGCCTACAGCAAGGACTTCGAAACCCTGAAGGTGGACT
  	TCCTGAGCAAGCTGCCCGAGATGCTGAAGATGTTCGAGGACC
  	GGCTGTGCCACAAGACCTACCTGAATGGCGACCACGTGACAC
  	ACCCCGACTTCATGCTGTACGACGCCCTGGATGTGGTGCTGTA
  	CATGGACCCCATGTGCCTGGACGCCTTTCCAAAGCTCGTGTGC
  	TTCAAGAAGCGGATCGAGGCCATTCCTCAGATCGACAAGTACC
  	TGAAGTCCAGCAAGTATATCGCTTGGCCCCTGCAAGGCTGGCA
  	GGCCACATTTGGAGGCGGAGATCACCCTCCTAAGATGAGCATC
  	AGAGGCGTCGGCGGCAACGGCAACAGCAGAATCCCTTCTCAC
  	AATGGCGACGGCAGCAACAGGCGGAGCCAGAATACCAAGGGC
  	AACAACAAGGTGGAAGATCGCGTGTGCAGCCTGTACAGCTCC
  	AGAAGCAACGAGAACCGCGAGAGCCCTTATGCCGTGGTGGAT
  	GTGTCCAGCATGATCGAGAGCACCCCTACCAGCGGCGAGACA
  	ACAAGAGCTAGTAGAGGCGTGCTGAGCCGGTTTCAGAGAGGC
  	CTCGTTCGGATTGCCGACAAAGTGCGGAGAGCCGTGCAGTGTG
  	CTTGGAGCAGTGTGTCCACAAGCAGAAGCAGCGCCACAAGAG
  	CCGCCGAATCTGGCAGCTCTAGCAGAACAGCTAGAGGCGCCA
  	GCAGCGGCTACAGAGAGTATTCTCCATCTGCCGCCAGAGGCCT
  	GCGGCTGATGTTTACAGATTTCTGGCGGACCCGGGTGCTGAGA
  	CAGACATCTCCTATGGCTGGCGTGTTCGGCAACCTGGACGTGA
  	ACGAAGCCAGACTGATGGCCGCCTACACAAGCGAGTGTGCCG
  	ATCACCTGGAAGCCAAAGAACTGGCCGGACCTGATGGCGTGG
  	CAGCCGCTAGAGAAATCGCCAAGAGATGGGAGAAGAGAGTGC
  	GGGACCTGCAGGATAAGGGCGCTGCTAGAAAGCTGCTGAACG
  	ACCCTCTGGGCAGAAGAACCCCTAACTACCAGAGCAAGAACC
  	CCGGCGAGTACACCGTGGGCAACTCCATGTTCTACGACGGACC
  	CCAGGTGGCCAACCTGCAGAATGTGGATACAGGCTTCTGGCTG
  	GACATGCAGCACCTGTCTGATGTGGTCCTGAGCAGAGAGATCC
  	AGACCGGCCTGAGAGCCAGAGCCACACTGGAAGAGTCCATGC
  	CTATGCTCGAGAATCTGGAAGAACGGTTCAGACGGCTGCAAG
  	AGACATGCGACGCCGCCAGAACAGAGATCGAGGAAAGCGGCT
  	GGACCAGAGAAAGCGCCTCCAGAATGGAAGGCGACGAAGCCC
  	AAGGACCTAGCAGAGTGCAGCAGGCCTTCCAGAGCTTCGTGA
  	ACGAGTGCAACAGCATCGAGTTCAGCTTCGGCTCCTTCGGCGA
  	ACATGTGCGGGTGCTGTGTGCCAGAGTTAGCAGAGGACTTGCT
  	GCCGCTGGCGAGGCCATCAGAAGATGCTTCTCTTGCTGCAAGG
  	GCAGCACCCACAGATACGCCCCTAGAGATGATCTGAGCCCTG
  	AGGGCGCATCTCTGGCCGAAACACTGGCCAGATTTGCCGACG
  	ACATGGGCATTGAAAGAGGCGCCGACGGAACCTACGACATCC
  	CTCTGGTGGACGATTGGAGAAGGGGCGTGCCATCTATCGAAG
  	GCGAGGGCAGCGATAGCATCTACGAGATCATGATGCCCATCT
  	ACGAAGTGATGAACATGGACCTGGAAACCCGGCGGAGCTTTG
  	CCGTGCAACAGGGCCATTACCAGGATCCTAGAGCCAGCGACT
  	ACGACCTGCCTAGAGCCTCCGATTATGATCTGCCTCGGAGCCC
  	CTATCCTACACCTCCTCTGCCTCCAAGATACCAGCTTCAGAAT
  	ATGGACGTGGAAGCCGGATTCCGCGAGGCCGTGTATGCTAGCT
  	TTGTGGCCGGCATGTACAACTACGTGGTCACCCAGCCTCAAGA
  	GAGAATCCCCAACAGCCAGCAGGTCGAGGGCATCCTGAGAGA
  	TATGCTGACCAACGGCGACCAGACCTTCCGCGACCTGATGAAG
  	AGATGGAACAGAGAGGTGGACAGAGAG
  Ct875_E_NGM_nIgK_nGST_cHis	ATGGAAACCCCTGCTCAGCTGCTGTTCCTGCTGCTGCTGTGGC	208
  	TGCCTGATACCACAGGCATGAGCCCTATCCTCGGCTACTGGAA
  	GATCAAAGGCCTGGTGCAGCCCACCAGACTGCTGCTGGAATA
  	CCTGGAAGAGAAGTACGAGGAACACCTGTACGAGCGCGACGA
  	GGGCGATAAGTGGCGGAACAAGAAGTTCGAGCTGGGCCTCGA
  	GTTCCCCAACCTGCCTTACTACATCGACGGCGACGTGAAGCTG
  	ACCCAGAGCATGGCCATCATCCGGTATATCGCCGACAAGCAC
  	AACATGCTCGGCGGCTGCCCTAAAGAGCGGGCCGAGATTTCTA
  	TGCTGGAAGGCGCCGTGCTGGACATCAGATACGGCGTGTCCA
  	GAATCGCCTACAGCAAGGACTTCGAAACCCTGAAGGTGGACT
  	TCCTGAGCAAGCTGCCCGAGATGCTGAAGATGTTCGAGGACC
  	GGCTGTGCCACAAGACCTACCTGAATGGCGACCACGTGACAC
  	ACCCCGACTTCATGCTGTACGACGCCCTGGATGTGGTGCTGTA
  	CATGGACCCCATGTGCCTGGACGCCTTTCCAAAGCTCGTGTGC
  	TTCAAGAAGCGGATCGAGGCCATTCCTCAGATCGACAAGTACC
  	TGAAGTCCAGCAAGTATATCGCTTGGCCCCTGCAAGGCTGGCA
  	GGCCACATTTGGAGGCGGAGATCACCCTCCTAAGATGAGCATC
  	AGAGGCGTCGGCGGCAACGGCAACAGCAGAATCCCTTCTCAC
  	AATGGCGACGGCAGCAACAGGCGGAGCCAGAATACCAAGGGC
  	AACAACAAGGTGGAAGATCGCGTGTGCAGCCTGTACAGCTCC
  	AGAAGCAACGAGAACCGCGAGAGCCCTTATGCCGTGGTGGAT
  	GTGTCCAGCATGATCGAGAGCACCCCTACCAGCGGCGAGACA
  	ACAAGAGCTAGTAGAGGCGTGCTGAGCCGGTTTCAGAGAGGC
  	CTCGTTCGGATTGCCGACAAAGTGCGGAGAGCCGTGCAGTGTG
  	CTTGGAGCAGTGTGTCCACAAGCAGAAGCAGCGCCACAAGAG
  	CCGCCGAATCTGGCAGCTCTAGCAGAACAGCTAGAGGCGCCA
  	GCAGCGGCTACAGAGAGTATTCTCCATCTGCCGCCAGAGGCCT
  	GCGGCTGATGTTTACAGATTTCTGGCGGACCCGGGTGCTGAGA
  	CAGACATCTCCTATGGCTGGCGTGTTCGGCAACCTGGACGTGA
  	ACGAAGCCAGACTGATGGCCGCCTACACAAGCGAGTGTGCCG
  	ATCACCTGGAAGCCAAAGAACTGGCCGGACCTGATGGCGTGG
  	CAGCCGCTAGAGAAATCGCCAAGAGATGGGAGAAGAGAGTGC
  	GGGACCTGCAGGATAAGGGCGCTGCTAGAAAGCTGCTGAACG
  	ACCCTCTGGGCAGAAGAACCCCTAACTACCAGAGCAAGAACC
  	CCGGCGAGTACACCGTGGGCAACTCCATGTTCTACGACGGACC
  	CCAGGTGGCCAACCTGCAGAATGTGGATACAGGCTTCTGGCTG
  	GACATGCAGCACCTGTCTGATGTGGTCCTGAGCAGAGAGATCC
  	AGACCGGCCTGAGAGCCAGAGCCACACTGGAAGAGTCCATGC
  	CTATGCTCGAGAATCTGGAAGAACGGTTCAGACGGCTGCAAG
  	AGACATGCGACGCCGCCAGAACAGAGATCGAGGAAAGCGGCT
  	GGACCAGAGAAAGCGCCTCCAGAATGGAAGGCGACGAAGCCC
  	AAGGACCTAGCAGAGTGCAGCAGGCCTTCCAGAGCTTCGTGA
  	ACGAGTGCAACAGCATCGAGTTCAGCTTCGGCTCCTTCGGCGA
  	ACATGTGCGGGTGCTGTGTGCCAGAGTTAGCAGAGGACTTGCT
  	GCCGCTGGCGAGGCCATCAGAAGATGCTTCTCTTGCTGCAAGG
  	GCAGCACCCACAGATACGCCCCTAGAGATGATCTGAGCCCTG
  	AGGGCGCATCTCTGGCCGAAACACTGGCCAGATTTGCCGACG
  	ACATGGGCATTGAAAGAGGCGCCGACGGAACCTACGACATCC
  	CTCTGGTGGACGATTGGAGAAGGGGCGTGCCATCTATCGAAG
  	GCGAGGGCAGCGATAGCATCTACGAGATCATGATGCCCATCT
  	ACGAAGTGATGAACATGGACCTGGAAACCCGGCGGAGCTTTG
  	CCGTGCAACAGGGCCATTACCAGGATCCTAGAGCCAGCGACT
  	ACGACCTGCCTAGAGCCTCCGATTATGATCTGCCTCGGAGCCC
  	CTATCCTACACCTCCTCTGCCTCCAAGATACCAGCTTCAGAAT
  	ATGGACGTGGAAGCCGGATTCCGCGAGGCCGTGTATGCTAGCT
  	TTGTGGCCGGCATGTACAACTACGTGGTCACCCAGCCTCAAGA
  	GAGAATCCCCAACAGCCAGCAGGTCGAGGGCATCCTGAGAGA
  	TATGCTGACCAACGGCGACCAGACCTTCCGCGACCTGATGAAG
  	AGATGGAACAGAGAGGTGGACAGAGAGCACCACCACCATCAC
  	CAT
  Ct875_E_1_458_NGM_nIgK_nGST	ATGGAAACCCCTGCTCAGCTGCTGTTCCTGCTGCTGCTGTGGC	209
  	TGCCTGATACCACAGGCATGAGCCCTATCCTCGGCTACTGGAA
  	GATCAAAGGCCTGGTGCAGCCCACCAGACTGCTGCTGGAATA
  	CCTGGAAGAGAAGTACGAGGAACACCTGTACGAGCGCGACGA
  	GGGCGATAAGTGGCGGAACAAGAAGTTCGAGCTGGGCCTCGA
  	GTTCCCCAACCTGCCTTACTACATCGACGGCGACGTGAAGCTG
  	ACCCAGAGCATGGCCATCATCCGGTATATCGCCGACAAGCAC
  	AACATGCTCGGCGGCTGCCCTAAAGAGCGGGCCGAGATTTCTA
  	TGCTGGAAGGCGCCGTGCTGGACATCAGATACGGCGTGTCCA
  	GAATCGCCTACAGCAAGGACTTCGAAACCCTGAAGGTGGACT
  	TCCTGAGCAAGCTGCCCGAGATGCTGAAGATGTTCGAGGACC
  	GGCTGTGCCACAAGACCTACCTGAATGGCGACCACGTGACAC
  	ACCCCGACTTCATGCTGTACGACGCCCTGGATGTGGTGCTGTA
  	CATGGACCCCATGTGCCTGGACGCCTTTCCAAAGCTCGTGTGC
  	TTCAAGAAGCGGATCGAGGCCATTCCTCAGATCGACAAGTACC
  	TGAAGTCCAGCAAGTATATCGCTTGGCCCCTGCAAGGCTGGCA
  	GGCCACATTTGGAGGCGGAGATCACCCTCCTAAGATGAGCATC
  	AGAGGCGTCGGCGGCAACGGCAACAGCAGAATCCCTTCTCAC
  	AATGGCGACGGCAGCAACAGGCGGAGCCAGAATACCAAGGGC
  	AACAACAAGGTGGAAGATCGCGTGTGCAGCCTGTACAGCTCC
  	AGAAGCAACGAGAACCGCGAGAGCCCTTATGCCGTGGTGGAT
  	GTGTCCAGCATGATCGAGAGCACCCCTACCAGCGGCGAGACA
  	ACAAGAGCTAGTAGAGGCGTGCTGAGCCGGTTTCAGAGAGGC
  	CTCGTTCGGATTGCCGACAAAGTGCGGAGAGCCGTGCAGTGTG
  	CTTGGAGCAGTGTGTCCACAAGCAGAAGCAGCGCCACAAGAG
  	CCGCCGAATCTGGCAGCTCTAGCAGAACAGCTAGAGGCGCCA
  	GCAGCGGCTACAGAGAGTATTCTCCATCTGCCGCCAGAGGCCT
  	GCGGCTGATGTTTACAGATTTCTGGCGGACCCGGGTGCTGAGA
  	CAGACATCTCCTATGGCTGGCGTGTTCGGCAACCTGGACGTGA
  	ACGAAGCCAGACTGATGGCCGCCTACACAAGCGAGTGTGCCG
  	ATCACCTGGAAGCCAAAGAACTGGCCGGACCTGATGGCGTGG
  	CAGCCGCTAGAGAAATCGCCAAGAGATGGGAGAAGAGAGTGC
  	GGGACCTGCAGGATAAGGGCGCTGCTAGAAAGCTGCTGAACG
  	ACCCTCTGGGCAGAAGAACCCCTAACTACCAGAGCAAGAACC
  	CCGGCGAGTACACCGTGGGCAACTCCATGTTCTACGACGGACC
  	CCAGGTGGCCAACCTGCAGAATGTGGATACAGGCTTCTGGCTG
  	GACATGCAGCACCTGTCTGATGTGGTCCTGAGCAGAGAGATCC
  	AGACCGGCCTGAGAGCCAGAGCCACACTGGAAGAGTCCATGC
  	CTATGCTCGAGAATCTGGAAGAACGGTTCAGACGGCTGCAAG
  	AGACATGCGACGCCGCCAGAACAGAGATCGAGGAAAGCGGCT
  	GGACCAGAGAAAGCGCCTCCAGAATGGAAGGCGACGAAGCCC
  	AAGGACCTAGCAGAGTGCAGCAGGCCTTCCAGAGCTTCGTGA
  	ACGAGTGCAACAGCATCGAGTTCAGCTTCGGCTCCTTCGGCGA
  	ACATGTGCGGGTGCTGTGTGCCAGAGTTAGCAGAGGACTTGCT
  	GCCGCTGGCGAGGCCATCAGAAGATGCTTCTCTTGCTGCAAGG
  	GCAGCACCCACAGATACGCCCCTAGAGATGATCTGAGCCCTG
  	AGGGCGCATCTCTGGCCGAAACACTGGCCAGATTTGCCGACG
  	ACATGGGCATTGAAAGAGGCGCCGACGGAACCTACGACATCC
  	CTCTGGTGGACGATTGGAGAAGGGGCGTGCCATCTATCGAAG
  	GCGAGGGATCT
  Ct875_E_1_458_NGM_nIgK_nGST_cHis	ATGGAAACCCCTGCTCAGCTGCTGTTCCTGCTGCTGCTGTGGC	210
  	TGCCTGATACCACAGGCATGAGCCCTATCCTCGGCTACTGGAA
  	GATCAAAGGCCTGGTGCAGCCCACCAGACTGCTGCTGGAATA
  	CCTGGAAGAGAAGTACGAGGAACACCTGTACGAGCGCGACGA
  	GGGCGATAAGTGGCGGAACAAGAAGTTCGAGCTGGGCCTCGA
  	GTTCCCCAACCTGCCTTACTACATCGACGGCGACGTGAAGCTG
  	ACCCAGAGCATGGCCATCATCCGGTATATCGCCGACAAGCAC
  	AACATGCTCGGCGGCTGCCCTAAAGAGCGGGCCGAGATTTCTA
  	TGCTGGAAGGCGCCGTGCTGGACATCAGATACGGCGTGTCCA
  	GAATCGCCTACAGCAAGGACTTCGAAACCCTGAAGGTGGACT
  	TCCTGAGCAAGCTGCCCGAGATGCTGAAGATGTTCGAGGACC
  	GGCTGTGCCACAAGACCTACCTGAATGGCGACCACGTGACAC
  	ACCCCGACTTCATGCTGTACGACGCCCTGGATGTGGTGCTGTA
  	CATGGACCCCATGTGCCTGGACGCCTTTCCAAAGCTCGTGTGC
  	TTCAAGAAGCGGATCGAGGCCATTCCTCAGATCGACAAGTACC
  	TGAAGTCCAGCAAGTATATCGCTTGGCCCCTGCAAGGCTGGCA
  	GGCCACATTTGGAGGCGGAGATCACCCTCCTAAGATGAGCATC
  	AGAGGCGTCGGCGGCAACGGCAACAGCAGAATCCCTTCTCAC
  	AATGGCGACGGCAGCAACAGGCGGAGCCAGAATACCAAGGGC
  	AACAACAAGGTGGAAGATCGCGTGTGCAGCCTGTACAGCTCC
  	AGAAGCAACGAGAACCGCGAGAGCCCTTATGCCGTGGTGGAT
  	GTGTCCAGCATGATCGAGAGCACCCCTACCAGCGGCGAGACA
  	ACAAGAGCTAGTAGAGGCGTGCTGAGCCGGTTTCAGAGAGGC
  	CTCGTTCGGATTGCCGACAAAGTGCGGAGAGCCGTGCAGTGTG
  	CTTGGAGCAGTGTGTCCACAAGCAGAAGCAGCGCCACAAGAG
  	CCGCCGAATCTGGCAGCTCTAGCAGAACAGCTAGAGGCGCCA
  	GCAGCGGCTACAGAGAGTATTCTCCATCTGCCGCCAGAGGCCT
  	GCGGCTGATGTTTACAGATTTCTGGCGGACCCGGGTGCTGAGA
  	CAGACATCTCCTATGGCTGGCGTGTTCGGCAACCTGGACGTGA
  	ACGAAGCCAGACTGATGGCCGCCTACACAAGCGAGTGTGCCG
  	ATCACCTGGAAGCCAAAGAACTGGCCGGACCTGATGGCGTGG
  	CAGCCGCTAGAGAAATCGCCAAGAGATGGGAGAAGAGAGTGC
  	GGGACCTGCAGGATAAGGGCGCTGCTAGAAAGCTGCTGAACG
  	ACCCTCTGGGCAGAAGAACCCCTAACTACCAGAGCAAGAACC
  	CCGGCGAGTACACCGTGGGCAACTCCATGTTCTACGACGGACC
  	CCAGGTGGCCAACCTGCAGAATGTGGATACAGGCTTCTGGCTG
  	GACATGCAGCACCTGTCTGATGTGGTCCTGAGCAGAGAGATCC
  	AGACCGGCCTGAGAGCCAGAGCCACACTGGAAGAGTCCATGC
  	CTATGCTCGAGAATCTGGAAGAACGGTTCAGACGGCTGCAAG
  	AGACATGCGACGCCGCCAGAACAGAGATCGAGGAAAGCGGCT
  	GGACCAGAGAAAGCGCCTCCAGAATGGAAGGCGACGAAGCCC
  	AAGGACCTAGCAGAGTGCAGCAGGCCTTCCAGAGCTTCGTGA
  	ACGAGTGCAACAGCATCGAGTTCAGCTTCGGCTCCTTCGGCGA
  	ACATGTGCGGGTGCTGTGTGCCAGAGTTAGCAGAGGACTTGCT
  	GCCGCTGGCGAGGCCATCAGAAGATGCTTCTCTTGCTGCAAGG
  	GCAGCACCCACAGATACGCCCCTAGAGATGATCTGAGCCCTG
  	AGGGCGCATCTCTGGCCGAAACACTGGCCAGATTTGCCGACG
  	ACATGGGCATTGAAAGAGGCGCCGACGGAACCTACGACATCC
  	CTCTGGTGGACGATTGGAGAAGGGGCGTGCCATCTATCGAAG
  	GCGAGGGCTCTCACCACCACCATCACCAT
  Ct875_E_1_458_NGM_nIgK	ATGGAAACCCCTGCTCAGCTGCTGTTCCTGCTGCTGCTGTGGC	211
  	TGCCTGATACCACCGGCATGTCTATCAGAGGCGTTGGCGGCAA
  	CGGCAACAGCAGAATCCCTAGCCATAATGGCGACGGCAGCAA
  	CAGGCGGAGCCAGAATACCAAGGGCAACAACAAGGTGGAAG
  	ATCGCGTGTGCAGCCTGTACAGCTCCAGAAGCAACGAGAACC
  	GCGAGAGCCCTTATGCCGTGGTGGATGTGTCCAGCATGATCGA
  	GAGCACCCCTACCAGCGGCGAGACAACAAGAGCTAGTAGAGG
  	CGTGCTGAGCCGGTTTCAGAGAGGCCTCGTTCGGATCGCTGAC
  	AAAGTGCGGAGAGCCGTGCAGTGTGCCTGGTCTAGTGTGTCCA
  	CAAGCAGAAGCAGCGCCACAAGAGCCGCCGAGAGCGGATCTT
  	CTAGCAGAACAGCTAGAGGCGCCAGCAGCGGCTACAGAGAGT
  	ATTCTCCATCTGCCGCCAGAGGCCTGCGGCTGATGTTTACAGA
  	TTTCTGGCGGACCCGGGTGCTGAGACAGACATCTCCTATGGCT
  	GGCGTGTTCGGCAACCTGGATGTGAATGAGGCCAGACTGATG
  	GCCGCCTACACAAGCGAATGTGCCGATCACCTGGAAGCCAAA
  	GAGCTGGCTGGACCTGACGGTGTTGCCGCCGCTAGAGAAATC
  	GCCAAGAGATGGGAGAAGAGAGTGCGGGACCTGCAGGATAA
  	GGGCGCTGCTAGAAAGCTGCTGAACGACCCTCTGGGCAGAAG
  	AACCCCTAACTACCAGAGCAAGAACCCCGGCGAGTACACCGT
  	GGGCAACTCCATGTTCTACGACGGACCCCAGGTGGCCAACCTG
  	CAGAATGTGGATACAGGCTTCTGGCTGGATATGCAGCACCTGA
  	GCGACGTGGTGCTGTCCAGAGAGATCCAGACAGGCCTGAGAG
  	CCAGAGCCACACTGGAAGAGTCCATGCCTATGCTCGAGAACCT
  	GGAAGAGAGATTCCGGCGGCTGCAAGAGACATGTGACGCCGC
  	CAGAACCGAGATCGAGGAAAGCGGCTGGACAAGAGAAAGCG
  	CCTCCAGAATGGAAGGCGACGAAGCCCAAGGACCTAGCAGAG
  	TGCAGCAGGCCTTCCAGAGCTTCGTGAACGAGTGCAACAGCAT
  	CGAGTTCAGCTTCGGCTCCTTCGGCGAACATGTGCGGGTGCTG
  	TGTGCCAGAGTTAGCAGAGGACTTGCTGCCGCTGGCGAGGCC
  	ATCAGAAGATGCTTCTCTTGCTGCAAGGGCAGCACCCACAGAT
  	ACGCCCCTAGAGATGATCTGAGCCCTGAGGGCGCTTCTCTGGC
  	CGAAACACTGGCCAGATTCGCCGACGATATGGGCATTGAAAG
  	AGGCGCCGACGGAACCTACGACATCCCTCTGGTGGACGATTG
  	GAGAAGGGGCGTGCCATCTATCGAAGGCGAGGGATCT
  Ct875_E_1_458_NGM_nIgK_cHis	ATGGAAACCCCTGCTCAGCTGCTGTTCCTGCTGCTGCTGTGGC	212
  	TGCCTGATACCACCGGCATGTCTATCAGAGGCGTTGGCGGCAA
  	CGGCAACAGCAGAATCCCTAGCCATAATGGCGACGGCAGCAA
  	CAGGCGGAGCCAGAATACCAAGGGCAACAACAAGGTGGAAG
  	ATCGCGTGTGCAGCCTGTACAGCTCCAGAAGCAACGAGAACC
  	GCGAGAGCCCTTATGCCGTGGTGGATGTGTCCAGCATGATCGA
  	GAGCACCCCTACCAGCGGCGAGACAACAAGAGCTAGTAGAGG
  	CGTGCTGAGCCGGTTTCAGAGAGGCCTCGTTCGGATCGCTGAC
  	AAAGTGCGGAGAGCCGTGCAGTGTGCCTGGTCTAGTGTGTCCA
  	CAAGCAGAAGCAGCGCCACAAGAGCCGCCGAGAGCGGATCTT
  	CTAGCAGAACAGCTAGAGGCGCCAGCAGCGGCTACAGAGAGT
  	ATTCTCCATCTGCCGCCAGAGGCCTGCGGCTGATGTTTACAGA
  	TTTCTGGCGGACCCGGGTGCTGAGACAGACATCTCCTATGGCT
  	GGCGTGTTCGGCAACCTGGATGTGAATGAGGCCAGACTGATG
  	GCCGCCTACACAAGCGAATGTGCCGATCACCTGGAAGCCAAA
  	GAGCTGGCTGGACCTGACGGTGTTGCCGCCGCTAGAGAAATC
  	GCCAAGAGATGGGAGAAGAGAGTGCGGGACCTGCAGGATAA
  	GGGCGCTGCTAGAAAGCTGCTGAACGACCCTCTGGGCAGAAG
  	AACCCCTAACTACCAGAGCAAGAACCCCGGCGAGTACACCGT
  	GGGCAACTCCATGTTCTACGACGGACCCCAGGTGGCCAACCTG
  	CAGAATGTGGATACAGGCTTCTGGCTGGATATGCAGCACCTGA
  	GCGACGTGGTGCTGTCCAGAGAGATCCAGACAGGCCTGAGAG
  	CCAGAGCCACACTGGAAGAGTCCATGCCTATGCTCGAGAACCT
  	GGAAGAGAGATTCCGGCGGCTGCAAGAGACATGTGACGCCGC
  	CAGAACCGAGATCGAGGAAAGCGGCTGGACAAGAGAAAGCG
  	CCTCCAGAATGGAAGGCGACGAAGCCCAAGGACCTAGCAGAG
  	TGCAGCAGGCCTTCCAGAGCTTCGTGAACGAGTGCAACAGCAT
  	CGAGTTCAGCTTCGGCTCCTTCGGCGAACATGTGCGGGTGCTG
  	TGTGCCAGAGTTAGCAGAGGACTTGCTGCCGCTGGCGAGGCC
  	ATCAGAAGATGCTTCTCTTGCTGCAAGGGCAGCACCCACAGAT
  	ACGCCCCTAGAGATGATCTGAGCCCTGAGGGCGCTTCTCTGGC
  	CGAAACACTGGCCAGATTCGCCGACGATATGGGCATTGAAAG
  	AGGCGCCGACGGAACCTACGACATCCCTCTGGTGGACGATTG
  	GAGAAGGGGCGTGCCATCTATCGAAGGCGAGGGCTCTCACCA
  	CCACCATCACCAT
  Ct875_E_1_574_NGM_nIgK	ATGGAAACCCCTGCTCAGCTGCTGTTCCTGCTGCTGCTGTGGC	213
  	TGCCTGATACCACCGGCATGTCTATCAGAGGCGTTGGCGGCAA
  	CGGCAACAGCAGAATCCCTAGCCATAATGGCGACGGCAGCAA
  	CAGGCGGAGCCAGAATACCAAGGGCAACAACAAGGTGGAAG
  	ATCGCGTGTGCAGCCTGTACAGCTCCAGAAGCAACGAGAACC
  	GCGAGAGCCCTTATGCCGTGGTGGATGTGTCCAGCATGATCGA
  	GAGCACCCCTACCAGCGGCGAGACAACAAGAGCTAGTAGAGG
  	CGTGCTGAGCCGGTTTCAGAGAGGCCTCGTTCGGATCGCTGAC
  	AAAGTGCGGAGAGCCGTGCAGTGTGCCTGGTCTAGTGTGTCCA
  	CAAGCAGAAGCAGCGCCACAAGAGCCGCCGAGAGCGGATCTT
  	CTAGCAGAACAGCTAGAGGCGCCAGCAGCGGCTACAGAGAGT
  	ATTCTCCATCTGCCGCCAGAGGCCTGCGGCTGATGTTTACAGA
  	TTTCTGGCGGACCCGGGTGCTGAGACAGACATCTCCTATGGCT
  	GGCGTGTTCGGCAACCTGGATGTGAATGAGGCCAGACTGATG
  	GCCGCCTACACAAGCGAATGTGCCGATCACCTGGAAGCCAAA
  	GAGCTGGCTGGACCTGACGGTGTTGCCGCCGCTAGAGAAATC
  	GCCAAGAGATGGGAGAAGAGAGTGCGGGACCTGCAGGATAA
  	GGGCGCTGCTAGAAAGCTGCTGAACGACCCTCTGGGCAGAAG
  	AACCCCTAACTACCAGAGCAAGAACCCCGGCGAGTACACCGT
  	GGGCAACTCCATGTTCTACGACGGACCCCAGGTGGCCAACCTG
  	CAGAATGTGGATACAGGCTTCTGGCTGGATATGCAGCACCTGA
  	GCGACGTGGTGCTGTCCAGAGAGATCCAGACAGGCCTGAGAG
  	CCAGAGCCACACTGGAAGAGTCCATGCCTATGCTCGAGAACCT
  	GGAAGAGAGATTCCGGCGGCTGCAAGAGACATGTGACGCCGC
  	CAGAACCGAGATCGAGGAAAGCGGCTGGACAAGAGAAAGCG
  	CCTCCAGAATGGAAGGCGACGAAGCCCAAGGACCTAGCAGAG
  	TGCAGCAGGCCTTCCAGAGCTTCGTGAACGAGTGCAACAGCAT
  	CGAGTTCAGCTTCGGCTCCTTCGGCGAACATGTGCGGGTGCTG
  	TGTGCCAGAGTTAGCAGAGGACTTGCTGCCGCTGGCGAGGCC
  	ATCAGAAGATGCTTCTCTTGCTGCAAGGGCAGCACCCACAGAT
  	ACGCCCCTAGAGATGATCTGAGCCCTGAGGGCGCTTCTCTGGC
  	CGAAACACTGGCCAGATTCGCCGACGATATGGGCATTGAAAG
  	AGGCGCCGACGGAACCTACGACATCCCTCTGGTGGACGATTG
  	GAGAAGGGGCGTGCCATCTATCGAAGGCGAGGGCAGCGATAG
  	CATCTACGAGATCATGATGCCCATCTACGAAGTGATGAACATG
  	GACCTGGAAACCCGGCGGAGCTTTGCCGTGCAGCAAGGCCAT
  	TACCAGGATCCTAGAGCCAGCGACTACGACCTGCCTAGAGCCT
  	CCGATTATGATCTGCCTCGGAGCCCCTATCCTACACCTCCTCTG
  	CCTCCAAGATACCAGCTTCAGAATATGGACGTGGAAGCCGGA
  	TTCCGCGAGGCCGTGTATGCTAGCTTTGTGGCCGGCATGTACA
  	ACTACGTGGTCACCCAGCCTCAAGAGAGAATCCCCAACAGCC
  	AGCAGGTCGAGGGCATCCTGAGAGATATGCTGACCAACGGCG
  	AC
  Ct875_E_1_574_nIgK_nGST	ATGGAAACCCCTGCTCAGCTGCTGTTCCTGCTGCTGCTGTGGC	214
  	TGCCTGATACCACAGGCATGAGCCCTATCCTCGGCTACTGGAA
  	GATCAAAGGCCTGGTGCAGCCCACCAGACTGCTGCTGGAATA
  	CCTGGAAGAGAAGTACGAGGAACACCTGTACGAGCGCGACGA
  	GGGCGATAAGTGGCGGAACAAGAAGTTCGAGCTGGGCCTCGA
  	GTTCCCCAACCTGCCTTACTACATCGACGGCGACGTGAAGCTG
  	ACCCAGAGCATGGCCATCATCCGGTATATCGCCGACAAGCAC
  	AACATGCTCGGCGGCTGCCCTAAAGAGCGGGCCGAGATTTCTA
  	TGCTGGAAGGCGCCGTGCTGGACATCAGATACGGCGTGTCCA
  	GAATCGCCTACAGCAAGGACTTCGAAACCCTGAAGGTGGACT
  	TCCTGAGCAAGCTGCCCGAGATGCTGAAGATGTTCGAGGACC
  	GGCTGTGCCACAAGACCTACCTGAATGGCGACCACGTGACAC
  	ACCCCGACTTCATGCTGTACGACGCCCTGGATGTGGTGCTGTA
  	CATGGACCCCATGTGCCTGGACGCCTTTCCAAAGCTCGTGTGC
  	TTCAAGAAGCGGATCGAGGCCATTCCTCAGATCGACAAGTACC
  	TGAAGTCCAGCAAGTATATCGCTTGGCCCCTGCAAGGCTGGCA
  	GGCCACATTTGGAGGCGGAGATCACCCTCCTAAGATGAGCATC
  	AGAGGCGTCGGCGGCAACGGCAACAGCAGAATCCCTTCTCAC
  	AATGGCGACGGCAGCAACAGGCGGAGCCAGAATACCAAGGGC
  	AACAACAAGGTGGAAGATCGCGTGTGCAGCCTGTACAGCTCC
  	AGAAGCAACGAGAACCGCGAGAGCCCTTATGCCGTGGTGGAT
  	GTGTCCAGCATGATCGAGAGCACCCCTACCAGCGGCGAGACA
  	ACAAGAGCTAGTAGAGGCGTGCTGAGCCGGTTTCAGAGAGGC
  	CTCGTTCGGATTGCCGACAAAGTGCGGAGAGCCGTGCAGTGTG
  	CTTGGAGCAGTGTGTCCACAAGCAGAAGCAGCGCCACAAGAG
  	CCGCCGAATCTGGCAGCTCTAGCAGAACAGCTAGAGGCGCCA
  	GCAGCGGCTACAGAGAGTATTCTCCATCTGCCGCCAGAGGCCT
  	GCGGCTGATGTTTACAGATTTCTGGCGGACCCGGGTGCTGAGA
  	CAGACATCTCCTATGGCTGGCGTGTTCGGCAACCTGGACGTGA
  	ACGAAGCCAGACTGATGGCCGCCTACACAAGCGAGTGTGCCG
  	ATCACCTGGAAGCCAAAGAACTGGCCGGACCTGATGGCGTGG
  	CAGCCGCTAGAGAAATCGCCAAGAGATGGGAGAAGAGAGTGC
  	GGGACCTGCAGGATAAGGGCGCTGCTAGAAAGCTGCTGAACG
  	ACCCTCTGGGCAGAAGAACCCCTAACTACCAGAGCAAGAACC
  	CCGGCGAGTACACCGTGGGCAACTCCATGTTCTACGACGGACC
  	CCAGGTGGCCAACCTGCAGAATGTGGATACAGGCTTCTGGCTG
  	GACATGAGCAACCTGAGCGACGTGGTCCTGAGCAGAGAGATC
  	CAGACAGGCCTGAGAGCCAGAGCCACACTGGAAGAGTCCATG
  	CCTATGCTCGAGAATCTGGAAGAACGGTTCAGACGGCTGCAA
  	GAGACATGCGACGCCGCCAGAACAGAGATCGAGGAAAGCGGC
  	TGGACCAGAGAAAGCGCCTCCAGAATGGAAGGCGACGAAGCC
  	CAAGGACCTAGCAGAGTGCAGCAGGCCTTCCAGAGCTTCGTG
  	AACGAGTGCAACAGCATCGAGTTCAGCTTCGGCTCCTTCGGCG
  	AACATGTGCGGGTGCTGTGTGCCAGAGTTAGCAGAGGACTTGC
  	TGCCGCTGGCGAGGCCATCAGAAGATGCTTCTCTTGCTGCAAG
  	GGCAGCACCCACAGATACGCCCCTAGAGATGATCTGAGCCCT
  	GAGGGCGCATCTCTGGCCGAAACACTGGCCAGATTTGCCGAC
  	GACATGGGCATTGAAAGAGGCGCCGACGGAACCTACGACATC
  	CCTCTGGTGGACGATTGGAGAAGGGGCGTGCCATCTATCGAA
  	GGCGAGGGCAGCGATAGCATCTACGAGATCATGATGCCCATC
  	TACGAAGTGATGAACATGGACCTGGAAACCCGGCGGAGCTTT
  	GCCGTGCAACAGGGCCATTACCAGGATCCTAGAGCCAGCGAC
  	TACGACCTGCCTAGAGCCTCCGATTATGATCTGCCTCGGAGCC
  	CCTATCCTACACCTCCTCTGCCTCCAAGATACCAGCTTCAGAA
  	TATGGACGTGGAAGCCGGATTCCGCGAGGCCGTGTATGCTAGC
  	TTTGTGGCCGGCATGTACAACTACGTGGTCACCCAGCCTCAAG
  	AGAGAATCCCCAACAGCCAGCAGGTCGAGGGCATCCTGAGAG
  	ATATGCTGACCAACGGCAGC
  Ct875_E_1_574_nIgK_nGST_cHis	ATGGAAACCCCTGCTCAGCTGCTGTTCCTGCTGCTGCTGTGGC	215
  	TGCCTGATACCACAGGCATGAGCCCTATCCTCGGCTACTGGAA
  	GATCAAAGGCCTGGTGCAGCCCACCAGACTGCTGCTGGAATA
  	CCTGGAAGAGAAGTACGAGGAACACCTGTACGAGCGCGACGA
  	GGGCGATAAGTGGCGGAACAAGAAGTTCGAGCTGGGCCTCGA
  	GTTCCCCAACCTGCCTTACTACATCGACGGCGACGTGAAGCTG
  	ACCCAGAGCATGGCCATCATCCGGTATATCGCCGACAAGCAC
  	AACATGCTCGGCGGCTGCCCTAAAGAGCGGGCCGAGATTTCTA
  	TGCTGGAAGGCGCCGTGCTGGACATCAGATACGGCGTGTCCA
  	GAATCGCCTACAGCAAGGACTTCGAAACCCTGAAGGTGGACT
  	TCCTGAGCAAGCTGCCCGAGATGCTGAAGATGTTCGAGGACC
  	GGCTGTGCCACAAGACCTACCTGAATGGCGACCACGTGACAC
  	ACCCCGACTTCATGCTGTACGACGCCCTGGATGTGGTGCTGTA
  	CATGGACCCCATGTGCCTGGACGCCTTTCCAAAGCTCGTGTGC
  	TTCAAGAAGCGGATCGAGGCCATTCCTCAGATCGACAAGTACC
  	TGAAGTCCAGCAAGTATATCGCTTGGCCCCTGCAAGGCTGGCA
  	GGCCACATTTGGAGGCGGAGATCACCCTCCTAAGATGAGCATC
  	AGAGGCGTCGGCGGCAACGGCAACAGCAGAATCCCTTCTCAC
  	AATGGCGACGGCAGCAACAGGCGGAGCCAGAATACCAAGGGC
  	AACAACAAGGTGGAAGATCGCGTGTGCAGCCTGTACAGCTCC
  	AGAAGCAACGAGAACCGCGAGAGCCCTTATGCCGTGGTGGAT
  	GTGTCCAGCATGATCGAGAGCACCCCTACCAGCGGCGAGACA
  	ACAAGAGCTAGTAGAGGCGTGCTGAGCCGGTTTCAGAGAGGC
  	CTCGTTCGGATTGCCGACAAAGTGCGGAGAGCCGTGCAGTGTG
  	CTTGGAGCAGTGTGTCCACAAGCAGAAGCAGCGCCACAAGAG
  	CCGCCGAATCTGGCAGCTCTAGCAGAACAGCTAGAGGCGCCA
  	GCAGCGGCTACAGAGAGTATTCTCCATCTGCCGCCAGAGGCCT
  	GCGGCTGATGTTTACAGATTTCTGGCGGACCCGGGTGCTGAGA
  	CAGACATCTCCTATGGCTGGCGTGTTCGGCAACCTGGACGTGA
  	ACGAAGCCAGACTGATGGCCGCCTACACAAGCGAGTGTGCCG
  	ATCACCTGGAAGCCAAAGAACTGGCCGGACCTGATGGCGTGG
  	CAGCCGCTAGAGAAATCGCCAAGAGATGGGAGAAGAGAGTGC
  	GGGACCTGCAGGATAAGGGCGCTGCTAGAAAGCTGCTGAACG
  	ACCCTCTGGGCAGAAGAACCCCTAACTACCAGAGCAAGAACC
  	CCGGCGAGTACACCGTGGGCAACTCCATGTTCTACGACGGACC
  	CCAGGTGGCCAACCTGCAGAATGTGGATACAGGCTTCTGGCTG
  	GACATGAGCAACCTGAGCGACGTGGTCCTGAGCAGAGAGATC
  	CAGACAGGCCTGAGAGCCAGAGCCACACTGGAAGAGTCCATG
  	CCTATGCTCGAGAATCTGGAAGAACGGTTCAGACGGCTGCAA
  	GAGACATGCGACGCCGCCAGAACAGAGATCGAGGAAAGCGGC
  	TGGACCAGAGAAAGCGCCTCCAGAATGGAAGGCGACGAAGCC
  	CAAGGACCTAGCAGAGTGCAGCAGGCCTTCCAGAGCTTCGTG
  	AACGAGTGCAACAGCATCGAGTTCAGCTTCGGCTCCTTCGGCG
  	AACATGTGCGGGTGCTGTGTGCCAGAGTTAGCAGAGGACTTGC
  	TGCCGCTGGCGAGGCCATCAGAAGATGCTTCTCTTGCTGCAAG
  	GGCAGCACCCACAGATACGCCCCTAGAGATGATCTGAGCCCT
  	GAGGGCGCATCTCTGGCCGAAACACTGGCCAGATTTGCCGAC
  	GACATGGGCATTGAAAGAGGCGCCGACGGAACCTACGACATC
  	CCTCTGGTGGACGATTGGAGAAGGGGCGTGCCATCTATCGAA
  	GGCGAGGGCAGCGATAGCATCTACGAGATCATGATGCCCATC
  	TACGAAGTGATGAACATGGACCTGGAAACCCGGCGGAGCTTT
  	GCCGTGCAACAGGGCCATTACCAGGATCCTAGAGCCAGCGAC
  	TACGACCTGCCTAGAGCCTCCGATTATGATCTGCCTCGGAGCC
  	CCTATCCTACACCTCCTCTGCCTCCAAGATACCAGCTTCAGAA
  	TATGGACGTGGAAGCCGGATTCCGCGAGGCCGTGTATGCTAGC
  	TTTGTGGCCGGCATGTACAACTACGTGGTCACCCAGCCTCAAG
  	AGAGAATCCCCAACAGCCAGCAGGTCGAGGGCATCCTGAGAG
  	ATATGCTGACCAACGGCAGCCACCACCACCATCACCAT
  Ct875_E_nIgK_nGST	ATGGAAACCCCTGCTCAGCTGCTGTTCCTGCTGCTGCTGTGGC	216
  	TGCCTGATACCACAGGCATGAGCCCTATCCTCGGCTACTGGAA
  	GATCAAAGGCCTGGTGCAGCCCACCAGACTGCTGCTGGAATA
  	CCTGGAAGAGAAGTACGAGGAACACCTGTACGAGCGCGACGA
  	GGGCGATAAGTGGCGGAACAAGAAGTTCGAGCTGGGCCTCGA
  	GTTCCCCAACCTGCCTTACTACATCGACGGCGACGTGAAGCTG
  	ACCCAGAGCATGGCCATCATCCGGTATATCGCCGACAAGCAC
  	AACATGCTCGGCGGCTGCCCTAAAGAGCGGGCCGAGATTTCTA
  	TGCTGGAAGGCGCCGTGCTGGACATCAGATACGGCGTGTCCA
  	GAATCGCCTACAGCAAGGACTTCGAAACCCTGAAGGTGGACT
  	TCCTGAGCAAGCTGCCCGAGATGCTGAAGATGTTCGAGGACC
  	GGCTGTGCCACAAGACCTACCTGAATGGCGACCACGTGACAC
  	ACCCCGACTTCATGCTGTACGACGCCCTGGATGTGGTGCTGTA
  	CATGGACCCCATGTGCCTGGACGCCTTTCCAAAGCTCGTGTGC
  	TTCAAGAAGCGGATCGAGGCCATTCCTCAGATCGACAAGTACC
  	TGAAGTCCAGCAAGTATATCGCTTGGCCCCTGCAAGGCTGGCA
  	GGCCACATTTGGAGGCGGAGATCACCCTCCTAAGATGAGCATC
  	AGAGGCGTCGGCGGCAACGGCAACAGCAGAATCCCTTCTCAC
  	AATGGCGACGGCAGCAACAGGCGGAGCCAGAATACCAAGGGC
  	AACAACAAGGTGGAAGATCGCGTGTGCAGCCTGTACAGCTCC
  	AGAAGCAACGAGAACCGCGAGAGCCCTTATGCCGTGGTGGAT
  	GTGTCCAGCATGATCGAGAGCACCCCTACCAGCGGCGAGACA
  	ACAAGAGCTAGTAGAGGCGTGCTGAGCCGGTTTCAGAGAGGC
  	CTCGTTCGGATTGCCGACAAAGTGCGGAGAGCCGTGCAGTGTG
  	CTTGGAGCAGTGTGTCCACAAGCAGAAGCAGCGCCACAAGAG
  	CCGCCGAATCTGGCAGCTCTAGCAGAACAGCTAGAGGCGCCA
  	GCAGCGGCTACAGAGAGTATTCTCCATCTGCCGCCAGAGGCCT
  	GCGGCTGATGTTTACAGATTTCTGGCGGACCCGGGTGCTGAGA
  	CAGACATCTCCTATGGCTGGCGTGTTCGGCAACCTGGACGTGA
  	ACGAAGCCAGACTGATGGCCGCCTACACAAGCGAGTGTGCCG
  	ATCACCTGGAAGCCAAAGAACTGGCCGGACCTGATGGCGTGG
  	CAGCCGCTAGAGAAATCGCCAAGAGATGGGAGAAGAGAGTGC
  	GGGACCTGCAGGATAAGGGCGCTGCTAGAAAGCTGCTGAACG
  	ACCCTCTGGGCAGAAGAACCCCTAACTACCAGAGCAAGAACC
  	CCGGCGAGTACACCGTGGGCAACTCCATGTTCTACGACGGACC
  	CCAGGTGGCCAACCTGCAGAATGTGGATACAGGCTTCTGGCTG
  	GACATGAGCAACCTGAGCGACGTGGTCCTGAGCAGAGAGATC
  	CAGACAGGCCTGAGAGCCAGAGCCACACTGGAAGAGTCCATG
  	CCTATGCTCGAGAATCTGGAAGAACGGTTCAGACGGCTGCAA
  	GAGACATGCGACGCCGCCAGAACAGAGATCGAGGAAAGCGGC
  	TGGACCAGAGAAAGCGCCTCCAGAATGGAAGGCGACGAAGCC
  	CAAGGACCTAGCAGAGTGCAGCAGGCCTTCCAGAGCTTCGTG
  	AACGAGTGCAACAGCATCGAGTTCAGCTTCGGCTCCTTCGGCG
  	AACATGTGCGGGTGCTGTGTGCCAGAGTTAGCAGAGGACTTGC
  	TGCCGCTGGCGAGGCCATCAGAAGATGCTTCTCTTGCTGCAAG
  	GGCAGCACCCACAGATACGCCCCTAGAGATGATCTGAGCCCT
  	GAGGGCGCATCTCTGGCCGAAACACTGGCCAGATTTGCCGAC
  	GACATGGGCATTGAAAGAGGCGCCGACGGAACCTACGACATC
  	CCTCTGGTGGACGATTGGAGAAGGGGCGTGCCATCTATCGAA
  	GGCGAGGGCAGCGATAGCATCTACGAGATCATGATGCCCATC
  	TACGAAGTGATGAACATGGACCTGGAAACCCGGCGGAGCTTT
  	GCCGTGCAACAGGGCCATTACCAGGATCCTAGAGCCAGCGAC
  	TACGACCTGCCTAGAGCCTCCGATTATGATCTGCCTCGGAGCC
  	CCTATCCTACACCTCCTCTGCCTCCAAGATACCAGCTTCAGAA
  	TATGGACGTGGAAGCCGGATTCCGCGAGGCCGTGTATGCTAGC
  	TTTGTGGCCGGCATGTACAACTACGTGGTCACCCAGCCTCAAG
  	AGAGAATCCCCAACAGCCAGCAGGTCGAGGGCATCCTGAGAG
  	ATATGCTGACCAACGGCAGCCAGACCTTCCGCGACCTGATGAA
  	GAGATGGAACAGAGAGGTGGACAGAGAG
  Ct875_E_nIgK_nGST_cHis	ATGGAAACCCCTGCTCAGCTGCTGTTCCTGCTGCTGCTGTGGC	217
  	TGCCTGATACCACAGGCATGAGCCCTATCCTCGGCTACTGGAA
  	GATCAAAGGCCTGGTGCAGCCCACCAGACTGCTGCTGGAATA
  	CCTGGAAGAGAAGTACGAGGAACACCTGTACGAGCGCGACGA
  	GGGCGATAAGTGGCGGAACAAGAAGTTCGAGCTGGGCCTCGA
  	GTTCCCCAACCTGCCTTACTACATCGACGGCGACGTGAAGCTG
  	ACCCAGAGCATGGCCATCATCCGGTATATCGCCGACAAGCAC
  	AACATGCTCGGCGGCTGCCCTAAAGAGCGGGCCGAGATTTCTA
  	TGCTGGAAGGCGCCGTGCTGGACATCAGATACGGCGTGTCCA
  	GAATCGCCTACAGCAAGGACTTCGAAACCCTGAAGGTGGACT
  	TCCTGAGCAAGCTGCCCGAGATGCTGAAGATGTTCGAGGACC
  	GGCTGTGCCACAAGACCTACCTGAATGGCGACCACGTGACAC
  	ACCCCGACTTCATGCTGTACGACGCCCTGGATGTGGTGCTGTA
  	CATGGACCCCATGTGCCTGGACGCCTTTCCAAAGCTCGTGTGC
  	TTCAAGAAGCGGATCGAGGCCATTCCTCAGATCGACAAGTACC
  	TGAAGTCCAGCAAGTATATCGCTTGGCCCCTGCAAGGCTGGCA
  	GGCCACATTTGGAGGCGGAGATCACCCTCCTAAGATGAGCATC
  	AGAGGCGTCGGCGGCAACGGCAACAGCAGAATCCCTTCTCAC
  	AATGGCGACGGCAGCAACAGGCGGAGCCAGAATACCAAGGGC
  	AACAACAAGGTGGAAGATCGCGTGTGCAGCCTGTACAGCTCC
  	AGAAGCAACGAGAACCGCGAGAGCCCTTATGCCGTGGTGGAT
  	GTGTCCAGCATGATCGAGAGCACCCCTACCAGCGGCGAGACA
  	ACAAGAGCTAGTAGAGGCGTGCTGAGCCGGTTTCAGAGAGGC
  	CTCGTTCGGATTGCCGACAAAGTGCGGAGAGCCGTGCAGTGTG
  	CTTGGAGCAGTGTGTCCACAAGCAGAAGCAGCGCCACAAGAG
  	CCGCCGAATCTGGCAGCTCTAGCAGAACAGCTAGAGGCGCCA
  	GCAGCGGCTACAGAGAGTATTCTCCATCTGCCGCCAGAGGCCT
  	GCGGCTGATGTTTACAGATTTCTGGCGGACCCGGGTGCTGAGA
  	CAGACATCTCCTATGGCTGGCGTGTTCGGCAACCTGGACGTGA
  	ACGAAGCCAGACTGATGGCCGCCTACACAAGCGAGTGTGCCG
  	ATCACCTGGAAGCCAAAGAACTGGCCGGACCTGATGGCGTGG
  	CAGCCGCTAGAGAAATCGCCAAGAGATGGGAGAAGAGAGTGC
  	GGGACCTGCAGGATAAGGGCGCTGCTAGAAAGCTGCTGAACG
  	ACCCTCTGGGCAGAAGAACCCCTAACTACCAGAGCAAGAACC
  	CCGGCGAGTACACCGTGGGCAACTCCATGTTCTACGACGGACC
  	CCAGGTGGCCAACCTGCAGAATGTGGATACAGGCTTCTGGCTG
  	GACATGAGCAACCTGAGCGACGTGGTCCTGAGCAGAGAGATC
  	CAGACAGGCCTGAGAGCCAGAGCCACACTGGAAGAGTCCATG
  	CCTATGCTCGAGAATCTGGAAGAACGGTTCAGACGGCTGCAA
  	GAGACATGCGACGCCGCCAGAACAGAGATCGAGGAAAGCGGC
  	TGGACCAGAGAAAGCGCCTCCAGAATGGAAGGCGACGAAGCC
  	CAAGGACCTAGCAGAGTGCAGCAGGCCTTCCAGAGCTTCGTG
  	AACGAGTGCAACAGCATCGAGTTCAGCTTCGGCTCCTTCGGCG
  	AACATGTGCGGGTGCTGTGTGCCAGAGTTAGCAGAGGACTTGC
  	TGCCGCTGGCGAGGCCATCAGAAGATGCTTCTCTTGCTGCAAG
  	GGCAGCACCCACAGATACGCCCCTAGAGATGATCTGAGCCCT
  	GAGGGCGCATCTCTGGCCGAAACACTGGCCAGATTTGCCGAC
  	GACATGGGCATTGAAAGAGGCGCCGACGGAACCTACGACATC
  	CCTCTGGTGGACGATTGGAGAAGGGGCGTGCCATCTATCGAA
  	GGCGAGGGCAGCGATAGCATCTACGAGATCATGATGCCCATC
  	TACGAAGTGATGAACATGGACCTGGAAACCCGGCGGAGCTTT
  	GCCGTGCAACAGGGCCATTACCAGGATCCTAGAGCCAGCGAC
  	TACGACCTGCCTAGAGCCTCCGATTATGATCTGCCTCGGAGCC
  	CCTATCCTACACCTCCTCTGCCTCCAAGATACCAGCTTCAGAA
  	TATGGACGTGGAAGCCGGATTCCGCGAGGCCGTGTATGCTAGC
  	TTTGTGGCCGGCATGTACAACTACGTGGTCACCCAGCCTCAAG
  	AGAGAATCCCCAACAGCCAGCAGGTCGAGGGCATCCTGAGAG
  	ATATGCTGACCAACGGCAGCCAGACCTTCCGCGACCTGATGAA
  	GAGATGGAACAGAGAGGTGGACAGAGAGCACCACCACCATCA
  	CCAT
  Ct875_E_nFc	ATGGAAACCCCTGCTCAGCTGCTGTTCCTGCTGCTGCTGTGGC	218
  	TGCCTGATACAACCGGCGAGCCTAAGAGCTGCGACAAGACCC
  	ACACCTGTCCTCCATGTCCTGCTCCAGAACTGCTCGGCGGACC
  	TTCCGTGTTCCTGTTTCCTCCAAAGCCTAAGGACACCCTGATG
  	ATCAGCAGAACCCCTGAAGTGACCTGCGTGGTGGTGGATGTGT
  	CCCACGAGGATCCCGAAGTGAAGTTCAATTGGTACGTGGACG
  	GCGTGGAAGTGCACAACGCCAAGACCAAGCCTAGAGAGGAAC
  	AGTACAACAGCACCTACAGAGTGGTGTCCGTGCTGACCGTGCT
  	GCACCAGGATTGGCTGAACGGCAAAGAGTACAAGTGCAAGGT
  	GTCCAACAAGGCCCTGCCTGCTCCTATCGAGAAGACCATCAGC
  	AAGGCCAAGGGCCAGCCAAGAGAACCCCAGGTGTACACACTG
  	CCTCCAAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTG
  	ACCTGTCTGGTCAAGGGCTTCTACCCCTCCGATATCGCCGTGG
  	AATGGGAGAGCAATGGCCAGCCTGAGAACAACTACAAGACAA
  	CCCCTCCTGTGCTGGACAGCGACGGCTCATTCTTCCTGTACAG
  	CAAGCTGACAGTGGACAAGAGCAGATGGCAGCAGGGCAACGT
  	GTTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAATCACTAC
  	ACCCAGAAGTCCCTGTCTCTGAGCCCCGGCAAGATGAGCATCA
  	GAGGCGTTGGCGGCAACGGCAACAGCAGAATCCCTAGCCATA
  	ATGGCGACGGCAGCAACAGGCGGAGCCAGAATACCAAGGGCA
  	ACAACAAGGTGGAAGATCGCGTGTGCAGCCTGTACTCCAGCA
  	GAAGCAACGAGAACCGCGAGAGCCCTTATGCCGTGGTCGACG
  	TGTCCAGCATGATCGAGAGCACACCTACCAGCGGCGAGACAA
  	CCAGAGCTAGTAGAGGCGTGCTGAGCCGGTTTCAGAGAGGCC
  	TCGTTCGGATCGCTGACAAAGTGCGGAGAGCCGTGCAGTGTGC
  	CTGGTCTAGTGTGTCCACCAGCAGATCCTCTGCCACAAGAGCC
  	GCCGAGTCTGGCAGCTCTAGCAGAACAGCTAGAGGCGCCAGC
  	AGCGGCTACAGAGAGTATTCTCCATCTGCCGCCAGAGGCCTGC
  	GGCTGATGTTTACAGATTTCTGGCGGACCCGGGTGCTGAGACA
  	GACATCTCCTATGGCTGGCGTGTTCGGCAACCTGGATGTGAAT
  	GAGGCCAGACTGATGGCCGCCTACACAAGCGAATGTGCCGAT
  	CACCTGGAAGCCAAAGAGCTGGCTGGACCTGACGGTGTTGCC
  	GCCGCTAGAGAAATCGCCAAGAGATGGGAGAAGAGAGTGCGG
  	GACCTGCAGGATAAGGGCGCTGCTAGAAAGCTGCTGAACGAC
  	CCTCTGGGCAGAAGAACCCCTAACTACCAGAGCAAGAACCCC
  	GGCGAGTACACCGTGGGCAACTCCATGTTCTACGACGGACCTC
  	AGGTGGCCAACCTGCAGAATGTGGATACCGGCTTCTGGCTGGA
  	TATGAGCAACCTGAGCGACGTGGTGCTGTCCAGAGAGATCCA
  	GACAGGCCTGAGAGCCAGAGCCACACTGGAAGAGTCCATGCC
  	TATGCTCGAGAACCTGGAAGAGAGATTCCGGCGGCTGCAAGA
  	GACATGTGACGCCGCCAGAACCGAGATCGAGGAAAGCGGCTG
  	GACCAGAGAAAGCGCCTCCAGAATGGAAGGCGACGAAGCCCA
  	AGGACCTAGCAGAGTGCAGCAGGCCTTCCAGAGCTTCGTGAA
  	CGAGTGCAACAGCATCGAGTTCAGCTTCGGCTCCTTCGGCGAA
  	CATGTGCGGGTGCTGTGTGCCAGAGTTAGCAGAGGACTTGCTG
  	CCGCTGGCGAGGCCATCAGAAGATGCTTCTCTTGCTGCAAGGG
  	CAGCACCCACAGATACGCCCCTAGAGATGATCTGAGCCCTGA
  	GGGCGCATCTCTGGCCGAAACACTGGCCAGATTCGCCGACGAT
  	ATGGGCATTGAAAGAGGCGCCGACGGAACCTACGACATCCCT
  	CTGGTGGACGATTGGAGAAGGGGCGTGCCATCTATCGAAGGC
  	GAGGGCAGCGATAGCATCTACGAGATCATGATGCCCATCTAC
  	GAAGTGATGAACATGGACCTGGAAACCCGGCGGAGCTTCGCT
  	GTTCAGCAGGGCCATTACCAGGATCCTAGAGCCAGCGACTAC
  	GACCTGCCTAGAGCCTCCGATTATGATCTGCCTCGGAGCCCCT
  	ATCCTACACCTCCACTGCCACCTAGATACCAGCTCCAGAATAT
  	GGACGTGGAAGCCGGATTCCGCGAGGCCGTGTATGCTAGCTTT
  	GTGGCCGGCATGTACAACTACGTGGTCACCCAGCCTCAAGAGC
  	GGATCCCCAATTCTCAGCAGGTCGAGGGCATCCTGAGGGACAT
  	GCTGACAAATGGCAGCCAGACCTTCCGGGACCTGATGAAGAG
  	ATGGAACAGAGAGGTGGACAGAGAG
  Ct875_E_nFc_cHis	ATGGAAACCCCTGCTCAGCTGCTGTTCCTGCTGCTGCTGTGGC	219
  	TGCCTGATACAACCGGCGAGCCTAAGAGCTGCGACAAGACCC
  	ACACCTGTCCTCCATGTCCTGCTCCAGAACTGCTCGGCGGACC
  	TTCCGTGTTCCTGTTTCCTCCAAAGCCTAAGGACACCCTGATG
  	ATCAGCAGAACCCCTGAAGTGACCTGCGTGGTGGTGGATGTGT
  	CCCACGAGGATCCCGAAGTGAAGTTCAATTGGTACGTGGACG
  	GCGTGGAAGTGCACAACGCCAAGACCAAGCCTAGAGAGGAAC
  	AGTACAACAGCACCTACAGAGTGGTGTCCGTGCTGACCGTGCT
  	GCACCAGGATTGGCTGAACGGCAAAGAGTACAAGTGCAAGGT
  	GTCCAACAAGGCCCTGCCTGCTCCTATCGAGAAGACCATCAGC
  	AAGGCCAAGGGCCAGCCAAGAGAACCCCAGGTGTACACACTG
  	CCTCCAAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTG
  	ACCTGTCTGGTCAAGGGCTTCTACCCCTCCGATATCGCCGTGG
  	AATGGGAGAGCAATGGCCAGCCTGAGAACAACTACAAGACAA
  	CCCCTCCTGTGCTGGACAGCGACGGCTCATTCTTCCTGTACAG
  	CAAGCTGACAGTGGACAAGAGCAGATGGCAGCAGGGCAACGT
  	GTTCAGCTGCAGCGTGATGCACGAGGCCCTGCACAATCACTAC
  	ACCCAGAAGTCCCTGTCTCTGAGCCCCGGCAAGATGAGCATCA
  	GAGGCGTTGGCGGCAACGGCAACAGCAGAATCCCTAGCCATA
  	ATGGCGACGGCAGCAACAGGCGGAGCCAGAATACCAAGGGCA
  	ACAACAAGGTGGAAGATCGCGTGTGCAGCCTGTACTCCAGCA
  	GAAGCAACGAGAACCGCGAGAGCCCTTATGCCGTGGTCGACG
  	TGTCCAGCATGATCGAGAGCACACCTACCAGCGGCGAGACAA
  	CCAGAGCTAGTAGAGGCGTGCTGAGCCGGTTTCAGAGAGGCC
  	TCGTTCGGATCGCTGACAAAGTGCGGAGAGCCGTGCAGTGTGC
  	CTGGTCTAGTGTGTCCACCAGCAGATCCTCTGCCACAAGAGCC
  	GCCGAGTCTGGCAGCTCTAGCAGAACAGCTAGAGGCGCCAGC
  	AGCGGCTACAGAGAGTATTCTCCATCTGCCGCCAGAGGCCTGC
  	GGCTGATGTTTACAGATTTCTGGCGGACCCGGGTGCTGAGACA
  	GACATCTCCTATGGCTGGCGTGTTCGGCAACCTGGATGTGAAT
  	GAGGCCAGACTGATGGCCGCCTACACAAGCGAATGTGCCGAT
  	CACCTGGAAGCCAAAGAGCTGGCTGGACCTGACGGTGTTGCC
  	GCCGCTAGAGAAATCGCCAAGAGATGGGAGAAGAGAGTGCGG
  	GACCTGCAGGATAAGGGCGCTGCTAGAAAGCTGCTGAACGAC
  	CCTCTGGGCAGAAGAACCCCTAACTACCAGAGCAAGAACCCC
  	GGCGAGTACACCGTGGGCAACTCCATGTTCTACGACGGACCTC
  	AGGTGGCCAACCTGCAGAATGTGGATACCGGCTTCTGGCTGGA
  	TATGAGCAACCTGAGCGACGTGGTGCTGTCCAGAGAGATCCA
  	GACAGGCCTGAGAGCCAGAGCCACACTGGAAGAGTCCATGCC
  	TATGCTCGAGAACCTGGAAGAGAGATTCCGGCGGCTGCAAGA
  	GACATGTGACGCCGCCAGAACCGAGATCGAGGAAAGCGGCTG
  	GACCAGAGAAAGCGCCTCCAGAATGGAAGGCGACGAAGCCCA
  	AGGACCTAGCAGAGTGCAGCAGGCCTTCCAGAGCTTCGTGAA
  	CGAGTGCAACAGCATCGAGTTCAGCTTCGGCTCCTTCGGCGAA
  	CATGTGCGGGTGCTGTGTGCCAGAGTTAGCAGAGGACTTGCTG
  	CCGCTGGCGAGGCCATCAGAAGATGCTTCTCTTGCTGCAAGGG
  	CAGCACCCACAGATACGCCCCTAGAGATGATCTGAGCCCTGA
  	GGGCGCATCTCTGGCCGAAACACTGGCCAGATTCGCCGACGAT
  	ATGGGCATTGAAAGAGGCGCCGACGGAACCTACGACATCCCT
  	CTGGTGGACGATTGGAGAAGGGGCGTGCCATCTATCGAAGGC
  	GAGGGCAGCGATAGCATCTACGAGATCATGATGCCCATCTAC
  	GAAGTGATGAACATGGACCTGGAAACCCGGCGGAGCTTCGCT
  	GTTCAGCAGGGCCATTACCAGGATCCTAGAGCCAGCGACTAC
  	GACCTGCCTAGAGCCTCCGATTATGATCTGCCTCGGAGCCCCT
  	ATCCTACACCTCCACTGCCACCTAGATACCAGCTCCAGAATAT
  	GGACGTGGAAGCCGGATTCCGCGAGGCCGTGTATGCTAGCTTT
  	GTGGCCGGCATGTACAACTACGTGGTCACCCAGCCTCAAGAGC
  	GGATCCCCAATTCTCAGCAGGTCGAGGGCATCCTGAGGGACAT
  	GCTGACAAATGGCAGCCAGACCTTCCGGGACCTGATGAAGAG
  	ATGGAACAGAGAGGTGGACCGCGAGCACCACCACCATCACCAT
  Ct043_E_NGM_nIgK_no4A	ATGGAAACCCCTGCTCAGCTGCTGTTCCTGCTGCTGCTGTGGC	220
  	TGCCTGATACCACCGGAATGAGCAGACAGAACGCCGAGGAGA
  	ACCTGAAGAACTTCGCCAAAGAGCTGAAGCTGCCCGACGTGG
  	CCTTCGACCAGAACAATGCCTGCATCCTGTTCGTGGACGGCGA
  	GTTCTCTCTGCACCTGACCTACGAGGAACACAGCGACCGGCTG
  	TATGTGTACGCCCCTCTGCTGGATGGCCTGCCTGACAACCCTC
  	AGAGAAAGCTGGCCCTGTACGAGAAGCTGCTGGAAGGCTCTA
  	TGCTCGGCGGACAAATGGCTGGTGGCGGAGTGGGAGTTGCCA
  	CCAAAGAACAGCTGATCCTGATGCACTGCGTGCTGGACATGA
  	AGTACGCCGAGACTAACCTGCTGAAGGCTTTCGCCCAGCTGTT
  	CATCGAGACAGTGGTCAAGTGGCGGACCGTGTGCAGCGATAT
  	TAGCGCCGGCAGAGAACCCACCGTGGACACCATGCCTCAAAT
  	GCCACAAGGCGGCGGAGGCGGAATTCAACCTCCTCCAGCCGG
  	AATTAGAGCC
  Ct043_E_NGM_nIgK_cHis_no4A	ATGGAAACCCCTGCTCAGCTGCTGTTCCTGCTGCTGCTGTGGC	221
  	TGCCTGATACCACCGGAATGAGCAGACAGAACGCCGAGGAGA
  	ACCTGAAGAACTTCGCCAAAGAGCTGAAGCTGCCCGACGTGG
  	CCTTCGACCAGAACAATGCCTGCATCCTGTTCGTGGACGGCGA
  	GTTCTCTCTGCACCTGACCTACGAGGAACACAGCGACCGGCTG
  	TATGTGTACGCCCCTCTGCTGGATGGCCTGCCTGACAACCCTC
  	AGAGAAAGCTGGCCCTGTACGAGAAGCTGCTGGAAGGCTCTA
  	TGCTCGGCGGACAAATGGCTGGTGGCGGAGTGGGAGTTGCCA
  	CCAAAGAACAGCTGATCCTGATGCACTGCGTGCTGGACATGA
  	AGTACGCCGAGACTAACCTGCTGAAGGCTTTCGCCCAGCTGTT
  	CATCGAGACAGTGGTCAAGTGGCGGACCGTGTGCAGCGATAT
  	TAGCGCCGGCAGAGAACCCACCGTGGACACCATGCCTCAAAT
  	GCCACAAGGCGGCGGAGGCGGAATTCAACCTCCTCCAGCCGG
  	AATCAGAGCCCACCACCATCACCATCAT
  Ct043_E_nIgK_no4A	ATGGAAACCCCTGCTCAGCTGCTGTTCCTGCTGCTGCTGTGGC	222
  	TGCCTGATACCACCGGAATGAGCAGACAGAACGCCGAGGAGA
  	ACCTGAAGAACTTCGCCAAAGAGCTGAAGCTGCCCGACGTGG
  	CCTTCGACCAGAACAATACCTGCATCCTGTTCGTGGACGGCGA
  	GTTCAGCCTGCACCTGACCTACGAGGAACACAGCGACCGGCT
  	GTATGTGTACGCCCCTCTGCTGGATGGCCTGCCTGACAACCCT
  	CAGAGAAAGCTGGCCCTGTACGAGAAGCTGCTGGAAGGCTCT
  	ATGCTCGGCGGACAAATGGCTGGTGGCGGAGTGGGAGTTGCC
  	ACCAAAGAACAGCTGATCCTGATGCACTGCGTGCTGGACATG
  	AAGTACGCCGAGACTAACCTGCTGAAGGCTTTCGCCCAGCTGT
  	TCATCGAGACAGTGGTCAAGTGGCGGACCGTGTGCAGCGATA
  	TTAGCGCCGGCAGAGAACCCACCGTGGACACCATGCCTCAAA
  	TGCCACAAGGCGGCGGAGGCGGAATTCAACCTCCTCCAGCCG
  	GAATTAGAGCC
  Ct043_E_nIgK_cHis_no4A	ATGGAAACCCCTGCTCAGCTGCTGTTCCTGCTGCTGCTGTGGC	223
  	TGCCTGATACCACCGGAATGAGCAGACAGAACGCCGAGGAGA
  	ACCTGAAGAACTTCGCCAAAGAGCTGAAGCTGCCCGACGTGG
  	CCTTCGACCAGAACAATACCTGCATCCTGTTCGTGGACGGCGA
  	GTTCAGCCTGCACCTGACCTACGAGGAACACAGCGACCGGCT
  	GTATGTGTACGCCCCTCTGCTGGATGGCCTGCCTGACAACCCT
  	CAGAGAAAGCTGGCCCTGTACGAGAAGCTGCTGGAAGGCTCT
  	ATGCTCGGCGGACAAATGGCTGGTGGCGGAGTGGGAGTTGCC
  	ACCAAAGAACAGCTGATCCTGATGCACTGCGTGCTGGACATG
  	AAGTACGCCGAGACTAACCTGCTGAAGGCTTTCGCCCAGCTGT
  	TCATCGAGACAGTGGTCAAGTGGCGGACCGTGTGCAGCGATA
  	TTAGCGCCGGCAGAGAACCCACCGTGGACACCATGCCTCAAA
  	TGCCACAAGGCGGCGGAGGCGGAATTCAACCTCCTCCAGCCG
  	GAATCAGAGCCCACCACCATCACCATCAT
  Chlamydia_Ct812_pd_serovarD_nIgK_cHis_nopolyN	ATGGAAACTCCTGCCCAACTGTTGTTCCTTCTGCTGCTCTGGTT	224
  	GCCCGACACCACCGGATCGTGCGTGGATCTCCACGCTGGCGGC
  	CAGTCCGTGAACGAGCTTGTGTACGTGGGCCCACAGGCCGTGC
  	TTCTGCTGGACCAGATCAGAGATCTCTTCGTGGGTTCCAAGGA
  	CTCCCAGGCCGAGGGACAGTACCGGCTCATCGTCGGCGACCCT
  	TCAAGCTTCCAAGAGAAGGATGCCGACACTCTTCCGGGGAAG
  	GTGGAACAGTCCACTCTGTTTTCCGTGACCAACCCAGTCGTGT
  	TTCAAGGGGTGGACCAGCAGGACCAGGTGTCCAGCCAAGGAC
  	TGATCTGTTCATTCACCTCGAGCAATTTGGACAGCCCCCGGGA
  	CGGCGAATCGTTCCTTGGCATCGCATTCGTGGGAGACTCATCC
  	AAAGCAGGAATCACCCTTACCGATGTGAAGGCGTCCCTGAGC
  	GGCGCTGCTCTGTACTCCACCGAAGATCTCATCTTCGAGAAGA
  	TCAAGGGTGGACTGGAGTTCGCCAGCTGCTCCTCACTGGAACA
  	GGGAGGAGCCTGTGCCGCCCAAAGCATCCTCATCCACGATTGC
  	CAGGGGCTCCAAGTGAAGCATTGTACCACTGCCGTGAACGCC
  	GAGGGATCATCCGCTAACGATCACCTCGGTTTCGGAGGGGGTG
  	CCTTCTTCGTGACCGGTTCGCTGTCGGGAGAGAAGTCACTGTA
  	TATGCCCGCGGGCGACATGGTGGTCGCCAACTGCGATGGAGC
  	CATCTCATTCGAGGGAAACTCCGCCAACTTCGCAAACGGCGGC
  	GCTATCGCCGCTAGCGGGAAGGTGCTGTTCGTGGCTAACGACA
  	AGAAGACGTCCTTCATCGAGAACCGCGCCCTGTCGGGAGGTG
  	CCATTGCCGCCAGCTCCGACATTGCCTTCCAGAACTGTGCGGA
  	ACTGGTGTTCAAAGGAAACTGCGCCATCGGCACCGAAGATAA
  	GGGAAGCCTGGGAGGCGGCGCCATTTCCTCCCTCGGCACCGTG
  	CTGCTTCAGGGAAACCACGGCATCACTTGTGACAAGAACGAA
  	AGCGCGTCCCAGGGGGGAGCGATCTTCGGGAAGAACTGCCAG
  	ATTTCCGACAACGAGGGACCGGTGGTGTTCAGAGACTCCACTG
  	CCTGCCTGGGCGGCGGAGCGATCGCAGCACAGGAAATTGTCA
  	GCATCCAGAACAACCAGGCCGGCATCAGCTTCGAGGGGGGAA
  	AGGCTTCGTTCGGCGGAGGTATTGCCTGCGGATCGTTCTCGTC
  	CGCGGGCGGAGCCTCCGTGCTCGGAACCATCGACATTTCCAAG
  	AACCTGGGCGCTATCTCGTTTTCTCGCACCCTGTGCACTACTTC
  	CGACCTGGGTCAGATGGAGTACCAGGGAGGCGGAGCGCTGTT
  	TGGAGAGAACATCTCTCTGAGCGAGAACGCGGGAGTGCTGAC
  	CTTCAAGGACAACATTGTGAAGACCTTCGCCTCAAACGGAAA
  	GATCCTGGGGGGAGGCGCCATCCTGGCAACCGGGAAGGTCGA
  	AATCACCAACAATTCAGAGGGTATCTCCTTCACTGGCAACGCC
  	CGGGCCCCCCAAGCCCTGCCGACTCAGGAAGAGTTCCCCCTGT
  	TCTCCAAGAAGGAAGGACGCCCTTTGTCATCCGGCTACTCCGG
  	TGGTGGAGCGATTCTGGGTCGGGAAGTGGCCATCCTGCATAAT
  	GCGGCCGTGGTGTTTGAGCAGAACAGACTCCAATGCTCCGAA
  	GAAGAGGCCACCCTCCTGGGGTGCTGCGGGGGCGGAGCAGTG
  	CATGGCATGGATTCCACTTCCATCGTGGGAAACTCCAGCGTCC
  	GCTTCGGAAACAACTACGCTATGGGACAGGGAGTGTCAGGCG
  	GGGCCCTGCTGTCCAAGACCGTCCAGTTGGCCGGAAACGGTTC
  	GGTGGATTTCTCACGCAATATCGCCTCGCTGGGAGGCGGCGCG
  	CTGCAGGCCTCCGAAGGAAATTGCGAACTGGTCGACAACGGC
  	TACGTGCTGTTCCGGGACAACCGCGGCAGGGTGTACGGCGGA
  	GCAATCTCGTGCCTTCGGGGCGACGTCGTGATCTCGGGAAATA
  	AGGGACGGGTCGAGTTTAAGGACAACATCGCTACCAGGCTCT
  	ACGTGGAGGAAACTGTGGAGAAGGTGGAGGAAGTGGAGCCTG
  	CCCCGGAACAGAAGGACAACAACGAGCTGTCGTTCCTCGGTC
  	GGGCAGAACAGTCCTTCATTACTGCCGCCAACCAGGCCCTGTT
  	CGCGTCCGAAGATGGTGACCTCAGCCCGGAATCCAGCATCTCC
  	TCCGAGGAACTGGCCAAGCGGAGAGAATGCGCGGGAGGCGCA
  	ATCTTTGCGAAGCGGGTCCGGATCGTGGACAACCAGGAAGCT
  	GTGGTGTTCAGCAACAACTTTTCCGACATCTACGGTGGTGCAA
  	TTTTCACCGGCTCACTCCGGGAGGAGGACAAGCTGGACGGCC
  	AGATTCCCGAGGTGCTCATTTCCGGCAATGCCGGCGACGTGGT
  	GTTCTCCGGAAACTCCTCCAAGAGGGACGAACACCTCCCGCAT
  	ACCGGAGGAGGAGCCATCTGCACTCAGAACCTGACGATCTCG
  	CAGAACACCGGCAATGTGCTGTTCTACAACAACGTCGCATGTT
  	CCGGTGGCGCCGTCAGAATCGAGGACCACGGAAACGTGCTGC
  	TGGAAGCATTCGGGGGTGATATTGTGTTCAAGGGAAACAGCA
  	GCTTCCGGGCCCAGGGATCAGATGCAATCTACTTCGCCGGGAA
  	GGAGAGCCACATTACCGCCCTGAACGCCACCGAGGGTCACGC
  	CATCGTGTTCCACGATGCCCTGGTGTTCGAGAACCTGGAGGAG
  	CGCAAGAGCGCCGAAGTGCTGCTTATCAATTCCCGCGAGAACC
  	CGGGCTACACCGGATCCATCCGGTTCCTCGAAGCGGAGTCGAA
  	GGTCCCGCAGTGTATTCATGTGCAACAGGGGTCCCTGGAACTG
  	CTTAACGGAGCCACCCTGTGCTCCTACGGCTTTAAGCAGGACG
  	CGGGCGCTAAACTGGTGCTGGCGGCCGGCGCCAAGCTTAAGA
  	TCCTCGACTCCGGAACCCCGGTGCAGCAGGGGCACGCTATTAG
  	CAAGCCTGAAGCCGAGATTGAGTCGTCATCCGAACCCGAAGG
  	GGCGCACTCCCTGTGGATAGCCAAGAACGCGCAGACCACCGT
  	GCCAATGGTCGATATCCACACAATCTCCGTGGACCTCGCCAGC
  	TTCTCGTCGAGCCAGCAGGAGGGAACTGTCGAAGCGCCTCAG
  	GTCATCGTGCCGGGAGGTTCCTACGTGCGCTCGGGGGAGCTCA
  	ACCTGGAACTCGTGAATACCACTGGAACGGGATATGAGAACC
  	ACGCCCTGCTGAAGAACGAAGCCAAAGTGCCACTGATGTCCTT
  	CGTCGCCTCCGGCGACGAGGCCTCCGCCGAGATTAGCAACCTG
  	TCGGTGTCAGATCTGCAAATTCACGTGGTGACCCCTGAGATTG
  	AGGAGGACACCTACGGGCACATGGGCGATTGGTCCGAGGCGA
  	AGATCCAGGACGGCACACTGGTCATTTCATGGAACCCTACCGG
  	ACATCACCACCACCATCAC
  Chlamydia_Ct812_pd_serovarD_nIgK_nopolyN	ATGGAAACTCCTGCCCAACTGTTGTTCCTTCTGCTGCTCTGGTT	225
  	GCCCGACACCACCGGATCGTGCGTGGATCTCCACGCTGGCGGC
  	CAGTCCGTGAACGAGCTTGTGTACGTGGGCCCACAGGCCGTGC
  	TTCTGCTGGACCAGATCAGAGATCTCTTCGTGGGTTCCAAGGA
  	CTCCCAGGCCGAGGGACAGTACCGGCTCATCGTCGGCGACCCT
  	TCAAGCTTCCAAGAGAAGGATGCCGACACTCTTCCGGGGAAG
  	GTGGAACAGTCCACTCTGTTTTCCGTGACCAACCCAGTCGTGT
  	TTCAAGGGGTGGACCAGCAGGACCAGGTGTCCAGCCAAGGAC
  	TGATCTGTTCATTCACCTCGAGCAATTTGGACAGCCCCCGGGA
  	CGGCGAATCGTTCCTTGGCATCGCATTCGTGGGAGACTCATCC
  	AAAGCAGGAATCACCCTTACCGATGTGAAGGCGTCCCTGAGC
  	GGCGCTGCTCTGTACTCCACCGAAGATCTCATCTTCGAGAAGA
  	TCAAGGGTGGACTGGAGTTCGCCAGCTGCTCCTCACTGGAACA
  	GGGAGGAGCCTGTGCCGCCCAAAGCATCCTCATCCACGATTGC
  	CAGGGGCTCCAAGTGAAGCATTGTACCACTGCCGTGAACGCC
  	GAGGGATCATCCGCTAACGATCACCTCGGTTTCGGAGGGGGTG
  	CCTTCTTCGTGACCGGTTCGCTGTCGGGAGAGAAGTCACTGTA
  	TATGCCCGCGGGCGACATGGTGGTCGCCAACTGCGATGGAGC
  	CATCTCATTCGAGGGAAACTCCGCCAACTTCGCAAACGGCGGC
  	GCTATCGCCGCTAGCGGGAAGGTGCTGTTCGTGGCTAACGACA
  	AGAAGACGTCCTTCATCGAGAACCGCGCCCTGTCGGGAGGTG
  	CCATTGCCGCCAGCTCCGACATTGCCTTCCAGAACTGTGCGGA
  	ACTGGTGTTCAAAGGAAACTGCGCCATCGGCACCGAAGATAA
  	GGGAAGCCTGGGAGGCGGCGCCATTTCCTCCCTCGGCACCGTG
  	CTGCTTCAGGGAAACCACGGCATCACTTGTGACAAGAACGAA
  	AGCGCGTCCCAGGGGGGAGCGATCTTCGGGAAGAACTGCCAG
  	ATTTCCGACAACGAGGGACCGGTGGTGTTCAGAGACTCCACTG
  	CCTGCCTGGGCGGCGGAGCGATCGCAGCACAGGAAATTGTCA
  	GCATCCAGAACAACCAGGCCGGCATCAGCTTCGAGGGGGGAA
  	AGGCTTCGTTCGGCGGAGGTATTGCCTGCGGATCGTTCTCGTC
  	CGCGGGCGGAGCCTCCGTGCTCGGAACCATCGACATTTCCAAG
  	AACCTGGGCGCTATCTCGTTTTCTCGCACCCTGTGCACTACTTC
  	CGACCTGGGTCAGATGGAGTACCAGGGAGGCGGAGCGCTGTT
  	TGGAGAGAACATCTCTCTGAGCGAGAACGCGGGAGTGCTGAC
  	CTTCAAGGACAACATTGTGAAGACCTTCGCCTCAAACGGAAA
  	GATCCTGGGGGGAGGCGCCATCCTGGCAACCGGGAAGGTCGA
  	AATCACCAACAATTCAGAGGGTATCTCCTTCACTGGCAACGCC
  	CGGGCCCCCCAAGCCCTGCCGACTCAGGAAGAGTTCCCCCTGT
  	TCTCCAAGAAGGAAGGACGCCCTTTGTCATCCGGCTACTCCGG
  	TGGTGGAGCGATTCTGGGTCGGGAAGTGGCCATCCTGCATAAT
  	GCGGCCGTGGTGTTTGAGCAGAACAGACTCCAATGCTCCGAA
  	GAAGAGGCCACCCTCCTGGGGTGCTGCGGGGGCGGAGCAGTG
  	CATGGCATGGATTCCACTTCCATCGTGGGAAACTCCAGCGTCC
  	GCTTCGGAAACAACTACGCTATGGGACAGGGAGTGTCAGGCG
  	GGGCCCTGCTGTCCAAGACCGTCCAGTTGGCCGGAAACGGTTC
  	GGTGGATTTCTCACGCAATATCGCCTCGCTGGGAGGCGGCGCG
  	CTGCAGGCCTCCGAAGGAAATTGCGAACTGGTCGACAACGGC
  	TACGTGCTGTTCCGGGACAACCGCGGCAGGGTGTACGGCGGA
  	GCAATCTCGTGCCTTCGGGGCGACGTCGTGATCTCGGGAAATA
  	AGGGACGGGTCGAGTTTAAGGACAACATCGCTACCAGGCTCT
  	ACGTGGAGGAAACTGTGGAGAAGGTGGAGGAAGTGGAGCCTG
  	CCCCGGAACAGAAGGACAACAACGAGCTGTCGTTCCTCGGTC
  	GGGCAGAACAGTCCTTCATTACTGCCGCCAACCAGGCCCTGTT
  	CGCGTCCGAAGATGGTGACCTCAGCCCGGAATCCAGCATCTCC
  	TCCGAGGAACTGGCCAAGCGGAGAGAATGCGCGGGAGGCGCA
  	ATCTTTGCGAAGCGGGTCCGGATCGTGGACAACCAGGAAGCT
  	GTGGTGTTCAGCAACAACTTTTCCGACATCTACGGTGGTGCAA
  	TTTTCACCGGCTCACTCCGGGAGGAGGACAAGCTGGACGGCC
  	AGATTCCCGAGGTGCTCATTTCCGGCAATGCCGGCGACGTGGT
  	GTTCTCCGGAAACTCCTCCAAGAGGGACGAACACCTCCCGCAT
  	ACCGGAGGAGGAGCCATCTGCACTCAGAACCTGACGATCTCG
  	CAGAACACCGGCAATGTGCTGTTCTACAACAACGTCGCATGTT
  	CCGGTGGCGCCGTCAGAATCGAGGACCACGGAAACGTGCTGC
  	TGGAAGCATTCGGGGGTGATATTGTGTTCAAGGGAAACAGCA
  	GCTTCCGGGCCCAGGGATCAGATGCAATCTACTTCGCCGGGAA
  	GGAGAGCCACATTACCGCCCTGAACGCCACCGAGGGTCACGC
  	CATCGTGTTCCACGATGCCCTGGTGTTCGAGAACCTGGAGGAG
  	CGCAAGAGCGCCGAAGTGCTGCTTATCAATTCCCGCGAGAACC
  	CGGGCTACACCGGATCCATCCGGTTCCTCGAAGCGGAGTCGAA
  	GGTCCCGCAGTGTATTCATGTGCAACAGGGGTCCCTGGAACTG
  	CTTAACGGAGCCACCCTGTGCTCCTACGGCTTTAAGCAGGACG
  	CGGGCGCTAAACTGGTGCTGGCGGCCGGCGCCAAGCTTAAGA
  	TCCTCGACTCCGGAACCCCGGTGCAGCAGGGGCACGCTATTAG
  	CAAGCCTGAAGCCGAGATTGAGTCGTCATCCGAACCCGAAGG
  	GGCGCACTCCCTGTGGATAGCCAAGAACGCGCAGACCACCGT
  	GCCAATGGTCGATATCCACACAATCTCCGTGGACCTCGCCAGC
  	TTCTCGTCGAGCCAGCAGGAGGGAACTGTCGAAGCGCCTCAG
  	GTCATCGTGCCGGGAGGTTCCTACGTGCGCTCGGGGGAGCTCA
  	ACCTGGAACTCGTGAATACCACTGGAACGGGATATGAGAACC
  	ACGCCCTGCTGAAGAACGAAGCCAAAGTGCCACTGATGTCCTT
  	CGTCGCCTCCGGCGACGAGGCCTCCGCCGAGATTAGCAACCTG
  	TCGGTGTCAGATCTGCAAATTCACGTGGTGACCCCTGAGATTG
  	AGGAGGACACCTACGGGCACATGGGCGATTGGTCCGAGGCGA
  	AGATCCAGGACGGCACACTGGTCATTTCATGGAACCCTACCGGA
  Ct812pd_PmpD_D_NGM_nIgK_nopolyN	ATGGAAACTCCTGCCCAACTGTTGTTCCTTCTGCTGCTCTGGTT	226
  	GCCCGACACCACCGGATCGTGCGTGGATCTCCACGCTGGCGGC
  	CAGTCCGTGAACGAGCTTGTGTACGTGGGCCCACAGGCCGTGC
  	TTCTGCTGGACCAGATCAGAGATCTCTTCGTGGGTTCCAAGGA
  	CTCCCAGGCCGAGGGACAGTACCGGCTCATCGTCGGCGACCCT
  	TCAAGCTTCCAAGAGAAGGATGCCGACACTCTTCCGGGGAAG
  	GTGGAACAGTCCACTCTGTTTTCCGTGACCAACCCAGTCGTGT
  	TTCAAGGGGTGGACCAGCAGGACCAGGTGTCCAGCCAAGGAC
  	TGATCTGTTCATTCACCTCGAGCAATTTGGACAGCCCCCGGGA
  	CGGCGAATCGTTCCTTGGCATCGCATTCGTGGGAGACTCATCC
  	AAAGCAGGAATCACCCTTACCGATGTGAAGGCGTCCCTGAGC
  	GGCGCTGCTCTGTACTCCACCGAAGATCTCATCTTCGAGAAGA
  	TCAAGGGTGGACTGGAGTTCGCCAGCTGCTCCTCACTGGAACA
  	GGGAGGAGCCTGTGCCGCCCAAAGCATCCTCATCCACGATTGC
  	CAGGGGCTCCAAGTGAAGCATTGTACCACTGCCGTGAACGCC
  	GAGGGATCATCCGCTAACGATCACCTCGGTTTCGGAGGGGGTG
  	CCTTCTTCGTGACCGGTTCGCTGTCGGGAGAGAAGTCACTGTA
  	TATGCCCGCGGGCGACATGGTGGTCGCCAACTGCGATGGAGC
  	CATCTCATTCGAGGGAAACTCCGCCAACTTCGCAAACGGCGGC
  	GCTATCGCCGCTAGCGGGAAGGTGCTGTTCGTGGCTAACGACA
  	AGAAGACGTCCTTCATCGAGAACCGCGCCCTGTCGGGAGGTG
  	CCATTGCCGCCAGCTCCGACATTGCCTTCCAGAACTGTGCGGA
  	ACTGGTGTTCAAAGGAAACTGCGCCATCGGCACCGAAGATAA
  	GGGAAGCCTGGGAGGCGGCGCCATTTCCTCCCTCGGCACCGTG
  	CTGCTTCAGGGAAACCACGGCATCACTTGTGACAAGAACGAA
  	GCAGCGTCCCAGGGGGGAGCGATCTTCGGGAAGAACTGCCAG
  	ATTTCCGACAACGAGGGACCGGTGGTGTTCAGAGACTCCACTG
  	CCTGCCTGGGCGGCGGAGCGATCGCAGCACAGGAAATTGTCA
  	GCATCCAGAACAACCAGGCCGGCATCAGCTTCGAGGGGGGAA
  	AGGCTTCGTTCGGCGGAGGTATTGCCTGCGGATCGTTCTCGTC
  	CGCGGGCGGAGCCTCCGTGCTCGGAACCATCGACATTTCCAAG
  	AACCTGGGCGCTATCTCGTTTTCTCGCACCCTGTGCACTACTTC
  	CGACCTGGGTCAGATGGAGTACCAGGGAGGCGGAGCGCTGTT
  	TGGAGAGAACATCGCTCTGAGCGAGAACGCGGGAGTGCTGAC
  	CTTCAAGGACAACATTGTGAAGACCTTCGCCTCAAACGGAAA
  	GATCCTGGGGGGAGGCGCCATCCTGGCAACCGGGAAGGTCGA
  	AATCACCAACAATGCAGAGGGTATCTCCTTCACTGGCAACGCC
  	CGGGCCCCCCAAGCCCTGCCGACTCAGGAAGAGTTCCCCCTGT
  	TCTCCAAGAAGGAAGGACGCCCTTTGTCATCCGGCTACTCCGG
  	TGGTGGAGCGATTCTGGGTCGGGAAGTGGCCATCCTGCATAAT
  	GCGGCCGTGGTGTTTGAGCAGAACAGACTCCAATGCTCCGAA
  	GAAGAGGCCACCCTCCTGGGGTGCTGCGGGGGCGGAGCAGTG
  	CATGGCATGGATTCCACTTCCATCGTGGGAAACTCCGCAGTCC
  	GCTTCGGAAACAACTACGCTATGGGACAGGGAGTGTCAGGCG
  	GGGCCCTGCTGTCCAAGACCGTCCAGTTGGCCGGAAACGGTGC
  	GGTGGATTTCTCACGCAATATCGCCTCGCTGGGAGGCGGCGCG
  	CTGCAGGCCTCCGAAGGAAATTGCGAACTGGTCGACAACGGC
  	TACGTGCTGTTCCGGGACAACCGCGGCAGGGTGTACGGCGGA
  	GCAATCTCGTGCCTTCGGGGCGACGTCGTGATCTCGGGAAATA
  	AGGGACGGGTCGAGTTTAAGGACAACATCGCTACCAGGCTCT
  	ACGTGGAGGAAACTGTGGAGAAGGTGGAGGAAGTGGAGCCTG
  	CCCCGGAACAGAAGGACAACAACGAGCTGTCGTTCCTCGGTC
  	GGGCAGAACAGTCCTTCATTACTGCCGCCAACCAGGCCCTGTT
  	CGCGTCCGAAGATGGTGACCTCAGCCCGGAATCCAGCATCTCC
  	TCCGAGGAACTGGCCAAGCGGAGAGAATGCGCGGGAGGCGCA
  	ATCTTTGCGAAGCGGGTCCGGATCGTGGACAACCAGGAAGCT
  	GTGGTGTTCAGCAACAACTTTGCCGACATCTACGGTGGTGCAA
  	TTTTCACCGGCTCACTCCGGGAGGAGGACAAGCTGGACGGCC
  	AGATTCCCGAGGTGCTCATTTCCGGCAATGCCGGCGACGTGGT
  	GTTCTCCGGAAACTCCGCCAAGAGGGACGAACACCTCCCGCAT
  	ACCGGAGGAGGAGCCATCTGCACTCAGAACCTGGCAATCTCG
  	CAGAACACCGGCAATGTGCTGTTCTACAACAACGTCGCATGTT
  	CCGGTGGCGCCGTCAGAATCGAGGACCACGGAAACGTGCTGC
  	TGGAAGCATTCGGGGGTGATATTGTGTTCAAGGGAAACAGCG
  	CATTCCGGGCCCAGGGATCAGATGCAATCTACTTCGCCGGGAA
  	GGAGAGCCACATTACCGCCCTGAACGCCGCCGAGGGTCACGC
  	CATCGTGTTCCACGATGCCCTGGTGTTCGAGAACCTGGAGGAG
  	CGCAAGAGCGCCGAAGTGCTGCTTATCAATTCCCGCGAGAACC
  	CGGGCTACACCGGATCCATCCGGTTCCTCGAAGCGGAGTCGAA
  	GGTCCCGCAGTGTATTCATGTGCAACAGGGGTCCCTGGAACTG
  	CTTAACGGAGCCACCCTGTGCTCCTACGGCTTTAAGCAGGACG
  	CGGGCGCTAAACTGGTGCTGGCGGCCGGCGCCAAGCTTAAGA
  	TCCTCGACTCCGGAACCCCGGTGCAGCAGGGGCACGCTATTAG
  	CAAGCCTGAAGCCGAGATTGAGTCGTCATCCGAACCCGAAGG
  	GGCGCACTCCCTGTGGATAGCCAAGAACGCGCAGACCACCGT
  	GCCAATGGTCGATATCCACACAATCTCCGTGGACCTCGCCAGC
  	TTCTCGTCGAGCCAGCAGGAGGGAACTGTCGAAGCGCCTCAG
  	GTCATCGTGCCGGGAGGTTCCTACGTGCGCTCGGGGGAGCTCA
  	ACCTGGAACTCGTGAATACCGCTGGAACGGGATATGAGAACC
  	ACGCCCTGCTGAAGAACGAAGCCAAAGTGCCACTGATGTCCTT
  	CGTCGCCTCCGGCGACGAGGCCTCCGCCGAGATTAGCAACCTG
  	GCGGTGTCAGATCTGCAAATTCACGTGGTGACCCCTGAGATTG
  	AGGAGGACACCTACGGGCACATGGGCGATTGGTCCGAGGCGA
  	AGATCCAGGACGGCACACTGGTCATTTCATGGAACCCTGCCGGA
  Ct812pd_PmpD_D_NGM_nIgK_cHis_nopolyN	ATGGAAACTCCTGCCCAACTGTTGTTCCTTCTGCTGCTCTGGTT	227
  	GCCCGACACCACCGGATCGTGCGTGGATCTCCACGCTGGCGGC
  	CAGTCCGTGAACGAGCTTGTGTACGTGGGCCCACAGGCCGTGC
  	TTCTGCTGGACCAGATCAGAGATCTCTTCGTGGGTTCCAAGGA
  	CTCCCAGGCCGAGGGACAGTACCGGCTCATCGTCGGCGACCCT
  	TCAAGCTTCCAAGAGAAGGATGCCGACACTCTTCCGGGGAAG
  	GTGGAACAGTCCACTCTGTTTTCCGTGACCAACCCAGTCGTGT
  	TTCAAGGGGTGGACCAGCAGGACCAGGTGTCCAGCCAAGGAC
  	TGATCTGTTCATTCACCTCGAGCAATTTGGACAGCCCCCGGGA
  	CGGCGAATCGTTCCTTGGCATCGCATTCGTGGGAGACTCATCC
  	AAAGCAGGAATCACCCTTACCGATGTGAAGGCGTCCCTGAGC
  	GGCGCTGCTCTGTACTCCACCGAAGATCTCATCTTCGAGAAGA
  	TCAAGGGTGGACTGGAGTTCGCCAGCTGCTCCTCACTGGAACA
  	GGGAGGAGCCTGTGCCGCCCAAAGCATCCTCATCCACGATTGC
  	CAGGGGCTCCAAGTGAAGCATTGTACCACTGCCGTGAACGCC
  	GAGGGATCATCCGCTAACGATCACCTCGGTTTCGGAGGGGGTG
  	CCTTCTTCGTGACCGGTTCGCTGTCGGGAGAGAAGTCACTGTA
  	TATGCCCGCGGGCGACATGGTGGTCGCCAACTGCGATGGAGC
  	CATCTCATTCGAGGGAAACTCCGCCAACTTCGCAAACGGCGGC
  	GCTATCGCCGCTAGCGGGAAGGTGCTGTTCGTGGCTAACGACA
  	AGAAGACGTCCTTCATCGAGAACCGCGCCCTGTCGGGAGGTG
  	CCATTGCCGCCAGCTCCGACATTGCCTTCCAGAACTGTGCGGA
  	ACTGGTGTTCAAAGGAAACTGCGCCATCGGCACCGAAGATAA
  	GGGAAGCCTGGGAGGCGGCGCCATTTCCTCCCTCGGCACCGTG
  	CTGCTTCAGGGAAACCACGGCATCACTTGTGACAAGAACGAA
  	GCAGCGTCCCAGGGGGGAGCGATCTTCGGGAAGAACTGCCAG
  	ATTTCCGACAACGAGGGACCGGTGGTGTTCAGAGACTCCACTG
  	CCTGCCTGGGCGGCGGAGCGATCGCAGCACAGGAAATTGTCA
  	GCATCCAGAACAACCAGGCCGGCATCAGCTTCGAGGGGGGAA
  	AGGCTTCGTTCGGCGGAGGTATTGCCTGCGGATCGTTCTCGTC
  	CGCGGGCGGAGCCTCCGTGCTCGGAACCATCGACATTTCCAAG
  	AACCTGGGCGCTATCTCGTTTTCTCGCACCCTGTGCACTACTTC
  	CGACCTGGGTCAGATGGAGTACCAGGGAGGCGGAGCGCTGTT
  	TGGAGAGAACATCGCTCTGAGCGAGAACGCGGGAGTGCTGAC
  	CTTCAAGGACAACATTGTGAAGACCTTCGCCTCAAACGGAAA
  	GATCCTGGGGGGAGGCGCCATCCTGGCAACCGGGAAGGTCGA
  	AATCACCAACAATGCAGAGGGTATCTCCTTCACTGGCAACGCC
  	CGGGCCCCCCAAGCCCTGCCGACTCAGGAAGAGTTCCCCCTGT
  	TCTCCAAGAAGGAAGGACGCCCTTTGTCATCCGGCTACTCCGG
  	TGGTGGAGCGATTCTGGGTCGGGAAGTGGCCATCCTGCATAAT
  	GCGGCCGTGGTGTTTGAGCAGAACAGACTCCAATGCTCCGAA
  	GAAGAGGCCACCCTCCTGGGGTGCTGCGGGGGCGGAGCAGTG
  	CATGGCATGGATTCCACTTCCATCGTGGGAAACTCCGCAGTCC
  	GCTTCGGAAACAACTACGCTATGGGACAGGGAGTGTCAGGCG
  	GGGCCCTGCTGTCCAAGACCGTCCAGTTGGCCGGAAACGGTGC
  	GGTGGATTTCTCACGCAATATCGCCTCGCTGGGAGGCGGCGCG
  	CTGCAGGCCTCCGAAGGAAATTGCGAACTGGTCGACAACGGC
  	TACGTGCTGTTCCGGGACAACCGCGGCAGGGTGTACGGCGGA
  	GCAATCTCGTGCCTTCGGGGCGACGTCGTGATCTCGGGAAATA
  	AGGGACGGGTCGAGTTTAAGGACAACATCGCTACCAGGCTCT
  	ACGTGGAGGAAACTGTGGAGAAGGTGGAGGAAGTGGAGCCTG
  	CCCCGGAACAGAAGGACAACAACGAGCTGTCGTTCCTCGGTC
  	GGGCAGAACAGTCCTTCATTACTGCCGCCAACCAGGCCCTGTT
  	CGCGTCCGAAGATGGTGACCTCAGCCCGGAATCCAGCATCTCC
  	TCCGAGGAACTGGCCAAGCGGAGAGAATGCGCGGGAGGCGCA
  	ATCTTTGCGAAGCGGGTCCGGATCGTGGACAACCAGGAAGCT
  	GTGGTGTTCAGCAACAACTTTGCCGACATCTACGGTGGTGCAA
  	TTTTCACCGGCTCACTCCGGGAGGAGGACAAGCTGGACGGCC
  	AGATTCCCGAGGTGCTCATTTCCGGCAATGCCGGCGACGTGGT
  	GTTCTCCGGAAACTCCGCCAAGAGGGACGAACACCTCCCGCAT
  	ACCGGAGGAGGAGCCATCTGCACTCAGAACCTGGCAATCTCG
  	CAGAACACCGGCAATGTGCTGTTCTACAACAACGTCGCATGTT
  	CCGGTGGCGCCGTCAGAATCGAGGACCACGGAAACGTGCTGC
  	TGGAAGCATTCGGGGGTGATATTGTGTTCAAGGGAAACAGCG
  	CATTCCGGGCCCAGGGATCAGATGCAATCTACTTCGCCGGGAA
  	GGAGAGCCACATTACCGCCCTGAACGCCGCCGAGGGTCACGC
  	CATCGTGTTCCACGATGCCCTGGTGTTCGAGAACCTGGAGGAG
  	CGCAAGAGCGCCGAAGTGCTGCTTATCAATTCCCGCGAGAACC
  	CGGGCTACACCGGATCCATCCGGTTCCTCGAAGCGGAGTCGAA
  	GGTCCCGCAGTGTATTCATGTGCAACAGGGGTCCCTGGAACTG
  	CTTAACGGAGCCACCCTGTGCTCCTACGGCTTTAAGCAGGACG
  	CGGGCGCTAAACTGGTGCTGGCGGCCGGCGCCAAGCTTAAGA
  	TCCTCGACTCCGGAACCCCGGTGCAGCAGGGGCACGCTATTAG
  	CAAGCCTGAAGCCGAGATTGAGTCGTCATCCGAACCCGAAGG
  	GGCGCACTCCCTGTGGATAGCCAAGAACGCGCAGACCACCGT
  	GCCAATGGTCGATATCCACACAATCTCCGTGGACCTCGCCAGC
  	TTCTCGTCGAGCCAGCAGGAGGGAACTGTCGAAGCGCCTCAG
  	GTCATCGTGCCGGGAGGTTCCTACGTGCGCTCGGGGGAGCTCA
  	ACCTGGAACTCGTGAATACCGCTGGAACGGGATATGAGAACC
  	ACGCCCTGCTGAAGAACGAAGCCAAAGTGCCACTGATGTCCTT
  	CGTCGCCTCCGGCGACGAGGCCTCCGCCGAGATTAGCAACCTG
  	GCGGTGTCAGATCTGCAAATTCACGTGGTGACCCCTGAGATTG
  	AGGAGGACACCTACGGGCACATGGGCGATTGGTCCGAGGCGA
  	AGATCCAGGACGGCACACTGGTCATTTCATGGAACCCTGCCGG
  	ACATCACCACCACCATCAC
  Ct871pd_PmpG_D_NGM_nIgK	ATGGAAACCCCTGCTCAGCTGCTGTTCCTGCTGCTGCTGTGGC	228
  	TGCCTGATACAACAGGCGCCGAGATCATGATTCCCCAGGGCAT
  	CTACGACGGCGAAACCCTGACCGTGTCTTTCCCCTATACCGTG
  	ATCGGCGATCCTAGCGGCACCACCGTGTTTTCTGCTGGCGAGC
  	TGACCCTGAAGAACCTGGACAACTCTATCGCCGCTCTGCCCCT
  	GAGCTGCTTCGGAAATCTGCTGGGCAGCTTCACCGTGCTCGGC
  	AGAGGACACAGCCTGACCTTCGAGAACATCCGGACCAGCACA
  	AATGGCGCTGCCCTGAGCGATAGCGCCAATAGCGGCCTGTTTA
  	CCATCGAGGGCTTCAAAGAGCTGAGCTTCAGCAACTGCAACA
  	GCCTGCTGGCAGTGCTGCCTGCCGCCACAACAAATAGCGGCA
  	GCCAGACACCTACCACCACCAGCACACCTTCTAACGGCGCCAT
  	CTACAGCAAGACCGACCTGCTGCTCCTGAACAACGAGAAGTTC
  	AGCTTCTACTCCAACCTGGTGTCCGGCGACGGCGGAGCCATTG
  	ATGCCAAATCTCTGACCGTGCAGGGCATCAGCAAGCTGTGCGT
  	GTTCCAAGAGAACACAGCCCAGGCTGATGGCGGAGCCTGTCA
  	GGTGGTCACAAGCTTTAGCGCCATGGCCAACGAGGCCCCTATC
  	GCCTTTATTGCCAATGTGGCCGGCGTTAGAGGCGGAGGAATTG
  	CCGCTGTTCAGGATGGACAGCAGGGCGTGTCCAGCAGCACAA
  	GCACTGAGGATCCTGTGGTGTCCTTCAGCAGAAACACCGCCGT
  	GGAATTCGATGGCAACGTGGCCAGAGTTGGCGGCGGAATCTA
  	CAGCTACGGAAACGTGGCCTTTCTGAACAATGGCAAGACCCTG
  	TTCCTCAACAACGTGGCAAGCCCCGTGTATATCGCCGCCGAGC
  	AGCCTACAAATGGCCAGGCCTCTAATACCGCCGACAACTATGG
  	CGACGGTGGCGCAATCTTCTGCAAGAATGGTGCTCAGGCCGCT
  	GGCAGCAACAATGCCGGCTCTGTGTCCTTTGATGGCGAAGGCG
  	TGGTGTTCTTCTCCTCTAACGTGGCCGCTGGAAAAGGCGGCGC
  	TATCTACGCCAAGAAACTGAGCGTGGCCAACTGCGGCCCTGTG
  	CAGTTTCTGGGCAATATCGCCAATGATGGCGGTGCCATCTACC
  	TGGGAGAGTCCGGCGAACTGTCTCTGAGCGCCGATTACGGCG
  	ACATCATCTTCGACGGCAACCTGAAGCGGACCGCCAAAGAAA
  	ATGCCGCCGATGTGAATGGCGTGACAGTGTCCAGCCAGGCCAT
  	CTCTATGGGCTCTGGCGGCAAGATCACCACACTGAGAGCCAA
  	GGCCGGCCACCAGATCCTGTTCAACGACCCTATCGAGATGGCC
  	AATGGCAACAACCAGCCTGCTCAGAGCAGCGAGCCCCTGAAG
  	ATTAACGATGGCGAGGGCTACACCGGCGATATCGTGTTCGCCA
  	ACGGCAACAGCGCCCTGTACCAGAATGTGGCCATCGAGCAGG
  	GCAGAATCGTGCTGAGAGAGAAGGCCAAGCTGAGCGTGAACA
  	GCCTGAGTCAGACAGGCGGCAGCCTGTATATGGAAGCCGGCA
  	GCACCCTGGACTTCGTGACACCTCAACCTCCACAGCAACCTCC
  	AGCCGCCAACCAGCTGATCACCCTGTCTAATCTGCACCTGAGC
  	CTGAGTTCCCTGCTGGCCAACAACGCCGTGACCAATCCTCCTA
  	CCAATCCACCAGCTCAGGACTCTCACCCTGCCATCATCGGCTC
  	TACAACAGCCGGAAGCGTGACAATCAGCGGCCCCATCTTCTTC
  	GAGGACCTGGACGATACCGCCTACGACAGATACGATTGGCTG
  	GGCTCCAACCAGAAAATCGACGTGCTGAAACTGCAGCTGGGC
  	ACCCAGCCATCTGCCAACGCTCCATCTGATCTGACCCTGGGCA
  	ACGAGATGCCTAAGTACGGCTACCAAGGCAGCTGGAAGCTGG
  	CCTGGGATCCTAACACAGCCAACAATGGCCCCTACACACTGAA
  	GGCCACCTGGACCAAGACAGGC
  Ct871pd_PmpG_D_NGM_nIgK_cHis	ATGGAAACCCCTGCTCAGCTGCTGTTCCTGCTGCTGCTGTGGC	229
  	TGCCTGATACAACAGGCGCCGAGATCATGATTCCCCAGGGCAT
  	CTACGACGGCGAAACCCTGACCGTGTCTTTCCCCTATACCGTG
  	ATCGGCGATCCTAGCGGCACCACCGTGTTTTCTGCTGGCGAGC
  	TGACCCTGAAGAACCTGGACAACTCTATCGCCGCTCTGCCCCT
  	GAGCTGCTTCGGAAATCTGCTGGGCAGCTTCACCGTGCTCGGC
  	AGAGGACACAGCCTGACCTTCGAGAACATCCGGACCAGCACA
  	AATGGCGCTGCCCTGAGCGATAGCGCCAATAGCGGCCTGTTTA
  	CCATCGAGGGCTTCAAAGAGCTGAGCTTCAGCAACTGCAACA
  	GCCTGCTGGCAGTGCTGCCTGCCGCCACAACAAATAGCGGCA
  	GCCAGACACCTACCACCACCAGCACACCTTCTAACGGCGCCAT
  	CTACAGCAAGACCGACCTGCTGCTCCTGAACAACGAGAAGTTC
  	AGCTTCTACTCCAACCTGGTGTCCGGCGACGGCGGAGCCATTG
  	ATGCCAAATCTCTGACCGTGCAGGGCATCAGCAAGCTGTGCGT
  	GTTCCAAGAGAACACAGCCCAGGCTGATGGCGGAGCCTGTCA
  	GGTGGTCACAAGCTTTAGCGCCATGGCCAACGAGGCCCCTATC
  	GCCTTTATTGCCAATGTGGCCGGCGTTAGAGGCGGAGGAATTG
  	CCGCTGTTCAGGATGGACAGCAGGGCGTGTCCAGCAGCACAA
  	GCACTGAGGATCCTGTGGTGTCCTTCAGCAGAAACACCGCCGT
  	GGAATTCGATGGCAACGTGGCCAGAGTTGGCGGCGGAATCTA
  	CAGCTACGGAAACGTGGCCTTTCTGAACAATGGCAAGACCCTG
  	TTCCTCAACAACGTGGCAAGCCCCGTGTATATCGCCGCCGAGC
  	AGCCTACAAATGGCCAGGCCTCTAATACCGCCGACAACTATGG
  	CGACGGTGGCGCAATCTTCTGCAAGAATGGTGCTCAGGCCGCT
  	GGCAGCAACAATGCCGGCTCTGTGTCCTTTGATGGCGAAGGCG
  	TGGTGTTCTTCTCCTCTAACGTGGCCGCTGGAAAAGGCGGCGC
  	TATCTACGCCAAGAAACTGAGCGTGGCCAACTGCGGCCCTGTG
  	CAGTTTCTGGGCAATATCGCCAATGATGGCGGTGCCATCTACC
  	TGGGAGAGTCCGGCGAACTGTCTCTGAGCGCCGATTACGGCG
  	ACATCATCTTCGACGGCAACCTGAAGCGGACCGCCAAAGAAA
  	ATGCCGCCGATGTGAATGGCGTGACAGTGTCCAGCCAGGCCAT
  	CTCTATGGGCTCTGGCGGCAAGATCACCACACTGAGAGCCAA
  	GGCCGGCCACCAGATCCTGTTCAACGACCCTATCGAGATGGCC
  	AATGGCAACAACCAGCCTGCTCAGAGCAGCGAGCCCCTGAAG
  	ATTAACGATGGCGAGGGCTACACCGGCGATATCGTGTTCGCCA
  	ACGGCAACAGCGCCCTGTACCAGAATGTGGCCATCGAGCAGG
  	GCAGAATCGTGCTGAGAGAGAAGGCCAAGCTGAGCGTGAACA
  	GCCTGAGTCAGACAGGCGGCAGCCTGTATATGGAAGCCGGCA
  	GCACCCTGGACTTCGTGACACCTCAACCTCCACAGCAACCTCC
  	AGCCGCCAACCAGCTGATCACCCTGTCTAATCTGCACCTGAGC
  	CTGAGTTCCCTGCTGGCCAACAACGCCGTGACCAATCCTCCTA
  	CCAATCCACCAGCTCAGGACTCTCACCCTGCCATCATCGGCTC
  	TACAACAGCCGGAAGCGTGACAATCAGCGGCCCCATCTTCTTC
  	GAGGACCTGGACGATACCGCCTACGACAGATACGATTGGCTG
  	GGCTCCAACCAGAAAATCGACGTGCTGAAACTGCAGCTGGGC
  	ACCCAGCCATCTGCCAACGCTCCATCTGATCTGACCCTGGGCA
  	ACGAGATGCCTAAGTACGGCTACCAAGGCAGCTGGAAGCTGG
  	CCTGGGATCCTAACACAGCCAACAATGGCCCCTACACACTGAA
  	GGCCACCTGGACCAAGACAGGCCACCACCATCACCATCAC
  Ct460_D_S16A_nIgK	ATGGAAACCCCTGCTCAGCTGCTGTTCCTGCTGCTGCTGTGGC	230
  	TGCCTGATACCACAGGCATGAGCCAGAACAAGAACAGCGCCT
  	TCATGCAGCCCGTGAACGTGGCAGCTGATCTGGCCGCTATAGT
  	TGGCGCTGGCCCTATGCCTAGAACCGAGATCATCAAGAAGAT
  	GTGGGACTACATTAAGAAGAACGGCCTGCAGGACCCCACCAA
  	CAAGCGGAACATCAACCCCGACGACAAGCTGGCCAAGGTGTT
  	CGGCACAGAGAAGCCCATCGACATGTTCCAGATGACCAAGAT
  	GGTGTCCCAGCACATCATCAAG
  Ct460_D_S16A_nIgK_cHis	ATGGAAACCCCTGCTCAGCTGCTGTTCCTGCTGCTGCTGTGGC	231
  	TGCCTGATACCACAGGCATGAGCCAGAACAAGAACAGCGCCT
  	TCATGCAGCCCGTGAACGTGGCAGCTGATCTGGCCGCTATAGT
  	TGGCGCTGGCCCTATGCCTAGAACCGAGATCATCAAGAAGAT
  	GTGGGACTACATTAAGAAGAACGGCCTGCAGGACCCCACCAA
  	CAAGCGGAACATCAACCCCGACGACAAGCTGGCCAAGGTGTT
  	CGGCACAGAGAAGCCCATCGACATGTTCCAGATGACCAAGAT
  	GGTGTCCCAGCACATCATCAAGCACCACCACCATCACCAC
  Ct875_E_S274Q_N275H_S574D_nIgK	ATGGAAACCCCTGCCCAGCTGCTGTTCCTGCTGCTGCTGTGGC	232
  	TGCCTGACACCACCGGCATGAGCATCAGAGGCGTGGGCGGCA
  	ACGGCAACAGCAGAATCCCTAGCCACAACGGCGACGGCAGCA
  	ACAGGCGGAGCCAGAACACCAAGGGCAACAACAAGGTGGAA
  	GATAGAGTGTGCAGCCTGTACAGCAGCCGGTCCAACGAGAAC
  	CGCGAGAGCCCTTATGCCGTGGTGGACGTGTCCAGCATGATCG
  	AGAGCACCCCCACCAGCGGCGAGACAACCAGAGCTAGTAGAG
  	GCGTGCTGAGCCGGTTCCAGAGGGGCCTCGTGCGGATTGCTGA
  	CAAAGTGCGGAGAGCCGTGCAGTGCGCTTGGAGCAGCGTGTC
  	CACAAGCAGAAGCAGCGCCACAAGAGCCGCCGAGAGCGGCA
  	GCTCTAGCAGAACAGCTAGAGGCGCCAGCAGCGGCTACAGAG
  	AGTACAGCCCTTCTGCCGCTCGGGGCCTGCGGCTGATGTTCAC
  	CGACTTTTGGCGGACCCGGGTGCTGAGACAGACCTCTCCTATG
  	GCCGGCGTGTTCGGCAACCTGGACGTGAACGAGGCCAGACTG
  	ATGGCCGCCTACACCAGCGAGTGTGCCGATCACCTGGAAGCC
  	AAAGAGCTGGCCGGACCTGACGGCGTGGCAGCCGCTAGAGAA
  	ATCGCCAAGAGATGGGAGAAGAGAGTGCGGGACCTGCAGGAC
  	AAGGGCGCTGCCAGAAAGCTGCTGAACGACCCCCTGGGCAGA
  	CGGACCCCCAACTACCAGAGCAAGAACCCCGGCGAGTACACC
  	GTGGGCAACTCCATGTTCTACGACGGCCCCCAGGTGGCCAACC
  	TGCAGAATGTGGATACCGGCTTCTGGCTGGACATGCAGCACCT
  	GAGCGACGTGGTGCTGTCCAGAGAGATCCAGACCGGCCTGAG
  	AGCCAGAGCCACCCTGGAAGAGTCCATGCCCATGCTGGAAAA
  	TCTGGAAGAGAGATTCCGGCGGCTGCAGGAAACCTGCGACGC
  	CGCCAGAACCGAGATCGAGGAAAGCGGCTGGACCCGGGAAAG
  	CGCCTCCAGAATGGAAGGCGACGAAGCCCAGGGCCCCAGCAG
  	AGTGCAGCAGGCCTTTCAGAGCTTCGTGAATGAGTGCAACAGC
  	ATCGAGTTCAGCTTCGGCTCCTTCGGCGAGCACGTGCGGGTGC
  	TGTGTGCCAGAGTGTCAAGAGGACTGGCCGCTGCCGGCGAGG
  	CCATCAGAAGATGCTTCAGCTGCTGCAAGGGCAGCACCCACA
  	GATACGCCCCCAGAGATGACCTGTCTCCTGAGGGCGCCTCTCT
  	GGCCGAAACCCTGGCCAGATTCGCCGACGACATGGGCATCGA
  	AAGAGGCGCCGACGGCACCTACGACATCCCCCTGGTGGACGA
  	TTGGAGAAGGGGCGTGCCATCCATCGAGGGCGAGGGCAGCGA
  	TAGCATCTACGAGATCATGATGCCCATCTACGAAGTGATGAAC
  	ATGGACCTGGAAACCCGGCGGAGCTTCGCCGTGCAGCAGGGC
  	CATTACCAGGACCCCAGAGCCAGCGACTACGACCTGCCTAGA
  	GCCTCCGATTACGATCTGCCCAGAAGCCCCTACCCCACCCCTC
  	CACTGCCTCCCAGATACCAGCTGCAGAACATGGATGTGGAAG
  	CCGGCTTTCGCGAGGCCGTGTACGCCTCTTTTGTGGCCGGCAT
  	GTACAACTACGTCGTGACCCAGCCCCAGGAACGGATCCCCAAT
  	AGCCAGCAGGTGGAAGGCATCCTGCGGGACATGCTGACCAAC
  	GGCGATCAGACCTTCCGGGACCTGATGAAGCGGTGGAACAGA
  	GAGGTGGACCGCGAG
  Ct875_E_S274Q_N275H_S574D_nIgK_cHis	ATGGAAACCCCTGCCCAGCTGCTGTTCCTGCTGCTGCTGTGGC	233
  	TGCCTGACACCACCGGCATGAGCATCAGAGGCGTGGGCGGCA
  	ACGGCAACAGCAGAATCCCTAGCCACAACGGCGACGGCAGCA
  	ACAGGCGGAGCCAGAACACCAAGGGCAACAACAAGGTGGAA
  	GATAGAGTGTGCAGCCTGTACAGCAGCCGGTCCAACGAGAAC
  	CGCGAGAGCCCTTATGCCGTGGTGGACGTGTCCAGCATGATCG
  	AGAGCACCCCCACCAGCGGCGAGACAACCAGAGCTAGTAGAG
  	GCGTGCTGAGCCGGTTCCAGAGGGGCCTCGTGCGGATTGCTGA
  	CAAAGTGCGGAGAGCCGTGCAGTGCGCTTGGAGCAGCGTGTC
  	CACAAGCAGAAGCAGCGCCACAAGAGCCGCCGAGAGCGGCA
  	GCTCTAGCAGAACAGCTAGAGGCGCCAGCAGCGGCTACAGAG
  	AGTACAGCCCTTCTGCCGCTCGGGGCCTGCGGCTGATGTTCAC
  	CGACTTTTGGCGGACCCGGGTGCTGAGACAGACCTCTCCTATG
  	GCCGGCGTGTTCGGCAACCTGGACGTGAACGAGGCCAGACTG
  	ATGGCCGCCTACACCAGCGAGTGTGCCGATCACCTGGAAGCC
  	AAAGAGCTGGCCGGACCTGACGGCGTGGCAGCCGCTAGAGAA
  	ATCGCCAAGAGATGGGAGAAGAGAGTGCGGGACCTGCAGGAC
  	AAGGGCGCTGCCAGAAAGCTGCTGAACGACCCCCTGGGCAGA
  	CGGACCCCCAACTACCAGAGCAAGAACCCCGGCGAGTACACC
  	GTGGGCAACTCCATGTTCTACGACGGCCCCCAGGTGGCCAACC
  	TGCAGAATGTGGATACCGGCTTCTGGCTGGACATGCAGCACCT
  	GAGCGACGTGGTGCTGTCCAGAGAGATCCAGACCGGCCTGAG
  	AGCCAGAGCCACCCTGGAAGAGTCCATGCCCATGCTGGAAAA
  	TCTGGAAGAGAGATTCCGGCGGCTGCAGGAAACCTGCGACGC
  	CGCCAGAACCGAGATCGAGGAAAGCGGCTGGACCCGGGAAAG
  	CGCCTCCAGAATGGAAGGCGACGAAGCCCAGGGCCCCAGCAG
  	AGTGCAGCAGGCCTTTCAGAGCTTCGTGAATGAGTGCAACAGC
  	ATCGAGTTCAGCTTCGGCTCCTTCGGCGAGCACGTGCGGGTGC
  	TGTGTGCCAGAGTGTCAAGAGGACTGGCCGCTGCCGGCGAGG
  	CCATCAGAAGATGCTTCAGCTGCTGCAAGGGCAGCACCCACA
  	GATACGCCCCCAGAGATGACCTGTCTCCTGAGGGCGCCTCTCT
  	GGCCGAAACCCTGGCCAGATTCGCCGACGACATGGGCATCGA
  	AAGAGGCGCCGACGGCACCTACGACATCCCCCTGGTGGACGA
  	TTGGAGAAGGGGCGTGCCATCCATCGAGGGCGAGGGCAGCGA
  	TAGCATCTACGAGATCATGATGCCCATCTACGAAGTGATGAAC
  	ATGGACCTGGAAACCCGGCGGAGCTTCGCCGTGCAGCAGGGC
  	CATTACCAGGACCCCAGAGCCAGCGACTACGACCTGCCTAGA
  	GCCTCCGATTACGATCTGCCCAGAAGCCCCTACCCCACCCCTC
  	CACTGCCTCCCAGATACCAGCTGCAGAACATGGATGTGGAAG
  	CCGGCTTTCGCGAGGCCGTGTACGCCTCTTTTGTGGCCGGCAT
  	GTACAACTACGTCGTGACCCAGCCCCAGGAACGGATCCCCAAT
  	AGCCAGCAGGTGGAAGGCATCCTGCGGGACATGCTGACCAAC
  	GGCGATCAGACCTTCCGGGACCTGATGAAGCGGTGGAACAGA
  	GAGGTGGACCGCGAGCACCACCATCACCACCAC
  Ct622_E_S13N_S179A_S220N_nIgK	ATGGAAACCCCTGCCCAACTGCTTTTCTTGCTGCTGCTCTGGCT	234
  	CCCTGACACCACCGGAATGGAATCTGGACCCGAGTCCGTGTCA
  	AGCAACCAGAACTCCATGAACCCCATCATTAATGGACAGATC
  	GCATCCAATTCCGAAACCAAGGAAAGCACCAAGGCATCGGAG
  	GCCTCCCCATCCGCCTCAAGCTCCGTGTCGTCCTGGTCGTTTCT
  	GTCGAGCGCGAAGAATGCCCTGATCTCACTGCGGGACGCGATT
  	CTGAACAAGAACAGCTCCCCAACCGACTCCCTGAGCCAACTCG
  	AGGCCTCAACTTCCACTTCGACTGTGACTAGGGTCGCTGCCAA
  	GGATTATGACGAGGCCAAGAGCAACTTCGACACCGCCAAGAG
  	CGGACTGGAAAACGCCAAAACCCTGGCCGAATACGAAACTAA
  	GATGGCCGATCTCATGGCGGCCCTGCAAGACATGGAACGGCT
  	GGCGAACTCCGATCCGTCCAACAACCACACTGAGGAAGTGAA
  	CAACATCAAGAAGGCTCTCGAGGCCCAGAAGGATACCATCGA
  	CAAGTTGAACAAGCTTGTGACGCTGCAGAACCAAAACAAGGC
  	CCTGACGGAAGTGCTCAAAACCACCGACTCGGCCGACCAGAT
  	TCCGGCCATCAACAGCCAGCTGGAGATTAACAAGAACTCGGC
  	CGATCAGATTATCAAGGACCTGGAGCGCCAGAACATTAACTA
  	CGAGGCCGTCTTGACTAACGCCGGCGAAGTGATCAAGGCGTC
  	ATCCGAAGCCGGCATTAAGCTGGGACAGGCGCTGCAATCCAT
  	CGTCGACGCCGGCGACCAGTCCCAGGCGGCGGTGCTGCAGGC
  	CCAGCAGAACAACTCCCCCGATAACATCGCTGCAACCAAGGA
  	ACTGATTGACGCGGCCGAAACCAAAGTCAACGAACTGAAGCA
  	GGAGCACACTGGTCTGACCGACTCGCCGCTCGTGAAGAAGGC
  	CGAAGAACAGATCAGCCAGGCTCAGAAGGATATCCAGGAAAT
  	CAAGCCTTCGGGGAGCGACATCCCGATCGTGGGACCGTCCGGT
  	TCCGCCGCTTCCGCCGGGTCCGCAGCCGGGGCCCTTAAGTCGT
  	CGAACAATAGCGGCAGAATATCCCTGCTGCTCGACGATGTGG
  	ATAACGAGATGGCCGCCATTGCGCTGCAAGGATTCCGGTCCAT
  	GATCGAGCAGTTCAACGTGAACAACCCCGCCACCGCCAAGGA
  	GCTGCAGGCTATGGAGGCCCAACTCACTGCCATGTCCGACCAG
  	CTCGTGGGAGCGGACGGAGAACTGCCAGCCGAGATCCAGGCC
  	ATCAAGGACGCTCTGGCCCAGGCACTGAAGCAGCCGTCCGCG
  	GATGGCCTGGCCACCGCCATGGGCCAGGTCGCGTTCGCCGCCG
  	CTAAAGTCGGCGGAGGTTCGGCCGGCACTGCCGGGACCGTGC
  	AGATGAATGTCAAGCAGCTGTACAAGACTGCGTTCTCGTCGAC
  	CAGCTCCAGCTCCTACGCCGCGGCCCTGTCCGACGGTTACAGC
  	GCGTACAAGACCCTGAACTCCCTTTACTCCGAATCGAGATCCG
  	GGGTCCAGTCCGCAATTTCACAAACCGCCAATCCTGCCCTGTC
  	GCGCTCAGTGTCACGCAGCGGCATCGAGTCACAGGGCAGAAG
  	CGCCGACGCTAGCCAAAGGGCCGCAGAAACCATTGTGCGGGA
  	CTCCCAGACACTTGGAGATGTCTACAGCCGCCTCCAAGTGCTG
  	GACTCCCTCATGTCCACCATCGTGTCAAACCCTCAGGCTAACC
  	AGGAGGAAATCATGCAGAAGCTGACCGCAAGCATTTCCAAGG
  	CTCCGCAGTTTGGATACCCCGCTGTGCAAAACTCCGCGGACAG
  	CTTGCAGAAATTCGCAGCCCAGTTGGAGAGGGAGTTCGTGGA
  	CGGGGAGCGGTCCCTCGCGGAGTCCCAGGAGAACGCATTCCG
  	GAAGCAGCCCGCCTTCATTCAACAAGTGCTTGTGAACATCGCC
  	TCCCTGTTCTCCGGTTACCTGTCT
  Ct622_E_S13N_S179A_S220N_nIgK_cHis	ATGGAAACCCCTGCCCAACTGCTTTTCTTGCTGCTGCTCTGGCT	235
  	CCCTGACACCACCGGAATGGAATCTGGACCCGAGTCCGTGTCA
  	AGCAACCAGAACTCCATGAACCCCATCATTAATGGACAGATC
  	GCATCCAATTCCGAAACCAAGGAAAGCACCAAGGCATCGGAG
  	GCCTCCCCATCCGCCTCAAGCTCCGTGTCGTCCTGGTCGTTTCT
  	GTCGAGCGCGAAGAATGCCCTGATCTCACTGCGGGACGCGATT
  	CTGAACAAGAACAGCTCCCCAACCGACTCCCTGAGCCAACTCG
  	AGGCCTCAACTTCCACTTCGACTGTGACTAGGGTCGCTGCCAA
  	GGATTATGACGAGGCCAAGAGCAACTTCGACACCGCCAAGAG
  	CGGACTGGAAAACGCCAAAACCCTGGCCGAATACGAAACTAA
  	GATGGCCGATCTCATGGCGGCCCTGCAAGACATGGAACGGCT
  	GGCGAACTCCGATCCGTCCAACAACCACACTGAGGAAGTGAA
  	CAACATCAAGAAGGCTCTCGAGGCCCAGAAGGATACCATCGA
  	CAAGTTGAACAAGCTTGTGACGCTGCAGAACCAAAACAAGGC
  	CCTGACGGAAGTGCTCAAAACCACCGACTCGGCCGACCAGAT
  	TCCGGCCATCAACAGCCAGCTGGAGATTAACAAGAACTCGGC
  	CGATCAGATTATCAAGGACCTGGAGCGCCAGAACATTAACTA
  	CGAGGCCGTCTTGACTAACGCCGGCGAAGTGATCAAGGCGTC
  	ATCCGAAGCCGGCATTAAGCTGGGACAGGCGCTGCAATCCAT
  	CGTCGACGCCGGCGACCAGTCCCAGGCGGCGGTGCTGCAGGC
  	CCAGCAGAACAACTCCCCCGATAACATCGCTGCAACCAAGGA
  	ACTGATTGACGCGGCCGAAACCAAAGTCAACGAACTGAAGCA
  	GGAGCACACTGGTCTGACCGACTCGCCGCTCGTGAAGAAGGC
  	CGAAGAACAGATCAGCCAGGCTCAGAAGGATATCCAGGAAAT
  	CAAGCCTTCGGGGAGCGACATCCCGATCGTGGGACCGTCCGGT
  	TCCGCCGCTTCCGCCGGGTCCGCAGCCGGGGCCCTTAAGTCGT
  	CGAACAATAGCGGCAGAATATCCCTGCTGCTCGACGATGTGG
  	ATAACGAGATGGCCGCCATTGCGCTGCAAGGATTCCGGTCCAT
  	GATCGAGCAGTTCAACGTGAACAACCCCGCCACCGCCAAGGA
  	GCTGCAGGCTATGGAGGCCCAACTCACTGCCATGTCCGACCAG
  	CTCGTGGGAGCGGACGGAGAACTGCCAGCCGAGATCCAGGCC
  	ATCAAGGACGCTCTGGCCCAGGCACTGAAGCAGCCGTCCGCG
  	GATGGCCTGGCCACCGCCATGGGCCAGGTCGCGTTCGCCGCCG
  	CTAAAGTCGGCGGAGGTTCGGCCGGCACTGCCGGGACCGTGC
  	AGATGAATGTCAAGCAGCTGTACAAGACTGCGTTCTCGTCGAC
  	CAGCTCCAGCTCCTACGCCGCGGCCCTGTCCGACGGTTACAGC
  	GCGTACAAGACCCTGAACTCCCTTTACTCCGAATCGAGATCCG
  	GGGTCCAGTCCGCAATTTCACAAACCGCCAATCCTGCCCTGTC
  	GCGCTCAGTGTCACGCAGCGGCATCGAGTCACAGGGCAGAAG
  	CGCCGACGCTAGCCAAAGGGCCGCAGAAACCATTGTGCGGGA
  	CTCCCAGACACTTGGAGATGTCTACAGCCGCCTCCAAGTGCTG
  	GACTCCCTCATGTCCACCATCGTGTCAAACCCTCAGGCTAACC
  	AGGAGGAAATCATGCAGAAGCTGACCGCAAGCATTTCCAAGG
  	CTCCGCAGTTTGGATACCCCGCTGTGCAAAACTCCGCGGACAG
  	CTTGCAGAAATTCGCAGCCCAGTTGGAGAGGGAGTTCGTGGA
  	CGGGGAGCGGTCCCTCGCGGAGTCCCAGGAGAACGCATTCCG
  	GAAGCAGCCCGCCTTCATTCAACAAGTGCTTGTGAACATCGCC
  	TCCCTGTTCTCCGGTTACCTGTCTCATCACCACCACCATCAC
  Cta1_E_noTM_nIgK_cHis	ATGGAAACCCCTGCCCAGCTGCTGTTCCTGCTGCTGCTGTGGC	236
  	TGCCTGATACCACCGGCCCTAGCAGCACCCAGGACAACAGAT
  	CCATGGACCAGCAGGACAGCGAGGAATTTCTGCTGCAGAACA
  	CCCTGGAAGATAGCGAGATCATCAGCATCCCCGACACCATGA
  	ACCAGATCGCCATCGACACCGAGAAGTGGTTCTACCTGAACA
  	AGGACTGCACCAACGTGGGCCCCATCTCCATCGTGCAGCTGAC
  	CGCCTTCCTGAAAGAGTGCAAGCACAGCCCCGAGAAGGGCAT
  	CGACCCCCAGGAACTGTGGGTGTGGAAGAAAGGCATGCCCAA
  	CTGGGAGAAAGTGAAGAACATCCCCGAGCTGAGCGGCACCGT
  	GAAGGACGAGCACCACCACCATCACCAC
  Cta1_E_noTM_nIgK	ATGGAAACCCCTGCCCAGCTGCTGTTCCTGCTGCTGCTGTGGC	237
  	TGCCTGATACCACCGGCCCTAGCAGCACCCAGGACAACAGAT
  	CCATGGACCAGCAGGACAGCGAGGAATTTCTGCTGCAGAACA
  	CCCTGGAAGATAGCGAGATCATCAGCATCCCCGACACCATGA
  	ACCAGATCGCCATCGACACCGAGAAGTGGTTCTACCTGAACA
  	AGGACTGCACCAACGTGGGCCCCATCTCCATCGTGCAGCTGAC
  	CGCCTTCCTGAAAGAGTGCAAGCACAGCCCCGAGAAGGGCAT
  	CGACCCCCAGGAACTGTGGGTGTGGAAGAAAGGCATGCCCAA
  	CTGGGAGAAAGTGAAGAACATCCCCGAGCTGAGCGGCACCGT
  	GAAGGACGAA
  Cta1_E_cHis	ATGAACAGCGGGATGTTCCCCTTCACCTTCTTTCTGCTGTACAT	238
  	CTGCCTGGGCATGCTGACCGCCTACCTGGCCAACAAGAAGAA
  	CCGGAACCTGATCGGCTGGTTCCTGGCCGGCATGTTCTTCGGA
  	ATCTTCGCCATCATTTTTCTGCTGATCCTGCCCCCCCTGCCCAG
  	CAGCACACAGGACAACAGATCCATGGACCAGCAGGACAGCGA
  	AGAGTTCCTGCTGCAGAACACCCTGGAAGATAGCGAGATCAT
  	CAGCATCCCCGACACCATGAACCAGATCGCCATCGACACCGA
  	GAAGTGGTTCTACCTGAACAAGGACTGCACCAACGTGGGCCC
  	CATCTCCATCGTGCAGCTGACAGCCTTCCTGAAAGAGTGCAAG
  	CACAGCCCCGAGAAGGGCATCGACCCCCAGGAACTGTGGGTG
  	TGGAAGAAAGGCATGCCCAACTGGGAGAAAGTGAAGAACATC
  	CCCGAGCTGAGCGGCACCGTGAAGGACGAGCACCACCACCAT
  	CACCAC
  Cta1_E	ATGAACAGCGGGATGTTCCCCTTCACCTTCTTTCTGCTGTACAT	239
  	CTGCCTGGGCATGCTGACCGCCTACCTGGCCAACAAGAAGAA
  	CCGGAACCTGATCGGCTGGTTCCTGGCCGGCATGTTCTTCGGA
  	ATCTTCGCCATCATTTTTCTGCTGATCCTGCCCCCCCTGCCCAG
  	CAGCACACAGGACAACAGATCCATGGACCAGCAGGACAGCGA
  	AGAGTTCCTGCTGCAGAACACCCTGGAAGATAGCGAGATCAT
  	CAGCATCCCCGACACCATGAACCAGATCGCCATCGACACCGA
  	GAAGTGGTTCTACCTGAACAAGGACTGCACCAACGTGGGCCC
  	CATCTCCATCGTGCAGCTGACAGCCTTCCTGAAAGAGTGCAAG
  	CACAGCCCCGAGAAGGGCATCGACCCCCAGGAACTGTGGGTG
  	TGGAAGAAAGGCATGCCCAACTGGGAGAAAGTGAAGAACATC
  	CCCGAGCTGAGCGGCACCGTGAAGGACGAA
  Ct443_E_nIgK_cHis_mod	ATGGAAACCCCTGCCCAGCTGCTGTTCCTGCTCCTGCTGTGGC	240
  	TGCCTGATACCACAGGCAGCGGCGTGCTGGAAACCAGCATGG
  	CCGAGAGCCTGAGCACCAACGTGATCAGCCTGGCCGACACCA
  	AGGCCAAGGACAACACCAGCCACAAGAGCAAGAAGGCCCGG
  	AAGAACCACAGCAAAGAAACCCTGGTGGACCGGAAAGAGGTG
  	GCCCCTGTGCACGAGTCTAAGGCCACAGGCCCCAAGCAGGAC
  	AGCTGCTTCGGCCGGATGTACACCGTGAAAGTGAACGACGAC
  	CGGAACGTGGAAATCACCCAGGCCGTGCCTGAGTACGCCACA
  	GTGGGCAGCCCTTACCCCATCGAGATCACCGCCACCGGCAAG
  	AGGGATTGCGTGGATGTGATCATTACCCAACAGCTGCCTTGCG
  	AGGCCGAGTTCGTGCGCTCTGATCCTGCCACCACCCCTACCGC
  	CGATGGCAAGCTCGTGTGGAAGATCGACAGACTGGGCCAGGG
  	CGAGAAGTCCAAAATCACTGTGTGGGTCAAGCCCCTGAAAGA
  	GGGGTGCTGCTTTACCGCAGCCACCGTGTGTGCCTGCCCCGAG
  	ATTAGAAGCGTGACCAAGTGTGGCCAGCCCGCCATCTGCGTGA
  	AGCAGGAAGGACCTGAGAACGCCTGCCTGAGATGCCCCGTGG
  	TGTACAAGATCAACGTCGTGAACCAGGGCACCGCCATTGCCA
  	GAAACGTGGTGGTGGAAAACCCCGTGCCCGACGGCTACGCCC
  	ACAGCTCTGGACAGAGAGTGCTGACCTTCACCCTGGGCGACAT
  	GCAGCCCGGCGAGCACAGAACCATCACCGTGGAATTCTGCCC
  	CCTGAAGCGGGGCAGAGCCACCAACATTGCGACAGTGTCCTA
  	CTGTGGCGGGCACAAGAACACCGCCTCCGTGACCACCGTGATC
  	AACGAGCCTTGCGTGCAGGTGTCCATTGCCGGCGCTGACTGGT
  	CCTACGTGTGCAAGCCAGTGGAGTACGTGATCTCCGTGTCCAA
  	CCCCGGCGACCTGGTGCTGAGAGATGTGGTGGTTGAGGATACC
  	CTGAGCCCTGGCGTGACAGTCCTGGAAGCTGCTGGCGCCCAGA
  	TCAGCTGCAACAAGGTGGTGTGGACAGTGAAAGAGCTGAACC
  	CCGGGGAGTCCCTGCAGTACAAGGTGCTCGTGCGGGCCCAGA
  	CCCCTGGCCAGTTCACCAACAATGTGGTCGTGAAGTCCTGCAG
  	CGACTGCGGCACCTGTACCTCTTGTGCCGAGGCCACCACGTAC
  	TGGAAAGGCGTGGCCGCTACCCATATGTGCGTGGTGGATACCT
  	GCGACCCCGTCTGCGTGGGCGAAAACACCGTGTACCGGATCTG
  	TGTGACCAACCGGGGCAGCGCCGAGGACACCAATGTGTCCCT
  	GATGCTGAAGTTCTCCAAAGAACTGCAACCCGTGAGCTTCAGC
  	GGCCCCACCAAGGGAACAATCACTGGCAACACCGTCGTTTTCG
  	ACAGCCTGCCTCGGCTGGGCTCTAAGGAAACTGTGGAGTTCAG
  	CGTGACACTGAAGGCCGTGTCTGCCGGGGATGCTAGAGGCGA
  	GGCCATCCTGAGCAGCGACACACTGACGGTCCCTGTGTCCGAC
  	ACCGAGAATACCCACATCTACCACCACCATCATCACCAT
  Ct443_E_nIgK_mod	ATGGAAACCCCTGCCCAGCTGCTGTTCCTGCTCCTGCTGTGGC	241
  	TGCCTGATACCACAGGCAGCGGCGTGCTGGAAACCAGCATGG
  	CCGAGAGCCTGAGCACCAACGTGATCAGCCTGGCCGACACCA
  	AGGCCAAGGACAACACCAGCCACAAGAGCAAGAAGGCCCGG
  	AAGAACCACAGCAAAGAAACCCTGGTGGACCGGAAAGAGGTG
  	GCCCCTGTGCACGAGTCTAAGGCCACAGGCCCCAAGCAGGAC
  	AGCTGCTTCGGCCGGATGTACACCGTGAAAGTGAACGACGAC
  	CGGAACGTGGAAATCACCCAGGCCGTGCCTGAGTACGCCACA
  	GTGGGCAGCCCTTACCCCATCGAGATCACCGCCACCGGCAAG
  	AGGGATTGCGTGGATGTGATCATTACCCAACAGCTGCCTTGCG
  	AGGCCGAGTTCGTGCGCTCTGATCCTGCCACCACCCCTACCGC
  	CGATGGCAAGCTCGTGTGGAAGATCGACAGACTGGGCCAGGG
  	CGAGAAGTCCAAAATCACTGTGTGGGTCAAGCCCCTGAAAGA
  	GGGGTGCTGCTTTACCGCAGCCACCGTGTGTGCCTGCCCCGAG
  	ATTAGAAGCGTGACCAAGTGTGGCCAGCCCGCCATCTGCGTGA
  	AGCAGGAAGGACCTGAGAACGCCTGCCTGAGATGCCCCGTGG
  	TGTACAAGATCAACGTCGTGAACCAGGGCACCGCCATTGCCA
  	GAAACGTGGTGGTGGAAAACCCCGTGCCCGACGGCTACGCCC
  	ACAGCTCTGGACAGAGAGTGCTGACCTTCACCCTGGGCGACAT
  	GCAGCCCGGCGAGCACAGAACCATCACCGTGGAATTCTGCCC
  	CCTGAAGCGGGGCAGAGCCACCAACATTGCGACAGTGTCCTA
  	CTGTGGCGGGCACAAGAACACCGCCTCCGTGACCACCGTGATC
  	AACGAGCCTTGCGTGCAGGTGTCCATTGCCGGCGCTGACTGGT
  	CCTACGTGTGCAAGCCAGTGGAGTACGTGATCTCCGTGTCCAA
  	CCCCGGCGACCTGGTGCTGAGAGATGTGGTGGTTGAGGATACC
  	CTGAGCCCTGGCGTGACAGTCCTGGAAGCTGCTGGCGCCCAGA
  	TCAGCTGCAACAAGGTGGTGTGGACAGTGAAAGAGCTGAACC
  	CCGGGGAGTCCCTGCAGTACAAGGTGCTCGTGCGGGCCCAGA
  	CCCCTGGCCAGTTCACCAACAATGTGGTCGTGAAGTCCTGCAG
  	CGACTGCGGCACCTGTACCTCTTGTGCCGAGGCCACCACGTAC
  	TGGAAAGGCGTGGCCGCTACCCATATGTGCGTGGTGGATACCT
  	GCGACCCCGTCTGCGTGGGCGAAAACACCGTGTACCGGATCTG
  	TGTGACCAACCGGGGCAGCGCCGAGGACACCAATGTGTCCCT
  	GATGCTGAAGTTCTCCAAAGAACTGCAACCCGTGAGCTTCAGC
  	GGCCCCACCAAGGGAACAATCACTGGCAACACCGTCGTTTTCG
  	ACAGCCTGCCTCGGCTGGGCTCTAAGGAAACTGTGGAGTTCAG
  	CGTGACACTGAAGGCCGTGTCTGCCGGGGATGCTAGAGGCGA
  	GGCCATCCTGAGCAGCGACACACTGACGGTCCCTGTGTCCGAC
  	ACCGAGAATACCCACATCTAC
  Ct875_E_nIgK_CO004	ATGGAAACTCCCGCACAGTTACTTTTCTTGTTGCTTCTATGGCT	242
  	CCCCGATACCACCGGGATGAGCATCAGAGGCGTCGGCGGGAA
  	CGGCAACAGCAGAATTCCCTCCCACAACGGCGACGGCAGCAA
  	CAGAAGATCCCAGAACACAAAGGGCAATAATAAGGTCGAGGA
  	CAGAGTGTGCAGCCTCTACTCCAGCAGGTCTAACGAGAATAG
  	GGAGTCCCCGTACGCCGTTGTCGACGTGAGTTCTATGATAGAG
  	AGCACGCCCACGTCCGGAGAAACAACTAGAGCAAGCAGGGGC
  	GTCCTGAGCCGGTTCCAGAGAGGTCTGGTGCGAATTGCCGACA
  	AGGTGAGACGGGCAGTGCAATGCGCCTGGAGCAGCGTCTCCA
  	CCAGCAGAAGCAGCGCCACCCGCGCTGCCGAATCAGGCAGCA
  	GCTCCAGAACGGCACGGGGCGCCTCCTCCGGCTACCGAGAGT
  	ACTCCCCTAGCGCCGCCAGAGGCCTGAGACTGATGTTCACCGA
  	TTTTTGGAGGACACGGGTTCTGAGACAGACCTCCCCCATGGCT
  	GGGGTGTTCGGCAACCTGGACGTCAATGAAGCCAGACTCATG
  	GCCGCATATACTTCTGAGTGCGCTGACCACCTGGAAGCTAAGG
  	AACTGGCGGGCCCCGATGGCGTGGCCGCGGCCCGGGAGATCG
  	CCAAGAGATGGGAGAAGAGAGTGCGGGACCTGCAAGACAAG
  	GGGGCCGCCCGGAAGCTGCTGAACGATCCCTTGGGCCGCCGG
  	ACACCGAACTATCAGAGCAAGAACCCGGGCGAGTACACCGTG
  	GGAAACAGCATGTTCTATGACGGACCTCAGGTGGCAAACCTG
  	CAGAACGTGGACACTGGATTTTGGCTCGACATGAGTAACCTCT
  	CCGATGTCGTTCTGTCTCGTGAGATACAGACAGGTCTGCGGGC
  	TAGAGCCACCCTTGAGGAGAGCATGCCTATGTTGGAGAATCTG
  	GAGGAGCGGTTCAGAAGACTGCAGGAGACTTGCGATGCCGCC
  	AGGACCGAGATTGAGGAGAGCGGCTGGACCCGGGAAAGCGCC
  	TCAAGGATGGAGGGAGACGAGGCCCAGGGACCCTCCAGGGTT
  	CAGCAGGCCTTCCAGTCGTTCGTGAATGAATGCAACAGCATCG
  	AGTTCAGCTTCGGAAGCTTCGGAGAGCACGTGCGAGTGCTGTG
  	CGCCAGAGTATCCAGAGGTCTGGCCGCTGCAGGCGAGGCCAT
  	CCGGAGATGCTTCTCCTGCTGCAAAGGCAGCACCCACAGGTAT
  	GCTCCCAGGGATGATCTTTCTCCCGAGGGAGCCAGCCTGGCTG
  	AGACTCTTGCAAGATTCGCCGATGACATGGGGATCGAGCGGG
  	GCGCTGACGGCACCTACGACATTCCCCTGGTGGACGACTGGAG
  	GAGGGGAGTGCCCTCCATCGAGGGCGAGGGCTCCGATTCAAT
  	CTATGAGATCATGATGCCTATTTACGAGGTGATGAACATGGAC
  	CTGGAGACAAGAAGAAGTTTCGCCGTCCAGCAGGGTCATTAC
  	CAGGACCCCCGAGCAAGCGACTACGATCTGCCTCGCGCCAGC
  	GATTACGACCTGCCTAGAAGCCCCTACCCTACACCTCCACTGC
  	CCCCAAGATATCAGCTCCAGAACATGGACGTGGAGGCCGGCT
  	TCAGGGAGGCCGTGTACGCCAGCTTTGTGGCCGGCATGTACAA
  	CTATGTCGTGACACAGCCTCAGGAACGCATTCCCAATAGCCAA
  	CAGGTGGAGGGCATCCTGAGAGACATGCTGACCAACGGCTCT
  	CAGACTTTTAGAGATCTGATGAAAAGATGGAACAGAGAAGTG
  	GACAGGGAG
  Ct875_E_nIgK_CO003	ATGGAAACACCAGCTCAGCTCCTTTTCTTACTCCTCTTGTGGTT	243
  	GCCGGATACCACAGGCATGAGCATCCGGGGCGTCGGCGGCAA
  	CGGAAACAGCCGGATCCCCAGCCACAACGGAGACGGCTCTAA
  	TAGAAGATCACAGAATACCAAGGGAAATAACAAGGTCGAAGA
  	TAGAGTCTGCAGCTTATATTCCAGCAGATCCAACGAGAATAGG
  	GAAAGCCCCTACGCCGTCGTTGACGTGAGCTCCATGATCGAAA
  	GCACCCCAACAAGTGGCGAGACTACAAGAGCCTCAAGGGGCG
  	TCCTGTCAAGATTCCAAAGAGGCCTGGTGAGGATCGCAGACA
  	AGGTGCGGCGGGCCGTGCAGTGCGCCTGGAGCTCTGTGTCGAC
  	AAGCAGATCAAGTGCCACCAGGGCCGCCGAGAGCGGATCCTC
  	CAGTCGGACCGCCCGCGGCGCCTCTAGTGGGTACAGAGAATA
  	TAGTCCCAGCGCCGCTAGGGGGCTGCGCCTCATGTTCACCGAC
  	TTCTGGAGAACCCGCGTGCTCAGGCAGACATCCCCTATGGCCG
  	GGGTGTTCGGCAACCTGGACGTGAACGAGGCCCGGCTTATGG
  	CCGCATATACAAGCGAGTGTGCCGACCACCTGGAGGCCAAGG
  	AGCTGGCTGGCCCCGACGGCGTGGCCGCCGCACGCGAGATTG
  	CCAAGAGGTGGGAAAAGAGGGTGAGAGATCTGCAGGATAAG
  	GGCGCCGCCAGAAAACTGCTGAATGACCCCCTGGGGAGGAGG
  	ACACCCAATTACCAGTCAAAGAATCCAGGGGAGTACACTGTT
  	GGAAATTCTATGTTTTATGACGGCCCTCAGGTGGCCAACCTTC
  	AGAATGTGGACACAGGCTTCTGGCTTGACATGAGCAACCTCAG
  	CGACGTGGTGCTGTCTAGGGAGATCCAGACAGGCTTAAGAGC
  	ACGGGCTACCCTGGAAGAGTCGATGCCCATGCTCGAAAATCTG
  	GAGGAGAGGTTCAGACGCCTGCAAGAGACATGCGACGCCGCG
  	AGGACTGAAATCGAGGAGAGCGGCTGGACCAGGGAGTCCGCT
  	TCTCGCATGGAAGGGGACGAGGCTCAGGGCCCCAGCAGGGTG
  	CAGCAGGCCTTCCAGAGCTTTGTGAACGAGTGCAACTCCATTG
  	AGTTCAGCTTTGGAAGCTTCGGAGAGCACGTGCGGGTGCTGTG
  	CGCCCGCGTGTCCAGGGGCCTGGCCGCAGCTGGCGAGGCTAT
  	ACGTCGCTGCTTCAGCTGTTGTAAGGGAAGCACCCATAGGTAC
  	GCCCCTCGTGACGATCTGTCTCCCGAAGGGGCCAGCCTGGCTG
  	AGACACTGGCCCGCTTCGCCGATGATATGGGGATTGAACGGG
  	GCGCCGACGGAACCTACGACATCCCTCTTGTGGACGACTGGAG
  	GAGAGGCGTCCCCTCTATCGAGGGCGAGGGCTCTGACTCCATC
  	TACGAGATTATGATGCCTATCTACGAGGTCATGAACATGGACC
  	TGGAAACCAGAAGAAGCTTCGCAGTTCAGCAGGGACACTACC
  	AAGACCCACGGGCTAGTGATTATGACCTCCCAAGAGCATCCG
  	ACTATGATCTGCCAAGGTCACCTTACCCTACCCCACCCCTGCC
  	CCCACGGTACCAGTTACAGAACATGGATGTGGAGGCCGGCTTC
  	AGGGAAGCCGTCTATGCATCCTTCGTGGCCGGCATGTACAACT
  	ACGTGGTGACTCAACCTCAGGAACGGATCCCCAACAGTCAGC
  	AGGTGGAGGGGATCCTTAGGGATATGCTGACTAATGGAAGCC
  	AGACCTTCAGAGATCTGATGAAGCGGTGGAATAGGGAGGTGG
  	ACAGGGAG
  Ct875_E_nIgK_CO002	ATGGAGACACCCGCACAGCTCCTCTTCTTATTGCTCTTGTGGCT	244
  	ACCGGACACCACAGGCATGTCTATCCGGGGCGTTGGCGGGAA
  	CGGCAACTCTAGGATCCCCTCTCACAACGGCGACGGGAGCAA
  	CAGGAGAAGCCAGAACACCAAAGGCAATAACAAAGTCGAGG
  	ACAGAGTTTGTTCTCTCTATAGCTCTAGGAGCAACGAAAACCG
  	CGAATCTCCTTACGCCGTCGTCGACGTCAGCAGCATGATAGAG
  	TCAACCCCTACCTCTGGAGAAACAACACGCGCCTCCAGAGGC
  	GTTCTGTCCAGGTTCCAGAGGGGCCTGGTGAGAATTGCCGACA
  	AGGTCAGACGAGCCGTGCAGTGTGCCTGGTCCAGCGTCTCTAC
  	CAGCAGAAGCTCCGCCACCAGAGCCGCTGAGAGTGGCAGCTC
  	CAGCAGGACAGCCAGGGGGGCTTCCAGCGGCTATAGAGAGTA
  	TAGCCCTTCAGCCGCCAGAGGCCTGCGGCTGATGTTCACAGAC
  	TTTTGGAGAACAAGGGTGCTGCGGCAGACCAGCCCCATGGCC
  	GGCGTGTTTGGCAATCTGGACGTGAACGAGGCCCGGCTGATG
  	GCCGCATACACCAGCGAGTGTGCGGACCACCTGGAGGCAAAG
  	GAGCTGGCTGGACCCGACGGTGTGGCCGCTGCCCGAGAAATT
  	GCCAAGAGGTGGGAGAAGAGAGTTCGCGACCTGCAGGATAAG
  	GGCGCCGCACGGAAACTCCTGAACGACCCACTCGGCAGAAGA
  	ACCCCCAACTACCAGTCAAAGAACCCTGGGGAGTATACCGTG
  	GGAAATTCAATGTTCTACGATGGCCCTCAGGTTGCTAATCTCC
  	AGAACGTGGACACTGGGTTCTGGCTGGACATGAGCAACCTGA
  	GTGACGTGGTGCTGTCTCGGGAAATTCAGACAGGCCTGCGGGC
  	CAGAGCCACCCTGGAAGAGTCCATGCCTATGCTTGAGAACCTG
  	GAGGAGCGCTTTAGGCGACTCCAAGAAACCTGCGATGCTGCC
  	AGGACCGAGATCGAGGAGTCTGGATGGACCAGAGAAAGCGCC
  	TCCAGGATGGAGGGCGATGAGGCCCAGGGCCCCAGCAGGGTG
  	CAGCAGGCTTTCCAGAGCTTCGTGAACGAATGTAACAGTATCG
  	AATTCTCTTTCGGTAGCTTCGGCGAGCACGTGCGGGTGTTATG
  	CGCCAGGGTCAGCAGGGGCCTGGCGGCCGCCGGCGAGGCCAT
  	CAGAAGATGCTTCAGCTGTTGCAAAGGCTCAACCCACAGATAT
  	GCCCCTAGGGACGATCTGTCTCCAGAGGGCGCTAGCTTGGCCG
  	AGACACTAGCAAGGTTCGCCGACGATATGGGTATCGAGAGGG
  	GCGCCGACGGTACCTACGACATCCCCCTGGTGGACGACTGGA
  	GGAGAGGCGTGCCCAGTATTGAGGGCGAGGGATCCGACAGCA
  	TCTACGAGATCATGATGCCGATCTACGAGGTGATGAATATGGA
  	TCTGGAGACTCGTAGATCATTCGCTGTCCAGCAGGGCCACTAC
  	CAGGATCCTAGAGCCTCGGACTACGACTTGCCCAGGGCTAGCG
  	ATTACGACCTGCCTAGATCCCCCTACCCCACTCCCCCTCTTCCC
  	CCTCGGTATCAGCTGCAGAACATGGACGTGGAGGCCGGTTTCC
  	GAGAGGCTGTGTACGCCTCCTTCGTGGCCGGGATGTACAACTA
  	CGTCGTGACCCAGCCCCAGGAGAGAATCCCTAATTCCCAGCAG
  	GTGGAGGGCATCTTGAGAGATATGCTCACAAACGGGAGCCAG
  	ACCTTTCGTGACTTAATGAAGCGATGGAACAGAGAGGTGGAT
  	AGGGAG
  Ct875_E_nIgK_CO001	ATGGAAACCCCCGCCCAGCTTCTCTTCCTCCTCTTGCTTTGGCT	245
  	CCCAGACACAACCGGCATGAGTATCAGAGGCGTAGGAGGCAA
  	CGGCAATAGCCGTATCCCCTCACACAACGGCGACGGCTCCAAC
  	AGACGGAGCCAGAACACCAAGGGGAATAATAAGGTGGAGGA
  	CCGGGTCTGTTCACTTTACAGCTCCAGGTCTAACGAGAATCGG
  	GAAAGCCCTTACGCCGTAGTCGACGTTAGCAGTATGATCGAAA
  	GCACCCCCACCAGCGGCGAGACAACAAGGGCCTCTCGAGGAG
  	TTCTGAGCAGATTTCAGAGAGGCCTGGTGCGGATCGCCGACAA
  	GGTGCGGAGAGCCGTGCAGTGCGCCTGGAGCAGCGTGAGTAC
  	ATCTCGGAGCAGCGCCACCAGAGCAGCCGAAAGCGGCTCATC
  	TAGCAGGACCGCTAGAGGCGCCAGCTCGGGGTACAGGGAATA
  	TTCACCCTCCGCCGCAAGGGGGCTGAGACTGATGTTTACAGAC
  	TTCTGGAGAACCAGGGTGCTGCGCCAGACAAGCCCAATGGCA
  	GGGGTGTTTGGTAACCTGGATGTGAATGAGGCCAGACTGATG
  	GCCGCCTACACTTCTGAGTGCGCGGATCATCTTGAGGCCAAGG
  	AACTGGCAGGCCCCGACGGCGTGGCCGCCGCCCGGGAGATTG
  	CTAAGAGATGGGAGAAGCGGGTCAGAGATCTGCAGGATAAGG
  	GGGCCGCTAGGAAACTCCTGAATGACCCCCTAGGCAGGAGAA
  	CCCCTAACTACCAGAGCAAAAATCCTGGGGAATACACCGTGG
  	GCAATTCCATGTTTTACGATGGCCCCCAAGTCGCAAACCTCCA
  	GAATGTGGACACCGGCTTCTGGCTGGACATGTCCAACTTGAGC
  	GACGTGGTTCTAAGCAGAGAAATCCAGACCGGACTCCGCGCG
  	AGAGCTACACTCGAGGAAAGCATGCCTATGCTGGAGAATCTG
  	GAGGAGCGATTCCGTCGTCTACAGGAGACTTGTGACGCCGCTA
  	GGACCGAGATCGAGGAGAGCGGCTGGACAAGAGAAAGCGCCT
  	CTCGAATGGAGGGCGATGAGGCCCAGGGCCCCTCCCGGGTGC
  	AGCAGGCCTTTCAGAGCTTCGTGAATGAGTGCAATTCTATTGA
  	GTTCAGCTTCGGCTCTTTTGGCGAGCACGTGCGGGTGCTTTGC
  	GCCAGGGTGTCCCGGGGACTGGCAGCCGCCGGCGAGGCCATA
  	AGAAGATGTTTCTCCTGCTGCAAGGGCAGCACCCACCGGTATG
  	CTCCCAGAGACGACCTGTCTCCAGAAGGGGCATCGCTGGCCG
  	AGACACTGGCACGGTTCGCCGACGATATGGGCATTGAGAGGG
  	GAGCCGACGGCACTTATGATATCCCTCTCGTGGACGACTGGAG
  	AAGAGGAGTCCCCTCAATTGAGGGCGAAGGATCCGATTCTATC
  	TATGAGATCATGATGCCTATCTACGAAGTGATGAATATGGACC
  	TGGAAACCAGGAGATCTTTCGCTGTGCAGCAGGGCCATTACCA
  	GGATCCCCGCGCCAGCGATTATGACCTGCCCAGAGCCTCAGAC
  	TACGATTTGCCCAGAAGCCCCTACCCCACCCCTCCGCTGCCCC
  	CTAGATACCAGCTGCAGAATATGGACGTGGAGGCTGGCTTTAG
  	GGAGGCTGTGTACGCTAGCTTCGTGGCCGGCATGTACAACTAC
  	GTGGTGACACAGCCCCAGGAGAGAATTCCCAATTCTCAACAA
  	GTAGAGGGCATCCTGAGAGACATGTTAACAAACGGATCTCAG
  	ACCTTCCGCGACCTGATGAAGCGGTGGAACCGGGAAGTGGAC
  	CGCGAG
  Ct875_E_nIgK_cHis_CO005	ATGGAAACACCCGCCCAGCTCCTCTTTCTACTTCTCCTTTGGCT	246
  	TCCCGACACCACCGGTATGAGCATTAGAGGAGTCGGCGGGAA
  	CGGGAATAGCCGTATCCCCTCCCACAACGGCGACGGCAGCAA
  	CCGCAGAAGCCAGAATACTAAGGGAAACAATAAGGTTGAGGA
  	CCGCGTCTGTAGCTTGTACAGCTCAAGAAGTAACGAGAACAG
  	AGAGAGCCCCTACGCCGTGGTCGACGTTTCCAGCATGATCGAG
  	TCAACGCCCACAAGCGGCGAAACCACCCGCGCGTCAAGGGGG
  	GTCCTGTCCCGGTTCCAGAGAGGCCTGGTGAGGATCGCCGACA
  	AGGTGAGACGGGCCGTGCAGTGCGCCTGGTCCAGCGTCAGCA
  	CATCACGGTCCTCCGCTACCAGGGCCGCCGAGTCAGGCAGCA
  	GCTCTCGTACCGCCCGGGGAGCCTCAAGCGGGTACAGAGAGT
  	ACAGCCCTTCTGCCGCTAGAGGCCTGAGACTCATGTTTACAGA
  	CTTCTGGCGGACAAGGGTTCTCAGGCAGACTAGCCCTATGGCT
  	GGCGTGTTTGGCAATCTTGATGTTAACGAAGCCAGGCTGATGG
  	CTGCATATACAAGCGAATGCGCCGACCATCTGGAAGCTAAGG
  	AGCTGGCCGGGCCCGACGGCGTGGCCGCTGCCAGGGAGATCG
  	CCAAGAGGTGGGAGAAAAGGGTGCGAGATCTCCAGGATAAGG
  	GAGCAGCTAGAAAGCTGCTGAACGACCCCCTGGGCAGGCGGA
  	CCCCTAACTACCAGAGCAAAAATCCGGGCGAGTACACCGTCG
  	GCAACAGCATGTTTTACGATGGCCCTCAGGTGGCCAACCTTCA
  	GAACGTGGACACCGGCTTCTGGCTCGATATGTCTAATCTTTCC
  	GACGTCGTGCTCAGCCGGGAAATCCAGACTGGTCTGCGCGCCA
  	GAGCTACCTTGGAAGAGAGCATGCCCATGCTGGAGAACCTGG
  	AGGAGAGATTTCGGCGCTTACAGGAAACATGTGACGCTGCTA
  	GGACCGAGATTGAAGAGAGCGGGTGGACAAGGGAGTCGGCG
  	AGCAGGATGGAGGGGGACGAGGCCCAGGGCCCCAGCAGGGT
  	GCAACAGGCTTTTCAGTCCTTCGTGAACGAGTGCAACAGCATC
  	GAGTTCTCCTTCGGCAGCTTCGGGGAGCACGTGAGAGTGTTGT
  	GCGCCCGCGTGTCTAGGGGATTAGCCGCCGCAGGCGAAGCCA
  	TCCGGCGCTGCTTCAGCTGCTGCAAGGGCTCCACCCATCGCTA
  	CGCCCCTAGAGACGACCTGTCTCCCGAAGGCGCCTCCCTGGCC
  	GAGACTCTGGCCCGATTCGCCGATGACATGGGCATCGAGCGG
  	GGGGCCGATGGCACCTACGACATCCCTCTGGTCGATGACTGGC
  	GGAGGGGCGTTCCCTCTATTGAGGGCGAGGGCTCTGACTCTAT
  	TTACGAGATTATGATGCCCATCTACGAAGTGATGAACATGGAC
  	TTGGAAACTCGCAGATCGTTTGCAGTGCAACAGGGTCATTACC
  	AGGACCCTAGAGCCTCCGATTATGACCTGCCAAGAGCTAGCG
  	ATTATGACCTCCCTAGATCACCCTACCCCACACCTCCTCTCCCT
  	CCACGGTATCAGCTGCAGAACATGGACGTTGAGGCAGGGTTT
  	AGGGAGGCCGTGTACGCCAGCTTCGTGGCAGGCATGTATAATT
  	ATGTGGTAACCCAGCCACAGGAGCGAATTCCCAACTCTCAACA
  	GGTGGAGGGCATCCTGAGAGACATGCTCACCAACGGCAGCCA
  	AACCTTCAGGGACCTTATGAAACGGTGGAATAGAGAAGTTGA
  	TCGCGAGCACCACCACCACCACCAC
  Ct875_E_nIgK_cHis_CO004	ATGGAAACTCCCGCACAGTTACTTTTCTTGTTGCTTCTATGGCT	247
  	CCCCGATACCACCGGGATGAGCATCAGAGGCGTCGGCGGGAA
  	CGGCAACAGCAGAATTCCCTCCCACAACGGCGACGGCAGCAA
  	CAGAAGATCCCAGAACACAAAGGGCAATAATAAGGTCGAGGA
  	CAGAGTGTGCAGCCTCTACTCCAGCAGGTCTAACGAGAATAG
  	GGAGTCCCCGTACGCCGTTGTCGACGTGAGTTCTATGATAGAG
  	AGCACGCCCACGTCCGGAGAAACAACTAGAGCAAGCAGGGGC
  	GTCCTGAGCCGGTTCCAGAGAGGTCTGGTGCGAATTGCCGACA
  	AGGTGAGACGGGCAGTGCAATGCGCCTGGAGCAGCGTCTCCA
  	CCAGCAGAAGCAGCGCCACCCGCGCTGCCGAATCAGGCAGCA
  	GCTCCAGAACGGCACGGGGCGCCTCCTCCGGCTACCGAGAGT
  	ACTCCCCTAGCGCCGCCAGAGGCCTGAGACTGATGTTCACCGA
  	TTTTTGGAGGACACGGGTTCTGAGACAGACCTCCCCCATGGCT
  	GGGGTGTTCGGCAACCTGGACGTCAATGAAGCCAGACTCATG
  	GCCGCATATACTTCTGAGTGCGCTGACCACCTGGAAGCTAAGG
  	AACTGGCGGGCCCCGATGGCGTGGCCGCGGCCCGGGAGATCG
  	CCAAGAGATGGGAGAAGAGAGTGCGGGACCTGCAAGACAAG
  	GGGGCCGCCCGGAAGCTGCTGAACGATCCCTTGGGCCGCCGG
  	ACACCGAACTATCAGAGCAAGAACCCGGGCGAGTACACCGTG
  	GGAAACAGCATGTTCTATGACGGACCTCAGGTGGCAAACCTG
  	CAGAACGTGGACACTGGATTTTGGCTCGACATGAGTAACCTCT
  	CCGATGTCGTTCTGTCTCGTGAGATACAGACAGGTCTGCGGGC
  	TAGAGCCACCCTTGAGGAGAGCATGCCTATGTTGGAGAATCTG
  	GAGGAGCGGTTCAGAAGACTGCAGGAGACTTGCGATGCCGCC
  	AGGACCGAGATTGAGGAGAGCGGCTGGACCCGGGAAAGCGCC
  	TCAAGGATGGAGGGAGACGAGGCCCAGGGACCCTCCAGGGTT
  	CAGCAGGCCTTCCAGTCGTTCGTGAATGAATGCAACAGCATCG
  	AGTTCAGCTTCGGAAGCTTCGGAGAGCACGTGCGAGTGCTGTG
  	CGCCAGAGTATCCAGAGGTCTGGCCGCTGCAGGCGAGGCCAT
  	CCGGAGATGCTTCTCCTGCTGCAAAGGCAGCACCCACAGGTAT
  	GCTCCCAGGGATGATCTTTCTCCCGAGGGAGCCAGCCTGGCTG
  	AGACTCTTGCAAGATTCGCCGATGACATGGGGATCGAGCGGG
  	GCGCTGACGGCACCTACGACATTCCCCTGGTGGACGACTGGAG
  	GAGGGGAGTGCCCTCCATCGAGGGCGAGGGCTCCGATTCAAT
  	CTATGAGATCATGATGCCTATTTACGAGGTGATGAACATGGAC
  	CTGGAGACAAGAAGAAGTTTCGCCGTCCAGCAGGGTCATTAC
  	CAGGACCCCCGAGCAAGCGACTACGATCTGCCTCGCGCCAGC
  	GATTACGACCTGCCTAGAAGCCCCTACCCTACACCTCCACTGC
  	CCCCAAGATATCAGCTCCAGAACATGGACGTGGAGGCCGGCT
  	TCAGGGAGGCCGTGTACGCCAGCTTTGTGGCCGGCATGTACAA
  	CTATGTCGTGACACAGCCTCAGGAACGCATTCCCAATAGCCAA
  	CAGGTGGAGGGCATCCTGAGAGACATGCTGACCAACGGCTCT
  	CAGACTTTTAGAGATCTGATGAAAAGATGGAACAGAGAAGTG
  	GACAGGGAGCACCACCACCACCACCAC
  Ct875_E_nIgK_cHis_CO003	ATGGAAACACCAGCTCAGCTCCTTTTCTTACTCCTCTTGTGGTT	248
  	GCCGGATACCACAGGCATGAGCATCCGGGGCGTCGGCGGCAA
  	CGGAAACAGCCGGATCCCCAGCCACAACGGAGACGGCTCTAA
  	TAGAAGATCACAGAATACCAAGGGAAATAACAAGGTCGAAGA
  	TAGAGTCTGCAGCTTATATTCCAGCAGATCCAACGAGAATAGG
  	GAAAGCCCCTACGCCGTCGTTGACGTGAGCTCCATGATCGAAA
  	GCACCCCAACAAGTGGCGAGACTACAAGAGCCTCAAGGGGCG
  	TCCTGTCAAGATTCCAAAGAGGCCTGGTGAGGATCGCAGACA
  	AGGTGCGGCGGGCCGTGCAGTGCGCCTGGAGCTCTGTGTCGAC
  	AAGCAGATCAAGTGCCACCAGGGCCGCCGAGAGCGGATCCTC
  	CAGTCGGACCGCCCGCGGCGCCTCTAGTGGGTACAGAGAATA
  	TAGTCCCAGCGCCGCTAGGGGGCTGCGCCTCATGTTCACCGAC
  	TTCTGGAGAACCCGCGTGCTCAGGCAGACATCCCCTATGGCCG
  	GGGTGTTCGGCAACCTGGACGTGAACGAGGCCCGGCTTATGG
  	CCGCATATACAAGCGAGTGTGCCGACCACCTGGAGGCCAAGG
  	AGCTGGCTGGCCCCGACGGCGTGGCCGCCGCACGCGAGATTG
  	CCAAGAGGTGGGAAAAGAGGGTGAGAGATCTGCAGGATAAG
  	GGCGCCGCCAGAAAACTGCTGAATGACCCCCTGGGGAGGAGG
  	ACACCCAATTACCAGTCAAAGAATCCAGGGGAGTACACTGTT
  	GGAAATTCTATGTTTTATGACGGCCCTCAGGTGGCCAACCTTC
  	AGAATGTGGACACAGGCTTCTGGCTTGACATGAGCAACCTCAG
  	CGACGTGGTGCTGTCTAGGGAGATCCAGACAGGCTTAAGAGC
  	ACGGGCTACCCTGGAAGAGTCGATGCCCATGCTCGAAAATCTG
  	GAGGAGAGGTTCAGACGCCTGCAAGAGACATGCGACGCCGCG
  	AGGACTGAAATCGAGGAGAGCGGCTGGACCAGGGAGTCCGCT
  	TCTCGCATGGAAGGGGACGAGGCTCAGGGCCCCAGCAGGGTG
  	CAGCAGGCCTTCCAGAGCTTTGTGAACGAGTGCAACTCCATTG
  	AGTTCAGCTTTGGAAGCTTCGGAGAGCACGTGCGGGTGCTGTG
  	CGCCCGCGTGTCCAGGGGCCTGGCCGCAGCTGGCGAGGCTAT
  	ACGTCGCTGCTTCAGCTGTTGTAAGGGAAGCACCCATAGGTAC
  	GCCCCTCGTGACGATCTGTCTCCCGAAGGGGCCAGCCTGGCTG
  	AGACACTGGCCCGCTTCGCCGATGATATGGGGATTGAACGGG
  	GCGCCGACGGAACCTACGACATCCCTCTTGTGGACGACTGGAG
  	GAGAGGCGTCCCCTCTATCGAGGGCGAGGGCTCTGACTCCATC
  	TACGAGATTATGATGCCTATCTACGAGGTCATGAACATGGACC
  	TGGAAACCAGAAGAAGCTTCGCAGTTCAGCAGGGACACTACC
  	AAGACCCACGGGCTAGTGATTATGACCTCCCAAGAGCATCCG
  	ACTATGATCTGCCAAGGTCACCTTACCCTACCCCACCCCTGCC
  	CCCACGGTACCAGTTACAGAACATGGATGTGGAGGCCGGCTTC
  	AGGGAAGCCGTCTATGCATCCTTCGTGGCCGGCATGTACAACT
  	ACGTGGTGACTCAACCTCAGGAACGGATCCCCAACAGTCAGC
  	AGGTGGAGGGGATCCTTAGGGATATGCTGACTAATGGAAGCC
  	AGACCTTCAGAGATCTGATGAAGCGGTGGAATAGGGAGGTGG
  	ACAGGGAGCACCATCACCATCACCAC
  Ct875_E_nIgK_cHis_CO002	ATGGAGACACCCGCACAGCTCCTCTTCTTATTGCTCTTGTGGCT	249
  	ACCGGACACCACAGGCATGTCTATCCGGGGCGTTGGCGGGAA
  	CGGCAACTCTAGGATCCCCTCTCACAACGGCGACGGGAGCAA
  	CAGGAGAAGCCAGAACACCAAAGGCAATAACAAAGTCGAGG
  	ACAGAGTTTGTTCTCTCTATAGCTCTAGGAGCAACGAAAACCG
  	CGAATCTCCTTACGCCGTCGTCGACGTCAGCAGCATGATAGAG
  	TCAACCCCTACCTCTGGAGAAACAACACGCGCCTCCAGAGGC
  	GTTCTGTCCAGGTTCCAGAGGGGCCTGGTGAGAATTGCCGACA
  	AGGTCAGACGAGCCGTGCAGTGTGCCTGGTCCAGCGTCTCTAC
  	CAGCAGAAGCTCCGCCACCAGAGCCGCTGAGAGTGGCAGCTC
  	CAGCAGGACAGCCAGGGGGGCTTCCAGCGGCTATAGAGAGTA
  	TAGCCCTTCAGCCGCCAGAGGCCTGCGGCTGATGTTCACAGAC
  	TTTTGGAGAACAAGGGTGCTGCGGCAGACCAGCCCCATGGCC
  	GGCGTGTTTGGCAATCTGGACGTGAACGAGGCCCGGCTGATG
  	GCCGCATACACCAGCGAGTGTGCGGACCACCTGGAGGCAAAG
  	GAGCTGGCTGGACCCGACGGTGTGGCCGCTGCCCGAGAAATT
  	GCCAAGAGGTGGGAGAAGAGAGTTCGCGACCTGCAGGATAAG
  	GGCGCCGCACGGAAACTCCTGAACGACCCACTCGGCAGAAGA
  	ACCCCCAACTACCAGTCAAAGAACCCTGGGGAGTATACCGTG
  	GGAAATTCAATGTTCTACGATGGCCCTCAGGTTGCTAATCTCC
  	AGAACGTGGACACTGGGTTCTGGCTGGACATGAGCAACCTGA
  	GTGACGTGGTGCTGTCTCGGGAAATTCAGACAGGCCTGCGGGC
  	CAGAGCCACCCTGGAAGAGTCCATGCCTATGCTTGAGAACCTG
  	GAGGAGCGCTTTAGGCGACTCCAAGAAACCTGCGATGCTGCC
  	AGGACCGAGATCGAGGAGTCTGGATGGACCAGAGAAAGCGCC
  	TCCAGGATGGAGGGCGATGAGGCCCAGGGCCCCAGCAGGGTG
  	CAGCAGGCTTTCCAGAGCTTCGTGAACGAATGTAACAGTATCG
  	AATTCTCTTTCGGTAGCTTCGGCGAGCACGTGCGGGTGTTATG
  	CGCCAGGGTCAGCAGGGGCCTGGCGGCCGCCGGCGAGGCCAT
  	CAGAAGATGCTTCAGCTGTTGCAAAGGCTCAACCCACAGATAT
  	GCCCCTAGGGACGATCTGTCTCCAGAGGGCGCTAGCTTGGCCG
  	AGACACTAGCAAGGTTCGCCGACGATATGGGTATCGAGAGGG
  	GCGCCGACGGTACCTACGACATCCCCCTGGTGGACGACTGGA
  	GGAGAGGCGTGCCCAGTATTGAGGGCGAGGGATCCGACAGCA
  	TCTACGAGATCATGATGCCGATCTACGAGGTGATGAATATGGA
  	TCTGGAGACTCGTAGATCATTCGCTGTCCAGCAGGGCCACTAC
  	CAGGATCCTAGAGCCTCGGACTACGACTTGCCCAGGGCTAGCG
  	ATTACGACCTGCCTAGATCCCCCTACCCCACTCCCCCTCTTCCC
  	CCTCGGTATCAGCTGCAGAACATGGACGTGGAGGCCGGTTTCC
  	GAGAGGCTGTGTACGCCTCCTTCGTGGCCGGGATGTACAACTA
  	CGTCGTGACCCAGCCCCAGGAGAGAATCCCTAATTCCCAGCAG
  	GTGGAGGGCATCTTGAGAGATATGCTCACAAACGGGAGCCAG
  	ACCTTTCGTGACTTAATGAAGCGATGGAACAGAGAGGTGGAT
  	AGGGAGCACCACCATCACCACCAC
  Ct875_E_nIgK_cHis_CO001	ATGGAAACCCCCGCCCAGCTTCTCTTCCTCCTCTTGCTTTGGCT	250
  	CCCAGACACAACCGGCATGAGTATCAGAGGCGTAGGAGGCAA
  	CGGCAATAGCCGTATCCCCTCACACAACGGCGACGGCTCCAAC
  	AGACGGAGCCAGAACACCAAGGGGAATAATAAGGTGGAGGA
  	CCGGGTCTGTTCACTTTACAGCTCCAGGTCTAACGAGAATCGG
  	GAAAGCCCTTACGCCGTAGTCGACGTTAGCAGTATGATCGAAA
  	GCACCCCCACCAGCGGCGAGACAACAAGGGCCTCTCGAGGAG
  	TTCTGAGCAGATTTCAGAGAGGCCTGGTGCGGATCGCCGACAA
  	GGTGCGGAGAGCCGTGCAGTGCGCCTGGAGCAGCGTGAGTAC
  	ATCTCGGAGCAGCGCCACCAGAGCAGCCGAAAGCGGCTCATC
  	TAGCAGGACCGCTAGAGGCGCCAGCTCGGGGTACAGGGAATA
  	TTCACCCTCCGCCGCAAGGGGGCTGAGACTGATGTTTACAGAC
  	TTCTGGAGAACCAGGGTGCTGCGCCAGACAAGCCCAATGGCA
  	GGGGTGTTTGGTAACCTGGATGTGAATGAGGCCAGACTGATG
  	GCCGCCTACACTTCTGAGTGCGCGGATCATCTTGAGGCCAAGG
  	AACTGGCAGGCCCCGACGGCGTGGCCGCCGCCCGGGAGATTG
  	CTAAGAGATGGGAGAAGCGGGTCAGAGATCTGCAGGATAAGG
  	GGGCCGCTAGGAAACTCCTGAATGACCCCCTAGGCAGGAGAA
  	CCCCTAACTACCAGAGCAAAAATCCTGGGGAATACACCGTGG
  	GCAATTCCATGTTTTACGATGGCCCCCAAGTCGCAAACCTCCA
  	GAATGTGGACACCGGCTTCTGGCTGGACATGTCCAACTTGAGC
  	GACGTGGTTCTAAGCAGAGAAATCCAGACCGGACTCCGCGCG
  	AGAGCTACACTCGAGGAAAGCATGCCTATGCTGGAGAATCTG
  	GAGGAGCGATTCCGTCGTCTACAGGAGACTTGTGACGCCGCTA
  	GGACCGAGATCGAGGAGAGCGGCTGGACAAGAGAAAGCGCCT
  	CTCGAATGGAGGGCGATGAGGCCCAGGGCCCCTCCCGGGTGC
  	AGCAGGCCTTTCAGAGCTTCGTGAATGAGTGCAATTCTATTGA
  	GTTCAGCTTCGGCTCTTTTGGCGAGCACGTGCGGGTGCTTTGC
  	GCCAGGGTGTCCCGGGGACTGGCAGCCGCCGGCGAGGCCATA
  	AGAAGATGTTTCTCCTGCTGCAAGGGCAGCACCCACCGGTATG
  	CTCCCAGAGACGACCTGTCTCCAGAAGGGGCATCGCTGGCCG
  	AGACACTGGCACGGTTCGCCGACGATATGGGCATTGAGAGGG
  	GAGCCGACGGCACTTATGATATCCCTCTCGTGGACGACTGGAG
  	AAGAGGAGTCCCCTCAATTGAGGGCGAAGGATCCGATTCTATC
  	TATGAGATCATGATGCCTATCTACGAAGTGATGAATATGGACC
  	TGGAAACCAGGAGATCTTTCGCTGTGCAGCAGGGCCATTACCA
  	GGATCCCCGCGCCAGCGATTATGACCTGCCCAGAGCCTCAGAC
  	TACGATTTGCCCAGAAGCCCCTACCCCACCCCTCCGCTGCCCC
  	CTAGATACCAGCTGCAGAATATGGACGTGGAGGCTGGCTTTAG
  	GGAGGCTGTGTACGCTAGCTTCGTGGCCGGCATGTACAACTAC
  	GTGGTGACACAGCCCCAGGAGAGAATTCCCAATTCTCAACAA
  	GTAGAGGGCATCCTGAGAGACATGTTAACAAACGGATCTCAG
  	ACCTTCCGCGACCTGATGAAGCGGTGGAACCGGGAAGTGGAC
  	CGCGAGCACCACCACCACCATCAT
  Ct875_E_nIgK_nFLAG	ATGGAAACCCCTGCCCAGCTGCTGTTCCTGCTGCTGCTGTGGC	251
  	TGCCTGACACCACCGGCGACTATAAAGACCACGATGGCGATT
  	ACAAAGATCACGACATCGATTACAAGGATGACGACGACAAAA
  	TGAGCATCAGAGGCGTGGGCGGCAACGGCAACAGCAGAATCC
  	CTAGCCACAACGGCGACGGCAGCAACAGGCGGAGCCAGAACA
  	CCAAGGGCAACAACAAGGTGGAAGATAGAGTGTGCAGCCTGT
  	ACAGCAGCCGGTCCAACGAGAACCGCGAGAGCCCTTATGCCG
  	TGGTGGACGTGTCCAGCATGATCGAGAGCACCCCCACCAGCG
  	GCGAGACAACCAGAGCTAGTAGAGGCGTGCTGAGCCGGTTCC
  	AGAGGGGCCTCGTGCGGATTGCTGACAAAGTGCGGAGAGCCG
  	TGCAGTGCGCTTGGAGCAGCGTGTCCACAAGCAGAAGCAGCG
  	CCACAAGAGCCGCCGAGAGCGGCAGCTCTAGCAGAACAGCTA
  	GAGGCGCCAGCAGCGGCTACAGAGAGTACAGCCCTTCTGCCG
  	CTCGGGGCCTGCGGCTGATGTTCACCGACTTTTGGCGGACCCG
  	GGTGCTGAGACAGACCTCTCCTATGGCCGGCGTGTTCGGCAAC
  	CTGGACGTGAACGAGGCCAGACTGATGGCCGCCTACACCAGC
  	GAGTGTGCCGATCACCTGGAAGCCAAAGAGCTGGCCGGACCT
  	GACGGCGTGGCAGCCGCTAGAGAAATCGCCAAGAGATGGGAG
  	AAGAGAGTGCGGGACCTGCAGGACAAGGGCGCTGCCAGAAAG
  	CTGCTGAACGACCCCCTGGGCAGACGGACCCCCAACTACCAG
  	AGCAAGAACCCCGGCGAGTACACCGTGGGCAACTCCATGTTCT
  	ACGACGGCCCCCAGGTGGCCAACCTGCAGAATGTGGATACCG
  	GCTTCTGGCTGGACATGAGCAACCTGAGCGACGTGGTGCTGTC
  	CAGAGAGATCCAGACCGGCCTGAGAGCCAGAGCCACCCTGGA
  	AGAGTCCATGCCCATGCTGGAAAATCTGGAAGAGAGATTCCG
  	GCGGCTGCAGGAAACCTGCGACGCCGCCAGAACCGAGATCGA
  	GGAAAGCGGCTGGACCCGGGAAAGCGCCTCCAGAATGGAAGG
  	CGACGAAGCCCAGGGCCCCAGCAGAGTGCAGCAGGCCTTTCA
  	GAGCTTCGTGAATGAGTGCAACAGCATCGAGTTCAGCTTCGGC
  	TCCTTCGGCGAGCACGTGCGGGTGCTGTGTGCCAGAGTGTCAA
  	GAGGACTGGCCGCTGCCGGCGAGGCCATCAGAAGATGCTTCA
  	GCTGCTGCAAGGGCAGCACCCACAGATACGCCCCCAGAGATG
  	ACCTGTCTCCTGAGGGCGCCTCTCTGGCCGAAACCCTGGCCAG
  	ATTCGCCGACGACATGGGCATCGAAAGAGGCGCCGACGGCAC
  	CTACGACATCCCCCTGGTGGACGATTGGAGAAGGGGCGTGCC
  	ATCCATCGAGGGCGAGGGCAGCGATAGCATCTACGAGATCAT
  	GATGCCCATCTACGAAGTGATGAACATGGACCTGGAAACCCG
  	GCGGAGCTTCGCCGTGCAGCAGGGCCATTACCAGGACCCCAG
  	AGCCAGCGACTACGACCTGCCTAGAGCCTCCGATTACGATCTG
  	CCCAGAAGCCCCTACCCCACCCCTCCACTGCCTCCCAGATACC
  	AGCTGCAGAACATGGATGTGGAAGCCGGCTTTCGCGAGGCCG
  	TGTACGCCTCTTTTGTGGCCGGCATGTACAACTACGTCGTGAC
  	CCAGCCCCAGGAACGGATCCCCAATAGCCAGCAGGTGGAAGG
  	CATCCTGCGGGACATGCTGACCAACGGCAGCCAGACCTTCCGG
  	GACCTGATGAAGCGGTGGAACAGAGAGGTGGACCGCGAG
  Ct875_E_nIgK_cFLAG	ATGGAAACCCCTGCCCAGCTGCTGTTCCTGCTGCTGCTGTGGC	252
  	TGCCTGACACCACCGGCATGAGCATCAGAGGCGTGGGCGGCA
  	ACGGCAACAGCAGAATCCCTAGCCACAACGGCGACGGCAGCA
  	ACAGGCGGAGCCAGAACACCAAGGGCAACAACAAGGTGGAA
  	GATAGAGTGTGCAGCCTGTACAGCAGCCGGTCCAACGAGAAC
  	CGCGAGAGCCCTTATGCCGTGGTGGACGTGTCCAGCATGATCG
  	AGAGCACCCCCACCAGCGGCGAGACAACCAGAGCTAGTAGAG
  	GCGTGCTGAGCCGGTTCCAGAGGGGCCTCGTGCGGATTGCTGA
  	CAAAGTGCGGAGAGCCGTGCAGTGCGCTTGGAGCAGCGTGTC
  	CACAAGCAGAAGCAGCGCCACAAGAGCCGCCGAGAGCGGCA
  	GCTCTAGCAGAACAGCTAGAGGCGCCAGCAGCGGCTACAGAG
  	AGTACAGCCCTTCTGCCGCTCGGGGCCTGCGGCTGATGTTCAC
  	CGACTTTTGGCGGACCCGGGTGCTGAGACAGACCTCTCCTATG
  	GCCGGCGTGTTCGGCAACCTGGACGTGAACGAGGCCAGACTG
  	ATGGCCGCCTACACCAGCGAGTGTGCCGATCACCTGGAAGCC
  	AAAGAGCTGGCCGGACCTGACGGCGTGGCAGCCGCTAGAGAA
  	ATCGCCAAGAGATGGGAGAAGAGAGTGCGGGACCTGCAGGAC
  	AAGGGCGCTGCCAGAAAGCTGCTGAACGACCCCCTGGGCAGA
  	CGGACCCCCAACTACCAGAGCAAGAACCCCGGCGAGTACACC
  	GTGGGCAACTCCATGTTCTACGACGGCCCCCAGGTGGCCAACC
  	TGCAGAATGTGGATACCGGCTTCTGGCTGGACATGAGCAACCT
  	GAGCGACGTGGTGCTGTCCAGAGAGATCCAGACCGGCCTGAG
  	AGCCAGAGCCACCCTGGAAGAGTCCATGCCCATGCTGGAAAA
  	TCTGGAAGAGAGATTCCGGCGGCTGCAGGAAACCTGCGACGC
  	CGCCAGAACCGAGATCGAGGAAAGCGGCTGGACCCGGGAAAG
  	CGCCTCCAGAATGGAAGGCGACGAAGCCCAGGGCCCCAGCAG
  	AGTGCAGCAGGCCTTTCAGAGCTTCGTGAATGAGTGCAACAGC
  	ATCGAGTTCAGCTTCGGCTCCTTCGGCGAGCACGTGCGGGTGC
  	TGTGTGCCAGAGTGTCAAGAGGACTGGCCGCTGCCGGCGAGG
  	CCATCAGAAGATGCTTCAGCTGCTGCAAGGGCAGCACCCACA
  	GATACGCCCCCAGAGATGACCTGTCTCCTGAGGGCGCCTCTCT
  	GGCCGAAACCCTGGCCAGATTCGCCGACGACATGGGCATCGA
  	AAGAGGCGCCGACGGCACCTACGACATCCCCCTGGTGGACGA
  	TTGGAGAAGGGGCGTGCCATCCATCGAGGGCGAGGGCAGCGA
  	TAGCATCTACGAGATCATGATGCCCATCTACGAAGTGATGAAC
  	ATGGACCTGGAAACCCGGCGGAGCTTCGCCGTGCAGCAGGGC
  	CATTACCAGGACCCCAGAGCCAGCGACTACGACCTGCCTAGA
  	GCCTCCGATTACGATCTGCCCAGAAGCCCCTACCCCACCCCTC
  	CACTGCCTCCCAGATACCAGCTGCAGAACATGGATGTGGAAG
  	CCGGCTTTCGCGAGGCCGTGTACGCCTCTTTTGTGGCCGGCAT
  	GTACAACTACGTCGTGACCCAGCCCCAGGAACGGATCCCCAAT
  	AGCCAGCAGGTGGAAGGCATCCTGCGGGACATGCTGACCAAC
  	GGCAGCCAGACCTTCCGGGACCTGATGAAGCGGTGGAACAGA
  	GAGGTGGACCGCGAGGACTATAAAGACCACGATGGCGATTAC
  	AAAGATCACGACATCGATTACAAGGATGACGACGACAAA
  Ct875_E_nIgK_nHis	ATGGAAACCCCTGCCCAGCTGCTGTTCCTGCTGCTGCTGTGGC	253
  	TGCCTGACACCACCGGCCACCACCATCACCACCACATGAGCAT
  	CAGAGGCGTGGGCGGCAACGGCAACAGCAGAATCCCTAGCCA
  	CAACGGCGACGGCAGCAACAGGCGGAGCCAGAACACCAAGG
  	GCAACAACAAGGTGGAAGATAGAGTGTGCAGCCTGTACAGCA
  	GCCGGTCCAACGAGAACCGCGAGAGCCCTTATGCCGTGGTGG
  	ACGTGTCCAGCATGATCGAGAGCACCCCCACCAGCGGCGAGA
  	CAACCAGAGCTAGTAGAGGCGTGCTGAGCCGGTTCCAGAGGG
  	GCCTCGTGCGGATTGCTGACAAAGTGCGGAGAGCCGTGCAGT
  	GCGCTTGGAGCAGCGTGTCCACAAGCAGAAGCAGCGCCACAA
  	GAGCCGCCGAGAGCGGCAGCTCTAGCAGAACAGCTAGAGGCG
  	CCAGCAGCGGCTACAGAGAGTACAGCCCTTCTGCCGCTCGGG
  	GCCTGCGGCTGATGTTCACCGACTTTTGGCGGACCCGGGTGCT
  	GAGACAGACCTCTCCTATGGCCGGCGTGTTCGGCAACCTGGAC
  	GTGAACGAGGCCAGACTGATGGCCGCCTACACCAGCGAGTGT
  	GCCGATCACCTGGAAGCCAAAGAGCTGGCCGGACCTGACGGC
  	GTGGCAGCCGCTAGAGAAATCGCCAAGAGATGGGAGAAGAGA
  	GTGCGGGACCTGCAGGACAAGGGCGCTGCCAGAAAGCTGCTG
  	AACGACCCCCTGGGCAGACGGACCCCCAACTACCAGAGCAAG
  	AACCCCGGCGAGTACACCGTGGGCAACTCCATGTTCTACGACG
  	GCCCCCAGGTGGCCAACCTGCAGAATGTGGATACCGGCTTCTG
  	GCTGGACATGAGCAACCTGAGCGACGTGGTGCTGTCCAGAGA
  	GATCCAGACCGGCCTGAGAGCCAGAGCCACCCTGGAAGAGTC
  	CATGCCCATGCTGGAAAATCTGGAAGAGAGATTCCGGCGGCT
  	GCAGGAAACCTGCGACGCCGCCAGAACCGAGATCGAGGAAAG
  	CGGCTGGACCCGGGAAAGCGCCTCCAGAATGGAAGGCGACGA
  	AGCCCAGGGCCCCAGCAGAGTGCAGCAGGCCTTTCAGAGCTT
  	CGTGAATGAGTGCAACAGCATCGAGTTCAGCTTCGGCTCCTTC
  	GGCGAGCACGTGCGGGTGCTGTGTGCCAGAGTGTCAAGAGGA
  	CTGGCCGCTGCCGGCGAGGCCATCAGAAGATGCTTCAGCTGCT
  	GCAAGGGCAGCACCCACAGATACGCCCCCAGAGATGACCTGT
  	CTCCTGAGGGCGCCTCTCTGGCCGAAACCCTGGCCAGATTCGC
  	CGACGACATGGGCATCGAAAGAGGCGCCGACGGCACCTACGA
  	CATCCCCCTGGTGGACGATTGGAGAAGGGGCGTGCCATCCATC
  	GAGGGCGAGGGCAGCGATAGCATCTACGAGATCATGATGCCC
  	ATCTACGAAGTGATGAACATGGACCTGGAAACCCGGCGGAGC
  	TTCGCCGTGCAGCAGGGCCATTACCAGGACCCCAGAGCCAGC
  	GACTACGACCTGCCTAGAGCCTCCGATTACGATCTGCCCAGAA
  	GCCCCTACCCCACCCCTCCACTGCCTCCCAGATACCAGCTGCA
  	GAACATGGATGTGGAAGCCGGCTTTCGCGAGGCCGTGTACGC
  	CTCTTTTGTGGCCGGCATGTACAACTACGTCGTGACCCAGCCC
  	CAGGAACGGATCCCCAATAGCCAGCAGGTGGAAGGCATCCTG
  	CGGGACATGCTGACCAACGGCAGCCAGACCTTCCGGGACCTG
  	ATGAAGCGGTGGAACAGAGAGGTGGACCGCGAG
  MOMP_E_nTMEM149	ATGGGCCCTGGCAGATGTCTGCTGACAGCCCTGCTGCTGCTGG	254
  	CCCTGGCTCCTCCACCTGAAGCTCTGCCCGTGGGAAATCCTGC
  	CGAGCCCAGCCTGATGATCGACGGCATTCTGTGGGAGGGCTTC
  	GGCGGCGACCCTTGCGATCCTTGTACCACTTGGTGCGACGCCA
  	TCAGCATGAGAATGGGCTACTACGGCGACTTCGTGTTCGACCG
  	GGTGCTGAAAACCGACGTGAACAAAGAATTCCAGATGGGCGA
  	CAAGCCCACCAGCACCACCGGAAATGCCACCGCCCCTACCAC
  	CCTGACCGCCAGAGAAAATCCCGCCTACGGCCGGCACATGCA
  	GGACGCCGAGATGTTCACCAACGCCGCCTGCATGGCCCTGAAC
  	ATCTGGGACAGATTCGACGTGTTCTGCACCCTGGGCGCCAGCA
  	GCGGCTACCTGAAGGGCAATAGCGCCAGCTTCAACCTCGTGG
  	GCCTGTTCGGCGACAACGAGAACCAGAGCACCGTGAAAACAA
  	ACAGCGTGCCCAACATGAGCCTGGACCAGAGCGTGGTGGAAC
  	TGTACACCGACACCGCATTCTCTTGGAGCGTGGGAGCCAGAGC
  	TGCCCTGTGGGAGTGTGGATGTGCCACACTGGGCGCTAGCTTC
  	CAGTACGCCCAGAGCAAGCCCAAGGTGGAAGAACTGAACGTG
  	CTGTGCAATGCCGCCGAGTTCACCATCAACAAGCCTAAGGGCT
  	ACGTGGGCCAGGAATTCCCCCTGGCCCTGATCGCCGGAACAG
  	ATGCCGCCACCGGAACAAAGGACGCCAGCATCGACTACCACG
  	AGTGGCAGGCTTCTCTGGCCCTGTCCTACCGGCTGAATATGTT
  	CACCCCCTACATCGGCGTGAAGTGGTCCCGGGCCAGCTTCGAT
  	GCCGACACCATCAGAATCGCCCAGCCCAAGAGCGCCACCGCC
  	ATCTTCGATACCACCACACTGAACCCCACCATTGCCGGCGCTG
  	GCGACGTGAAAGCCTCTGCCGAAGGACAGCTGGGCGACACAA
  	TGCAGATCGTGTCCCTGCAGCTGAACAAGATGAAGTCCCGGA
  	AGTCCTGCGGAATCGCCGTGGGCACCACAATCGTGGACGCCG
  	ATAAGTACGCCGTGACCGTGGAAACCCGGCTGATCGATGAGA
  	GGGCCGCTCACGTGAACGCCCAGTTCAGATTC
  MOMP_E_nTMEM149_cHis	ATGGGCCCTGGCAGATGTCTGCTGACAGCCCTGCTGCTGCTGG	255
  	CCCTGGCTCCTCCACCTGAAGCTCTGCCCGTGGGAAATCCTGC
  	CGAGCCCAGCCTGATGATCGACGGCATTCTGTGGGAGGGCTTC
  	GGCGGCGACCCTTGCGATCCTTGTACCACTTGGTGCGACGCCA
  	TCAGCATGAGAATGGGCTACTACGGCGACTTCGTGTTCGACCG
  	GGTGCTGAAAACCGACGTGAACAAAGAATTCCAGATGGGCGA
  	CAAGCCCACCAGCACCACCGGAAATGCCACCGCCCCTACCAC
  	CCTGACCGCCAGAGAAAATCCCGCCTACGGCCGGCACATGCA
  	GGACGCCGAGATGTTCACCAACGCCGCCTGCATGGCCCTGAAC
  	ATCTGGGACAGATTCGACGTGTTCTGCACCCTGGGCGCCAGCA
  	GCGGCTACCTGAAGGGCAATAGCGCCAGCTTCAACCTCGTGG
  	GCCTGTTCGGCGACAACGAGAACCAGAGCACCGTGAAAACAA
  	ACAGCGTGCCCAACATGAGCCTGGACCAGAGCGTGGTGGAAC
  	TGTACACCGACACCGCATTCTCTTGGAGCGTGGGAGCCAGAGC
  	TGCCCTGTGGGAGTGTGGATGTGCCACACTGGGCGCTAGCTTC
  	CAGTACGCCCAGAGCAAGCCCAAGGTGGAAGAACTGAACGTG
  	CTGTGCAATGCCGCCGAGTTCACCATCAACAAGCCTAAGGGCT
  	ACGTGGGCCAGGAATTCCCCCTGGCCCTGATCGCCGGAACAG
  	ATGCCGCCACCGGAACAAAGGACGCCAGCATCGACTACCACG
  	AGTGGCAGGCTTCTCTGGCCCTGTCCTACCGGCTGAATATGTT
  	CACCCCCTACATCGGCGTGAAGTGGTCCCGGGCCAGCTTCGAT
  	GCCGACACCATCAGAATCGCCCAGCCCAAGAGCGCCACCGCC
  	ATCTTCGATACCACCACACTGAACCCCACCATTGCCGGCGCTG
  	GCGACGTGAAAGCCTCTGCCGAAGGACAGCTGGGCGACACAA
  	TGCAGATCGTGTCCCTGCAGCTGAACAAGATGAAGTCCCGGA
  	AGTCCTGCGGAATCGCCGTGGGCACCACAATCGTGGACGCCG
  	ATAAGTACGCCGTGACCGTGGAAACCCGGCTGATCGATGAGA
  	GGGCCGCTCACGTGAACGCCCAGTTCAGATTCCACCACCACCA
  	TCACCAC
  MOMP_E_nFLRT2	ATGGGCCTGCAGACCACCAAGTGGCCTAGCCACGGCGCATTCT	256
  	TTCTGAAGTCCTGGCTGATCATCTCCCTGGGCCTGTACAGCCA
  	GGTGTCCAAGCTGCTGGCTCTGCCCGTGGGAAATCCTGCCGAG
  	CCCAGCCTGATGATCGACGGCATTCTGTGGGAGGGCTTCGGCG
  	GCGACCCTTGCGATCCTTGTACCACTTGGTGCGACGCCATCAG
  	CATGAGAATGGGCTACTACGGCGACTTCGTGTTCGACCGGGTG
  	CTGAAAACCGACGTGAACAAAGAATTCCAGATGGGCGACAAG
  	CCCACCAGCACCACCGGAAATGCCACCGCCCCTACCACCCTGA
  	CCGCCAGAGAAAATCCCGCCTACGGCCGGCACATGCAGGACG
  	CCGAGATGTTCACCAACGCCGCCTGCATGGCCCTGAACATCTG
  	GGACAGATTCGACGTGTTCTGCACCCTGGGCGCCAGCAGCGGC
  	TACCTGAAGGGCAATAGCGCCAGCTTCAACCTCGTGGGCCTGT
  	TCGGCGACAACGAGAACCAGAGCACCGTGAAAACAAACAGCG
  	TGCCCAACATGAGCCTGGACCAGAGCGTGGTGGAACTGTACA
  	CCGACACCGCATTCTCTTGGAGCGTGGGAGCCAGAGCTGCCCT
  	GTGGGAGTGTGGATGTGCCACACTGGGCGCTAGCTTCCAGTAC
  	GCCCAGAGCAAGCCCAAGGTGGAAGAACTGAACGTGCTGTGC
  	AATGCCGCCGAGTTCACCATCAACAAGCCTAAGGGCTACGTG
  	GGCCAGGAATTCCCCCTGGCCCTGATCGCCGGAACAGATGCCG
  	CCACCGGAACAAAGGACGCCAGCATCGACTACCACGAGTGGC
  	AGGCTTCTCTGGCCCTGTCCTACCGGCTGAATATGTTCACCCCC
  	TACATCGGCGTGAAGTGGTCCCGGGCCAGCTTCGATGCCGACA
  	CCATCAGAATCGCCCAGCCCAAGAGCGCCACCGCCATCTTCGA
  	TACCACCACACTGAACCCCACCATTGCCGGCGCTGGCGACGTG
  	AAAGCCTCTGCCGAAGGACAGCTGGGCGACACAATGCAGATC
  	GTGTCCCTGCAGCTGAACAAGATGAAGTCCCGGAAGTCCTGCG
  	GAATCGCCGTGGGCACCACAATCGTGGACGCCGATAAGTACG
  	CCGTGACCGTGGAAACCCGGCTGATCGATGAGAGGGCCGCTC
  	ACGTGAACGCCCAGTTCAGATTC
  MOMP_E_nFLRT2_cHis	ATGGGCCTGCAGACCACCAAGTGGCCTAGCCACGGCGCATTCT	257
  	TTCTGAAGTCCTGGCTGATCATCTCCCTGGGCCTGTACAGCCA
  	GGTGTCCAAGCTGCTGGCTCTGCCCGTGGGAAATCCTGCCGAG
  	CCCAGCCTGATGATCGACGGCATTCTGTGGGAGGGCTTCGGCG
  	GCGACCCTTGCGATCCTTGTACCACTTGGTGCGACGCCATCAG
  	CATGAGAATGGGCTACTACGGCGACTTCGTGTTCGACCGGGTG
  	CTGAAAACCGACGTGAACAAAGAATTCCAGATGGGCGACAAG
  	CCCACCAGCACCACCGGAAATGCCACCGCCCCTACCACCCTGA
  	CCGCCAGAGAAAATCCCGCCTACGGCCGGCACATGCAGGACG
  	CCGAGATGTTCACCAACGCCGCCTGCATGGCCCTGAACATCTG
  	GGACAGATTCGACGTGTTCTGCACCCTGGGCGCCAGCAGCGGC
  	TACCTGAAGGGCAATAGCGCCAGCTTCAACCTCGTGGGCCTGT
  	TCGGCGACAACGAGAACCAGAGCACCGTGAAAACAAACAGCG
  	TGCCCAACATGAGCCTGGACCAGAGCGTGGTGGAACTGTACA
  	CCGACACCGCATTCTCTTGGAGCGTGGGAGCCAGAGCTGCCCT
  	GTGGGAGTGTGGATGTGCCACACTGGGCGCTAGCTTCCAGTAC
  	GCCCAGAGCAAGCCCAAGGTGGAAGAACTGAACGTGCTGTGC
  	AATGCCGCCGAGTTCACCATCAACAAGCCTAAGGGCTACGTG
  	GGCCAGGAATTCCCCCTGGCCCTGATCGCCGGAACAGATGCCG
  	CCACCGGAACAAAGGACGCCAGCATCGACTACCACGAGTGGC
  	AGGCTTCTCTGGCCCTGTCCTACCGGCTGAATATGTTCACCCCC
  	TACATCGGCGTGAAGTGGTCCCGGGCCAGCTTCGATGCCGACA
  	CCATCAGAATCGCCCAGCCCAAGAGCGCCACCGCCATCTTCGA
  	TACCACCACACTGAACCCCACCATTGCCGGCGCTGGCGACGTG
  	AAAGCCTCTGCCGAAGGACAGCTGGGCGACACAATGCAGATC
  	GTGTCCCTGCAGCTGAACAAGATGAAGTCCCGGAAGTCCTGCG
  	GAATCGCCGTGGGCACCACAATCGTGGACGCCGATAAGTACG
  	CCGTGACCGTGGAAACCCGGCTGATCGATGAGAGGGCCGCTC
  	ACGTGAACGCCCAGTTCAGATTCCACCACCACCATCACCAC
  MOMP_E_nIgK	ATGGAAACCCCTGCCCAGCTGCTGTTCCTGCTGCTGCTGTGGC	258
  	TGCCTGACACCACCGGCCTGCCCGTGGGAAATCCTGCCGAGCC
  	CAGCCTGATGATCGACGGCATTCTGTGGGAGGGCTTCGGCGGC
  	GACCCTTGCGATCCTTGTACCACTTGGTGCGACGCCATCAGCA
  	TGAGAATGGGCTACTACGGCGACTTCGTGTTCGACCGGGTGCT
  	GAAAACCGACGTGAACAAAGAATTCCAGATGGGCGACAAGCC
  	CACCAGCACCACCGGAAATGCCACCGCCCCTACCACCCTGACC
  	GCCAGAGAAAATCCCGCCTACGGCCGGCACATGCAGGACGCC
  	GAGATGTTCACCAACGCCGCCTGCATGGCCCTGAACATCTGGG
  	ACAGATTCGACGTGTTCTGCACCCTGGGCGCCAGCAGCGGCTA
  	CCTGAAGGGCAATAGCGCCAGCTTCAACCTCGTGGGCCTGTTC
  	GGCGACAACGAGAACCAGAGCACCGTGAAAACAAACAGCGTG
  	CCCAACATGAGCCTGGACCAGAGCGTGGTGGAACTGTACACC
  	GACACCGCATTCTCTTGGAGCGTGGGAGCCAGAGCTGCCCTGT
  	GGGAGTGTGGATGTGCCACACTGGGCGCTAGCTTCCAGTACGC
  	CCAGAGCAAGCCCAAGGTGGAAGAACTGAACGTGCTGTGCAA
  	TGCCGCCGAGTTCACCATCAACAAGCCTAAGGGCTACGTGGGC
  	CAGGAATTCCCCCTGGCCCTGATCGCCGGAACAGATGCCGCCA
  	CCGGAACAAAGGACGCCAGCATCGACTACCACGAGTGGCAGG
  	CTTCTCTGGCCCTGTCCTACCGGCTGAATATGTTCACCCCCTAC
  	ATCGGCGTGAAGTGGTCCCGGGCCAGCTTCGATGCCGACACCA
  	TCAGAATCGCCCAGCCCAAGAGCGCCACCGCCATCTTCGATAC
  	CACCACACTGAACCCCACCATTGCCGGCGCTGGCGACGTGAA
  	AGCCTCTGCCGAAGGACAGCTGGGCGACACAATGCAGATCGT
  	GTCCCTGCAGCTGAACAAGATGAAGTCCCGGAAGTCCTGCGG
  	AATCGCCGTGGGCACCACAATCGTGGACGCCGATAAGTACGC
  	CGTGACCGTGGAAACCCGGCTGATCGATGAGAGGGCCGCTCA
  	CGTGAACGCCCAGTTCAGATTC
  MOMP_E_nIgK_cHis	ATGGAAACCCCTGCCCAGCTGCTGTTCCTGCTGCTGCTGTGGC	259
  	TGCCTGACACCACCGGCCTGCCCGTGGGAAATCCTGCCGAGCC
  	CAGCCTGATGATCGACGGCATTCTGTGGGAGGGCTTCGGCGGC
  	GACCCTTGCGATCCTTGTACCACTTGGTGCGACGCCATCAGCA
  	TGAGAATGGGCTACTACGGCGACTTCGTGTTCGACCGGGTGCT
  	GAAAACCGACGTGAACAAAGAATTCCAGATGGGCGACAAGCC
  	CACCAGCACCACCGGAAATGCCACCGCCCCTACCACCCTGACC
  	GCCAGAGAAAATCCCGCCTACGGCCGGCACATGCAGGACGCC
  	GAGATGTTCACCAACGCCGCCTGCATGGCCCTGAACATCTGGG
  	ACAGATTCGACGTGTTCTGCACCCTGGGCGCCAGCAGCGGCTA
  	CCTGAAGGGCAATAGCGCCAGCTTCAACCTCGTGGGCCTGTTC
  	GGCGACAACGAGAACCAGAGCACCGTGAAAACAAACAGCGTG
  	CCCAACATGAGCCTGGACCAGAGCGTGGTGGAACTGTACACC
  	GACACCGCATTCTCTTGGAGCGTGGGAGCCAGAGCTGCCCTGT
  	GGGAGTGTGGATGTGCCACACTGGGCGCTAGCTTCCAGTACGC
  	CCAGAGCAAGCCCAAGGTGGAAGAACTGAACGTGCTGTGCAA
  	TGCCGCCGAGTTCACCATCAACAAGCCTAAGGGCTACGTGGGC
  	CAGGAATTCCCCCTGGCCCTGATCGCCGGAACAGATGCCGCCA
  	CCGGAACAAAGGACGCCAGCATCGACTACCACGAGTGGCAGG
  	CTTCTCTGGCCCTGTCCTACCGGCTGAATATGTTCACCCCCTAC
  	ATCGGCGTGAAGTGGTCCCGGGCCAGCTTCGATGCCGACACCA
  	TCAGAATCGCCCAGCCCAAGAGCGCCACCGCCATCTTCGATAC
  	CACCACACTGAACCCCACCATTGCCGGCGCTGGCGACGTGAA
  	AGCCTCTGCCGAAGGACAGCTGGGCGACACAATGCAGATCGT
  	GTCCCTGCAGCTGAACAAGATGAAGTCCCGGAAGTCCTGCGG
  	AATCGCCGTGGGCACCACAATCGTGGACGCCGATAAGTACGC
  	CGTGACCGTGGAAACCCGGCTGATCGATGAGAGGGCCGCTCA
  	CGTGAACGCCCAGTTCAGATTCCACCACCACCATCACCAC
  MOMP_E_nOsteo	ATGTGGTGGCGGCTGTGGTGGCTTCTCCTTCTCCTCCTGCTGCT	260
  	GTGGCCCATGGTGTGGGCCCTGCCCGTGGGAAATCCTGCCGAG
  	CCCAGCCTGATGATCGACGGCATTCTGTGGGAGGGCTTCGGCG
  	GCGACCCTTGCGATCCTTGTACCACTTGGTGCGACGCCATCAG
  	CATGAGAATGGGCTACTACGGCGACTTCGTGTTCGACCGGGTG
  	CTGAAAACCGACGTGAACAAAGAATTCCAGATGGGCGACAAG
  	CCCACCAGCACCACCGGAAATGCCACCGCCCCTACCACCCTGA
  	CCGCCAGAGAAAATCCCGCCTACGGCCGGCACATGCAGGACG
  	CCGAGATGTTCACCAACGCCGCCTGCATGGCCCTGAACATCTG
  	GGACAGATTCGACGTGTTCTGCACCCTGGGCGCCAGCAGCGGC
  	TACCTGAAGGGCAATAGCGCCAGCTTCAACCTCGTGGGCCTGT
  	TCGGCGACAACGAGAACCAGAGCACCGTGAAAACAAACAGCG
  	TGCCCAACATGAGCCTGGACCAGAGCGTGGTGGAACTGTACA
  	CCGACACCGCATTCTCTTGGAGCGTGGGAGCCAGAGCTGCCCT
  	GTGGGAGTGTGGATGTGCCACACTGGGCGCTAGCTTCCAGTAC
  	GCCCAGAGCAAGCCCAAGGTGGAAGAACTGAACGTGCTGTGC
  	AATGCCGCCGAGTTCACCATCAACAAGCCTAAGGGCTACGTG
  	GGCCAGGAATTCCCCCTGGCCCTGATCGCCGGAACAGATGCCG
  	CCACCGGAACAAAGGACGCCAGCATCGACTACCACGAGTGGC
  	AGGCTTCTCTGGCCCTGTCCTACCGGCTGAATATGTTCACCCCC
  	TACATCGGCGTGAAGTGGTCCCGGGCCAGCTTCGATGCCGACA
  	CCATCAGAATCGCCCAGCCCAAGAGCGCCACCGCCATCTTCGA
  	TACCACCACACTGAACCCCACCATTGCCGGCGCTGGCGACGTG
  	AAAGCCTCTGCCGAAGGACAGCTGGGCGACACAATGCAGATC
  	GTGTCCCTGCAGCTGAACAAGATGAAGTCCCGGAAGTCCTGCG
  	GAATCGCCGTGGGCACCACAATCGTGGACGCCGATAAGTACG
  	CCGTGACCGTGGAAACCCGGCTGATCGATGAGAGGGCCGCTC
  	ACGTGAACGCCCAGTTCAGATTC
  MOMP_E_nOsteo_cHis	ATGTGGTGGCGGCTGTGGTGGCTTCTCCTTCTCCTCCTGCTGCT	261
  	GTGGCCCATGGTGTGGGCCCTGCCCGTGGGAAATCCTGCCGAG
  	CCCAGCCTGATGATCGACGGCATTCTGTGGGAGGGCTTCGGCG
  	GCGACCCTTGCGATCCTTGTACCACTTGGTGCGACGCCATCAG
  	CATGAGAATGGGCTACTACGGCGACTTCGTGTTCGACCGGGTG
  	CTGAAAACCGACGTGAACAAAGAATTCCAGATGGGCGACAAG
  	CCCACCAGCACCACCGGAAATGCCACCGCCCCTACCACCCTGA
  	CCGCCAGAGAAAATCCCGCCTACGGCCGGCACATGCAGGACG
  	CCGAGATGTTCACCAACGCCGCCTGCATGGCCCTGAACATCTG
  	GGACAGATTCGACGTGTTCTGCACCCTGGGCGCCAGCAGCGGC
  	TACCTGAAGGGCAATAGCGCCAGCTTCAACCTCGTGGGCCTGT
  	TCGGCGACAACGAGAACCAGAGCACCGTGAAAACAAACAGCG
  	TGCCCAACATGAGCCTGGACCAGAGCGTGGTGGAACTGTACA
  	CCGACACCGCATTCTCTTGGAGCGTGGGAGCCAGAGCTGCCCT
  	GTGGGAGTGTGGATGTGCCACACTGGGCGCTAGCTTCCAGTAC
  	GCCCAGAGCAAGCCCAAGGTGGAAGAACTGAACGTGCTGTGC
  	AATGCCGCCGAGTTCACCATCAACAAGCCTAAGGGCTACGTG
  	GGCCAGGAATTCCCCCTGGCCCTGATCGCCGGAACAGATGCCG
  	CCACCGGAACAAAGGACGCCAGCATCGACTACCACGAGTGGC
  	AGGCTTCTCTGGCCCTGTCCTACCGGCTGAATATGTTCACCCCC
  	TACATCGGCGTGAAGTGGTCCCGGGCCAGCTTCGATGCCGACA
  	CCATCAGAATCGCCCAGCCCAAGAGCGCCACCGCCATCTTCGA
  	TACCACCACACTGAACCCCACCATTGCCGGCGCTGGCGACGTG
  	AAAGCCTCTGCCGAAGGACAGCTGGGCGACACAATGCAGATC
  	GTGTCCCTGCAGCTGAACAAGATGAAGTCCCGGAAGTCCTGCG
  	GAATCGCCGTGGGCACCACAATCGTGGACGCCGATAAGTACG
  	CCGTGACCGTGGAAACCCGGCTGATCGATGAGAGGGCCGCTC
  	ACGTGAACGCCCAGTTCAGATTCCACCACCACCATCACCAC
  Ct-858_E_H97A_nIgK	ATGGAAACCCCTGCCCAGCTGCTGTTCCTGCTGCTGCTGTGGC	262
  	TGCCTGATACCACAGGCGTGCGGGGAGAGTCCCTCGTGTGCAA
  	GAATGCCCTGCAGGACCTGAGCTTCCTGGAACATCTGCTGCAA
  	GTGAAGTACGCCCCCAAGACCTGGAAAGAGCAGTACCTGGGC
  	TGGGACCTGGTGCAGTCCTCTGTGTCTGCCCAGCAGAAGCTGC
  	GGACCCAGGAAAACCCCTCTACCAGCTTCTGTCAGCAAGTGCT
  	GGCCGACTTCATCGGCGGCCTGAACGATTTCGCCGCCGGCGTG
  	ACCTTTTTCGCCATCGAGAGCGCCTACCTGCCCTACACCGTGC
  	AGAAGTCCAGCGACGGCCGGTTCTACTTCGTGGACATCATGAC
  	CTTCAGCAGCGAGATCAGAGTGGGCGACGAGCTGCTGGAAGT
  	GGATGGCGCTCCTGTGCAGGATGTGCTGGCCACACTGTACGGC
  	AGCAACCACAAGGGCACAGCCGCCGAAGAATCTGCCGCCCTG
  	AGAACCCTGTTCAGCCGGATGGCCTCTCTGGGCCACAAGGTGC
  	CAAGCGGCAGAACCACCCTGAAGATCAGACGGCCCTTTGGCA
  	CCACCCGGGAAGTGCGCGTGAAGTGGCGCTATGTGCCTGAGG
  	GCGTGGGCGACCTGGCCACAATCGCCCCTTCTATCAGAGCCCC
  	CCAGCTGCAGAAATCCATGCGGTCATTCTTCCCAAAGAAGGAC
  	GACGCCTTCCACCGGTCCAGCAGCCTGTTCTACAGCCCTATGG
  	TGCCCCACTTCTGGGCCGAGCTGAGAAACCACTACGCCACCTC
  	CGGCCTGAAGTCCGGCTACAACATCGGCAGCACCGACGGCTTT
  	CTGCCCGTGATCGGACCCGTGATCTGGGAGAGCGAGGGCCTGT
  	TCAGAGCCTACATCAGCAGCGTGACCGACGGCGACGGCAAGA
  	GCCACAAAGTGGGCTTTCTGAGAATCCCCACCTACAGCTGGCA
  	GGACATGGAAGATTTCGACCCCAGCGGCCCACCCCCCTGGGA
  	GGAATTTGCCAAGATCATCCAGGTGTTCAGCAGCAACACCGA
  	GGCCCTGATCATCGACCAGACCAACAACCCTGGCGGCAGCGT
  	GCTGTACCTGTACGCCCTGCTGAGCATGCTGACCGACAGACCC
  	CTGGAACTGCCCAAGCACCGGATGATCCTGACCCAGGACGAG
  	GTGGTGGACGCCCTGGATTGGCTGACCCTGCTGGAAAACGTGG
  	ACACCAACGTGGAAAGCCGGCTGGCCCTGGGCGACAACATGG
  	AAGGCTACACAGTGGATCTGCAGGTGGCCGAGTACCTGAAAA
  	GCTTCGGCAGACAGGTGCTGAACTGCTGGTCCAAGGGCGACA
  	TCGAGCTGAGCACCCCCATCCCCCTGTTCGGCTTCGAGAAGAT
  	CCACCCCCACCCCAGAGTGCAGTACAGCAAGCCCATCTGCGTG
  	CTGATCAACGAGCAGGACTTCTCCTGCGCCGACTTCTTCCCAG
  	TGGTGCTGAAGGACAACGACAGAGCCCTGATCGTGGGCACCA
  	GAACAGCTGGCGCTGGCGGCTTCGTGTTCAACGTGCAGTTCCC
  	CAACCGGACCGGCATCAAGACCTGTAGCCTGACAGGCTCTCTG
  	GCCGTGCGGGAACACGGCGCCTTCATCGAGAACATCGGCGTG
  	GAACCCCACATCGACCTGCCTTTCACCGCCAACGACATCCGGT
  	ACAAGGGCTACTCTGAGTACCTGGACAAAGTGAAGAAACTCG
  	TGTGCCAGCTGATTAACAACGACGGCACCATCATCCTGGCCGA
  	GGACGGCAGCTTC
  Ct858_E_H97A_nIgK_cHis	ATGGAAACCCCTGCCCAGCTGCTGTTCCTGCTGCTGCTGTGGC	263
  	TGCCTGATACCACAGGCGTGCGGGGAGAGTCCCTCGTGTGCAA
  	GAATGCCCTGCAGGACCTGAGCTTCCTGGAACATCTGCTGCAA
  	GTGAAGTACGCCCCCAAGACCTGGAAAGAGCAGTACCTGGGC
  	TGGGACCTGGTGCAGTCCTCTGTGTCTGCCCAGCAGAAGCTGC
  	GGACCCAGGAAAACCCCTCTACCAGCTTCTGTCAGCAAGTGCT
  	GGCCGACTTCATCGGCGGCCTGAACGATTTCGCCGCCGGCGTG
  	ACCTTTTTCGCCATCGAGAGCGCCTACCTGCCCTACACCGTGC
  	AGAAGTCCAGCGACGGCCGGTTCTACTTCGTGGACATCATGAC
  	CTTCAGCAGCGAGATCAGAGTGGGCGACGAGCTGCTGGAAGT
  	GGATGGCGCTCCTGTGCAGGATGTGCTGGCCACACTGTACGGC
  	AGCAACCACAAGGGCACAGCCGCCGAAGAATCTGCCGCCCTG
  	AGAACCCTGTTCAGCCGGATGGCCTCTCTGGGCCACAAGGTGC
  	CAAGCGGCAGAACCACCCTGAAGATCAGACGGCCCTTTGGCA
  	CCACCCGGGAAGTGCGCGTGAAGTGGCGCTATGTGCCTGAGG
  	GCGTGGGCGACCTGGCCACAATCGCCCCTTCTATCAGAGCCCC
  	CCAGCTGCAGAAATCCATGCGGTCATTCTTCCCAAAGAAGGAC
  	GACGCCTTCCACCGGTCCAGCAGCCTGTTCTACAGCCCTATGG
  	TGCCCCACTTCTGGGCCGAGCTGAGAAACCACTACGCCACCTC
  	CGGCCTGAAGTCCGGCTACAACATCGGCAGCACCGACGGCTTT
  	CTGCCCGTGATCGGACCCGTGATCTGGGAGAGCGAGGGCCTGT
  	TCAGAGCCTACATCAGCAGCGTGACCGACGGCGACGGCAAGA
  	GCCACAAAGTGGGCTTTCTGAGAATCCCCACCTACAGCTGGCA
  	GGACATGGAAGATTTCGACCCCAGCGGCCCACCCCCCTGGGA
  	GGAATTTGCCAAGATCATCCAGGTGTTCAGCAGCAACACCGA
  	GGCCCTGATCATCGACCAGACCAACAACCCTGGCGGCAGCGT
  	GCTGTACCTGTACGCCCTGCTGAGCATGCTGACCGACAGACCC
  	CTGGAACTGCCCAAGCACCGGATGATCCTGACCCAGGACGAG
  	GTGGTGGACGCCCTGGATTGGCTGACCCTGCTGGAAAACGTGG
  	ACACCAACGTGGAAAGCCGGCTGGCCCTGGGCGACAACATGG
  	AAGGCTACACAGTGGATCTGCAGGTGGCCGAGTACCTGAAAA
  	GCTTCGGCAGACAGGTGCTGAACTGCTGGTCCAAGGGCGACA
  	TCGAGCTGAGCACCCCCATCCCCCTGTTCGGCTTCGAGAAGAT
  	CCACCCCCACCCCAGAGTGCAGTACAGCAAGCCCATCTGCGTG
  	CTGATCAACGAGCAGGACTTCTCCTGCGCCGACTTCTTCCCAG
  	TGGTGCTGAAGGACAACGACAGAGCCCTGATCGTGGGCACCA
  	GAACAGCTGGCGCTGGCGGCTTCGTGTTCAACGTGCAGTTCCC
  	CAACCGGACCGGCATCAAGACCTGTAGCCTGACAGGCTCTCTG
  	GCCGTGCGGGAACACGGCGCCTTCATCGAGAACATCGGCGTG
  	GAACCCCACATCGACCTGCCTTTCACCGCCAACGACATCCGGT
  	ACAAGGGCTACTCTGAGTACCTGGACAAAGTGAAGAAACTCG
  	TGTGCCAGCTGATTAACAACGACGGCACCATCATCCTGGCCGA
  	GGACGGCAGCTTCCACCACCACCATCACCAC
  Ct858_E_S491A_nIgK	ATGGAAACCCCTGCCCAGCTGCTGTTCCTGCTGCTGCTGTGGC	264
  	TGCCTGATACCACAGGCGTGCGGGGAGAGTCCCTCGTGTGCAA
  	GAATGCCCTGCAGGACCTGAGCTTCCTGGAACATCTGCTGCAA
  	GTGAAGTACGCCCCCAAGACCTGGAAAGAGCAGTACCTGGGC
  	TGGGACCTGGTGCAGTCCTCTGTGTCTGCCCAGCAGAAGCTGC
  	GGACCCAGGAAAACCCCTCTACCAGCTTCTGTCAGCAAGTGCT
  	GGCCGACTTCATCGGCGGCCTGAACGATTTCCATGCCGGCGTG
  	ACCTTTTTCGCCATCGAGAGCGCCTACCTGCCCTACACCGTGC
  	AGAAGTCCAGCGACGGCCGGTTCTACTTCGTGGACATCATGAC
  	CTTCAGCAGCGAGATCAGAGTGGGCGACGAGCTGCTGGAAGT
  	GGATGGCGCTCCTGTGCAGGATGTGCTGGCCACACTGTACGGC
  	AGCAACCACAAGGGCACAGCCGCCGAAGAATCTGCCGCCCTG
  	AGAACCCTGTTCAGCCGGATGGCCTCTCTGGGCCACAAGGTGC
  	CAAGCGGCAGAACCACCCTGAAGATCAGACGGCCCTTTGGCA
  	CCACCCGGGAAGTGCGCGTGAAGTGGCGCTATGTGCCTGAGG
  	GCGTGGGCGACCTGGCCACAATCGCCCCTTCTATCAGAGCCCC
  	CCAGCTGCAGAAATCCATGCGGTCATTCTTCCCAAAGAAGGAC
  	GACGCCTTCCACCGGTCCAGCAGCCTGTTCTACAGCCCTATGG
  	TGCCCCACTTCTGGGCCGAGCTGAGAAACCACTACGCCACCTC
  	CGGCCTGAAGTCCGGCTACAACATCGGCAGCACCGACGGCTTT
  	CTGCCCGTGATCGGACCCGTGATCTGGGAGAGCGAGGGCCTGT
  	TCAGAGCCTACATCAGCAGCGTGACCGACGGCGACGGCAAGA
  	GCCACAAAGTGGGCTTTCTGAGAATCCCCACCTACAGCTGGCA
  	GGACATGGAAGATTTCGACCCCAGCGGCCCACCCCCCTGGGA
  	GGAATTTGCCAAGATCATCCAGGTGTTCAGCAGCAACACCGA
  	GGCCCTGATCATCGACCAGACCAACAACCCTGGCGGCAGCGT
  	GCTGTACCTGTACGCCCTGCTGAGCATGCTGACCGACAGACCC
  	CTGGAACTGCCCAAGCACCGGATGATCCTGACCCAGGACGAG
  	GTGGTGGACGCCCTGGATTGGCTGACCCTGCTGGAAAACGTGG
  	ACACCAACGTGGAAAGCCGGCTGGCCCTGGGCGACAACATGG
  	AAGGCTACACAGTGGATCTGCAGGTGGCCGAGTACCTGAAAA
  	GCTTCGGCAGACAGGTGCTGAACTGCTGGTCCAAGGGCGACA
  	TCGAGCTGAGCACCCCCATCCCCCTGTTCGGCTTCGAGAAGAT
  	CCACCCCCACCCCAGAGTGCAGTACAGCAAGCCCATCTGCGTG
  	CTGATCAACGAGCAGGACTTCGCCTGCGCCGACTTCTTCCCAG
  	TGGTGCTGAAGGACAACGACAGAGCCCTGATCGTGGGCACCA
  	GAACAGCTGGCGCTGGCGGCTTCGTGTTCAACGTGCAGTTCCC
  	CAACCGGACCGGCATCAAGACCTGTAGCCTGACAGGCTCTCTG
  	GCCGTGCGGGAACACGGCGCCTTCATCGAGAACATCGGCGTG
  	GAACCCCACATCGACCTGCCTTTCACCGCCAACGACATCCGGT
  	ACAAGGGCTACTCTGAGTACCTGGACAAAGTGAAGAAACTCG
  	TGTGCCAGCTGATTAACAACGACGGCACCATCATCCTGGCCGA
  	GGACGGCAGCTTC
  Ct858_E_S491A_nIgK_cHis	ATGGAAACCCCTGCCCAGCTGCTGTTCCTGCTGCTGCTGTGGC	265
  	TGCCTGATACCACAGGCGTGCGGGGAGAGTCCCTCGTGTGCAA
  	GAATGCCCTGCAGGACCTGAGCTTCCTGGAACATCTGCTGCAA
  	GTGAAGTACGCCCCCAAGACCTGGAAAGAGCAGTACCTGGGC
  	TGGGACCTGGTGCAGTCCTCTGTGTCTGCCCAGCAGAAGCTGC
  	GGACCCAGGAAAACCCCTCTACCAGCTTCTGTCAGCAAGTGCT
  	GGCCGACTTCATCGGCGGCCTGAACGATTTCCATGCCGGCGTG
  	ACCTTTTTCGCCATCGAGAGCGCCTACCTGCCCTACACCGTGC
  	AGAAGTCCAGCGACGGCCGGTTCTACTTCGTGGACATCATGAC
  	CTTCAGCAGCGAGATCAGAGTGGGCGACGAGCTGCTGGAAGT
  	GGATGGCGCTCCTGTGCAGGATGTGCTGGCCACACTGTACGGC
  	AGCAACCACAAGGGCACAGCCGCCGAAGAATCTGCCGCCCTG
  	AGAACCCTGTTCAGCCGGATGGCCTCTCTGGGCCACAAGGTGC
  	CAAGCGGCAGAACCACCCTGAAGATCAGACGGCCCTTTGGCA
  	CCACCCGGGAAGTGCGCGTGAAGTGGCGCTATGTGCCTGAGG
  	GCGTGGGCGACCTGGCCACAATCGCCCCTTCTATCAGAGCCCC
  	CCAGCTGCAGAAATCCATGCGGTCATTCTTCCCAAAGAAGGAC
  	GACGCCTTCCACCGGTCCAGCAGCCTGTTCTACAGCCCTATGG
  	TGCCCCACTTCTGGGCCGAGCTGAGAAACCACTACGCCACCTC
  	CGGCCTGAAGTCCGGCTACAACATCGGCAGCACCGACGGCTTT
  	CTGCCCGTGATCGGACCCGTGATCTGGGAGAGCGAGGGCCTGT
  	TCAGAGCCTACATCAGCAGCGTGACCGACGGCGACGGCAAGA
  	GCCACAAAGTGGGCTTTCTGAGAATCCCCACCTACAGCTGGCA
  	GGACATGGAAGATTTCGACCCCAGCGGCCCACCCCCCTGGGA
  	GGAATTTGCCAAGATCATCCAGGTGTTCAGCAGCAACACCGA
  	GGCCCTGATCATCGACCAGACCAACAACCCTGGCGGCAGCGT
  	GCTGTACCTGTACGCCCTGCTGAGCATGCTGACCGACAGACCC
  	CTGGAACTGCCCAAGCACCGGATGATCCTGACCCAGGACGAG
  	GTGGTGGACGCCCTGGATTGGCTGACCCTGCTGGAAAACGTGG
  	ACACCAACGTGGAAAGCCGGCTGGCCCTGGGCGACAACATGG
  	AAGGCTACACAGTGGATCTGCAGGTGGCCGAGTACCTGAAAA
  	GCTTCGGCAGACAGGTGCTGAACTGCTGGTCCAAGGGCGACA
  	TCGAGCTGAGCACCCCCATCCCCCTGTTCGGCTTCGAGAAGAT
  	CCACCCCCACCCCAGAGTGCAGTACAGCAAGCCCATCTGCGTG
  	CTGATCAACGAGCAGGACTTCGCCTGCGCCGACTTCTTCCCAG
  	TGGTGCTGAAGGACAACGACAGAGCCCTGATCGTGGGCACCA
  	GAACAGCTGGCGCTGGCGGCTTCGTGTTCAACGTGCAGTTCCC
  	CAACCGGACCGGCATCAAGACCTGTAGCCTGACAGGCTCTCTG
  	GCCGTGCGGGAACACGGCGCCTTCATCGAGAACATCGGCGTG
  	GAACCCCACATCGACCTGCCTTTCACCGCCAACGACATCCGGT
  	ACAAGGGCTACTCTGAGTACCTGGACAAAGTGAAGAAACTCG
  	TGTGCCAGCTGATTAACAACGACGGCACCATCATCCTGGCCGA
  	GGACGGCAGCTTCCACCACCACCATCACCAC
  Ct089_E_T306A_nIgK	ATGGAAACCCCTGCCCAGCTGCTGTTCCTGCTGCTGCTGTGGC	266
  	TGCCTGACACCACCGGCATGACAGCATCTGGCGGAGCTGGCG
  	GCCTGGGCTCTACACAGACAGTGGATGTGGCCAGGGCCCAGG
  	CTGCTGCCGCTACACAGGATGCCCAGGAAGTGATCGGCAGCC
  	AGGAAGCCAGCGAGGCCTCTATGCTGAAGGGCTGCGAGGACC
  	TGATCAACCCTGCCGCCGCTACCCGCATCAAGAAGAAAGAGG
  	AAAAGTTCGAGTCCCTGGAAGCCAGACGGAAGCCCACCGCCG
  	ACAAGGCCGAGAAGAAGTCCGAGAGCACCGAGGAAAAGGGC
  	GACACCCCCCTGGAAGATCGGTTCACCGAGGATCTGAGCGAG
  	GTGTCCGGCGAGGACTTCCGGGGCCTGAAGAACAGCTTCGAC
  	GACGACAGCAGCCCCGAGGAAATCCTGGACGCCCTGACCAGC
  	AAGTTCAGCGACCCCACCATCAAGGACCTGGCCCTGGACTACC
  	TGATCCAGACCGCCCCCAGCGACCGGAAGCTGAAGTCTGCCCT
  	GATTCAGGCCAAGCACCAGCTGATGAGCCAGAACCCCCAGGC
  	CATCGTGGGCGGCAGAAATGTGCTGCTGGCCTCCGAGACATTC
  	GCCAGCAGAGCCAACACCAGCCCCAGCTCCCTGCGGAGCCTG
  	TATCTGCAAGTGACCAGCTCCCCCAGCAACTGCGACAACCTGA
  	GACAGATGCTGGCTAGCTACCTGCCCTCCGAGAAAACCGCCGT
  	GATGGAATTCCTCGTGAACGGCATGGTGGCCGACCTGAAAAG
  	CGAGGGCCCTAGCATCCCTCCCGCCAAGCTGCAGGTGTACATG
  	ACCGAGCTGAGCAACCTGCAGGCCCTGCACAGCGTGGACAGC
  	TTTTTCGACCGGAACATCGGCAACCTGGAAAACAGCCTGAAGC
  	ACGAGGGCCACGCCCCCATCCCTTCTCTGACAACCGGCAATCT
  	GGCCAAGACCTTCCTGCAGCTGGTGGAAGATAAGTTCCCCAGC
  	AGCTCCAAGGCCCAGAAGGCCCTGAACGAGCTCGTGGGCCCT
  	GATACCGGACCTCAGACCGAGGTGCTGAACCTGTTCTTTCGGG
  	CCCTGAATGGCTGCTCCCCCCGGATCTTTTCTGGCGCTGAGAA
  	GAAGCAGCAGCTGGCCAGCGTGATCACCAACACCCTGGATGC
  	CATCAACGCCGACAACGAGGACTACCCCAAGCCCGGCGACTT
  	CCCCAGAAGCAGCTTTAGCAGCACCCCCCCTCATGCCCCTGTG
  	CCCCAGTCTGAGATCCCTACCAGCCCAACCAGCACCCAGCCTC
  	CAAGCCCT
  Ct089_E_T306A_nIgK_cHis	ATGGAAACCCCTGCCCAGCTGCTGTTCCTGCTGCTGCTGTGGC	267
  	TGCCTGACACCACCGGCATGACAGCATCTGGCGGAGCTGGCG
  	GCCTGGGCTCTACACAGACAGTGGATGTGGCCAGGGCCCAGG
  	CTGCTGCCGCTACACAGGATGCCCAGGAAGTGATCGGCAGCC
  	AGGAAGCCAGCGAGGCCTCTATGCTGAAGGGCTGCGAGGACC
  	TGATCAACCCTGCCGCCGCTACCCGCATCAAGAAGAAAGAGG
  	AAAAGTTCGAGTCCCTGGAAGCCAGACGGAAGCCCACCGCCG
  	ACAAGGCCGAGAAGAAGTCCGAGAGCACCGAGGAAAAGGGC
  	GACACCCCCCTGGAAGATCGGTTCACCGAGGATCTGAGCGAG
  	GTGTCCGGCGAGGACTTCCGGGGCCTGAAGAACAGCTTCGAC
  	GACGACAGCAGCCCCGAGGAAATCCTGGACGCCCTGACCAGC
  	AAGTTCAGCGACCCCACCATCAAGGACCTGGCCCTGGACTACC
  	TGATCCAGACCGCCCCCAGCGACCGGAAGCTGAAGTCTGCCCT
  	GATTCAGGCCAAGCACCAGCTGATGAGCCAGAACCCCCAGGC
  	CATCGTGGGCGGCAGAAATGTGCTGCTGGCCTCCGAGACATTC
  	GCCAGCAGAGCCAACACCAGCCCCAGCTCCCTGCGGAGCCTG
  	TATCTGCAAGTGACCAGCTCCCCCAGCAACTGCGACAACCTGA
  	GACAGATGCTGGCTAGCTACCTGCCCTCCGAGAAAACCGCCGT
  	GATGGAATTCCTCGTGAACGGCATGGTGGCCGACCTGAAAAG
  	CGAGGGCCCTAGCATCCCTCCCGCCAAGCTGCAGGTGTACATG
  	ACCGAGCTGAGCAACCTGCAGGCCCTGCACAGCGTGGACAGC
  	TTTTTCGACCGGAACATCGGCAACCTGGAAAACAGCCTGAAGC
  	ACGAGGGCCACGCCCCCATCCCTTCTCTGACAACCGGCAATCT
  	GGCCAAGACCTTCCTGCAGCTGGTGGAAGATAAGTTCCCCAGC
  	AGCTCCAAGGCCCAGAAGGCCCTGAACGAGCTCGTGGGCCCT
  	GATACCGGACCTCAGACCGAGGTGCTGAACCTGTTCTTTCGGG
  	CCCTGAATGGCTGCTCCCCCCGGATCTTTTCTGGCGCTGAGAA
  	GAAGCAGCAGCTGGCCAGCGTGATCACCAACACCCTGGATGC
  	CATCAACGCCGACAACGAGGACTACCCCAAGCCCGGCGACTT
  	CCCCAGAAGCAGCTTTAGCAGCACCCCCCCTCATGCCCCTGTG
  	CCCCAGTCTGAGATCCCTACCAGCCCAACCAGCACCCAGCCTC
  	CAAGCCCTCACCACCACCATCACCAC
  Ct089_E_S198A_T306A_nIgK	ATGGAAACCCCTGCCCAGCTGCTGTTCCTGCTGCTGCTGTGGC	268
  	TGCCTGACACCACCGGCATGACAGCATCTGGCGGAGCTGGCG
  	GCCTGGGCTCTACACAGACAGTGGATGTGGCCAGGGCCCAGG
  	CTGCTGCCGCTACACAGGATGCCCAGGAAGTGATCGGCAGCC
  	AGGAAGCCAGCGAGGCCTCTATGCTGAAGGGCTGCGAGGACC
  	TGATCAACCCTGCCGCCGCTACCCGCATCAAGAAGAAAGAGG
  	AAAAGTTCGAGTCCCTGGAAGCCAGACGGAAGCCCACCGCCG
  	ACAAGGCCGAGAAGAAGTCCGAGAGCACCGAGGAAAAGGGC
  	GACACCCCCCTGGAAGATCGGTTCACCGAGGATCTGAGCGAG
  	GTGTCCGGCGAGGACTTCCGGGGCCTGAAGAACAGCTTCGAC
  	GACGACAGCAGCCCCGAGGAAATCCTGGACGCCCTGACCAGC
  	AAGTTCAGCGACCCCACCATCAAGGACCTGGCCCTGGACTACC
  	TGATCCAGACCGCCCCCAGCGACCGGAAGCTGAAGTCTGCCCT
  	GATTCAGGCCAAGCACCAGCTGATGAGCCAGAACCCCCAGGC
  	CATCGTGGGCGGCAGAAATGTGCTGCTGGCCTCCGAGACATTC
  	GCCAGCAGAGCCAACACCGCCCCCAGCTCCCTGCGGAGCCTGT
  	ATCTGCAAGTGACCAGCTCCCCCAGCAACTGCGACAACCTGAG
  	ACAGATGCTGGCTAGCTACCTGCCCTCCGAGAAAACCGCCGTG
  	ATGGAATTCCTCGTGAACGGCATGGTGGCCGACCTGAAAAGC
  	GAGGGCCCTAGCATCCCTCCCGCCAAGCTGCAGGTGTACATGA
  	CCGAGCTGAGCAACCTGCAGGCCCTGCACAGCGTGGACAGCT
  	TTTTCGACCGGAACATCGGCAACCTGGAAAACAGCCTGAAGC
  	ACGAGGGCCACGCCCCCATCCCTTCTCTGACAACCGGCAATCT
  	GGCCAAGACCTTCCTGCAGCTGGTGGAAGATAAGTTCCCCAGC
  	AGCTCCAAGGCCCAGAAGGCCCTGAACGAGCTCGTGGGCCCT
  	GATACCGGACCTCAGACCGAGGTGCTGAACCTGTTCTTTCGGG
  	CCCTGAATGGCTGCTCCCCCCGGATCTTTTCTGGCGCTGAGAA
  	GAAGCAGCAGCTGGCCAGCGTGATCACCAACACCCTGGATGC
  	CATCAACGCCGACAACGAGGACTACCCCAAGCCCGGCGACTT
  	CCCCAGAAGCAGCTTTAGCAGCACCCCCCCTCATGCCCCTGTG
  	CCCCAGTCTGAGATCCCTACCAGCCCAACCAGCACCCAGCCTC
  	CAAGCCCT
  Ct089_E_S198A_T306A_nIgK_cHis	ATGGAAACCCCTGCCCAGCTGCTGTTCCTGCTGCTGCTGTGGC	269
  	TGCCTGACACCACCGGCATGACAGCATCTGGCGGAGCTGGCG
  	GCCTGGGCTCTACACAGACAGTGGATGTGGCCAGGGCCCAGG
  	CTGCTGCCGCTACACAGGATGCCCAGGAAGTGATCGGCAGCC
  	AGGAAGCCAGCGAGGCCTCTATGCTGAAGGGCTGCGAGGACC
  	TGATCAACCCTGCCGCCGCTACCCGCATCAAGAAGAAAGAGG
  	AAAAGTTCGAGTCCCTGGAAGCCAGACGGAAGCCCACCGCCG
  	ACAAGGCCGAGAAGAAGTCCGAGAGCACCGAGGAAAAGGGC
  	GACACCCCCCTGGAAGATCGGTTCACCGAGGATCTGAGCGAG
  	GTGTCCGGCGAGGACTTCCGGGGCCTGAAGAACAGCTTCGAC
  	GACGACAGCAGCCCCGAGGAAATCCTGGACGCCCTGACCAGC
  	AAGTTCAGCGACCCCACCATCAAGGACCTGGCCCTGGACTACC
  	TGATCCAGACCGCCCCCAGCGACCGGAAGCTGAAGTCTGCCCT
  	GATTCAGGCCAAGCACCAGCTGATGAGCCAGAACCCCCAGGC
  	CATCGTGGGCGGCAGAAATGTGCTGCTGGCCTCCGAGACATTC
  	GCCAGCAGAGCCAACACCGCCCCCAGCTCCCTGCGGAGCCTGT
  	ATCTGCAAGTGACCAGCTCCCCCAGCAACTGCGACAACCTGAG
  	ACAGATGCTGGCTAGCTACCTGCCCTCCGAGAAAACCGCCGTG
  	ATGGAATTCCTCGTGAACGGCATGGTGGCCGACCTGAAAAGC
  	GAGGGCCCTAGCATCCCTCCCGCCAAGCTGCAGGTGTACATGA
  	CCGAGCTGAGCAACCTGCAGGCCCTGCACAGCGTGGACAGCT
  	TTTTCGACCGGAACATCGGCAACCTGGAAAACAGCCTGAAGC
  	ACGAGGGCCACGCCCCCATCCCTTCTCTGACAACCGGCAATCT
  	GGCCAAGACCTTCCTGCAGCTGGTGGAAGATAAGTTCCCCAGC
  	AGCTCCAAGGCCCAGAAGGCCCTGAACGAGCTCGTGGGCCCT
  	GATACCGGACCTCAGACCGAGGTGCTGAACCTGTTCTTTCGGG
  	CCCTGAATGGCTGCTCCCCCCGGATCTTTTCTGGCGCTGAGAA
  	GAAGCAGCAGCTGGCCAGCGTGATCACCAACACCCTGGATGC
  	CATCAACGCCGACAACGAGGACTACCCCAAGCCCGGCGACTT
  	CCCCAGAAGCAGCTTTAGCAGCACCCCCCCTCATGCCCCTGTG
  	CCCCAGTCTGAGATCCCTACCAGCCCAACCAGCACCCAGCCTC
  	CAAGCCCTCACCACCACCATCACCAC
  Ct089_E_S198A_nIgK	ATGGAAACCCCTGCCCAGCTGCTGTTCCTGCTGCTGCTGTGGC	270
  	TGCCTGACACCACCGGCATGACAGCATCTGGCGGAGCTGGCG
  	GCCTGGGCTCTACACAGACAGTGGATGTGGCCAGGGCCCAGG
  	CTGCTGCCGCTACACAGGATGCCCAGGAAGTGATCGGCAGCC
  	AGGAAGCCAGCGAGGCCTCTATGCTGAAGGGCTGCGAGGACC
  	TGATCAACCCTGCCGCCGCTACCCGCATCAAGAAGAAAGAGG
  	AAAAGTTCGAGTCCCTGGAAGCCAGACGGAAGCCCACCGCCG
  	ACAAGGCCGAGAAGAAGTCCGAGAGCACCGAGGAAAAGGGC
  	GACACCCCCCTGGAAGATCGGTTCACCGAGGATCTGAGCGAG
  	GTGTCCGGCGAGGACTTCCGGGGCCTGAAGAACAGCTTCGAC
  	GACGACAGCAGCCCCGAGGAAATCCTGGACGCCCTGACCAGC
  	AAGTTCAGCGACCCCACCATCAAGGACCTGGCCCTGGACTACC
  	TGATCCAGACCGCCCCCAGCGACCGGAAGCTGAAGTCTGCCCT
  	GATTCAGGCCAAGCACCAGCTGATGAGCCAGAACCCCCAGGC
  	CATCGTGGGCGGCAGAAATGTGCTGCTGGCCTCCGAGACATTC
  	GCCAGCAGAGCCAACACCGCCCCCAGCTCCCTGCGGAGCCTGT
  	ATCTGCAAGTGACCAGCTCCCCCAGCAACTGCGACAACCTGAG
  	ACAGATGCTGGCTAGCTACCTGCCCTCCGAGAAAACCGCCGTG
  	ATGGAATTCCTCGTGAACGGCATGGTGGCCGACCTGAAAAGC
  	GAGGGCCCTAGCATCCCTCCCGCCAAGCTGCAGGTGTACATGA
  	CCGAGCTGAGCAACCTGCAGGCCCTGCACAGCGTGGACAGCT
  	TTTTCGACCGGAACATCGGCAACCTGGAAAACAGCCTGAAGC
  	ACGAGGGCCACGCCCCCATCCCTTCTCTGACAACCGGCAATCT
  	GACCAAGACCTTCCTGCAGCTGGTGGAAGATAAGTTCCCCAGC
  	AGCTCCAAGGCCCAGAAGGCCCTGAACGAGCTCGTGGGCCCT
  	GATACCGGACCTCAGACCGAGGTGCTGAACCTGTTCTTTCGGG
  	CCCTGAATGGCTGCTCCCCCCGGATCTTTTCTGGCGCTGAGAA
  	GAAGCAGCAGCTGGCCAGCGTGATCACCAACACCCTGGATGC
  	CATCAACGCCGACAACGAGGACTACCCCAAGCCCGGCGACTT
  	CCCCAGAAGCAGCTTTAGCAGCACCCCCCCTCATGCCCCTGTG
  	CCCCAGTCTGAGATCCCTACCAGCCCAACCAGCACCCAGCCTC
  	CAAGCCCT
  Ct089_E_S198A_nIgK_cHis	ATGGAAACCCCTGCCCAGCTGCTGTTCCTGCTGCTGCTGTGGC	271
  	TGCCTGACACCACCGGCATGACAGCATCTGGCGGAGCTGGCG
  	GCCTGGGCTCTACACAGACAGTGGATGTGGCCAGGGCCCAGG
  	CTGCTGCCGCTACACAGGATGCCCAGGAAGTGATCGGCAGCC
  	AGGAAGCCAGCGAGGCCTCTATGCTGAAGGGCTGCGAGGACC
  	TGATCAACCCTGCCGCCGCTACCCGCATCAAGAAGAAAGAGG
  	AAAAGTTCGAGTCCCTGGAAGCCAGACGGAAGCCCACCGCCG
  	ACAAGGCCGAGAAGAAGTCCGAGAGCACCGAGGAAAAGGGC
  	GACACCCCCCTGGAAGATCGGTTCACCGAGGATCTGAGCGAG
  	GTGTCCGGCGAGGACTTCCGGGGCCTGAAGAACAGCTTCGAC
  	GACGACAGCAGCCCCGAGGAAATCCTGGACGCCCTGACCAGC
  	AAGTTCAGCGACCCCACCATCAAGGACCTGGCCCTGGACTACC
  	TGATCCAGACCGCCCCCAGCGACCGGAAGCTGAAGTCTGCCCT
  	GATTCAGGCCAAGCACCAGCTGATGAGCCAGAACCCCCAGGC
  	CATCGTGGGCGGCAGAAATGTGCTGCTGGCCTCCGAGACATTC
  	GCCAGCAGAGCCAACACCGCCCCCAGCTCCCTGCGGAGCCTGT
  	ATCTGCAAGTGACCAGCTCCCCCAGCAACTGCGACAACCTGAG
  	ACAGATGCTGGCTAGCTACCTGCCCTCCGAGAAAACCGCCGTG
  	ATGGAATTCCTCGTGAACGGCATGGTGGCCGACCTGAAAAGC
  	GAGGGCCCTAGCATCCCTCCCGCCAAGCTGCAGGTGTACATGA
  	CCGAGCTGAGCAACCTGCAGGCCCTGCACAGCGTGGACAGCT
  	TTTTCGACCGGAACATCGGCAACCTGGAAAACAGCCTGAAGC
  	ACGAGGGCCACGCCCCCATCCCTTCTCTGACAACCGGCAATCT
  	GACCAAGACCTTCCTGCAGCTGGTGGAAGATAAGTTCCCCAGC
  	AGCTCCAAGGCCCAGAAGGCCCTGAACGAGCTCGTGGGCCCT
  	GATACCGGACCTCAGACCGAGGTGCTGAACCTGTTCTTTCGGG
  	CCCTGAATGGCTGCTCCCCCCGGATCTTTTCTGGCGCTGAGAA
  	GAAGCAGCAGCTGGCCAGCGTGATCACCAACACCCTGGATGC
  	CATCAACGCCGACAACGAGGACTACCCCAAGCCCGGCGACTT
  	CCCCAGAAGCAGCTTTAGCAGCACCCCCCCTCATGCCCCTGTG
  	CCCCAGTCTGAGATCCCTACCAGCCCAACCAGCACCCAGCCTC
  	CAAGCCCTCACCACCACCATCACCAC
  Chlamydia_Ct875_nIgk_cHis	ATGGAAACCCCTGCCCAGCTGCTGTTCCTGCTGCTGCTGTGGC	272
  	TGCCTGACACCACCGGCATGAGCATCAGAGGCGTGGGCGGCA
  	ACGGCAACAGCAGAATCCCTAGCCACAACGGCGACGGCAGCA
  	ACAGGCGGAGCCAGAACACCAAGGGCAACAACAAGGTGGAA
  	GATAGAGTGTGCAGCCTGTACAGCAGCCGGTCCAACGAGAAC
  	CGCGAGAGCCCTTATGCCGTGGTGGACGTGTCCAGCATGATCG
  	AGAGCACCCCCACCAGCGGCGAGACAACCAGAGCTAGTAGAG
  	GCGTGCTGAGCCGGTTCCAGAGGGGCCTCGTGCGGATTGCTGA
  	CAAAGTGCGGAGAGCCGTGCAGTGCGCTTGGAGCAGCGTGTC
  	CACAAGCAGAAGCAGCGCCACAAGAGCCGCCGAGAGCGGCA
  	GCTCTAGCAGAACAGCTAGAGGCGCCAGCAGCGGCTACAGAG
  	AGTACAGCCCTTCTGCCGCTCGGGGCCTGCGGCTGATGTTCAC
  	CGACTTTTGGCGGACCCGGGTGCTGAGACAGACCTCTCCTATG
  	GCCGGCGTGTTCGGCAACCTGGACGTGAACGAGGCCAGACTG
  	ATGGCCGCCTACACCAGCGAGTGTGCCGATCACCTGGAAGCC
  	AAAGAGCTGGCCGGACCTGACGGCGTGGCAGCCGCTAGAGAA
  	ATCGCCAAGAGATGGGAGAAGAGAGTGCGGGACCTGCAGGAC
  	AAGGGCGCTGCCAGAAAGCTGCTGAACGACCCCCTGGGCAGA
  	CGGACCCCCAACTACCAGAGCAAGAACCCCGGCGAGTACACC
  	GTGGGCAACTCCATGTTCTACGACGGCCCCCAGGTGGCCAACC
  	TGCAGAATGTGGATACCGGCTTCTGGCTGGACATGAGCAACCT
  	GAGCGACGTGGTGCTGTCCAGAGAGATCCAGACCGGCCTGAG
  	AGCCAGAGCCACCCTGGAAGAGTCCATGCCCATGCTGGAAAA
  	TCTGGAAGAGAGATTCCGGCGGCTGCAGGAAACCTGCGACGC
  	CGCCAGAACCGAGATCGAGGAAAGCGGCTGGACCCGGGAAAG
  	CGCCTCCAGAATGGAAGGCGACGAAGCCCAGGGCCCCAGCAG
  	AGTGCAGCAGGCCTTTCAGAGCTTCGTGAATGAGTGCAACAGC
  	ATCGAGTTCAGCTTCGGCTCCTTCGGCGAGCACGTGCGGGTGC
  	TGTGTGCCAGAGTGTCAAGAGGACTGGCCGCTGCCGGCGAGG
  	CCATCAGAAGATGCTTCAGCTGCTGCAAGGGCAGCACCCACA
  	GATACGCCCCCAGAGATGACCTGTCTCCTGAGGGCGCCTCTCT
  	GGCCGAAACCCTGGCCAGATTCGCCGACGACATGGGCATCGA
  	AAGAGGCGCCGACGGCACCTACGACATCCCCCTGGTGGACGA
  	TTGGAGAAGGGGCGTGCCATCCATCGAGGGCGAGGGCAGCGA
  	TAGCATCTACGAGATCATGATGCCCATCTACGAAGTGATGAAC
  	ATGGACCTGGAAACCCGGCGGAGCTTCGCCGTGCAGCAGGGC
  	CATTACCAGGACCCCAGAGCCAGCGACTACGACCTGCCTAGA
  	GCCTCCGATTACGATCTGCCCAGAAGCCCCTACCCCACCCCTC
  	CACTGCCTCCCAGATACCAGCTGCAGAACATGGATGTGGAAG
  	CCGGCTTTCGCGAGGCCGTGTACGCCTCTTTTGTGGCCGGCAT
  	GTACAACTACGTCGTGACCCAGCCCCAGGAACGGATCCCCAAT
  	AGCCAGCAGGTGGAAGGCATCCTGCGGGACATGCTGACCAAC
  	GGCAGCCAGACCTTCCGGGACCTGATGAAGCGGTGGAACAGA
  	GAGGTGGACCGCGAGCACCACCATCACCACCAC
  MOMP_serovarD	ATGAAGAAACTGCTGAAGTCCGTGCTGGTGTTCGCCGCCCTGT	273
  	CTAGCGCAAGCTCTCTGCAGGCTCTGCCCGTGGGAAATCCTGC
  	CGAGCCCAGCCTGATGATCGACGGCATTCTGTGGGAGGGCTTC
  	GGCGGCGACCCTTGCGATCCTTGTGCTACTTGGTGCGACGCCA
  	TCAGCATGAGAGTGGGCTACTACGGCGACTTCGTGTTCGACCG
  	GGTGCTGAAAACCGACGTGAACAAAGAATTCCAGATGGGCGC
  	CAAGCCCACCACCGACACCGGAAATTCTGCCGCCCCTAGCACC
  	CTGACCGCCAGAGAGAATCCTGCCTACGGCCGGCACATGCAG
  	GACGCCGAGATGTTCACCAACGCCGCCTGCATGGCCCTGAACA
  	TCTGGGACAGATTCGACGTGTTCTGCACCCTGGGCGCCACCAG
  	CGGCTACCTGAAAGGCAATAGCGCCAGCTTCAACCTCGTGGGC
  	CTGTTCGGCGACAACGAGAACCAGAAAACCGTGAAGGCCGAG
  	AGCGTGCCCAACATGAGCTTCGACCAGAGCGTGGTGGAACTG
  	TACACCGATACCACCTTCGCTTGGAGCGTGGGAGCCAGAGCCG
  	CTCTGTGGGAATGTGGCTGTGCCACACTGGGGGCCAGCTTCCA
  	GTACGCCCAGAGCAAGCCCAAGGTGGAAGAACTGAACGTGCT
  	GTGCAATGCCGCCGAGTTCACCATCAACAAGCCTAAGGGCTAC
  	GTGGGCAAAGAGTTCCCCCTGGATCTGACCGCCGGAACCGAT
  	GCCGCCACCGGAACAAAGGACGCCAGCATCGACTACCACGAG
  	TGGCAGGCTTCTCTGGCCCTGAGCTACCGGCTGAATATGTTCA
  	CCCCCTACATCGGCGTGAAGTGGTCCAGAGCCAGCTTCGACGC
  	CGACACCATCAGAATCGCCCAGCCCAAGAGCGCCACCGCCAT
  	CTTTGATACCACCACCCTGAACCCCACCATTGCCGGCGCTGGC
  	GACGTGAAAACAGGCGCCGAAGGACAGCTGGGCGACACAATG
  	CAGATCGTGTCCCTGCAGCTGAACAAGATGAAGTCCCGGAAG
  	TCCTGCGGAATCGCCGTGGGCACCACAATCGTGGACGCCGATA
  	AGTACGCCGTGACCGTGGAAACCCGGCTGATCGATGAGAGGG
  	CCGCTCACGTGAACGCCCAGTTCAGATTC
  Chlamydia_Ct871_pd_serovarD_nIgK	ATGGAAACCCCCGCCCAACTCCTGTTCCTTCTTCTGCTCTGGCT	274
  	CCCTGACACTACTGGTGCTGAGATTATGATACCTCAGGGAATC
  	TACGACGGAGAGACTCTGACTGTCTCGTTCCCGTATACCGTGA
  	TCGGCGACCCCTCTGGCACCACCGTCTTTTCCGCCGGGGAGCT
  	GACCCTGAAAAACCTGGACAACAGCATCGCGGCCCTGCCCCT
  	GAGCTGTTTCGGAAACTTGTTGGGTTCCTTCACTGTGCTCGGA
  	CGGGGTCACTCCCTGACCTTTGAGAATATCCGGACTTCGACTA
  	ACGGCGCCGCCCTGTCGGATTCAGCCAACTCCGGACTCTTCAC
  	CATCGAAGGCTTCAAGGAACTCAGCTTTAGCAATTGCAACTCG
  	CTGCTGGCGGTGCTGCCAGCGGCTACCACTAACAACGGATCCC
  	AAACTCCCACCACCACTTCGACTCCGTCCAATGGGACCATCTA
  	CTCCAAGACCGATCTCCTTCTCCTGAACAACGAGAAGTTCTCC
  	TTCTACTCCAACCTGGTGTCCGGGGATGGGGGTGCCATTGACG
  	CCAAGTCACTGACAGTGCAGGGCATCTCCAAGCTCTGTGTGTT
  	CCAAGAAAACACCGCCCAGGCCGATGGGGGAGCGTGCCAGGT
  	CGTCACCTCCTTCTCTGCAATGGCCAACGAGGCCCCCATCGCC
  	TTCATTGCAAACGTGGCGGGCGTGCGCGGCGGCGGCATTGCCG
  	CGGTGCAAGACGGCCAGCAGGGAGTGTCGTCCTCAACCTCGA
  	CCGAAGATCCGGTCGTGTCCTTCTCCCGGAATACTGCCGTGGA
  	ATTCGACGGAAACGTGGCTCGCGTGGGAGGCGGAATCTACAG
  	CTATGGAAACGTCGCCTTTCTGAACAACGGCAAAACGCTTTTC
  	CTGAACAATGTCGCTAGCCCTGTGTACATCGCTGCCGAACAGC
  	CGACCAACGGACAGGCATCCAACACCAGCGACAACTATGGCG
  	ATGGCGGCGCGATCTTCTGCAAGAACGGGGCCCAGGCGGCCG
  	GGAGCAACAACTCAGGATCCGTGTCCTTCGACGGAGAAGGCG
  	TCGTGTTCTTCTCCTCAAACGTGGCTGCCGGAAAGGGTGGAGC
  	CATCTACGCGAAGAAGCTCTCCGTGGCCAATTGCGGACCGGTC
  	CAGTTCCTGGGAAACATTGCCAACGACGGAGGTGCAATCTACC
  	TGGGAGAAAGCGGAGAACTGTCGCTCTCCGCCGACTACGGCG
  	ATATCATCTTCGACGGCAACCTCAAGCGGACCGCAAAGGAGA
  	ACGCGGCAGACGTCAATGGAGTGACCGTGTCGAGCCAAGCCA
  	TTTCAATGGGTTCCGGCGGGAAGATCACCACCTTGAGGGCCAA
  	GGCCGGCCACCAGATTCTGTTCAACGATCCTATTGAGATGGCC
  	AACGGGAACAACCAGCCTGCGCAGTCCTCGGAACCCCTGAAG
  	ATCAATGACGGAGAGGGCTACACTGGAGACATCGTGTTCGCC
  	AACGGAAACTCCACCTTGTACCAGAACGTGACGATTGAGCAG
  	GGGAGAATTGTGCTGAGAGAAAAAGCGAAGCTGTCCGTGAAT
  	AGCTTGAGCCAGACCGGGGGCTCACTGTACATGGAGGCCGGA
  	TCCACCCTGGACTTCGTGACACCGCAGCCACCGCAGCAGCCTC
  	CCGCCGCGAACCAACTGATTACCCTCTCGAACCTTCACCTGAG
  	CCTGTCCTCACTGCTGGCAAACAACGCTGTGACTAACCCTCCA
  	ACCAACCCGCCGGCCCAGGACAGCCATCCGGCCATTATCGGCT
  	CCACCACCGCCGGTTCTGTGACCATCAGCGGCCCAATCTTTTT
  	CGAGGATCTGGACGACACCGCTTACGACCGCTACGATTGGCTG
  	GGATCCAACCAGAAGATCGACGTGCTTAAGCTGCAACTGGGA
  	ACGCAACCCTCCGCCAACGCCCCGTCGGACCTGACCCTGGGGA
  	ACGAAATGCCTAAGTACGGATACCAGGGGAGCTGGAAGCTCG
  	CCTGGGATCCCAACACCGCCAACAACGGTCCGTACACTCTGAA
  	GGCCACCTGGACTAAGACTGGT
  Chlamydia_Ct871_pd_serovarD_nIgK_cHis	ATGGAAACCCCCGCCCAACTCCTGTTCCTTCTTCTGCTCTGGCT	275
  	CCCTGACACTACTGGTGCTGAGATTATGATACCTCAGGGAATC
  	TACGACGGAGAGACTCTGACTGTCTCGTTCCCGTATACCGTGA
  	TCGGCGACCCCTCTGGCACCACCGTCTTTTCCGCCGGGGAGCT
  	GACCCTGAAAAACCTGGACAACAGCATCGCGGCCCTGCCCCT
  	GAGCTGTTTCGGAAACTTGTTGGGTTCCTTCACTGTGCTCGGA
  	CGGGGTCACTCCCTGACCTTTGAGAATATCCGGACTTCGACTA
  	ACGGCGCCGCCCTGTCGGATTCAGCCAACTCCGGACTCTTCAC
  	CATCGAAGGCTTCAAGGAACTCAGCTTTAGCAATTGCAACTCG
  	CTGCTGGCGGTGCTGCCAGCGGCTACCACTAACAACGGATCCC
  	AAACTCCCACCACCACTTCGACTCCGTCCAATGGGACCATCTA
  	CTCCAAGACCGATCTCCTTCTCCTGAACAACGAGAAGTTCTCC
  	TTCTACTCCAACCTGGTGTCCGGGGATGGGGGTGCCATTGACG
  	CCAAGTCACTGACAGTGCAGGGCATCTCCAAGCTCTGTGTGTT
  	CCAAGAAAACACCGCCCAGGCCGATGGGGGAGCGTGCCAGGT
  	CGTCACCTCCTTCTCTGCAATGGCCAACGAGGCCCCCATCGCC
  	TTCATTGCAAACGTGGCGGGCGTGCGCGGCGGCGGCATTGCCG
  	CGGTGCAAGACGGCCAGCAGGGAGTGTCGTCCTCAACCTCGA
  	CCGAAGATCCGGTCGTGTCCTTCTCCCGGAATACTGCCGTGGA
  	ATTCGACGGAAACGTGGCTCGCGTGGGAGGCGGAATCTACAG
  	CTATGGAAACGTCGCCTTTCTGAACAACGGCAAAACGCTTTTC
  	CTGAACAATGTCGCTAGCCCTGTGTACATCGCTGCCGAACAGC
  	CGACCAACGGACAGGCATCCAACACCAGCGACAACTATGGCG
  	ATGGCGGCGCGATCTTCTGCAAGAACGGGGCCCAGGCGGCCG
  	GGAGCAACAACTCAGGATCCGTGTCCTTCGACGGAGAAGGCG
  	TCGTGTTCTTCTCCTCAAACGTGGCTGCCGGAAAGGGTGGAGC
  	CATCTACGCGAAGAAGCTCTCCGTGGCCAATTGCGGACCGGTC
  	CAGTTCCTGGGAAACATTGCCAACGACGGAGGTGCAATCTACC
  	TGGGAGAAAGCGGAGAACTGTCGCTCTCCGCCGACTACGGCG
  	ATATCATCTTCGACGGCAACCTCAAGCGGACCGCAAAGGAGA
  	ACGCGGCAGACGTCAATGGAGTGACCGTGTCGAGCCAAGCCA
  	TTTCAATGGGTTCCGGCGGGAAGATCACCACCTTGAGGGCCAA
  	GGCCGGCCACCAGATTCTGTTCAACGATCCTATTGAGATGGCC
  	AACGGGAACAACCAGCCTGCGCAGTCCTCGGAACCCCTGAAG
  	ATCAATGACGGAGAGGGCTACACTGGAGACATCGTGTTCGCC
  	AACGGAAACTCCACCTTGTACCAGAACGTGACGATTGAGCAG
  	GGGAGAATTGTGCTGAGAGAAAAAGCGAAGCTGTCCGTGAAT
  	AGCTTGAGCCAGACCGGGGGCTCACTGTACATGGAGGCCGGA
  	TCCACCCTGGACTTCGTGACACCGCAGCCACCGCAGCAGCCTC
  	CCGCCGCGAACCAACTGATTACCCTCTCGAACCTTCACCTGAG
  	CCTGTCCTCACTGCTGGCAAACAACGCTGTGACTAACCCTCCA
  	ACCAACCCGCCGGCCCAGGACAGCCATCCGGCCATTATCGGCT
  	CCACCACCGCCGGTTCTGTGACCATCAGCGGCCCAATCTTTTT
  	CGAGGATCTGGACGACACCGCTTACGACCGCTACGATTGGCTG
  	GGATCCAACCAGAAGATCGACGTGCTTAAGCTGCAACTGGGA
  	ACGCAACCCTCCGCCAACGCCCCGTCGGACCTGACCCTGGGGA
  	ACGAAATGCCTAAGTACGGATACCAGGGGAGCTGGAAGCTCG
  	CCTGGGATCCCAACACCGCCAACAACGGTCCGTACACTCTGAA
  	GGCCACCTGGACTAAGACTGGTCACCATCATCACCACCAC
  Chlamydia_Ct871_pd_serovarL2_nIgK	ATGGAAACCCCTGCCCAACTTCTGTTCCTCCTTCTGCTCTGGCT	276
  	CCCCGACACTACCGGTGCTGAGATCATGATTCCGCAAGGCATC
  	TACGACGGGGAAACTCTGACCGTGTCCTTTCCATACACCGTCA
  	TTGGTGATCCTTCCGGAACTACCGTGTTCTCCGCGGGCGAACT
  	GACCTTGAAGAATCTTGACAATTCCATCGCGGCCCTGCCCCTG
  	AGCTGCTTCGGCAACTTGCTGGGATCGTTCACTGTGCTGGGGC
  	GCGGACATTCGCTGACTTTCGAAAACATTAGAACCAGCACCAA
  	CGGTGCTGCGCTTTCGAATAGCGCCGCTGATGGCTTGTTCACC
  	ATCGAGGGTTTCAAGGAACTGAGCTTCTCCAACTGCAACTCGC
  	TGCTCGCCGTGCTGCCGGCCGCTACTACGAACAAGGGCAGCCA
  	GACTCCGACGACAACCTCCACTCCCTCAAACGGCACCATCTAC
  	TCCAAGACCGATCTGCTGCTGCTCAACAACGAGAAGTTCTCAT
  	TCTACTCCAACCTCGTGTCCGGCGACGGAGGCGCAATTGACGC
  	CAAGAGCCTGACCGTGCAGGGAATCTCAAAGCTGTGCGTCTTT
  	CAAGAGAACACTGCGCAGGCAGACGGAGGAGCCTGTCAGGTC
  	GTGACCTCCTTTTCCGCCATGGCCAACGAGGCCCCTATCGCCT
  	TCGTGGCCAACGTGGCCGGCGTGCGGGGTGGAGGAATCGCAG
  	CCGTGCAAGACGGCCAGCAGGGAGTGTCTAGCAGCACTTCCA
  	CCGAGGACCCCGTGGTGTCGTTCTCCCGGAACACCGCCGTGGA
  	GTTCGATGGAAACGTGGCGCGCGTGGGGGGAGGCATCTACTC
  	CTACGGGAACGTCGCCTTTCTTAACAACGGAAAGACCCTGTTC
  	CTGAACAATGTGGCCTCGCCGGTGTACATCGCCGCCAAGCAGC
  	CAACTAGCGGCCAGGCCTCCAACACCTCCAACAACTATGGCG
  	ACGGCGGAGCCATCTTCTGCAAGAACGGCGCTCAAGCTGGAT
  	CGAACAACAGCGGTTCTGTCTCCTTCGACGGCGAAGGAGTCGT
  	GTTTTTCTCCTCCAACGTCGCGGCCGGCAAAGGGGGGGCCATA
  	TACGCGAAGAAACTGTCAGTGGCGAACTGCGGACCCGTGCAG
  	TTCCTCCGGAACATTGCCAACGACGGGGGTGCAATCTACCTGG
  	GAGAGTCAGGAGAACTGAGCCTCTCGGCGGATTACGGCGACA
  	TCATTTTCGACGGAAATCTGAAGCGGACCGCCAAGGAAAACG
  	CGGCAGATGTGAACGGGGTCACCGTGTCAAGCCAGGCCATTTC
  	TATGGGGTCCGGAGGGAAGATTACCACCCTGCGCGCCAAGGC
  	CGGCCATCAGATTCTCTTCAACGACCCTATCGAGATGGCTAAT
  	GGAAACAATCAGCCCGCCCAGTCCTCCAAGCTGCTGAAAATC
  	AACGACGGAGAGGGGTACACCGGGGATATCGTGTTCGCCAAC
  	GGAAGCTCGACTCTCTACCAAAACGTGACCATTGAGCAGGGG
  	AGGATCGTGCTGAGGGAAAAGGCTAAGCTGTCCGTCAACTCG
  	CTGAGCCAGACCGGAGGCTCCCTCTACATGGAAGCAGGATCG
  	ACGCTGGACTTCGTGACTCCGCAACCACCGCAGCAGCCTCCCG
  	CCGCCAACCAGCTGATCACCTTGTCCAATCTGCACCTGAGCCT
  	GTCGTCCTTGCTCGCCAACAACGCCGTGACTAACCCTCCTACT
  	AACCCGCCGGCCCAGGACTCGCACCCGGCCGTCATCGGATCA
  	ACCACAGCAGGAAGCGTGACTATCTCCGGTCCTATCTTCTTCG
  	AGGACCTGGATGACACCGCCTACGATAGATACGATTGGTTGG
  	GTTCCAACCAGAAGATTAACGTGCTGAAGCTGCAGCTGGGAA
  	CCAAGCCACCGGCGAACGCCCCGTCCGACCTGACCCTCGGCA
  	ACGAAATGCCCAAATACGGATACCAGGGCTCCTGGAAGCTCG
  	CGTGGGACCCCAATACCGCGAACAACGGTCCCTATACACTCAA
  	GGCCACTTGGACCAAGACCGGC
  Chlamydia_Ct871_pd_serovarL2_nIgK_cHis	ATGGAAACCCCTGCCCAACTTCTGTTCCTCCTTCTGCTCTGGCT	277
  	CCCCGACACTACCGGTGCTGAGATCATGATTCCGCAAGGCATC
  	TACGACGGGGAAACTCTGACCGTGTCCTTTCCATACACCGTCA
  	TTGGTGATCCTTCCGGAACTACCGTGTTCTCCGCGGGCGAACT
  	GACCTTGAAGAATCTTGACAATTCCATCGCGGCCCTGCCCCTG
  	AGCTGCTTCGGCAACTTGCTGGGATCGTTCACTGTGCTGGGGC
  	GCGGACATTCGCTGACTTTCGAAAACATTAGAACCAGCACCAA
  	CGGTGCTGCGCTTTCGAATAGCGCCGCTGATGGCTTGTTCACC
  	ATCGAGGGTTTCAAGGAACTGAGCTTCTCCAACTGCAACTCGC
  	TGCTCGCCGTGCTGCCGGCCGCTACTACGAACAAGGGCAGCCA
  	GACTCCGACGACAACCTCCACTCCCTCAAACGGCACCATCTAC
  	TCCAAGACCGATCTGCTGCTGCTCAACAACGAGAAGTTCTCAT
  	TCTACTCCAACCTCGTGTCCGGCGACGGAGGCGCAATTGACGC
  	CAAGAGCCTGACCGTGCAGGGAATCTCAAAGCTGTGCGTCTTT
  	CAAGAGAACACTGCGCAGGCAGACGGAGGAGCCTGTCAGGTC
  	GTGACCTCCTTTTCCGCCATGGCCAACGAGGCCCCTATCGCCT
  	TCGTGGCCAACGTGGCCGGCGTGCGGGGTGGAGGAATCGCAG
  	CCGTGCAAGACGGCCAGCAGGGAGTGTCTAGCAGCACTTCCA
  	CCGAGGACCCCGTGGTGTCGTTCTCCCGGAACACCGCCGTGGA
  	GTTCGATGGAAACGTGGCGCGCGTGGGGGGAGGCATCTACTC
  	CTACGGGAACGTCGCCTTTCTTAACAACGGAAAGACCCTGTTC
  	CTGAACAATGTGGCCTCGCCGGTGTACATCGCCGCCAAGCAGC
  	CAACTAGCGGCCAGGCCTCCAACACCTCCAACAACTATGGCG
  	ACGGCGGAGCCATCTTCTGCAAGAACGGCGCTCAAGCTGGAT
  	CGAACAACAGCGGTTCTGTCTCCTTCGACGGCGAAGGAGTCGT
  	GTTTTTCTCCTCCAACGTCGCGGCCGGCAAAGGGGGGGCCATA
  	TACGCGAAGAAACTGTCAGTGGCGAACTGCGGACCCGTGCAG
  	TTCCTCCGGAACATTGCCAACGACGGGGGTGCAATCTACCTGG
  	GAGAGTCAGGAGAACTGAGCCTCTCGGCGGATTACGGCGACA
  	TCATTTTCGACGGAAATCTGAAGCGGACCGCCAAGGAAAACG
  	CGGCAGATGTGAACGGGGTCACCGTGTCAAGCCAGGCCATTTC
  	TATGGGGTCCGGAGGGAAGATTACCACCCTGCGCGCCAAGGC
  	CGGCCATCAGATTCTCTTCAACGACCCTATCGAGATGGCTAAT
  	GGAAACAATCAGCCCGCCCAGTCCTCCAAGCTGCTGAAAATC
  	AACGACGGAGAGGGGTACACCGGGGATATCGTGTTCGCCAAC
  	GGAAGCTCGACTCTCTACCAAAACGTGACCATTGAGCAGGGG
  	AGGATCGTGCTGAGGGAAAAGGCTAAGCTGTCCGTCAACTCG
  	CTGAGCCAGACCGGAGGCTCCCTCTACATGGAAGCAGGATCG
  	ACGCTGGACTTCGTGACTCCGCAACCACCGCAGCAGCCTCCCG
  	CCGCCAACCAGCTGATCACCTTGTCCAATCTGCACCTGAGCCT
  	GTCGTCCTTGCTCGCCAACAACGCCGTGACTAACCCTCCTACT
  	AACCCGCCGGCCCAGGACTCGCACCCGGCCGTCATCGGATCA
  	ACCACAGCAGGAAGCGTGACTATCTCCGGTCCTATCTTCTTCG
  	AGGACCTGGATGACACCGCCTACGATAGATACGATTGGTTGG
  	GTTCCAACCAGAAGATTAACGTGCTGAAGCTGCAGCTGGGAA
  	CCAAGCCACCGGCGAACGCCCCGTCCGACCTGACCCTCGGCA
  	ACGAAATGCCCAAATACGGATACCAGGGCTCCTGGAAGCTCG
  	CGTGGGACCCCAATACCGCGAACAACGGTCCCTATACACTCAA
  	GGCCACTTGGACCAAGACCGGCCACCACCATCACCACCAC
  Chlamydia_Ct812_pd_serovarD_nIgK	ATGGAAACTCCTGCCCAACTGTTGTTCCTTCTGCTGCTCTGGTT	278
  	GCCCGACACCACCGGATCGTGCGTGGATCTCCACGCTGGCGGC
  	CAGTCCGTGAACGAGCTTGTGTACGTGGGCCCACAGGCCGTGC
  	TTCTGCTGGACCAGATCAGAGATCTCTTCGTGGGTTCCAAGGA
  	CTCCCAGGCCGAGGGACAGTACCGGCTCATCGTCGGCGACCCT
  	TCAAGCTTCCAAGAGAAGGATGCCGACACTCTTCCGGGGAAG
  	GTGGAACAGTCCACTCTGTTTTCCGTGACCAACCCAGTCGTGT
  	TTCAAGGGGTGGACCAGCAGGACCAGGTGTCCAGCCAAGGAC
  	TGATCTGTTCATTCACCTCGAGCAATTTGGACAGCCCCCGGGA
  	CGGCGAATCGTTCCTTGGCATCGCATTCGTGGGAGACTCATCC
  	AAAGCAGGAATCACCCTTACCGATGTGAAGGCGTCCCTGAGC
  	GGCGCTGCTCTGTACTCCACCGAAGATCTCATCTTCGAGAAGA
  	TCAAGGGTGGACTGGAGTTCGCCAGCTGCTCCTCACTGGAACA
  	GGGAGGAGCCTGTGCCGCCCAAAGCATCCTCATCCACGATTGC
  	CAGGGGCTCCAAGTGAAGCATTGTACCACTGCCGTGAACGCC
  	GAGGGATCATCCGCTAACGATCACCTCGGTTTCGGAGGGGGTG
  	CCTTCTTCGTGACCGGTTCGCTGTCGGGAGAAAAGTCACTGTA
  	TATGCCCGCGGGCGACATGGTGGTCGCCAACTGCGATGGAGC
  	CATCTCATTCGAGGGAAACTCCGCCAACTTCGCAAACGGCGGC
  	GCTATCGCCGCTAGCGGGAAGGTGCTGTTCGTGGCTAACGACA
  	AGAAAACGTCCTTCATCGAAAACCGCGCCCTGTCGGGAGGTG
  	CCATTGCCGCCAGCTCCGACATTGCCTTCCAAAACTGTGCGGA
  	ACTGGTGTTCAAAGGAAACTGCGCCATCGGCACCGAAGATAA
  	GGGAAGCCTGGGGGGGGGCGCCATTTCCTCCCTCGGCACCGTG
  	CTGCTTCAGGGAAACCACGGCATCACTTGTGACAAGAACGAA
  	AGCGCGTCCCAGGGGGGAGCGATCTTCGGGAAAAACTGCCAG
  	ATTTCCGACAACGAGGGACCGGTGGTGTTCAGAGACTCCACTG
  	CCTGCCTGGGCGGCGGAGCGATCGCAGCACAGGAAATTGTCA
  	GCATCCAGAACAACCAGGCCGGCATCAGCTTCGAGGGGGGAA
  	AGGCTTCGTTCGGCGGAGGTATTGCCTGCGGATCGTTCTCGTC
  	CGCGGGCGGAGCCTCCGTGCTCGGAACCATCGACATTTCCAAG
  	AACCTGGGCGCTATCTCGTTTTCTCGCACCCTGTGCACTACTTC
  	CGACCTGGGTCAGATGGAGTACCAGGGAGGCGGAGCGCTGTT
  	TGGAGAGAACATCTCTCTGAGCGAGAACGCGGGAGTGCTGAC
  	CTTCAAGGACAACATTGTGAAAACCTTCGCCTCAAACGGAAA
  	GATCCTGGGGGGAGGCGCCATCCTGGCAACCGGGAAGGTCGA
  	AATCACCAACAATTCAGAGGGTATCTCCTTCACTGGCAACGCC
  	CGGGCCCCCCAAGCCCTGCCGACTCAGGAAGAGTTCCCCCTGT
  	TCTCCAAGAAGGAAGGACGCCCTTTGTCATCCGGCTACTCCGG
  	TGGTGGAGCGATTCTGGGTCGGGAAGTGGCCATCCTGCATAAT
  	GCGGCCGTGGTGTTTGAGCAAAACAGACTCCAATGCTCCGAA
  	GAAGAGGCCACCCTCCTGGGGTGCTGCGGGGGCGGAGCAGTG
  	CATGGCATGGATTCCACTTCCATCGTGGGAAACTCCAGCGTCC
  	GCTTCGGAAACAACTACGCTATGGGACAGGGAGTGTCAGGGG
  	GGGCCCTGCTGTCCAAGACCGTCCAGTTGGCCGGAAACGGTTC
  	GGTGGATTTCTCACGCAATATCGCCTCGCTGGGAGGCGGCGCG
  	CTGCAGGCCTCCGAAGGAAATTGCGAACTGGTCGACAACGGC
  	TACGTGCTGTTCCGGGACAACCGCGGCAGGGTGTACGGCGGA
  	GCAATCTCGTGCCTTCGGGGCGACGTCGTGATCTCGGGAAATA
  	AGGGACGGGTCGAGTTTAAGGACAACATCGCTACCAGGCTCT
  	ACGTGGAGGAAACTGTGGAGAAGGTGGAGGAAGTGGAGCCTG
  	CCCCGGAACAGAAGGACAACAACGAGCTGTCGTTCCTCGGTC
  	GGGCAGAACAGTCCTTCATTACTGCCGCCAACCAGGCCCTGTT
  	CGCGTCCGAAGATGGTGACCTCAGCCCGGAATCCAGCATCTCC
  	TCCGAGGAACTGGCCAAGCGGAGAGAATGCGCGGGAGGCGCA
  	ATCTTTGCGAAGCGGGTCCGGATCGTGGACAACCAGGAAGCT
  	GTGGTGTTCAGCAACAACTTTTCCGACATCTACGGTGGTGCAA
  	TTTTCACCGGCTCACTCCGGGAGGAGGACAAGCTGGACGGCC
  	AGATTCCCGAGGTGCTCATTTCCGGCAATGCCGGCGACGTGGT
  	GTTCTCCGGAAACTCCTCCAAGAGGGACGAACACCTCCCGCAT
  	ACCGGAGGAGGAGCCATCTGCACTCAGAACCTGACGATCTCG
  	CAGAACACCGGCAATGTGCTGTTCTACAACAACGTCGCATGTT
  	CCGGTGGCGCCGTCAGAATCGAGGACCACGGAAACGTGCTGC
  	TGGAAGCATTCGGGGGTGATATTGTGTTCAAGGGAAACAGCA
  	GCTTCCGGGCCCAGGGATCAGATGCAATCTACTTCGCCGGGAA
  	GGAGAGCCACATTACCGCCCTGAACGCCACCGAGGGTCACGC
  	CATCGTGTTCCACGATGCCCTGGTGTTCGAAAACCTGGAGGAG
  	CGCAAGAGCGCCGAAGTGCTGCTTATCAATTCCCGCGAAAACC
  	CGGGCTACACCGGATCCATCCGGTTCCTCGAAGCGGAGTCGAA
  	GGTCCCGCAGTGTATTCATGTGCAACAGGGGTCCCTGGAACTG
  	CTTAACGGAGCCACCCTGTGCTCCTACGGCTTTAAGCAGGACG
  	CGGGCGCTAAACTGGTGCTGGCGGCCGGCGCCAAGCTTAAGA
  	TCCTCGACTCCGGAACCCCGGTGCAGCAGGGGCACGCTATTAG
  	CAAGCCTGAAGCCGAGATTGAGTCGTCATCCGAACCCGAAGG
  	GGCGCACTCCCTGTGGATAGCCAAGAACGCGCAGACCACCGT
  	GCCAATGGTCGATATCCACACAATCTCCGTGGACCTCGCCAGC
  	TTCTCGTCGAGCCAGCAGGAGGGAACTGTCGAAGCGCCTCAG
  	GTCATCGTGCCGGGAGGTTCCTACGTGCGCTCGGGGGAGCTCA
  	ACCTGGAACTCGTGAATACCACTGGAACGGGATATGAGAACC
  	ACGCCCTGCTGAAGAACGAAGCCAAAGTGCCACTGATGTCCTT
  	CGTCGCCTCCGGCGACGAGGCCTCCGCCGAGATTAGCAACCTG
  	TCGGTGTCAGATCTGCAAATTCACGTGGTGACCCCTGAGATTG
  	AGGAGGACACCTACGGGCACATGGGCGATTGGTCCGAGGCGA
  	AGATCCAGGACGGCACACTGGTCATTTCATGGAACCCTACCGGA
  Chlamydia_Ct812_pd_serovarD_nIgK_cHis	ATGGAAACTCCTGCCCAACTGTTGTTCCTTCTGCTGCTCTGGTT	279
  	GCCCGACACCACCGGATCGTGCGTGGATCTCCACGCTGGCGGC
  	CAGTCCGTGAACGAGCTTGTGTACGTGGGCCCACAGGCCGTGC
  	TTCTGCTGGACCAGATCAGAGATCTCTTCGTGGGTTCCAAGGA
  	CTCCCAGGCCGAGGGACAGTACCGGCTCATCGTCGGCGACCCT
  	TCAAGCTTCCAAGAGAAGGATGCCGACACTCTTCCGGGGAAG
  	GTGGAACAGTCCACTCTGTTTTCCGTGACCAACCCAGTCGTGT
  	TTCAAGGGGTGGACCAGCAGGACCAGGTGTCCAGCCAAGGAC
  	TGATCTGTTCATTCACCTCGAGCAATTTGGACAGCCCCCGGGA
  	CGGCGAATCGTTCCTTGGCATCGCATTCGTGGGAGACTCATCC
  	AAAGCAGGAATCACCCTTACCGATGTGAAGGCGTCCCTGAGC
  	GGCGCTGCTCTGTACTCCACCGAAGATCTCATCTTCGAGAAGA
  	TCAAGGGTGGACTGGAGTTCGCCAGCTGCTCCTCACTGGAACA
  	GGGAGGAGCCTGTGCCGCCCAAAGCATCCTCATCCACGATTGC
  	CAGGGGCTCCAAGTGAAGCATTGTACCACTGCCGTGAACGCC
  	GAGGGATCATCCGCTAACGATCACCTCGGTTTCGGAGGGGGTG
  	CCTTCTTCGTGACCGGTTCGCTGTCGGGAGAAAAGTCACTGTA
  	TATGCCCGCGGGCGACATGGTGGTCGCCAACTGCGATGGAGC
  	CATCTCATTCGAGGGAAACTCCGCCAACTTCGCAAACGGCGGC
  	GCTATCGCCGCTAGCGGGAAGGTGCTGTTCGTGGCTAACGACA
  	AGAAAACGTCCTTCATCGAAAACCGCGCCCTGTCGGGAGGTG
  	CCATTGCCGCCAGCTCCGACATTGCCTTCCAAAACTGTGCGGA
  	ACTGGTGTTCAAAGGAAACTGCGCCATCGGCACCGAAGATAA
  	GGGAAGCCTGGGGGGGGGCGCCATTTCCTCCCTCGGCACCGTG
  	CTGCTTCAGGGAAACCACGGCATCACTTGTGACAAGAACGAA
  	AGCGCGTCCCAGGGGGGAGCGATCTTCGGGAAAAACTGCCAG
  	ATTTCCGACAACGAGGGACCGGTGGTGTTCAGAGACTCCACTG
  	CCTGCCTGGGCGGCGGAGCGATCGCAGCACAGGAAATTGTCA
  	GCATCCAGAACAACCAGGCCGGCATCAGCTTCGAGGGGGGAA
  	AGGCTTCGTTCGGCGGAGGTATTGCCTGCGGATCGTTCTCGTC
  	CGCGGGCGGAGCCTCCGTGCTCGGAACCATCGACATTTCCAAG
  	AACCTGGGCGCTATCTCGTTTTCTCGCACCCTGTGCACTACTTC
  	CGACCTGGGTCAGATGGAGTACCAGGGAGGCGGAGCGCTGTT
  	TGGAGAGAACATCTCTCTGAGCGAGAACGCGGGAGTGCTGAC
  	CTTCAAGGACAACATTGTGAAAACCTTCGCCTCAAACGGAAA
  	GATCCTGGGGGGAGGCGCCATCCTGGCAACCGGGAAGGTCGA
  	AATCACCAACAATTCAGAGGGTATCTCCTTCACTGGCAACGCC
  	CGGGCCCCCCAAGCCCTGCCGACTCAGGAAGAGTTCCCCCTGT
  	TCTCCAAGAAGGAAGGACGCCCTTTGTCATCCGGCTACTCCGG
  	TGGTGGAGCGATTCTGGGTCGGGAAGTGGCCATCCTGCATAAT
  	GCGGCCGTGGTGTTTGAGCAAAACAGACTCCAATGCTCCGAA
  	GAAGAGGCCACCCTCCTGGGGTGCTGCGGGGGCGGAGCAGTG
  	CATGGCATGGATTCCACTTCCATCGTGGGAAACTCCAGCGTCC
  	GCTTCGGAAACAACTACGCTATGGGACAGGGAGTGTCAGGGG
  	GGGCCCTGCTGTCCAAGACCGTCCAGTTGGCCGGAAACGGTTC
  	GGTGGATTTCTCACGCAATATCGCCTCGCTGGGAGGCGGCGCG
  	CTGCAGGCCTCCGAAGGAAATTGCGAACTGGTCGACAACGGC
  	TACGTGCTGTTCCGGGACAACCGCGGCAGGGTGTACGGCGGA
  	GCAATCTCGTGCCTTCGGGGCGACGTCGTGATCTCGGGAAATA
  	AGGGACGGGTCGAGTTTAAGGACAACATCGCTACCAGGCTCT
  	ACGTGGAGGAAACTGTGGAGAAGGTGGAGGAAGTGGAGCCTG
  	CCCCGGAACAGAAGGACAACAACGAGCTGTCGTTCCTCGGTA
  	GAGCCGAACAGTCCTTCATTACTGCCGCCAACCAGGCCCTGTT
  	CGCGTCCGAAGATGGTGACCTCAGCCCGGAATCCAGCATCTCC
  	TCCGAGGAACTGGCCAAGCGGAGAGAATGCGCGGGAGGCGCA
  	ATCTTTGCGAAGCGGGTCCGGATCGTGGACAACCAGGAAGCT
  	GTGGTGTTCAGCAACAACTTTTCCGACATCTACGGTGGTGCAA
  	TTTTCACCGGCTCACTCCGGGAGGAGGACAAGCTGGACGGCC
  	AGATTCCCGAGGTGCTCATTTCCGGCAATGCCGGCGACGTGGT
  	GTTCTCCGGAAACTCCTCCAAGAGGGACGAACACCTCCCGCAT
  	ACCGGAGGAGGAGCCATCTGCACTCAGAACCTGACGATCTCG
  	CAGAACACCGGCAATGTGCTGTTCTACAACAACGTCGCATGTT
  	CCGGTGGCGCCGTCAGAATCGAGGACCACGGAAACGTGCTGC
  	TGGAAGCATTCGGGGGTGATATTGTGTTCAAGGGAAACAGCA
  	GCTTCCGGGCCCAGGGATCAGATGCAATCTACTTCGCCGGGAA
  	GGAGAGCCACATTACCGCCCTGAACGCCACCGAGGGTCACGC
  	CATCGTGTTCCACGATGCCCTGGTGTTCGAAAACCTGGAGGAG
  	CGCAAGAGCGCCGAAGTGCTGCTTATCAATTCCCGCGAAAACC
  	CGGGCTACACCGGATCCATCCGGTTCCTCGAAGCGGAGTCGAA
  	GGTCCCGCAGTGTATTCATGTGCAACAGGGGTCCCTGGAACTG
  	CTTAACGGAGCCACCCTGTGCTCCTACGGCTTTAAGCAGGACG
  	CGGGCGCTAAACTGGTGCTGGCGGCCGGCGCCAAGCTTAAGA
  	TCCTCGACTCCGGAACCCCGGTGCAGCAGGGGCACGCTATTAG
  	CAAGCCTGAAGCCGAGATTGAGTCGTCATCCGAACCCGAAGG
  	GGCGCACTCCCTGTGGATAGCCAAGAACGCGCAGACCACCGT
  	GCCAATGGTCGATATCCACACAATCTCCGTGGACCTCGCCAGC
  	TTCTCGTCGAGCCAGCAGGAGGGAACTGTCGAAGCGCCTCAG
  	GTCATCGTGCCGGGAGGTTCCTACGTGCGCTCGGGGGAGCTCA
  	ACCTGGAACTCGTGAATACCACTGGAACGGGATATGAGAACC
  	ACGCCCTGCTGAAGAACGAAGCCAAAGTGCCACTGATGTCCTT
  	CGTCGCCTCCGGGGACGAGGCCTCCGCCGAGATTAGCAACCTG
  	TCGGTGTCAGATCTGCAAATTCACGTGGTCACCCCTGAGATTG
  	AGGAGGACACCTACGGGCACATGGGCGATTGGTCCGAGGCGA
  	AGATCCAGGACGGCACACTGGTCATTTCATGGAACCCTACCGG
  	ACATCACCACCACCATCAC
  Chlamydia_Ct812_pd_serovarL2_nIgk	ATGGAAACTCCTGCCCAACTGTTGTTCCTTCTGCTGCTCTGGTT	280
  	GCCCGACACCACCGGATCGTGCGTGGATCTCCACGCTGGCGGC
  	CAGTCCGTGAACGAGCTTGTGTACGTGGGCCCACAGGCCGTGC
  	TTCTGCTGGACCAGATCAGAGATCTCTTCGTGGGTTCCAAGGA
  	CTCCCAGGCCGAGGGACAGTACCGGCTCATCGTCGGCGACCCT
  	TCAAGCTTCCAAGAGAAGGATGCCGACACTCTTCCGGGGAAG
  	GTGGAACAGTCCACTCTGTTTTCCGTGACCAACCCAGTCGTGT
  	TTCAAGGGGTGGACCAGCAGGACCAGGTGTCCAGCCAAGGAC
  	TGATCTGTTCATTCACCTCGAGCAATTTGGACAGCCCCCGGGA
  	CGGCGAATCGTTCCTTGGCATCGCATTCGTGGGAGACTCATCC
  	AAAGCAGGAATCACCCTTACCGATGTGAAGGCGTCCCTGAGC
  	GGCGCTGCTCTGTACTCCACCGAAGATCTCATCTTCGAGAAGA
  	TCAAGGGTGGACTGGAGTTCGCCAGCTGCTCCTCACTGGAACA
  	GGGAGGAGCCTGTGCCGCCCAAAGCATCCTCATCCACGATTGC
  	CAGGGGCTCCAAGTGAAGCATTGTACCACTGCCGTGAACGCC
  	GAGGGATCATCCGCTAACGATCACCTCGGTTTCGGAGGGGGTG
  	CCTTCTTCGTGACCGGTTCGCTGTCGGGAGAAAAGTCACTGTA
  	TATGCCCGCGGGCGACATGGTGGTCGCCAACTGCGATGGAGC
  	CATCTCATTCGAGGGAAACTCCGCCAACTTCGCAAACGGCGGC
  	GCTATCGCCGCTAGCGGGAAGGTGCTGTTCGTGGCTAACGACA
  	AGAAAACGTCCTTCATCGAAAACCGCGCCCTGTCGGGAGGTG
  	CCATTGCCGCCAGCTCCGACATTGCCTTCCAAAACTGTGCGGA
  	ACTGGTGTTCAAAGGAAACTGCGCCATCGGCACCGAAGATAA
  	GGGAAGCCTGGGGGGGGGCGCCATTTCCTCCCTCGGCACCGTG
  	CTGCTTCAGGGAAACCACGGCATCACTTGTGACAAGAACGAA
  	AGCGCGTCCCAGGGGGGAGCGATCTTCGGGAAAAACTGCCAG
  	ATTTCCGACAACGAGGGACCGGTGGTGTTCAGAGACTCCACTG
  	CCTGCCTGGGCGGCGGAGCGATCGCAGCACAGGAAATTGTCA
  	GCATCCAGAACAACCAGGCCGGCATCAGCTTCGAGGGGGGAA
  	AGGCTTCGTTCGGCGGAGGTATTGCCTGCGGATCGTTCTCGTC
  	CGCGGGCGGAGCCTCCGTGCTCGGAACCATCGACATTTCCAAG
  	AACCTGGGCGCTATCTCGTTTTCTCGCACCCTGTGCACTACTTC
  	CGACCTGGGTCAGATGGAGTACCAGGGAGGCGGAGCGCTGTT
  	TGGAGAGAACATCTCTCTGAGCGAGAACGCGGGAGTGCTGAC
  	CTTCAAGGACAACATTGTGAAAACCTTCGCCTCAAACGGAAA
  	GATCCTGGGGGGAGGCGCCATCCTGGCAACCGGGAAGGTCGA
  	AATCACCAACAATTCAGGCGGTATCTCCTTCACTGGCAACGCC
  	CGGGCCCCCCAAGCCCTGCCGACTCAGGAAGAGTTCCCCCTGT
  	TCTCCAAGAAGGAAGGACGCCCTTTGTCATCCGGCTACTCCGG
  	TGGTGGAGCGATTCTGGGTCGGGAAGTGGCCATCCTGCATAAT
  	GCGGCCGTGGTGTTTGAGCAAAACAGACTCCAATGCTCCGAA
  	GAAGAGGCCACCCTCCTGGGGTGCTGCGGGGGCGGAGCAGTG
  	CATGGCATGGATTCCACTTCCATCGTGGGAAACTCCAGCGTCC
  	GCTTCGGAAACAACTACGCTATGGGACAGGGAGTGTCAGGGG
  	GGGCCCTGCTGTCCAAGACCGTCCAGTTGGCCGGAAACGGTTC
  	GGTGGATTTCTCACGCAATATCGCCTCGCTGGGAGGCGGCGCG
  	CTGCAGGCCTCCGAAGGAAATTGCGAACTGGTCGACAACGGC
  	TACGTGCTGTTCCGGGACAACCGCGGCAGGGTGTACGGCGGA
  	GCAATCTCGTGCCTTCGGGGCGACGTCGTGATCTCGGGAAATA
  	AGGGACGGGTCGAGTTTAAGGACAACATCGCTACCAGGCTCT
  	ACGTGGAGGAAACTGTGGAGAAGGTGGAGGAAGTGGAGCCTG
  	CCCCGGAACAGAAGGACAACAACGAGCTGTCGTTCCTCGGTTC
  	CGTCGAACAGTCCTTCATTACTGCCGCCAACCAGGCCCTGTTC
  	GCGTCCGAAGATGGTGACCTCAGCCCGGAATCCAGCATCTCCT
  	CCGAGGAACTGGCCAAGCGGAGAGAATGCGCGGGAGGCGCA
  	ATCTTTGCGAAGCGGGTCCGGATCGTGGACAACCAGGAAGCT
  	GTGGTGTTCAGCAACAACTTTTCCGACATCTACGGTGGTGCAA
  	TTTTCACCGGCTCACTCCGGGAGGAGGACAAGCTGGACGGCC
  	AGATTCCCGAGGTGCTCATTTCCGGCAATGCCGGCGACGTGGT
  	GTTCTCCGGAAACTCCTCCAAGAGGGACGAACACCTCCCGCAT
  	ACCGGAGGAGGAGCCATCTGCACTCAGAACCTGACGATCTCG
  	CAGAACACCGGCAATGTGCTGTTCTACAACAACGTCGCATGTT
  	CCGGTGGCGCCGTCAGAATCGAGGACCACGGAAACGTGCTGC
  	TGGAAGCATTCGGGGGTGATATTGTGTTCAAGGGAAACAGCA
  	GCTTCCGGGCCCAGGGATCAGATGCAATCTACTTCGCCGGGAA
  	GGAGAGCCACATTACCGCCCTGAACGCCACCGAGGGTCACGC
  	CATCGTGTTCCACGATGCCCTGGTGTTCGAAAACCTGAAGGAG
  	CGCAAGAGCGCCGAAGTGCTGCTTATCAATTCCCGCGAAAACC
  	CGGGCTACACCGGATCCATCCGGTTCCTCGAAGCGGAGTCGAA
  	GGTCCCGCAGTGTATTCATGTGCAACAGGGGTCCCTGGAACTG
  	CTTAACGGAGCCACCCTGTGCTCCTACGGCTTTAAGCAGGACG
  	CGGGCGCTAAACTGGTGCTGGCGGCCGGCTCCAAGCTTAAGAT
  	CCTCGACTCCGGAACCCCGGTGCAGGGGCACGCTATTAGCAA
  	GCCTGAAGCCGAGATTGAGTCGTCATCCGAACCCGAAGGGGC
  	GCACTCCCTGTGGATAGCCAAGAACGCGCAGACCACCGTGCC
  	AATGGTCGATATCCACACAATCTCCGTGGACCTCGCCAGCTTC
  	TCGTCGAGCCAGCAGGAGGGAACTGTCGAAGCGCCTCAGGTC
  	ATCGTGCCGGGAGGTTCCTACGTGCGCTCGGGGGAGCTCAACC
  	TGGAACTCGTGAATACCACTGGAACGGGATATGAGAACCACG
  	CCCTGCTGAAGAACGAAGCCAAAGTGCCACTGATGTCCTTCGT
  	CGCCTCCTCCGACGAGGCCTCCGCCGAGATTAGCAACCTGTCG
  	GTGTCAGATCTGCAAATTCACGTGGCCACCCCTGAGATTGAGG
  	AGGACACCTACGGGCACATGGGCGATTGGTCCGAGGCGAAGA
  	TCCAGGACGGCACACTGGTCATTTCATGGAACCCTACCGGA
  Chlamydia_Ct812_pd_serovarL2_nIgk_cHis	ATGGAAACTCCTGCCCAACTGTTGTTCCTTCTGCTGCTCTGGTT	281
  	GCCCGACACCACCGGATCGTGCGTGGATCTCCACGCTGGCGGC
  	CAGTCCGTGAACGAGCTTGTGTACGTGGGCCCACAGGCCGTGC
  	TTCTGCTGGACCAGATCAGAGATCTCTTCGTGGGTTCCAAGGA
  	CTCCCAGGCCGAGGGACAGTACCGGCTCATCGTCGGCGACCCT
  	TCAAGCTTCCAAGAGAAGGATGCCGACACTCTTCCGGGGAAG
  	GTGGAACAGTCCACTCTGTTTTCCGTGACCAACCCAGTCGTGT
  	TTCAAGGGGTGGACCAGCAGGACCAGGTGTCCAGCCAAGGAC
  	TGATCTGTTCATTCACCTCGAGCAATTTGGACAGCCCCCGGGA
  	CGGCGAATCGTTCCTTGGCATCGCATTCGTGGGAGACTCATCC
  	AAAGCAGGAATCACCCTTACCGATGTGAAGGCGTCCCTGAGC
  	GGCGCTGCTCTGTACTCCACCGAAGATCTCATCTTCGAGAAGA
  	TCAAGGGTGGACTGGAGTTCGCCAGCTGCTCCTCACTGGAACA
  	GGGAGGAGCCTGTGCCGCCCAAAGCATCCTCATCCACGATTGC
  	CAGGGGCTCCAAGTGAAGCATTGTACCACTGCCGTGAACGCC
  	GAGGGATCATCCGCTAACGATCACCTCGGTTTCGGAGGGGGTG
  	CCTTCTTCGTGACCGGTTCGCTGTCGGGAGAAAAGTCACTGTA
  	TATGCCCGCGGGCGACATGGTGGTCGCCAACTGCGATGGAGC
  	CATCTCATTCGAGGGAAACTCCGCCAACTTCGCAAACGGCGGC
  	GCTATCGCCGCTAGCGGGAAGGTGCTGTTCGTGGCTAACGACA
  	AGAAAACGTCCTTCATCGAAAACCGCGCCCTGTCGGGAGGTG
  	CCATTGCCGCCAGCTCCGACATTGCCTTCCAAAACTGTGCGGA
  	ACTGGTGTTCAAAGGAAACTGCGCCATCGGCACCGAAGATAA
  	GGGAAGCCTGGGGGGGGGCGCCATTTCCTCCCTCGGCACCGTG
  	CTGCTTCAGGGAAACCACGGCATCACTTGTGACAAGAACGAA
  	AGCGCGTCCCAGGGGGGAGCGATCTTCGGGAAAAACTGCCAG
  	ATTTCCGACAACGAGGGACCGGTGGTGTTCAGAGACTCCACTG
  	CCTGCCTGGGCGGCGGAGCGATCGCAGCACAGGAAATTGTCA
  	GCATCCAGAACAACCAGGCCGGCATCAGCTTCGAGGGGGGAA
  	AGGCTTCGTTCGGCGGAGGTATTGCCTGCGGATCGTTCTCGTC
  	CGCGGGCGGAGCCTCCGTGCTCGGAACCATCGACATTTCCAAG
  	AACCTGGGCGCTATCTCGTTTTCTCGCACCCTGTGCACTACTTC
  	CGACCTGGGTCAGATGGAGTACCAGGGAGGCGGAGCGCTGTT
  	TGGAGAGAACATCTCTCTGAGCGAGAACGCGGGAGTGCTGAC
  	CTTCAAGGACAACATTGTGAAAACCTTCGCCTCAAACGGAAA
  	GATCCTGGGGGGAGGCGCCATCCTGGCAACCGGGAAGGTCGA
  	AATCACCAACAATTCAGGCGGTATCTCCTTCACTGGCAACGCC
  	CGGGCCCCCCAAGCCCTGCCGACTCAGGAAGAGTTCCCCCTGT
  	TCTCCAAGAAGGAAGGACGCCCTTTGTCATCCGGCTACTCCGG
  	TGGTGGAGCGATTCTGGGTCGGGAAGTGGCCATCCTGCATAAT
  	GCGGCCGTGGTGTTTGAGCAAAACAGACTCCAATGCTCCGAA
  	GAAGAGGCCACCCTCCTGGGGTGCTGCGGGGGCGGAGCAGTG
  	CATGGCATGGATTCCACTTCCATCGTGGGAAACTCCAGCGTCC
  	GCTTCGGAAACAACTACGCTATGGGACAGGGAGTGTCAGGGG
  	GGGCCCTGCTGTCCAAGACCGTCCAGTTGGCCGGAAACGGTTC
  	GGTGGATTTCTCACGCAATATCGCCTCGCTGGGAGGCGGCGCG
  	CTGCAGGCCTCCGAAGGAAATTGCGAACTGGTCGACAACGGC
  	TACGTGCTGTTCCGGGACAACCGCGGCAGGGTGTACGGCGGA
  	GCAATCTCGTGCCTTCGGGGCGACGTCGTGATCTCGGGAAATA
  	AGGGACGGGTCGAGTTTAAGGACAACATCGCTACCAGGCTCT
  	ACGTGGAGGAAACTGTGGAGAAGGTGGAGGAAGTGGAGCCTG
  	CCCCGGAACAGAAGGACAACAACGAGCTGTCGTTCCTCGGTTC
  	CGTCGAACAGTCCTTCATTACTGCCGCCAACCAGGCCCTGTTC
  	GCGTCCGAAGATGGTGACCTCAGCCCGGAATCCAGCATCTCCT
  	CCGAGGAACTGGCCAAGCGGAGAGAATGCGCGGGAGGCGCA
  	ATCTTTGCGAAGCGGGTCCGGATCGTGGACAACCAGGAAGCT
  	GTGGTGTTCAGCAACAACTTTTCCGACATCTACGGTGGTGCAA
  	TTTTCACCGGCTCACTCCGGGAGGAGGACAAGCTGGACGGCC
  	AGATTCCCGAGGTGCTCATTTCCGGCAATGCCGGCGACGTGGT
  	GTTCTCCGGAAACTCCTCCAAGAGGGACGAACACCTCCCGCAT
  	ACCGGAGGAGGAGCCATCTGCACTCAGAACCTGACGATCTCG
  	CAGAACACCGGCAATGTGCTGTTCTACAACAACGTCGCATGTT
  	CCGGTGGCGCCGTCAGAATCGAGGACCACGGAAACGTGCTGC
  	TGGAAGCATTCGGGGGTGATATTGTGTTCAAGGGAAACAGCA
  	GCTTCCGGGCCCAGGGATCAGATGCAATCTACTTCGCCGGGAA
  	GGAGAGCCACATTACCGCCCTGAACGCCACCGAGGGTCACGC
  	CATCGTGTTCCACGATGCCCTGGTGTTCGAAAACCTGAAGGAG
  	CGCAAGAGCGCCGAAGTGCTGCTTATCAATTCCCGCGAAAACC
  	CGGGCTACACCGGATCCATCCGGTTCCTCGAAGCGGAGTCGAA
  	GGTCCCGCAGTGTATTCATGTGCAACAGGGGTCCCTGGAACTG
  	CTTAACGGAGCCACCCTGTGCTCCTACGGCTTTAAGCAGGACG
  	CGGGCGCTAAACTGGTGCTGGCGGCCGGCTCCAAGCTTAAGAT
  	CCTCGACTCCGGAACCCCGGTGCAGGGGCACGCTATTAGCAA
  	GCCTGAAGCCGAGATTGAGTCGTCATCCGAACCCGAAGGGGC
  	GCACTCCCTGTGGATAGCCAAGAACGCGCAGACCACCGTGCC
  	AATGGTCGATATCCACACAATCTCCGTGGACCTCGCCAGCTTC
  	TCGTCGAGCCAGCAGGAGGGAACTGTCGAAGCGCCTCAGGTC
  	ATCGTGCCGGGAGGTTCCTACGTGCGCTCGGGGGAGCTCAACC
  	TGGAACTCGTGAATACCACTGGAACGGGATATGAGAACCACG
  	CCCTGCTGAAGAACGAAGCCAAAGTGCCACTGATGTCCTTCGT
  	CGCCTCCTCCGACGAGGCCTCCGCCGAGATTAGCAACCTGTCG
  	GTGTCAGATCTGCAAATTCACGTGGCCACCCCTGAGATTGAGG
  	AGGACACCTACGGGCACATGGGCGATTGGTCCGAGGCGAAGA
  	TCCAGGACGGCACACTGGTCATTTCATGGAACCCTACCGGACA
  	TCACCACCACCATCAC
  Chlamydia_Ct460_serovarD_nIgk	ATGGAAACTCCTGCCCAACTCCTGTTCTTGCTGCTGCTTTGGCT	282
  	CCCTGACACTACCGGAATGAGCCAGAACAAGAACTCGGCATT
  	CATGCAGCCGGTCAATGTGTCCGCCGATCTGGCCGCCATTGTG
  	GGAGCTGGGCCCATGCCACGGACCGAAATCATCAAAAAGATG
  	TGGGACTACATTAAGAAGAACGGCCTGCAGGACCCGACCAAC
  	AAGCGCAACATCAACCCGGACGATAAGCTGGCGAAGGTGTTC
  	GGTACCGAGAAGCCCATCGACATGTTTCAAATGACCAAGATG
  	GTGTCCCAGCACATCATTAAG
  Chlamydia_Ct460_serovarD_nIgk_cHis	ATGGAAACTCCTGCCCAACTCCTGTTCTTGCTGCTGCTTTGGCT	283
  	CCCTGACACTACCGGAATGAGCCAGAACAAGAACTCGGCATT
  	CATGCAGCCGGTCAATGTGTCCGCCGATCTGGCCGCCATTGTG
  	GGAGCTGGGCCCATGCCACGGACCGAAATCATCAAAAAGATG
  	TGGGACTACATTAAGAAGAACGGCCTGCAGGACCCGACCAAC
  	AAGCGCAACATCAACCCGGACGATAAGCTGGCGAAGGTGTTC
  	GGTACCGAGAAGCCCATCGACATGTTTCAAATGACCAAGATG
  	GTGTCCCAGCACATCATTAAGCACCACCACCATCACCAT
  Chlamydia_Ct460_serovarL2_nIgk	ATGGAAACTCCTGCCCAACTGTTGTTCCTGCTGCTTCTCTGGCT	284
  	CCCTGACACTACCGGAATGTCGCAGAACAAGAACTCCGCCTTC
  	ATGCAACCCGTGAACGTGTCAGCGGACCTGGCAGCTATTGTCG
  	GTGCCGGGCCGATGCCCCGCACCGAAATCATCAAGAAGATGT
  	GGGACTACATCAAGGAGAACAGCCTGCAGGATCCAACCAACA
  	AGCGGAATATCAACCCGGACGATAAGCTGGCCAAAGTGTTCG
  	GCACCGAGAAGCCGATTGACATGTTTCAGATGACCAAGATGG
  	TGTCCCAGCACATCATTAAG
  Chlamydia_Ct460_serovarL2_nIgk_cHis	ATGGAAACTCCTGCCCAACTGTTGTTCCTGCTGCTTCTCTGGCT	285
  	CCCTGACACTACCGGAATGTCGCAGAACAAGAACTCCGCCTTC
  	ATGCAACCCGTGAACGTGTCAGCGGACCTGGCAGCTATTGTCG
  	GTGCCGGGCCGATGCCCCGCACCGAAATCATCAAGAAGATGT
  	GGGACTACATCAAGGAGAACAGCCTGCAGGATCCAACCAACA
  	AGCGGAATATCAACCCGGACGATAAGCTGGCCAAAGTGTTCG
  	GCACCGAGAAGCCGATTGACATGTTTCAGATGACCAAGATGG
  	TGTCCCAGCACATCATTAAGCACCACCACCATCATCAC
  Chlamydia_Ct622_serovarE_nIgk	ATGGAAACCCCTGCCCAACTGCTTTTCTTGCTGCTGCTCTGGCT	286
  	CCCTGACACCACCGGAATGGAATCTGGACCCGAGTCCGTGTCA
  	AGCAACCAGTCCTCCATGAACCCCATCATTAATGGACAGATCG
  	CATCCAATTCCGAAACCAAGGAAAGCACCAAGGCATCGGAGG
  	CCTCCCCATCCGCCTCAAGCTCCGTGTCGTCCTGGTCGTTTCTG
  	TCGAGCGCGAAGAATGCCCTGATCTCACTGCGGGACGCGATTC
  	TGAACAAGAACAGCTCCCCAACCGACTCCCTGAGCCAACTCG
  	AGGCCTCAACTTCCACTTCGACTGTGACTAGGGTCGCTGCCAA
  	GGATTATGACGAGGCCAAGAGCAACTTCGACACCGCCAAGAG
  	CGGACTGGAAAACGCCAAAACCCTGGCCGAATACGAAACTAA
  	GATGGCCGATCTCATGGCGGCCCTGCAAGACATGGAACGGCT
  	GGCGAACTCCGATCCGTCCAACAACCACACTGAGGAAGTGAA
  	CAACATCAAGAAGGCTCTCGAGGCCCAGAAGGATACCATCGA
  	CAAGTTGAACAAGCTTGTGACGCTGCAGAACCAAAACAAGTC
  	CCTGACGGAAGTGCTCAAAACCACCGACTCGGCCGACCAGAT
  	TCCGGCCATCAACAGCCAGCTGGAGATTAACAAGAACTCGGC
  	CGATCAGATTATCAAGGACCTGGAGCGCCAGAACATTTCCTAC
  	GAGGCCGTCTTGACTAACGCCGGCGAAGTGATCAAGGCGTCA
  	TCCGAAGCCGGCATTAAGCTGGGACAGGCGCTGCAATCCATC
  	GTCGACGCCGGCGACCAGTCCCAGGCGGCGGTGCTGCAGGCC
  	CAGCAGAACAACTCCCCCGATAACATCGCTGCAACCAAGGAA
  	CTGATTGACGCGGCCGAAACCAAAGTCAACGAACTGAAGCAG
  	GAGCACACTGGTCTGACCGACTCGCCGCTCGTGAAGAAGGCC
  	GAAGAACAGATCAGCCAGGCTCAGAAGGATATCCAGGAAATC
  	AAGCCTTCGGGGAGCGACATCCCGATCGTGGGACCGTCCGGTT
  	CCGCCGCTTCCGCCGGGTCCGCAGCCGGGGCCCTTAAGTCGTC
  	GAACAATAGCGGCAGAATATCCCTGCTGCTCGACGATGTGGAT
  	AACGAGATGGCCGCCATTGCGCTGCAAGGATTCCGGTCCATGA
  	TCGAGCAGTTCAACGTGAACAACCCCGCCACCGCCAAGGAGC
  	TGCAGGCTATGGAGGCCCAACTCACTGCCATGTCCGACCAGCT
  	CGTGGGAGCGGACGGAGAACTGCCAGCCGAGATCCAGGCCAT
  	CAAGGACGCTCTGGCCCAGGCACTGAAGCAGCCGTCCGCGGA
  	TGGCCTGGCCACCGCCATGGGCCAGGTCGCGTTCGCCGCCGCT
  	AAAGTCGGCGGAGGTTCGGCCGGCACTGCCGGGACCGTGCAG
  	ATGAATGTCAAGCAGCTGTACAAGACTGCGTTCTCGTCGACCA
  	GCTCCAGCTCCTACGCCGCGGCCCTGTCCGACGGTTACAGCGC
  	GTACAAGACCCTGAACTCCCTTTACTCCGAATCGAGATCCGGG
  	GTCCAGTCCGCAATTTCACAAACCGCCAATCCTGCCCTGTCGC
  	GCTCAGTGTCACGCAGCGGCATCGAGTCACAGGGCAGAAGCG
  	CCGACGCTAGCCAAAGGGCCGCAGAAACCATTGTGCGGGACT
  	CCCAGACACTTGGAGATGTCTACAGCCGCCTCCAAGTGCTGGA
  	CTCCCTCATGTCCACCATCGTGTCAAACCCTCAGGCTAACCAG
  	GAGGAAATCATGCAGAAGCTGACCGCAAGCATTTCCAAGGCT
  	CCGCAGTTTGGATACCCCGCTGTGCAAAACTCCGCGGACAGCT
  	TGCAGAAATTCGCAGCCCAGTTGGAGAGGGAGTTCGTGGACG
  	GGGAGCGGTCCCTCGCGGAGTCCCAGGAGAACGCATTCCGGA
  	AGCAGCCCGCCTTCATTCAACAAGTGCTTGTGAACATCGCCTC
  	CCTGTTCTCCGGTTACCTGTCT
  Chlamydia_Ct622_serovarE_nIgk_cHis	ATGGAAACCCCTGCCCAACTGCTTTTCTTGCTGCTGCTCTGGCT	289
  	CCCTGACACCACCGGAATGGAATCTGGACCCGAGTCCGTGTCA
  	AGCAACCAGTCCTCCATGAACCCCATCATTAATGGACAGATCG
  	CATCCAATTCCGAAACCAAGGAAAGCACCAAGGCATCGGAGG
  	CCTCCCCATCCGCCTCAAGCTCCGTGTCGTCCTGGTCGTTTCTG
  	TCGAGCGCGAAGAATGCCCTGATCTCACTGCGGGACGCGATTC
  	TGAACAAGAACAGCTCCCCAACCGACTCCCTGAGCCAACTCG
  	AGGCCTCAACTTCCACTTCGACTGTGACTAGGGTCGCTGCCAA
  	GGATTATGACGAGGCCAAGAGCAACTTCGACACCGCCAAGAG
  	CGGACTGGAAAACGCCAAAACCCTGGCCGAATACGAAACTAA
  	GATGGCCGATCTCATGGCGGCCCTGCAAGACATGGAACGGCT
  	GGCGAACTCCGATCCGTCCAACAACCACACTGAGGAAGTGAA
  	CAACATCAAGAAGGCTCTCGAGGCCCAGAAGGATACCATCGA
  	CAAGTTGAACAAGCTTGTGACGCTGCAGAACCAAAACAAGTC
  	CCTGACGGAAGTGCTCAAAACCACCGACTCGGCCGACCAGAT
  	TCCGGCCATCAACAGCCAGCTGGAGATTAACAAGAACTCGGC
  	CGATCAGATTATCAAGGACCTGGAGCGCCAGAACATTTCCTAC
  	GAGGCCGTCTTGACTAACGCCGGCGAAGTGATCAAGGCGTCA
  	TCCGAAGCCGGCATTAAGCTGGGACAGGCGCTGCAATCCATC
  	GTCGACGCCGGCGACCAGTCCCAGGCGGCGGTGCTGCAGGCC
  	CAGCAGAACAACTCCCCCGATAACATCGCTGCAACCAAGGAA
  	CTGATTGACGCGGCCGAAACCAAAGTCAACGAACTGAAGCAG
  	GAGCACACTGGTCTGACCGACTCGCCGCTCGTGAAGAAGGCC
  	GAAGAACAGATCAGCCAGGCTCAGAAGGATATCCAGGAAATC
  	AAGCCTTCGGGGAGCGACATCCCGATCGTGGGACCGTCCGGTT
  	CCGCCGCTTCCGCCGGGTCCGCAGCCGGGGCCCTTAAGTCGTC
  	GAACAATAGCGGCAGAATATCCCTGCTGCTCGACGATGTGGAT
  	AACGAGATGGCCGCCATTGCGCTGCAAGGATTCCGGTCCATGA
  	TCGAGCAGTTCAACGTGAACAACCCCGCCACCGCCAAGGAGC
  	TGCAGGCTATGGAGGCCCAACTCACTGCCATGTCCGACCAGCT
  	CGTGGGAGCGGACGGAGAACTGCCAGCCGAGATCCAGGCCAT
  	CAAGGACGCTCTGGCCCAGGCACTGAAGCAGCCGTCCGCGGA
  	TGGCCTGGCCACCGCCATGGGCCAGGTCGCGTTCGCCGCCGCT
  	AAAGTCGGCGGAGGTTCGGCCGGCACTGCCGGGACCGTGCAG
  	ATGAATGTCAAGCAGCTGTACAAGACTGCGTTCTCGTCGACCA
  	GCTCCAGCTCCTACGCCGCGGCCCTGTCCGACGGTTACAGCGC
  	GTACAAGACCCTGAACTCCCTTTACTCCGAATCGAGATCCGGG
  	GTCCAGTCCGCAATTTCACAAACCGCCAATCCTGCCCTGTCGC
  	GCTCAGTGTCACGCAGCGGCATCGAGTCACAGGGCAGAAGCG
  	CCGACGCTAGCCAAAGGGCCGCAGAAACCATTGTGCGGGACT
  	CCCAGACACTTGGAGATGTCTACAGCCGCCTCCAAGTGCTGGA
  	CTCCCTCATGTCCACCATCGTGTCAAACCCTCAGGCTAACCAG
  	GAGGAAATCATGCAGAAGCTGACCGCAAGCATTTCCAAGGCT
  	CCGCAGTTTGGATACCCCGCTGTGCAAAACTCCGCGGACAGCT
  	TGCAGAAATTCGCAGCCCAGTTGGAGAGGGAGTTCGTGGACG
  	GGGAGCGGTCCCTCGCGGAGTCCCAGGAGAACGCATTCCGGA
  	AGCAGCCCGCCTTCATTCAACAAGTGCTTGTGAACATCGCCTC
  	CCTGTTCTCCGGTTACCTGTCTCATCACCACCACCATCAC
  Chlamydia_Ct858_nIgk	ATGGAAACCCCTGCCCAGCTGCTGTTCCTGCTGCTGCTGTGGC	288
  	TGCCTGATACCACAGGCGTGCGGGGAGAGTCCCTCGTGTGCAA
  	GAATGCCCTGCAGGACCTGAGCTTCCTGGAACATCTGCTGCAA
  	GTGAAGTACGCCCCCAAGACCTGGAAAGAGCAGTACCTGGGC
  	TGGGACCTGGTGCAGTCCTCTGTGTCTGCCCAGCAGAAGCTGC
  	GGACCCAGGAAAACCCCTCTACCAGCTTCTGTCAGCAAGTGCT
  	GGCCGACTTCATCGGCGGCCTGAACGATTTCCATGCCGGCGTG
  	ACCTTTTTCGCCATCGAGAGCGCCTACCTGCCCTACACCGTGC
  	AGAAGTCCAGCGACGGCCGGTTCTACTTCGTGGACATCATGAC
  	CTTCAGCAGCGAGATCAGAGTGGGCGACGAGCTGCTGGAAGT
  	GGATGGCGCTCCTGTGCAGGATGTGCTGGCCACACTGTACGGC
  	AGCAACCACAAGGGCACAGCCGCCGAAGAATCTGCCGCCCTG
  	AGAACCCTGTTCAGCCGGATGGCCTCTCTGGGCCACAAGGTGC
  	CAAGCGGCAGAACCACCCTGAAGATCAGACGGCCCTTTGGCA
  	CCACCCGGGAAGTGCGCGTGAAGTGGCGCTATGTGCCTGAGG
  	GCGTGGGCGACCTGGCCACAATCGCCCCTTCTATCAGAGCCCC
  	CCAGCTGCAGAAATCCATGCGGTCATTCTTCCCAAAGAAGGAC
  	GACGCCTTCCACCGGTCCAGCAGCCTGTTCTACAGCCCTATGG
  	TGCCCCACTTCTGGGCCGAGCTGAGAAACCACTACGCCACCTC
  	CGGCCTGAAGTCCGGCTACAACATCGGCAGCACCGACGGCTTT
  	CTGCCCGTGATCGGACCCGTGATCTGGGAGAGCGAGGGCCTGT
  	TCAGAGCCTACATCAGCAGCGTGACCGACGGCGACGGCAAGA
  	GCCACAAAGTGGGCTTTCTGAGAATCCCCACCTACAGCTGGCA
  	GGACATGGAAGATTTCGACCCCAGCGGCCCACCCCCCTGGGA
  	GGAATTTGCCAAGATCATCCAGGTGTTCAGCAGCAACACCGA
  	GGCCCTGATCATCGACCAGACCAACAACCCTGGCGGCAGCGT
  	GCTGTACCTGTACGCCCTGCTGAGCATGCTGACCGACAGACCC
  	CTGGAACTGCCCAAGCACCGGATGATCCTGACCCAGGACGAG
  	GTGGTGGACGCCCTGGATTGGCTGACCCTGCTGGAAAACGTGG
  	ACACCAACGTGGAAAGCCGGCTGGCCCTGGGCGACAACATGG
  	AAGGCTACACAGTGGATCTGCAGGTGGCCGAGTACCTGAAAA
  	GCTTCGGCAGACAGGTGCTGAACTGCTGGTCCAAGGGCGACA
  	TCGAGCTGAGCACCCCCATCCCCCTGTTCGGCTTCGAGAAGAT
  	CCACCCCCACCCCAGAGTGCAGTACAGCAAGCCCATCTGCGTG
  	CTGATCAACGAGCAGGACTTCTCCTGCGCCGACTTCTTCCCAG
  	TGGTGCTGAAGGACAACGACAGAGCCCTGATCGTGGGCACCA
  	GAACAGCTGGCGCTGGCGGCTTCGTGTTCAACGTGCAGTTCCC
  	CAACCGGACCGGCATCAAGACCTGTAGCCTGACAGGCTCTCTG
  	GCCGTGCGGGAACACGGCGCCTTCATCGAGAACATCGGCGTG
  	GAACCCCACATCGACCTGCCTTTCACCGCCAACGACATCCGGT
  	ACAAGGGCTACTCTGAGTACCTGGACAAAGTGAAGAAACTCG
  	TGTGCCAGCTGATTAACAACGACGGCACCATCATCCTGGCCGA
  	GGACGGCAGCTTC
  Chlamydia_Ct858_nIgk_cHis	ATGGAAACCCCTGCCCAGCTGCTGTTCCTGCTGCTGCTGTGGC	289
  	TGCCTGATACCACAGGCGTGCGGGGAGAGTCCCTCGTGTGCAA
  	GAATGCCCTGCAGGACCTGAGCTTCCTGGAACATCTGCTGCAA
  	GTGAAGTACGCCCCCAAGACCTGGAAAGAGCAGTACCTGGGC
  	TGGGACCTGGTGCAGTCCTCTGTGTCTGCCCAGCAGAAGCTGC
  	GGACCCAGGAAAACCCCTCTACCAGCTTCTGTCAGCAAGTGCT
  	GGCCGACTTCATCGGCGGCCTGAACGATTTCCATGCCGGCGTG
  	ACCTTTTTCGCCATCGAGAGCGCCTACCTGCCCTACACCGTGC
  	AGAAGTCCAGCGACGGCCGGTTCTACTTCGTGGACATCATGAC
  	CTTCAGCAGCGAGATCAGAGTGGGCGACGAGCTGCTGGAAGT
  	GGATGGCGCTCCTGTGCAGGATGTGCTGGCCACACTGTACGGC
  	AGCAACCACAAGGGCACAGCCGCCGAAGAATCTGCCGCCCTG
  	AGAACCCTGTTCAGCCGGATGGCCTCTCTGGGCCACAAGGTGC
  	CAAGCGGCAGAACCACCCTGAAGATCAGACGGCCCTTTGGCA
  	CCACCCGGGAAGTGCGCGTGAAGTGGCGCTATGTGCCTGAGG
  	GCGTGGGCGACCTGGCCACAATCGCCCCTTCTATCAGAGCCCC
  	CCAGCTGCAGAAATCCATGCGGTCATTCTTCCCAAAGAAGGAC
  	GACGCCTTCCACCGGTCCAGCAGCCTGTTCTACAGCCCTATGG
  	TGCCCCACTTCTGGGCCGAGCTGAGAAACCACTACGCCACCTC
  	CGGCCTGAAGTCCGGCTACAACATCGGCAGCACCGACGGCTTT
  	CTGCCCGTGATCGGACCCGTGATCTGGGAGAGCGAGGGCCTGT
  	TCAGAGCCTACATCAGCAGCGTGACCGACGGCGACGGCAAGA
  	GCCACAAAGTGGGCTTTCTGAGAATCCCCACCTACAGCTGGCA
  	GGACATGGAAGATTTCGACCCCAGCGGCCCACCCCCCTGGGA
  	GGAATTTGCCAAGATCATCCAGGTGTTCAGCAGCAACACCGA
  	GGCCCTGATCATCGACCAGACCAACAACCCTGGCGGCAGCGT
  	GCTGTACCTGTACGCCCTGCTGAGCATGCTGACCGACAGACCC
  	CTGGAACTGCCCAAGCACCGGATGATCCTGACCCAGGACGAG
  	GTGGTGGACGCCCTGGATTGGCTGACCCTGCTGGAAAACGTGG
  	ACACCAACGTGGAAAGCCGGCTGGCCCTGGGCGACAACATGG
  	AAGGCTACACAGTGGATCTGCAGGTGGCCGAGTACCTGAAAA
  	GCTTCGGCAGACAGGTGCTGAACTGCTGGTCCAAGGGCGACA
  	TCGAGCTGAGCACCCCCATCCCCCTGTTCGGCTTCGAGAAGAT
  	CCACCCCCACCCCAGAGTGCAGTACAGCAAGCCCATCTGCGTG
  	CTGATCAACGAGCAGGACTTCTCCTGCGCCGACTTCTTCCCAG
  	TGGTGCTGAAGGACAACGACAGAGCCCTGATCGTGGGCACCA
  	GAACAGCTGGCGCTGGCGGCTTCGTGTTCAACGTGCAGTTCCC
  	CAACCGGACCGGCATCAAGACCTGTAGCCTGACAGGCTCTCTG
  	GCCGTGCGGGAACACGGCGCCTTCATCGAGAACATCGGCGTG
  	GAACCCCACATCGACCTGCCTTTCACCGCCAACGACATCCGGT
  	ACAAGGGCTACTCTGAGTACCTGGACAAAGTGAAGAAACTCG
  	TGTGCCAGCTGATTAACAACGACGGCACCATCATCCTGGCCGA
  	GGACGGCAGCTTCCACCACCACCATCACCAC
  Chlamydia_Ct875_nIgk	ATGGAAACCCCTGCCCAGCTGCTGTTCCTGCTGCTGCTGTGGC	290
  	TGCCTGACACCACCGGCATGAGCATCAGAGGCGTGGGCGGCA
  	ACGGCAACAGCAGAATCCCTAGCCACAACGGCGACGGCAGCA
  	ACAGGCGGAGCCAGAACACCAAGGGCAACAACAAGGTGGAA
  	GATAGAGTGTGCAGCCTGTACAGCAGCCGGTCCAACGAGAAC
  	CGCGAGAGCCCTTATGCCGTGGTGGACGTGTCCAGCATGATCG
  	AGAGCACCCCCACCAGCGGCGAGACAACCAGAGCTAGTAGAG
  	GCGTGCTGAGCCGGTTCCAGAGGGGCCTCGTGCGGATTGCTGA
  	CAAAGTGCGGAGAGCCGTGCAGTGCGCTTGGAGCAGCGTGTC
  	CACAAGCAGAAGCAGCGCCACAAGAGCCGCCGAGAGCGGCA
  	GCTCTAGCAGAACAGCTAGAGGCGCCAGCAGCGGCTACAGAG
  	AGTACAGCCCTTCTGCCGCTCGGGGCCTGCGGCTGATGTTCAC
  	CGACTTTTGGCGGACCCGGGTGCTGAGACAGACCTCTCCTATG
  	GCCGGCGTGTTCGGCAACCTGGACGTGAACGAGGCCAGACTG
  	ATGGCCGCCTACACCAGCGAGTGTGCCGATCACCTGGAAGCC
  	AAAGAGCTGGCCGGACCTGACGGCGTGGCAGCCGCTAGAGAA
  	ATCGCCAAGAGATGGGAGAAGAGAGTGCGGGACCTGCAGGAC
  	AAGGGCGCTGCCAGAAAGCTGCTGAACGACCCCCTGGGCAGA
  	CGGACCCCCAACTACCAGAGCAAGAACCCCGGCGAGTACACC
  	GTGGGCAACTCCATGTTCTACGACGGCCCCCAGGTGGCCAACC
  	TGCAGAATGTGGATACCGGCTTCTGGCTGGACATGAGCAACCT
  	GAGCGACGTGGTGCTGTCCAGAGAGATCCAGACCGGCCTGAG
  	AGCCAGAGCCACCCTGGAAGAGTCCATGCCCATGCTGGAAAA
  	TCTGGAAGAGAGATTCCGGCGGCTGCAGGAAACCTGCGACGC
  	CGCCAGAACCGAGATCGAGGAAAGCGGCTGGACCCGGGAAAG
  	CGCCTCCAGAATGGAAGGCGACGAAGCCCAGGGCCCCAGCAG
  	AGTGCAGCAGGCCTTTCAGAGCTTCGTGAATGAGTGCAACAGC
  	ATCGAGTTCAGCTTCGGCTCCTTCGGCGAGCACGTGCGGGTGC
  	TGTGTGCCAGAGTGTCAAGAGGACTGGCCGCTGCCGGCGAGG
  	CCATCAGAAGATGCTTCAGCTGCTGCAAGGGCAGCACCCACA
  	GATACGCCCCCAGAGATGACCTGTCTCCTGAGGGCGCCTCTCT
  	GGCCGAAACCCTGGCCAGATTCGCCGACGACATGGGCATCGA
  	AAGAGGCGCCGACGGCACCTACGACATCCCCCTGGTGGACGA
  	TTGGAGAAGGGGCGTGCCATCCATCGAGGGCGAGGGCAGCGA
  	TAGCATCTACGAGATCATGATGCCCATCTACGAAGTGATGAAC
  	ATGGACCTGGAAACCCGGCGGAGCTTCGCCGTGCAGCAGGGC
  	CATTACCAGGACCCCAGAGCCAGCGACTACGACCTGCCTAGA
  	GCCTCCGATTACGATCTGCCCAGAAGCCCCTACCCCACCCCTC
  	CACTGCCTCCCAGATACCAGCTGCAGAACATGGATGTGGAAG
  	CCGGCTTTCGCGAGGCCGTGTACGCCTCTTTTGTGGCCGGCAT
  	GTACAACTACGTCGTGACCCAGCCCCAGGAACGGATCCCCAAT
  	AGCCAGCAGGTGGAAGGCATCCTGCGGGACATGCTGACCAAC
  	GGCAGCCAGACCTTCCGGGACCTGATGAAGCGGTGGAACAGA
  	GAGGTGGACCGCGAG
  Chlamydia_Ct875_nIgk_cHis	ATGGAAACCCCTGCCCAGCTGCTGTTCCTGCTGCTGCTGTGGC	291
  	TGCCTGACACCACCGGCATGAGCATCAGAGGCGTGGGCGGCA
  	ACGGCAACAGCAGAATCCCTAGCCACAACGGCGACGGCAGCA
  	ACAGGCGGAGCCAGAACACCAAGGGCAACAACAAGGTGGAA
  	GATAGAGTGTGCAGCCTGTACAGCAGCCGGTCCAACGAGAAC
  	CGCGAGAGCCCTTATGCCGTGGTGGACGTGTCCAGCATGATCG
  	AGAGCACCCCCACCAGCGGCGAGACAACCAGAGCTAGTAGAG
  	GCGTGCTGAGCCGGTTCCAGAGGGGCCTCGTGCGGATTGCTGA
  	CAAAGTGCGGAGAGCCGTGCAGTGCGCTTGGAGCAGCGTGTC
  	CACAAGCAGAAGCAGCGCCACAAGAGCCGCCGAGAGCGGCA
  	GCTCTAGCAGAACAGCTAGAGGCGCCAGCAGCGGCTACAGAG
  	AGTACAGCCCTTCTGCCGCTCGGGGCCTGCGGCTGATGTTCAC
  	CGACTTTTGGCGGACCCGGGTGCTGAGACAGACCTCTCCTATG
  	GCCGGCGTGTTCGGCAACCTGGACGTGAACGAGGCCAGACTG
  	ATGGCCGCCTACACCAGCGAGTGTGCCGATCACCTGGAAGCC
  	AAAGAGCTGGCCGGACCTGACGGCGTGGCAGCCGCTAGAGAA
  	ATCGCCAAGAGATGGGAGAAGAGAGTGCGGGACCTGCAGGAC
  	AAGGGCGCTGCCAGAAAGCTGCTGAACGACCCCCTGGGCAGA
  	CGGACCCCCAACTACCAGAGCAAGAACCCCGGCGAGTACACC
  	GTGGGCAACTCCATGTTCTACGACGGCCCCCAGGTGGCCAACC
  	TGCAGAATGTGGATACCGGCTTCTGGCTGGACATGAGCAACCT
  	GAGCGACGTGGTGCTGTCCAGAGAGATCCAGACCGGCCTGAG
  	AGCCAGAGCCACCCTGGAAGAGTCCATGCCCATGCTGGAAAA
  	TCTGGAAGAGAGATTCCGGCGGCTGCAGGAAACCTGCGACGC
  	CGCCAGAACCGAGATCGAGGAAAGCGGCTGGACCCGGGAAAG
  	CGCCTCCAGAATGGAAGGCGACGAAGCCCAGGGCCCCAGCAG
  	AGTGCAGCAGGCCTTTCAGAGCTTCGTGAATGAGTGCAACAGC
  	ATCGAGTTCAGCTTCGGCTCCTTCGGCGAGCACGTGCGGGTGC
  	TGTGTGCCAGAGTGTCAAGAGGACTGGCCGCTGCCGGCGAGG
  	CCATCAGAAGATGCTTCAGCTGCTGCAAGGGCAGCACCCACA
  	GATACGCCCCCAGAGATGACCTGTCTCCTGAGGGCGCCTCTCT
  	GGCCGAAACCCTGGCCAGATTCGCCGACGACATGGGCATCGA
  	AAGAGGCGCCGACGGCACCTACGACATCCCCCTGGTGGACGA
  	TTGGAGAAGGGGCGTGCCATCCATCGAGGGCGAGGGCAGCGA
  	TAGCATCTACGAGATCATGATGCCCATCTACGAAGTGATGAAC
  	ATGGACCTGGAAACCCGGCGGAGCTTCGCCGTGCAGCAGGGC
  	CATTACCAGGACCCCAGAGCCAGCGACTACGACCTGCCTAGA
  	GCCTCCGATTACGATCTGCCCAGAAGCCCCTACCCCACCCCTC
  	CACTGCCTCCCAGATACCAGCTGCAGAACATGGATGTGGAAG
  	CCGGCTTTCGCGAGGCCGTGTACGCCTCTTTTGTGGCCGGCAT
  	GTACAACTACGTCGTGACCCAGCCCCAGGAACGGATCCCCAAT
  	AGCCAGCAGGTGGAAGGCATCCTGCGGGACATGCTGACCAAC
  	GGCAGCCAGACCTTCCGGGACCTGATGAAGCGGTGGAACAGA
  	GAGGTGGACCGCGAGCACCACCATCACCACCAC
  Chlamydia_Ct089_nIgk	ATGGAAACCCCTGCCCAGCTGCTGTTCCTGCTGCTGCTGTGGC	292
  	TGCCTGACACCACCGGCATGACAGCATCTGGCGGAGCTGGCG
  	GCCTGGGCTCTACACAGACAGTGGATGTGGCCAGGGCCCAGG
  	CTGCTGCCGCTACACAGGATGCCCAGGAAGTGATCGGCAGCC
  	AGGAAGCCAGCGAGGCCTCTATGCTGAAGGGCTGCGAGGACC
  	TGATCAACCCTGCCGCCGCTACCCGCATCAAGAAGAAAGAGG
  	AAAAGTTCGAGTCCCTGGAAGCCAGACGGAAGCCCACCGCCG
  	ACAAGGCCGAGAAGAAGTCCGAGAGCACCGAGGAAAAGGGC
  	GACACCCCCCTGGAAGATCGGTTCACCGAGGATCTGAGCGAG
  	GTGTCCGGCGAGGACTTCCGGGGCCTGAAGAACAGCTTCGAC
  	GACGACAGCAGCCCCGAGGAAATCCTGGACGCCCTGACCAGC
  	AAGTTCAGCGACCCCACCATCAAGGACCTGGCCCTGGACTACC
  	TGATCCAGACCGCCCCCAGCGACCGGAAGCTGAAGTCTGCCCT
  	GATTCAGGCCAAGCACCAGCTGATGAGCCAGAACCCCCAGGC
  	CATCGTGGGCGGCAGAAATGTGCTGCTGGCCTCCGAGACATTC
  	GCCAGCAGAGCCAACACCAGCCCCAGCTCCCTGCGGAGCCTG
  	TATCTGCAAGTGACCAGCTCCCCCAGCAACTGCGACAACCTGA
  	GACAGATGCTGGCTAGCTACCTGCCCTCCGAGAAAACCGCCGT
  	GATGGAATTCCTCGTGAACGGCATGGTGGCCGACCTGAAAAG
  	CGAGGGCCCTAGCATCCCTCCCGCCAAGCTGCAGGTGTACATG
  	ACCGAGCTGAGCAACCTGCAGGCCCTGCACAGCGTGGACAGC
  	TTTTTCGACCGGAACATCGGCAACCTGGAAAACAGCCTGAAGC
  	ACGAGGGCCACGCCCCCATCCCTTCTCTGACAACCGGCAATCT
  	GACCAAGACCTTCCTGCAGCTGGTGGAAGATAAGTTCCCCAGC
  	AGCTCCAAGGCCCAGAAGGCCCTGAACGAGCTCGTGGGCCCT
  	GATACCGGACCTCAGACCGAGGTGCTGAACCTGTTCTTTCGGG
  	CCCTGAATGGCTGCTCCCCCCGGATCTTTTCTGGCGCTGAGAA
  	GAAGCAGCAGCTGGCCAGCGTGATCACCAACACCCTGGATGC
  	CATCAACGCCGACAACGAGGACTACCCCAAGCCCGGCGACTT
  	CCCCAGAAGCAGCTTTAGCAGCACCCCCCCTCATGCCCCTGTG
  	CCCCAGTCTGAGATCCCTACCAGCCCAACCAGCACCCAGCCTC
  	CAAGCCCT
  Chlamydia_Ct089_nIgk_cHis	ATGGAAACCCCTGCCCAGCTGCTGTTCCTGCTGCTGCTGTGGC	293
  	TGCCTGACACCACCGGCATGACAGCATCTGGCGGAGCTGGCG
  	GCCTGGGCTCTACACAGACAGTGGATGTGGCCAGGGCCCAGG
  	CTGCTGCCGCTACACAGGATGCCCAGGAAGTGATCGGCAGCC
  	AGGAAGCCAGCGAGGCCTCTATGCTGAAGGGCTGCGAGGACC
  	TGATCAACCCTGCCGCCGCTACCCGCATCAAGAAGAAAGAGG
  	AAAAGTTCGAGTCCCTGGAAGCCAGACGGAAGCCCACCGCCG
  	ACAAGGCCGAGAAGAAGTCCGAGAGCACCGAGGAAAAGGGC
  	GACACCCCCCTGGAAGATCGGTTCACCGAGGATCTGAGCGAG
  	GTGTCCGGCGAGGACTTCCGGGGCCTGAAGAACAGCTTCGAC
  	GACGACAGCAGCCCCGAGGAAATCCTGGACGCCCTGACCAGC
  	AAGTTCAGCGACCCCACCATCAAGGACCTGGCCCTGGACTACC
  	TGATCCAGACCGCCCCCAGCGACCGGAAGCTGAAGTCTGCCCT
  	GATTCAGGCCAAGCACCAGCTGATGAGCCAGAACCCCCAGGC
  	CATCGTGGGCGGCAGAAATGTGCTGCTGGCCTCCGAGACATTC
  	GCCAGCAGAGCCAACACCAGCCCCAGCTCCCTGCGGAGCCTG
  	TATCTGCAAGTGACCAGCTCCCCCAGCAACTGCGACAACCTGA
  	GACAGATGCTGGCTAGCTACCTGCCCTCCGAGAAAACCGCCGT
  	GATGGAATTCCTCGTGAACGGCATGGTGGCCGACCTGAAAAG
  	CGAGGGCCCTAGCATCCCTCCCGCCAAGCTGCAGGTGTACATG
  	ACCGAGCTGAGCAACCTGCAGGCCCTGCACAGCGTGGACAGC
  	TTTTTCGACCGGAACATCGGCAACCTGGAAAACAGCCTGAAGC
  	ACGAGGGCCACGCCCCCATCCCTTCTCTGACAACCGGCAATCT
  	GACCAAGACCTTCCTGCAGCTGGTGGAAGATAAGTTCCCCAGC
  	AGCTCCAAGGCCCAGAAGGCCCTGAACGAGCTCGTGGGCCCT
  	GATACCGGACCTCAGACCGAGGTGCTGAACCTGTTCTTTCGGG
  	CCCTGAATGGCTGCTCCCCCCGGATCTTTTCTGGCGCTGAGAA
  	GAAGCAGCAGCTGGCCAGCGTGATCACCAACACCCTGGATGC
  	CATCAACGCCGACAACGAGGACTACCCCAAGCCCGGCGACTT
  	CCCCAGAAGCAGCTTTAGCAGCACCCCCCCTCATGCCCCTGTG
  	CCCCAGTCTGAGATCCCTACCAGCCCAACCAGCACCCAGCCTC
  	CAAGCCCTCACCACCACCATCACCAC
  Chlamydia_MOMP	ATGAAAAAACTCTTAAAATCGGCGTTTTTATCCGCCGCATTTTT	294
  	TGCTGGTCACGCCTCCTTACACGCTTTGCCTGTAGGGAACCCA
  	GCAGAGCCAAGTTTATTAATTGATGGAACGATATGGGAAGGT
  	ATGTCAGGAGATCCATGTGATCCTTGCGCTACTTGGTGCGACG
  	CGATTAGCTTACGCGTAGGATTTTACGGAGATTATGTTTTCGA
  	CAGAGTCCTCAAGACAGATGTGCCACAGAAGTTTTCAATGGG
  	GCCTATACCTACTTCAAGTACTTCTCCTGAAGACTCAGCTATA
  	CTAACAGAGAGAAATAACGCAGCGTATGGAAAACATATGCAC
  	GATGCGGAGTTGTTCACAAATGCAGGTTACATTGCGCTAAATA
  	TTTGGGACCGTTTCGACATCTTTTGTACCTTAGGAGCTACTAGT
  	GGGTATTTTAAAGGGAATTCTTCATCTTTCAACTTGATCGGATT
  	GATTGGTATTTCAGGAGCAGACCTTAACAGCAAGCTCCCAAAC
  	GCAAATATTTCTAACGGCGTAGTAGAGCTATATACAGACACAA
  	CCTTCTCTTGGAGCGTTGGAGCTCGCGGAGCTTTGTGGGAGTG
  	TGGTTGCGCTACTTTAGGAGCAGAATTCCAATACGCACAATCG
  	AAACCTCGCGTTCAAGAATTGAATGTCTTGTCTAACGTAGCAC
  	AATTTACTGTACACAAACCTCGGGGATATGTAGGCCAGCCTCT
  	ACCTCTTCCACTGACTGCAGGAACAGCAACTGATTCTAATGAT
  	AAATTGAAAAATGCCACGATCAACTACCATGAATGGCAAGTC
  	GGTGCAGCATTGTCATATAGACTGAATATGCTCGTTCCTTACA
  	TCGGTGTTCAGTGGTCCAGAGCTACTTTTGATGCAGATACTAT
  	CCAAATTGCGGAACCAAAATTAGCTTCGCCAATTTTCAACTTG
  	ACAACATGGAATCCAACATTATTAGGACAAGCAACTTCAGTA
  	GATAGCGGAAACAAGTTTGCTGACTCCCTACAAATTGTTTCTC
  	TTCAAATTAACAAGTTGAAGTCCAGAAAAGCTTGTGGTGTTTC
  	CATGGGAGCAACTTTACTTGATGCCGATAAATGGGCAATCAAT
  	GGGGAACTTCGTTTAATTAACGAAAGAGCTGCTCACCTTTCTG
  	CTCAATGCAGATTC
  Chlamydia mRNA coding region Sequences
  Cta1_E_EXT_noTM_nIgK	AUGGAAACCCCUGCCCAGCUGCUGUUCCUGCUGCUGCUGUG	320
  	GCUGCCUGAUACCACCGGCCCUCCCCUGCCCAGCAGCACACA
  	GGACAACAGAUCCAUGGACCAGCAGGACAGCGAAGAGUUCC
  	UGCUGCAGAACACCCUGGAAGAUAGCGAGAUCAUCAGCAUC
  	CCCGACACCAUGAACCAGAUCGCCAUCGACACCGAGAAGUGG
  	UUCUACCUGAACAAGGACUGCACCAACGUGGGCCCCAUCUCC
  	AUCGUGCAGCUGACAGCCUUCCUGAAAGAGUGCAAGCACAG
  	CCCCGAGAAGGGCAUCGACCCCCAGGAACUGUGGGUGUGGA
  	AGAAAGGCAUGCCCAACUGGGAGAAAGUGAAGAACAUCCCC
  	GAGCUGAGCGGCACCGUGAAGGACGAG
  Cta1_E_EXT_noTM_nIgK_cHis	AUGGAAACCCCUGCCCAGCUGCUGUUCCUGCUGCUGCUGUG	321
  	GCUGCCUGAUACCACCGGCCCUCCCCUGCCCAGCAGCACACA
  	GGACAACAGAUCCAUGGACCAGCAGGACAGCGAAGAGUUCC
  	UGCUGCAGAACACCCUGGAAGAUAGCGAGAUCAUCAGCAUC
  	CCCGACACCAUGAACCAGAUCGCCAUCGACACCGAGAAGUGG
  	UUCUACCUGAACAAGGACUGCACCAACGUGGGCCCCAUCUCC
  	AUCGUGCAGCUGACAGCCUUCCUGAAAGAGUGCAAGCACAG
  	CCCCGAGAAGGGCAUCGACCCCCAGGAACUGUGGGUGUGGA
  	AGAAAGGCAUGCCCAACUGGGAGAAAGUGAAGAACAUCCCC
  	GAGCUGAGCGGCACCGUGAAGGACGAGCACCACCACCAUCAC
  	CAC
  CT875_E_NGM_nFC_cHis	AUGGAAACCCCUGCUCAGCUGCUGUUCCUGCUGCUGCUGUG	322
  	GCUGCCUGAUACAACCGGCGAGCCUAAGAGCUGCGACAAGA
  	CCCACACCUGUCCUCCAUGUCCUGCUCCAGAACUGCUCGGCG
  	GACCUUCCGUGUUCCUGUUUCCUCCAAAGCCUAAGGACACCC
  	UGAUGAUCAGCAGAACCCCUGAAGUGACCUGCGUGGUGGUG
  	GAUGUGUCCCACGAGGAUCCCGAAGUGAAGUUCAAUUGGUA
  	CGUGGACGGCGUGGAAGUGCACAACGCCAAGACCAAGCCUA
  	GAGAGGAACAGUACAACAGCACCUACAGAGUGGUGUCCGUG
  	CUGACCGUGCUGCACCAGGAUUGGCUGAACGGCAAAGAGUA
  	CAAGUGCAAGGUGUCCAACAAGGCCCUGCCUGCUCCUAUCG
  	AGAAGACCAUCAGCAAGGCCAAGGGCCAGCCAAGAGAACCC
  	CAGGUGUACACACUGCCUCCAAGCAGAGAUGAGCUGACCAA
  	GAACCAGGUGUCCCUGACCUGUCUGGUCAAGGGCUUCUACC
  	CCUCCGAUAUCGCCGUGGAAUGGGAGAGCAAUGGCCAGCCU
  	GAGAACAACUACAAGACAACCCCUCCUGUGCUGGACAGCGA
  	CGGCUCAUUCUUCCUGUACAGCAAGCUGACAGUGGACAAGA
  	GCAGAUGGCAGCAGGGCAACGUGUUCAGCUGCAGCGUGAUG
  	CACGAGGCCCUGCACAAUCACUACACCCAGAAGUCCCUGUCU
  	CUGAGCCCCGGCAAGAUGAGCAUCAGAGGCGUGGGCGGCAA
  	CGGCAACAGCAGAAUCCCUAGCCACAACGGCGACGGCAGCAA
  	CAGGCGGAGCCAGAACACCAAGGGCAACAACAAGGUGGAAG
  	AUAGAGUGUGCAGCCUGUACAGCAGCCGGUCCAACGAGAAC
  	CGCGAGAGCCCUUAUGCCGUGGUGGACGUGUCCAGCAUGAU
  	CGAGAGCACCCCCACCAGCGGCGAGACAACCAGAGCUAGUAG
  	AGGCGUGCUGAGCCGGUUCCAGAGGGGCCUCGUGCGGAUUG
  	CUGACAAAGUGCGGAGAGCCGUGCAGUGCGCUUGGAGCAGC
  	GUGUCCACAAGCAGAAGCAGCGCCACAAGAGCCGCCGAGAG
  	CGGCAGCUCUAGCAGAACAGCUAGAGGCGCCAGCAGCGGCU
  	ACAGAGAGUACAGCCCUUCUGCCGCUCGGGGCCUGCGGCUG
  	AUGUUCACCGACUUUUGGCGGACCCGGGUGCUGAGACAGAC
  	CUCUCCUAUGGCCGGCGUGUUCGGCAACCUGGACGUGAACG
  	AGGCCAGACUGAUGGCCGCCUACACCAGCGAGUGUGCCGAU
  	CACCUGGAAGCCAAAGAGCUGGCCGGACCUGACGGCGUGGC
  	AGCCGCUAGAGAAAUCGCCAAGAGAUGGGAGAAGAGAGUGC
  	GGGACCUGCAGGACAAGGGCGCUGCCAGAAAGCUGCUGAAC
  	GACCCCCUGGGCAGACGGACCCCCAACUACCAGAGCAAGAAC
  	CCCGGCGAGUACACCGUGGGCAACUCCAUGUUCUACGACGGC
  	CCCCAGGUGGCCAACCUGCAGAAUGUGGAUACCGGCUUCUG
  	GCUGGACAUGCAGCACCUGAGCGACGUGGUGCUGUCCAGAG
  	AGAUCCAGACCGGCCUGAGAGCCAGAGCCACCCUGGAAGAG
  	UCCAUGCCCAUGCUGGAAAAUCUGGAAGAGAGAUUCCGGCG
  	GCUGCAGGAAACCUGCGACGCCGCCAGAACCGAGAUCGAGG
  	AAAGCGGCUGGACCCGGGAAAGCGCCUCCAGAAUGGAAGGC
  	GACGAAGCCCAGGGCCCCAGCAGAGUGCAGCAGGCCUUUCA
  	GAGCUUCGUGAAUGAGUGCAACAGCAUCGAGUUCAGCUUCG
  	GCUCCUUCGGCGAGCACGUGCGGGUGCUGUGUGCCAGAGUG
  	UCAAGAGGACUGGCCGCUGCCGGCGAGGCCAUCAGAAGAUG
  	CUUCAGCUGCUGCAAGGGCAGCACCCACAGAUACGCCCCCAG
  	AGAUGACCUGUCUCCUGAGGGCGCCUCUCUGGCCGAAACCCU
  	GGCCAGAUUCGCCGACGACAUGGGCAUCGAAAGAGGCGCCG
  	ACGGCACCUACGACAUCCCCCUGGUGGACGAUUGGAGAAGG
  	GGCGUGCCAUCCAUCGAGGGCGAGGGCAGCGAUAGCAUCUA
  	CGAGAUCAUGAUGCCCAUCUACGAAGUGAUGAACAUGGACC
  	UGGAAACCCGGCGGAGCUUCGCCGUGCAGCAGGGCCAUUAC
  	CAGGACCCCAGAGCCAGCGACUACGACCUGCCUAGAGCCUCC
  	GAUUACGAUCUGCCCAGAAGCCCCUACCCCACCCCUCCACUG
  	CCUCCCAGAUACCAGCUGCAGAACAUGGAUGUGGAAGCCGG
  	CUUUCGCGAGGCCGUGUACGCCUCUUUUGUGGCCGGCAUGU
  	ACAACUACGUCGUGACCCAGCCCCAGGAACGGAUCCCCAAUA
  	GCCAGCAGGUGGAAGGCAUCCUGCGGGACAUGCUGACCAAC
  	GGCGACCAGACCUUCCGGGACCUGAUGAAGCGGUGGAACAG
  	AGAGGUGGACCGCGAGAUGAGCCCUAUCCUCGGCUACUGGA
  	AGAUCAAAGGCCUGGUGCAGCCCACCAGACUGCUGCUGGAA
  	UACCUGGAAGAGAAGUACGAGGAACACCUGUACGAGCGCGA
  	CGAGGGCGAUAAGUGGCGGAACAAGAAGUUCGAGCUGGGCC
  	UCGAGUUCCCCAACCUGCCUUACUACAUCGACGGCGACGUGA
  	AGCUGACCCAGAGCAUGGCCAUCAUCCGGUAUAUCGCCGAC
  	AAGCACAACAUGCUCGGCGGCUGCCCUAAAGAGCGGGCCGA
  	GAUUUCUAUGCUGGAAGGCGCCGUGCUGGACAUCAGAUACG
  	GCGUGUCCAGAAUCGCCUACAGCAAGGACUUCGAAACCCUG
  	AAGGUGGACUUCCUGAGCAAGCUGCCCGAGAUGCUGAAGAU
  	GUUCGAGGACCGGCUGUGCCACAAGACCUACCUGAAUGGCG
  	ACCACGUGACACACCCCGACUUCAUGCUGUACGACGCCCUGG
  	AUGUGGUGCUGUACAUGGACCCCAUGUGCCUGGACGCCUUU
  	CCAAAGCUCGUGUGCUUCAAGAAGCGGAUCGAGGCCAUUCC
  	UCAGAUCGACAAGUACCUGAAGUCCAGCAAGUAUAUCGCUU
  	GGCCCCUGCAAGGCUGGCAGGCCACAUUUGGAGGCGGAGAU
  	CACCCUCCUAAG
  CT875_E_nFC_cHis	AUGGAAACCCCUGCUCAGCUGCUGUUCCUGCUGCUGCUGUG	323
  	GCUGCCUGAUACAACCGGCGAGCCUAAGAGCUGCGACAAGA
  	CCCACACCUGUCCUCCAUGUCCUGCUCCAGAACUGCUCGGCG
  	GACCUUCCGUGUUCCUGUUUCCUCCAAAGCCUAAGGACACCC
  	UGAUGAUCAGCAGAACCCCUGAAGUGACCUGCGUGGUGGUG
  	GAUGUGUCCCACGAGGAUCCCGAAGUGAAGUUCAAUUGGUA
  	CGUGGACGGCGUGGAAGUGCACAACGCCAAGACCAAGCCUA
  	GAGAGGAACAGUACAACAGCACCUACAGAGUGGUGUCCGUG
  	CUGACCGUGCUGCACCAGGAUUGGCUGAACGGCAAAGAGUA
  	CAAGUGCAAGGUGUCCAACAAGGCCCUGCCUGCUCCUAUCG
  	AGAAGACCAUCAGCAAGGCCAAGGGCCAGCCAAGAGAACCC
  	CAGGUGUACACACUGCCUCCAAGCAGAGAUGAGCUGACCAA
  	GAACCAGGUGUCCCUGACCUGUCUGGUCAAGGGCUUCUACC
  	CCUCCGAUAUCGCCGUGGAAUGGGAGAGCAAUGGCCAGCCU
  	GAGAACAACUACAAGACAACCCCUCCUGUGCUGGACAGCGA
  	CGGCUCAUUCUUCCUGUACAGCAAGCUGACAGUGGACAAGA
  	GCAGAUGGCAGCAGGGCAACGUGUUCAGCUGCAGCGUGAUG
  	CACGAGGCCCUGCACAAUCACUACACCCAGAAGUCCCUGUCU
  	CUGAGCCCCGGCAAGAUGAGCAUCAGAGGCGUGGGCGGCAA
  	CGGCAACAGCAGAAUCCCUAGCCACAACGGCGACGGCAGCAA
  	CAGGCGGAGCCAGAACACCAAGGGCAACAACAAGGUGGAAG
  	AUAGAGUGUGCAGCCUGUACAGCAGCCGGUCCAACGAGAAC
  	CGCGAGAGCCCUUAUGCCGUGGUGGACGUGUCCAGCAUGAU
  	CGAGAGCACCCCCACCAGCGGCGAGACAACCAGAGCUAGUAG
  	AGGCGUGCUGAGCCGGUUCCAGAGGGGCCUCGUGCGGAUUG
  	CUGACAAAGUGCGGAGAGCCGUGCAGUGCGCUUGGAGCAGC
  	GUGUCCACAAGCAGAAGCAGCGCCACAAGAGCCGCCGAGAG
  	CGGCAGCUCUAGCAGAACAGCUAGAGGCGCCAGCAGCGGCU
  	ACAGAGAGUACAGCCCUUCUGCCGCUCGGGGCCUGCGGCUG
  	AUGUUCACCGACUUUUGGCGGACCCGGGUGCUGAGACAGAC
  	CUCUCCUAUGGCCGGCGUGUUCGGCAACCUGGACGUGAACG
  	AGGCCAGACUGAUGGCCGCCUACACCAGCGAGUGUGCCGAU
  	CACCUGGAAGCCAAAGAGCUGGCCGGACCUGACGGCGUGGC
  	AGCCGCUAGAGAAAUCGCCAAGAGAUGGGAGAAGAGAGUGC
  	GGGACCUGCAGGACAAGGGCGCUGCCAGAAAGCUGCUGAAC
  	GACCCCCUGGGCAGACGGACCCCCAACUACCAGAGCAAGAAC
  	CCCGGCGAGUACACCGUGGGCAACUCCAUGUUCUACGACGGC
  	CCCCAGGUGGCCAACCUGCAGAAUGUGGAUACCGGCUUCUG
  	GCUGGACAUGAGCAACCUGAGCGACGUGGUGCUGUCCAGAG
  	AGAUCCAGACCGGCCUGAGAGCCAGAGCCACCCUGGAAGAG
  	UCCAUGCCCAUGCUGGAAAAUCUGGAAGAGAGAUUCCGGCG
  	GCUGCAGGAAACCUGCGACGCCGCCAGAACCGAGAUCGAGG
  	AAAGCGGCUGGACCCGGGAAAGCGCCUCCAGAAUGGAAGGC
  	GACGAAGCCCAGGGCCCCAGCAGAGUGCAGCAGGCCUUUCA
  	GAGCUUCGUGAAUGAGUGCAACAGCAUCGAGUUCAGCUUCG
  	GCUCCUUCGGCGAGCACGUGCGGGUGCUGUGUGCCAGAGUG
  	UCAAGAGGACUGGCCGCUGCCGGCGAGGCCAUCAGAAGAUG
  	CUUCAGCUGCUGCAAGGGCAGCACCCACAGAUACGCCCCCAG
  	AGAUGACCUGUCUCCUGAGGGCGCCUCUCUGGCCGAAACCCU
  	GGCCAGAUUCGCCGACGACAUGGGCAUCGAAAGAGGCGCCG
  	ACGGCACCUACGACAUCCCCCUGGUGGACGAUUGGAGAAGG
  	GGCGUGCCAUCCAUCGAGGGCGAGGGCAGCGAUAGCAUCUA
  	CGAGAUCAUGAUGCCCAUCUACGAAGUGAUGAACAUGGACC
  	UGGAAACCCGGCGGAGCUUCGCCGUGCAGCAGGGCCAUUAC
  	CAGGACCCCAGAGCCAGCGACUACGACCUGCCUAGAGCCUCC
  	GAUUACGAUCUGCCCAGAAGCCCCUACCCCACCCCUCCACUG
  	CCUCCCAGAUACCAGCUGCAGAACAUGGAUGUGGAAGCCGG
  	CUUUCGCGAGGCCGUGUACGCCUCUUUUGUGGCCGGCAUGU
  	ACAACUACGUCGUGACCCAGCCCCAGGAACGGAUCCCCAAUA
  	GCCAGCAGGUGGAAGGCAUCCUGCGGGACAUGCUGACCAAC
  	GGCAGCCAGACCUUCCGGGACCUGAUGAAGCGGUGGAACAG
  	AGAGGUGGACCGCGAGCACCACCAUCACCACCAC
  CT875_E_NGM_nFC	AUGGAAACCCCUGCUCAGCUGCUGUUCCUGCUGCUGCUGUG	324
  	GCUGCCUGAUACAACCGGCGAGCCUAAGAGCUGCGACAAGA
  	CCCACACCUGUCCUCCAUGUCCUGCUCCAGAACUGCUCGGCG
  	GACCUUCCGUGUUCCUGUUUCCUCCAAAGCCUAAGGACACCC
  	UGAUGAUCAGCAGAACCCCUGAAGUGACCUGCGUGGUGGUG
  	GAUGUGUCCCACGAGGAUCCCGAAGUGAAGUUCAAUUGGUA
  	CGUGGACGGCGUGGAAGUGCACAACGCCAAGACCAAGCCUA
  	GAGAGGAACAGUACAACAGCACCUACAGAGUGGUGUCCGUG
  	CUGACCGUGCUGCACCAGGAUUGGCUGAACGGCAAAGAGUA
  	CAAGUGCAAGGUGUCCAACAAGGCCCUGCCUGCUCCUAUCG
  	AGAAGACCAUCAGCAAGGCCAAGGGCCAGCCAAGAGAACCC
  	CAGGUGUACACACUGCCUCCAAGCAGAGAUGAGCUGACCAA
  	GAACCAGGUGUCCCUGACCUGUCUGGUCAAGGGCUUCUACC
  	CCUCCGAUAUCGCCGUGGAAUGGGAGAGCAAUGGCCAGCCU
  	GAGAACAACUACAAGACAACCCCUCCUGUGCUGGACAGCGA
  	CGGCUCAUUCUUCCUGUACAGCAAGCUGACAGUGGACAAGA
  	GCAGAUGGCAGCAGGGCAACGUGUUCAGCUGCAGCGUGAUG
  	CACGAGGCCCUGCACAAUCACUACACCCAGAAGUCCCUGUCU
  	CUGAGCCCCGGCAAGAUGAGCAUCAGAGGCGUGGGCGGCAA
  	CGGCAACAGCAGAAUCCCUAGCCACAACGGCGACGGCAGCAA
  	CAGGCGGAGCCAGAACACCAAGGGCAACAACAAGGUGGAAG
  	AUAGAGUGUGCAGCCUGUACAGCAGCCGGUCCAACGAGAAC
  	CGCGAGAGCCCUUAUGCCGUGGUGGACGUGUCCAGCAUGAU
  	CGAGAGCACCCCCACCAGCGGCGAGACAACCAGAGCUAGUAG
  	AGGCGUGCUGAGCCGGUUCCAGAGGGGCCUCGUGCGGAUUG
  	CUGACAAAGUGCGGAGAGCCGUGCAGUGCGCUUGGAGCAGC
  	GUGUCCACAAGCAGAAGCAGCGCCACAAGAGCCGCCGAGAG
  	CGGCAGCUCUAGCAGAACAGCUAGAGGCGCCAGCAGCGGCU
  	ACAGAGAGUACAGCCCUUCUGCCGCUCGGGGCCUGCGGCUG
  	AUGUUCACCGACUUUUGGCGGACCCGGGUGCUGAGACAGAC
  	CUCUCCUAUGGCCGGCGUGUUCGGCAACCUGGACGUGAACG
  	AGGCCAGACUGAUGGCCGCCUACACCAGCGAGUGUGCCGAU
  	CACCUGGAAGCCAAAGAGCUGGCCGGACCUGACGGCGUGGC
  	AGCCGCUAGAGAAAUCGCCAAGAGAUGGGAGAAGAGAGUGC
  	GGGACCUGCAGGACAAGGGCGCUGCCAGAAAGCUGCUGAAC
  	GACCCCCUGGGCAGACGGACCCCCAACUACCAGAGCAAGAAC
  	CCCGGCGAGUACACCGUGGGCAACUCCAUGUUCUACGACGGC
  	CCCCAGGUGGCCAACCUGCAGAAUGUGGAUACCGGCUUCUG
  	GCUGGACAUGCAGCACCUGAGCGACGUGGUGCUGUCCAGAG
  	AGAUCCAGACCGGCCUGAGAGCCAGAGCCACCCUGGAAGAG
  	UCCAUGCCCAUGCUGGAAAAUCUGGAAGAGAGAUUCCGGCG
  	GCUGCAGGAAACCUGCGACGCCGCCAGAACCGAGAUCGAGG
  	AAAGCGGCUGGACCCGGGAAAGCGCCUCCAGAAUGGAAGGC
  	GACGAAGCCCAGGGCCCCAGCAGAGUGCAGCAGGCCUUUCA
  	GAGCUUCGUGAAUGAGUGCAACAGCAUCGAGUUCAGCUUCG
  	GCUCCUUCGGCGAGCACGUGCGGGUGCUGUGUGCCAGAGUG
  	UCAAGAGGACUGGCCGCUGCCGGCGAGGCCAUCAGAAGAUG
  	CUUCAGCUGCUGCAAGGGCAGCACCCACAGAUACGCCCCCAG
  	AGAUGACCUGUCUCCUGAGGGCGCCUCUCUGGCCGAAACCCU
  	GGCCAGAUUCGCCGACGACAUGGGCAUCGAAAGAGGCGCCG
  	ACGGCACCUACGACAUCCCCCUGGUGGACGAUUGGAGAAGG
  	GGCGUGCCAUCCAUCGAGGGCGAGGGCAGCGAUAGCAUCUA
  	CGAGAUCAUGAUGCCCAUCUACGAAGUGAUGAACAUGGACC
  	UGGAAACCCGGCGGAGCUUCGCCGUGCAGCAGGGCCAUUAC
  	CAGGACCCCAGAGCCAGCGACUACGACCUGCCUAGAGCCUCC
  	GAUUACGAUCUGCCCAGAAGCCCCUACCCCACCCCUCCACUG
  	CCUCCCAGAUACCAGCUGCAGAACAUGGAUGUGGAAGCCGG
  	CUUUCGCGAGGCCGUGUACGCCUCUUUUGUGGCCGGCAUGU
  	ACAACUACGUCGUGACCCAGCCCCAGGAACGGAUCCCCAAUA
  	GCCAGCAGGUGGAAGGCAUCCUGCGGGACAUGCUGACCAAC
  	GGCGACCAGACCUUCCGGGACCUGAUGAAGCGGUGGAACAG
  	AGAGGUGGACCGCGAG
  CT875_E_nFC	AUGGAAACCCCUGCUCAGCUGCUGUUCCUGCUGCUGCUGUG	325
  	GCUGCCUGAUACAACCGGCGAGCCUAAGAGCUGCGACAAGA
  	CCCACACCUGUCCUCCAUGUCCUGCUCCAGAACUGCUCGGCG
  	GACCUUCCGUGUUCCUGUUUCCUCCAAAGCCUAAGGACACCC
  	UGAUGAUCAGCAGAACCCCUGAAGUGACCUGCGUGGUGGUG
  	GAUGUGUCCCACGAGGAUCCCGAAGUGAAGUUCAAUUGGUA
  	CGUGGACGGCGUGGAAGUGCACAACGCCAAGACCAAGCCUA
  	GAGAGGAACAGUACAACAGCACCUACAGAGUGGUGUCCGUG
  	CUGACCGUGCUGCACCAGGAUUGGCUGAACGGCAAAGAGUA
  	CAAGUGCAAGGUGUCCAACAAGGCCCUGCCUGCUCCUAUCG
  	AGAAGACCAUCAGCAAGGCCAAGGGCCAGCCAAGAGAACCC
  	CAGGUGUACACACUGCCUCCAAGCAGAGAUGAGCUGACCAA
  	GAACCAGGUGUCCCUGACCUGUCUGGUCAAGGGCUUCUACC
  	CCUCCGAUAUCGCCGUGGAAUGGGAGAGCAAUGGCCAGCCU
  	GAGAACAACUACAAGACAACCCCUCCUGUGCUGGACAGCGA
  	CGGCUCAUUCUUCCUGUACAGCAAGCUGACAGUGGACAAGA
  	GCAGAUGGCAGCAGGGCAACGUGUUCAGCUGCAGCGUGAUG
  	CACGAGGCCCUGCACAAUCACUACACCCAGAAGUCCCUGUCU
  	CUGAGCCCCGGCAAGAUGAGCAUCAGAGGCGUGGGCGGCAA
  	CGGCAACAGCAGAAUCCCUAGCCACAACGGCGACGGCAGCAA
  	CAGGCGGAGCCAGAACACCAAGGGCAACAACAAGGUGGAAG
  	AUAGAGUGUGCAGCCUGUACAGCAGCCGGUCCAACGAGAAC
  	CGCGAGAGCCCUUAUGCCGUGGUGGACGUGUCCAGCAUGAU
  	CGAGAGCACCCCCACCAGCGGCGAGACAACCAGAGCUAGUAG
  	AGGCGUGCUGAGCCGGUUCCAGAGGGGCCUCGUGCGGAUUG
  	CUGACAAAGUGCGGAGAGCCGUGCAGUGCGCUUGGAGCAGC
  	GUGUCCACAAGCAGAAGCAGCGCCACAAGAGCCGCCGAGAG
  	CGGCAGCUCUAGCAGAACAGCUAGAGGCGCCAGCAGCGGCU
  	ACAGAGAGUACAGCCCUUCUGCCGCUCGGGGCCUGCGGCUG
  	AUGUUCACCGACUUUUGGCGGACCCGGGUGCUGAGACAGAC
  	CUCUCCUAUGGCCGGCGUGUUCGGCAACCUGGACGUGAACG
  	AGGCCAGACUGAUGGCCGCCUACACCAGCGAGUGUGCCGAU
  	CACCUGGAAGCCAAAGAGCUGGCCGGACCUGACGGCGUGGC
  	AGCCGCUAGAGAAAUCGCCAAGAGAUGGGAGAAGAGAGUGC
  	GGGACCUGCAGGACAAGGGCGCUGCCAGAAAGCUGCUGAAC
  	GACCCCCUGGGCAGACGGACCCCCAACUACCAGAGCAAGAAC
  	CCCGGCGAGUACACCGUGGGCAACUCCAUGUUCUACGACGGC
  	CCCCAGGUGGCCAACCUGCAGAAUGUGGAUACCGGCUUCUG
  	GCUGGACAUGAGCAACCUGAGCGACGUGGUGCUGUCCAGAG
  	AGAUCCAGACCGGCCUGAGAGCCAGAGCCACCCUGGAAGAG
  	UCCAUGCCCAUGCUGGAAAAUCUGGAAGAGAGAUUCCGGCG
  	GCUGCAGGAAACCUGCGACGCCGCCAGAACCGAGAUCGAGG
  	AAAGCGGCUGGACCCGGGAAAGCGCCUCCAGAAUGGAAGGC
  	GACGAAGCCCAGGGCCCCAGCAGAGUGCAGCAGGCCUUUCA
  	GAGCUUCGUGAAUGAGUGCAACAGCAUCGAGUUCAGCUUCG
  	GCUCCUUCGGCGAGCACGUGCGGGUGCUGUGUGCCAGAGUG
  	UCAAGAGGACUGGCCGCUGCCGGCGAGGCCAUCAGAAGAUG
  	CUUCAGCUGCUGCAAGGGCAGCACCCACAGAUACGCCCCCAG
  	AGAUGACCUGUCUCCUGAGGGCGCCUCUCUGGCCGAAACCCU
  	GGCCAGAUUCGCCGACGACAUGGGCAUCGAAAGAGGCGCCG
  	ACGGCACCUACGACAUCCCCCUGGUGGACGAUUGGAGAAGG
  	GGCGUGCCAUCCAUCGAGGGCGAGGGCAGCGAUAGCAUCUA
  	CGAGAUCAUGAUGCCCAUCUACGAAGUGAUGAACAUGGACC
  	UGGAAACCCGGCGGAGCUUCGCCGUGCAGCAGGGCCAUUAC
  	CAGGACCCCAGAGCCAGCGACUACGACCUGCCUAGAGCCUCC
  	GAUUACGAUCUGCCCAGAAGCCCCUACCCCACCCCUCCACUG
  	CCUCCCAGAUACCAGCUGCAGAACAUGGAUGUGGAAGCCGG
  	CUUUCGCGAGGCCGUGUACGCCUCUUUUGUGGCCGGCAUGU
  	ACAACUACGUCGUGACCCAGCCCCAGGAACGGAUCCCCAAUA
  	GCCAGCAGGUGGAAGGCAUCCUGCGGGACAUGCUGACCAAC
  	GGCAGCCAGACCUUCCGGGACCUGAUGAAGCGGUGGAACAG
  	AGAGGUGGACCGCGAG
  CT875_E_NGM_nIgK_nGst_cHis	AUGGAAACCCCUGCCCAGCUGCUGUUCCUGCUGCUGCUGUG	326
  	GCUGCCUGACACCACCGGCAUGAGCCCUAUCCUCGGCUACUG
  	GAAGAUCAAAGGCCUGGUGCAGCCCACCAGACUGCUGCUGG
  	AAUACCUGGAAGAGAAGUACGAGGAACACCUGUACGAGCGC
  	GACGAGGGCGAUAAGUGGCGGAACAAGAAGUUCGAGCUGGG
  	CCUCGAGUUCCCCAACCUGCCUUACUACAUCGACGGCGACGU
  	GAAGCUGACCCAGAGCAUGGCCAUCAUCCGGUAUAUCGCCG
  	ACAAGCACAACAUGCUCGGCGGCUGCCCUAAAGAGCGGGCC
  	GAGAUUUCUAUGCUGGAAGGCGCCGUGCUGGACAUCAGAUA
  	CGGCGUGUCCAGAAUCGCCUACAGCAAGGACUUCGAAACCC
  	UGAAGGUGGACUUCCUGAGCAAGCUGCCCGAGAUGCUGAAG
  	AUGUUCGAGGACCGGCUGUGCCACAAGACCUACCUGAAUGG
  	CGACCACGUGACACACCCCGACUUCAUGCUGUACGACGCCCU
  	GGAUGUGGUGCUGUACAUGGACCCCAUGUGCCUGGACGCCU
  	UUCCAAAGCUCGUGUGCUUCAAGAAGCGGAUCGAGGCCAUU
  	CCUCAGAUCGACAAGUACCUGAAGUCCAGCAAGUAUAUCGC
  	UUGGCCCCUGCAAGGCUGGCAGGCCACAUUUGGAGGCGGAG
  	AUCACCCUCCUAAGAUGAGCAUCAGAGGCGUGGGCGGCAAC
  	GGCAACAGCAGAAUCCCUAGCCACAACGGCGACGGCAGCAAC
  	AGGCGGAGCCAGAACACCAAGGGCAACAACAAGGUGGAAGA
  	UAGAGUGUGCAGCCUGUACAGCAGCCGGUCCAACGAGAACC
  	GCGAGAGCCCUUAUGCCGUGGUGGACGUGUCCAGCAUGAUC
  	GAGAGCACCCCCACCAGCGGCGAGACAACCAGAGCUAGUAG
  	AGGCGUGCUGAGCCGGUUCCAGAGGGGCCUCGUGCGGAUUG
  	CUGACAAAGUGCGGAGAGCCGUGCAGUGCGCUUGGAGCAGC
  	GUGUCCACAAGCAGAAGCAGCGCCACAAGAGCCGCCGAGAG
  	CGGCAGCUCUAGCAGAACAGCUAGAGGCGCCAGCAGCGGCU
  	ACAGAGAGUACAGCCCUUCUGCCGCUCGGGGCCUGCGGCUG
  	AUGUUCACCGACUUUUGGCGGACCCGGGUGCUGAGACAGAC
  	CUCUCCUAUGGCCGGCGUGUUCGGCAACCUGGACGUGAACG
  	AGGCCAGACUGAUGGCCGCCUACACCAGCGAGUGUGCCGAU
  	CACCUGGAAGCCAAAGAGCUGGCCGGACCUGACGGCGUGGC
  	AGCCGCUAGAGAAAUCGCCAAGAGAUGGGAGAAGAGAGUGC
  	GGGACCUGCAGGACAAGGGCGCUGCCAGAAAGCUGCUGAAC
  	GACCCCCUGGGCAGACGGACCCCCAACUACCAGAGCAAGAAC
  	CCCGGCGAGUACACCGUGGGCAACUCCAUGUUCUACGACGGC
  	CCCCAGGUGGCCAACCUGCAGAAUGUGGAUACCGGCUUCUG
  	GCUGGACAUGCAGCACCUGAGCGACGUGGUGCUGUCCAGAG
  	AGAUCCAGACCGGCCUGAGAGCCAGAGCCACCCUGGAAGAG
  	UCCAUGCCCAUGCUGGAAAAUCUGGAAGAGAGAUUCCGGCG
  	GCUGCAGGAAACCUGCGACGCCGCCAGAACCGAGAUCGAGG
  	AAAGCGGCUGGACCCGGGAAAGCGCCUCCAGAAUGGAAGGC
  	GACGAAGCCCAGGGCCCCAGCAGAGUGCAGCAGGCCUUUCA
  	GAGCUUCGUGAAUGAGUGCAACAGCAUCGAGUUCAGCUUCG
  	GCUCCUUCGGCGAGCACGUGCGGGUGCUGUGUGCCAGAGUG
  	UCAAGAGGACUGGCCGCUGCCGGCGAGGCCAUCAGAAGAUG
  	CUUCAGCUGCUGCAAGGGCAGCACCCACAGAUACGCCCCCAG
  	AGAUGACCUGUCUCCUGAGGGCGCCUCUCUGGCCGAAACCCU
  	GGCCAGAUUCGCCGACGACAUGGGCAUCGAAAGAGGCGCCG
  	ACGGCACCUACGACAUCCCCCUGGUGGACGAUUGGAGAAGG
  	GGCGUGCCAUCCAUCGAGGGCGAGGGCAGCGAUAGCAUCUA
  	CGAGAUCAUGAUGCCCAUCUACGAAGUGAUGAACAUGGACC
  	UGGAAACCCGGCGGAGCUUCGCCGUGCAGCAGGGCCAUUAC
  	CAGGACCCCAGAGCCAGCGACUACGACCUGCCUAGAGCCUCC
  	GAUUACGAUCUGCCCAGAAGCCCCUACCCCACCCCUCCACUG
  	CCUCCCAGAUACCAGCUGCAGAACAUGGAUGUGGAAGCCGG
  	CUUUCGCGAGGCCGUGUACGCCUCUUUUGUGGCCGGCAUGU
  	ACAACUACGUCGUGACCCAGCCCCAGGAACGGAUCCCCAAUA
  	GCCAGCAGGUGGAAGGCAUCCUGCGGGACAUGCUGACCAAC
  	GGCGACCAGACCUUCCGGGACCUGAUGAAGCGGUGGAACAG
  	AGAGGUGGACCGCGAGCACCACCAUCACCACCAC
  CT875_E_nIgK_nGst_cHis	AUGGAAACCCCUGCCCAGCUGCUGUUCCUGCUGCUGCUGUG	327
  	GCUGCCUGACACCACCGGCAUGAGCCCUAUCCUCGGCUACUG
  	GAAGAUCAAAGGCCUGGUGCAGCCCACCAGACUGCUGCUGG
  	AAUACCUGGAAGAGAAGUACGAGGAACACCUGUACGAGCGC
  	GACGAGGGCGAUAAGUGGCGGAACAAGAAGUUCGAGCUGGG
  	CCUCGAGUUCCCCAACCUGCCUUACUACAUCGACGGCGACGU
  	GAAGCUGACCCAGAGCAUGGCCAUCAUCCGGUAUAUCGCCG
  	ACAAGCACAACAUGCUCGGCGGCUGCCCUAAAGAGCGGGCC
  	GAGAUUUCUAUGCUGGAAGGCGCCGUGCUGGACAUCAGAUA
  	CGGCGUGUCCAGAAUCGCCUACAGCAAGGACUUCGAAACCC
  	UGAAGGUGGACUUCCUGAGCAAGCUGCCCGAGAUGCUGAAG
  	AUGUUCGAGGACCGGCUGUGCCACAAGACCUACCUGAAUGG
  	CGACCACGUGACACACCCCGACUUCAUGCUGUACGACGCCCU
  	GGAUGUGGUGCUGUACAUGGACCCCAUGUGCCUGGACGCCU
  	UUCCAAAGCUCGUGUGCUUCAAGAAGCGGAUCGAGGCCAUU
  	CCUCAGAUCGACAAGUACCUGAAGUCCAGCAAGUAUAUCGC
  	UUGGCCCCUGCAAGGCUGGCAGGCCACAUUUGGAGGCGGAG
  	AUCACCCUCCUAAGAUGAGCAUCAGAGGCGUGGGCGGCAAC
  	GGCAACAGCAGAAUCCCUAGCCACAACGGCGACGGCAGCAAC
  	AGGCGGAGCCAGAACACCAAGGGCAACAACAAGGUGGAAGA
  	UAGAGUGUGCAGCCUGUACAGCAGCCGGUCCAACGAGAACC
  	GCGAGAGCCCUUAUGCCGUGGUGGACGUGUCCAGCAUGAUC
  	GAGAGCACCCCCACCAGCGGCGAGACAACCAGAGCUAGUAG
  	AGGCGUGCUGAGCCGGUUCCAGAGGGGCCUCGUGCGGAUUG
  	CUGACAAAGUGCGGAGAGCCGUGCAGUGCGCUUGGAGCAGC
  	GUGUCCACAAGCAGAAGCAGCGCCACAAGAGCCGCCGAGAG
  	CGGCAGCUCUAGCAGAACAGCUAGAGGCGCCAGCAGCGGCU
  	ACAGAGAGUACAGCCCUUCUGCCGCUCGGGGCCUGCGGCUG
  	AUGUUCACCGACUUUUGGCGGACCCGGGUGCUGAGACAGAC
  	CUCUCCUAUGGCCGGCGUGUUCGGCAACCUGGACGUGAACG
  	AGGCCAGACUGAUGGCCGCCUACACCAGCGAGUGUGCCGAU
  	CACCUGGAAGCCAAAGAGCUGGCCGGACCUGACGGCGUGGC
  	AGCCGCUAGAGAAAUCGCCAAGAGAUGGGAGAAGAGAGUGC
  	GGGACCUGCAGGACAAGGGCGCUGCCAGAAAGCUGCUGAAC
  	GACCCCCUGGGCAGACGGACCCCCAACUACCAGAGCAAGAAC
  	CCCGGCGAGUACACCGUGGGCAACUCCAUGUUCUACGACGGC
  	CCCCAGGUGGCCAACCUGCAGAAUGUGGAUACCGGCUUCUG
  	GCUGGACAUGAGCAACCUGAGCGACGUGGUGCUGUCCAGAG
  	AGAUCCAGACCGGCCUGAGAGCCAGAGCCACCCUGGAAGAG
  	UCCAUGCCCAUGCUGGAAAAUCUGGAAGAGAGAUUCCGGCG
  	GCUGCAGGAAACCUGCGACGCCGCCAGAACCGAGAUCGAGG
  	AAAGCGGCUGGACCCGGGAAAGCGCCUCCAGAAUGGAAGGC
  	GACGAAGCCCAGGGCCCCAGCAGAGUGCAGCAGGCCUUUCA
  	GAGCUUCGUGAAUGAGUGCAACAGCAUCGAGUUCAGCUUCG
  	GCUCCUUCGGCGAGCACGUGCGGGUGCUGUGUGCCAGAGUG
  	UCAAGAGGACUGGCCGCUGCCGGCGAGGCCAUCAGAAGAUG
  	CUUCAGCUGCUGCAAGGGCAGCACCCACAGAUACGCCCCCAG
  	AGAUGACCUGUCUCCUGAGGGCGCCUCUCUGGCCGAAACCCU
  	GGCCAGAUUCGCCGACGACAUGGGCAUCGAAAGAGGCGCCG
  	ACGGCACCUACGACAUCCCCCUGGUGGACGAUUGGAGAAGG
  	GGCGUGCCAUCCAUCGAGGGCGAGGGCAGCGAUAGCAUCUA
  	CGAGAUCAUGAUGCCCAUCUACGAAGUGAUGAACAUGGACC
  	UGGAAACCCGGCGGAGCUUCGCCGUGCAGCAGGGCCAUUAC
  	CAGGACCCCAGAGCCAGCGACUACGACCUGCCUAGAGCCUCC
  	GAUUACGAUCUGCCCAGAAGCCCCUACCCCACCCCUCCACUG
  	CCUCCCAGAUACCAGCUGCAGAACAUGGAUGUGGAAGCCGG
  	CUUUCGCGAGGCCGUGUACGCCUCUUUUGUGGCCGGCAUGU
  	ACAACUACGUCGUGACCCAGCCCCAGGAACGGAUCCCCAAUA
  	GCCAGCAGGUGGAAGGCAUCCUGCGGGACAUGCUGACCAAC
  	GGCAGCCAGACCUUCCGGGACCUGAUGAAGCGGUGGAACAG
  	AGAGGUGGACCGCGAGCACCACCAUCACCACCAC
  CT875_E_NGM_nIgK_nGst	AUGGAAACCCCUGCCCAGCUGCUGUUCCUGCUGCUGCUGUG	328
  	GCUGCCUGACACCACCGGCAUGAGCCCUAUCCUCGGCUACUG
  	GAAGAUCAAAGGCCUGGUGCAGCCCACCAGACUGCUGCUGG
  	AAUACCUGGAAGAGAAGUACGAGGAACACCUGUACGAGCGC
  	GACGAGGGCGAUAAGUGGCGGAACAAGAAGUUCGAGCUGGG
  	CCUCGAGUUCCCCAACCUGCCUUACUACAUCGACGGCGACGU
  	GAAGCUGACCCAGAGCAUGGCCAUCAUCCGGUAUAUCGCCG
  	ACAAGCACAACAUGCUCGGCGGCUGCCCUAAAGAGCGGGCC
  	GAGAUUUCUAUGCUGGAAGGCGCCGUGCUGGACAUCAGAUA
  	CGGCGUGUCCAGAAUCGCCUACAGCAAGGACUUCGAAACCC
  	UGAAGGUGGACUUCCUGAGCAAGCUGCCCGAGAUGCUGAAG
  	AUGUUCGAGGACCGGCUGUGCCACAAGACCUACCUGAAUGG
  	CGACCACGUGACACACCCCGACUUCAUGCUGUACGACGCCCU
  	GGAUGUGGUGCUGUACAUGGACCCCAUGUGCCUGGACGCCU
  	UUCCAAAGCUCGUGUGCUUCAAGAAGCGGAUCGAGGCCAUU
  	CCUCAGAUCGACAAGUACCUGAAGUCCAGCAAGUAUAUCGC
  	UUGGCCCCUGCAAGGCUGGCAGGCCACAUUUGGAGGCGGAG
  	AUCACCCUCCUAAGAUGAGCAUCAGAGGCGUGGGCGGCAAC
  	GGCAACAGCAGAAUCCCUAGCCACAACGGCGACGGCAGCAAC
  	AGGCGGAGCCAGAACACCAAGGGCAACAACAAGGUGGAAGA
  	UAGAGUGUGCAGCCUGUACAGCAGCCGGUCCAACGAGAACC
  	GCGAGAGCCCUUAUGCCGUGGUGGACGUGUCCAGCAUGAUC
  	GAGAGCACCCCCACCAGCGGCGAGACAACCAGAGCUAGUAG
  	AGGCGUGCUGAGCCGGUUCCAGAGGGGCCUCGUGCGGAUUG
  	CUGACAAAGUGCGGAGAGCCGUGCAGUGCGCUUGGAGCAGC
  	GUGUCCACAAGCAGAAGCAGCGCCACAAGAGCCGCCGAGAG
  	CGGCAGCUCUAGCAGAACAGCUAGAGGCGCCAGCAGCGGCU
  	ACAGAGAGUACAGCCCUUCUGCCGCUCGGGGCCUGCGGCUG
  	AUGUUCACCGACUUUUGGCGGACCCGGGUGCUGAGACAGAC
  	CUCUCCUAUGGCCGGCGUGUUCGGCAACCUGGACGUGAACG
  	AGGCCAGACUGAUGGCCGCCUACACCAGCGAGUGUGCCGAU
  	CACCUGGAAGCCAAAGAGCUGGCCGGACCUGACGGCGUGGC
  	AGCCGCUAGAGAAAUCGCCAAGAGAUGGGAGAAGAGAGUGC
  	GGGACCUGCAGGACAAGGGCGCUGCCAGAAAGCUGCUGAAC
  	GACCCCCUGGGCAGACGGACCCCCAACUACCAGAGCAAGAAC
  	CCCGGCGAGUACACCGUGGGCAACUCCAUGUUCUACGACGGC
  	CCCCAGGUGGCCAACCUGCAGAAUGUGGAUACCGGCUUCUG
  	GCUGGACAUGCAGCACCUGAGCGACGUGGUGCUGUCCAGAG
  	AGAUCCAGACCGGCCUGAGAGCCAGAGCCACCCUGGAAGAG
  	UCCAUGCCCAUGCUGGAAAAUCUGGAAGAGAGAUUCCGGCG
  	GCUGCAGGAAACCUGCGACGCCGCCAGAACCGAGAUCGAGG
  	AAAGCGGCUGGACCCGGGAAAGCGCCUCCAGAAUGGAAGGC
  	GACGAAGCCCAGGGCCCCAGCAGAGUGCAGCAGGCCUUUCA
  	GAGCUUCGUGAAUGAGUGCAACAGCAUCGAGUUCAGCUUCG
  	GCUCCUUCGGCGAGCACGUGCGGGUGCUGUGUGCCAGAGUG
  	UCAAGAGGACUGGCCGCUGCCGGCGAGGCCAUCAGAAGAUG
  	CUUCAGCUGCUGCAAGGGCAGCACCCACAGAUACGCCCCCAG
  	AGAUGACCUGUCUCCUGAGGGCGCCUCUCUGGCCGAAACCCU
  	GGCCAGAUUCGCCGACGACAUGGGCAUCGAAAGAGGCGCCG
  	ACGGCACCUACGACAUCCCCCUGGUGGACGAUUGGAGAAGG
  	GGCGUGCCAUCCAUCGAGGGCGAGGGCAGCGAUAGCAUCUA
  	CGAGAUCAUGAUGCCCAUCUACGAAGUGAUGAACAUGGACC
  	UGGAAACCCGGCGGAGCUUCGCCGUGCAGCAGGGCCAUUAC
  	CAGGACCCCAGAGCCAGCGACUACGACCUGCCUAGAGCCUCC
  	GAUUACGAUCUGCCCAGAAGCCCCUACCCCACCCCUCCACUG
  	CCUCCCAGAUACCAGCUGCAGAACAUGGAUGUGGAAGCCGG
  	CUUUCGCGAGGCCGUGUACGCCUCUUUUGUGGCCGGCAUGU
  	ACAACUACGUCGUGACCCAGCCCCAGGAACGGAUCCCCAAUA
  	GCCAGCAGGUGGAAGGCAUCCUGCGGGACAUGCUGACCAAC
  	GGCGACCAGACCUUCCGGGACCUGAUGAAGCGGUGGAACAG
  	AGAGGUGGACCGCGAG
  CT875_E_nIgK_nGst	AUGGAAACCCCUGCCCAGCUGCUGUUCCUGCUGCUGCUGUG	329
  	GCUGCCUGACACCACCGGCAUGAGCCCUAUCCUCGGCUACUG
  	GAAGAUCAAAGGCCUGGUGCAGCCCACCAGACUGCUGCUGG
  	AAUACCUGGAAGAGAAGUACGAGGAACACCUGUACGAGCGC
  	GACGAGGGCGAUAAGUGGCGGAACAAGAAGUUCGAGCUGGG
  	CCUCGAGUUCCCCAACCUGCCUUACUACAUCGACGGCGACGU
  	GAAGCUGACCCAGAGCAUGGCCAUCAUCCGGUAUAUCGCCG
  	ACAAGCACAACAUGCUCGGCGGCUGCCCUAAAGAGCGGGCC
  	GAGAUUUCUAUGCUGGAAGGCGCCGUGCUGGACAUCAGAUA
  	CGGCGUGUCCAGAAUCGCCUACAGCAAGGACUUCGAAACCC
  	UGAAGGUGGACUUCCUGAGCAAGCUGCCCGAGAUGCUGAAG
  	AUGUUCGAGGACCGGCUGUGCCACAAGACCUACCUGAAUGG
  	CGACCACGUGACACACCCCGACUUCAUGCUGUACGACGCCCU
  	GGAUGUGGUGCUGUACAUGGACCCCAUGUGCCUGGACGCCU
  	UUCCAAAGCUCGUGUGCUUCAAGAAGCGGAUCGAGGCCAUU
  	CCUCAGAUCGACAAGUACCUGAAGUCCAGCAAGUAUAUCGC
  	UUGGCCCCUGCAAGGCUGGCAGGCCACAUUUGGAGGCGGAG
  	AUCACCCUCCUAAGAUGAGCAUCAGAGGCGUGGGCGGCAAC
  	GGCAACAGCAGAAUCCCUAGCCACAACGGCGACGGCAGCAAC
  	AGGCGGAGCCAGAACACCAAGGGCAACAACAAGGUGGAAGA
  	UAGAGUGUGCAGCCUGUACAGCAGCCGGUCCAACGAGAACC
  	GCGAGAGCCCUUAUGCCGUGGUGGACGUGUCCAGCAUGAUC
  	GAGAGCACCCCCACCAGCGGCGAGACAACCAGAGCUAGUAG
  	AGGCGUGCUGAGCCGGUUCCAGAGGGGCCUCGUGCGGAUUG
  	CUGACAAAGUGCGGAGAGCCGUGCAGUGCGCUUGGAGCAGC
  	GUGUCCACAAGCAGAAGCAGCGCCACAAGAGCCGCCGAGAG
  	CGGCAGCUCUAGCAGAACAGCUAGAGGCGCCAGCAGCGGCU
  	ACAGAGAGUACAGCCCUUCUGCCGCUCGGGGCCUGCGGCUG
  	AUGUUCACCGACUUUUGGCGGACCCGGGUGCUGAGACAGAC
  	CUCUCCUAUGGCCGGCGUGUUCGGCAACCUGGACGUGAACG
  	AGGCCAGACUGAUGGCCGCCUACACCAGCGAGUGUGCCGAU
  	CACCUGGAAGCCAAAGAGCUGGCCGGACCUGACGGCGUGGC
  	AGCCGCUAGAGAAAUCGCCAAGAGAUGGGAGAAGAGAGUGC
  	GGGACCUGCAGGACAAGGGCGCUGCCAGAAAGCUGCUGAAC
  	GACCCCCUGGGCAGACGGACCCCCAACUACCAGAGCAAGAAC
  	CCCGGCGAGUACACCGUGGGCAACUCCAUGUUCUACGACGGC
  	CCCCAGGUGGCCAACCUGCAGAAUGUGGAUACCGGCUUCUG
  	GCUGGACAUGAGCAACCUGAGCGACGUGGUGCUGUCCAGAG
  	AGAUCCAGACCGGCCUGAGAGCCAGAGCCACCCUGGAAGAG
  	UCCAUGCCCAUGCUGGAAAAUCUGGAAGAGAGAUUCCGGCG
  	GCUGCAGGAAACCUGCGACGCCGCCAGAACCGAGAUCGAGG
  	AAAGCGGCUGGACCCGGGAAAGCGCCUCCAGAAUGGAAGGC
  	GACGAAGCCCAGGGCCCCAGCAGAGUGCAGCAGGCCUUUCA
  	GAGCUUCGUGAAUGAGUGCAACAGCAUCGAGUUCAGCUUCG
  	GCUCCUUCGGCGAGCACGUGCGGGUGCUGUGUGCCAGAGUG
  	UCAAGAGGACUGGCCGCUGCCGGCGAGGCCAUCAGAAGAUG
  	CUUCAGCUGCUGCAAGGGCAGCACCCACAGAUACGCCCCCAG
  	AGAUGACCUGUCUCCUGAGGGCGCCUCUCUGGCCGAAACCCU
  	GGCCAGAUUCGCCGACGACAUGGGCAUCGAAAGAGGCGCCG
  	ACGGCACCUACGACAUCCCCCUGGUGGACGAUUGGAGAAGG
  	GGCGUGCCAUCCAUCGAGGGCGAGGGCAGCGAUAGCAUCUA
  	CGAGAUCAUGAUGCCCAUCUACGAAGUGAUGAACAUGGACC
  	UGGAAACCCGGCGGAGCUUCGCCGUGCAGCAGGGCCAUUAC
  	CAGGACCCCAGAGCCAGCGACUACGACCUGCCUAGAGCCUCC
  	GAUUACGAUCUGCCCAGAAGCCCCUACCCCACCCCUCCACUG
  	CCUCCCAGAUACCAGCUGCAGAACAUGGAUGUGGAAGCCGG
  	CUUUCGCGAGGCCGUGUACGCCUCUUUUGUGGCCGGCAUGU
  	ACAACUACGUCGUGACCCAGCCCCAGGAACGGAUCCCCAAUA
  	GCCAGCAGGUGGAAGGCAUCCUGCGGGACAUGCUGACCAAC
  	GGCAGCCAGACCUUCCGGGACCUGAUGAAGCGGUGGAACAG
  	AGAGGUGGACCGCGAG
  CT875_E_574_NGM_nIgK_cHis	AUGGAAACCCCUGCCCAGCUGCUGUUCCUGCUGCUGCUGUG	330
  	GCUGCCUGACACCACCGGCAUGAGCAUCAGAGGCGUGGGCG
  	GCAACGGCAACAGCAGAAUCCCUAGCCACAACGGCGACGGCA
  	GCAACAGGCGGAGCCAGAACACCAAGGGCAACAACAAGGUG
  	GAAGAUAGAGUGUGCAGCCUGUACAGCAGCCGGUCCAACGA
  	GAACCGCGAGAGCCCUUAUGCCGUGGUGGACGUGUCCAGCA
  	UGAUCGAGAGCACCCCCACCAGCGGCGAGACAACCAGAGCUA
  	GUAGAGGCGUGCUGAGCCGGUUCCAGAGGGGCCUCGUGCGG
  	AUUGCUGACAAAGUGCGGAGAGCCGUGCAGUGCGCUUGGAG
  	CAGCGUGUCCACAAGCAGAAGCAGCGCCACAAGAGCCGCCGA
  	GAGCGGCAGCUCUAGCAGAACAGCUAGAGGCGCCAGCAGCG
  	GCUACAGAGAGUACAGCCCUUCUGCCGCUCGGGGCCUGCGGC
  	UGAUGUUCACCGACUUUUGGCGGACCCGGGUGCUGAGACAG
  	ACCUCUCCUAUGGCCGGCGUGUUCGGCAACCUGGACGUGAA
  	CGAGGCCAGACUGAUGGCCGCCUACACCAGCGAGUGUGCCG
  	AUCACCUGGAAGCCAAAGAGCUGGCCGGACCUGACGGCGUG
  	GCAGCCGCUAGAGAAAUCGCCAAGAGAUGGGAGAAGAGAGU
  	GCGGGACCUGCAGGACAAGGGCGCUGCCAGAAAGCUGCUGA
  	ACGACCCCCUGGGCAGACGGACCCCCAACUACCAGAGCAAGA
  	ACCCCGGCGAGUACACCGUGGGCAACUCCAUGUUCUACGACG
  	GCCCCCAGGUGGCCAACCUGCAGAAUGUGGAUACCGGCUUC
  	UGGCUGGACAUGCAGCACCUGAGCGACGUGGUGCUGUCCAG
  	AGAGAUCCAGACCGGCCUGAGAGCCAGAGCCACCCUGGAAG
  	AGUCCAUGCCCAUGCUGGAAAAUCUGGAAGAGAGAUUCCGG
  	CGGCUGCAGGAAACCUGCGACGCCGCCAGAACCGAGAUCGA
  	GGAAAGCGGCUGGACCCGGGAAAGCGCCUCCAGAAUGGAAG
  	GCGACGAAGCCCAGGGCCCCAGCAGAGUGCAGCAGGCCUUUC
  	AGAGCUUCGUGAAUGAGUGCAACAGCAUCGAGUUCAGCUUC
  	GGCUCCUUCGGCGAGCACGUGCGGGUGCUGUGUGCCAGAGU
  	GUCAAGAGGACUGGCCGCUGCCGGCGAGGCCAUCAGAAGAU
  	GCUUCAGCUGCUGCAAGGGCAGCACCCACAGAUACGCCCCCA
  	GAGAUGACCUGUCUCCUGAGGGCGCCUCUCUGGCCGAAACCC
  	UGGCCAGAUUCGCCGACGACAUGGGCAUCGAAAGAGGCGCC
  	GACGGCACCUACGACAUCCCCCUGGUGGACGAUUGGAGAAG
  	GGGCGUGCCAUCCAUCGAGGGCGAGGGCAGCGAUAGCAUCU
  	ACGAGAUCAUGAUGCCCAUCUACGAAGUGAUGAACAUGGAC
  	CUGGAAACCCGGCGGAGCUUCGCCGUGCAGCAGGGCCAUUA
  	CCAGGACCCCAGAGCCAGCGACUACGACCUGCCUAGAGCCUC
  	CGAUUACGAUCUGCCCAGAAGCCCCUACCCCACCCCUCCACU
  	GCCUCCCAGAUACCAGCUGCAGAACAUGGAUGUGGAAGCCG
  	GCUUUCGCGAGGCCGUGUACGCCUCUUUUGUGGCCGGCAUG
  	UACAACUACGUCGUGACCCAGCCCCAGGAACGGAUCCCCAAU
  	AGCCAGCAGGUGGAAGGCAUCCUGCGGGACAUGCUGACCAA
  	CGGCGACCACCACCAUCACCACCAC
  CT875_E_458_NGM_nIgK_cHis	AUGGAAACCCCUGCCCAGCUGCUGUUCCUGCUGCUGCUGUG	331
  	GCUGCCUGACACCACCGGCAUGAGCAUCAGAGGCGUGGGCG
  	GCAACGGCAACAGCAGAAUCCCUAGCCACAACGGCGACGGCA
  	GCAACAGGCGGAGCCAGAACACCAAGGGCAACAACAAGGUG
  	GAAGAUAGAGUGUGCAGCCUGUACAGCAGCCGGUCCAACGA
  	GAACCGCGAGAGCCCUUAUGCCGUGGUGGACGUGUCCAGCA
  	UGAUCGAGAGCACCCCCACCAGCGGCGAGACAACCAGAGCUA
  	GUAGAGGCGUGCUGAGCCGGUUCCAGAGGGGCCUCGUGCGG
  	AUUGCUGACAAAGUGCGGAGAGCCGUGCAGUGCGCUUGGAG
  	CAGCGUGUCCACAAGCAGAAGCAGCGCCACAAGAGCCGCCGA
  	GAGCGGCAGCUCUAGCAGAACAGCUAGAGGCGCCAGCAGCG
  	GCUACAGAGAGUACAGCCCUUCUGCCGCUCGGGGCCUGCGGC
  	UGAUGUUCACCGACUUUUGGCGGACCCGGGUGCUGAGACAG
  	ACCUCUCCUAUGGCCGGCGUGUUCGGCAACCUGGACGUGAA
  	CGAGGCCAGACUGAUGGCCGCCUACACCAGCGAGUGUGCCG
  	AUCACCUGGAAGCCAAAGAGCUGGCCGGACCUGACGGCGUG
  	GCAGCCGCUAGAGAAAUCGCCAAGAGAUGGGAGAAGAGAGU
  	GCGGGACCUGCAGGACAAGGGCGCUGCCAGAAAGCUGCUGA
  	ACGACCCCCUGGGCAGACGGACCCCCAACUACCAGAGCAAGA
  	ACCCCGGCGAGUACACCGUGGGCAACUCCAUGUUCUACGACG
  	GCCCCCAGGUGGCCAACCUGCAGAAUGUGGAUACCGGCUUC
  	UGGCUGGACAUGCAGCACCUGAGCGACGUGGUGCUGUCCAG
  	AGAGAUCCAGACCGGCCUGAGAGCCAGAGCCACCCUGGAAG
  	AGUCCAUGCCCAUGCUGGAAAAUCUGGAAGAGAGAUUCCGG
  	CGGCUGCAGGAAACCUGCGACGCCGCCAGAACCGAGAUCGA
  	GGAAAGCGGCUGGACCCGGGAAAGCGCCUCCAGAAUGGAAG
  	GCGACGAAGCCCAGGGCCCCAGCAGAGUGCAGCAGGCCUUUC
  	AGAGCUUCGUGAAUGAGUGCAACAGCAUCGAGUUCAGCUUC
  	GGCUCCUUCGGCGAGCACGUGCGGGUGCUGUGUGCCAGAGU
  	GUCAAGAGGACUGGCCGCUGCCGGCGAGGCCAUCAGAAGAU
  	GCUUCAGCUGCUGCAAGGGCAGCACCCACAGAUACGCCCCCA
  	GAGAUGACCUGUCUCCUGAGGGCGCCUCUCUGGCCGAAACCC
  	UGGCCAGAUUCGCCGACGACAUGGGCAUCGAAAGAGGCGCC
  	GACGGCACCUACGACAUCCCCCUGGUGGACGAUUGGAGAAG
  	GGGCGUGCCAUCCAUCGAGGGCGAGGGCAGCCACCACCAUCA
  	CCACCAC
  CT875_E_574_nIgK_cHis	AUGGAAACCCCUGCCCAGCUGCUGUUCCUGCUGCUGCUGUG	332
  	GCUGCCUGACACCACCGGCAUGAGCAUCAGAGGCGUGGGCG
  	GCAACGGCAACAGCAGAAUCCCUAGCCACAACGGCGACGGCA
  	GCAACAGGCGGAGCCAGAACACCAAGGGCAACAACAAGGUG
  	GAAGAUAGAGUGUGCAGCCUGUACAGCAGCCGGUCCAACGA
  	GAACCGCGAGAGCCCUUAUGCCGUGGUGGACGUGUCCAGCA
  	UGAUCGAGAGCACCCCCACCAGCGGCGAGACAACCAGAGCUA
  	GUAGAGGCGUGCUGAGCCGGUUCCAGAGGGGCCUCGUGCGG
  	AUUGCUGACAAAGUGCGGAGAGCCGUGCAGUGCGCUUGGAG
  	CAGCGUGUCCACAAGCAGAAGCAGCGCCACAAGAGCCGCCGA
  	GAGCGGCAGCUCUAGCAGAACAGCUAGAGGCGCCAGCAGCG
  	GCUACAGAGAGUACAGCCCUUCUGCCGCUCGGGGCCUGCGGC
  	UGAUGUUCACCGACUUUUGGCGGACCCGGGUGCUGAGACAG
  	ACCUCUCCUAUGGCCGGCGUGUUCGGCAACCUGGACGUGAA
  	CGAGGCCAGACUGAUGGCCGCCUACACCAGCGAGUGUGCCG
  	AUCACCUGGAAGCCAAAGAGCUGGCCGGACCUGACGGCGUG
  	GCAGCCGCUAGAGAAAUCGCCAAGAGAUGGGAGAAGAGAGU
  	GCGGGACCUGCAGGACAAGGGCGCUGCCAGAAAGCUGCUGA
  	ACGACCCCCUGGGCAGACGGACCCCCAACUACCAGAGCAAGA
  	ACCCCGGCGAGUACACCGUGGGCAACUCCAUGUUCUACGACG
  	GCCCCCAGGUGGCCAACCUGCAGAAUGUGGAUACCGGCUUC
  	UGGCUGGACAUGAGCAACCUGAGCGACGUGGUGCUGUCCAG
  	AGAGAUCCAGACCGGCCUGAGAGCCAGAGCCACCCUGGAAG
  	AGUCCAUGCCCAUGCUGGAAAAUCUGGAAGAGAGAUUCCGG
  	CGGCUGCAGGAAACCUGCGACGCCGCCAGAACCGAGAUCGA
  	GGAAAGCGGCUGGACCCGGGAAAGCGCCUCCAGAAUGGAAG
  	GCGACGAAGCCCAGGGCCCCAGCAGAGUGCAGCAGGCCUUUC
  	AGAGCUUCGUGAAUGAGUGCAACAGCAUCGAGUUCAGCUUC
  	GGCUCCUUCGGCGAGCACGUGCGGGUGCUGUGUGCCAGAGU
  	GUCAAGAGGACUGGCCGCUGCCGGCGAGGCCAUCAGAAGAU
  	GCUUCAGCUGCUGCAAGGGCAGCACCCACAGAUACGCCCCCA
  	GAGAUGACCUGUCUCCUGAGGGCGCCUCUCUGGCCGAAACCC
  	UGGCCAGAUUCGCCGACGACAUGGGCAUCGAAAGAGGCGCC
  	GACGGCACCUACGACAUCCCCCUGGUGGACGAUUGGAGAAG
  	GGGCGUGCCAUCCAUCGAGGGCGAGGGCAGCGAUAGCAUCU
  	ACGAGAUCAUGAUGCCCAUCUACGAAGUGAUGAACAUGGAC
  	CUGGAAACCCGGCGGAGCUUCGCCGUGCAGCAGGGCCAUUA
  	CCAGGACCCCAGAGCCAGCGACUACGACCUGCCUAGAGCCUC
  	CGAUUACGAUCUGCCCAGAAGCCCCUACCCCACCCCUCCACU
  	GCCUCCCAGAUACCAGCUGCAGAACAUGGAUGUGGAAGCCG
  	GCUUUCGCGAGGCCGUGUACGCCUCUUUUGUGGCCGGCAUG
  	UACAACUACGUCGUGACCCAGCCCCAGGAACGGAUCCCCAAU
  	AGCCAGCAGGUGGAAGGCAUCCUGCGGGACAUGCUGACCAA
  	CGGCAGCCACCACCAUCACCACCAC
  CT875_E_458_nIgK_cHis	AUGGAAACCCCUGCCCAGCUGCUGUUCCUGCUGCUGCUGUG	333
  	GCUGCCUGACACCACCGGCAUGAGCAUCAGAGGCGUGGGCG
  	GCAACGGCAACAGCAGAAUCCCUAGCCACAACGGCGACGGCA
  	GCAACAGGCGGAGCCAGAACACCAAGGGCAACAACAAGGUG
  	GAAGAUAGAGUGUGCAGCCUGUACAGCAGCCGGUCCAACGA
  	GAACCGCGAGAGCCCUUAUGCCGUGGUGGACGUGUCCAGCA
  	UGAUCGAGAGCACCCCCACCAGCGGCGAGACAACCAGAGCUA
  	GUAGAGGCGUGCUGAGCCGGUUCCAGAGGGGCCUCGUGCGG
  	AUUGCUGACAAAGUGCGGAGAGCCGUGCAGUGCGCUUGGAG
  	CAGCGUGUCCACAAGCAGAAGCAGCGCCACAAGAGCCGCCGA
  	GAGCGGCAGCUCUAGCAGAACAGCUAGAGGCGCCAGCAGCG
  	GCUACAGAGAGUACAGCCCUUCUGCCGCUCGGGGCCUGCGGC
  	UGAUGUUCACCGACUUUUGGCGGACCCGGGUGCUGAGACAG
  	ACCUCUCCUAUGGCCGGCGUGUUCGGCAACCUGGACGUGAA
  	CGAGGCCAGACUGAUGGCCGCCUACACCAGCGAGUGUGCCG
  	AUCACCUGGAAGCCAAAGAGCUGGCCGGACCUGACGGCGUG
  	GCAGCCGCUAGAGAAAUCGCCAAGAGAUGGGAGAAGAGAGU
  	GCGGGACCUGCAGGACAAGGGCGCUGCCAGAAAGCUGCUGA
  	ACGACCCCCUGGGCAGACGGACCCCCAACUACCAGAGCAAGA
  	ACCCCGGCGAGUACACCGUGGGCAACUCCAUGUUCUACGACG
  	GCCCCCAGGUGGCCAACCUGCAGAAUGUGGAUACCGGCUUC
  	UGGCUGGACAUGAGCAACCUGAGCGACGUGGUGCUGUCCAG
  	AGAGAUCCAGACCGGCCUGAGAGCCAGAGCCACCCUGGAAG
  	AGUCCAUGCCCAUGCUGGAAAAUCUGGAAGAGAGAUUCCGG
  	CGGCUGCAGGAAACCUGCGACGCCGCCAGAACCGAGAUCGA
  	GGAAAGCGGCUGGACCCGGGAAAGCGCCUCCAGAAUGGAAG
  	GCGACGAAGCCCAGGGCCCCAGCAGAGUGCAGCAGGCCUUUC
  	AGAGCUUCGUGAAUGAGUGCAACAGCAUCGAGUUCAGCUUC
  	GGCUCCUUCGGCGAGCACGUGCGGGUGCUGUGUGCCAGAGU
  	GUCAAGAGGACUGGCCGCUGCCGGCGAGGCCAUCAGAAGAU
  	GCUUCAGCUGCUGCAAGGGCAGCACCCACAGAUACGCCCCCA
  	GAGAUGACCUGUCUCCUGAGGGCGCCUCUCUGGCCGAAACCC
  	UGGCCAGAUUCGCCGACGACAUGGGCAUCGAAAGAGGCGCC
  	GACGGCACCUACGACAUCCCCCUGGUGGACGAUUGGAGAAG
  	GGGCGUGCCAUCCAUCGAGGGCGAGGGCAGCCACCACCAUCA
  	CCACCAC
  CT875_E_574_NGM_nIgK	AUGGAAACCCCUGCCCAGCUGCUGUUCCUGCUGCUGCUGUG	334
  	GCUGCCUGACACCACCGGCAUGAGCAUCAGAGGCGUGGGCG
  	GCAACGGCAACAGCAGAAUCCCUAGCCACAACGGCGACGGCA
  	GCAACAGGCGGAGCCAGAACACCAAGGGCAACAACAAGGUG
  	GAAGAUAGAGUGUGCAGCCUGUACAGCAGCCGGUCCAACGA
  	GAACCGCGAGAGCCCUUAUGCCGUGGUGGACGUGUCCAGCA
  	UGAUCGAGAGCACCCCCACCAGCGGCGAGACAACCAGAGCUA
  	GUAGAGGCGUGCUGAGCCGGUUCCAGAGGGGCCUCGUGCGG
  	AUUGCUGACAAAGUGCGGAGAGCCGUGCAGUGCGCUUGGAG
  	CAGCGUGUCCACAAGCAGAAGCAGCGCCACAAGAGCCGCCGA
  	GAGCGGCAGCUCUAGCAGAACAGCUAGAGGCGCCAGCAGCG
  	GCUACAGAGAGUACAGCCCUUCUGCCGCUCGGGGCCUGCGGC
  	UGAUGUUCACCGACUUUUGGCGGACCCGGGUGCUGAGACAG
  	ACCUCUCCUAUGGCCGGCGUGUUCGGCAACCUGGACGUGAA
  	CGAGGCCAGACUGAUGGCCGCCUACACCAGCGAGUGUGCCG
  	AUCACCUGGAAGCCAAAGAGCUGGCCGGACCUGACGGCGUG
  	GCAGCCGCUAGAGAAAUCGCCAAGAGAUGGGAGAAGAGAGU
  	GCGGGACCUGCAGGACAAGGGCGCUGCCAGAAAGCUGCUGA
  	ACGACCCCCUGGGCAGACGGACCCCCAACUACCAGAGCAAGA
  	ACCCCGGCGAGUACACCGUGGGCAACUCCAUGUUCUACGACG
  	GCCCCCAGGUGGCCAACCUGCAGAAUGUGGAUACCGGCUUC
  	UGGCUGGACAUGCAGCACCUGAGCGACGUGGUGCUGUCCAG
  	AGAGAUCCAGACCGGCCUGAGAGCCAGAGCCACCCUGGAAG
  	AGUCCAUGCCCAUGCUGGAAAAUCUGGAAGAGAGAUUCCGG
  	CGGCUGCAGGAAACCUGCGACGCCGCCAGAACCGAGAUCGA
  	GGAAAGCGGCUGGACCCGGGAAAGCGCCUCCAGAAUGGAAG
  	GCGACGAAGCCCAGGGCCCCAGCAGAGUGCAGCAGGCCUUUC
  	AGAGCUUCGUGAAUGAGUGCAACAGCAUCGAGUUCAGCUUC
  	GGCUCCUUCGGCGAGCACGUGCGGGUGCUGUGUGCCAGAGU
  	GUCAAGAGGACUGGCCGCUGCCGGCGAGGCCAUCAGAAGAU
  	GCUUCAGCUGCUGCAAGGGCAGCACCCACAGAUACGCCCCCA
  	GAGAUGACCUGUCUCCUGAGGGCGCCUCUCUGGCCGAAACCC
  	UGGCCAGAUUCGCCGACGACAUGGGCAUCGAAAGAGGCGCC
  	GACGGCACCUACGACAUCCCCCUGGUGGACGAUUGGAGAAG
  	GGGCGUGCCAUCCAUCGAGGGCGAGGGCAGCGAUAGCAUCU
  	ACGAGAUCAUGAUGCCCAUCUACGAAGUGAUGAACAUGGAC
  	CUGGAAACCCGGCGGAGCUUCGCCGUGCAGCAGGGCCAUUA
  	CCAGGACCCCAGAGCCAGCGACUACGACCUGCCUAGAGCCUC
  	CGAUUACGAUCUGCCCAGAAGCCCCUACCCCACCCCUCCACU
  	GCCUCCCAGAUACCAGCUGCAGAACAUGGAUGUGGAAGCCG
  	GCUUUCGCGAGGCCGUGUACGCCUCUUUUGUGGCCGGCAUG
  	UACAACUACGUCGUGACCCAGCCCCAGGAACGGAUCCCCAAU
  	AGCCAGCAGGUGGAAGGCAUCCUGCGGGACAUGCUGACCAA
  	CGGCGAC
  CT875_E_458_NGM_nIgK	AUGGAAACCCCUGCCCAGCUGCUGUUCCUGCUGCUGCUGUG	335
  	GCUGCCUGACACCACCGGCAUGAGCAUCAGAGGCGUGGGCG
  	GCAACGGCAACAGCAGAAUCCCUAGCCACAACGGCGACGGCA
  	GCAACAGGCGGAGCCAGAACACCAAGGGCAACAACAAGGUG
  	GAAGAUAGAGUGUGCAGCCUGUACAGCAGCCGGUCCAACGA
  	GAACCGCGAGAGCCCUUAUGCCGUGGUGGACGUGUCCAGCA
  	UGAUCGAGAGCACCCCCACCAGCGGCGAGACAACCAGAGCUA
  	GUAGAGGCGUGCUGAGCCGGUUCCAGAGGGGCCUCGUGCGG
  	AUUGCUGACAAAGUGCGGAGAGCCGUGCAGUGCGCUUGGAG
  	CAGCGUGUCCACAAGCAGAAGCAGCGCCACAAGAGCCGCCGA
  	GAGCGGCAGCUCUAGCAGAACAGCUAGAGGCGCCAGCAGCG
  	GCUACAGAGAGUACAGCCCUUCUGCCGCUCGGGGCCUGCGGC
  	UGAUGUUCACCGACUUUUGGCGGACCCGGGUGCUGAGACAG
  	ACCUCUCCUAUGGCCGGCGUGUUCGGCAACCUGGACGUGAA
  	CGAGGCCAGACUGAUGGCCGCCUACACCAGCGAGUGUGCCG
  	AUCACCUGGAAGCCAAAGAGCUGGCCGGACCUGACGGCGUG
  	GCAGCCGCUAGAGAAAUCGCCAAGAGAUGGGAGAAGAGAGU
  	GCGGGACCUGCAGGACAAGGGCGCUGCCAGAAAGCUGCUGA
  	ACGACCCCCUGGGCAGACGGACCCCCAACUACCAGAGCAAGA
  	ACCCCGGCGAGUACACCGUGGGCAACUCCAUGUUCUACGACG
  	GCCCCCAGGUGGCCAACCUGCAGAAUGUGGAUACCGGCUUC
  	UGGCUGGACAUGCAGCACCUGAGCGACGUGGUGCUGUCCAG
  	AGAGAUCCAGACCGGCCUGAGAGCCAGAGCCACCCUGGAAG
  	AGUCCAUGCCCAUGCUGGAAAAUCUGGAAGAGAGAUUCCGG
  	CGGCUGCAGGAAACCUGCGACGCCGCCAGAACCGAGAUCGA
  	GGAAAGCGGCUGGACCCGGGAAAGCGCCUCCAGAAUGGAAG
  	GCGACGAAGCCCAGGGCCCCAGCAGAGUGCAGCAGGCCUUUC
  	AGAGCUUCGUGAAUGAGUGCAACAGCAUCGAGUUCAGCUUC
  	GGCUCCUUCGGCGAGCACGUGCGGGUGCUGUGUGCCAGAGU
  	GUCAAGAGGACUGGCCGCUGCCGGCGAGGCCAUCAGAAGAU
  	GCUUCAGCUGCUGCAAGGGCAGCACCCACAGAUACGCCCCCA
  	GAGAUGACCUGUCUCCUGAGGGCGCCUCUCUGGCCGAAACCC
  	UGGCCAGAUUCGCCGACGACAUGGGCAUCGAAAGAGGCGCC
  	GACGGCACCUACGACAUCCCCCUGGUGGACGAUUGGAGAAG
  	GGGCGUGCCAUCCAUCGAGGGCGAGGGCAGC
  CT875_E_574_nIgK	AUGGAAACCCCUGCCCAGCUGCUGUUCCUGCUGCUGCUGUG	336
  	GCUGCCUGACACCACCGGCAUGAGCAUCAGAGGCGUGGGCG
  	GCAACGGCAACAGCAGAAUCCCUAGCCACAACGGCGACGGCA
  	GCAACAGGCGGAGCCAGAACACCAAGGGCAACAACAAGGUG
  	GAAGAUAGAGUGUGCAGCCUGUACAGCAGCCGGUCCAACGA
  	GAACCGCGAGAGCCCUUAUGCCGUGGUGGACGUGUCCAGCA
  	UGAUCGAGAGCACCCCCACCAGCGGCGAGACAACCAGAGCUA
  	GUAGAGGCGUGCUGAGCCGGUUCCAGAGGGGCCUCGUGCGG
  	AUUGCUGACAAAGUGCGGAGAGCCGUGCAGUGCGCUUGGAG
  	CAGCGUGUCCACAAGCAGAAGCAGCGCCACAAGAGCCGCCGA
  	GAGCGGCAGCUCUAGCAGAACAGCUAGAGGCGCCAGCAGCG
  	GCUACAGAGAGUACAGCCCUUCUGCCGCUCGGGGCCUGCGGC
  	UGAUGUUCACCGACUUUUGGCGGACCCGGGUGCUGAGACAG
  	ACCUCUCCUAUGGCCGGCGUGUUCGGCAACCUGGACGUGAA
  	CGAGGCCAGACUGAUGGCCGCCUACACCAGCGAGUGUGCCG
  	AUCACCUGGAAGCCAAAGAGCUGGCCGGACCUGACGGCGUG
  	GCAGCCGCUAGAGAAAUCGCCAAGAGAUGGGAGAAGAGAGU
  	GCGGGACCUGCAGGACAAGGGCGCUGCCAGAAAGCUGCUGA
  	ACGACCCCCUGGGCAGACGGACCCCCAACUACCAGAGCAAGA
  	ACCCCGGCGAGUACACCGUGGGCAACUCCAUGUUCUACGACG
  	GCCCCCAGGUGGCCAACCUGCAGAAUGUGGAUACCGGCUUC
  	UGGCUGGACAUGAGCAACCUGAGCGACGUGGUGCUGUCCAG
  	AGAGAUCCAGACCGGCCUGAGAGCCAGAGCCACCCUGGAAG
  	AGUCCAUGCCCAUGCUGGAAAAUCUGGAAGAGAGAUUCCGG
  	CGGCUGCAGGAAACCUGCGACGCCGCCAGAACCGAGAUCGA
  	GGAAAGCGGCUGGACCCGGGAAAGCGCCUCCAGAAUGGAAG
  	GCGACGAAGCCCAGGGCCCCAGCAGAGUGCAGCAGGCCUUUC
  	AGAGCUUCGUGAAUGAGUGCAACAGCAUCGAGUUCAGCUUC
  	GGCUCCUUCGGCGAGCACGUGCGGGUGCUGUGUGCCAGAGU
  	GUCAAGAGGACUGGCCGCUGCCGGCGAGGCCAUCAGAAGAU
  	GCUUCAGCUGCUGCAAGGGCAGCACCCACAGAUACGCCCCCA
  	GAGAUGACCUGUCUCCUGAGGGCGCCUCUCUGGCCGAAACCC
  	UGGCCAGAUUCGCCGACGACAUGGGCAUCGAAAGAGGCGCC
  	GACGGCACCUACGACAUCCCCCUGGUGGACGAUUGGAGAAG
  	GGGCGUGCCAUCCAUCGAGGGCGAGGGCAGCGAUAGCAUCU
  	ACGAGAUCAUGAUGCCCAUCUACGAAGUGAUGAACAUGGAC
  	CUGGAAACCCGGCGGAGCUUCGCCGUGCAGCAGGGCCAUUA
  	CCAGGACCCCAGAGCCAGCGACUACGACCUGCCUAGAGCCUC
  	CGAUUACGAUCUGCCCAGAAGCCCCUACCCCACCCCUCCACU
  	GCCUCCCAGAUACCAGCUGCAGAACAUGGAUGUGGAAGCCG
  	GCUUUCGCGAGGCCGUGUACGCCUCUUUUGUGGCCGGCAUG
  	UACAACUACGUCGUGACCCAGCCCCAGGAACGGAUCCCCAAU
  	AGCCAGCAGGUGGAAGGCAUCCUGCGGGACAUGCUGACCAA
  	CGGCAGC
  CT875_E_458_nIgK	AUGGAAACCCCUGCCCAGCUGCUGUUCCUGCUGCUGCUGUG	337
  	GCUGCCUGACACCACCGGCAUGAGCAUCAGAGGCGUGGGCG
  	GCAACGGCAACAGCAGAAUCCCUAGCCACAACGGCGACGGCA
  	GCAACAGGCGGAGCCAGAACACCAAGGGCAACAACAAGGUG
  	GAAGAUAGAGUGUGCAGCCUGUACAGCAGCCGGUCCAACGA
  	GAACCGCGAGAGCCCUUAUGCCGUGGUGGACGUGUCCAGCA
  	UGAUCGAGAGCACCCCCACCAGCGGCGAGACAACCAGAGCUA
  	GUAGAGGCGUGCUGAGCCGGUUCCAGAGGGGCCUCGUGCGG
  	AUUGCUGACAAAGUGCGGAGAGCCGUGCAGUGCGCUUGGAG
  	CAGCGUGUCCACAAGCAGAAGCAGCGCCACAAGAGCCGCCGA
  	GAGCGGCAGCUCUAGCAGAACAGCUAGAGGCGCCAGCAGCG
  	GCUACAGAGAGUACAGCCCUUCUGCCGCUCGGGGCCUGCGGC
  	UGAUGUUCACCGACUUUUGGCGGACCCGGGUGCUGAGACAG
  	ACCUCUCCUAUGGCCGGCGUGUUCGGCAACCUGGACGUGAA
  	CGAGGCCAGACUGAUGGCCGCCUACACCAGCGAGUGUGCCG
  	AUCACCUGGAAGCCAAAGAGCUGGCCGGACCUGACGGCGUG
  	GCAGCCGCUAGAGAAAUCGCCAAGAGAUGGGAGAAGAGAGU
  	GCGGGACCUGCAGGACAAGGGCGCUGCCAGAAAGCUGCUGA
  	ACGACCCCCUGGGCAGACGGACCCCCAACUACCAGAGCAAGA
  	ACCCCGGCGAGUACACCGUGGGCAACUCCAUGUUCUACGACG
  	GCCCCCAGGUGGCCAACCUGCAGAAUGUGGAUACCGGCUUC
  	UGGCUGGACAUGAGCAACCUGAGCGACGUGGUGCUGUCCAG
  	AGAGAUCCAGACCGGCCUGAGAGCCAGAGCCACCCUGGAAG
  	AGUCCAUGCCCAUGCUGGAAAAUCUGGAAGAGAGAUUCCGG
  	CGGCUGCAGGAAACCUGCGACGCCGCCAGAACCGAGAUCGA
  	GGAAAGCGGCUGGACCCGGGAAAGCGCCUCCAGAAUGGAAG
  	GCGACGAAGCCCAGGGCCCCAGCAGAGUGCAGCAGGCCUUUC
  	AGAGCUUCGUGAAUGAGUGCAACAGCAUCGAGUUCAGCUUC
  	GGCUCCUUCGGCGAGCACGUGCGGGUGCUGUGUGCCAGAGU
  	GUCAAGAGGACUGGCCGCUGCCGGCGAGGCCAUCAGAAGAU
  	GCUUCAGCUGCUGCAAGGGCAGCACCCACAGAUACGCCCCCA
  	GAGAUGACCUGUCUCCUGAGGGCGCCUCUCUGGCCGAAACCC
  	UGGCCAGAUUCGCCGACGACAUGGGCAUCGAAAGAGGCGCC
  	GACGGCACCUACGACAUCCCCCUGGUGGACGAUUGGAGAAG
  	GGGCGUGCCAUCCAUCGAGGGCGAGGGCAGC
  CT875_E_1_574_NGM_nIgK_cHis	AUGGAAACCCCUGCUCAGCUGCUGUUCCUGCUGCUGCUGUG	338
  	GCUGCCUGAUACCACCGGCAUGUCUAUCAGAGGCGUUGGCG
  	GCAACGGCAACAGCAGAAUCCCUAGCCAUAAUGGCGACGGC
  	AGCAACAGGCGGAGCCAGAAUACCAAGGGCAACAACAAGGU
  	GGAAGAUCGCGUGUGCAGCCUGUACAGCUCCAGAAGCAACG
  	AGAACCGCGAGAGCCCUUAUGCCGUGGUGGAUGUGUCCAGC
  	AUGAUCGAGAGCACCCCUACCAGCGGCGAGACAACAAGAGC
  	UAGUAGAGGCGUGCUGAGCCGGUUUCAGAGAGGCCUCGUUC
  	GGAUCGCUGACAAAGUGCGGAGAGCCGUGCAGUGUGCCUGG
  	UCUAGUGUGUCCACAAGCAGAAGCAGCGCCACAAGAGCCGC
  	CGAGAGCGGAUCUUCUAGCAGAACAGCUAGAGGCGCCAGCA
  	GCGGCUACAGAGAGUAUUCUCCAUCUGCCGCCAGAGGCCUG
  	CGGCUGAUGUUUACAGAUUUCUGGCGGACCCGGGUGCUGAG
  	ACAGACAUCUCCUAUGGCUGGCGUGUUCGGCAACCUGGAUG
  	UGAAUGAGGCCAGACUGAUGGCCGCCUACACAAGCGAAUGU
  	GCCGAUCACCUGGAAGCCAAAGAGCUGGCUGGACCUGACGG
  	UGUUGCCGCCGCUAGAGAAAUCGCCAAGAGAUGGGAGAAGA
  	GAGUGCGGGACCUGCAGGAUAAGGGCGCUGCUAGAAAGCUG
  	CUGAACGACCCUCUGGGCAGAAGAACCCCUAACUACCAGAGC
  	AAGAACCCCGGCGAGUACACCGUGGGCAACUCCAUGUUCUA
  	CGACGGACCCCAGGUGGCCAACCUGCAGAAUGUGGAUACAG
  	GCUUCUGGCUGGAUAUGCAGCACCUGAGCGACGUGGUGCUG
  	UCCAGAGAGAUCCAGACAGGCCUGAGAGCCAGAGCCACACU
  	GGAAGAGUCCAUGCCUAUGCUCGAGAACCUGGAAGAGAGAU
  	UCCGGCGGCUGCAAGAGACAUGUGACGCCGCCAGAACCGAG
  	AUCGAGGAAAGCGGCUGGACAAGAGAAAGCGCCUCCAGAAU
  	GGAAGGCGACGAAGCCCAAGGACCUAGCAGAGUGCAGCAGG
  	CCUUCCAGAGCUUCGUGAACGAGUGCAACAGCAUCGAGUUC
  	AGCUUCGGCUCCUUCGGCGAACAUGUGCGGGUGCUGUGUGC
  	CAGAGUUAGCAGAGGACUUGCUGCCGCUGGCGAGGCCAUCA
  	GAAGAUGCUUCUCUUGCUGCAAGGGCAGCACCCACAGAUAC
  	GCCCCUAGAGAUGAUCUGAGCCCUGAGGGCGCUUCUCUGGC
  	CGAAACACUGGCCAGAUUCGCCGACGAUAUGGGCAUUGAAA
  	GAGGCGCCGACGGAACCUACGACAUCCCUCUGGUGGACGAU
  	UGGAGAAGGGGCGUGCCAUCUAUCGAAGGCGAGGGCAGCGA
  	UAGCAUCUACGAGAUCAUGAUGCCCAUCUACGAAGUGAUGA
  	ACAUGGACCUGGAAACCCGGCGGAGCUUUGCCGUGCAGCAA
  	GGCCAUUACCAGGAUCCUAGAGCCAGCGACUACGACCUGCCU
  	AGAGCCUCCGAUUAUGAUCUGCCUCGGAGCCCCUAUCCUACA
  	CCUCCUCUGCCUCCAAGAUACCAGCUUCAGAAUAUGGACGU
  	GGAAGCCGGAUUCCGCGAGGCCGUGUAUGCUAGCUUUGUGG
  	CCGGCAUGUACAACUACGUGGUCACCCAGCCUCAAGAGAGA
  	AUCCCCAACAGCCAGCAGGUCGAGGGCAUCCUGAGAGAUAU
  	GCUGACCAACGGCGACCACCACCAUCACCAUCAU
  CT875_E_NGM_nFc	AUGGAAACCCCUGCUCAGCUGCUGUUCCUGCUGCUGCUGUG	339
  	GCUGCCUGAUACAACCGGCGAGCCUAAGAGCUGCGACAAGA
  	CCCACACCUGUCCUCCAUGUCCUGCUCCAGAACUGCUCGGCG
  	GACCUUCCGUGUUCCUGUUUCCUCCAAAGCCUAAGGACACCC
  	UGAUGAUCAGCAGAACCCCUGAAGUGACCUGCGUGGUGGUG
  	GAUGUGUCCCACGAGGAUCCCGAAGUGAAGUUCAAUUGGUA
  	CGUGGACGGCGUGGAAGUGCACAACGCCAAGACCAAGCCUA
  	GAGAGGAACAGUACAACAGCACCUACAGAGUGGUGUCCGUG
  	CUGACCGUGCUGCACCAGGAUUGGCUGAACGGCAAAGAGUA
  	CAAGUGCAAGGUGUCCAACAAGGCCCUGCCUGCUCCUAUCG
  	AGAAGACCAUCAGCAAGGCCAAGGGCCAGCCAAGAGAACCC
  	CAGGUGUACACACUGCCUCCAAGCAGAGAUGAGCUGACCAA
  	GAACCAGGUGUCCCUGACCUGUCUGGUCAAGGGCUUCUACC
  	CCUCCGAUAUCGCCGUGGAAUGGGAGAGCAAUGGCCAGCCU
  	GAGAACAACUACAAGACAACCCCUCCUGUGCUGGACAGCGA
  	CGGCUCAUUCUUCCUGUACAGCAAGCUGACAGUGGACAAGA
  	GCAGAUGGCAGCAGGGCAACGUGUUCAGCUGCAGCGUGAUG
  	CACGAGGCCCUGCACAAUCACUACACCCAGAAGUCCCUGUCU
  	CUGAGCCCCGGCAAGAUGAGCAUCAGAGGCGUUGGCGGCAA
  	CGGCAACAGCAGAAUCCCUAGCCAUAAUGGCGACGGCAGCA
  	ACAGGCGGAGCCAGAAUACCAAGGGCAACAACAAGGUGGAA
  	GAUCGCGUGUGCAGCCUGUACUCCAGCAGAAGCAACGAGAA
  	CCGCGAGAGCCCUUAUGCCGUGGUCGACGUGUCCAGCAUGA
  	UCGAGAGCACACCUACCAGCGGCGAGACAACCAGAGCUAGU
  	AGAGGCGUGCUGAGCCGGUUUCAGAGAGGCCUCGUUCGGAU
  	CGCUGACAAAGUGCGGAGAGCCGUGCAGUGUGCCUGGUCUA
  	GUGUGUCCACCAGCAGAUCCUCUGCCACAAGAGCCGCCGAGU
  	CUGGCAGCUCUAGCAGAACAGCUAGAGGCGCCAGCAGCGGC
  	UACAGAGAGUAUUCUCCAUCUGCCGCCAGAGGCCUGCGGCU
  	GAUGUUUACAGAUUUCUGGCGGACCCGGGUGCUGAGACAGA
  	CAUCUCCUAUGGCUGGCGUGUUCGGCAACCUGGAUGUGAAU
  	GAGGCCAGACUGAUGGCCGCCUACACAAGCGAAUGUGCCGA
  	UCACCUGGAAGCCAAAGAGCUGGCUGGACCUGACGGUGUUG
  	CCGCCGCUAGAGAAAUCGCCAAGAGAUGGGAGAAGAGAGUG
  	CGGGACCUGCAGGAUAAGGGCGCUGCUAGAAAGCUGCUGAA
  	CGACCCUCUGGGCAGAAGAACCCCUAACUACCAGAGCAAGA
  	ACCCCGGCGAGUACACCGUGGGCAACUCCAUGUUCUACGACG
  	GACCUCAGGUGGCCAACCUGCAGAAUGUGGAUACCGGCUUC
  	UGGCUGGAUAUGCAGCACCUGUCCGAUGUGGUGCUGUCCAG
  	AGAGAUCCAGACCGGCCUGAGAGCCAGAGCCACACUGGAAG
  	AGUCCAUGCCUAUGCUCGAGAACCUGGAAGAGAGAUUCCGG
  	CGGCUGCAAGAGACAUGUGACGCCGCCAGAACCGAGAUCGA
  	GGAAAGCGGCUGGACCAGAGAAAGCGCCUCCAGAAUGGAAG
  	GCGACGAAGCCCAAGGACCUAGCAGAGUGCAGCAGGCCUUC
  	CAGAGCUUCGUGAACGAGUGCAACAGCAUCGAGUUCAGCUU
  	CGGCUCCUUCGGCGAACAUGUGCGGGUGCUGUGUGCCAGAG
  	UUAGCAGAGGACUUGCUGCCGCUGGCGAGGCCAUCAGAAGA
  	UGCUUCUCUUGCUGCAAGGGCAGCACCCACAGAUACGCCCCU
  	AGAGAUGAUCUGAGCCCUGAGGGCGCAUCUCUGGCCGAAAC
  	ACUGGCCAGAUUCGCCGACGAUAUGGGCAUUGAAAGAGGCG
  	CCGACGGAACCUACGACAUCCCUCUGGUGGACGAUUGGAGA
  	AGGGGCGUGCCAUCUAUCGAAGGCGAGGGCAGCGAUAGCAU
  	CUACGAGAUCAUGAUGCCCAUCUACGAAGUGAUGAACAUGG
  	ACCUGGAAACCCGGCGGAGCUUCGCUGUUCAGCAGGGCCAU
  	UACCAGGAUCCUAGAGCCAGCGACUACGACCUGCCUAGAGCC
  	UCCGAUUAUGAUCUGCCUCGGAGCCCCUAUCCUACACCUCCA
  	CUGCCACCUAGAUACCAGCUCCAGAAUAUGGACGUGGAAGC
  	CGGAUUCCGCGAGGCCGUGUAUGCUAGCUUUGUGGCCGGCA
  	UGUACAACUACGUGGUCACCCAGCCUCAAGAGCGGAUCCCCA
  	AUUCUCAGCAGGUCGAGGGCAUCCUGAGGGACAUGCUGACC
  	AAUGGCGACCAGACCUUCCGGGACCUGAUGAAGAGAUGGAA
  	CAGAGAGGUGGACAGAGAG
  CT875_E_NGM_nFc_cHis	AUGGAAACCCCUGCUCAGCUGCUGUUCCUGCUGCUGCUGUG	340
  	GCUGCCUGAUACAACCGGCGAGCCUAAGAGCUGCGACAAGA
  	CCCACACCUGUCCUCCAUGUCCUGCUCCAGAACUGCUCGGCG
  	GACCUUCCGUGUUCCUGUUUCCUCCAAAGCCUAAGGACACCC
  	UGAUGAUCAGCAGAACCCCUGAAGUGACCUGCGUGGUGGUG
  	GAUGUGUCCCACGAGGAUCCCGAAGUGAAGUUCAAUUGGUA
  	CGUGGACGGCGUGGAAGUGCACAACGCCAAGACCAAGCCUA
  	GAGAGGAACAGUACAACAGCACCUACAGAGUGGUGUCCGUG
  	CUGACCGUGCUGCACCAGGAUUGGCUGAACGGCAAAGAGUA
  	CAAGUGCAAGGUGUCCAACAAGGCCCUGCCUGCUCCUAUCG
  	AGAAGACCAUCAGCAAGGCCAAGGGCCAGCCAAGAGAACCC
  	CAGGUGUACACACUGCCUCCAAGCAGAGAUGAGCUGACCAA
  	GAACCAGGUGUCCCUGACCUGUCUGGUCAAGGGCUUCUACC
  	CCUCCGAUAUCGCCGUGGAAUGGGAGAGCAAUGGCCAGCCU
  	GAGAACAACUACAAGACAACCCCUCCUGUGCUGGACAGCGA
  	CGGCUCAUUCUUCCUGUACAGCAAGCUGACAGUGGACAAGA
  	GCAGAUGGCAGCAGGGCAACGUGUUCAGCUGCAGCGUGAUG
  	CACGAGGCCCUGCACAAUCACUACACCCAGAAGUCCCUGUCU
  	CUGAGCCCCGGCAAGAUGAGCAUCAGAGGCGUUGGCGGCAA
  	CGGCAACAGCAGAAUCCCUAGCCAUAAUGGCGACGGCAGCA
  	ACAGGCGGAGCCAGAAUACCAAGGGCAACAACAAGGUGGAA
  	GAUCGCGUGUGCAGCCUGUACUCCAGCAGAAGCAACGAGAA
  	CCGCGAGAGCCCUUAUGCCGUGGUCGACGUGUCCAGCAUGA
  	UCGAGAGCACACCUACCAGCGGCGAGACAACCAGAGCUAGU
  	AGAGGCGUGCUGAGCCGGUUUCAGAGAGGCCUCGUUCGGAU
  	CGCUGACAAAGUGCGGAGAGCCGUGCAGUGUGCCUGGUCUA
  	GUGUGUCCACCAGCAGAUCCUCUGCCACAAGAGCCGCCGAGU
  	CUGGCAGCUCUAGCAGAACAGCUAGAGGCGCCAGCAGCGGC
  	UACAGAGAGUAUUCUCCAUCUGCCGCCAGAGGCCUGCGGCU
  	GAUGUUUACAGAUUUCUGGCGGACCCGGGUGCUGAGACAGA
  	CAUCUCCUAUGGCUGGCGUGUUCGGCAACCUGGAUGUGAAU
  	GAGGCCAGACUGAUGGCCGCCUACACAAGCGAAUGUGCCGA
  	UCACCUGGAAGCCAAAGAGCUGGCUGGACCUGACGGUGUUG
  	CCGCCGCUAGAGAAAUCGCCAAGAGAUGGGAGAAGAGAGUG
  	CGGGACCUGCAGGAUAAGGGCGCUGCUAGAAAGCUGCUGAA
  	CGACCCUCUGGGCAGAAGAACCCCUAACUACCAGAGCAAGA
  	ACCCCGGCGAGUACACCGUGGGCAACUCCAUGUUCUACGACG
  	GACCUCAGGUGGCCAACCUGCAGAAUGUGGAUACCGGCUUC
  	UGGCUGGAUAUGCAGCACCUGUCCGAUGUGGUGCUGUCCAG
  	AGAGAUCCAGACCGGCCUGAGAGCCAGAGCCACACUGGAAG
  	AGUCCAUGCCUAUGCUCGAGAACCUGGAAGAGAGAUUCCGG
  	CGGCUGCAAGAGACAUGUGACGCCGCCAGAACCGAGAUCGA
  	GGAAAGCGGCUGGACCAGAGAAAGCGCCUCCAGAAUGGAAG
  	GCGACGAAGCCCAAGGACCUAGCAGAGUGCAGCAGGCCUUC
  	CAGAGCUUCGUGAACGAGUGCAACAGCAUCGAGUUCAGCUU
  	CGGCUCCUUCGGCGAACAUGUGCGGGUGCUGUGUGCCAGAG
  	UUAGCAGAGGACUUGCUGCCGCUGGCGAGGCCAUCAGAAGA
  	UGCUUCUCUUGCUGCAAGGGCAGCACCCACAGAUACGCCCCU
  	AGAGAUGAUCUGAGCCCUGAGGGCGCAUCUCUGGCCGAAAC
  	ACUGGCCAGAUUCGCCGACGAUAUGGGCAUUGAAAGAGGCG
  	CCGACGGAACCUACGACAUCCCUCUGGUGGACGAUUGGAGA
  	AGGGGCGUGCCAUCUAUCGAAGGCGAGGGCAGCGAUAGCAU
  	CUACGAGAUCAUGAUGCCCAUCUACGAAGUGAUGAACAUGG
  	ACCUGGAAACCCGGCGGAGCUUCGCUGUUCAGCAGGGCCAU
  	UACCAGGAUCCUAGAGCCAGCGACUACGACCUGCCUAGAGCC
  	UCCGAUUAUGAUCUGCCUCGGAGCCCCUAUCCUACACCUCCA
  	CUGCCACCUAGAUACCAGCUCCAGAAUAUGGACGUGGAAGC
  	CGGAUUCCGCGAGGCCGUGUAUGCUAGCUUUGUGGCCGGCA
  	UGUACAACUACGUGGUCACCCAGCCUCAAGAGCGGAUCCCCA
  	AUUCUCAGCAGGUCGAGGGCAUCCUGAGGGACAUGCUGACC
  	AAUGGCGACCAGACCUUCCGGGACCUGAUGAAGAGAUGGAA
  	CAGAGAGGUGGACCGCGAGCACCACCACCAUCACCAU
  CT875_E_1_574_NGM_nIgK_nGST	AUGGAAACCCCUGCUCAGCUGCUGUUCCUGCUGCUGCUGUG	341
  	GCUGCCUGAUACCACAGGCAUGAGCCCUAUCCUCGGCUACUG
  	GAAGAUCAAAGGCCUGGUGCAGCCCACCAGACUGCUGCUGG
  	AAUACCUGGAAGAGAAGUACGAGGAACACCUGUACGAGCGC
  	GACGAGGGCGAUAAGUGGCGGAACAAGAAGUUCGAGCUGGG
  	CCUCGAGUUCCCCAACCUGCCUUACUACAUCGACGGCGACGU
  	GAAGCUGACCCAGAGCAUGGCCAUCAUCCGGUAUAUCGCCG
  	ACAAGCACAACAUGCUCGGCGGCUGCCCUAAAGAGCGGGCC
  	GAGAUUUCUAUGCUGGAAGGCGCCGUGCUGGACAUCAGAUA
  	CGGCGUGUCCAGAAUCGCCUACAGCAAGGACUUCGAAACCC
  	UGAAGGUGGACUUCCUGAGCAAGCUGCCCGAGAUGCUGAAG
  	AUGUUCGAGGACCGGCUGUGCCACAAGACCUACCUGAAUGG
  	CGACCACGUGACACACCCCGACUUCAUGCUGUACGACGCCCU
  	GGAUGUGGUGCUGUACAUGGACCCCAUGUGCCUGGACGCCU
  	UUCCAAAGCUCGUGUGCUUCAAGAAGCGGAUCGAGGCCAUU
  	CCUCAGAUCGACAAGUACCUGAAGUCCAGCAAGUAUAUCGC
  	UUGGCCCCUGCAAGGCUGGCAGGCCACAUUUGGAGGCGGAG
  	AUCACCCUCCUAAGAUGAGCAUCAGAGGCGUCGGCGGCAAC
  	GGCAACAGCAGAAUCCCUUCUCACAAUGGCGACGGCAGCAA
  	CAGGCGGAGCCAGAAUACCAAGGGCAACAACAAGGUGGAAG
  	AUCGCGUGUGCAGCCUGUACAGCUCCAGAAGCAACGAGAAC
  	CGCGAGAGCCCUUAUGCCGUGGUGGAUGUGUCCAGCAUGAU
  	CGAGAGCACCCCUACCAGCGGCGAGACAACAAGAGCUAGUA
  	GAGGCGUGCUGAGCCGGUUUCAGAGAGGCCUCGUUCGGAUU
  	GCCGACAAAGUGCGGAGAGCCGUGCAGUGUGCUUGGAGCAG
  	UGUGUCCACAAGCAGAAGCAGCGCCACAAGAGCCGCCGAAU
  	CUGGCAGCUCUAGCAGAACAGCUAGAGGCGCCAGCAGCGGC
  	UACAGAGAGUAUUCUCCAUCUGCCGCCAGAGGCCUGCGGCU
  	GAUGUUUACAGAUUUCUGGCGGACCCGGGUGCUGAGACAGA
  	CAUCUCCUAUGGCUGGCGUGUUCGGCAACCUGGACGUGAAC
  	GAAGCCAGACUGAUGGCCGCCUACACAAGCGAGUGUGCCGA
  	UCACCUGGAAGCCAAAGAACUGGCCGGACCUGAUGGCGUGG
  	CAGCCGCUAGAGAAAUCGCCAAGAGAUGGGAGAAGAGAGUG
  	CGGGACCUGCAGGAUAAGGGCGCUGCUAGAAAGCUGCUGAA
  	CGACCCUCUGGGCAGAAGAACCCCUAACUACCAGAGCAAGA
  	ACCCCGGCGAGUACACCGUGGGCAACUCCAUGUUCUACGACG
  	GACCCCAGGUGGCCAACCUGCAGAAUGUGGAUACAGGCUUC
  	UGGCUGGACAUGCAGCACCUGUCUGAUGUGGUCCUGAGCAG
  	AGAGAUCCAGACCGGCCUGAGAGCCAGAGCCACACUGGAAG
  	AGUCCAUGCCUAUGCUCGAGAAUCUGGAAGAACGGUUCAGA
  	CGGCUGCAAGAGACAUGCGACGCCGCCAGAACAGAGAUCGA
  	GGAAAGCGGCUGGACCAGAGAAAGCGCCUCCAGAAUGGAAG
  	GCGACGAAGCCCAAGGACCUAGCAGAGUGCAGCAGGCCUUC
  	CAGAGCUUCGUGAACGAGUGCAACAGCAUCGAGUUCAGCUU
  	CGGCUCCUUCGGCGAACAUGUGCGGGUGCUGUGUGCCAGAG
  	UUAGCAGAGGACUUGCUGCCGCUGGCGAGGCCAUCAGAAGA
  	UGCUUCUCUUGCUGCAAGGGCAGCACCCACAGAUACGCCCCU
  	AGAGAUGAUCUGAGCCCUGAGGGCGCAUCUCUGGCCGAAAC
  	ACUGGCCAGAUUUGCCGACGACAUGGGCAUUGAAAGAGGCG
  	CCGACGGAACCUACGACAUCCCUCUGGUGGACGAUUGGAGA
  	AGGGGCGUGCCAUCUAUCGAAGGCGAGGGCAGCGAUAGCAU
  	CUACGAGAUCAUGAUGCCCAUCUACGAAGUGAUGAACAUGG
  	ACCUGGAAACCCGGCGGAGCUUUGCCGUGCAACAGGGCCAU
  	UACCAGGAUCCUAGAGCCAGCGACUACGACCUGCCUAGAGCC
  	UCCGAUUAUGAUCUGCCUCGGAGCCCCUAUCCUACACCUCCU
  	CUGCCUCCAAGAUACCAGCUUCAGAAUAUGGACGUGGAAGC
  	CGGAUUCCGCGAGGCCGUGUAUGCUAGCUUUGUGGCCGGCA
  	UGUACAACUACGUGGUCACCCAGCCUCAAGAGAGAAUCCCC
  	AACAGCCAGCAGGUCGAGGGCAUCCUGAGAGAUAUGCUGAC
  	CAACGGCGAC
  CT875_E_1_574_NGM_nIgK_nGST_cHis	AUGGAAACCCCUGCUCAGCUGCUGUUCCUGCUGCUGCUGUG	342
  	GCUGCCUGAUACCACAGGCAUGAGCCCUAUCCUCGGCUACUG
  	GAAGAUCAAAGGCCUGGUGCAGCCCACCAGACUGCUGCUGG
  	AAUACCUGGAAGAGAAGUACGAGGAACACCUGUACGAGCGC
  	GACGAGGGCGAUAAGUGGCGGAACAAGAAGUUCGAGCUGGG
  	CCUCGAGUUCCCCAACCUGCCUUACUACAUCGACGGCGACGU
  	GAAGCUGACCCAGAGCAUGGCCAUCAUCCGGUAUAUCGCCG
  	ACAAGCACAACAUGCUCGGCGGCUGCCCUAAAGAGCGGGCC
  	GAGAUUUCUAUGCUGGAAGGCGCCGUGCUGGACAUCAGAUA
  	CGGCGUGUCCAGAAUCGCCUACAGCAAGGACUUCGAAACCC
  	UGAAGGUGGACUUCCUGAGCAAGCUGCCCGAGAUGCUGAAG
  	AUGUUCGAGGACCGGCUGUGCCACAAGACCUACCUGAAUGG
  	CGACCACGUGACACACCCCGACUUCAUGCUGUACGACGCCCU
  	GGAUGUGGUGCUGUACAUGGACCCCAUGUGCCUGGACGCCU
  	UUCCAAAGCUCGUGUGCUUCAAGAAGCGGAUCGAGGCCAUU
  	CCUCAGAUCGACAAGUACCUGAAGUCCAGCAAGUAUAUCGC
  	UUGGCCCCUGCAAGGCUGGCAGGCCACAUUUGGAGGCGGAG
  	AUCACCCUCCUAAGAUGAGCAUCAGAGGCGUCGGCGGCAAC
  	GGCAACAGCAGAAUCCCUUCUCACAAUGGCGACGGCAGCAA
  	CAGGCGGAGCCAGAAUACCAAGGGCAACAACAAGGUGGAAG
  	AUCGCGUGUGCAGCCUGUACAGCUCCAGAAGCAACGAGAAC
  	CGCGAGAGCCCUUAUGCCGUGGUGGAUGUGUCCAGCAUGAU
  	CGAGAGCACCCCUACCAGCGGCGAGACAACAAGAGCUAGUA
  	GAGGCGUGCUGAGCCGGUUUCAGAGAGGCCUCGUUCGGAUU
  	GCCGACAAAGUGCGGAGAGCCGUGCAGUGUGCUUGGAGCAG
  	UGUGUCCACAAGCAGAAGCAGCGCCACAAGAGCCGCCGAAU
  	CUGGCAGCUCUAGCAGAACAGCUAGAGGCGCCAGCAGCGGC
  	UACAGAGAGUAUUCUCCAUCUGCCGCCAGAGGCCUGCGGCU
  	GAUGUUUACAGAUUUCUGGCGGACCCGGGUGCUGAGACAGA
  	CAUCUCCUAUGGCUGGCGUGUUCGGCAACCUGGACGUGAAC
  	GAAGCCAGACUGAUGGCCGCCUACACAAGCGAGUGUGCCGA
  	UCACCUGGAAGCCAAAGAACUGGCCGGACCUGAUGGCGUGG
  	CAGCCGCUAGAGAAAUCGCCAAGAGAUGGGAGAAGAGAGUG
  	CGGGACCUGCAGGAUAAGGGCGCUGCUAGAAAGCUGCUGAA
  	CGACCCUCUGGGCAGAAGAACCCCUAACUACCAGAGCAAGA
  	ACCCCGGCGAGUACACCGUGGGCAACUCCAUGUUCUACGACG
  	GACCCCAGGUGGCCAACCUGCAGAAUGUGGAUACAGGCUUC
  	UGGCUGGACAUGCAGCACCUGUCUGAUGUGGUCCUGAGCAG
  	AGAGAUCCAGACCGGCCUGAGAGCCAGAGCCACACUGGAAG
  	AGUCCAUGCCUAUGCUCGAGAAUCUGGAAGAACGGUUCAGA
  	CGGCUGCAAGAGACAUGCGACGCCGCCAGAACAGAGAUCGA
  	GGAAAGCGGCUGGACCAGAGAAAGCGCCUCCAGAAUGGAAG
  	GCGACGAAGCCCAAGGACCUAGCAGAGUGCAGCAGGCCUUC
  	CAGAGCUUCGUGAACGAGUGCAACAGCAUCGAGUUCAGCUU
  	CGGCUCCUUCGGCGAACAUGUGCGGGUGCUGUGUGCCAGAG
  	UUAGCAGAGGACUUGCUGCCGCUGGCGAGGCCAUCAGAAGA
  	UGCUUCUCUUGCUGCAAGGGCAGCACCCACAGAUACGCCCCU
  	AGAGAUGAUCUGAGCCCUGAGGGCGCAUCUCUGGCCGAAAC
  	ACUGGCCAGAUUUGCCGACGACAUGGGCAUUGAAAGAGGCG
  	CCGACGGAACCUACGACAUCCCUCUGGUGGACGAUUGGAGA
  	AGGGGCGUGCCAUCUAUCGAAGGCGAGGGCAGCGAUAGCAU
  	CUACGAGAUCAUGAUGCCCAUCUACGAAGUGAUGAACAUGG
  	ACCUGGAAACCCGGCGGAGCUUUGCCGUGCAACAGGGCCAU
  	UACCAGGAUCCUAGAGCCAGCGACUACGACCUGCCUAGAGCC
  	UCCGAUUAUGAUCUGCCUCGGAGCCCCUAUCCUACACCUCCU
  	CUGCCUCCAAGAUACCAGCUUCAGAAUAUGGACGUGGAAGC
  	CGGAUUCCGCGAGGCCGUGUAUGCUAGCUUUGUGGCCGGCA
  	UGUACAACUACGUGGUCACCCAGCCUCAAGAGAGAAUCCCC
  	AACAGCCAGCAGGUCGAGGGCAUCCUGAGAGAUAUGCUGAC
  	CAACGGCGACCACCACCAUCACCAUCAU
  CT875_E_NGM_nIgK_nGST	AUGGAAACCCCUGCUCAGCUGCUGUUCCUGCUGCUGCUGUG	343
  	GCUGCCUGAUACCACAGGCAUGAGCCCUAUCCUCGGCUACUG
  	GAAGAUCAAAGGCCUGGUGCAGCCCACCAGACUGCUGCUGG
  	AAUACCUGGAAGAGAAGUACGAGGAACACCUGUACGAGCGC
  	GACGAGGGCGAUAAGUGGCGGAACAAGAAGUUCGAGCUGGG
  	CCUCGAGUUCCCCAACCUGCCUUACUACAUCGACGGCGACGU
  	GAAGCUGACCCAGAGCAUGGCCAUCAUCCGGUAUAUCGCCG
  	ACAAGCACAACAUGCUCGGCGGCUGCCCUAAAGAGCGGGCC
  	GAGAUUUCUAUGCUGGAAGGCGCCGUGCUGGACAUCAGAUA
  	CGGCGUGUCCAGAAUCGCCUACAGCAAGGACUUCGAAACCC
  	UGAAGGUGGACUUCCUGAGCAAGCUGCCCGAGAUGCUGAAG
  	AUGUUCGAGGACCGGCUGUGCCACAAGACCUACCUGAAUGG
  	CGACCACGUGACACACCCCGACUUCAUGCUGUACGACGCCCU
  	GGAUGUGGUGCUGUACAUGGACCCCAUGUGCCUGGACGCCU
  	UUCCAAAGCUCGUGUGCUUCAAGAAGCGGAUCGAGGCCAUU
  	CCUCAGAUCGACAAGUACCUGAAGUCCAGCAAGUAUAUCGC
  	UUGGCCCCUGCAAGGCUGGCAGGCCACAUUUGGAGGCGGAG
  	AUCACCCUCCUAAGAUGAGCAUCAGAGGCGUCGGCGGCAAC
  	GGCAACAGCAGAAUCCCUUCUCACAAUGGCGACGGCAGCAA
  	CAGGCGGAGCCAGAAUACCAAGGGCAACAACAAGGUGGAAG
  	AUCGCGUGUGCAGCCUGUACAGCUCCAGAAGCAACGAGAAC
  	CGCGAGAGCCCUUAUGCCGUGGUGGAUGUGUCCAGCAUGAU
  	CGAGAGCACCCCUACCAGCGGCGAGACAACAAGAGCUAGUA
  	GAGGCGUGCUGAGCCGGUUUCAGAGAGGCCUCGUUCGGAUU
  	GCCGACAAAGUGCGGAGAGCCGUGCAGUGUGCUUGGAGCAG
  	UGUGUCCACAAGCAGAAGCAGCGCCACAAGAGCCGCCGAAU
  	CUGGCAGCUCUAGCAGAACAGCUAGAGGCGCCAGCAGCGGC
  	UACAGAGAGUAUUCUCCAUCUGCCGCCAGAGGCCUGCGGCU
  	GAUGUUUACAGAUUUCUGGCGGACCCGGGUGCUGAGACAGA
  	CAUCUCCUAUGGCUGGCGUGUUCGGCAACCUGGACGUGAAC
  	GAAGCCAGACUGAUGGCCGCCUACACAAGCGAGUGUGCCGA
  	UCACCUGGAAGCCAAAGAACUGGCCGGACCUGAUGGCGUGG
  	CAGCCGCUAGAGAAAUCGCCAAGAGAUGGGAGAAGAGAGUG
  	CGGGACCUGCAGGAUAAGGGCGCUGCUAGAAAGCUGCUGAA
  	CGACCCUCUGGGCAGAAGAACCCCUAACUACCAGAGCAAGA
  	ACCCCGGCGAGUACACCGUGGGCAACUCCAUGUUCUACGACG
  	GACCCCAGGUGGCCAACCUGCAGAAUGUGGAUACAGGCUUC
  	UGGCUGGACAUGCAGCACCUGUCUGAUGUGGUCCUGAGCAG
  	AGAGAUCCAGACCGGCCUGAGAGCCAGAGCCACACUGGAAG
  	AGUCCAUGCCUAUGCUCGAGAAUCUGGAAGAACGGUUCAGA
  	CGGCUGCAAGAGACAUGCGACGCCGCCAGAACAGAGAUCGA
  	GGAAAGCGGCUGGACCAGAGAAAGCGCCUCCAGAAUGGAAG
  	GCGACGAAGCCCAAGGACCUAGCAGAGUGCAGCAGGCCUUC
  	CAGAGCUUCGUGAACGAGUGCAACAGCAUCGAGUUCAGCUU
  	CGGCUCCUUCGGCGAACAUGUGCGGGUGCUGUGUGCCAGAG
  	UUAGCAGAGGACUUGCUGCCGCUGGCGAGGCCAUCAGAAGA
  	UGCUUCUCUUGCUGCAAGGGCAGCACCCACAGAUACGCCCCU
  	AGAGAUGAUCUGAGCCCUGAGGGCGCAUCUCUGGCCGAAAC
  	ACUGGCCAGAUUUGCCGACGACAUGGGCAUUGAAAGAGGCG
  	CCGACGGAACCUACGACAUCCCUCUGGUGGACGAUUGGAGA
  	AGGGGCGUGCCAUCUAUCGAAGGCGAGGGCAGCGAUAGCAU
  	CUACGAGAUCAUGAUGCCCAUCUACGAAGUGAUGAACAUGG
  	ACCUGGAAACCCGGCGGAGCUUUGCCGUGCAACAGGGCCAU
  	UACCAGGAUCCUAGAGCCAGCGACUACGACCUGCCUAGAGCC
  	UCCGAUUAUGAUCUGCCUCGGAGCCCCUAUCCUACACCUCCU
  	CUGCCUCCAAGAUACCAGCUUCAGAAUAUGGACGUGGAAGC
  	CGGAUUCCGCGAGGCCGUGUAUGCUAGCUUUGUGGCCGGCA
  	UGUACAACUACGUGGUCACCCAGCCUCAAGAGAGAAUCCCC
  	AACAGCCAGCAGGUCGAGGGCAUCCUGAGAGAUAUGCUGAC
  	CAACGGCGACCAGACCUUCCGCGACCUGAUGAAGAGAUGGA
  	ACAGAGAGGUGGACAGAGAG
  CT875_E_NGM_nIgK_nGST_cHis	AUGGAAACCCCUGCUCAGCUGCUGUUCCUGCUGCUGCUGUG	344
  	GCUGCCUGAUACCACAGGCAUGAGCCCUAUCCUCGGCUACUG
  	GAAGAUCAAAGGCCUGGUGCAGCCCACCAGACUGCUGCUGG
  	AAUACCUGGAAGAGAAGUACGAGGAACACCUGUACGAGCGC
  	GACGAGGGCGAUAAGUGGCGGAACAAGAAGUUCGAGCUGGG
  	CCUCGAGUUCCCCAACCUGCCUUACUACAUCGACGGCGACGU
  	GAAGCUGACCCAGAGCAUGGCCAUCAUCCGGUAUAUCGCCG
  	ACAAGCACAACAUGCUCGGCGGCUGCCCUAAAGAGCGGGCC
  	GAGAUUUCUAUGCUGGAAGGCGCCGUGCUGGACAUCAGAUA
  	CGGCGUGUCCAGAAUCGCCUACAGCAAGGACUUCGAAACCC
  	UGAAGGUGGACUUCCUGAGCAAGCUGCCCGAGAUGCUGAAG
  	AUGUUCGAGGACCGGCUGUGCCACAAGACCUACCUGAAUGG
  	CGACCACGUGACACACCCCGACUUCAUGCUGUACGACGCCCU
  	GGAUGUGGUGCUGUACAUGGACCCCAUGUGCCUGGACGCCU
  	UUCCAAAGCUCGUGUGCUUCAAGAAGCGGAUCGAGGCCAUU
  	CCUCAGAUCGACAAGUACCUGAAGUCCAGCAAGUAUAUCGC
  	UUGGCCCCUGCAAGGCUGGCAGGCCACAUUUGGAGGCGGAG
  	AUCACCCUCCUAAGAUGAGCAUCAGAGGCGUCGGCGGCAAC
  	GGCAACAGCAGAAUCCCUUCUCACAAUGGCGACGGCAGCAA
  	CAGGCGGAGCCAGAAUACCAAGGGCAACAACAAGGUGGAAG
  	AUCGCGUGUGCAGCCUGUACAGCUCCAGAAGCAACGAGAAC
  	CGCGAGAGCCCUUAUGCCGUGGUGGAUGUGUCCAGCAUGAU
  	CGAGAGCACCCCUACCAGCGGCGAGACAACAAGAGCUAGUA
  	GAGGCGUGCUGAGCCGGUUUCAGAGAGGCCUCGUUCGGAUU
  	GCCGACAAAGUGCGGAGAGCCGUGCAGUGUGCUUGGAGCAG
  	UGUGUCCACAAGCAGAAGCAGCGCCACAAGAGCCGCCGAAU
  	CUGGCAGCUCUAGCAGAACAGCUAGAGGCGCCAGCAGCGGC
  	UACAGAGAGUAUUCUCCAUCUGCCGCCAGAGGCCUGCGGCU
  	GAUGUUUACAGAUUUCUGGCGGACCCGGGUGCUGAGACAGA
  	CAUCUCCUAUGGCUGGCGUGUUCGGCAACCUGGACGUGAAC
  	GAAGCCAGACUGAUGGCCGCCUACACAAGCGAGUGUGCCGA
  	UCACCUGGAAGCCAAAGAACUGGCCGGACCUGAUGGCGUGG
  	CAGCCGCUAGAGAAAUCGCCAAGAGAUGGGAGAAGAGAGUG
  	CGGGACCUGCAGGAUAAGGGCGCUGCUAGAAAGCUGCUGAA
  	CGACCCUCUGGGCAGAAGAACCCCUAACUACCAGAGCAAGA
  	ACCCCGGCGAGUACACCGUGGGCAACUCCAUGUUCUACGACG
  	GACCCCAGGUGGCCAACCUGCAGAAUGUGGAUACAGGCUUC
  	UGGCUGGACAUGCAGCACCUGUCUGAUGUGGUCCUGAGCAG
  	AGAGAUCCAGACCGGCCUGAGAGCCAGAGCCACACUGGAAG
  	AGUCCAUGCCUAUGCUCGAGAAUCUGGAAGAACGGUUCAGA
  	CGGCUGCAAGAGACAUGCGACGCCGCCAGAACAGAGAUCGA
  	GGAAAGCGGCUGGACCAGAGAAAGCGCCUCCAGAAUGGAAG
  	GCGACGAAGCCCAAGGACCUAGCAGAGUGCAGCAGGCCUUC
  	CAGAGCUUCGUGAACGAGUGCAACAGCAUCGAGUUCAGCUU
  	CGGCUCCUUCGGCGAACAUGUGCGGGUGCUGUGUGCCAGAG
  	UUAGCAGAGGACUUGCUGCCGCUGGCGAGGCCAUCAGAAGA
  	UGCUUCUCUUGCUGCAAGGGCAGCACCCACAGAUACGCCCCU
  	AGAGAUGAUCUGAGCCCUGAGGGCGCAUCUCUGGCCGAAAC
  	ACUGGCCAGAUUUGCCGACGACAUGGGCAUUGAAAGAGGCG
  	CCGACGGAACCUACGACAUCCCUCUGGUGGACGAUUGGAGA
  	AGGGGCGUGCCAUCUAUCGAAGGCGAGGGCAGCGAUAGCAU
  	CUACGAGAUCAUGAUGCCCAUCUACGAAGUGAUGAACAUGG
  	ACCUGGAAACCCGGCGGAGCUUUGCCGUGCAACAGGGCCAU
  	UACCAGGAUCCUAGAGCCAGCGACUACGACCUGCCUAGAGCC
  	UCCGAUUAUGAUCUGCCUCGGAGCCCCUAUCCUACACCUCCU
  	CUGCCUCCAAGAUACCAGCUUCAGAAUAUGGACGUGGAAGC
  	CGGAUUCCGCGAGGCCGUGUAUGCUAGCUUUGUGGCCGGCA
  	UGUACAACUACGUGGUCACCCAGCCUCAAGAGAGAAUCCCC
  	AACAGCCAGCAGGUCGAGGGCAUCCUGAGAGAUAUGCUGAC
  	CAACGGCGACCAGACCUUCCGCGACCUGAUGAAGAGAUGGA
  	ACAGAGAGGUGGACAGAGAGCACCACCACCAUCACCAU
  CT875_E_1_458_NGM_nIgK_nGST	AUGGAAACCCCUGCUCAGCUGCUGUUCCUGCUGCUGCUGUG	345
  	GCUGCCUGAUACCACAGGCAUGAGCCCUAUCCUCGGCUACUG
  	GAAGAUCAAAGGCCUGGUGCAGCCCACCAGACUGCUGCUGG
  	AAUACCUGGAAGAGAAGUACGAGGAACACCUGUACGAGCGC
  	GACGAGGGCGAUAAGUGGCGGAACAAGAAGUUCGAGCUGGG
  	CCUCGAGUUCCCCAACCUGCCUUACUACAUCGACGGCGACGU
  	GAAGCUGACCCAGAGCAUGGCCAUCAUCCGGUAUAUCGCCG
  	ACAAGCACAACAUGCUCGGCGGCUGCCCUAAAGAGCGGGCC
  	GAGAUUUCUAUGCUGGAAGGCGCCGUGCUGGACAUCAGAUA
  	CGGCGUGUCCAGAAUCGCCUACAGCAAGGACUUCGAAACCC
  	UGAAGGUGGACUUCCUGAGCAAGCUGCCCGAGAUGCUGAAG
  	AUGUUCGAGGACCGGCUGUGCCACAAGACCUACCUGAAUGG
  	CGACCACGUGACACACCCCGACUUCAUGCUGUACGACGCCCU
  	GGAUGUGGUGCUGUACAUGGACCCCAUGUGCCUGGACGCCU
  	UUCCAAAGCUCGUGUGCUUCAAGAAGCGGAUCGAGGCCAUU
  	CCUCAGAUCGACAAGUACCUGAAGUCCAGCAAGUAUAUCGC
  	UUGGCCCCUGCAAGGCUGGCAGGCCACAUUUGGAGGCGGAG
  	AUCACCCUCCUAAGAUGAGCAUCAGAGGCGUCGGCGGCAAC
  	GGCAACAGCAGAAUCCCUUCUCACAAUGGCGACGGCAGCAA
  	CAGGCGGAGCCAGAAUACCAAGGGCAACAACAAGGUGGAAG
  	AUCGCGUGUGCAGCCUGUACAGCUCCAGAAGCAACGAGAAC
  	CGCGAGAGCCCUUAUGCCGUGGUGGAUGUGUCCAGCAUGAU
  	CGAGAGCACCCCUACCAGCGGCGAGACAACAAGAGCUAGUA
  	GAGGCGUGCUGAGCCGGUUUCAGAGAGGCCUCGUUCGGAUU
  	GCCGACAAAGUGCGGAGAGCCGUGCAGUGUGCUUGGAGCAG
  	UGUGUCCACAAGCAGAAGCAGCGCCACAAGAGCCGCCGAAU
  	CUGGCAGCUCUAGCAGAACAGCUAGAGGCGCCAGCAGCGGC
  	UACAGAGAGUAUUCUCCAUCUGCCGCCAGAGGCCUGCGGCU
  	GAUGUUUACAGAUUUCUGGCGGACCCGGGUGCUGAGACAGA
  	CAUCUCCUAUGGCUGGCGUGUUCGGCAACCUGGACGUGAAC
  	GAAGCCAGACUGAUGGCCGCCUACACAAGCGAGUGUGCCGA
  	UCACCUGGAAGCCAAAGAACUGGCCGGACCUGAUGGCGUGG
  	CAGCCGCUAGAGAAAUCGCCAAGAGAUGGGAGAAGAGAGUG
  	CGGGACCUGCAGGAUAAGGGCGCUGCUAGAAAGCUGCUGAA
  	CGACCCUCUGGGCAGAAGAACCCCUAACUACCAGAGCAAGA
  	ACCCCGGCGAGUACACCGUGGGCAACUCCAUGUUCUACGACG
  	GACCCCAGGUGGCCAACCUGCAGAAUGUGGAUACAGGCUUC
  	UGGCUGGACAUGCAGCACCUGUCUGAUGUGGUCCUGAGCAG
  	AGAGAUCCAGACCGGCCUGAGAGCCAGAGCCACACUGGAAG
  	AGUCCAUGCCUAUGCUCGAGAAUCUGGAAGAACGGUUCAGA
  	CGGCUGCAAGAGACAUGCGACGCCGCCAGAACAGAGAUCGA
  	GGAAAGCGGCUGGACCAGAGAAAGCGCCUCCAGAAUGGAAG
  	GCGACGAAGCCCAAGGACCUAGCAGAGUGCAGCAGGCCUUC
  	CAGAGCUUCGUGAACGAGUGCAACAGCAUCGAGUUCAGCUU
  	CGGCUCCUUCGGCGAACAUGUGCGGGUGCUGUGUGCCAGAG
  	UUAGCAGAGGACUUGCUGCCGCUGGCGAGGCCAUCAGAAGA
  	UGCUUCUCUUGCUGCAAGGGCAGCACCCACAGAUACGCCCCU
  	AGAGAUGAUCUGAGCCCUGAGGGCGCAUCUCUGGCCGAAAC
  	ACUGGCCAGAUUUGCCGACGACAUGGGCAUUGAAAGAGGCG
  	CCGACGGAACCUACGACAUCCCUCUGGUGGACGAUUGGAGA
  	AGGGGCGUGCCAUCUAUCGAAGGCGAGGGAUCU
  CT875_E_1_458_NGM_nIgK_nGST_cHis	AUGGAAACCCCUGCUCAGCUGCUGUUCCUGCUGCUGCUGUG	346
  	GCUGCCUGAUACCACAGGCAUGAGCCCUAUCCUCGGCUACUG
  	GAAGAUCAAAGGCCUGGUGCAGCCCACCAGACUGCUGCUGG
  	AAUACCUGGAAGAGAAGUACGAGGAACACCUGUACGAGCGC
  	GACGAGGGCGAUAAGUGGCGGAACAAGAAGUUCGAGCUGGG
  	CCUCGAGUUCCCCAACCUGCCUUACUACAUCGACGGCGACGU
  	GAAGCUGACCCAGAGCAUGGCCAUCAUCCGGUAUAUCGCCG
  	ACAAGCACAACAUGCUCGGCGGCUGCCCUAAAGAGCGGGCC
  	GAGAUUUCUAUGCUGGAAGGCGCCGUGCUGGACAUCAGAUA
  	CGGCGUGUCCAGAAUCGCCUACAGCAAGGACUUCGAAACCC
  	UGAAGGUGGACUUCCUGAGCAAGCUGCCCGAGAUGCUGAAG
  	AUGUUCGAGGACCGGCUGUGCCACAAGACCUACCUGAAUGG
  	CGACCACGUGACACACCCCGACUUCAUGCUGUACGACGCCCU
  	GGAUGUGGUGCUGUACAUGGACCCCAUGUGCCUGGACGCCU
  	UUCCAAAGCUCGUGUGCUUCAAGAAGCGGAUCGAGGCCAUU
  	CCUCAGAUCGACAAGUACCUGAAGUCCAGCAAGUAUAUCGC
  	UUGGCCCCUGCAAGGCUGGCAGGCCACAUUUGGAGGCGGAG
  	AUCACCCUCCUAAGAUGAGCAUCAGAGGCGUCGGCGGCAAC
  	GGCAACAGCAGAAUCCCUUCUCACAAUGGCGACGGCAGCAA
  	CAGGCGGAGCCAGAAUACCAAGGGCAACAACAAGGUGGAAG
  	AUCGCGUGUGCAGCCUGUACAGCUCCAGAAGCAACGAGAAC
  	CGCGAGAGCCCUUAUGCCGUGGUGGAUGUGUCCAGCAUGAU
  	CGAGAGCACCCCUACCAGCGGCGAGACAACAAGAGCUAGUA
  	GAGGCGUGCUGAGCCGGUUUCAGAGAGGCCUCGUUCGGAUU
  	GCCGACAAAGUGCGGAGAGCCGUGCAGUGUGCUUGGAGCAG
  	UGUGUCCACAAGCAGAAGCAGCGCCACAAGAGCCGCCGAAU
  	CUGGCAGCUCUAGCAGAACAGCUAGAGGCGCCAGCAGCGGC
  	UACAGAGAGUAUUCUCCAUCUGCCGCCAGAGGCCUGCGGCU
  	GAUGUUUACAGAUUUCUGGCGGACCCGGGUGCUGAGACAGA
  	CAUCUCCUAUGGCUGGCGUGUUCGGCAACCUGGACGUGAAC
  	GAAGCCAGACUGAUGGCCGCCUACACAAGCGAGUGUGCCGA
  	UCACCUGGAAGCCAAAGAACUGGCCGGACCUGAUGGCGUGG
  	CAGCCGCUAGAGAAAUCGCCAAGAGAUGGGAGAAGAGAGUG
  	CGGGACCUGCAGGAUAAGGGCGCUGCUAGAAAGCUGCUGAA
  	CGACCCUCUGGGCAGAAGAACCCCUAACUACCAGAGCAAGA
  	ACCCCGGCGAGUACACCGUGGGCAACUCCAUGUUCUACGACG
  	GACCCCAGGUGGCCAACCUGCAGAAUGUGGAUACAGGCUUC
  	UGGCUGGACAUGCAGCACCUGUCUGAUGUGGUCCUGAGCAG
  	AGAGAUCCAGACCGGCCUGAGAGCCAGAGCCACACUGGAAG
  	AGUCCAUGCCUAUGCUCGAGAAUCUGGAAGAACGGUUCAGA
  	CGGCUGCAAGAGACAUGCGACGCCGCCAGAACAGAGAUCGA
  	GGAAAGCGGCUGGACCAGAGAAAGCGCCUCCAGAAUGGAAG
  	GCGACGAAGCCCAAGGACCUAGCAGAGUGCAGCAGGCCUUC
  	CAGAGCUUCGUGAACGAGUGCAACAGCAUCGAGUUCAGCUU
  	CGGCUCCUUCGGCGAACAUGUGCGGGUGCUGUGUGCCAGAG
  	UUAGCAGAGGACUUGCUGCCGCUGGCGAGGCCAUCAGAAGA
  	UGCUUCUCUUGCUGCAAGGGCAGCACCCACAGAUACGCCCCU
  	AGAGAUGAUCUGAGCCCUGAGGGCGCAUCUCUGGCCGAAAC
  	ACUGGCCAGAUUUGCCGACGACAUGGGCAUUGAAAGAGGCG
  	CCGACGGAACCUACGACAUCCCUCUGGUGGACGAUUGGAGA
  	AGGGGCGUGCCAUCUAUCGAAGGCGAGGGCUCUCACCACCA
  	CCAUCACCAU
  CT875_E_1_458_NGM_nIgK	AUGGAAACCCCUGCUCAGCUGCUGUUCCUGCUGCUGCUGUG	347
  	GCUGCCUGAUACCACCGGCAUGUCUAUCAGAGGCGUUGGCG
  	GCAACGGCAACAGCAGAAUCCCUAGCCAUAAUGGCGACGGC
  	AGCAACAGGCGGAGCCAGAAUACCAAGGGCAACAACAAGGU
  	GGAAGAUCGCGUGUGCAGCCUGUACAGCUCCAGAAGCAACG
  	AGAACCGCGAGAGCCCUUAUGCCGUGGUGGAUGUGUCCAGC
  	AUGAUCGAGAGCACCCCUACCAGCGGCGAGACAACAAGAGC
  	UAGUAGAGGCGUGCUGAGCCGGUUUCAGAGAGGCCUCGUUC
  	GGAUCGCUGACAAAGUGCGGAGAGCCGUGCAGUGUGCCUGG
  	UCUAGUGUGUCCACAAGCAGAAGCAGCGCCACAAGAGCCGC
  	CGAGAGCGGAUCUUCUAGCAGAACAGCUAGAGGCGCCAGCA
  	GCGGCUACAGAGAGUAUUCUCCAUCUGCCGCCAGAGGCCUG
  	CGGCUGAUGUUUACAGAUUUCUGGCGGACCCGGGUGCUGAG
  	ACAGACAUCUCCUAUGGCUGGCGUGUUCGGCAACCUGGAUG
  	UGAAUGAGGCCAGACUGAUGGCCGCCUACACAAGCGAAUGU
  	GCCGAUCACCUGGAAGCCAAAGAGCUGGCUGGACCUGACGG
  	UGUUGCCGCCGCUAGAGAAAUCGCCAAGAGAUGGGAGAAGA
  	GAGUGCGGGACCUGCAGGAUAAGGGCGCUGCUAGAAAGCUG
  	CUGAACGACCCUCUGGGCAGAAGAACCCCUAACUACCAGAGC
  	AAGAACCCCGGCGAGUACACCGUGGGCAACUCCAUGUUCUA
  	CGACGGACCCCAGGUGGCCAACCUGCAGAAUGUGGAUACAG
  	GCUUCUGGCUGGAUAUGCAGCACCUGAGCGACGUGGUGCUG
  	UCCAGAGAGAUCCAGACAGGCCUGAGAGCCAGAGCCACACU
  	GGAAGAGUCCAUGCCUAUGCUCGAGAACCUGGAAGAGAGAU
  	UCCGGCGGCUGCAAGAGACAUGUGACGCCGCCAGAACCGAG
  	AUCGAGGAAAGCGGCUGGACAAGAGAAAGCGCCUCCAGAAU
  	GGAAGGCGACGAAGCCCAAGGACCUAGCAGAGUGCAGCAGG
  	CCUUCCAGAGCUUCGUGAACGAGUGCAACAGCAUCGAGUUC
  	AGCUUCGGCUCCUUCGGCGAACAUGUGCGGGUGCUGUGUGC
  	CAGAGUUAGCAGAGGACUUGCUGCCGCUGGCGAGGCCAUCA
  	GAAGAUGCUUCUCUUGCUGCAAGGGCAGCACCCACAGAUAC
  	GCCCCUAGAGAUGAUCUGAGCCCUGAGGGCGCUUCUCUGGC
  	CGAAACACUGGCCAGAUUCGCCGACGAUAUGGGCAUUGAAA
  	GAGGCGCCGACGGAACCUACGACAUCCCUCUGGUGGACGAU
  	UGGAGAAGGGGCGUGCCAUCUAUCGAAGGCGAGGGAUCU
  CT875_E_1_458_NGM_nIgK_cHis	AUGGAAACCCCUGCUCAGCUGCUGUUCCUGCUGCUGCUGUG	348
  	GCUGCCUGAUACCACCGGCAUGUCUAUCAGAGGCGUUGGCG
  	GCAACGGCAACAGCAGAAUCCCUAGCCAUAAUGGCGACGGC
  	AGCAACAGGCGGAGCCAGAAUACCAAGGGCAACAACAAGGU
  	GGAAGAUCGCGUGUGCAGCCUGUACAGCUCCAGAAGCAACG
  	AGAACCGCGAGAGCCCUUAUGCCGUGGUGGAUGUGUCCAGC
  	AUGAUCGAGAGCACCCCUACCAGCGGCGAGACAACAAGAGC
  	UAGUAGAGGCGUGCUGAGCCGGUUUCAGAGAGGCCUCGUUC
  	GGAUCGCUGACAAAGUGCGGAGAGCCGUGCAGUGUGCCUGG
  	UCUAGUGUGUCCACAAGCAGAAGCAGCGCCACAAGAGCCGC
  	CGAGAGCGGAUCUUCUAGCAGAACAGCUAGAGGCGCCAGCA
  	GCGGCUACAGAGAGUAUUCUCCAUCUGCCGCCAGAGGCCUG
  	CGGCUGAUGUUUACAGAUUUCUGGCGGACCCGGGUGCUGAG
  	ACAGACAUCUCCUAUGGCUGGCGUGUUCGGCAACCUGGAUG
  	UGAAUGAGGCCAGACUGAUGGCCGCCUACACAAGCGAAUGU
  	GCCGAUCACCUGGAAGCCAAAGAGCUGGCUGGACCUGACGG
  	UGUUGCCGCCGCUAGAGAAAUCGCCAAGAGAUGGGAGAAGA
  	GAGUGCGGGACCUGCAGGAUAAGGGCGCUGCUAGAAAGCUG
  	CUGAACGACCCUCUGGGCAGAAGAACCCCUAACUACCAGAGC
  	AAGAACCCCGGCGAGUACACCGUGGGCAACUCCAUGUUCUA
  	CGACGGACCCCAGGUGGCCAACCUGCAGAAUGUGGAUACAG
  	GCUUCUGGCUGGAUAUGCAGCACCUGAGCGACGUGGUGCUG
  	UCCAGAGAGAUCCAGACAGGCCUGAGAGCCAGAGCCACACU
  	GGAAGAGUCCAUGCCUAUGCUCGAGAACCUGGAAGAGAGAU
  	UCCGGCGGCUGCAAGAGACAUGUGACGCCGCCAGAACCGAG
  	AUCGAGGAAAGCGGCUGGACAAGAGAAAGCGCCUCCAGAAU
  	GGAAGGCGACGAAGCCCAAGGACCUAGCAGAGUGCAGCAGG
  	CCUUCCAGAGCUUCGUGAACGAGUGCAACAGCAUCGAGUUC
  	AGCUUCGGCUCCUUCGGCGAACAUGUGCGGGUGCUGUGUGC
  	CAGAGUUAGCAGAGGACUUGCUGCCGCUGGCGAGGCCAUCA
  	GAAGAUGCUUCUCUUGCUGCAAGGGCAGCACCCACAGAUAC
  	GCCCCUAGAGAUGAUCUGAGCCCUGAGGGCGCUUCUCUGGC
  	CGAAACACUGGCCAGAUUCGCCGACGAUAUGGGCAUUGAAA
  	GAGGCGCCGACGGAACCUACGACAUCCCUCUGGUGGACGAU
  	UGGAGAAGGGGCGUGCCAUCUAUCGAAGGCGAGGGCUCUCA
  	CCACCACCAUCACCAU
  CT875_E_1_574_NGM_nIgK	AUGGAAACCCCUGCUCAGCUGCUGUUCCUGCUGCUGCUGUG	349
  	GCUGCCUGAUACCACCGGCAUGUCUAUCAGAGGCGUUGGCG
  	GCAACGGCAACAGCAGAAUCCCUAGCCAUAAUGGCGACGGC
  	AGCAACAGGCGGAGCCAGAAUACCAAGGGCAACAACAAGGU
  	GGAAGAUCGCGUGUGCAGCCUGUACAGCUCCAGAAGCAACG
  	AGAACCGCGAGAGCCCUUAUGCCGUGGUGGAUGUGUCCAGC
  	AUGAUCGAGAGCACCCCUACCAGCGGCGAGACAACAAGAGC
  	UAGUAGAGGCGUGCUGAGCCGGUUUCAGAGAGGCCUCGUUC
  	GGAUCGCUGACAAAGUGCGGAGAGCCGUGCAGUGUGCCUGG
  	UCUAGUGUGUCCACAAGCAGAAGCAGCGCCACAAGAGCCGC
  	CGAGAGCGGAUCUUCUAGCAGAACAGCUAGAGGCGCCAGCA
  	GCGGCUACAGAGAGUAUUCUCCAUCUGCCGCCAGAGGCCUG
  	CGGCUGAUGUUUACAGAUUUCUGGCGGACCCGGGUGCUGAG
  	ACAGACAUCUCCUAUGGCUGGCGUGUUCGGCAACCUGGAUG
  	UGAAUGAGGCCAGACUGAUGGCCGCCUACACAAGCGAAUGU
  	GCCGAUCACCUGGAAGCCAAAGAGCUGGCUGGACCUGACGG
  	UGUUGCCGCCGCUAGAGAAAUCGCCAAGAGAUGGGAGAAGA
  	GAGUGCGGGACCUGCAGGAUAAGGGCGCUGCUAGAAAGCUG
  	CUGAACGACCCUCUGGGCAGAAGAACCCCUAACUACCAGAGC
  	AAGAACCCCGGCGAGUACACCGUGGGCAACUCCAUGUUCUA
  	CGACGGACCCCAGGUGGCCAACCUGCAGAAUGUGGAUACAG
  	GCUUCUGGCUGGAUAUGCAGCACCUGAGCGACGUGGUGCUG
  	UCCAGAGAGAUCCAGACAGGCCUGAGAGCCAGAGCCACACU
  	GGAAGAGUCCAUGCCUAUGCUCGAGAACCUGGAAGAGAGAU
  	UCCGGCGGCUGCAAGAGACAUGUGACGCCGCCAGAACCGAG
  	AUCGAGGAAAGCGGCUGGACAAGAGAAAGCGCCUCCAGAAU
  	GGAAGGCGACGAAGCCCAAGGACCUAGCAGAGUGCAGCAGG
  	CCUUCCAGAGCUUCGUGAACGAGUGCAACAGCAUCGAGUUC
  	AGCUUCGGCUCCUUCGGCGAACAUGUGCGGGUGCUGUGUGC
  	CAGAGUUAGCAGAGGACUUGCUGCCGCUGGCGAGGCCAUCA
  	GAAGAUGCUUCUCUUGCUGCAAGGGCAGCACCCACAGAUAC
  	GCCCCUAGAGAUGAUCUGAGCCCUGAGGGCGCUUCUCUGGC
  	CGAAACACUGGCCAGAUUCGCCGACGAUAUGGGCAUUGAAA
  	GAGGCGCCGACGGAACCUACGACAUCCCUCUGGUGGACGAU
  	UGGAGAAGGGGCGUGCCAUCUAUCGAAGGCGAGGGCAGCGA
  	UAGCAUCUACGAGAUCAUGAUGCCCAUCUACGAAGUGAUGA
  	ACAUGGACCUGGAAACCCGGCGGAGCUUUGCCGUGCAGCAA
  	GGCCAUUACCAGGAUCCUAGAGCCAGCGACUACGACCUGCCU
  	AGAGCCUCCGAUUAUGAUCUGCCUCGGAGCCCCUAUCCUACA
  	CCUCCUCUGCCUCCAAGAUACCAGCUUCAGAAUAUGGACGU
  	GGAAGCCGGAUUCCGCGAGGCCGUGUAUGCUAGCUUUGUGG
  	CCGGCAUGUACAACUACGUGGUCACCCAGCCUCAAGAGAGA
  	AUCCCCAACAGCCAGCAGGUCGAGGGCAUCCUGAGAGAUAU
  	GCUGACCAACGGCGAC
  CT875_E_1_574_nIgK_nGST	AUGGAAACCCCUGCUCAGCUGCUGUUCCUGCUGCUGCUGUG	350
  	GCUGCCUGAUACCACAGGCAUGAGCCCUAUCCUCGGCUACUG
  	GAAGAUCAAAGGCCUGGUGCAGCCCACCAGACUGCUGCUGG
  	AAUACCUGGAAGAGAAGUACGAGGAACACCUGUACGAGCGC
  	GACGAGGGCGAUAAGUGGCGGAACAAGAAGUUCGAGCUGGG
  	CCUCGAGUUCCCCAACCUGCCUUACUACAUCGACGGCGACGU
  	GAAGCUGACCCAGAGCAUGGCCAUCAUCCGGUAUAUCGCCG
  	ACAAGCACAACAUGCUCGGCGGCUGCCCUAAAGAGCGGGCC
  	GAGAUUUCUAUGCUGGAAGGCGCCGUGCUGGACAUCAGAUA
  	CGGCGUGUCCAGAAUCGCCUACAGCAAGGACUUCGAAACCC
  	UGAAGGUGGACUUCCUGAGCAAGCUGCCCGAGAUGCUGAAG
  	AUGUUCGAGGACCGGCUGUGCCACAAGACCUACCUGAAUGG
  	CGACCACGUGACACACCCCGACUUCAUGCUGUACGACGCCCU
  	GGAUGUGGUGCUGUACAUGGACCCCAUGUGCCUGGACGCCU
  	UUCCAAAGCUCGUGUGCUUCAAGAAGCGGAUCGAGGCCAUU
  	CCUCAGAUCGACAAGUACCUGAAGUCCAGCAAGUAUAUCGC
  	UUGGCCCCUGCAAGGCUGGCAGGCCACAUUUGGAGGCGGAG
  	AUCACCCUCCUAAGAUGAGCAUCAGAGGCGUCGGCGGCAAC
  	GGCAACAGCAGAAUCCCUUCUCACAAUGGCGACGGCAGCAA
  	CAGGCGGAGCCAGAAUACCAAGGGCAACAACAAGGUGGAAG
  	AUCGCGUGUGCAGCCUGUACAGCUCCAGAAGCAACGAGAAC
  	CGCGAGAGCCCUUAUGCCGUGGUGGAUGUGUCCAGCAUGAU
  	CGAGAGCACCCCUACCAGCGGCGAGACAACAAGAGCUAGUA
  	GAGGCGUGCUGAGCCGGUUUCAGAGAGGCCUCGUUCGGAUU
  	GCCGACAAAGUGCGGAGAGCCGUGCAGUGUGCUUGGAGCAG
  	UGUGUCCACAAGCAGAAGCAGCGCCACAAGAGCCGCCGAAU
  	CUGGCAGCUCUAGCAGAACAGCUAGAGGCGCCAGCAGCGGC
  	UACAGAGAGUAUUCUCCAUCUGCCGCCAGAGGCCUGCGGCU
  	GAUGUUUACAGAUUUCUGGCGGACCCGGGUGCUGAGACAGA
  	CAUCUCCUAUGGCUGGCGUGUUCGGCAACCUGGACGUGAAC
  	GAAGCCAGACUGAUGGCCGCCUACACAAGCGAGUGUGCCGA
  	UCACCUGGAAGCCAAAGAACUGGCCGGACCUGAUGGCGUGG
  	CAGCCGCUAGAGAAAUCGCCAAGAGAUGGGAGAAGAGAGUG
  	CGGGACCUGCAGGAUAAGGGCGCUGCUAGAAAGCUGCUGAA
  	CGACCCUCUGGGCAGAAGAACCCCUAACUACCAGAGCAAGA
  	ACCCCGGCGAGUACACCGUGGGCAACUCCAUGUUCUACGACG
  	GACCCCAGGUGGCCAACCUGCAGAAUGUGGAUACAGGCUUC
  	UGGCUGGACAUGAGCAACCUGAGCGACGUGGUCCUGAGCAG
  	AGAGAUCCAGACAGGCCUGAGAGCCAGAGCCACACUGGAAG
  	AGUCCAUGCCUAUGCUCGAGAAUCUGGAAGAACGGUUCAGA
  	CGGCUGCAAGAGACAUGCGACGCCGCCAGAACAGAGAUCGA
  	GGAAAGCGGCUGGACCAGAGAAAGCGCCUCCAGAAUGGAAG
  	GCGACGAAGCCCAAGGACCUAGCAGAGUGCAGCAGGCCUUC
  	CAGAGCUUCGUGAACGAGUGCAACAGCAUCGAGUUCAGCUU
  	CGGCUCCUUCGGCGAACAUGUGCGGGUGCUGUGUGCCAGAG
  	UUAGCAGAGGACUUGCUGCCGCUGGCGAGGCCAUCAGAAGA
  	UGCUUCUCUUGCUGCAAGGGCAGCACCCACAGAUACGCCCCU
  	AGAGAUGAUCUGAGCCCUGAGGGCGCAUCUCUGGCCGAAAC
  	ACUGGCCAGAUUUGCCGACGACAUGGGCAUUGAAAGAGGCG
  	CCGACGGAACCUACGACAUCCCUCUGGUGGACGAUUGGAGA
  	AGGGGCGUGCCAUCUAUCGAAGGCGAGGGCAGCGAUAGCAU
  	CUACGAGAUCAUGAUGCCCAUCUACGAAGUGAUGAACAUGG
  	ACCUGGAAACCCGGCGGAGCUUUGCCGUGCAACAGGGCCAU
  	UACCAGGAUCCUAGAGCCAGCGACUACGACCUGCCUAGAGCC
  	UCCGAUUAUGAUCUGCCUCGGAGCCCCUAUCCUACACCUCCU
  	CUGCCUCCAAGAUACCAGCUUCAGAAUAUGGACGUGGAAGC
  	CGGAUUCCGCGAGGCCGUGUAUGCUAGCUUUGUGGCCGGCA
  	UGUACAACUACGUGGUCACCCAGCCUCAAGAGAGAAUCCCC
  	AACAGCCAGCAGGUCGAGGGCAUCCUGAGAGAUAUGCUGAC
  	CAACGGCAGC
  CT875_E_1_574_nIgK_nGST_cHis	AUGGAAACCCCUGCUCAGCUGCUGUUCCUGCUGCUGCUGUG	351
  	GCUGCCUGAUACCACAGGCAUGAGCCCUAUCCUCGGCUACUG
  	GAAGAUCAAAGGCCUGGUGCAGCCCACCAGACUGCUGCUGG
  	AAUACCUGGAAGAGAAGUACGAGGAACACCUGUACGAGCGC
  	GACGAGGGCGAUAAGUGGCGGAACAAGAAGUUCGAGCUGGG
  	CCUCGAGUUCCCCAACCUGCCUUACUACAUCGACGGCGACGU
  	GAAGCUGACCCAGAGCAUGGCCAUCAUCCGGUAUAUCGCCG
  	ACAAGCACAACAUGCUCGGCGGCUGCCCUAAAGAGCGGGCC
  	GAGAUUUCUAUGCUGGAAGGCGCCGUGCUGGACAUCAGAUA
  	CGGCGUGUCCAGAAUCGCCUACAGCAAGGACUUCGAAACCC
  	UGAAGGUGGACUUCCUGAGCAAGCUGCCCGAGAUGCUGAAG
  	AUGUUCGAGGACCGGCUGUGCCACAAGACCUACCUGAAUGG
  	CGACCACGUGACACACCCCGACUUCAUGCUGUACGACGCCCU
  	GGAUGUGGUGCUGUACAUGGACCCCAUGUGCCUGGACGCCU
  	UUCCAAAGCUCGUGUGCUUCAAGAAGCGGAUCGAGGCCAUU
  	CCUCAGAUCGACAAGUACCUGAAGUCCAGCAAGUAUAUCGC
  	UUGGCCCCUGCAAGGCUGGCAGGCCACAUUUGGAGGCGGAG
  	AUCACCCUCCUAAGAUGAGCAUCAGAGGCGUCGGCGGCAAC
  	GGCAACAGCAGAAUCCCUUCUCACAAUGGCGACGGCAGCAA
  	CAGGCGGAGCCAGAAUACCAAGGGCAACAACAAGGUGGAAG
  	AUCGCGUGUGCAGCCUGUACAGCUCCAGAAGCAACGAGAAC
  	CGCGAGAGCCCUUAUGCCGUGGUGGAUGUGUCCAGCAUGAU
  	CGAGAGCACCCCUACCAGCGGCGAGACAACAAGAGCUAGUA
  	GAGGCGUGCUGAGCCGGUUUCAGAGAGGCCUCGUUCGGAUU
  	GCCGACAAAGUGCGGAGAGCCGUGCAGUGUGCUUGGAGCAG
  	UGUGUCCACAAGCAGAAGCAGCGCCACAAGAGCCGCCGAAU
  	CUGGCAGCUCUAGCAGAACAGCUAGAGGCGCCAGCAGCGGC
  	UACAGAGAGUAUUCUCCAUCUGCCGCCAGAGGCCUGCGGCU
  	GAUGUUUACAGAUUUCUGGCGGACCCGGGUGCUGAGACAGA
  	CAUCUCCUAUGGCUGGCGUGUUCGGCAACCUGGACGUGAAC
  	GAAGCCAGACUGAUGGCCGCCUACACAAGCGAGUGUGCCGA
  	UCACCUGGAAGCCAAAGAACUGGCCGGACCUGAUGGCGUGG
  	CAGCCGCUAGAGAAAUCGCCAAGAGAUGGGAGAAGAGAGUG
  	CGGGACCUGCAGGAUAAGGGCGCUGCUAGAAAGCUGCUGAA
  	CGACCCUCUGGGCAGAAGAACCCCUAACUACCAGAGCAAGA
  	ACCCCGGCGAGUACACCGUGGGCAACUCCAUGUUCUACGACG
  	GACCCCAGGUGGCCAACCUGCAGAAUGUGGAUACAGGCUUC
  	UGGCUGGACAUGAGCAACCUGAGCGACGUGGUCCUGAGCAG
  	AGAGAUCCAGACAGGCCUGAGAGCCAGAGCCACACUGGAAG
  	AGUCCAUGCCUAUGCUCGAGAAUCUGGAAGAACGGUUCAGA
  	CGGCUGCAAGAGACAUGCGACGCCGCCAGAACAGAGAUCGA
  	GGAAAGCGGCUGGACCAGAGAAAGCGCCUCCAGAAUGGAAG
  	GCGACGAAGCCCAAGGACCUAGCAGAGUGCAGCAGGCCUUC
  	CAGAGCUUCGUGAACGAGUGCAACAGCAUCGAGUUCAGCUU
  	CGGCUCCUUCGGCGAACAUGUGCGGGUGCUGUGUGCCAGAG
  	UUAGCAGAGGACUUGCUGCCGCUGGCGAGGCCAUCAGAAGA
  	UGCUUCUCUUGCUGCAAGGGCAGCACCCACAGAUACGCCCCU
  	AGAGAUGAUCUGAGCCCUGAGGGCGCAUCUCUGGCCGAAAC
  	ACUGGCCAGAUUUGCCGACGACAUGGGCAUUGAAAGAGGCG
  	CCGACGGAACCUACGACAUCCCUCUGGUGGACGAUUGGAGA
  	AGGGGCGUGCCAUCUAUCGAAGGCGAGGGCAGCGAUAGCAU
  	CUACGAGAUCAUGAUGCCCAUCUACGAAGUGAUGAACAUGG
  	ACCUGGAAACCCGGCGGAGCUUUGCCGUGCAACAGGGCCAU
  	UACCAGGAUCCUAGAGCCAGCGACUACGACCUGCCUAGAGCC
  	UCCGAUUAUGAUCUGCCUCGGAGCCCCUAUCCUACACCUCCU
  	CUGCCUCCAAGAUACCAGCUUCAGAAUAUGGACGUGGAAGC
  	CGGAUUCCGCGAGGCCGUGUAUGCUAGCUUUGUGGCCGGCA
  	UGUACAACUACGUGGUCACCCAGCCUCAAGAGAGAAUCCCC
  	AACAGCCAGCAGGUCGAGGGCAUCCUGAGAGAUAUGCUGAC
  	CAACGGCAGCCACCACCACCAUCACCAU
  CT875_E_nIgK_nGST	AUGGAAACCCCUGCUCAGCUGCUGUUCCUGCUGCUGCUGUG	352
  	GCUGCCUGAUACCACAGGCAUGAGCCCUAUCCUCGGCUACUG
  	GAAGAUCAAAGGCCUGGUGCAGCCCACCAGACUGCUGCUGG
  	AAUACCUGGAAGAGAAGUACGAGGAACACCUGUACGAGCGC
  	GACGAGGGCGAUAAGUGGCGGAACAAGAAGUUCGAGCUGGG
  	CCUCGAGUUCCCCAACCUGCCUUACUACAUCGACGGCGACGU
  	GAAGCUGACCCAGAGCAUGGCCAUCAUCCGGUAUAUCGCCG
  	ACAAGCACAACAUGCUCGGCGGCUGCCCUAAAGAGCGGGCC
  	GAGAUUUCUAUGCUGGAAGGCGCCGUGCUGGACAUCAGAUA
  	CGGCGUGUCCAGAAUCGCCUACAGCAAGGACUUCGAAACCC
  	UGAAGGUGGACUUCCUGAGCAAGCUGCCCGAGAUGCUGAAG
  	AUGUUCGAGGACCGGCUGUGCCACAAGACCUACCUGAAUGG
  	CGACCACGUGACACACCCCGACUUCAUGCUGUACGACGCCCU
  	GGAUGUGGUGCUGUACAUGGACCCCAUGUGCCUGGACGCCU
  	UUCCAAAGCUCGUGUGCUUCAAGAAGCGGAUCGAGGCCAUU
  	CCUCAGAUCGACAAGUACCUGAAGUCCAGCAAGUAUAUCGC
  	UUGGCCCCUGCAAGGCUGGCAGGCCACAUUUGGAGGCGGAG
  	AUCACCCUCCUAAGAUGAGCAUCAGAGGCGUCGGCGGCAAC
  	GGCAACAGCAGAAUCCCUUCUCACAAUGGCGACGGCAGCAA
  	CAGGCGGAGCCAGAAUACCAAGGGCAACAACAAGGUGGAAG
  	AUCGCGUGUGCAGCCUGUACAGCUCCAGAAGCAACGAGAAC
  	CGCGAGAGCCCUUAUGCCGUGGUGGAUGUGUCCAGCAUGAU
  	CGAGAGCACCCCUACCAGCGGCGAGACAACAAGAGCUAGUA
  	GAGGCGUGCUGAGCCGGUUUCAGAGAGGCCUCGUUCGGAUU
  	GCCGACAAAGUGCGGAGAGCCGUGCAGUGUGCUUGGAGCAG
  	UGUGUCCACAAGCAGAAGCAGCGCCACAAGAGCCGCCGAAU
  	CUGGCAGCUCUAGCAGAACAGCUAGAGGCGCCAGCAGCGGC
  	UACAGAGAGUAUUCUCCAUCUGCCGCCAGAGGCCUGCGGCU
  	GAUGUUUACAGAUUUCUGGCGGACCCGGGUGCUGAGACAGA
  	CAUCUCCUAUGGCUGGCGUGUUCGGCAACCUGGACGUGAAC
  	GAAGCCAGACUGAUGGCCGCCUACACAAGCGAGUGUGCCGA
  	UCACCUGGAAGCCAAAGAACUGGCCGGACCUGAUGGCGUGG
  	CAGCCGCUAGAGAAAUCGCCAAGAGAUGGGAGAAGAGAGUG
  	CGGGACCUGCAGGAUAAGGGCGCUGCUAGAAAGCUGCUGAA
  	CGACCCUCUGGGCAGAAGAACCCCUAACUACCAGAGCAAGA
  	ACCCCGGCGAGUACACCGUGGGCAACUCCAUGUUCUACGACG
  	GACCCCAGGUGGCCAACCUGCAGAAUGUGGAUACAGGCUUC
  	UGGCUGGACAUGAGCAACCUGAGCGACGUGGUCCUGAGCAG
  	AGAGAUCCAGACAGGCCUGAGAGCCAGAGCCACACUGGAAG
  	AGUCCAUGCCUAUGCUCGAGAAUCUGGAAGAACGGUUCAGA
  	CGGCUGCAAGAGACAUGCGACGCCGCCAGAACAGAGAUCGA
  	GGAAAGCGGCUGGACCAGAGAAAGCGCCUCCAGAAUGGAAG
  	GCGACGAAGCCCAAGGACCUAGCAGAGUGCAGCAGGCCUUC
  	CAGAGCUUCGUGAACGAGUGCAACAGCAUCGAGUUCAGCUU
  	CGGCUCCUUCGGCGAACAUGUGCGGGUGCUGUGUGCCAGAG
  	UUAGCAGAGGACUUGCUGCCGCUGGCGAGGCCAUCAGAAGA
  	UGCUUCUCUUGCUGCAAGGGCAGCACCCACAGAUACGCCCCU
  	AGAGAUGAUCUGAGCCCUGAGGGCGCAUCUCUGGCCGAAAC
  	ACUGGCCAGAUUUGCCGACGACAUGGGCAUUGAAAGAGGCG
  	CCGACGGAACCUACGACAUCCCUCUGGUGGACGAUUGGAGA
  	AGGGGCGUGCCAUCUAUCGAAGGCGAGGGCAGCGAUAGCAU
  	CUACGAGAUCAUGAUGCCCAUCUACGAAGUGAUGAACAUGG
  	ACCUGGAAACCCGGCGGAGCUUUGCCGUGCAACAGGGCCAU
  	UACCAGGAUCCUAGAGCCAGCGACUACGACCUGCCUAGAGCC
  	UCCGAUUAUGAUCUGCCUCGGAGCCCCUAUCCUACACCUCCU
  	CUGCCUCCAAGAUACCAGCUUCAGAAUAUGGACGUGGAAGC
  	CGGAUUCCGCGAGGCCGUGUAUGCUAGCUUUGUGGCCGGCA
  	UGUACAACUACGUGGUCACCCAGCCUCAAGAGAGAAUCCCC
  	AACAGCCAGCAGGUCGAGGGCAUCCUGAGAGAUAUGCUGAC
  	CAACGGCAGCCAGACCUUCCGCGACCUGAUGAAGAGAUGGA
  	ACAGAGAGGUGGACAGAGAG
  CT875_E_nIgK_nGST_cHis	AUGGAAACCCCUGCUCAGCUGCUGUUCCUGCUGCUGCUGUG	353
  	GCUGCCUGAUACCACAGGCAUGAGCCCUAUCCUCGGCUACUG
  	GAAGAUCAAAGGCCUGGUGCAGCCCACCAGACUGCUGCUGG
  	AAUACCUGGAAGAGAAGUACGAGGAACACCUGUACGAGCGC
  	GACGAGGGCGAUAAGUGGCGGAACAAGAAGUUCGAGCUGGG
  	CCUCGAGUUCCCCAACCUGCCUUACUACAUCGACGGCGACGU
  	GAAGCUGACCCAGAGCAUGGCCAUCAUCCGGUAUAUCGCCG
  	ACAAGCACAACAUGCUCGGCGGCUGCCCUAAAGAGCGGGCC
  	GAGAUUUCUAUGCUGGAAGGCGCCGUGCUGGACAUCAGAUA
  	CGGCGUGUCCAGAAUCGCCUACAGCAAGGACUUCGAAACCC
  	UGAAGGUGGACUUCCUGAGCAAGCUGCCCGAGAUGCUGAAG
  	AUGUUCGAGGACCGGCUGUGCCACAAGACCUACCUGAAUGG
  	CGACCACGUGACACACCCCGACUUCAUGCUGUACGACGCCCU
  	GGAUGUGGUGCUGUACAUGGACCCCAUGUGCCUGGACGCCU
  	UUCCAAAGCUCGUGUGCUUCAAGAAGCGGAUCGAGGCCAUU
  	CCUCAGAUCGACAAGUACCUGAAGUCCAGCAAGUAUAUCGC
  	UUGGCCCCUGCAAGGCUGGCAGGCCACAUUUGGAGGCGGAG
  	AUCACCCUCCUAAGAUGAGCAUCAGAGGCGUCGGCGGCAAC
  	GGCAACAGCAGAAUCCCUUCUCACAAUGGCGACGGCAGCAA
  	CAGGCGGAGCCAGAAUACCAAGGGCAACAACAAGGUGGAAG
  	AUCGCGUGUGCAGCCUGUACAGCUCCAGAAGCAACGAGAAC
  	CGCGAGAGCCCUUAUGCCGUGGUGGAUGUGUCCAGCAUGAU
  	CGAGAGCACCCCUACCAGCGGCGAGACAACAAGAGCUAGUA
  	GAGGCGUGCUGAGCCGGUUUCAGAGAGGCCUCGUUCGGAUU
  	GCCGACAAAGUGCGGAGAGCCGUGCAGUGUGCUUGGAGCAG
  	UGUGUCCACAAGCAGAAGCAGCGCCACAAGAGCCGCCGAAU
  	CUGGCAGCUCUAGCAGAACAGCUAGAGGCGCCAGCAGCGGC
  	UACAGAGAGUAUUCUCCAUCUGCCGCCAGAGGCCUGCGGCU
  	GAUGUUUACAGAUUUCUGGCGGACCCGGGUGCUGAGACAGA
  	CAUCUCCUAUGGCUGGCGUGUUCGGCAACCUGGACGUGAAC
  	GAAGCCAGACUGAUGGCCGCCUACACAAGCGAGUGUGCCGA
  	UCACCUGGAAGCCAAAGAACUGGCCGGACCUGAUGGCGUGG
  	CAGCCGCUAGAGAAAUCGCCAAGAGAUGGGAGAAGAGAGUG
  	CGGGACCUGCAGGAUAAGGGCGCUGCUAGAAAGCUGCUGAA
  	CGACCCUCUGGGCAGAAGAACCCCUAACUACCAGAGCAAGA
  	ACCCCGGCGAGUACACCGUGGGCAACUCCAUGUUCUACGACG
  	GACCCCAGGUGGCCAACCUGCAGAAUGUGGAUACAGGCUUC
  	UGGCUGGACAUGAGCAACCUGAGCGACGUGGUCCUGAGCAG
  	AGAGAUCCAGACAGGCCUGAGAGCCAGAGCCACACUGGAAG
  	AGUCCAUGCCUAUGCUCGAGAAUCUGGAAGAACGGUUCAGA
  	CGGCUGCAAGAGACAUGCGACGCCGCCAGAACAGAGAUCGA
  	GGAAAGCGGCUGGACCAGAGAAAGCGCCUCCAGAAUGGAAG
  	GCGACGAAGCCCAAGGACCUAGCAGAGUGCAGCAGGCCUUC
  	CAGAGCUUCGUGAACGAGUGCAACAGCAUCGAGUUCAGCUU
  	CGGCUCCUUCGGCGAACAUGUGCGGGUGCUGUGUGCCAGAG
  	UUAGCAGAGGACUUGCUGCCGCUGGCGAGGCCAUCAGAAGA
  	UGCUUCUCUUGCUGCAAGGGCAGCACCCACAGAUACGCCCCU
  	AGAGAUGAUCUGAGCCCUGAGGGCGCAUCUCUGGCCGAAAC
  	ACUGGCCAGAUUUGCCGACGACAUGGGCAUUGAAAGAGGCG
  	CCGACGGAACCUACGACAUCCCUCUGGUGGACGAUUGGAGA
  	AGGGGCGUGCCAUCUAUCGAAGGCGAGGGCAGCGAUAGCAU
  	CUACGAGAUCAUGAUGCCCAUCUACGAAGUGAUGAACAUGG
  	ACCUGGAAACCCGGCGGAGCUUUGCCGUGCAACAGGGCCAU
  	UACCAGGAUCCUAGAGCCAGCGACUACGACCUGCCUAGAGCC
  	UCCGAUUAUGAUCUGCCUCGGAGCCCCUAUCCUACACCUCCU
  	CUGCCUCCAAGAUACCAGCUUCAGAAUAUGGACGUGGAAGC
  	CGGAUUCCGCGAGGCCGUGUAUGCUAGCUUUGUGGCCGGCA
  	UGUACAACUACGUGGUCACCCAGCCUCAAGAGAGAAUCCCC
  	AACAGCCAGCAGGUCGAGGGCAUCCUGAGAGAUAUGCUGAC
  	CAACGGCAGCCAGACCUUCCGCGACCUGAUGAAGAGAUGGA
  	ACAGAGAGGUGGACAGAGAGCACCACCACCAUCACCAU
  CT875_E_nFc	AUGGAAACCCCUGCUCAGCUGCUGUUCCUGCUGCUGCUGUG	354
  	GCUGCCUGAUACAACCGGCGAGCCUAAGAGCUGCGACAAGA
  	CCCACACCUGUCCUCCAUGUCCUGCUCCAGAACUGCUCGGCG
  	GACCUUCCGUGUUCCUGUUUCCUCCAAAGCCUAAGGACACCC
  	UGAUGAUCAGCAGAACCCCUGAAGUGACCUGCGUGGUGGUG
  	GAUGUGUCCCACGAGGAUCCCGAAGUGAAGUUCAAUUGGUA
  	CGUGGACGGCGUGGAAGUGCACAACGCCAAGACCAAGCCUA
  	GAGAGGAACAGUACAACAGCACCUACAGAGUGGUGUCCGUG
  	CUGACCGUGCUGCACCAGGAUUGGCUGAACGGCAAAGAGUA
  	CAAGUGCAAGGUGUCCAACAAGGCCCUGCCUGCUCCUAUCG
  	AGAAGACCAUCAGCAAGGCCAAGGGCCAGCCAAGAGAACCC
  	CAGGUGUACACACUGCCUCCAAGCAGAGAUGAGCUGACCAA
  	GAACCAGGUGUCCCUGACCUGUCUGGUCAAGGGCUUCUACC
  	CCUCCGAUAUCGCCGUGGAAUGGGAGAGCAAUGGCCAGCCU
  	GAGAACAACUACAAGACAACCCCUCCUGUGCUGGACAGCGA
  	CGGCUCAUUCUUCCUGUACAGCAAGCUGACAGUGGACAAGA
  	GCAGAUGGCAGCAGGGCAACGUGUUCAGCUGCAGCGUGAUG
  	CACGAGGCCCUGCACAAUCACUACACCCAGAAGUCCCUGUCU
  	CUGAGCCCCGGCAAGAUGAGCAUCAGAGGCGUUGGCGGCAA
  	CGGCAACAGCAGAAUCCCUAGCCAUAAUGGCGACGGCAGCA
  	ACAGGCGGAGCCAGAAUACCAAGGGCAACAACAAGGUGGAA
  	GAUCGCGUGUGCAGCCUGUACUCCAGCAGAAGCAACGAGAA
  	CCGCGAGAGCCCUUAUGCCGUGGUCGACGUGUCCAGCAUGA
  	UCGAGAGCACACCUACCAGCGGCGAGACAACCAGAGCUAGU
  	AGAGGCGUGCUGAGCCGGUUUCAGAGAGGCCUCGUUCGGAU
  	CGCUGACAAAGUGCGGAGAGCCGUGCAGUGUGCCUGGUCUA
  	GUGUGUCCACCAGCAGAUCCUCUGCCACAAGAGCCGCCGAGU
  	CUGGCAGCUCUAGCAGAACAGCUAGAGGCGCCAGCAGCGGC
  	UACAGAGAGUAUUCUCCAUCUGCCGCCAGAGGCCUGCGGCU
  	GAUGUUUACAGAUUUCUGGCGGACCCGGGUGCUGAGACAGA
  	CAUCUCCUAUGGCUGGCGUGUUCGGCAACCUGGAUGUGAAU
  	GAGGCCAGACUGAUGGCCGCCUACACAAGCGAAUGUGCCGA
  	UCACCUGGAAGCCAAAGAGCUGGCUGGACCUGACGGUGUUG
  	CCGCCGCUAGAGAAAUCGCCAAGAGAUGGGAGAAGAGAGUG
  	CGGGACCUGCAGGAUAAGGGCGCUGCUAGAAAGCUGCUGAA
  	CGACCCUCUGGGCAGAAGAACCCCUAACUACCAGAGCAAGA
  	ACCCCGGCGAGUACACCGUGGGCAACUCCAUGUUCUACGACG
  	GACCUCAGGUGGCCAACCUGCAGAAUGUGGAUACCGGCUUC
  	UGGCUGGAUAUGAGCAACCUGAGCGACGUGGUGCUGUCCAG
  	AGAGAUCCAGACAGGCCUGAGAGCCAGAGCCACACUGGAAG
  	AGUCCAUGCCUAUGCUCGAGAACCUGGAAGAGAGAUUCCGG
  	CGGCUGCAAGAGACAUGUGACGCCGCCAGAACCGAGAUCGA
  	GGAAAGCGGCUGGACCAGAGAAAGCGCCUCCAGAAUGGAAG
  	GCGACGAAGCCCAAGGACCUAGCAGAGUGCAGCAGGCCUUC
  	CAGAGCUUCGUGAACGAGUGCAACAGCAUCGAGUUCAGCUU
  	CGGCUCCUUCGGCGAACAUGUGCGGGUGCUGUGUGCCAGAG
  	UUAGCAGAGGACUUGCUGCCGCUGGCGAGGCCAUCAGAAGA
  	UGCUUCUCUUGCUGCAAGGGCAGCACCCACAGAUACGCCCCU
  	AGAGAUGAUCUGAGCCCUGAGGGCGCAUCUCUGGCCGAAAC
  	ACUGGCCAGAUUCGCCGACGAUAUGGGCAUUGAAAGAGGCG
  	CCGACGGAACCUACGACAUCCCUCUGGUGGACGAUUGGAGA
  	AGGGGCGUGCCAUCUAUCGAAGGCGAGGGCAGCGAUAGCAU
  	CUACGAGAUCAUGAUGCCCAUCUACGAAGUGAUGAACAUGG
  	ACCUGGAAACCCGGCGGAGCUUCGCUGUUCAGCAGGGCCAU
  	UACCAGGAUCCUAGAGCCAGCGACUACGACCUGCCUAGAGCC
  	UCCGAUUAUGAUCUGCCUCGGAGCCCCUAUCCUACACCUCCA
  	CUGCCACCUAGAUACCAGCUCCAGAAUAUGGACGUGGAAGC
  	CGGAUUCCGCGAGGCCGUGUAUGCUAGCUUUGUGGCCGGCA
  	UGUACAACUACGUGGUCACCCAGCCUCAAGAGCGGAUCCCCA
  	AUUCUCAGCAGGUCGAGGGCAUCCUGAGGGACAUGCUGACA
  	AAUGGCAGCCAGACCUUCCGGGACCUGAUGAAGAGAUGGAA
  	CAGAGAGGUGGACAGAGAG
  CT875_E_nFc_cHis	AUGGAAACCCCUGCUCAGCUGCUGUUCCUGCUGCUGCUGUG	355
  	GCUGCCUGAUACAACCGGCGAGCCUAAGAGCUGCGACAAGA
  	CCCACACCUGUCCUCCAUGUCCUGCUCCAGAACUGCUCGGCG
  	GACCUUCCGUGUUCCUGUUUCCUCCAAAGCCUAAGGACACCC
  	UGAUGAUCAGCAGAACCCCUGAAGUGACCUGCGUGGUGGUG
  	GAUGUGUCCCACGAGGAUCCCGAAGUGAAGUUCAAUUGGUA
  	CGUGGACGGCGUGGAAGUGCACAACGCCAAGACCAAGCCUA
  	GAGAGGAACAGUACAACAGCACCUACAGAGUGGUGUCCGUG
  	CUGACCGUGCUGCACCAGGAUUGGCUGAACGGCAAAGAGUA
  	CAAGUGCAAGGUGUCCAACAAGGCCCUGCCUGCUCCUAUCG
  	AGAAGACCAUCAGCAAGGCCAAGGGCCAGCCAAGAGAACCC
  	CAGGUGUACACACUGCCUCCAAGCAGAGAUGAGCUGACCAA
  	GAACCAGGUGUCCCUGACCUGUCUGGUCAAGGGCUUCUACC
  	CCUCCGAUAUCGCCGUGGAAUGGGAGAGCAAUGGCCAGCCU
  	GAGAACAACUACAAGACAACCCCUCCUGUGCUGGACAGCGA
  	CGGCUCAUUCUUCCUGUACAGCAAGCUGACAGUGGACAAGA
  	GCAGAUGGCAGCAGGGCAACGUGUUCAGCUGCAGCGUGAUG
  	CACGAGGCCCUGCACAAUCACUACACCCAGAAGUCCCUGUCU
  	CUGAGCCCCGGCAAGAUGAGCAUCAGAGGCGUUGGCGGCAA
  	CGGCAACAGCAGAAUCCCUAGCCAUAAUGGCGACGGCAGCA
  	ACAGGCGGAGCCAGAAUACCAAGGGCAACAACAAGGUGGAA
  	GAUCGCGUGUGCAGCCUGUACUCCAGCAGAAGCAACGAGAA
  	CCGCGAGAGCCCUUAUGCCGUGGUCGACGUGUCCAGCAUGA
  	UCGAGAGCACACCUACCAGCGGCGAGACAACCAGAGCUAGU
  	AGAGGCGUGCUGAGCCGGUUUCAGAGAGGCCUCGUUCGGAU
  	CGCUGACAAAGUGCGGAGAGCCGUGCAGUGUGCCUGGUCUA
  	GUGUGUCCACCAGCAGAUCCUCUGCCACAAGAGCCGCCGAGU
  	CUGGCAGCUCUAGCAGAACAGCUAGAGGCGCCAGCAGCGGC
  	UACAGAGAGUAUUCUCCAUCUGCCGCCAGAGGCCUGCGGCU
  	GAUGUUUACAGAUUUCUGGCGGACCCGGGUGCUGAGACAGA
  	CAUCUCCUAUGGCUGGCGUGUUCGGCAACCUGGAUGUGAAU
  	GAGGCCAGACUGAUGGCCGCCUACACAAGCGAAUGUGCCGA
  	UCACCUGGAAGCCAAAGAGCUGGCUGGACCUGACGGUGUUG
  	CCGCCGCUAGAGAAAUCGCCAAGAGAUGGGAGAAGAGAGUG
  	CGGGACCUGCAGGAUAAGGGCGCUGCUAGAAAGCUGCUGAA
  	CGACCCUCUGGGCAGAAGAACCCCUAACUACCAGAGCAAGA
  	ACCCCGGCGAGUACACCGUGGGCAACUCCAUGUUCUACGACG
  	GACCUCAGGUGGCCAACCUGCAGAAUGUGGAUACCGGCUUC
  	UGGCUGGAUAUGAGCAACCUGAGCGACGUGGUGCUGUCCAG
  	AGAGAUCCAGACAGGCCUGAGAGCCAGAGCCACACUGGAAG
  	AGUCCAUGCCUAUGCUCGAGAACCUGGAAGAGAGAUUCCGG
  	CGGCUGCAAGAGACAUGUGACGCCGCCAGAACCGAGAUCGA
  	GGAAAGCGGCUGGACCAGAGAAAGCGCCUCCAGAAUGGAAG
  	GCGACGAAGCCCAAGGACCUAGCAGAGUGCAGCAGGCCUUC
  	CAGAGCUUCGUGAACGAGUGCAACAGCAUCGAGUUCAGCUU
  	CGGCUCCUUCGGCGAACAUGUGCGGGUGCUGUGUGCCAGAG
  	UUAGCAGAGGACUUGCUGCCGCUGGCGAGGCCAUCAGAAGA
  	UGCUUCUCUUGCUGCAAGGGCAGCACCCACAGAUACGCCCCU
  	AGAGAUGAUCUGAGCCCUGAGGGCGCAUCUCUGGCCGAAAC
  	ACUGGCCAGAUUCGCCGACGAUAUGGGCAUUGAAAGAGGCG
  	CCGACGGAACCUACGACAUCCCUCUGGUGGACGAUUGGAGA
  	AGGGGCGUGCCAUCUAUCGAAGGCGAGGGCAGCGAUAGCAU
  	CUACGAGAUCAUGAUGCCCAUCUACGAAGUGAUGAACAUGG
  	ACCUGGAAACCCGGCGGAGCUUCGCUGUUCAGCAGGGCCAU
  	UACCAGGAUCCUAGAGCCAGCGACUACGACCUGCCUAGAGCC
  	UCCGAUUAUGAUCUGCCUCGGAGCCCCUAUCCUACACCUCCA
  	CUGCCACCUAGAUACCAGCUCCAGAAUAUGGACGUGGAAGC
  	CGGAUUCCGCGAGGCCGUGUAUGCUAGCUUUGUGGCCGGCA
  	UGUACAACUACGUGGUCACCCAGCCUCAAGAGCGGAUCCCCA
  	AUUCUCAGCAGGUCGAGGGCAUCCUGAGGGACAUGCUGACA
  	AAUGGCAGCCAGACCUUCCGGGACCUGAUGAAGAGAUGGAA
  	CAGAGAGGUGGACCGCGAGCACCACCACCAUCACCAU
  CT043_E_NGM_nIgK_no4A	AUGGAAACCCCUGCUCAGCUGCUGUUCCUGCUGCUGCUGUG	356
  	GCUGCCUGAUACCACCGGAAUGAGCAGACAGAACGCCGAGG
  	AGAACCUGAAGAACUUCGCCAAAGAGCUGAAGCUGCCCGAC
  	GUGGCCUUCGACCAGAACAAUGCCUGCAUCCUGUUCGUGGA
  	CGGCGAGUUCUCUCUGCACCUGACCUACGAGGAACACAGCG
  	ACCGGCUGUAUGUGUACGCCCCUCUGCUGGAUGGCCUGCCU
  	GACAACCCUCAGAGAAAGCUGGCCCUGUACGAGAAGCUGCU
  	GGAAGGCUCUAUGCUCGGCGGACAAAUGGCUGGUGGCGGAG
  	UGGGAGUUGCCACCAAAGAACAGCUGAUCCUGAUGCACUGC
  	GUGCUGGACAUGAAGUACGCCGAGACUAACCUGCUGAAGGC
  	UUUCGCCCAGCUGUUCAUCGAGACAGUGGUCAAGUGGCGGA
  	CCGUGUGCAGCGAUAUUAGCGCCGGCAGAGAACCCACCGUG
  	GACACCAUGCCUCAAAUGCCACAAGGCGGCGGAGGCGGAAU
  	UCAACCUCCUCCAGCCGGAAUUAGAGCC
  CT043_E_NGM_nIgK_cHis_no4A	AUGGAAACCCCUGCUCAGCUGCUGUUCCUGCUGCUGCUGUG	357
  	GCUGCCUGAUACCACCGGAAUGAGCAGACAGAACGCCGAGG
  	AGAACCUGAAGAACUUCGCCAAAGAGCUGAAGCUGCCCGAC
  	GUGGCCUUCGACCAGAACAAUGCCUGCAUCCUGUUCGUGGA
  	CGGCGAGUUCUCUCUGCACCUGACCUACGAGGAACACAGCG
  	ACCGGCUGUAUGUGUACGCCCCUCUGCUGGAUGGCCUGCCU
  	GACAACCCUCAGAGAAAGCUGGCCCUGUACGAGAAGCUGCU
  	GGAAGGCUCUAUGCUCGGCGGACAAAUGGCUGGUGGCGGAG
  	UGGGAGUUGCCACCAAAGAACAGCUGAUCCUGAUGCACUGC
  	GUGCUGGACAUGAAGUACGCCGAGACUAACCUGCUGAAGGC
  	UUUCGCCCAGCUGUUCAUCGAGACAGUGGUCAAGUGGCGGA
  	CCGUGUGCAGCGAUAUUAGCGCCGGCAGAGAACCCACCGUG
  	GACACCAUGCCUCAAAUGCCACAAGGCGGCGGAGGCGGAAU
  	UCAACCUCCUCCAGCCGGAAUCAGAGCCCACCACCAUCACCA
  	UCAU
  CT043_E_nIgK_no4A	AUGGAAACCCCUGCUCAGCUGCUGUUCCUGCUGCUGCUGUG	358
  	GCUGCCUGAUACCACCGGAAUGAGCAGACAGAACGCCGAGG
  	AGAACCUGAAGAACUUCGCCAAAGAGCUGAAGCUGCCCGAC
  	GUGGCCUUCGACCAGAACAAUACCUGCAUCCUGUUCGUGGA
  	CGGCGAGUUCAGCCUGCACCUGACCUACGAGGAACACAGCG
  	ACCGGCUGUAUGUGUACGCCCCUCUGCUGGAUGGCCUGCCU
  	GACAACCCUCAGAGAAAGCUGGCCCUGUACGAGAAGCUGCU
  	GGAAGGCUCUAUGCUCGGCGGACAAAUGGCUGGUGGCGGAG
  	UGGGAGUUGCCACCAAAGAACAGCUGAUCCUGAUGCACUGC
  	GUGCUGGACAUGAAGUACGCCGAGACUAACCUGCUGAAGGC
  	UUUCGCCCAGCUGUUCAUCGAGACAGUGGUCAAGUGGCGGA
  	CCGUGUGCAGCGAUAUUAGCGCCGGCAGAGAACCCACCGUG
  	GACACCAUGCCUCAAAUGCCACAAGGCGGCGGAGGCGGAAU
  	UCAACCUCCUCCAGCCGGAAUUAGAGCC
  CT043_E_nIgK_cHis_no4A	AUGGAAACCCCUGCUCAGCUGCUGUUCCUGCUGCUGCUGUG	359
  	GCUGCCUGAUACCACCGGAAUGAGCAGACAGAACGCCGAGG
  	AGAACCUGAAGAACUUCGCCAAAGAGCUGAAGCUGCCCGAC
  	GUGGCCUUCGACCAGAACAAUACCUGCAUCCUGUUCGUGGA
  	CGGCGAGUUCAGCCUGCACCUGACCUACGAGGAACACAGCG
  	ACCGGCUGUAUGUGUACGCCCCUCUGCUGGAUGGCCUGCCU
  	GACAACCCUCAGAGAAAGCUGGCCCUGUACGAGAAGCUGCU
  	GGAAGGCUCUAUGCUCGGCGGACAAAUGGCUGGUGGCGGAG
  	UGGGAGUUGCCACCAAAGAACAGCUGAUCCUGAUGCACUGC
  	GUGCUGGACAUGAAGUACGCCGAGACUAACCUGCUGAAGGC
  	UUUCGCCCAGCUGUUCAUCGAGACAGUGGUCAAGUGGCGGA
  	CCGUGUGCAGCGAUAUUAGCGCCGGCAGAGAACCCACCGUG
  	GACACCAUGCCUCAAAUGCCACAAGGCGGCGGAGGCGGAAU
  	UCAACCUCCUCCAGCCGGAAUCAGAGCCCACCACCAUCACCA
  	UCAU
  Chlamydia_CT812_pd_serovarD_nIgK_cHis_nopolyN	AUGGAAACUCCUGCCCAACUGUUGUUCCUUCUGCUGCUCUG	360
  	GUUGCCCGACACCACCGGAUCGUGCGUGGAUCUCCACGCUGG
  	CGGCCAGUCCGUGAACGAGCUUGUGUACGUGGGCCCACAGG
  	CCGUGCUUCUGCUGGACCAGAUCAGAGAUCUCUUCGUGGGU
  	UCCAAGGACUCCCAGGCCGAGGGACAGUACCGGCUCAUCGUC
  	GGCGACCCUUCAAGCUUCCAAGAGAAGGAUGCCGACACUCU
  	UCCGGGGAAGGUGGAACAGUCCACUCUGUUUUCCGUGACCA
  	ACCCAGUCGUGUUUCAAGGGGUGGACCAGCAGGACCAGGUG
  	UCCAGCCAAGGACUGAUCUGUUCAUUCACCUCGAGCAAUUU
  	GGACAGCCCCCGGGACGGCGAAUCGUUCCUUGGCAUCGCAU
  	UCGUGGGAGACUCAUCCAAAGCAGGAAUCACCCUUACCGAU
  	GUGAAGGCGUCCCUGAGCGGCGCUGCUCUGUACUCCACCGA
  	AGAUCUCAUCUUCGAGAAGAUCAAGGGUGGACUGGAGUUCG
  	CCAGCUGCUCCUCACUGGAACAGGGAGGAGCCUGUGCCGCCC
  	AAAGCAUCCUCAUCCACGAUUGCCAGGGGCUCCAAGUGAAG
  	CAUUGUACCACUGCCGUGAACGCCGAGGGAUCAUCCGCUAA
  	CGAUCACCUCGGUUUCGGAGGGGGUGCCUUCUUCGUGACCG
  	GUUCGCUGUCGGGAGAGAAGUCACUGUAUAUGCCCGCGGGC
  	GACAUGGUGGUCGCCAACUGCGAUGGAGCCAUCUCAUUCGA
  	GGGAAACUCCGCCAACUUCGCAAACGGCGGCGCUAUCGCCGC
  	UAGCGGGAAGGUGCUGUUCGUGGCUAACGACAAGAAGACGU
  	CCUUCAUCGAGAACCGCGCCCUGUCGGGAGGUGCCAUUGCCG
  	CCAGCUCCGACAUUGCCUUCCAGAACUGUGCGGAACUGGUG
  	UUCAAAGGAAACUGCGCCAUCGGCACCGAAGAUAAGGGAAG
  	CCUGGGAGGCGGCGCCAUUUCCUCCCUCGGCACCGUGCUGCU
  	UCAGGGAAACCACGGCAUCACUUGUGACAAGAACGAAAGCG
  	CGUCCCAGGGGGGAGCGAUCUUCGGGAAGAACUGCCAGAUU
  	UCCGACAACGAGGGACCGGUGGUGUUCAGAGACUCCACUGC
  	CUGCCUGGGCGGCGGAGCGAUCGCAGCACAGGAAAUUGUCA
  	GCAUCCAGAACAACCAGGCCGGCAUCAGCUUCGAGGGGGGA
  	AAGGCUUCGUUCGGCGGAGGUAUUGCCUGCGGAUCGUUCUC
  	GUCCGCGGGCGGAGCCUCCGUGCUCGGAACCAUCGACAUUUC
  	CAAGAACCUGGGCGCUAUCUCGUUUUCUCGCACCCUGUGCAC
  	UACUUCCGACCUGGGUCAGAUGGAGUACCAGGGAGGCGGAG
  	CGCUGUUUGGAGAGAACAUCUCUCUGAGCGAGAACGCGGGA
  	GUGCUGACCUUCAAGGACAACAUUGUGAAGACCUUCGCCUC
  	AAACGGAAAGAUCCUGGGGGGAGGCGCCAUCCUGGCAACCG
  	GGAAGGUCGAAAUCACCAACAAUUCAGAGGGUAUCUCCUUC
  	ACUGGCAACGCCCGGGCCCCCCAAGCCCUGCCGACUCAGGAA
  	GAGUUCCCCCUGUUCUCCAAGAAGGAAGGACGCCCUUUGUC
  	AUCCGGCUACUCCGGUGGUGGAGCGAUUCUGGGUCGGGAAG
  	UGGCCAUCCUGCAUAAUGCGGCCGUGGUGUUUGAGCAGAAC
  	AGACUCCAAUGCUCCGAAGAAGAGGCCACCCUCCUGGGGUG
  	CUGCGGGGGCGGAGCAGUGCAUGGCAUGGAUUCCACUUCCA
  	UCGUGGGAAACUCCAGCGUCCGCUUCGGAAACAACUACGCU
  	AUGGGACAGGGAGUGUCAGGCGGGGCCCUGCUGUCCAAGAC
  	CGUCCAGUUGGCCGGAAACGGUUCGGUGGAUUUCUCACGCA
  	AUAUCGCCUCGCUGGGAGGCGGCGCGCUGCAGGCCUCCGAA
  	GGAAAUUGCGAACUGGUCGACAACGGCUACGUGCUGUUCCG
  	GGACAACCGCGGCAGGGUGUACGGCGGAGCAAUCUCGUGCC
  	UUCGGGGCGACGUCGUGAUCUCGGGAAAUAAGGGACGGGUC
  	GAGUUUAAGGACAACAUCGCUACCAGGCUCUACGUGGAGGA
  	AACUGUGGAGAAGGUGGAGGAAGUGGAGCCUGCCCCGGAAC
  	AGAAGGACAACAACGAGCUGUCGUUCCUCGGUCGGGCAGAA
  	CAGUCCUUCAUUACUGCCGCCAACCAGGCCCUGUUCGCGUCC
  	GAAGAUGGUGACCUCAGCCCGGAAUCCAGCAUCUCCUCCGA
  	GGAACUGGCCAAGCGGAGAGAAUGCGCGGGAGGCGCAAUCU
  	UUGCGAAGCGGGUCCGGAUCGUGGACAACCAGGAAGCUGUG
  	GUGUUCAGCAACAACUUUUCCGACAUCUACGGUGGUGCAAU
  	UUUCACCGGCUCACUCCGGGAGGAGGACAAGCUGGACGGCC
  	AGAUUCCCGAGGUGCUCAUUUCCGGCAAUGCCGGCGACGUG
  	GUGUUCUCCGGAAACUCCUCCAAGAGGGACGAACACCUCCCG
  	CAUACCGGAGGAGGAGCCAUCUGCACUCAGAACCUGACGAU
  	CUCGCAGAACACCGGCAAUGUGCUGUUCUACAACAACGUCG
  	CAUGUUCCGGUGGCGCCGUCAGAAUCGAGGACCACGGAAAC
  	GUGCUGCUGGAAGCAUUCGGGGGUGAUAUUGUGUUCAAGGG
  	AAACAGCAGCUUCCGGGCCCAGGGAUCAGAUGCAAUCUACU
  	UCGCCGGGAAGGAGAGCCACAUUACCGCCCUGAACGCCACCG
  	AGGGUCACGCCAUCGUGUUCCACGAUGCCCUGGUGUUCGAG
  	AACCUGGAGGAGCGCAAGAGCGCCGAAGUGCUGCUUAUCAA
  	UUCCCGCGAGAACCCGGGCUACACCGGAUCCAUCCGGUUCCU
  	CGAAGCGGAGUCGAAGGUCCCGCAGUGUAUUCAUGUGCAAC
  	AGGGGUCCCUGGAACUGCUUAACGGAGCCACCCUGUGCUCC
  	UACGGCUUUAAGCAGGACGCGGGCGCUAAACUGGUGCUGGC
  	GGCCGGCGCCAAGCUUAAGAUCCUCGACUCCGGAACCCCGGU
  	GCAGCAGGGGCACGCUAUUAGCAAGCCUGAAGCCGAGAUUG
  	AGUCGUCAUCCGAACCCGAAGGGGCGCACUCCCUGUGGAUA
  	GCCAAGAACGCGCAGACCACCGUGCCAAUGGUCGAUAUCCAC
  	ACAAUCUCCGUGGACCUCGCCAGCUUCUCGUCGAGCCAGCAG
  	GAGGGAACUGUCGAAGCGCCUCAGGUCAUCGUGCCGGGAGG
  	UUCCUACGUGCGCUCGGGGGAGCUCAACCUGGAACUCGUGA
  	AUACCACUGGAACGGGAUAUGAGAACCACGCCCUGCUGAAG
  	AACGAAGCCAAAGUGCCACUGAUGUCCUUCGUCGCCUCCGGC
  	GACGAGGCCUCCGCCGAGAUUAGCAACCUGUCGGUGUCAGA
  	UCUGCAAAUUCACGUGGUGACCCCUGAGAUUGAGGAGGACA
  	CCUACGGGCACAUGGGCGAUUGGUCCGAGGCGAAGAUCCAG
  	GACGGCACACUGGUCAUUUCAUGGAACCCUACCGGACAUCA
  	CCACCACCAUCAC
  Chlamydia_CT812_pd_serovarD_nIgK_nopolyN	AUGGAAACUCCUGCCCAACUGUUGUUCCUUCUGCUGCUCUG	361
  	GUUGCCCGACACCACCGGAUCGUGCGUGGAUCUCCACGCUGG
  	CGGCCAGUCCGUGAACGAGCUUGUGUACGUGGGCCCACAGG
  	CCGUGCUUCUGCUGGACCAGAUCAGAGAUCUCUUCGUGGGU
  	UCCAAGGACUCCCAGGCCGAGGGACAGUACCGGCUCAUCGUC
  	GGCGACCCUUCAAGCUUCCAAGAGAAGGAUGCCGACACUCU
  	UCCGGGGAAGGUGGAACAGUCCACUCUGUUUUCCGUGACCA
  	ACCCAGUCGUGUUUCAAGGGGUGGACCAGCAGGACCAGGUG
  	UCCAGCCAAGGACUGAUCUGUUCAUUCACCUCGAGCAAUUU
  	GGACAGCCCCCGGGACGGCGAAUCGUUCCUUGGCAUCGCAU
  	UCGUGGGAGACUCAUCCAAAGCAGGAAUCACCCUUACCGAU
  	GUGAAGGCGUCCCUGAGCGGCGCUGCUCUGUACUCCACCGA
  	AGAUCUCAUCUUCGAGAAGAUCAAGGGUGGACUGGAGUUCG
  	CCAGCUGCUCCUCACUGGAACAGGGAGGAGCCUGUGCCGCCC
  	AAAGCAUCCUCAUCCACGAUUGCCAGGGGCUCCAAGUGAAG
  	CAUUGUACCACUGCCGUGAACGCCGAGGGAUCAUCCGCUAA
  	CGAUCACCUCGGUUUCGGAGGGGGUGCCUUCUUCGUGACCG
  	GUUCGCUGUCGGGAGAGAAGUCACUGUAUAUGCCCGCGGGC
  	GACAUGGUGGUCGCCAACUGCGAUGGAGCCAUCUCAUUCGA
  	GGGAAACUCCGCCAACUUCGCAAACGGCGGCGCUAUCGCCGC
  	UAGCGGGAAGGUGCUGUUCGUGGCUAACGACAAGAAGACGU
  	CCUUCAUCGAGAACCGCGCCCUGUCGGGAGGUGCCAUUGCCG
  	CCAGCUCCGACAUUGCCUUCCAGAACUGUGCGGAACUGGUG
  	UUCAAAGGAAACUGCGCCAUCGGCACCGAAGAUAAGGGAAG
  	CCUGGGAGGCGGCGCCAUUUCCUCCCUCGGCACCGUGCUGCU
  	UCAGGGAAACCACGGCAUCACUUGUGACAAGAACGAAAGCG
  	CGUCCCAGGGGGGAGCGAUCUUCGGGAAGAACUGCCAGAUU
  	UCCGACAACGAGGGACCGGUGGUGUUCAGAGACUCCACUGC
  	CUGCCUGGGCGGCGGAGCGAUCGCAGCACAGGAAAUUGUCA
  	GCAUCCAGAACAACCAGGCCGGCAUCAGCUUCGAGGGGGGA
  	AAGGCUUCGUUCGGCGGAGGUAUUGCCUGCGGAUCGUUCUC
  	GUCCGCGGGCGGAGCCUCCGUGCUCGGAACCAUCGACAUUUC
  	CAAGAACCUGGGCGCUAUCUCGUUUUCUCGCACCCUGUGCAC
  	UACUUCCGACCUGGGUCAGAUGGAGUACCAGGGAGGCGGAG
  	CGCUGUUUGGAGAGAACAUCUCUCUGAGCGAGAACGCGGGA
  	GUGCUGACCUUCAAGGACAACAUUGUGAAGACCUUCGCCUC
  	AAACGGAAAGAUCCUGGGGGGAGGCGCCAUCCUGGCAACCG
  	GGAAGGUCGAAAUCACCAACAAUUCAGAGGGUAUCUCCUUC
  	ACUGGCAACGCCCGGGCCCCCCAAGCCCUGCCGACUCAGGAA
  	GAGUUCCCCCUGUUCUCCAAGAAGGAAGGACGCCCUUUGUC
  	AUCCGGCUACUCCGGUGGUGGAGCGAUUCUGGGUCGGGAAG
  	UGGCCAUCCUGCAUAAUGCGGCCGUGGUGUUUGAGCAGAAC
  	AGACUCCAAUGCUCCGAAGAAGAGGCCACCCUCCUGGGGUG
  	CUGCGGGGGCGGAGCAGUGCAUGGCAUGGAUUCCACUUCCA
  	UCGUGGGAAACUCCAGCGUCCGCUUCGGAAACAACUACGCU
  	AUGGGACAGGGAGUGUCAGGCGGGGCCCUGCUGUCCAAGAC
  	CGUCCAGUUGGCCGGAAACGGUUCGGUGGAUUUCUCACGCA
  	AUAUCGCCUCGCUGGGAGGCGGCGCGCUGCAGGCCUCCGAA
  	GGAAAUUGCGAACUGGUCGACAACGGCUACGUGCUGUUCCG
  	GGACAACCGCGGCAGGGUGUACGGCGGAGCAAUCUCGUGCC
  	UUCGGGGCGACGUCGUGAUCUCGGGAAAUAAGGGACGGGUC
  	GAGUUUAAGGACAACAUCGCUACCAGGCUCUACGUGGAGGA
  	AACUGUGGAGAAGGUGGAGGAAGUGGAGCCUGCCCCGGAAC
  	AGAAGGACAACAACGAGCUGUCGUUCCUCGGUCGGGCAGAA
  	CAGUCCUUCAUUACUGCCGCCAACCAGGCCCUGUUCGCGUCC
  	GAAGAUGGUGACCUCAGCCCGGAAUCCAGCAUCUCCUCCGA
  	GGAACUGGCCAAGCGGAGAGAAUGCGCGGGAGGCGCAAUCU
  	UUGCGAAGCGGGUCCGGAUCGUGGACAACCAGGAAGCUGUG
  	GUGUUCAGCAACAACUUUUCCGACAUCUACGGUGGUGCAAU
  	UUUCACCGGCUCACUCCGGGAGGAGGACAAGCUGGACGGCC
  	AGAUUCCCGAGGUGCUCAUUUCCGGCAAUGCCGGCGACGUG
  	GUGUUCUCCGGAAACUCCUCCAAGAGGGACGAACACCUCCCG
  	CAUACCGGAGGAGGAGCCAUCUGCACUCAGAACCUGACGAU
  	CUCGCAGAACACCGGCAAUGUGCUGUUCUACAACAACGUCG
  	CAUGUUCCGGUGGCGCCGUCAGAAUCGAGGACCACGGAAAC
  	GUGCUGCUGGAAGCAUUCGGGGGUGAUAUUGUGUUCAAGGG
  	AAACAGCAGCUUCCGGGCCCAGGGAUCAGAUGCAAUCUACU
  	UCGCCGGGAAGGAGAGCCACAUUACCGCCCUGAACGCCACCG
  	AGGGUCACGCCAUCGUGUUCCACGAUGCCCUGGUGUUCGAG
  	AACCUGGAGGAGCGCAAGAGCGCCGAAGUGCUGCUUAUCAA
  	UUCCCGCGAGAACCCGGGCUACACCGGAUCCAUCCGGUUCCU
  	CGAAGCGGAGUCGAAGGUCCCGCAGUGUAUUCAUGUGCAAC
  	AGGGGUCCCUGGAACUGCUUAACGGAGCCACCCUGUGCUCC
  	UACGGCUUUAAGCAGGACGCGGGCGCUAAACUGGUGCUGGC
  	GGCCGGCGCCAAGCUUAAGAUCCUCGACUCCGGAACCCCGGU
  	GCAGCAGGGGCACGCUAUUAGCAAGCCUGAAGCCGAGAUUG
  	AGUCGUCAUCCGAACCCGAAGGGGCGCACUCCCUGUGGAUA
  	GCCAAGAACGCGCAGACCACCGUGCCAAUGGUCGAUAUCCAC
  	ACAAUCUCCGUGGACCUCGCCAGCUUCUCGUCGAGCCAGCAG
  	GAGGGAACUGUCGAAGCGCCUCAGGUCAUCGUGCCGGGAGG
  	UUCCUACGUGCGCUCGGGGGAGCUCAACCUGGAACUCGUGA
  	AUACCACUGGAACGGGAUAUGAGAACCACGCCCUGCUGAAG
  	AACGAAGCCAAAGUGCCACUGAUGUCCUUCGUCGCCUCCGGC
  	GACGAGGCCUCCGCCGAGAUUAGCAACCUGUCGGUGUCAGA
  	UCUGCAAAUUCACGUGGUGACCCCUGAGAUUGAGGAGGACA
  	CCUACGGGCACAUGGGCGAUUGGUCCGAGGCGAAGAUCCAG
  	GACGGCACACUGGUCAUUUCAUGGAACCCUACCGGA
  CT812pd_PmpD_D_NGM_nIgK_nopolyN	AUGGAAACUCCUGCCCAACUGUUGUUCCUUCUGCUGCUCUG	362
  	GUUGCCCGACACCACCGGAUCGUGCGUGGAUCUCCACGCUGG
  	CGGCCAGUCCGUGAACGAGCUUGUGUACGUGGGCCCACAGG
  	CCGUGCUUCUGCUGGACCAGAUCAGAGAUCUCUUCGUGGGU
  	UCCAAGGACUCCCAGGCCGAGGGACAGUACCGGCUCAUCGUC
  	GGCGACCCUUCAAGCUUCCAAGAGAAGGAUGCCGACACUCU
  	UCCGGGGAAGGUGGAACAGUCCACUCUGUUUUCCGUGACCA
  	ACCCAGUCGUGUUUCAAGGGGUGGACCAGCAGGACCAGGUG
  	UCCAGCCAAGGACUGAUCUGUUCAUUCACCUCGAGCAAUUU
  	GGACAGCCCCCGGGACGGCGAAUCGUUCCUUGGCAUCGCAU
  	UCGUGGGAGACUCAUCCAAAGCAGGAAUCACCCUUACCGAU
  	GUGAAGGCGUCCCUGAGCGGCGCUGCUCUGUACUCCACCGA
  	AGAUCUCAUCUUCGAGAAGAUCAAGGGUGGACUGGAGUUCG
  	CCAGCUGCUCCUCACUGGAACAGGGAGGAGCCUGUGCCGCCC
  	AAAGCAUCCUCAUCCACGAUUGCCAGGGGCUCCAAGUGAAG
  	CAUUGUACCACUGCCGUGAACGCCGAGGGAUCAUCCGCUAA
  	CGAUCACCUCGGUUUCGGAGGGGGUGCCUUCUUCGUGACCG
  	GUUCGCUGUCGGGAGAGAAGUCACUGUAUAUGCCCGCGGGC
  	GACAUGGUGGUCGCCAACUGCGAUGGAGCCAUCUCAUUCGA
  	GGGAAACUCCGCCAACUUCGCAAACGGCGGCGCUAUCGCCGC
  	UAGCGGGAAGGUGCUGUUCGUGGCUAACGACAAGAAGACGU
  	CCUUCAUCGAGAACCGCGCCCUGUCGGGAGGUGCCAUUGCCG
  	CCAGCUCCGACAUUGCCUUCCAGAACUGUGCGGAACUGGUG
  	UUCAAAGGAAACUGCGCCAUCGGCACCGAAGAUAAGGGAAG
  	CCUGGGAGGCGGCGCCAUUUCCUCCCUCGGCACCGUGCUGCU
  	UCAGGGAAACCACGGCAUCACUUGUGACAAGAACGAAGCAG
  	CGUCCCAGGGGGGAGCGAUCUUCGGGAAGAACUGCCAGAUU
  	UCCGACAACGAGGGACCGGUGGUGUUCAGAGACUCCACUGC
  	CUGCCUGGGCGGCGGAGCGAUCGCAGCACAGGAAAUUGUCA
  	GCAUCCAGAACAACCAGGCCGGCAUCAGCUUCGAGGGGGGA
  	AAGGCUUCGUUCGGCGGAGGUAUUGCCUGCGGAUCGUUCUC
  	GUCCGCGGGCGGAGCCUCCGUGCUCGGAACCAUCGACAUUUC
  	CAAGAACCUGGGCGCUAUCUCGUUUUCUCGCACCCUGUGCAC
  	UACUUCCGACCUGGGUCAGAUGGAGUACCAGGGAGGCGGAG
  	CGCUGUUUGGAGAGAACAUCGCUCUGAGCGAGAACGCGGGA
  	GUGCUGACCUUCAAGGACAACAUUGUGAAGACCUUCGCCUC
  	AAACGGAAAGAUCCUGGGGGGAGGCGCCAUCCUGGCAACCG
  	GGAAGGUCGAAAUCACCAACAAUGCAGAGGGUAUCUCCUUC
  	ACUGGCAACGCCCGGGCCCCCCAAGCCCUGCCGACUCAGGAA
  	GAGUUCCCCCUGUUCUCCAAGAAGGAAGGACGCCCUUUGUC
  	AUCCGGCUACUCCGGUGGUGGAGCGAUUCUGGGUCGGGAAG
  	UGGCCAUCCUGCAUAAUGCGGCCGUGGUGUUUGAGCAGAAC
  	AGACUCCAAUGCUCCGAAGAAGAGGCCACCCUCCUGGGGUG
  	CUGCGGGGGCGGAGCAGUGCAUGGCAUGGAUUCCACUUCCA
  	UCGUGGGAAACUCCGCAGUCCGCUUCGGAAACAACUACGCU
  	AUGGGACAGGGAGUGUCAGGCGGGGCCCUGCUGUCCAAGAC
  	CGUCCAGUUGGCCGGAAACGGUGCGGUGGAUUUCUCACGCA
  	AUAUCGCCUCGCUGGGAGGCGGCGCGCUGCAGGCCUCCGAA
  	GGAAAUUGCGAACUGGUCGACAACGGCUACGUGCUGUUCCG
  	GGACAACCGCGGCAGGGUGUACGGCGGAGCAAUCUCGUGCC
  	UUCGGGGCGACGUCGUGAUCUCGGGAAAUAAGGGACGGGUC
  	GAGUUUAAGGACAACAUCGCUACCAGGCUCUACGUGGAGGA
  	AACUGUGGAGAAGGUGGAGGAAGUGGAGCCUGCCCCGGAAC
  	AGAAGGACAACAACGAGCUGUCGUUCCUCGGUCGGGCAGAA
  	CAGUCCUUCAUUACUGCCGCCAACCAGGCCCUGUUCGCGUCC
  	GAAGAUGGUGACCUCAGCCCGGAAUCCAGCAUCUCCUCCGA
  	GGAACUGGCCAAGCGGAGAGAAUGCGCGGGAGGCGCAAUCU
  	UUGCGAAGCGGGUCCGGAUCGUGGACAACCAGGAAGCUGUG
  	GUGUUCAGCAACAACUUUGCCGACAUCUACGGUGGUGCAAU
  	UUUCACCGGCUCACUCCGGGAGGAGGACAAGCUGGACGGCC
  	AGAUUCCCGAGGUGCUCAUUUCCGGCAAUGCCGGCGACGUG
  	GUGUUCUCCGGAAACUCCGCCAAGAGGGACGAACACCUCCCG
  	CAUACCGGAGGAGGAGCCAUCUGCACUCAGAACCUGGCAAU
  	CUCGCAGAACACCGGCAAUGUGCUGUUCUACAACAACGUCG
  	CAUGUUCCGGUGGCGCCGUCAGAAUCGAGGACCACGGAAAC
  	GUGCUGCUGGAAGCAUUCGGGGGUGAUAUUGUGUUCAAGGG
  	AAACAGCGCAUUCCGGGCCCAGGGAUCAGAUGCAAUCUACU
  	UCGCCGGGAAGGAGAGCCACAUUACCGCCCUGAACGCCGCCG
  	AGGGUCACGCCAUCGUGUUCCACGAUGCCCUGGUGUUCGAG
  	AACCUGGAGGAGCGCAAGAGCGCCGAAGUGCUGCUUAUCAA
  	UUCCCGCGAGAACCCGGGCUACACCGGAUCCAUCCGGUUCCU
  	CGAAGCGGAGUCGAAGGUCCCGCAGUGUAUUCAUGUGCAAC
  	AGGGGUCCCUGGAACUGCUUAACGGAGCCACCCUGUGCUCC
  	UACGGCUUUAAGCAGGACGCGGGCGCUAAACUGGUGCUGGC
  	GGCCGGCGCCAAGCUUAAGAUCCUCGACUCCGGAACCCCGGU
  	GCAGCAGGGGCACGCUAUUAGCAAGCCUGAAGCCGAGAUUG
  	AGUCGUCAUCCGAACCCGAAGGGGCGCACUCCCUGUGGAUA
  	GCCAAGAACGCGCAGACCACCGUGCCAAUGGUCGAUAUCCAC
  	ACAAUCUCCGUGGACCUCGCCAGCUUCUCGUCGAGCCAGCAG
  	GAGGGAACUGUCGAAGCGCCUCAGGUCAUCGUGCCGGGAGG
  	UUCCUACGUGCGCUCGGGGGAGCUCAACCUGGAACUCGUGA
  	AUACCGCUGGAACGGGAUAUGAGAACCACGCCCUGCUGAAG
  	AACGAAGCCAAAGUGCCACUGAUGUCCUUCGUCGCCUCCGGC
  	GACGAGGCCUCCGCCGAGAUUAGCAACCUGGCGGUGUCAGA
  	UCUGCAAAUUCACGUGGUGACCCCUGAGAUUGAGGAGGACA
  	CCUACGGGCACAUGGGCGAUUGGUCCGAGGCGAAGAUCCAG
  	GACGGCACACUGGUCAUUUCAUGGAACCCUGCCGGA
  CT812pd_PmpD_D_NGM_nIgK_cHis_nopolyN	AUGGAAACUCCUGCCCAACUGUUGUUCCUUCUGCUGCUCUG	363
  	GUUGCCCGACACCACCGGAUCGUGCGUGGAUCUCCACGCUGG
  	CGGCCAGUCCGUGAACGAGCUUGUGUACGUGGGCCCACAGG
  	CCGUGCUUCUGCUGGACCAGAUCAGAGAUCUCUUCGUGGGU
  	UCCAAGGACUCCCAGGCCGAGGGACAGUACCGGCUCAUCGUC
  	GGCGACCCUUCAAGCUUCCAAGAGAAGGAUGCCGACACUCU
  	UCCGGGGAAGGUGGAACAGUCCACUCUGUUUUCCGUGACCA
  	ACCCAGUCGUGUUUCAAGGGGUGGACCAGCAGGACCAGGUG
  	UCCAGCCAAGGACUGAUCUGUUCAUUCACCUCGAGCAAUUU
  	GGACAGCCCCCGGGACGGCGAAUCGUUCCUUGGCAUCGCAU
  	UCGUGGGAGACUCAUCCAAAGCAGGAAUCACCCUUACCGAU
  	GUGAAGGCGUCCCUGAGCGGCGCUGCUCUGUACUCCACCGA
  	AGAUCUCAUCUUCGAGAAGAUCAAGGGUGGACUGGAGUUCG
  	CCAGCUGCUCCUCACUGGAACAGGGAGGAGCCUGUGCCGCCC
  	AAAGCAUCCUCAUCCACGAUUGCCAGGGGCUCCAAGUGAAG
  	CAUUGUACCACUGCCGUGAACGCCGAGGGAUCAUCCGCUAA
  	CGAUCACCUCGGUUUCGGAGGGGGUGCCUUCUUCGUGACCG
  	GUUCGCUGUCGGGAGAGAAGUCACUGUAUAUGCCCGCGGGC
  	GACAUGGUGGUCGCCAACUGCGAUGGAGCCAUCUCAUUCGA
  	GGGAAACUCCGCCAACUUCGCAAACGGCGGCGCUAUCGCCGC
  	UAGCGGGAAGGUGCUGUUCGUGGCUAACGACAAGAAGACGU
  	CCUUCAUCGAGAACCGCGCCCUGUCGGGAGGUGCCAUUGCCG
  	CCAGCUCCGACAUUGCCUUCCAGAACUGUGCGGAACUGGUG
  	UUCAAAGGAAACUGCGCCAUCGGCACCGAAGAUAAGGGAAG
  	CCUGGGAGGCGGCGCCAUUUCCUCCCUCGGCACCGUGCUGCU
  	UCAGGGAAACCACGGCAUCACUUGUGACAAGAACGAAGCAG
  	CGUCCCAGGGGGGAGCGAUCUUCGGGAAGAACUGCCAGAUU
  	UCCGACAACGAGGGACCGGUGGUGUUCAGAGACUCCACUGC
  	CUGCCUGGGCGGCGGAGCGAUCGCAGCACAGGAAAUUGUCA
  	GCAUCCAGAACAACCAGGCCGGCAUCAGCUUCGAGGGGGGA
  	AAGGCUUCGUUCGGCGGAGGUAUUGCCUGCGGAUCGUUCUC
  	GUCCGCGGGCGGAGCCUCCGUGCUCGGAACCAUCGACAUUUC
  	CAAGAACCUGGGCGCUAUCUCGUUUUCUCGCACCCUGUGCAC
  	UACUUCCGACCUGGGUCAGAUGGAGUACCAGGGAGGCGGAG
  	CGCUGUUUGGAGAGAACAUCGCUCUGAGCGAGAACGCGGGA
  	GUGCUGACCUUCAAGGACAACAUUGUGAAGACCUUCGCCUC
  	AAACGGAAAGAUCCUGGGGGGAGGCGCCAUCCUGGCAACCG
  	GGAAGGUCGAAAUCACCAACAAUGCAGAGGGUAUCUCCUUC
  	ACUGGCAACGCCCGGGCCCCCCAAGCCCUGCCGACUCAGGAA
  	GAGUUCCCCCUGUUCUCCAAGAAGGAAGGACGCCCUUUGUC
  	AUCCGGCUACUCCGGUGGUGGAGCGAUUCUGGGUCGGGAAG
  	UGGCCAUCCUGCAUAAUGCGGCCGUGGUGUUUGAGCAGAAC
  	AGACUCCAAUGCUCCGAAGAAGAGGCCACCCUCCUGGGGUG
  	CUGCGGGGGCGGAGCAGUGCAUGGCAUGGAUUCCACUUCCA
  	UCGUGGGAAACUCCGCAGUCCGCUUCGGAAACAACUACGCU
  	AUGGGACAGGGAGUGUCAGGCGGGGCCCUGCUGUCCAAGAC
  	CGUCCAGUUGGCCGGAAACGGUGCGGUGGAUUUCUCACGCA
  	AUAUCGCCUCGCUGGGAGGCGGCGCGCUGCAGGCCUCCGAA
  	GGAAAUUGCGAACUGGUCGACAACGGCUACGUGCUGUUCCG
  	GGACAACCGCGGCAGGGUGUACGGCGGAGCAAUCUCGUGCC
  	UUCGGGGCGACGUCGUGAUCUCGGGAAAUAAGGGACGGGUC
  	GAGUUUAAGGACAACAUCGCUACCAGGCUCUACGUGGAGGA
  	AACUGUGGAGAAGGUGGAGGAAGUGGAGCCUGCCCCGGAAC
  	AGAAGGACAACAACGAGCUGUCGUUCCUCGGUCGGGCAGAA
  	CAGUCCUUCAUUACUGCCGCCAACCAGGCCCUGUUCGCGUCC
  	GAAGAUGGUGACCUCAGCCCGGAAUCCAGCAUCUCCUCCGA
  	GGAACUGGCCAAGCGGAGAGAAUGCGCGGGAGGCGCAAUCU
  	UUGCGAAGCGGGUCCGGAUCGUGGACAACCAGGAAGCUGUG
  	GUGUUCAGCAACAACUUUGCCGACAUCUACGGUGGUGCAAU
  	UUUCACCGGCUCACUCCGGGAGGAGGACAAGCUGGACGGCC
  	AGAUUCCCGAGGUGCUCAUUUCCGGCAAUGCCGGCGACGUG
  	GUGUUCUCCGGAAACUCCGCCAAGAGGGACGAACACCUCCCG
  	CAUACCGGAGGAGGAGCCAUCUGCACUCAGAACCUGGCAAU
  	CUCGCAGAACACCGGCAAUGUGCUGUUCUACAACAACGUCG
  	CAUGUUCCGGUGGCGCCGUCAGAAUCGAGGACCACGGAAAC
  	GUGCUGCUGGAAGCAUUCGGGGGUGAUAUUGUGUUCAAGGG
  	AAACAGCGCAUUCCGGGCCCAGGGAUCAGAUGCAAUCUACU
  	UCGCCGGGAAGGAGAGCCACAUUACCGCCCUGAACGCCGCCG
  	AGGGUCACGCCAUCGUGUUCCACGAUGCCCUGGUGUUCGAG
  	AACCUGGAGGAGCGCAAGAGCGCCGAAGUGCUGCUUAUCAA
  	UUCCCGCGAGAACCCGGGCUACACCGGAUCCAUCCGGUUCCU
  	CGAAGCGGAGUCGAAGGUCCCGCAGUGUAUUCAUGUGCAAC
  	AGGGGUCCCUGGAACUGCUUAACGGAGCCACCCUGUGCUCC
  	UACGGCUUUAAGCAGGACGCGGGCGCUAAACUGGUGCUGGC
  	GGCCGGCGCCAAGCUUAAGAUCCUCGACUCCGGAACCCCGGU
  	GCAGCAGGGGCACGCUAUUAGCAAGCCUGAAGCCGAGAUUG
  	AGUCGUCAUCCGAACCCGAAGGGGCGCACUCCCUGUGGAUA
  	GCCAAGAACGCGCAGACCACCGUGCCAAUGGUCGAUAUCCAC
  	ACAAUCUCCGUGGACCUCGCCAGCUUCUCGUCGAGCCAGCAG
  	GAGGGAACUGUCGAAGCGCCUCAGGUCAUCGUGCCGGGAGG
  	UUCCUACGUGCGCUCGGGGGAGCUCAACCUGGAACUCGUGA
  	AUACCGCUGGAACGGGAUAUGAGAACCACGCCCUGCUGAAG
  	AACGAAGCCAAAGUGCCACUGAUGUCCUUCGUCGCCUCCGGC
  	GACGAGGCCUCCGCCGAGAUUAGCAACCUGGCGGUGUCAGA
  	UCUGCAAAUUCACGUGGUGACCCCUGAGAUUGAGGAGGACA
  	CCUACGGGCACAUGGGCGAUUGGUCCGAGGCGAAGAUCCAG
  	GACGGCACACUGGUCAUUUCAUGGAACCCUGCCGGACAUCA
  	CCACCACCAUCAC
  Ct871pd_PmpG_D_NGM_nIgK	AUGGAAACCCCUGCUCAGCUGCUGUUCCUGCUGCUGCUGUG	364
  	GCUGCCUGAUACAACAGGCGCCGAGAUCAUGAUUCCCCAGG
  	GCAUCUACGACGGCGAAACCCUGACCGUGUCUUUCCCCUAUA
  	CCGUGAUCGGCGAUCCUAGCGGCACCACCGUGUUUUCUGCU
  	GGCGAGCUGACCCUGAAGAACCUGGACAACUCUAUCGCCGC
  	UCUGCCCCUGAGCUGCUUCGGAAAUCUGCUGGGCAGCUUCA
  	CCGUGCUCGGCAGAGGACACAGCCUGACCUUCGAGAACAUCC
  	GGACCAGCACAAAUGGCGCUGCCCUGAGCGAUAGCGCCAAU
  	AGCGGCCUGUUUACCAUCGAGGGCUUCAAAGAGCUGAGCUU
  	CAGCAACUGCAACAGCCUGCUGGCAGUGCUGCCUGCCGCCAC
  	AACAAAUAGCGGCAGCCAGACACCUACCACCACCAGCACACC
  	UUCUAACGGCGCCAUCUACAGCAAGACCGACCUGCUGCUCCU
  	GAACAACGAGAAGUUCAGCUUCUACUCCAACCUGGUGUCCG
  	GCGACGGCGGAGCCAUUGAUGCCAAAUCUCUGACCGUGCAG
  	GGCAUCAGCAAGCUGUGCGUGUUCCAAGAGAACACAGCCCA
  	GGCUGAUGGCGGAGCCUGUCAGGUGGUCACAAGCUUUAGCG
  	CCAUGGCCAACGAGGCCCCUAUCGCCUUUAUUGCCAAUGUG
  	GCCGGCGUUAGAGGCGGAGGAAUUGCCGCUGUUCAGGAUGG
  	ACAGCAGGGCGUGUCCAGCAGCACAAGCACUGAGGAUCCUG
  	UGGUGUCCUUCAGCAGAAACACCGCCGUGGAAUUCGAUGGC
  	AACGUGGCCAGAGUUGGCGGCGGAAUCUACAGCUACGGAAA
  	CGUGGCCUUUCUGAACAAUGGCAAGACCCUGUUCCUCAACA
  	ACGUGGCAAGCCCCGUGUAUAUCGCCGCCGAGCAGCCUACAA
  	AUGGCCAGGCCUCUAAUACCGCCGACAACUAUGGCGACGGU
  	GGCGCAAUCUUCUGCAAGAAUGGUGCUCAGGCCGCUGGCAG
  	CAACAAUGCCGGCUCUGUGUCCUUUGAUGGCGAAGGCGUGG
  	UGUUCUUCUCCUCUAACGUGGCCGCUGGAAAAGGCGGCGCU
  	AUCUACGCCAAGAAACUGAGCGUGGCCAACUGCGGCCCUGU
  	GCAGUUUCUGGGCAAUAUCGCCAAUGAUGGCGGUGCCAUCU
  	ACCUGGGAGAGUCCGGCGAACUGUCUCUGAGCGCCGAUUAC
  	GGCGACAUCAUCUUCGACGGCAACCUGAAGCGGACCGCCAA
  	AGAAAAUGCCGCCGAUGUGAAUGGCGUGACAGUGUCCAGCC
  	AGGCCAUCUCUAUGGGCUCUGGCGGCAAGAUCACCACACUG
  	AGAGCCAAGGCCGGCCACCAGAUCCUGUUCAACGACCCUAUC
  	GAGAUGGCCAAUGGCAACAACCAGCCUGCUCAGAGCAGCGA
  	GCCCCUGAAGAUUAACGAUGGCGAGGGCUACACCGGCGAUA
  	UCGUGUUCGCCAACGGCAACAGCGCCCUGUACCAGAAUGUG
  	GCCAUCGAGCAGGGCAGAAUCGUGCUGAGAGAGAAGGCCAA
  	GCUGAGCGUGAACAGCCUGAGUCAGACAGGCGGCAGCCUGU
  	AUAUGGAAGCCGGCAGCACCCUGGACUUCGUGACACCUCAA
  	CCUCCACAGCAACCUCCAGCCGCCAACCAGCUGAUCACCCUG
  	UCUAAUCUGCACCUGAGCCUGAGUUCCCUGCUGGCCAACAAC
  	GCCGUGACCAAUCCUCCUACCAAUCCACCAGCUCAGGACUCU
  	CACCCUGCCAUCAUCGGCUCUACAACAGCCGGAAGCGUGACA
  	AUCAGCGGCCCCAUCUUCUUCGAGGACCUGGACGAUACCGCC
  	UACGACAGAUACGAUUGGCUGGGCUCCAACCAGAAAAUCGA
  	CGUGCUGAAACUGCAGCUGGGCACCCAGCCAUCUGCCAACGC
  	UCCAUCUGAUCUGACCCUGGGCAACGAGAUGCCUAAGUACG
  	GCUACCAAGGCAGCUGGAAGCUGGCCUGGGAUCCUAACACA
  	GCCAACAAUGGCCCCUACACACUGAAGGCCACCUGGACCAAG
  	ACAGGC
  Ct871pd_PmpG_D_NGM_nIgK_cHis	AUGGAAACCCCUGCUCAGCUGCUGUUCCUGCUGCUGCUGUG	365
  	GCUGCCUGAUACAACAGGCGCCGAGAUCAUGAUUCCCCAGG
  	GCAUCUACGACGGCGAAACCCUGACCGUGUCUUUCCCCUAUA
  	CCGUGAUCGGCGAUCCUAGCGGCACCACCGUGUUUUCUGCU
  	GGCGAGCUGACCCUGAAGAACCUGGACAACUCUAUCGCCGC
  	UCUGCCCCUGAGCUGCUUCGGAAAUCUGCUGGGCAGCUUCA
  	CCGUGCUCGGCAGAGGACACAGCCUGACCUUCGAGAACAUCC
  	GGACCAGCACAAAUGGCGCUGCCCUGAGCGAUAGCGCCAAU
  	AGCGGCCUGUUUACCAUCGAGGGCUUCAAAGAGCUGAGCUU
  	CAGCAACUGCAACAGCCUGCUGGCAGUGCUGCCUGCCGCCAC
  	AACAAAUAGCGGCAGCCAGACACCUACCACCACCAGCACACC
  	UUCUAACGGCGCCAUCUACAGCAAGACCGACCUGCUGCUCCU
  	GAACAACGAGAAGUUCAGCUUCUACUCCAACCUGGUGUCCG
  	GCGACGGCGGAGCCAUUGAUGCCAAAUCUCUGACCGUGCAG
  	GGCAUCAGCAAGCUGUGCGUGUUCCAAGAGAACACAGCCCA
  	GGCUGAUGGCGGAGCCUGUCAGGUGGUCACAAGCUUUAGCG
  	CCAUGGCCAACGAGGCCCCUAUCGCCUUUAUUGCCAAUGUG
  	GCCGGCGUUAGAGGCGGAGGAAUUGCCGCUGUUCAGGAUGG
  	ACAGCAGGGCGUGUCCAGCAGCACAAGCACUGAGGAUCCUG
  	UGGUGUCCUUCAGCAGAAACACCGCCGUGGAAUUCGAUGGC
  	AACGUGGCCAGAGUUGGCGGCGGAAUCUACAGCUACGGAAA
  	CGUGGCCUUUCUGAACAAUGGCAAGACCCUGUUCCUCAACA
  	ACGUGGCAAGCCCCGUGUAUAUCGCCGCCGAGCAGCCUACAA
  	AUGGCCAGGCCUCUAAUACCGCCGACAACUAUGGCGACGGU
  	GGCGCAAUCUUCUGCAAGAAUGGUGCUCAGGCCGCUGGCAG
  	CAACAAUGCCGGCUCUGUGUCCUUUGAUGGCGAAGGCGUGG
  	UGUUCUUCUCCUCUAACGUGGCCGCUGGAAAAGGCGGCGCU
  	AUCUACGCCAAGAAACUGAGCGUGGCCAACUGCGGCCCUGU
  	GCAGUUUCUGGGCAAUAUCGCCAAUGAUGGCGGUGCCAUCU
  	ACCUGGGAGAGUCCGGCGAACUGUCUCUGAGCGCCGAUUAC
  	GGCGACAUCAUCUUCGACGGCAACCUGAAGCGGACCGCCAA
  	AGAAAAUGCCGCCGAUGUGAAUGGCGUGACAGUGUCCAGCC
  	AGGCCAUCUCUAUGGGCUCUGGCGGCAAGAUCACCACACUG
  	AGAGCCAAGGCCGGCCACCAGAUCCUGUUCAACGACCCUAUC
  	GAGAUGGCCAAUGGCAACAACCAGCCUGCUCAGAGCAGCGA
  	GCCCCUGAAGAUUAACGAUGGCGAGGGCUACACCGGCGAUA
  	UCGUGUUCGCCAACGGCAACAGCGCCCUGUACCAGAAUGUG
  	GCCAUCGAGCAGGGCAGAAUCGUGCUGAGAGAGAAGGCCAA
  	GCUGAGCGUGAACAGCCUGAGUCAGACAGGCGGCAGCCUGU
  	AUAUGGAAGCCGGCAGCACCCUGGACUUCGUGACACCUCAA
  	CCUCCACAGCAACCUCCAGCCGCCAACCAGCUGAUCACCCUG
  	UCUAAUCUGCACCUGAGCCUGAGUUCCCUGCUGGCCAACAAC
  	GCCGUGACCAAUCCUCCUACCAAUCCACCAGCUCAGGACUCU
  	CACCCUGCCAUCAUCGGCUCUACAACAGCCGGAAGCGUGACA
  	AUCAGCGGCCCCAUCUUCUUCGAGGACCUGGACGAUACCGCC
  	UACGACAGAUACGAUUGGCUGGGCUCCAACCAGAAAAUCGA
  	CGUGCUGAAACUGCAGCUGGGCACCCAGCCAUCUGCCAACGC
  	UCCAUCUGAUCUGACCCUGGGCAACGAGAUGCCUAAGUACG
  	GCUACCAAGGCAGCUGGAAGCUGGCCUGGGAUCCUAACACA
  	GCCAACAAUGGCCCCUACACACUGAAGGCCACCUGGACCAAG
  	ACAGGCCACCACCAUCACCAUCAC
  CT460_D_S16A_nIgK	AUGGAAACCCCUGCUCAGCUGCUGUUCCUGCUGCUGCUGUG	366
  	GCUGCCUGAUACCACAGGCAUGAGCCAGAACAAGAACAGCG
  	CCUUCAUGCAGCCCGUGAACGUGGCAGCUGAUCUGGCCGCU
  	AUAGUUGGCGCUGGCCCUAUGCCUAGAACCGAGAUCAUCAA
  	GAAGAUGUGGGACUACAUUAAGAAGAACGGCCUGCAGGACC
  	CCACCAACAAGCGGAACAUCAACCCCGACGACAAGCUGGCCA
  	AGGUGUUCGGCACAGAGAAGCCCAUCGACAUGUUCCAGAUG
  	ACCAAGAUGGUGUCCCAGCACAUCAUCAAG
  CT460_D_S16A_nIgK_cHis	AUGGAAACCCCUGCUCAGCUGCUGUUCCUGCUGCUGCUGUG	367
  	GCUGCCUGAUACCACAGGCAUGAGCCAGAACAAGAACAGCG
  	CCUUCAUGCAGCCCGUGAACGUGGCAGCUGAUCUGGCCGCU
  	AUAGUUGGCGCUGGCCCUAUGCCUAGAACCGAGAUCAUCAA
  	GAAGAUGUGGGACUACAUUAAGAAGAACGGCCUGCAGGACC
  	CCACCAACAAGCGGAACAUCAACCCCGACGACAAGCUGGCCA
  	AGGUGUUCGGCACAGAGAAGCCCAUCGACAUGUUCCAGAUG
  	ACCAAGAUGGUGUCCCAGCACAUCAUCAAGCACCACCACCAU
  	CACCAC
  CT875_E_S274Q_N275H_S574D_nIgK	AUGGAAACCCCUGCCCAGCUGCUGUUCCUGCUGCUGCUGUG	368
  	GCUGCCUGACACCACCGGCAUGAGCAUCAGAGGCGUGGGCG
  	GCAACGGCAACAGCAGAAUCCCUAGCCACAACGGCGACGGCA
  	GCAACAGGCGGAGCCAGAACACCAAGGGCAACAACAAGGUG
  	GAAGAUAGAGUGUGCAGCCUGUACAGCAGCCGGUCCAACGA
  	GAACCGCGAGAGCCCUUAUGCCGUGGUGGACGUGUCCAGCA
  	UGAUCGAGAGCACCCCCACCAGCGGCGAGACAACCAGAGCUA
  	GUAGAGGCGUGCUGAGCCGGUUCCAGAGGGGCCUCGUGCGG
  	AUUGCUGACAAAGUGCGGAGAGCCGUGCAGUGCGCUUGGAG
  	CAGCGUGUCCACAAGCAGAAGCAGCGCCACAAGAGCCGCCGA
  	GAGCGGCAGCUCUAGCAGAACAGCUAGAGGCGCCAGCAGCG
  	GCUACAGAGAGUACAGCCCUUCUGCCGCUCGGGGCCUGCGGC
  	UGAUGUUCACCGACUUUUGGCGGACCCGGGUGCUGAGACAG
  	ACCUCUCCUAUGGCCGGCGUGUUCGGCAACCUGGACGUGAA
  	CGAGGCCAGACUGAUGGCCGCCUACACCAGCGAGUGUGCCG
  	AUCACCUGGAAGCCAAAGAGCUGGCCGGACCUGACGGCGUG
  	GCAGCCGCUAGAGAAAUCGCCAAGAGAUGGGAGAAGAGAGU
  	GCGGGACCUGCAGGACAAGGGCGCUGCCAGAAAGCUGCUGA
  	ACGACCCCCUGGGCAGACGGACCCCCAACUACCAGAGCAAGA
  	ACCCCGGCGAGUACACCGUGGGCAACUCCAUGUUCUACGACG
  	GCCCCCAGGUGGCCAACCUGCAGAAUGUGGAUACCGGCUUC
  	UGGCUGGACAUGCAGCACCUGAGCGACGUGGUGCUGUCCAG
  	AGAGAUCCAGACCGGCCUGAGAGCCAGAGCCACCCUGGAAG
  	AGUCCAUGCCCAUGCUGGAAAAUCUGGAAGAGAGAUUCCGG
  	CGGCUGCAGGAAACCUGCGACGCCGCCAGAACCGAGAUCGA
  	GGAAAGCGGCUGGACCCGGGAAAGCGCCUCCAGAAUGGAAG
  	GCGACGAAGCCCAGGGCCCCAGCAGAGUGCAGCAGGCCUUUC
  	AGAGCUUCGUGAAUGAGUGCAACAGCAUCGAGUUCAGCUUC
  	GGCUCCUUCGGCGAGCACGUGCGGGUGCUGUGUGCCAGAGU
  	GUCAAGAGGACUGGCCGCUGCCGGCGAGGCCAUCAGAAGAU
  	GCUUCAGCUGCUGCAAGGGCAGCACCCACAGAUACGCCCCCA
  	GAGAUGACCUGUCUCCUGAGGGCGCCUCUCUGGCCGAAACCC
  	UGGCCAGAUUCGCCGACGACAUGGGCAUCGAAAGAGGCGCC
  	GACGGCACCUACGACAUCCCCCUGGUGGACGAUUGGAGAAG
  	GGGCGUGCCAUCCAUCGAGGGCGAGGGCAGCGAUAGCAUCU
  	ACGAGAUCAUGAUGCCCAUCUACGAAGUGAUGAACAUGGAC
  	CUGGAAACCCGGCGGAGCUUCGCCGUGCAGCAGGGCCAUUA
  	CCAGGACCCCAGAGCCAGCGACUACGACCUGCCUAGAGCCUC
  	CGAUUACGAUCUGCCCAGAAGCCCCUACCCCACCCCUCCACU
  	GCCUCCCAGAUACCAGCUGCAGAACAUGGAUGUGGAAGCCG
  	GCUUUCGCGAGGCCGUGUACGCCUCUUUUGUGGCCGGCAUG
  	UACAACUACGUCGUGACCCAGCCCCAGGAACGGAUCCCCAAU
  	AGCCAGCAGGUGGAAGGCAUCCUGCGGGACAUGCUGACCAA
  	CGGCGAUCAGACCUUCCGGGACCUGAUGAAGCGGUGGAACA
  	GAGAGGUGGACCGCGAG
  CT875_E_S274Q_N275H_S574D_nIgK_cHis	AUGGAAACCCCUGCCCAGCUGCUGUUCCUGCUGCUGCUGUG	369
  	GCUGCCUGACACCACCGGCAUGAGCAUCAGAGGCGUGGGCG
  	GCAACGGCAACAGCAGAAUCCCUAGCCACAACGGCGACGGCA
  	GCAACAGGCGGAGCCAGAACACCAAGGGCAACAACAAGGUG
  	GAAGAUAGAGUGUGCAGCCUGUACAGCAGCCGGUCCAACGA
  	GAACCGCGAGAGCCCUUAUGCCGUGGUGGACGUGUCCAGCA
  	UGAUCGAGAGCACCCCCACCAGCGGCGAGACAACCAGAGCUA
  	GUAGAGGCGUGCUGAGCCGGUUCCAGAGGGGCCUCGUGCGG
  	AUUGCUGACAAAGUGCGGAGAGCCGUGCAGUGCGCUUGGAG
  	CAGCGUGUCCACAAGCAGAAGCAGCGCCACAAGAGCCGCCGA
  	GAGCGGCAGCUCUAGCAGAACAGCUAGAGGCGCCAGCAGCG
  	GCUACAGAGAGUACAGCCCUUCUGCCGCUCGGGGCCUGCGGC
  	UGAUGUUCACCGACUUUUGGCGGACCCGGGUGCUGAGACAG
  	ACCUCUCCUAUGGCCGGCGUGUUCGGCAACCUGGACGUGAA
  	CGAGGCCAGACUGAUGGCCGCCUACACCAGCGAGUGUGCCG
  	AUCACCUGGAAGCCAAAGAGCUGGCCGGACCUGACGGCGUG
  	GCAGCCGCUAGAGAAAUCGCCAAGAGAUGGGAGAAGAGAGU
  	GCGGGACCUGCAGGACAAGGGCGCUGCCAGAAAGCUGCUGA
  	ACGACCCCCUGGGCAGACGGACCCCCAACUACCAGAGCAAGA
  	ACCCCGGCGAGUACACCGUGGGCAACUCCAUGUUCUACGACG
  	GCCCCCAGGUGGCCAACCUGCAGAAUGUGGAUACCGGCUUC
  	UGGCUGGACAUGCAGCACCUGAGCGACGUGGUGCUGUCCAG
  	AGAGAUCCAGACCGGCCUGAGAGCCAGAGCCACCCUGGAAG
  	AGUCCAUGCCCAUGCUGGAAAAUCUGGAAGAGAGAUUCCGG
  	CGGCUGCAGGAAACCUGCGACGCCGCCAGAACCGAGAUCGA
  	GGAAAGCGGCUGGACCCGGGAAAGCGCCUCCAGAAUGGAAG
  	GCGACGAAGCCCAGGGCCCCAGCAGAGUGCAGCAGGCCUUUC
  	AGAGCUUCGUGAAUGAGUGCAACAGCAUCGAGUUCAGCUUC
  	GGCUCCUUCGGCGAGCACGUGCGGGUGCUGUGUGCCAGAGU
  	GUCAAGAGGACUGGCCGCUGCCGGCGAGGCCAUCAGAAGAU
  	GCUUCAGCUGCUGCAAGGGCAGCACCCACAGAUACGCCCCCA
  	GAGAUGACCUGUCUCCUGAGGGCGCCUCUCUGGCCGAAACCC
  	UGGCCAGAUUCGCCGACGACAUGGGCAUCGAAAGAGGCGCC
  	GACGGCACCUACGACAUCCCCCUGGUGGACGAUUGGAGAAG
  	GGGCGUGCCAUCCAUCGAGGGCGAGGGCAGCGAUAGCAUCU
  	ACGAGAUCAUGAUGCCCAUCUACGAAGUGAUGAACAUGGAC
  	CUGGAAACCCGGCGGAGCUUCGCCGUGCAGCAGGGCCAUUA
  	CCAGGACCCCAGAGCCAGCGACUACGACCUGCCUAGAGCCUC
  	CGAUUACGAUCUGCCCAGAAGCCCCUACCCCACCCCUCCACU
  	GCCUCCCAGAUACCAGCUGCAGAACAUGGAUGUGGAAGCCG
  	GCUUUCGCGAGGCCGUGUACGCCUCUUUUGUGGCCGGCAUG
  	UACAACUACGUCGUGACCCAGCCCCAGGAACGGAUCCCCAAU
  	AGCCAGCAGGUGGAAGGCAUCCUGCGGGACAUGCUGACCAA
  	CGGCGAUCAGACCUUCCGGGACCUGAUGAAGCGGUGGAACA
  	GAGAGGUGGACCGCGAGCACCACCAUCACCACCAC
  CT622_E_S13N_S179A_S220N_nIgK	AUGGAAACCCCUGCCCAACUGCUUUUCUUGCUGCUGCUCUG	370
  	GCUCCCUGACACCACCGGAAUGGAAUCUGGACCCGAGUCCGU
  	GUCAAGCAACCAGAACUCCAUGAACCCCAUCAUUAAUGGAC
  	AGAUCGCAUCCAAUUCCGAAACCAAGGAAAGCACCAAGGCA
  	UCGGAGGCCUCCCCAUCCGCCUCAAGCUCCGUGUCGUCCUGG
  	UCGUUUCUGUCGAGCGCGAAGAAUGCCCUGAUCUCACUGCG
  	GGACGCGAUUCUGAACAAGAACAGCUCCCCAACCGACUCCCU
  	GAGCCAACUCGAGGCCUCAACUUCCACUUCGACUGUGACUA
  	GGGUCGCUGCCAAGGAUUAUGACGAGGCCAAGAGCAACUUC
  	GACACCGCCAAGAGCGGACUGGAAAACGCCAAAACCCUGGCC
  	GAAUACGAAACUAAGAUGGCCGAUCUCAUGGCGGCCCUGCA
  	AGACAUGGAACGGCUGGCGAACUCCGAUCCGUCCAACAACC
  	ACACUGAGGAAGUGAACAACAUCAAGAAGGCUCUCGAGGCC
  	CAGAAGGAUACCAUCGACAAGUUGAACAAGCUUGUGACGCU
  	GCAGAACCAAAACAAGGCCCUGACGGAAGUGCUCAAAACCA
  	CCGACUCGGCCGACCAGAUUCCGGCCAUCAACAGCCAGCUGG
  	AGAUUAACAAGAACUCGGCCGAUCAGAUUAUCAAGGACCUG
  	GAGCGCCAGAACAUUAACUACGAGGCCGUCUUGACUAACGC
  	CGGCGAAGUGAUCAAGGCGUCAUCCGAAGCCGGCAUUAAGC
  	UGGGACAGGCGCUGCAAUCCAUCGUCGACGCCGGCGACCAG
  	UCCCAGGCGGCGGUGCUGCAGGCCCAGCAGAACAACUCCCCC
  	GAUAACAUCGCUGCAACCAAGGAACUGAUUGACGCGGCCGA
  	AACCAAAGUCAACGAACUGAAGCAGGAGCACACUGGUCUGA
  	CCGACUCGCCGCUCGUGAAGAAGGCCGAAGAACAGAUCAGC
  	CAGGCUCAGAAGGAUAUCCAGGAAAUCAAGCCUUCGGGGAG
  	CGACAUCCCGAUCGUGGGACCGUCCGGUUCCGCCGCUUCCGC
  	CGGGUCCGCAGCCGGGGCCCUUAAGUCGUCGAACAAUAGCG
  	GCAGAAUAUCCCUGCUGCUCGACGAUGUGGAUAACGAGAUG
  	GCCGCCAUUGCGCUGCAAGGAUUCCGGUCCAUGAUCGAGCA
  	GUUCAACGUGAACAACCCCGCCACCGCCAAGGAGCUGCAGGC
  	UAUGGAGGCCCAACUCACUGCCAUGUCCGACCAGCUCGUGG
  	GAGCGGACGGAGAACUGCCAGCCGAGAUCCAGGCCAUCAAG
  	GACGCUCUGGCCCAGGCACUGAAGCAGCCGUCCGCGGAUGGC
  	CUGGCCACCGCCAUGGGCCAGGUCGCGUUCGCCGCCGCUAAA
  	GUCGGCGGAGGUUCGGCCGGCACUGCCGGGACCGUGCAGAU
  	GAAUGUCAAGCAGCUGUACAAGACUGCGUUCUCGUCGACCA
  	GCUCCAGCUCCUACGCCGCGGCCCUGUCCGACGGUUACAGCG
  	CGUACAAGACCCUGAACUCCCUUUACUCCGAAUCGAGAUCCG
  	GGGUCCAGUCCGCAAUUUCACAAACCGCCAAUCCUGCCCUGU
  	CGCGCUCAGUGUCACGCAGCGGCAUCGAGUCACAGGGCAGA
  	AGCGCCGACGCUAGCCAAAGGGCCGCAGAAACCAUUGUGCG
  	GGACUCCCAGACACUUGGAGAUGUCUACAGCCGCCUCCAAG
  	UGCUGGACUCCCUCAUGUCCACCAUCGUGUCAAACCCUCAGG
  	CUAACCAGGAGGAAAUCAUGCAGAAGCUGACCGCAAGCAUU
  	UCCAAGGCUCCGCAGUUUGGAUACCCCGCUGUGCAAAACUCC
  	GCGGACAGCUUGCAGAAAUUCGCAGCCCAGUUGGAGAGGGA
  	GUUCGUGGACGGGGAGCGGUCCCUCGCGGAGUCCCAGGAGA
  	ACGCAUUCCGGAAGCAGCCCGCCUUCAUUCAACAAGUGCUU
  	GUGAACAUCGCCUCCCUGUUCUCCGGUUACCUGUCU
  CT622_E_S13N_S179A_S220N_nIgK_cHis	AUGGAAACCCCUGCCCAACUGCUUUUCUUGCUGCUGCUCUG	371
  	GCUCCCUGACACCACCGGAAUGGAAUCUGGACCCGAGUCCGU
  	GUCAAGCAACCAGAACUCCAUGAACCCCAUCAUUAAUGGAC
  	AGAUCGCAUCCAAUUCCGAAACCAAGGAAAGCACCAAGGCA
  	UCGGAGGCCUCCCCAUCCGCCUCAAGCUCCGUGUCGUCCUGG
  	UCGUUUCUGUCGAGCGCGAAGAAUGCCCUGAUCUCACUGCG
  	GGACGCGAUUCUGAACAAGAACAGCUCCCCAACCGACUCCCU
  	GAGCCAACUCGAGGCCUCAACUUCCACUUCGACUGUGACUA
  	GGGUCGCUGCCAAGGAUUAUGACGAGGCCAAGAGCAACUUC
  	GACACCGCCAAGAGCGGACUGGAAAACGCCAAAACCCUGGCC
  	GAAUACGAAACUAAGAUGGCCGAUCUCAUGGCGGCCCUGCA
  	AGACAUGGAACGGCUGGCGAACUCCGAUCCGUCCAACAACC
  	ACACUGAGGAAGUGAACAACAUCAAGAAGGCUCUCGAGGCC
  	CAGAAGGAUACCAUCGACAAGUUGAACAAGCUUGUGACGCU
  	GCAGAACCAAAACAAGGCCCUGACGGAAGUGCUCAAAACCA
  	CCGACUCGGCCGACCAGAUUCCGGCCAUCAACAGCCAGCUGG
  	AGAUUAACAAGAACUCGGCCGAUCAGAUUAUCAAGGACCUG
  	GAGCGCCAGAACAUUAACUACGAGGCCGUCUUGACUAACGC
  	CGGCGAAGUGAUCAAGGCGUCAUCCGAAGCCGGCAUUAAGC
  	UGGGACAGGCGCUGCAAUCCAUCGUCGACGCCGGCGACCAG
  	UCCCAGGCGGCGGUGCUGCAGGCCCAGCAGAACAACUCCCCC
  	GAUAACAUCGCUGCAACCAAGGAACUGAUUGACGCGGCCGA
  	AACCAAAGUCAACGAACUGAAGCAGGAGCACACUGGUCUGA
  	CCGACUCGCCGCUCGUGAAGAAGGCCGAAGAACAGAUCAGC
  	CAGGCUCAGAAGGAUAUCCAGGAAAUCAAGCCUUCGGGGAG
  	CGACAUCCCGAUCGUGGGACCGUCCGGUUCCGCCGCUUCCGC
  	CGGGUCCGCAGCCGGGGCCCUUAAGUCGUCGAACAAUAGCG
  	GCAGAAUAUCCCUGCUGCUCGACGAUGUGGAUAACGAGAUG
  	GCCGCCAUUGCGCUGCAAGGAUUCCGGUCCAUGAUCGAGCA
  	GUUCAACGUGAACAACCCCGCCACCGCCAAGGAGCUGCAGGC
  	UAUGGAGGCCCAACUCACUGCCAUGUCCGACCAGCUCGUGG
  	GAGCGGACGGAGAACUGCCAGCCGAGAUCCAGGCCAUCAAG
  	GACGCUCUGGCCCAGGCACUGAAGCAGCCGUCCGCGGAUGGC
  	CUGGCCACCGCCAUGGGCCAGGUCGCGUUCGCCGCCGCUAAA
  	GUCGGCGGAGGUUCGGCCGGCACUGCCGGGACCGUGCAGAU
  	GAAUGUCAAGCAGCUGUACAAGACUGCGUUCUCGUCGACCA
  	GCUCCAGCUCCUACGCCGCGGCCCUGUCCGACGGUUACAGCG
  	CGUACAAGACCCUGAACUCCCUUUACUCCGAAUCGAGAUCCG
  	GGGUCCAGUCCGCAAUUUCACAAACCGCCAAUCCUGCCCUGU
  	CGCGCUCAGUGUCACGCAGCGGCAUCGAGUCACAGGGCAGA
  	AGCGCCGACGCUAGCCAAAGGGCCGCAGAAACCAUUGUGCG
  	GGACUCCCAGACACUUGGAGAUGUCUACAGCCGCCUCCAAG
  	UGCUGGACUCCCUCAUGUCCACCAUCGUGUCAAACCCUCAGG
  	CUAACCAGGAGGAAAUCAUGCAGAAGCUGACCGCAAGCAUU
  	UCCAAGGCUCCGCAGUUUGGAUACCCCGCUGUGCAAAACUCC
  	GCGGACAGCUUGCAGAAAUUCGCAGCCCAGUUGGAGAGGGA
  	GUUCGUGGACGGGGAGCGGUCCCUCGCGGAGUCCCAGGAGA
  	ACGCAUUCCGGAAGCAGCCCGCCUUCAUUCAACAAGUGCUU
  	GUGAACAUCGCCUCCCUGUUCUCCGGUUACCUGUCUCAUCAC
  	CACCACCAUCAC
  Cta1_E_noTM_nIgK_cHis	AUGGAAACCCCUGCCCAGCUGCUGUUCCUGCUGCUGCUGUG	372
  	GCUGCCUGAUACCACCGGCCCUAGCAGCACCCAGGACAACAG
  	AUCCAUGGACCAGCAGGACAGCGAGGAAUUUCUGCUGCAGA
  	ACACCCUGGAAGAUAGCGAGAUCAUCAGCAUCCCCGACACCA
  	UGAACCAGAUCGCCAUCGACACCGAGAAGUGGUUCUACCUG
  	AACAAGGACUGCACCAACGUGGGCCCCAUCUCCAUCGUGCAG
  	CUGACCGCCUUCCUGAAAGAGUGCAAGCACAGCCCCGAGAA
  	GGGCAUCGACCCCCAGGAACUGUGGGUGUGGAAGAAAGGCA
  	UGCCCAACUGGGAGAAAGUGAAGAACAUCCCCGAGCUGAGC
  	GGCACCGUGAAGGACGAGCACCACCACCAUCACCAC
  Cta1_E_noTM_nIgK	AUGGAAACCCCUGCCCAGCUGCUGUUCCUGCUGCUGCUGUG	373
  	GCUGCCUGAUACCACCGGCCCUAGCAGCACCCAGGACAACAG
  	AUCCAUGGACCAGCAGGACAGCGAGGAAUUUCUGCUGCAGA
  	ACACCCUGGAAGAUAGCGAGAUCAUCAGCAUCCCCGACACCA
  	UGAACCAGAUCGCCAUCGACACCGAGAAGUGGUUCUACCUG
  	AACAAGGACUGCACCAACGUGGGCCCCAUCUCCAUCGUGCAG
  	CUGACCGCCUUCCUGAAAGAGUGCAAGCACAGCCCCGAGAA
  	GGGCAUCGACCCCCAGGAACUGUGGGUGUGGAAGAAAGGCA
  	UGCCCAACUGGGAGAAAGUGAAGAACAUCCCCGAGCUGAGC
  	GGCACCGUGAAGGACGAA
  Cta1_E_cHis	AUGAACAGCGGGAUGUUCCCCUUCACCUUCUUUCUGCUGUA	374
  	CAUCUGCCUGGGCAUGCUGACCGCCUACCUGGCCAACAAGAA
  	GAACCGGAACCUGAUCGGCUGGUUCCUGGCCGGCAUGUUCU
  	UCGGAAUCUUCGCCAUCAUUUUUCUGCUGAUCCUGCCCCCCC
  	UGCCCAGCAGCACACAGGACAACAGAUCCAUGGACCAGCAG
  	GACAGCGAAGAGUUCCUGCUGCAGAACACCCUGGAAGAUAG
  	CGAGAUCAUCAGCAUCCCCGACACCAUGAACCAGAUCGCCAU
  	CGACACCGAGAAGUGGUUCUACCUGAACAAGGACUGCACCA
  	ACGUGGGCCCCAUCUCCAUCGUGCAGCUGACAGCCUUCCUGA
  	AAGAGUGCAAGCACAGCCCCGAGAAGGGCAUCGACCCCCAG
  	GAACUGUGGGUGUGGAAGAAAGGCAUGCCCAACUGGGAGAA
  	AGUGAAGAACAUCCCCGAGCUGAGCGGCACCGUGAAGGACG
  	AGCACCACCACCAUCACCAC
  Cta1_E	AUGAACAGCGGGAUGUUCCCCUUCACCUUCUUUCUGCUGUA	375
  	CAUCUGCCUGGGCAUGCUGACCGCCUACCUGGCCAACAAGAA
  	GAACCGGAACCUGAUCGGCUGGUUCCUGGCCGGCAUGUUCU
  	UCGGAAUCUUCGCCAUCAUUUUUCUGCUGAUCCUGCCCCCCC
  	UGCCCAGCAGCACACAGGACAACAGAUCCAUGGACCAGCAG
  	GACAGCGAAGAGUUCCUGCUGCAGAACACCCUGGAAGAUAG
  	CGAGAUCAUCAGCAUCCCCGACACCAUGAACCAGAUCGCCAU
  	CGACACCGAGAAGUGGUUCUACCUGAACAAGGACUGCACCA
  	ACGUGGGCCCCAUCUCCAUCGUGCAGCUGACAGCCUUCCUGA
  	AAGAGUGCAAGCACAGCCCCGAGAAGGGCAUCGACCCCCAG
  	GAACUGUGGGUGUGGAAGAAAGGCAUGCCCAACUGGGAGAA
  	AGUGAAGAACAUCCCCGAGCUGAGCGGCACCGUGAAGGACG
  	AA
  CT443_E_nIgK_cHis_mod	AUGGAAACCCCUGCCCAGCUGCUGUUCCUGCUCCUGCUGUGG	376
  	CUGCCUGAUACCACAGGCAGCGGCGUGCUGGAAACCAGCAU
  	GGCCGAGAGCCUGAGCACCAACGUGAUCAGCCUGGCCGACAC
  	CAAGGCCAAGGACAACACCAGCCACAAGAGCAAGAAGGCCC
  	GGAAGAACCACAGCAAAGAAACCCUGGUGGACCGGAAAGAG
  	GUGGCCCCUGUGCACGAGUCUAAGGCCACAGGCCCCAAGCAG
  	GACAGCUGCUUCGGCCGGAUGUACACCGUGAAAGUGAACGA
  	CGACCGGAACGUGGAAAUCACCCAGGCCGUGCCUGAGUACG
  	CCACAGUGGGCAGCCCUUACCCCAUCGAGAUCACCGCCACCG
  	GCAAGAGGGAUUGCGUGGAUGUGAUCAUUACCCAACAGCUG
  	CCUUGCGAGGCCGAGUUCGUGCGCUCUGAUCCUGCCACCACC
  	CCUACCGCCGAUGGCAAGCUCGUGUGGAAGAUCGACAGACU
  	GGGCCAGGGCGAGAAGUCCAAAAUCACUGUGUGGGUCAAGC
  	CCCUGAAAGAGGGGUGCUGCUUUACCGCAGCCACCGUGUGU
  	GCCUGCCCCGAGAUUAGAAGCGUGACCAAGUGUGGCCAGCC
  	CGCCAUCUGCGUGAAGCAGGAAGGACCUGAGAACGCCUGCC
  	UGAGAUGCCCCGUGGUGUACAAGAUCAACGUCGUGAACCAG
  	GGCACCGCCAUUGCCAGAAACGUGGUGGUGGAAAACCCCGU
  	GCCCGACGGCUACGCCCACAGCUCUGGACAGAGAGUGCUGAC
  	CUUCACCCUGGGCGACAUGCAGCCCGGCGAGCACAGAACCAU
  	CACCGUGGAAUUCUGCCCCCUGAAGCGGGGCAGAGCCACCAA
  	CAUUGCGACAGUGUCCUACUGUGGCGGGCACAAGAACACCG
  	CCUCCGUGACCACCGUGAUCAACGAGCCUUGCGUGCAGGUG
  	UCCAUUGCCGGCGCUGACUGGUCCUACGUGUGCAAGCCAGU
  	GGAGUACGUGAUCUCCGUGUCCAACCCCGGCGACCUGGUGC
  	UGAGAGAUGUGGUGGUUGAGGAUACCCUGAGCCCUGGCGUG
  	ACAGUCCUGGAAGCUGCUGGCGCCCAGAUCAGCUGCAACAA
  	GGUGGUGUGGACAGUGAAAGAGCUGAACCCCGGGGAGUCCC
  	UGCAGUACAAGGUGCUCGUGCGGGCCCAGACCCCUGGCCAG
  	UUCACCAACAAUGUGGUCGUGAAGUCCUGCAGCGACUGCGG
  	CACCUGUACCUCUUGUGCCGAGGCCACCACGUACUGGAAAG
  	GCGUGGCCGCUACCCAUAUGUGCGUGGUGGAUACCUGCGAC
  	CCCGUCUGCGUGGGCGAAAACACCGUGUACCGGAUCUGUGU
  	GACCAACCGGGGCAGCGCCGAGGACACCAAUGUGUCCCUGA
  	UGCUGAAGUUCUCCAAAGAACUGCAACCCGUGAGCUUCAGC
  	GGCCCCACCAAGGGAACAAUCACUGGCAACACCGUCGUUUUC
  	GACAGCCUGCCUCGGCUGGGCUCUAAGGAAACUGUGGAGUU
  	CAGCGUGACACUGAAGGCCGUGUCUGCCGGGGAUGCUAGAG
  	GCGAGGCCAUCCUGAGCAGCGACACACUGACGGUCCCUGUG
  	UCCGACACCGAGAAUACCCACAUCUACCACCACCAUCAUCAC
  	CAU
  CT443_E_nIgK_mod	AUGGAAACCCCUGCCCAGCUGCUGUUCCUGCUCCUGCUGUGG	377
  	CUGCCUGAUACCACAGGCAGCGGCGUGCUGGAAACCAGCAU
  	GGCCGAGAGCCUGAGCACCAACGUGAUCAGCCUGGCCGACAC
  	CAAGGCCAAGGACAACACCAGCCACAAGAGCAAGAAGGCCC
  	GGAAGAACCACAGCAAAGAAACCCUGGUGGACCGGAAAGAG
  	GUGGCCCCUGUGCACGAGUCUAAGGCCACAGGCCCCAAGCAG
  	GACAGCUGCUUCGGCCGGAUGUACACCGUGAAAGUGAACGA
  	CGACCGGAACGUGGAAAUCACCCAGGCCGUGCCUGAGUACG
  	CCACAGUGGGCAGCCCUUACCCCAUCGAGAUCACCGCCACCG
  	GCAAGAGGGAUUGCGUGGAUGUGAUCAUUACCCAACAGCUG
  	CCUUGCGAGGCCGAGUUCGUGCGCUCUGAUCCUGCCACCACC
  	CCUACCGCCGAUGGCAAGCUCGUGUGGAAGAUCGACAGACU
  	GGGCCAGGGCGAGAAGUCCAAAAUCACUGUGUGGGUCAAGC
  	CCCUGAAAGAGGGGUGCUGCUUUACCGCAGCCACCGUGUGU
  	GCCUGCCCCGAGAUUAGAAGCGUGACCAAGUGUGGCCAGCC
  	CGCCAUCUGCGUGAAGCAGGAAGGACCUGAGAACGCCUGCC
  	UGAGAUGCCCCGUGGUGUACAAGAUCAACGUCGUGAACCAG
  	GGCACCGCCAUUGCCAGAAACGUGGUGGUGGAAAACCCCGU
  	GCCCGACGGCUACGCCCACAGCUCUGGACAGAGAGUGCUGAC
  	CUUCACCCUGGGCGACAUGCAGCCCGGCGAGCACAGAACCAU
  	CACCGUGGAAUUCUGCCCCCUGAAGCGGGGCAGAGCCACCAA
  	CAUUGCGACAGUGUCCUACUGUGGCGGGCACAAGAACACCG
  	CCUCCGUGACCACCGUGAUCAACGAGCCUUGCGUGCAGGUG
  	UCCAUUGCCGGCGCUGACUGGUCCUACGUGUGCAAGCCAGU
  	GGAGUACGUGAUCUCCGUGUCCAACCCCGGCGACCUGGUGC
  	UGAGAGAUGUGGUGGUUGAGGAUACCCUGAGCCCUGGCGUG
  	ACAGUCCUGGAAGCUGCUGGCGCCCAGAUCAGCUGCAACAA
  	GGUGGUGUGGACAGUGAAAGAGCUGAACCCCGGGGAGUCCC
  	UGCAGUACAAGGUGCUCGUGCGGGCCCAGACCCCUGGCCAG
  	UUCACCAACAAUGUGGUCGUGAAGUCCUGCAGCGACUGCGG
  	CACCUGUACCUCUUGUGCCGAGGCCACCACGUACUGGAAAG
  	GCGUGGCCGCUACCCAUAUGUGCGUGGUGGAUACCUGCGAC
  	CCCGUCUGCGUGGGCGAAAACACCGUGUACCGGAUCUGUGU
  	GACCAACCGGGGCAGCGCCGAGGACACCAAUGUGUCCCUGA
  	UGCUGAAGUUCUCCAAAGAACUGCAACCCGUGAGCUUCAGC
  	GGCCCCACCAAGGGAACAAUCACUGGCAACACCGUCGUUUUC
  	GACAGCCUGCCUCGGCUGGGCUCUAAGGAAACUGUGGAGUU
  	CAGCGUGACACUGAAGGCCGUGUCUGCCGGGGAUGCUAGAG
  	GCGAGGCCAUCCUGAGCAGCGACACACUGACGGUCCCUGUG
  	UCCGACACCGAGAAUACCCACAUCUAC
  CT875_E_nIgK_CO004	AUGGAAACUCCCGCACAGUUACUUUUCUUGUUGCUUCUAUG	378
  	GCUCCCCGAUACCACCGGGAUGAGCAUCAGAGGCGUCGGCG
  	GGAACGGCAACAGCAGAAUUCCCUCCCACAACGGCGACGGCA
  	GCAACAGAAGAUCCCAGAACACAAAGGGCAAUAAUAAGGUC
  	GAGGACAGAGUGUGCAGCCUCUACUCCAGCAGGUCUAACGA
  	GAAUAGGGAGUCCCCGUACGCCGUUGUCGACGUGAGUUCUA
  	UGAUAGAGAGCACGCCCACGUCCGGAGAAACAACUAGAGCA
  	AGCAGGGGCGUCCUGAGCCGGUUCCAGAGAGGUCUGGUGCG
  	AAUUGCCGACAAGGUGAGACGGGCAGUGCAAUGCGCCUGGA
  	GCAGCGUCUCCACCAGCAGAAGCAGCGCCACCCGCGCUGCCG
  	AAUCAGGCAGCAGCUCCAGAACGGCACGGGGCGCCUCCUCCG
  	GCUACCGAGAGUACUCCCCUAGCGCCGCCAGAGGCCUGAGAC
  	UGAUGUUCACCGAUUUUUGGAGGACACGGGUUCUGAGACAG
  	ACCUCCCCCAUGGCUGGGGUGUUCGGCAACCUGGACGUCAA
  	UGAAGCCAGACUCAUGGCCGCAUAUACUUCUGAGUGCGCUG
  	ACCACCUGGAAGCUAAGGAACUGGCGGGCCCCGAUGGCGUG
  	GCCGCGGCCCGGGAGAUCGCCAAGAGAUGGGAGAAGAGAGU
  	GCGGGACCUGCAAGACAAGGGGGCCGCCCGGAAGCUGCUGA
  	ACGAUCCCUUGGGCCGCCGGACACCGAACUAUCAGAGCAAG
  	AACCCGGGCGAGUACACCGUGGGAAACAGCAUGUUCUAUGA
  	CGGACCUCAGGUGGCAAACCUGCAGAACGUGGACACUGGAU
  	UUUGGCUCGACAUGAGUAACCUCUCCGAUGUCGUUCUGUCU
  	CGUGAGAUACAGACAGGUCUGCGGGCUAGAGCCACCCUUGA
  	GGAGAGCAUGCCUAUGUUGGAGAAUCUGGAGGAGCGGUUCA
  	GAAGACUGCAGGAGACUUGCGAUGCCGCCAGGACCGAGAUU
  	GAGGAGAGCGGCUGGACCCGGGAAAGCGCCUCAAGGAUGGA
  	GGGAGACGAGGCCCAGGGACCCUCCAGGGUUCAGCAGGCCU
  	UCCAGUCGUUCGUGAAUGAAUGCAACAGCAUCGAGUUCAGC
  	UUCGGAAGCUUCGGAGAGCACGUGCGAGUGCUGUGCGCCAG
  	AGUAUCCAGAGGUCUGGCCGCUGCAGGCGAGGCCAUCCGGA
  	GAUGCUUCUCCUGCUGCAAAGGCAGCACCCACAGGUAUGCU
  	CCCAGGGAUGAUCUUUCUCCCGAGGGAGCCAGCCUGGCUGA
  	GACUCUUGCAAGAUUCGCCGAUGACAUGGGGAUCGAGCGGG
  	GCGCUGACGGCACCUACGACAUUCCCCUGGUGGACGACUGG
  	AGGAGGGGAGUGCCCUCCAUCGAGGGCGAGGGCUCCGAUUC
  	AAUCUAUGAGAUCAUGAUGCCUAUUUACGAGGUGAUGAACA
  	UGGACCUGGAGACAAGAAGAAGUUUCGCCGUCCAGCAGGGU
  	CAUUACCAGGACCCCCGAGCAAGCGACUACGAUCUGCCUCGC
  	GCCAGCGAUUACGACCUGCCUAGAAGCCCCUACCCUACACCU
  	CCACUGCCCCCAAGAUAUCAGCUCCAGAACAUGGACGUGGA
  	GGCCGGCUUCAGGGAGGCCGUGUACGCCAGCUUUGUGGCCG
  	GCAUGUACAACUAUGUCGUGACACAGCCUCAGGAACGCAUU
  	CCCAAUAGCCAACAGGUGGAGGGCAUCCUGAGAGACAUGCU
  	GACCAACGGCUCUCAGACUUUUAGAGAUCUGAUGAAAAGAU
  	GGAACAGAGAAGUGGACAGGGAG
  CT875_E_nIgK_CO003	AUGGAAACACCAGCUCAGCUCCUUUUCUUACUCCUCUUGUG	379
  	GUUGCCGGAUACCACAGGCAUGAGCAUCCGGGGCGUCGGCG
  	GCAACGGAAACAGCCGGAUCCCCAGCCACAACGGAGACGGCU
  	CUAAUAGAAGAUCACAGAAUACCAAGGGAAAUAACAAGGUC
  	GAAGAUAGAGUCUGCAGCUUAUAUUCCAGCAGAUCCAACGA
  	GAAUAGGGAAAGCCCCUACGCCGUCGUUGACGUGAGCUCCA
  	UGAUCGAAAGCACCCCAACAAGUGGCGAGACUACAAGAGCC
  	UCAAGGGGCGUCCUGUCAAGAUUCCAAAGAGGCCUGGUGAG
  	GAUCGCAGACAAGGUGCGGCGGGCCGUGCAGUGCGCCUGGA
  	GCUCUGUGUCGACAAGCAGAUCAAGUGCCACCAGGGCCGCC
  	GAGAGCGGAUCCUCCAGUCGGACCGCCCGCGGCGCCUCUAGU
  	GGGUACAGAGAAUAUAGUCCCAGCGCCGCUAGGGGGCUGCG
  	CCUCAUGUUCACCGACUUCUGGAGAACCCGCGUGCUCAGGCA
  	GACAUCCCCUAUGGCCGGGGUGUUCGGCAACCUGGACGUGA
  	ACGAGGCCCGGCUUAUGGCCGCAUAUACAAGCGAGUGUGCC
  	GACCACCUGGAGGCCAAGGAGCUGGCUGGCCCCGACGGCGU
  	GGCCGCCGCACGCGAGAUUGCCAAGAGGUGGGAAAAGAGGG
  	UGAGAGAUCUGCAGGAUAAGGGCGCCGCCAGAAAACUGCUG
  	AAUGACCCCCUGGGGAGGAGGACACCCAAUUACCAGUCAAA
  	GAAUCCAGGGGAGUACACUGUUGGAAAUUCUAUGUUUUAUG
  	ACGGCCCUCAGGUGGCCAACCUUCAGAAUGUGGACACAGGC
  	UUCUGGCUUGACAUGAGCAACCUCAGCGACGUGGUGCUGUC
  	UAGGGAGAUCCAGACAGGCUUAAGAGCACGGGCUACCCUGG
  	AAGAGUCGAUGCCCAUGCUCGAAAAUCUGGAGGAGAGGUUC
  	AGACGCCUGCAAGAGACAUGCGACGCCGCGAGGACUGAAAU
  	CGAGGAGAGCGGCUGGACCAGGGAGUCCGCUUCUCGCAUGG
  	AAGGGGACGAGGCUCAGGGCCCCAGCAGGGUGCAGCAGGCC
  	UUCCAGAGCUUUGUGAACGAGUGCAACUCCAUUGAGUUCAG
  	CUUUGGAAGCUUCGGAGAGCACGUGCGGGUGCUGUGCGCCC
  	GCGUGUCCAGGGGCCUGGCCGCAGCUGGCGAGGCUAUACGU
  	CGCUGCUUCAGCUGUUGUAAGGGAAGCACCCAUAGGUACGC
  	CCCUCGUGACGAUCUGUCUCCCGAAGGGGCCAGCCUGGCUGA
  	GACACUGGCCCGCUUCGCCGAUGAUAUGGGGAUUGAACGGG
  	GCGCCGACGGAACCUACGACAUCCCUCUUGUGGACGACUGG
  	AGGAGAGGCGUCCCCUCUAUCGAGGGCGAGGGCUCUGACUC
  	CAUCUACGAGAUUAUGAUGCCUAUCUACGAGGUCAUGAACA
  	UGGACCUGGAAACCAGAAGAAGCUUCGCAGUUCAGCAGGGA
  	CACUACCAAGACCCACGGGCUAGUGAUUAUGACCUCCCAAG
  	AGCAUCCGACUAUGAUCUGCCAAGGUCACCUUACCCUACCCC
  	ACCCCUGCCCCCACGGUACCAGUUACAGAACAUGGAUGUGG
  	AGGCCGGCUUCAGGGAAGCCGUCUAUGCAUCCUUCGUGGCC
  	GGCAUGUACAACUACGUGGUGACUCAACCUCAGGAACGGAU
  	CCCCAACAGUCAGCAGGUGGAGGGGAUCCUUAGGGAUAUGC
  	UGACUAAUGGAAGCCAGACCUUCAGAGAUCUGAUGAAGCGG
  	UGGAAUAGGGAGGUGGACAGGGAG
  CT875_E_nIgK_CO002	AUGGAGACACCCGCACAGCUCCUCUUCUUAUUGCUCUUGUG	380
  	GCUACCGGACACCACAGGCAUGUCUAUCCGGGGCGUUGGCG
  	GGAACGGCAACUCUAGGAUCCCCUCUCACAACGGCGACGGG
  	AGCAACAGGAGAAGCCAGAACACCAAAGGCAAUAACAAAGU
  	CGAGGACAGAGUUUGUUCUCUCUAUAGCUCUAGGAGCAACG
  	AAAACCGCGAAUCUCCUUACGCCGUCGUCGACGUCAGCAGCA
  	UGAUAGAGUCAACCCCUACCUCUGGAGAAACAACACGCGCC
  	UCCAGAGGCGUUCUGUCCAGGUUCCAGAGGGGCCUGGUGAG
  	AAUUGCCGACAAGGUCAGACGAGCCGUGCAGUGUGCCUGGU
  	CCAGCGUCUCUACCAGCAGAAGCUCCGCCACCAGAGCCGCUG
  	AGAGUGGCAGCUCCAGCAGGACAGCCAGGGGGGCUUCCAGC
  	GGCUAUAGAGAGUAUAGCCCUUCAGCCGCCAGAGGCCUGCG
  	GCUGAUGUUCACAGACUUUUGGAGAACAAGGGUGCUGCGGC
  	AGACCAGCCCCAUGGCCGGCGUGUUUGGCAAUCUGGACGUG
  	AACGAGGCCCGGCUGAUGGCCGCAUACACCAGCGAGUGUGC
  	GGACCACCUGGAGGCAAAGGAGCUGGCUGGACCCGACGGUG
  	UGGCCGCUGCCCGAGAAAUUGCCAAGAGGUGGGAGAAGAGA
  	GUUCGCGACCUGCAGGAUAAGGGCGCCGCACGGAAACUCCU
  	GAACGACCCACUCGGCAGAAGAACCCCCAACUACCAGUCAAA
  	GAACCCUGGGGAGUAUACCGUGGGAAAUUCAAUGUUCUACG
  	AUGGCCCUCAGGUUGCUAAUCUCCAGAACGUGGACACUGGG
  	UUCUGGCUGGACAUGAGCAACCUGAGUGACGUGGUGCUGUC
  	UCGGGAAAUUCAGACAGGCCUGCGGGCCAGAGCCACCCUGG
  	AAGAGUCCAUGCCUAUGCUUGAGAACCUGGAGGAGCGCUUU
  	AGGCGACUCCAAGAAACCUGCGAUGCUGCCAGGACCGAGAU
  	CGAGGAGUCUGGAUGGACCAGAGAAAGCGCCUCCAGGAUGG
  	AGGGCGAUGAGGCCCAGGGCCCCAGCAGGGUGCAGCAGGCU
  	UUCCAGAGCUUCGUGAACGAAUGUAACAGUAUCGAAUUCUC
  	UUUCGGUAGCUUCGGCGAGCACGUGCGGGUGUUAUGCGCCA
  	GGGUCAGCAGGGGCCUGGCGGCCGCCGGCGAGGCCAUCAGA
  	AGAUGCUUCAGCUGUUGCAAAGGCUCAACCCACAGAUAUGC
  	CCCUAGGGACGAUCUGUCUCCAGAGGGCGCUAGCUUGGCCG
  	AGACACUAGCAAGGUUCGCCGACGAUAUGGGUAUCGAGAGG
  	GGCGCCGACGGUACCUACGACAUCCCCCUGGUGGACGACUGG
  	AGGAGAGGCGUGCCCAGUAUUGAGGGCGAGGGAUCCGACAG
  	CAUCUACGAGAUCAUGAUGCCGAUCUACGAGGUGAUGAAUA
  	UGGAUCUGGAGACUCGUAGAUCAUUCGCUGUCCAGCAGGGC
  	CACUACCAGGAUCCUAGAGCCUCGGACUACGACUUGCCCAGG
  	GCUAGCGAUUACGACCUGCCUAGAUCCCCCUACCCCACUCCC
  	CCUCUUCCCCCUCGGUAUCAGCUGCAGAACAUGGACGUGGA
  	GGCCGGUUUCCGAGAGGCUGUGUACGCCUCCUUCGUGGCCG
  	GGAUGUACAACUACGUCGUGACCCAGCCCCAGGAGAGAAUC
  	CCUAAUUCCCAGCAGGUGGAGGGCAUCUUGAGAGAUAUGCU
  	CACAAACGGGAGCCAGACCUUUCGUGACUUAAUGAAGCGAU
  	GGAACAGAGAGGUGGAUAGGGAG
  CT875_E_nIgK_CO001	AUGGAAACCCCCGCCCAGCUUCUCUUCCUCCUCUUGCUUUGG	381
  	CUCCCAGACACAACCGGCAUGAGUAUCAGAGGCGUAGGAGG
  	CAACGGCAAUAGCCGUAUCCCCUCACACAACGGCGACGGCUC
  	CAACAGACGGAGCCAGAACACCAAGGGGAAUAAUAAGGUGG
  	AGGACCGGGUCUGUUCACUUUACAGCUCCAGGUCUAACGAG
  	AAUCGGGAAAGCCCUUACGCCGUAGUCGACGUUAGCAGUAU
  	GAUCGAAAGCACCCCCACCAGCGGCGAGACAACAAGGGCCUC
  	UCGAGGAGUUCUGAGCAGAUUUCAGAGAGGCCUGGUGCGGA
  	UCGCCGACAAGGUGCGGAGAGCCGUGCAGUGCGCCUGGAGC
  	AGCGUGAGUACAUCUCGGAGCAGCGCCACCAGAGCAGCCGA
  	AAGCGGCUCAUCUAGCAGGACCGCUAGAGGCGCCAGCUCGG
  	GGUACAGGGAAUAUUCACCCUCCGCCGCAAGGGGGCUGAGA
  	CUGAUGUUUACAGACUUCUGGAGAACCAGGGUGCUGCGCCA
  	GACAAGCCCAAUGGCAGGGGUGUUUGGUAACCUGGAUGUGA
  	AUGAGGCCAGACUGAUGGCCGCCUACACUUCUGAGUGCGCG
  	GAUCAUCUUGAGGCCAAGGAACUGGCAGGCCCCGACGGCGU
  	GGCCGCCGCCCGGGAGAUUGCUAAGAGAUGGGAGAAGCGGG
  	UCAGAGAUCUGCAGGAUAAGGGGGCCGCUAGGAAACUCCUG
  	AAUGACCCCCUAGGCAGGAGAACCCCUAACUACCAGAGCAA
  	AAAUCCUGGGGAAUACACCGUGGGCAAUUCCAUGUUUUACG
  	AUGGCCCCCAAGUCGCAAACCUCCAGAAUGUGGACACCGGCU
  	UCUGGCUGGACAUGUCCAACUUGAGCGACGUGGUUCUAAGC
  	AGAGAAAUCCAGACCGGACUCCGCGCGAGAGCUACACUCGA
  	GGAAAGCAUGCCUAUGCUGGAGAAUCUGGAGGAGCGAUUCC
  	GUCGUCUACAGGAGACUUGUGACGCCGCUAGGACCGAGAUC
  	GAGGAGAGCGGCUGGACAAGAGAAAGCGCCUCUCGAAUGGA
  	GGGCGAUGAGGCCCAGGGCCCCUCCCGGGUGCAGCAGGCCUU
  	UCAGAGCUUCGUGAAUGAGUGCAAUUCUAUUGAGUUCAGCU
  	UCGGCUCUUUUGGCGAGCACGUGCGGGUGCUUUGCGCCAGG
  	GUGUCCCGGGGACUGGCAGCCGCCGGCGAGGCCAUAAGAAG
  	AUGUUUCUCCUGCUGCAAGGGCAGCACCCACCGGUAUGCUCC
  	CAGAGACGACCUGUCUCCAGAAGGGGCAUCGCUGGCCGAGA
  	CACUGGCACGGUUCGCCGACGAUAUGGGCAUUGAGAGGGGA
  	GCCGACGGCACUUAUGAUAUCCCUCUCGUGGACGACUGGAG
  	AAGAGGAGUCCCCUCAAUUGAGGGCGAAGGAUCCGAUUCUA
  	UCUAUGAGAUCAUGAUGCCUAUCUACGAAGUGAUGAAUAUG
  	GACCUGGAAACCAGGAGAUCUUUCGCUGUGCAGCAGGGCCA
  	UUACCAGGAUCCCCGCGCCAGCGAUUAUGACCUGCCCAGAGC
  	CUCAGACUACGAUUUGCCCAGAAGCCCCUACCCCACCCCUCC
  	GCUGCCCCCUAGAUACCAGCUGCAGAAUAUGGACGUGGAGG
  	CUGGCUUUAGGGAGGCUGUGUACGCUAGCUUCGUGGCCGGC
  	AUGUACAACUACGUGGUGACACAGCCCCAGGAGAGAAUUCC
  	CAAUUCUCAACAAGUAGAGGGCAUCCUGAGAGACAUGUUAA
  	CAAACGGAUCUCAGACCUUCCGCGACCUGAUGAAGCGGUGG
  	AACCGGGAAGUGGACCGCGAG
  CT875_E_nIgK_cHis_CO005	AUGGAAACACCCGCCCAGCUCCUCUUUCUACUUCUCCUUUGG	382
  	CUUCCCGACACCACCGGUAUGAGCAUUAGAGGAGUCGGCGG
  	GAACGGGAAUAGCCGUAUCCCCUCCCACAACGGCGACGGCAG
  	CAACCGCAGAAGCCAGAAUACUAAGGGAAACAAUAAGGUUG
  	AGGACCGCGUCUGUAGCUUGUACAGCUCAAGAAGUAACGAG
  	AACAGAGAGAGCCCCUACGCCGUGGUCGACGUUUCCAGCAU
  	GAUCGAGUCAACGCCCACAAGCGGCGAAACCACCCGCGCGUC
  	AAGGGGGGUCCUGUCCCGGUUCCAGAGAGGCCUGGUGAGGA
  	UCGCCGACAAGGUGAGACGGGCCGUGCAGUGCGCCUGGUCC
  	AGCGUCAGCACAUCACGGUCCUCCGCUACCAGGGCCGCCGAG
  	UCAGGCAGCAGCUCUCGUACCGCCCGGGGAGCCUCAAGCGGG
  	UACAGAGAGUACAGCCCUUCUGCCGCUAGAGGCCUGAGACU
  	CAUGUUUACAGACUUCUGGCGGACAAGGGUUCUCAGGCAGA
  	CUAGCCCUAUGGCUGGCGUGUUUGGCAAUCUUGAUGUUAAC
  	GAAGCCAGGCUGAUGGCUGCAUAUACAAGCGAAUGCGCCGA
  	CCAUCUGGAAGCUAAGGAGCUGGCCGGGCCCGACGGCGUGG
  	CCGCUGCCAGGGAGAUCGCCAAGAGGUGGGAGAAAAGGGUG
  	CGAGAUCUCCAGGAUAAGGGAGCAGCUAGAAAGCUGCUGAA
  	CGACCCCCUGGGCAGGCGGACCCCUAACUACCAGAGCAAAAA
  	UCCGGGCGAGUACACCGUCGGCAACAGCAUGUUUUACGAUG
  	GCCCUCAGGUGGCCAACCUUCAGAACGUGGACACCGGCUUCU
  	GGCUCGAUAUGUCUAAUCUUUCCGACGUCGUGCUCAGCCGG
  	GAAAUCCAGACUGGUCUGCGCGCCAGAGCUACCUUGGAAGA
  	GAGCAUGCCCAUGCUGGAGAACCUGGAGGAGAGAUUUCGGC
  	GCUUACAGGAAACAUGUGACGCUGCUAGGACCGAGAUUGAA
  	GAGAGCGGGUGGACAAGGGAGUCGGCGAGCAGGAUGGAGGG
  	GGACGAGGCCCAGGGCCCCAGCAGGGUGCAACAGGCUUUUC
  	AGUCCUUCGUGAACGAGUGCAACAGCAUCGAGUUCUCCUUC
  	GGCAGCUUCGGGGAGCACGUGAGAGUGUUGUGCGCCCGCGU
  	GUCUAGGGGAUUAGCCGCCGCAGGCGAAGCCAUCCGGCGCU
  	GCUUCAGCUGCUGCAAGGGCUCCACCCAUCGCUACGCCCCUA
  	GAGACGACCUGUCUCCCGAAGGCGCCUCCCUGGCCGAGACUC
  	UGGCCCGAUUCGCCGAUGACAUGGGCAUCGAGCGGGGGGCC
  	GAUGGCACCUACGACAUCCCUCUGGUCGAUGACUGGCGGAG
  	GGGCGUUCCCUCUAUUGAGGGCGAGGGCUCUGACUCUAUUU
  	ACGAGAUUAUGAUGCCCAUCUACGAAGUGAUGAACAUGGAC
  	UUGGAAACUCGCAGAUCGUUUGCAGUGCAACAGGGUCAUUA
  	CCAGGACCCUAGAGCCUCCGAUUAUGACCUGCCAAGAGCUA
  	GCGAUUAUGACCUCCCUAGAUCACCCUACCCCACACCUCCUC
  	UCCCUCCACGGUAUCAGCUGCAGAACAUGGACGUUGAGGCA
  	GGGUUUAGGGAGGCCGUGUACGCCAGCUUCGUGGCAGGCAU
  	GUAUAAUUAUGUGGUAACCCAGCCACAGGAGCGAAUUCCCA
  	ACUCUCAACAGGUGGAGGGCAUCCUGAGAGACAUGCUCACC
  	AACGGCAGCCAAACCUUCAGGGACCUUAUGAAACGGUGGAA
  	UAGAGAAGUUGAUCGCGAGCACCACCACCACCACCAC
  CT875_E_nIgK_cHis_CO004	AUGGAAACUCCCGCACAGUUACUUUUCUUGUUGCUUCUAUG	383
  	GCUCCCCGAUACCACCGGGAUGAGCAUCAGAGGCGUCGGCG
  	GGAACGGCAACAGCAGAAUUCCCUCCCACAACGGCGACGGCA
  	GCAACAGAAGAUCCCAGAACACAAAGGGCAAUAAUAAGGUC
  	GAGGACAGAGUGUGCAGCCUCUACUCCAGCAGGUCUAACGA
  	GAAUAGGGAGUCCCCGUACGCCGUUGUCGACGUGAGUUCUA
  	UGAUAGAGAGCACGCCCACGUCCGGAGAAACAACUAGAGCA
  	AGCAGGGGCGUCCUGAGCCGGUUCCAGAGAGGUCUGGUGCG
  	AAUUGCCGACAAGGUGAGACGGGCAGUGCAAUGCGCCUGGA
  	GCAGCGUCUCCACCAGCAGAAGCAGCGCCACCCGCGCUGCCG
  	AAUCAGGCAGCAGCUCCAGAACGGCACGGGGCGCCUCCUCCG
  	GCUACCGAGAGUACUCCCCUAGCGCCGCCAGAGGCCUGAGAC
  	UGAUGUUCACCGAUUUUUGGAGGACACGGGUUCUGAGACAG
  	ACCUCCCCCAUGGCUGGGGUGUUCGGCAACCUGGACGUCAA
  	UGAAGCCAGACUCAUGGCCGCAUAUACUUCUGAGUGCGCUG
  	ACCACCUGGAAGCUAAGGAACUGGCGGGCCCCGAUGGCGUG
  	GCCGCGGCCCGGGAGAUCGCCAAGAGAUGGGAGAAGAGAGU
  	GCGGGACCUGCAAGACAAGGGGGCCGCCCGGAAGCUGCUGA
  	ACGAUCCCUUGGGCCGCCGGACACCGAACUAUCAGAGCAAG
  	AACCCGGGCGAGUACACCGUGGGAAACAGCAUGUUCUAUGA
  	CGGACCUCAGGUGGCAAACCUGCAGAACGUGGACACUGGAU
  	UUUGGCUCGACAUGAGUAACCUCUCCGAUGUCGUUCUGUCU
  	CGUGAGAUACAGACAGGUCUGCGGGCUAGAGCCACCCUUGA
  	GGAGAGCAUGCCUAUGUUGGAGAAUCUGGAGGAGCGGUUCA
  	GAAGACUGCAGGAGACUUGCGAUGCCGCCAGGACCGAGAUU
  	GAGGAGAGCGGCUGGACCCGGGAAAGCGCCUCAAGGAUGGA
  	GGGAGACGAGGCCCAGGGACCCUCCAGGGUUCAGCAGGCCU
  	UCCAGUCGUUCGUGAAUGAAUGCAACAGCAUCGAGUUCAGC
  	UUCGGAAGCUUCGGAGAGCACGUGCGAGUGCUGUGCGCCAG
  	AGUAUCCAGAGGUCUGGCCGCUGCAGGCGAGGCCAUCCGGA
  	GAUGCUUCUCCUGCUGCAAAGGCAGCACCCACAGGUAUGCU
  	CCCAGGGAUGAUCUUUCUCCCGAGGGAGCCAGCCUGGCUGA
  	GACUCUUGCAAGAUUCGCCGAUGACAUGGGGAUCGAGCGGG
  	GCGCUGACGGCACCUACGACAUUCCCCUGGUGGACGACUGG
  	AGGAGGGGAGUGCCCUCCAUCGAGGGCGAGGGCUCCGAUUC
  	AAUCUAUGAGAUCAUGAUGCCUAUUUACGAGGUGAUGAACA
  	UGGACCUGGAGACAAGAAGAAGUUUCGCCGUCCAGCAGGGU
  	CAUUACCAGGACCCCCGAGCAAGCGACUACGAUCUGCCUCGC
  	GCCAGCGAUUACGACCUGCCUAGAAGCCCCUACCCUACACCU
  	CCACUGCCCCCAAGAUAUCAGCUCCAGAACAUGGACGUGGA
  	GGCCGGCUUCAGGGAGGCCGUGUACGCCAGCUUUGUGGCCG
  	GCAUGUACAACUAUGUCGUGACACAGCCUCAGGAACGCAUU
  	CCCAAUAGCCAACAGGUGGAGGGCAUCCUGAGAGACAUGCU
  	GACCAACGGCUCUCAGACUUUUAGAGAUCUGAUGAAAAGAU
  	GGAACAGAGAAGUGGACAGGGAGCACCACCACCACCACCAC
  CT875_E_nIgK_cHis_CO003	AUGGAAACACCAGCUCAGCUCCUUUUCUUACUCCUCUUGUG	384
  	GUUGCCGGAUACCACAGGCAUGAGCAUCCGGGGCGUCGGCG
  	GCAACGGAAACAGCCGGAUCCCCAGCCACAACGGAGACGGCU
  	CUAAUAGAAGAUCACAGAAUACCAAGGGAAAUAACAAGGUC
  	GAAGAUAGAGUCUGCAGCUUAUAUUCCAGCAGAUCCAACGA
  	GAAUAGGGAAAGCCCCUACGCCGUCGUUGACGUGAGCUCCA
  	UGAUCGAAAGCACCCCAACAAGUGGCGAGACUACAAGAGCC
  	UCAAGGGGCGUCCUGUCAAGAUUCCAAAGAGGCCUGGUGAG
  	GAUCGCAGACAAGGUGCGGCGGGCCGUGCAGUGCGCCUGGA
  	GCUCUGUGUCGACAAGCAGAUCAAGUGCCACCAGGGCCGCC
  	GAGAGCGGAUCCUCCAGUCGGACCGCCCGCGGCGCCUCUAGU
  	GGGUACAGAGAAUAUAGUCCCAGCGCCGCUAGGGGGCUGCG
  	CCUCAUGUUCACCGACUUCUGGAGAACCCGCGUGCUCAGGCA
  	GACAUCCCCUAUGGCCGGGGUGUUCGGCAACCUGGACGUGA
  	ACGAGGCCCGGCUUAUGGCCGCAUAUACAAGCGAGUGUGCC
  	GACCACCUGGAGGCCAAGGAGCUGGCUGGCCCCGACGGCGU
  	GGCCGCCGCACGCGAGAUUGCCAAGAGGUGGGAAAAGAGGG
  	UGAGAGAUCUGCAGGAUAAGGGCGCCGCCAGAAAACUGCUG
  	AAUGACCCCCUGGGGAGGAGGACACCCAAUUACCAGUCAAA
  	GAAUCCAGGGGAGUACACUGUUGGAAAUUCUAUGUUUUAUG
  	ACGGCCCUCAGGUGGCCAACCUUCAGAAUGUGGACACAGGC
  	UUCUGGCUUGACAUGAGCAACCUCAGCGACGUGGUGCUGUC
  	UAGGGAGAUCCAGACAGGCUUAAGAGCACGGGCUACCCUGG
  	AAGAGUCGAUGCCCAUGCUCGAAAAUCUGGAGGAGAGGUUC
  	AGACGCCUGCAAGAGACAUGCGACGCCGCGAGGACUGAAAU
  	CGAGGAGAGCGGCUGGACCAGGGAGUCCGCUUCUCGCAUGG
  	AAGGGGACGAGGCUCAGGGCCCCAGCAGGGUGCAGCAGGCC
  	UUCCAGAGCUUUGUGAACGAGUGCAACUCCAUUGAGUUCAG
  	CUUUGGAAGCUUCGGAGAGCACGUGCGGGUGCUGUGCGCCC
  	GCGUGUCCAGGGGCCUGGCCGCAGCUGGCGAGGCUAUACGU
  	CGCUGCUUCAGCUGUUGUAAGGGAAGCACCCAUAGGUACGC
  	CCCUCGUGACGAUCUGUCUCCCGAAGGGGCCAGCCUGGCUGA
  	GACACUGGCCCGCUUCGCCGAUGAUAUGGGGAUUGAACGGG
  	GCGCCGACGGAACCUACGACAUCCCUCUUGUGGACGACUGG
  	AGGAGAGGCGUCCCCUCUAUCGAGGGCGAGGGCUCUGACUC
  	CAUCUACGAGAUUAUGAUGCCUAUCUACGAGGUCAUGAACA
  	UGGACCUGGAAACCAGAAGAAGCUUCGCAGUUCAGCAGGGA
  	CACUACCAAGACCCACGGGCUAGUGAUUAUGACCUCCCAAG
  	AGCAUCCGACUAUGAUCUGCCAAGGUCACCUUACCCUACCCC
  	ACCCCUGCCCCCACGGUACCAGUUACAGAACAUGGAUGUGG
  	AGGCCGGCUUCAGGGAAGCCGUCUAUGCAUCCUUCGUGGCC
  	GGCAUGUACAACUACGUGGUGACUCAACCUCAGGAACGGAU
  	CCCCAACAGUCAGCAGGUGGAGGGGAUCCUUAGGGAUAUGC
  	UGACUAAUGGAAGCCAGACCUUCAGAGAUCUGAUGAAGCGG
  	UGGAAUAGGGAGGUGGACAGGGAGCACCAUCACCAUCACCAC
  CT875_E_nIgK_cHis_CO002	AUGGAGACACCCGCACAGCUCCUCUUCUUAUUGCUCUUGUG	385
  	GCUACCGGACACCACAGGCAUGUCUAUCCGGGGCGUUGGCG
  	GGAACGGCAACUCUAGGAUCCCCUCUCACAACGGCGACGGG
  	AGCAACAGGAGAAGCCAGAACACCAAAGGCAAUAACAAAGU
  	CGAGGACAGAGUUUGUUCUCUCUAUAGCUCUAGGAGCAACG
  	AAAACCGCGAAUCUCCUUACGCCGUCGUCGACGUCAGCAGCA
  	UGAUAGAGUCAACCCCUACCUCUGGAGAAACAACACGCGCC
  	UCCAGAGGCGUUCUGUCCAGGUUCCAGAGGGGCCUGGUGAG
  	AAUUGCCGACAAGGUCAGACGAGCCGUGCAGUGUGCCUGGU
  	CCAGCGUCUCUACCAGCAGAAGCUCCGCCACCAGAGCCGCUG
  	AGAGUGGCAGCUCCAGCAGGACAGCCAGGGGGGCUUCCAGC
  	GGCUAUAGAGAGUAUAGCCCUUCAGCCGCCAGAGGCCUGCG
  	GCUGAUGUUCACAGACUUUUGGAGAACAAGGGUGCUGCGGC
  	AGACCAGCCCCAUGGCCGGCGUGUUUGGCAAUCUGGACGUG
  	AACGAGGCCCGGCUGAUGGCCGCAUACACCAGCGAGUGUGC
  	GGACCACCUGGAGGCAAAGGAGCUGGCUGGACCCGACGGUG
  	UGGCCGCUGCCCGAGAAAUUGCCAAGAGGUGGGAGAAGAGA
  	GUUCGCGACCUGCAGGAUAAGGGCGCCGCACGGAAACUCCU
  	GAACGACCCACUCGGCAGAAGAACCCCCAACUACCAGUCAAA
  	GAACCCUGGGGAGUAUACCGUGGGAAAUUCAAUGUUCUACG
  	AUGGCCCUCAGGUUGCUAAUCUCCAGAACGUGGACACUGGG
  	UUCUGGCUGGACAUGAGCAACCUGAGUGACGUGGUGCUGUC
  	UCGGGAAAUUCAGACAGGCCUGCGGGCCAGAGCCACCCUGG
  	AAGAGUCCAUGCCUAUGCUUGAGAACCUGGAGGAGCGCUUU
  	AGGCGACUCCAAGAAACCUGCGAUGCUGCCAGGACCGAGAU
  	CGAGGAGUCUGGAUGGACCAGAGAAAGCGCCUCCAGGAUGG
  	AGGGCGAUGAGGCCCAGGGCCCCAGCAGGGUGCAGCAGGCU
  	UUCCAGAGCUUCGUGAACGAAUGUAACAGUAUCGAAUUCUC
  	UUUCGGUAGCUUCGGCGAGCACGUGCGGGUGUUAUGCGCCA
  	GGGUCAGCAGGGGCCUGGCGGCCGCCGGCGAGGCCAUCAGA
  	AGAUGCUUCAGCUGUUGCAAAGGCUCAACCCACAGAUAUGC
  	CCCUAGGGACGAUCUGUCUCCAGAGGGCGCUAGCUUGGCCG
  	AGACACUAGCAAGGUUCGCCGACGAUAUGGGUAUCGAGAGG
  	GGCGCCGACGGUACCUACGACAUCCCCCUGGUGGACGACUGG
  	AGGAGAGGCGUGCCCAGUAUUGAGGGCGAGGGAUCCGACAG
  	CAUCUACGAGAUCAUGAUGCCGAUCUACGAGGUGAUGAAUA
  	UGGAUCUGGAGACUCGUAGAUCAUUCGCUGUCCAGCAGGGC
  	CACUACCAGGAUCCUAGAGCCUCGGACUACGACUUGCCCAGG
  	GCUAGCGAUUACGACCUGCCUAGAUCCCCCUACCCCACUCCC
  	CCUCUUCCCCCUCGGUAUCAGCUGCAGAACAUGGACGUGGA
  	GGCCGGUUUCCGAGAGGCUGUGUACGCCUCCUUCGUGGCCG
  	GGAUGUACAACUACGUCGUGACCCAGCCCCAGGAGAGAAUC
  	CCUAAUUCCCAGCAGGUGGAGGGCAUCUUGAGAGAUAUGCU
  	CACAAACGGGAGCCAGACCUUUCGUGACUUAAUGAAGCGAU
  	GGAACAGAGAGGUGGAUAGGGAGCACCACCAUCACCACCAC
  CT875_E_nIgK_cHis_CO001	AUGGAAACCCCCGCCCAGCUUCUCUUCCUCCUCUUGCUUUGG	386
  	CUCCCAGACACAACCGGCAUGAGUAUCAGAGGCGUAGGAGG
  	CAACGGCAAUAGCCGUAUCCCCUCACACAACGGCGACGGCUC
  	CAACAGACGGAGCCAGAACACCAAGGGGAAUAAUAAGGUGG
  	AGGACCGGGUCUGUUCACUUUACAGCUCCAGGUCUAACGAG
  	AAUCGGGAAAGCCCUUACGCCGUAGUCGACGUUAGCAGUAU
  	GAUCGAAAGCACCCCCACCAGCGGCGAGACAACAAGGGCCUC
  	UCGAGGAGUUCUGAGCAGAUUUCAGAGAGGCCUGGUGCGGA
  	UCGCCGACAAGGUGCGGAGAGCCGUGCAGUGCGCCUGGAGC
  	AGCGUGAGUACAUCUCGGAGCAGCGCCACCAGAGCAGCCGA
  	AAGCGGCUCAUCUAGCAGGACCGCUAGAGGCGCCAGCUCGG
  	GGUACAGGGAAUAUUCACCCUCCGCCGCAAGGGGGCUGAGA
  	CUGAUGUUUACAGACUUCUGGAGAACCAGGGUGCUGCGCCA
  	GACAAGCCCAAUGGCAGGGGUGUUUGGUAACCUGGAUGUGA
  	AUGAGGCCAGACUGAUGGCCGCCUACACUUCUGAGUGCGCG
  	GAUCAUCUUGAGGCCAAGGAACUGGCAGGCCCCGACGGCGU
  	GGCCGCCGCCCGGGAGAUUGCUAAGAGAUGGGAGAAGCGGG
  	UCAGAGAUCUGCAGGAUAAGGGGGCCGCUAGGAAACUCCUG
  	AAUGACCCCCUAGGCAGGAGAACCCCUAACUACCAGAGCAA
  	AAAUCCUGGGGAAUACACCGUGGGCAAUUCCAUGUUUUACG
  	AUGGCCCCCAAGUCGCAAACCUCCAGAAUGUGGACACCGGCU
  	UCUGGCUGGACAUGUCCAACUUGAGCGACGUGGUUCUAAGC
  	AGAGAAAUCCAGACCGGACUCCGCGCGAGAGCUACACUCGA
  	GGAAAGCAUGCCUAUGCUGGAGAAUCUGGAGGAGCGAUUCC
  	GUCGUCUACAGGAGACUUGUGACGCCGCUAGGACCGAGAUC
  	GAGGAGAGCGGCUGGACAAGAGAAAGCGCCUCUCGAAUGGA
  	GGGCGAUGAGGCCCAGGGCCCCUCCCGGGUGCAGCAGGCCUU
  	UCAGAGCUUCGUGAAUGAGUGCAAUUCUAUUGAGUUCAGCU
  	UCGGCUCUUUUGGCGAGCACGUGCGGGUGCUUUGCGCCAGG
  	GUGUCCCGGGGACUGGCAGCCGCCGGCGAGGCCAUAAGAAG
  	AUGUUUCUCCUGCUGCAAGGGCAGCACCCACCGGUAUGCUCC
  	CAGAGACGACCUGUCUCCAGAAGGGGCAUCGCUGGCCGAGA
  	CACUGGCACGGUUCGCCGACGAUAUGGGCAUUGAGAGGGGA
  	GCCGACGGCACUUAUGAUAUCCCUCUCGUGGACGACUGGAG
  	AAGAGGAGUCCCCUCAAUUGAGGGCGAAGGAUCCGAUUCUA
  	UCUAUGAGAUCAUGAUGCCUAUCUACGAAGUGAUGAAUAUG
  	GACCUGGAAACCAGGAGAUCUUUCGCUGUGCAGCAGGGCCA
  	UUACCAGGAUCCCCGCGCCAGCGAUUAUGACCUGCCCAGAGC
  	CUCAGACUACGAUUUGCCCAGAAGCCCCUACCCCACCCCUCC
  	GCUGCCCCCUAGAUACCAGCUGCAGAAUAUGGACGUGGAGG
  	CUGGCUUUAGGGAGGCUGUGUACGCUAGCUUCGUGGCCGGC
  	AUGUACAACUACGUGGUGACACAGCCCCAGGAGAGAAUUCC
  	CAAUUCUCAACAAGUAGAGGGCAUCCUGAGAGACAUGUUAA
  	CAAACGGAUCUCAGACCUUCCGCGACCUGAUGAAGCGGUGG
  	AACCGGGAAGUGGACCGCGAGCACCACCACCACCAUCAU
  CT875_E_nIgK_nFLAG	AUGGAAACCCCUGCCCAGCUGCUGUUCCUGCUGCUGCUGUG	387
  	GCUGCCUGACACCACCGGCGACUAUAAAGACCACGAUGGCG
  	AUUACAAAGAUCACGACAUCGAUUACAAGGAUGACGACGAC
  	AAAAUGAGCAUCAGAGGCGUGGGCGGCAACGGCAACAGCAG
  	AAUCCCUAGCCACAACGGCGACGGCAGCAACAGGCGGAGCCA
  	GAACACCAAGGGCAACAACAAGGUGGAAGAUAGAGUGUGCA
  	GCCUGUACAGCAGCCGGUCCAACGAGAACCGCGAGAGCCCUU
  	AUGCCGUGGUGGACGUGUCCAGCAUGAUCGAGAGCACCCCC
  	ACCAGCGGCGAGACAACCAGAGCUAGUAGAGGCGUGCUGAG
  	CCGGUUCCAGAGGGGCCUCGUGCGGAUUGCUGACAAAGUGC
  	GGAGAGCCGUGCAGUGCGCUUGGAGCAGCGUGUCCACAAGC
  	AGAAGCAGCGCCACAAGAGCCGCCGAGAGCGGCAGCUCUAG
  	CAGAACAGCUAGAGGCGCCAGCAGCGGCUACAGAGAGUACA
  	GCCCUUCUGCCGCUCGGGGCCUGCGGCUGAUGUUCACCGACU
  	UUUGGCGGACCCGGGUGCUGAGACAGACCUCUCCUAUGGCC
  	GGCGUGUUCGGCAACCUGGACGUGAACGAGGCCAGACUGAU
  	GGCCGCCUACACCAGCGAGUGUGCCGAUCACCUGGAAGCCAA
  	AGAGCUGGCCGGACCUGACGGCGUGGCAGCCGCUAGAGAAA
  	UCGCCAAGAGAUGGGAGAAGAGAGUGCGGGACCUGCAGGAC
  	AAGGGCGCUGCCAGAAAGCUGCUGAACGACCCCCUGGGCAG
  	ACGGACCCCCAACUACCAGAGCAAGAACCCCGGCGAGUACAC
  	CGUGGGCAACUCCAUGUUCUACGACGGCCCCCAGGUGGCCAA
  	CCUGCAGAAUGUGGAUACCGGCUUCUGGCUGGACAUGAGCA
  	ACCUGAGCGACGUGGUGCUGUCCAGAGAGAUCCAGACCGGC
  	CUGAGAGCCAGAGCCACCCUGGAAGAGUCCAUGCCCAUGCU
  	GGAAAAUCUGGAAGAGAGAUUCCGGCGGCUGCAGGAAACCU
  	GCGACGCCGCCAGAACCGAGAUCGAGGAAAGCGGCUGGACC
  	CGGGAAAGCGCCUCCAGAAUGGAAGGCGACGAAGCCCAGGG
  	CCCCAGCAGAGUGCAGCAGGCCUUUCAGAGCUUCGUGAAUG
  	AGUGCAACAGCAUCGAGUUCAGCUUCGGCUCCUUCGGCGAG
  	CACGUGCGGGUGCUGUGUGCCAGAGUGUCAAGAGGACUGGC
  	CGCUGCCGGCGAGGCCAUCAGAAGAUGCUUCAGCUGCUGCA
  	AGGGCAGCACCCACAGAUACGCCCCCAGAGAUGACCUGUCUC
  	CUGAGGGCGCCUCUCUGGCCGAAACCCUGGCCAGAUUCGCCG
  	ACGACAUGGGCAUCGAAAGAGGCGCCGACGGCACCUACGAC
  	AUCCCCCUGGUGGACGAUUGGAGAAGGGGCGUGCCAUCCAU
  	CGAGGGCGAGGGCAGCGAUAGCAUCUACGAGAUCAUGAUGC
  	CCAUCUACGAAGUGAUGAACAUGGACCUGGAAACCCGGCGG
  	AGCUUCGCCGUGCAGCAGGGCCAUUACCAGGACCCCAGAGCC
  	AGCGACUACGACCUGCCUAGAGCCUCCGAUUACGAUCUGCCC
  	AGAAGCCCCUACCCCACCCCUCCACUGCCUCCCAGAUACCAG
  	CUGCAGAACAUGGAUGUGGAAGCCGGCUUUCGCGAGGCCGU
  	GUACGCCUCUUUUGUGGCCGGCAUGUACAACUACGUCGUGA
  	CCCAGCCCCAGGAACGGAUCCCCAAUAGCCAGCAGGUGGAAG
  	GCAUCCUGCGGGACAUGCUGACCAACGGCAGCCAGACCUUCC
  	GGGACCUGAUGAAGCGGUGGAACAGAGAGGUGGACCGCGAG
  CT875_E_nIgK_cFLAG	AUGGAAACCCCUGCCCAGCUGCUGUUCCUGCUGCUGCUGUG	388
  	GCUGCCUGACACCACCGGCAUGAGCAUCAGAGGCGUGGGCG
  	GCAACGGCAACAGCAGAAUCCCUAGCCACAACGGCGACGGCA
  	GCAACAGGCGGAGCCAGAACACCAAGGGCAACAACAAGGUG
  	GAAGAUAGAGUGUGCAGCCUGUACAGCAGCCGGUCCAACGA
  	GAACCGCGAGAGCCCUUAUGCCGUGGUGGACGUGUCCAGCA
  	UGAUCGAGAGCACCCCCACCAGCGGCGAGACAACCAGAGCUA
  	GUAGAGGCGUGCUGAGCCGGUUCCAGAGGGGCCUCGUGCGG
  	AUUGCUGACAAAGUGCGGAGAGCCGUGCAGUGCGCUUGGAG
  	CAGCGUGUCCACAAGCAGAAGCAGCGCCACAAGAGCCGCCGA
  	GAGCGGCAGCUCUAGCAGAACAGCUAGAGGCGCCAGCAGCG
  	GCUACAGAGAGUACAGCCCUUCUGCCGCUCGGGGCCUGCGGC
  	UGAUGUUCACCGACUUUUGGCGGACCCGGGUGCUGAGACAG
  	ACCUCUCCUAUGGCCGGCGUGUUCGGCAACCUGGACGUGAA
  	CGAGGCCAGACUGAUGGCCGCCUACACCAGCGAGUGUGCCG
  	AUCACCUGGAAGCCAAAGAGCUGGCCGGACCUGACGGCGUG
  	GCAGCCGCUAGAGAAAUCGCCAAGAGAUGGGAGAAGAGAGU
  	GCGGGACCUGCAGGACAAGGGCGCUGCCAGAAAGCUGCUGA
  	ACGACCCCCUGGGCAGACGGACCCCCAACUACCAGAGCAAGA
  	ACCCCGGCGAGUACACCGUGGGCAACUCCAUGUUCUACGACG
  	GCCCCCAGGUGGCCAACCUGCAGAAUGUGGAUACCGGCUUC
  	UGGCUGGACAUGAGCAACCUGAGCGACGUGGUGCUGUCCAG
  	AGAGAUCCAGACCGGCCUGAGAGCCAGAGCCACCCUGGAAG
  	AGUCCAUGCCCAUGCUGGAAAAUCUGGAAGAGAGAUUCCGG
  	CGGCUGCAGGAAACCUGCGACGCCGCCAGAACCGAGAUCGA
  	GGAAAGCGGCUGGACCCGGGAAAGCGCCUCCAGAAUGGAAG
  	GCGACGAAGCCCAGGGCCCCAGCAGAGUGCAGCAGGCCUUUC
  	AGAGCUUCGUGAAUGAGUGCAACAGCAUCGAGUUCAGCUUC
  	GGCUCCUUCGGCGAGCACGUGCGGGUGCUGUGUGCCAGAGU
  	GUCAAGAGGACUGGCCGCUGCCGGCGAGGCCAUCAGAAGAU
  	GCUUCAGCUGCUGCAAGGGCAGCACCCACAGAUACGCCCCCA
  	GAGAUGACCUGUCUCCUGAGGGCGCCUCUCUGGCCGAAACCC
  	UGGCCAGAUUCGCCGACGACAUGGGCAUCGAAAGAGGCGCC
  	GACGGCACCUACGACAUCCCCCUGGUGGACGAUUGGAGAAG
  	GGGCGUGCCAUCCAUCGAGGGCGAGGGCAGCGAUAGCAUCU
  	ACGAGAUCAUGAUGCCCAUCUACGAAGUGAUGAACAUGGAC
  	CUGGAAACCCGGCGGAGCUUCGCCGUGCAGCAGGGCCAUUA
  	CCAGGACCCCAGAGCCAGCGACUACGACCUGCCUAGAGCCUC
  	CGAUUACGAUCUGCCCAGAAGCCCCUACCCCACCCCUCCACU
  	GCCUCCCAGAUACCAGCUGCAGAACAUGGAUGUGGAAGCCG
  	GCUUUCGCGAGGCCGUGUACGCCUCUUUUGUGGCCGGCAUG
  	UACAACUACGUCGUGACCCAGCCCCAGGAACGGAUCCCCAAU
  	AGCCAGCAGGUGGAAGGCAUCCUGCGGGACAUGCUGACCAA
  	CGGCAGCCAGACCUUCCGGGACCUGAUGAAGCGGUGGAACA
  	GAGAGGUGGACCGCGAGGACUAUAAAGACCACGAUGGCGAU
  	UACAAAGAUCACGACAUCGAUUACAAGGAUGACGACGACAAA
  CT875_E_nIgK_nHis	AUGGAAACCCCUGCCCAGCUGCUGUUCCUGCUGCUGCUGUG	389
  	GCUGCCUGACACCACCGGCCACCACCAUCACCACCACAUGAG
  	CAUCAGAGGCGUGGGCGGCAACGGCAACAGCAGAAUCCCUA
  	GCCACAACGGCGACGGCAGCAACAGGCGGAGCCAGAACACCA
  	AGGGCAACAACAAGGUGGAAGAUAGAGUGUGCAGCCUGUAC
  	AGCAGCCGGUCCAACGAGAACCGCGAGAGCCCUUAUGCCGU
  	GGUGGACGUGUCCAGCAUGAUCGAGAGCACCCCCACCAGCG
  	GCGAGACAACCAGAGCUAGUAGAGGCGUGCUGAGCCGGUUC
  	CAGAGGGGCCUCGUGCGGAUUGCUGACAAAGUGCGGAGAGC
  	CGUGCAGUGCGCUUGGAGCAGCGUGUCCACAAGCAGAAGCA
  	GCGCCACAAGAGCCGCCGAGAGCGGCAGCUCUAGCAGAACA
  	GCUAGAGGCGCCAGCAGCGGCUACAGAGAGUACAGCCCUUC
  	UGCCGCUCGGGGCCUGCGGCUGAUGUUCACCGACUUUUGGC
  	GGACCCGGGUGCUGAGACAGACCUCUCCUAUGGCCGGCGUG
  	UUCGGCAACCUGGACGUGAACGAGGCCAGACUGAUGGCCGC
  	CUACACCAGCGAGUGUGCCGAUCACCUGGAAGCCAAAGAGC
  	UGGCCGGACCUGACGGCGUGGCAGCCGCUAGAGAAAUCGCC
  	AAGAGAUGGGAGAAGAGAGUGCGGGACCUGCAGGACAAGGG
  	CGCUGCCAGAAAGCUGCUGAACGACCCCCUGGGCAGACGGAC
  	CCCCAACUACCAGAGCAAGAACCCCGGCGAGUACACCGUGGG
  	CAACUCCAUGUUCUACGACGGCCCCCAGGUGGCCAACCUGCA
  	GAAUGUGGAUACCGGCUUCUGGCUGGACAUGAGCAACCUGA
  	GCGACGUGGUGCUGUCCAGAGAGAUCCAGACCGGCCUGAGA
  	GCCAGAGCCACCCUGGAAGAGUCCAUGCCCAUGCUGGAAAA
  	UCUGGAAGAGAGAUUCCGGCGGCUGCAGGAAACCUGCGACG
  	CCGCCAGAACCGAGAUCGAGGAAAGCGGCUGGACCCGGGAA
  	AGCGCCUCCAGAAUGGAAGGCGACGAAGCCCAGGGCCCCAGC
  	AGAGUGCAGCAGGCCUUUCAGAGCUUCGUGAAUGAGUGCAA
  	CAGCAUCGAGUUCAGCUUCGGCUCCUUCGGCGAGCACGUGC
  	GGGUGCUGUGUGCCAGAGUGUCAAGAGGACUGGCCGCUGCC
  	GGCGAGGCCAUCAGAAGAUGCUUCAGCUGCUGCAAGGGCAG
  	CACCCACAGAUACGCCCCCAGAGAUGACCUGUCUCCUGAGGG
  	CGCCUCUCUGGCCGAAACCCUGGCCAGAUUCGCCGACGACAU
  	GGGCAUCGAAAGAGGCGCCGACGGCACCUACGACAUCCCCCU
  	GGUGGACGAUUGGAGAAGGGGCGUGCCAUCCAUCGAGGGCG
  	AGGGCAGCGAUAGCAUCUACGAGAUCAUGAUGCCCAUCUAC
  	GAAGUGAUGAACAUGGACCUGGAAACCCGGCGGAGCUUCGC
  	CGUGCAGCAGGGCCAUUACCAGGACCCCAGAGCCAGCGACUA
  	CGACCUGCCUAGAGCCUCCGAUUACGAUCUGCCCAGAAGCCC
  	CUACCCCACCCCUCCACUGCCUCCCAGAUACCAGCUGCAGAA
  	CAUGGAUGUGGAAGCCGGCUUUCGCGAGGCCGUGUACGCCU
  	CUUUUGUGGCCGGCAUGUACAACUACGUCGUGACCCAGCCCC
  	AGGAACGGAUCCCCAAUAGCCAGCAGGUGGAAGGCAUCCUG
  	CGGGACAUGCUGACCAACGGCAGCCAGACCUUCCGGGACCUG
  	AUGAAGCGGUGGAACAGAGAGGUGGACCGCGAG
  MOMP_E_nTMEM149	AUGGGCCCUGGCAGAUGUCUGCUGACAGCCCUGCUGCUGCU	390
  	GGCCCUGGCUCCUCCACCUGAAGCUCUGCCCGUGGGAAAUCC
  	UGCCGAGCCCAGCCUGAUGAUCGACGGCAUUCUGUGGGAGG
  	GCUUCGGCGGCGACCCUUGCGAUCCUUGUACCACUUGGUGC
  	GACGCCAUCAGCAUGAGAAUGGGCUACUACGGCGACUUCGU
  	GUUCGACCGGGUGCUGAAAACCGACGUGAACAAAGAAUUCC
  	AGAUGGGCGACAAGCCCACCAGCACCACCGGAAAUGCCACCG
  	CCCCUACCACCCUGACCGCCAGAGAAAAUCCCGCCUACGGCC
  	GGCACAUGCAGGACGCCGAGAUGUUCACCAACGCCGCCUGCA
  	UGGCCCUGAACAUCUGGGACAGAUUCGACGUGUUCUGCACC
  	CUGGGCGCCAGCAGCGGCUACCUGAAGGGCAAUAGCGCCAG
  	CUUCAACCUCGUGGGCCUGUUCGGCGACAACGAGAACCAGA
  	GCACCGUGAAAACAAACAGCGUGCCCAACAUGAGCCUGGAC
  	CAGAGCGUGGUGGAACUGUACACCGACACCGCAUUCUCUUG
  	GAGCGUGGGAGCCAGAGCUGCCCUGUGGGAGUGUGGAUGUG
  	CCACACUGGGCGCUAGCUUCCAGUACGCCCAGAGCAAGCCCA
  	AGGUGGAAGAACUGAACGUGCUGUGCAAUGCCGCCGAGUUC
  	ACCAUCAACAAGCCUAAGGGCUACGUGGGCCAGGAAUUCCC
  	CCUGGCCCUGAUCGCCGGAACAGAUGCCGCCACCGGAACAAA
  	GGACGCCAGCAUCGACUACCACGAGUGGCAGGCUUCUCUGG
  	CCCUGUCCUACCGGCUGAAUAUGUUCACCCCCUACAUCGGCG
  	UGAAGUGGUCCCGGGCCAGCUUCGAUGCCGACACCAUCAGA
  	AUCGCCCAGCCCAAGAGCGCCACCGCCAUCUUCGAUACCACC
  	ACACUGAACCCCACCAUUGCCGGCGCUGGCGACGUGAAAGCC
  	UCUGCCGAAGGACAGCUGGGCGACACAAUGCAGAUCGUGUC
  	CCUGCAGCUGAACAAGAUGAAGUCCCGGAAGUCCUGCGGAA
  	UCGCCGUGGGCACCACAAUCGUGGACGCCGAUAAGUACGCC
  	GUGACCGUGGAAACCCGGCUGAUCGAUGAGAGGGCCGCUCA
  	CGUGAACGCCCAGUUCAGAUUC
  MOMP_E_nTMEM149_cHis	AUGGGCCCUGGCAGAUGUCUGCUGACAGCCCUGCUGCUGCU	391
  	GGCCCUGGCUCCUCCACCUGAAGCUCUGCCCGUGGGAAAUCC
  	UGCCGAGCCCAGCCUGAUGAUCGACGGCAUUCUGUGGGAGG
  	GCUUCGGCGGCGACCCUUGCGAUCCUUGUACCACUUGGUGC
  	GACGCCAUCAGCAUGAGAAUGGGCUACUACGGCGACUUCGU
  	GUUCGACCGGGUGCUGAAAACCGACGUGAACAAAGAAUUCC
  	AGAUGGGCGACAAGCCCACCAGCACCACCGGAAAUGCCACCG
  	CCCCUACCACCCUGACCGCCAGAGAAAAUCCCGCCUACGGCC
  	GGCACAUGCAGGACGCCGAGAUGUUCACCAACGCCGCCUGCA
  	UGGCCCUGAACAUCUGGGACAGAUUCGACGUGUUCUGCACC
  	CUGGGCGCCAGCAGCGGCUACCUGAAGGGCAAUAGCGCCAG
  	CUUCAACCUCGUGGGCCUGUUCGGCGACAACGAGAACCAGA
  	GCACCGUGAAAACAAACAGCGUGCCCAACAUGAGCCUGGAC
  	CAGAGCGUGGUGGAACUGUACACCGACACCGCAUUCUCUUG
  	GAGCGUGGGAGCCAGAGCUGCCCUGUGGGAGUGUGGAUGUG
  	CCACACUGGGCGCUAGCUUCCAGUACGCCCAGAGCAAGCCCA
  	AGGUGGAAGAACUGAACGUGCUGUGCAAUGCCGCCGAGUUC
  	ACCAUCAACAAGCCUAAGGGCUACGUGGGCCAGGAAUUCCC
  	CCUGGCCCUGAUCGCCGGAACAGAUGCCGCCACCGGAACAAA
  	GGACGCCAGCAUCGACUACCACGAGUGGCAGGCUUCUCUGG
  	CCCUGUCCUACCGGCUGAAUAUGUUCACCCCCUACAUCGGCG
  	UGAAGUGGUCCCGGGCCAGCUUCGAUGCCGACACCAUCAGA
  	AUCGCCCAGCCCAAGAGCGCCACCGCCAUCUUCGAUACCACC
  	ACACUGAACCCCACCAUUGCCGGCGCUGGCGACGUGAAAGCC
  	UCUGCCGAAGGACAGCUGGGCGACACAAUGCAGAUCGUGUC
  	CCUGCAGCUGAACAAGAUGAAGUCCCGGAAGUCCUGCGGAA
  	UCGCCGUGGGCACCACAAUCGUGGACGCCGAUAAGUACGCC
  	GUGACCGUGGAAACCCGGCUGAUCGAUGAGAGGGCCGCUCA
  	CGUGAACGCCCAGUUCAGAUUCCACCACCACCAUCACCAC
  MOMP_E_nFLRU2	AUGGGCCUGCAGACCACCAAGUGGCCUAGCCACGGCGCAUUC	392
  	UUUCUGAAGUCCUGGCUGAUCAUCUCCCUGGGCCUGUACAG
  	CCAGGUGUCCAAGCUGCUGGCUCUGCCCGUGGGAAAUCCUG
  	CCGAGCCCAGCCUGAUGAUCGACGGCAUUCUGUGGGAGGGC
  	UUCGGCGGCGACCCUUGCGAUCCUUGUACCACUUGGUGCGA
  	CGCCAUCAGCAUGAGAAUGGGCUACUACGGCGACUUCGUGU
  	UCGACCGGGUGCUGAAAACCGACGUGAACAAAGAAUUCCAG
  	AUGGGCGACAAGCCCACCAGCACCACCGGAAAUGCCACCGCC
  	CCUACCACCCUGACCGCCAGAGAAAAUCCCGCCUACGGCCGG
  	CACAUGCAGGACGCCGAGAUGUUCACCAACGCCGCCUGCAUG
  	GCCCUGAACAUCUGGGACAGAUUCGACGUGUUCUGCACCCU
  	GGGCGCCAGCAGCGGCUACCUGAAGGGCAAUAGCGCCAGCU
  	UCAACCUCGUGGGCCUGUUCGGCGACAACGAGAACCAGAGC
  	ACCGUGAAAACAAACAGCGUGCCCAACAUGAGCCUGGACCA
  	GAGCGUGGUGGAACUGUACACCGACACCGCAUUCUCUUGGA
  	GCGUGGGAGCCAGAGCUGCCCUGUGGGAGUGUGGAUGUGCC
  	ACACUGGGCGCUAGCUUCCAGUACGCCCAGAGCAAGCCCAAG
  	GUGGAAGAACUGAACGUGCUGUGCAAUGCCGCCGAGUUCAC
  	CAUCAACAAGCCUAAGGGCUACGUGGGCCAGGAAUUCCCCC
  	UGGCCCUGAUCGCCGGAACAGAUGCCGCCACCGGAACAAAG
  	GACGCCAGCAUCGACUACCACGAGUGGCAGGCUUCUCUGGCC
  	CUGUCCUACCGGCUGAAUAUGUUCACCCCCUACAUCGGCGUG
  	AAGUGGUCCCGGGCCAGCUUCGAUGCCGACACCAUCAGAAU
  	CGCCCAGCCCAAGAGCGCCACCGCCAUCUUCGAUACCACCAC
  	ACUGAACCCCACCAUUGCCGGCGCUGGCGACGUGAAAGCCUC
  	UGCCGAAGGACAGCUGGGCGACACAAUGCAGAUCGUGUCCC
  	UGCAGCUGAACAAGAUGAAGUCCCGGAAGUCCUGCGGAAUC
  	GCCGUGGGCACCACAAUCGUGGACGCCGAUAAGUACGCCGU
  	GACCGUGGAAACCCGGCUGAUCGAUGAGAGGGCCGCUCACG
  	UGAACGCCCAGUUCAGAUUC
  MOMP_E_nFLRU2_cHis	AUGGGCCUGCAGACCACCAAGUGGCCUAGCCACGGCGCAUUC	393
  	UUUCUGAAGUCCUGGCUGAUCAUCUCCCUGGGCCUGUACAG
  	CCAGGUGUCCAAGCUGCUGGCUCUGCCCGUGGGAAAUCCUG
  	CCGAGCCCAGCCUGAUGAUCGACGGCAUUCUGUGGGAGGGC
  	UUCGGCGGCGACCCUUGCGAUCCUUGUACCACUUGGUGCGA
  	CGCCAUCAGCAUGAGAAUGGGCUACUACGGCGACUUCGUGU
  	UCGACCGGGUGCUGAAAACCGACGUGAACAAAGAAUUCCAG
  	AUGGGCGACAAGCCCACCAGCACCACCGGAAAUGCCACCGCC
  	CCUACCACCCUGACCGCCAGAGAAAAUCCCGCCUACGGCCGG
  	CACAUGCAGGACGCCGAGAUGUUCACCAACGCCGCCUGCAUG
  	GCCCUGAACAUCUGGGACAGAUUCGACGUGUUCUGCACCCU
  	GGGCGCCAGCAGCGGCUACCUGAAGGGCAAUAGCGCCAGCU
  	UCAACCUCGUGGGCCUGUUCGGCGACAACGAGAACCAGAGC
  	ACCGUGAAAACAAACAGCGUGCCCAACAUGAGCCUGGACCA
  	GAGCGUGGUGGAACUGUACACCGACACCGCAUUCUCUUGGA
  	GCGUGGGAGCCAGAGCUGCCCUGUGGGAGUGUGGAUGUGCC
  	ACACUGGGCGCUAGCUUCCAGUACGCCCAGAGCAAGCCCAAG
  	GUGGAAGAACUGAACGUGCUGUGCAAUGCCGCCGAGUUCAC
  	CAUCAACAAGCCUAAGGGCUACGUGGGCCAGGAAUUCCCCC
  	UGGCCCUGAUCGCCGGAACAGAUGCCGCCACCGGAACAAAG
  	GACGCCAGCAUCGACUACCACGAGUGGCAGGCUUCUCUGGCC
  	CUGUCCUACCGGCUGAAUAUGUUCACCCCCUACAUCGGCGUG
  	AAGUGGUCCCGGGCCAGCUUCGAUGCCGACACCAUCAGAAU
  	CGCCCAGCCCAAGAGCGCCACCGCCAUCUUCGAUACCACCAC
  	ACUGAACCCCACCAUUGCCGGCGCUGGCGACGUGAAAGCCUC
  	UGCCGAAGGACAGCUGGGCGACACAAUGCAGAUCGUGUCCC
  	UGCAGCUGAACAAGAUGAAGUCCCGGAAGUCCUGCGGAAUC
  	GCCGUGGGCACCACAAUCGUGGACGCCGAUAAGUACGCCGU
  	GACCGUGGAAACCCGGCUGAUCGAUGAGAGGGCCGCUCACG
  	UGAACGCCCAGUUCAGAUUCCACCACCACCAUCACCAC
  MOMP_E_nIgK	AUGGAAACCCCUGCCCAGCUGCUGUUCCUGCUGCUGCUGUG	394
  	GCUGCCUGACACCACCGGCCUGCCCGUGGGAAAUCCUGCCGA
  	GCCCAGCCUGAUGAUCGACGGCAUUCUGUGGGAGGGCUUCG
  	GCGGCGACCCUUGCGAUCCUUGUACCACUUGGUGCGACGCCA
  	UCAGCAUGAGAAUGGGCUACUACGGCGACUUCGUGUUCGAC
  	CGGGUGCUGAAAACCGACGUGAACAAAGAAUUCCAGAUGGG
  	CGACAAGCCCACCAGCACCACCGGAAAUGCCACCGCCCCUAC
  	CACCCUGACCGCCAGAGAAAAUCCCGCCUACGGCCGGCACAU
  	GCAGGACGCCGAGAUGUUCACCAACGCCGCCUGCAUGGCCCU
  	GAACAUCUGGGACAGAUUCGACGUGUUCUGCACCCUGGGCG
  	CCAGCAGCGGCUACCUGAAGGGCAAUAGCGCCAGCUUCAACC
  	UCGUGGGCCUGUUCGGCGACAACGAGAACCAGAGCACCGUG
  	AAAACAAACAGCGUGCCCAACAUGAGCCUGGACCAGAGCGU
  	GGUGGAACUGUACACCGACACCGCAUUCUCUUGGAGCGUGG
  	GAGCCAGAGCUGCCCUGUGGGAGUGUGGAUGUGCCACACUG
  	GGCGCUAGCUUCCAGUACGCCCAGAGCAAGCCCAAGGUGGA
  	AGAACUGAACGUGCUGUGCAAUGCCGCCGAGUUCACCAUCA
  	ACAAGCCUAAGGGCUACGUGGGCCAGGAAUUCCCCCUGGCCC
  	UGAUCGCCGGAACAGAUGCCGCCACCGGAACAAAGGACGCC
  	AGCAUCGACUACCACGAGUGGCAGGCUUCUCUGGCCCUGUCC
  	UACCGGCUGAAUAUGUUCACCCCCUACAUCGGCGUGAAGUG
  	GUCCCGGGCCAGCUUCGAUGCCGACACCAUCAGAAUCGCCCA
  	GCCCAAGAGCGCCACCGCCAUCUUCGAUACCACCACACUGAA
  	CCCCACCAUUGCCGGCGCUGGCGACGUGAAAGCCUCUGCCGA
  	AGGACAGCUGGGCGACACAAUGCAGAUCGUGUCCCUGCAGC
  	UGAACAAGAUGAAGUCCCGGAAGUCCUGCGGAAUCGCCGUG
  	GGCACCACAAUCGUGGACGCCGAUAAGUACGCCGUGACCGU
  	GGAAACCCGGCUGAUCGAUGAGAGGGCCGCUCACGUGAACG
  	CCCAGUUCAGAUUC
  MOMP_E_nIgK_cHis	AUGGAAACCCCUGCCCAGCUGCUGUUCCUGCUGCUGCUGUG	395
  	GCUGCCUGACACCACCGGCCUGCCCGUGGGAAAUCCUGCCGA
  	GCCCAGCCUGAUGAUCGACGGCAUUCUGUGGGAGGGCUUCG
  	GCGGCGACCCUUGCGAUCCUUGUACCACUUGGUGCGACGCCA
  	UCAGCAUGAGAAUGGGCUACUACGGCGACUUCGUGUUCGAC
  	CGGGUGCUGAAAACCGACGUGAACAAAGAAUUCCAGAUGGG
  	CGACAAGCCCACCAGCACCACCGGAAAUGCCACCGCCCCUAC
  	CACCCUGACCGCCAGAGAAAAUCCCGCCUACGGCCGGCACAU
  	GCAGGACGCCGAGAUGUUCACCAACGCCGCCUGCAUGGCCCU
  	GAACAUCUGGGACAGAUUCGACGUGUUCUGCACCCUGGGCG
  	CCAGCAGCGGCUACCUGAAGGGCAAUAGCGCCAGCUUCAACC
  	UCGUGGGCCUGUUCGGCGACAACGAGAACCAGAGCACCGUG
  	AAAACAAACAGCGUGCCCAACAUGAGCCUGGACCAGAGCGU
  	GGUGGAACUGUACACCGACACCGCAUUCUCUUGGAGCGUGG
  	GAGCCAGAGCUGCCCUGUGGGAGUGUGGAUGUGCCACACUG
  	GGCGCUAGCUUCCAGUACGCCCAGAGCAAGCCCAAGGUGGA
  	AGAACUGAACGUGCUGUGCAAUGCCGCCGAGUUCACCAUCA
  	ACAAGCCUAAGGGCUACGUGGGCCAGGAAUUCCCCCUGGCCC
  	UGAUCGCCGGAACAGAUGCCGCCACCGGAACAAAGGACGCC
  	AGCAUCGACUACCACGAGUGGCAGGCUUCUCUGGCCCUGUCC
  	UACCGGCUGAAUAUGUUCACCCCCUACAUCGGCGUGAAGUG
  	GUCCCGGGCCAGCUUCGAUGCCGACACCAUCAGAAUCGCCCA
  	GCCCAAGAGCGCCACCGCCAUCUUCGAUACCACCACACUGAA
  	CCCCACCAUUGCCGGCGCUGGCGACGUGAAAGCCUCUGCCGA
  	AGGACAGCUGGGCGACACAAUGCAGAUCGUGUCCCUGCAGC
  	UGAACAAGAUGAAGUCCCGGAAGUCCUGCGGAAUCGCCGUG
  	GGCACCACAAUCGUGGACGCCGAUAAGUACGCCGUGACCGU
  	GGAAACCCGGCUGAUCGAUGAGAGGGCCGCUCACGUGAACG
  	CCCAGUUCAGAUUCCACCACCACCAUCACCAC
  MOMP_E_nOsteo	AUGUGGUGGCGGCUGUGGUGGCUUCUCCUUCUCCUCCUGCU	396
  	GCUGUGGCCCAUGGUGUGGGCCCUGCCCGUGGGAAAUCCUG
  	CCGAGCCCAGCCUGAUGAUCGACGGCAUUCUGUGGGAGGGC
  	UUCGGCGGCGACCCUUGCGAUCCUUGUACCACUUGGUGCGA
  	CGCCAUCAGCAUGAGAAUGGGCUACUACGGCGACUUCGUGU
  	UCGACCGGGUGCUGAAAACCGACGUGAACAAAGAAUUCCAG
  	AUGGGCGACAAGCCCACCAGCACCACCGGAAAUGCCACCGCC
  	CCUACCACCCUGACCGCCAGAGAAAAUCCCGCCUACGGCCGG
  	CACAUGCAGGACGCCGAGAUGUUCACCAACGCCGCCUGCAUG
  	GCCCUGAACAUCUGGGACAGAUUCGACGUGUUCUGCACCCU
  	GGGCGCCAGCAGCGGCUACCUGAAGGGCAAUAGCGCCAGCU
  	UCAACCUCGUGGGCCUGUUCGGCGACAACGAGAACCAGAGC
  	ACCGUGAAAACAAACAGCGUGCCCAACAUGAGCCUGGACCA
  	GAGCGUGGUGGAACUGUACACCGACACCGCAUUCUCUUGGA
  	GCGUGGGAGCCAGAGCUGCCCUGUGGGAGUGUGGAUGUGCC
  	ACACUGGGCGCUAGCUUCCAGUACGCCCAGAGCAAGCCCAAG
  	GUGGAAGAACUGAACGUGCUGUGCAAUGCCGCCGAGUUCAC
  	CAUCAACAAGCCUAAGGGCUACGUGGGCCAGGAAUUCCCCC
  	UGGCCCUGAUCGCCGGAACAGAUGCCGCCACCGGAACAAAG
  	GACGCCAGCAUCGACUACCACGAGUGGCAGGCUUCUCUGGCC
  	CUGUCCUACCGGCUGAAUAUGUUCACCCCCUACAUCGGCGUG
  	AAGUGGUCCCGGGCCAGCUUCGAUGCCGACACCAUCAGAAU
  	CGCCCAGCCCAAGAGCGCCACCGCCAUCUUCGAUACCACCAC
  	ACUGAACCCCACCAUUGCCGGCGCUGGCGACGUGAAAGCCUC
  	UGCCGAAGGACAGCUGGGCGACACAAUGCAGAUCGUGUCCC
  	UGCAGCUGAACAAGAUGAAGUCCCGGAAGUCCUGCGGAAUC
  	GCCGUGGGCACCACAAUCGUGGACGCCGAUAAGUACGCCGU
  	GACCGUGGAAACCCGGCUGAUCGAUGAGAGGGCCGCUCACG
  	UGAACGCCCAGUUCAGAUUC
  MOMP_E_nOsteo_cHis	AUGUGGUGGCGGCUGUGGUGGCUUCUCCUUCUCCUCCUGCU	397
  	GCUGUGGCCCAUGGUGUGGGCCCUGCCCGUGGGAAAUCCUG
  	CCGAGCCCAGCCUGAUGAUCGACGGCAUUCUGUGGGAGGGC
  	UUCGGCGGCGACCCUUGCGAUCCUUGUACCACUUGGUGCGA
  	CGCCAUCAGCAUGAGAAUGGGCUACUACGGCGACUUCGUGU
  	UCGACCGGGUGCUGAAAACCGACGUGAACAAAGAAUUCCAG
  	AUGGGCGACAAGCCCACCAGCACCACCGGAAAUGCCACCGCC
  	CCUACCACCCUGACCGCCAGAGAAAAUCCCGCCUACGGCCGG
  	CACAUGCAGGACGCCGAGAUGUUCACCAACGCCGCCUGCAUG
  	GCCCUGAACAUCUGGGACAGAUUCGACGUGUUCUGCACCCU
  	GGGCGCCAGCAGCGGCUACCUGAAGGGCAAUAGCGCCAGCU
  	UCAACCUCGUGGGCCUGUUCGGCGACAACGAGAACCAGAGC
  	ACCGUGAAAACAAACAGCGUGCCCAACAUGAGCCUGGACCA
  	GAGCGUGGUGGAACUGUACACCGACACCGCAUUCUCUUGGA
  	GCGUGGGAGCCAGAGCUGCCCUGUGGGAGUGUGGAUGUGCC
  	ACACUGGGCGCUAGCUUCCAGUACGCCCAGAGCAAGCCCAAG
  	GUGGAAGAACUGAACGUGCUGUGCAAUGCCGCCGAGUUCAC
  	CAUCAACAAGCCUAAGGGCUACGUGGGCCAGGAAUUCCCCC
  	UGGCCCUGAUCGCCGGAACAGAUGCCGCCACCGGAACAAAG
  	GACGCCAGCAUCGACUACCACGAGUGGCAGGCUUCUCUGGCC
  	CUGUCCUACCGGCUGAAUAUGUUCACCCCCUACAUCGGCGUG
  	AAGUGGUCCCGGGCCAGCUUCGAUGCCGACACCAUCAGAAU
  	CGCCCAGCCCAAGAGCGCCACCGCCAUCUUCGAUACCACCAC
  	ACUGAACCCCACCAUUGCCGGCGCUGGCGACGUGAAAGCCUC
  	UGCCGAAGGACAGCUGGGCGACACAAUGCAGAUCGUGUCCC
  	UGCAGCUGAACAAGAUGAAGUCCCGGAAGUCCUGCGGAAUC
  	GCCGUGGGCACCACAAUCGUGGACGCCGAUAAGUACGCCGU
  	GACCGUGGAAACCCGGCUGAUCGAUGAGAGGGCCGCUCACG
  	UGAACGCCCAGUUCAGAUUCCACCACCACCAUCACCAC
  CT-858_E_H97A_nIgK	AUGGAAACCCCUGCCCAGCUGCUGUUCCUGCUGCUGCUGUG	398
  	GCUGCCUGAUACCACAGGCGUGCGGGGAGAGUCCCUCGUGU
  	GCAAGAAUGCCCUGCAGGACCUGAGCUUCCUGGAACAUCUG
  	CUGCAAGUGAAGUACGCCCCCAAGACCUGGAAAGAGCAGUA
  	CCUGGGCUGGGACCUGGUGCAGUCCUCUGUGUCUGCCCAGC
  	AGAAGCUGCGGACCCAGGAAAACCCCUCUACCAGCUUCUGUC
  	AGCAAGUGCUGGCCGACUUCAUCGGCGGCCUGAACGAUUUC
  	GCCGCCGGCGUGACCUUUUUCGCCAUCGAGAGCGCCUACCUG
  	CCCUACACCGUGCAGAAGUCCAGCGACGGCCGGUUCUACUUC
  	GUGGACAUCAUGACCUUCAGCAGCGAGAUCAGAGUGGGCGA
  	CGAGCUGCUGGAAGUGGAUGGCGCUCCUGUGCAGGAUGUGC
  	UGGCCACACUGUACGGCAGCAACCACAAGGGCACAGCCGCCG
  	AAGAAUCUGCCGCCCUGAGAACCCUGUUCAGCCGGAUGGCC
  	UCUCUGGGCCACAAGGUGCCAAGCGGCAGAACCACCCUGAA
  	GAUCAGACGGCCCUUUGGCACCACCCGGGAAGUGCGCGUGA
  	AGUGGCGCUAUGUGCCUGAGGGCGUGGGCGACCUGGCCACA
  	AUCGCCCCUUCUAUCAGAGCCCCCCAGCUGCAGAAAUCCAUG
  	CGGUCAUUCUUCCCAAAGAAGGACGACGCCUUCCACCGGUCC
  	AGCAGCCUGUUCUACAGCCCUAUGGUGCCCCACUUCUGGGCC
  	GAGCUGAGAAACCACUACGCCACCUCCGGCCUGAAGUCCGGC
  	UACAACAUCGGCAGCACCGACGGCUUUCUGCCCGUGAUCGG
  	ACCCGUGAUCUGGGAGAGCGAGGGCCUGUUCAGAGCCUACA
  	UCAGCAGCGUGACCGACGGCGACGGCAAGAGCCACAAAGUG
  	GGCUUUCUGAGAAUCCCCACCUACAGCUGGCAGGACAUGGA
  	AGAUUUCGACCCCAGCGGCCCACCCCCCUGGGAGGAAUUUGC
  	CAAGAUCAUCCAGGUGUUCAGCAGCAACACCGAGGCCCUGA
  	UCAUCGACCAGACCAACAACCCUGGCGGCAGCGUGCUGUACC
  	UGUACGCCCUGCUGAGCAUGCUGACCGACAGACCCCUGGAAC
  	UGCCCAAGCACCGGAUGAUCCUGACCCAGGACGAGGUGGUG
  	GACGCCCUGGAUUGGCUGACCCUGCUGGAAAACGUGGACAC
  	CAACGUGGAAAGCCGGCUGGCCCUGGGCGACAACAUGGAAG
  	GCUACACAGUGGAUCUGCAGGUGGCCGAGUACCUGAAAAGC
  	UUCGGCAGACAGGUGCUGAACUGCUGGUCCAAGGGCGACAU
  	CGAGCUGAGCACCCCCAUCCCCCUGUUCGGCUUCGAGAAGAU
  	CCACCCCCACCCCAGAGUGCAGUACAGCAAGCCCAUCUGCGU
  	GCUGAUCAACGAGCAGGACUUCUCCUGCGCCGACUUCUUCCC
  	AGUGGUGCUGAAGGACAACGACAGAGCCCUGAUCGUGGGCA
  	CCAGAACAGCUGGCGCUGGCGGCUUCGUGUUCAACGUGCAG
  	UUCCCCAACCGGACCGGCAUCAAGACCUGUAGCCUGACAGGC
  	UCUCUGGCCGUGCGGGAACACGGCGCCUUCAUCGAGAACAU
  	CGGCGUGGAACCCCACAUCGACCUGCCUUUCACCGCCAACGA
  	CAUCCGGUACAAGGGCUACUCUGAGUACCUGGACAAAGUGA
  	AGAAACUCGUGUGCCAGCUGAUUAACAACGACGGCACCAUC
  	AUCCUGGCCGAGGACGGCAGCUUC
  CT858_E_H97A_nIgK_cHis	AUGGAAACCCCUGCCCAGCUGCUGUUCCUGCUGCUGCUGUG	399
  	GCUGCCUGAUACCACAGGCGUGCGGGGAGAGUCCCUCGUGU
  	GCAAGAAUGCCCUGCAGGACCUGAGCUUCCUGGAACAUCUG
  	CUGCAAGUGAAGUACGCCCCCAAGACCUGGAAAGAGCAGUA
  	CCUGGGCUGGGACCUGGUGCAGUCCUCUGUGUCUGCCCAGC
  	AGAAGCUGCGGACCCAGGAAAACCCCUCUACCAGCUUCUGUC
  	AGCAAGUGCUGGCCGACUUCAUCGGCGGCCUGAACGAUUUC
  	GCCGCCGGCGUGACCUUUUUCGCCAUCGAGAGCGCCUACCUG
  	CCCUACACCGUGCAGAAGUCCAGCGACGGCCGGUUCUACUUC
  	GUGGACAUCAUGACCUUCAGCAGCGAGAUCAGAGUGGGCGA
  	CGAGCUGCUGGAAGUGGAUGGCGCUCCUGUGCAGGAUGUGC
  	UGGCCACACUGUACGGCAGCAACCACAAGGGCACAGCCGCCG
  	AAGAAUCUGCCGCCCUGAGAACCCUGUUCAGCCGGAUGGCC
  	UCUCUGGGCCACAAGGUGCCAAGCGGCAGAACCACCCUGAA
  	GAUCAGACGGCCCUUUGGCACCACCCGGGAAGUGCGCGUGA
  	AGUGGCGCUAUGUGCCUGAGGGCGUGGGCGACCUGGCCACA
  	AUCGCCCCUUCUAUCAGAGCCCCCCAGCUGCAGAAAUCCAUG
  	CGGUCAUUCUUCCCAAAGAAGGACGACGCCUUCCACCGGUCC
  	AGCAGCCUGUUCUACAGCCCUAUGGUGCCCCACUUCUGGGCC
  	GAGCUGAGAAACCACUACGCCACCUCCGGCCUGAAGUCCGGC
  	UACAACAUCGGCAGCACCGACGGCUUUCUGCCCGUGAUCGG
  	ACCCGUGAUCUGGGAGAGCGAGGGCCUGUUCAGAGCCUACA
  	UCAGCAGCGUGACCGACGGCGACGGCAAGAGCCACAAAGUG
  	GGCUUUCUGAGAAUCCCCACCUACAGCUGGCAGGACAUGGA
  	AGAUUUCGACCCCAGCGGCCCACCCCCCUGGGAGGAAUUUGC
  	CAAGAUCAUCCAGGUGUUCAGCAGCAACACCGAGGCCCUGA
  	UCAUCGACCAGACCAACAACCCUGGCGGCAGCGUGCUGUACC
  	UGUACGCCCUGCUGAGCAUGCUGACCGACAGACCCCUGGAAC
  	UGCCCAAGCACCGGAUGAUCCUGACCCAGGACGAGGUGGUG
  	GACGCCCUGGAUUGGCUGACCCUGCUGGAAAACGUGGACAC
  	CAACGUGGAAAGCCGGCUGGCCCUGGGCGACAACAUGGAAG
  	GCUACACAGUGGAUCUGCAGGUGGCCGAGUACCUGAAAAGC
  	UUCGGCAGACAGGUGCUGAACUGCUGGUCCAAGGGCGACAU
  	CGAGCUGAGCACCCCCAUCCCCCUGUUCGGCUUCGAGAAGAU
  	CCACCCCCACCCCAGAGUGCAGUACAGCAAGCCCAUCUGCGU
  	GCUGAUCAACGAGCAGGACUUCUCCUGCGCCGACUUCUUCCC
  	AGUGGUGCUGAAGGACAACGACAGAGCCCUGAUCGUGGGCA
  	CCAGAACAGCUGGCGCUGGCGGCUUCGUGUUCAACGUGCAG
  	UUCCCCAACCGGACCGGCAUCAAGACCUGUAGCCUGACAGGC
  	UCUCUGGCCGUGCGGGAACACGGCGCCUUCAUCGAGAACAU
  	CGGCGUGGAACCCCACAUCGACCUGCCUUUCACCGCCAACGA
  	CAUCCGGUACAAGGGCUACUCUGAGUACCUGGACAAAGUGA
  	AGAAACUCGUGUGCCAGCUGAUUAACAACGACGGCACCAUC
  	AUCCUGGCCGAGGACGGCAGCUUCCACCACCACCAUCACCAC
  CT858_E_S491A_nIgK	AUGGAAACCCCUGCCCAGCUGCUGUUCCUGCUGCUGCUGUG	400
  	GCUGCCUGAUACCACAGGCGUGCGGGGAGAGUCCCUCGUGU
  	GCAAGAAUGCCCUGCAGGACCUGAGCUUCCUGGAACAUCUG
  	CUGCAAGUGAAGUACGCCCCCAAGACCUGGAAAGAGCAGUA
  	CCUGGGCUGGGACCUGGUGCAGUCCUCUGUGUCUGCCCAGC
  	AGAAGCUGCGGACCCAGGAAAACCCCUCUACCAGCUUCUGUC
  	AGCAAGUGCUGGCCGACUUCAUCGGCGGCCUGAACGAUUUC
  	CAUGCCGGCGUGACCUUUUUCGCCAUCGAGAGCGCCUACCUG
  	CCCUACACCGUGCAGAAGUCCAGCGACGGCCGGUUCUACUUC
  	GUGGACAUCAUGACCUUCAGCAGCGAGAUCAGAGUGGGCGA
  	CGAGCUGCUGGAAGUGGAUGGCGCUCCUGUGCAGGAUGUGC
  	UGGCCACACUGUACGGCAGCAACCACAAGGGCACAGCCGCCG
  	AAGAAUCUGCCGCCCUGAGAACCCUGUUCAGCCGGAUGGCC
  	UCUCUGGGCCACAAGGUGCCAAGCGGCAGAACCACCCUGAA
  	GAUCAGACGGCCCUUUGGCACCACCCGGGAAGUGCGCGUGA
  	AGUGGCGCUAUGUGCCUGAGGGCGUGGGCGACCUGGCCACA
  	AUCGCCCCUUCUAUCAGAGCCCCCCAGCUGCAGAAAUCCAUG
  	CGGUCAUUCUUCCCAAAGAAGGACGACGCCUUCCACCGGUCC
  	AGCAGCCUGUUCUACAGCCCUAUGGUGCCCCACUUCUGGGCC
  	GAGCUGAGAAACCACUACGCCACCUCCGGCCUGAAGUCCGGC
  	UACAACAUCGGCAGCACCGACGGCUUUCUGCCCGUGAUCGG
  	ACCCGUGAUCUGGGAGAGCGAGGGCCUGUUCAGAGCCUACA
  	UCAGCAGCGUGACCGACGGCGACGGCAAGAGCCACAAAGUG
  	GGCUUUCUGAGAAUCCCCACCUACAGCUGGCAGGACAUGGA
  	AGAUUUCGACCCCAGCGGCCCACCCCCCUGGGAGGAAUUUGC
  	CAAGAUCAUCCAGGUGUUCAGCAGCAACACCGAGGCCCUGA
  	UCAUCGACCAGACCAACAACCCUGGCGGCAGCGUGCUGUACC
  	UGUACGCCCUGCUGAGCAUGCUGACCGACAGACCCCUGGAAC
  	UGCCCAAGCACCGGAUGAUCCUGACCCAGGACGAGGUGGUG
  	GACGCCCUGGAUUGGCUGACCCUGCUGGAAAACGUGGACAC
  	CAACGUGGAAAGCCGGCUGGCCCUGGGCGACAACAUGGAAG
  	GCUACACAGUGGAUCUGCAGGUGGCCGAGUACCUGAAAAGC
  	UUCGGCAGACAGGUGCUGAACUGCUGGUCCAAGGGCGACAU
  	CGAGCUGAGCACCCCCAUCCCCCUGUUCGGCUUCGAGAAGAU
  	CCACCCCCACCCCAGAGUGCAGUACAGCAAGCCCAUCUGCGU
  	GCUGAUCAACGAGCAGGACUUCGCCUGCGCCGACUUCUUCCC
  	AGUGGUGCUGAAGGACAACGACAGAGCCCUGAUCGUGGGCA
  	CCAGAACAGCUGGCGCUGGCGGCUUCGUGUUCAACGUGCAG
  	UUCCCCAACCGGACCGGCAUCAAGACCUGUAGCCUGACAGGC
  	UCUCUGGCCGUGCGGGAACACGGCGCCUUCAUCGAGAACAU
  	CGGCGUGGAACCCCACAUCGACCUGCCUUUCACCGCCAACGA
  	CAUCCGGUACAAGGGCUACUCUGAGUACCUGGACAAAGUGA
  	AGAAACUCGUGUGCCAGCUGAUUAACAACGACGGCACCAUC
  	AUCCUGGCCGAGGACGGCAGCUUC
  CT858_E_S491A_nIgK_cHis	AUGGAAACCCCUGCCCAGCUGCUGUUCCUGCUGCUGCUGUG	401
  	GCUGCCUGAUACCACAGGCGUGCGGGGAGAGUCCCUCGUGU
  	GCAAGAAUGCCCUGCAGGACCUGAGCUUCCUGGAACAUCUG
  	CUGCAAGUGAAGUACGCCCCCAAGACCUGGAAAGAGCAGUA
  	CCUGGGCUGGGACCUGGUGCAGUCCUCUGUGUCUGCCCAGC
  	AGAAGCUGCGGACCCAGGAAAACCCCUCUACCAGCUUCUGUC
  	AGCAAGUGCUGGCCGACUUCAUCGGCGGCCUGAACGAUUUC
  	CAUGCCGGCGUGACCUUUUUCGCCAUCGAGAGCGCCUACCUG
  	CCCUACACCGUGCAGAAGUCCAGCGACGGCCGGUUCUACUUC
  	GUGGACAUCAUGACCUUCAGCAGCGAGAUCAGAGUGGGCGA
  	CGAGCUGCUGGAAGUGGAUGGCGCUCCUGUGCAGGAUGUGC
  	UGGCCACACUGUACGGCAGCAACCACAAGGGCACAGCCGCCG
  	AAGAAUCUGCCGCCCUGAGAACCCUGUUCAGCCGGAUGGCC
  	UCUCUGGGCCACAAGGUGCCAAGCGGCAGAACCACCCUGAA
  	GAUCAGACGGCCCUUUGGCACCACCCGGGAAGUGCGCGUGA
  	AGUGGCGCUAUGUGCCUGAGGGCGUGGGCGACCUGGCCACA
  	AUCGCCCCUUCUAUCAGAGCCCCCCAGCUGCAGAAAUCCAUG
  	CGGUCAUUCUUCCCAAAGAAGGACGACGCCUUCCACCGGUCC
  	AGCAGCCUGUUCUACAGCCCUAUGGUGCCCCACUUCUGGGCC
  	GAGCUGAGAAACCACUACGCCACCUCCGGCCUGAAGUCCGGC
  	UACAACAUCGGCAGCACCGACGGCUUUCUGCCCGUGAUCGG
  	ACCCGUGAUCUGGGAGAGCGAGGGCCUGUUCAGAGCCUACA
  	UCAGCAGCGUGACCGACGGCGACGGCAAGAGCCACAAAGUG
  	GGCUUUCUGAGAAUCCCCACCUACAGCUGGCAGGACAUGGA
  	AGAUUUCGACCCCAGCGGCCCACCCCCCUGGGAGGAAUUUGC
  	CAAGAUCAUCCAGGUGUUCAGCAGCAACACCGAGGCCCUGA
  	UCAUCGACCAGACCAACAACCCUGGCGGCAGCGUGCUGUACC
  	UGUACGCCCUGCUGAGCAUGCUGACCGACAGACCCCUGGAAC
  	UGCCCAAGCACCGGAUGAUCCUGACCCAGGACGAGGUGGUG
  	GACGCCCUGGAUUGGCUGACCCUGCUGGAAAACGUGGACAC
  	CAACGUGGAAAGCCGGCUGGCCCUGGGCGACAACAUGGAAG
  	GCUACACAGUGGAUCUGCAGGUGGCCGAGUACCUGAAAAGC
  	UUCGGCAGACAGGUGCUGAACUGCUGGUCCAAGGGCGACAU
  	CGAGCUGAGCACCCCCAUCCCCCUGUUCGGCUUCGAGAAGAU
  	CCACCCCCACCCCAGAGUGCAGUACAGCAAGCCCAUCUGCGU
  	GCUGAUCAACGAGCAGGACUUCGCCUGCGCCGACUUCUUCCC
  	AGUGGUGCUGAAGGACAACGACAGAGCCCUGAUCGUGGGCA
  	CCAGAACAGCUGGCGCUGGCGGCUUCGUGUUCAACGUGCAG
  	UUCCCCAACCGGACCGGCAUCAAGACCUGUAGCCUGACAGGC
  	UCUCUGGCCGUGCGGGAACACGGCGCCUUCAUCGAGAACAU
  	CGGCGUGGAACCCCACAUCGACCUGCCUUUCACCGCCAACGA
  	CAUCCGGUACAAGGGCUACUCUGAGUACCUGGACAAAGUGA
  	AGAAACUCGUGUGCCAGCUGAUUAACAACGACGGCACCAUC
  	AUCCUGGCCGAGGACGGCAGCUUCCACCACCACCAUCACCAC
  CT089_E_T306A_nIgK	AUGGAAACCCCUGCCCAGCUGCUGUUCCUGCUGCUGCUGUG	402
  	GCUGCCUGACACCACCGGCAUGACAGCAUCUGGCGGAGCUG
  	GCGGCCUGGGCUCUACACAGACAGUGGAUGUGGCCAGGGCC
  	CAGGCUGCUGCCGCUACACAGGAUGCCCAGGAAGUGAUCGG
  	CAGCCAGGAAGCCAGCGAGGCCUCUAUGCUGAAGGGCUGCG
  	AGGACCUGAUCAACCCUGCCGCCGCUACCCGCAUCAAGAAGA
  	AAGAGGAAAAGUUCGAGUCCCUGGAAGCCAGACGGAAGCCC
  	ACCGCCGACAAGGCCGAGAAGAAGUCCGAGAGCACCGAGGA
  	AAAGGGCGACACCCCCCUGGAAGAUCGGUUCACCGAGGAUC
  	UGAGCGAGGUGUCCGGCGAGGACUUCCGGGGCCUGAAGAAC
  	AGCUUCGACGACGACAGCAGCCCCGAGGAAAUCCUGGACGCC
  	CUGACCAGCAAGUUCAGCGACCCCACCAUCAAGGACCUGGCC
  	CUGGACUACCUGAUCCAGACCGCCCCCAGCGACCGGAAGCUG
  	AAGUCUGCCCUGAUUCAGGCCAAGCACCAGCUGAUGAGCCA
  	GAACCCCCAGGCCAUCGUGGGCGGCAGAAAUGUGCUGCUGG
  	CCUCCGAGACAUUCGCCAGCAGAGCCAACACCAGCCCCAGCU
  	CCCUGCGGAGCCUGUAUCUGCAAGUGACCAGCUCCCCCAGCA
  	ACUGCGACAACCUGAGACAGAUGCUGGCUAGCUACCUGCCC
  	UCCGAGAAAACCGCCGUGAUGGAAUUCCUCGUGAACGGCAU
  	GGUGGCCGACCUGAAAAGCGAGGGCCCUAGCAUCCCUCCCGC
  	CAAGCUGCAGGUGUACAUGACCGAGCUGAGCAACCUGCAGG
  	CCCUGCACAGCGUGGACAGCUUUUUCGACCGGAACAUCGGC
  	AACCUGGAAAACAGCCUGAAGCACGAGGGCCACGCCCCCAUC
  	CCUUCUCUGACAACCGGCAAUCUGGCCAAGACCUUCCUGCAG
  	CUGGUGGAAGAUAAGUUCCCCAGCAGCUCCAAGGCCCAGAA
  	GGCCCUGAACGAGCUCGUGGGCCCUGAUACCGGACCUCAGAC
  	CGAGGUGCUGAACCUGUUCUUUCGGGCCCUGAAUGGCUGCU
  	CCCCCCGGAUCUUUUCUGGCGCUGAGAAGAAGCAGCAGCUG
  	GCCAGCGUGAUCACCAACACCCUGGAUGCCAUCAACGCCGAC
  	AACGAGGACUACCCCAAGCCCGGCGACUUCCCCAGAAGCAGC
  	UUUAGCAGCACCCCCCCUCAUGCCCCUGUGCCCCAGUCUGAG
  	AUCCCUACCAGCCCAACCAGCACCCAGCCUCCAAGCCCU
  CT089_E_T306A_nIgK_cHis	AUGGAAACCCCUGCCCAGCUGCUGUUCCUGCUGCUGCUGUG	403
  	GCUGCCUGACACCACCGGCAUGACAGCAUCUGGCGGAGCUG
  	GCGGCCUGGGCUCUACACAGACAGUGGAUGUGGCCAGGGCC
  	CAGGCUGCUGCCGCUACACAGGAUGCCCAGGAAGUGAUCGG
  	CAGCCAGGAAGCCAGCGAGGCCUCUAUGCUGAAGGGCUGCG
  	AGGACCUGAUCAACCCUGCCGCCGCUACCCGCAUCAAGAAGA
  	AAGAGGAAAAGUUCGAGUCCCUGGAAGCCAGACGGAAGCCC
  	ACCGCCGACAAGGCCGAGAAGAAGUCCGAGAGCACCGAGGA
  	AAAGGGCGACACCCCCCUGGAAGAUCGGUUCACCGAGGAUC
  	UGAGCGAGGUGUCCGGCGAGGACUUCCGGGGCCUGAAGAAC
  	AGCUUCGACGACGACAGCAGCCCCGAGGAAAUCCUGGACGCC
  	CUGACCAGCAAGUUCAGCGACCCCACCAUCAAGGACCUGGCC
  	CUGGACUACCUGAUCCAGACCGCCCCCAGCGACCGGAAGCUG
  	AAGUCUGCCCUGAUUCAGGCCAAGCACCAGCUGAUGAGCCA
  	GAACCCCCAGGCCAUCGUGGGCGGCAGAAAUGUGCUGCUGG
  	CCUCCGAGACAUUCGCCAGCAGAGCCAACACCAGCCCCAGCU
  	CCCUGCGGAGCCUGUAUCUGCAAGUGACCAGCUCCCCCAGCA
  	ACUGCGACAACCUGAGACAGAUGCUGGCUAGCUACCUGCCC
  	UCCGAGAAAACCGCCGUGAUGGAAUUCCUCGUGAACGGCAU
  	GGUGGCCGACCUGAAAAGCGAGGGCCCUAGCAUCCCUCCCGC
  	CAAGCUGCAGGUGUACAUGACCGAGCUGAGCAACCUGCAGG
  	CCCUGCACAGCGUGGACAGCUUUUUCGACCGGAACAUCGGC
  	AACCUGGAAAACAGCCUGAAGCACGAGGGCCACGCCCCCAUC
  	CCUUCUCUGACAACCGGCAAUCUGGCCAAGACCUUCCUGCAG
  	CUGGUGGAAGAUAAGUUCCCCAGCAGCUCCAAGGCCCAGAA
  	GGCCCUGAACGAGCUCGUGGGCCCUGAUACCGGACCUCAGAC
  	CGAGGUGCUGAACCUGUUCUUUCGGGCCCUGAAUGGCUGCU
  	CCCCCCGGAUCUUUUCUGGCGCUGAGAAGAAGCAGCAGCUG
  	GCCAGCGUGAUCACCAACACCCUGGAUGCCAUCAACGCCGAC
  	AACGAGGACUACCCCAAGCCCGGCGACUUCCCCAGAAGCAGC
  	UUUAGCAGCACCCCCCCUCAUGCCCCUGUGCCCCAGUCUGAG
  	AUCCCUACCAGCCCAACCAGCACCCAGCCUCCAAGCCCUCAC
  	CACCACCAUCACCAC
  CT089_E_S198A_T306A_nIgK	AUGGAAACCCCUGCCCAGCUGCUGUUCCUGCUGCUGCUGUG	404
  	GCUGCCUGACACCACCGGCAUGACAGCAUCUGGCGGAGCUG
  	GCGGCCUGGGCUCUACACAGACAGUGGAUGUGGCCAGGGCC
  	CAGGCUGCUGCCGCUACACAGGAUGCCCAGGAAGUGAUCGG
  	CAGCCAGGAAGCCAGCGAGGCCUCUAUGCUGAAGGGCUGCG
  	AGGACCUGAUCAACCCUGCCGCCGCUACCCGCAUCAAGAAGA
  	AAGAGGAAAAGUUCGAGUCCCUGGAAGCCAGACGGAAGCCC
  	ACCGCCGACAAGGCCGAGAAGAAGUCCGAGAGCACCGAGGA
  	AAAGGGCGACACCCCCCUGGAAGAUCGGUUCACCGAGGAUC
  	UGAGCGAGGUGUCCGGCGAGGACUUCCGGGGCCUGAAGAAC
  	AGCUUCGACGACGACAGCAGCCCCGAGGAAAUCCUGGACGCC
  	CUGACCAGCAAGUUCAGCGACCCCACCAUCAAGGACCUGGCC
  	CUGGACUACCUGAUCCAGACCGCCCCCAGCGACCGGAAGCUG
  	AAGUCUGCCCUGAUUCAGGCCAAGCACCAGCUGAUGAGCCA
  	GAACCCCCAGGCCAUCGUGGGCGGCAGAAAUGUGCUGCUGG
  	CCUCCGAGACAUUCGCCAGCAGAGCCAACACCGCCCCCAGCU
  	CCCUGCGGAGCCUGUAUCUGCAAGUGACCAGCUCCCCCAGCA
  	ACUGCGACAACCUGAGACAGAUGCUGGCUAGCUACCUGCCC
  	UCCGAGAAAACCGCCGUGAUGGAAUUCCUCGUGAACGGCAU
  	GGUGGCCGACCUGAAAAGCGAGGGCCCUAGCAUCCCUCCCGC
  	CAAGCUGCAGGUGUACAUGACCGAGCUGAGCAACCUGCAGG
  	CCCUGCACAGCGUGGACAGCUUUUUCGACCGGAACAUCGGC
  	AACCUGGAAAACAGCCUGAAGCACGAGGGCCACGCCCCCAUC
  	CCUUCUCUGACAACCGGCAAUCUGGCCAAGACCUUCCUGCAG
  	CUGGUGGAAGAUAAGUUCCCCAGCAGCUCCAAGGCCCAGAA
  	GGCCCUGAACGAGCUCGUGGGCCCUGAUACCGGACCUCAGAC
  	CGAGGUGCUGAACCUGUUCUUUCGGGCCCUGAAUGGCUGCU
  	CCCCCCGGAUCUUUUCUGGCGCUGAGAAGAAGCAGCAGCUG
  	GCCAGCGUGAUCACCAACACCCUGGAUGCCAUCAACGCCGAC
  	AACGAGGACUACCCCAAGCCCGGCGACUUCCCCAGAAGCAGC
  	UUUAGCAGCACCCCCCCUCAUGCCCCUGUGCCCCAGUCUGAG
  	AUCCCUACCAGCCCAACCAGCACCCAGCCUCCAAGCCCU
  CT089_E_S198A_T306A_nIgK_cHis	AUGGAAACCCCUGCCCAGCUGCUGUUCCUGCUGCUGCUGUG	405
  	GCUGCCUGACACCACCGGCAUGACAGCAUCUGGCGGAGCUG
  	GCGGCCUGGGCUCUACACAGACAGUGGAUGUGGCCAGGGCC
  	CAGGCUGCUGCCGCUACACAGGAUGCCCAGGAAGUGAUCGG
  	CAGCCAGGAAGCCAGCGAGGCCUCUAUGCUGAAGGGCUGCG
  	AGGACCUGAUCAACCCUGCCGCCGCUACCCGCAUCAAGAAGA
  	AAGAGGAAAAGUUCGAGUCCCUGGAAGCCAGACGGAAGCCC
  	ACCGCCGACAAGGCCGAGAAGAAGUCCGAGAGCACCGAGGA
  	AAAGGGCGACACCCCCCUGGAAGAUCGGUUCACCGAGGAUC
  	UGAGCGAGGUGUCCGGCGAGGACUUCCGGGGCCUGAAGAAC
  	AGCUUCGACGACGACAGCAGCCCCGAGGAAAUCCUGGACGCC
  	CUGACCAGCAAGUUCAGCGACCCCACCAUCAAGGACCUGGCC
  	CUGGACUACCUGAUCCAGACCGCCCCCAGCGACCGGAAGCUG
  	AAGUCUGCCCUGAUUCAGGCCAAGCACCAGCUGAUGAGCCA
  	GAACCCCCAGGCCAUCGUGGGCGGCAGAAAUGUGCUGCUGG
  	CCUCCGAGACAUUCGCCAGCAGAGCCAACACCGCCCCCAGCU
  	CCCUGCGGAGCCUGUAUCUGCAAGUGACCAGCUCCCCCAGCA
  	ACUGCGACAACCUGAGACAGAUGCUGGCUAGCUACCUGCCC
  	UCCGAGAAAACCGCCGUGAUGGAAUUCCUCGUGAACGGCAU
  	GGUGGCCGACCUGAAAAGCGAGGGCCCUAGCAUCCCUCCCGC
  	CAAGCUGCAGGUGUACAUGACCGAGCUGAGCAACCUGCAGG
  	CCCUGCACAGCGUGGACAGCUUUUUCGACCGGAACAUCGGC
  	AACCUGGAAAACAGCCUGAAGCACGAGGGCCACGCCCCCAUC
  	CCUUCUCUGACAACCGGCAAUCUGGCCAAGACCUUCCUGCAG
  	CUGGUGGAAGAUAAGUUCCCCAGCAGCUCCAAGGCCCAGAA
  	GGCCCUGAACGAGCUCGUGGGCCCUGAUACCGGACCUCAGAC
  	CGAGGUGCUGAACCUGUUCUUUCGGGCCCUGAAUGGCUGCU
  	CCCCCCGGAUCUUUUCUGGCGCUGAGAAGAAGCAGCAGCUG
  	GCCAGCGUGAUCACCAACACCCUGGAUGCCAUCAACGCCGAC
  	AACGAGGACUACCCCAAGCCCGGCGACUUCCCCAGAAGCAGC
  	UUUAGCAGCACCCCCCCUCAUGCCCCUGUGCCCCAGUCUGAG
  	AUCCCUACCAGCCCAACCAGCACCCAGCCUCCAAGCCCUCAC
  	CACCACCAUCACCAC
  CT089_E_S198A_nIgK	AUGGAAACCCCUGCCCAGCUGCUGUUCCUGCUGCUGCUGUG	406
  	GCUGCCUGACACCACCGGCAUGACAGCAUCUGGCGGAGCUG
  	GCGGCCUGGGCUCUACACAGACAGUGGAUGUGGCCAGGGCC
  	CAGGCUGCUGCCGCUACACAGGAUGCCCAGGAAGUGAUCGG
  	CAGCCAGGAAGCCAGCGAGGCCUCUAUGCUGAAGGGCUGCG
  	AGGACCUGAUCAACCCUGCCGCCGCUACCCGCAUCAAGAAGA
  	AAGAGGAAAAGUUCGAGUCCCUGGAAGCCAGACGGAAGCCC
  	ACCGCCGACAAGGCCGAGAAGAAGUCCGAGAGCACCGAGGA
  	AAAGGGCGACACCCCCCUGGAAGAUCGGUUCACCGAGGAUC
  	UGAGCGAGGUGUCCGGCGAGGACUUCCGGGGCCUGAAGAAC
  	AGCUUCGACGACGACAGCAGCCCCGAGGAAAUCCUGGACGCC
  	CUGACCAGCAAGUUCAGCGACCCCACCAUCAAGGACCUGGCC
  	CUGGACUACCUGAUCCAGACCGCCCCCAGCGACCGGAAGCUG
  	AAGUCUGCCCUGAUUCAGGCCAAGCACCAGCUGAUGAGCCA
  	GAACCCCCAGGCCAUCGUGGGCGGCAGAAAUGUGCUGCUGG
  	CCUCCGAGACAUUCGCCAGCAGAGCCAACACCGCCCCCAGCU
  	CCCUGCGGAGCCUGUAUCUGCAAGUGACCAGCUCCCCCAGCA
  	ACUGCGACAACCUGAGACAGAUGCUGGCUAGCUACCUGCCC
  	UCCGAGAAAACCGCCGUGAUGGAAUUCCUCGUGAACGGCAU
  	GGUGGCCGACCUGAAAAGCGAGGGCCCUAGCAUCCCUCCCGC
  	CAAGCUGCAGGUGUACAUGACCGAGCUGAGCAACCUGCAGG
  	CCCUGCACAGCGUGGACAGCUUUUUCGACCGGAACAUCGGC
  	AACCUGGAAAACAGCCUGAAGCACGAGGGCCACGCCCCCAUC
  	CCUUCUCUGACAACCGGCAAUCUGACCAAGACCUUCCUGCAG
  	CUGGUGGAAGAUAAGUUCCCCAGCAGCUCCAAGGCCCAGAA
  	GGCCCUGAACGAGCUCGUGGGCCCUGAUACCGGACCUCAGAC
  	CGAGGUGCUGAACCUGUUCUUUCGGGCCCUGAAUGGCUGCU
  	CCCCCCGGAUCUUUUCUGGCGCUGAGAAGAAGCAGCAGCUG
  	GCCAGCGUGAUCACCAACACCCUGGAUGCCAUCAACGCCGAC
  	AACGAGGACUACCCCAAGCCCGGCGACUUCCCCAGAAGCAGC
  	UUUAGCAGCACCCCCCCUCAUGCCCCUGUGCCCCAGUCUGAG
  	AUCCCUACCAGCCCAACCAGCACCCAGCCUCCAAGCCCU
  CT089_E_S198A_nIgK_cHis	AUGGAAACCCCUGCCCAGCUGCUGUUCCUGCUGCUGCUGUG	407
  	GCUGCCUGACACCACCGGCAUGACAGCAUCUGGCGGAGCUG
  	GCGGCCUGGGCUCUACACAGACAGUGGAUGUGGCCAGGGCC
  	CAGGCUGCUGCCGCUACACAGGAUGCCCAGGAAGUGAUCGG
  	CAGCCAGGAAGCCAGCGAGGCCUCUAUGCUGAAGGGCUGCG
  	AGGACCUGAUCAACCCUGCCGCCGCUACCCGCAUCAAGAAGA
  	AAGAGGAAAAGUUCGAGUCCCUGGAAGCCAGACGGAAGCCC
  	ACCGCCGACAAGGCCGAGAAGAAGUCCGAGAGCACCGAGGA
  	AAAGGGCGACACCCCCCUGGAAGAUCGGUUCACCGAGGAUC
  	UGAGCGAGGUGUCCGGCGAGGACUUCCGGGGCCUGAAGAAC
  	AGCUUCGACGACGACAGCAGCCCCGAGGAAAUCCUGGACGCC
  	CUGACCAGCAAGUUCAGCGACCCCACCAUCAAGGACCUGGCC
  	CUGGACUACCUGAUCCAGACCGCCCCCAGCGACCGGAAGCUG
  	AAGUCUGCCCUGAUUCAGGCCAAGCACCAGCUGAUGAGCCA
  	GAACCCCCAGGCCAUCGUGGGCGGCAGAAAUGUGCUGCUGG
  	CCUCCGAGACAUUCGCCAGCAGAGCCAACACCGCCCCCAGCU
  	CCCUGCGGAGCCUGUAUCUGCAAGUGACCAGCUCCCCCAGCA
  	ACUGCGACAACCUGAGACAGAUGCUGGCUAGCUACCUGCCC
  	UCCGAGAAAACCGCCGUGAUGGAAUUCCUCGUGAACGGCAU
  	GGUGGCCGACCUGAAAAGCGAGGGCCCUAGCAUCCCUCCCGC
  	CAAGCUGCAGGUGUACAUGACCGAGCUGAGCAACCUGCAGG
  	CCCUGCACAGCGUGGACAGCUUUUUCGACCGGAACAUCGGC
  	AACCUGGAAAACAGCCUGAAGCACGAGGGCCACGCCCCCAUC
  	CCUUCUCUGACAACCGGCAAUCUGACCAAGACCUUCCUGCAG
  	CUGGUGGAAGAUAAGUUCCCCAGCAGCUCCAAGGCCCAGAA
  	GGCCCUGAACGAGCUCGUGGGCCCUGAUACCGGACCUCAGAC
  	CGAGGUGCUGAACCUGUUCUUUCGGGCCCUGAAUGGCUGCU
  	CCCCCCGGAUCUUUUCUGGCGCUGAGAAGAAGCAGCAGCUG
  	GCCAGCGUGAUCACCAACACCCUGGAUGCCAUCAACGCCGAC
  	AACGAGGACUACCCCAAGCCCGGCGACUUCCCCAGAAGCAGC
  	UUUAGCAGCACCCCCCCUCAUGCCCCUGUGCCCCAGUCUGAG
  	AUCCCUACCAGCCCAACCAGCACCCAGCCUCCAAGCCCUCAC
  	CACCACCAUCACCAC
  Chlamydia_CT875_nIgk_cHis	AUGGAAACCCCUGCCCAGCUGCUGUUCCUGCUGCUGCUGUG	408
  	GCUGCCUGACACCACCGGCAUGAGCAUCAGAGGCGUGGGCG
  	GCAACGGCAACAGCAGAAUCCCUAGCCACAACGGCGACGGCA
  	GCAACAGGCGGAGCCAGAACACCAAGGGCAACAACAAGGUG
  	GAAGAUAGAGUGUGCAGCCUGUACAGCAGCCGGUCCAACGA
  	GAACCGCGAGAGCCCUUAUGCCGUGGUGGACGUGUCCAGCA
  	UGAUCGAGAGCACCCCCACCAGCGGCGAGACAACCAGAGCUA
  	GUAGAGGCGUGCUGAGCCGGUUCCAGAGGGGCCUCGUGCGG
  	AUUGCUGACAAAGUGCGGAGAGCCGUGCAGUGCGCUUGGAG
  	CAGCGUGUCCACAAGCAGAAGCAGCGCCACAAGAGCCGCCGA
  	GAGCGGCAGCUCUAGCAGAACAGCUAGAGGCGCCAGCAGCG
  	GCUACAGAGAGUACAGCCCUUCUGCCGCUCGGGGCCUGCGGC
  	UGAUGUUCACCGACUUUUGGCGGACCCGGGUGCUGAGACAG
  	ACCUCUCCUAUGGCCGGCGUGUUCGGCAACCUGGACGUGAA
  	CGAGGCCAGACUGAUGGCCGCCUACACCAGCGAGUGUGCCG
  	AUCACCUGGAAGCCAAAGAGCUGGCCGGACCUGACGGCGUG
  	GCAGCCGCUAGAGAAAUCGCCAAGAGAUGGGAGAAGAGAGU
  	GCGGGACCUGCAGGACAAGGGCGCUGCCAGAAAGCUGCUGA
  	ACGACCCCCUGGGCAGACGGACCCCCAACUACCAGAGCAAGA
  	ACCCCGGCGAGUACACCGUGGGCAACUCCAUGUUCUACGACG
  	GCCCCCAGGUGGCCAACCUGCAGAAUGUGGAUACCGGCUUC
  	UGGCUGGACAUGAGCAACCUGAGCGACGUGGUGCUGUCCAG
  	AGAGAUCCAGACCGGCCUGAGAGCCAGAGCCACCCUGGAAG
  	AGUCCAUGCCCAUGCUGGAAAAUCUGGAAGAGAGAUUCCGG
  	CGGCUGCAGGAAACCUGCGACGCCGCCAGAACCGAGAUCGA
  	GGAAAGCGGCUGGACCCGGGAAAGCGCCUCCAGAAUGGAAG
  	GCGACGAAGCCCAGGGCCCCAGCAGAGUGCAGCAGGCCUUUC
  	AGAGCUUCGUGAAUGAGUGCAACAGCAUCGAGUUCAGCUUC
  	GGCUCCUUCGGCGAGCACGUGCGGGUGCUGUGUGCCAGAGU
  	GUCAAGAGGACUGGCCGCUGCCGGCGAGGCCAUCAGAAGAU
  	GCUUCAGCUGCUGCAAGGGCAGCACCCACAGAUACGCCCCCA
  	GAGAUGACCUGUCUCCUGAGGGCGCCUCUCUGGCCGAAACCC
  	UGGCCAGAUUCGCCGACGACAUGGGCAUCGAAAGAGGCGCC
  	GACGGCACCUACGACAUCCCCCUGGUGGACGAUUGGAGAAG
  	GGGCGUGCCAUCCAUCGAGGGCGAGGGCAGCGAUAGCAUCU
  	ACGAGAUCAUGAUGCCCAUCUACGAAGUGAUGAACAUGGAC
  	CUGGAAACCCGGCGGAGCUUCGCCGUGCAGCAGGGCCAUUA
  	CCAGGACCCCAGAGCCAGCGACUACGACCUGCCUAGAGCCUC
  	CGAUUACGAUCUGCCCAGAAGCCCCUACCCCACCCCUCCACU
  	GCCUCCCAGAUACCAGCUGCAGAACAUGGAUGUGGAAGCCG
  	GCUUUCGCGAGGCCGUGUACGCCUCUUUUGUGGCCGGCAUG
  	UACAACUACGUCGUGACCCAGCCCCAGGAACGGAUCCCCAAU
  	AGCCAGCAGGUGGAAGGCAUCCUGCGGGACAUGCUGACCAA
  	CGGCAGCCAGACCUUCCGGGACCUGAUGAAGCGGUGGAACA
  	GAGAGGUGGACCGCGAGCACCACCAUCACCACCAC
  MOMP_serovarD	AUGAAGAAACUGCUGAAGUCCGUGCUGGUGUUCGCCGCCCU	409
  	GUCUAGCGCAAGCUCUCUGCAGGCUCUGCCCGUGGGAAAUC
  	CUGCCGAGCCCAGCCUGAUGAUCGACGGCAUUCUGUGGGAG
  	GGCUUCGGCGGCGACCCUUGCGAUCCUUGUGCUACUUGGUG
  	CGACGCCAUCAGCAUGAGAGUGGGCUACUACGGCGACUUCG
  	UGUUCGACCGGGUGCUGAAAACCGACGUGAACAAAGAAUUC
  	CAGAUGGGCGCCAAGCCCACCACCGACACCGGAAAUUCUGCC
  	GCCCCUAGCACCCUGACCGCCAGAGAGAAUCCUGCCUACGGC
  	CGGCACAUGCAGGACGCCGAGAUGUUCACCAACGCCGCCUGC
  	AUGGCCCUGAACAUCUGGGACAGAUUCGACGUGUUCUGCAC
  	CCUGGGCGCCACCAGCGGCUACCUGAAAGGCAAUAGCGCCAG
  	CUUCAACCUCGUGGGCCUGUUCGGCGACAACGAGAACCAGA
  	AAACCGUGAAGGCCGAGAGCGUGCCCAACAUGAGCUUCGAC
  	CAGAGCGUGGUGGAACUGUACACCGAUACCACCUUCGCUUG
  	GAGCGUGGGAGCCAGAGCCGCUCUGUGGGAAUGUGGCUGUG
  	CCACACUGGGGGCCAGCUUCCAGUACGCCCAGAGCAAGCCCA
  	AGGUGGAAGAACUGAACGUGCUGUGCAAUGCCGCCGAGUUC
  	ACCAUCAACAAGCCUAAGGGCUACGUGGGCAAAGAGUUCCC
  	CCUGGAUCUGACCGCCGGAACCGAUGCCGCCACCGGAACAAA
  	GGACGCCAGCAUCGACUACCACGAGUGGCAGGCUUCUCUGG
  	CCCUGAGCUACCGGCUGAAUAUGUUCACCCCCUACAUCGGCG
  	UGAAGUGGUCCAGAGCCAGCUUCGACGCCGACACCAUCAGA
  	AUCGCCCAGCCCAAGAGCGCCACCGCCAUCUUUGAUACCACC
  	ACCCUGAACCCCACCAUUGCCGGCGCUGGCGACGUGAAAACA
  	GGCGCCGAAGGACAGCUGGGCGACACAAUGCAGAUCGUGUC
  	CCUGCAGCUGAACAAGAUGAAGUCCCGGAAGUCCUGCGGAA
  	UCGCCGUGGGCACCACAAUCGUGGACGCCGAUAAGUACGCC
  	GUGACCGUGGAAACCCGGCUGAUCGAUGAGAGGGCCGCUCA
  	CGUGAACGCCCAGUUCAGAUUC
  Chlamydia_CT871_pd_serovarD_nIgK	AUGGAAACCCCCGCCCAACUCCUGUUCCUUCUUCUGCUCUGG	410
  	CUCCCUGACACUACUGGUGCUGAGAUUAUGAUACCUCAGGG
  	AAUCUACGACGGAGAGACUCUGACUGUCUCGUUCCCGUAUA
  	CCGUGAUCGGCGACCCCUCUGGCACCACCGUCUUUUCCGCCG
  	GGGAGCUGACCCUGAAAAACCUGGACAACAGCAUCGCGGCC
  	CUGCCCCUGAGCUGUUUCGGAAACUUGUUGGGUUCCUUCAC
  	UGUGCUCGGACGGGGUCACUCCCUGACCUUUGAGAAUAUCC
  	GGACUUCGACUAACGGCGCCGCCCUGUCGGAUUCAGCCAACU
  	CCGGACUCUUCACCAUCGAAGGCUUCAAGGAACUCAGCUUU
  	AGCAAUUGCAACUCGCUGCUGGCGGUGCUGCCAGCGGCUAC
  	CACUAACAACGGAUCCCAAACUCCCACCACCACUUCGACUCC
  	GUCCAAUGGGACCAUCUACUCCAAGACCGAUCUCCUUCUCCU
  	GAACAACGAGAAGUUCUCCUUCUACUCCAACCUGGUGUCCG
  	GGGAUGGGGGUGCCAUUGACGCCAAGUCACUGACAGUGCAG
  	GGCAUCUCCAAGCUCUGUGUGUUCCAAGAAAACACCGCCCA
  	GGCCGAUGGGGGAGCGUGCCAGGUCGUCACCUCCUUCUCUG
  	CAAUGGCCAACGAGGCCCCCAUCGCCUUCAUUGCAAACGUGG
  	CGGGCGUGCGCGGCGGCGGCAUUGCCGCGGUGCAAGACGGC
  	CAGCAGGGAGUGUCGUCCUCAACCUCGACCGAAGAUCCGGU
  	CGUGUCCUUCUCCCGGAAUACUGCCGUGGAAUUCGACGGAA
  	ACGUGGCUCGCGUGGGAGGCGGAAUCUACAGCUAUGGAAAC
  	GUCGCCUUUCUGAACAACGGCAAAACGCUUUUCCUGAACAA
  	UGUCGCUAGCCCUGUGUACAUCGCUGCCGAACAGCCGACCAA
  	CGGACAGGCAUCCAACACCAGCGACAACUAUGGCGAUGGCG
  	GCGCGAUCUUCUGCAAGAACGGGGCCCAGGCGGCCGGGAGC
  	AACAACUCAGGAUCCGUGUCCUUCGACGGAGAAGGCGUCGU
  	GUUCUUCUCCUCAAACGUGGCUGCCGGAAAGGGUGGAGCCA
  	UCUACGCGAAGAAGCUCUCCGUGGCCAAUUGCGGACCGGUC
  	CAGUUCCUGGGAAACAUUGCCAACGACGGAGGUGCAAUCUA
  	CCUGGGAGAAAGCGGAGAACUGUCGCUCUCCGCCGACUACG
  	GCGAUAUCAUCUUCGACGGCAACCUCAAGCGGACCGCAAAG
  	GAGAACGCGGCAGACGUCAAUGGAGUGACCGUGUCGAGCCA
  	AGCCAUUUCAAUGGGUUCCGGCGGGAAGAUCACCACCUUGA
  	GGGCCAAGGCCGGCCACCAGAUUCUGUUCAACGAUCCUAUU
  	GAGAUGGCCAACGGGAACAACCAGCCUGCGCAGUCCUCGGA
  	ACCCCUGAAGAUCAAUGACGGAGAGGGCUACACUGGAGACA
  	UCGUGUUCGCCAACGGAAACUCCACCUUGUACCAGAACGUG
  	ACGAUUGAGCAGGGGAGAAUUGUGCUGAGAGAAAAAGCGAA
  	GCUGUCCGUGAAUAGCUUGAGCCAGACCGGGGGCUCACUGU
  	ACAUGGAGGCCGGAUCCACCCUGGACUUCGUGACACCGCAGC
  	CACCGCAGCAGCCUCCCGCCGCGAACCAACUGAUUACCCUCU
  	CGAACCUUCACCUGAGCCUGUCCUCACUGCUGGCAAACAACG
  	CUGUGACUAACCCUCCAACCAACCCGCCGGCCCAGGACAGCC
  	AUCCGGCCAUUAUCGGCUCCACCACCGCCGGUUCUGUGACCA
  	UCAGCGGCCCAAUCUUUUUCGAGGAUCUGGACGACACCGCU
  	UACGACCGCUACGAUUGGCUGGGAUCCAACCAGAAGAUCGA
  	CGUGCUUAAGCUGCAACUGGGAACGCAACCCUCCGCCAACGC
  	CCCGUCGGACCUGACCCUGGGGAACGAAAUGCCUAAGUACG
  	GAUACCAGGGGAGCUGGAAGCUCGCCUGGGAUCCCAACACC
  	GCCAACAACGGUCCGUACACUCUGAAGGCCACCUGGACUAA
  	GACUGGU
  Chlamydia_CT871_pd_serovarD_nIgK_cHis	AUGGAAACCCCCGCCCAACUCCUGUUCCUUCUUCUGCUCUGG	411
  	CUCCCUGACACUACUGGUGCUGAGAUUAUGAUACCUCAGGG
  	AAUCUACGACGGAGAGACUCUGACUGUCUCGUUCCCGUAUA
  	CCGUGAUCGGCGACCCCUCUGGCACCACCGUCUUUUCCGCCG
  	GGGAGCUGACCCUGAAAAACCUGGACAACAGCAUCGCGGCC
  	CUGCCCCUGAGCUGUUUCGGAAACUUGUUGGGUUCCUUCAC
  	UGUGCUCGGACGGGGUCACUCCCUGACCUUUGAGAAUAUCC
  	GGACUUCGACUAACGGCGCCGCCCUGUCGGAUUCAGCCAACU
  	CCGGACUCUUCACCAUCGAAGGCUUCAAGGAACUCAGCUUU
  	AGCAAUUGCAACUCGCUGCUGGCGGUGCUGCCAGCGGCUAC
  	CACUAACAACGGAUCCCAAACUCCCACCACCACUUCGACUCC
  	GUCCAAUGGGACCAUCUACUCCAAGACCGAUCUCCUUCUCCU
  	GAACAACGAGAAGUUCUCCUUCUACUCCAACCUGGUGUCCG
  	GGGAUGGGGGUGCCAUUGACGCCAAGUCACUGACAGUGCAG
  	GGCAUCUCCAAGCUCUGUGUGUUCCAAGAAAACACCGCCCA
  	GGCCGAUGGGGGAGCGUGCCAGGUCGUCACCUCCUUCUCUG
  	CAAUGGCCAACGAGGCCCCCAUCGCCUUCAUUGCAAACGUGG
  	CGGGCGUGCGCGGCGGCGGCAUUGCCGCGGUGCAAGACGGC
  	CAGCAGGGAGUGUCGUCCUCAACCUCGACCGAAGAUCCGGU
  	CGUGUCCUUCUCCCGGAAUACUGCCGUGGAAUUCGACGGAA
  	ACGUGGCUCGCGUGGGAGGCGGAAUCUACAGCUAUGGAAAC
  	GUCGCCUUUCUGAACAACGGCAAAACGCUUUUCCUGAACAA
  	UGUCGCUAGCCCUGUGUACAUCGCUGCCGAACAGCCGACCAA
  	CGGACAGGCAUCCAACACCAGCGACAACUAUGGCGAUGGCG
  	GCGCGAUCUUCUGCAAGAACGGGGCCCAGGCGGCCGGGAGC
  	AACAACUCAGGAUCCGUGUCCUUCGACGGAGAAGGCGUCGU
  	GUUCUUCUCCUCAAACGUGGCUGCCGGAAAGGGUGGAGCCA
  	UCUACGCGAAGAAGCUCUCCGUGGCCAAUUGCGGACCGGUC
  	CAGUUCCUGGGAAACAUUGCCAACGACGGAGGUGCAAUCUA
  	CCUGGGAGAAAGCGGAGAACUGUCGCUCUCCGCCGACUACG
  	GCGAUAUCAUCUUCGACGGCAACCUCAAGCGGACCGCAAAG
  	GAGAACGCGGCAGACGUCAAUGGAGUGACCGUGUCGAGCCA
  	AGCCAUUUCAAUGGGUUCCGGCGGGAAGAUCACCACCUUGA
  	GGGCCAAGGCCGGCCACCAGAUUCUGUUCAACGAUCCUAUU
  	GAGAUGGCCAACGGGAACAACCAGCCUGCGCAGUCCUCGGA
  	ACCCCUGAAGAUCAAUGACGGAGAGGGCUACACUGGAGACA
  	UCGUGUUCGCCAACGGAAACUCCACCUUGUACCAGAACGUG
  	ACGAUUGAGCAGGGGAGAAUUGUGCUGAGAGAAAAAGCGAA
  	GCUGUCCGUGAAUAGCUUGAGCCAGACCGGGGGCUCACUGU
  	ACAUGGAGGCCGGAUCCACCCUGGACUUCGUGACACCGCAGC
  	CACCGCAGCAGCCUCCCGCCGCGAACCAACUGAUUACCCUCU
  	CGAACCUUCACCUGAGCCUGUCCUCACUGCUGGCAAACAACG
  	CUGUGACUAACCCUCCAACCAACCCGCCGGCCCAGGACAGCC
  	AUCCGGCCAUUAUCGGCUCCACCACCGCCGGUUCUGUGACCA
  	UCAGCGGCCCAAUCUUUUUCGAGGAUCUGGACGACACCGCU
  	UACGACCGCUACGAUUGGCUGGGAUCCAACCAGAAGAUCGA
  	CGUGCUUAAGCUGCAACUGGGAACGCAACCCUCCGCCAACGC
  	CCCGUCGGACCUGACCCUGGGGAACGAAAUGCCUAAGUACG
  	GAUACCAGGGGAGCUGGAAGCUCGCCUGGGAUCCCAACACC
  	GCCAACAACGGUCCGUACACUCUGAAGGCCACCUGGACUAA
  	GACUGGUCACCAUCAUCACCACCAC
  Chlamydia_CT871_pd_serovarL2_nIgK	AUGGAAACCCCUGCCCAACUUCUGUUCCUCCUUCUGCUCUGG	412
  	CUCCCCGACACUACCGGUGCUGAGAUCAUGAUUCCGCAAGGC
  	AUCUACGACGGGGAAACUCUGACCGUGUCCUUUCCAUACAC
  	CGUCAUUGGUGAUCCUUCCGGAACUACCGUGUUCUCCGCGG
  	GCGAACUGACCUUGAAGAAUCUUGACAAUUCCAUCGCGGCC
  	CUGCCCCUGAGCUGCUUCGGCAACUUGCUGGGAUCGUUCAC
  	UGUGCUGGGGCGCGGACAUUCGCUGACUUUCGAAAACAUUA
  	GAACCAGCACCAACGGUGCUGCGCUUUCGAAUAGCGCCGCU
  	GAUGGCUUGUUCACCAUCGAGGGUUUCAAGGAACUGAGCUU
  	CUCCAACUGCAACUCGCUGCUCGCCGUGCUGCCGGCCGCUAC
  	UACGAACAAGGGCAGCCAGACUCCGACGACAACCUCCACUCC
  	CUCAAACGGCACCAUCUACUCCAAGACCGAUCUGCUGCUGCU
  	CAACAACGAGAAGUUCUCAUUCUACUCCAACCUCGUGUCCG
  	GCGACGGAGGCGCAAUUGACGCCAAGAGCCUGACCGUGCAG
  	GGAAUCUCAAAGCUGUGCGUCUUUCAAGAGAACACUGCGCA
  	GGCAGACGGAGGAGCCUGUCAGGUCGUGACCUCCUUUUCCG
  	CCAUGGCCAACGAGGCCCCUAUCGCCUUCGUGGCCAACGUGG
  	CCGGCGUGCGGGGUGGAGGAAUCGCAGCCGUGCAAGACGGC
  	CAGCAGGGAGUGUCUAGCAGCACUUCCACCGAGGACCCCGU
  	GGUGUCGUUCUCCCGGAACACCGCCGUGGAGUUCGAUGGAA
  	ACGUGGCGCGCGUGGGGGGAGGCAUCUACUCCUACGGGAAC
  	GUCGCCUUUCUUAACAACGGAAAGACCCUGUUCCUGAACAA
  	UGUGGCCUCGCCGGUGUACAUCGCCGCCAAGCAGCCAACUAG
  	CGGCCAGGCCUCCAACACCUCCAACAACUAUGGCGACGGCGG
  	AGCCAUCUUCUGCAAGAACGGCGCUCAAGCUGGAUCGAACA
  	ACAGCGGUUCUGUCUCCUUCGACGGCGAAGGAGUCGUGUUU
  	UUCUCCUCCAACGUCGCGGCCGGCAAAGGGGGGGCCAUAUA
  	CGCGAAGAAACUGUCAGUGGCGAACUGCGGACCCGUGCAGU
  	UCCUCCGGAACAUUGCCAACGACGGGGGUGCAAUCUACCUG
  	GGAGAGUCAGGAGAACUGAGCCUCUCGGCGGAUUACGGCGA
  	CAUCAUUUUCGACGGAAAUCUGAAGCGGACCGCCAAGGAAA
  	ACGCGGCAGAUGUGAACGGGGUCACCGUGUCAAGCCAGGCC
  	AUUUCUAUGGGGUCCGGAGGGAAGAUUACCACCCUGCGCGC
  	CAAGGCCGGCCAUCAGAUUCUCUUCAACGACCCUAUCGAGA
  	UGGCUAAUGGAAACAAUCAGCCCGCCCAGUCCUCCAAGCUGC
  	UGAAAAUCAACGACGGAGAGGGGUACACCGGGGAUAUCGUG
  	UUCGCCAACGGAAGCUCGACUCUCUACCAAAACGUGACCAU
  	UGAGCAGGGGAGGAUCGUGCUGAGGGAAAAGGCUAAGCUGU
  	CCGUCAACUCGCUGAGCCAGACCGGAGGCUCCCUCUACAUGG
  	AAGCAGGAUCGACGCUGGACUUCGUGACUCCGCAACCACCGC
  	AGCAGCCUCCCGCCGCCAACCAGCUGAUCACCUUGUCCAAUC
  	UGCACCUGAGCCUGUCGUCCUUGCUCGCCAACAACGCCGUGA
  	CUAACCCUCCUACUAACCCGCCGGCCCAGGACUCGCACCCGG
  	CCGUCAUCGGAUCAACCACAGCAGGAAGCGUGACUAUCUCC
  	GGUCCUAUCUUCUUCGAGGACCUGGAUGACACCGCCUACGA
  	UAGAUACGAUUGGUUGGGUUCCAACCAGAAGAUUAACGUGC
  	UGAAGCUGCAGCUGGGAACCAAGCCACCGGCGAACGCCCCGU
  	CCGACCUGACCCUCGGCAACGAAAUGCCCAAAUACGGAUACC
  	AGGGCUCCUGGAAGCUCGCGUGGGACCCCAAUACCGCGAAC
  	AACGGUCCCUAUACACUCAAGGCCACUUGGACCAAGACCGGC
  Chlamydia_CT871_pd_serovarL2_nIgK_cHis	AUGGAAACCCCUGCCCAACUUCUGUUCCUCCUUCUGCUCUGG	413
  	CUCCCCGACACUACCGGUGCUGAGAUCAUGAUUCCGCAAGGC
  	AUCUACGACGGGGAAACUCUGACCGUGUCCUUUCCAUACAC
  	CGUCAUUGGUGAUCCUUCCGGAACUACCGUGUUCUCCGCGG
  	GCGAACUGACCUUGAAGAAUCUUGACAAUUCCAUCGCGGCC
  	CUGCCCCUGAGCUGCUUCGGCAACUUGCUGGGAUCGUUCAC
  	UGUGCUGGGGCGCGGACAUUCGCUGACUUUCGAAAACAUUA
  	GAACCAGCACCAACGGUGCUGCGCUUUCGAAUAGCGCCGCU
  	GAUGGCUUGUUCACCAUCGAGGGUUUCAAGGAACUGAGCUU
  	CUCCAACUGCAACUCGCUGCUCGCCGUGCUGCCGGCCGCUAC
  	UACGAACAAGGGCAGCCAGACUCCGACGACAACCUCCACUCC
  	CUCAAACGGCACCAUCUACUCCAAGACCGAUCUGCUGCUGCU
  	CAACAACGAGAAGUUCUCAUUCUACUCCAACCUCGUGUCCG
  	GCGACGGAGGCGCAAUUGACGCCAAGAGCCUGACCGUGCAG
  	GGAAUCUCAAAGCUGUGCGUCUUUCAAGAGAACACUGCGCA
  	GGCAGACGGAGGAGCCUGUCAGGUCGUGACCUCCUUUUCCG
  	CCAUGGCCAACGAGGCCCCUAUCGCCUUCGUGGCCAACGUGG
  	CCGGCGUGCGGGGUGGAGGAAUCGCAGCCGUGCAAGACGGC
  	CAGCAGGGAGUGUCUAGCAGCACUUCCACCGAGGACCCCGU
  	GGUGUCGUUCUCCCGGAACACCGCCGUGGAGUUCGAUGGAA
  	ACGUGGCGCGCGUGGGGGGAGGCAUCUACUCCUACGGGAAC
  	GUCGCCUUUCUUAACAACGGAAAGACCCUGUUCCUGAACAA
  	UGUGGCCUCGCCGGUGUACAUCGCCGCCAAGCAGCCAACUAG
  	CGGCCAGGCCUCCAACACCUCCAACAACUAUGGCGACGGCGG
  	AGCCAUCUUCUGCAAGAACGGCGCUCAAGCUGGAUCGAACA
  	ACAGCGGUUCUGUCUCCUUCGACGGCGAAGGAGUCGUGUUU
  	UUCUCCUCCAACGUCGCGGCCGGCAAAGGGGGGGCCAUAUA
  	CGCGAAGAAACUGUCAGUGGCGAACUGCGGACCCGUGCAGU
  	UCCUCCGGAACAUUGCCAACGACGGGGGUGCAAUCUACCUG
  	GGAGAGUCAGGAGAACUGAGCCUCUCGGCGGAUUACGGCGA
  	CAUCAUUUUCGACGGAAAUCUGAAGCGGACCGCCAAGGAAA
  	ACGCGGCAGAUGUGAACGGGGUCACCGUGUCAAGCCAGGCC
  	AUUUCUAUGGGGUCCGGAGGGAAGAUUACCACCCUGCGCGC
  	CAAGGCCGGCCAUCAGAUUCUCUUCAACGACCCUAUCGAGA
  	UGGCUAAUGGAAACAAUCAGCCCGCCCAGUCCUCCAAGCUGC
  	UGAAAAUCAACGACGGAGAGGGGUACACCGGGGAUAUCGUG
  	UUCGCCAACGGAAGCUCGACUCUCUACCAAAACGUGACCAU
  	UGAGCAGGGGAGGAUCGUGCUGAGGGAAAAGGCUAAGCUGU
  	CCGUCAACUCGCUGAGCCAGACCGGAGGCUCCCUCUACAUGG
  	AAGCAGGAUCGACGCUGGACUUCGUGACUCCGCAACCACCGC
  	AGCAGCCUCCCGCCGCCAACCAGCUGAUCACCUUGUCCAAUC
  	UGCACCUGAGCCUGUCGUCCUUGCUCGCCAACAACGCCGUGA
  	CUAACCCUCCUACUAACCCGCCGGCCCAGGACUCGCACCCGG
  	CCGUCAUCGGAUCAACCACAGCAGGAAGCGUGACUAUCUCC
  	GGUCCUAUCUUCUUCGAGGACCUGGAUGACACCGCCUACGA
  	UAGAUACGAUUGGUUGGGUUCCAACCAGAAGAUUAACGUGC
  	UGAAGCUGCAGCUGGGAACCAAGCCACCGGCGAACGCCCCGU
  	CCGACCUGACCCUCGGCAACGAAAUGCCCAAAUACGGAUACC
  	AGGGCUCCUGGAAGCUCGCGUGGGACCCCAAUACCGCGAAC
  	AACGGUCCCUAUACACUCAAGGCCACUUGGACCAAGACCGGC
  	CACCACCAUCACCACCAC
  Chlamydia_CT812_pd_serovarD_nIgK	AUGGAAACUCCUGCCCAACUGUUGUUCCUUCUGCUGCUCUG	414
  	GUUGCCCGACACCACCGGAUCGUGCGUGGAUCUCCACGCUGG
  	CGGCCAGUCCGUGAACGAGCUUGUGUACGUGGGCCCACAGG
  	CCGUGCUUCUGCUGGACCAGAUCAGAGAUCUCUUCGUGGGU
  	UCCAAGGACUCCCAGGCCGAGGGACAGUACCGGCUCAUCGUC
  	GGCGACCCUUCAAGCUUCCAAGAGAAGGAUGCCGACACUCU
  	UCCGGGGAAGGUGGAACAGUCCACUCUGUUUUCCGUGACCA
  	ACCCAGUCGUGUUUCAAGGGGUGGACCAGCAGGACCAGGUG
  	UCCAGCCAAGGACUGAUCUGUUCAUUCACCUCGAGCAAUUU
  	GGACAGCCCCCGGGACGGCGAAUCGUUCCUUGGCAUCGCAU
  	UCGUGGGAGACUCAUCCAAAGCAGGAAUCACCCUUACCGAU
  	GUGAAGGCGUCCCUGAGCGGCGCUGCUCUGUACUCCACCGA
  	AGAUCUCAUCUUCGAGAAGAUCAAGGGUGGACUGGAGUUCG
  	CCAGCUGCUCCUCACUGGAACAGGGAGGAGCCUGUGCCGCCC
  	AAAGCAUCCUCAUCCACGAUUGCCAGGGGCUCCAAGUGAAG
  	CAUUGUACCACUGCCGUGAACGCCGAGGGAUCAUCCGCUAA
  	CGAUCACCUCGGUUUCGGAGGGGGUGCCUUCUUCGUGACCG
  	GUUCGCUGUCGGGAGAAAAGUCACUGUAUAUGCCCGCGGGC
  	GACAUGGUGGUCGCCAACUGCGAUGGAGCCAUCUCAUUCGA
  	GGGAAACUCCGCCAACUUCGCAAACGGCGGCGCUAUCGCCGC
  	UAGCGGGAAGGUGCUGUUCGUGGCUAACGACAAGAAAACGU
  	CCUUCAUCGAAAACCGCGCCCUGUCGGGAGGUGCCAUUGCCG
  	CCAGCUCCGACAUUGCCUUCCAAAACUGUGCGGAACUGGUG
  	UUCAAAGGAAACUGCGCCAUCGGCACCGAAGAUAAGGGAAG
  	CCUGGGGGGGGGCGCCAUUUCCUCCCUCGGCACCGUGCUGCU
  	UCAGGGAAACCACGGCAUCACUUGUGACAAGAACGAAAGCG
  	CGUCCCAGGGGGGAGCGAUCUUCGGGAAAAACUGCCAGAUU
  	UCCGACAACGAGGGACCGGUGGUGUUCAGAGACUCCACUGC
  	CUGCCUGGGCGGCGGAGCGAUCGCAGCACAGGAAAUUGUCA
  	GCAUCCAGAACAACCAGGCCGGCAUCAGCUUCGAGGGGGGA
  	AAGGCUUCGUUCGGCGGAGGUAUUGCCUGCGGAUCGUUCUC
  	GUCCGCGGGCGGAGCCUCCGUGCUCGGAACCAUCGACAUUUC
  	CAAGAACCUGGGCGCUAUCUCGUUUUCUCGCACCCUGUGCAC
  	UACUUCCGACCUGGGUCAGAUGGAGUACCAGGGAGGCGGAG
  	CGCUGUUUGGAGAGAACAUCUCUCUGAGCGAGAACGCGGGA
  	GUGCUGACCUUCAAGGACAACAUUGUGAAAACCUUCGCCUC
  	AAACGGAAAGAUCCUGGGGGGAGGCGCCAUCCUGGCAACCG
  	GGAAGGUCGAAAUCACCAACAAUUCAGAGGGUAUCUCCUUC
  	ACUGGCAACGCCCGGGCCCCCCAAGCCCUGCCGACUCAGGAA
  	GAGUUCCCCCUGUUCUCCAAGAAGGAAGGACGCCCUUUGUC
  	AUCCGGCUACUCCGGUGGUGGAGCGAUUCUGGGUCGGGAAG
  	UGGCCAUCCUGCAUAAUGCGGCCGUGGUGUUUGAGCAAAAC
  	AGACUCCAAUGCUCCGAAGAAGAGGCCACCCUCCUGGGGUG
  	CUGCGGGGGCGGAGCAGUGCAUGGCAUGGAUUCCACUUCCA
  	UCGUGGGAAACUCCAGCGUCCGCUUCGGAAACAACUACGCU
  	AUGGGACAGGGAGUGUCAGGGGGGGCCCUGCUGUCCAAGAC
  	CGUCCAGUUGGCCGGAAACGGUUCGGUGGAUUUCUCACGCA
  	AUAUCGCCUCGCUGGGAGGCGGCGCGCUGCAGGCCUCCGAA
  	GGAAAUUGCGAACUGGUCGACAACGGCUACGUGCUGUUCCG
  	GGACAACCGCGGCAGGGUGUACGGCGGAGCAAUCUCGUGCC
  	UUCGGGGCGACGUCGUGAUCUCGGGAAAUAAGGGACGGGUC
  	GAGUUUAAGGACAACAUCGCUACCAGGCUCUACGUGGAGGA
  	AACUGUGGAGAAGGUGGAGGAAGUGGAGCCUGCCCCGGAAC
  	AGAAGGACAACAACGAGCUGUCGUUCCUCGGUCGGGCAGAA
  	CAGUCCUUCAUUACUGCCGCCAACCAGGCCCUGUUCGCGUCC
  	GAAGAUGGUGACCUCAGCCCGGAAUCCAGCAUCUCCUCCGA
  	GGAACUGGCCAAGCGGAGAGAAUGCGCGGGAGGCGCAAUCU
  	UUGCGAAGCGGGUCCGGAUCGUGGACAACCAGGAAGCUGUG
  	GUGUUCAGCAACAACUUUUCCGACAUCUACGGUGGUGCAAU
  	UUUCACCGGCUCACUCCGGGAGGAGGACAAGCUGGACGGCC
  	AGAUUCCCGAGGUGCUCAUUUCCGGCAAUGCCGGCGACGUG
  	GUGUUCUCCGGAAACUCCUCCAAGAGGGACGAACACCUCCCG
  	CAUACCGGAGGAGGAGCCAUCUGCACUCAGAACCUGACGAU
  	CUCGCAGAACACCGGCAAUGUGCUGUUCUACAACAACGUCG
  	CAUGUUCCGGUGGCGCCGUCAGAAUCGAGGACCACGGAAAC
  	GUGCUGCUGGAAGCAUUCGGGGGUGAUAUUGUGUUCAAGGG
  	AAACAGCAGCUUCCGGGCCCAGGGAUCAGAUGCAAUCUACU
  	UCGCCGGGAAGGAGAGCCACAUUACCGCCCUGAACGCCACCG
  	AGGGUCACGCCAUCGUGUUCCACGAUGCCCUGGUGUUCGAA
  	AACCUGGAGGAGCGCAAGAGCGCCGAAGUGCUGCUUAUCAA
  	UUCCCGCGAAAACCCGGGCUACACCGGAUCCAUCCGGUUCCU
  	CGAAGCGGAGUCGAAGGUCCCGCAGUGUAUUCAUGUGCAAC
  	AGGGGUCCCUGGAACUGCUUAACGGAGCCACCCUGUGCUCC
  	UACGGCUUUAAGCAGGACGCGGGCGCUAAACUGGUGCUGGC
  	GGCCGGCGCCAAGCUUAAGAUCCUCGACUCCGGAACCCCGGU
  	GCAGCAGGGGCACGCUAUUAGCAAGCCUGAAGCCGAGAUUG
  	AGUCGUCAUCCGAACCCGAAGGGGCGCACUCCCUGUGGAUA
  	GCCAAGAACGCGCAGACCACCGUGCCAAUGGUCGAUAUCCAC
  	ACAAUCUCCGUGGACCUCGCCAGCUUCUCGUCGAGCCAGCAG
  	GAGGGAACUGUCGAAGCGCCUCAGGUCAUCGUGCCGGGAGG
  	UUCCUACGUGCGCUCGGGGGAGCUCAACCUGGAACUCGUGA
  	AUACCACUGGAACGGGAUAUGAGAACCACGCCCUGCUGAAG
  	AACGAAGCCAAAGUGCCACUGAUGUCCUUCGUCGCCUCCGGC
  	GACGAGGCCUCCGCCGAGAUUAGCAACCUGUCGGUGUCAGA
  	UCUGCAAAUUCACGUGGUGACCCCUGAGAUUGAGGAGGACA
  	CCUACGGGCACAUGGGCGAUUGGUCCGAGGCGAAGAUCCAG
  	GACGGCACACUGGUCAUUUCAUGGAACCCUACCGGA
  Chlamydia_CT812_pd_serovarD_nIgK_cHis	AUGGAAACUCCUGCCCAACUGUUGUUCCUUCUGCUGCUCUG	415
  	GUUGCCCGACACCACCGGAUCGUGCGUGGAUCUCCACGCUGG
  	CGGCCAGUCCGUGAACGAGCUUGUGUACGUGGGCCCACAGG
  	CCGUGCUUCUGCUGGACCAGAUCAGAGAUCUCUUCGUGGGU
  	UCCAAGGACUCCCAGGCCGAGGGACAGUACCGGCUCAUCGUC
  	GGCGACCCUUCAAGCUUCCAAGAGAAGGAUGCCGACACUCU
  	UCCGGGGAAGGUGGAACAGUCCACUCUGUUUUCCGUGACCA
  	ACCCAGUCGUGUUUCAAGGGGUGGACCAGCAGGACCAGGUG
  	UCCAGCCAAGGACUGAUCUGUUCAUUCACCUCGAGCAAUUU
  	GGACAGCCCCCGGGACGGCGAAUCGUUCCUUGGCAUCGCAU
  	UCGUGGGAGACUCAUCCAAAGCAGGAAUCACCCUUACCGAU
  	GUGAAGGCGUCCCUGAGCGGCGCUGCUCUGUACUCCACCGA
  	AGAUCUCAUCUUCGAGAAGAUCAAGGGUGGACUGGAGUUCG
  	CCAGCUGCUCCUCACUGGAACAGGGAGGAGCCUGUGCCGCCC
  	AAAGCAUCCUCAUCCACGAUUGCCAGGGGCUCCAAGUGAAG
  	CAUUGUACCACUGCCGUGAACGCCGAGGGAUCAUCCGCUAA
  	CGAUCACCUCGGUUUCGGAGGGGGUGCCUUCUUCGUGACCG
  	GUUCGCUGUCGGGAGAAAAGUCACUGUAUAUGCCCGCGGGC
  	GACAUGGUGGUCGCCAACUGCGAUGGAGCCAUCUCAUUCGA
  	GGGAAACUCCGCCAACUUCGCAAACGGCGGCGCUAUCGCCGC
  	UAGCGGGAAGGUGCUGUUCGUGGCUAACGACAAGAAAACGU
  	CCUUCAUCGAAAACCGCGCCCUGUCGGGAGGUGCCAUUGCCG
  	CCAGCUCCGACAUUGCCUUCCAAAACUGUGCGGAACUGGUG
  	UUCAAAGGAAACUGCGCCAUCGGCACCGAAGAUAAGGGAAG
  	CCUGGGGGGGGGCGCCAUUUCCUCCCUCGGCACCGUGCUGCU
  	UCAGGGAAACCACGGCAUCACUUGUGACAAGAACGAAAGCG
  	CGUCCCAGGGGGGAGCGAUCUUCGGGAAAAACUGCCAGAUU
  	UCCGACAACGAGGGACCGGUGGUGUUCAGAGACUCCACUGC
  	CUGCCUGGGCGGCGGAGCGAUCGCAGCACAGGAAAUUGUCA
  	GCAUCCAGAACAACCAGGCCGGCAUCAGCUUCGAGGGGGGA
  	AAGGCUUCGUUCGGCGGAGGUAUUGCCUGCGGAUCGUUCUC
  	GUCCGCGGGCGGAGCCUCCGUGCUCGGAACCAUCGACAUUUC
  	CAAGAACCUGGGCGCUAUCUCGUUUUCUCGCACCCUGUGCAC
  	UACUUCCGACCUGGGUCAGAUGGAGUACCAGGGAGGCGGAG
  	CGCUGUUUGGAGAGAACAUCUCUCUGAGCGAGAACGCGGGA
  	GUGCUGACCUUCAAGGACAACAUUGUGAAAACCUUCGCCUC
  	AAACGGAAAGAUCCUGGGGGGAGGCGCCAUCCUGGCAACCG
  	GGAAGGUCGAAAUCACCAACAAUUCAGAGGGUAUCUCCUUC
  	ACUGGCAACGCCCGGGCCCCCCAAGCCCUGCCGACUCAGGAA
  	GAGUUCCCCCUGUUCUCCAAGAAGGAAGGACGCCCUUUGUC
  	AUCCGGCUACUCCGGUGGUGGAGCGAUUCUGGGUCGGGAAG
  	UGGCCAUCCUGCAUAAUGCGGCCGUGGUGUUUGAGCAAAAC
  	AGACUCCAAUGCUCCGAAGAAGAGGCCACCCUCCUGGGGUG
  	CUGCGGGGGCGGAGCAGUGCAUGGCAUGGAUUCCACUUCCA
  	UCGUGGGAAACUCCAGCGUCCGCUUCGGAAACAACUACGCU
  	AUGGGACAGGGAGUGUCAGGGGGGGCCCUGCUGUCCAAGAC
  	CGUCCAGUUGGCCGGAAACGGUUCGGUGGAUUUCUCACGCA
  	AUAUCGCCUCGCUGGGAGGCGGCGCGCUGCAGGCCUCCGAA
  	GGAAAUUGCGAACUGGUCGACAACGGCUACGUGCUGUUCCG
  	GGACAACCGCGGCAGGGUGUACGGCGGAGCAAUCUCGUGCC
  	UUCGGGGCGACGUCGUGAUCUCGGGAAAUAAGGGACGGGUC
  	GAGUUUAAGGACAACAUCGCUACCAGGCUCUACGUGGAGGA
  	AACUGUGGAGAAGGUGGAGGAAGUGGAGCCUGCCCCGGAAC
  	AGAAGGACAACAACGAGCUGUCGUUCCUCGGUAGAGCCGAA
  	CAGUCCUUCAUUACUGCCGCCAACCAGGCCCUGUUCGCGUCC
  	GAAGAUGGUGACCUCAGCCCGGAAUCCAGCAUCUCCUCCGA
  	GGAACUGGCCAAGCGGAGAGAAUGCGCGGGAGGCGCAAUCU
  	UUGCGAAGCGGGUCCGGAUCGUGGACAACCAGGAAGCUGUG
  	GUGUUCAGCAACAACUUUUCCGACAUCUACGGUGGUGCAAU
  	UUUCACCGGCUCACUCCGGGAGGAGGACAAGCUGGACGGCC
  	AGAUUCCCGAGGUGCUCAUUUCCGGCAAUGCCGGCGACGUG
  	GUGUUCUCCGGAAACUCCUCCAAGAGGGACGAACACCUCCCG
  	CAUACCGGAGGAGGAGCCAUCUGCACUCAGAACCUGACGAU
  	CUCGCAGAACACCGGCAAUGUGCUGUUCUACAACAACGUCG
  	CAUGUUCCGGUGGCGCCGUCAGAAUCGAGGACCACGGAAAC
  	GUGCUGCUGGAAGCAUUCGGGGGUGAUAUUGUGUUCAAGGG
  	AAACAGCAGCUUCCGGGCCCAGGGAUCAGAUGCAAUCUACU
  	UCGCCGGGAAGGAGAGCCACAUUACCGCCCUGAACGCCACCG
  	AGGGUCACGCCAUCGUGUUCCACGAUGCCCUGGUGUUCGAA
  	AACCUGGAGGAGCGCAAGAGCGCCGAAGUGCUGCUUAUCAA
  	UUCCCGCGAAAACCCGGGCUACACCGGAUCCAUCCGGUUCCU
  	CGAAGCGGAGUCGAAGGUCCCGCAGUGUAUUCAUGUGCAAC
  	AGGGGUCCCUGGAACUGCUUAACGGAGCCACCCUGUGCUCC
  	UACGGCUUUAAGCAGGACGCGGGCGCUAAACUGGUGCUGGC
  	GGCCGGCGCCAAGCUUAAGAUCCUCGACUCCGGAACCCCGGU
  	GCAGCAGGGGCACGCUAUUAGCAAGCCUGAAGCCGAGAUUG
  	AGUCGUCAUCCGAACCCGAAGGGGCGCACUCCCUGUGGAUA
  	GCCAAGAACGCGCAGACCACCGUGCCAAUGGUCGAUAUCCAC
  	ACAAUCUCCGUGGACCUCGCCAGCUUCUCGUCGAGCCAGCAG
  	GAGGGAACUGUCGAAGCGCCUCAGGUCAUCGUGCCGGGAGG
  	UUCCUACGUGCGCUCGGGGGAGCUCAACCUGGAACUCGUGA
  	AUACCACUGGAACGGGAUAUGAGAACCACGCCCUGCUGAAG
  	AACGAAGCCAAAGUGCCACUGAUGUCCUUCGUCGCCUCCGG
  	GGACGAGGCCUCCGCCGAGAUUAGCAACCUGUCGGUGUCAG
  	AUCUGCAAAUUCACGUGGUCACCCCUGAGAUUGAGGAGGAC
  	ACCUACGGGCACAUGGGCGAUUGGUCCGAGGCGAAGAUCCA
  	GGACGGCACACUGGUCAUUUCAUGGAACCCUACCGGACAUC
  	ACCACCACCAUCAC
  Chlamydia_CT812_pd_serovarL2_nIgk	AUGGAAACUCCUGCCCAACUGUUGUUCCUUCUGCUGCUCUG	416
  	GUUGCCCGACACCACCGGAUCGUGCGUGGAUCUCCACGCUGG
  	CGGCCAGUCCGUGAACGAGCUUGUGUACGUGGGCCCACAGG
  	CCGUGCUUCUGCUGGACCAGAUCAGAGAUCUCUUCGUGGGU
  	UCCAAGGACUCCCAGGCCGAGGGACAGUACCGGCUCAUCGUC
  	GGCGACCCUUCAAGCUUCCAAGAGAAGGAUGCCGACACUCU
  	UCCGGGGAAGGUGGAACAGUCCACUCUGUUUUCCGUGACCA
  	ACCCAGUCGUGUUUCAAGGGGUGGACCAGCAGGACCAGGUG
  	UCCAGCCAAGGACUGAUCUGUUCAUUCACCUCGAGCAAUUU
  	GGACAGCCCCCGGGACGGCGAAUCGUUCCUUGGCAUCGCAU
  	UCGUGGGAGACUCAUCCAAAGCAGGAAUCACCCUUACCGAU
  	GUGAAGGCGUCCCUGAGCGGCGCUGCUCUGUACUCCACCGA
  	AGAUCUCAUCUUCGAGAAGAUCAAGGGUGGACUGGAGUUCG
  	CCAGCUGCUCCUCACUGGAACAGGGAGGAGCCUGUGCCGCCC
  	AAAGCAUCCUCAUCCACGAUUGCCAGGGGCUCCAAGUGAAG
  	CAUUGUACCACUGCCGUGAACGCCGAGGGAUCAUCCGCUAA
  	CGAUCACCUCGGUUUCGGAGGGGGUGCCUUCUUCGUGACCG
  	GUUCGCUGUCGGGAGAAAAGUCACUGUAUAUGCCCGCGGGC
  	GACAUGGUGGUCGCCAACUGCGAUGGAGCCAUCUCAUUCGA
  	GGGAAACUCCGCCAACUUCGCAAACGGCGGCGCUAUCGCCGC
  	UAGCGGGAAGGUGCUGUUCGUGGCUAACGACAAGAAAACGU
  	CCUUCAUCGAAAACCGCGCCCUGUCGGGAGGUGCCAUUGCCG
  	CCAGCUCCGACAUUGCCUUCCAAAACUGUGCGGAACUGGUG
  	UUCAAAGGAAACUGCGCCAUCGGCACCGAAGAUAAGGGAAG
  	CCUGGGGGGGGGCGCCAUUUCCUCCCUCGGCACCGUGCUGCU
  	UCAGGGAAACCACGGCAUCACUUGUGACAAGAACGAAAGCG
  	CGUCCCAGGGGGGAGCGAUCUUCGGGAAAAACUGCCAGAUU
  	UCCGACAACGAGGGACCGGUGGUGUUCAGAGACUCCACUGC
  	CUGCCUGGGCGGCGGAGCGAUCGCAGCACAGGAAAUUGUCA
  	GCAUCCAGAACAACCAGGCCGGCAUCAGCUUCGAGGGGGGA
  	AAGGCUUCGUUCGGCGGAGGUAUUGCCUGCGGAUCGUUCUC
  	GUCCGCGGGCGGAGCCUCCGUGCUCGGAACCAUCGACAUUUC
  	CAAGAACCUGGGCGCUAUCUCGUUUUCUCGCACCCUGUGCAC
  	UACUUCCGACCUGGGUCAGAUGGAGUACCAGGGAGGCGGAG
  	CGCUGUUUGGAGAGAACAUCUCUCUGAGCGAGAACGCGGGA
  	GUGCUGACCUUCAAGGACAACAUUGUGAAAACCUUCGCCUC
  	AAACGGAAAGAUCCUGGGGGGAGGCGCCAUCCUGGCAACCG
  	GGAAGGUCGAAAUCACCAACAAUUCAGGCGGUAUCUCCUUC
  	ACUGGCAACGCCCGGGCCCCCCAAGCCCUGCCGACUCAGGAA
  	GAGUUCCCCCUGUUCUCCAAGAAGGAAGGACGCCCUUUGUC
  	AUCCGGCUACUCCGGUGGUGGAGCGAUUCUGGGUCGGGAAG
  	UGGCCAUCCUGCAUAAUGCGGCCGUGGUGUUUGAGCAAAAC
  	AGACUCCAAUGCUCCGAAGAAGAGGCCACCCUCCUGGGGUG
  	CUGCGGGGGCGGAGCAGUGCAUGGCAUGGAUUCCACUUCCA
  	UCGUGGGAAACUCCAGCGUCCGCUUCGGAAACAACUACGCU
  	AUGGGACAGGGAGUGUCAGGGGGGGCCCUGCUGUCCAAGAC
  	CGUCCAGUUGGCCGGAAACGGUUCGGUGGAUUUCUCACGCA
  	AUAUCGCCUCGCUGGGAGGCGGCGCGCUGCAGGCCUCCGAA
  	GGAAAUUGCGAACUGGUCGACAACGGCUACGUGCUGUUCCG
  	GGACAACCGCGGCAGGGUGUACGGCGGAGCAAUCUCGUGCC
  	UUCGGGGCGACGUCGUGAUCUCGGGAAAUAAGGGACGGGUC
  	GAGUUUAAGGACAACAUCGCUACCAGGCUCUACGUGGAGGA
  	AACUGUGGAGAAGGUGGAGGAAGUGGAGCCUGCCCCGGAAC
  	AGAAGGACAACAACGAGCUGUCGUUCCUCGGUUCCGUCGAA
  	CAGUCCUUCAUUACUGCCGCCAACCAGGCCCUGUUCGCGUCC
  	GAAGAUGGUGACCUCAGCCCGGAAUCCAGCAUCUCCUCCGA
  	GGAACUGGCCAAGCGGAGAGAAUGCGCGGGAGGCGCAAUCU
  	UUGCGAAGCGGGUCCGGAUCGUGGACAACCAGGAAGCUGUG
  	GUGUUCAGCAACAACUUUUCCGACAUCUACGGUGGUGCAAU
  	UUUCACCGGCUCACUCCGGGAGGAGGACAAGCUGGACGGCC
  	AGAUUCCCGAGGUGCUCAUUUCCGGCAAUGCCGGCGACGUG
  	GUGUUCUCCGGAAACUCCUCCAAGAGGGACGAACACCUCCCG
  	CAUACCGGAGGAGGAGCCAUCUGCACUCAGAACCUGACGAU
  	CUCGCAGAACACCGGCAAUGUGCUGUUCUACAACAACGUCG
  	CAUGUUCCGGUGGCGCCGUCAGAAUCGAGGACCACGGAAAC
  	GUGCUGCUGGAAGCAUUCGGGGGUGAUAUUGUGUUCAAGGG
  	AAACAGCAGCUUCCGGGCCCAGGGAUCAGAUGCAAUCUACU
  	UCGCCGGGAAGGAGAGCCACAUUACCGCCCUGAACGCCACCG
  	AGGGUCACGCCAUCGUGUUCCACGAUGCCCUGGUGUUCGAA
  	AACCUGAAGGAGCGCAAGAGCGCCGAAGUGCUGCUUAUCAA
  	UUCCCGCGAAAACCCGGGCUACACCGGAUCCAUCCGGUUCCU
  	CGAAGCGGAGUCGAAGGUCCCGCAGUGUAUUCAUGUGCAAC
  	AGGGGUCCCUGGAACUGCUUAACGGAGCCACCCUGUGCUCC
  	UACGGCUUUAAGCAGGACGCGGGCGCUAAACUGGUGCUGGC
  	GGCCGGCUCCAAGCUUAAGAUCCUCGACUCCGGAACCCCGGU
  	GCAGGGGCACGCUAUUAGCAAGCCUGAAGCCGAGAUUGAGU
  	CGUCAUCCGAACCCGAAGGGGCGCACUCCCUGUGGAUAGCCA
  	AGAACGCGCAGACCACCGUGCCAAUGGUCGAUAUCCACACA
  	AUCUCCGUGGACCUCGCCAGCUUCUCGUCGAGCCAGCAGGAG
  	GGAACUGUCGAAGCGCCUCAGGUCAUCGUGCCGGGAGGUUC
  	CUACGUGCGCUCGGGGGAGCUCAACCUGGAACUCGUGAAUA
  	CCACUGGAACGGGAUAUGAGAACCACGCCCUGCUGAAGAAC
  	GAAGCCAAAGUGCCACUGAUGUCCUUCGUCGCCUCCUCCGAC
  	GAGGCCUCCGCCGAGAUUAGCAACCUGUCGGUGUCAGAUCU
  	GCAAAUUCACGUGGCCACCCCUGAGAUUGAGGAGGACACCU
  	ACGGGCACAUGGGCGAUUGGUCCGAGGCGAAGAUCCAGGAC
  	GGCACACUGGUCAUUUCAUGGAACCCUACCGGA
  Chlamydia_CT812_pd_serovarL2_nIgk_cHis	AUGGAAACUCCUGCCCAACUGUUGUUCCUUCUGCUGCUCUG	417
  	GUUGCCCGACACCACCGGAUCGUGCGUGGAUCUCCACGCUGG
  	CGGCCAGUCCGUGAACGAGCUUGUGUACGUGGGCCCACAGG
  	CCGUGCUUCUGCUGGACCAGAUCAGAGAUCUCUUCGUGGGU
  	UCCAAGGACUCCCAGGCCGAGGGACAGUACCGGCUCAUCGUC
  	GGCGACCCUUCAAGCUUCCAAGAGAAGGAUGCCGACACUCU
  	UCCGGGGAAGGUGGAACAGUCCACUCUGUUUUCCGUGACCA
  	ACCCAGUCGUGUUUCAAGGGGUGGACCAGCAGGACCAGGUG
  	UCCAGCCAAGGACUGAUCUGUUCAUUCACCUCGAGCAAUUU
  	GGACAGCCCCCGGGACGGCGAAUCGUUCCUUGGCAUCGCAU
  	UCGUGGGAGACUCAUCCAAAGCAGGAAUCACCCUUACCGAU
  	GUGAAGGCGUCCCUGAGCGGCGCUGCUCUGUACUCCACCGA
  	AGAUCUCAUCUUCGAGAAGAUCAAGGGUGGACUGGAGUUCG
  	CCAGCUGCUCCUCACUGGAACAGGGAGGAGCCUGUGCCGCCC
  	AAAGCAUCCUCAUCCACGAUUGCCAGGGGCUCCAAGUGAAG
  	CAUUGUACCACUGCCGUGAACGCCGAGGGAUCAUCCGCUAA
  	CGAUCACCUCGGUUUCGGAGGGGGUGCCUUCUUCGUGACCG
  	GUUCGCUGUCGGGAGAAAAGUCACUGUAUAUGCCCGCGGGC
  	GACAUGGUGGUCGCCAACUGCGAUGGAGCCAUCUCAUUCGA
  	GGGAAACUCCGCCAACUUCGCAAACGGCGGCGCUAUCGCCGC
  	UAGCGGGAAGGUGCUGUUCGUGGCUAACGACAAGAAAACGU
  	CCUUCAUCGAAAACCGCGCCCUGUCGGGAGGUGCCAUUGCCG
  	CCAGCUCCGACAUUGCCUUCCAAAACUGUGCGGAACUGGUG
  	UUCAAAGGAAACUGCGCCAUCGGCACCGAAGAUAAGGGAAG
  	CCUGGGGGGGGGCGCCAUUUCCUCCCUCGGCACCGUGCUGCU
  	UCAGGGAAACCACGGCAUCACUUGUGACAAGAACGAAAGCG
  	CGUCCCAGGGGGGAGCGAUCUUCGGGAAAAACUGCCAGAUU
  	UCCGACAACGAGGGACCGGUGGUGUUCAGAGACUCCACUGC
  	CUGCCUGGGCGGCGGAGCGAUCGCAGCACAGGAAAUUGUCA
  	GCAUCCAGAACAACCAGGCCGGCAUCAGCUUCGAGGGGGGA
  	AAGGCUUCGUUCGGCGGAGGUAUUGCCUGCGGAUCGUUCUC
  	GUCCGCGGGCGGAGCCUCCGUGCUCGGAACCAUCGACAUUUC
  	CAAGAACCUGGGCGCUAUCUCGUUUUCUCGCACCCUGUGCAC
  	UACUUCCGACCUGGGUCAGAUGGAGUACCAGGGAGGCGGAG
  	CGCUGUUUGGAGAGAACAUCUCUCUGAGCGAGAACGCGGGA
  	GUGCUGACCUUCAAGGACAACAUUGUGAAAACCUUCGCCUC
  	AAACGGAAAGAUCCUGGGGGGAGGCGCCAUCCUGGCAACCG
  	GGAAGGUCGAAAUCACCAACAAUUCAGGCGGUAUCUCCUUC
  	ACUGGCAACGCCCGGGCCCCCCAAGCCCUGCCGACUCAGGAA
  	GAGUUCCCCCUGUUCUCCAAGAAGGAAGGACGCCCUUUGUC
  	AUCCGGCUACUCCGGUGGUGGAGCGAUUCUGGGUCGGGAAG
  	UGGCCAUCCUGCAUAAUGCGGCCGUGGUGUUUGAGCAAAAC
  	AGACUCCAAUGCUCCGAAGAAGAGGCCACCCUCCUGGGGUG
  	CUGCGGGGGCGGAGCAGUGCAUGGCAUGGAUUCCACUUCCA
  	UCGUGGGAAACUCCAGCGUCCGCUUCGGAAACAACUACGCU
  	AUGGGACAGGGAGUGUCAGGGGGGGCCCUGCUGUCCAAGAC
  	CGUCCAGUUGGCCGGAAACGGUUCGGUGGAUUUCUCACGCA
  	AUAUCGCCUCGCUGGGAGGCGGCGCGCUGCAGGCCUCCGAA
  	GGAAAUUGCGAACUGGUCGACAACGGCUACGUGCUGUUCCG
  	GGACAACCGCGGCAGGGUGUACGGCGGAGCAAUCUCGUGCC
  	UUCGGGGCGACGUCGUGAUCUCGGGAAAUAAGGGACGGGUC
  	GAGUUUAAGGACAACAUCGCUACCAGGCUCUACGUGGAGGA
  	AACUGUGGAGAAGGUGGAGGAAGUGGAGCCUGCCCCGGAAC
  	AGAAGGACAACAACGAGCUGUCGUUCCUCGGUUCCGUCGAA
  	CAGUCCUUCAUUACUGCCGCCAACCAGGCCCUGUUCGCGUCC
  	GAAGAUGGUGACCUCAGCCCGGAAUCCAGCAUCUCCUCCGA
  	GGAACUGGCCAAGCGGAGAGAAUGCGCGGGAGGCGCAAUCU
  	UUGCGAAGCGGGUCCGGAUCGUGGACAACCAGGAAGCUGUG
  	GUGUUCAGCAACAACUUUUCCGACAUCUACGGUGGUGCAAU
  	UUUCACCGGCUCACUCCGGGAGGAGGACAAGCUGGACGGCC
  	AGAUUCCCGAGGUGCUCAUUUCCGGCAAUGCCGGCGACGUG
  	GUGUUCUCCGGAAACUCCUCCAAGAGGGACGAACACCUCCCG
  	CAUACCGGAGGAGGAGCCAUCUGCACUCAGAACCUGACGAU
  	CUCGCAGAACACCGGCAAUGUGCUGUUCUACAACAACGUCG
  	CAUGUUCCGGUGGCGCCGUCAGAAUCGAGGACCACGGAAAC
  	GUGCUGCUGGAAGCAUUCGGGGGUGAUAUUGUGUUCAAGGG
  	AAACAGCAGCUUCCGGGCCCAGGGAUCAGAUGCAAUCUACU
  	UCGCCGGGAAGGAGAGCCACAUUACCGCCCUGAACGCCACCG
  	AGGGUCACGCCAUCGUGUUCCACGAUGCCCUGGUGUUCGAA
  	AACCUGAAGGAGCGCAAGAGCGCCGAAGUGCUGCUUAUCAA
  	UUCCCGCGAAAACCCGGGCUACACCGGAUCCAUCCGGUUCCU
  	CGAAGCGGAGUCGAAGGUCCCGCAGUGUAUUCAUGUGCAAC
  	AGGGGUCCCUGGAACUGCUUAACGGAGCCACCCUGUGCUCC
  	UACGGCUUUAAGCAGGACGCGGGCGCUAAACUGGUGCUGGC
  	GGCCGGCUCCAAGCUUAAGAUCCUCGACUCCGGAACCCCGGU
  	GCAGGGGCACGCUAUUAGCAAGCCUGAAGCCGAGAUUGAGU
  	CGUCAUCCGAACCCGAAGGGGCGCACUCCCUGUGGAUAGCCA
  	AGAACGCGCAGACCACCGUGCCAAUGGUCGAUAUCCACACA
  	AUCUCCGUGGACCUCGCCAGCUUCUCGUCGAGCCAGCAGGAG
  	GGAACUGUCGAAGCGCCUCAGGUCAUCGUGCCGGGAGGUUC
  	CUACGUGCGCUCGGGGGAGCUCAACCUGGAACUCGUGAAUA
  	CCACUGGAACGGGAUAUGAGAACCACGCCCUGCUGAAGAAC
  	GAAGCCAAAGUGCCACUGAUGUCCUUCGUCGCCUCCUCCGAC
  	GAGGCCUCCGCCGAGAUUAGCAACCUGUCGGUGUCAGAUCU
  	GCAAAUUCACGUGGCCACCCCUGAGAUUGAGGAGGACACCU
  	ACGGGCACAUGGGCGAUUGGUCCGAGGCGAAGAUCCAGGAC
  	GGCACACUGGUCAUUUCAUGGAACCCUACCGGACAUCACCAC
  	CACCAUCAC
  Chlamydia_CT460_serovarD_nIgk	AUGGAAACUCCUGCCCAACUCCUGUUCUUGCUGCUGCUUUG	418
  	GCUCCCUGACACUACCGGAAUGAGCCAGAACAAGAACUCGG
  	CAUUCAUGCAGCCGGUCAAUGUGUCCGCCGAUCUGGCCGCCA
  	UUGUGGGAGCUGGGCCCAUGCCACGGACCGAAAUCAUCAAA
  	AAGAUGUGGGACUACAUUAAGAAGAACGGCCUGCAGGACCC
  	GACCAACAAGCGCAACAUCAACCCGGACGAUAAGCUGGCGA
  	AGGUGUUCGGUACCGAGAAGCCCAUCGACAUGUUUCAAAUG
  	ACCAAGAUGGUGUCCCAGCACAUCAUUAAG
  Chlamydia_CT460_serovarD_nIgk_cHis	AUGGAAACUCCUGCCCAACUCCUGUUCUUGCUGCUGCUUUG	419
  	GCUCCCUGACACUACCGGAAUGAGCCAGAACAAGAACUCGG
  	CAUUCAUGCAGCCGGUCAAUGUGUCCGCCGAUCUGGCCGCCA
  	UUGUGGGAGCUGGGCCCAUGCCACGGACCGAAAUCAUCAAA
  	AAGAUGUGGGACUACAUUAAGAAGAACGGCCUGCAGGACCC
  	GACCAACAAGCGCAACAUCAACCCGGACGAUAAGCUGGCGA
  	AGGUGUUCGGUACCGAGAAGCCCAUCGACAUGUUUCAAAUG
  	ACCAAGAUGGUGUCCCAGCACAUCAUUAAGCACCACCACCAU
  	CACCAU
  Chlamydia_CT460_serovarL2_nIgk	AUGGAAACUCCUGCCCAACUGUUGUUCCUGCUGCUUCUCUG	420
  	GCUCCCUGACACUACCGGAAUGUCGCAGAACAAGAACUCCGC
  	CUUCAUGCAACCCGUGAACGUGUCAGCGGACCUGGCAGCUA
  	UUGUCGGUGCCGGGCCGAUGCCCCGCACCGAAAUCAUCAAG
  	AAGAUGUGGGACUACAUCAAGGAGAACAGCCUGCAGGAUCC
  	AACCAACAAGCGGAAUAUCAACCCGGACGAUAAGCUGGCCA
  	AAGUGUUCGGCACCGAGAAGCCGAUUGACAUGUUUCAGAUG
  	ACCAAGAUGGUGUCCCAGCACAUCAUUAAG
  Chlamydia_CT460_serovarL2_nIgk_cHis	AUGGAAACUCCUGCCCAACUGUUGUUCCUGCUGCUUCUCUG	421
  	GCUCCCUGACACUACCGGAAUGUCGCAGAACAAGAACUCCGC
  	CUUCAUGCAACCCGUGAACGUGUCAGCGGACCUGGCAGCUA
  	UUGUCGGUGCCGGGCCGAUGCCCCGCACCGAAAUCAUCAAG
  	AAGAUGUGGGACUACAUCAAGGAGAACAGCCUGCAGGAUCC
  	AACCAACAAGCGGAAUAUCAACCCGGACGAUAAGCUGGCCA
  	AAGUGUUCGGCACCGAGAAGCCGAUUGACAUGUUUCAGAUG
  	ACCAAGAUGGUGUCCCAGCACAUCAUUAAGCACCACCACCAU
  	CAUCAC
  Chlamydia_CT622_serovarE_nIgk	AUGGAAACCCCUGCCCAACUGCUUUUCUUGCUGCUGCUCUG	422
  	GCUCCCUGACACCACCGGAAUGGAAUCUGGACCCGAGUCCGU
  	GUCAAGCAACCAGUCCUCCAUGAACCCCAUCAUUAAUGGAC
  	AGAUCGCAUCCAAUUCCGAAACCAAGGAAAGCACCAAGGCA
  	UCGGAGGCCUCCCCAUCCGCCUCAAGCUCCGUGUCGUCCUGG
  	UCGUUUCUGUCGAGCGCGAAGAAUGCCCUGAUCUCACUGCG
  	GGACGCGAUUCUGAACAAGAACAGCUCCCCAACCGACUCCCU
  	GAGCCAACUCGAGGCCUCAACUUCCACUUCGACUGUGACUA
  	GGGUCGCUGCCAAGGAUUAUGACGAGGCCAAGAGCAACUUC
  	GACACCGCCAAGAGCGGACUGGAAAACGCCAAAACCCUGGCC
  	GAAUACGAAACUAAGAUGGCCGAUCUCAUGGCGGCCCUGCA
  	AGACAUGGAACGGCUGGCGAACUCCGAUCCGUCCAACAACC
  	ACACUGAGGAAGUGAACAACAUCAAGAAGGCUCUCGAGGCC
  	CAGAAGGAUACCAUCGACAAGUUGAACAAGCUUGUGACGCU
  	GCAGAACCAAAACAAGUCCCUGACGGAAGUGCUCAAAACCA
  	CCGACUCGGCCGACCAGAUUCCGGCCAUCAACAGCCAGCUGG
  	AGAUUAACAAGAACUCGGCCGAUCAGAUUAUCAAGGACCUG
  	GAGCGCCAGAACAUUUCCUACGAGGCCGUCUUGACUAACGC
  	CGGCGAAGUGAUCAAGGCGUCAUCCGAAGCCGGCAUUAAGC
  	UGGGACAGGCGCUGCAAUCCAUCGUCGACGCCGGCGACCAG
  	UCCCAGGCGGCGGUGCUGCAGGCCCAGCAGAACAACUCCCCC
  	GAUAACAUCGCUGCAACCAAGGAACUGAUUGACGCGGCCGA
  	AACCAAAGUCAACGAACUGAAGCAGGAGCACACUGGUCUGA
  	CCGACUCGCCGCUCGUGAAGAAGGCCGAAGAACAGAUCAGC
  	CAGGCUCAGAAGGAUAUCCAGGAAAUCAAGCCUUCGGGGAG
  	CGACAUCCCGAUCGUGGGACCGUCCGGUUCCGCCGCUUCCGC
  	CGGGUCCGCAGCCGGGGCCCUUAAGUCGUCGAACAAUAGCG
  	GCAGAAUAUCCCUGCUGCUCGACGAUGUGGAUAACGAGAUG
  	GCCGCCAUUGCGCUGCAAGGAUUCCGGUCCAUGAUCGAGCA
  	GUUCAACGUGAACAACCCCGCCACCGCCAAGGAGCUGCAGGC
  	UAUGGAGGCCCAACUCACUGCCAUGUCCGACCAGCUCGUGG
  	GAGCGGACGGAGAACUGCCAGCCGAGAUCCAGGCCAUCAAG
  	GACGCUCUGGCCCAGGCACUGAAGCAGCCGUCCGCGGAUGGC
  	CUGGCCACCGCCAUGGGCCAGGUCGCGUUCGCCGCCGCUAAA
  	GUCGGCGGAGGUUCGGCCGGCACUGCCGGGACCGUGCAGAU
  	GAAUGUCAAGCAGCUGUACAAGACUGCGUUCUCGUCGACCA
  	GCUCCAGCUCCUACGCCGCGGCCCUGUCCGACGGUUACAGCG
  	CGUACAAGACCCUGAACUCCCUUUACUCCGAAUCGAGAUCCG
  	GGGUCCAGUCCGCAAUUUCACAAACCGCCAAUCCUGCCCUGU
  	CGCGCUCAGUGUCACGCAGCGGCAUCGAGUCACAGGGCAGA
  	AGCGCCGACGCUAGCCAAAGGGCCGCAGAAACCAUUGUGCG
  	GGACUCCCAGACACUUGGAGAUGUCUACAGCCGCCUCCAAG
  	UGCUGGACUCCCUCAUGUCCACCAUCGUGUCAAACCCUCAGG
  	CUAACCAGGAGGAAAUCAUGCAGAAGCUGACCGCAAGCAUU
  	UCCAAGGCUCCGCAGUUUGGAUACCCCGCUGUGCAAAACUCC
  	GCGGACAGCUUGCAGAAAUUCGCAGCCCAGUUGGAGAGGGA
  	GUUCGUGGACGGGGAGCGGUCCCUCGCGGAGUCCCAGGAGA
  	ACGCAUUCCGGAAGCAGCCCGCCUUCAUUCAACAAGUGCUU
  	GUGAACAUCGCCUCCCUGUUCUCCGGUUACCUGUCU
  Chlamydia_CT622_serovarE_nIgk_cHis	AUGGAAACCCCUGCCCAACUGCUUUUCUUGCUGCUGCUCUG	423
  	GCUCCCUGACACCACCGGAAUGGAAUCUGGACCCGAGUCCGU
  	GUCAAGCAACCAGUCCUCCAUGAACCCCAUCAUUAAUGGAC
  	AGAUCGCAUCCAAUUCCGAAACCAAGGAAAGCACCAAGGCA
  	UCGGAGGCCUCCCCAUCCGCCUCAAGCUCCGUGUCGUCCUGG
  	UCGUUUCUGUCGAGCGCGAAGAAUGCCCUGAUCUCACUGCG
  	GGACGCGAUUCUGAACAAGAACAGCUCCCCAACCGACUCCCU
  	GAGCCAACUCGAGGCCUCAACUUCCACUUCGACUGUGACUA
  	GGGUCGCUGCCAAGGAUUAUGACGAGGCCAAGAGCAACUUC
  	GACACCGCCAAGAGCGGACUGGAAAACGCCAAAACCCUGGCC
  	GAAUACGAAACUAAGAUGGCCGAUCUCAUGGCGGCCCUGCA
  	AGACAUGGAACGGCUGGCGAACUCCGAUCCGUCCAACAACC
  	ACACUGAGGAAGUGAACAACAUCAAGAAGGCUCUCGAGGCC
  	CAGAAGGAUACCAUCGACAAGUUGAACAAGCUUGUGACGCU
  	GCAGAACCAAAACAAGUCCCUGACGGAAGUGCUCAAAACCA
  	CCGACUCGGCCGACCAGAUUCCGGCCAUCAACAGCCAGCUGG
  	AGAUUAACAAGAACUCGGCCGAUCAGAUUAUCAAGGACCUG
  	GAGCGCCAGAACAUUUCCUACGAGGCCGUCUUGACUAACGC
  	CGGCGAAGUGAUCAAGGCGUCAUCCGAAGCCGGCAUUAAGC
  	UGGGACAGGCGCUGCAAUCCAUCGUCGACGCCGGCGACCAG
  	UCCCAGGCGGCGGUGCUGCAGGCCCAGCAGAACAACUCCCCC
  	GAUAACAUCGCUGCAACCAAGGAACUGAUUGACGCGGCCGA
  	AACCAAAGUCAACGAACUGAAGCAGGAGCACACUGGUCUGA
  	CCGACUCGCCGCUCGUGAAGAAGGCCGAAGAACAGAUCAGC
  	CAGGCUCAGAAGGAUAUCCAGGAAAUCAAGCCUUCGGGGAG
  	CGACAUCCCGAUCGUGGGACCGUCCGGUUCCGCCGCUUCCGC
  	CGGGUCCGCAGCCGGGGCCCUUAAGUCGUCGAACAAUAGCG
  	GCAGAAUAUCCCUGCUGCUCGACGAUGUGGAUAACGAGAUG
  	GCCGCCAUUGCGCUGCAAGGAUUCCGGUCCAUGAUCGAGCA
  	GUUCAACGUGAACAACCCCGCCACCGCCAAGGAGCUGCAGGC
  	UAUGGAGGCCCAACUCACUGCCAUGUCCGACCAGCUCGUGG
  	GAGCGGACGGAGAACUGCCAGCCGAGAUCCAGGCCAUCAAG
  	GACGCUCUGGCCCAGGCACUGAAGCAGCCGUCCGCGGAUGGC
  	CUGGCCACCGCCAUGGGCCAGGUCGCGUUCGCCGCCGCUAAA
  	GUCGGCGGAGGUUCGGCCGGCACUGCCGGGACCGUGCAGAU
  	GAAUGUCAAGCAGCUGUACAAGACUGCGUUCUCGUCGACCA
  	GCUCCAGCUCCUACGCCGCGGCCCUGUCCGACGGUUACAGCG
  	CGUACAAGACCCUGAACUCCCUUUACUCCGAAUCGAGAUCCG
  	GGGUCCAGUCCGCAAUUUCACAAACCGCCAAUCCUGCCCUGU
  	CGCGCUCAGUGUCACGCAGCGGCAUCGAGUCACAGGGCAGA
  	AGCGCCGACGCUAGCCAAAGGGCCGCAGAAACCAUUGUGCG
  	GGACUCCCAGACACUUGGAGAUGUCUACAGCCGCCUCCAAG
  	UGCUGGACUCCCUCAUGUCCACCAUCGUGUCAAACCCUCAGG
  	CUAACCAGGAGGAAAUCAUGCAGAAGCUGACCGCAAGCAUU
  	UCCAAGGCUCCGCAGUUUGGAUACCCCGCUGUGCAAAACUCC
  	GCGGACAGCUUGCAGAAAUUCGCAGCCCAGUUGGAGAGGGA
  	GUUCGUGGACGGGGAGCGGUCCCUCGCGGAGUCCCAGGAGA
  	ACGCAUUCCGGAAGCAGCCCGCCUUCAUUCAACAAGUGCUU
  	GUGAACAUCGCCUCCCUGUUCUCCGGUUACCUGUCUCAUCAC
  	CACCACCAUCAC
  Chlamydia_CT858_nIgk	AUGGAAACCCCUGCCCAGCUGCUGUUCCUGCUGCUGCUGUG	424
  	GCUGCCUGAUACCACAGGCGUGCGGGGAGAGUCCCUCGUGU
  	GCAAGAAUGCCCUGCAGGACCUGAGCUUCCUGGAACAUCUG
  	CUGCAAGUGAAGUACGCCCCCAAGACCUGGAAAGAGCAGUA
  	CCUGGGCUGGGACCUGGUGCAGUCCUCUGUGUCUGCCCAGC
  	AGAAGCUGCGGACCCAGGAAAACCCCUCUACCAGCUUCUGUC
  	AGCAAGUGCUGGCCGACUUCAUCGGCGGCCUGAACGAUUUC
  	CAUGCCGGCGUGACCUUUUUCGCCAUCGAGAGCGCCUACCUG
  	CCCUACACCGUGCAGAAGUCCAGCGACGGCCGGUUCUACUUC
  	GUGGACAUCAUGACCUUCAGCAGCGAGAUCAGAGUGGGCGA
  	CGAGCUGCUGGAAGUGGAUGGCGCUCCUGUGCAGGAUGUGC
  	UGGCCACACUGUACGGCAGCAACCACAAGGGCACAGCCGCCG
  	AAGAAUCUGCCGCCCUGAGAACCCUGUUCAGCCGGAUGGCC
  	UCUCUGGGCCACAAGGUGCCAAGCGGCAGAACCACCCUGAA
  	GAUCAGACGGCCCUUUGGCACCACCCGGGAAGUGCGCGUGA
  	AGUGGCGCUAUGUGCCUGAGGGCGUGGGCGACCUGGCCACA
  	AUCGCCCCUUCUAUCAGAGCCCCCCAGCUGCAGAAAUCCAUG
  	CGGUCAUUCUUCCCAAAGAAGGACGACGCCUUCCACCGGUCC
  	AGCAGCCUGUUCUACAGCCCUAUGGUGCCCCACUUCUGGGCC
  	GAGCUGAGAAACCACUACGCCACCUCCGGCCUGAAGUCCGGC
  	UACAACAUCGGCAGCACCGACGGCUUUCUGCCCGUGAUCGG
  	ACCCGUGAUCUGGGAGAGCGAGGGCCUGUUCAGAGCCUACA
  	UCAGCAGCGUGACCGACGGCGACGGCAAGAGCCACAAAGUG
  	GGCUUUCUGAGAAUCCCCACCUACAGCUGGCAGGACAUGGA
  	AGAUUUCGACCCCAGCGGCCCACCCCCCUGGGAGGAAUUUGC
  	CAAGAUCAUCCAGGUGUUCAGCAGCAACACCGAGGCCCUGA
  	UCAUCGACCAGACCAACAACCCUGGCGGCAGCGUGCUGUACC
  	UGUACGCCCUGCUGAGCAUGCUGACCGACAGACCCCUGGAAC
  	UGCCCAAGCACCGGAUGAUCCUGACCCAGGACGAGGUGGUG
  	GACGCCCUGGAUUGGCUGACCCUGCUGGAAAACGUGGACAC
  	CAACGUGGAAAGCCGGCUGGCCCUGGGCGACAACAUGGAAG
  	GCUACACAGUGGAUCUGCAGGUGGCCGAGUACCUGAAAAGC
  	UUCGGCAGACAGGUGCUGAACUGCUGGUCCAAGGGCGACAU
  	CGAGCUGAGCACCCCCAUCCCCCUGUUCGGCUUCGAGAAGAU
  	CCACCCCCACCCCAGAGUGCAGUACAGCAAGCCCAUCUGCGU
  	GCUGAUCAACGAGCAGGACUUCUCCUGCGCCGACUUCUUCCC
  	AGUGGUGCUGAAGGACAACGACAGAGCCCUGAUCGUGGGCA
  	CCAGAACAGCUGGCGCUGGCGGCUUCGUGUUCAACGUGCAG
  	UUCCCCAACCGGACCGGCAUCAAGACCUGUAGCCUGACAGGC
  	UCUCUGGCCGUGCGGGAACACGGCGCCUUCAUCGAGAACAU
  	CGGCGUGGAACCCCACAUCGACCUGCCUUUCACCGCCAACGA
  	CAUCCGGUACAAGGGCUACUCUGAGUACCUGGACAAAGUGA
  	AGAAACUCGUGUGCCAGCUGAUUAACAACGACGGCACCAUC
  	AUCCUGGCCGAGGACGGCAGCUUC
  Chlamydia_CT858_nIgk_cHis	AUGGAAACCCCUGCCCAGCUGCUGUUCCUGCUGCUGCUGUG	425
  	GCUGCCUGAUACCACAGGCGUGCGGGGAGAGUCCCUCGUGU
  	GCAAGAAUGCCCUGCAGGACCUGAGCUUCCUGGAACAUCUG
  	CUGCAAGUGAAGUACGCCCCCAAGACCUGGAAAGAGCAGUA
  	CCUGGGCUGGGACCUGGUGCAGUCCUCUGUGUCUGCCCAGC
  	AGAAGCUGCGGACCCAGGAAAACCCCUCUACCAGCUUCUGUC
  	AGCAAGUGCUGGCCGACUUCAUCGGCGGCCUGAACGAUUUC
  	CAUGCCGGCGUGACCUUUUUCGCCAUCGAGAGCGCCUACCUG
  	CCCUACACCGUGCAGAAGUCCAGCGACGGCCGGUUCUACUUC
  	GUGGACAUCAUGACCUUCAGCAGCGAGAUCAGAGUGGGCGA
  	CGAGCUGCUGGAAGUGGAUGGCGCUCCUGUGCAGGAUGUGC
  	UGGCCACACUGUACGGCAGCAACCACAAGGGCACAGCCGCCG
  	AAGAAUCUGCCGCCCUGAGAACCCUGUUCAGCCGGAUGGCC
  	UCUCUGGGCCACAAGGUGCCAAGCGGCAGAACCACCCUGAA
  	GAUCAGACGGCCCUUUGGCACCACCCGGGAAGUGCGCGUGA
  	AGUGGCGCUAUGUGCCUGAGGGCGUGGGCGACCUGGCCACA
  	AUCGCCCCUUCUAUCAGAGCCCCCCAGCUGCAGAAAUCCAUG
  	CGGUCAUUCUUCCCAAAGAAGGACGACGCCUUCCACCGGUCC
  	AGCAGCCUGUUCUACAGCCCUAUGGUGCCCCACUUCUGGGCC
  	GAGCUGAGAAACCACUACGCCACCUCCGGCCUGAAGUCCGGC
  	UACAACAUCGGCAGCACCGACGGCUUUCUGCCCGUGAUCGG
  	ACCCGUGAUCUGGGAGAGCGAGGGCCUGUUCAGAGCCUACA
  	UCAGCAGCGUGACCGACGGCGACGGCAAGAGCCACAAAGUG
  	GGCUUUCUGAGAAUCCCCACCUACAGCUGGCAGGACAUGGA
  	AGAUUUCGACCCCAGCGGCCCACCCCCCUGGGAGGAAUUUGC
  	CAAGAUCAUCCAGGUGUUCAGCAGCAACACCGAGGCCCUGA
  	UCAUCGACCAGACCAACAACCCUGGCGGCAGCGUGCUGUACC
  	UGUACGCCCUGCUGAGCAUGCUGACCGACAGACCCCUGGAAC
  	UGCCCAAGCACCGGAUGAUCCUGACCCAGGACGAGGUGGUG
  	GACGCCCUGGAUUGGCUGACCCUGCUGGAAAACGUGGACAC
  	CAACGUGGAAAGCCGGCUGGCCCUGGGCGACAACAUGGAAG
  	GCUACACAGUGGAUCUGCAGGUGGCCGAGUACCUGAAAAGC
  	UUCGGCAGACAGGUGCUGAACUGCUGGUCCAAGGGCGACAU
  	CGAGCUGAGCACCCCCAUCCCCCUGUUCGGCUUCGAGAAGAU
  	CCACCCCCACCCCAGAGUGCAGUACAGCAAGCCCAUCUGCGU
  	GCUGAUCAACGAGCAGGACUUCUCCUGCGCCGACUUCUUCCC
  	AGUGGUGCUGAAGGACAACGACAGAGCCCUGAUCGUGGGCA
  	CCAGAACAGCUGGCGCUGGCGGCUUCGUGUUCAACGUGCAG
  	UUCCCCAACCGGACCGGCAUCAAGACCUGUAGCCUGACAGGC
  	UCUCUGGCCGUGCGGGAACACGGCGCCUUCAUCGAGAACAU
  	CGGCGUGGAACCCCACAUCGACCUGCCUUUCACCGCCAACGA
  	CAUCCGGUACAAGGGCUACUCUGAGUACCUGGACAAAGUGA
  	AGAAACUCGUGUGCCAGCUGAUUAACAACGACGGCACCAUC
  	AUCCUGGCCGAGGACGGCAGCUUCCACCACCACCAUCACCAC
  Chlamydia_CT875_nIgk	AUGGAAACCCCUGCCCAGCUGCUGUUCCUGCUGCUGCUGUG	426
  	GCUGCCUGACACCACCGGCAUGAGCAUCAGAGGCGUGGGCG
  	GCAACGGCAACAGCAGAAUCCCUAGCCACAACGGCGACGGCA
  	GCAACAGGCGGAGCCAGAACACCAAGGGCAACAACAAGGUG
  	GAAGAUAGAGUGUGCAGCCUGUACAGCAGCCGGUCCAACGA
  	GAACCGCGAGAGCCCUUAUGCCGUGGUGGACGUGUCCAGCA
  	UGAUCGAGAGCACCCCCACCAGCGGCGAGACAACCAGAGCUA
  	GUAGAGGCGUGCUGAGCCGGUUCCAGAGGGGCCUCGUGCGG
  	AUUGCUGACAAAGUGCGGAGAGCCGUGCAGUGCGCUUGGAG
  	CAGCGUGUCCACAAGCAGAAGCAGCGCCACAAGAGCCGCCGA
  	GAGCGGCAGCUCUAGCAGAACAGCUAGAGGCGCCAGCAGCG
  	GCUACAGAGAGUACAGCCCUUCUGCCGCUCGGGGCCUGCGGC
  	UGAUGUUCACCGACUUUUGGCGGACCCGGGUGCUGAGACAG
  	ACCUCUCCUAUGGCCGGCGUGUUCGGCAACCUGGACGUGAA
  	CGAGGCCAGACUGAUGGCCGCCUACACCAGCGAGUGUGCCG
  	AUCACCUGGAAGCCAAAGAGCUGGCCGGACCUGACGGCGUG
  	GCAGCCGCUAGAGAAAUCGCCAAGAGAUGGGAGAAGAGAGU
  	GCGGGACCUGCAGGACAAGGGCGCUGCCAGAAAGCUGCUGA
  	ACGACCCCCUGGGCAGACGGACCCCCAACUACCAGAGCAAGA
  	ACCCCGGCGAGUACACCGUGGGCAACUCCAUGUUCUACGACG
  	GCCCCCAGGUGGCCAACCUGCAGAAUGUGGAUACCGGCUUC
  	UGGCUGGACAUGAGCAACCUGAGCGACGUGGUGCUGUCCAG
  	AGAGAUCCAGACCGGCCUGAGAGCCAGAGCCACCCUGGAAG
  	AGUCCAUGCCCAUGCUGGAAAAUCUGGAAGAGAGAUUCCGG
  	CGGCUGCAGGAAACCUGCGACGCCGCCAGAACCGAGAUCGA
  	GGAAAGCGGCUGGACCCGGGAAAGCGCCUCCAGAAUGGAAG
  	GCGACGAAGCCCAGGGCCCCAGCAGAGUGCAGCAGGCCUUUC
  	AGAGCUUCGUGAAUGAGUGCAACAGCAUCGAGUUCAGCUUC
  	GGCUCCUUCGGCGAGCACGUGCGGGUGCUGUGUGCCAGAGU
  	GUCAAGAGGACUGGCCGCUGCCGGCGAGGCCAUCAGAAGAU
  	GCUUCAGCUGCUGCAAGGGCAGCACCCACAGAUACGCCCCCA
  	GAGAUGACCUGUCUCCUGAGGGCGCCUCUCUGGCCGAAACCC
  	UGGCCAGAUUCGCCGACGACAUGGGCAUCGAAAGAGGCGCC
  	GACGGCACCUACGACAUCCCCCUGGUGGACGAUUGGAGAAG
  	GGGCGUGCCAUCCAUCGAGGGCGAGGGCAGCGAUAGCAUCU
  	ACGAGAUCAUGAUGCCCAUCUACGAAGUGAUGAACAUGGAC
  	CUGGAAACCCGGCGGAGCUUCGCCGUGCAGCAGGGCCAUUA
  	CCAGGACCCCAGAGCCAGCGACUACGACCUGCCUAGAGCCUC
  	CGAUUACGAUCUGCCCAGAAGCCCCUACCCCACCCCUCCACU
  	GCCUCCCAGAUACCAGCUGCAGAACAUGGAUGUGGAAGCCG
  	GCUUUCGCGAGGCCGUGUACGCCUCUUUUGUGGCCGGCAUG
  	UACAACUACGUCGUGACCCAGCCCCAGGAACGGAUCCCCAAU
  	AGCCAGCAGGUGGAAGGCAUCCUGCGGGACAUGCUGACCAA
  	CGGCAGCCAGACCUUCCGGGACCUGAUGAAGCGGUGGAACA
  	GAGAGGUGGACCGCGAG
  Chlamydia_CT875_nIgk_cHis	AUGGAAACCCCUGCCCAGCUGCUGUUCCUGCUGCUGCUGUG	427
  	GCUGCCUGACACCACCGGCAUGAGCAUCAGAGGCGUGGGCG
  	GCAACGGCAACAGCAGAAUCCCUAGCCACAACGGCGACGGCA
  	GCAACAGGCGGAGCCAGAACACCAAGGGCAACAACAAGGUG
  	GAAGAUAGAGUGUGCAGCCUGUACAGCAGCCGGUCCAACGA
  	GAACCGCGAGAGCCCUUAUGCCGUGGUGGACGUGUCCAGCA
  	UGAUCGAGAGCACCCCCACCAGCGGCGAGACAACCAGAGCUA
  	GUAGAGGCGUGCUGAGCCGGUUCCAGAGGGGCCUCGUGCGG
  	AUUGCUGACAAAGUGCGGAGAGCCGUGCAGUGCGCUUGGAG
  	CAGCGUGUCCACAAGCAGAAGCAGCGCCACAAGAGCCGCCGA
  	GAGCGGCAGCUCUAGCAGAACAGCUAGAGGCGCCAGCAGCG
  	GCUACAGAGAGUACAGCCCUUCUGCCGCUCGGGGCCUGCGGC
  	UGAUGUUCACCGACUUUUGGCGGACCCGGGUGCUGAGACAG
  	ACCUCUCCUAUGGCCGGCGUGUUCGGCAACCUGGACGUGAA
  	CGAGGCCAGACUGAUGGCCGCCUACACCAGCGAGUGUGCCG
  	AUCACCUGGAAGCCAAAGAGCUGGCCGGACCUGACGGCGUG
  	GCAGCCGCUAGAGAAAUCGCCAAGAGAUGGGAGAAGAGAGU
  	GCGGGACCUGCAGGACAAGGGCGCUGCCAGAAAGCUGCUGA
  	ACGACCCCCUGGGCAGACGGACCCCCAACUACCAGAGCAAGA
  	ACCCCGGCGAGUACACCGUGGGCAACUCCAUGUUCUACGACG
  	GCCCCCAGGUGGCCAACCUGCAGAAUGUGGAUACCGGCUUC
  	UGGCUGGACAUGAGCAACCUGAGCGACGUGGUGCUGUCCAG
  	AGAGAUCCAGACCGGCCUGAGAGCCAGAGCCACCCUGGAAG
  	AGUCCAUGCCCAUGCUGGAAAAUCUGGAAGAGAGAUUCCGG
  	CGGCUGCAGGAAACCUGCGACGCCGCCAGAACCGAGAUCGA
  	GGAAAGCGGCUGGACCCGGGAAAGCGCCUCCAGAAUGGAAG
  	GCGACGAAGCCCAGGGCCCCAGCAGAGUGCAGCAGGCCUUUC
  	AGAGCUUCGUGAAUGAGUGCAACAGCAUCGAGUUCAGCUUC
  	GGCUCCUUCGGCGAGCACGUGCGGGUGCUGUGUGCCAGAGU
  	GUCAAGAGGACUGGCCGCUGCCGGCGAGGCCAUCAGAAGAU
  	GCUUCAGCUGCUGCAAGGGCAGCACCCACAGAUACGCCCCCA
  	GAGAUGACCUGUCUCCUGAGGGCGCCUCUCUGGCCGAAACCC
  	UGGCCAGAUUCGCCGACGACAUGGGCAUCGAAAGAGGCGCC
  	GACGGCACCUACGACAUCCCCCUGGUGGACGAUUGGAGAAG
  	GGGCGUGCCAUCCAUCGAGGGCGAGGGCAGCGAUAGCAUCU
  	ACGAGAUCAUGAUGCCCAUCUACGAAGUGAUGAACAUGGAC
  	CUGGAAACCCGGCGGAGCUUCGCCGUGCAGCAGGGCCAUUA
  	CCAGGACCCCAGAGCCAGCGACUACGACCUGCCUAGAGCCUC
  	CGAUUACGAUCUGCCCAGAAGCCCCUACCCCACCCCUCCACU
  	GCCUCCCAGAUACCAGCUGCAGAACAUGGAUGUGGAAGCCG
  	GCUUUCGCGAGGCCGUGUACGCCUCUUUUGUGGCCGGCAUG
  	UACAACUACGUCGUGACCCAGCCCCAGGAACGGAUCCCCAAU
  	AGCCAGCAGGUGGAAGGCAUCCUGCGGGACAUGCUGACCAA
  	CGGCAGCCAGACCUUCCGGGACCUGAUGAAGCGGUGGAACA
  	GAGAGGUGGACCGCGAGCACCACCAUCACCACCAC
  Chlamydia_CT089_nIgk	AUGGAAACCCCUGCCCAGCUGCUGUUCCUGCUGCUGCUGUG	428
  	GCUGCCUGACACCACCGGCAUGACAGCAUCUGGCGGAGCUG
  	GCGGCCUGGGCUCUACACAGACAGUGGAUGUGGCCAGGGCC
  	CAGGCUGCUGCCGCUACACAGGAUGCCCAGGAAGUGAUCGG
  	CAGCCAGGAAGCCAGCGAGGCCUCUAUGCUGAAGGGCUGCG
  	AGGACCUGAUCAACCCUGCCGCCGCUACCCGCAUCAAGAAGA
  	AAGAGGAAAAGUUCGAGUCCCUGGAAGCCAGACGGAAGCCC
  	ACCGCCGACAAGGCCGAGAAGAAGUCCGAGAGCACCGAGGA
  	AAAGGGCGACACCCCCCUGGAAGAUCGGUUCACCGAGGAUC
  	UGAGCGAGGUGUCCGGCGAGGACUUCCGGGGCCUGAAGAAC
  	AGCUUCGACGACGACAGCAGCCCCGAGGAAAUCCUGGACGCC
  	CUGACCAGCAAGUUCAGCGACCCCACCAUCAAGGACCUGGCC
  	CUGGACUACCUGAUCCAGACCGCCCCCAGCGACCGGAAGCUG
  	AAGUCUGCCCUGAUUCAGGCCAAGCACCAGCUGAUGAGCCA
  	GAACCCCCAGGCCAUCGUGGGCGGCAGAAAUGUGCUGCUGG
  	CCUCCGAGACAUUCGCCAGCAGAGCCAACACCAGCCCCAGCU
  	CCCUGCGGAGCCUGUAUCUGCAAGUGACCAGCUCCCCCAGCA
  	ACUGCGACAACCUGAGACAGAUGCUGGCUAGCUACCUGCCC
  	UCCGAGAAAACCGCCGUGAUGGAAUUCCUCGUGAACGGCAU
  	GGUGGCCGACCUGAAAAGCGAGGGCCCUAGCAUCCCUCCCGC
  	CAAGCUGCAGGUGUACAUGACCGAGCUGAGCAACCUGCAGG
  	CCCUGCACAGCGUGGACAGCUUUUUCGACCGGAACAUCGGC
  	AACCUGGAAAACAGCCUGAAGCACGAGGGCCACGCCCCCAUC
  	CCUUCUCUGACAACCGGCAAUCUGACCAAGACCUUCCUGCAG
  	CUGGUGGAAGAUAAGUUCCCCAGCAGCUCCAAGGCCCAGAA
  	GGCCCUGAACGAGCUCGUGGGCCCUGAUACCGGACCUCAGAC
  	CGAGGUGCUGAACCUGUUCUUUCGGGCCCUGAAUGGCUGCU
  	CCCCCCGGAUCUUUUCUGGCGCUGAGAAGAAGCAGCAGCUG
  	GCCAGCGUGAUCACCAACACCCUGGAUGCCAUCAACGCCGAC
  	AACGAGGACUACCCCAAGCCCGGCGACUUCCCCAGAAGCAGC
  	UUUAGCAGCACCCCCCCUCAUGCCCCUGUGCCCCAGUCUGAG
  	AUCCCUACCAGCCCAACCAGCACCCAGCCUCCAAGCCCU
  Chlamydia_CT089_nIgk_cHis	AUGGAAACCCCUGCCCAGCUGCUGUUCCUGCUGCUGCUGUG	429
  	GCUGCCUGACACCACCGGCAUGACAGCAUCUGGCGGAGCUG
  	GCGGCCUGGGCUCUACACAGACAGUGGAUGUGGCCAGGGCC
  	CAGGCUGCUGCCGCUACACAGGAUGCCCAGGAAGUGAUCGG
  	CAGCCAGGAAGCCAGCGAGGCCUCUAUGCUGAAGGGCUGCG
  	AGGACCUGAUCAACCCUGCCGCCGCUACCCGCAUCAAGAAGA
  	AAGAGGAAAAGUUCGAGUCCCUGGAAGCCAGACGGAAGCCC
  	ACCGCCGACAAGGCCGAGAAGAAGUCCGAGAGCACCGAGGA
  	AAAGGGCGACACCCCCCUGGAAGAUCGGUUCACCGAGGAUC
  	UGAGCGAGGUGUCCGGCGAGGACUUCCGGGGCCUGAAGAAC
  	AGCUUCGACGACGACAGCAGCCCCGAGGAAAUCCUGGACGCC
  	CUGACCAGCAAGUUCAGCGACCCCACCAUCAAGGACCUGGCC
  	CUGGACUACCUGAUCCAGACCGCCCCCAGCGACCGGAAGCUG
  	AAGUCUGCCCUGAUUCAGGCCAAGCACCAGCUGAUGAGCCA
  	GAACCCCCAGGCCAUCGUGGGCGGCAGAAAUGUGCUGCUGG
  	CCUCCGAGACAUUCGCCAGCAGAGCCAACACCAGCCCCAGCU
  	CCCUGCGGAGCCUGUAUCUGCAAGUGACCAGCUCCCCCAGCA
  	ACUGCGACAACCUGAGACAGAUGCUGGCUAGCUACCUGCCC
  	UCCGAGAAAACCGCCGUGAUGGAAUUCCUCGUGAACGGCAU
  	GGUGGCCGACCUGAAAAGCGAGGGCCCUAGCAUCCCUCCCGC
  	CAAGCUGCAGGUGUACAUGACCGAGCUGAGCAACCUGCAGG
  	CCCUGCACAGCGUGGACAGCUUUUUCGACCGGAACAUCGGC
  	AACCUGGAAAACAGCCUGAAGCACGAGGGCCACGCCCCCAUC
  	CCUUCUCUGACAACCGGCAAUCUGACCAAGACCUUCCUGCAG
  	CUGGUGGAAGAUAAGUUCCCCAGCAGCUCCAAGGCCCAGAA
  	GGCCCUGAACGAGCUCGUGGGCCCUGAUACCGGACCUCAGAC
  	CGAGGUGCUGAACCUGUUCUUUCGGGCCCUGAAUGGCUGCU
  	CCCCCCGGAUCUUUUCUGGCGCUGAGAAGAAGCAGCAGCUG
  	GCCAGCGUGAUCACCAACACCCUGGAUGCCAUCAACGCCGAC
  	AACGAGGACUACCCCAAGCCCGGCGACUUCCCCAGAAGCAGC
  	UUUAGCAGCACCCCCCCUCAUGCCCCUGUGCCCCAGUCUGAG
  	AUCCCUACCAGCCCAACCAGCACCCAGCCUCCAAGCCCUCAC
  	CACCACCAUCACCAC
  Chlamydia_MOMP	AUGAAAAAACUCUUAAAAUCGGCGUUUUUAUCCGCCGCAUU	430
  	UUUUGCUGGUCACGCCUCCUUACACGCUUUGCCUGUAGGGA
  	ACCCAGCAGAGCCAAGUUUAUUAAUUGAUGGAACGAUAUGG
  	GAAGGUAUGUCAGGAGAUCCAUGUGAUCCUUGCGCUACUUG
  	GUGCGACGCGAUUAGCUUACGCGUAGGAUUUUACGGAGAUU
  	AUGUUUUCGACAGAGUCCUCAAGACAGAUGUGCCACAGAAG
  	UUUUCAAUGGGGCCUAUACCUACUUCAAGUACUUCUCCUGA
  	AGACUCAGCUAUACUAACAGAGAGAAAUAACGCAGCGUAUG
  	GAAAACAUAUGCACGAUGCGGAGUUGUUCACAAAUGCAGGU
  	UACAUUGCGCUAAAUAUUUGGGACCGUUUCGACAUCUUUUG
  	UACCUUAGGAGCUACUAGUGGGUAUUUUAAAGGGAAUUCUU
  	CAUCUUUCAACUUGAUCGGAUUGAUUGGUAUUUCAGGAGCA
  	GACCUUAACAGCAAGCUCCCAAACGCAAAUAUUUCUAACGG
  	CGUAGUAGAGCUAUAUACAGACACAACCUUCUCUUGGAGCG
  	UUGGAGCUCGCGGAGCUUUGUGGGAGUGUGGUUGCGCUACU
  	UUAGGAGCAGAAUUCCAAUACGCACAAUCGAAACCUCGCGU
  	UCAAGAAUUGAAUGUCUUGUCUAACGUAGCACAAUUUACUG
  	UACACAAACCUCGGGGAUAUGUAGGCCAGCCUCUACCUCUU
  	CCACUGACUGCAGGAACAGCAACUGAUUCUAAUGAUAAAUU
  	GAAAAAUGCCACGAUCAACUACCAUGAAUGGCAAGUCGGUG
  	CAGCAUUGUCAUAUAGACUGAAUAUGCUCGUUCCUUACAUC
  	GGUGUUCAGUGGUCCAGAGCUACUUUUGAUGCAGAUACUAU
  	CCAAAUUGCGGAACCAAAAUUAGCUUCGCCAAUUUUCAACU
  	UGACAACAUGGAAUCCAACAUUAUUAGGACAAGCAACUUCA
  	GUAGAUAGCGGAAACAAGUUUGCUGACUCCCUACAAAUUGU
  	UUCUCUUCAAAUUAACAAGUUGAAGUCCAGAAAAGCUUGUG
  	GUGUUUCCAUGGGAGCAACUUUACUUGAUGCCGAUAAAUGG
  	GCAAUCAAUGGGGAACUUCGUUUAAUUAACGAAAGAGCUGC
  	UCACCUUUCUGCUCAAUGCAGAUUC
  * All Chlamydia mRNA vaccines contain standard 5′UTR and 3′UTR sequences and G5 Cap
  5′UTR:
  (SEQ ID NO: 295)
  TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGA
  AGAGTAAGAAGAAATATAAGAGCCACC
  5′UTR without promoter sequence:
  (SEQ ID NO: 296
  GGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAATATAAGAGCCACC
  3′UTR:
  (SEQ ID NO: 297)
  TGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCC
  CCTTCCTGCACCCGTACCCCCGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC

• TABLE 9
  Chlamydia mRNA Vaccine Expression Test

  	In vitro expression
  	(IF = immunofluorescence;
  	L = lysate, S = supernatant;
  mRNA Name	cS = Concentrated supernatant)
  Chlamydia_Ct089_nIgk_cHis	yes, (L, S, cS) high expression,
  	evidence of glycosylation
  Chlamydia_Ct460_serovarD_nIgk_cHis	yes (L, cS) medium expression,
  	likely glycosylated
  Chlamydia_Ct622_serovarE_nIgk_cHis	yes (cS only), low expression secreted,
  	evidence of Glycosylation
  Chlamydia_Ct858_nIgk_cHis	yes, (L only by WB and
  	LCMS -exp4, 7). In exp
  	15 saw band (ran a bit small
  	in both L and cSup (weak))
  Chlamydia_Ct871_pd_serovarD_nIgK_cHis	yes (L, cS), medium expression,
  	possibly glycosylated
  Chlamydia_Ct875_nIgk_cHis	yes (L, cS), very weak expression
  Ct089_E_S198A_nIgK_cHis	yes, (L, S, cS) high expression, evidence
  	of glycosylation
  Ct089_E_S198A_T306A_nIgK_cHis	yes, (L, S, cS) high expression,
  	evidence of residual glycosylation,
  	looks similar to T306A single mutant
  Ct089_E_T306A_nIgK_cHis	yes, (L, S, cS) high expression,
  	evidence of residual glycosylation
  Ct443_E_nIgK_cHis_mod	yes (L, cS), v weak in sup,
  	maybe glycosylated
  Ct622_E_S13N_S179A_S220N_nIgK_cHis	yes, mostly in cS. Evidence of
  	N-linked gly and possible other
  	modifications as multiple
  	sizes present in mutant
  Ct858_E_S491A_nIgK_cHis	yes, (L and cS) v. weakly secreted.
  	Comparable to wt in same exp.
  	Size looks a bit small.
  Ct875_E_nIgK_cHis_CO002	yes (L, cS), very very weak
  	expression
  Ct875_E_nIgK_cHis_CO003	yes (L, cS), very weak expression,
  	maybe slightly better then
  	original but not dramatic
  Ct875_E_nIgK_cHis_CO004	yes (L, cS), very very weak expression
  Ct875_E_nIgK_cHis_CO005	yes, similar to 1707458
  Ct875_E_nIgK_nHis	no expression
  Ct875_E_S274Q_N275H_5574D_nIgK_cHis	well expressed in L, not in sup.
  	Possible evidence of minor N-linked
  	glycosylation but would need
  	confirming
  Ctal_E_cHis	yes (strong in L, weak in cS)
  Ctal_E_noTM_nIgK_cHis	multiple bands in L, weak in sup
  MOMP_E_ nTMEM149	yes, surface expression (IF)
  MOMP_E_nFLRT2	yes, surface expression (IF)
  MOMP_E_nIgK	yes, surface expression (IF)
  MOMP_E_nOsteo	yes, surface expression (IF)
  MOMP_serovarE	yes, surface expression (IF)
  MOMP_serovarF	yes, surface expression (IF)
  MOMP_serovarG	yes, surface expression (IF)
  OMPA_H_CO	yes, surface expression (IF)

• TABLE 10
  Flagellin Nucleic Acid Sequences

  		SEQ ID
  Name	Sequence	NO:
  NT (5′	TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTAT	298
  UTR, ORF,	AGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAATATAAG
  3′ UTR)	AGCCACCATGGCACAAGTCATTAATACAAACAGCCTGTCGCTG
  	TTGACCCAGAATAACCTGAACAAATCCCAGTCCGCACTGGGCA
  	CTGCTATCGAGCGTTTGTCTTCCGGTCTGCGTATCAACAGCGCG
  	AAAGACGATGCGGCAGGACAGGCGATTGCTAACCGTTTTACCG
  	CGAACATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGA
  	CGGTATCTCCATTGCGCAGACCACTGAAGGCGCGCTGAACGAA
  	ATCAACAACAACCTGCAGCGTGTGCGTGAACTGGCGGTTCAGT
  	CTGCGAATGGTACTAACTCCCAGTCTGACCTCGACTCCATCCAG
  	GCTGAAATCACCCAGCGCCTGAACGAAATCGACCGTGTATCCG
  	GCCAGACTCAGTTCAACGGCGTGAAAGTCCTGGCGCAGGACAA
  	CACCCTGACCATCCAGGTTGGTGCCAACGACGGTGAAACTATC
  	GATATTGATTTAAAAGAAATCAGCTCTAAAACACTGGGACTTG
  	ATAAGCTTAATGTCCAAGATGCCTACACCCCGAAAGAAACTGC
  	TGTAACCGTTGATAAAACTACCTATAAAAATGGTACAGATCCT
  	ATTACAGCCCAGAGCAATACTGATATCCAAACTGCAATTGGCG
  	GTGGTGCAACGGGGGTTACTGGGGCTGATATCAAATTTAAAGA
  	TGGTCAATACTATTTAGATGTTAAAGGCGGTGCTTCTGCTGGTG
  	TTTATAAAGCCACTTATGATGAAACTACAAAGAAAGTTAATAT
  	TGATACGACTGATAAAACTCCGTTGGCAACTGCGGAAGCTACA
  	GCTATTCGGGGAACGGCCACTATAACCCACAACCAAATTGCTG
  	AAGTAACAAAAGAGGGTGTTGATACGACCACAGTTGCGGCTCA
  	ACTTGCTGCAGCAGGGGTTACTGGCGCCGATAAGGACAATACT
  	AGCCTTGTAAAACTATCGTTTGAGGATAAAAACGGTAAGGTTA
  	TTGATGGTGGCTATGCAGTGAAAATGGGCGACGATTTCTATGC
  	CGCTACATATGATGAGAAAACAGGTGCAATTACTGCTAAAACC
  	ACTACTTATACAGATGGTACTGGCGTTGCTCAAACTGGAGCTGT
  	GAAATTTGGTGGCGCAAATGGTAAATCTGAAGTTGTTACTGCT
  	ACCGATGGTAAGACTTACTTAGCAAGCGACCTTGACAAACATA
  	ACTTCAGAACAGGCGGTGAGCTTAAAGAGGTTAATACAGATAA
  	GACTGAAAACCCACTGCAGAAAATTGATGCTGCCTTGGCACAG
  	GTTGATACACTTCGTTCTGACCTGGGTGCGGTTCAGAACCGTTT
  	CAACTCCGCTATCACCAACCTGGGCAATACCGTAAATAACCTG
  	TCTTCTGCCCGTAGCCGTATCGAAGATTCCGACTACGCAACCGA
  	AGTCTCCAACATGTCTCGCGCGCAGATTCTGCAGCAGGCCGGT
  	ACCTCCGTTCTGGCGCAGGCGAACCAGGTTCCGCAAAACGTCC
  	TCTCTTTACTGCGTTGATAATAGGCTGGAGCCTCGGTGGCCATG
  	CTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTG
  	CACCCGTACCCCCGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC
  ORF	ATGGCACAAGTCATTAATACAAACAGCCTGTCGCTGTTGACCC	299
  Sequence,	AGAATAACCTGAACAAATCCCAGTCCGCACTGGGCACTGCTAT
  NT	CGAGCGTTTGTCTTCCGGTCTGCGTATCAACAGCGCGAAAGAC
  	GATGCGGCAGGACAGGCGATTGCTAACCGTTTTACCGCGAACA
  	TCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGTAT
  	CTCCATTGCGCAGACCACTGAAGGCGCGCTGAACGAAATCAAC
  	AACAACCTGCAGCGTGTGCGTGAACTGGCGGTTCAGTCTGCGA
  	ATGGTACTAACTCCCAGTCTGACCTCGACTCCATCCAGGCTGAA
  	ATCACCCAGCGCCTGAACGAAATCGACCGTGTATCCGGCCAGA
  	CTCAGTTCAACGGCGTGAAAGTCCTGGCGCAGGACAACACCCT
  	GACCATCCAGGTTGGTGCCAACGACGGTGAAACTATCGATATT
  	GATTTAAAAGAAATCAGCTCTAAAACACTGGGACTTGATAAGC
  	TTAATGTCCAAGATGCCTACACCCCGAAAGAAACTGCTGTAAC
  	CGTTGATAAAACTACCTATAAAAATGGTACAGATCCTATTACA
  	GCCCAGAGCAATACTGATATCCAAACTGCAATTGGCGGTGGTG
  	CAACGGGGGTTACTGGGGCTGATATCAAATTTAAAGATGGTCA
  	ATACTATTTAGATGTTAAAGGCGGTGCTTCTGCTGGTGTTTATA
  	AAGCCACTTATGATGAAACTACAAAGAAAGTTAATATTGATAC
  	GACTGATAAAACTCCGTTGGCAACTGCGGAAGCTACAGCTATT
  	CGGGGAACGGCCACTATAACCCACAACCAAATTGCTGAAGTAA
  	CAAAAGAGGGTGTTGATACGACCACAGTTGCGGCTCAACTTGC
  	TGCAGCAGGGGTTACTGGCGCCGATAAGGACAATACTAGCCTT
  	GTAAAACTATCGTTTGAGGATAAAAACGGTAAGGTTATTGATG
  	GTGGCTATGCAGTGAAAATGGGCGACGATTTCTATGCCGCTAC
  	ATATGATGAGAAAACAGGTGCAATTACTGCTAAAACCACTACT
  	TATACAGATGGTACTGGCGTTGCTCAAACTGGAGCTGTGAAAT
  	TTGGTGGCGCAAATGGTAAATCTGAAGTTGTTACTGCTACCGAT
  	GGTAAGACTTACTTAGCAAGCGACCTTGACAAACATAACTTCA
  	GAACAGGCGGTGAGCTTAAAGAGGTTAATACAGATAAGACTG
  	AAAACCCACTGCAGAAAATTGATGCTGCCTTGGCACAGGTTGA
  	TACACTTCGTTCTGACCTGGGTGCGGTTCAGAACCGTTTCAACT
  	CCGCTATCACCAACCTGGGCAATACCGTAAATAACCTGTCTTCT
  	GCCCGTAGCCGTATCGAAGATTCCGACTACGCAACCGAAGTCT
  	CCAACATGTCTCGCGCGCAGATTCTGCAGCAGGCCGGTACCTC
  	CGTTCTGGCGCAGGCGAACCAGGTTCCGCAAAACGTCCTCTCTT
  	TACTGCGT
  mRNA	G*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAA	300
  Sequence	GAGCCACCAUGGCACAAGUCAUUAAUACAAACAGCCUGUCGC
  (assumes	UGUUGACCCAGAAUAACCUGAACAAAUCCCAGUCCGCACUGG
  T100 tail)	GCACUGCUAUCGAGCGUUUGUCUUCCGGUCUGCGUAUCAACA
  	GCGCGAAAGACGAUGCGGCAGGACAGGCGAUUGCUAACCGUU
  	UUACCGCGAACAUCAAAGGUCUGACUCAGGCUUCCCGUAACG
  	CUAACGACGGUAUCUCCAUUGCGCAGACCACUGAAGGCGCGC
  	UGAACGAAAUCAACAACAACCUGCAGCGUGUGCGUGAACUGG
  	CGGUUCAGUCUGCGAAUGGUACUAACUCCCAGUCUGACCUCG
  	ACUCCAUCCAGGCUGAAAUCACCCAGCGCCUGAACGAAAUCG
  	ACCGUGUAUCCGGCCAGACUCAGUUCAACGGCGUGAAAGUCC
  	UGGCGCAGGACAACACCCUGACCAUCCAGGUUGGUGCCAACG
  	ACGGUGAAACUAUCGAUAUUGAUUUAAAAGAAAUCAGCUCU
  	AAAACACUGGGACUUGAUAAGCUUAAUGUCCAAGAUGCCUAC
  	ACCCCGAAAGAAACUGCUGUAACCGUUGAUAAAACUACCUAU
  	AAAAAUGGUACAGAUCCUAUUACAGCCCAGAGCAAUACUGAU
  	AUCCAAACUGCAAUUGGCGGUGGUGCAACGGGGGUUACUGG
  	GGCUGAUAUCAAAUUUAAAGAUGGUCAAUACUAUUUAGAUG
  	UUAAAGGCGGUGCUUCUGCUGGUGUUUAUAAAGCCACUUAU
  	GAUGAAACUACAAAGAAAGUUAAUAUUGAUACGACUGAUAA
  	AACUCCGUUGGCAACUGCGGAAGCUACAGCUAUUCGGGGAAC
  	GGCCACUAUAACCCACAACCAAAUUGCUGAAGUAACAAAAGA
  	GGGUGUUGAUACGACCACAGUUGCGGCUCAACUUGCUGCAGC
  	AGGGGUUACUGGCGCCGAUAAGGACAAUACUAGCCUUGUAA
  	AACUAUCGUUUGAGGAUAAAAACGGUAAGGUUAUUGAUGGU
  	GGCUAUGCAGUGAAAAUGGGCGACGAUUUCUAUGCCGCUACA
  	UAUGAUGAGAAAACAGGUGCAAUUACUGCUAAAACCACUAC
  	UUAUACAGAUGGUACUGGCGUUGCUCAAACUGGAGCUGUGA
  	AAUUUGGUGGCGCAAAUGGUAAAUCUGAAGUUGUUACUGCU
  	ACCGAUGGUAAGACUUACUUAGCAAGCGACCUUGACAAACAU
  	AACUUCAGAACAGGCGGUGAGCUUAAAGAGGUUAAUACAGA
  	UAAGACUGAAAACCCACUGCAGAAAAUUGAUGCUGCCUUGGC
  	ACAGGUUGAUACACUUCGUUCUGACCUGGGUGCGGUUCAGAA
  	CCGUUUCAACUCCGCUAUCACCAACCUGGGCAAUACCGUAAA
  	UAACCUGUCUUCUGCCCGUAGCCGUAUCGAAGAUUCCGACUA
  	CGCAACCGAAGUCUCCAACAUGUCUCGCGCGCAGAUUCUGCA
  	GCAGGCCGGUACCUCCGUUCUGGCGCAGGCGAACCAGGUUCC
  	GCAAAACGUCCUCUCUUUACUGCGUUGAUAAUAGGCUGGAGC
  	CUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCC
  	CCUCCUCCCCUUCCUGCACCCGUACCCCCGUGGUCUUUGAAU
  	AAAGUCUGAGUGGGCGGCAAAAAAAAAAAAAAAAAAAAAAA
  	AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
  	AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUAG

• TABLE 11
  Flagellin Amino Acid Sequences

  		SEQ ID
  Name	Sequence	NO:
  ORF	MAQVINTNSLSLLTQNNLNKSQSALGTAIERLSSGLRINSAKDDAA	301
  Sequence,	GQAIANRFTANIKGLTQASRNANDGISIAQTTEGALNEINNNLQRV
  AA	RELAVQSANGTNSQSDLDSIQAEITQRLNEIDRVSGQTQFNGVKVL
  	AQDNTLTIQVGANDGETIDIDLKEISSKTLGLDKLNVQDAYTPKET
  	AVTVDKTTYKNGTDPITAQSNTDIQTAIGGGATGVTGADIKFKDG
  	QYYLDVKGGASAGVYKATYDETTKKVNIDTTDKTPLATAEATAI
  	RGTATITHNQIAEVTKEGVDTTTVAAQLAAAGVTGADKDNTSLV
  	KLSFEDKNGKVIDGGYAVKMGDDFYAATYDEKTGAITAKTTTYT
  	DGTGVAQTGAVKFGGANGKSEVVTATDGKTYLASDLDKHNFRT
  	GGELKEVNTDKTENPLQKIDAALAQVDTLRSDLGAVQNRFNSAIT
  	NLGNTVNNLSSARSRIEDSDYATEVSNMSRAQILQQAGTSVLAQA
  	NQVPQNVLSLLR
  Flagellin-	MAQVINTNSLSLLTQNNLNKSQSALGTAIERLSSGLRINSAKDDAA	302
  GS linker-	GQAIANRFTANIKGLTQASRNANDGISIAQTTEGALNEINNNLQRV
  circumsporozoite	RELAVQSANSTNSQSDLDSIQAEITQRLNEIDRVSGQTQFNGVKVL
  protein	AQDNTLTIQVGANDGETIDIDLKQINSQTLGLDTLNVQQKYKVSD
  (CSP)	TAATVTGYADTTIALDNSTFKASATGLGGTDQKIDGDLKFDDTTG
  	KYYAKVTVTGGTGKDGYYEVSVDKTNGEVTLAGGATSPLTGGLP
  	ATATEDVKNVQVANADLTEAKAALTAAGVTGTASVVKMSYTDN
  	NGKTIDGGLAVKVGDDYYSATQNKDGSISINTTKYTADDGTSKTA
  	LNKLGGADGKTEVVSIGGKTYAASKAEGHNFKAQPDLAEAAATT
  	TENPLQKIDAALAQVDTLRSDLGAVQNRFNSAITNLGNTVNNLTS
  	ARSRIEDSDYATEVSNMSRAQILQQAGTSVLAQANQVPQNVLSLL
  	RGGGGSGGGGSMMAPDPNANPNANPNANPNANPNANPNANPNA
  	NPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPN
  	ANPNANPNKNNQGNGQGHNMPNDPNRNVDENANANNAVKNNN
  	NEEPSDKHIEQYLKKIKNSISTEWSPCSVTCGNGIQVRIKPGSANKP
  	KDELDYENDIEKKICKMEKCSSVFNVVNS
  Flagellin-	MMAPDPNANPNANPNANPNANPNANPNANPNANPNANPNANPN	303
  RPVT	ANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNKNN
  linker-	QGNGQGHNMPNDPNRNVDENANANNAVKNNNNEEPSDKHIEQY
  circumsporozoite	LKKIKNSISTEWSPCSVTCGNGIQVRIKPGSANKPKDELDYENDIEK
  protein	KICKMEKCSSVFNVVNSRPVT MAQVINTNSLSLLTQNNLNKSQSA
  (CSP)	LGTAIERLSSGLRINSAKDDAAGQAIANRFTANIKGLTQASRNAND
  	GISIAQTTEGALNEINNNLQRVRELAVQSANSTNSQSDLDSIQAEIT
  	QRLNEIDRVSGQTQFNGVKVLAQDNTLTIQVGANDGETIDIDLKQI
  	NSQTLGLDTLNVQQKYKVSDTAATVTGYADTTIALDNSTFKASAT
  	GLGGTDQKIDGDLKFDDTTGKYYAKVTVTGGTGKDGYYEVSVD
  	KTNGEVTLAGGATSPLTGGLPATATEDVKNVQVANADLTEAKAA
  	LTAAGVTGTASVVKMSYTDNNGKTIDGGLAVKVGDDYYSATQN
  	KDGSISINTTKYTADDGTSKTALNKLGGADGKTEVVSIGGKTYAA
  	SKAEGHNFKAQPDLAEAAATTTENPLQKIDAALAQVDTLRSDLG
  	AVQNRFNSAITNLGNTVNNLTSARSRIEDSDYATEVSNMSRAQILQ
  	QAGTSVLAQANQVPQNVLSLLR

• TABLE 12
  Signal Peptides

  		SEQ ID
  Description	Sequence	NO:
  HuIgGk signal	METPAQLLFLLLLWLPDTTG	304
  peptide
  IgE heavy chain	MDWTWILFLVAAATRVHS	305
  epsilon-1 signal
  peptide
  Japanese	MLGSNSGQRVVFTILLLLVAPAYS	306
  encephalitis PRM
  signal sequence
  VSVg protein	MKCLLYLAFLFIGVNCA	307
  signal sequence
  Japanese	MWLVSLAIVTACAGA	308
  encephalitis JEV
  signal sequence

• TABLE 13
  Leader Sequences

  		SEQ
  		ID
  Leader	Amino Acid Sequence	NO:
  Native Cm-MOMP	MKKLLKSVLAFAVLGSASSLHA	309
  Native CtD/CtE-MOMP	MKKLLKSVLVFAALGSASSLQA	310
  Shigella flexneri	MKSKFLVLALCVPAIFTTHA	311
  (SopA)
  Salmonella enterica	MKTHVIAVMIIAVFSESVYA	312
  (PgtE)
  Yersinia pestis (Pla)	MKKSSIVATIITILSGSANA	313
  E. coli OmpP	MQTKLLAIMLAAPVVFSSQEASA	314
  E. coli OmpA	MKKTAIAIAVALAGFATVAQA	315
  pectate lyase B of	MKYLLPTAAAGLLLLAAQPAMA	316
  Erwinia carotovora CE
  (PelB)

• TABLE 14
  In Vitro Expression of Chlamydia Trachomatic Antigens
  from Candidate mRNA Vaccines

  			Observed
  	Expected	Observed	Size in	Observed
  	Size	Size in	cell	Size in
  Antigen	(kDa)	in vitro QC	supernatants	cell lysates

  Ct-089	48.37	56.34	~60-75	~55, 70, 75
  Ct-858	68.02	75.65	—	~70
  	(zymogen)
  Ct-875	69.08	71.84	~70	—
  Ct-622	71.9	~79	~90	80
  Ct-460	12.7	11-12	11-13	~13
  PmPG_pd	72	~80	~85	~80
  Cta1	19.9	20.5	19	19-27
  Ct-443	59.3	—	~60	60
  			(diffused
  			and weak)
  Ct821pd_D	124	—	no band	~125

EQUIVALENTS
• Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the disclosure described herein. Such equivalents are intended to be encompassed by the following claims.
• All references, including patent documents, disclosed herein are incorporated by reference in their entirety.

Claims (103)

What is claimed is:

1. A sexually transmitted disease (STD) vaccine, comprising:

at least one RNA polynucleotide having an open reading frame encoding at least one STD antigenic polypeptide, formulated in a cationic lipid nanoparticle.

2. The STD vaccine of claim 1, wherein the antigenic polypeptide is selected from human papillomavirus (HPV), herpes simplex virus (HSV) and Chlamydia trachomatis antigenic polypeptides.

3. A human papillomavirus (HPV) vaccine, comprising:

at least one ribonucleic acid (RNA) polynucleotide having an open reading frame encoding at least one HPV antigenic polypeptide or an immunogenic fragment thereof.

4. The vaccine of claim 3, wherein the at least one antigenic polypeptide is selected from HPV E1 protein, HPV E2 protein, HPV E4 protein, HPV E5 protein, HPV E6 protein, HPV E7 protein, HPV L1 protein, and HPV L2 protein, optionally wherein the HPV serotype is selected from HPV serotypes 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 and 82.

5. The vaccine of claim 3 or 4, wherein the vaccine comprises at least one RNA polynucleotide having an open reading frame encoding at least two antigenic polypeptides or immunogenic fragments thereof selected from HPV E1 protein, HPV E2 protein, HPV E4 protein, HPV E5 protein, HPV E6 protein, HPV E7 protein, HPV L1 protein, and HPV L2 protein.

6. The vaccine of any one of claims 3-5, wherein the vaccine comprises at least two RNA polynucleotides, each having an open reading frame encoding at least one antigenic polypeptide or an immunogenic fragment thereof selected from HPV E1 protein, HPV E2 protein, HPV E4 protein, HPV E5 protein, HPV E6 protein, HPV E7 protein, HPV L1 protein, and HPV L2 protein, wherein the HPV antigenic polypeptide encoded by one of the open reading frames differs from the HPV antigenic polypeptide encoded by another of the open reading frames.

7. The vaccine of any one of claims 3-6, wherein the at least one antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 31-61.

8. The vaccine of any one of claims 3-7, wherein the at least one RNA polypeptide is encoded by a nucleic acid sequence identified by any one of SEQ ID NO: 1-30, and/or wherein the at least one RNA polypeptide comprises a nucleic acid sequence identified by any one of SEQ ID NO: 431-461.

9. The vaccine of any one of claims 3-8, wherein the at least one antigenic polypeptide has an amino acid sequence that has at least 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 31-61.

10. The vaccine of any one of claims 3-9, wherein the at least one antigenic polypeptide has an amino acid sequence that has 95%-99% identity to an amino acid sequence identified by any one of SEQ ID NO: 31-61.

11. The vaccine of any one of claims 3-10, wherein the at least one antigenic polypeptide has an amino acid sequence that has at least 90% identity to an amino acid sequence of SEQ ID NO: 31-61 and wherein the antigenic polypeptide or immunogenic fragment thereof has membrane fusion activity, attaches to cell receptors, causes fusion of viral and cellular membranes, and/or is responsible for binding of the virus to a cell being infected.

12. The vaccine of any one of claims 3-11, wherein the at least one antigenic polypeptide has an amino acid sequence that has 90%-99% identity to an amino acid sequence of SEQ ID NO: 31-61 and wherein the antigenic polypeptide or immunogenic fragment thereof has membrane fusion activity, attaches to cell receptors, causes fusion of viral and cellular membranes, and/or is responsible for binding of the virus to a cell being infected.

13. A Chlamydia vaccine, comprising:

at least one ribonucleic acid (RNA) polynucleotide having an open reading frame encoding at least one Chlamydia trachomatis antigenic polypeptide or an immunogenic fragment thereof.

14. The vaccine of claim 13, wherein the at least one antigenic polypeptide is a major outer membrane protein (MOMP) or an immunogenic fragment thereof, optionally having a Chlamydia trachomatis serovar selected serovar H, F, E, D, I, G, J and K.

15. The vaccine of claim 13 or 14, wherein the vaccine comprises at least one RNA polynucleotide having an open reading frame encoding at least two antigenic polypeptides or immunogenic fragments thereof selected from a MOMP of serovar H, a MOMP of serovar F, a MOMP of serovar E, a MOMP of serovar D, a MOMP of serovar I, a MOMP of serovar G, a MOMP of serovar J, and a MOMP of serovar K.

16. The vaccine of any one of claims 13-15, wherein the vaccine comprises at least two RNA polynucleotides, each having an open reading frame encoding at least one antigenic polypeptide or an immunogenic fragment thereof selected from a MOMP of serovar H, a MOMP of serovar F, a MOMP of serovar E, a MOMP of serovar D, a MOMP of serovar I, a MOMP of serovar G, a MOMP of serovar J, and a MOMP of serovar K, wherein the antigenic polypeptide encoded by one of the open reading frames differs from the antigenic polypeptide encoded by another of the open reading frames.

17. The vaccine of any one of claims 13-16, wherein the at least one antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 65-183.

18. The vaccine of any one of claims 13-17, wherein the at least one RNA polypeptide is encoded by a nucleic acid sequence identified by any one of SEQ ID NO: 62-64 or 184-294, and/or wherein the at least one RNA polypeptide comprises a nucleic acid sequence identified by any one of SEQ ID NO: 317-430.

19. The vaccine of any one of claims 13-18, wherein the at least one antigenic polypeptide has an amino acid sequence that has at least 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 65-183.

20. The vaccine of any one of claims 13-19, wherein the at least one antigenic polypeptide has an amino acid sequence that has 95%-99% identity to an amino acid sequence identified by any one of SEQ ID NO: 65-183.

21. The vaccine of any one of claims 13-20, wherein the at least one antigenic polypeptide has an amino acid sequence that has at least 90% identity to an amino acid sequence of SEQ ID NO: 65-183 and wherein the antigenic polypeptide or immunogenic fragment thereof has membrane fusion activity, attaches to cell receptors, causes fusion of viral and cellular membranes, and/or is responsible for binding of the virus to a cell being infected.

22. The vaccine of any one of claims 13-21, wherein the at least one antigenic polypeptide has an amino acid sequence that has 90%-99% identity to an amino acid sequence of SEQ ID NO: 65-183 and wherein the antigenic polypeptide or immunogenic fragment thereof has membrane fusion activity, attaches to cell receptors, causes fusion of viral and cellular membranes, and/or is responsible for binding of the virus to a cell being infected.

23. A sexually transmitted disease (STD) vaccine, comprising:

at least one ribonucleic acid (RNA) polynucleotide having an open reading frame encoding at least two antigenic polypeptides selected from human papillomavirus (HPV) antigenic polypeptides or immunogenic fragments thereof, herpes simplex virus (HSV) antigenic polypeptides or immunogenic fragments thereof, and Chlamydia trachomatis antigenic polypeptides or immunogenic fragments thereof.

24. The vaccine of claim 23, wherein at least one HPV antigenic polypeptide is selected from HPV E1 protein, HPV E2 protein, HPV E4 protein, HPV E5 protein, HPV E6 protein, HPV E7 protein, HPV L1 protein, and HPV L2 protein; and/or wherein at least one HSV antigenic polypeptide is selected from glycoprotein B, HSV glycoprotein C, HSV glycoprotein D, HSV glycoprotein E, and HSV (glycoprotein I); and/or wherein at least one Chlamydia trachomatis antigenic polypeptide is a MOMP antigenic polypeptide.

25. The vaccine of claim 23, wherein the vaccine comprises at least one RNA polynucleotide having an open reading frame encoding at least two antigenic polypeptides or immunogenic fragments thereof selected from HPV antigenic polypeptides or immunogenic fragments thereof, HSV antigenic polypeptides or immunogenic fragments thereof, and Chlamydia trachomatis antigenic polypeptides or immunogenic fragments thereof.

26. The vaccine of any one of claims 23-25, wherein the vaccine comprises at least two RNA polynucleotides, each having an open reading frame encoding at least one antigenic polypeptide or an immunogenic fragment thereof selected from HPV antigenic polypeptides or immunogenic fragments thereof, HSV antigenic polypeptides or immunogenic fragments thereof, and Chlamydia trachomatis antigenic polypeptides or immunogenic fragments thereof, wherein the antigenic polypeptide encoded by one of the open reading frames differs from the antigenic polypeptide encoded by another of the open reading frames.

27. The vaccine of any one of claims 23-26, wherein the at least one antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 31-61 or 65-183.

28. The vaccine of any one of claims 23-27, wherein the at least one RNA polypeptide is encoded by a nucleic acid sequence identified by any one of SEQ ID NO: 1-28, 62-64 or 184-294, and/or wherein the at least one RNA polypeptide comprises a nucleic acid sequence identified by any one of SEQ ID NO: 317-319 or 320-461.

29. The vaccine of any one of claims 23-25, wherein the at least one antigenic polypeptide has an amino acid sequence that has at least 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 31-61 or 65-183.

30. The vaccine of any one of claims 23-25, wherein the at least one antigenic polypeptide has an amino acid sequence that has 95%-99% identity to an amino acid sequence identified by any one of SEQ ID NO: 31-61 or 65-183.

31. The vaccine of any one of claims 23-25, wherein the at least one antigenic polypeptide has an amino acid sequence that has at least 90% identity to an amino acid sequence of SEQ ID NO: 31-61 or 65-183 and wherein the antigenic polypeptide or immunogenic fragment thereof has membrane fusion activity, attaches to cell receptors, causes fusion of viral and cellular membranes, and/or is responsible for binding of the virus to a cell being infected.

32. The vaccine of any one of claims 23-25, wherein the at least one antigenic polypeptide has an amino acid sequence that has 90%-99% identity to an amino acid sequence of SEQ ID NO: 31-61 or 65-183 and wherein the antigenic polypeptide or immunogenic fragment thereof has membrane fusion activity, attaches to cell receptors, causes fusion of viral and cellular membranes, and/or is responsible for binding of the virus to a cell being infected.

33. The vaccine of any one of claims 1-32, wherein the at least one RNA polynucleotide has less than 80% identity to wild-type mRNA sequence.

34. The vaccine of any one of claims 1-32, wherein at least one RNA polynucleotide has at least 80% identity to wild-type mRNA sequence, but does not include wild-type mRNA sequence.

35. The vaccine of any one of claims 1-34, wherein the at least one antigenic polypeptide has membrane fusion activity, attaches to cell receptors, causes fusion of viral and cellular membranes, and/or is responsible for binding of the virus to a cell being infected.

36. The vaccine of any one of claims 1-35, wherein the at least one RNA polynucleotide comprises at least one chemical modification.

37. The vaccine of claim 36, wherein the chemical modification is selected from pseudouridine, N1-methylpseudouridine, N1-ethylpseudouridine, 2-thiouridine, 4′-thiouridine, 5-methylcytosine, 5-methyluridine, 2-thio-1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methoxyuridine and 2′-O-methyl uridine.

38. The vaccine of claim 36 or 37, wherein the chemical modification is in the 5-position of the uracil.

39. The vaccine of any one of claims 36-38, wherein the chemical modification is a N1-methylpseudouridine or N1-ethylpseudouridine.

40. The vaccine of any one of claims 36-39, wherein at least 80% of the uracil in the open reading frame have a chemical modification.

41. The vaccine of claim 40, wherein at least 90% of the uracil in the open reading frame have a chemical modification.

42. The vaccine of claim 41, wherein 100% of the uracil in the open reading frame have a chemical modification.

43. The vaccine of any one of claims 1-42, wherein at least one RNA polynucleotide further encodes at least one 5′ terminal cap.

44. The vaccine of claim 43, wherein the 5′ terminal cap is 7mG(5′)ppp(5′)NlmpNp.

45. The vaccine of any one of claims 1-44, wherein at least one antigenic polypeptide or immunogenic fragment thereof is fused to a signal peptide selected from: a HuIgGk signal peptide (METPAQLLFLLLLWLPDTTG; SEQ ID NO: 304); IgE heavy chain epsilon-1 signal peptide (MDWTWILFLVAAATRVHS; SEQ ID NO: 305); Japanese encephalitis PRM signal sequence (MLGSNSGQRVVFTILLLLVAPAYS; SEQ ID NO: 306), VSVg protein signal sequence (MKCLLYLAFLFIGVNCA; SEQ ID NO: 307) and Japanese encephalitis JEV signal sequence (MWLVSLAIVTACAGA; SEQ ID NO: 308).

46. The vaccine of claim 45, wherein the signal peptide is fused to the N-terminus of at least one antigenic polypeptide.

47. The vaccine of claim 45, wherein the signal peptide is fused to the C-terminus of at least one antigenic polypeptide.

48. The vaccine of any one of claims 1-47, wherein the antigenic polypeptide or immunogenic fragment thereof comprises a mutated N-linked glycosylation site.

49. The vaccine of any one of claims 3-48 formulated in a nanoparticle.

50. The vaccine of claim 49, wherein the nanoparticle is a lipid nanoparticle.

51. The vaccine of claim 1, 2, 50 or 51, wherein the nanoparticle has a mean diameter of 50-200 nm.

52. The vaccine of claim 1, 2, 50 or 51, wherein the lipid nanoparticle comprises a cationic lipid, a PEG-modified lipid, a sterol and a non-cationic lipid.

53. The vaccine of claim 52, wherein the lipid nanoparticle carrier comprises a molar ratio of about 20-60% cationic lipid, 0.5-15% PEG-modified lipid, 25-55% sterol, and 25% non-cationic lipid.

54. The vaccine of claim 52 or 53, wherein the cationic lipid is an ionizable cationic lipid and the non-cationic lipid is a neutral lipid, and the sterol is a cholesterol.

55. The vaccine of any one of claim 53 or 54, wherein the cationic lipid is selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319).

56. The vaccine of any one of claims 1, 2, 50-55, wherein the lipid nanoparticle comprises a compound of Formula (I), optionally Compound 3, 18, 20, 25, 26, 29, 30, 60, 108-112, or 122.

57. The vaccine of any one of claims 1, 2, 50-55, wherein the lipid nanoparticle comprises a compound of Formula (II).

58. The vaccine of any one of claims 1-57, wherein the nanoparticle has a polydispersity value of less than 0.4.

59. The vaccine of any one of claims 1-58, wherein the nanoparticle has a net neutral charge at a neutral pH value.

60. The vaccine of any one of claims 1-59 further comprising an adjuvant.

61. The vaccine of claim 60, wherein the adjuvant is a flagellin protein or peptide.

62. The vaccine of claim 61, wherein the flagellin protein or peptide comprises an amino acid sequence identified by any one of SEQ ID NO: 301-303.

63. The vaccine of any one of claims 1-62, wherein the open reading frame is codon-optimized.

64. The vaccine of any one of claims 1-63, wherein the vaccine is multivalent.

65. The vaccine of any one of claims 1-64 formulated in an effective amount to produce an antigen-specific immune response.

66. A method of inducing an immune response in a subject, the method comprising administering to the subject the vaccine of any one of claims 1-65 in an amount effective to produce an antigen-specific immune response in the subject.

67. The method of claim 66, wherein the antigen specific immune response comprises a T cell response or a B cell response.

68. The method of claim 66 or 67, wherein the subject is administered a single dose of the vaccine.

69. The method of claim 66 or 67, wherein the subject is administered a booster dose of the vaccine.

70. The method of any one of claims 66-69, wherein the vaccine is administered to the subject by intradermal injection or intramuscular injection.

71. The method of any one of claims 66-70, wherein an anti-antigenic polypeptide antibody titer produced in the subject is increased by at least 1 log relative to a control.

72. The method of any one of claims 66-71, wherein an anti-antigenic polypeptide antibody titer produced in the subject is increased by 1-3 log relative to a control.

73. The method of any one of claims 66-72, wherein the anti-antigenic polypeptide antibody titer produced in the subject is increased at least 2 times relative to a control.

74. The method of any one of claims 66-73, wherein the anti-antigenic polypeptide antibody titer produced in the subject is increased 2-10 times relative to a control.

75. The method of any one of claims 71-74, wherein the control is an anti-antigenic polypeptide antibody titer produced in a subject who has not been administered a vaccine against the virus.

76. The method of any one of claims 71-74, wherein the control is an anti-antigenic polypeptide antibody titer produced in a subject who has been administered a live attenuated vaccine or an inactivated vaccine against the virus.

77. The method of any one of claims 71-74, wherein the control is an anti-antigenic polypeptide antibody titer produced in a subject who has been administered a recombinant protein vaccine or purified protein vaccine against the virus.

78. The method of any one of claims 71-74, wherein the control is an anti-antigenic polypeptide antibody titer produced in a subject who has been administered a VLP vaccine against the virus.

79. The method of any one of claims 66-78, wherein the effective amount is a dose equivalent to an at least 2-fold reduction in the standard of care dose of a recombinant protein vaccine or a purified protein vaccine against the virus, and wherein an anti-antigenic polypeptide antibody titer produced in the subject is equivalent to an anti-antigenic polypeptide antibody titer produced in a control subject administered the standard of care dose of a recombinant protein vaccine or a purified protein vaccine against the virus, respectively.

80. The method of any one of claims 66-78, wherein the effective amount is a dose equivalent to an at least 2-fold reduction in the standard of care dose of a live attenuated vaccine or an inactivated vaccine against the virus, and wherein an anti-antigenic polypeptide antibody titer produced in the subject is equivalent to an anti-antigenic polypeptide antibody titer produced in a control subject administered the standard of care dose of a live attenuated vaccine or an inactivated vaccine against the virus, respectively.

81. The method of any one of claims 66-78, wherein the effective amount is a dose equivalent to an at least 2-fold reduction in the standard of care dose of a VLP vaccine against the virus, and wherein an anti-antigenic polypeptide antibody titer produced in the subject is equivalent to an anti-antigenic polypeptide antibody titer produced in a control subject administered the standard of care dose of a VLP vaccine against the virus.

82. The method of any one of claims 66-81, wherein the effective amount is a total dose of 50 μg-1000 μg.

83. The method of claim 82, wherein the effective amount is a dose of 25 μg, 100 μg, 400 μg, or 500 μg administered to the subject a total of two times.

84. The method of any one of claims 66-83, wherein the efficacy of the vaccine against the virus is greater than 65%.

85. The method of any one of claims 66-84, wherein the vaccine immunizes the subject against the virus for up to 2 years.

86. The method of any one of claims 66-84, wherein the vaccine immunizes the subject against the virus for more than 2 years.

87. The method of any one of claims 66-86, wherein the subject has an age of about 12 to about 50 years old.

88. The method of any one of claims 66-87, wherein the subject has been exposed to the virus, wherein the subject is infected with the virus, or wherein the subject is at risk of infection by the virus.

89. The method of any one of claims 66-88, wherein the subject is immunocompromised.

90. The vaccine of any one of claims 1-65 for use in a method of inducing an antigen specific immune response in a subject, the method comprising administering to the subject the vaccine in an amount effective to produce an antigen specific immune response in the subject.

91. Use of the vaccine of any one of claims 1-65 in the manufacture of a medicament for use in a method of inducing an antigen specific immune response in a subject, the method comprising administering to the subject the vaccine in an amount effective to produce an antigen specific immune response in the subject.

92. An engineered nucleic acid encoding at least one RNA polynucleotide of a vaccine of any one of claims 1-65.

93. A pharmaceutical composition for use in vaccination of a subject comprising an effective dose of mRNA encoding a sexually transmitted disease antigen, wherein the effective dose is sufficient to produce detectable levels of antigen as measured in serum of the subject at 1-72 hours post administration.

94. The composition of claim 93, wherein the cut off index of the antigen is 1-2.

95. A pharmaceutical composition for use in vaccination of a subject comprising an effective dose of mRNA encoding a sexually transmitted disease antigen, wherein the effective dose is sufficient to produce a 1,000-10,000 neutralization titer produced by neutralizing antibody against said antigen as measured in serum of the subject at 1-72 hours post administration.

96. A vaccine comprising an mRNA encoding a sexually transmitted disease antigen formulated in a lipid nanoparticle comprising compounds of Formula (I):

or a salt or isomer thereof, wherein:

R₁ is selected from the group consisting of C_5-30 alkyl, C_5-20 alkenyl, —R*YR″, —YR″, and —R″M′R′;

R₂ and R₃ are independently selected from the group consisting of H, C_1-14 alkyl, C_2-14 alkenyl, —R*YR″, —YR″, and —R*OR″, or R₂ and R₃, together with the atom to which they are attached, form a heterocycle or carbocycle;

R₄ is selected from the group consisting of a C_3-6 carbocycle, —(CH₂)_nQ, —(CH₂)_nCHQR, —CHQR, —CQ(R)₂, and unsubstituted C_1-6 alkyl, where Q is selected from a carbocycle, heterocycle, —OR, —O(CH₂)_nN(R)₂, —C(O)OR, —OC(O)R, —CX₃, —CX₂H, —CXH₂, —CN, —N(R)₂, —C(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R, —N(R)C(O)N(R)₂, —N(R)C(S)N(R)₂, —N(R)R₈, —O(CH₂)_nOR, —N(R)C(═NR₉)N(R)₂, —N(R)C(═CHR₉)N(R)₂, —OC(O)N(R)₂, —N(R)C(O)OR, —N(OR)C(O)R, —N(OR)S(O)₂R, —N(OR)C(O)OR, —N(OR)C(O)N(R)₂, —N(OR)C(S)N(R)₂, —N(OR)C(═NR₉)N(R)₂, —N(OR)C(═CHR₉)N(R)₂, —C(═NR₉)N(R)₂, —C(═NR₉)R, —C(O)N(R)O R, and —C(R)N(R)₂C(O)OR, and each n is independently selected from 1, 2, 3, 4, and 5;

each R₅ is independently selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;

each R₆ is independently selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;

M and M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)₂—, —S—S—, an aryl group, and a heteroaryl group;

R₇ is selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;

R₈ is selected from the group consisting of C_3-6 carbocycle and heterocycle;

R₉ is selected from the group consisting of H, CN, NO₂, C_1-6 alkyl, —OR, —S(O)₂R, —S(O)₂N(R)₂, C_2-6 alkenyl, C_3-6 carbocycle and heterocycle;

each R is independently selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;

each R′ is independently selected from the group consisting of C_1-18 alkyl, C_2-18 alkenyl, —R*YR″, —YR″, and H;

each R″ is independently selected from the group consisting of C_3-14 alkyl and C_3-14 alkenyl;

each R* is independently selected from the group consisting of C_1-12 alkyl and C_2-12 alkenyl;

each Y is independently a C_3-6 carbocycle;

each X is independently selected from the group consisting of F, Cl, Br, and I; and

m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13.

97. The vaccine of claim 96, wherein a subset of compounds of Formula (I) includes those in which when R₄ is —(CH₂)_nQ, —(CH₂)_nCHQR, —CHQR, or -CQ(R)₂, then (i) Q is not —N(R)₂ when n is 1, 2, 3, 4 or 5, or (ii) Q is not 5, 6, or 7-membered heterocycloalkyl when n is 1 or 2.

98. The vaccine of claim 96, wherein a subset of compounds of Formula (I) includes those in which

R₁ is selected from the group consisting of C_5-30 alkyl, C_5-20 alkenyl, —R*YR″, —YR″, and —R″M′R′;

R₂ and R₃ are independently selected from the group consisting of H, C_1-14 alkyl, C_2-14 alkenyl, —R*YR″, —YR″, and —R*OR″, or R₂ and R₃, together with the atom to which they are attached, form a heterocycle or carbocycle;

R₄ is selected from the group consisting of a C_3-6 carbocycle, —(CH₂)_nQ, —(CH₂)_nCHQR, —CHQR, —CQ(R)₂, and unsubstituted C_1-6 alkyl, where Q is selected from a C_3-6 carbocycle, a 5- to 14-membered heteroaryl having one or more heteroatoms selected from N, O, and S, —OR, —O(CH₂)—N(R)₂, —C(O)OR, —OC(O)R, —CX₃, —CX₂H, —CXH₂, —CN, —C(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R, —N(R)C(O)N(R)₂, —N(R)C(S)N(R)₂, —CRN(R)₂C(O)OR, —N(R)R₈, —O(CH₂)_nOR, —N(R)C(═NR₉)N(R)₂, —N(R)C(═CHR₉)N(R)₂, —OC(O)N(R)₂, —N(R)C(O)OR, —N(OR)C(O)R, —N(OR)S(O)₂R, —N(OR)C(O)OR, —N(OR)C(O)N(R)₂, —N(OR)C(S)N(R)₂, —N(OR)C(═NR₉)N(R)₂, —N(OR)C(═CHR₉)N(R)₂, —C(═NR₉)N(R)₂, —C(═NR₉)R, —C(O)N(R)O R, and a 5- to 14-membered heterocycloalkyl having one or more heteroatoms selected from N, O, and S which is substituted with one or more substituents selected from oxo (═O), OH, amino, mono- or di-alkylamino, and C_1-3 alkyl, and each n is independently selected from 1, 2, 3, 4, and 5;

each R₅ is independently selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;

each R₆ is independently selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;

M and M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)₂—, —S—S—, an aryl group, and a heteroaryl group;

R₇ is selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;

R₈ is selected from the group consisting of C_3-6 carbocycle and heterocycle;

R₉ is selected from the group consisting of H, CN, NO₂, C_1-6 alkyl, —OR, —S(O)₂R, —S(O)₂N(R)₂, C_2-6 alkenyl, C_3-6 carbocycle and heterocycle;

each R is independently selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;

each R′ is independently selected from the group consisting of C_1-18 alkyl, C_2-18 alkenyl, —R*YR″, —YR″, and H;

each R″ is independently selected from the group consisting of C_3-14 alkyl and C_3-14 alkenyl;

each R* is independently selected from the group consisting of C_1-12 alkyl and C_2-12 alkenyl;

each Y is independently a C_3-6 carbocycle;

each X is independently selected from the group consisting of F, Cl, Br, and I; and

m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,

or salts or isomers thereof.

99. The vaccine of claim 96, wherein a subset of compounds of Formula (I) includes those in which

R₁ is selected from the group consisting of C_5-30 alkyl, C_5-20 alkenyl, —R*YR″, —YR″, and —R″M′R′;

R₂ and R₃ are independently selected from the group consisting of H, C_1-14 alkyl, C_2-14 alkenyl, —R*YR″, —YR″, and —R*OR″, or R₂ and R₃, together with the atom to which they are attached, form a heterocycle or carbocycle;

R₄ is selected from the group consisting of a C_3-6 carbocycle, —(CH₂)_nQ, —(CH₂)_nCHQR, —CHQR, —CQ(R)₂, and unsubstituted C_1-6 alkyl, where Q is selected from a C_3-6 carbocycle, a 5- to 14-membered heterocycle having one or more heteroatoms selected from N, O, and S, —OR, —O(CH₂)—N(R)₂, —C(O)OR, —OC(O)R, —CX₃, —CX₂H, —CXH₂, —CN, —C(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R, —N(R)C(O)N(R)₂, —N(R)C(S)N(R)₂, —CRN(R)₂C(O)OR, —N(R)R₈, —O(CH₂)_nOR, —N(R)C(═NR₉)N(R)₂, —N(R)C(═CHR₉)N(R)₂, —OC(O)N(R)₂, —N(R)C(O)OR, —N(OR)C(O)R, —N(OR)S(O)₂R, —N(OR)C(O)OR, —N(OR)C(O)N(R)₂, —N(OR)C(S)N(R)₂, —N(OR)C(═NR₉)N(R)₂, —N(OR)C(═CHR₉)N(R)₂, —C(═NR₉)R, —C(O)N(R)OR, and —C(═NR₉) N(R)₂, and each n is independently selected from 1, 2, 3, 4, and 5; and when Q is a 5- to 14-membered heterocycle and (i) R₄ is —(CH₂)_nQ in which n is 1 or 2, or (ii) R₄ is —(CH₂)_nCHQR in which n is 1, or (iii) R₄ is —CHQR, and —CQ(R)₂, then Q is either a 5- to 14-membered heteroaryl or 8- to 14-membered heterocycloalkyl;

each R₅ is independently selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;

each R₆ is independently selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;

M and M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)₂—, —S—S—, an aryl group, and a heteroaryl group;

R₇ is selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;

R₈ is selected from the group consisting of C_3-6 carbocycle and heterocycle;

R₉ is selected from the group consisting of H, CN, NO₂, C_1-6 alkyl, —OR, —S(O)₂R, —S(O)₂N(R)₂, C_2-6 alkenyl, C_3-6 carbocycle and heterocycle;

each R is independently selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;

each R′ is independently selected from the group consisting of C_1-18 alkyl, C_2-18 alkenyl, —R*YR″, —YR″, and H;

each R″ is independently selected from the group consisting of C_3-14 alkyl and C_3-14 alkenyl;

each R* is independently selected from the group consisting of C_1-12 alkyl and C_2-12 alkenyl;

each Y is independently a C_3-6 carbocycle;

each X is independently selected from the group consisting of F, Cl, Br, and I; and

m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,

or salts or isomers thereof.

100. The vaccine of claim 96, wherein a subset of compounds of Formula (I) includes those in which

R₁ is selected from the group consisting of C_5-30 alkyl, C_5-20 alkenyl, —R*YR″, —YR″, and —R″M′R′;

R₂ and R₃ are independently selected from the group consisting of H, C_1-14 alkyl, C_2-14 alkenyl, —R*YR″, —YR″, and —R*OR″, or R₂ and R₃, together with the atom to which they are attached, form a heterocycle or carbocycle;

R₄ is selected from the group consisting of a C_3-6 carbocycle, —(CH₂)_nQ, —(CH₂)_nCHQR, —CHQR, —CQ(R)₂, and unsubstituted C_1-6 alkyl, where Q is selected from a C_3-6 carbocycle, a 5- to 14-membered heteroaryl having one or more heteroatoms selected from N, O, and S, —OR, —O(CH₂)_nN(R)₂, —C(O)OR, —OC(O)R, —CX₃, —CX₂H, —CXH₂, —CN, —C(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R, —N(R)C(O)N(R)₂, —N(R)C(S)N(R)₂, —CRN(R)₂C(O)OR, —N(R)R₈, —O(CH₂)_nOR, —N(R)C(═NR₉)N(R)₂, —N(R)C(═CHR₉)N(R)₂, —OC(O)N(R)₂, —N(R)C(O)OR, —N(OR)C(O)R, —N(OR)S(O)₂R, —N(OR)C(O)OR, —N(OR)C(O)N(R)₂, —N(OR)C(S)N(R)₂, —N(OR)C(═NR₉)N(R)₂, —N(OR)C(═CHR₉)N(R)₂, —C(═NR₉)R, —C(O)N(R)OR, and —C(═NR₉) N(R)₂, and each n is independently selected from 1, 2, 3, 4, and 5;

each R₅ is independently selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;

each R₆ is independently selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;

M and M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)₂—, —S—S—, an aryl group, and a heteroaryl group;

R₇ is selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;

R₈ is selected from the group consisting of C_3-6 carbocycle and heterocycle;

R₉ is selected from the group consisting of H, CN, NO₂, C_1-6 alkyl, —OR, —S(O)₂R, —S(O)₂N(R)₂, C_2-6 alkenyl, C_3-6 carbocycle and heterocycle;

each R is independently selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;

each R′ is independently selected from the group consisting of C_1-18 alkyl, C_2-18 alkenyl, —R*YR″, —YR″, and H;

each R″ is independently selected from the group consisting of C_3-14 alkyl and C_3-14 alkenyl;

each R* is independently selected from the group consisting of C_1-12 alkyl and C_2-12 alkenyl;

each Y is independently a C_3-6 carbocycle;

each X is independently selected from the group consisting of F, Cl, Br, and I; and

m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,

or salts or isomers thereof.

101. The vaccine of claim 96, wherein subset of compounds of Formula (I) includes those in which

R₁ is selected from the group consisting of C_5-30 alkyl, C_5-20 alkenyl, —R*YR″, —YR″, and —R″M′R′;

R₂ and R₃ are independently selected from the group consisting of H, C_2-14 alkyl, C_2-14 alkenyl, —R*YR″, —YR″, and —R*OR″, or R₂ and R₃, together with the atom to which they are attached, form a heterocycle or carbocycle;

R₄ is —(CH₂)_nQ or —(CH₂)_nCHQR, where Q is —N(R)₂, and n is selected from 3, 4, and 5;

each R₅ is independently selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;

each R₆ is independently selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;

M and M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)₂—, —S—S—, an aryl group, and a heteroaryl group;

R₇ is selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;

each R is independently selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;

each R′ is independently selected from the group consisting of C_1-18 alkyl, C_2-18 alkenyl, —R*YR″, —YR″, and H;

each R″ is independently selected from the group consisting of C_3-14 alkyl and C_3-14 alkenyl;

each R* is independently selected from the group consisting of C_1-12 alkyl and C_1-12 alkenyl;

each Y is independently a C_3-6 carbocycle;

each X is independently selected from the group consisting of F, Cl, Br, and I; and

m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,

or salts or isomers thereof.

102. The vaccine of claim 96, wherein a subset of compounds of Formula (I) includes those in which

R₁ is selected from the group consisting of C_5-30 alkyl, C_5-20 alkenyl, —R*YR″, —YR″, and —R″M′R′;

R₂ and R₃ are independently selected from the group consisting of C_1-14 alkyl, C_2-14 alkenyl, —R*YR″, —YR″, and —R*OR″, or R₂ and R₃, together with the atom to which they are attached, form a heterocycle or carbocycle;

R₄ is selected from the group consisting of —(CH₂)_nQ, —(CH₂)_nCHQR, —CHQR, and —CQ(R)₂, where Q is —N(R)₂, and n is selected from 1, 2, 3, 4, and 5;

each R₅ is independently selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;

each R₆ is independently selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;

M and M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)₂—, —S—S—, an aryl group, and a heteroaryl group;

R₇ is selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;

each R is independently selected from the group consisting of C_1-3 alkyl, C_2-3 alkenyl, and H;

each R′ is independently selected from the group consisting of C_1-18 alkyl, C_2-18 alkenyl, —R*YR″, —YR″, and H;

each R″ is independently selected from the group consisting of C_3-14 alkyl and C_3-14 alkenyl;

each R* is independently selected from the group consisting of C_1-12 alkyl and C_1-12 alkenyl;

each Y is independently a C_3-6 carbocycle;

each X is independently selected from the group consisting of F, Cl, Br, and I; and

m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,

or salts or isomers thereof.

103. The vaccine of claim 96, wherein a subset of compounds of Formula (I) includes those of Formula (IA):

or a salt or isomer thereof, wherein 1 is selected from 1, 2, 3, 4, and 5; m is selected from 5, 6, 7, 8, and 9; M₁ is a bond or M′; R₄ is unsubstituted C_1-3 alkyl, or —(CH₂)_nQ, in which Q is OH, —NHC(S)N(R)₂, —NHC(O)N(R)₂, —N(R)C(O)R, —N(R)S(O)₂R, —N(R)R₈, —NHC(═NR₉)N(R)₂, —NHC(═CHR₉)N(R)₂, —OC(O)N(R)₂, —N(R)C(O)OR, heteroaryl or heterocycloalkyl; M and M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—, —P(O)(OR′)O—, —S—S—, an aryl group, and a heteroaryl group; and R₂ and R₃ are independently selected from the group consisting of H, C_1-14 alkyl, and C_2-14 alkenyl.

Images